Page last updated: 2024-10-27

fluorouracil and Adenocarcinoma, Basal Cell

fluorouracil has been researched along with Adenocarcinoma, Basal Cell in 4932 studies

Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.

Research Excerpts

ExcerptRelevanceReference
" The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)."9.41Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021)
"The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy."9.34Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020)
" We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma."9.34Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020)
"BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer."9.34Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020)
"Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)."9.34Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020)
"5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)."9.30Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019)
"Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control."9.30Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."9.27S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)."9.27FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018)
"Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma."9.22Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."9.20A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
" This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma."9.20Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015)
"The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed."9.20Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015)
"This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)."9.20A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."9.20Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
"Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity."9.20Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015)
"We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)."9.19Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014)
"This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma."9.19Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014)
"To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma."9.19Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014)
" We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas."9.17A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013)
"This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)."9.17Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
"The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer."9.17Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013)
"To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)."9.17Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013)
"To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas."9.17Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013)
"To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)."9.16Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012)
"We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy."9.16A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012)
"The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)."9.16Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012)
"PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine."9.16A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."9.16Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1."9.16Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012)
" This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients."9.16A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012)
"Capecitabine produces an objective response rate of up to 25% in anthracycline-treated, taxane-resistant metastatic breast cancer (MBC)."9.16A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). ( Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M, 2012)
"To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)."9.16Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012)
"This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma."9.16Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012)
"To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas."9.15Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011)
"Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3."9.15Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer."9.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011)
"The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)."9.15Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011)
"The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial."9.15Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011)
"This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer."9.15A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer."9.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011)
"Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1."9.15S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011)
"Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients."9.14Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009)
"The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward."9.14An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009)
"This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma."9.14Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009)
"This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)."9.14Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009)
"We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia."9.14A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009)
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer."9.14Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009)
"A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer."9.14FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010)
"Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression."9.14S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010)
"We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)."9.14Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009)
"The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer."9.14Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010)
"Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile."9.14Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010)
"The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients."9.14Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. ( Andersen, J; Andersson, M; Ejlertsen, B; Jensen, MB; Kamby, C; Knoop, AS; Mouridsen, HT, 2010)
"To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma."9.14[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010)
"The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma."9.14A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010)
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer."9.14Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010)
"Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles."9.14Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010)
"The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer."9.14Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."9.14Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy."9.14Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010)
"601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy."9.14Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010)
"Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer."9.14Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. ( Atieh-Graham, D; D'Andrea, G; Drullinsky, P; Fornier, MN; Gilewski, T; Hudis, C; Lake, D; Mills, N; Norton, L; Patel, H; Patil, S; Seidman, AD; Sklarin, N; Sugarman, SM; Traina, T; Troso-Sandoval, T; Wasserheit-Lieblich, C; Yuan, J, 2010)
"The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy."9.13Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008)
"We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction."9.13Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008)
"Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks."9.13Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008)
"We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer."9.13A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008)
"This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen."9.13Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008)
"XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)."9.13Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008)
"Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin."9.13The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."9.13Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel."9.13Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. ( Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."9.13Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas."9.13Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008)
"The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer."9.13Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008)
"Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)."9.13Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008)
"Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil."9.13Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008)
"Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)."9.13Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008)
"During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures."9.13Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008)
"The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established."9.12Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006)
"Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia."9.12Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006)
"Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer."9.12Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
"Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction."9.12Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006)
"To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)."9.12FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006)
"To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer."9.12Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006)
"We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma."9.12A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006)
"The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma."9.12Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006)
"The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer."9.12Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006)
"To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer."9.12[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006)
"PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial."9.12Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007)
"In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer."9.12Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006)
"Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease."9.12Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006)
"To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide."9.12[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007)
"To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population."9.12A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007)
"To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin."9.12Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007)
"The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma."9.12Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007)
"This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer."9.12A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007)
"Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin."9.11A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."9.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."9.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."9.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
"The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma."9.11First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."9.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
"To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis."9.11Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004)
"Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)."9.11Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004)
"A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer."9.11Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004)
"The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)."9.11Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004)
"The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)."9.11Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005)
"Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)."9.11Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005)
"To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer."9.11Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005)
"In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks."9.11Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005)
"The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma."9.10A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002)
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas."9.10Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."9.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
"In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU."9.10Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002)
"Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)."9.10Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002)
"This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer."9.10Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
" We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver."9.10Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003)
"This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer."9.10A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003)
"Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)."9.10Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003)
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57."9.10Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003)
"In breast cancer, chemotherapy regimens that include infusional 5-fluorouracil (5-FU) lead to high response rates, but require central venous access and pumps."9.10An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer. ( Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P, 2003)
"The purpose of the study was to determine the efficacy and safety of docetaxel plus continuous infusion of 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracyclines."9.10Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer. ( Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N, 2003)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer."9.10Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003)
"To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer."9.10Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003)
"The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer."9.10Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003)
"This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer."9.10Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003)
"Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas."9.10Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003)
"To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens."9.10A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003)
" once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment."9.10Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003)
"This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."9.10Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."9.10Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."9.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)."9.10Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002)
"To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer."9.10Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002)
"To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients."9.10A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002)
" cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer."9.09Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer."9.09A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999)
"To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone."9.09Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999)
"The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer."9.09Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999)
"Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil."9.09Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000)
"It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure."9.09Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000)
"The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer."9.09Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000)
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."9.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."9.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
" This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma."9.09Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001)
"To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma."9.09Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001)
"The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma."9.09Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. ( Aoki, Y; Sasaki, M; Sato, T; Tanaka, K; Tsuneki, I; Watanabe, M, 2001)
"To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum."9.09Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001)
"Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma."9.09Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001)
"Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV."9.09Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
"To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer."9.09Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001)
" 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas."9.09A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)."9.09Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001)
"To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma."9.09Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001)
"Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer."9.08Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995)
"A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks."9.085-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995)
" levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder."9.08Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996)
"5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer."9.085-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996)
"In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2."9.08Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996)
"Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer."9.08Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996)
"A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma."9.08A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997)
") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma."9.08[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997)
"The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients."9.08A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997)
"The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix."9.08Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997)
"Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)."9.08High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998)
"The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma."9.08The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. ( Crawley, C; Cunningham, D; Hill, A; Norman, A; Ross, P, 1998)
"To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)."9.08Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998)
"In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known."9.08Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998)
"FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer."9.08Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998)
"Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i."9.07Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994)
"We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer."9.07The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. ( Bélanger, K; Dionne, J; Gagné, L; Guévin, R; Jolivet, J; Latreille, J; Potvin, M; Rudinskas, L; Wilson, J; Yelle, L, 1994)
"Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks."9.07Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993)
"We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19."9.07Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993)
"A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer."9.07A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993)
"In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas."9.07Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993)
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas."9.07A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992)
"A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients."9.07Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU."9.07Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992)
"One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6."9.07A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992)
"We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin."9.07Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991)
"Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide."9.07Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991)
"Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest."9.07Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991)
"To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes."9.07Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."9.06Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."9.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)."9.06Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989)
"Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i."9.06A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989)
"Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)."9.065-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987)
"We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma."9.06Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986)
"Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin."9.05A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983)
"Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)."9.05MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984)
"Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan."9.04Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978)
"One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide."9.04Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977)
"In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs."9.04Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975)
"The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)."8.95A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017)
", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)."8.86Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010)
"A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy."8.77Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988)
"This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil."8.31Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023)
"Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities."8.31Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023)
"The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy."8.31The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023)
"The primary mode of therapy for individuals with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy, commonly 5-Fluorouracil (5-FU)."8.31Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells. ( Chauhan, A; Cheng, L; Garrett, H; Idrovo, JP; Meguid, RA; Meng, X; Pratap, A; Qualman, A; The, E; Wani, S, 2023)
"Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist."8.12Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022)
" This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs."8.12Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
"FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited."8.12Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022)
" Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells."8.12The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022)
"We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine."8.12A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. ( Botsen, D; Bouche, O; Gossery, C; Gratiaux, J; Rezzag-Mahcene, C; Slimano, F; Visseaux, L, 2022)
"The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells."8.12Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022)
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019."7.96First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020)
"The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)."7.91Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019)
"Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU."7.91Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019)
" We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations."7.91Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
"Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy."7.91Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019)
" Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)."7.88Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018)
"Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells."7.88Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018)
"Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated."7.855-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017)
"To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy."7.83Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016)
"We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer."7.83In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016)
" In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms."7.83Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016)
"When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis."7.83Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016)
"Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)."7.83Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016)
"An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas."7.81Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015)
"The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma."7.81Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015)
"In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity."7.81Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015)
"Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy."7.80Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014)
" The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China."7.80Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014)
"We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer."7.80The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014)
"We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer."7.80An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014)
"The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)."7.80The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014)
"The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma."7.79Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013)
" This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil."7.79Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013)
"The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma."7.79Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. ( Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013)
"To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma."7.79Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013)
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer."7.79Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013)
" In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms."7.79The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013)
"Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy."7.79Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013)
" This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC."7.79Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013)
" The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiotherapy in the treatment of resected locally advanced stomach or gastroesophageal junction adenocarcinoma."7.79Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. ( Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J, 2013)
"A recent study showed that both 5-fluorouracil (5FU)-stimulated apoptosis and Fas-mediated apoptosis in human endometrial adenocarcinoma cells are enhanced by targeted knockdown of endogenous death-associated protein kinase (DAPK) with DAPK small-interfering RNAs."7.78Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells. ( Bai, T; Tanaka, J; Tanaka, T; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yukawa, K, 2012)
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation."7.78Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012)
"To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts."7.78FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012)
" The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy."7.78Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012)
"To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)."7.77A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011)
"Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities."7.77Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011)
"There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)."7.77Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011)
"The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)."7.77Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011)
"FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients."7.77Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma."7.77Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011)
"To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)."7.775-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011)
"To investigate anticancer effects of 5-fluorouracil (5-FU) combined with CL, extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma cell line (JEC)."7.77[Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma]. ( Dai, ZK; Yang, XS; Yu, LM, 2011)
"Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required."7.77Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993)
"To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo."7.76Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010)
" We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer."7.76Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010)
"The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)."7.76Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010)
"The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)."7.76EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010)
"5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma."7.76A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010)
"We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma."7.76[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010)
"To investigate acquired 5-fluorouracil (5FU)-resistance in cancer cells, we established four monoclonal 5FU-resistant cell lines from human endometrial adenocarcinoma cells by long-term 5FU-exposure cultures and limiting dilution cultures."7.76Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. ( Bai, T; Tanaka, T; Toujima, S, 2010)
"The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients."7.76Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010)
"A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas."7.75Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009)
"We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU."7.75[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009)
"A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described."7.75A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009)
"The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known."7.75Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009)
"It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma."7.75Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009)
" We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy."7.75Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009)
"5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration."7.75Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009)
" The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix."7.75Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009)
"We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus."7.74Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008)
"To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma."7.74Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008)
"We aimed at developing a more detailed understanding of cyclin D1 in early stage human breast cancer and defining the biologic profiles with different prognostic value correlating cyclin D1 gene amplification and chromosome 11 aneusomy with bio-pathologic variables of known clinical importance."7.74Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. ( Buglioni, S; Cianciulli, A; Cognetti, F; Di Benedetto, A; Merola, R; Mottolese, M; Orlandi, G; Perracchio, L; Pinnarò, P; Sperduti, I; Venturo, I, 2007)
"To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer."7.74Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007)
"Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors."7.74Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007)
"Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer."7.74Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007)
"A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer."7.74Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007)
"Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas."7.74Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007)
" Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer."7.74[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007)
"Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)."7.74Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008)
"To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma."7.73Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005)
"To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)."7.73Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006)
"We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy."7.73[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005)
"We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy."7.73Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005)
"Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003."7.73Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."7.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."7.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
"Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine."7.725-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004)
"High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers."7.72Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004)
"Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)."7.72Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004)
"The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials."7.71[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002)
"LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks."7.71Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."7.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis."7.71Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001)
"To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy."7.71p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001)
"The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy."7.71Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002)
"We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy."7.71mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002)
"This case can be considered the first documented Irinotecan-induced immune thrombocytopenia."7.70Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998)
"During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection."7.70Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."7.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol."7.70Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999)
"5-Fluorouracil combined with leucovorin and/or cisplatin has been used in the treatment of gastrointestinal adenocarcinoma and may be useful in primary adenocarcinoma of the bladder."7.70Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder. ( Awakura, Y; Fukuyama, T; Fukuzawa, S; Nonomura, M; Yamamoto, M, 1999)
"To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer."7.70[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998)
"The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer."7.70Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000)
"To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump."7.70Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000)
"Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil."7.70Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000)
"To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP."7.70Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999)
"We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin."7.69[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995)
"We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole."7.69Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995)
"To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells."7.695-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995)
"One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed."7.69A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995)
"Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment."7.69Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995)
"The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells."7.69Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994)
"We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)."7.69[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994)
"We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach."7.695-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994)
"Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220."7.69Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994)
"To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU."7.69[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994)
"Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days."7.69Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994)
"Low-dose consecutive intra-arterial infusion therapy with cisplatin and 5-fluorouracil as neoadjuvant chemotherapy was performed on 3 cases of cervical adenocarcinoma (two stage IIb and one stage IIIb)."7.69[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1996)
"Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)."7.69Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995)
"A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung."7.69[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996)
"In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%."7.69Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995)
"After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area."7.695-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996)
"In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally."7.69Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997)
"5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone."7.695-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997)
"Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)."7.69Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995)
"We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer."7.68[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993)
"Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule."7.68Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993)
" Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy."7.68Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992)
"Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i."7.68Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992)
"We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment."7.68A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991)
"Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1."7.68[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)."7.68In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991)
"Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)."7.68A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991)
"Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil."7.68Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990)
"A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)."7.68Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."7.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture."7.67Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984)
"The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells."7.67Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984)
"Twenty-one patients with adenocarcinoma of the cecum were treated in a pilot study between October, 1972 and June, 1982 by right hemicolectomy and received adjuvant postoperative irradiation (40-45 Gy/4-5 weeks) and 5-Fluorouracil (5-FU)."7.67Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study. ( Cormier, WJ; Jazy, FK; Krause, RJ; Meyer, RL; Shehata, WM, 1984)
"Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen."7.67Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989)
"Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals."7.67Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989)
"Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma."7.67Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989)
"The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse."7.67Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989)
"A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i."7.67Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989)
"Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1."7.67Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989)
"Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)."7.67Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989)
"A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU."7.67Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989)
"We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)."7.67Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989)
"Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma."7.67Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986)
"5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas."7.67Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986)
"Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients."7.675-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987)
"The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity."7.67Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986)
"When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity."7.67Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987)
"A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)."7.67[A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988)
"An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion."7.67High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988)
"A marked inhibition of the growth of solid tumor adenocarcinoma 755 was achieved by the combination of 5-fluorouracil (5-FU) with bromovinyldeoxyuridine (BVDU)."7.67Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ( Araki, E; De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1988)
"The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks."7.67An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987)
"Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX."7.67Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987)
"We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma."7.67Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987)
"The effect of various guanine ribonucleotides on the antitumor activity of 5-fluorouracil (FUra) was investigated by its action on adenocarcinoma 755."7.67Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755. ( Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987)
"The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary."7.675-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986)
"Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks."7.675-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986)
"In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed."7.67Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987)
"To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted."7.67Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985)
"Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells."7.67The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986)
"The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A."7.66In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982)
"Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)."7.66Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982)
"Because alpha-difluoromethylornithine (DFMO) reduces the incidence of experimental colon cancers, inhibits the growth of human lung cancer cells and human leukemia cells in culture, and in combination with methylglyoxal (bis)guanylhydrazone induces remission in children with leukemia, its effectiveness against a human colon adenocarcinoma cell line (Colo 205) was tested alone and in combination with 5-fluorouracil (5-FU)."7.66Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. ( Diekema, KA; Kingsnorth, AN; Malt, RA; McCann, PP; Russell, WE, 1983)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."7.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer."7.66Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983)
"A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer."7.66Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981)
"The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)."7.66Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983)
"A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice."7.66Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982)
"After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia."7.66[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982)
"This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)."7.66The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982)
"The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system."7.66Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980)
"Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)."7.665-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma."7.66Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980)
"28 patients with advanced adenocarcinomas were treated with combinations of 5-fluorouracil and mitomycin-C (FM, 21 patients) or of 5-fluorouracil, adriamycin and mitomycin-C (FAM, 7 patients)."7.66[Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas]. ( Hammer, B; Jungi, WF; Mayr, AC; Senn, HJ; Späti, B, 1980)
"Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)."7.665-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980)
"The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma."7.66Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981)
"In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively."7.66Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979)
"Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)."7.665-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979)
"Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations."7.65Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977)
"Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate."7.65Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977)
"For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy."7.01A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023)
"A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity."6.90Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."6.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
"Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients."6.82Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016)
"With the changed dosing schedule, this regimen was very well tolerated."6.82Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016)
" We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer."6.79Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014)
"4%) and renal adverse events (all grades: CS, 18."6.78Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013)
"Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a."6.78Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013)
"The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen."6.78Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013)
" Toxic effects were graded according to NCI-CTC version 3."6.78The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013)
"Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU."6.77A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3."6.76A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011)
"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."6.75A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent."6.74A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."6.74Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
"Capecitabine was administered at a dose of 1,000 mg/m(2) b."6.74Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009)
"Vorinostat was given orally twice daily for 1 week every 2 weeks."6.74A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
"Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks."6.74Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009)
"The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented."6.74Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009)
"Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT."6.73Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008)
"Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included."6.73Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007)
"Dipyridamole 75 mg was administered orally three times daily during the FU administration."6.73Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007)
"Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI."6.73A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008)
"Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities."6.73Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
"Pancreatic cancer is chemo-radiosensitive."6.72Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006)
"Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials."6.71Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003)
"Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1."6.71A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003)
"Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost."6.71A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004)
"Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever."6.71A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005)
"Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h."6.71A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005)
"Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay."6.69Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998)
" We then tested the effect of GM-CSF given with a more toxic regimen of 5-FU/LV/IFN-alpha (IFN alpha-2a)."6.69A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. ( Allegra, C; Behan, K; Chen, A; Flemming, D; Grem, JL; Grollman, F; Haller, D; Hamilton, JM; Harold, N; Johnston, PG; Lash, A; Liewehr, D; Monahan, B; Morrison, G; Quinn, M; Shapiro, JD; Steinberg, SM; Takimoto, C; Vaughn, D, 1999)
"Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma."6.69Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000)
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7."6.69Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000)
" The dosage was as follows: group A received FA i."6.68Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996)
"Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1."6.68Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996)
" The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity."6.68A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997)
"Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses."6.68A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997)
" We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity."6.67Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. ( Buccellato, C; Cipolla, C; Comande, S; Curto, G; Gebbia, N; Gebbia, V; Latteri, M; Testa, A; Valenza, R, 1994)
"To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)."6.67Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994)
"Nine patients with advanced breast cancer received CAF (cyclophosphamide at 100 mg/m2/day p."6.67Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. ( Dutcher, JP; Liebes, L; Robert, NJ; Schwartz, EL; Sparano, JA; Wadler, S, 1993)
" in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)."6.67Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991)
"Treatment with capecitabine lead to clinical amelioration."6.44Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. ( Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G, 2007)
"Irinotecan or CPT11 is a topoisomerase 1 inhibitor."6.40[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998)
"Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10."6.40[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998)
"The purpose of this study was to evaluate the effectiveness of several new approaches designed to enhance the activity of fluorouracil (5-FU) in the management of advanced colorectal cancer."6.16Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. ( Cullinan, SA; Everson, LK; Krook, JE; Laurie, JA; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1989)
"5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance."5.91Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023)
"Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent."5.91In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023)
"A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis."5.91Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023)
"Folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) or modified FOLFIRINOX (mFFX) is the first-line standard of care for metastatic pancreatic adenocarcinoma; effective and safe treatment strategies are needed as survival remains poor."5.69Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial. ( Bai, X; Chen, Y; Fu, Q; Gao, S; Guo, C; Huang, D; Li, X; Liang, T; Que, R; Shen, Y; Wu, J; Xiao, W; Xue, X; Zhang, M; Zhang, Q; Zhang, X, 2023)
"In this prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinous appendiceal adenocarcinoma, patients did not derive clinical benefit from fluorouracil-based chemotherapy, given there were no objective responses, no difference in OS when treatment was delayed 6 months, and no difference in the rate of tumor growth while receiving chemotherapy."5.69Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial. ( Beaty, KA; Eng, C; Foo, WC; Fournier, K; Hornstein, N; Lano, E; Mansfield, P; Matamoros, A; Overman, MJ; Rafeeq, S; Raghav, KP; Scally, C; Scofield, LC; Shen, JP; Taggart, M; Tidwell, RS; Uppal, A; Yousef, AM; Zeineddine, FA; Zeineddine, MA, 2023)
" This open-label randomized phase II trial (2:1) investigated the efficacy of combining pazopanib with FLO (5-fluorouracil, oxaliplatin) vs FLO alone (internal control arm) as first-line treatment in patients with advanced adenocarcinoma of the stomach and gastroesophageal junction (GEJ)."5.51Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510. ( Al-Batran, SE; Bartels, P; Breithaupt, K; Gläser, D; Hinke, A; Högner, A; Homann, N; Lorenz, M; Malfertheiner, P; Siveke, JT; Stein, A; Tamm, I; Thuss-Patience, P; Vogel, A, 2022)
"The objective of this study was to evaluate the efficacy and safety of induction chemotherapy (ICT), GOFL (gemcitabine, oxaliplatin plus fluorouracil (5-FU)/leucovorin) versus modified FOLFIRINOX (irinotecan, oxaliplatin plus 5-FU/leucovorin), followed by concurrent chemoradiotherapy (CCRT) in locally advanced pancreatic adenocarcinoma (LAPC)."5.51A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study. ( Ch'ang, HJ; Chang, PY; Chen, LT; Chiang, NJ; Chiu, YF; Li, CP; Lin, J; Lin, SJ; Shan, YS; Su, YY; Yang, SH, 2022)
"The perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin plus docetaxel (FLOT) was recommended by the Chinese Society of Clinical Oncology Guidelines for gastric cancer (2018 edition) for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (class IIA)."5.51Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. ( Jia, SJ; Liu, Q; Song, LY; Wang, C; Zeng, H; Zeng, X, 2022)
"Most patients had disease progression as the best response to treatment (75."5.51Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019)
"A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver."5.51Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019)
"Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon."5.51Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019)
"Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects."5.48Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018)
"All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively."5.48Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018)
"Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy."5.46Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017)
"Peritoneal metastasis is common in gastric cancer."5.46Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017)
"Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab."5.46Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017)
" Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen."5.42Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015)
" The trial TyRosine kinase Inhibitor for the treatment of Chemorefractory Colorectal Cancer (TRICC-C) trial evaluates the addition of nintedanib to mFOLFOX6 (fluorouracil, folinic acid and oxaliplatin) in patients with metastatic colorectal cancer (mCRC)."5.41Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111). ( Berger, AW; Büchner-Steudel, P; Decker, T; Ettrich, TJ; Güthle, M; Hannig, CV; Hebart, HF; Heinemann, V; Hermann, PC; Herrmann, T; Hoffmann, T; Hofheinz, RD; Perkhofer, L; Seufferlein, T, 2021)
" A phase I and Ib study of modified oxaliplatin, leucovorin, and fluorouracil (mFOLFOX6) with ADX revealed encouraging antitumor activity in patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma."5.41Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1). ( Ajani, JA; Bendell, J; Bhargava, P; Bodoky, G; Cunningham, D; He, J; Shah, MA; Starodub, A; Thai, D; Wainberg, ZA; Yip, D, 2021)
"Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic."5.40Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014)
" In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179."5.40Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014)
"Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer."5.40Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014)
"Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases."5.39Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013)
"5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms."5.38Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012)
" Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy."5.38Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012)
"The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status."5.37Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011)
" Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases."5.36The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010)
"Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen."5.36Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010)
"Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity."5.36Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010)
"Colorectal cancer is one of the leading malignancies in the world."5.36Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010)
"Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen."5.36[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010)
"Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal."5.35Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008)
"The global, randomized NAPOLI-1 phase 3 trial reported a survival benefit with liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after previous gemcitabine-based therapy."5.34Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study. ( Bang, YJ; Belanger, B; Chen, JS; Chen, LT; Chiu, CF; Choi, HJ; Kim, JS; Lee, KH; Li, CP; Oh, DY; Park, JO; Rau, KM; Shan, YS; Shim, HJ, 2020)
" We hypothesized that sunitinib in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) would be a tolerable and effective regimen in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma."5.34Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. ( Attwood, K; Boland, PM; Fountzilas, C; Gosain, R; Iyer, R; Khushalani, N; Mukherjee, S; Tan, W, 2020)
"Using data from the 4-year follow-up results of an open, randomised, phase II study, this patient-based cost-effectiveness analysis compares mFOLFIRI (irinotecan, 5-fluorouracil and leucovorin, the IRI arm) with mFOLFOX7 (oxaliplatin, 5-fluorouracil and leucovorin, the OXA arm) as first-line treatments in patients with locally advanced gastric adenocarcinoma (GC)."5.34Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study. ( Bi, F; Chen, H; Li, Q; Wen, F; Zhang, P; Zheng, H; Zhou, J; Zhou, K, 2020)
"BACKGROUND The aim of this study was to perform an accurate exploration on the efficacy of oxaliplatin/5-fluorouracil/capecitabine-cetuximab combination therapy and its effects on K-Ras mutations in advanced colorectal cancer."5.34Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer. ( Chen, J; Chen, Z; Huang, J; Ma, X; Wei, L; Wen, J; Wu, D, 2020)
"Cetuximab has been shown to be clinically active when given in combination with irinotecan in patients with irinotecan-refractory metastatic colorectal cancer (mCRC)."5.34Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G). ( Baba, E; Boku, N; Denda, T; Esaki, T; Fujii, H; Goto, M; Hara, H; Hironaka, S; Hosokawa, A; Hyodo, I; Ishida, H; Kadowaki, S; Kishimoto, J; Koh, Y; Kuramochi, H; Makiyama, A; Matsumoto, S; Moriwaki, T; Muro, K; Nishina, T; Okuda, H; Otsu, S; Ozaki, Y; Sakai, D; Sakamoto, T; Sato, M; Satoh, T; Shimokawa, H; Shinozaki, K; Sugimoto, N; Tamagawa, H; Tamura, T; Taniguchi, H; Tokunaga, S; Tsuda, T; Tsuji, A; Tsushima, T; Yamazaki, K; Yasui, H, 2020)
"Previously published work has demonstrated that combining gemcitabine with irreversible electroporation (IRE) results in increased drug delivery to pancreatic adenocarcinoma cells in vivo."5.34Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma. ( Bhutiani, N; Chen, Y; Li, Y; Martin, RCG; Pandit, H; Pulliam, ZR; Shi, X; Tan, M; Yu, Y; Zheng, Q, 2020)
"Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis."5.34[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007)
"Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations."5.34Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007)
"5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells."5.33Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005)
"Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)."5.33Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005)
"Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity."5.33Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006)
"These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer."5.32Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003)
"Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%."5.31A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002)
"Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)."5.31Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000)
"We investigated the expression patterns of Ki67 and p53 in metastatic pancreatic adenocarcinomas and analyzed their relationship with disease progression-free survival (PFS) and overall survival (OS) in the overall study population and in patients treated with a gemcitabine-containing chemotherapy versus FOLFIRINOX chemotherapy."5.30Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis. ( Assi, H; Charafeddine, M; Hammoud, MS; Makki, I; Mukherji, D; Nassif, S; Shamseddine, A; Temraz, S; Tfayli, A, 2019)
"5-Fluorouracil (5-FU) and platinum-based perioperative chemotherapy is standard of care for resectable gastric adenocarcinoma (RGA)."5.30Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). ( Bachet, JB; Cohen, R; Colin, D; de la Fouchardière, C; Ferraz, JM; Kim, S; Lefevre, M; Louvet, C; Meurisse, A; Svrcek, M; Tournigand, C; Watson, S, 2019)
"Apatinib mesylate combined with chemotherapy for the treatment of patients with gastroesophageal junction adenocarcinoma was safe and effective, with improved survival benefit compared with control."5.30Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma. ( Chen, J; Hua, Z; Lu, B; Lu, C; Qu, C; Sun, Z; Tong, R; Zhang, J, 2019)
" The mean total dosage was 6."5.30[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997)
"5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens."5.30Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998)
"5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a."5.29Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993)
"Irinotecan and etoposide were combined using the (d x 5)2 i."5.29Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."5.28Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991)
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."5.28Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989)
"Aflibercept (ziv-aflibercept) significantly improves progression-free (PFS) and overall survival (OS) when added to 5-fluorouracil, leucovorin and irinotecan (FOLFIRI), compared with FOLFIRI alone, in patients with metastatic colorectal cancer previously treated with oxaliplatin-based therapy."5.27Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial. ( Dochy, E; Lakomy, R; Macarulla, T; Magherini, E; Moiseyenko, VM; Papamichael, D; Prausova, J; Ruff, P; Soussan-Lazard, K; Van Cutsem, E; van Hazel, GA, 2018)
"Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line treatment of metastatic colorectal cancer (mCRC)."5.27S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial. ( Denda, T; Gamoh, M; Ishioka, C; Iwanaga, I; Kobayashi, K; Kobayashi, Y; Komatsu, Y; Kotake, M; Miyamoto, Y; Morita, S; Nakamura, M; Ohori, H; Sato, A; Shimada, K; Shimodaira, H; Takahashi, S; Tsuda, M; Yamada, Y; Yamaguchi, T; Yuki, S, 2018)
"FOLFOXIRI (Fluorouracil, folinate, oxaliplatin, and irinotecan) plus bevacizumab improved progression-free survival (PFS) and overall survival in patients with metastatic colorectal cancer (mCRC), compared with FOLFIRI (fluorouracil, folinate, and irinotecan) plus bevacizumab, but significantly increased the incidences of adverse events."5.27A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study. ( Bando, H; Emi, Y; Iwamoto, S; Kagawa, Y; Kanazawa, A; Kato, T; Kotaka, M; Muro, K; Nakamura, M; Nakayama, G; Oki, E; Sakisaka, H; Taniguchi, H; Touyama, T; Tsuji, A; Yamaguchi, T; Yamanaka, T; Yamazaki, K; Yoshino, T, 2018)
" Patients aged 18 years or older with high-risk stage II and stage III colorectal cancer underwent central randomisation with minimisation for centre, choice of regimen, sex, disease site, N stage, T stage, and the starting dose of capecitabine."5.273 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. ( Allan, K; Azzabi, A; Boyd, KA; Bridgewater, J; Briggs, A; Cassidy, J; Cunningham, D; Dhadda, AS; Ellis, R; Essapen, S; Falk, S; Farrugia, D; Glimelius, B; Gollins, S; Harkin, A; Harrison, M; Haydon, A; Hickish, T; Hollander, NH; Iveson, TJ; Kerr, RS; McQueen, J; Medley, L; Olesen, RK; Paul, J; Propper, D; Raouf, S; Rees, C; Saunders, MP; Scudder, C; Tabernero, J; Wasan, HS; Waterston, A; Weaver, A; Webb, A; Wilson, C, 2018)
"Both FOLFIRINOX and gemcitabine/nab-paclitaxel (G-nP) are used increasingly in the neoadjuvant treatment (NAT) of pancreatic ductal adenocarcinoma (PDA)."5.27FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma. ( Bahary, N; Dhir, M; Hamad, A; Hogg, ME; Singhi, AD; Zeh, HJ; Zenati, MS; Zureikat, AH, 2018)
"Patients with metastatic adenocarcinoma of the pancreas or biliary tract, previously untreated or having received 1 cytotoxic regimen for advanced disease, were treated with gemcitabine 1000 mg/m intravenously (IV) over 100 minutes, cisplatin 35 mg/m IV over 30 minutes, and 5-FU 2400 mg/m IV over 48 hours on day 1 of a 14-day cycle."5.27A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers. ( Davis, EJ; Griffith, KA; Kim, EJ; McDonnell, KJ; Ruch, JM; Zalupski, MM, 2018)
"Laboratory experiments using breast cancer cells in long-term tissue culture revealed that tamoxifen is cytotoxic, estrogen stimulates the growth of ER-positive cells and can rescue cells from tamoxifen's effect, and sequential MTX/5-FU is synergistic in rapidly growing breast cancer cells."5.27Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. ( Allegra, JC, 1983)
"The prognosis of bile duct cancer is still poor."5.27[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986)
" Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs."5.27Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985)
"5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i."5.275-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986)
"Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)."5.26[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982)
"Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity."5.26A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. ( Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM, 1982)
"Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission."5.26Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982)
"0001) vs 5-FU/LV alone in metastatic pancreatic adenocarcinoma patients previously treated with gemcitabine-based therapy."5.24Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis. ( Blanc, JF; Botteman, MF; Chen, LT; Cubillo, A; de Jong, FA; Hubner, RA; Melisi, D; Pelzer, U; Siveke, JT; Solem, CT; Von Hoff, DD; Wan, Y; Wang-Gillam, A; Yang, Y, 2017)
"The AIO-FLOT3 (Arbeitsgemeinschaft Internistische Onkologie-fluorouracil, leucovorin, oxaliplatin, and docetaxel) trial is a prospective, phase 2 trial of 252 patients with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma."5.24Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial. ( Al-Batran, SE; Arnold, D; Bechstein, W; Berkhoff, S; Egger, M; Fischbach, W; Grimm, K; Hartmann, JT; Höffkes, HG; Hofheinz, RD; Homann, N; Illerhaus, G; Jäger, E; Koenigsmann, M; Kraus, TW; Luley, KB; Martens, UM; Mayer, F; Messmann, H; Moehler, M; Mönig, S; Pauligk, C; Post, S; Prasnikar, N; Probst, S; Ronellenfitsch, U; Schmalenberg, H; Stoehlmacher, J, 2017)
"Purpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Trial 0116 (Phase III trial of postoperative adjuvant radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated superior survival for patients who received postoperative chemoradiotherapy with bolus fluorouracil (FU) and leucovorin (LV) compared with surgery alone."5.24Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). ( Alberts, SR; Berg, DJ; Bjarnason, GA; Ciombor, K; Dragovich, T; Enzinger, PC; Fuchs, CS; Goldberg, RM; Gunderson, LL; Haller, DG; Ilson, D; Mamon, HJ; Mayer, RJ; Meyerhardt, J; Niedzwiecki, D; O'Reilly, E; Swanson, RS; Tepper, JE; Venook, AP; Willett, CG; Ye, X, 2017)
"Patients with untreated metastatic adenocarcinoma of the stomach, gastroesophageal junction, or distal esophagus received mFOLFOX6 (leucovorin 400 mg/m, fluorouracil 400 mg/m bolus and 2400 mg/m continuous infusion over 46 h, oxaliplatin 85 mg/m) and bevacizumab (10 mg/kg) every 2 weeks until disease progression or intolerance."5.24Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma. ( Deng, Y; Doddamane, I; Fischbach, NA; Hochster, HS; Karimeddini, D; Kortmansky, JS; Lacy, J; Li, J; Stein, S; Yao, X; Zhang, Y, 2017)
"The aim of the study was to assess the clinical activity and toxicity of oxaliplatin and leucovorin in combination with bolus and continuous infusional 5-fluorouracil administered every 2 weeks (modified FOLFOX-6 regimen) to patients with adenocarcinoma of an unknown primary site (ACUP)."5.22A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site. ( Bae, WK; Choi, YH; Chung, IJ; Kang, HJ; Kim, BS; Lee, HR; Na, II; Shim, HJ; Shin, DY; Song, EK; Yang, SH; Yuh, YJ, 2016)
"The HE6C/05 trial randomized 441 patients with stage II-III colorectal adenocarcinoma to adjuvant XELOX (capecitabine, oxaliplatin) or modified FOLFOX6 (5-fluorouracil, leucovorin, oxaliplatin)."5.22Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. ( Cohen, SA; Fountzilas, G; Gkakou, C; Gourgioti, G; Grady, WM; Kalogeras, KT; Karavasilis, V; Kotoula, V; Papaxoinis, G; Pectasides, D; Pentheroudakis, G; Raptou, G; Wirtz, R; Wu, C; Yu, M, 2016)
"Based upon preclinical data showing synergy with mTOR inhibition and platinum chemotherapy, this study explores the safety and tolerability of combining everolimus with mFOLFOX6 for patients with metastatic gastroesophageal adenocarcinoma."5.22Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma. ( Chao, J; Chung, S; Chung, V; Fakih, MG; Frankel, P; Koehler, S; Lau, SC; Leong, L; Lim, D; Luevanos, E; Ruel, N; Yeon, C, 2016)
"Docetaxel is active in esophagogastric junction (EGJ) adenocarcinoma, and DCF (docetaxel/cisplatin/5-fluorouracil) has shown good results in the neoadjuvant setting."5.22A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. ( Al-Fakeeh, A; Al-Ruzug, I; Alcindor, T; Doerksen, T; Ferri, L; Mulla, N; Santos, F, 2016)
"We sought to assess the benefit-risk balance of FOLFIRINOX versus gemcitabine in patients with metastatic pancreatic adenocarcinoma."5.22An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. ( Buyse, M; Conroy, T; Desseigne, F; Gourgou-Bourgade, S; Ozenne, B; Péron, J; Roche, L; Roy, P; Stanbury, T; Ychou, M, 2016)
"Patients more than 18 years of age with gastric adenocarcinoma were randomized 1:1 to capecitabine-cisplatin plus either bevacizumab or placebo."5.20Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study). ( Bu, L; Chen, L; Dai, G; Li, J; Liu, Y; Pan, H; Piao, Y; Qin, S; Shen, L; Shu, Y; Wang, J; Wang, L; Xu, J; Xu, R; Yang, Z; Yu, S, 2015)
"The FIRIS study previously demonstrated non-inferiority of IRIS (irinotecan plus S-1) to FOLFIRI (5-fluorouracil/leucovorin with irinotecan) for progression-free survival as the second-line chemotherapy for metastatic colorectal cancer (mCRC) as the primary endpoint."5.20A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study. ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K; Yasui, H, 2015)
" This study is to investigate the efficacy and tolerability of erlotinib plus capecitabine as first-line treatment in older Chinese patients (≥ 65 years) with lung adenocarcinoma."5.20Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study. ( Chen, GY; Cheng, Y; Feng, JF; Gu, CP; Huang, Y; Li, XL; Ma, LX; Shi, MQ; Song, XQ; Zhang, L; Zhang, YP; Zhao, HY; Zhou, D, 2015)
"Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment."5.20Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma. ( Bazhin, AV; Harig, S; Hartwig, W; Jäger, D; Karakhanova, S; Mosl, B; Ryschich, E; Schmidt, J; Werner, J, 2015)
"The oral multikinase inhibitor regorafenib improves overall survival (OS) in patients with metastatic colorectal cancer (CRC) for which all standard treatments have failed."5.20Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. ( Argilés, G; Benson, A; Cascinu, S; Ciardiello, F; Grunert, J; Guillén Ponce, C; Köhne, CH; Luigi Garosi, V; Macpherson, IR; Rivera, F; Saunders, MP; Sobrero, A; Strumberg, D; Tabernero, J; Van Cutsem, E; Wagner, A; Zalcberg, J, 2015)
"We performed a multicenter phase II study of sorafenib 200 mg orally twice daily along with oxaliplatin 85 mg/m(2) IV on days 1 and 15, followed by capecitabine 2250 mg/m(2) orally every 8 h for six doses starting on days 1 and 15 of a 28-day cycle in patients who had no more than one previous chemotherapy regimen for their pancreatic adenocarcinoma."5.20A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer. ( Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM, 2015)
" This study was to compare the efficacy of TME with versus without preoperative concurrent chemoradiotherapy (CCRT) involving XELOX regimen (oxaliplatin plus capecitabine) in Chinese patients with stages II and III mid/low rectal adenocarcinoma."5.20Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial. ( Chen, G; Ding, PR; Fan, WH; Gao, YH; Li, LR; Lu, ZH; Pan, ZZ; Wan, DS; Wang, FL; Wu, XJ; Zeng, ZF, 2015)
"In this multicentre, open-label, randomised, phase 3 study we randomly assigned patients with rectal adenocarcinoma, clinically staged as cT3-4 or any node-positive disease, to two groups: a control group receiving standard fluorouracil-based combined modality treatment, consisting of preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (1000 mg/m(2) on days 1-5 and 29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m(2) on days 1-5 and 29); or to an investigational group receiving preoperative radiotherapy of 50·4 Gy in 28 fractions plus infusional fluorouracil (250 mg/m(2) on days 1-14 and 22-35) and oxaliplatin (50 mg/m(2) on days 1, 8, 22, and 29), followed by surgery and eight cycles of oxaliplatin (100 mg/m(2) on days 1 and 15), leucovorin (400 mg/m(2) on days 1 and 15), and infusional fluorouracil (2400 mg/m(2) on days 1-2 and 15-16)."5.20Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. ( Arnold, D; Fietkau, R; Folprecht, G; Ghadimi, M; Grabenbauer, GG; Graeven, U; Hoffmanns, H; Hofheinz, RD; Hohenberger, W; Hothorn, T; Lang-Welzenbach, M; Liersch, T; Lindemann, F; Raab, HR; Rödel, C; Sauer, R; Schlenska-Lange, A; Staib, L; Ströbel, P; Wilhelm, M; Wittekind, C; Wolff, HA, 2015)
"This randomised, open-label, phase I/II study evaluated the efficacy and safety of nintedanib, an oral, triple angiokinase inhibitor, combined with chemotherapy, relative to bevacizumab plus chemotherapy as first-line therapy in patients with metastatic colorectal cancer (mCRC)."5.20A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients. ( Bennouna, J; Bouché, O; Capdevila, J; Carrato, A; D'Haens, G; Dressler, H; Ducreux, M; Latini, L; Oum'Hamed, Z; Prenen, H; Sobrero, A; Staines, H; Studeny, M; Van Cutsem, E, 2015)
"The TRICOLORE trial is a multicenter, randomized, open-label, controlled phase III study which aims to evaluate the non-inferiority of combination therapy with S-1/irinotecan/bevacizumab (a 3-week regimen [SIRB] or 4-week regimen [IRIS/bevacizumab]) to oxaliplatin-based standard treatment (mFOLFOX6/bevacizumab or CapeOX/bevacizumab) in patients with metastatic colorectal cancer who had not previously received chemotherapy."5.20Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer. ( Gamoh, M; Goto, R; Ishioka, C; Komatsu, Y; Kurihara, M; Morita, S; Sato, A; Shimada, K; Takahashi, S; Yamada, Y; Yamaguchi, T; Yuki, S, 2015)
"The aim of the study was to compare efficacy and safety of first-line palliative chemotherapy with (EOX) epirubicin/oxaliplatin/capecitabine and (mDCF) docetaxel/cisplatin/5FU/leucovorin regimens for untreated advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma."5.20Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. ( Budzynski, A; Fijorek, K; Konopka, K; Krzemieniecki, K; Lazar, A; Matlok, M; Ochenduszko, S; Pedziwiatr, M; Puskulluoglu, M; Sinczak-Kuta, A; Urbanczyk, K, 2015)
"Docetaxel, cisplatin, and fluorouracil (DCF) is a standard first-line three-drug chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is associated with significant toxicity."5.20Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium. ( Capanu, M; Henderson, C; Janjigian, YY; Kelsen, DP; Kemeny, M; Krishnamurthi, S; Mehrotra, B; Ocean, A; Ritch, P; Shah, MA; Shibata, S; Stoller, R; Su, YB, 2015)
"In this phase I study, we sought to determine the feasibility and tolerability of neoadjuvant short course radiotherapy (SC-CRT) delivered with photon RT with concurrent capecitabine for resectable pancreatic adenocarcinoma."5.19Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. ( Ancukiewicz, M; Blaszkowsky, LS; Fernandez-del Castillo, C; Ferrone, CR; Hong, TS; Kwak, EL; Lillemoe, KD; Mamon, HJ; Napolitano, BN; Ryan, DP; Swanson, RS; Tseng, YD; Wo, JY, 2014)
"Human equilibrative nucleoside transporter 1 (hENT1) levels in pancreatic adenocarcinoma may predict survival in patients who receive adjuvant gemcitabine after resection."5.19Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. ( Anthoney, A; Bassi, C; Büchler, MW; Campbell, F; Carter, R; Charnley, RM; Costello, E; Cox, TF; Deakin, M; Dervenis, C; Garner, E; Ghaneh, P; Glimelius, B; Goldstein, D; Greenhalf, W; Halloran, CM; Jackson, R; Lacaine, F; Lamb, RF; Mackey, JR; Mayerle, J; McDonald, AC; Middleton, MR; Moore, MJ; Neoptolemos, JP; Oláh, A; Palmer, DH; Rawcliffe, CL; Scarfe, AG; Scarpa, A; Shannon, J; Tebbutt, NC; Valle, JW, 2014)
"The purpose of this phase I study was to determine the safety, toxicity, maximum tolerated dose, and pharmacokinetics of capecitabine when administered concurrently with radiotherapy in patients with localised, inoperable pancreatic adenocarcinoma."5.19A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer. ( Crellin, A; Evans, TR; Harden, S; James, A; Lumsden, GR; McDonald, AC; Morrison, R; Paul, J; Roxburgh, P; Sweeting, L, 2014)
"We analyzed data from patients with stage III colon adenocarcinoma randomly assigned to groups given fluorouracil and leucovorin or IFL after surgery, from April 1999 through April 2001."5.19CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. ( Bertagnolli, MM; Dzieciatkowski, S; Emond, MJ; Foster, NR; Goldberg, RM; Grady, WM; Lao, VV; Luo, Y; Maizels, N; Monnat, RJ; Nam, E; Niedzwiecki, D; Renfro, LA; Saltz, LB; Shiovitz, S; Venook, A; Warren, RS, 2014)
"We investigated the efficacy and safety of a new second-line chemotherapy of combining folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) with both panitumumab and bevacizumab to treat patients with metastatic colorectal cancer (mCRC)."5.19Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer. ( Fan, Z; Han, G; He, L; Qin, Z; Xie, S; Xu, W, 2014)
"This phase II trial aimed to evaluate the efficacy and safety of docetaxel, cisplatin, and fluorouracil (DCF) combination in neoadjuvant setting in patients with locally advanced gastric adenocarcinoma."5.19Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. ( Abali, H; Bostanci, B; Civelek, B; Oguz, D; Oksuzoglu, B; Ozdemir, N; Vural, M; Yalcin, B; Yalcin, S; Zengin, N, 2014)
"To compare epirubicin, cisplatin, and capecitabine (ECX) with fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatments in patients with advanced gastric or esophagogastric junction (EGJ) adenocarcinoma."5.19Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd ( André, T; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Boucher, E; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Louvet, C; Maillard, E; Nguyen, S; Rebischung, C; Ries, P; Rougier, P; Ychou, M, 2014)
"The incidence of diarrhea during chemotherapy was significantly lower in the S-1 plus lafutidine group than in the group treated with S-1 alone (10% vs."5.19Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. ( Hanazaki, K; Kitagawa, H; Kobayashi, M; Maeda, H; Munekage, E; Namikawa, T, 2014)
" We evaluated the safety, tolerability, and efficacy of the combination capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas."5.17A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas. ( Altomare, I; Arrowood, CC; Bendell, JC; Blobe, GC; Brady, JC; Conkling, P; Cushman, SM; Favaro, J; Hsu, SD; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Pang, H; Uronis, HE; Zafar, SY, 2013)
"This randomized, double-blind, placebo-controlled, phase IIb study evaluated adding sorafenib to first-line modified FOLFOX6 (mFOLFOX6) for metastatic colorectal cancer (mCRC)."5.17Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial. ( Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L, 2013)
"The pro-drug capecitabine is approved for treatment of anthracycline- and paclitaxel-resistant metastatic breast cancer."5.17Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer. ( Armstrong, DK; Connolly, RM; Davidson, NE; Fetting, JH; Garrett-Mayer, E; Hoskins, JM; Jeter, SC; McLeod, HL; Rudek, MA; Stearns, V; Watkins, SP; Wolff, AC; Wright, LA; Zhao, M, 2013)
"To investigate the safety and efficacy of pemetrexed combined with chemotherapy as second or third line in patients with stage IV colorectal cancer (CRC)."5.17Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer. ( Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY; You, SX, 2013)
"The purpose of this multicenter phase II study was to evaluate the efficacy and safety of a combination of irinotecan, 5-fluorouracil (5-FU), and leucovorin (FOLFIRI) plus bevacizumab as first-line chemotherapy in Japanese patients with metastatic colorectal cancer."5.17FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study. ( Akiyama, Y; Aoki, T; Fujii, M; Hagiwara, K; Hironaka, K; Kochi, M; Nakajima, T; Osuka, F; Takahashi, T; Takeuchi, M; Teranishi, F, 2013)
"To determine the maximum tolerated radiation dose (MTD) of an integrated boost to the tumor subvolume infiltrating vessels, delivered simultaneously with radical dose to the whole tumor and concomitant capecitabine in patients with pretreated advanced pancreatic adenocarcinoma."5.17Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study. ( Balzano, G; Bettinardi, V; Calandrino, R; Castoldi, R; Cattaneo, GM; Cereda, S; Di Muzio, N; Gianolli, L; Gusmini, S; Longobardi, B; Passoni, P; Reni, M; Slim, N; Staudacher, C, 2013)
"To evaluate the safety and tolerability of two different weekly doses of the fully humanized epidermal growth factor receptor (EGFR)-targeting monoclonal antibody matuzumab combined with high-dose 5-fluorouracil, leucovorin and cisplatin (PLF) in the first-line treatment of patients with EGFR-positive advanced gastric and esophagogastric adenocarcinomas."5.17Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas. ( Heeger, S; Lüpfert, C; Przyborek, M; Schleucher, N; Trarbach, T; Vanhoefer, U, 2013)
"Patients with localized, operable gastric or gastroesophageal adenocarcinoma received two cycles of induction chemotherapy of fluorouracil, docetaxel, and cisplatin (TPF) followed by 45 Gy of radiation and concurrent fluorouracil plus docetaxel then surgery for nonmetastatic patients."5.17Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome. ( Abd-Allah, D; El-Shazly, W; Khedr, G; Rostom, Y; Zaghloul, H, 2013)
"Patients with metastatic gastric, gastro-oesophageal junction, or distal oesophageal adenocarcinoma were randomized 1:1:1 to CX (cisplatin 80 mg/m(2) IV Q3W; capecitabine 1000 mg/m(2) P."5.17Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer. ( Adewoye, AH; Bampton, CL; Bass, MB; Bodoky, G; Eatock, MM; Nanayakkara, N; Strickland, AH; Sun, YN; Swieboda-Sadlej, A; Tebbutt, NC; Valladares-Ayerbes, M; Van Cutsem, E; Zhong, ZD, 2013)
"Ninety-nine consecutive patients with cT2-4N0-2M0 distal rectal adenocarcinoma were enrolled in a clinical trial (NCT00254683) and underwent baseline PET/CT followed by 54 Gy and 5-fluorouracil-based CRT."5.17Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation. ( Bailão Aguilar, P; Buchpiguel, CA; Gama-Rodrigues, J; Habr-Gama, A; Lynn, P; Nahas, SC; Ono, CR; Perez, RO; Proscurshim, I; São Julião, GP, 2013)
"Patients with resectable, T3-4 and/or nodal involvement rectal adenocarcinoma were treated with oxaliplatin 60 mg/m(2) weekly and 5-fluorouracil 200 mg/m(2)/d infused continuously for five days, over a period of five weeks, and radiotherapy (45 Gy/25 fractions)."5.17Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer. ( Anselmi, E; Ardizzoni, A; Bui, S; Camisa, R; Cascinu, S; Crafa, P; Dell'abate, P; Fontana, E; Galdy, S; Leonardi, F; Losardo, PL; Negri, FV; Pucci, F; Roncoroni, L, 2013)
"To assess safety and efficacy of folinic acid, 5-fluorouracil, gemcitabine (FFG) and folinic acid, fluorouracil, oxaliplatin (FOLFOX4) regimens with added bevacizumab as first-line treatment in patients with advanced colorectal cancer (CRC)."5.16Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer. ( Gill, JF; Hentschel, P; Higby, DJ; Khan, MQ; Leichman, CG; Madajewicz, S; Malik, SK; Nicol, SJ; Ritch, PS; Waterhouse, DM; Zhao, L, 2012)
"We conducted a Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics (PK) of CKD-732 [6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate] in combination with capecitabine and oxaliplatin (XELOX) in nine metastatic colorectal cancer patients who had progressed on irinotecan-based chemotherapy."5.16A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy. ( Ahn, JB; Chung, HC; Hong, YS; Kim, C; Kim, DH; Kim, HR; Kim, TW; Lee, YJ; Park, KS; Rha, SY; Roh, JK; Shin, SJ, 2012)
"The aims of this study is to determine the maximum tolerated dose of capecitabine and oxaliplatin (CAPOX) delivered concurrent with radiation therapy (RT) in the treatment of locally advanced pancreatic adenocarcinoma and to retrospectively compare outcomes with this regimen to concurrent 5-fluorouracil or capecitabine with RT (5FU-RT) or concurrent gemcitabine-based chemotherapy with RT (GEM-RT)."5.16Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. ( Anker, C; Hazard, L; Jones, K; Mulvihill, S; Scaife, C; Shaban, A; Weis, J, 2012)
"PEFG regimen (P:cisplatin, E:epirubicin, F:5-fluorouracil, G:gemcitabine) significantly prolonged progression-free (PFS) and overall survival (OS) of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine."5.16A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen). ( Balzano, G; Belli, C; Cappio, S; Cereda, S; Doglioni, C; Fugazza, C; Ghidini, M; Longoni, S; Nicoletti, R; Passoni, P; Reni, M; Rezzonico, S; Rognone, A; Slim, N; Villa, E, 2012)
" From August 2008 to December 2010, stage II and III colorectal cancer patients receiving capecitabine-based chemotherapy enrolled in the trial voluntarily."5.16Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. ( Chen, G; Kong, LH; Lu, ZH; Pan, ZZ; Wan, DS; Wu, XJ; Zhang, RX, 2012)
"Patients with T2-T4/N+ rectal adenocarcinoma were randomly assigned to arm A-preoperative CRT with 5-fluorouracil (5-FU) continuous infusion followed by surgery-or arm B-induction oxaliplatin, folinic acid and 5-FU followed by CRT and surgery."5.16Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study. ( Delaunoit, T; Demetter, P; Demols, A; Franchimont, D; Hendlisz, A; Maréchal, R; Peeters, M; Polus, M; Van de Stadt, J; Van Houtte, P; Van Laethem, JL; Verset, G; Vos, B, 2012)
"Between October 2006 and December 2009, 36 patients with non-metastatic rectal adenocarcinoma were treated with chemoradiotherapy of irinotecan (50 mg/m(2) weekly), 5-fluorouracil (250 mg/m(2) for 5 days/week) and pelvic radiation (45 Gy/1."5.16Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma. ( El-Hadaad, HA; Roshdy, S; Wahba, HA, 2012)
"The AIO KRK-0306 trial compares the efficacy of infusional 5-fluorouracil, folinic acid, irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in first-line treatment of metastatic colorectal cancer (mCRC)."5.16FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. ( Decker, T; Fischer von Weikersthal, L; Giessen, C; Heinemann, V; Heintges, T; Jäger, E; Jung, A; Kirchner, T; Modest, DP; Neumann, J; Scheithauer, W; Stintzing, S; Stoll, C; Vehling-Kaiser, U, 2012)
"Therapy-naive patients, age 18-75 years, Karnofsky Performance Status (KPS)>60, gross total resection of stage IB-III pancreatic adenocarcinoma, stratified for center and surgical margins, were randomly assigned to receive either gemcitabine 1 g/m2 weekly on days 1, 8, and 15 (arm A) or the PEFG regimen (cisplatin and epirubicin 40 mg/m2, day 1; gemcitabine 600 mg/m2, days 1, 8; 5-fluorouracil 200 mg/m2 daily, days 1-28) (arm B)."5.16Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. ( Aprile, G; Balzano, G; Cereda, S; Di Carlo, V; Di Muzio, N; Fugazza, C; Magli, A; Milandri, C; Passoni, P; Reni, M; Rognone, A; Saletti, P; Tronconi, MC; Villa, E; Zerbi, A, 2012)
" This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients."5.16A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. ( Burtness, B; Cohen, SJ; Denlinger, CS; Dotan, E; Lee, J; Meropol, NJ; Mintzer, D; Ruth, K; Sylvester, J; Tuttle, H; Zhu, F, 2012)
"This study aimed at assessing the efficacy and safety of biweekly oxaliplatin in combination with continuous infusional 5-fluorouracil and leucovorin (modified FOLFOX regimen) in patients with advanced small bowel adenocarcinoma (SBA)."5.16A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. ( Feng, M; Liu, YW; Qiu, F; Xiang, XJ; Xiong, JP; Yan, J; Yu, F; Zhan, ZY; Zhang, L; Zhao, JG, 2012)
"Capecitabine produces an objective response rate of up to 25% in anthracycline-treated, taxane-resistant metastatic breast cancer (MBC)."5.16A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). ( Gradishar, WJ; Guo, M; Li, T; Perez, EA; Sledge, GW; Sparano, JA; Wang, M, 2012)
"To determine the safety and efficacy of neoadjuvant gemcitabine/capecitabine followed by surgery for the treatment of locally advanced pancreatic adenocarcinoma (LAPC)."5.16Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma. ( Han, DJ; Kim, JH; Kim, MH; Kim, SC; Kim, TW; Lee, JL; Lee, SK; Lee, SS; Park, DH; Park, JH; Seo, DW; Shin, SH, 2012)
"This prospective multicentre phase II trial assessed the feasibility and efficacy of perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in patients with gastro-oesophageal adenocarcinoma."5.16Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}. ( Arnold, D; Bichev, D; Breithaupt, K; Daum, S; Florschütz, A; Gahn, B; Glanemann, M; Hofheinz, RD; Kneba, M; Kretzschmar, A; Mantovani-Löffler, L; Reichardt, P; Schlattmann, P; Schumacher, G; Thuss-Patience, PC, 2012)
" Given preclinical evidence of synergy when a fluoropyrimidine is added to gemcitabine plus a taxane in a sequence-specific schedule, we conducted a phase I study to evaluate the combination of nab-paclitaxel, gemcitabine, and capecitabine administered biweekly in patients with metastatic pancreatic adenocarcinoma."5.16A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer. ( Dito, E; Jones, KA; Kantoff, E; Ko, AH; Ong, A; Tempero, MA; Truong, TG, 2012)
"To investigate the efficacy and toxicity of the docetaxel and capecitabine combination in patients with previously treated, unresectable adenocarcinoma of the pancreas."5.15Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial. ( Bozionelou, V; Georgoulias, V; Giassas, S; Kalbakis, K; Katopodis, O; Kentepozidis, N; Mavroudis, D; Polyzos, A; Rovithi, M; Vamvakas, L, 2011)
"Previously untreated patients with metastatic gastroesophageal adenocarcinoma received bevacizumab 10 mg/kg, docetaxel 40 mg/m², fluorouracil 400 mg/m², leucovorin 400 mg/m² on day 1, fluorouracil 1,000 mg/m²/d × 2 days intravenous continuous infusion beginning on day 1, and cisplatin 40 mg/m² on day 3."5.15Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. ( Capanu, M; Ilson, DH; Jhawer, M; Kelsen, DP; Lefkowitz, RA; Robinson, E; Shah, MA, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin, levoforinate, and infusional 5-fluorouracil (FOLFOX4) as a second-line therapy for Japanese patients with unresectable advanced or metastatic colorectal cancer."5.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. ( Emi, Y; Fujita, F; Hasegawa, H; Inomata, M; Kakeji, Y; Kitazono, M; Maehara, Y; Morikita, T; Ogata, Y; Oki, E; Sadanaga, N; Saeki, H; Samura, H; Shirabe, K; Shirouzu, K; Tanaka, T; Tokunaga, S; Yamamoto, M, 2011)
"The AIO KRK-0104 randomized phase II trial investigated the efficacy and safety of cetuximab combined with capecitabine and irinotecan (CAPIRI) or capecitabine and oxaliplatin (CAPOX) in the first-line treatment of metastatic colorectal cancer (mCRC)."5.15Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group. ( Abenhardt, W; Decker, T; Dietzfelbinger, H; Haberl, C; Hass, HG; Heinemann, V; Jung, A; Kappauf, H; Klein, S; Mittermüller, J; Moosmann, N; Oruzio, D; Puchtler, G; Schalhorn, A; Schulze, M; Stauch, M; Stintzing, S; Vehling-Kaiser, U; von Weikersthal, LF; Zellmann, K, 2011)
"Eighty patients with gastric adenocarcinoma after curative gastrectomy were randomized to receive a 2-h infusion of leucovorin (LV; 200mg/m(2)/d) followed by a 5-fluorouracil (5-FU) bolus (400mg/m(2)/d) and 22-h infusion (600 mg/m(2)/d) for 2 consecutive days every 2 weeks, either alone or together with oxaliplatin 85 mg/m(2) as a 2-h infusion on day 1 (FOLFOX4 regimen or LV5Fu2 regimen)."5.15Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. ( Ba, MC; Cui, SZ; Shi, HJ; Tang, YQ; Zhang, XL, 2011)
"The impact of the addition of gemcitabine to 5-fluorouracil (5-FU) chemoradiation (CRT) on 5-year overall survival (OS) in resected pancreatic adenocarcinoma are presented with updated results of a phase III trial."5.15Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. ( Abrams, R; Benson, AB; Hoffman, JP; Konski, A; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Willett, CG; Winter, KA, 2011)
"This study was designed to determine the efficacy and tolerability of a novel 2-week regimen of capecitabine, oxaliplatin (OHP), and bevacizumab in patients with chemo-naive advanced colorectal cancer."5.15A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. ( Bendell, JC; Blobe, GC; Fernando, NH; Honeycutt, W; Hurwitz, HI; Morse, MA; Pang, H; Wong, NS, 2011)
"An ancillary phase II study was conducted to study interindividual variability in cetuximab pharmacokinetics and its influence on progression-free survival (PFS) in metastatic colorectal cancer patients cotreated with irinotecan and 5-fluorouracil."5.15Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. ( Azzopardi, N; Boisdron-Celle, M; Gamelin, E; Gouilleux-Gruart, V; Lecomte, T; Morel, A; Paintaud, G; Piller, F; Ternant, D; Vignault-Desvignes, C; Watier, H, 2011)
"This multicenter phase II study was designed to determine the efficacy and tolerability of oxaliplatin in combination with levofolinate and infusion 5-fluorouracil (FOLFOX4) as first-line therapy for Japanese patients with unresectable metastatic colorectal cancer."5.15A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience. ( Baba, H; Egashira, A; Emi, Y; Fujita, F; Hasegawa, H; Hayashi, N; Higashi, H; Inomata, M; Kakeji, Y; Kohakura, F; Kohnoe, S; Maehara, Y; Niwa, K; Ogata, Y; Ohga, T; Oki, E; Samura, H; Shirabe, K; Tokunaga, S; Toyama, T; Yamamoto, M, 2011)
"Patients with clinically staged II or III esophageal adenocarcinoma received oxaliplatin 85 mg/m(2) on days 1, 15, and 29; protracted-infusion fluorouracil (PI-FU) 180 mg/m(2)/d on days 8 through 43; and external-beam radiation therapy (EBRT) 5 days a week at 1."5.15S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma. ( Benedetti, JK; Billingsley, KG; Blanke, CD; Bohanes, PO; Corless, CL; Danenberg, KD; Gold, PJ; Goldman, BH; Iqbal, S; Leichman, LP; Lenz, HJ; Thomas, CR, 2011)
"In this prospective pilot study, we assessed the efficacy and safety of the FOLFIRI regimen (irinotecan 180 mg/m², leucovorin 200 mg/m² d1 followed by bolus 400 mg/m² 5-fluorouracil (5-FU) and by a 46-h 2400 mg/m² 5-FU infusion, every 2 weeks) in patients with advanced esophageal or junctional adenocarcinoma."5.15FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study. ( Bourgeois, V; Ferte, C; Hebbar, M; Ladrat, L; Lindet, C; Mariette, C; Peugniez, C; Romano, O; Triboulet, JP, 2011)
"Oxaliplatin, irinotecan, and capecitabine given in a novel, weekly schedule does induce responses in advanced gastric and GEJ adenocarcinoma."5.14A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. ( Brell, JM; Dowlati, A; Ivy, SP; Javle, M; Kantharaj, BN; Krishnamurthi, SS; Pelley, R; Rath, L; Remick, SC; Saltzman, J; Schluchter, MD; Wollner, I, 2009)
"Oxaliplatin combined with either fluorouracil/leucovorin (OXAFAFU) or capecitabine (OXXEL) has a demonstrated activity in metastatic colorectal cancer patients."5.14Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401. ( Barberis, G; Cannone, M; Comella, P; Condemi, G; Farris, A; Filippelli, G; Maiorino, L; Massidda, B; Natale, D; Palmeri, S, 2009)
"The combination of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX-4) is still a reference regimen in advanced colorectal cancer; however, the addition of new biologic compounds represents a significant way forward."5.14An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer. ( Anthoney, A; Bauer, J; Caponigro, F; Govaerts, AS; Lacombe, D; Marréaud, S; Milano, A; Twelves, C, 2009)
"This study assessed radiotherapy combined with capecitabine and oxaliplatin in patients with primary, inextirpable colorectal adenocarcinoma."5.14Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study. ( Anderson, H; Berglund, K; Byström, P; Ekelund, M; Fernebro, E; Glimelius, B; Gunnlaugsson, A; Holm, T; Johnsson, A; Kjellén, E; Påhlman, L, 2009)
"A phase II study was performed to assess the activity of oxaliplatin plus 5-fluorouracil (5-FU) modulated by leucovorin, as second-line treatment in locally advanced or metastatic pancreas adenocarcinoma pretreated with gemcitabine-containing schedule."5.14Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer. ( Bellone, G; Bertetto, O; Chiappino, I; Ciuffreda, L; Giacobino, A; Milanesi, E; Novarino, A; Rahimi, F; Satolli, MA, 2009)
"This Simon 2-stage phase II trial was designed to document antitumor activity of capecitabine in combination with erlotinib in patients with previously untreated metastatic colorectal cancer (CRC)."5.14Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer. ( Grossbard, M; Homel, P; Kozuch, P; Malamud, S; Mirzoyev, T; Wasserman, C, 2009)
"The feasibility, safety, and efficacy of planned sequential administration of docetaxel and irinotecan with 5-fluorouracil (5-FU)/leucovorin in advanced upper gastrointestinal adenocarcinoma (UGIA) are unknown."5.14An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer. ( Berglund, A; Byström, P; Frödin, JE; Glimelius, B; Johansson, B; Letocha, H; Nygren, P; Pedersen, D, 2010)
"We examined the effect of aspirin on survival following resection for squamous cell carcinoma (SCC) of the esophagus or adenocarcinoma of the gastric cardia."5.14A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia. ( Drew, PA; Jamieson, GG; Liu, JF; Wu, TC; Zhu, GJ, 2009)
"Oxaliplatin is a promising drug for cancer therapy and the oxaliplatin/5-fluorouracil/leucovorin (FOLFOX) regimen has become the standard adjuvant treatment for colorectal cancer."5.14Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. ( Airoldi, M; Cattel, L; Drescher, A; Jaehde, U; Milla, P; Weber, G, 2009)
"This phase II trial investigated the efficacy and safety of oxaliplatin (O), 5-fluorouracil (5-FU), and folinic acid (FA) (OFF) as second-line treatment for patients with metastatic pancreatic adenocarcinoma after failure of first-line gemcitabine treatment."5.14Second-line therapy in refractory pancreatic cancer. results of a phase II study. ( Dörken, B; Hilbig, A; Oettle, H; Pelzer, U; Riess, H; Roll, L; Stieler, J, 2009)
"Gemcitabine-based chemotherapy is a commonly used first-line treatment for patients with pancreatic and biliary tract cancer."5.14Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer. ( Jeong, JS; Kim, BG; Kim, HJ; Kim, SH; Kim, YH; Kwon, HC; Lee, S; Oh, SY; Rho, MH; Rho, MS, 2009)
"Treatment-naive patients with stage III non-resectable pancreatic adenocarcinoma were treated with PEFG/PEXG (cisplatin, epirubicin, 5-fluorouracil (F)/capecitabine (X), gemcitabine) or PDXG (docetaxel substituting epirubicin) regimen for 6 months followed by radiotherapy (50-60 Gy) with concurrent F or X or G."5.14Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Rognone, A; Villa, E; Zerbi, A, 2009)
"A randomized multicenter phase III study was conducted to compare the sequential docetaxel followed by epirubicin/cyclophosphamide combination with that of FEC regimen as adjuvant chemotherapy in women with axillary node-positive early breast cancer."5.14FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG). ( Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N, 2010)
"A subgroup analysis of oxaliplatin (LOHP)+irinotecan (CPT-11)+5-fluorouracil (5FU) and leucovorin (LV) (FOLFOXIRI regimen) versus irinotecan+5FU/LV (FOLFIRI regimen) as first-line treatment of patients >65 years old with metastatic colorectal cancer is presented."5.14Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG). ( Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karampeazis, A; Kouroussis, Ch; Polyzos, A; Souglakos, J; Vamvakas, L; Ziras, N, 2010)
"Patients with locally advanced, unresectable, or metastatic adenocarcinoma of the stomach received trimetrexate 110 mg/m IV over 60 minutes day 1, followed by 5-FU 500 mg/m IV bolus and LV 200 mg/m IV over 60 minutes day 2, followed by oral LV 15 mg every 6 hours x 7 doses, all weekly for 6 weeks followed by 2 weeks of rest, continued until progression."5.14S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach. ( Abbruzzese, JL; Blanke, CD; Budd, GT; Chansky, K; Christman, KL; Hundahl, SA; Issell, BF; Macdonald, JS; Van Veldhuizen, PJ, 2010)
"This study compared chemotherapy discontinuation with maintenance therapy with leucovorin and fluorouracil after six cycles of folinic acid, fluorouracil, and oxaliplatin (FOLFOX) chemotherapy in the first-line treatment of metastatic colorectal cancer."5.14Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. ( Afchain, P; André, T; Artru, P; Bennamoun, M; Carola, E; Chibaudel, B; Colin, P; de Gramont, A; Dupuis, O; Flesch, M; Larsen, AK; Lledo, G; Louvet, C; Mabro, M; Maindrault-Goebel, F; Mineur, L; Tournigand, C, 2009)
" We enrolled patients aged 20-75 years or younger, who had histologically proven gastric adenocarcinoma, and randomly assigned them by minimisation to receive either: a continuous infusion of fluorouracil (800 mg/m(2) per day, on days 1-5) every 4 weeks (n=234); intravenous irinotecan (70 mg/m(2), on days 1 and 15) and cisplatin (80 mg/m(2), on day 1) every 4 weeks (n=236); or oral S-1 (40 mg/m(2), twice a day, on days 1-28) every 6 weeks (n=234)."5.14Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. ( Boku, N; Doi, T; Fukuda, H; Koizumi, W; Nasu, J; Ohtsu, A; Saito, H; Sawaki, A; Shirao, K; Takiuchi, H; Yamaguchi, K; Yamamoto, S, 2009)
"A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic colorectal cancer."5.14Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer. ( Adenis, A; Bennouna, J; Conroy, T; Douillard, JY; Ducreux, M; Faroux, R; Hebbar, M; Kockler, L; Llédo, G; Rebischung, C; Ychou, M, 2010)
"We undertook a phase 3, parallel, randomised trial (SWOG-8814, INT-0100) in postmenopausal women with hormone-receptor-positive, node-positive breast cancer to test two major objectives: whether the primary outcome, disease-free survival, was longer with cyclophosphamide, doxorubicin, and fluorouracil (CAF) given every 4 weeks for six cycles plus 5 years of daily tamoxifen than with tamoxifen alone; and whether disease-free survival was longer with CAF followed by tamoxifen (CAF-T) than with CAF plus concurrent tamoxifen (CAFT)."5.14Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. ( Abeloff, MD; Albain, KS; Barlow, WE; Burton, GV; Cobau, CD; Farrar, WB; Green, SJ; Henderson, IC; Ingle, JN; Ketchel, SJ; Levine, EG; Lew, D; Lichter, AS; Livingston, RB; Martino, S; Muss, HB; Osborne, CK; Pritchard, KI; Ravdin, PM; Schneider, DJ, 2009)
"The primary objective of this study was to determine the activity and safety profile of biweekly oxaliplatin combined with continuous oral capecitabine in the first-line treatment of metastatic colorectal cancer."5.14Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin. ( Bargagli, G; Bellan, C; Conca, R; Fiaschi, AI; Francini, E; Francini, G; Lazzi, S; Lorenzi, B; Martellucci, I; Pascucci, A; Petrioli, R, 2010)
"We compared 1 year of treatment with trastuzumab (given as neoadjuvant and adjuvant treatment; n=117) with no trastuzumab (118), in women with HER2-positive locally advanced or inflammatory breast cancer treated with a neoadjuvant chemotherapy regimen consisting of doxorubicin, paclitaxel, cyclophosphamide, methotrexate, and fluorouracil."5.14Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER ( Baronio, R; Barton, C; Baselga, J; Bozhok, A; Byakhow, M; Ciruelos, E; Climent, MA; Eiermann, W; Feyereislova, A; Gianni, L; Lichinitser, M; Lluch, A; Manikhas, A; Mansutti, M; Ojeda, B; Semiglazov, V; Tjulandin, S; Valagussa, P; Vazquez, F; Zambetti, M, 2010)
"Cisplatin/S-1 did not prolong OS of patients with advanced gastric or gastroesophageal adenocarcinoma compared with cisplatin/infusional fluorouracil, but it did result in a significantly improved safety profile."5.14Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. ( Ajani, JA; Bodoky, G; Falcon, S; Garin, A; Gorbunova, V; Lang, I; Lichinitser, M; Moiseyenko, V; Rodriguez, W; Vynnychenko, I, 2010)
"The Danish Breast Cancer Cooperative Group (DBCG) 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) against no adjuvant systemic therapy in high-risk breast cancer patients."5.14Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer. ( Andersen, J; Andersson, M; Ejlertsen, B; Jensen, MB; Kamby, C; Knoop, AS; Mouridsen, HT, 2010)
"Accumulating data indicate that docetaxel plus cisplatin and 5-fluorouracil has certain effect on advanced gastric or gastro-oesophageal junction adenocarcinoma."5.14A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma. ( Guo, JF; Nie, XY; Peng, J; Wang, B; Wu, F; Xing, H; Zhang, B; Zhu, GY, 2010)
"To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma."5.14[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial]. ( Liu, Y; Ma, T; Ye, ZB; Zhang, J; Zhu, ZG, 2010)
"Adding irinotecan and/or oxaliplatin to every-2-week 5-fluorouracil (5-FU)/leucovorin (LV) prolongs survival in patients with colorectal cancer (CRC) but increases neutropenia frequency."5.14A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy. ( Dreiling, L; Gollard, R; Hecht, JR; Heim, W; Malik, I; Mo, M; Patel, R; Pillai, M; Swan, F, 2010)
"This phase II trial evaluated the efficacy and safety of cetuximab combined with FOLFOX6 (leucovorin [LV] 5-fluorouracil [5-FU]/oxaliplatin) in the first-line treatment of patients with advanced or metastatic colorectal cancer."5.14A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer. ( Badarinath, S; Boccia, RV; Cosgriff, TM; Dakhil, SR; Headley, DL, 2010)
"The regimen of docetaxel and capecitabine is a well-tolerated, easily administered and active outpatient regimen for advanced gastric and GE adenocarcinoma."5.14A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas. ( Hantel, A; Hwang, J; Javle, M; Khorana, AA; Kiefer, G; Lo, SS; Rajasenan, K; Ramanathan, RK; Schmotzer, A; Shayne, M; Simon, S; Wang, H, 2010)
"Chemotherapy-naive patients with locally advanced or metastatic, histologically proven adenocarcinoma of the pancreas were treated with a 21-day regimen of gemcitabine [1000 mg/m² day (d) 1, d8], escalating doses of oxaliplatin (80-130 mg/m² d1) and capecitabine (650-800 mg/m² b."5.14Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial. ( Cescato, C; Herrmann, R; Hess, V; Jost, L; Lee, L; Lohri, A; Pestalozzi, B; Potthast, S; Pratsch, S; Stillhart, P; Widmer, L; Winterhalder, R, 2010)
"In this multicentre phase I-II trial we evaluated the feasibility and efficacy of capecitabine and oxaliplatin followed by the combination of these two drugs with radiotherapy in patients with locally advanced pancreatic or biliary tract cancer."5.14Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study. ( Anderson, H; Glimelius, B; Gunnlaugsson, A; Johnsson, A; Lind, P, 2010)
"Patients with histologically confirmed metastatic or locally advanced adenocarcinoma of the stomach or gastroesophageal junction received docetaxel 25 mg/m2 and oxaliplatin 50 mg/m2 on days 1 and 8 with capecitabine 625 mg/m2 twice daily from day 1-14, in 21-day cycles."5.14Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma. ( Aggarwal, S; Goel, G; Jauhri, M; Negi, A, 2010)
"The FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) regimen has been shown to be better than FOLFIRI (fluorouracil, folinate, and irinotecan) in a phase 3 trial in patients with metastatic colorectal cancer."5.14Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. ( Amoroso, D; Andreuccetti, M; Ciarlo, A; Cortesi, E; Cremolini, C; Cupini, S; Del Monte, F; Falcone, A; Fontanini, G; Fornaro, L; Granetto, C; Loupakis, F; Lupi, C; Masi, G; Salvatore, L; Sensi, E, 2010)
"Fluorouracil and folinic acid with either oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) are widely used as first-line or second-line chemotherapy for metastatic colorectal cancer."5.14Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study). ( Baba, H; Boku, N; Denda, T; Esaki, T; Hyodo, I; Ina, K; Komatsu, Y; Kuwano, H; Morita, S; Muro, K; Nishina, T; Sameshima, S; Satoh, T; Shimada, Y; Sugihara, K; Takiuchi, H; Tokunaga, S; Tsuji, A; Watanabe, M; Yamaguchi, K, 2010)
"Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma."5.14Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). ( Bedenne, L; Bonnetain, F; Cattan, S; Chauffert, B; Dahan, L; Gasmi, M; Hammel, P; Legoux, JL; Michel, P; Mitry, E; Phelip, JM; Raoul, JL; Rougier, P; Seitz, JF; Ychou, M, 2010)
"This study reports the long-term follow-up of patients with metastatic colorectal cancer (CRC) participating in a randomised phase II study that compared the efficacy and toxicity of the combination of irinotecan (IRI), fluorouracil (FU) with leucovorin (LV) (arm A) versus sequential chemotherapy with IRI plus FU/LV followed by oxaliplatin (OXA) plus FU/LV (arm B) as first line therapy."5.14Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer. ( Aravantinos, G; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalofonos, HP; Kosmidis, P; Linardou, H; Makatsoris, T; Papadimitriou, C; Papakostas, P; Papamichael, D; Pectasides, D; Pentheroudakis, G; Samelis, G; Skondra, M; Stavropoulos, M; Syrigos, KN; Varthalitis, I; Vourli, G; Xanthakis, I; Xiros, N, 2010)
"601 patients with advanced or metastatic colorectal cancer receiving first-, second-, or third-line irinotecan-based therapy were regularly analyzed for response and toxicity until the end of therapy."5.14Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study. ( Ababneh, Y; Fahlke, J; Galle, PR; Maintz, C; Moehler, M; Musch, R; Schimanski, CC; Schmidt, B; Siebler, J; Soeling, U; Verpoort, K, 2010)
"Cyclophosphamide/methotrexate/fluorouracil (CMF) is a proven adjuvant option for patients with early-stage breast cancer."5.14Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer. ( Atieh-Graham, D; D'Andrea, G; Drullinsky, P; Fornier, MN; Gilewski, T; Hudis, C; Lake, D; Mills, N; Norton, L; Patel, H; Patil, S; Seidman, AD; Sklarin, N; Sugarman, SM; Traina, T; Troso-Sandoval, T; Wasserheit-Lieblich, C; Yuan, J, 2010)
" This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract."5.13Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. ( Becerra, CR; Frenkel, EP; Tavana, D; Tran, HT; Verma, UN; Williams, NS, 2008)
"Consenting operable patients with stage II or III adenocarcinoma of the rectum received capecitabine (825 mg/m2 PO BID, 5 days/wk x 5 weeks) and SIB-IMRT delivering 55 Gy (2."5.13Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial. ( Ballonoff, A; Kane, M; Kavanagh, B; McCarter, M; Nash, R; Pearlman, N; Raben, D; Schefter, TE; Shah, RJ, 2008)
"The results indicate that the modified CAPOX regimen is safe and effective as salvage treatment in patients with advanced colorectal cancer who were previously treated with irinotecan-based frontline therapy."5.13Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study. ( Amarantidis, K; Ardavanis, A; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Polyzos, A; Souglakos, J; Tsousis, S; Vamvakas, L; Vardakis, N; Varthalitis, I; Ziras, N, 2008)
"We aimed to establish the superiority (or noninferiority if superiority was not achieved) in terms of time to progression (TTP) of irinotecan/5-fluorouracil (IF) over cisplatin/5-fluorouracil (CF) in chemonaive patients with adenocarcinoma of the stomach/esophagogastric junction."5.13Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. ( Barone, C; Bugat, R; Cisar, L; Dank, M; Goker, E; Peschel, C; Valvere, V; Wang, K; Wenczl, M; Yalcin, S; Zaluski, J, 2008)
"Patients with measurable, metastatic adenocarcinoma of the stomach or esophagogastric junction and no prior chemotherapy received oxaliplatin 85 mg/m(2), leucovorin 200 mg/m(2), and fluorouracil 2600 mg/m(2) as a 24-h infusion in combination with docetaxel 50 mg/m(2) (FLOT) on day 1 every 2 weeks."5.13Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Clemens, MR; Fritz, M; Hartmann, JT; Hofheinz, R; Homann, N; Jäger, E; Mahlberg, R; Pauligk, C; Probst, S; Rethwisch, V; Seipelt, G; Sievert, M; Stoehlmacher, J, 2008)
"To evaluate the antitumor activity and toxicity of 5-fluorouracil (FU)/leucovorin (LV) and capecitabine (C) given with either oxaliplatin (OX) or camptothecin (CPT-11) in the treatment of chemotherapy naive patients with metastatic colorectal cancer."5.13Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer. ( Bisegna, R; Bratta, M; Candeloro, G; Necozione, S; Rea, S; Recchia, F, 2008)
"We investigated the gefitinib, 5-fluorouracil (5-FU), leucovorin and oxaliplatin (IFOX) regimen as first-line therapy in patients with metastatic colorectal cancer."5.13A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. ( Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI, 2008)
"This study was conducted to assess the tolerability and efficacy of a ternary bimonthly irinotecan (CPT-11) - oxaliplatin (OHP) - infusional 5-fluorouracil (5-FU)/folinic acid (FA) combination in advanced colorectal cancer patients who had received prior CPT-11 and/or OHP-based chemotherapy regimen."5.13Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy. ( Checcacci, D; Del Buono, S; Filippelli, F; Mazzei, T; Mazzocchi, V; Mini, E; Nobili, S, 2008)
"XELIRI (capecitabine/irinotecan) is effective and well tolerated in metastatic colorectal cancer (mCRC)."5.13Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer. ( Asmar, L; Berger, M; Boehm, KA; Cartwright, T; Cohn, A; Hyman, W; Kuefler, P; Nugent, JE; Richards, D; Ruxer, RL; Vukelja, S, 2008)
"Patients with localized, potentially resectable pancreatic adenocarcinoma were treated with 50 Gy irradiation combined with 5-fluorouracil by continuous infusion (300 mg ."5.13Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial. ( Le Scodan, R; Mercier, C; Mornex, F; Partensky, C; Roy, P; Scoazec, JY; Valette, PJ; Ychou, M, 2008)
"Since the combination of capecitabine and irinotecan has successfully been used as a first-line treatment in metastatic colorectal cancer (MCRC), we expected promising results when given as a second-line treatment to metastatic colorectal patients who had been pretreated with 5-Fluorouracil and Oxaliplatin."5.13The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer. ( Ahn, JB; Cho, BC; Choi, HJ; Chung, HC; Jeung, HC; Rha, SY; Roh, JK; Shin, SJ, 2008)
" A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer."5.13Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer. ( El-Rayes, BF; Ferris, AM; Heilbrun, LK; Manza, SG; Philip, PA; Rusin, B; Shields, AF; Vaishampayan, U; Venkatramanamoorthy, R; Zalupski, MM, 2008)
"We investigated in patients with T2-T3 N0-3 ER, PgR <10% and HER2 negative breast cancers the activity both in terms of pathological (pCR) and objective responses of four courses of cisplatin containing chemotherapy (ECF, epirubicin, cisplatin, and fluorouracil as continuous infusion) followed by three courses of weekly paclitaxel."5.13Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. ( Balduzzi, A; Bottiglieri, L; Colleoni, M; Ghisini, R; Giovanardi, F; Goldhirsch, A; Luini, A; Orlando, L; Rocca, A; Torrisi, R; Veronesi, P; Viale, G, 2008)
"The study aimed to demonstrate the noninferiority of capecitabine to 5-fluorouracil (5-FU)/folinic acid (FA), in relation to progression-free survival (PFS) after first-line treatment of metastatic colorectal cancer and the benefit of adding celecoxib (C) to irinotecan/fluoropyrimidine regimens compared with placebo (P)."5.13Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. ( Becker, K; Bethe, U; Bleiberg, H; Bokemeyer, C; Braumann, D; De Greve, J; Debois, M; Hartmann, JT; Janssens, J; Joosens, E; Köhne, CH; Lang, I; Link, H; Müller, L; Reimer, P; Späth-Schwalbe, E; Van Cutsem, E; Van Den Brande, J; Vergauwe, P; Wilke, HJ, 2008)
"Patients with lymph node-positive breast cancer (n = 2887) were randomly assigned to one of four treatments: 1) sequential control (four cycles of doxorubicin at 75 mg/m2, followed by three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil [CMF]); 2) concurrent control (four cycles of doxorubicin at 60 mg/m2 plus cyclophosphamide at 600 mg/m2, followed by three cycles of CMF); 3) sequential docetaxel (three cycles of doxorubicin at 75 mg/m2, followed by three cycles of docetaxel at 100 mg/m2, followed by three cycles of CMF); 4) concurrent docetaxel (four cycles of doxorubicin at 50 mg/m2 plus docetaxel at 75 mg/m2, followed by three cycles of CMF)."5.13Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial. ( Andersson, M; Balil, A; Bendahmane, B; Buyse, M; Castiglione-Gertsch, M; Crown, J; Di Leo, A; Dolci, S; Francis, P; Gelber, RD; Goldhirsch, A; Gutiérrez, J; Jakesz, R; Jamin, S; Lang, I; Nordenskjöld, B; Piccart-Gebhart, M; van Hazel, G; Vorobiof, D, 2008)
"This prospective multicentre phase II study characterises the toxicity and activity of first-line capecitabine and oxaliplatin combination therapy (CAPOX) in advanced biliary system adenocarcinomas."5.13Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. ( Gregor, M; Hartmann, JT; Hass, HG; Hochhaus, A; Hofheinz, RD; Horger, MS; Klump, B; Koppenhöfer, U; Nehls, O; Oettle, H; Stieler, J; Trojan, J, 2008)
" Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without (32)P, followed by gemcitabine."5.1332P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial. ( Al-Saadi, S; Black, T; Bloomston, M; Bowers, C; Briggs, J; Carey, L; Carroll, R; Chervenick, P; Chheda, H; Cooper, J; Goldin, S; Grundy, S; Kudryk, B; Luzardo, G; Rosemurgy, A; Zervos, E; Zwiebel, B, 2008)
"The aim of this study was to evaluate the effects of a combination of folinic acid, 5-fluorouracil (5FU) and irinotecan (FOLFIRI 1) administered every 2 weeks in a population of elderly subjects with advanced colorectal cancer."5.13Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. ( Badetti, JL; Berdah, JF; Chamorey, E; Codoul, JF; François, E; Hébert, C; Lesbats, G; Mari, V; Teissier, E, 2008)
"Oxaliplatin in combination with capecitabine prolongs survival in patients with metastatic colorectal cancer (mCRC)."5.13Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil. ( Balteskard, L; Berglund, A; Fokstuen, T; Ogreid, D; Pfeiffer, P; Ploen, J; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, K; Yilmaz, M, 2008)
"Among patients with locally advanced metastatic pancreatic adenocarcinoma, gemcitabine has been shown to improve outcomes compared with fluorouracil."5.13Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. ( Abrams, RA; Benson, AB; Fromm, ML; Haddock, MG; Hoffman, JP; Konski, A; Kudrimoti, MR; Macdonald, JS; Regine, WF; Rich, TA; Safran, H; Schaefer, P; Willett, CG; Winter, KA, 2008)
"Patients with previously untreated advanced adenocarcinoma of the stomach or esophagogastric junction were randomly assigned to receive either fluorouracil 2,600 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2), and oxaliplatin 85 mg/m(2) (FLO) every 2 weeks or fluorouracil 2,000 mg/m(2) via 24-hour infusion, leucovorin 200 mg/m(2) weekly, and cisplatin 50 mg/m(2) every 2 weeks (FLP)."5.13Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. ( Al-Batran, SE; Atmaca, A; Bokemeyer, C; Derigs, HG; Grossmann, J; Hartmann, JT; Hegewisch-Becker, S; Hofheinz, R; Hollerbach, S; Homann, N; Jäger, E; Knuth, A; Pauligk, C; Probst, S; Rethwisch, V; Schmalenberg, H; Schuch, G; Seipelt, G; Stoehlmacher, J; Wilhelm, G, 2008)
"This multicentre phase II study evaluated the efficacy and safety of preoperative capecitabine plus oxaliplatin and radiotherapy (RT) in patients with locally advanced rectal cancer (T3/T4 rectal adenocarcinoma with or without nodal involvement)."5.13Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer. ( Bieri, G; Burkhard, R; Heitzmann, F; Hess, V; Koeberle, D; Neuweiler, J; Ruhstaller, T; Rust, C; Terraciano, L; Toepfer, M; von Moos, R; Winterhalder, R, 2008)
"During the period from January 1990 to January 1996 a total of 953 patients with lymph node negative primary breast cancer were randomised to oral pamidronate (n=460) 150 mg twice daily for 4 years or no adjuvant pamidronate (n=493) in order to investigate whether oral pamidronate can prevent the occurrence of bone metastases and fractures."5.13Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. ( Andersen, J; Bergh, J; Bjerregaard, B; Cold, S; Edlund, P; Ejlertsen, B; Ewertz, M; Jensen, MB; Kamby, C; Kristensen, B; Lindman, H; Mouridsen, HT; Nordenskjöld, B, 2008)
"The efficacy of oxaliplatin combined with capecitabine (XELOX) as second-line therapy in patients with advanced colorectal cancer (ACRC) resistant to irinotecan is not well established."5.12Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil. ( Baltesgard, L; Ehrsson, H; Fokstuen, T; Glimelius, B; Mortensen, JP; Pfeiffer, P; Qvortrup, C; Starkhammar, H; Sørbye, H; Tveit, KM; Wallin, I; Øgreid, D, 2006)
"Oxaliplatin and capecitabine in combination demonstrates activity in metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia."5.12Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Fitch, TR; Foster, NR; Jatoi, A; Knost, JA; Murphy, BR; Nikcevich, DA; Rowland, KM, 2006)
"Oxaliplatin and 5-fluorouracil (5-FU) act synergistically in colorectal cancer."5.12Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer. ( Cho, HK; Chung, SJ; Kang, JH; Kim, DD; Kuh, HJ; Lee, ES; Lee, JW; Lee, KS; Park, JK; Shim, CK, 2006)
"Previous studies suggest that the combination of docetaxel and capecitabine are worthy of further testing in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction."5.12Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group. ( Alberts, SR; Dakhil, SR; Flynn, PJ; Foster, N; Giordano, KF; Jatoi, A; Mailliard, JA; Nikcevich, DA; Stella, PJ; Tschetter, LK, 2006)
"To compare the efficacy and toxicity of oxaliplatin (L-OHP) in combination with irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFOXIRI) vs irinotecan and 5-FU/LV (FOLFIRI) as first-line treatment of patients with metastatic colorectal cancer (MCC)."5.12FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog ( Androulakis, N; Athanasiadis, A; Georgoulias, V; Kakolyris, S; Kalykaki, A; Kouroussis, Ch; Mavroudis, D; Polyzos, A; Samonis, G; Souglakos, J; Syrigos, K; Tsousis, S; Vamvakas, L; Ziras, N, 2006)
"To investigate the combination of erlotinib, capecitabine, and oxaliplatin in patients who were previously treated for metastatic colorectal cancer."5.12Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. ( Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Meyerhardt, JA; Michelini, A; Ryan, DP; Sheehan, S; Vincitore, M; Zhu, AX, 2006)
"We investigated 2-weekly intravenous irinotecan combined with oral capecitabine in patients with advanced gastroesophageal adenocarcinoma."5.12A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma. ( Anthoney, DA; Burge, ME; Halstead, F; Jackson, DP; Seymour, MT; Smith, D; Topham, C, 2006)
"A randomized phase II study evaluating oxaliplatin alone (OXA), infusional 5-fluorouracil alone (5-FU) and an oxaliplatin/infusional 5-FU combination (OXFU) in untreated advanced pancreatic adenocarcinoma has been conducted."5.12Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial. ( Boige, V; Bouché, O; Breau, JL; Bugat, R; Cvitkovic, E; Ducreux, M; Etienne, PL; Mitry, E; Morvan, F; Ould-Kaci, M; Rougier, P; Seitz, JF; Tigaud, JM, 2006)
"The goal was to evaluate the impact of postoperative IAC followed or not by systemic gemcitabine in patients after curative resection for pancreatic adenocarcinoma."5.12Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. ( Cantore, M; Capelli, P; Fiorentini, G; Iacono, C; Lombardi, M; Mambrini, A; Pacetti, P; Pagani, M; Pederzoli, P; Pulica, C; Serio, G; Torri, T, 2006)
"The purpose of this study was to evaluate the antitumor activity and toxicity of fixed sequences of capecitabine/oxaliplatin followed by capecitabine/irinotecan in patients with previously untreated metastatic colorectal cancer."5.12Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. ( Alvarez, JV; Arcediano, A; Cassinello, J; Castro, IG; Colmenarejo, A; Filipovich, E; López, MJ; Marcos, F; Pujol, E; Segovia, F, 2006)
"Oxaliplatin (OXA), raltitrexed (RTX), 5-fluorouracil (FU) and folinic acid (FA) have shown activity in metastatic colorectal cancer, radioenhancing effect and synergism when combined."5.12Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study. ( Avallone, A; Budillon, A; Cascini, LG; Comella, P; Delrio, P; Guida, C; Lastoria, S; Marone, P; Morrica, B; Parisi, V; Petrillo, A; Tatangelo, F, 2006)
"The aim of the study was to evaluate the safety and efficacy of the raltitrexed/5-fluorouracil/levofolinic acid combination regimen as first-line chemotherapy for elderly patients with advanced/metastatic colorectal cancer."5.12Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas. ( Bordonaro, R; Borsellino, N; Callari, A; Caruso, M; Cicero, G; Ferraù, F; Gebbia, V; Tirrito, ML; Tralongo, P; Valenza, R; Verderame, F, 2006)
"To evaluate the efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer."5.12[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer]. ( Chen, JZ; Liao, WJ; Luo, RC; Zheng, H, 2006)
"PEFG regimen (cisplatin and epirubicin 40 mg/m2 day 1, gemcitabine 600 mg/m2 days 1 and 8, 5-fluorouracil (FU) 200 mg/m2/day continuous infusion) significantly improved the outcome of patients with advanced pancreatic adenocarcinoma (PA) with respect to standard gemcitabine in a previous phase III trial."5.12Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma. ( Balzano, G; Bonetto, E; Cereda, S; Di Carlo, V; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Viganò, MG; Zerbi, A, 2007)
"A regimen of epirubicin, cisplatin, and infused fluorouracil (ECF) improves survival among patients with incurable locally advanced or metastatic gastric adenocarcinoma."5.12Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. ( Allum, WH; Chua, YJ; Cunningham, D; Falk, SJ; Iveson, TJ; Langley, RE; Lofts, FJ; Nicolson, M; Scarffe, JH; Smith, DB; Stenning, SP; Thompson, JN; Van de Velde, CJ; Verma, M; Weeden, S, 2006)
"From February, 2001 to September, 2002, the Southwest Oncology Group (SWOG) accrued 65 patients with advanced gastric adenocarcinoma to a phase II trial of weekly 5-FU, leucovorin, and the orally-administered uridine analog PN401."5.12Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study. ( Abbruzzese, JL; Cobb, PW; Doroshow, JH; Issell, BF; Macdonald, JS; McCoy, S; Patel, T; Yost, KJ, 2006)
"A phase III trial suggested that a PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen might improve the outcome compared to gemcitabine in advanced pancreatic adenocarcinoma."5.12Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial. ( Bonetto, E; Bordonaro, R; Cereda, S; Cordio, S; Di Carlo, V; Galli, L; Johnson, CD; Milandri, C; Passoni, P; Reni, M; Spreafico, A; Staudacher, C, 2006)
"In this study, the maximum tolerated dose and toxicity profile of FOLFIRI (infusional fluorouracil [5-FU]/leucovorin/irinotecan) plus gefitinib (an oral inhibitor of the epidermal growth factor receptor) were evaluated as first-line therapy in patients with metastatic colorectal cancer."5.12Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer. ( Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX, 2006)
"Blood samples from 125 patients with primary adenocarcinoma of the mid-low rectum who received 5-fluorouracil-based chemotherapy and external beam radiotherapy (median dose 48."5.12A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation. ( Agostini, M; Ambrosi, A; Friso, ML; Leon, A; Lise, M; Lisi, V; Nitti, D; Pasetto, LM; Pucciarelli, S; Terrazzino, S, 2006)
"Radiochemotherapy using gemcitabine followed by gemcitabine and capecitabine is an active regimen with manageable toxicity after resection of extrahepatic bile duct cancer but has significant toxicity in unresectable disease."5.12Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial. ( Caca, K; Hauss, J; Hildebrandt, G; Liebmann, A; Miethe, S; Mossner, J; Schoppmeyer, K; Wiedmann, M; Witzigmann, H, 2006)
"Patients with squamous cell carcinoma or adenocarcinoma of the esophagus initially received capecitabine, carboplatin, and paclitaxel with RT (1."5.12A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma. ( Bendell, JC; Blobe, GC; Czito, BG; D'Amico, TA; Fernando, NH; Harpole, DH; Honeycutt, W; Hurwitz, HI; Kelsey, CR; Morse, MA; Willett, CG; Yu, D, 2007)
"Patients with previously untreated metastatic colorectal cancer were enrolled in a phase II trial of infusional 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), bevacizumab and erlotinib."5.12Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer. ( Battu, S; Bhargava, P; Blaszkowsky, L; Earle, CC; Enzinger, P; Fuchs, CS; Lawrence, C; Mayer, RJ; Meyerhardt, JA; Ryan, DP; Stuart, K; Zhu, AX, 2007)
"To evaluate the efficacy, side-effects and quality of life in the advanced colorectal cancer patients treated by irinotecan plus fuorouracil and leucovorin with thalidomide or without thalidomide."5.12[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer]. ( Chu, DT; Li, J; Qin, SK; Song, SP; Zhang, HG; Zhang, YJ, 2007)
"After recovery from surgery for adenocarcinoma of the gastroesophageal junction or stomach, all patients were treated with capecitabine monotherapy, 1,000 mg/m2 twice daily for 2 weeks."5.12A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer. ( Bartelink, H; Boot, H; Cats, A; Crosby, TD; Dubbelman, R; Jansen, EP; Saunders, MP; Verheij, M, 2007)
"The objective was to evaluate the efficacy and toxicity of leucovorin plus 5-fluorouracil combined with oxaliplatin (modified FOLFOX regimen) every 2 weeks on previously untreated advanced colorectal cancer patients in the Chinese population."5.12A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer. ( Qiu, F; Tang, XM; Tao, QS; Xiang, XJ; Xiong, JP; Xu, J; Yu, F; Zhang, L; Zhong, LX, 2007)
"Patients with adenocarcinoma of the rectum stage >or=T3 or >or=N1 were treated with capecitabine 1330 mg/m per day in 2 divided doses days 1 to 42 and 50."5.12A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer. ( Ben-Josef, E; Desai, SP; El-Rayes, BF; Greenson, JK; Griffith, KA; Huang, EH; Knol, JA; McGinn, CJ; Philip, PA; Zalupski, MM, 2007)
"To evaluate the efficacy and toxicity of leucovorin (LV) plus 5-fluorouracil (5-FU) combined with oxaliplatin every 2 weeks on previously untreated advanced colorectal cancer patients in Chinese population."5.12A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience. ( Bao, HY; Fang, WJ; Huang, S; Shen, P; Shi, GM; Xu, N; Yu, LF; Zhang, XC, 2007)
"This phase III study compared the safety and efficacy of the following three different irinotecan-containing regimens in the first-line treatment of metastatic colorectal cancer: irinotecan plus infusional fluorouracil (FU)/leucovorin (LV) (FOLFIRI), irinotecan plus bolus FU/LV (mIFL), and irinotecan plus oral capecitabine (CapeIRI)."5.12Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. ( Barrueco, J; Fuchs, CS; Ganju, V; Jeffery, M; Marshall, J; Mitchell, E; Richards, D; Schulz, J; Soufi-Mahjoubi, R; Wang, B; Wierzbicki, R, 2007)
"Chinese patients with curatively resected Stage III colon adenocarcinoma, who received adjuvant capecitabine, were entered into a prospective database."5.12Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer. ( Chau, KK; Choy, TS; Fu, YT; Law, CC; So, PF; Wong, KH, 2007)
"To evaluate the combination of bevacizumab with infusional 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan (FOLFIRI) in patients with advanced colorectal cancer (CRC) pretreated with combination regimens including irinotecan and oxaliplatin."5.12Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. ( Kim, HJ; Kim, SH; Kwon, HC; Lee, S; Oh, SY, 2007)
"The aim of this study was to evaluate the activity and safety of 5-fluorouracil (5-FU)/leucovorin (LV) and irinotecan as first- or second-line treatment in patients with advanced gastric adenocarcinoma."5.12Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma. ( Chrysanthopoulos, C; Gerolymos, MK; Iconomou, G; Kalofonos, HP; Kontogeorgou, E; Koutras, AK; Makatsoris, T; Tsiata, E; Vourli, G, 2007)
"This multicenter, randomized trial compared overall response rate between pemetrexed plus irinotecan (ALIRI) and leucovorin-modulated 5-fluorouracil plus irinotecan (FOLFIRI) in patients with advanced colorectal cancer."5.12A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. ( Bazin, IS; Biakhov, MY; Blatter, J; Goldstein, D; Gorbounova, VA; Granov, DA; Hossain, AM; Kaiser, C; Ma, D; Underhill, C, 2007)
"Three agents with differing mechanisms of action are available for treatment of advanced colorectal cancer: fluorouracil, irinotecan, and oxaliplatin."5.11A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. ( Alberts, SR; Findlay, BP; Fuchs, CS; Goldberg, RM; Morton, RF; Pitot, HC; Ramanathan, RK; Sargent, DJ; Williamson, SK, 2004)
" In all, 18 patients with peritoneal and/or local metastases from colorectal adenocarcinoma underwent debulking surgery followed by 5-fluorouracil (5-FU) 550 mg m(-2) day(-1) i."5.11Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. ( Berglund, A; Glimelius, B; Graf, W; Hansson, J; Mahteme, H; Nygren, P; Påhlman, L, 2004)
"Patients with proven adenocarcinoma of the stomach were randomised to receive four courses of chemotherapy using 5-Fluorouracil, doxorubicin and methotrexate (FAMTX) prior to surgery or to undergo surgery alone."5.11Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. ( de Vries, JE; Hartgrink, HH; Kranenbarg, EK; Putter, H; Songun, I; Tesselaar, ME; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 2004)
"This multicentre phase I/II study was designed to determine the maximum tolerated dose of irinotecan when combined with 5-fluorouracil and folinic acid according to the Mayo Clinic schedule and to evaluate the activity of this combination as first-line therapy in patients with advanced colorectal cancer."5.11Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer. ( Boussard, B; Carmichael, J; Daniel, F; Davidson, N; Falk, S; Jacobs, C; Kuehr, T; Rapoport, BL; Ruff, P; Thaler, J, 2004)
"Combination therapy of irinotecan, folinic acid (FA) and 5-fluorouracil (5-FU) has been proven to be highly effective for the treatment of metastatic colorectal cancer."5.11Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer. ( Adami, B; Galle, PR; Heike, M; Hohl, H; Höhler, T; Klein, O; Moehler, M; Schroeder, M; Siebler, J; Steinmann, S; Teufel, A; Zanke, C, 2004)
"FOLFOX, a bimonthly combination of leucovorin, 5-fluorouracil and oxaliplatin, is active in metastatic colorectal cancer, but sometimes causes cumulative sensory neurotoxicity."5.11Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer. ( André, T; Artru, P; Carola, E; de Gramont, A; Louvet, C; Mabro, M; Maindrault-Goebel, F; Tournigand, C, 2004)
"The aim of this study was to evaluate efficacy and safety of the combination chemotherapy with irinotecan plus capecitabine in patients with advanced colorectal adenocarcinoma."5.11First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer. ( Baek, JH; Bang, SM; Cho, EK; Im, SA; Lee, JH; Oh, JH; Park, SH; Park, YS; Shin, DB, 2004)
"The effectiveness of capecitabine, an oral fluoropyrimidine carbamate, is well documented in previously untreated metastatic colorectal cancer patients (overall response rate: 25%)."5.11Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy. ( Bang, YJ; Heo, DS; Joh, YH; Kim, DW; Kim, NK; Kim, TM; Kim, TY; Kwon, JH; Lee, JJ; Oh, DY; Yu, SJ, 2004)
"To determine if the preoperative administration of tegafur and uracil (UFT) to patients with lung adenocarcinoma could induce apoptosis."5.11Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT). ( Futagawa, T; Izumi, H; Konno, H; Miyamoto, H; Morio, A; Oh, T; Yamazaki, A, 2004)
"Irinotecan (CPT-11) is an effective drug in patients with advanced colorectal cancer (CRC)."5.11Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer. ( Balcells, M; Benavides, M; Carabantes, F; Cobo, M; García-Alfonso, P; Gil-Calle, S; Graupera, J; Muñoz-Martín, A; Pérez-Manga, G; Villar, E, 2004)
"To determine the efficacy and safety of a biweekly regimen of leucovorin (LV) plus fluorouracil (FU) alone or in combination with cisplatin or irinotecan in patients with previously untreated metastatic gastric adenocarcinoma and to select the best arm for a phase III study."5.11Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie ( Arsène, D; Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Etienne, PL; Giovannini, M; Guérin-Meyer, V; Kaminsky, MC; Lledo, G; Milan, C; Mitry, E; Paitel, JF; Raoul, JL; Rougier, P; Seitz, JF, 2004)
"A combination of irinotecan 125 mg/m2, 5-fluorouracil (5-FU) 500 mg/m2, and leucovorin (LV) 20 mg/m2 (Saltz regimen; treatment on days 1, 8, 15, and 22 every 6 weeks) is widely used for the treatment of metastatic colorectal cancer."5.11Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. ( Arai, T; Goto, A; Hamaguchi, T; Hosokawa, A; Muro, K; Shimada, Y; Shirao, K; Ura, T; Yamada, Y, 2004)
" The authors evaluated 6-month survival, response, and toxicity associated with a combination of gemcitabine, 5-fluorouracil (5-FU), and leucovorin (LV) in patients with unresectable or metastatic biliary tract or gallbladder adenocarcinoma (ACA)."5.11Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial. ( Al-Khatib, H; Alberts, SR; Burgart, L; Cera, PJ; Finch, TR; Flynn, PJ; Knost, JA; Levitt, R; Mahoney, MR; Tschetter, LK; Windschitl, HE, 2005)
"The addition of oxaliplatin to fluorouracil (FU) and leucovorin (LV) improves the outcome of patients with colorectal cancer (CRC)."5.11Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. ( Benson, A; Brandt, DS; Burger, B; Garay, CA; Gupta, S; Gurtler, J; Hallman, D; Hochster, H; Kemeny, N; Kennedy, P; Polikoff, J; Shumaker, G; Wertheim, M, 2004)
"The efficacy of combination therapy with irinotecan and capecitabine has been demonstrated for the first-line treatment of metastatic colorectal cancer (MCRC)."5.11Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study. ( Gnad-Vogt, U; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Pilz, L; Saussele, S; Wein, A, 2005)
"Patients with metastatic or locally advanced gastric adenocarcinoma without prior chemotherapy were randomly assigned to receive either ECF (epirubicin 50 mg/m(2) day 1, cisplatin 60 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks) or DF (docetaxel 75 mg/m(2) day 1, and fluorouracil 200 mg/m(2) days 1 through 21, every 3 weeks)."5.11Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. ( Dörken, B; Hennesser, D; Kingreen, D; Kretzschmar, A; Micheel, S; Pink, D; Reichardt, P; Repp, M; Scholz, C; Thuss-Patience, PC, 2005)
"Gemcitabine is considered the gold standard treatment for unresectable pancreatic adenocarcinoma."5.11Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology. ( Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rabbi, C; Rosati, G; Zamagni, D, 2004)
"We conducted a phase II study to assess the efficacy and tolerability of irinotecan and cisplatin as salvage chemotherapy in patients with advanced gastric adenocarcinoma, progressing after both 5-fluorouracil (5-FU)- and taxane-containing regimen."5.11Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes. ( Bang, SM; Cho, EK; Choi, EY; Chung, M; Ki Lee, W; Lee, JH; Park, SH; Shin, DB, 2005)
"The present study was conducted to evaluate the efficacy and safety of the combination of Oxaliplatin, Leucovorin and 5-FU as second line therapy, following relapse to Gemcitabine, in patients with advanced adenocarcinoma of the pancreas."5.11Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study. ( Felekouras, E; Gouveris, P; Kopterides, P; Kopteridis, P; Kosmas, C; Loukeris, D; Papalambros, E; Sigala, F; Skopelitis, H; Tsavaris, N; Zorbala-Sypsa, A, 2005)
"Cumulative gastrointestinal toxicities and neutropenia were the DLTs of docetaxel, capecitabine, and carboplatin."5.11Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer. ( Akerman, P; Barnett, JM; Berkenblit, A; Harrington, D; Iannitti, D; Maia, C; Miner, T; Nadeem, A; Rathore, R; Roye, D; Safran, H; Stuart, K; Tsai, JY, 2005)
"To investigate the gefitinib, fluorouracil (FU), leucovorin, and oxaliplatin regimen (IFOX) in previously treated patients with metastatic colorectal cancer."5.11Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. ( Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA, 2005)
"In this phase II randomized study, untreated patients with confirmed advanced gastric or gastroesophageal adenocarcinoma received either DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5) or DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1) every 3 weeks."5.11Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma. ( Ajani, JA; Assadourian, S; Cabral Filho, S; Chao, Y; Fodor, MB; Majlis, A; Moiseyenko, VM; Tjulandin, SA; Van Cutsem, E, 2005)
"5-fluorouracil (5-FU), irinotecan, and oxaliplatin are the most active drugs in advanced colorectal cancer (CRC), and survival is improved with patient exposure to all of them."5.11FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer. ( Aparicio, J; Balcells, M; Busquier, I; Campos, JM; Fernandez-Martos, C; Llorca, C; Maestu, I; Perez-Enguix, D; Vincent, JM, 2005)
"In this study we evaluated the activity and toxicity of a combination of 5-fluorouracil continuous infusion and vinorelbine as second or third line chemotherapy in metastatic breast cancer (MBC)."5.11[Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer]. ( Brito Villanueva, WO; Cárdenas Estrada, E; González Guerrero, JF; González Vela, JL; Hernández Barajas, D; Sánchez Guillén, JM; Treviño Aguirre, SA, 2005)
"The aim of this study was to compare the longitudinal quality of life (QoL) between LV5FU2-irinotecan and LV5FU2 alone or LV5FU2-cisplatin in a randomized Phase II trial in patients with metastatic gastric adenocarcinoma."5.11Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology. ( Arveux, P; Bedenne, L; Bonnetain, F; Bouché, O; Conroy, T; Etienne, PL; Giovannini, M; Girault, C; Mitry, E; Raoul, JL; Rougier, P; Seitz, JF, 2005)
"The purpose of this study was to evaluate the dose-limiting toxicity (DLT) and maximum tolerated dose of capecitabine when used in combination with epirubicin and cisplatin (ECC) in patients with oesophageal or gastric adenocarcinoma."5.10A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma. ( Blackie, R; Evans, TR; Fullarton, GM; McDonald, AC; McInnes, A; Morrison, R; Paul, J; Pentheroudakis, G; Raby, N; Soukop, M, 2002)
"We studied the activity of combined oxaliplatin and fluorouracil-leucovorin in 16 consecutive patients with advanced biliary tract adenocarcinomas."5.10Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial. ( Arkenau, HT; Gregor, M; Greschniok, A; Hass, HG; Klump, B; Nehls, O; Porschen, R, 2002)
"To evaluate the feasibility and a possible activity range of combination irinotecan (CPT-11), oxaliplatin, and 5-FU in advanced colorectal cancer (ACC)."5.10Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. ( Aramendía, JM; Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; González-Cao, M; Martín-Algarra, S; Martínez-Monge, R; Rodríguez, J; Salgado, JE, 2002)
"In the present study, we evaluated the efficacy and safety of the weekly combination of etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) when administered as second-line chemotherapy in patients with relapsed/refractory advanced colorectal cancer (ACC), previously treated with weekly LV+5-FU."5.10Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer. ( Gennatas, K; Kosmas, C; Kouraklis, G; Margaris, E; Papastratis, G; Rokana, S; Skopelitis, E; Tsavaris, N; Vadiaka, M; Xila, V; Zografos, G, 2002)
"Irinotecan (CPT-11) has been shown to prolong survival and improve quality of life in comparison to best supportive care in colorectal cancer patients with pretreatment of bolus 5-fluorouracil (5-FU)."5.10Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study. ( Emig, M; Hartung, G; Hehlmann, R; Hochhaus, A; Hofheinz, R; Pilz, L; Queisser, W; Samel, S; Willeke, F, 2002)
"The purpose of this study was to evaluate the efficacy and tolerance of a combination of irinotecan, oxaliplatin, and 5-fluorouracil (5-FU)/leucovorin in advanced colorectal cancer (ACC)."5.10Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. ( Brugarolas, A; Calvo, E; Cortés, J; de Irala, J; Fernández-Hidalgo, O; García-Foncillas, J; Martín-Algarra, S; Martínez-Monge, R; Rebollo, J; Rodríguez, J, 2002)
"This multicentre phase II study evaluated the efficacy and safety of irinotecan combined with the Nordic schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line therapy in patients with advanced colorectal cancer."5.10Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer. ( Boussard, B; Frödin, JE; Glimelius, B; Kjaer, M; Linné, T; Oulid-Aïssa, D; Pfeiffer, P; Pyrhönen, S; Ristamäki, R; Skovsgaard, T; Tveit, KM, 2002)
"Patients with previously untreated metastatic or unresectable measurable gastric adenocarcinoma received oral capecitabine 1250 mg/m(2) twice daily, days 1-14, and i."5.10Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer. ( Ahn, JH; Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JS; Oh, ST; Yook, JH, 2002)
" We did a randomised trial to compare an intrahepatic arterial (IHA) fluorouracil and folinic acid regimen with the standard intravenous de Gramont fluorouracil and folinic acid regimen for patients with adenocarcinoma of the colon or rectum, with metastases confined to the liver."5.10Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial. ( Buckels, J; Cain, D; Kerr, DJ; Ledermann, J; Mayer, D; McArdle, CS; Schlag, PM; Sherlock, DJ; Stephens, RJ; Taylor, I, 2003)
"The aim of this study was to determine whether the efficacy of the combination of 5-fluorouracil (5-FU), leucovorin (LV) and radiation therapy (RT) could be improved by the addition of interferon-alpha2b (IFN-alpha) in patients who have had a 'curative' resection, for rectal adenocarcinoma (Dukes' B2/C; T3 N0, T4 N0, N1-3)."5.10Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b. ( Andreadis, H; Androulakis, G; Batalis, T; Besbeas, S; Dardoufas, C; Gennatas, C; Hatzistylianos, G; Katsos, J; Komporozos, V; Legakis, N; Mallas, H; Mouratidou, D; Papadimitriou, J; Peros, G; Philippakis, M; Photopoulos, A; Pisiotis, C; Polymeneas, G; Pouli, A; Retalis, G; Samanidis, L; Smyrniotis, V; Stamatiadis, A; Tsavaris, N; Vasiliou, J; Voros, D, 2003)
"This phase II multicenter trial evaluated the efficacy and toxicity of weekly paclitaxel, 5-fluorouracil, and leucovorin administered as first-line therapy for metastatic breast cancer."5.10A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer. ( Asmar, L; Canfield, VA; Ellis, PG; Ferri, WA; Hynes, HE; Loesch, DM; Parker, GA; Robert, NJ, 2003)
"Out of various high-dose 5-fluorouracil (5-FU) regimens given with or without folinic acid (FA), the optimal 5-FU schedule has still to be defined as treatment for metastatic colorectal cancer (CRC)."5.10Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study. ( Boehme, M; Galle, PR; Gutzler, F; Moehler, M; Raeth, U; Rudi, J; Steinmann, S; Stremmel, W, 2003)
"In this phase II trial, we used the combination of gemcitabine and 5-fluorouracil (5-FU) to treat 26 patients: 17 (65%) with advanced pancreatic adenocarcinoma and 9 (35%) with advanced biliary tract adenocarcinoma (10 locally advanced and 16 metastatic); 15 (57."5.10Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer. ( Aragão, BC; Guimarães, RC; Moore, FC; Murad, AM; Padua, CA; Rodrigues, VH; Scalabrini-Neto, AO, 2003)
"In breast cancer, chemotherapy regimens that include infusional 5-fluorouracil (5-FU) lead to high response rates, but require central venous access and pumps."5.10An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer. ( Atalay, G; Biganzoli, L; Bonnefoi, H; Cufer, T; Mauriac, L; Piccart, M; Schaefer, P, 2003)
"The purpose of the study was to determine the efficacy and safety of docetaxel plus continuous infusion of 5-fluorouracil (5-FU) in patients with metastatic breast cancer previously treated with anthracyclines."5.10Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer. ( Besson, D; Bougnoux, P; Bourgeois, H; Delozier, T; Gamelin, E; Lortholary, A; Lotz, V; Monnier, A; Riffaud, JCh; Tubiana-Mathieu, N, 2003)
"We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous infusion (PVI 5-FU) against the standard bolus regimen of 5-FU and folinic acid (5-FU/FA) given for 6 months as adjuvant treatment in colorectal cancer."5.10Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. ( Chau, I; Cunningham, D; Hickish, T; Hill, M; Iveson, T; Jodrell, D; Lofts, F; Norman, AR; Oates, J; Ross, PJ; Saini, A; Tait, D, 2003)
"To determine the activity of biweekly oxaliplatin, combined with weekly bolus fluorouracil (FU) and low-dose leucovorin (LV) chemotherapy (bFOL), as first-line therapy for patients with metastatic colorectal cancer."5.10Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer. ( Chachoua, A; Escalon, J; Hochster, H; Muggia, F; Speyer, J; Zeleniuch-Jacquotte, A, 2003)
"The aim of this phase II study was to investigate the tolerance and efficacy of a second-line irinotecan/mitomycin C combination in patients with advanced gastric or colorectal cancer, pretreated with 5-fluorouracil."5.10Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer. ( Bamias, A; Papamichael, D; Pavlidis, N; Syrigos, K, 2003)
"The purpose of this study was to determine the efficacy and toxicity of oxaliplatin in combination with weekly bolus 5-fluorouracil (5-FU) and leucovorin (LV) in patients with 5-FU-pretreated advanced colorectal cancer."5.10Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study. ( Changchien, CR; Chen, JS; Chiang, JM; Hsieh, PS; Tang, R; Yang, TS; Yeh, CY, 2003)
"This study was designed to evaluate the safety and tolerability of oxaliplatin combined with weekly boluses of 5-fluorouracil (5-FU) and low doses of leucovorin (LV) and to determine objective response, progression-free survival, and overall survival of patients with previously untreated advanced colorectal cancer."5.10Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer. ( Arcediano, A; Cassinello, J; Colmenarejo, A; Escudero, P; García, I; González del Val, R; Guillem, V; Marcos, F; Marfà, X; Oruezábal, MJ; Pérez-Carrión, R; Pujol, E; Salud, A; Valero, J, 2003)
"To evaluate the efficacy and safety of irinotecan as second-line treatment in patients with advanced colorectal cancer (ACC) failing or relapsing after 5-fluorouracil (5-FU) plus leucovorin (LV) standard chemotherapy."5.10Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study. ( Dimitrakopoulos, A; Giannakakis, T; Gouveris, P; Karadima, D; Kosmas, C; Margaris, H; Papalambros, E; Papastratis, G; Polyzos, A; Rokana, S; Tsavaris, N; Tsipras, H; Vadiaka, M; Ziras, N, 2003)
"Phase II studies have suggested an improved response rate and acceptable toxicity profile associated with gemcitabine combinations compared to gemcitabine alone for treatment of metastatic adenocarcinoma of the pancreas."5.10Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas. ( Araneo, M; Bruckner, HW; DeGregorio, P; Firoozi, K; Frager, D; Grossbard, ML; Homel, P; Jindal, K; Kozuch, P; Marino, J; Mortazabi, F, 2003)
"To evaluate the toxicity and efficacy of a modified deGramont regimen of 5-fluorouracil (5-FU), leucovorin, and oxaliplatin in patients with advanced colorectal cancer who have progressed on at least one but not more than two prior chemotherapy regimens."5.10A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer. ( Catarius, KJ; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Kulke, MH; Mayer, RJ; Ryan, DP; Stuart, K; Winkelmann, J, 2003)
" A total of 26 patients with adenocarcinoma of the stomach were treated with 3D-conformal radiation therapy to a dose of 45 Gy in 25 fractions with concurrent continuous infusional 5-fluorouracil (5-FU)."5.10Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation. ( Foo, K; Leong, T; Lim Joon, D; Michael, M; Ngan, S; Thomas, R; Thompson, A; Weih, L; Zalcberg, J, 2003)
" once every 3 weeks was assessed in 60 patients with advanced colorectal cancer (CRC) showing failure to 5-fluorouracil (5-FU) treatment."5.10Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study. ( Abad, A; Antón, A; Aranda, E; Balcells, M; Carrato, A; Cervantes, A; Díaz-Rubio, E; Fenández-Martos, C; Gallén, M; Huarte, L; Marcuello, E; Massutti, B; Sastre, J, 2003)
"This study combined oxaliplatin with the Nordic bolus schedule of 5-fluorouracil (5-FU) and folinic acid (FA) as first-line treatment in metastatic colorectal cancer."5.10Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer. ( Dahl, O; Sørbye, H, 2003)
"Gemcitabine is considered the golden standard treatment for unresectable pancreatic adenocarcinoma."5.10Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer. ( Aitini, E; Cantore, M; Caudana, R; Ceravolo, C; Comella, G; Del Freo, A; Fiorentini, G; Luppi, G; Mambrini, A; Marangolo, M; Miserocchi, L; Piazza, E; Rosati, G; Zamagni, D, 2003)
") 5-fluorouracil (5-FU)/LV chemotherapy in metastatic colorectal cancer and to compare 5-FU exposure with these two treatment options."5.10Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer. ( Borner, MM; Caponigro, F; Comella, G; de Boer, RF; de Wit, R; Fumoleau, P; Greim, G; Martin, C; Peters, GJ; Schoffski, P; Sulkes, A; van der Born, K; Wanders, J, 2002)
"Hand-foot syndrome (HFS) has been previously reported as a side effect in 45-56% of patients treated with capecitabine."5.10Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. ( Abushullaih, S; Hoff, PM; Munsell, M; Saad, ED, 2002)
"The present study aimed at evaluating the efficacy of Raltitrexed, a specific thymidilate synthase inhibitor, in patients with advanced colorectal cancer (ACC) in relapse (>8 weeks) after a prior response or disease stabilization to first-line chemotherapy combination with lrinotecan+5-Fluorouracil (5-FU)+Leucovorin (LV)."5.10Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy. ( Kosmas, C; Koufos, C; Tsavaris, N; Vadiaka, M, 2002)
"To determine the efficacy and tolerability of combining oxaliplatin with capecitabine in the treatment of advanced nonpretreated and pretreated colorectal cancer."5.10Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer. ( Borner, MM; Brauchli, P; Castiglione-Gertsch, M; Dietrich, D; Goldhirsch, A; Hanselmann, S; Herrmann, R; Honegger, H; Morant, R; Müller, S; Pestalozzi, BC; Roth, AD; Saletti, P; Stupp, R; Wernli, M, 2002)
"The aim of this study was to evaluate the toxicity and efficacy of combination chemotherapy with weekly 24-h continuous infusion of 5-fluorouracil (5-FU)/folinic acid, weekly paclitaxel and 3-weekly cisplatin in patients with unresectable, locally advanced or metastatic gastric adenocarcinoma."5.10Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Haag, C; Hartmann, JT; Hempel, V; Honecker, F; Kanz, L; Kollmannsberger, C; Quietzsch, D; Schroeder, M; Spott, C, 2002)
"Thirty-two consecutive patients with a palpable adenocarcinoma of the rectum received preoperative RT (45 Gy in 25 fractions over 5 weeks) plus continuous chemotherapy with doxifluridine and leucovorin or 5-fluorouracil by continuous intravenous infusion during RT."5.10Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response. ( Andreola, S; Baratti, D; Bozzetti, F; Mariani, L; Spinelli, P; Stani, SC; Valvo, F, 2002)
"To evaluate the activity and safety of an alternating schedule of irinotecan (CPT-11) with high-dose 5-fluorouracil (5-FU) given as a weekly 48-hour infusion in combination with leucovorin (LV) in the first-line treatment of metastatic colorectal cancer (MCRC) patients."5.10A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer. ( Manzione, L; Reggiardo, G; Rosati, G; Rossi, A, 2002)
" Ten patients with unresectable adenocarcinoma of the pancreas received preoperative chemotherapy [5-fluorouracil (5-FU)], bypass surgery and postoperative chemotherapy (5-FU, doxorubicin and cisplatin) plus sandostatin and radiotherapy (45 Gy, 25 fractions, 5 days a week)."5.10Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma. ( Golematis, BC; Kouloulias, VE; Kouvaris, JR; Mystakidou, K; Nikita, KS; Uzunoglu, NK; Vlahos, LJ, 2002)
" cerevisiae fusion protein) on the incidence, duration, and complications of neutropenia and thrombocytopenia after moderate-dose fluorouracil 600 mg/m(2), doxorubicin 60 mg/m(2), and cyclophosphamide 750 mg/m(2) (FAC) chemotherapy in patients with stage II and III breast cancer."5.09Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer. ( Agura, E; Dimitrov, N; Duncan, L; Garrison, L; Hyman, W; Jones, SE; Khandelwal, P; Kirby, R; Lange, M; McIntyre, K; Mennel, R; Orr, D; Regan, D; Roque, T; Schuster, M, 1999)
"To determine the maximum tolerable doses (MTDs) of irinotecan (CPT-11) and 5-fluorouracil (5-FU) plus levofolinic acid (LFA) administered together every two weeks, to define the toxicity profile of this regimen, and to have a preliminary evidence of its activity in the first-line management of advanced colorectal cancer patients."5.09Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. ( Avallone, A; Casaretti, R; Catalano, G; Comella, G; Comella, P; Comis, S; De Vita, F; Faranda, A; Gravina, A; Orditura, M; Petrillo, A, 1999)
"This multicenter phase II study was designed to assess the efficacy of the alternating schedule of tomudex with methotrexate (MTX)/5-fluorouracil (5-FU)/leucovorin (LV) in first-line chemotherapy for metastatic colorectal cancer."5.09A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer. ( Agostinelli, R; Baldelli, AM; Barni, S; Cascinu, S; Catalano, G; Catalano, V; Frontini, L; Gasparini, G; Giuliodori, L; Labianca, R; Martignoni, G; Mattioli, R; Silva, RR, 1999)
"To evaluate the objective tumor response rates and toxicities of leucovorin (LV) plus fluorouracil (5-FU) cancer regimen combined with oxaliplatin (85 mg/m(2)) every 2 weeks on metastatic colorectal cancer patients with documented proof of progression while on bimonthly LV and 5-FU alone."5.09Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. ( André, T; Beerblock, K; Bensmaine, MA; Bouché, O; Carola, E; de Gramont, A; Desseigne, F; Dupont-André, G; François, E; Louvet, C; Lucas, V; Merrouche, Y; Morvan, F, 1999)
"This prospective phase II clinical trial was performed to explore the activity and efficacy of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric adenocarcinoma."5.09Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen. ( Aragao, BC; Cabral, LO; Guimaraes, RC; Murad, AM; Petroianu, A; Scalabrini-Neto, AO, 1999)
"The present study was conducted to investigate the efficacy and toxicity of a cisplatin and 5-fluorouracil (5-FU) combination in previously treated advanced breast cancer."5.09Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185). ( Abeloff, MD; Hochster, H; Kucuk, O; Pandya, KJ; Skeel, RT, 1999)
"We randomly assigned 156 patients at the time of resection of hepatic metastases from colorectal cancer to receive six cycles of hepatic arterial infusion with floxuridine and dexamethasone plus intravenous fluorouracil, with or without leucovorin, or six weeks of similar systemic therapy alone."5.09Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. ( Bertino, JR; Blumgart, LH; Brennan, MF; Cohen, AM; Conti, JA; Fong, Y; Huang, Y; Kemeny, N; Shi, W; Stockman, J; Sullivan, D; Turnbull, AD, 1999)
"Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil."5.09Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. ( Alakl, M; Awad, L; Carmichael, J; Cunningham, D; Douillard, JY; Gruia, G; Iveson, T; James, RD; Jandik, P; Karasek, P; Navarro, M; Roth, AD; Rougier, P, 2000)
"It has been shown that irinotecan is superior to infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer after 5-FU failure."5.09Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer. ( Bellanger, A; Durand-Zaleski, I; Juhel, H; Levy-Piedbois, C; Piedbois, P; Schmitt, C, 2000)
"Oxaliplatin is a novel platinum derivative, which, combined with 5-fluorouracil (5-FU), and folinic acid (FA), demonstrates synergistic activity in metastatic colorectal cancer (MCC)."5.09Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. ( Fountzilas, G; Janinis, J; Papagianopoulos, P; Papakostas, P; Samelis, G; Skarlos, D, 2000)
"The purpose of this study was to evaluate the efficacy, toxicity, and safety of outpatient chemotherapy with weekly high-dose 5-fluorouracil (HD-5FU) in previously treated patients (pts) with metastatic colorectal cancer."5.09Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer. ( Cohen, Y; Lavrenkov, K; Mermershtain, W, 2000)
"Biweekly intravenous infusions of low-dose cisplatin (CDDP) and 5-fluorouracil (5-FU) were evaluated in 80 patients with advanced or recurrent gastric, colorectal, pancreatic or gallbladder adenocarcinoma."5.09[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma]. ( Kamata, T; Kanno, M; Koyasaki, N; Morita, A; Nakamoto, A; Onishi, I; Takeda, T, 2000)
" Those with locally invasive, unresectable, regional pancreatic adenocarcinoma initially were treated with simultaneous split-course RT plus 5-fluorouracil, streptozotocin, and cisplatin (RT-FSP) followed by selective surgery (Group 1)."5.09Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. ( Bruckner, H; Cooperman, A; Kiefer, L; Paradiso, J; Snady, H, 2000)
"In a previous study of treatment for advanced colorectal cancer, the LV5FU2 regimen, comprising leucovorin (LV) plus bolus and infusional fluorouracil (5FU) every 2 weeks, was superior to the standard North Central Cancer Treatment Group/Mayo Clinic 5-day bolus 5FU/LV regimen."5.09Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. ( Bonetti, A; Boni, C; Cassidy, J; Cervantes, A; Cortes-Funes, H; de Braud, F; de Gramont, A; Figer, A; Freyer, G; Hendler, D; Hmissi, A; Homerin, M; Le Bail, N; Louvet, C; Morvan, F; Papamichael, D; Seymour, M; Wilson, C, 2000)
"To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel, cisplatin and 24 h continuous infusion of 5-FU/folinic acid in patients (pts) with unresectable, locally advanced or metastatic gastric adenocarcinoma."5.09A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer. ( Baronius, W; Bokemeyer, C; Clemens, M; Haag, C; Hartmann, JT; Hempel, V; Kanz, L; Kollmannsberger, C; Lingenfelser, T; Quietzsch, D; Schroeder, M, 2000)
"The aim of this study was to investigate the clinical pharmacokinetics of 5-fluorouracil (5-FU) and its major metabolite 5-fluoro-5,6-dihydrouracil (5-FDHU) in 20 colorectal cancer patients given two dose levels of 5-FU, 250 and 370 mg/m2, administered by i."5.09Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients. ( Allegrini, G; Barsanti, G; Battistoni, M; Bocci, G; Conte, PF; Danesi, R; Del Tacca, M; Di Paolo, AD; Falcone, A; Innocenti, F; Melosi, A, 2000)
"Patients with stage IIIA or early stage IV gastric adenocarcinoma received neoadjuvant 5-fluorouracil, Leucovorin, Adriamycin, and Cisplatin and underwent gastrectomy or esophagogastrectomy with intraoperative radiotherapy (IORT; 1000 cGY) to the gastric bed and postoperative radiation therapy."5.09Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma. ( Fisher, SA; Harbison, SP; Henry, DH; Stiller, GD; Weese, JL, 2000)
"Studies of bimonthly 48-hour regimens of high-dose leucovorin (LV) (FOLinic acid), 5-fluorouracil (5-FU) by continuous infusion combined with OXaliplatin (FOLFOX) in pretreated patients with metastatic colorectal cancer suggest that oxaliplatin dose intensity is an important prognostic factor for response rate and progression-free survival (PFS)."5.09Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). ( André, T; Artru, P; Carola, E; de Gramont, A; Gilles, V; Izrael, V; Krulik, M; Lotz, JP; Louvet, C; Mabro, M; Maindrault-Goebel, F; Molitor, JL; Tournigand, C, 2000)
"The purpose of this prospective study was to assess the efficacy, clinical benefit and safety of irinotecan (CPT-11) in patients with 5-fluorouracil-resistant metastatic colorectal cancer (CRC)."5.09Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy. ( Jirajarus, M; Ratanatharathorn, V; Sirachainan, E; Sirilerttrakul, S, 2000)
"Chemotherapy-naïve patients with measurable advanced adenocarcinoma of the pancreas were treated with gemcitabine 1,000 mg/m(2) intravenously weekly x 3 followed by 1 week of rest every 4 weeks and 200 mg/m(2)/day CI fluorouracil until disease progression or limiting toxicity."5.09Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. ( Aebi, S; Borner, MM; Büchler, MW; Friess, H; Ludwig, CU; Maurer, CA; Pampallona, S; Rauch, DP, 2001)
" In this study 137 patients with gastric adenocarcinoma, all with positive nodes, were randomized after curative resection so that 69 received epidoxorubicin (EPI), leucovorin (LV) and 5-fluorouracil (5-FU) on days 1-3 every 3 weeks for 7 months, whereas the remaining 68 did not."5.09Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up. ( Andreoli, F; Boffi, B; Cini, G; Francesconi, D; Mazzanti, R; Medi, F; Mercatelli, A; Moretti, R; Neri, B; Romano, S; Siliani, L; Tarquini, R, 2001)
" This study was conducted to prospectively examine the tolerance and early efficacy of adjuvant gemcitabine following radiotherapy with concurrent 5-fluorouracil (5-FU) for nonmetastatic pancreatic adenocarcinoma."5.09Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas. ( Kachnic, LA; Lauve, AD; Manning, MA; Neifeld, JP; Shaw, JE, 2001)
"A multicenter phase II trial was initiated in order to evaluate the weekly, high-dose 24-hour infusion of 5-fluorouracil (5-FU) plus folinic acid (FA) in patients with unresectable colorectal cancer hepatic metastases."5.09Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas. ( Gassel, HJ; Heinrich, S; Junginger, T; Köhne, CH; Lorenz, M; Mattes, E; Mueller, HH; Saeger, HD; Schramm, H; Staib-Sebler, E; Vetter, G, 2001)
"We have reported a 33% partial response rate with acceptable toxicity using weekly 24-h infusion of high-dose 5-fluorouracil (5-FU) and leucovorin (LV) in patients with far advanced biliary tract cancers (BTC)."5.09Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas. ( Chen, JS; Jan, YY; Liau, CT; Lin, YC, 2001)
"To evaluate the efficacy and toxicity of a cisplatin, epirubicin, gemcitabine, and fluorouracil (PEF-G) schedule on stage IV pancreatic adenocarcinoma."5.09Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma. ( Balzano, G; Di Carlo, V; Galli, L; Nicoletti, R; Panucci, MG; Passoni, P; Reni, M; Villa, E; Zerbi, A, 2001)
"The goal of this work was to evaluate response rate, toxicity, and survival in treatment with intraarterial 5-fluorouracil (5-FU) and cisplatin in a neoadjuvant setting; this combination was administered to patients with locally advanced cervical adenocarcinoma."5.09Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma. ( Aoki, Y; Sasaki, M; Sato, T; Tanaka, K; Tsuneki, I; Watanabe, M, 2001)
" Thirty patients with poorly-differentiated carcinoma or poorly-differentiated adenocarcinoma (group A) received a combination of cisplatin and etoposide."5.09Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study. ( Borel, C; Ducreux, M; Fizazi, K; Le Chevalier, T; Ruffié, P; Saghatchian, M; Théodore, C, 2001)
"To assess the toxicity and the efficacy of preoperative radiotherapy with continuous infusion 5-fluorouracil (5-FU) for locally advanced adenocarcinoma of the rectum."5.09Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group. ( Bell, A; Burmeister, BH; Fisher, R; Goldstein, D; Joseph, D; Kneebone, A; MacKay, JR; Ngan, SY; Rischin, D; Schache, DJ, 2001)
"Gemcitabine alone or 5-fluorouracil (5-FU) according to several schedules are used for palliation of metastatic and locally advanced (LA) pancreatic adenocarcinoma."5.09Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). ( André, T; Balosso, J; Cattan, S; Colin, P; de Gramont, A; Flesch, M; Fonck, M; Hammel, P; Landi, B; Louvet, C; Ruszniewski, P; Selle, F, 2001)
"Forty-four patients with carcinoma of the esophagus or gastroesophageal junction were prospectively entered into a phase II trial of preoperative 5-fluorouracil, cisplatin, and interferon alfa with concurrent external beam radiotherapy before esophagectomy."5.09Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma. ( Gooding, WE; Lew, JI; Posner, MC; Ribeiro, U; Safatle-Ribeiro, AV, 2001)
"Thirty-three metastatic colorectal cancer patients were randomized to receive a 60-minute infusion of irinotecan before or after a 48-hour infusion of 5-FU modulated by LV."5.09Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. ( Allegrini, G; Comis, S; Conte, P; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Lencioni, M; Masi, G; Pfanner, E, 2001)
" After radical resection of adenocarcinoma of the colon (pT1-4 pN>0 M0 and pT3-4 pN0 M0) and perioperative chemotherapy, patients were randomised to three treatment arms: observation only (A), 5-fluorouracil (5-FU) 450 mg/m(2) plus levamisol (B), or 5-FU 600 mg/m(2) (C)."5.09Response shift in the perception of health for utility evaluation. an explorative investigation. ( Bernhard, J; Hürny, C; Lowy, A; Maibach, R, 2001)
"To compare the efficacy and safety of orally administered capecitabine (Xeloda; Roche Laboratories, Inc, Nutley, NJ), a novel fluoropyrimidine carbamate designed to mimic continuous fluorouracil (5-FU) infusion but with preferential activation at the tumor site, with that of intravenous (IV) 5-FU plus leucovorin (5-FU/LV) as first-line treatment for metastatic colorectal cancer."5.09Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. ( Allman, D; Bajetta, E; Boyer, M; Bugat, R; Cassidy, J; Findlay, M; Frings, S; Harper, P; Jahn, M; McKendrick, J; Osterwalder, B; Perez-Manga, G; Rosso, R; Rougier, P; Schmiegel, WH; Seitz, JF; Thompson, P; Twelves, C; Van Cutsem, E; Vieitez, JM; Weitzel, C, 2001)
" 5-fluorouracil (5-FU), and leucovorin (LCV) was conducted in patients with advanced gastric adenocarcinomas."5.09A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma. ( Benson, AB; Berlin, J; Blanke, CD; Haller, DG; Hsieh, YC; Miller, LL; Mori, M; Rothenberg, ML, 2001)
"Capecitabine and oxaliplatin are both active anticancer agents in the treatment of patients with advanced colorectal cancer (ACRC)."5.09Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study. ( Carpi, A; Cherubini, R; Cognetti, F; Di Costanzo, E; Gasperoni, S; Moscetti, L; Paoloni, FP; Sdrobolini, A; Zeuli, M, 2001)
"To reduce the Hickman line-associated morbidity of continuous infusion 5-fluorouracil combined with epirubicin and cisplatin (ECF) and to investigate the need for infusional regimens, we conducted a retrospective study in patients with advanced gastro-oesophageal adenocarcinoma."5.09Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma. ( Dunlop, DJ; Eatock, MM; Lim, KC; Pentheroudakis, G; Soukop, M, 2001)
"From August 1995 through March 1996, seven patients with unresectable adenocarcinoma of the pancreas underwent CS, with preoperative chemotherapy (5-fluorouracil [FU] for 96 h), plus 45-Gy external beam postoperative irradiation with a 6-MeV linear accelerator (1."5.09Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy. ( Golematis, VC; Kouloulias, VE; Kouvaris, JR; Nikita, KS; Papavasiliou, CG; Uzunoglu, NK; Vlahos, LJ, 2001)
"To compare the efficacy and safety of recombinant human granulocyte colony-stimulating factor (rHuG-CSF) versus its inert vehicle in patients with unilateral nonmetastatic inflammatory breast cancer treated with fluorouracil, epirubicin, and cyclophosphamide high-dose (FEC-HD) neoadjuvant chemotherapy."5.08Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. ( Chevallier, B; Chollet, P; Fargeot, P; Fizames, C; Fumoleau, P; Genot, JY; Kerbrat, P; Merrouche, Y; Olivier, JP; Roche, H, 1995)
"Forty-nine patients with localized unresectable adenocarcinoma of the pancreas were treated in a multimodality program of initial IORT and perioperative chemotherapy (fluorouracil [5-FU]/leucovorin) followed by combined external-beam radiation (40 to 55 Gy) and continued chemotherapy."5.08Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. ( Barbot, D; Biermann, W; Cantor, R; Mohiuddin, M; Regine, WF; Rosato, F; Stevens, J, 1995)
"These studies demonstrate that the concurrent addition of modest dose cisplatin and infusional dose fluorouracil to radiation in the definitive, preoperative, and palliative settings contribute to high rates of durable dysphagia-free survival, with overall survival comparable to (and possibly better than) the chemoradiation arm of the recently reported Intergroup Study, but at the cost of less morbidity."5.08Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study. ( Ackland, SP; Burmeister, BH; Denham, JW; Devitt, P; Gill, PG; Hamilton, CS; Jamieson, GG; Lamb, DS; O'Brien, M; Yeoh, E, 1995)
"Between 1966 and 1983 we selected 209 patients with colorectal adenocarcinomas, stage B (14%) and C (86%) of Dukes, treated with convenient surgery in 100% of cases, 5-fluorouracil in 85% and postoperative radiotherapy with telecobalt in 46."5.08[Is radiotherapy necessary in the control of colorectal cancer?]. ( Molina Esquivel, J; Rodríguez del Rincón, E; Vargas Sandoval, G; Velázquez López, J, 1995)
"Modulation of 5-fluorouracil (5-FU) is currently being investigated in advanced colorectal cancer."5.08Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin. ( Astone, A; Barone, C; Cassano, A; Corsi, DC; Fontana, T; Noviello, MR; Pozzo, C, 1995)
"A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i."5.085-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas). ( Aschele, C; Bolli, E; Connio, M; Guglielmi, A; Ligas, B; Mondini, G; Mori, A; Rosso, R; Saccomanno, S; Sobrero, A, 1995)
"A total of 56 consecutive patients with metastatic colorectal cancer received treatment with 5-fluorouracil (5-FU) given at 425 mg/m2 by rapid intravenous infusion, immediately preceded by leucovorin (LV) given at 20 mg/m2, with cycles being repeated every 4 weeks."5.085-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study. ( Dale, J; Fried, G; Haim, N; Stein, M; Tsalik, M, 1995)
"From May 1988 to June 1992, 129 eligible patients suffering from measurable advanced colorectal cancer were enrolled in a randomized study comparing bolus fluorouracil plus leucovorin (FU-FA); continuous fluorouracil infusion (FU-cont); FUcont plus cyclophosphamide and mitomycin C (FUMIC)."5.08A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma. ( Bonnel, C; Caudry, M; Caudry, Y; Dujols, JP; Floquet, A; Marsault, C; Maton, O; Pujol, J; Quétin, P; Skawinski, P, 1995)
"We tested the hypothesis that polymerase chain reaction (PCR) quantitation of the enzyme thymidylate synthase (TS) within a primary adenocarcinoma of the stomach, has an inverse relationship to response and survival for patients who receive fluorouracil (5FU)-based chemotherapy."5.08Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Garcia, Y; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Li, J; Silberman, H, 1996)
"After curative resection for gastric adenocarcinoma, 103 patients, all with positive nodes, were randomised so that 48 received adjuvant chemotherapy of epidoxorubicin (EPI) 75 mg m-2 on day 1, leucovorin (LV) 200 mg m-2 on days 1-3 and 5-fluorouracil (5-FU) 450 mg m-2 on days 1-3, every 21 days for 7 months, whereas the remaining 55 did not."5.08Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study. ( Andreoli, F; Borrelli, D; Bruno, L; Cini, G; de Leonardis, V; Fabbroni, S; Intini, C; Neri, B; Pernice, LM; Romano, S; Valeri, A, 1996)
"Fourteen patients with surgically resected periampullary adenocarcinoma were treated with adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation and concurrent infusional 5-fluorouracil and leucovorin (5-FU/LV)."5.08Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy. ( Abrams, RA; Cameron, JL; Carducci, MA; Grochow, LB; Hruban, RH; Yeo, CJ; Zahurak, ML, 1996)
"The primary objective of this study was to determine the response rate of patients with metastatic colorectal cancer to combined therapy with 5-fluorouracil (5-FU), leucovorin, and intravenous azidothymidine (AZT), a thymidine nucleoside analog."5.08Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer. ( Akerley, W; Beitz, J; Bigley, J; Browne, M; Clark, J; Cole, B; Cummings, F; Darnowski, J; Kennedy, T; Sikov, W; Wanebo, H; Weitberg, A, 1996)
" levofolinic acid and oral hydroxyurea on a weekly schedule is well tolerated by the vast majority of patients with locally advanced and/or metastatic carcinoma of the pancreas or the gallbladder."5.08Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.). ( Colucci, G; Fortunato, S; Gebbia, N; Gebbia, V; Giotta, F; Giuseppe, S; Majello, E; Pezzella, G; Riccardi, F; Testa, A, 1996)
"5-Fluorouracil (5-FU) remains the most active therapeutic agent in advanced colorectal cancer."5.085-Fluorouracil continuous infusion in metastatic colorectal cancer. ( Ang, PT; Tan, EH, 1996)
"Evidence suggests that interferon-alpha (IFN-alpha) augments the antineoplastic activity of 5-fluorouracil (5-FU) in human adenocarcinoma cell lines in vitro and may enhance the efficacy of 5-FU in patients with advanced colorectal carcinoma."5.08Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292. ( Benson, AB; Bushunow, PW; Dutcher, JP; Flynn, PJ; Hansen, R; Kirkwood, J; Lipsitz, S; Sparano, JA; Wadler, S, 1996)
"In a pilot study we treated 19 patients suffering from recurrent or locally advanced inoperable colorectal cancer, with concurrent hypofractionated radiotherapy (4-5 Gy/fraction, 2 fractions per week) and 5-fluorouracil bolus, 1 hour before RT at doses of 300 mg/m2."5.08Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study. ( Kapsoritakis, A; Kosma, L; Koukourakis, M; Mouder, N; Skarlatos, J; Yannakakis, D; Zambatis, C, 1996)
"Treatment using a combination of 5-fluorouracil (5-FU), interferon-alpha (IFN alpha-2a) and interleukin 2 (IL-2) has been shown to mediate disease regression in selected patients with advanced colorectal cancer."5.08Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer. ( Goey, SH; Gratama, JW; Mertelsmann, RH; Osterwalder, B; Primrose, JN; Stoter, G; Verweij, J; Ward, U, 1996)
"Fifty-nine patients with invasive primary gastric adenocarcinoma who were deemed resectable for cure entered a clinical trial that called for 2 cycles of protracted infusion 5-fluorouracil with weekly leucovorin and cisplatin chemotherapy followed by surgery."5.08Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report. ( Baranda, J; Casagrande, Y; Crookes, P; Groshen, S; Laine, L; Leichman, CG; Leichman, L; Silberman, H; Stain, S; Tan, M, 1997)
"The combination of radiation therapy with fluorouracil (5-FU)-based chemotherapy is generally accepted as appropriate postoperative therapy for patients with adenocarcinomas of the rectum that extend through the bowel wall or with lymph nodes positive for tumor."5.08Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114. ( Benson, AB; Cooke, E; Cummings, B; Gunderson, LL; Hollis, D; Macdonald, JS; Martenson, JA; O'Connell, MJ; Petroni, GR; Tepper, JE, 1997)
"A Phase II study was performed to evaluate the activity and toxicity of 5-fluorouracil, leucovorin, Adriamycin, and cisplatin combination chemotherapy (FLAP) in patients with previously untreated advanced gastric and gastroesophageal (GE) junction adenocarcinoma."5.08A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program ( Armstead, B; Douglass, HO; Haller, DG; Holroyde, C; Meropol, NJ; Mintzer, D; Nuamah, I; Vaughn, DJ, 1997)
") of 5-fluorouracil (5-FU) plus daily low-dose cisplatin (CDDP) was evaluated in 45 patients with advanced and recurrent unresected colorectal, lung, gastric and pancreatic adenocarcinoma."5.08[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma]. ( Denno, R; Hiraike, N; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takasaka, H; Yagihashi, A; Yamamitsu, S; Yamashiro, K, 1997)
"The aim of this phase I study was to establish the maximum tolerated dose (MTD) of 5-fluorouracil (5-FU), administered as a 5-day chronomodulated infusion in combination with 1-folinic acid (FA) to ambulatory metastatic colorectal cancer patients."5.08A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer. ( Aschelter, AM; Franchi, F; Gallà, DA; Garufi, C; Giunta, S; Lévi, F; Narduzzi, C; Nisticò, C; Pace, R; Silecchia, GF; Terzoli, E, 1997)
"Eighteen patients with esophageal carcinoma (16 adenocarcinoma, two squamous cell carcinoma) were treated with two cycles of induction chemotherapy consisting of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) 175 mg/m2 (3-hour infusion), cisplatin 20 mg/m2/d x 4 days, and 5-fluorouracil 1 g/m2/d (continuous infusion x 4 days) separated by a 28-day interval before surgical resection."5.08Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus. ( Belani, CP; Day, R; Ferson, PF; Keenan, RJ; Kim, R; Landreaneau, RJ; Lembersky, B; Luketich, JD; Posner, M; Ramanathan, RK; Seeger, J, 1997)
"We have previously shown that relative thymidylate synthase (TS) mRNA levels in primary gastric adenocarcinomas treated with fluorouracil (5-FU) and cisplatin are inversely associated with response and survival."5.08ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. ( Baranda, J; Cohen, H; Crookes, P; Danenberg, KD; Danenberg, PV; Groshen, S; Hayashi, K; Konda, B; Laine, L; Leichman, CG; Leichman, L; Lenz, HJ; Metzger, R; Salonga, D; Silberman, H, 1998)
"The objective of the study was to determine the response rate and associated toxicity of 5-fluorouracil and high-dose leucovorin in patients with recurrent adenocarcinoma of the cervix."5.08Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study. ( Andersen, WA; Blessing, JA; Look, KY; Manetta, A; McGehee, R; Valea, FA; Webster, KD, 1997)
"Patients with histologically confirmed advanced colorectal cancer were randomized to receive folinic acid (FA; 500 mg/mq in 2-hour intravenous infusion) and 5-fluorouracil (5FU; 600 mg/mq given as an intravenous bolus 1 hour after FA), beginning every week for 6 weeks, followed by a 2-week rest period, either without hydroxyurea (HU, arm A) or with HU (35 mg/kg per day) given orally in three administrations (every 8 hours) starting 6 hours after 5FU administration (arm B)."5.08High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research. ( Algeri, R; Angiona, S; Belsanti, V; Boni, C; Corgna, E; Di Costanzo, F; Figoli, F; Gasperoni, S; Luppi, G; Malacarne, P; Marzola, M; Passalacqua, R; Sdrobolini, A; Zironi, S, 1998)
"The purpose of this study was to review the efficacy of a protracted venous infusion of 5-fluorouracil (PVI 5-FU)-based chemotherapy in advanced small bowel adenocarcinoma."5.08The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. ( Crawley, C; Cunningham, D; Hill, A; Norman, A; Ross, P, 1998)
"To compare raltitrexed (Tomudex; Zeneca Pharmaceuticals Ltd, Macclesfield, United Kingdom) a direct, specific thymidylate synthase (TS) inhibitor with fluorouracil (5-FU) plus high-dose leucovorin (LV) as first-line treatment for advanced colorectal cancer (ACC)."5.08Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group. ( Cocconi, G; Cunningham, D; Francois, E; Gustavsson, B; Hietschold, SM; Kerr, D; Possinger, K; Van Cutsem, E; van Hazel, G, 1998)
"In phase II trials, irinotecan is active in patients with advanced colorectal cancer, but the survival and clinical benefit of irinotecan compared with second-line fluorouracil by continuous infusion is not known."5.08Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. ( Awad, L; Bajetta, E; Bleiberg, H; Herait, P; Jacques, C; Labianca, R; Morant, R; Navarro, M; Niederle, N; Possinger, K; Rougier, P; Van Cutsem, E; Wils, J, 1998)
"FOLFOX2, a bimonthly regimen of high-dose leucovorin (LV), 48-hour continuous infusion of 5-fluorouracil (5-FU) (LV-5-FU) and oxaliplatin (100 mg/m2) produced a high response rate (46%; 95% confidence interval (95% CI): 31%-60%) in 5-FU pre-treated patients with metastatic colorectal cancer."5.08Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. ( André, T; de Gramont, A; Louvet, C; Raymond, E; Tournigand, C, 1998)
"Preoperative chemotherapy with a combination of cisplatin and fluorouracil did not improve overall survival among patients with epidermoid cancer or adenocarcinoma of the esophagus."5.08Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. ( Ajani, J; Estes, N; Ginsberg, R; Gunderson, L; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Pajak, TF; Roth, JA; Sheahan, DG, 1998)
"Thirty-seven consecutive patients with advanced and/or metastatic gastric adenocarcinoma received a combination of 5-fluorouracil 600 mg/m2 on days 1, 8, 29, 36; epidoxorubicin 75 mg/m2 i."5.07Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach. ( Bajardi, G; Cannata, G; Cipolla, C; Curto, G; Gebbia, V; Latteri, M; Mastrandrea, G; Pischedda, G; Testa, A; Valenza, R, 1994)
"Twenty-nine patients with adenocarcinomas of gastrointestinal or unknown primary, and three with advanced neuroendocrine tumours, were entered into a study of bolus plus infusional 5-fluorouracil (FUra) modulated with high-dose leucovorin (LV) and recombinant interferon alpha 2a (IFN-alpha)."5.07Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study. ( Hall, MR; Johnson, PW; Seymour, MT; Slevin, ML; Wrigley, PF, 1994)
"We have studied a mitoxantrone, 5-fluorouracil (5-FU) and leucovorin chemotherapy regimen in metastatic breast cancer."5.07The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer. ( Bélanger, K; Dionne, J; Gagné, L; Guévin, R; Jolivet, J; Latreille, J; Potvin, M; Rudinskas, L; Wilson, J; Yelle, L, 1994)
"Seventeen patients with either newly diagnosed breast cancer with more than four involved axillary nodes (five patients) or metastatic breast cancer (12 patients) were treated with cyclophosphamide 1 g/m2, doxorubicin 50 mg/m2, and fluorouracil 500 mg/m2 (CAF) intravenously (IV) once every 3 weeks."5.07Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil. ( Gelmon, KA; O'Reilly, SE; Onetto, N; Page, RA; Parente, J; Plenderleith, IH; Rubinger, M, 1993)
"From April 1990 to April 1992, a comparative study was carried out in 46 patients with advanced breast cancer treated by CMxMF (Cyclophosphamide, mitoxantrone, methotrexate, 5-fluorouracil) and CAMF regimens (Cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil)."5.07[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients]. ( Chen, JA, 1993)
"From December 1983 through December 1990, 27 patients with primary unresectable but localized pancreatic adenocarcinoma received high-dose (50 to 54 Gy) external beam irradiation with or without concomitant bolus 5-fluorouracil followed by surgical exploration and intraoperative electron beam irradiation (20 Gy) at the Mayo Clinic."5.07High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. ( Cha, SS; Donohue, JH; Garton, GR; Gunderson, LL; Martin, JK; McIlrath, DC; Nagorney, DM, 1993)
"We therefore initiated a Phase II study in which fluorouracil (370 mg/m2, day 1 through 5) plus folinic acid (200 mg/m2 day 1 through 5) was administered in a subset of 17 patients (median age, 57 years) affected by histologically diagnosed adenocarcinoma of unknown primary location characterized by liver metastases and elevated CEA of CA 19."5.07Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary. ( Bajetta, E; Buzzoni, R; Colleoni, M; Nolè, F, 1993)
"Potentiation of the antitumor activity of 5-fluorouracil (5-FU) by folinic acid has been demonstrated in patients with colorectal adenocarcinoma."5.075-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens. ( André, T; Goldschmidt, E; Grison, X; Hannoun, L; Lotz, JP; Machover, D; Marquet, J; Metzger, G; Richaud, J; Zittoun, J, 1993)
"A prospectively randomized trial was performed to determine whether the combination of fluorouracil (FU) plus leucovorin (FU-LV) administered orally is more effective than equitoxic FU for patients with metastatic colorectal cancer."5.07A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer. ( Brenckman, WD; Bukowski, RM; Clendennin, NJ; Collier, MA; Guaspari, A; Laufman, LR; McKinnis, RA; Sullivan, BA, 1993)
"In a randomized trial we compared single-agent epirubicin with the FEM (5-fluorouracil/epirubicin/mitomycin) combination in patients with locally advanced and/or metastatic adenocarcinoma of the pancreas."5.07Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas. ( Coombes, RC; Glees, J; Topham, C, 1993)
"5-Fluorouracil (5-FU) has modest activity as a single agent in a number of human adenocarcinomas."5.07A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site. ( Coit, D; Colofiore, J; Kelsen, D; Martin, DS; Sawyer, R, 1992)
"A high rate of response to 5-fluorouracil (5FU) and alpha-interferon (alpha IFN) combination therapy has been reported in metastatic colorectal cancer patients."5.07Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study. ( Burghouts, JT; de Mulder, PH; Punt, CJ; Wagener, DJ, 1992)
"Thirty-eight patients with advanced colorectal adenocarcinoma were entered on a phase II trial of 5-fluorouracil (5-FU) in continuous infusion, using a portable pump."5.07Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma. ( Ammarguellat, H; Benhamed, M; Ghosn, M; Goldberg, J; Kac, J; Laplaige, P; Piot, G; Rougier, P; Theodore, C; Tigaud, JM, 1992)
"To evaluate the contribution of semustine (MeCCNU) to adjuvant benefit, previously untreated patients with histologically proven adenocarcinoma of the rectum who had undergone curative resection were randomized to treatment with combination radiation therapy and fluorouracil (5-FU) followed by either 12 months of 5-FU and MeCCNU or 6 months of escalating 5-FU."5.07Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group. ( , 1992)
"One hundred sixty consecutive patients with histologically confirmed colorectal cancer (advanced disease) without prior chemotherapy were entered in a randomized trial comparing 5-fluorouracil (5-FU) 1,000 mg/m2 intravenously per day for 5 consecutive days in continuous infusion versus cisplatin (CP) 100 mg/m2 on day 1 plus 5-FU as described on days 2 to 6."5.07A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.). ( Antón, A; Aranda, E; Belón, J; Carrato, A; Cruz-Hernández, J; Díaz-Rubio, E; Jimeno, J; Martin, M; Massuti, B; Sánchez, J, 1992)
"This phase III prospective, randomized, and stratified trial was undertaken to evaluate the efficacy of four courses of combined fluorouracil (1000 mg per square meter of body-surface area daily for four days) and cisplatin (75 mg per square meter on the first day) plus 5000 cGy of radiation therapy, as compared with 6400 cGy of radiation therapy alone, in patients with squamous-cell carcinoma or adenocarcinoma of the thoracic esophagus."5.07Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. ( al-Sarraf, M; Brindle, J; Byhardt, R; Cooper, J; Davis, L; Emami, B; Herskovic, A; Leichman, L; Martz, K; Vaitkevicius, V, 1992)
"We conducted a phase II clinical trial of 5-fluorouracil (5 day continuous infusion), cis-diamminedichloroplatinum and etoposide in previously untreated patients with metastatic carcinoma of unknown primary origin."5.07Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin. ( Abbruzzese, JL; Faintuch, J; Frost, P; Raber, MN; Sumrall, C, 1991)
"Twenty-seven women with metastatic breast cancer were treated with doxorubicin (Adriamycin, Adria Laboratories, Columbus, OH) every other week, alternating with 5-fluorouracil (5FU) and high-dose calcium leucovorin, for a 12-week induction regimen, followed by weekly doxorubicin and oral daily cyclophosphamide."5.07Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study. ( Coltman, CA; Ellis, GK; Green, S; Hynes, HE; Livingston, RB; Rivkin, S; Schulman, S, 1991)
"Forty-two previously untreated patients with advanced, measurable adenocarcinoma of the pancreas were treated with weekly fluorouracil (5-FU; 600 mg/m2 intravenous [IV]) and leucovorin 500 mg/m2 IV for 6 weeks followed by a 2-week rest."5.07Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. ( Arbuck, SG; DeCaprio, JA; Gonin, R; Mayer, RJ, 1991)
"To improve current adjuvant results in high-risk breast cancer, in February 1982 we activated a prospective randomized trial using both intravenous cyclophosphamide, methotrexate, and fluorouracil (CMF) and Adriamycin (doxorubicin; Farmitalia-Carlo Erba, Milan, Italy) involving patients with resectable mammary carcinoma and more than three positive axillary lymph nodes."5.07Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. ( Bonadonna, G; Buzzoni, R; Valagussa, P; Zambetti, M, 1991)
"This study evaluated combined 5-fluorouracil (5FU) and doxorubicin as postoperative adjuvant chemotherapy for patients who had undergone potentially curative resection of a primary gastric adenocarcinoma."5.07A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer. ( Beart, RW; Foley, JF; Krook, JE; Kugler, JW; Leigh, JE; O'Connell, MJ; Pfeifle, DM; Twito, DI; Wieand, HS, 1991)
"Seventy-four patients with liver metastasis from proved colorectal primary adenocarcinoma were entered into a prospective, randomized clinical trial to evaluate treatment with intra-arterial floxuridine compared with standard outpatient therapy with fluorouracil delivered by intravenous bolus injection."5.06Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. ( Fitzgibbons, RJ; Krook, JE; Mailliard, JA; Martin, JK; Nagorney, DM; O'Connell, MJ; Rubin, J; Tschetter, LK; Wieand, HS, 1990)
"One hundred eighty-seven patients with histologically proven advanced pancreatic adenocarcinoma were randomly assigned to therapy with 5-fluorouracil (5-FU) alone, to the Mallinson regimen (combined and sequential 5-FU, cyclophosphamide, methotrexate, vincristine, and mitomycin C), or to combined 5-FU, doxorubicin, and cisplatin (FAP)."5.06A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. ( Barlow, JF; Cullinan, S; Foley, JF; Kardinal, CG; Krook, JE; Moertel, CG; Norris, BD; Schutt, AJ; Tschetter, LK; Wieand, HS, 1990)
"Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU."5.065-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990)
"In preparation for a national Phase III study of dose and dose intensity in the treatment of node-positive, Stage II adenocarcinoma of the female breast, CALGB instituted a pilot study of intensive intravenous outpatient CAF (cyclophosphamide, Adriamycin, 5-fluorouracil) for four months."5.06A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443. ( Aisner, J; Budman, DR; Costanza, M; Korzun, AH; Rice, MA; Silver, R; Wood, W; Younger, J, 1990)
"We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion."5.06Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group. ( Beart, RW; Fitzgibbons, RJ; Leigh, JE; Moertel, CG; van Heerden, JA; Wieand, HS; Windschitl, HE; Wolff, BG, 1990)
"Seventy-four previously untreated patients with metastatic colorectal adenocarcinoma were prospectively randomized into one of three treatment regimens: (1) 5-fluorouracil (5-FU) 450 mg/m2 as an intravenous (IV) bolus daily for five days or toxicity, then 200 mg/m2 IV bolus every other day for six doses; (2) methotrexate (MTX) 50 mg/m2 in normal saline by IV infusion over four hours followed by an IV bolus of 5-FU 600 mg/m2."5.06A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. ( Burke, P; Creaven, P; Emrich, LJ; Herrera, L; Mittelman, A; Petrelli, N; Rustum, Y; Stulc, J, 1987)
"Twenty-two patients with inoperable adenocarcinoma of the pancreas were treated with 5-fluorouracil (5-FU), mitomycin C (Mito-C), and 1(-2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (MeCCNU)."5.06Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas. ( Chapman, J; Chinn, B; Groshko, G; Maniscalco, B; Piper, D; Reznik, S; Vaughn, C; Ward, D, 1989)
"Seventy-seven patients with previously untreated, measurable, histologically confirmed, metastatic adenocarcinoma of the rectum or sigmoid were randomized to receive either epirubicin 90 mg/m2 (75 mg/m2 if prior radiotherapy) i."5.06A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma. ( Blum, RH; Lafleur, F; Molinaro, P, 1989)
"The effect of hepatic irradiation (RT) after intraarterial 5-fluorouracil (5-FU) was evaluated in 37 randomized patients with colorectal adenocarcinoma hepatic metastases."5.06Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study. ( Demets, D; Lee, JW; Ramirez, G; Stephenson, JA; Wiley, AL; Wirtanen, GW, 1989)
"One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses."5.06Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group. ( , 1986)
"Using a randomized prospective trial design, chemotherapy with 5-fluorouracil, vincristine, and mitomycin C (FOMi) was compared with cyclophosphamide, doxorubicin, and cisplatin (CAP) and with FOMi alternating with CAP (FOMi/CAP) in 452 eligible patients with metastatic large-cell undifferentiated and adenocarcinoma of the lung."5.06Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study. ( Chen, TT; Coltman, CA; Fletcher, WS; Livingston, RB; Miller, TP; O'Bryan, RM; Stephens, RL; Vance, RB; Weiss, GB, 1986)
"In this prospective randomized study the effect of oral Ftorafur was compared with that of intravenous 5-fluorouracil in patients with advanced adenocarcinoma of the stomach, colon or rectum."5.06Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum. ( Bjerkeset, T; Fjøsne, HE, 1986)
"Fifty patients with inoperable adenocarcinoma of the lung were randomized in a prospective study to receive either standard doses or high doses of 5-fluorouracil, adriamycin, and mitomycin-C (FAM versus Hi-FAM)."5.065-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules. ( Ip, M; Kung, TM; Lam, WK; Sham, MK; So, SY, 1987)
"We report the results of an expanded trial of 5-fluorouracil (5-FU) combined with high-dose folinic acid for treatment of patients with advanced colorectal or advanced gastric adenocarcinoma."5.06Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Chollet, P; Fourtillan, JB; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1986)
"A multi-institutional cooperative study of patients with locally advanced, recurrent, or metastatic gastric adenocarcinoma who had not previously received chemotherapy was conducted, prospectively randomizing patients to receive either doxorubicin or the three-drug combination, 5-fluorouracil (5-FU), doxorubicin (Adriamycin; Adria Laboratories, Columbus, Ohio), and BCNU (FAB)."5.06Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies. ( Fox, RM; Gill, G; Levi, JA; Tattersall, MH; Thomson, D; Woods, RL, 1986)
"This prospective randomized study in nonhormonally responsive adenocarcinoma of the prostate shows that response rates to melphalan vs cyclophosphamide groups were virtually identical."5.06Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma. ( Berry, WR; Cox, EB; Graham, SD; Laszlo, J; Paulson, DF; Walker, A, 1986)
"In patients with metastatic hormone-relapsed adenocarcinoma of the prostate, adriamycin was compared to 5-fluorouracil in a randomized trial in 99 patients and adriamycin alone was studied in an open trial in 48 patients."5.05A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response. ( Begg, CB; Brodovsky, H; Creech, R; DeWys, WD; Khandekar, J, 1983)
"Thirty-four patients with advanced adenocarcinoma of the gastrointestinal tract have been treated with high-dose 5-fluorouracil modulated by concomitant allopurinol therapy, in combination with either razoxane or adriamycin."5.05A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract. ( Ashford, RF; Bakowski, M; Evans, M; Hellman, K; Jones, R; Lambert, J; Newton, K; Peters, N; Phillips, R; Smith, BJ, 1983)
"This prospective evaluation of 5-fluorouracil (5-FU) and methyl-CCNU administered in combination to patients with surgery for histologically proved gastric adenocarcinoma is based upon 312 patients randomized between August 1974 and May 1980."5.05Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report. ( Amadeo, JH; Higgins, GA; Humphrey, EW; Keehn, RJ; Smith, DE, 1983)
"Between September 1976 and June 1982, 308 patients with operable breast cancer with 1-3 involved axillary nodes were stratified according to institution, type of mastectomy, and time from surgery to protocol entry, and then randomized to receive either six or 12 months of adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)."5.05Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience. ( Bartolucci, A; Ketcham, A; Liu, C; Marcial, V; Moore, M; Smalley, R; Velez-Garcia, E; Vogel, CL, 1983)
"Thirty-two evaluable patients with advanced measurable gastric adenocarcinoma were treated with a combination of 5-fluorouracil, adriamycin, and BCNU (FAB)."5.055-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer. ( Di Lauro, L; Lopez, M; Papaldo, P; Perno, CF, 1984)
"Because of biochemical and tissue culture evidence casting doubt on the physiologic relevance of reported synergy afforded by sequential administration of methotrexate (MTX) followed by 5-fluorouracil (5-FU), a randomized controlled clinical trial was conducted in 108 patients with advanced cancer, including 70 with squamous cell carcinoma (SCC) of the head and neck, nine with SCC of other primary sites, 24 with colorectal, and five with gastric adenocarcinomas."5.05Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration. ( Coates, AS; Fox, RM; Hedley, D; Raghavan, D; Swanson, C; Tattersall, MH, 1984)
"Twenty-nine patients with advanced adenocarcinoma of the pancreas were treated with a combination of mitomycin-C, 5-fluorouracil, and adriamycin (MIFA III)."5.05MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas. ( Cheng, EW; Magill, GB; Sordillo, PP; Sternberg, CN, 1984)
"Two hundred forty-one patients with unresectable gastric adenocarcinoma were entered, between December 1978 and March 1981, into a prospectively randomized comparison of three chemotherapy regimens to identify therapeutic activity and determine patient tolerability: (1) 5-fluorouracil plus Adriamycin (FA); (2) FA plus methyl-CCNU (FAMe); and (3) FA plus mitomycin C (FAMi)."5.05Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group. ( , 1984)
"The FAM combination with the simultaneous administration of 5-fluorouracil, doxorubicin, and mitomycin C is considered standard chemotherapy for gastric adenocarcinoma."5.05Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study. ( Athens, J; Chen, TT; Costanzi, JJ; Haas, C; Heilbrun, LK; McDonald, B; Oishi, N; Panettiere, FJ; Talley, RW, 1984)
"In a prospectively randomized trial, patients with advanced locally recurrent or metastatic gastric adenocarcinoma were randomized to receive 5-fluorouracil (5-FU) and methyl-CCNU; 5-FU, Adriamycin (Adria Laboratories, Columbus, Ohio), and methyl-CCNU; 5-FU, Adriamycin, and mitomycin C; or Adriamycin and mitomycin C alone."5.05An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277). ( Douglass, HO; Goudsmit, A; Klaassen, DJ; Lavin, PT; Paul, AR, 1984)
"In a randomized, multicenter study, 168 evaluable patients with colorectal adenocarcinoma at B2, C1 or C2 stages of the Dukes, Astler and Coller classification, were treated after radical surgery with BCG and 5-fluorouracil alone (regimen A) or in combination with hydroxyurea, methyl-CCNU and mitomycin C (regimen B)."5.05Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma. ( De Vecchis, L; Lagomarsino Caprino, MC; Mazzei, T; Periti, P; Popoli, P, 1984)
"One hundred twenty-one patients with advanced measurable adenocarcinoma of the colon were randomized for treatment with intravenous 5-fluorouracil (IV 5-FU) alone, 15 mg/kg/week vs."5.05Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. ( Bateman, JR; Chlebowski, RT; Kardinal, C; Pajak, T; Silverberg, I; Weiner, J, 1980)
"One-hundred-ninety-four eligible and evaluable patients with histologically confirmed locally unresectable adenocarcinoma of the pancreas were randomly assigned to therapy with high-dose (6000 rads) radiation therapy alone, to moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU), and to high-dose radiation plus 5-FU."5.05Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. ( Barkin, J; Bateman, J; Brooks, J; Chaffey, J; Childs, DS; Corson, JM; Douglas, HO; Frytak, S; Hahn, RG; Holbrook, MA; Kalser, M; Knowlton, A; Lavin, PT; Lessner, H; Livstone, E; Lokich, J; Mann-Kaplan, R; Moertel, CG; Nave, H; Novak, JW; O'Connell, MJ; Ramming, K; Reitemeier, RJ; Rubin, J; Schutt, AJ; Spiro, H; Thomas, P; Weiland, LH; Zamcheck, N, 1981)
"To assess the effects of postoperative radiation therapy and chemotherapy on tumor recurrence and patient survival, 227 patients (data on 202 of whom were analyzed) who had undergone "curative" surgical resection for rectal adenocarcinoma were prospectively and randomly assigned to one of four treatments: no adjuvant therapy (concurrent controls, 58 patients), postoperative radiotherapy with 4000 or 4800 rad (50 patients), postoperative chemotherapy (fluorouracil and semustine [methyl-CCNU], 48 patients), or a combination of radiation therapy and chemotherapy (46 patients)."5.05Prolongation of the disease-free interval in surgically treated rectal carcinoma. ( , 1985)
"After en bloc resection of gastric adenocarcinoma, 180 patients were randomized to 2 years of 5-fluorouracil (5-FU) + semustine (MeCCNU) chemotherapy or to observation only."5.05Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). ( Brunner, KW; Douglass, HO; Engstrom, PF; Lavin, PT, 1985)
"30 patients with advanced metastatic gastric adenocarcinoma, having a measurable indicator lesion, were randomized (1:2) to receive (intravenously) either weekly 5-fluorouracil alone (15 mg/kg) or combination treatment with cyclophosphamide (20 mg/kg) given on day 1 and 5-FU (15 mg/kg) given weekly on weeks 2-5, beginning on day 8."5.05Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma. ( Bateman, JR; Chlebowski, RT; Glass, A; Silverberg, I; Weiner, JM, 1985)
"From 1977 until 1980, 179 patients with newly diagnosed FIGO stages IIB, III or IV ovarian adenocarcinoma were randomized in a two-armed clinical trial: dihydroxybusulfan (B) 600 mg/m2 p."5.05A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma. ( Aabo, K; Dombernowsky, P; Hald, I; Hansen, HH; Hørbov, S; Lundvall, F; Nielsen, NC; Sørensen, BL; Sørensen, HM, 1985)
"One hundred ninety-one patients with pathologically confirmed, locally unresectable adenocarcinoma of the stomach (57 patients) and pancreas (91 patients), were randomly allocated to therapy with 5-fluorouracil (5-FU) alone, 600 mg/m2 intravenously (IV) once weekly, or radiation therapy, 4,000 rad, plus adjuvant 5-FU, 600 mg/m2 IV, the first three days of radiotherapy, then follow-up maintenance 5-FU, 600 mg/m2, weekly."5.05Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. ( Catton, GE; Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Moertel, CG, 1985)
"Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan."5.04Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978)
"Thirty-one patients with carcinoma of the breast with metastases were treated by adrenalectomy-oophorectomy and randomized either for combined chemotherapy, vincristine, fluorouracil, methotrexate and thiotepa, beginning within one week after operation and continuing for three months or no chemotherapy."5.04Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases. ( Cady, B; Oberfield, RA; Pazianos, AG; Salzman, FA, 1979)
"One hundred and sixteen patients with advanced and metastatic adenocarcinoma of the pancreas were randomized to treatment with combined Streptozotocin and 5-fluorouracil or combined Streptozotocin and cyclophosphamide."5.04Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide. ( Carbone, PP; Douglas, HO; Hanley, J; Moertel, CG, 1977)
"One hundred and thirty-two previously untreated patients with metastatic adenocarcinoma of the gastrointestinal (GI) tract were randomized to receive either a 120-hr infusion of 5-fluorouracil (5FU) with mitomycin-C or mitomycin-C alone."5.04Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas. ( Baker, LH; Buroker, TR; Kim, PN; Ratanatharathron, V; Vaitkevicius, VK; Wojtaszak, B, 1978)
"An adjuvant program of fluorouracil for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968."5.04Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report. ( Brown, PW; Horsley, JS; Lawrence, W; Romero, C; Terz, JJ, 1978)
"Eighteen previously untreated patients with advanced nonresectable adenocarcinoma of the stomach were treated with a four-drug regimen consisting of 5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C."5.045-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer. ( Bunn, PA; Cohen, MH; Eddy, JL; Ihde, DC; Minna, JD; Nugent, JL, 1978)
"In a randomized multi-institutional trial of the Eastern Cooperative Oncology Group, 316 patients with advanced measurable colorectal adenocarcinoma were treated with a weekly schedule of 5-fluorouracil given orally and intravenously with oral-5-fluorouracil in combination with cyclophosphamide or 6-thioguanine, or with oral Methyl CCNU administered once every eight weeks."5.04Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2- ( Carbone, P; Conroy, JF; Douglass, HO; Lavin, PT; Woll, J, 1978)
"Twenty-seven patients with a diagnosis of metastatic adenocarcinoma of the prostate were treated in a randomized, prospective trial with either Cyclophosphamide or a combination of Adriamycin, 5-Fluorouracil, and Cyclophosphamide."5.04Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. ( Bateman, JR; Chlebowski, RT; Hestorff, R; Sardoff, L; Weiner, J, 1978)
"In a prospective, multi-centre, randomized study of 109 patients with metastatic gastro-intestinal adenocarcinomas the response rate, survival time and side-effects of two drug combinations, carmustin +5-fluorouracil and carmustin + ftorafur, were compared (same carmustin dosage in both groups)."5.04[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)]. ( Arnold, H; Drings, P; Geldmacher, J; Hartwich, G; Kredel, L; Mayer, M; Neidhardt, B; Queisser, W; Rösch, W; Schaefer, J; von Oldershausen, HF; Wahrendorf, J, 1979)
"Seventy-six patients with advanced gastric adenocarcinoma were studied in a prospecitive, randmoised, controlled trial using vincristine, methotrexate, cyclophosphamide, and 5-fluorouracil in an initiation course and mitomycin-C with 5-fluorouracil as maintenance therapy."5.04Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study. ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1979)
"A prospective randomized clinical trial of treatment with vincristine, cyclophosphamide, methotrexate and 5-fluorouracil after conventional curative treatment for stage II breast cancer is described."5.04Four drug combination cytotoxic chemotherapy following surgery for breast cancer. ( Bates, IS; Brinkley, D; Edelstyn, GA; MacRae, KD; Spittle, H; Wheeler, T, 1978)
"A combined intraoperative and postoperative adjuvant program of 5 minus Fluorouracil (5 FU) for patients undergoing "curative" resection for adenocarcinoma of the colon and rectum was initiated as a randomized clinical trial in January 1968."5.04Chemotherapy as an adjuvant to surgery for colorectal cancer. ( Brown, PW; Donaldson, M; Horsley, S; Lawrence, W; Lovett, WL; Regelson, W; Ruffner, BW; Terz, JJ, 1975)
"In a randomized series of 70 patients with with colo rectal adenocarcinoma, a comparison of systemic 5-fluorouracil chemotherapy administered as a continuous 120-hours infusion vs."5.04Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. ( Baker, LH; Reed, ML; Seifert, P; Vaitkevicius, VK, 1975)
"The primary purpose of this study was to explore the short-term efficacy of different cisplatin and fluorouracil-based chemotherapy regimens in the treatment of patients with esophagogastric junctional adenocarcinoma (EGJA) using a network meta-analysis (NMA)."4.95A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma. ( Hu, JH; Song, DJ; Wang, C; Xie, SP; Xu, ZL, 2017)
" This review focuses on the development and establishment of the Dark Agouti rat mammary adenocarcinoma model by the Mucositis Research Group of the University of Adelaide over the past 20 years to characterize the mechanisms underlying methotrexate-, 5-fluorouracil-, and irinotecan-induced mucositis."4.91Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art. ( Bateman, E; Keefe, D; Mayo, B; Stringer, A; Thorpe, D; Vanhoecke, B; Vanlancker, E, 2015)
"Nucleoside analogs such as gemcitabine and 5-fluorouracil are currently the cornerstone of chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC)."4.90Role of solute carrier transporters in pancreatic cancer: a review. ( Lemstrová, R; Melichar, B; Mohelnikova-Duchonova, B; Souček, P, 2014)
"This meta-analysis was performed to determine whether the addition of monoclonal antibodies (mAbs) of epidermal growth factor receptor (EGFR) to oxaliplatin-based chemotherapy treatment improves efficacy in KRAS wild-type metastatic colorectal cancer (mCRC), and whether infusional 5-fluorouracil (5-FU) and oxaliplatin is a preferred combination for EGFR mAbs."4.89Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody. ( Du, Z; He, X; Hu, Q; Li, M; Li, Q; Sang, Y; Tang, R; Wen, F; Zhang, P; Zhou, Y, 2013)
"We report on a case of a 65-year-old Chinese male with locally advanced gastric adenocarcinoma achieving pathological complete response after neoadjuvant chemotherapy with capecitabine and oxaliplatin (XELOX) regimen."4.89Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma. ( Chang, SL; Chen, YN; Jiao, ZK; Li, Y; Tan, BB; Tian, Y; Zhang, ZD; Zhao, Q; Zhao, XF, 2013)
"Metastatic pancreatic ductal adenocarcinoma has a grim prognosis and gemcitabine has been the reference treatment for 15 years."4.87Metastatic pancreatic cancer: old drugs, new paradigms. ( Adenis, A; Conroy, T; Gavoille, C, 2011)
", Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC)."4.86Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. ( Boehm, KA; Cartwright, T; McCollum, D, 2010)
" In patients with metastatic or locally advanced/recurrent gastric or gastro-oesophageal junction adenocarcinoma, the median time to tumour progression was significantly prolonged with 3-week cycles of intravenous (IV) docetaxel plus cisplatin and fluorouracil (5-fluorouracil) compared with 4-week cycles of IV cisplatin plus IV fluorouracil (5."4.84Docetaxel: in gastric cancer. ( Deeks, ED; Scott, LJ, 2007)
"A patient with resected adenocarcinoma of the pancreas was treated with adjuvant radio-chemo-immunotherapy using a combination of low-dose Cisplatin, 5-Fluorouracil and Interferon alpha together with external beam radiation."4.83Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759]. ( Buchler, MW; Fritz, S; Hoffmann, K; Jager, D; Lindel, K; Marten, A; Schmidt, J, 2006)
"The addition of oxaliplatin and irinotecan to the armamentarium for the treatment of colorectal cancer (CRC) has resulted in significant improvements in response rates and survival."4.82The role of bevacizumab as first-line therapy for colon cancer. ( Marshall, J, 2005)
"Gemcitabine administered as a weekly 1,000 mg/m2 30 minutes infusion is considered as the standard treatment of non resectable pancreatic adenocarcinoma."4.81[Gemcitabine-based combinations in inoperable pancreatic cancers]. ( André, T; Artru, P; Louvet, C, 2002)
"The current standard therapy for metastatic pancreatic adenocarcinoma is the single-agent gemcitabine, by the increasingly used fixed rate infusion of 10 mg/m2/min."4.81Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review. ( Bruckner, HW; Evans, A; Kozuch, P; Petryk, M, 2001)
"The combination of cisplatin and continuous-infusion 5-fluorouracil is the standard regimen for the treatment of both squamous cell carcinoma and adenocarcinoma."4.81[Chemotherapy for the patients with esophageal cancer]. ( Ando, N; Shih, CH, 2002)
" Until ongoing phase III trials confirm these benefits, the current standard treatment for metastatic pancreatic adenocarcinoma remains single agent gemcitabine."4.81A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma. ( Bruckner, HW; Kozuch, P; Petryk, M, 2002)
" Chemotherapy with fluorouracil (5FU) plus leucovorin remains a standard in the treatment of patients with metastatic colorectal cancer."4.80[Irinotecan in combination for colon cancer]. ( André, T; de Gramond, A; Ducreux, M; Gil-Delgado, M; Khayat, D; Ychou, M, 1998)
"We report a patient who developed multifocal cerebral demyelination with the use of 5-fluorouracil, levamisole, and leucovorin as adjuvant treatment for intestinal adenocarcinoma."4.79Cerebral demyelination with 5-fluorouracil and levamisole. ( Fassas, AB; Gattani, AM; Morgello, S, 1994)
"For patients with localized pancreatic adenocarcinoma, the combination of radiation therapy and 5-fluorouracil has been shown to enhance patient survival."4.78Current approaches to multimodality management of advanced pancreatic cancer. ( Douglass, HO, 1993)
" From October 1985 to October 1987, 43 patients with local-regional esophageal cancer (adenocarcinoma in 21, squamous cell in 22) were treated with cisplatin, vinblastine, and 5-fluorouracil chemotherapy concurrent with 4,500 cGy radiation therapy for 21 days before transhiatal esophagectomy 3 weeks later."4.78Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma. ( Bromberg, J; Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Takasugi, BJ; Urba, S, 1990)
"Growth of human adenocarcinomas of the colon and rectum in immunoincompetent mice has allowed for a greater understanding of the interaction of 5-fluorouracil, its metabolism, and mechanism(s) of cytotoxicity under conditions of tumor growth in situ."4.77Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy. ( Hazelton, BJ; Houghton, JA; Houghton, PJ; Radparvar, S, 1989)
"A patient receiving the antitumor agent mitomycin C (MMC) in combination with 5-fluorouracil and adriamycin because of adenocarcinoma of Vater's papilla manifested hemolytic-uremic syndrome (HUS) after five cycles of 5-fluorouracil-adriamycin-MMC combination chemotherapy."4.77Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy. ( Binsack, T; Mergenthaler, HG; Wilmanns, W, 1988)
"There is limited real-world data on the efficacy of 2-weekly cycles of docetaxel, oxaliplatin, leucovorin, and fluorouracil (FLOT) compared to epirubicin, oxaliplatin, and capecitabine (EOX) as perioperative therapy in esophagogastric adenocarcinomas (EGAC)."4.31Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. ( Bhandare, M; Bhargava, P; Booma, N; Chaudhari, V; Chaugule, D; Das, S; Kannan, S; Kapoor, A; Mantri, A; Ostwal, V; Ramaswamy, A; Shrikhande, SV; Srinivas, S, 2023)
"This case report describes a patient with cutaneous intestinal metaplasia with invasive adenocarcinoma treated successfully with intralesional fluorouracil."4.31Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil. ( Dahiya, M; Eilers, D; Joseph, MX; Tao, J; Vaudreuil, A, 2023)
"Adjuvant capecitabine monotherapy is an option for colon and upper rectum adenocarcinoma patients, providing they have stage II disease with an intermediate risk of recurrence, or stage III but they are above 70's or they have comorbidities."4.31Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role? ( Aravantinos, G; Dessypris, N; Gkoura, S; Karampinos, K; Mauri, D; Miaris, N; Samantas, E; Sgouros, J; Spathas, N; Stamoulis, G; Theodoropoulos, I; Tzoudas, F; Visvikis, A, 2023)
"Retrospective study included all resected patients with pancreatic adenocarcinoma who underwent neoadjuvant chemotherapy with FOLFIRINOX or gemcitabine/Abraxane."4.31Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer. ( Caron, M; Fitzgerald, TL; Nicolais, LM; Verdini, N, 2023)
"Chemotherapy using 5-fluorouracil (5-FU) is currently considered the most effective treatment for advanced colon adenocarcinoma (COAD)."4.31FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance. ( Chen, W; Lei, Y; Tian, X; Wang, D; Wei, J, 2023)
"The NAPOLI-I trial showed better outcome of nanoliposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) compared to 5-FU/LV in patients with advanced pancreatic ductal adenocarcinoma cancer (advPDAC) progressed to gemcitabine-based therapy."4.31The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma. ( Antonuzzo, L; Barsotti, G; Bergamo, F; Casalino, S; De Toni, C; De Vita, F; Fasano, M; Giommoni, E; Giordano, G; Lonardi, S; Melisi, D; Merz, V; Milella, M; Noventa, S; Pinto, C; Pretta, A; Procaccio, L; Satolli, MA; Scartozzi, M; Spadi, R; Vaccaro, V; Zaniboni, A; Zecchetto, C; Zichi, C, 2023)
" This case report discusses the clinical trial treatment of a patient with rectal adenocarcinoma by a new ropidoxuridine-capecitabine-radiotherapy combination."4.31A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer. ( Collins, JM; Kinsella, TJ; Kunos, CA; Piekarz, R, 2023)
"The primary mode of therapy for individuals with locally advanced esophageal adenocarcinoma (EAC) is neoadjuvant chemotherapy, commonly 5-Fluorouracil (5-FU)."4.31Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells. ( Chauhan, A; Cheng, L; Garrett, H; Idrovo, JP; Meguid, RA; Meng, X; Pratap, A; Qualman, A; The, E; Wani, S, 2023)
"We hypothesized that perioperative FOLFOX (5-fluorouracil, leucovorin, oxaliplatin) might be used as an alternative to standard FLOT (docetaxel, 5-fluorouracil, leucovorin, and oxaliplatin) in patients with locally advanced oesogastric adenocarcinomas (OGA), particularly those with frailties."4.12Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. ( Adenis, A; Khellaf, L; Mazard, T; Mourregot, A; Portales, F; Quesada, S; Samalin, E; Thezenas, S; Ychou, M, 2022)
"Gemcitabine (Gem) alone or with Nab-paclitaxel (Gem-Nab) is used as second-line treatment for metastatic pancreatic adenocarcinoma (mPA) after FOLFIRINOX (FFX) failure; however, no comparative data exist."4.12Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study. ( Artru, P; Auclin, E; Bechade, D; Ducoulombier, A; Edeline, J; Gilabert, M; Hautefeuille, V; Lièvre, A; Morin, C; Pernot, S; Sarabi, M; Taieb, J; Tougeron, D; Wasselin, J; Zaibet, S, 2022)
"Large pragmatic studies of patients who received 5-fluorouracil with leucovorin, irinotecan, and oxaliplatin ([m]FOLFIRINOX) as initial treatment for localized pancreatic ductal adenocarcinoma (PDAC) are lacking."4.12FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. ( Besselink, MG; Doppenberg, D; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O' Reilly, EM; Paniccia, A; Prakash, LR; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022)
"Recent studies have suggested the suboptimal efficacy of liposomal irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) patients previously treated with conventional irinotecan."4.12Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin. ( Bai, LY; Chan, DC; Chen, JS; Chen, LT; Chen, YY; Cheng, FM; Chiang, NJ; Chiu, SC; Chiu, TJ; Chou, WC; Chuang, SC; Hsueh, SW; Li, CP; Peng, CM; Shan, YS; Su, YY; Yang, SH; Yen, CJ, 2022)
"Perioperative FLOT (fluorouracil plus leucovorin, oxaliplatin, and docetaxel) chemotherapy is a recent regimen used to treat resectable oesophagogastric (OG) adenocarcinoma, associated with improved overall survival versus earlier chemotherapy strategies."4.12Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. ( Allum, WH; Bhogal, RH; Chau, I; Chaudry, A; Cunningham, D; Fribbens, C; Gerlinger, M; Kumar, S; Malietzis, G; Moussa, O; Rao, S; Starling, N; Watkins, D, 2022)
" This study evaluated the percentages of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) undergoing second-line therapy with 5-fluorouracil (5-FU)-based regimens that experienced AEs during treatment and received medication to manage those AEs."4.12Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma. ( Cockrum, P; Kim, G; Surinach, A; Wainberg, Z; Wang, S, 2022)
"FOLFIRINOX (leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin) and gemcitabine plus nab-paclitaxel are the 2 common first-line therapies for metastatic adenocarcinoma of the pancreas (mPC), but they have not been directly compared in a clinical trial, and comparative clinical data analyses on their effectiveness are limited."4.12Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. ( Amar-Farkash, S; Aran, D; Collisson, EA; Klein-Brill, A; Lawrence, G, 2022)
"Nab -paclitaxel and gemcitabine (GnP) or FOLFIRINOX (a combination of leucovorin, fluorouracil, irinotecan, and oxaliplatin [FFX]) is currently recognized as the standard first-line regimen for unresectable pancreatic ductal adenocarcinoma (PDAC)."4.12Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer. ( Fujita, Y; Hayashi, K; Hirano, A; Hori, Y; Inoue, T; Kataoka, H; Kato, A; Kato, H; Miyabe, K; Naiki-Ito, A; Naitoh, I; Natsume, M; Nishi, Y; Okumura, F; Sano, H; Takada, H; Takahashi, S; Yoshida, M, 2022)
"To evaluate response rate, toxicity, and efficacy of the novel combination of nab-paclitaxel, oxaliplatin, 5-fluorouracil, and leucovorin [FOLFOX-A] in patients with advanced pancreatic ductal adenocarcinoma [PDAC]."4.12The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318. ( Almhanna, K; Beard, RE; Breakstone, R; Dionson, S; Dipetrillo, T; Kastura, M; Leonard, KL; Olszewski, A; Raufi, A; Renaud, J; Safran, H; Sturtevant, A; Wood, R, 2022)
"The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinoma (PDAC) is uncertain."4.12Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. ( Besselink, MG; Crane, CH; Doppenberg, D; Ellsworth, SG; Groot Koerkamp, B; Janssen, QP; Jarnagin, WR; Katz, MHG; O'Reilly, EM; Paniccia, A; Prakash, LR; Reyngold, M; Tzeng, CD; van Dam, JL; van Eijck, CHJ; Wei, AC; Zureikat, AH, 2022)
"There is increased use of neoadjuvant fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) in the management of localized pancreatic ductal adenocarcinoma (PDAC), yet there are few validated biomarkers of treatment response."4.12Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma. ( Court, CM; D'Angelica, MI; Drebin, JA; Ecker, BL; Gonen, M; Janssen, QP; Jarnagin, WR; O'Reilly, EM; Tao, AJ; Wei, AC, 2022)
" Therefore, this study aimed to clarify the role of PYCR1 and its interaction with SLC25A10 in a chemotherapeutic agent 5-fluorouracil (5-FU)'s toxicity to colorectal cancer cells."4.12The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer. ( Mai, Z; Qiu, X; Song, Y; Xia, W; Yang, X; Ye, Y; Zhang, M; Zhou, B, 2022)
"We report the case of a 74-years old patient with jejunum adenocarcinoma treated by capecitabine."4.12A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient. ( Botsen, D; Bouche, O; Gossery, C; Gratiaux, J; Rezzag-Mahcene, C; Slimano, F; Visseaux, L, 2022)
"The aim of this study was to investigate the antitumor effects of quercetin and luteolin combined with 5-Fluorouracil (5-FU) in HT-29 human colorectal cancer cells."4.12Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma ( Ağca, CA; Aşkın, H; Erdoğan, MK, 2022)
"Perioperative FLOT (5-fluorouracil, oxaliplatin and docetaxel) has recently become the gold standard treatment for fit patients with operable gastric (GC) or gastroesophageal (GEJ) adenocarcinoma, getting a 5-year overall survival (OS) of 45%, over 23% with surgery alone."4.02Results of the observational prospective RealFLOT study. ( Antonuzzo, L; Brugia, M; De Vita, F; Di Donato, S; Fancelli, S; Formica, V; Fornaro, L; Giommoni, E; Giovanardi, F; Iachetta, F; Lavacchi, D; Pecora, I; Pillozzi, S; Pompella, L; Pozzo, C; Prisciandaro, M; Puzzoni, M; Romagnani, A; Satolli, MA; Sisani, M; Spallanzani, A; Stragliotto, S; Strippoli, A; Tirino, G, 2021)
"Neoadjuvant folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) and chemoradiation have been used to downstage borderline and locally advanced pancreatic ductal adenocarcinoma (PDAC)."4.02Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. ( Allen, JN; Cai, L; Clark, JW; Deshpande, V; Fernández-Del Castillo, C; Ferrone, CR; Ferrone, S; Hong, TS; Kontos, F; Kurokawa, T; Lillemoe, KD; Michelakos, T; Neyaz, A; Qadan, M; Ryan, DP; Sabbatino, F; Taylor, MS; Ting, DT; Villani, V; Warshaw, AL; Weekes, CD; Wo, JY; Yamada, T, 2021)
"FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab is the preferred first-line treatment for right-sided metastatic colorectal cancer with RAS mutation."4.02Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report. ( Aomatsu, N; Ikeda, K; Kurihara, S; Maeda, K; Matsutani, S; Miyamoto, H; Nishii, T; Okada, T; Tachimori, A; Takeuchi, K; Tsujio, G; Uchima, Y, 2021)
"The use of FOLFIRINOX (a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) is one of the therapeutic standards in pancreatic adenocarcinoma."4.02Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis. ( Ben Abdelghani, M; Caron, B; Duclos, B; Kurtz, JE; Nguimpi-Tambou, M; Noirclerc, M; Reimund, JM; Sondag, D, 2021)
"A combination of nab-paclitaxel plus gemcitabine (N+G) has recently become a standard first-line treatment in patients with metastatic pancreatic adenocarcinoma (MPA), but there are currently no published data concerning second-line treatment after N+G."3.96Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study. ( Artru, P; Béchade, D; Desrame, J; Hautefeuille, V; Le Roy, B; Locher, C; Lourenco, N; Pernot, S; Pointet, AL; Pozet, A; Soularue, E; Taieb, J; Tougeron, D; Trouilloud, I; Williet, N, 2020)
"In this multicenter retrospective cohort analysis, we identified patients with metastatic biliary tract adenocarcinoma who were treated with Nal-IRI in combination with 5-fluorouracil and folinic acid following tumor progression under standard therapy at one of the study centers between May 2016 and January 2019."3.96First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer. ( Buchinger, D; Djanani, A; Prager, GW; Schmiderer, A; Taghizadeh, H; Unseld, M; Wilthoner, K, 2020)
"FOLFIRINOX [fluorouracil (5-FU), irinotecan, oxaliplatin] and gemcitabine plus nab-paclitaxel are standard treatments for patients with pancreatic ductal adenocarcinoma (PDAC)."3.96FOLFIRINOX ( Begg, SKS; Birnbaum, DJ; Castillo, CF; Clark, JW; Lillemoe, KD; Liss, AS; Mino-Kenudson, M; Schilling, O; Warshaw, AL; Wellner, UF, 2020)
" In this study we aim to compare the efficacy and toxicity of two regimens FOLFOX (leucoverin, 5-fluorouracil and oxaliplatin) and modified DCF (mDCF) (docetaxel, cisplatin, and 5-fluorouracil) in patients with advanced gastric adenocarcinoma."3.96Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma. ( Danandeh Mehr, A; Habibzadeh, A; Molaei, M; Pourghasemian, M, 2020)
"A 63-year-old Japanese male with stomach adenocarcinoma received oral 5-fluorouracil derivative, cisplatin and trastuzumab chemotherapy."3.96A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants. ( Fujiki, S; Hiratsuka, A; Ishiguro, M; Kawai, D; Ogura, K; Okada, H; Takeda, H; Takenaka, R; Tsugeno, H, 2020)
"We aimed to evaluate the efficacy and safety of 5-fluorouracil-based neoadjuvant chemoradiotherapy (NACRT) in patients with resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC)."3.91Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study. ( Abe, Y; Aiura, K; Endo, Y; Fukada, J; Hori, S; Itano, O; Kitagawa, Y; Kitago, M; Masugi, Y; Nakano, Y; Oshima, G; Shinoda, M; Yagi, H, 2019)
"The first-line chemotherapy of colorectal cancer (CRC), besides surgery, comprises administration of 5-Fluorouracil (5FU)."3.91Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo. ( Cumova, A; Galanova, N; Horak, J; Hucl, T; Kostovcikova, K; Kozics, K; Macinga, P; Opattova, A; Rejhova, A; Sliva, D; Turnovcova, K; Vodenkova, S; Vodicka, P; Vodickova, L, 2019)
" The aim of this study is to determine if SBRT with either chemotherapy (CMT) (Fluorouracil (5FU) or capecitabine) or Nelfinavir (NFV) to pancreatic adenocarcinoma induces lymphopenia to the same degree as CFRT with 5FU or capecitabine and how any associated difference affects patient survival outcomes."3.91Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer. ( Baine, MJ; Li, S; Li, X; Lin, C; Wu, G; Zhao, N, 2019)
"Coronary vasospasm associated with fluoropyrimidine (FP)-based chemotherapy is a potentially serious complication and reported to occur more often with infusional 5-fluorouracil (5-FU) or capecitabine than with bolus 5-FU."3.91Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine. ( Chakrabarti, S; Eiring, R; Finnes, H; Grothey, A; Halfdanarson, T; Hartgers, M; Lobo, R; Mitchell, J; Okano, A; Sara, J, 2019)
" We describe a strongly suspected elderly cancer patient's DDI between aprepitant and opium powder in the context of an irinotecan-based regimen manifested by nightmares and visual hallucinations."3.91Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction. ( Azzouz, B; Bouché, O; Clarenne, J; Narjoux, G; Slimano, F; Zeller, PS, 2019)
"Eighty-three patients were treated with locally advanced or metastatic adenocarcinoma of the pancreas with either FOLFIRINOX or nab-Paclitxel and Gemcitabine (nabPGem) as first- or second line therapy."3.91Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter? ( Andalibi, H; Heinrich, B; Kafka, A; Klaus, A; Öhler, L; Schima, W; Vogl, UM; Vormittag, L; Winkler, T, 2019)
"Oxaliplatin, combined with capecitabine (CAPOX) or infused 5-fluorouracil (FOLFOX), is standard of care in the adjuvant treatment of colorectal cancer (CRC)."3.91Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. ( Bono, P; Hänninen, UA; Karhunen, M; Lamminmäki, A; Osterlund, P; Soveri, LM, 2019)
"The objective is to investigate whether thymidylate synthase gene TS 5'-UTR polymorphism of peripheral blood mononuclear cells are associated with clinical outcomes of patients with stage II-III rectal adenocarcinoma treated with adjuvant 5-fluorouracil (5-FU) chemotherapy in Chinese population."3.91Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy. ( Chen, C; Li, S; Su, X; Wang, G; Xiao, H; Zhang, H, 2019)
" Therefore, we examined the effects of flavones against CYR61-overexpressing human gastric adenocarcinoma AGS (AGS-cyr61) cells, which show remarkable resistance to 5-fluorouracil (5-FU), adriamycin (ADR), tamoxifen (TAM), paclitaxel (PAC), and docetaxel (DOC)."3.88Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells. ( Cho, SK; Hyun, HB; Moon, JY, 2018)
"Perioperative epirubicin, cisplatin and 5-FU or capecitabine (ECF/X) chemotherapy is recognised as a standard of care for patients with resectable gastroesophageal adenocarcinoma; however, there is limited evidence regarding its use in older patients."3.88Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. ( Hepworth, R; Smith, E; Tin, AW; Wadd, N; Walker, J; Wilson, D, 2018)
"Lactoferrin nanoparticles demonstrated an attractive drug delivery module to manage the colon adenocarcinoma as it has improved the antiproliferative activity of 5-FU and Oxaliplatin against colon adenocarcinoma cells."3.88Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study. ( Ahmed, F; Kondapi, AK; Kumari, S, 2018)
"nab-Paclitaxel plus gemcitabine (nab-P + G) and FOLFIRINOX (FFX) are among the most common first-line (1L) therapies for metastatic adenocarcinoma of the pancreas (MPAC), but real-world data on their comparative effectiveness are limited."3.88Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States. ( Kim, S; Marshall, JL; Parisi, M; Patterson-Lomba, O; Signorovitch, JE; Ung, B; Xiang, CQ; Yang, H, 2018)
"Improved outcomes with FOLFIRINOX or gemcitabine with nab-paclitaxel in the treatment of metastatic pancreatic adenocarcinoma (PDAC) have prompted incorporation of these regimens into neoadjuvant treatment of locally advanced unresectable PDAC."3.88Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma. ( Allen, JN; Blaszkowsky, LS; Clark, JW; Fernandez-Del Castillo, C; Ferrone, CR; Hong, TS; Keane, FK; Kwak, EL; Lillemoe, KD; Ryan, DP; Wo, JY, 2018)
"Although 5-fluorouracil (5-FU) is known to interfere with the synthesis of ribonucleic acid and deoxyribonucleic acid, the mechanism underlying its therapeutic efficacy in colorectal cancer (CRC) has not been fully elucidated."3.855-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. ( Cao, L; Du, C; Gu, J; Huang, D; Peng, Y; Wang, H; Yang, Y; Yao, Y; Zhao, Y; Zhu, WG, 2017)
" In this study, we chose human colorectal adenocarcinoma cell line HT-29 as the experimental model, and investigated the differential biological effects between 250 mGy single dose LDIR and 250 mGy intermittent LDIR pretreatments in high dose irradiation (HDIR) radiotherapy and 5-fluorouracil (5-FU) based chemotherapy."3.85Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( Li, Y; Wang, Y; Yang, L; Yin, D, 2017)
"Starting 7 days after transplantation of colonic adenocarcinoma colon-26 cells, STZ-treated and control mice were intraperitoneally administered oxaliplatin, fluorouracil, and levofolinate (FOLFOX) every 2 weeks."3.85Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil. ( Hashida, T; Ikemura, M, 2017)
" A 44-year-old male underwent right hemicolectomy followed by capecitabine for a moderately differentiated adenocarcinoma of the colon."3.85Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE. ( Azrumelashvili, T; Chikovani, T; Janikashvili, N; Kikodze, N; Mizandari, M; Paksashvili, N; Pantsulaia, I; Shanava, K, 2017)
"To assess anatomic changes on computed tomography (CT) after neoadjuvant FOLFIRINOX (5-fluorouracil/leucovorin/irinotecan/oxaliplatin) chemotherapy for secondary resected borderline resectable (BR) and locally advanced (LA) pancreatic adenocarcinoma and their accuracy to predict resectability and pathological response."3.85CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. ( Antunes, C; Bachet, JB; Cassinotto, C; Lucidarme, O; Pietrasz, D; Sa Cunha, A; Wagner, M; Zappa, M, 2017)
"To evaluate the outcomes and toxicity of concurrent full-dose gemcitabine and intensity-modulated radiation therapy (IMRT) for patients with borderline resectable and locally advanced pancreatic adenocarcinoma after induction chemotherapy."3.83Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. ( Badiyan, SN; Hawkins, WG; Khwaja, S; Lee, AY; Linehan, DC; Menias, CO; Myerson, RJ; Olsen, JR; Parikh, PJ; Strasberg, SM; Wang-Gillam, A; Yano, M, 2016)
"We evaluated the usefulness of the in vitro adenosine triphosphate-based chemotherapy response assay (ATP-CRA) for prediction of clinical response to fluorouracil-based adjuvant chemotherapy in stage II colorectal cancer."3.83In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer. ( Kang, J; Kim, IK; Kwon, HY; Lee, KY; Sohn, SK, 2016)
" We sought to evaluate the pharmacokinetics of cisplatin and 5-fluorouracil in plasma and peritoneal dialysate in a patient being treated for esophageal adenocarcinoma."3.83A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. ( Beumer, JH; Eads, JR; Holleran, JL; Meropol, NJ; Negrea, L; Strychor, S, 2016)
"Ten patients with histologically diagnosed peritoneal metastases of adenocarcinoma or pseudomyxoma peritonei underwent cytoreductive surgery and received HIPEC with 5-fluorouracil for 90 min, delivered via our modified system."3.83Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin. ( Cavazos, M; Cravioto-Villanueva, A; Esquivel, J; Luna-Perez, P; Martinez-Gomez, H; Montiel, H; Ramirez, ML; Solorzano, J, 2016)
" In this study, we investigated the effect of NNMT on 5-fluorouracil (5-FU) sensitivity of colorectal cancer (CRC) cells, and the underlying mechanisms."3.83Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway. ( Li, F; Li, G; Liu, H; Ruan, Z; Wang, X; Wang, Y; Xie, X; Yu, H; Zhang, J; Zhou, Y, 2016)
"A 17 year-old male with metastatic pancreatic adenocarcinoma, under chemotherapy containing 5-fluorouracil, presented severe left ventricular dysfunction requiring mechanical ventilation and inotropes administration."3.83Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma. ( Chinali, M; De Pasquale, MD; De Sio, L; Giordano, U; Grimaldi, C; Mastronuzzi, A; Serra, A, 2016)
"When we examine a patient with symptoms of acute enteritis in the course of chemotherapy with oral fluoropyrimidines such as uracil-tegafur (often referred to as UFT), we usually suspect 5-fluorouracil-induced enterocolitis."3.83Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur. ( Abe, N; Fujinaga, A; Hayashi, H; Hirata, K; Ito, K; Komatsu, Y; Matsuda, K; Uchida, T, 2016)
"Two estrogen receptor (ER)-positive esophageal adenocarcinoma cell lines (OE-19 and OE-33) were treated with combinations of tamoxifen, cisplatin and 5-fluorouracil (5-FU)."3.83Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells. ( Astill, DS; Bastian, I; Ding, GQ; Due, SL; Hussey, DJ; Sukocheva, OA; Vat, L; Watson, DI, 2016)
"Perioperative chemotherapy with 5-fluorouracil and cisplatin, with or without epirubicin, improves overall survival in resectable gastroesophageal junction and gastric adenocarcinoma."3.83Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. ( Afchain, P; Aparicio, T; Artru, P; Bachet, JB; Baumgaertner, I; Benallaoua, M; Boige, V; Boubaya, M; Coriat, R; des Guetz, G; Lecaille, C; Locher, C; Mary, F; Samalin, E; Tougeron, D; Zaanan, A, 2016)
"To compare the treatment outcomes of concurrent involved-field radiotherapy and XELOX (oxaliplatin and capecitabine) versus XELOX chemotherapy alone in gastric adenocarcinoma patients with locoregional recurrence."3.81Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. ( Huang, Y; Li, WH; Li, YQ; Liu, N; Liu, SG; Liu, XB; Liu, YH; Wang, FL; Yu, J; Yuan, ST; Zhang, JD; Zhang, Y, 2015)
"The MAGIC/UK Medical Research Council (MRC) trial set the standard of care for treatment of resectable gastric and junctional adenocarcinoma, demonstrating that perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (ECF) confers a survival benefit over surgery alone."3.81Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery. ( Kalachand, R; King, S; Mongan, AM; Muldoon, C; O'Byrne, K; O'Farrell, NJ; Power, D; Ravi, N; Reynolds, JV, 2015)
"First-line treatment with FOLFIRINOX significantly increases overall survival (OS) in patients with metastatic pancreatic adenocarcinoma (PA) compared with gemcitabine."3.81FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. ( Bachet, JB; Blanc, JF; Carbonnel, F; Coriat, R; Cueff, A; De La Fouchardière, C; Francois, E; Gauthier, M; Lécaille, C; Malka, D; Manfredi, S; Marthey, L; Sa-Cunha, A; Solub, D; Taieb, J; Terrebonne, E; Thirot Bidault, A; Trouilloud, I, 2015)
" Here, we showed that miR-22 inhibited autophagy and promoted apoptosis to increase the sensitivity of colorectal cancer (CRC) cells to 5-fluorouracil (5-FU) treatment both in vitro and in vivo."3.81MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells. ( Kong, J; Lai, M; Li, C; Tang, J; Wang, J; Wu, Y; Xu, E; Zhang, H, 2015)
"Patients with locally advanced (cT3 or N+) esophageal and esophagogastric junction adenocarcinoma undergoing neoadjuvant TCF [Taxotere, cisplatin 5-fluorouracil (5-FU)], ECF (epirubicin, cisplatin, 5-FU), or FLOT (docetaxel, oxaliplatin, leucovorin, and 5-FU) at the McGill University Health Center from March 2007 to September 2012 were identified from a prospective database."3.81Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided? ( Alcindor, T; Asselah, J; Cools-Lartigue, J; Eckert, E; Ferri, LE; Jones, D; Rousseau, M; Spicer, J; Vanhuyse, M; Zourikian, T, 2015)
"An aptamer (Apt) conjugated hyaluronan/chitosan nanoparticles (HACSNPs) were prepared as carrier for targeted delivery of 5-fluorouracil (5FU) to mucin1 (MUC1) overexpressing colorectal adenocarcinomas."3.81Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas. ( Atyabi, F; Dinarvand, R; Esfandyari-Manesh, M; Ghasemi, Z; Mottaghitalab, F; Sayari, E, 2015)
"The use of PORT was associated with improved local control in the gemcitabine era for patients with resected, node-positive, pancreatic adenocarcinoma."3.81Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. ( Christein, JD; Dulaney, CR; Heslin, MJ; Jacob, R; Keene, KS; López-Araujo, J; McDonald, AM; Posey, JA; Wood, TE, 2015)
"Perioperative chemotherapy with epirubicin, cisplatin and 5-fluorouracil (5-FU) (ECF)-like regimens is the European standard for patients with adenocarcinoma of the gastroesophageal junction (GEJ) or gastric body (GaCa) stage UICC II/III (staged according to the Union for International Cancer Control)."3.81High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. ( Bichev, D; Breithaupt, K; Daum, S; Dogan, Y; Schmidt, SC; Thuss-Patience, PC; Treese, C; von Winterfeld, M, 2015)
"In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment, showing significant improvement in overall survival after surgery, although with substantial toxicity."3.81Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. ( Candamio-Folgar, S; Lopez-Lopez, R; Martínez-Lago, N; Padin-Iruegas, ME; Vazquez-Rivera, F; Vidal-Insua, Y; Vieito-Villar, M, 2015)
"The combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) is considered the first-line chemotherapy for fit patients with advanced pancreatic ductal adenocarcinoma (PDAC) but carries an unfavourable adverse event (AE) profile."3.81Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience. ( Basu, B; Calder, J; Corrie, P; Ghorani, E; Hewitt, C; Wong, HH, 2015)
"Hand-foot syndrome (HFS) is the most frequently reported side effect of oral capecitabine therapy."3.80Topical henna ameliorated capecitabine-induced hand-foot syndrome. ( Ilyas, S; Saif, MW; Wasif, K, 2014)
" A 65-year-old man started chemotherapy for metastatic pancreatic adenocarcinoma with oxaliplatin-irinotecan-leucovorin-5-fluorouracil (FOLFIRINOX)."3.80A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria. ( Dasanu, CA; Joseph, R, 2014)
"Despite the use of 5-fluorouracil (5-FU)-based adjuvant treatments, a large proportion of patients with high-risk stage II/III colorectal cancer will relapse."3.80AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer. ( Arthur, K; Blayney, JK; Dunne, PD; Greer, S; Johnston, PG; Kalimutho, M; Longley, DB; Loughrey, M; McArt, DG; Ong, CW; Redmond, K; Salto-Tellez, M; Srivastava, S; Van Schaeybroeck, S; Wang, T, 2014)
" In the present study, we evaluated ERCC1 expression levels in uterine cervical adenocarcinoma cell lines to assess whether they are affected by treatment with cisplatin with and without 5-fluorouracil (5-FU)."3.80ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells. ( Fujii, T; Hasegawa, K; Kato, R; Minami, Y; Torii, Y; Udagawa, Y, 2014)
" The aim of this study is to evaluate the efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy in advanced gastric adenocarcinoma patients in China."3.80Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation. ( Bai, L; Jin, Y; Li, YH; Luo, HY; Qiu, MZ; Ren, C; Wang, DS; Wang, FH; Wang, ZQ; Wei, XL; Xu, RH; Yang, DJ; Zhang, DS; Zhou, YX, 2014)
"To report a metastatic colorectal cancer patient with hyperbilirubinemia treated with a combination of bevacizumab and FOLFIRI (5-fluorouracil, leucovorin, and irinotecan) using uridine diphosphate glucuronosyl transferase (UGT1A1) genotyping."3.80FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping. ( Chang, SF; Chen, CF; Hu, HM; Huang, ML; Wang, JY; Yeh, YS, 2014)
"A 71-year-old patient receiving combination chemotherapy (irinotecan, oxaliplatin and 5-fluorouracil (5-FU)) for metastatic pancreas cancer was admitted after her first cycle of chemotherapy with a severe and unexpectedly prolonged episode of neutropenic sepsis associated with pancytopenia and marked mucositis."3.80A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer. ( Gillmore, R; Suarez Martinez-Falero, B, 2014)
"We retrospectively investigated the relationship between IVS14+1 G > A genotype of the dihydropyrimidine dehydrogenase (DPD) gene with plasma concentration of 5-fluorouracil (5-FU) as well as adverse reactions in 80 patients with locally advanced or metastatic colorectal cancer."3.80The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: ( Cai, X; Fang, JM; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2014)
"Current NCCN guidelines recommend epirubicin (E), cisplatin (C), and 5-fluorouracil (F) as a first-line therapeutic approach for operable gastric adenocarcinoma (GC)."3.80Molecular profiling in gastric cancer: examining potential targets for chemotherapy. ( Christians, KK; Eastwood, D; Gamblin, TC; George, B; Johnston, FM; Miura, JT; Thomas, J; Tsai, S; Turaga, KK, 2014)
"Our clinical study indicates esophageal adenocarcinoma patients on metformin had a better treatment response than those without metformin."3.80Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. ( Ajani, JA; Chen, Q; Honjo, S; Johnson, RL; Scott, AW; Skinner, HD; Song, S; Stroehlein, J, 2014)
"We surmise that 5-fluorouracil, levofolinate, and oxaliplatin have the potential to provide a good response for tumors that are sensitive to fluorinated pyrimidine and platinum-containing anticancer drugs such as breast cancer."3.80An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report. ( Goto, M; Ishiyama, S; Kojima, Y; Komiyama, H; Niwa, K; Okuzawa, A; Sakamoto, K; Sugimoto, K; Takahashi, M; Tomiki, Y; Yaginuma, Y, 2014)
"The aim of this study was to investigate the antitumor effect of rapamycin, an inhibitor of mammalian target of rapamycin (mTOR) signaling, combined with 5-fluorouracil treatment on CT-26 colorectal adenocarcinoma cells implanted into BALB/c mice."3.80The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells. ( Chang, GR; Chao, TH; Chen, PL; Chen, WY; Mao, FC, 2014)
"Patients with biopsy-proven adenocarcinoma of the rectum staged cT3-T4 by endoscopic ultrasound or magnetic resonance imaging received neoadjuvant continuous infusion of 5-fluorouracil for five weeks and concomitant radiotherapy."3.80Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation. ( Ayuso-Colella, JR; Bombí, JA; Burkholder, I; Castells, A; Conill, C; Cuatrecasas, M; Delgado, S; Feliz, L; Fernández-Esparrach, G; Gallego, R; García-Albéniz, X; Ginés, A; Hochhaus, A; Hofheinz, RD; María de Lacy, A; Maurel, J; Miquel, R; Pagés, M; Pereira, V; Pineda, E; Reig, O; Sosa, A; Victoria, I, 2014)
"The aim of the present study was to evaluate the change of thymidine phosphorylase (TP) activity in gastric adenocarcinoma and adjacent tissue upon the intraarterial administration of 5-fluorouracil (5-FU)."3.80The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue. ( Dumanskiy, Y; Khomutov, E; Matviyenko, A; Stashkevych, M; Zinkovych, I, 2014)
"From March 2009 through April 2012, 22 patients were treated with proton therapy and concomitant capecitabine (1000 mg PO twice daily) for resected (n = 5); marginally resectable (n = 5); and unresectable/inoperable (n = 12) biopsy-proven pancreatic and ampullary adenocarcinoma."3.79Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity. ( Asbun, HJ; Awad, ZT; George, TJ; Ho, MW; Hoppe, BS; Huh, S; Mendenhall, NP; Morris, CG; Nichols, RC; Zaiden, RA, 2013)
"The efficacy of triple-drug combination regimens such as epirubicin, oxaliplatin and capecitabine (EOX) is superior to standard cisplatin/5-fluorouracil, but considerable toxicity needs to be taken into account in patients with upper gastrointestinal adenocarcinoma."3.79Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma. ( Asari, R; Ba-Ssalamah, A; Birner, P; Datler, P; Hejna, M; Pluschnig, U; Preusser, M; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013)
" This study was to investigate whether downregulation of Bcl-2 expression by small interfering RNA (siRNA) against the Bcl-2 gene would enhance the apoptosis and sensitivity of gastric adenocarcinoma SGC-7901 cell to 5-Fluorouracil."3.79Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells. ( Liu, H; Liu, Y; Wu, FR; Xia, Q; Yu, DF, 2013)
"The efficacy of triple-drug combination regimens such as docetaxel, cisplatin and 5-fluorouracil (DCF), and epirubicin, oxaliplatin and capecitabine (EOX), is superior to standard cisplatin/5-fluorouracil in patients with upper gastrointestinal adenocarcinoma."3.79Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract. ( Asari, R; Ba-Ssalamah, A; Birner, P; Hejna, M; Ilhan-Mutlu, A; Pluschnig, U; Preusser, M; Püspök, A; Schoppmann, SF; Schwameis, K; Zacherl, J, 2013)
"To evaluate the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the first line treatment of advanced gastric adenocarcinoma."3.79Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma. ( Liu, Y; Ma, T; Shi, M; Xi, W; Yang, L; Ye, Z; Zhang, J; Zhu, Z, 2013)
"The aim of this study was to evaluate the efficacy and tolerability of a gemcitabine, 5-fluorouracil and leucovorin (GEMFUFOL) chemotherapy regimen as first line treatment of metastatic biliary tract cancer."3.79Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers. ( Oztop, I; Unal, OU; Unek, IT; Yilmaz, AU, 2013)
" In this study, we had investigated the synergistic effects of low dose fluorouracil (5-Fu) and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells and explored the potential mechanisms."3.79The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells. ( He, J; Huang, M; Huang, Y; Ren, D; Yi, C; Zhao, F; Zhu, H, 2013)
" We aimed to investigate the effects of fish oil emulsion (FOE) rich in n-3 PUFA with the standard chemotherapeutic agents 5-fluorouracil (5-FU), oxaliplatin (OX) or irinotecan (IRI) on two human colorectal adenocarcinoma cells with different genetic backgrounds."3.79Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway. ( Cai, F; Clerc, A; Dupertuis, YM; Granci, V; Lecumberri, E; Pichard, C, 2013)
"The prognostic impact of CpG island methylator phenotype (CIMP) and microsatellite instability (MSI) on the treatment outcome of colon cancer patients receiving adjuvant 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX) is unclear."3.79Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer. ( Bae, JM; Bang, YJ; Cho, NY; Han, SW; Im, SA; Jeong, SY; Kang, GH; Kim, TY; Lee, HJ; Lee, KH; Oh, DY; Park, JG; Park, KJ, 2013)
"Five prognostic factors had been previously identified in patients with metastatic colorectal cancer (MCRC) who received irinotecan-based second-line chemotherapy."3.79Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. ( Fukushima, H; Komatsu, Y; Muro, K; Naito, Y; Shitara, K; Takano, T; Yamazaki, K; Yasui, H; Yuki, S, 2013)
" Surgery Division of Verona University, 155 consecutive patients with locally advanced esophageal cancers (90 SCC, 65 adenocarcinoma) were treated with a single protocol of neoadjuvant CRT (docetaxel, cisplatin, and 5-fluorouracil with 50."3.79Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center. ( Casella, F; de Manzoni, G; Giacopuzzi, S; Pasini, F; Verlato, G; Weindelmayer, J; Zanoni, A; Zhao, E, 2013)
" This study sought to enrich cancer stem cells and explore cancer stem-like cell clones using 5-fluorouracil (5-FU) in the lung adenocarcinoma cell line, SPC."3.79Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC. ( Jia, XS; Li, X; Li, XL; Shi, MM; Wang, EH; Xiong, YL; Zhang, L, 2013)
" The aim of this study is to retrospectively evaluate the safety and efficacy of adjuvant epirubicin-based triplet chemotherapy and radiotherapy in the treatment of resected locally advanced stomach or gastroesophageal junction adenocarcinoma."3.79Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. ( Cai, G; Li, G; Ma, X; Zhang, Z; Zhu, J, 2013)
"Patients with Dukes' B colon cancer benefit from adjuvant chemotherapy and should be presented with this treatment option."3.79Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04) ( Atkins, JN; Bear, HD; Jones, J; Mamounas, E; Rockette, H; Song, K; Wieand, S; Wolmark, N, 1999)
"The aim of this study was to determine the pathological complete remission (pCR) rate, and its relationship to clinical outcome, in patients with adenocarcinoma of the stomach or oesophagogastric junction receiving preoperative 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) every 2 weeks."3.78Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel. ( Al-Batran, SE; Altmannsberger, HM; Atmaca, A; Bruch, HP; Homann, N; Jäger, E; Luley, K; Noack, F; Pauligk, C; Werner Kraus, T, 2012)
"Studies treating adenocarcinoma of the pancreas with gemcitabine alone or in combination with a doublet have demonstrated modest improvements in survival."3.78A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma. ( Blackford, A; Chung, K; Cosgrove, D; De Jesus-Acosta, A; Diaz, LA; Donehower, RC; Flores, EI; Kinsman, K; Laheru, D; Le, DT; Oliver, GR; Wilfong, LS; Zheng, L, 2012)
"FOLFOXIRI demonstrated higher efficacy compared to 5-fluorouracil, leucovorin, irinotecan (FOLFIRI) as first-line treatment of metastatic colorectal cancer."3.78Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen. ( Allegrini, G; Baldi, GG; Brunetti, IM; Cortesi, E; Cremolini, C; Cupini, S; Falcone, A; Fornaro, L; Granetto, C; Loupakis, F; Masi, G; Ricci, S; Salvatore, L; Tuzi, A; Vasile, E, 2012)
"We assessed DNA repair efficiency over time, in vitro, in human colon adenocarcinoma HT-29 (wild-type KRAS) and HCT-116 (mutated KRAS) cell lines treated with Dbait in combination with 5-fluorouracil and/or camptothecin."3.78Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer. ( Berger, F; Biau, J; Bousquet, G; Devun, F; Dutreix, M; Herbette, A; Robine, S; Roulin, C; Sun, JS, 2012)
"The patients with local advanced and metastatic colorectal cancer, receiving fluorouracil-based chemotherapy, and with an average plasma concentration of fluorouracil between 25 - 35 mg/L have a better prognosis, and lower incidence of adverse reactions such as bone marrow suppression, mucositis and diarrhea."3.78[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy]. ( Cai, X; Gu, HL; Hu, J; Song, WF; Wang, LW; Xue, P; Yang, HY, 2012)
"Human adenocarcinoma cells, colonic (Caco-2) and ovarian (59 M) cells, were incubated with 5-fluorouracil (1-300 µg·mL(-1) ) or paclitaxel (1-200 µg·mL(-1) ) in the presence or absence of platelets (1."3.78Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. ( Bazou, D; Inkielewicz-Stepniak, I; Jow, H; Medina, C; O'Driscoll, L; Radomski, A; Radomski, MW; Radziwon-Balicka, A; Treumann, A, 2012)
"A recent study showed that both 5-fluorouracil (5FU)-stimulated apoptosis and Fas-mediated apoptosis in human endometrial adenocarcinoma cells are enhanced by targeted knockdown of endogenous death-associated protein kinase (DAPK) with DAPK small-interfering RNAs."3.78Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells. ( Bai, T; Tanaka, J; Tanaka, T; Toujima, S; Utsunomiya, H; Utsunomiya, T; Yukawa, K, 2012)
"Capecitabine plus oxaliplatin combination (XELOX) is the first-line treatment in metastatic colorectal cancer."3.78Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. ( Alì, G; Calabrese, R; Lenzi, P; Moretti, P; Orsucci, D; Petrozzi, L; Pizzanelli, C; Ricci, G; Siciliano, G, 2012)
"Five patients with primary colorectal adenocarcinoma or anal squamous cell carcinoma were started on a 2-weeks-on, 1-week-off capecitabine dosing regimen in addition to other chemotherapeutic agents and/or radiation."3.78Capecitabine-induced chest pain relieved by diltiazem. ( Ambrosy, AP; Fisher, GA; Kunz, PL; Witteles, RM, 2012)
"To evaluate the efficacy and safety of the FOLFIRI regimen in patients with metastatic pancreatic adenocarcinoma (PAC) after the failure of gemcitabine and platinum salts."3.78FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. ( Bengrine-Lefèvre, L; Bonnetain, F; Hammel, P; Hentic, O; Lévy, P; Louvet, C; Neuzillet, C; Raymond, E; Rebours, V; Rousseau, B; Ruszniewski, P, 2012)
" The absence of any abnormalities in the infant makes irinotecan and fluorouracil a valid therapeutic option for colon cancer during pregnancy."3.78Irinotecan during pregnancy in metastatic colon cancer. ( Cassandrini, PA; Cirillo, M; Lunardi, G; Musola, M; Venturini, M, 2012)
"Fourteen cases of metastatic brain tumors from lung cancer underwent biochemical modulation chemotherapy with daily administration of small doses of CDDP (5 or 10 mg/day) and continuous infusion of 5-FU (300 mg/day) for three tow six weeks."3.78[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer]. ( Hagiwara, Y; Kanayama, T; Moriuchi, S; Nakagawa, H; Yamada, M, 1997)
"To assess whether early lung cancer prediction might be informed by an mRNA assay for 5-fluorouracil pathway genes in peripheral blood mononuclear cells (PBMNCs), we examined specimens taken from 51 adenocarcinoma patients and 38 controls (including six patients with benign tumors)."3.77A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma. ( Aida, S; Fujita, Y; Hasegawa, S; Hiroi, S; Kawai, T; Mio, T; Nakanishi, K; Ogata, S; Ozeki, Y; Takeuchi, K; Tanaka, F; Tominaga, S; Wada, H, 2011)
"Capecitabine plus oxaliplatin (CAPOX) is an established treatment option in colorectal cancer, but can be associated with severe toxicities."3.77Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction. ( Baird, R; Barbachano, Y; Biondo, A; Chau, I; Chhaya, V; Cunningham, D; Karpathakis, A; McLachlan, J; Rahman, S, 2011)
"Cisplatin-/5-fluorouracil-resistant oesophageal squamous cell carcinoma (SCC) and adenocarcinoma (EAC) cell lines were established, and the impact of ectopic upregulation of miR-106a and miR-148a on response to both drugs was assessed."3.77Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells. ( Haier, J; Hummel, R; Hussey, DJ; Kist, J; Michael, MZ; Smith, C; Watson, DI, 2011)
"There has been limited data on capecitabine monotherapy in metastatic colorectal cancer (CRC) patients who were previously treated with both oxaliplatin/5-fluorouracil(FU)/leucovorin (FOLFOX) and irinotecan/5-FU/leucovorin (FOLFIRI)."3.77Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer. ( Choi, YJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2011)
"The aim of this retrospective study was to evaluate the efficacy and safety of weekly high-dose 5-fluorouracil (5-FU)/folinic acid (FA) as 24-h infusion (AIO regimen) plus irinotecan in patients with histologically proven metastatic gastroesophageal adenocarcinoma (UICC stage IV)."3.77Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b ( Albrecht, H; Boxberger, F; Busse, D; Golcher, H; Hahn, EG; Hohenberger, W; Janka, R; Konturek, PC; Koucky, K; Männlein, G; Neurath, MF; Ostermeier, N; Reulbach, U; Schildberg, C; Siebler, J; Wein, A; Wolff, K, 2011)
" Here we show that ATP-binding cassette member B5 (ABCB5) identifies therapy-refractory tumor cells in colorectal cancer patients following fluorouracil (5-FU)-based chemoradiation therapy and provide evidence for a functional role of ABCB5 in colorectal cancer 5-FU resistance."3.77ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients. ( Frank, MH; Frank, NY; Gasser, M; Gold, JS; Huang, Q; Ma, J; Murphy, GF; Saab, KR; Schanche, R; Schatton, T; Waaga-Gasser, AM; Wilson, BJ; Zhan, Q, 2011)
"FOLFOX (a combination of leucovorin, fluorouracil and oxaliplatin) has achieved substantial success in the treatment of colorectal cancer (CRC) patients."3.77Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients. ( Eshima, K; Horie, H; Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Konishi, T; Matsuda, K; Muto, T; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"Regimens containing bevacizumab and 5-fluorouracil have achieved substantial progress in the treatment of colorectal cancer."3.77Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients. ( Iinuma, H; Ikeuchi, H; Ishihara, S; Kobunai, T; Matsuda, K; Nozawa, K; Watanabe, T; Yamamoto, Y, 2011)
"A retrospective analysis was carried out to evaluate toxicity and efficacy of the combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil (DCF) plus granulocyte colony-stimulating factor prophylaxis (G-CSF) in patients with metastatic gastric and gastroesophageal junction adenocarcinoma."3.77Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna. ( Ba-Ssalamah, A; Bojic, M; Datler, P; Hejna, M; Maresch, J; Pluschnig, U; Schoppmann, SF; Thallinger, CM; Zacherl, J, 2011)
"XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC)."3.77Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement. ( Chau, J; Chua, DT; Lee, AW; Lee, V; McGhee, SM; Ng, WT; Tse, VC, 2011)
"To evaluate the efficacy and toxicity of irinotecan and oxaliplatin plus 5-fluorouracil (FU) and leucovorin (FOLFIRINOX) as second-line therapy in metastatic pancreatic adenocarcinoma (MPA)."3.775-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma. ( Assaf, E; Baumgaertner, I; Bouaita, L; Culine, S; Delbaldo, C; Grenier, J; Paul, M; Pouessel, D; Sellam, Z; Sobhani, I; Tayar, C; Verlinde-Carvalho, M, 2011)
"The aim of this study was to investigate efficacy and toxicity of a modified 5-fluorouracil (5-FU), folinic acid, oxaliplatin (mFOLFOX-4) regimen followed by infusional 5-FU concomitant with radiotherapy for curatively resected stage III rectum adenocarcinoma patients."3.77Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma. ( Aksoy, S; Babacan, NA; Cihan, Ş; Odabaş, H; Öksüzoğlu, B; Özdemir, N; Uncu, D; Zengin, N, 2011)
" Perioperative treatment with epirubicin, cisplatin, and 5-fluorouracil combination chemotherapy and surgery is considered the standard treatment of locally advanced gastric adenocarcinoma."3.77Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer. ( Amini, A; Sanati, H, 2011)
"To investigate anticancer effects of 5-fluorouracil (5-FU) combined with CL, extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma cell line (JEC)."3.77[Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma]. ( Dai, ZK; Yang, XS; Yu, LM, 2011)
"The aim of this study was to determine whether the relative mRNA expressions of the thymidylate synthase (TYMS) and the excision repair cross-complementing 1 (ERCC1) genes are associated with in vitro chemosensitivity to 5-fluorouracil (5-FU) and oxaliplatin in colorectal cancer, respectively."3.77Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer. ( Cho, YB; Choi, SH; Chun, HK; Chung, HJ; Kim, HC; Lee, WY; Yun, SH, 2011)
"For a woman with poorly-differentiated anal canal adenocarcinoma in acknowledgment of metastasis to right inguinal lymph node, we gave radiotherapy combined with capecitabine as chemotherapy."3.77[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node]. ( Ide, Y; Makino, S; Murata, K, 2011)
"5-fluorouracil was administered at a daily dose of 450 mg/m2 followed by folinic acid 200 mg/m2 for four consecutive days every four weeks."3.77Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature. ( Briassoulis, E; Klouvas, G; Nicolaides, C; Pavlidis, N, 1994)
"Failure rate of colorectal cancer after surgical resection remains around 50% and adjuvant treatments are clearly required."3.77Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU. ( Nordlinger, B; Rougier, P, 1993)
"Current and proposed trials in esophageal cancer have changed their focus accordingly to meet this new treatment challenge."3.77The use of mitomycin in esophageal cancer. ( Coia, LR, 1993)
"Mitomycin has also demonstrated efficacy when given in combination with doxorubicin and in the three-drug regimen FAM (5-fluorouracil/doxorubicin/mitomycin)."3.77Mitomycin therapy in gastric cancer. ( Macdonald, JS; Schnall, S, 1993)
"Levamisole is a synthetic, orally active agent that has antihelmintic and immunomodulatory properties."3.77Levamisole in the adjuvant treatment of colon cancer. ( Hutson, PR; Mutch, RS, 1991)
"To investigate the mechanism of enhancing apoptosis-inducing effects of 5-fluorouracil on human colorectal adenocarcinoma cells by stable transfection of extrinsic Fas-associated death domain protein (FADD) gene, both in vitro and in vivo."3.76Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells. ( Jiang, Y; Luo, H; Yin, A; Zhang, X, 2010)
" We investigated whether p53 polymorphism and mutation were associated with in vitro sensitivity to 5-fluorouracil (5-FU) in patients with colorectal cancer."3.76Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer. ( Higashiguchi, T; Hotta, T; Iwahashi, M; Matsuda, K; Nasu, T; Oku, Y; Takifuji, K; Tominaga, T; Yamaue, H; Yokoyama, S, 2010)
"The aim was to determine the values of p53 tumour expression and microsatellite instability (MSI) phenotype to predict benefit from adjuvant chemotherapy of colon cancer by 5-fluorouracil and leucovorin (FL) alone or with oxaliplatin (FOLFOX)."3.76Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. ( Cuilliere-Dartigues, P; de Gramont, A; Dumont, S; Duval, A; Fléjou, JF; Gayet, B; Guilloux, A; Louvet, C; Parc, Y; Praz, F; Tiret, E; Validire, P; Zaanan, A, 2010)
"The purpose of the present study was to investigate polymorphisms related to the metabolism of fluoropyrimidine and oxaliplatin, thymidylate synthase (TS) and excision repair cross-complementing gene 1 (ERCC1) 118, in metastatic colorectal cancer patients treated with capecitabine and oxaliplatin (XELOX)."3.76EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer. ( Andersen, RF; Jakobsen, A; Jensen, LH; Ploen, J; Spindler, KG, 2010)
"5-fluoro-uracil (FU) is a common agent in postoperative chemoradiation in gastric adenocarcinoma."3.76A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma. ( Akboru, H; Bati, Y; Isikli, L; Unsal, M; Yoney, A, 2010)
"We performed retrospective study in order to compare oxaliplatin, leucovorin, and fluorouracil (FOLFOX) versus irinotecan, leucovorin, and fluorouracil (FOLFIRI) in recurred or metastatic gastric adenocarcinoma."3.76[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma]. ( Jeong, HY; Kang, SH; Kim, JI; Kim, SH; Lee, BS; Moon, HS; Sung, JK, 2010)
"We examined the pre-treatment tumour biopsies (n=40) obtained from patients with rectal adenocarcinoma (clinical International Union Against Cancer stage ll/III) who were scheduled to receive neoadjuvant 5-fluorouracil-based chemoradiotherapy for EGFR, VEGF and HIF-1 expression by quantitative real-time polymerase chain reaction."3.76Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg ( Inoue, Y; Kusunoki, M; Miki, C; Okugawa, Y; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2010)
"A 78-year-old male with stage III colorectal adenocarcinoma was prescribed with weekly iv 5-fluorouracil and folinic acid (FU/FA)."3.76Do 5-fluorouracil therapies alter CYP2C19 metaboliser status? ( Helsby, NA; Laking, GR; Lo, WY; Thompson, P, 2010)
" In the first phase III study, the ToGA trial, HER2-positive patients with advanced gastroesophageal and gastric adenocarcinoma were randomized to receive 5-fluorouracil/capecitabine and cisplatin either alone or in combination with trastuzumab."3.76Targeted HER2 treatment in advanced gastric cancer. ( Jørgensen, JT, 2010)
"Survival and recurrence patterns of 91 patients with adenocarcinoma of the stomach who had received surgery followed by radiotherapy combined with fluorouracil and leucovorin (n = 5), capecitabine (n = 39), or capecitabine and cisplatin (n = 47) were analyzed and compared with survival and recurrence patterns of 694 patients from the DGCT (D1, n = 369; D2, n = 325)."3.76Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer. ( Bakker, B; Boot, H; Cats, A; Dikken, JL; Hartgrink, HH; Jansen, EP; Kranenbarg, EM; Peeters, KC; Putter, H; van de Velde, CJ; Verheij, M, 2010)
" Using multiparameter cytometry we explored the effects of doxorubicin (DOX), cisplatin (CDDP) and 5-fluorouracil (5-FU) on four types of endometrioid adenocarcinoma cell lines (HEC-1A, HEC-1B, Ishikawa, KLE) correlating the drug-induced increases in phosphorylated H2AX (gammaH2AX) with cell cycle phase, induction of apoptosis and induction of cell senescence, the latter detected by analysis of beta-galactosidase."3.76DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines. ( Darzynkiewicz, Z; Ikeda, M; Kurose, A; Sawai, T; Sugiyama, T; Takatori, E; Traganos, F, 2010)
" In this study, we examined the chemoresistance to 5-Fluorouracil (5-FU) using MCF-7 breast cancer MTS."3.76Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids. ( Jeon, HM; Jeong, EK; Kang, HS; Kim, CH; Lee, SY, 2010)
"Epirubicin, cisplatin or 5-fluorouracil was administered to severe combined immune-deficient mice bearing OE19 oesophageal adenocarcinoma xenografts."3.76Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy. ( Appleyard, V; Baker, L; Exon, D; Kelly, P; Lamont, D; Murray, K; Paulin, F; Suttie, S; Thompson, A, 2010)
"The aim of this study was to determine whether pretherapeutic protein expression levels of the excision repair cross-complementing (ERCC1) enzyme, thymidylate synthetase (TS), multidrug-resistance protein 1 (MRP-1) and P-glycoprotein (P-gp) are associated with tumour response to cisplatin and fluorouracil (5-FU)-based neoadjuvant chemotherapy in oesophageal adenocarcinomas."3.76High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. ( Becker, K; Feith, M; Hofler, H; Langer, R; Lordick, F; Ott, K; Specht, K, 2010)
"To investigate acquired 5-fluorouracil (5FU)-resistance in cancer cells, we established four monoclonal 5FU-resistant cell lines from human endometrial adenocarcinoma cells by long-term 5FU-exposure cultures and limiting dilution cultures."3.76Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma. ( Bai, T; Tanaka, T; Toujima, S, 2010)
"Between January 2006 and November 2009, 17 patients (median age of 61 years) with advanced pancreatic adenocarcinoma, after receiving gemcitabine-containing chemotherapy as first-line median ECOG performance status 1 and with adequate organ function, were treated with either weekly docetaxel at 25 mg/m(2) or 3-weekly docetaxel regimen (docetaxel at 75 mg/m(2) or docetaxel-gemcitabine-capecitabine or docetaxel-gemcitabine) until progressive disease."3.76Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study. ( Kaley, K; Penney, R; Saif, MW; Syrigos, K, 2010)
"One hundred fifty-six patients with locally advanced or metastatic esophageal adenocarcinoma received neoadjuvant chemotherapy with cisplatin, 5-fluorouracil, and leucovorin followed by resection."3.76Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma. ( Friess, H; Holzmann, B; Knoefel, WT; Peiper, M; Schauer, MC; Theisen, J, 2010)
"The combination regimen of mitomycin-C/5-FU/leucovorin showed marginal activity and tolerable toxicity profiles in heavily pretreated metastatic colorectal cancer patients."3.76Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma. ( Choi, IK; Choi, YJ; Kang, EJ; Kim, JS; Kim, ST; Kim, YH; Oh, SC; Park, KH; Seo, JH; Shin, SW, 2010)
"A recent meta-analysis study showed that post-operative adjuvant chemotherapy with UFT, an oral combination drug composed of tegafur [prodrug of 5-fluorouracil (5-FU)] and uracil [inhibitor of dihydropyrimidine dehydrogenase (DPD)] was associated with improved survival in patients with lung adenocarcinomas, but not in those with lung squamous cell carcinomas."3.75Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung. ( Araki, O; Chida, M; Honma, K; Ishihama, H; Karube, Y; Masawa, N; Miyoshi, S; Seki, N; Tamura, M; Umezu, H, 2009)
" In the present study we investigate the effects of HIF-1 modulation on the response of the human colon adenocarcinoma cell line HCT116 to 5-fluorouracil (5FU)."3.75Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. ( Gariboldi, MB; Marras, E; Molteni, R; Monti, E; Perletti, G; Ravizza, R, 2009)
"The aim of this study was to determine whether the expression of the excision repair cross-complementing 1 (ERCC1), thymidylate synthase (TS) and glutathione S-transferase pi (GSTpi) predict clinical outcome in patients with advanced colorectal cancer treated with fluorouracil (5-FU)/oxaliplatin chemotherapy."3.75Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer. ( Choi, HJ; Kim, DC; Kim, HJ; Kim, SH; Kwon, HC; Lee, DM; Lee, JH; Lee, S; Oh, SY; Park, KJ; Roh, MS, 2009)
"We report an elderly patient with esophageal adenocarcinoma in whom a complete response (CR) was obtained by chemoradiotherapy using daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU."3.75[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation]. ( Furuta, T; Futami, H; Hamaya, Y; Ikuma, M; Iwaizumi, M; Kodaira, C; Muramatsu, A; Nishino, M; Osawa, S; Sugimoto, K; Takagaki, K; Yamada, T; Yoshida, K, 2009)
"A case of acute heart failure due to Takotsubo cardiomyopathy induced by 5-fluorouracil is described."3.75A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. ( Hata, N; Kobayashi, N; Mizuno, K; Shinada, T; Shirakabe, A; Yokoyama, S, 2009)
"The correlations between adenomatous polyposis coli (APC) mutations and 5-fluorouracil (5-FU) adjuvant chemotherapy and colorectal cancer (CRC) patients' prognosis are not well known."3.75Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects. ( Chen, SP; Chen, YL; Chiu, SC; Harn, HJ; Kang, JC; Lin, PC; Lin, SZ; Pang, CY; Su, CC; Wu, CC, 2009)
"Stage II-III colorectal cancer patients treated with adjuvant FOLFOX or fluorouracil/leucovorin (5-FU/LV) at Roswell Park Cancer Institute between 2002 and 2006 were identified."3.75Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. ( Angitapalli, R; Fakih, MG; Kumar, PR; Litwin, AM; Lombardo, J; Mashtare, T; Nasser, E; Wilding, GE, 2009)
"It is the aim of this study to assess the outcome of patients who received neoadjuvant 5-fluorouracil-cisplatin chemoradiation (CRT) for stage I/III pancreatic adenocarcinoma."3.75Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. ( de Chaisemartin, C; Delpero, JR; Giovannini, M; Guiramand, J; Lelong, B; Moureau-Zabotto, L; Moutardier, V; Turrini, O; Viret, F, 2009)
"As surgery and chemotherapy may act as adjuvants providing antitumor immunity benefits, we ran phenotypical and functional immunomonitoring in patients with resectable pancreatic adenocarcinoma and advanced metastatic disease receiving combined treatment (cisplatin, gemcitabine, 5-FU)."3.75Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy. ( Addeo, A; Bellone, G; Brondino, G; Campra, D; Ciuffreda, L; Fronda, GR; Giacobino, A; Novarino, A; Prati, A; Vizio, B, 2009)
" The authors of this report reviewed their experience in a consecutive, unselected series of patients who received adjuvant 5-fluorouracil (5-FU) and radiation therapy (RT) for resected pancreatic adenocarcinoma."3.75Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. ( Hattangadi, JA; Hong, TS; Mamon, HJ; Yeap, BY, 2009)
" We report a case of a patient with metastatic lung adenocarcinoma with high levels of LDH and CEA with clear partial response to capecitabine after several lines of chemotherapy."3.75Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. ( Mendiola, C; Vaz, MA, 2009)
"We studied 150 surgically resected colorectal adenocarcinoma patients who received postoperative 5-Fluorouracil (5-FU) chemotherapy."3.75Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma. ( Bronner, MP; Chang, SJ; Cho, MY; Eom, M; Kim, IY; Kim, MD; Koh, SB; Ren, DN; Seong, SH; Yi, SY, 2009)
"One hundred and twenty-one MCRC patients with histologically proven adenocarcinoma and baseline ECOG performance status of < or =2 were treated with oxaplatin and (or) irinotecan-based chemotherapy regimens."3.75[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy]. ( An, X; Feng, F; He, YJ; Jiang, WQ; Li, YH; Wang, FH; Wang, ZQ; Xiang, XJ; Xu, RH, 2009)
"5-Fluorouracil (5-FU) is considered to be the backbone of colorectal cancer (CRC) systemic therapy since the great majority of recommended regimens include its administration."3.75Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma. ( Garita, R; Michelin, OC; Okoshi, K; Paiva, BS; Paiva, CE, 2009)
"5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma."3.75APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling. ( Aly, E; Binnie, N; Collie-Duguid, ES; Gilbert, F; Loudon, M; MacDonald, G; McKinlay, A; Murray, GI; O'Kelly, T; Petty, RD; Samuel, LM; Semple, S; Wang, W, 2009)
" The aim of this study was to elucidate whether hyperoxia also enhances any actual uptake of 5FU (5-fluorouracil) into the tumor tissue and if this can be explained by changes in the interstitium and extracellular matrix."3.75Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma. ( Kolmannskog, O; Moen, I; Reed, RK; Salvesen, GS; Stuhr, LE; Tronstad, KJ, 2009)
"Human colorectal cancer cells were treated, individually and in combination, with Rosco, taxol, 5-Fluorouracil (5-FU), doxorubicine or vinblastine."3.74Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells. ( Abaza, MS; Al-Attiyah, RJ; Bahman, AM, 2008)
"We report the effectiveness of a combination chemotherapy consisting of ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus."3.74Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus. ( Fujii, Y; Fukui, I; Ishikawa, Y; Kawakami, S; Komai, Y; Okubo, Y; Takeshita, H; Tatokoro, M; Yamamoto, S; Yonese, J, 2008)
"Preoperative chemoradiation with 5-fluorouracil (5-FU) has improved local control and resectability in patients with locally advanced rectal adenocarcinoma."3.74Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer. ( Kauh, J; Koshy, M; Landry, J; Lawson, JD; Staley, C, 2008)
"To compare the efficacy and tolerability of the regimen FOLFOX [1eucovorin (LV), 5-fluorouracil (5-Fu) and oxaliplatin] and the regimen PLF (Paclitaxel, leucovorin and 5-Fu) for treatment of advanced gastric adenocarcinoma."3.74[FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma]. ( Huang, Y; Lin, TY; Rong, J; Xiao, J; Ye, S; Zhai, LZ, 2008)
"To present our clinical experience of 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen administered as an adjuvant chemotherapy to 2 patients with advanced jejunal adenocarcinoma."3.74Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases. ( Chen, CW; Hsieh, JS; Su, YC; Wang, JY; Wang, WM; Wu, JY, 2008)
" This article presents the case of a 69-year-old African American man with a gastric adenocarcinoma status post gastrectomy who received 5-fluorouracil (5-FU) plus leucovorin for 5 days, to be followed by radiation plus capecitabine given 5 days per week for 5 weeks, and then 8 weeks of capecitabine monotherapy."3.74Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity? ( Saif, MW; Sandoval, A, 2008)
"We have evaluated the 5-fluorouracil sensitivity of cancer cells from colorectal cancer patients using the collagen gel droplet embedded drug sensitivity test under multiple drug concentrations and contact durations."3.74Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis. ( Futagawa, S; Kitajima, M; Konishi, N; Nagaoka, I; Nishimura, K; Noguchi, H; Ochiai, T; Sato, G; Watanabe, T, 2007)
"We aimed at developing a more detailed understanding of cyclin D1 in early stage human breast cancer and defining the biologic profiles with different prognostic value correlating cyclin D1 gene amplification and chromosome 11 aneusomy with bio-pathologic variables of known clinical importance."3.74Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile. ( Buglioni, S; Cianciulli, A; Cognetti, F; Di Benedetto, A; Merola, R; Mottolese, M; Orlandi, G; Perracchio, L; Pinnarò, P; Sperduti, I; Venturo, I, 2007)
"Docetaxel, capecitabine and 5-fluorouracil have been shown to be active in the treatment of metastatic gastric adenocarcinoma."3.74Chemoimmunotherapy in the treatment of metastatic gastric cancer. ( Amiconi, G; Blasio, AD; Candeloro, G; Cesta, A; Necozione, S; Rea, S; Recchia, F; Saggio, G, 2007)
"To evaluate the efficacy and safety of a regimen using Irinotecan, 5FU and Leucovorin for patients with advanced or recurrent colorectal cancer."3.74Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes. ( Iinuma, N; Ishizone, S; Koide, N; Maruta, F; Miyagawa, S; Nakayama, J; Yanagisawa, Y, 2007)
"Since 5-fluorouracil (5-FU)-based chemotherapy has become standard adjuvant treatment for patients with node-positive colonic adenocarcinoma, there has arisen the need for predictive factors."3.74Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma? ( Barten, M; Ostwald, C; Prall, F; Schiffmann, L, 2007)
"Cetuximab (Erbitux) in combination with irinotecan is the most promising combination in heavily pretreated patients with advanced colorectal cancer."3.74Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. ( Iversen, A; Jensen, BV; Nielsen, D; Pfeiffer, P; Vejlø, C; Yilmaz, M, 2007)
"A combination of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) is one of the standard regimens for palliative and adjuvant chemotherapy for colorectal cancer."3.74Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer. ( Asaka, M; Doi, T; Fuse, N; Kojima, T; Muto, M; Ohtsu, A; Tahara, M; Takeuchi, S; Taku, K; Yoshida, S, 2007)
"Oxaliplatin, Irinotecan, 5-fluorouracil and leucovorin are commonly used to treat advanced colorectal cancer in Western countries."3.74Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer. ( Aso, M; Higashi, H; Imamura, S; Kakeji, Y; Katoh, H; Maehara, S; Maehara, Y; Makino, I; Saeki, H; Tanaka, J, 2007)
"We report a 59-year-old woman diagnosed with metastasic colorectal cancer who developed immune hemolytic anemia during FOLFOX chemotherapy (oxaliplatin/leucovorin/5-fluorouracil)."3.74Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature. ( Albiol, S; Cobo, F; De Celis, G; Latorre, X; Pereira, A; Pujadas, J, 2007)
"Adjuvant chemotherapy with uracil-tegafur has been demonstrated to prolong survival among patients with resected lung adenocarcinomas."3.74Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. ( Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Ouchida, M; Soh, J; Suehisa, H; Takata, M; Toyooka, S; Uchida, A, 2007)
" Here human gastric adenocarcinoma (AGS) cells were treated with lethal dose 10 and 50 (LD(10) and LD(50)), determined by using the MTT assay, of the three drugs, epirubicin, 5-fluorouracil and cisplatin, commonly used in the treatment of patients with gastro-oesophageal cancer."3.74[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. ( Park, KG; Smith, TA; Suttie, SA, 2007)
"We report the case of a 38-year-old man with metastatic ductal eccrine adenocarcinoma (DEA) of the left breast responding to 5-flourouracil, epirubicin and cyclophosphamide (FEC) chemotherapy."3.74Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast. ( Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S, 2007)
" Therefore, we analyzed expression and prognostic significance of E2F-1 along with thymidylate synthase (TS) in R(0)-resected gastric adenocarcinoma patients, who underwent adjuvant chemoradiation therapy with 5-fluorouracil (5-FU) and leucovorin."3.74Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. ( Heo, JS; Kang, WK; Kim, KM; Kim, S; Lee, I; Lee, J; Lim, DH; Lim, HY; Lim, T; Noh, JH; Park, CK; Park, JO; Park, YS; Sohn, TS, 2008)
"Low tumour expression levels of thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) have been linked with improved outcome for colorectal cancer (CRC) patients treated with 5-fluorouracil (5-FU)."3.74Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. ( Diasio, RB; Han, HC; Iacopetta, B; Joseph, D; Ng, SS; Salto-Tellez, M; Shah, N; Soo, RA; Soong, R; Tai, BC; Tan, WL; Zeps, N, 2008)
"Formalin fixed, paraffin embedded pre-therapeutical tumor biopsies (n = 22) and post-therapeutical resection specimens (n = 40) from patients with rectal adenocarcinoma (clinical UICC stage II/III) receiving standardized neoadjuvant 5-fluorouracil (5-FU) based chemoradiotherapy were studied for Ki67 and p53 expression by immunohistochemistry and correlated with TS mRNA expression by quantitative TaqMan real-time PCR after laser microdissection."3.74Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy. ( Aust, DE; Baretton, GB; Becker, H; Jakob, C; Liersch, T; Meyer, W, 2008)
"The chemotherapy regimen suitable for advanced colorectal cancer patients previously treated with 5 fluorouracil (5FU); oxaliplatin and irinotecan remains an unresolved issue."3.74A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies. ( Borg, C; Chaigneau, L; Demarchi, MF; Legat, C; Limat, S; Nguyen, T; Pivot, X; Stein, U; Thiery-Vuillemin, A; Viel, E, 2008)
"To evaluate retrospectively the efficacy and chronic toxicities of concurrent radiotherapy and chronomodulated infusion 5-fluorouracil (5-FU) in patients with pancreatic adenocarcinoma."3.73Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma. ( Adams, R; Jones, RS; Keene, KS; Penberthy, DR; Rich, TA; Shepard, RC, 2005)
"To investigate the inhibitive effects of matrine and 5-fluorouracil (5-FU) on the growth of human gastric adenocarcinoma cell line SGC-7901 when transplanted into nude mice and to investigate the bone marrow toxicity of these compounds."3.73Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice. ( Fu, H; Hu, MJ; Qiao, MM; Wu, YL; Zeng, H; Zhang, S; Zhang, YP, 2005)
"To examine the prevalence of anemia and its impact of hemoglobin (Hgb) levels in predicting outcomes of 5-fluorouracil (FU)-based first-line chemotherapy for patients with advanced gastric cancer (AGC)."3.73Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer. ( Bang, SM; Cho, EK; Jung, CW; Kang, WK; Kim, K; Kim, S; Kim, WS; Lee, J; Lee, JH; Lee, SH; Park, JO; Park, K; Park, SH; Park, YS; Shin, DB, 2006)
"We successfully treated four advanced colorectal cancers with irinotecan (CPT-11) plus 5-fluorouracil (5-FU) and l-leucovorin (l-LV) combination chemotherapy."3.73[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy]. ( Aiba, M; Kamoshita, N; Makita, F; Morishita, Y; Nagashima, T; Ohwada, S; Takeyoshi, I; Tokiniwa, H, 2005)
"We conducted a retrospective analysis of prognosis factors for survival in breast cancer patients with 1-3 axillary lymph node metastases and tried to identify a subset of patients with good prognosis suitable for cyclophosphamide, methotrexate and 5-fluorouracil (CMF) adjuvant chemotherapy."3.73Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy. ( Chang, HK; Chen, MF; Chen, SC; Hsueh, S; Hwang, TL; Lin, YC; Lo, YF; Tsai, CS, 2005)
"To test the hypothesis that TS3'UTR polymorphisms predict outcomes in 146 Caucasian patients with esophageal adenocarcinoma treated with preoperative 5-fluorouracil-based chemoradiation."3.73Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation. ( Ajani, JA; Correa, AM; Cox, JD; Komaki, R; Liao, Z; Liu, H; Roth, JA; Swisher, SG; Wang, L; Wei, Q; Wu, TT, 2006)
"To establish a 5-fluorouracil (5-FU)-resistant pancreatic adenocarcinoma (PAC) cell strain, and to investigate its biological characteristics."3.73[Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU]. ( Chen, G; Guo, JC; Liao, Q; Zhang, LY; Zhao, YP, 2005)
"To assess the efficacy of 5-fluorouracil (5-FU) and either platinum compounds or irinotecan in patients with advanced small bowel adenocarcinoma (SBA), for whom data on the efficacy of chemotherapy are scarce."3.73Combination chemotherapy in advanced small bowel adenocarcinoma. ( Boige, V; Ducreux, M; Elias, D; Lasser, P; Lebray, P; Locher, C; Malka, D, 2005)
"The study comprised 141 rectal adenocarcinoma patients who underwent preoperative radiotherapy with 5-fluorouracil (FU) based chemotherapy, followed by radical surgery."3.73Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer. ( Baik, SH; Cho, CW; Kim, NK; Lee, KY; Park, YA; Seong, J; Sohn, SK, 2006)
"A 56-year-old woman diagnosed with a poorly differentiated cecal adenocarcinoma with metastases to ovaries, omentum, and sigmoid colon went into remission after 12 cycles of infusional 5-fluorouracil, luecovorin, and oxaliplatin (FOLFOX-4 regimen)."3.73Oxaliplatin-related acute myelogenous leukemia. ( Carneiro, BA; Eldibany, M; Kaminer, L; Kaul, K; Locker, GY; Sreekantaiah, C, 2006)
"Retrospectively, we analysed 23 consecutive patients who were treated with epirubicin, cisplatin and oral capecitabine for inoperable or metastatic oesophagogastric adenocarcinoma during 2002 and 2003."3.73Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma. ( Boot, H; Corporaal, S; Legdeur, MC; Russel, MG; Smit, WM; van der Palen, J, 2006)
"Capecitabine is an oral prodrug of 5-fluorouracil used in the treatment of adenocarcinoma of the colon."3.73Capecitabine-induced cerebellar toxicity. ( Gill, S; Renouf, D, 2006)
"Bevacizumab (Avastin) in combination with intravenous 5-fluorouracil-based chemotherapy as first-line as well as second-line treatment of metastatic colorectal cancer improves survival."3.73Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. ( Gotlib, V; Khaled, S; Lapko, I; Mar, N; Saif, MW, 2006)
"The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer."3.72Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003)
"Forty patients with advanced adenocarcinoma of the rectum underwent preoperative chemoradiation on a prospective trial with irinotecan (50 mg/m2), 5-fluorouracil (225 mg/m2), and concomitant external-beam radiation (45-54 Gy) followed by complete surgical resection of the tumor with total mesorectal excision."3.72Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. ( Anné, PR; Fry, RD; Goldstein, SD; Isenberg, GA; Mahmoud, NN; Mitchell, E; Rose, DG; Stein, DE, 2003)
"Fluorouracil (5-FU) is widely used in the treatment of colorectal cancer."3.72Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy. ( Batist, G; Cohen, V; Morin, I; Panet-Raymond, V; Rozen, R; Sabbaghian, N, 2003)
"Among the various pathophysiologic mechanisms proposed to explain the 5-fluorouracil cardiotoxicity, coronary vasospasm, occurring most frequently after the completion of the second or third dose of the cycle, has gained wide acceptance."3.72Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy. ( Giaccon, G; Mariani, G; Mastore, M, 2003)
" For practical reasons and for the convenience of the patient, we used XELOX (Xeloda 2000 mg/m2 orally on days 1-14 and oxaliplatin 130 mg/m2 as a 30-min infusion on day 1) in patients with advanced colorectal cancer resistant to irinotecan and 5-fluorouracil."3.72Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer. ( Hahn, P; Jensen, HA; Pfeiffer, P, 2003)
"Four pancreatic adenocarcinoma cell lines were evaluated for their sensitivity to 5-fluorouracil (5-FU) and gemcitabine and two of these, Suit-2 and Panc-1, were chosen for combination experiments because they showed moderate and poor sensitivity, respectively, to 5-FU and gemcitabine."3.725-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells. ( Costello, E; Ghaneh, P; Greenhalf, W; Halloran, CM; Neoptolemos, JP; Shore, S; Wilson, D; Zumstein, L, 2004)
"High expression of thymidylate synthase (TS) is allegedly associated with the chemoresistance to 5-fluorouracil (5-FU) in colorectal cancers."3.72Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to ( Inada, K; Kamoshida, S; Maruta, M; Matsuoka, H; Matsuyama, A; Shimomura, R; Shiogama, K; Tsutsumi, Y, 2004)
"We pretreated cell lines derived from human melanomas, adenocarcinomas, and lymphomas with the PPIs omeprazole, esomeprazole, or pantoprazole and tested their response to cytotoxic drugs in cell death assays."3.72Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. ( Arancia, G; Belardelli, F; De Milito, A; Fais, S; Federici, C; Iessi, E; Logozzi, M; Lozupone, F; Luciani, F; Lugini, L; Marra, M; Molinari, A; Montinaro, A; Parmiani, G; Rivoltini, L; Spada, M, 2004)
"Three dogs with advanced-stage adenocarcinoma of the gastrointestinal tract were treated by use of resection, adjuvant chemotherapy with cisplatin and 5-fluorouracil, and second-look laparotomy (SLL)."3.72Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs. ( Gilson, SD; Stanclift, RM, 2004)
" To evaluate the therapeutic effectiveness and safety of oxaliplatin combined with 5-fluorouracil and leucovorin on the patients with gastric carcinoma after palliative gastric resection, we analyzed all of the cases of gastric adenocarcinoma undergone palliative gastric resection in our Cancer Center in recent years."3.72[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer]. ( Chen, YB; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ, 2004)
"A 60-year-old woman with a history of unresectable colon adenocarcinoma was treated by chemotherapy with a combination of oxaliplatin with leucovorin and fluorouracil."3.71Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer. ( Carrie, E; Gagnadoux, F; Lebeau, B; Monnier-Cholley, L; Roiron, C, 2002)
"One hundred and three patients with recurrent adenocarcinoma of the rectum underwent reirradiation with concurrent 5-fluorouracil-based chemotherapy."3.71Long-term results of reirradiation for patients with recurrent rectal carcinoma. ( Marks, G; Marks, J; Mohiuddin, M, 2002)
"We studied longitudinally inflammatory reactions and serum C-reactive protein (S-CRP) levels in 52 colorectal cancer patients treated with a median of six 3-weekly cycles of raltitrexed 1."3.71Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma. ( Elomaa, I; Joensuu, H; Orpana, A; Osterlund, P; Repo, H, 2002)
"The most commonly used treatment in the palliative first-line therapy of metastatic pancreatic adenocarcinoma is the Gemcitabine (Gem) monotherapy, while several combination therapies are currently being tested in clinical trials."3.71[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma]. ( Boxberger, F; Brueckl, WM; Hahn, EG; Happich, K; Hohenberger, W; Schirner, I; Wein, A, 2002)
"The goal of this study was to ascertain the first cycle intolerability rate of the standard Mayo Clinic regimen, 5-fluorouracil (5-FU) 425 mg/m2 with low-dose folinic acid (FA) 20 mg/m2, as a rapid bolus intravenous injection (5-FU/FA) for 5 days every 4-5 weeks for advanced colorectal cancer chemotherapy."3.71Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose. ( Ho, C; Stitt, L; Tomiak, A; Vincent, M; Whiston, F; Winquist, E, 2002)
"One patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT."3.71[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT]. ( Ishikawa, K; Maeda, Y; Makuuchi, H; Murayama, C; Sadahiro, S; Saguchi, T; Suzuki, T; Yamamoto, T; Yasuda, S, 2002)
"LSMs for 5-fluorouracil and 5-fluoro-5,6-dihydrouracil therapeutic monitoring have been developed in 80 patients with colorectal cancer (training set) given 5-fluorouracil, 370 mg/m(2) per day as an intravenous bolus, plus leucovorin, 100 mg/m(2) per day, for 5 days every 4 weeks."3.71Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. ( Amadori, D; Cionini, L; Danesi, R; Del Tacca, M; Di Paolo, A; Falcone, A; Ibrahim, T; Mini, E; Vannozzi, F, 2002)
"A 62-year-old male patient who developed Philadelphia chromosome-positive chronic myeloid leukemia (CML) after cisplatin and 5-fluorouracil treatment for colon adenocarcinoma is reported."3.71Chronic myeloid leukemia in a patient with colon adenocarcinoma. ( Gokel, Y; Paydas, S, 2002)
"A retrospective chart review was performed on 141 consecutive patients who received neoadjuvant chemoradiation (5-fluorouracil +/- cisplatin and 4,500-5,040 cGy) for biopsy-proven locally advanced adenocarcinoma of the rectum."3.71Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. ( Anscher, MS; Clary, B; Hartwig, M; Hurwitz, H; Jowell, P; Lee, C; Ludwig, K; Mantyh, C; McGrath, K; Morse, M; Noone, RB; Onaitis, MW; Pappas, TN; Seigler, HF; Tyler , DS, 2001)
"The aim of the study was to define the maximum tolerated dose (MTD) of the combination of raltitrexed plus carmofur, and to evaluate the tolerability and efficacy of this combination in metastatic colorectal cancer."3.71A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer. ( Elomaa, I; Joensuu, H; Osterlund, P; Virkkunen, P, 2001)
"The aim of this study is to clarify whether the expression of metallothionein (MT) is related with the malignant potential in primary colorectal cancer and/or synchronous liver metastasis."3.71Expression of metallothionein in colorectal cancers and synchronous liver metastases. ( Dhar, DK; Hishikawa, Y; Kimoto, T; Kohno, H; Koji, T; Kubota, H; Nagasue, N; Tachibana, M; Ueda, S, 2001)
"To identify the prognostically highest risk patients, DNA content and p53 nuclear or cytoplasmic accumulation, evaluated by monoclonal antibody DO7 and polyclonal antibody CM1, were determined in 94 surgically resected stage II (Dukes B2) colorectal cancers, treated or not with adjuvant 5-fluorouracil-based chemotherapy."3.71p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy. ( Benevolo, M; Brenna, A; Buglioni, S; Cosimelli, M; D'Agnano, I; D'Angelo, C; Mottolese, M; Perrone Donnorso, R; Vasselli, S; Zupi, G, 2001)
"Resection specimens from 47 cases of oesophageal adenocarcinoma treated with preoperative 5-fluorouracil/cisplatin and radiotherapy were reviewed."3.71A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. ( Dunne, B; Griffin, M; Kelly, A; Mulligan, E; Reynolds, JV, 2001)
"Direct intraperitoneal chemotherapy with cisplatin or mitomycin prevents peritoneal carcinomatosis in experimental investigations."3.71Prophylaxis of peritoneal carcinomatosis in experimental investigations. ( Boltze, C; Halangk, W; Hribaschek, A; Kuhn, R; Lippert, H; Pross, M; Ridwelski, K, 2001)
"5-Fluorouracil (5-FU) and 5'-deoxy-5-fluorouridine (5'-DFUR), a prodrug of 5-FU, are representative of the chemotherapeutic agents for colorectal adenocarcinomas."3.71Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo. ( Iwahashi, M; Nagata, T; Nakamori, M; Yamaue, H, 2002)
"The aim of this study was to assess in patients with advanced colorectal cancer which factors were associated with short-term survival (6 months or less) and progression to first-line 5-fluorouracil (5-FU) chemotherapy."3.71Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens. ( Cellerino, R; Lippe, P; Massacesi, C; Piga, A; Pistilli, B; Rocchi, MB; Valeri, M, 2002)
"We investigated the relevance of mdm2 and p53 primary tumour expression to the clinical outcome of a consecutive series of advanced colorectal cancer patients treated with a 5-fluorouracil-based chemotherapy."3.71mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer. ( Costa, A; De Lena, M; Lacava, J; Leone, A; Paradiso, A; Ranieri, G; Silvestris, N; Simone, G; Vallejo, C, 2002)
"Sixteen patients with rectal adenocarcinoma up to 3 cm above the pectineal line with initial indications for abdominoperineal resection (APR) were submitted to a 5040-cGy (28 x 180 cGy) radiotherapy dose and chemotherapy during the first 3 and last 3 days of radiotherapy, using 425 mg/m2/day of 5-fluorouracil (5FU) and 20 mg/m2/day of folinic acid."3.70Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial. ( Filho, WD; Lopes, A; Nakagawa, WT; Novaes, PE; Rossi, BM, 1998)
"It has been observed previously that the pulmonary metastases of colorectal adenocarcinoma are less responsive to therapy with fluorouracil (FUra) as compared with other sites of metastasis (liver, local)."3.70Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. ( Banerjee, D; Bertino, JR; Danenberg, KD; Danenberg, PV; Fu, J; Gorlick, R; Jhanwar, S; Kemeny, N; Klimstra, D; Longo, GS; Metzger, R; Miles, JS; Salonga, D, 1998)
"This case can be considered the first documented Irinotecan-induced immune thrombocytopenia."3.70Irinotecan-induced immune thrombocytopenia. ( Bierling, P; Bozec, L; Cvitkovic, E; Debat, P; Fromont, P; Lévi, F; Misset, JL, 1998)
"During a 4-year period we treated 20 patients with locally advanced adenocarcinoma of the rectum using a protocol of preoperative simultaneous pelvic irradiation (4,030-6,040 cGy) and infusion chemotherapy (5-fluorouracil 100 mg/m2 per day over 96 hours and mitomycin 10 mg/m2) followed by surgical resection."3.70Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma. ( Burke, SJ; Knight, DC; Kwasnik, EM; Percarpio, BA, 1998)
"To determine the effect of combined treatment with 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan) and 5-fluorouracil/ folinic acid (5FU/FA) in vitro using HCT-8 human intestinal adenocarcinoma cells."3.70Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity. ( Erlichman, C; Kaufmann, SH; Mullany, S; Svingen, PA, 1998)
"The purpose of this study was to investigate the side-effects experienced by patients with colorectal cancer receiving 5-fluorouracil + folinic acid chemotherapy."3.70Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer. ( Dikken, C; Sitzia, J, 1998)
"Patients with radiographically resectable localized adenocarcinoma of the pancreatic head were entered onto a preoperative protocol that consisted of a 2-week course of fluorouracil (5-FU) 300 mg/m2 daily 5 days per week and concomitant rapid-fractionation radiation 30 Gy, 3 Gy daily 5 days per week."3.70Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma. ( Abbruzzese, JL; Charnsangavej, C; Cleary, KR; Evans, DB; Goswitz, MS; Janjan, NA; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 1998)
" However, new chemotherapy, based on the synergistic antitumor activities of 5-fluorouracil (5-FU) and cisplatin (CDDP) producing biochemical modulation in solid cancers diagnosed as adenocarcinoma, has recently been reported to be effective."3.70Biochemical modulation therapy for pancreatic cancer. ( Denno, R; Hirata, K; Katsuramaki, T; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Takashima, T; Yamamitsu, S, 1998)
"The clonogenic hybrid spheroid assay has been used to determine the toxicity of 5-fluorouracil (5-FU), alone or in combination with indomethacin, in LoVo cells (a human colon adenocarcinoma line)."3.70Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids. ( Djordjevic, B; Lange, CS; Rotman, M; Schwartz, MS, 1998)
"A selective inflammatory reaction involving actinic keratosis may occur in patients receiving systemic 5-fluorouracil as part of a chemotherapeutic protocol."3.70Selective inflammatory effect of systemic fluorouracil in actinic keratosis. ( Mehregan, D; Mohindra, R; Nabai, H, 1999)
"Diarrhea and oral mucositis are the most frequently reported gastrointestinal side effects caused by 5-fluorouracil (5-FU)."3.705-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma. ( Fata, F; Kelsen, DP; Kemeny, N; Klimstra, D; O'Reilly, E; Ron, IG, 1999)
"(1) The clinical file of gemcitabine in locally advanced metastatic adenocarcinoma of the pancreas mainly comprises one comparative trial versus 5 fluorouracil that shows the superiority of gemcitabine on a mixed end point (pain, functional capacities, weight)."3.70Gemcitabine and cancer of the pancreas: new preparation. Helpful or not? ( , 1999)
"5-Fluorouracil combined with leucovorin and/or cisplatin has been used in the treatment of gastrointestinal adenocarcinoma and may be useful in primary adenocarcinoma of the bladder."3.70Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder. ( Awakura, Y; Fukuyama, T; Fukuzawa, S; Nonomura, M; Yamamoto, M, 1999)
"Fifteen patients with rectal adenocarcinoma were endoscopically biopsied and given short-term [5 fluorouracil (5FU) (600 mg/m2) and Ca-Folinate (60 mg/m2) for two days] cytostatic therapy."3.70Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors. ( Benyó, I; Bodnár, Z; Farczádi, E; Kaszás, I; Szántó, J; Szende, B; Szlobodnyik, J, 1999)
"To evaluate safety and efficacy of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer."3.70[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer]. ( Dai, A; Feng, J; Zheng, X, 1998)
"Epirubicin, cisplatin and continuous 5-fluorouracil (5-FU) infusion (ECF) has been reported to result in high clinical response rates in advanced gastro-oesophageal adenocarcinoma and is currently the 'gold standard' chemotherapy regimen for this tumour site."3.70Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. ( Banerji, U; Geh, JI; Glynne-Jones, R; Harrison, RA; Kwok, QS; Livingstone, JI; Mitchell, IC; Townsend, ER, 2000)
"The authors describe the retrospective analysis of treatment by 5-fluorouracil and interferon-a aof 34 patients with advanced colorectal cancer."3.70Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients. ( András, C; Antal, L; Csiki, Z; Gál, I; Szegedi, G; Takács, I, 2000)
"To report 5-fluorouracil in combination with folinic acid as a cause of severe nonischemic heart failure and to demonstrate the potential usefulness of an intra-aortic balloon pump."3.70Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump. ( David, JS; Gaussorgues, P; Gueugniaud, PY; Hepp, A; Petit, P, 2000)
"(1) To determine the toxicity of an intensified postoperative adjuvant regimen for periampullary adenocarcinoma (pancreatic and nonpancreatic) utilizing concurrent 5-fluorouracil (5-FU), leucovorin (LV), dipyridamole (DPM), and mitomycin-C (MMC) combined with split-course locoregional external beam radiotherapy (EBRT) to 50 Gy."3.70Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Donehower, RC; Grochow, LB; Hruban, RH; Hurwitz, H; Jaffee, EM; Korman, LT; Lillemoe, KD; O'Reilly, S; Yeo, CJ; Zahurek, ML, 2000)
"Thymidylate synthase (TS) expression in colorectal cancer metastases has been shown to predict for the clinical response to 5-fluorouracil."3.70Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil. ( Aschele, C; Debernardis, D; Maley, F; Sobrero, A; Tunesi, G, 2000)
"To study the schedule-dependent reversion of cis-diamminedichloroplatinum (CDDP) resistance by 5-fluorouracil (5-Fu) in a CDDP resistant human lung adenocarcinoma cell line A549DDP."3.70Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP. ( Liu, X; Zhan, M, 1999)
"The relationship between augmentation of cytotoxic activity of 5-fluorouracil (FUra) by l-leucovorin (l-LV) and combination schedule was investigated using human colon adenocarcinoma KM 20 C cell line."3.69[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil]. ( Okabe, H; Takeda, S; Toko, T; Unemi, N; Yuasa, C, 1995)
"We report a case of double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin."3.69[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin]. ( Akiyama, S; Hibi, K; Ito, K; Kasai, Y; Kondo, K; Nonami, T; Takagi, H, 1995)
"125 stage III breast cancer patients, including 51 cases of inflammatory carcinoma, were treated with the following combined modality approach: three courses of primary 5-fluorouracil, doxorubicin, cyclophosphamide (FAC) chemotherapy followed by locoregional treatment and subsequent adjuvant chemotherapy consisting of three courses of FAC alternating with three courses of cyclophosphamide, methotrexate, 5-fluorouracil (CMF)."3.69Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. ( Campora, E; Canavese, G; Catturich, A; Corvò, R; Gardin, G; Guenzi, M; Naso, C; Pronzato, P; Repetto, L; Rosso, R, 1995)
"We observed leukoencephalopathy in 1 patient, and progressive dementia in another, during the administration of 5-fluorouracil (5-FU) and levamisole."3.69Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases. ( Dobranowski, J; Fawcet, SE; Figueredo, AT; Molloy, DW; Paulseth, JE, 1995)
"To determine the effect of cellular proliferation and cell cycle stage on the ability of postirradiation 5-fluorouracil (5-FU) to radiosensitize cultured human colon adenocarcinoma Clone A cells."3.695-Fluorouracil-radiation interactions in human colon adenocarcinoma cells. ( Buchholz, DJ; Lepek, KJ; Murray, D; Rich, TA, 1995)
"One hundred and seven previously untreated patients with measurable metastatic colorectal cancer who were treated with 5-fluorouracil (5FU) and leucovorin (LV) in two different maximum doses and schedules were retrospectively analyzed."3.69A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer. ( Bacoyannis, C; Basdanis, G; Foutzilas, G; Karvounis, N; Kosmidis, P; Markantonakis, P; Mylonakis, N; Sobolos, K; Tsavaris, N; Zisiadis, A, 1995)
" Here we have examined human gastric/esophageal adenocarcinoma cell lines for p53 mutational status, chemosensitivity to 5-fluorouracil, mitomycin C, and cis-dichlorodiammineplatinum(II), alteration in p53 levels following exposure of cells to these drugs, and the mechanisms involved in regulating p53 levels."3.69The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents. ( Albino, AP; Altorki, NK; Blundell, ML; de Oliveira, AR; Kelsen, DP; Lai, L; Loganzo, F; Maslak, P; Nabeya, Y; Schwartz, GK, 1995)
"Thirty-two patients with resectable (clinical stage IIa, n = 17; IIb, n = 1; III, n = 14) squamous cell cancer (n = 15) or adenocarcinoma (n = 17) were treated with neoadjuvant chemotherapy (cisplatin, 5-fluorouracil, leukovorin), resection, and postoperative chemoradiotherapy (hydroxyurea, 5-fluorouracil; 50-66 Gy)."3.69Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction. ( Drinkard, LC; Ferguson, MK; Haraf, DJ; Hoffman, PC; Reeder, LB; Vokes, EE, 1995)
"Exposure of the human colon adenocarcinoma HT29 cells to different concentrations of 5-fluorouracil (5FU) for 24 h resulted in a dose-dependent increase in the cellular glutathione (GSH) level which remained elevated up to 72 h following 5FU treatment."3.69Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells. ( Boyce, HW; Chen, LT; Chen, MF, 1995)
"The purpose of this study was to assess the efficacy of verapamil (20 microM) and hyperthermia (42 degrees C) as modifiers of 5-fluorouracil (5-FU), used at different concentrations, in inhibiting the growth of gastric adenocarcinoma cells."3.69Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro. ( Brenner, RV; Buras, RR; Evans, SR; Nauta, RJ; Shabahang, M; Shchepotin, IB, 1994)
"We reported a case of successful treatment of disseminated breast cancer with epirubicin (EPI), 5-fluorouracil (5-FU), and medroxyprogesterone (MPA)."3.69[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)]. ( Fujisawa, J; Satoh, Y; Uchino, J; Une, Y, 1994)
"To examine if preferential retention of somatostatin analogues observed in some tumors might be used for modulation of effects of cancer drugs by co-treatment with long acting somatostatin analogues, the effects of somatostatin analogue octreotide on the kinetics of 5-fluorouracil (FUra) and 5-fluorouridine (FUrd) metabolism were studied by 19F NMR spectroscopy in multicell tumor spheroids comprised of human colon HT-29 adenocarcinoma cells."3.69Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids. ( Chen, TB; Huzak, M; Macura, S; Vuk-Pavlović, S, 1994)
"We reviewed our results with chemotherapy for adenocarcinoma of the esophagus or gastroesophageal junction tumors in patients treated with 5-fluorouracil, Adriamycin, and mitomycin C (FAM) regimen as developed by MacDonald and colleagues for adenocarcinoma of the stomach."3.695-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors. ( Allred, C; Khansur, T; Tavassoli, M, 1994)
"Radiological and clinical evidence of acute necrosis in a meningioma following one cycle of chemotherapy with 5-fluorouracil, folinic acid, and levamisole was observed in a patient being treated for invasive rectal carcinoma."3.69Necrosis in a meningioma following systemic chemotherapy. Case report. ( Bernstein, M; Davidson, G; Erlichman, C; Villamil, A, 1994)
"Several classes of plant polyphenols namely, flavonoids, chalcones and coumarins exhibited varying degrees of inhibition on the cell proliferation of human colon adenocarcinoma cell line 220."3.69Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation. ( Das, NP; Yit, CC, 1994)
" To improve local control and decrease metastases, a 7-month regimen was used with standard-dose radiotherapy (RT), cisplatin (DDP), and continuous infusion (CI) 5-fluorouracil (5-FU) in patients with locoregional squamous/adenocarcinoma of the esophagus."3.69Chemoradiotherapy of esophageal carcinoma. ( Cummings, G; Gaspar, LE; Herskovic, AM; Khanuja, PS; Kinzie, JL; Kraut, MJ; Lattin, PB; Poplin, EA; Steiger, Z; Vaitkevicius, VK, 1994)
"To investigate the resistance against 5-fluorouracil (FU), thymidylate synthase (TS) mRNA level was measured by reverse transcription PCR (RT-PCR) technique and quantitated by a competitive-PCR method in human colon adenocarcinoma cell line, SNU-C1 and its FU resistant cell line, C1/FU."3.69[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells]. ( Aiba, K; Horikoshi, N; Minowa, S; Shibata, H; Shibata, J, 1994)
"Eighteen patients (17 evaluable for response) with metastatic breast cancer were treated with mitoxantrone 10 mg/m2 day 1, followed by 5-fluorouracil 375 mg/m2 day 1-5, and high-dose leucovorin 500 mg/m2 day 1-5 given every 28 days."3.69Mitoxantrone, 5-FU, and leucovorin in breast cancer. ( Honig, SF; Swain, SM, 1994)
"Low-dose consecutive intra-arterial infusion therapy with cisplatin and 5-fluorouracil as neoadjuvant chemotherapy was performed on 3 cases of cervical adenocarcinoma (two stage IIb and one stage IIIb)."3.69[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)]. ( Narimatsu, A; Okada, O, 1996)
"The use of 5-fluorouracil (5-FU) and levamisole in patients with Stage III adenocarcinoma of the colon has now become standard."3.69Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report. ( Gordon, J; Licho, R; Litofsky, NS; Ragland, R; Recht, L; Savarese, DM; Smith, TW, 1996)
"Thirty-seven patients with advanced colorectal cancer were treated with fluorouracil (5-FU) and folinic acid (FA) (Jan 1990-Dec 1992)."3.69Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department. ( Carey, PD; Farrer, C; Gordon, A; Guillou, PJ; Monson, JR; Pearce, S; Sommers, SS, 1995)
"A 53-year-old female patient was treated with combined radiochemotherapy with 5-fluorouracil (5-FU) because of adenocarcinoma of the lung."3.69[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?]. ( Härle, M; Jungius, KP; Maurer, U, 1996)
" The aim of this study was to define the toxicity (animal lethality) and the activity (growth delay assay, excision assay) of a bioreductive drug, tirapazamine, alone and combined with chemotherapy agents (5-FU, VP16, bleo, DTIC and c-DDP) on nude mice bearing xenografted human tumours: a rectal carcinoma (HRT18) and a melanoma (Na11+)."3.69The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. ( Guichard, M; Lartigau, E, 1996)
"Although intrahepatic infusion therapy with 5-fluorouracil for unresectable colorectal liver metastases may lead to improved overall survival for some patients, it is not clear why a response is not observed in others."3.69p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. ( Benhattar, J; Cerottini, JP; Givel, JC; Metthez, G; Saraga, E, 1996)
"In advanced adenocarcinoma of the pancreas treatment with 5-fluorouracil (5-FU) or ifosfamide results in response rates of approximately 20%."3.69Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas. ( Bakker, PJ; Gouma, DJ; Huizing, MT; Poorter, RL; Rauws, EA; Rietbroek, RC; Taat, CW; Veenhof, CH, 1995)
"Between 1977 and 1994, 173 patients (60 men, 113 women, aged 43-77 years [mean, 59 years]) with unresectable adenocarcinoma of the exocrine pancreas were treated, 106 with neutron irradiation alone and 67 with concomitant chemotherapy (fluorouracil [5-FU])."3.69Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy. ( Bennett, BR; Cohen, L; Hatcher, MA; Hendrickson, FR; Kroc, TK; Lennox, AJ, 1996)
" The objective of this study was to test the effect of tamoxifen and tamoxifen in combination with other agents [5-fluorouracil (5-FU) and interferon (IFN)] against experimental liver metastases of human colorectal tumor cells xenografted into nude mice."3.69Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon. ( Bender, E; Katoh, A; Mahaffey, W; Marrangoni, A; McKeating, J; Werner, A, 1996)
"After a loading dose of 4 x 90 mg folinic acid orally, a continuous infusion of 5-fluorouracil 500 mg/sqm/day for 5 days with concommitant folinic acid 6 x 60 mg/day orally, was administered to 29 consecutive patients with metastatic adenocarcinoma of the esophagus or esophagogastric junction area."3.695-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group. ( Kok, TC; Splinter, TA; van der Gaast, A, 1996)
" We report on a clinical deterioration, yet near-complete pathological and radiological response to a combination of cisplatin and fluorouracil in a patient with locally-advanced gastric adenocarcinoma."3.69Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma. ( Crellin, A; Guillou, PJ; Hassan, S; Macadam, R; Reynolds, JV; Sadek, SA; Somers, SS; Windsor, AC, 1995)
"A case of poorly differentiated adenocarcinoma of the small bowel with extensive lymph node metastases is herein presented, which responded to methotrexate/5-fluorouracil (MTX/5-FU) sequential therapy."3.69Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case. ( Imamura, M; Maetani, S; Nishitai, R; Onodera, H; Shimizu, K, 1997)
"We have investigated the effects of 5-fluorouracil (5-FU) on cell growth, DNA synthesis, morphological changes, DNA fragmentation and Fas antigen expression of cultured human uterine cervical carcinoma cells (OMC-1 squamous-cell carcinoma and OMC-4 adenocarcinoma)."3.69Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil. ( Inoki, C; Kumagai, K; Orino, I; Ueda, M; Ueki, K; Ueki, M, 1997)
" In this study, we characterized the growth-inhibitory effects of active metabolites of sulindac in cultured colon adenocarcinoma cells by determining the contribution of apoptosis and cell cycle arrest and the requirement for cyclooxygenase (COX) inhibition and p53 involvement and compared the effects of sulindac metabolites with the chemotherapeutic drug, 5-fluorouracil (5-FU)."3.69Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. ( Ahnen, DJ; Finn, TS; Fryer, BH; Li, H; Pamukcu, R; Piazza, GA; Rahm, AK; Stoumen, AL, 1997)
"In this phase IB study, 24 patients with advanced colorectal cancer were treated with escalating doses of weekly chronomodulated 48 h infusions of 5-fluorouracil (5-FU) biochemically modulated by methotrexate 40 mg/m2 and (6S)-leucovorin 8 x 45 mg orally."3.69Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study. ( Kamm, YL; Punt, CJ; Wagener, DJ, 1997)
" A high incidence of colorectal adenocarcinomas with varied grades of cell differentiation can be induced by 1,2-dimethylhydrazine (DMH) in rats."3.69Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats. ( Iwama, T; Kawachi, Y; Kudo, H; Murakami, S; Okayasu, I; Sagara, T; Sakamoto, S; Tsukada, K, 1997)
"To evaluate the effect of biochemical modulation by PALA and methotrexate on the therapeutic activity of 5-fluorouracil (5-FU) in patients with advanced pancreatic adenocarcinoma."3.69Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma. ( Berns, T; Harstrick, A; Hiddemann, W; Köhne, CH; Preusser, P; Schmoll, HJ; Seeber, S; Strumberg, D; Wilke, H, 1997)
"5-Fluorouracil (5-FU) has been an accepted effective against colorectal cancer, but combination regimens resulted in a lesser effect than 5-FU alone."3.695-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer. ( Imamura, M; Kawabata, K; Nio, Y, 1997)
"Previous studies using cultured colon adenocarcinoma cells demonstrated that a mixture of the diastereoiosomers of the biologically active (6S) and inactive (6R) forms of (6RS) leucovorin or 5-formyl-H4PteGlu (LV) and recombinant human alpha2a-interferon (rIFN-alpha2a) in combination significantly increased the cytotoxicity of 5-fluorouracil (FUra) (by 10-14-fold) whereas FUra combined with single modulators was less potentiated (3-fold)."3.69Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts. ( Cheshire, PJ; Houghton, JA; Morton, CL; Stewart, CF, 1995)
"To explore an anti-tumor effect of indomethacin on human colon adenocarcinoma cell line HCT116, and its mechanism."3.69[Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro]. ( Duan, C; Leng, A; Shi, J; Zhang, G, 1997)
"Based upon prior data suggesting that alpha-interferon possesses chemomodulatory activity, the Southwest Oncology Group conducted a study in which patients with hormone refractory, metastatic (stage D2) adenocarcinoma of the prostate were treated with 5-fluorouracil (5-FU) and Roferon-A."3.69Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study. ( Barnett, TC; Crawford, ED; Marshall, ME; O'Rourke, M; Wolf, M, 1996)
"In order to determine whether preresectional chemoradiotherapy (CTRT) would influence resectability, local control, and survival of patients with localized pancreatic adenocarcinoma, a 5 1/2-year prospective study of 39 patients treated with preoperative radiation therapy, 5-Fluorouracil (5-FU), and Mitomycin C has been performed."3.68A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma. ( Agarwal, P; Eisenberg, BL; Engstrom, P; Hoffman, JP; Litwin, S; Paul, AR; Scher, R; Solin, LJ; Watts, P; Weese, JL, 1993)
"We studied the levamisole toxic effects in adjuvant therapy for colorectal cancer."3.68[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer]. ( Beerblock, K; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Navarro-Carola, E; Soubrane, D; Varette, C, 1993)
"Our recent findings in vitro in the human colon adenocarcinoma cell line HCT-8 suggest that resistance to fluorouracil (5-FU) in patients with advanced colorectal cancer might be overcome by use of a different treatment schedule."3.68Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells. ( Aschele, C; Bertino, JR; Guglielmi, AP; Melioli, GG; Mori, AM; Rosso, R; Sobrero, AF, 1993)
"Between December 1988 and August 1992, 68 patients with adenocarcinoma (n = 39) and squamous carcinoma (n = 29) of the esophagus were entered prospectively in a treatment protocol to receive two cycles of cisplatin, 5-fluorouracil, etoposide, leucovorin, and 3,000 cGy of radiation to the involved esophagus and adjacent mediastinum, followed by resection."3.68Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma. ( Adkins, RB; Hoff, SJ; Johnson, DH; Merrill, WH; Murray, MJ; Sawyers, JL; Stewart, JR, 1993)
"A prospective trial was conducted involving 16 patients with colorectal adenocarcinoma using a regimen of continuous-infusion octreotide acetate (Sandostatin [octreotide acetate], Sandoz, East Hanover, NJ for the treatment of severe diarrhea induced by the weekly schedule of 5-fluorouracil (5-FU) in combination with leucovorin who were refractory to opiate therapy."3.68Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma. ( Creaven, P; Herrera, L; Petrelli, NJ; Rodriguez-Bigas, M; Rustum, Y, 1993)
"2-fold potentiation of 5-fluorouracil (FUra) cytotoxicity by recombinant human interferon-alpha 2a (rIFN-alpha 2a) in GC3/cl colon adenocarcinoma cells that was significantly enhanced to 14-fold when FUra was combined with rIFN-alpha 2a + a mixture of the diasteroisomers of the biologically active (6S) and inactive (6R) leucovorin or 5-formyl-H4PteGlu (LV), events that were reversible by thymidine (dThd)."3.68Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells. ( Adkins, DA; Houghton, JA; Morton, CL; Rahman, A, 1993)
"Various factors, including thymidylate synthase, thymidine kinase, 5-fluorouracil phosphorylation and degradation pathways, folate concentrations, and the stability of ternary complex, which influence thymidylate synthase inhibition rate of fluoropyrimidines, were studied in 87 human adenocarcinoma tissues."3.68Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues. ( Dohden, K; Ohmura, K; Watanabe, Y, 1993)
"Of 13 patients with adenocarcinoma treated with 5-fluorouracil, adriamycin, and mitomycin (FAM), nine showed minor histological changes compared with 14 control cases."3.68Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy. ( Allen, SM; Darnton, SJ; Edwards, CW; Matthews, HR, 1993)
"We report the fourth case of cerebral demyelinating disease associated with 5-fluorouracil and levamisole hydrochloride therapy for adenocarcinoma of the colon."3.68Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy. ( Kimmel, DW; Schutt, AJ, 1993)
"Forty-three patients with locoregional squamous cell carcinoma or adenocarcinoma of the esophagus or cardia were treated with fluorouracil (5-FU), cisplatin, and bolus vinblastine concurrent with radiation administered over 21 days."3.68Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report. ( Forastiere, AA; Orringer, MB; Perez-Tamayo, C; Urba, SG; Zahurak, M, 1993)
" Thirteen patients with adenocarcinoma of the pancreas received weekly 5-fluorouracil by rapid intravenous infusion midway through a 2-h infusion of high dose leucovorin during external beam radiation therapy."3.68Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study. ( Dobelbower, RR; Howard, JM; Konski, AA; Merrick, HW; Schifeling, DJ; Skeel, RT, 1992)
"Sequential therapy consisting of methotrexate (MTX) and 5-FU was performed together with the administration of heparin and FOY in 10 cases of gastric cancer with disseminated intravascular coagulation (DIC) causing systemic bone metastasis."3.68[Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation]. ( Ibuka, T; Imai, K; Ishiwata, J; Kobayashi, T; Monma, K; Ohno, T; Onozawa, Y; Sakaki, N; Sasaki, T; Tabata, I, 1992)
" Twenty-eight patients with cytologic or histologic proof of localized adenocarcinoma of the pancreatic head received preoperative chemoradiation (fluorouracil, 300 mg/m2 per day, and 50."3.68Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. ( Ames, FC; Byrd, DR; Charnsangavej, C; Cleary, KR; Connelly, JH; Evans, DB; Fenoglio, CJ; Levin, B; Rich, TA, 1992)
"Forty-one patients with metastatic colorectal cancer were treated every four weeks with methotrexate 25 mg/m2 i."3.68Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination. ( Cascinu, S; Catalano, G; Fedeli, A; Luzi Fedeli, S, 1992)
"A 63-year-old male had undergone combination chemotherapy including adriamycin, cisplatin, mitomycin C, 5-fluorouracil and vindesine for six months for double cancer of esophagus and stomach."3.68[Chemotherapy-associated hemolytic uremic syndrome--a case report]. ( Kanamaru, R; Kikuchi, H, 1992)
") administration of 5-fluorouracil (5-FU) or 5-fluoro-2'-deoxyuridine (FUdR) in BDF1 mice bearing murine mammary adenocarcinoma 755 and athymic mice bearing the transplantable human colon adenocarcinoma LS174T."3.68Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate. ( Hoshi, A; Iigo, M; Nakajima, Y, 1992)
" During a 12-month period seven patients with locally advanced adenocarcinoma of the rectum were treated preoperatively with simultaneous pelvic irradiation (4500-5040 cGy) and infusion chemotherapy (5-fluorouracil 1000 mg per m2 per day over 96 hours and mitomycin 10 mg per m2."3.68Combined modality preoperative therapy for unresectable rectal cancer. ( Alfano, F; Bitterman, J; Bowen, J; Percarpio, B; Ruszkowski, R; Sabbath, K, 1992)
"From October 1986 to January 1991, 47 patients with esophageal cancer (29 squamous, 18 adenocarcinoma) were treated with simultaneous radiotherapy (3000 or 3600 cGy) and chemotherapy (infusional 5-fluorouracil, cisplatin) delivered during a 5-week period."3.68Preoperative chemotherapy and radiotherapy for esophageal carcinoma. ( Andrus, CH; Baue, AE; Johnson, FE; Naunheim, KS; Petruska, P; Roy, TS; Schlueter, JM, 1992)
"Previous studies have demonstrated continuous-infusion 5-fluorouracil (CI 5-FU) to be an active single-agent treatment for breast cancer without significant myelotoxicity."3.68Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study. ( Carey, P; Saphner, T; Tormey, DC, 1992)
"A cerebral demyelinating disease developed in 3 patients during adjuvant therapy with 5-fluorouracil and levamisole for adenocarcinoma of the colon."3.68Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. ( Forsyth, PA; Hook, CC; Kimmel, DW; Kvols, LK; Moertel, CG; Rodriguez, M; Rubin, J; Scheithauer, BW, 1992)
"Between 2/87 and 2/91, 49 women with operable breast cancer involving greater than or equal to 10 axillary nodes were treated following mastectomy, with four cycles of Cyclophosphamide, Adriamycin, 5FU, followed by high doses of Cyclophosphamide, Cisplatin, Carmustine (HDCT) with autologous bone marrow transplant support."3.68Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B. ( Halperin, EC; Marks, LB; Peters, W; Prosnitz, LR; Rosner, GL; Ross, M; Vredenburgh, JJ, 1992)
"To determine if fluorouracil (5-FU) plus high-dose leucovorin (LV) enhances local response in patients receiving preoperative radiation therapy (RT) for adenocarcinoma of the rectum, we compared the degree of downstaging in patients receiving preoperative RT with or without chemotherapy."3.68Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. ( Cohen, AM; Enker, WE; Frankel, J; Kelsen, DP; Kemeny, N; Minsky, BD; Reichman, B; Saltz, L; Sigurdson, ER, 1992)
"We have evaluated the effect of 5-fluorouracil 600 mg/m2, doxorubicin ('Adriamycin') 40 mg/m2, and Mitomycin-C 4 mg/m2 (FAM) in two groups of patients with adenocarcinoma of the oesophagus, as either a preoperative or primary treatment."3.68A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus. ( Allen, SM; Cullen, MH; Matthews, HR; Steel, A; Walker, SJ, 1991)
"Eighty-seven colorectal adenocarcinomas from untreated patients were investigated by short term tumor cultures to test in vitro sensitivity to 5-fluorouracil and mitomycin C."3.685-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures. ( Barone, C; Codacci-Pisanelli, G; Codacci-Pisanelli, M; Ferri, GM; Franchi, F; Garufi, C; Grieco, A; Pagani, V; Seminara, P, 1991)
"Juzen-taiho-to (JTT; [Shi-quan-da-bu-tang], a Japanese modified Chinese herbal prescription) in combination with an anticancer drug UFT (5-fluorouracil derivative) prevented the body weight loss and the induction of the colonic cancer in rats treated with a chemical carcinogen 1,2-dimethylhydrazine (DMH), and suppressed markedly the activity of thymidylate synthetase (TS) involved in the de novo pathway of pyrimidine synthesis in colonic cancer induced by DMH."3.68Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats. ( Kasahara, N; Kato, T; Kawasaki, T; Kudo, H; Kuwa, K; Nakayama, T; Okamoto, R; Sakamoto, S; Suzuki, S, 1991)
"Forty seven patients with inoperable adenocarcinoma and large cell carcinoma of the lung were treated with a combination of cisplatin (25 mg/m2), ifosfamide (1."3.68[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung]. ( Asakawa, M; Fujita, A; Honda, R; Inoue, Y; Mori, T; Nakajima, S; Sasaki, H; Sekine, K; Suzuki, A, 1991)
"Because of conflicting reports of clinical synergy, we used the tetrazolium-based colorimetric (MTT) assay to test in vitro combination effects of methotrexate (MTX) plus 5-fluorouracil (FUra) in 4 schedules on 2 human non-small-cell lung cancer cell lines (adenocarcinoma, NC1-H23; bronchio-alveolar-cell carcinoma, NC1-H358), and 1 human colorectal adenocarcinoma cell line (SNU-C1)."3.68Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines. ( Gazdar, AF; Kramer, BS; Perng, RP; Tsai, CM, 1991)
"We have investigated effects of alpha-difluoromethylornithine (DFMO), both as a single agent and in combination with 5-fluorouracil (5-FU) against a human colon tumor xenograft (T6) grown as primary tissue culture in serum-free medium and in combination with doxorubicin (DX) against a human lung adenocarcinoma cell line (A549)."3.68In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin. ( Atabek, U; Zirvi, KA, 1991)
"Experimental chemotherapy with 5-fluorouracil (5-FU; 60 mg/kg), 1-hexylcarbamoyl-5-fluorouracil (HCFU; 70 mg/kg), 3-(3-(6-benzoyloxy-3-cyano-2-pyridyloxycarbonyl)benzoyl)-1-ethoxym ethyl-5- fluorouracil (BOF-A2; 30 mg/kg) and UFT (20 mg/kg as tegafur with uracil at a molar ratio of 1:4) was performed using human gastric (H-111) and colon (Co-4) carcinoma strains in nude mice."3.68Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition. ( Abe, O; Arisawa, Y; Fujita, S; Ishibiki, K; Josui, K; Kodaira, S; Kubota, T; Mabuchi, K; Suto, A; Yamamoto, T, 1991)
"Thirty-one assessable patients with metastatic adenocarcinoma of the gastrointestinal tract were entered onto a pilot study designed to assess the impact of recombinant interferon alpha-2a (rIFN alpha-2a) on the toxicity and pharmacokinetics of fluorouracil (5-FU) and leucovorin (LV)."3.68A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma. ( Balis, FM; Goldstein, LJ; Grem, JL; Hamilton, JM; Kramer, BS; McAtee, N; Murphy, RF; Sartor, O; Sorensen, JM; Steinberg, SM, 1991)
"We evaluated conventional pulse exposure versus continuous exposure models of 5-fluorouracil (5-FU) radiosensitization in HT-29 (human colon adenocarcinoma) and DU-145 (human prostate cancer adenocarcinoma) cell lines."3.685-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. ( Evans, RG; Kimler, BF; Smalley, SR, 1991)
"Fifteen patients with potentially resectable adenocarcinoma of the esophagus were treated with two cycles of preoperative chemotherapy with 5-fluorouracil (5-FU) and cisplatin (DDP)."3.68A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus. ( Bromberg, C; Carey, RW; Choi, NC; Grillo, HC; Hilgenberg, AD; Logan, DL; Mathisen, DJ; Wain, JC, 1991)
"Fifty-six previously untreated patients with biopsy-proven, locally advanced or metastatic and measurable adenocarcinoma of the pancreas were treated with the combination of a protracted intravenous infusion of 5-fluorouracil (5-FU) and low dose weekly bolus cisplatin administered continuously for 10 weeks followed by a 2-week rest period."3.68Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study. ( Ahlgren, J; Cantrell, JE; Difino, S; Fryer, J; Harvey, J; Lokich, J; Rothman, H, 1991)
"2,2'-Anhydro-5-ethyluridine (ANEUR), a potent inhibitor of uridine phosphorylase, markedly potentiated the antitumor activity of fluorouridine (FUR) against murine mammary adenocarcinoma 755 in BDF1 mice and human colon adenocarcinoma LS174T in athymic-nude mice."3.68Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine. ( De Clercq, E; Iigo, M; Nakajima, Y; Nishikata, K; Szabolcs, A; Szinai, I; Veres, Z, 1990)
"Peritoneal cells were derived from a patient (PK) with adenocarcinoma of the colon during the course of cisplatin/5-fluorouracil (5-FUra) treatment."3.68Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil. ( Haedicke, K; Kashani-Sabet, M; Leong, L; Lu, Y; Scanlon, KJ, 1990)
"Exposure to dehydroepiandrosterone caused a concentration-dependent accumulation of HT-29 human colonic adenocarcinoma cells in S-phase and sensitization toward the cytotoxic effects of fluorouracil deoxyriboside but not 5-fluorouracil."3.68Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells. ( Holbrook, CT; Klann, RC; Nyce, J, 1990)
"Twenty-nine evaluable patients with colorectal adenocarcinoma were treated in a phase I-II trial of combination chemotherapy with a 72-h continuous infusion of cisplatin (CDDP) and 5-fluorouracil (5-FU) with an infusion of VP-16 given at 24 and 48 h after the start of therapy."3.68A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma. ( Browne, MJ; Calabresi, P; Clark, JW; Cummings, FJ; Curt, G; Posner, M; Slapak, CA; Urba, S; Weitberg, A; Wiemann, M, 1990)
"A human colon adenocarcinoma cell line (GC3TK-) was selected for thymidine kinase (TK) deficiency from cloned parental cells (GC3C1) by exposure to 5-bromodeoxyuridine (BrdUrd)."3.68Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency. ( Germain, G; Houghton, JA; Houghton, PJ; Pennington, J; Radparvar, S; Rahman, A, 1990)
"Thirty-five consecutive patients with resectable adenocarcinoma of the esophagus or gastroesophageal junction were treated with two preoperative and three or four postoperative chemotherapy courses consisting of etoposide, fluorouracil, and cisplatin (EFP) to evaluate the rate of curative resection, clinical and pathologic response, toxic effects, and survival."3.68Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction. ( Abbruzzese, JL; Ajani, JA; DeCaro, L; Jackson, DE; Levin, B; McMurtrey, M; Mountain, C; Rich, TA; Roth, JA; Ryan, B, 1990)
"Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action."3.68Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990)
"In a search for compounds related to flavoneacetic acid with activity against solid tumors, a series of methyl-, methoxy-, chloro-, nitro-, and hydroxy-substituted xanthenone-4-acetic acids have been synthesized and evaluated against subcutaneously implanted colon adenocarcinoma 38 in vivo, using a short-term histology assay as a primary screening system."3.67Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo. ( Atwell, GJ; Baguley, BC; Calveley, SB; Denny, WA; Rewcastle, GW, 1989)
"Fifty-one patients with metastatic adenocarcinoma received Folinic Acid (FA) combined with 5-Fluorouracil (5FU) in a Phase I-II clinical trial."3.675-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy. ( Budd, GT; Bukowski, RM; Cunningham, J; Purvis, J; Weick, JK, 1984)
"The growth inhibitory effects of 5-fluorouracil (5-Fu) and the combination of 5-Fu and human leukocyte interferon (HuIFN-alpha) on the human salivary gland adenocarcinoma cell line HSG in culture were examined by measuring colony formation in the semi-solid agar medium and cell proliferation in the monolayer culture."3.67Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture. ( Hayashi, Y; Kobayashi, S; Nitta, T; Sato, M; Urata, M; Yanagawa, T; Yoshida, H; Yura, Y, 1984)
"The effect of 5-fluorouracil on the stability of DNA and the synthesis of DNA replication intermediates was analyzed in human colon adenocarcinoma cells."3.67Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. ( Lönn, S; Lönn, U, 1984)
"Twenty-one patients with adenocarcinoma of the cecum were treated in a pilot study between October, 1972 and June, 1982 by right hemicolectomy and received adjuvant postoperative irradiation (40-45 Gy/4-5 weeks) and 5-Fluorouracil (5-FU)."3.67Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study. ( Cormier, WJ; Jazy, FK; Krause, RJ; Meyer, RL; Shehata, WM, 1984)
"Twenty-two previously untreated patients with advanced gastric adenocarcinoma were treated with a modification of the original 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (FAM) combination chemotherapy."3.67Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM). ( Cohen, Y; Epelbaum, R; Haim, N; Robinson, E, 1984)
"A 68-year-old man was treated with FAM (5-fluorouracil, doxorubicin [Adriamycin], mitomycin-C) for metastic gastric adenocarcinoma."3.67Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma. ( Kerwin, DM; Smith, FP; Tsou, E; Waldhorn, RE, 1984)
"5-Fluorouracil(5-FU)is a widely used antitumor agent for treating patients with adenocarcinoma of gastroenterial tract and breast following intravenous or oral administration."3.67[5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil]. ( Hashimoto, I; Kashi, Y; Mikami, J; Nakamura, T; Nakanishi, Y; Nishidai, H; Sawada, Y; Yoshimoto, M, 1984)
"Eleven patients with advanced adenocarcinoma of the prostate were treated with a cyclic alternating chemotherapy (VIP-DMF therapy), consisting of a three-drug combination of vincristine, ifosfamide, and peplomycin; and a three-drug combination of adriamycin, mitomycin C and 5-fluorouracil."3.67[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate]. ( Akagi, T; Hara, M; Nanba, K; Obama, T; Ochi, J; Ozaki, Y; Saegusa, M; Tanahashi, T; Tsushima, T; Yoshimoto, J, 1987)
" Treatment regimens usually employed cis-diammine-dichloroplatinum (CDDP) plus peplomycin for squamous cell carcinoma, and CDDP plus vindesine for adenocarcinoma."3.67[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion]. ( Inoue, F; Mimura, H; Miyake, M; Mori, T; Orita, K; Takeda, I; Tanaka, N, 1988)
"Nine patients (5 males, 4 females; median age, 62 years) with recurrent high-grade malignancies of major (7 cases) and minor (2 cases) salivary gland origin (4 adenoid cystic carcinomas, 2 adenocarcinomas, 2 poorly differentiated carcinomas, 1 mixed malignant tumor) were treated with cisplatin (60 mg/m2), epirubicin (50 mg/m2) and 5-fluorouracil (600 mg/m2) (CEF) by intravenous injections on the first day of a 21-day regimen."3.67Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland. ( Airoldi, M; Brando, V; Gabriele, P; Giordano, C; Pedani, F, 1989)
"Thirty patients with advanced colorectal adenocarcinoma were treated by chemotherapy with an alternating regimen consisting of 5-fluorouracil (5-FU)-mitomycin C and 5-FU-dacarbazine at 3-week intervals."3.67Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study. ( Droz, JP; Herait, P; Kac, JL; Rougier, P; Theodore, C, 1989)
"Based on the in vitro and in vivo data suggesting synergistic cytolysis by the combination of 5-fluorouracil and interferon-gamma against a variety of malignant cell lines including a human colon carcinoma cell line (HT-29), we initiated studies in patients with advanced colon or rectal carcinoma."3.67Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma. ( Abbruzzese, JL; Ajani, JA; Edwards, C; Ende, K; Faintuch, JS; Gutterman, JU; Levin, B; Rios, AA; Saks, S, 1989)
"Twenty-one consecutive patients with primarily non-resectable adenocarcinoma of the rectum were treated with preoperative split-course radiotherapy (40 Gy) and simultaneous sequential methotrexate + 5-fluorouracil + leucovorin (MFL)."3.67Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies. ( Frykholm, G; Glimelius, B; Påhlman, L, 1989)
"When given orally in combination with L-cysteine, 5'-deoxy-5-fluorouridine (DFUR) brought about a significant reduction in the growth of adenocarcinoma 755 and a significant prolongation of life-span in mice bearing Lewis lung carcinoma without increased toxicity to the host as compared with DFUR alone, though L-cysteine alone did not show an appreciable antitumor activity."3.67Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine. ( Araki, E; Hoshi, A; Iigo, M; Nakajima, Y, 1989)
"The present study compared the antitumor activities of chemotherapy with 5-fluorouracil (5-FU) and with its prodrug 5'-deoxy-5-fluorouridine (5'-DFUR) in combination with radiotherapy on a solid colon 26 adenocarcinoma in the mouse."3.67Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma. ( Ishikawa, T; Ishitsuka, H; Ohkawa, T; Tanaka, Y, 1989)
" A total of 37 patients with advanced measurable adenocarcinoma of the stomach were treated with Adriamycin, methotrexate, and 5-fluorouracil (AMF)."3.67Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma. ( Abbruzzese, JL; Ajani, JA; Boman, BM; Faintuch, JS; Goudeau, P; Kanojia, MD; Levin, B, 1989)
"A total of 23 patients with advanced gastric adenocarcinoma were treated with a combination of moderate-dose methotrexate (MDMTX), 250 mg/m2 i."3.67Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma. ( Dickinson, R; Levi, J; Milliken, S; Presgrave, P; Woods, R, 1989)
"Nineteen patients with adenocarcinoma of unknown primary were treated with the m-FAM regimen, consisting of methotrexate 50 mg/m2 days 0, 28; 5-fluorouracil 600 mg/m2 days 1, 8, 29, 36; Adriamycin 30 mg/m2 days 1, 29; and mitomycin-C 10 mg/m2 day 1."3.67Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary. ( Falchuk, SC; Le Chevalier, T; Rouesse, J; Sevin, D; Spielman, M; Treat, J; Tremblay, C; Woolley, PV, 1989)
"Two trials of leucovorin (LV) and 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer were done, both using a 3-day loading dose and then weekly doses to minimize toxicity."3.67Clinical experience with leucovorin and 5-fluorouracil. ( Brenckman, WD; Collier, M; Duch, DS; Ferone, R; Knick, VB; Laufman, LR; Morgan, ED; Mullin, R; Stydnicki, KA, 1989)
"Sixty women with metastatic breast cancer refractory to at least one chemotherapeutic regimen were treated with fluorouracil (FUra) and high-dose continuous infusion folinic acid (leucovorin calcium)."3.67Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium. ( Akman, S; Bertrand, M; Carr, B; Doroshow, JH; Flanagan, B; Goldberg, D; Leong, L; Margolin, K; Newman, E; Odujinrin, O, 1989)
"Twelve patients with stage D2 adenocarcinoma of the prostate were treated with the combination chemotherapy of ifosfamide (2 g/body, i."3.67[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer]. ( Andoh, M; Fukui, I; Higashi, Y; Horiuchi, S; Kihara, K; Kitahara, S; Oshima, H; Takeuchi, S, 1989)
"A total of 24 patients with advanced colorectal adenocarcinoma were entered into a phase I-II study of 5-fluorouracil (5-FU) and cisplatin, 21 of whom had previously received 5-FU."3.67Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma. ( Creaven, PJ; Herrera, L; Madejewicz, S; Mittelman, A; Petrelli, NJ; Plager, J; Rustum, Y; Soloman, J, 1989)
"We report a case of recurrent adenocarcinoma of the bladder treated by intra-arterial infusion of 5-fluorouracil (5-FU)."3.67Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder. ( Fuchs, EF; Hatch, TR, 1989)
"Fluorine-19 NMR spectrometry was used to monitor the metabolism of two antineoplastic fluoropyrimidines, 5-fluorouracil (5FU) and 5'-deoxy-5-fluorouridine (5'dFUrd), in cell cultures of human pancreatic (Capan-1) and colon (HT-29) adenocarcinoma."3.67Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma. ( Faure, F; Hollande, E; Malet-Martino, MC; Martino, R; Palevody, C; Vialaneix, JP, 1986)
"5-Fluorouracil (FUra) has been administered to mice bearing xenografts of human colon adenocarcinomas."3.67Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Torrance, PM; Weiss, KD; Williams, LG, 1986)
"Fifty-four patients with adenocarcinoma and large cell carcinoma of the lung, 16 with localized surgically resected disease and 38 with metastatic disease, were treated with 5-fluorouracil, doxorubicin, and mitomycin-C (FAM), in an attempt to prolong previously reported survival times in the patients."3.675-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung. ( Shaw, MK; Shaw, MT, 1987)
"The combined effects of X-ray irradiation and 5-FU derivatives (5-FU, tegafur, HCFU) treatment were investigated in mouse adenocarcinoma-755."3.67[Combined effects of radiation and 5-FU derivatives]. ( Dokiya, T; Hashimoto, S; Kunieda, E; Miyamoto, H; Shigematsu, N; Tominaga, J, 1986)
"Neoadjuvant therapy combining 5-fluorouracil, mitomycin C, and moderate-dose radiotherapy was given preoperatively to 29 patients with adenocarcinoma of the rectum, 3 patients with squamous cell cancer, and 1 patient with basaloid carcinoma of the anus."3.67Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer. ( Muff, NS; Shetabi, H; Smith, DE, 1986)
"The chemotherapeutic action of tegafur (FT) against adenocarcinoma 755 in mice was markedly potentiated by oral administration of L-cysteine and L-cystine without increasing its toxicity."3.67Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine. ( Hoshi, A; Iigo, M; Kitagawa, H, 1986)
"When combined with bromovinyldeoxyuridine (BVdUrd), 5-fluorouracil (FUra) brought about a significant reduction in the growth of adenocarcinoma 755 tumors in mice, at doses at which either drug used alone (BVdUrd: 100 mg/kg) did not effect an appreciable antitumor activity."3.67Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1987)
"A 55-year-old female, in which an unresectable Borrmann II-type gastric cancer (moderately differentiated adenocarcinoma) extending from vicinity of the cardia to the lower portion of the corpus, with direct invasion into the pancreas and extensive lymph node metastases, confirmed by laparotomy, was treated postoperatively by 3 courses of chemotherapy with cisplatinum in combination with mitomycin C and 5-fluorouracil."3.67Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil. ( Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Sakata, K; Shimokawa, K; Suzuki, M; Tanemura, H, 1988)
"A 64-year-old woman who was diagnosed as inoperable intrahepatic bile duct cancer with massive liver metastasis was treated with 5-fluorouracil (5-FU), adriamycin (ADM) and mitomycin-C (MMC)."3.67[A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy]. ( Hasegawa, H; Kozakai, M; Misu, Y; Saitoh, Y; Shikata, J; Takada, T; Tsuchiya, S; Uchiyama, K; Yasuda, H, 1988)
"Twenty-two patients with disseminated adenocarcinoma of the large bowel received therapy with 5-fluorouracil 800-1000 mg/m2 as a 24 h infusion for 4 consecutive days with 60 mg/m2 intravenous folinic acid administered every 6 hours."3.67Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer. ( Higano, C; Mortimer, JE, 1988)
"An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion."3.67High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. ( Cady, J; De Gramont, A; Demuynck, B; Gonzalez-Canali, G; Grange, JD; Krulik, M; Lagadec, B; Loiseau, JP; Louvet, C; Maisani, JE, 1988)
"Between January 1981 and December 1986, 20 patients with adenocarcinoma of the esophagus and gastroesophageal junction were entered into a prospective study involving combined radiation therapy and chemotherapy (5-fluorouracil [5-FU] and mitomycin) as primary management."3.67Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. ( Coia, LR; Engstrom, PF; Paul, AR, 1988)
"A marked inhibition of the growth of solid tumor adenocarcinoma 755 was achieved by the combination of 5-fluorouracil (5-FU) with bromovinyldeoxyuridine (BVDU)."3.67Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels. ( Araki, E; De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y, 1988)
"Fourteen patients with advanced gastric adenocarcinoma were treated with continuous 5-fluorouracil (5-FU) infusion, 300 mg/m2/day, through an indwelling central venous catheter; 13 were evaluable for response."3.67Continuous 5-fluorouracil infusion in advanced gastric carcinoma. ( Anderson, T; Ausman, R; Beatty, P; Chitambar, C; Hansen, R; Moynihan, T; Quebbeman, E; Ritch, P; Vukelich, M, 1988)
"The EORTC Gastrointestinal Group has conducted a phase II trial in 47 patients with locally advanced or metastatic adenocarcinoma of the pancreas with epirubicin 90 mg/m2 intravenously on day 1 in combination with 5-fluorouracil 500 mg/m2 in a 2 hr infusion day 1-4, every 4 weeks."3.67An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas. ( Bleiberg, H; Blijham, G; Dalesio, O; Duez, N; Planting, A; Splinter, T; Weber, W; Wils, J, 1987)
"Forty-four patients with locally recurrent or metastatic colorectal adenocarcinoma were treated with methotrexate (MTX) 100 mg/m2 i."3.67Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma. ( Anderson, T; Hansen, RM; Ritch, PS, 1986)
"Thirteen patients with metastatic colorectal adenocarcinoma underwent treatment with continuous ambulatory 5-fluorouracil (5-FU) infusion 300 mg/m2/day and intermittent bolus methotrexate (MTX) (200 mg/m2) with calcium leucovorin (LCV) 10 mg/m2 orally every 6 h X four to eight doses given 24 h after MTX."3.67Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity. ( Anderson, T; Frick, J; Hansen, RM; Quebbeman, EJ; Ritch, PS, 1987)
"We report the results of an expanded trial of 5-fluorouracil (FUra) combined with high-dose folinic acid for treatment of patients with advanced colorectal or gastric adenocarcinoma."3.67Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid. ( Benavides, M; Chollet, P; Goldschmidt, E; Machover, D; Marquet, J; Metzger, G; Misset, JL; Schwarzenberg, L; Vandenbulcke, JM; Zittoun, J, 1987)
"Forty patients with adenocarcinoma of the cecum who underwent right hemicolectomy received regional irradiation for 40-45 Gy/4-5 weeks and weekly 5-Fluorouracil (5-FU)."3.67Regional adjuvant irradiation for adenocarcinoma of the cecum. ( Cormier, WJ; Jazy, FK; Meyer, RL; Shehata, WM; Welling, RE, 1987)
"The effect of various guanine ribonucleotides on the antitumor activity of 5-fluorouracil (FUra) was investigated by its action on adenocarcinoma 755."3.67Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755. ( Hoshi, A; Iigo, M; Nishimura, S; Yamaizumi, Z, 1987)
"A 59-year-old man undergoing systemic 5-fluorouracil treatment for metastatic adenocarcinoma of the stomach developed ocular lesions consisting of bilateral conjunctival ulcers and ulcerative blepharitis leading to ankyloblepharon."3.67Ankyloblepharon associated with systemic 5-fluorouracil treatment. ( Helm, CJ; Insler, MS, 1987)
"Twenty-five patients with locally advanced but resectable adenocarcinoma of the stomach were given concomitant postoperative radiotherapy to the tumor bed and chemotherapy with 5-Fluorouracil (5-FU)."3.67Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma. ( Gez, E; Sulkes, A; Weshler, Z; Yablonsky-Peretz, T, 1986)
"The cytotoxic effects of three anticancer drugs, methotrexate (MTX), 5-fluorouracil (5-Fu) and oridonin (Rub A), were investigated using a human gastric adenocarcinoma cell line (MGc80-3) and a human esophageal cancer cell line (CaEs-17) by means of colony-forming assay, dye exclusion test, measurement of incorporation of 3H-thymidine into DNA and examination of mitotic index."3.67[Comparison of in vitro assays for the cytotoxic effect of anticancer drugs]. ( Li, PY; Li, XT; Lin, C, 1986)
"The combination of 5-fluorouracil (5-FU), doxorubicin, and mitomycin (FAM) is often recommended for empiric management of patients with adenocarcinoma of unknown primary."3.675-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary. ( Ahlgren, JD; Goldberg, RM; Schein, PS; Smith, FP; Ueno, W, 1986)
"Twelve patients with adenocarcinoma of the pancreas and two patients with carcinoma of the extrahepatic biliary tree received combined therapy with 125I implant, precision high-dose (PHD) photon external beam therapy, and systemic 5-fluorouracil (5-FU)."3.67125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree. ( Ahuja, RK; Dobelbower, RR; Merrick, HW; Skeel, RT, 1986)
"Fifty-three patients with inoperable adenocarcinoma of the lung were treated with 5-fluorouracil, Adriamycin, and mitomycin-C (FAM) in two dose schedules: schedule 1--5-FU 600 mg/m2 days 1, 8, 29, and 36 and Adriamycin 30 mg/m2 days 1 and 29 and mitomycin-C 10 mg/m2 day 1 repeated every 8 weeks."3.675-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung. ( Burkes, R; DeBoer, G; Evans, WK; Paul, K; Shepherd, FA, 1986)
"The adjuvant effect of calmodulin antagonists (W-5 and W-7) to 5-fluorouracil (5-FU) was studied by using two human cultured cell lines derived from ovarian adenocarcinoma."3.67Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms. ( Kato, K; Kikuchi, Y; Kizawa, I; Oomori, K, 1987)
"In order to determine the contribution of thymidine (dThd) salvage to intrinsic resistance to antimetabolites (5-fluoropyrimidines, antifolates) in the human colon adenocarcinoma xenograft, H X GC3, a subline deficient in thymidine kinase has been developed."3.67Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage. ( Germain, G; Houghton, JA; Houghton, PJ; Torrance, PM, 1987)
"In order to test the possible cardiac-sparing effect of doxorubicin administered by six-hour intravenous infusion and to prospectively evaluate the role of resting left ventricular ejection fraction in monitoring these patients, 33 women with advanced breast cancer were treated with combination chemotherapy containing 5-fluorouracil, cyclophosphamide, and doxorubicin."3.67Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. ( Blum, RH; Dubin, N; Green, MD; Muggia, FM; Roses, D; Sanger, J; Speyer, JL; Wernz, JC, 1985)
"Bestatin enhanced the antitumor effects of mitomycin C, 5-fluorouracil and cis-dichlorodiammineplatinum against a syngeneic solid tumor of colon adenocarcinoma 26 in BALB/c mice."3.67Enhancement of antitumor effect of cytotoxic agents by bestatin. ( Abe, F; Ashizawa, J; Horinishi, H; Ishizuka, M; Matsuda, A; Shibuya, K; Takahashi, K; Takeuchi, T; Umezawa, H, 1985)
"To delineate the efficacy of continuous intravenous 5-fluorouracil (5-FU) infusion therapy for advanced colorectal adenocarcinoma, a study of 36 patients with measurable metastatic disease was conducted."3.67Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil. ( Ausman, R; Becker, T; Blake, D; Caballero, G; Hansen, R; Jenkins, D; Quebbeman, E; Ritch, P; Schulte, W; Tangen, L, 1985)
"Sequential methotrexate-5-fluorouracil (Mtx-5-Fu) reduces proliferation of human colon adenocarcinoma cells."3.67The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil. ( Lönn, S; Lönn, U, 1986)
"During the past three years we have entered 54 patients with gastric adenocarcinoma into a clinical trial of oral administration of injectable 5-fluorouracil (5-Fu)."3.67Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil. ( Wu, YF, 1985)
"Twenty-eight patients with advanced adenocarcinoma were treated with a combination of thymidine, 5-FU, and PALA."3.67Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination. ( Bedikian, A; Bodey, GP; Chiuten, DF; Freireich, EJ; Valdivieso, M, 1985)
"Twenty patients (15 male, 5 female) with nonresectable gastric adenocarcinoma were treated with FAP (5-fluorouracil 300 mg/m2 IV on days 1-5, adriamycin 50 mg/m2 IV on day 1, cisplatin 20 mg/m2 IV on days 1-5)."3.67Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer. ( Burghouts, JT; Hillen, HF; Hoogendoorn, GJ; Scheerder, H; van Dam, FE; van der Vegt, SG; Wagener, DJ; Wobbes, T; Yap, SH, 1985)
"Thirty-eight patients with advanced colorectal adenocarcinoma were treated with the following regimen: N5-10-methyltetrahydrofolate (MTHF) (200 mg/m2/day) and 5-fluorouracil (5-FU) (375 mg/m2/day) given concomitantly, consecutively for 5 days, every 4 weeks, in order to evaluate the potential advantage derived from the biochemical enhancement of cytotoxic activity of 5-FU by high-dose reduced folates."3.67Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer. ( Bruzzone, M; Nobile, MT; Rosso, R; Rubagotti, A; Sertoli, MR; Tagarelli, G, 1985)
"Twenty-seven patients with colorectal adenocarcinoma, (12) non-small cell bronchogenic carcinoma, (11) gastric adenocarcinoma (3), and adenocarcinoma of unknown primary lesion (1) were treated with the combination of thymidine (TdR), 5-fluorouracil (FU), and N-phosphonacetyl-L-aspartic acid (PALA)."3.67Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study. ( Bedikian, A; Benvenuto, JA; Bodey, GP; Chiuten, DF; Freireich, EJ; Loo, TL; Miller, A; Valdivieso, M, 1985)
"In a multicentre trial of adjuvant chemotherapy in gastric adenocarcinoma, a number of patients developed chronic haemolysis and renal failure following long-term treatment with 5-fluorouracil and mitomycin-C."3.66Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C. ( Brookes, VS; Fielding, JW; Howell, A; Jones, BG; Newman, CE, 1980)
"The predictive utility of several biochemical parameters of 5-fluorouracil (5-FUra) action was evaluated in four murine colonic adenocarcinomas: 5-FUra-sensitive Tumor 38 and 5-FUra-resistant Tumors 07/A, 51 and 06/A."3.66In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. ( Corbett, TH; Heidelberger, C; Moran, RG; Shahinian, AH; Spears, CP, 1982)
"Nineteen patients with unresectable and metastatic adenocarcinoma of the pancreas and ampulla of Vater were treated with intermittent regional infusion of the celiac axis (CAI) with the combination of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S)."3.66Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study. ( Bukowski, RM; Hewlett, JS; Livingston, RB; Theodors, A; Weick, JK, 1982)
"Twenty patients with advanced or recurrent endometrial adenocarcinoma were treated with combination chemotherapy consisting of Adriamycin, cyclophosphamide, 5-fluorouracil, and vincristine at three-week intervals."3.66Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels. ( Jänne, O; Kauppila, A; Kujansuu, E; Vihko, R, 1980)
"Sixty-three previously untreated patients with metastatic non-small cell lung cancer (40 patients with adenocarcinoma and 23 with large cell undifferentiated carcinoma) were treated with combination chemotherapy consisting of 5-FU (300 mg/m2) given as an iv bolus on Days 1-4 and vindesine (3 mg/m2) and mitomycin (10 mg/m2), both given as an iv bolus on Day 1 of each treatment course (FEMi)."3.66Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study. ( Carlin, DA; Grozea, PN; Miller, TP; Weick, JK, 1982)
"Following gastrectomy for locally advanced adenocarcinomas, three patients developed microangiopathic hemolytic anemia and renal failure shortly after completing courses of adjuvant chemotherapy with mitomycin and 5-FU."3.66Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome. ( Band, PR; Bettez, P; Giroux, L; Gruber, J; Jolivet, J; Laurin, S, 1983)
"Because alpha-difluoromethylornithine (DFMO) reduces the incidence of experimental colon cancers, inhibits the growth of human lung cancer cells and human leukemia cells in culture, and in combination with methylglyoxal (bis)guanylhydrazone induces remission in children with leukemia, its effectiveness against a human colon adenocarcinoma cell line (Colo 205) was tested alone and in combination with 5-fluorouracil (5-FU)."3.66Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line. ( Diekema, KA; Kingsnorth, AN; Malt, RA; McCann, PP; Russell, WE, 1983)
"Logothetis and von Eschenbach first 1981 reported encouraging preliminary results of the DMF regimen (Doxorubicine = Adriamycin, Mitomycin, 5 Fluorouracil) in hormone refractory adenocarcinoma of the prostate."3.66[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study]. ( Burk, K; Gropp, C; Rodeck, G, 1983)
"Sixty-two patients with metastatic hormonal refractory adenocarcinoma of the prostate received a combination of doxorubicin, mitomycin-C, and 5-fluorouracil (DMF)."3.66Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer. ( Grant, C; Johnson, DE; Logothetis, CJ; Ogden, S; Samuels, ML; Trindade, A; von Eschenbach, AC, 1983)
"Twenty-nine patients with advanced gastric adenocarcinoma were treated with 72-hour continuous intravenous infusion of 5-fluorouracil (30 mg/kg/24 hr) at 2-week intervals."3.66Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals. ( MacDonald, WC; Shah, A, 1983)
"Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer."3.66Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983)
" Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina."3.66Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983)
"Fourteen patients with adenocarcinoma of the gastrointestinal tract and pancreas treated with mitomycin C(MMC) and 5-fluorouracil (5-FU) had renal impairment 6-11 months from the beginning of MMC therapy."3.66Renal disease after mitomycin C therapy. ( Hanna, WT; Krauss, S; Murphy, WM; Regester, RF, 1981)
"A four-drug combination of intermittent high-dose cyclophosphamide with 5-fluorouracil, hexamethylmelamine, and prednisone was given to 19 patients with advanced breast cancer."3.66Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer. ( Chang, YC; Crowley, J; Falkson, G; Tormey, DC, 1981)
"A 72 year old man with rectal adenocarcinoma developed chronic renal failure when treated by surgery and subsequent chemotherapy (5-fluorouracil, Mitomycin C and Cytosine arabinoside) and immunotherapy."3.66Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs. ( Fornari, G; Mazzucco, G; Monga, G, 1982)
"The anti-inflammatory drug indomethacin was tested for antitumor activity against transplantable mouse colon adenocarcinoma 38 (colon 38)."3.66Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin. ( Goto, A; Narisawa, T; Sano, M; Sato, M; Takahashi, T, 1983)
"Six patients with metastatic urothelial carcinoma--4 transitional cell carcinomas and 2 adenocarcinomas--were treated with cis-platinum (CDDP), adriamycin (ADM) and 5-fluorouracil (5-FU)."3.66[Chemotherapy of metastatic urothelial carcinoma]. ( Kawai, T; Kihara, K; Ogawa, M; Sakuramoto, T; Washizuka, M, 1982)
"A series of four human colon adenocarcinomas, growing as xenografts in immune-deprived mice, have been used to evaluate the efficacy of 5-FU in combination with two purines, hypoxanthine (Hx) and allopurinol (HPP), which have reduced the toxicity of 5-FU in host mice."3.66Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts. ( Houghton, JA; Houghton, PJ, 1982)
" This ex vivo culture system was used to test the activity of 5-fluorouracil (5-FU) against four human colorectal adenocarcinoma cell lines (SW 403, SW 480, SW 620, and SW 707)."3.66Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents. ( Leibovitz, A; Morris, NG; Quarles, JM, 1982)
"Twenty-one patients, presenting with metastases only to bone from a primary adenocarcinoma of the breast having previously undergone mastectomy, tolerated aggressive cytotoxic chemotherapy (CAF--cyclophosphamide 500 mg/m2, Adriamycin 50 mg/m2, 5-fluorouracil 500 mg/m2 q 3 weeks) without significant clinical morbidity."3.66Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases. ( Malmud, LS; Scogna, DM; Smalley, RV, 1982)
"After perioperative adjuvant chemotherapy of a sigma-adenocarcinoma with 400 mg peptichemio and 500 mg 5-fluorouracil a 61-year-old woman developed a severe intoxication: myelosuppression with pancytopenia, gastroenteritis and ulcerative proctitis, toxic hepato- and myocardiopathy, impaired renal function and alopecia."3.66[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)]. ( Gasser, RW; Schmalzl, F, 1982)
"Twenty-five patients with advanced measurable adenocarcinoma of the colon were treated with 5-fluorouracil (FUra), 15 to 20 mg/kg/week i."3.66Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer. ( Bateman, JR; Block, JB; Chan, KK; Chlebowski, RT; Gota, CH; Weiner, JM, 1982)
"This study was designed to examine the possibilities for increasing the therapeutic index in the treatment of human colon adenocarcinomas maintained as xenografts in immune-deprived mice using combinations of methotrexate (MTX) that preceded 5-fluorouracil (FUra)."3.66The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas. ( Houghton, JA; Houghton, PJ; Tice, AJ, 1982)
"Twenty-five patients with histologically proved adenocarcinoma of the prostate were divided into two groups and submitted to combination therapy with estramustine (Estracyt), cyclophosphamide (Cytoxan), 5-fluorouracil, and Cisplatin."3.66Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer. ( Beckley, S; Maeso, E; Murphy, G; Pontes, E; Wajsman, Z, 1981)
"The antitumor activity of 1-hexylcarbamoyl-5-fluorouracil (HCFU) in various schedules of long-term oral administration was examined in spontaneous mammary adenocarcinoma of SHN mice, an autochthonous tumor system."3.66Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice. ( Hoshi, A; Iigo, M; Kuretani, K; Tokuzen, R, 1980)
"Consecutive studies were undertaken in advanced colorectal adenocarcinoma, comparing two different schedules of the combination methyl-CCNU, 6-thioguanine, and 5-fluorouracil in 89 patients."3.66Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer. ( Aroney, RS; Bell, DR; Chan, WK; Dalley, DN; Levi, JA, 1981)
"Thirty patients with unresectable adenocarcinoma of the lung were treated with high doses of 5-fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM)."3.665-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung. ( Ali, M; Brown, B; Ewer, M; Nogeire, C; Rosi, DR; Samuels, M, 1981)
"Antitumor activity of seven 5-fluorouracil derivatives having carbamoyl linkage with amino acid was examined against L-1210 leukemia, adenocarcinoma 755, ascites sarcoma 180, Ehrlich ascites carcinoma and Lewis lung carcinoma by oral administration."3.66Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration. ( Ando, N; Hoshi, A; Iigo, M; Inomata, M; Kuretani, K, 1981)
"1-Hexylcarbamoyl-5-fluorouracil (HCFU) and its parent compound 5-fluorouracil (5-FU) were tested PO for antitumor activity against mouse colon adenocarcinoma 26 (colon 26), colon adenocarcinoma 38 (colon 38), and Lewis lung carcinoma."3.66Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil. ( Iida, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T, 1980)
"28 patients with advanced adenocarcinomas were treated with combinations of 5-fluorouracil and mitomycin-C (FM, 21 patients) or of 5-fluorouracil, adriamycin and mitomycin-C (FAM, 7 patients)."3.66[Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas]. ( Hammer, B; Jungi, WF; Mayr, AC; Senn, HJ; Späti, B, 1980)
"Thirty-nine patients with advanced metastatic adenocarcinoma of the pancreas were treated with a combination of 5-fluorouracil, Adriamycin, and mitomycin-C (FAM)."3.665-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas. ( Hoth, DF; Karlin, DA; Levin, B; MacDonald, JS; Schein, PS; Smith, FP; Woolley, PV, 1980)
"The effect of sequential methotrexate and 5-fluorouracil on the clonal growth of the human colon adenocarcinoma cell, HCT-8, and the hormone-dependent human breast carcinoma cell, 47-DN, was examined."3.66Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines. ( Benz, C; Cadman, E; Choti, M; Schoenberg, M, 1980)
"The modulation of 5-fluorouracil (FUra) metabolism by methotrexate (MTX) pretreatment in monolayer cultures of human colorectal adenocarcinoma."3.66Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8. ( Benz, C; Cadman, E, 1981)
"Twenty-two patients with adenocarcinoma metastatic to the liver were treated with rapid fractionation whole-liver irradiation (1350-2100 rads in 300-rad fractions) with simultaneous intrahepatic 5-fluorouracil (10-15 mg/kg/day) and intrahepatic Adriamycin 2."3.66Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study. ( Cassidy, M; Friedman, M; Levine, M; Phillips, T; Resser, KJ; Spivack, S, 1979)
"From May 1972 until May 1976, 105 patients were entered on Central Oncology Group protocol 7230 to compare the combination of streptozotocin, tubercidin, and 5-fluorouracil (5-FU) versus 5-FU alone in the treatment of adenocarcinoma and islet cell carcinoma of the pancreas."3.665-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230. ( Aust, JB; Awrich, A; Fletcher, WS; Grage, TB; Hill, GJ; Klotz, JH; Minton, JP; Multhauf, PM, 1979)
"In two separate experiments, treatment of C3H/He mice bearing transplantable mammary adenocarcinomas (C3HBA) with a regimen of 6-propylthiouracil (PTUra) and 5-fluorouracil (FUra) plus chloroquine phosphate (CP) resulted in complete remissions of 77 and 65%, respectively."3.66Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate. ( Dagher, RK; Shoemaker, JP, 1979)
"Twenty-five patients with advanced measurable adenocarcinoma of the lung were treated with combination chemotherapy consisting of 5-fluorouracil, adriamycin, and mitomycin-C (FAM)."3.665-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung. ( Butler, TP; MacDonald, JS; Schein, PS; Smith, FP; Smith, LF; Woolley, PV, 1979)
"Combination chemotherapy consisting of cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil was evaluated in 21 patients with metastatic adenocarcinoma of the prostate who were unresponsive to conventional therapy."3.66Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate. ( Ikard, M; Shippel, RM; Soloway, MS, 1979)
"Thirty-five patients with advanced-stage metastatic or unresectable gastric adenocarcinoma were given combination chemotherapy consisting of fluorouracil, doxorubicin, and 1,3-bis (2-chlorbethyl)-1-nitrosourea."3.66Improved combination chemotherapy in advanced gastric cancer. ( Aroney, RS; Dalley, DN; Levi, JA, 1979)
"Three distinct subpopulations of tumor cells derived from a single parent strain BALB/cfC3H mammary adenocarcinoma were tested in vivo for sensitivity to cyclophosphamide, methotrexate, and 5-fluorouracil."3.66Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor. ( Calabresi, P; DeNucci, T; Dexter, DL; Heppner, GH; Miller, FR, 1978)
"Fifty-four patients with clinical evidence of residual colorectal adenocarcinoma following surgical removal of the primary tumor were treated with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside."3.66Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study. ( Davis, S; Park, YK, 1978)
"A number of chemotherapeutic agents, including L-asparaginase, actinomycin D, chloroethylcyclohexy-nitrosourea, 5-flourouracil, cyclophosphamide, hydroxyurea, cis-platinum, adriamycin and methotrexate, alone and in combination and at variable dose levels, were applied against the Dunning R3327 rat prostatic adenocarcinoma-subline G."3.66Further experience with chemotherapy in the Dunning prostatic adenocarcinoma. ( Block, NL; Camuzzi, F; Claflin, A; Politano, VA; Stover, B; Troner, M, 1978)
"Metastasizing mammary adenocarcinoma 13762 in female Fischer rats has been used as a model for studying postoperative adjuvant chemotherapy, using methotrexate (Mtx) and 5-fluouracil (5FU) either singly or in combinations."3.65Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma. ( Khwaja, TA; Lee, YT, 1977)
"Arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation achieves a definite objective improvement in patients with estrogen-resistant adenocarcinoma of the prostate."3.65Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder. ( Hoffman, AA; Nevin, JE, 1975)
"A carcinostatic substance (5-fluorouracil) was instilled into the mediastinal lymph nodes, the pleural cavity or the internal thoracic artery by continuous perfusion before operation on patients with bronchial carcinoma."3.65[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)]. ( Inoguchi, T; Kita, T; Kuwano, K; Yamasaki, I; Yazuka, K, 1976)
" Following surgical removal of spontaneous mammary adenocarcinomas, phenylalanine mustard, adriamycin, and 5-fluorouracil (PAF) were administered at 4, 2, and 50 mg/kg, respectively, once a week for six injections."3.65Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors. ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977)
"Two patients treated with 5-fluorouracil (5-FU) for disseminated adenocarcinoma of the colon developed cerebellar dysfunction typical of 5-FU neurotoxicity."3.65Oculomotor disturbances associated with 5-fluorouracil chemotherapy. ( Bixenman, WW; Nicholls, JV; Warwick, OH, 1977)
"Seven patients with advanced endometrial adenocarcinoma achieved objective tumor regression following chemotherapy with cyclophosphamide, Adriamycin, 5-fluorouracil, and medroxyprogesterone acetate."3.65Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate. ( Bruckner, HW; Deppe, G, 1977)
" In squamous cell cancer of the lung 48 patients were administered methotrexate (90 mg per course), 18 patients with adenocarcinoma--5-fluoruracil, 29 patients with undifferentiated cancer-cyclophosphane (3 g of each substance)."3.65[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)]. ( Abisatov, KhA; Khan, SV, 1976)
"In the present paper a test model was used to examine if human adenocarcinomas of the colon and the stomach are heterogenous as regards the sensitivity to cytosine arabinoside, melphalan, vinblastine sulphate, amethopterin and 5-fluorouracil in vitro."3.65Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs. ( Dencker, H; Håkansson, L; Tropé, C, 1975)
" 5-Fluorouracil (5 FU) is the first chemotherapeutic agent found to have a significant effect on gastrointestinal adenocarcinoma."3.64PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER. ( HART, GD, 1964)
" Secondary endpoints include the DFS of ctDNA positive patients versus ctDNA negative patients, the 2- and 3-year DFS rates, overall survival (OS), the impact of hallmark molecules on the treatment response, adverse events (AEs), and the impact of nutrition status or exercise on recurrence."3.30Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL ( Chen, X; Chen, Y; Guo, F; Han, G; Li, W; Ma, L; Pan, L; Shu, Y; Tang, J; Tian, Y; Xie, L; Xu, H; Zhang, J; Zhang, X, 2023)
" Currently, no trials have investigated the impact of perioperative immunotherapy in combination with chemotherapy for resectable gastric or GEJ adenocarcinoma."3.11Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). ( Brachet, PE; Castera-Tellier, M; Clarisse, B; Corbinais, S; Dorbeau, M; Dos Santos, M; Galais, MP; Guilloit, JM; Le Gallic, C; Leconte, A; Lequesne, J; Parzy, A; Poulain, L; Varatharajah, S; Vaur, D; Weiswald, LB, 2022)
"For patients with localized pancreatic cancer with minimal vascular involvement, optimal survivability requires a multidisciplinary approach of surgical resection and systemic chemotherapy."3.01A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma. ( DeRemer, DL; Fabregas, JC; George, TJ; Hitchcock, K; Hughes, SJ; Kayaleh, O; Lee, JH; Nassour, I; Ramnaraign, B; Rogers, SC; Russell, K; Sahin, I; Singhal, R; Thomas, RM; Turk, A; Zlotecki, R, 2023)
"Hyperthermia was defined as feasible if 70% of patients received at least eight treatments."3.01Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial. ( Bitzer, M; Fend, F; Gani, C; Gellermann, J; Heinrich, V; Königsrainer, A; Lamprecht, U; Moll, M; Wenz, S; Ziegler, A; Zips, D, 2021)
" We hypothesized that pelareorep in combination with pembrolizumab and chemotherapy in patients with PDAC would be safe and effective."2.94Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. ( Arora, SP; Cheetham, K; Coffey, M; Eng, KH; Fields, P; Fountzilas, C; Kalinski, P; Mahalingam, D; Moseley, JL; Nuovo, G; Raber, P; Wilkinson, GA; Zhang, B, 2020)
"This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line advanced pancreatic adenocarcinoma."2.94Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial. ( Andre, T; Bachet, JB; Bouche, O; Cros, J; De La Fouchardiere, C; El Hajbi, F; El Hariry, I; Fabienne, P; Faroux, R; Guimbaud, R; Gupta, A; Hamm, A; Hammel, P; Kay, R; Lecomte, T; Louvet, C; Metges, JP; Mineur, L; Rebischung, C; Tougeron, D; Tournigand, C, 2020)
" Evaluation of pharmacogenomically dosed perioperative gFOLFIRINOX (fluorouracil, leucovorin, oxaliplatin, and UGT1A1 genotype-directed irinotecan) to optimize efficacy while limiting toxic effects may have value."2.94Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. ( Allen, K; Alpert, L; Catenacci, DVT; Chase, L; de Wilton Marsh, R; Ferguson, MK; Gordon, B; Hart, J; Karrison, T; Kindler, HL; Kipping-Johnson, K; Liao, CY; Lomnicki, S; Markevicius, U; Maron, SB; Moore, K; Narula, S; Peterson, B; Polite, BN; Posner, MC; Prachand, VN; Racette, C; Rampurwala, MM; Roggin, KK; Setia, N; Siddiqui, UD; Turaga, K; Xiao, SY, 2020)
"A total of 137 patients with advanced colorectal cancer were recruited."2.94The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer. ( Chang, L; Fu, X; Han, G; Han, Z; Hui, D; Jia, R; Li, Q; Li, Y; Liu, H; Liu, N; Zhang, H; Zhang, Y; Zhu, H, 2020)
" On the basis of preclinical data, sequential dosing was evaluated in cohort 4 (ipafricept day 1 followed nab-paclitaxel + gemcitabine day 3)."2.94Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. ( Astsaturov, I; Brachmann, RK; Cardin, DB; Cohen, SJ; Denlinger, CS; Dotan, E; Kapoun, AM; Lenz, HJ; Messersmith, W; O'Neil, B; Shahda, S; Stagg, RJ; Uttamsingh, S; Weekes, C, 2020)
" Adverse event data collection is recorded at every visit."2.94Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma. ( Al Awabdeh, T; Al Darazi, M; Al Masri, M; Alqasem, K; Amarin, R; Charafeddine, M; Dabous, A; Daoud, F; Deeba, S; El Husseini, Z; Elkhaldi, M; Geara, F; Hushki, A; Jaber, O; Jamali, F; Kattan, J; Khalifeh, I; Kreidieh, M; Mohamad, I; Mukherji, D; Shamseddine, A; Temraz, S; Turfa, R; Zeidan, YH, 2020)
"A combined pancreatic cancer multimodality approach using CIT and radiosensitized radiotherapy is feasible and safe; delivery of immunotherapy can lead to T-cell immunity."2.90Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma. ( Are, C; Berim, LD; Grem, JL; Hollingsworth, MA; Lazenby, A; Lin, C; Ly, QP; Madiyalakan, M; Meza, JL; Nicodemus, CF; Padussis, J; Schwarz, JK; Verma, V, 2019)
"Patients affected with Stage IV colorectal cancer and unresectable metastases represent a heterogeneous group."2.90Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma. ( Crocetti, D; DE Felice, F; DE Toma, G; Fiori, E; Lamazza, A; Mingoli, A; Sapienza, P; Sterpetti, AV; Tarallo, M, 2019)
"However, treatment for locally advanced pancreatic cancer is still controversial."2.90FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan. ( Fukutomi, A; Kamei, K; Kobayashi, M; Kobayashi, S; Matsumoto, I; Matsuoka, H; Mizuno, N; Omae, K; Ozaka, M; Suzuki, S; Todaka, A; Ueno, H; Uesugi, K, 2019)
"A radical rectal cancer surgery was performed 6 to 8 weeks after the simultaneous chemoradiotherapy."2.90Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer. ( Chen, J; Dai, G; Du, X; Feng, L; Jia, B; Liu, H; Liu, Q; Wang, Y; Wen, K; Yang, Y; Zeng, M; Zhu, Y, 2019)
" We included patients with rectal cancer who received 4 courses of modified FOLFOX6 (mFOLFOX6) before rectal surgery and examined the postoperative complication rate, the clinicopathological response, and the rate of chemotherapy-related adverse events (UMIN 000012559)."2.90Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study. ( Funakoshi, T; Hattori, M; Hirose, K; Homma, S; Ichikawa, N; Iijima, H; Ishikawa, T; Ishizu, H; Kamiizumi, Y; Kawamata, F; Koike, M; Kon, H; Kuraya, D; Minagawa, N; Murata, R; Nomura, M; Ohno, Y; Omori, K; Sato, M; Takahashi, N; Takeda, K; Taketomi, A; Yokota, R; Yoshida, T, 2019)
"Pancreatic cancer is a highly lethal disease predominantly affecting older patients."2.90Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial. ( Blanc, JF; Chen, J; Chen, LT; de Jong, FA; Macarulla, T; Mirakhur, B; Siveke, JT; Wang-Gillam, A, 2019)
"The proportion of elderly patients in esophageal cancer is now growing, but there is a lack of evidence in term of treatment standard for this group of patients, which is what we aim to obtain through this prospective phase III study."2.90A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. ( Chang, X; Chen, J; Deng, L; Ge, X; Han, C; Li, C; Liang, J; Lin, Y; Ni, W; Pang, Q; Sun, X; Wang, L; Wang, P; Wang, W; Wang, X; Xiao, Z; Zhang, W; Zhao, Y; Zhou, Z, 2019)
"10-20% of patients with gastric cancer (GC) have HER2+ tumors."2.90EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden ( Caballero, C; Cats, A; Elme, A; Grabsch, HI; Kang, YK; Lordick, F; Marreaud, S; Martens, U; Mauer, M; Moehler, MH; Mueller, L; Rha, SY; Thuss-Patience, P; Tokunaga, M; Wagner, AD, 2019)
"9%) in arm B experienced grade 3/4 adverse events related to bevacizumab; the most frequent were 2 anastomotic fistulas (both in arm A) and abscesses (1 in arm A and 2 in arm B)."2.90Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study. ( Adenis, A; André, T; Azria, D; Bachet, JB; Balosso, J; Ben Abdelghani, M; Borg, C; Boudghène, F; Conroy, T; Coudert, M; François, Y; Ghiringhelli, F; Ionescu-Goga, M; Lakkis, Z; Mantion, G; Mornex, F; Quero, L; Rio, E; Roullet, B; Spaëth, D; Tanang, A; Vendrely, V, 2019)
"The primary end point was the 10-month progression-free rate (PFR); secondary end points included progression-free and overall survival, response rate, rate of metastases resection, and adverse events."2.87Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. ( Antoniotti, C; Aprile, G; Bergamo, F; Boni, L; Cardellino, GG; Coltelli, L; Corsi, DC; Cremolini, C; Dell'Aquila, E; Di Fabio, F; Falcone, A; Fontanini, G; Gemma, D; Grande, R; Lonardi, S; Lupi, C; Mancini, ML; Marcucci, L; Marmorino, F; Masi, G; Mescoli, C; Ronzoni, M; Salvatore, L; Tonini, G; Zagonel, V, 2018)
" The objective of this study was to compare outcome measures, adverse effects, and cost of FOLFOX4 and FOLFIRINOX treatments in rectal cancer patients."2.87Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. ( Chen, Y; Liu, J; Qi, F; Yan, Q; Zhang, G; Zheng, Z, 2018)
"3%), and 201 completed the treatment (early discontinuation was mainly due to intercurrent adverse events [AEs], 7."2.87Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study. ( Bengala, C; Bisagni, G; Brandes, AA; Cagossi, K; Gianni, L; Gori, S; Iannacone, C; Montemurro, F; Morandi, P; Stell, A; Zamagni, C; Zambetti, M, 2018)
"This phase I/II study was designed to determine the maximum tolerated dose of tivantinib in combination with standard dose FOLFOX for the treatment of patients with advanced solid tumors and to evaluate the safety and efficacy of this combination for patients with previously untreated metastatic adenocarcinoma of the distal esophagus, gastroesophageal (GE) junction, or stomach."2.84A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach. ( Bendell, J; Flores, M; Hemphill, B; Kurkjian, C; Pant, S; Patel, M; Thompson, D, 2017)
" Patients received once-daily vandetanib (planned dosing levels of 100, 200, and 300 mg) with concomitant daily radiotherapy (1."2.84Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection. ( Astsaturov, IA; Berger, AC; Boland, PM; Burtness, BA; Cheng, JD; Cohen, SJ; Cooper, HS; Davey, M; Lebenthal, A; Meyer, JE; Neuman, T; Olszanski, AJ; Scott, WJ, 2017)
"To compare acute adverse events (AE) and postoperative complication rates in a randomized trial of short-course (SC) versus long-course (LC) preoperative radiotherapy."2.84Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). ( Ackland, S; Ansari, N; Burmeister, B; Fisher, RJ; Heriot, A; Joseph, D; Mackay, J; McClure, B; McLachlan, SA; Ngan, SY; Solomon, MJ, 2017)
"KRAS mutations are common in pancreatic cancer, but directly targeting the KRAS protein has thus far been unsuccessful."2.84Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. ( Al Baghdadi, T; Blanke, CD; Cardin, D; Chung, V; Doyle, LA; Dy, IA; Guthrie, KA; Hendifar, AE; Hochster, HS; Hui, L; Lowy, AM; McDonough, S; Philip, PA; Seery, TE; Tejani, MA; Wang-Gillam, A, 2017)
"Patients with resected stage III colon cancers were randomized to adjuvant FOLFOX (folinic acid [leucovorin calcium], fluorouracil, and oxaliplatin) chemotherapy with or without cetuximab (North Central Cancer Treatment Group N0147 trial) or adjuvant FOLFOX chemotherapy with or without bevacizumab (National Surgical Adjuvant Breast and Bowel Project C-08 trial)."2.84Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. ( Alberts, SR; Allegra, CJ; Goldberg, RM; Meyers, JP; Pogue-Geile, KL; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Thibodeau, SN; Yothers, G, 2017)
"Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al."2.84Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care. ( Boller, E; Dingeldein, G; Ehscheidt, P; Flohr, T; Galle, PR; Geer, T; Göhler, T; Hebart, H; Heike, M; Indorf, M; Josten, KM; Karthaus, M; Lang, C; Moehler, M; Neise, M; Rudi, J; Schimanski, CC; Schmittel, A; Staib, F; Wierecky, J; Wörns, MA, 2017)
"In mouse models of pancreatic cancer, IPI-926, an oral Hedgehog inhibitor, increases chemotherapy delivery by depleting tumor-associated stroma."2.82A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma. ( Catenacci, DV; Chang, WC; Kantoff, E; Kate Kelley, R; Kindler, HL; Ko, AH; Lewis, S; LoConte, N; Tempero, MA; Vannier, MW; Venook, AP; Walker, EJ, 2016)
"Metastatic colorectal cancer (mCRC) frequently occurs in elderly patients."2.82Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02). ( Adhoute, X; Aparicio, T; Azzedine, A; Bedenne, L; Bouché, O; Breysacher, G; Charneau, J; Chone, L; Cretin, J; Gargot, D; Gasmi, M; Jouve, JL; Khemissa, F; Lavau-Denes, S; Lecomte, T; Legoux, JL; Lepère, C; Locher, C; Maillard, E; Michel, P; Mitry, E; Phelip, JM; Provençal, J; Sobhani, I, 2016)
"In the remaining seven (20%), the residual tumour clinically appeared benign."2.82Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign. ( Bujko, K; Malinowska, M; Mroz, A; Pietrzak, L; Rupinski, M; Rutkowski, A; Szczepkowski, M; Wyrwicz, L, 2016)
"With the changed dosing schedule, this regimen was very well tolerated."2.82Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. ( Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X, 2016)
"Patients with cT2-4 N0-2 M0 rectal cancer treated by standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy) or extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy) underwent sequential PET/CT imaging at baseline, 6 weeks and 12 weeks from radiation completion."2.82Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen. ( Buchpiguel, CA; Fernandez, LM; Figueiredo, MN; Gama-Rodrigues, J; Habr-Gama, A; Perez, RO; Proscurshim, I; São Julião, GP, 2016)
"Consecutive patients with distal rectal cancer undergoing neoadjuvant chemoradiation (50."2.82Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation. ( Fernandez, LM; Gama-Rodrigues, J; Habr-Gama, A; Jorge, JM; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2016)
"In advanced refractory esophagogastric cancer patients, monotherapy with SUN was associated with good tolerability but limited tumor response."2.82Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program. ( Al-Batran, SE; Galle, PR; Gepfner-Tuma, I; Hegewisch-Becker, S; Kanzler, S; Koenig, J; Kullmann, F; Maderer, A; Moehler, M; Otte, M; Rafiyan, MR; Ruessel, J; Schimanski, CC; Schmoll, HJ; Schollenberger, L; Siveke, JT; Thuss-Patience, PC; von Weikersthal, LF; Weißinger, F; Weusmann, J; Wilke, H, 2016)
"The rates of anastomotic leakage and stenosis were calculated for each treatment arm."2.82Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial. ( Deng, Y; Ma, T; Qin, Q; Wang, H; Wang, J; Wang, L; Zheng, J; Zhou, Z, 2016)
"Dutch Colorectal Cancer group, CKTO 2003-16, ISRCTN36266738."2.80Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. ( Berglund, Å; Breugom, AJ; Fokstuen, T; Gelderblom, H; Glimelius, B; Kapiteijn, E; Leer, JWH; Marijnen, CAM; Martijn, H; Meershoek-Klein Kranenbarg, E; Muller, EW; Nagtegaal, ID; Påhlman, L; Punt, CJA; Putter, H; Roodvoets, AGH; Rutten, HJT; Steup, WH; van de Velde, CJH; van den Broek, CBM; van Gijn, W, 2015)
"Thirty-four patients with unresectable esophageal cancer were enrolled and received DNF therapy."2.80Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer. ( Fukuchi, M; Ieta, K; Inose, T; Kato, H; Kuwano, H; Miyazaki, T; Nakajima, M; Ojima, H; Saito, K; Sakai, M; Sano, A; Sohda, M; Suzuki, S; Tanaka, N; Yokobori, T, 2015)
"Patients with locally advanced rectal cancer who achieve a pathological complete response to neoadjuvant chemoradiation have an improved prognosis."2.80Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. ( Avila, K; Cataldo, PA; Chow, OS; Coutsoftides, T; Dietz, DW; Fichera, A; Garcia-Aguilar, J; Herzig, DO; Hunt, SR; Kumar, AS; Marcet, JE; Oommen, S; Patil, S; Polite, BN; Smith, DD; Stamos, MJ; Ternent, CA; Varma, MG, 2015)
"1804 rectal cancer patients, staged cT3-4N0-2M0, participated in a multicenter study."2.80Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12. ( Baek, JY; Chie, EK; Cho, HM; Jang, HS; Jeong, BK; Jeong, JU; Kim, DY; Kim, JH; Kim, JS; Kim, K; Kim, SH; Kim, SY; Kim, TH; Lee, JH; Nam, TK; Oh, JH; Shim, BY; Yoon, MS, 2015)
"Stage II and III rectal cancer patients received, after total mesorectal excision, 2 cycles of XELOX regimen (oxaliplatin 130 mg/m(2) on day 1; capecitabine 1000 mg/m(2) bid on day 1 to 14, q21), followed by capecitabine (800 mg/m(2) bid daily; 20% dose at 12:00 AM and 80% dose at 12:00 PM) administered continuously during pelvic radiation (total 50."2.79Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study. ( Bajetta, E; Biondani, P; Buzzoni, R; Di Bartolomeo, M; Dotti, KF; Ferrario, E; Formisano, B; Gevorgyan, A; Grassi, P; Mariani, L; Pietrantonio, F; Valvo, F, 2014)
"Capecitabine dose was increased from 650 mg/m(2) to 825 mg/m(2) orally twice daily on the days of radiation therapy; erlotinib dose was increased from 50 mg orally daily in weeks 1 to 3, to 50 mg daily in weeks 1 to 6, to 100 mg daily in weeks 1 to 6."2.79Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. ( Chang, GJ; Clemons, MV; Crane, CH; Das, P; Delclos, ME; Eng, C; Garrett, CR; Kopetz, SE; Krishnan, S; Maru, DM; Munsell, MF; Rodriguez-Bigas, MA; Shureiqi, I; Skibber, JM; You, YN, 2014)
"For resectable gastric cancer, both postoperative chemoradiotherapy and perioperative chemotherapy demonstrate high-level evidence for improved survival in Western populations."2.79Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308. ( Aparicio, T; Breysacher, G; Chapet, S; Dousset, B; Faroux, R; Jouve, JL; Maillard, E; Martel-Lafay, I; Michel, P; Mornex, F; Nguyen, S; Pere-Verge, D; Pezet, D; Seitz, JF; Sobhani, I, 2014)
"Capecitabine was administered twice daily on every radiotherapy treatment day in a dose-escalation schedule (mg/m²) of 625 (level I, n = 6), 700 (level II, n = 6), 800 (level III, n = 6), 900 (level IV, n = 0) and 1000 (level V, n = 0)."2.79Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. ( Fang, H; Jin, J; Li, YX; Liu, XF; Liu, YP; Ren, H; Song, YW; Wang, SL; Wang, WH; Wang, X; Yu, ZH, 2014)
" After six chemotherapy cycles, the short-term efficacy was evaluated according to the Response Evaluation Criteria in Solid Tumors guidelines and adverse reactions were recorded according to National Cancer Institute Common Toxicity Criteria 2."2.79Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer. ( Chang, ZW; Dong, L; Han, ZF; Li, J; Lou, XP; Lu, P; Miao, JH, 2014)
"A database of esophageal cancer was queried for nonmetastatic patients with adenocarcinoma treated between 2000 and 2011 with CRT."2.79Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. ( Almhanna, K; Freilich, J; Fulp, WJ; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Yue, B, 2014)
"Pancreatic cancer is one of the leading causes of cancer-related deaths worldwide."2.79Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer. ( Belani, CP; Gusani, N; Jiang, Y; Kaifi, J; Kimchi, ET; Mackley, HB; Staveley-O'Carroll, KF; Zhu, J, 2014)
" Predicted Cp [median and 90% prediction interval] was simulated using the population pharmacokinetic model established for other cancers (PPK model) and compared to observed Cp."2.79Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial. ( Allison, DE; Han, K; Jin, J; Lowe, J; Maia, M; Sersch, MA, 2014)
"Gastric cancer is a heterogeneous disease, and the strategy of combining chemotherapy with HH inhibition may only be effective in tumors with high CD44 levels."2.79CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. ( Cohen, DJ; Janjigian, YY; Kim, TS; Lee, HJ; Park, DJ; Schmidt, B; Thomas, NJ; Yoon, C; Yoon, SS, 2014)
" We aimed to assess the safety, efficacy, biomarkers, and pharmacokinetics of rilotumumab combined with epirubicin, cisplatin, and capecitabine (ECX) in patients with advanced gastric or oesophagogastric junction cancer."2.79Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. ( Anderson, A; Davidenko, I; Deptala, A; Donehower, RC; Dubey, S; Harrison, M; Iveson, T; Jiang, Y; Lakshmaiah, K; Loh, E; Nirni, S; Oliner, KS; Tang, R; Thomas, A; Tjulandin, S; Zhu, M, 2014)
"Brunch Regimen for locally advanced rectal cancer consisting of neoadjuvant chronomodulated capecitabine and concurrent radiation therapy is effective and well tolerated with good safety profile, particularly with regard to the occurrence of hand and foot syndrome, in patients with locally advanced rectal cancer."2.79Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study. ( Akgun, Z; Balik, E; Cipe, G; Gural, Z; Kaytan-Saglam, E; Kilickap, S; Okyar, A; Saglam, S; Yildiz, S; Yucel, S, 2014)
"Capecitabine was administered on weekdays concurrently with pelvic radiotherapy at a daily dose of 1."2.79Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study. ( Hirakawa, K; Hosono, M; Maeda, K; Miki, Y; Nagahara, H; Shimatani, Y; Tsutsumi, S, 2014)
"Fluorouracil and cisplatin have been used most frequently as neoadjuvant therapy for esophageal cancer."2.79The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study. ( Ba-Ssalamah, A; Hejna, M; Kandioler, D; Kappel, S; Kührer, I; Mittlböck, M; Pluschnig, U; Schoppmann, SF; Wolf, B; Wrba, F; Zacherl, J; Zwrtek, R, 2014)
"Patients (pts) with metastatic rectal cancer and symptomatic primary, require local and systemic control."2.79Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer. ( Bressel, M; Chander, S; Cooray, P; Heriot, A; Hicks, R; Jefford, M; Leong, T; MacKay, JR; McClure, B; McKendrick, J; Michael, M; Ngan, SY; Steel, M; Zalcberg, J, 2014)
"We consider that our observations in gastric cancer patients in our clinic can be useful in the future randomised trials to point the way to improved outcomes."2.79Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. ( Coskun-Breuneval, M; Demirkasimoglu, T; Elgin, Y; Guney, Y; Kara, SP; Kucukpilakci, B; Misirlioglu, HC; Ozgen, A; Sanri, E; Ugur, VI, 2014)
"To explore the clinical effects of nimotuzumab combined with chemotherapy in the treatment of late gastric cancer."2.79Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer. ( Xu, CD, 2014)
"Patients with cT3 or cN1 and cM0 rectal cancer were eligible."2.79A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer. ( Cubillo, A; De Vicente, E; García-García, E; Hernando-Requejo, O; Hidalgo, M; López, U; López-Ríos, F; Morelli, P; Muro, A; Prados, S; Quijano, Y; Rodriguez-Pascual, J; Rubio, C, 2014)
" We evaluated the efficacy and safety of conatumumab (an agonistic monoclonal antibody against human death receptor 5) and ganitumab (a monoclonal antibody against the type 1 insulin-like growth factor receptor) combined with standard FOLFIRI chemotherapy as a second-line treatment in patients with mutant KRAS mCRC."2.78A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer. ( Choo, SP; Chuah, BYS; Cohn, AL; Cottrell, S; Dubey, S; Galimi, F; Hei, YJ; Kopp, MV; Loberg, R; Maurel, J; McCaffery, I; Mitchell, EP; Nowara, E; Pan, Y; Sakaeva, DD; Sastre, J; Suzuki, S; Tabernero, J, 2013)
"We compared the results of stage IV colorectal cancer patients treated within a large Dutch phase III trial (CAIRO), in which standard chemotherapy and standard safety eligibility criteria were used, to patients treated outside the trial during the trial accrual period in a representative selection of 29 Dutch hospitals."2.78Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands. ( Koopman, M; Mol, L; Ottevanger, PB; Punt, CJ; van Gils, CW, 2013)
"Adults with primary metastasized rectal cancer were enrolled."2.78Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. ( Beets, GL; Beukema, JC; de Jong, KP; Gelderblom, AJ; Havenga, K; Hospers, GA; Nagtegaal, ID; Rutten, HJ; Tamas, K; van de Velde, CJ; van Dijk, TH; Wiggers, T, 2013)
"Patients with advanced gastric cancer have a poor prognosis and few efficacious treatment options."2.78Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. ( Bodoky, G; Celik, I; Chung, HC; Gorbunova, V; Götte, H; Kang, YK; Kurteva, G; Lordick, F; Melezínková, H; Moehler, M; Moiseyenko, VM; Oh, SC; Park, JO; Salman, P; Sawaki, A; Volovat, C, 2013)
"An analysis of surgically resected esophageal cancer patients after nCRT was performed to determine an association between the number of LNs resected and survival."2.78Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. ( Almhanna, K; Chuong, MD; Hoffe, SE; Karl, RC; Meredith, K; Shridhar, R; Weber, JM, 2013)
"Metronidazole 10 g/m(2) was administered per rectum on days 8 and 15."2.78Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer. ( Barsukov, YA; Fedyanin, MY; Gordeyev, SS; Perevoshikov, AG; Tkachev, SI, 2013)
"4%) and renal adverse events (all grades: CS, 18."2.78Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study. ( Ajani, JA; Bodoky, G; Buyse, M; Carrato, A; Cascinu, S; Douillard, JY; Ferry, D; Gorbunova, V; Heinemann, V; Lichinitser, M; Moiseyenko, V; Zaucha, R, 2013)
"Squamous cell carcinoma is the most common malignant change."2.78Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution. ( Khemapech, N; Oranratanaphan, S, 2013)
"The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported."2.78HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab. ( Cervantes, A; Chau, I; Cunningham, D; Eltahir, Z; Glimelius, B; Gonzalez de Castro, D; Oates, J; Peckitt, C; Roy, A; Sclafani, F; Tabernero, J; Wotherspoon, A, 2013)
" There was no evidence of a pharmacokinetic drug-drug interaction between sunitinib and 5-FU."2.78A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer. ( Bellmunt, J; Gil-Martín, M; Gómez-Martín, C; Khosravan, R; Lechuga, MJ; Lin, X; Montagut, C; Núñez, JA; Puig, M; Salazar, R; Tursi, JM, 2013)
"Thirty-six metastatic colorectal cancer patients received every 2 weeks, as first- (17) or second-line (19) treatment a combined chronotherapy with CPT-11 (infused at day 1 from 2 to 8 a."2.78Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report ( Demolin, G; Focan, C; Focan-Henrard, D; Graas, MP; Kreutz, F; Longrée, L; Moeneclaey, N, 2013)
"The aims of this study were to establish the maximum tolerated dose (MTD) of oxaliplatin in combination with fixed doses of gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in solid tumors, including advanced pancreatic cancer, and to evaluate the toxicity of the regimen."2.78Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas. ( Chalasani, SB; Chung, MS; Grossbard, ML; Kozuch, PS; Malamud, S; Mirzoyev, T; Olszewski, AJ, 2013)
"Seventy-three patients with cT3-4 rectal cancer were enrolled."2.78Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01). ( Baek, JY; Chang, HJ; Jang, HS; Kim, DY; Kim, JG; Kim, MJ; Kim, SY; Kim, TH; Lee, JH; Lee, MA; Nam, TK; Oh, JH; Park, JW; Yeo, SG, 2013)
" Toxic effects were graded according to NCI-CTC version 3."2.78The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial. ( Abdel-Latif, RM; Anter, AH, 2013)
" However, because of decreased relative dose intensity during treatment, further study is warranted to determine optimal dosage and combination."2.77A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. ( Ahn, JY; Chung, HC; Hyung, WJ; Jeung, HC; Lee, SS; Noh, SH; Rha, SY, 2012)
"This study evaluated the maximum tolerated dose (MTD) of sunitinib, a multitargeted tyrosine kinase inhibitor, combined with FOLFIRI (irinotecan 180 mg/m2 given over 90 min i."2.77A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer. ( Aranda, E; Carrato, A; Chau, I; Countouriotis, AM; Cunningham, D; Guillen-Ponce, C; Iveson, TJ; Ramos, FJ; Ruiz-Garcia, A; Saunders, MP; Starling, N; Tabernero, J; Tursi, JM; Vázquez-Mazón, F; Wei, G, 2012)
"pCR was achieved in 67% of squamous cell carcinoma."2.77Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. ( Balagué, C; Bellmunt, J; Conill, C; Gallego, R; Iglesias, M; Martín-Richard, M; Maurel, J; Momblan, D; Montagut, C; Pera, M; Pétriz, L; Reig, A, 2012)
"Patients with locally advanced or low rectal cancer were treated with capecitabine 825 mg/m(2) twice daily on days 1-14 and 22-35, oxaliplatin 50mg/m(2) on days 1, 8, 22 and 29, bevacizumab 5mg/kg on days 14, 1, 15 and 29, and radiation 50."2.77Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. ( Berry, S; Easaw, J; Hay, J; Kennecke, H; Post, J; Rao, S; Tankel, K; Wong, R; Zhou, C, 2012)
"Clinically staged T2N0 rectal cancer patients were treated with capecitabine and oxaliplatin during radiation followed by LE."2.77A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial. ( Cataldo, P; Chan, E; Garcia-Aguilar, J; Marcet, J; Medich, D; Oommen, S; Pigazzi, A; Posner, MC; Shi, Q; Thomas, CR, 2012)
" The starting dosage of capecitabine was 2000 mg/m(2)/day (days 1-14, every 3 weeks)."2.77Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer. ( Bang, SM; Chang, HJ; Kang, SB; Kim, DW; Kim, JH; Kim, YJ; Lee, JS; Lee, KW, 2012)
"Oral capecitabine is an effective alternative to bolus 5-FU/FA as adjuvant treatment of patients with stage III colon cancer with efficacy benefits maintained at 5 years and in older patients."2.77Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. ( Cassidy, J; Díaz-Rubio, E; Gilberg, F; McKendrick, J; Scheithauer, W; Seitz, JF; Twelves, C; Van Hazel, G; Wong, A, 2012)
"Patients with T3 to T4 and/or N+ rectal cancer received preoperative IMRT (47."2.77Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial. ( Arbea, L; Aristu, J; Cambeiro, M; Chopitea, A; Díaz-González, JA; García-Foncillas, J; Gaztañaga, M; Hernández, JL; Martínez-Monge, R; Moreno, M; Nuñez, J; Ramos, LI; Rodríguez, J; Sola, JJ; Subtil, JC, 2012)
" The CCRT began 28 days after the first cycle of chemotherapy, and chemotherapy was given within the first four and last three days during the CCRT period, at a radiation dosage of 45 Gy/25 f, i."2.77Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery. ( Li, T; Song, Y; Yu, C; Yu, R; Zhu, W, 2012)
"Patients with stage II-IIIB gastric cancer who had had curative D2 gastrectomy were randomly assigned to receive adjuvant chemotherapy of eight 3-week cycles of oral capecitabine (1000 mg/m(2) twice daily on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m(2) on day 1 of each cycle) for 6 months or surgery only."2.77Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. ( Bang, YJ; Button, P; Cho, JY; Chung, HC; Ji, J; Kim, YH; Kim, YW; Lee, KH; Lee, KW; Mok, YJ; Noh, SH; Noh, SI; Park, YK; Sirzén, F; Yang, HK; Yeh, TS, 2012)
" The aim of the study was to compare efficacy and safety, including response rate (RR), progression-free survival (PFS), overall survival, and grade ≥3 adverse events, between patients aged ≥65 years and patients aged <65 years."2.77Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer. ( Bang, HY; Cho, YH; Hong Lee, M; Kim, SY; Lee, KY; Yoo, MW; Yoon, SY, 2012)
"Systemic chemotherapy for patients with gastric cancer has limited impact on overall survival."2.77Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. ( Inal, A; Isikdogan, A; Kaplan, MA; Kucukoner, M, 2012)
"Patients with MSI-H (n=34) colon cancer presented with a significantly lower risk of relapse after 12 months of follow-up compared with MSS (n=189) colon cancer patients (5 year time to relapse: MSI-H 0."2.77Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial. ( Benner, A; Dippold, W; Formentini, A; Kloor, M; Kornmann, M; Link, KH; Michel, S; Tikidzhieva, A; von Knebel Doeberitz, M, 2012)
"Capecitabine was administered at 825 t."2.77Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer. ( Alberola Candel, V; Alberola, A; Garde Noguera, J; Gasent Blesa, JM; Giner Bosch, V; Laforga Canales, JB; Peris Godoy, M; Provencio Pulla, M; Sanchez, JL; Soler Tortosa, M, 2012)
"New therapeutic options for metastatic pancreatic cancer are urgently needed."2.77Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. ( Bitzer, M; Boeck, S; Buechler, P; Endlicher, E; Geissler, M; Harder, J; Heinemann, V; Hofheinz, R; Ihorst, G; Kloeppel, G; Moehler, M; Reinacher-Schick, A; Röcken, C; Schmoor, C, 2012)
"Patients with stage II and III esophageal cancer were enrolled."2.77Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer. ( Chak, A; Chang, KJ; Hanna, N; Pinto, H; Reid, T; Senzer, N; Soetikno, R; Swisher, S, 2012)
"Leucovorin Sodium (LV/Na) has a high solubility, and is stable when given with continuous infusion of 5-FU."2.77A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer. ( Bleiberg, H; D'Haens, G; Deleu, I; Efira, A; Humblet, Y; Paesmans, M; Peeters, M; Rezaei Kalantari, H; Vandebroek, A; Vergauwe, P, 2012)
"Surgical resection of gastric cancer has produced suboptimal survival despite multiple randomized trials that used postoperative chemotherapy or more aggressive surgical procedures."2.77Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. ( Ajani, JA; Benedetti, JK; Blanke, CD; Estes, NC; Goldman, B; Gunderson, LL; Haller, DG; Hundahl, SA; Jessup, JM; Macdonald, JS; Martenson, JA; Smalley, SR; Stemmermann, GN, 2012)
" standard body-surface-area (BSA) dosing in a FOLFOX (folinic acid, fluorouracil, oxaliplatin) regimen in metastatic colorectal cancer (mCRC)."2.77Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study. ( Asevoaia, A; Boisdron-Celle, M; Capitain, O; Gamelin, E; Morel, A; Poirier, AL, 2012)
"Despite substantial developments in gastric cancer treatment, the majority of patients relapse after definitive surgery."2.77Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer. ( Hubert, A; Kadouri, L; Peretz, T; Rivkind, A; Rottenberg, Y; Sonnenblick, A; Vainer, GW; Wygoda, M, 2012)
"To evaluate the efficacy and safety of weekly paclitaxel combined with S-1 or fluorouracil in the first line treatment of advanced gastric carcinoma."2.77[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma]. ( Ba, Y; Deng, T; Guo, ZQ; Hu, CH; Huang, DZ; Meng, JC; Wan, HP; Wang, ML; Xiong, JP; Xu, N; Yan, Z; Yao, Y; Yu, Z; Yu, ZH; Zhang, Y; Zheng, RS; Zhuang, ZX, 2012)
"IGF-1 was associated with the number of metastases (p = 0."2.77Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy. ( Camphausen, K; Graves, CA; Kim, HJ; Kim, SH; Kwon, HC; Lee, JH; Lee, S; Oh, SY, 2012)
"Chemo-naïve patients with metastatic gastric cancer were enrolled to receive 4 cycles of TCF-dd (docetaxel initially 85 mg/m(2) and cisplatin initially 75 mg/m(2) on day 1 [later modified due to toxicity: 70 and 60 mg/m(2) respectively], l-folinic acid 100 mg/m(2) on days 1 and 2, 5-fluorouracil 400 mg/m(2) bolus and then 600 mg/m(2) as a 22 h continuous infusion on day 1 and 2, every 14 days)."2.76Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial. ( Brighenti, M; Buti, S; Dalla Chiesa, M; Donati, G; Lazzarelli, S; Passalacqua, R; Rovere, RK; Tomasello, G, 2011)
"Gemcitabine dose was fixed at 750 mg/m² over 75 min, capecitabine was given twice daily and escalated from 500 to 650 mg/m² at DL2 and docetaxel increased from 30 to 36 mg/m² at DL3."2.76A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Bloomston, M; Campbell, A; Culler, K; Hejna, G; Hill, ME; Kim, S; Li, X; Zalupski, M, 2011)
"Patients with clinical T3, T4, or N1-2 rectal cancer were subjected to a preoperative CCRT protocol with FOLFOX and bevacizumab (5 mg/kg) biweekly for 6 cycles followed by a standardized laparoscopic TME procedure, as detailed in the attached video."2.76Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX. ( Cheng, KW; Lai, HS; Liang, JT, 2011)
"A total of 268 patients with stage II gastric cancer underwent D2 resection in our Cancer Center between January 1990 and December 2006 were recruited."2.76No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. ( Chen, S; Chen, YB; Feng, XY; Guan, YX; Li, W; Li, YF; Sun, XW; Xu, DZ; Zhan, YQ; Zhou, ZW, 2011)
"Patients (N = 207) with nonresectable rectal cancer were randomized to preoperative CRT or RT (2 Gy × 25 ± 5-fluorouracil/leucovorin)."2.76Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study. ( Berglund, Å; Bruheim, K; Brændengen, M; Cvancarova, M; Glimelius, B; Tveit, KM, 2011)
"In patients with locally advanced rectal cancer (LARC), preoperative chemoradiation is known to improve local control, and down-staging of the tumor serves as a surrogate for survival."2.76Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study. ( Devries, AF; Eisterer, W; Fastner, G; Gnant, M; Greil, R; Jäger, R; Kapp, KS; Keil, F; Offner, F; Ofner, D; Rabl, H; Schaberl-Moser, R; Thaler, J; Tschmelitsch, J; Zitt, M, 2011)
"Patients with locally advanced rectal cancer (cT3, potentially resectable cT4 or N+) were randomly assigned to receive preoperative or postoperative CRT."2.76Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer. ( Kim, JC; Kim, JH; Kim, TW; Park, JH; Yoon, SM; Yu, CS, 2011)
"Grade 3-4 toxicity during neoadjuvant treatment was diarrhea (38."2.76Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study). ( Aprile, G; Aschele, C; Bardelli, A; Bochicchio, A; Di Fabio, F; Garufi, C; Giaquinta, S; Gion, M; Latiano, T; Maiello, E; Martoni, A; Pini, S; Pinto, C; Rosati, G; Torri, V, 2011)
"To observe and compare the response rate and toxicity of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer."2.76[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer]. ( Chen, DY; Qi, Q; Zhao, WY, 2011)
"This phase II study is performed to evaluate the efficacy and safety of capecitabine combined with preoperative radiotherapy (RT) in Chinese patients with locally advanced rectal cancer (LARC)."2.76Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer. ( Deng, J; Jin, J; Li, X; Lu, W; Meng, H; Wang, F; Xu, X; Xue, Z; Zhang, H; Zhou, G, 2011)
"To evaluate the safety and efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen (irinotecan plus 5-FU/LV) in the treatment of HER2-positive advanced gastric cancer."2.76[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer]. ( Chen, QQ; Gao, XP; Li, W; Pan, SY; Sun, J, 2011)
"The prognosis of patients with advanced gastric cancer (AGC) remains poor, and no single chemotherapy regimen is recognized as a global standard."2.76Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer. ( He, YJ; Li, YH; Luo, HY; Qiu, MZ; Ruan, DY; Teng, KY; Wang, FH; Wang, ZQ; Xu, RH, 2011)
"Patients with advanced pancreatic cancer who were refractory to prior gemcitabine- and 5-FU- based chemotherapy were enrolled in this study."2.75Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. ( Jeong, CY; Kang, JH; Kim, HG; Kim, HJ; Kim, TH; Kwon, HC; Lee, GW; Oh, SY, 2010)
"Patients with metastatic colorectal cancer received either FOLFOX-4 + bev or FOLFIRI + bev."2.75Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. ( Chin, K; Fujiwara, Y; Hatake, K; Ichimura, T; Kobayashi, K; Konishi, F; Kuboki, Y; Matsueda, K; Matsusaka, S; Mizunuma, N; Ogura, M; Ozaka, M; Shinozaki, E; Suenaga, M, 2010)
" After two cycles, a 4-week outpatient treatment of gemcitabine (1000 mg/m(2)) on days 1 and 15 combined with 5-FU (500 mg/m(2)) and CDDP (7 mg/m(2)) on days 1 and 15 was commenced."2.75Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers. ( Gion, T; Harimoto, N; Itoh, S; Maehara, Y; Sugimachi, K; Taketomi, A; Tsujita, E; Yamashita, Y, 2010)
"Celecoxib dosage was fixed."2.75A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer. ( Alqaisi, M; Bernal, P; Bush, D; Byrd, J; Garberoglio, C; Hussein, F; Malik, I, 2010)
"Preoperative treatment of rectal cancer with combined chemotherapy and radiation therapy has become a widely accepted strategy."2.75A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer. ( Chang, M; George, TJ; Grobmyer, S; Hochwald, S; King, J; Larson, B; Marsh, Rde W; Mendenhall, WM; Siddiqui, T; Zlotecki, RA, 2010)
"The presence of residual tumour by conventional imaging, dichotomised as positive or negative, and the level of FDG uptake (standardised uptake values, SUV) were compared with histopathology, which served as the reference standard."2.75Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer. ( Avril, N; Avril-Sassen, S; Dose-Schwarz, J; Jänicke, F; Lebeau, A; Mahner, S; Schwaiger, M; Tiling, R; Untch, M; Weber, C, 2010)
"Patients with previously treated solid tumors received axitinib (starting dose 5 mg twice daily) combined with FOLFOX plus bevacizumab (1, 2, or 5 mg/kg, cohorts 1-3, respectively), FOLFIRI (cohort 4), or FOLFOX (cohort 5)."2.75A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors. ( Abhyankar, V; Burgess, RE; Chen, Y; Infante, J; Kim, S; Robles, RL; Sharma, S; Tarazi, J; Tortorici, M; Trowbridge, RC, 2010)
"Patients with advanced gastric cancer (AGC), clinically unresectable because of local invasion or limited intra-abdominal metastasis in para-aortic lymph nodes and/or the peritoneum based on multidetector row computed tomography, were enrolled."2.75Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer. ( Chang, HM; Kang, YK; Kim, BS; Kim, TW; Lee, JL; Oh, ST; Ryu, MH; Sym, SJ; Yook, JH, 2010)
"Gemcitabine was given intravenously at a dose of 1000 mg/m(2) over 30 min on days 1, 8 and 15, repeated every 4 weeks."2.75Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. ( Boku, N; Fukuda, H; Fukutomi, A; Furuse, J; Hamamoto, Y; Ikeda, M; Ishii, H; Nakamura, K; Ohkawa, S; Okusaka, T, 2010)
"Bortezomib was administered on days 1, 4, 8, and 11 every 21 days for 2 cycles with 5-fluorouracil at 225 mg/m2/day continuously and 50."2.75A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. ( Bernard, SA; Calvo, BF; Caskey, LS; Chakravarthy, AB; Chan, E; Goldberg, RM; Ivanova, A; Kim, HJ; Myers, MO; O'Neil, BH; Raftery, L; Sanoff, HK; Tepper, JE; Wise, PE, 2010)
"Peritoneal carcinomatosis from colorectal cancer treated with chemotherapy alone results in median survival of 5 to 13 months, whereas CRS with HIPEC for early peritoneal carcinomatosis from colorectal cancer resulted in median survival of 48-63 months and 5 year survival of 51%."2.75Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases. ( Avital, I; Davis, JL; Kemp, CD; Ripley, RT; Steinberg, SM; Toomey, MA, 2010)
"Forty two patients with advanced gastric cancer received neoadjuvant chemotherapy and subsequently 40 patients underwent standardized gastrectomy (2 patients with tumor progression had therapy limited to palliative chemotherapy without surgery)."2.75[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. ( Alakus, H; Baldus, S; Bollschweiler, E; Brabender, J; Dietlein, M; Hölscher, AH; Metzger, R; Mönig, SP; Schmidt, M; Schneider, PM; Vallböhmer, D, 2010)
"Trastuzumab, a monoclonal antibody against human epidermal growth factor receptor 2 (HER2; also known as ERBB2), was investigated in combination with chemotherapy for first-line treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer."2.75Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. ( Aprile, G; Bang, YJ; Chung, HC; Feyereislova, A; Hill, J; Kang, YK; Kulikov, E; Lehle, M; Lordick, F; Ohtsu, A; Omuro, Y; Rüschoff, J; Satoh, T; Sawaki, A; Shen, L; Van Cutsem, E, 2010)
"The European Study Group for Pancreatic Cancer (ESPAC)-3 trial, an open-label, phase 3, randomized controlled trial conducted in 159 pancreatic cancer centers in Europe, Australasia, Japan, and Canada."2.75Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. ( Bassi, C; Büchler, MW; Buckels, JA; Butturini, G; Cunningham, D; Dervenis, C; Doi, R; Friess, H; Gallinger, S; Ghaneh, P; Goldstein, D; Izbicki, JR; Lerch, MM; Lind, PA; Mariette, C; McKay, CJ; Moore, MJ; Neoptolemos, JP; Oláh, A; Padbury, R; Palmer, DH; Rawcliffe, CL; Smith, D; Stocken, DD; Thompson, J; Valle, JW; Wente, MN, 2010)
"Standard adjuvant chemoradiotherapy of rectal cancer still consists of 5-fluorouracil (5-FU) only."2.75Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α. ( Baumann, W; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Staib, L; Wiegel, T, 2010)
"Twenty-one patients with advanced gastric cancer who had failed first-line therapy received irinotecan on days 1 and 8 plus capecitabine on days 1-14 for a 21-day cycle."2.75[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases]. ( Dong, CM; Kang, MF; Liu, Y; Luo, MQ, 2010)
"Tetrathiomolybdate (TM) is an oral copper chelator under development as an anti-angiogenic agent."2.74A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer. ( Brewer, GJ; Gartner, EM; Griffith, KA; Henja, GF; Merajver, SD; Pan, Q; Zalupski, MM, 2009)
"Patients with histologically proven gastric cancer and measurable metastatic disease received capecitabine 825 mg/m(2) twice daily (1,650 mg/m(2) per day) on days 1-14 and paclitaxel 175 mg/m(2) by intravenous infusion on day 1 every 3 weeks until disease progression or unacceptable toxicities."2.74Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens. ( Abakar-Mahamat, A; Baize, N; Berthier, F; Caroli-Bosc, FX; Mounier, N, 2009)
"Advanced or metastatic gastric cancer, which is one of the most common malignancies in Korea, is difficult to cure by surgery alone and generally requires combination chemotherapy."2.74Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer. ( Ahn, JS; Jung, JY; Kim, HJ; Kim, I; Kim, JH; Kwon, JH; Lee, JA; Lee, KS; Park, YI; Song, HH; Zang, DY, 2009)
" Because the replacement of 2-day-infusional 5-fluorouracil (5-FU) of FOLFIRI with oral tegafur-uracil/leucovorin (UFT/LV) would be highly beneficial for clinical management, we performed a phase I trial using oral UFT/LV and a pharmacokinetic evaluation."2.74Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer. ( Azuma, T; Chayahara, N; Hirai, M; Inoue, Y; Kadowaki, Y; Kasuga, M; Maeda, T; Miki, I; Nishisaki, H; Okumura, K; Okuno, T; Sakaeda, T; Tamura, T; Tsuda, M; Yamamori, M, 2009)
"The incidence of liver metastasis in group A was 34% which was lower than 50% in group B."2.74Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma. ( Fu, DL; Jin, C; Long, J; Ni, QX; Xu, J; Yang, F; Yao, L; Yu, XJ, 2009)
"However, the subgroup of colon cancer with stage III exhibited a statistically significant difference both for DFS, 58% vs."2.74Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. ( Bjerkeset, O; Carlsen, E; Dahl, O; Eide, TJ; Fluge, Ø; Halvorsen, TB; Myrvold, HE; Podhorny, N; Tveit, KM; Vonen, B; Wiig, JN, 2009)
"Capecitabine was administered at a dose of 1,000 mg/m(2) b."2.74Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. ( Bria, E; Carlini, P; Carpanese, L; Cognetti, F; De Marco, S; Gelibter, A; Milella, M; Nuzzo, C; Pino, MS; Ruggeri, EM; Sperduti, I, 2009)
"Vorinostat was given orally twice daily for 1 week every 2 weeks."2.74A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. ( Egorin, MJ; Espinoza-Delgado, I; Fakih, MG; Fetterly, G; Holleran, JL; Litwin, A; Pendyala, L; Ross, ME; Rustum, YM; Toth, K; Zwiebel, JA, 2009)
"Of these, 50 patients had untreated gastric cancer, and 14 had received previous therapy with nonplatinum-based therapy."2.74Phase II study of capecitabine plus cisplatin in patients with gastric cancer. ( AL-Ashry, MS; Ebrahim, MA; Salah-Eldin, MA, 2009)
"Between 1993 and 2003, 186 rectal cancer patients were enrolled."2.74Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection. ( Barbachano, Y; Chau, I; Chong, G; Cunningham, D; Watkins, D; Yau, T, 2009)
"Chinese drug ZW3 for the treatment of colonic cancer could improve the main clinical symptoms, improve the QOL, increase body weight and prolong the survival time of patients, showing a favorable integral effect."2.74Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. ( Shan, ZZ; You, JL; Zhou, LY, 2009)
"Patients with previously untreated gastric cancer with measurable disease received oxaliplatin (100 mg/m(2), day 1), followed by leucovorin (100 mg/m(2), day 1) and 5-FU (2,400 mg/m(2), days 1-2), which was repeated every 2 weeks."2.74Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma. ( Cho, JY; Choi, SH; Jeung, HC; Lee, SI; Lim, JY; Oh, KJ, 2009)
"This oxaliplatin combined with ELF regimen shows good efficacy and acceptable safety in advanced gastric cancer patients."2.74[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer]. ( Lou, F; Pan, HM; Zhu, YH, 2009)
"The quality of life (QL) of advanced gastric cancer patients receiving irinotecan, folinic acid and 5-fluorouracil (5-FU) (IF arm) or cisplatin with 5-FU (CF arm) is presented."2.74Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial. ( Barone, C; Bugat, R; Curran, D; Dank, M; Goker, E; Peschel, C; Pozzo, C; Valvere, V; Wenczl, M; Yalcin, S; Zaluski, J, 2009)
"Of the 96 patients with gastric cancers, 21 underwent R0 resection and afterward received adjuvant FOLFOX chemotherapy."2.74[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer]. ( Dai, H; Yan, D, 2009)
" This study was to investigate the efficacy and safety of oxaliplatin in combination with capecitabine as first-line chemotherapy for AGC patients."2.74[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. ( Dong, NN; Liu, ZF; Wang, MY; Zhang, Q, 2009)
"To investigate the efficiency, time to progression (TTP), overall survival (OS) and toxicity of epirubicin combined with DDP and 5-Fu (PELF regimen) for the treatment of advanced gastric cancer."2.74[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Zhang, XD, 2009)
"Pancreatic cancer is an extremely aggressive malignancy."2.74An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica ( Büchler, MW; Decker-Baumann, C; Harig, S; Jäger, D; Karapanagiotou-Schenkel, I; Märten, A; Ose, J; Rötzer, I; Schmidt, J; Wente, MN, 2009)
"This study was designed to determine the efficacy and safety of biweekly oxaliplatin in combination with infusional 5-fluouracil (5-FU) and leucovorin in patients with advanced gastric cancer (AGC)."2.73Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. ( Chang, YF; Chao, TY; Chen, PM; Chiou, TJ; Chiu, CF; Chung, CY; Hwang, WS; Lin, SF, 2008)
"The treatment of peritoneal carcinomatosis is based on cytoreduction followed by hyperthermic intraperitoneal chemotherapy and combined with adjuvant chemotherapy."2.738-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. ( Boot, H; Bruin, S; van Slooten, G; van Tinteren, H; Verwaal, VJ, 2008)
"Capecitabine was given at 725 mg/m(2) orally twice daily Monday through Friday concurrently with RT."2.73Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. ( Andrews, C; Bullarddunn, K; Fakih, MG; Levea, C; Park, YM; Pendyala, L; Puthillath, A; Rajput, A; Ross, ME; Rustum, YM; Toth, K; Yang, GY, 2008)
"Paclitaxel was administered as a 1-h intravenous (i."2.73A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer. ( Hamaguchi, T; Hirashima, Y; Kato, K; Matsubara, J; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2008)
" Incidence of grade 3/4 treatment-related adverse events during the first 12 weeks of treatment were 59%, 36%, and 67% for mFOLFOX6, bFOL, and CapeOx, respectively, (TREE-1) and 59%, 51%, and 56% for the corresponding treatments plus bevacizumab (TREE-2; primary end point)."2.73Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. ( Abubakr, Y; Childs, BH; Cohn, AL; Fehrenbacher, L; Hainsworth, JD; Hart, LL; Hedrick, E; Hochster, HS; Ramanathan, RK; Saif, MW; Schwartzberg, L; Wong, L, 2008)
"2004, 285 patients with stage IIB-IIIB cervical cancer treated in Maternal and Child Health Hospital of Jiangxi Province were randomly assigned to receive radiotherapy alone or concurrent chemoradiotherapy."2.73[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma]. ( Li, HP; Li, LY; Luo, B; Pan, M; Shu, KY; Zeng, SY, 2008)
"Capecitabine was given at an oral dosage of 825 mg/m(2)bid on each day of the radiotherapy period with the first daily dose applied 2 h before irradiation, followed by surgery 6 weeks later."2.73Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial. ( Budach, W; Debus, J; Dunst, J; Hinke, A; Hoelscher, T; Mose, S; Reese, T; Roedel, C; Rudat, V; Wulf, J; Zuehlke, H, 2008)
"In patients with pancreatic cancer, CAI/RT had no significant effect on local recurrence (log-rank P = 0."2.73Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. ( Hermans, JJ; Hop, WC; Incrocci, L; Jeekel, J; Kazemier, G; Morak, MJ; van Dekken, H; van der Gaast, A; van Eijck, CH, 2008)
"The objective of this study was to evaluate the efficacy and safety of the POF regimen (biweekly 5-fluorouracil/leucovorin combined with paclitaxel and oxaliplatin) as first-line treatment for advanced gastric cancer (AGC)."2.73A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer. ( Chen, L; Fan, NF; Guo, ZQ; Lin, RB; Liu, J; Wang, XJ, 2008)
"Celecoxib was given daily during CRT at one of five doses (200 mg bd to 600 mg bd)."2.73A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. ( Biagi, J; Dawson, SJ; Foo, KF; Hui, A; Jefford, M; Leong, T; Michael, M; Milner, AD; Ngan, SY; Thomas, RJ; Zalcberg, JR, 2007)
"The purpose of this phase II study was to evaluate the efficacy and safety of cetuximab combined with FOLFIRI as a first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma."2.73Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study). ( Berardi, R; Cascinu, S; Ceccarelli, C; Di Fabio, F; Funaioli, C; Giannetta, L; Giaquinta, S; Longobardi, C; Martoni, AA; Mutri, V; Piana, E; Pinto, C; Rojas Llimpe, FL; Siena, S, 2007)
"We sought to evaluate the efficacy and safety data of a combination regimen using weekly irinotecan in combination with capecitabine and concurrent radiotherapy (CapIri-RT) as neoadjuvant treatment in rectal cancer in a phase-II trial."2.73A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. ( Grobholz, R; Hochhaus, A; Hofheinz, RD; Horisberger, K; Kähler, G; Kraus-Tiefenbacher, U; Leitner, A; Post, S; Wenz, F; Willeke, F; Willer, A, 2007)
"Thirty-four patients with gastric cancer, 16 after failure of first-line chemotherapy and 18 after failure of at least two prior chemotherapies, were included."2.73Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study. ( Al-Batran, SE; Bokemeyer, C; Hartmann, JT; Horger, M; Jäger, E; Kanz, L; Königsrainer, A; Meisinger, I; Nehls, O; Pintoffl, JP; Quietzsch, D, 2007)
"Dipyridamole 75 mg was administered orally three times daily during the FU administration."2.73Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. ( Barstis, JJ; Bendetti, JK; Isacoff, WH; Jazieh, AR; Macdonald, JS; Philip, PA, 2007)
"Celecoxib was prescribed at a dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy."2.73Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. ( Avizonis, V; Dicker, AP; Eifel, PJ; Fromm, M; Gaffney, DK; Greven, K; Miller, B; Ryu, J; Small, W; Winter, K, 2007)
" In locally advanced rectal cancer, preoperative infusional chemotherapy combined with radiation was found to be less toxic than bolus chemotherapy and radiotherapy."2.73Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer. ( Elsaleh, H; Joseph, D; Kaminski, A, 2007)
"In radically resected gastric cancer patients, adjuvant chemotherapy with ELFE regimen does not improve OS over surgery alone."2.73Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). ( Cartenì, G; Catalano, G; Ciardiello, F; Colucci, G; De Vita, F; Di Martino, N; Galizia, G; Gebbia, V; Giuliani, F; Maiello, E; Manzione, L; Montemurro, F; Orditura, M; Romito, S, 2007)
"Patients with local/regional oesophageal cancer with adequate functional status should not be excluded from potentially curative treatment based on age alone."2.73Combined modality chemoradiation in elderly oesophageal cancer patients. ( Anderson, SE; Bains, M; Hummer, A; Ilson, DH; Kelsen, D; Minsky, BD, 2007)
" This approach to treatment of locally advanced pancreatic cancer is safe and promising, with good local control for a substantial proportion of patients, and merits testing in a randomised trial."2.73Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. ( Davies, T; Goldstein, D; Harvey, J; Kotasek, D; Michael, M; Reece, W; Shapiro, J; Spry, N; Underhill, C; Van Hazel, G; Walpole, E, 2007)
"T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabine of 1000 mg/m(2) twice daily (days 1-14, 25-38) added to RT with 50."2.73Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group. ( Cats, A; Havenga, K; Hospers, GA; Jansen, EP; Leer, JW; Marijnen, CA; Mulder, NH; Punt, CJ; Tesselaar, ME; Van de Velde, CJ; Van Krieken, HH; Wiggers, T, 2007)
"For patients with localized esophageal cancer, whether or not preoperative chemotherapy is administered, only an R0 resection results in substantial long-term survival."2.73Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. ( Ajani, JA; Estes, NC; Gunderson, LL; Haller, DG; Kelsen, DP; Kocha, W; Minsky, BD; Mortimer, J; Roth, JA; Willett, CG; Winter, KA, 2007)
"Eight patients had esophageal cancer and 9 had gastric cancer."2.73A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer. ( Akerman, P; Evans, D; Jean, M; Kennedy, T; Millis, R; Miner, T; Safran, H, 2007)
"We hypothesised that gastric cancer outcome could be improved with more effective and intensified postoperative chemoradiotherapy."2.73Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. ( Bartelink, H; Boot, H; Cats, A; Dubbelman, R; Jansen, EP; Verheij, M, 2007)
"Fifty-one patients with T3 or T4 gastric cancer received systemic 5-fluorouracil-based adjuvant chemotherapy, and intratumoral expression of TS and TP in 51 gastric cancer tissue samples was tested by real-time quantitative PCR."2.73Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer. ( Deng, JZ; Hua, D; Huang, ZH; Mao, Y, 2007)
"Patients with stage II colon cancer were randomised to either adjuvant chemotherapy with 5-FU/LV (100 mg m(-2) LV+450 mg m(-2) 5-FU weekly, weeks 1-6, in 8 weeks cycles x 7) or surveillance only."2.73A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer. ( Gnant, M; Greil, R; Herbst, F; Hofbauer, F; Jagoditsch, M; Jakesz, R; Rabl, H; Samonigg, H; Schaberl-Moser, R; Schippinger, W; Steger, GG; Thaler, J; Thödtmann, R; Tschmelitsch, J; Wohlmuth, P, 2007)
"Patients diagnosed with colorectal cancer (n=150) were randomly allocated to receive monthly 5-FU and leucovorin bolus injections (the Mayo regimen) or a bimonthly 5-FU bolus plus continuous infusion (the simplified de Gramont regimen) for 24 weeks as postoperative adjuvant therapy."2.73Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study. ( Elomaa, I; Joensuu, H; Korpela, R; Kouri, M; Ollus, A; Osterlund, P; Ruotsalainen, T; Saxelin, M; Valta, P, 2007)
"These specimens were evaluated for DNA aneuploidy (DI 2.73Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial. ( Crook, W; Eifel, PJ; Gaffney, DK; Grigsby, PW; Krishan, A; Lucci, JA; Markoe, AM; Morris, M; Winter, K; Wolfson, AH, 2008)
" Patients in the treatment group (34 patients) received chemotherapy of DCF (docetaxel/cisplatin/5-fluorouracil) regimen combined with Chinese herbal medicine, and patients in the control group (32 patients) were treated with chemotherapy of the same regimen alone."2.73[Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction]. ( Gao, H; Wang, HB; Wang, HZ, 2007)
"50 patients with squamous cell carcinoma (90%) or adenocarcinoma and mostly advanced tumor stage were treated (82% T3/T4 and 70% N1)."2.73Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost. ( Brunner, TB; Grabenbauer, GG; Melzner, W; Rupp, A; Sauer, R, 2008)
"Data of 211 patients with advanced pancreatic cancer who underwent FLEC regimen were analyzed."2.73Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy. ( Ballardini, M; Bassi, C; Cantore, M; Fiorentini, G; Guadagni, S; Iacono, C; Mambrini, A; Orlandi, M; Pacetti, P; Torri, T, 2008)
"To evaluate the therapeutic efficacy and adverse reaction of Aidi Injection (ADI) combined with FOLFOX4 regimen for treatment of patients with advanced colorectal cancer, and controlled with those of FOLFOX4 regimen alone."2.73[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone]. ( Dong, L; Fu, SY; Li, HJ, 2007)
"Patients (n = 567) with metastatic colorectal cancer were randomly assigned to receive FLIRI or Lv5FU2-IRI."2.73A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer. ( Albertsson, M; Balteskard, L; Berglund, A; Byström, P; Garmo, H; Glimelius, B; Heikkilä, R; Keldsen, N; Pfeiffer, P; Starkhammar, H; Sørbye, H; Tveit, K, 2008)
"Data sets of 855 colon cancer patients treated between 1992 and 1999 within a multicenter adjuvant trial comparing 5-FU modulation with folinic acid or interfereron-alpha were examined."2.73Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. ( Baumann, W; Ette, C; Formentini, A; Henne-Bruns, D; Kornmann, M; Kreuser, ED; Kron, M; Link, KH; Sander, S; Staib, L, 2008)
"PEFG regimen in gemcitabine refractory pancreatic cancer had an acceptable toxicity profile and interesting activity, and may constitute a treatment option in this setting."2.73PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy. ( Arcidiacono, PG; Balzano, G; Cereda, S; Di Carlo, V; Mazza, E; Nicoletti, R; Passoni, P; Reni, M; Staudacher, C; Zerbi, A, 2008)
"Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in PC patients."2.73Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. ( Boeck, S; Bruns, CJ; Golf, A; Haas, M; Heinemann, V; Issels, RD; Laessig, D; Moosmann, N; Schulz, C; Wilkowski, R, 2007)
"Individual FU dose adjustment based on pharmacokinetic monitoring resulted in significantly improved objective response rate, a trend to higher survival rate, and fewer grade 3/4 toxicities."2.73Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. ( Boisdron-Celle, M; Delva, R; Dorval, E; Gamelin, E; Jacob, J; Merrouche, Y; Morel, A; Pezet, D; Piot, G; Raoul, JL, 2008)
"Patients with clinically unresectable rectal cancer or for whom resection with histologically clear (R0) surgical margins was unlikely received continuous capecitabine (500-825 mg/m2 twice daily, 7 days/week), oxaliplatin 2-h intravenous infusion (130 mg/m2 days 1 and 29) and pelvic radiotherapy (Monday-Friday for 5 weeks, total dose 45 Gy in 25 daily 1."2.72A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer. ( Falk, SJ; Glynne-Jones, R; Maughan, TS; McDonald, AC; Sebag-Montefiore, D, 2006)
" Seventy-seven patients were randomly assigned to receive paclitaxel 175 mg/m2 or docetaxel 75 mg/m2 on day 1, in combination with 5-FU 500 mg/m2 continuous infusion on days 1-5."2.72Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil. ( Bang, SM; Cho, EK; Chung, M; Han, SH; Lee, JH; Lee, WK; Lee, Y; Park, SH; Shin, DB, 2006)
"Capecitabine and gefitinib were administered throughout the radiation course."2.72Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. ( Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D, 2006)
"Stage III colon cancer patients were enrolled and were divided into two groups: Group W, in which the histologic type of both primary tumors and metastatic lymph nodes was well-differentiated adenocarcinoma; and Group U, in which the primary tumors and the metastatic lymph nodes were of any type other than well-differentiated."2.72Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer. ( Hirota, T; Kodaira, S; Mori, T; Ohashi, Y, 2006)
"Pancreatic cancer is chemo-radiosensitive."2.72Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial. ( Bossard, N; Ducreux, M; Girard, N; Mornex, F; Partensky, C; Rouanet, P; Roy, P; Scoazec, JY; Seitz, JF; Smith, D; Valette, PJ; Ychou, M, 2006)
"Histologically diffuse-type gastric cancer is well known to have a poor prognosis and is often complicated with abdominal and pleural effusions."2.72A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501). ( Koizumi, W; Nakayama, N; Saigenji, K; Sasaki, T; Tanabe, S, 2006)
"In patients with rectal cancer who receive preoperative radiotherapy, adding fluorouracil-based chemotherapy preoperatively or postoperatively has no significant effect on survival."2.72Chemotherapy with preoperative radiotherapy in rectal cancer. ( Bardet, E; Beny, A; Bosset, JF; Calais, G; Collette, L; Daban, A; Maingon, P; Mineur, L; Ollier, JC; Radosevic-Jelic, L, 2006)
"The 5-year incidence of local recurrence was lower with chemoradiotherapy (8."2.72Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. ( Bedenne, L; Bonnetain, F; Bouché, O; Buecher, B; Chapet, O; Closon-Dejardin, MT; Conroy, T; Ducreux, M; Francois, E; Gérard, JP; Leduc, B; Mackiewicz, R; Maurel, J; Seitz, JF; Untereiner, M, 2006)
"Advanced gastric cancer patients were randomly assigned to docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (day 1) plus fluorouracil 750 mg/m2/d (days 1 to 5) every 3 weeks or cisplatin 100 mg/m2 (day 1) plus fluorouracil 1,000 mg/m2/d (days 1 to 5) every 4 weeks."2.72Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. ( Ajani, JA; Boni, C; Chao, Y; Constenla, M; Fodor, M; Majlis, A; Moiseyenko, VM; Risse, ML; Rodrigues, A; Tjulandin, S; Van Cutsem, E; Voznyi, E, 2006)
"169 patients with radically resected gastric cancer were randomized to receive CPT-11 (180 mg/m2 day 1), leucovorin (100 mg/m2 days 1-2), FU (400-600 mg/m2 days 1-2, q 14; for four cycles; FOLFIRI regimen), followed by docetaxel (85 mg/m2 day 1), cisplatin (75 mg/m2 day 1, q 21; for three cycles; arm A), or MMC (8 mg/m2 days 1-2 as 2-hour infusion, q 42; for four cycles; arm B)."2.72Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial. ( Agostana, B; Aitini, E; Ardizzoia, A; Ardizzoni, A; Bajetta, E; Bochicchio, AM; Bordonaro, R; Botta, M; Buzzoni, R; Cicero, G; Comella, G; Di Bartolomeo, M; Duro, M; Fagnani, D; Ferrario, E; Gevorgyan, A; Katia, D; Kildani, B; Mantovani, G; Mariani, L; Marini, G; Massidda, B; Mozzana, R; Oliani, C; Palazzo, S; Pinotti, G; Reguzzoni, G; Schieppati, G; Villa, E; Zilembo, N, 2006)
"Gemcitabine is an active antitumor agent in the treatment of advanced pancreatic cancer, and has shown potential synergistic activity with the oral fluoropyrimidine capecitabine in previous phase I/II trials."2.71Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. ( Depisch, D; Haider, K; Kornek, GV; Kwasny, W; Lang, F; Raderer, M; Scheithauer, W; Schmid, K; Schneeweiss, B; Schüll, B; Ulrich-Pur, H, 2003)
"Multimodal treatment of esophageal cancer showed promising results, although not significant, in terms of survival and disease progression for patients achieving a complete pathologic response."2.71Preoperative chemoradiotherapy in cancer of the thoracic esophagus. ( Baccarani, U; Bresadola, F; Bresadola, V; Buffoli, A; Cartei, G; Cedolini, C; Fongione, S; Iop, A; Sacco, C; Signor, M; Terrosu, G; Uzzau, A; Vigevani, E, 2003)
"After curative resection of a stage III colon cancer, adjuvant treatment with 5-FU plus leucovorin is generally well tolerated."2.715-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial. ( Arkenau, HT; Bermann, A; Porschen, R; Rettig, K; Strohmeyer, G, 2003)
"Metastatic gastric cancer is usually treated with cisplatin- and 5-FU-based chemotherapy regimens."2.71Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion. ( Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC, 2003)
"Ninety-two patients with esophageal cancer (65 with adenocarcinoma and 27 with squamous cell carcinoma) were treated in two sequential protocols of preoperative chemoradiotherapy."2.71Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. ( Burtness, B; Forastiere, AA; Heath, EI; Heitmiller, R; Kleinberg, L; Knisely, JP; Salem, R; Zahurak, M, 2003)
"Capecitabine was administered to single-patient cohorts at escalating doses of 1500, 2000, and 2500 mg/m2/day in two equally divided doses for 14 of 21 days, beginning on day 1."2.71A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma. ( Fehn, K; Landau, L; Makower, D; Mani, S; Sparano, JA; Versola, M; Wadler, S; Wissel, P, 2003)
" A Bayesian methodology was used to assess individual pharmacokinetic parameters using the NONMEM computer program."2.71Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. ( Bressolle, F; Debrigode, C; Duffour, J; Gourgou, S; Kramar, A; Pinguet, F; Ychou, M, 2003)
"Ten patients with advanced or recurrent cancer of the cervix with no prior chemotherapy were entered in a phase II trial from October 2000 to November 2001."2.71First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study. ( Behtash, N; Ghaemmaghami, F; Khanafshar, N; Modares, M; Moosavi, A; Toogeh, G; Yarandi, F, 2003)
"Patients with gastric cancer staged IB to IV(M0) were treated with chemoradiotherapy after curative resection with extensive (D2) lymph node dissection."2.71Postoperative chemoradiotherapy for gastric cancer. ( Choi, SH; Heo, JS; Im, YH; Jung, CW; Kang, WK; Kim, DY; Kim, K; Kim, S; Kim, WS; Kim, YI; Lee, KW; Lee, MH; Lim, DH; Noh, JH; Park, CH; Park, CK; Park, JO; Park, K; Park, SH; Sohn, TS, 2003)
"Attempted surgical salvage of rectal cancer recurrence is performed commonly in the United States."2.71Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114. ( Cooke, E; Hollis, D; Mayer, RJ; Niedzwiecki, D; O'Connell, M; Tepper, JE, 2003)
"Patients with locally advanced gastric cancer (cT3, cT4, N+, M0) have a dismal prognosis, despite complete resection."2.71Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. ( Becker, K; Busch, R; Dittler, HJ; Fink, U; Helmberger, H; Kollmannsberger, C; Ott, K; Sendler, A; Siewert, JR, 2003)
"The aim of this study was to define the maximum tolerated dose (MTD) of bolus mitomycin C (MMC) in combination with 24 h-continuous infusion of 5-flourouracil (FU) plus folinic acid, and to assess the toxicity and activity in patients with previously treated colorectal and gastric cancer."2.71Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study. ( Bokemeyer, C; Hartmann, JT; Hofheinz, RD; Honecker, F; Käfer, G; Kanz, L; Köhne, CH; Nehls, O; Oechsle, K; Quietzsch, D; Wein, A, 2003)
"In locally advanced pancreatic cancer, the utilization of chemotherapy and radiotherapy is increasing, although in view of the reported long-term results of several contemporary trials, further improvements are certainly needed."2.71Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. ( Adsay, V; Al-Sukhun, S; Ben-Josef, E; Forman, JD; Heilbrun, LK; Levin, K; Philip, PA; Shields, AF; Soulen, R; Vaitkevicius, VK; Weaver, D; Zalupski, MM, 2003)
"Treatment was given until disease progression or unacceptable toxicity."2.71A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer. ( Han, JY; Ju, SY; Kim, EA; Kim, HY; Lee, DH; Lee, JJ; Lee, JS; Shin, EH, 2003)
"5-FU/irinotecan is a valuable regimen for second-line treatment in 5-FU/platinum-resistant O-G carcinoma."2.71Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. ( Assersohn, L; Brown, G; Cunningham, D; Hill, ME; Norman, AR; Oates, J; Ward, C; Waters, JS, 2004)
"Weight gain was observed in 12 of 33 (36%) patients."2.71Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study. ( Androulakis, N; Aravantinos, G; Athanasiadis, A; Fountzilas, G; Georgoulias, V; Papakotoulas, P; Polyzos, A; Potamiannou, A; Rigatos, SK; Stathopoulos, GP; Syrigos, K; Tsiakopoulos, I; Ziras, N, 2004)
"Eniluracil and 5-FU were given with a 5-week course of preoperative radiotherapy of 4500 cGy, with a possible 540-cGy boost."2.71A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. ( Anscher, MS; Cohen, DP; Czito, BG; Ertel, PJ; Honeycutt, W; Hong, TJ; Hurwitz, HI; Lee, CG; Lockhart, AC; Ludwig, KA; Mangum, SG; Mantyh, C; Morse, MA; Petros, WP; Seigler, HF; Spector, NL; Tyler, DS, 2004)
"Four hundred three women with cervical cancer were randomly assigned to receive either EFRT or CTRT."2.71Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. ( Cooper, J; Eifel, PJ; Gershenson, D; Grigsby, PW; Levenback, C; Morris, M; Mutch, DG; Rotman, M; Winter, K, 2004)
"Mitomycin C (MMC) in combination with infusional 5-fluorouracil (FU) plus folinic acid (FA) is an effective treatment for metastatic gastrointestinal cancer."2.71Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer. ( Gnad, U; Hartmann, JT; Hehlmann, R; Hochhaus, A; Hofheinz, RD; Kreil, S; Saussele, S; Weisser, A; Willer, A, 2004)
"The median time to disease progression was 8 weeks, and the median overall survival was 15 weeks."2.71Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. ( Bria, E; Carlini, P; Cognetti, F; Di Cosimo, S; Gelibter, A; Malaguti, P; Milella, M; Pellicciotta, M; Ruggeri, EM; Terzoli, E, 2004)
"For patients with resectable rectal cancer receiving concurrent, full dose radiotherapy, the recommended dose of capecitabine for further study is 1800 mg m(-2) day(-1) when given in this schedule."2.71A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer. ( Leong, T; Lim Joon, D; Mackay, J; McKendrick, J; Michael, M; Ngan, SY; Zalcberg, JR, 2004)
"The paclitaxel dose was started at 75 mg/m(2) (n = 7) and escalated to 125 mg/m(2) (n = 5), at which point, dose-limiting toxicities occurred."2.71Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. ( Ancukiewicz, M; Choi, N; Donahue, D; Lynch, T; Mathisen, D; Park, SD; Wain, J; Wright, C, 2004)
"Gemcitabine was infused intravenously at a dose of 1000 mg once weekly for 3 consecutive weeks of every 4 weeks."2.715-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer. ( Chikamoto, A; Hiraoka, T; Ikeda, O; Imuta, M; Kanemitsu, K; Kudo, K; Nakahara, O; Takamori, H; Tanaka, H; Tsuji, T; Yamashita, Y, 2005)
" Patients in study arm A will be treated as outpatients with 5-Fluorouracil; Cisplatin and 3 million units Interferon alpha-2b for 5 1/2 weeks combined with external beam radiation."2.71Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759]. ( Büchler, MW; Debus, J; Diehl, V; Fritz, S; Goldschmidt, H; Herrmann, T; Hoffmann, K; Knaebel, HP; Krempien, R; Lindel, K; Mansmann, U; Märten, A; Schmidt, J; Schmitz-Winnenthal, H; Seiler, C, 2005)
"To define the maximum-tolerated dose of oxaliplatin given with cisplatin, protacted 96-h infusion of fluorouracil, and radiotherapy for patients with advanced esophageal cancer."2.71Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma. ( Cervantes, A; Chirivella, I; Conill, C; Gallego, R; Manzano, H; Marfa, X; Martin-Richard, M; Maurel, J; Pera, M; Salazar, R, 2005)
"Among 13 patients with advanced colorectal cancer, 10 required dose reductions of irinotecan and 5-FU because of dehydration, diarrhoea, and neutropenia, seven of whom required hospitalisation, three with neutropenic fever."2.71A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer. ( Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML, 2005)
"Patients (n=38) with colorectal cancer received IFN-alpha 5 MU/m(2) SC on days 1-6; on days 2-6, LV 200 mg/m(2) IV was given with 5-FU at initial doses of 370-425 mg/m(2)/h."2.71A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel. ( Ernst, A; Grem, JL; Grogan, L; Grollman, F; Ismail, AS; Kao, V; Kirsch, IR; Parr, A; Quinn, MG; Wright, MA, 2005)
"5-Fluorouracil (5-FU) has two major mechanisms by which it exerts its anticancer activity."2.71Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. ( Hoshino, S; Maekawa, T; Shirakusa, T; Yamashita, Y, 2005)
"In most cases, hyperbilirubinemia was associated with concomitant alterations in other hemolytic parameters."2.71Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis. ( Cassidy, J; Filipovic-Ljeskovic, I; Jelic, S; Nikolic-Tomasevic, Z; Tomasevic, Z, 2005)
"Patients with either adenocarcinoma or squamous cell carcinoma of the esophagus could enroll; however, patients could not have received prior chemotherapy for metastatic disease."2.71A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. ( Ahuja, H; Bailey, H; Berlin, JD; Hansen, R; Jumonville, A; Kim, K; McFarland, T; Morgan-Meadows, S; Mulkerin, D; Saphner, T; Thomas, JP, 2005)
"Forty patients with rectal cancer (T3-T4 and/or N+) received radiotherapy (1."2.71Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study. ( Aydin, S; Baurain, JF; Canon, JL; Coche, JC; Coster, B; Duck, L; Gilbeau, L; Honhon, B; Humblet, Y; Kartheuser, A; Kerger, J; Kirkove, C; Laurent, S; Machiels, JP; Octave-Prignot, M; Remouchamps, V; Scalliet, P; Sempoux, C; Van Maele, P, 2005)
"Fifteen patients with LA pancreatic cancer received three-dimensional conformal XRT to a dose of 50."2.71Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. ( Blanquicett, C; Carpenter, M; Diasio, RB; Eloubeidi, MA; Fiveash, J; Johnson, MR; Russo, S; Saif, MW; Steg, A; Thornton, J, 2005)
" Twenty four patients with advanced or metastatic biliary tumors were treated with epiadriamycin 50 mg/m2 and cisplatin 60 mg/m2 administered bolus in proper hepatic artery on day 1, combined with systemic continuous infusion of 5-fluorouracil 200 mg/m2/day, from day 1 to day 14, every 3 weeks."2.71Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study. ( Cantore, M; Carlone, N; Caudana, R; Fiorentini, G; Mambrini, A; Manni, A; Rabbi, C; Torri, T; Zamagni, D, 2003)
"Heptaplatin is a newly developed platinum derivative which has been reported to be less toxic than cisplatin."2.70Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer. ( Ahn, JH; Bahng, H; Chang, HM; Kang, WC; Kang, YK; Kim, TW; Kim, WK; Lee, JS; Park, JS, 2002)
"33 had squamous carcinoma and 7 adenocarcinoma; 15 were male; the locoregional metastatic ratio was 1:39; median ECOG performance status was 2 (range 1-3)."2.70A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. ( Ajarim, D; Al Fadda, M; Bazarbashi, S; El Weshi, A; Ezzat, A; Memon, M; Pai, C; Rahal, M; Raja, MA, 2002)
"Capecitabine was administered at escalating doses from 250 to 1,250 mg/m(2) bid (including weekends) for the duration of radiotherapy."2.70Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer. ( Dunst, J; Frings, S; Hinke, A; Kölling-Schlebusch, K; Reese, T; Sutter, T; Zühlke, H, 2002)
"Eniluracil is a potent, irreversible inactivator of dihydropyrimidine dehydrogenase, the major catabolic enzyme for 5-fluorouracil (5-FU)."2.70Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study. ( Abbruzzese, JL; Benedetti, JK; George, CS; Giguere, JK; Macdonald, JS; Neubauer, MA; Pruitt, BT; Rothenberg, ML; Seay, TE; Tanaka, MS, 2002)
" 5-FU dosage was fixed at 1,600 mg/m2 while docetaxel was evaluated at weekly 1-hour infusion dosages of 30, 40 and 50 mg/m2 to determine the MTD."2.70A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer. ( Chang, JY; Chen, LT; Chung, TR; Jan, CM; Liu, JM; Liu, TW; Shiah, HS; Whang-Peng, J; Wu, CW, 2002)
" This phase I study was designed to find the maximum tolerated dose (MTD) of weekly cisplatin in combination with standard doses of gemcitabine (1,000 mg/m(2), 30 min) and 5-FU (750 mg/m(2), 24 h)/folinic acid (200 mg/m(2), 30 min)."2.70Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer. ( Arnold, D; Hoepffner, N; Kern, M; Neuhaus, P; Oettle, H; Riess, H; Settmacher, U, 2002)
" We investigated the therapeutic and adverse drug reaction of intensive chemotherapy using cisplatin (CDDP), 5-FU and dl-leucovorin (LV) (PFL-therapy), which may be producing dual biochemical modulation effect of 5-FU for advanced colorectal carcinoma."2.70Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer. ( Arai, T; Fukahara, T; Ishikawa, T; Iwai, T; Kuwabara, H; Maruyama, S; Murase, N; Okabe, S; Ootsukasa, S; Tanami, H; Udagawa, M; Yamashita, H, 2002)
" The current study was conducted to evaluate the efficacy and toxicity of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma."2.70Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. ( Ishikawa, O; Matsuno, S; Okada, S; Okusaka, T; Saisho, H; Sato, K; Sato, T; Tokuuye, K; Wakasugi, H, 2001)
" Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma."2.70Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute. ( Chung, HC; Jeung, HC; Kim, BS; Min, JS; Noh, SH; Rha, SY, 2001)
"The purpose of this study was to analyze the tolerance and efficacy of full dose reirradiation combined with chemotherapy in patients with head and neck carcinoma (HNC) with a high risk of recurrence after salvage surgery."2.70Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. ( Bobin, S; Bourhis, J; De Crevoisier, R; Domenge, C; Eschwege, F; Janot, F; Koscielny, S; Luboinski, B; Lusinchi, A; Wibault, P, 2001)
"Patients with stage II and III rectal cancer received weekly 2-hour infusions of FA 500 mg/m2 followed by continuous 24-hour infusions of 5-FU 2,600 mg/m2 postoperatively via a Port-A-Cath system."2.70Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility. ( Bambach, M; Dencausse, Y; Dietzler, P; Edler, L; Hartung, G; Lindemann, H; Qeisser, W; Sturm, J; Wojatschek, C, 2001)
"The role of adjuvant treatment in pancreatic cancer remains uncertain."2.70Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. ( Almond, J; Bassi, C; Beger, H; Büchler, MW; Dervenis, C; Dunn, JA; Falconi, M; Fernandez-Cruz, L; Friess, H; Kerr, DJ; Lacaine, F; Link, K; Neoptolemos, JP; Pap, A; Pederzoli, P; Spooner, D; Stocken, DD, 2001)
"Inflammatory breast carcinoma (IBC) is a rare but aggressive form of breast carcinoma."2.70Paclitaxel in the multimodality treatment for inflammatory breast carcinoma. ( Booser, D; Buzdar, AU; Cristofanilli, M; Hortobagyi, GN; Hunt, K; Ibrahim, N; McNeese, M; Murray, JL; Rivera, E; Singletary, ES; Smith, T; Sneige, N; Stelling, C; Strom, E; Ueno, N; Valero, V; Wasaff, B, 2001)
"Weight gain was observed in 48% of patients, and dysphagia improved in 76%."2.70Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. ( Artru, P; Baujat, B; Carola, E; de Gramont, A; Krulik, M; Louvet, C; Mabro, M; Maindrault, F; Taïeb, J; Tournigand, C, 2002)
" Both before and after the addition of OXA, the 5-FU dose was individually adjusted according to the pharmacokinetic follow-up (target steady-state plasma concentrations 2."2.70Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. ( Boisdron-Celle, M; Brienza, S; Craipeau, C; Cvitkovic, E; Delva, R; Gamelin, E; Guérin-Meyer, V, 2002)
"To identify a dose and schedule of oxaliplatin (OXP) to be safely administered in combination with protracted-infusion (PI) fluorouracil (5-FU) and external-beam radiation therapy (XRT) for patients with primary esophageal carcinoma (EC)."2.70Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. ( Berdzik, J; Bodnar, L; Douglass, H; Greco, W; Khushalani, NI; Klippenstein, D; Leichman, CG; Leichman, L; Litwin, A; Nava, E; Nava, H; Pendyala, L; Proulx, G; Smith, J; Smith, P, 2002)
"Exclusive CRT approach is not safe to treat patients with low infiltrative rectal carcinoma."2.70Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe? ( David Filho, WJ; de O Ferreira, F; Ferrigno, R; Lopes, A; Nakagawa, WT; Nishimoto, IN; Rossi, BM; Vieira, RA, 2002)
"Diarrhea was experienced by six of 10 patients, and only three patients were able to receive six weekly chemotherapy treatments without dose reduction or delay."2.69Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin. ( Blumenson, LE; Creaven, PJ; Meropol, NJ, 1998)
" Toxicity was significant, with more than 50% of patients requiring treatment breaks and dosage reductions."2.69Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma. ( Flett, MQ; John, WJ, 1998)
" In a previous study with 5-FU stepwise dose escalation in a weekly regimen, and pharmacokinetic monitoring, we defined a therapeutic range for 5-FU plasma levels: 2,000 to 3,000 microg/L (area under the concentration-time curve at 0 to 8 hours [AUC0-8], 16 to 24 mg x h/L)."2.69Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. ( Alleaume, C; Boisdron-Celle, M; Burtin, P; Cailleux, PE; Danquechin-Dorval, E; Delva, R; Dumesnil, Y; Fety, R; Gamelin, E; Geslin, J; Gesta, P; Goudier, MJ; Larra, F; Lortholary, A; Maigre, M; Maillart, P; Maillet, ML; Person-Joly, MC; Picon, L; Regimbeau, C; Robert, J; Sire, M, 1998)
"Paclitaxel is an important new agent in the treatment of esophageal carcinoma, and further evaluation of this agent in combination chemotherapy is warranted."2.69Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. ( Ajani, J; Bhalla, K; Donegan, J; Forastiere, A; Huang, Y; Ilson, DH; Kelsen, DP; Martin, L; Patel, P; Pazdur, R; Reed, C, 1998)
"Because of the poor response of pancreatic cancer to conventional therapy, the authors performed a phase II pilot study to evaluate whether beta-interferon and retinoids, added to active chemotherapeutic agents, could increase response rate and survival in a group of patients who had metastatic disease."2.69Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids. ( Casucci, D; Frati, L; Gulino, A; Rea, S; Recchia, F; Sica, G, 1998)
"The cases with esophageal cancer, stomach cancer, pancreatic cancer, hepatocellular carcinoma or colonic cancer co-existing with their inoperable lesion(s) were considered in this chemotherapy."2.69[Biochemical modulation of 5-FU--effect of low dose CDDP]. ( Denno, R; Hirata, K; Kimura, H; Mukaiya, M; Oikawa, I; Sasaki, K; Shirasaka, T; Tsuji, A; Yamamitsu, S, 1999)
"Nonresectable colorectal cancer metastases in the liver respond to chemotherapy in 20-25% only."2.69Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer. ( Bangard, M; Bangard, N; Bender, H; Biersack, HJ; Metten, N; Mezger, J; Schomburg, A, 1999)
"Seventeen patients with stage II breast cancer were included."2.69The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy. ( Habbal, Z; Ibrahim, K; Kahwaji, S; Khalil, A; Medawar, W; Seoud, M; Shamseddine, A, 1998)
"Two of 13 patients with squamous cell carcinoma (SCC) had a complete response (CR), but one died of pneumonia after 9 months while still in CR, and the other still in CR after more than 5 years."2.69Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma. ( Bjarnason, GA; Cripps, C; Fields, AL; Goel, R; Hrincu, A; Jensen, JL; Kerr, IA; Khoo, KE; Warner, E, 1999)
"All patients had biopsy-proven invasive squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix."2.69Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. ( Bundy, BN; Clarke-Pearson, DL; Fowler, WC; Hannigan, EV; Liao, SY; Malfetano, JH; Sause, W; Whitney, CW, 1999)
"5-fluorouracil (5-FU) has been widely used for the treatment of gastrointestinal cancers."2.69[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers]. ( Horimi, T; Morita, S; Shirasaka, T; Takahashi, I; Takasaki, M; Tsuji, A, 1999)
"A total of 99 patients with advanced colorectal cancer were treated with carboplatin (80 mg/m2, day 1-7), 5-FU (750 mg/m2, day 1-5), leucovorin (100 mg/m2, day 1-5) every 4 weeks."2.69The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category? ( Jelić, S; Nikolić-Tomasević, Z; Popov, I; Radosavljević, D, 1999)
"We examined whether patients with colon cancer undergoing surgery with or without adjuvant chemotherapy change the internal standards on which they base their quality-of-life (QL) estimation, and, if they do so, whether this reframing alters interpretation of QL findings."2.69Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK) ( Bernhard, J; Herrmann, R; Hürny, C; Laffer, U; Maibach, R, 1999)
"Early gastric cancer or cardia carcinoma were excluded."2.69Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). ( de Vries, JE; Hermans, J; Keizer, HJ; Klementschitsch, P; Songun, I; van de Velde, CJ; van der Bijl, J; van Krieken, JH; Wils, JA, 1999)
" We then tested the effect of GM-CSF given with a more toxic regimen of 5-FU/LV/IFN-alpha (IFN alpha-2a)."2.69A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma. ( Allegra, C; Behan, K; Chen, A; Flemming, D; Grem, JL; Grollman, F; Haller, D; Hamilton, JM; Harold, N; Johnston, PG; Lash, A; Liewehr, D; Monahan, B; Morrison, G; Quinn, M; Shapiro, JD; Steinberg, SM; Takimoto, C; Vaughn, D, 1999)
"One hundred fourteen patients (55%) had pancreatic cancer (54 in the observation group and 60 in the treatment group)."2.69Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. ( Arnaud, JP; Couvreur, ML; de Wit, LT; Gonzalez, DG; Hennipman, A; Jeekel, J; Klinkenbijl, JH; Sahmoud, T; van Pel, R; Veenhof, CH; Wils, J, 1999)
"Median times to disease progression for the three treatment arms were as follows: 9."2.69Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore ( Lorenz, M; Müller, HH, 2000)
"Paclitaxel and cisplatin were administered as postoperative adjuvant therapy."2.69Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus. ( Burtness, BA; Canto, MI; Forastiere, AA; Heath, EI; Heitmiller, RF; Kaufman, HS; Kleinberg, L; Knisely, JP; Olukayode, K; Salem, R; Talamini, MA; Topazian, M; Wu, TT; Yang, SC, 2000)
"From 1992 to 1998, 34 of 131 total esophageal cancer patients were designated stage III (16 T3N1, 9 T4N0, 9 T4N1) and medically fit to enter a combined modality protocol with continuous infusion 5-fluorouracil (CIS-FU, 300 to 600 mg/m2/day), high-dose external beam irradiation (60 Gy), and interval esophagectomy."2.69Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study. ( Alexander, EP; Harmon, J; Lipman, T; Wadleigh, R, 2000)
"Acute disseminated intravascular coagulation (DIC) is a rare but severe complication of gastric adenocarcinoma."2.69Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation. ( Chang, FY; Chao, Y; Chi, KH; Hung, HC; King, KL; Li, CP; Teng, HC; Yen, SH, 2000)
"For advanced irresectible gastric cancer, sequential high-dose methotrexate and 5-fluorouracil (both on day 1) combined with adriamycin on day 15 (FAMTX regimen), cycled every 28 days, is a fairly effective but toxic treatment, with a high incidence of neutropenic fever, dose reductions and dose delays."2.69Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study. ( Boot, H; Craanen, M; Gerritsen, WR; Swart, M; Taal, BG; Westermann, AM, 2000)
"Five hundred patients with Dukes' C colon cancer were randomly assigned to adjuvant treatment for one year with 5-fluorouracil (450 mg/m2 i."2.69The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group. ( Bleeker, WA; Hermans, J; Mulder, NH; Otter, R; Plukker, JT, 2000)
"Of 28 enrolled patients with biliary tract cancer, complete responses were observed in 2 patients (7."2.69Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas. ( Choi, CW; Choi, IK; Kim, BS; Kim, CD; Kim, JS; Kim, YH; Seo, JH; Um, SH, 2000)
"To assess the effect and mechanism of composite Xiansu Capsule (CXSC) combined with chemotherapy in treating gastric carcinoma of mid-late stage."2.69[Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy]. ( Hua, B; Wang, A, 1999)
" However, in combination with radiation therapy, this regimen is tolerable when the primary goal is palliation of dysphagia near the end of life."2.68Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus. ( Turrisi, AT; Urba, SG, 1995)
"5-Fluorouracil has been reported to have modest antitumor activity in androgen independent prostate cancer."2.68The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer. ( Daliani, DD; Eisenberg, PD; Fueger, R; Logothetis, CJ; Lord, R; Weems, J, 1995)
"Out of 213 consecutive cases of colorectal cancer patients, 39 patients had liver metastasis (31 synchronous metastases and 8 metachronous metastases)."2.68[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer]. ( Ariga, T; Kinoshita, H; Maruyama, T; Ooshima, I; Ozaki, M; Shimada, H; Shouko, T; Takeda, A; Yoshimura, S, 1995)
"The histology was squamous cell carcinoma in 44 patients and adenocarcinoma in 3 patients with esophagus cancer."2.68Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update. ( Beattie, E; Malamud, S; Nussbaum, M; Vikram, B; Yu, L; Yudelman, I, 1995)
"40813) on adjuvant chemotherapy in gastric cancer, results obtained after administration of the FAM2 regimen (fluorouracil [5-FU], doxorubicin, and mitomycin) were compared with results obtained after surgery alone to assess the effect of this regimen on overall survival, time to progression, and disease-free interval."2.68Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer. ( Buyse, M; Dos Santos, JG; Duez, N; Fiorentino, M; Labianca, R; Lise, M; Marchet, A; Nitti, D; Rougier, P; Sahmoud, T, 1995)
"These findings suggest that colorectal cancer with aneuploidy and a DI above 1."2.68Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer. ( Hoshino, K; Kaibara, N; Kimura, O; Kurayoshi, K; Makino, M; Sugezawa, A, 1995)
" The Kaplan-Meier overall and cancer specific survival analysis estimates that the chronic administration of antimetabolites did not improve the cumulative 5-year survival in the SCC group."2.68[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer]. ( Hirota, Y; Hongo, J; Iijima, Y; Inagaki, M; Koyama, M; Ozaki, M; Wada, K, 1995)
"Six patients (21%) had residual cancer in the resected specimen, either at the primary site or--more often--in adjacent lymph nodes."2.68Treating esophageal cancer with a combination of chemotherapy, radiation, and excision. ( Bates, DM; Clyde, JC; Garcia, JM; Girvin, GW; Lin, PH; Matsumoto, GH, 1995)
"Lymphatic metastasis is one of the most important problems in the treatment of gynecologic malignancy."2.68[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report]. ( Cao, Z; You, Z; Zhou, S, 1995)
"There were 51 patients with colorectal cancer and 130 patients with appendiceal cancer."2.68Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. ( Jablonski, KA; Sugarbaker, PH, 1995)
"Twenty patients with non-resectable rectal cancer (Mason CS III-IV) have been irradiated from September 1989 through February 1994."2.68[Preoperative radiochemotherapy in primary non-resectable rectal cancer]. ( Dunst, J; Dworak, O; Keilholz, L; Köckerling, F; Sauer, R; Schwarz, B, 1995)
"Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period."2.68[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995)
"Stomatitis was seen more in arm B and C than in arm A."2.68[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group]. ( Akazawa, S; Konishi, T; Kumai, K; Kurihara, M; Ogawa, M; Ogawa, N; Ota, K; Sasaki, T; Taguchi, T; Tominaga, T, 1995)
"All patients had surgically documented minimal residual disease (1."2.68Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial. ( Averette, H; Berek, JS; Blessing, JA; Braly, PS; Homesley, HD, 1995)
" The dosage was as follows: group A received FA i."2.68Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial. ( Archimandritis, A; Bacoyiannis, C; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Kosmidis, P; Papachristodoulou, A; Papadimas, V; Polyzos, A; Sakelaropoulos, N; Tsavaris, N, 1996)
"We identified patients with gastric cancer at high risk for recurrence before therapy using endoscopic ultrasonography (EUS)."2.68Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil. ( Botet, J; Brennan, M; Gerdes, H; Huang, Y; Karpeh, M; Kelsen, D; Klimstra, D; Lauers, G; Lightdale, C; Quan, V; Saltz, L; Schwartz, G, 1996)
"Mitomycin C was infused over 25 minutes followed by 5-FU over 10 minutes."2.68Regional chemotherapy for inoperable pancreatic carcinoma. ( George, WJ; Muchmore, JH; Preslan, JE, 1996)
"One hundred and three cases of advanced gastric cancer were randomly allocated into Group A (Me-CCNU, 5-Fu and ADM) and Group B (ACNU, 5-Fu and ADM)."2.68[ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group]. ( Li, D; Xiao, S; Zhang, D, 1996)
"Sixty-eight patients with advanced colorectal cancer received every 2 weeks hydroxyurea per os 1."2.68Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer. ( Beerblock, K; Bennamoun, M; de Gramont, A; Demuynck, B; Grangé, JD; Krulik, M; Louvet, C; Mal, F; Moreau, S; Soubrane, D; Varette, C; Zylberait, D, 1996)
"Since 1984, 373 patients with oesophageal cancer have been treated on three prospective, but unrandomised, protocols involving radiation with concurrent cisplatin and infusional fluorouracil."2.68Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG) ( Burmeister, BH; Denham, JW; Hamilton, CS; Joseph, DJ; Lamb, DS; O'Brien, P; Spry, NA; Walker, QJ; Yeoh, E, 1996)
" The maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity."2.68A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas. ( Chang, J; Cunningham, D; Gore, M; Hill, A; Hill, M; Moore, H; Nicolson, M; Norman, A; O'Brien, M; Oates, J; Rigg, A; Ross, P; Watson, M, 1997)
"Twenty-five patients with esophageal cancer were treated in a phase I pilot protocol consisting of initial esophagectomy with gastroesophagostomy and subsequent combined chemotherapy and radiation."2.68Integration of surgery in multimodality therapy for esophageal cancer. ( Doolas, A; Ebie, N; Griem, K; Hartsell, W; Kang, HJ; Millikan, K; Murthy, AK; Recine, DC; Taylor, S, 1997)
" However, the toxicities observed with this dosage schedule were considerable and further studies are needed to develop a less toxic regimen."2.68Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin. ( Buzaid, AC; Cohen, N; Greenberg, BR; Slater, D; Sporn, JR, 1997)
"5-fluorouracil was given at a dose of 1000 mg/m2 for 5 consecutive days and cisplatin was given on day 2 at a dose of 100 mg/m2."2.68The French experience with infusional 5-FU in gastric and pancreatic cancer. ( Ducreux, M; Rougier, P, 1996)
"Patients with rectal cancer of stage dukes B and C were randomized into two groups."2.68[Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer]. ( Liu, L; Lu, J; Zhao, L, 1996)
"In patients of 70 years and under with prostate cancer resistant to androgen-deprivation therapy and who still have good performance status, ECF chemotherapy can achieve useful remissions."2.68A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen. ( Chao, D; Harland, SJ; von Schlippe, M, 1997)
"Forty patients with esophageal cancer were treated in a phase I and II trial of induction chemotherapy (cisplatin, 5-fluorouracil, and paclitaxel) at three dosage levels (75, 125, and 100 mg/m2) and concurrent hyperfractionated radiotherapy (45 Gy to the mediastinum, 58."2.68Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study. ( Carey, RW; Choi, NC; Grillo, HC; Grossbard, ML; Lynch, TJ; Mathisen, DJ; Moncure, AC; Wain, JC; Wright, CD, 1997)
"Two hundred patients with advanced colorectal cancer received PVI 5-FU 300 mg/m2/day for a maximum of 24 weeks and were randomised to PVI 5-FU alone or PVI 5-FU + MMC 10 mg/m2 (7 mg/m2 from June 1995) 6 weekly for 4 courses."2.68A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer. ( Cunningham, D; Iveson, T; Massey, A; Norman, A; Oates, J; Padhani, A; Popescu, R; Prendiville, J; Ross, P; Watson, M; Webb, A, 1997)
"The paclitaxel dose levels were 25 mg/m2 in four patients, 40 mg/m2 in five patients, 60 mg/m2 in nine patients, and paclitaxel 50 mg/m2 with 5-FU reduced to 200 mg/m2 in nine patients."2.68Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy. ( Coia, LR; Colarusso, P; Dresler, C; Goldberg, M; Weiner, LM, 1997)
"We studied how gastric cancer tissues and cells changed as a result of preoperative chemotherapy."2.68[Influence of preoperative on gastric cancer tissues and cells]. ( Chen, Z; Li, G; Liu, F, 1997)
"Eighteen patients with gastric cancer with peritoneal metastasis were treated with methotrexate/5-fluorouracil sequential therapy."2.67[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis]. ( Akiyama, T; Kiriyama, M; Kita, I; Kosaka, T; Nakano, Y; Saito, H; Sejima, T; Sugaya, J; Takano, Y; Tomita, F, 1994)
" We were not able to increase 5FU weekly dosage above 700 mg/m2 due to the occurrence of grade 3-4 gastrointestinal toxicity."2.67Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas. ( Buccellato, C; Cipolla, C; Comande, S; Curto, G; Gebbia, N; Gebbia, V; Latteri, M; Testa, A; Valenza, R, 1994)
" These results are consistent with either a dose-response effect or a threshold level of the dose or dose intensity."2.67Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. ( Budman, DR; Cooper, MR; Ellerton, JA; Ferree, CR; Hart, RD; Korzun, AH; Moore, A; Norton, L; Wood, WC; Younger, J, 1994)
"Chemoradiation for duodenal cancer has produced a complete pathologic response in all patients and survival has been excellent, suggesting efficacy of this regimen for duodenal cancer."2.67Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. ( Coia, L; Eisenberg, B; Hanks, G; Hoffman, J; Paul, A; Scher, R; Solin, L; Weese, J; Weiner, L, 1994)
" They were randomly assigned to receive one of the three drug combination regimens or to 5-FU alone administered by rapid injection in 5-day course."2.67Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group. ( Cullinan, SA; Krook, JE; Mailliard, JA; Moertel, CG; O'Connell, MJ; Poon, MA; Tschetter, LK; Wieand, HS, 1994)
"To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF)."2.67Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma. ( Arbuck, SG; Balis, F; Chen, A; Grem, JL; Hamilton, JM; Jordan, E; McAtee, N; Murphy, RF; Setser, A; Steinberg, S, 1994)
"A total of 23 advanced gastric cancer patients older than 65 years received 500 mg/m2 5-fluorouracil i."2.67Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study. ( Cascinu, S; Catalano, G; Fedeli, A, 1994)
"FLEP is an active combination for oesophageal cancer, especially when used preoperatively in LAD."2.675-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus. ( Achterrath, W; Berger, M; Berns, T; Fink, U; Harstrick, A; Knipp, H; Meyer, HJ; Preusser, P; Stahl, M; Wilke, H, 1994)
"Hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy."2.67Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer. ( Earle, JD; Foley, JF; Krook, JE; Kvols, LK; McKenna, PJ; Schutt, AJ; Tschetter, LK; Twito, DI; Wieand, HS, 1994)
"Grade 3 infections were seen in 9 cycles (5%)."2.67Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. ( Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H, 1993)
"Nine patients with advanced breast cancer received CAF (cyclophosphamide at 100 mg/m2/day p."2.67Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer. ( Dutcher, JP; Liebes, L; Robert, NJ; Schwartz, EL; Sparano, JA; Wadler, S, 1993)
"Combined modality treatment for cancer of the rectum has been shown to reduce recurrences and improve overall survival."2.67Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study. ( Ackland, SP; Bonaventura, A; Cooper, SG; Denham, JW; Hamilton, CS; Joseph, DJ; Stewart, JF, 1993)
" The recommended dosage schedule with this technique is cisplatin 25 mg/m2 and FU 750 mg total dose IP with FU 500 mg/m2 as a continuous 24-hour infusion daily for days 1 to 4."2.67Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer. ( Atiq, OT; Brennan, M; Kelsen, DP; Lin, S; Niedzwiecki, D; Saltz, L; Shiu, MH; Tong, W; Toomasi, F; Trochanowski, B, 1993)
"Thirteen patients had squamous cell carcinoma and 8 adenocarcinoma."2.67Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon. ( Fell, S; Haynes, H; Kaleya, R; Katz, HJ; Rozenblit, A; Wadler, S; Wiernik, PH, 1993)
"Mitomycin's role in anal cancer is being evaluated in a randomized clinical trial by the Radiation Therapy Oncology Group."2.67Mitomycin in anal canal carcinoma. ( Catton, CN; Cummings, BJ; Keane, TJ; O'Sullivan, B; Wong, CS, 1993)
"Hormone-refractory metastatic prostate cancer remains a therapeutic challenge."2.67Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study. ( Blumenstein, BA; Boileau, M; Crawford, ED; Fletcher, WS; Rivkin, SE; Wozniak, AJ, 1993)
"In patients with colorectal cancer, we have done a multicentre, randomised controlled trial comparing five-year survival after intraportal infusion of fluorouracil (1 g per day) plus heparin (10,000 U per day) (130 patients) or heparin alone (123) during curative resection and for 7 days thereafter, or after resection alone (145)."2.67Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma. ( Fielding, LP; Fry, JS; Grace, RH; Hittinger, R, 1992)
"A clinical trial for patients with gastric cancer amenable to curative resection was undertaken to determine feasibility and response to preoperative systemic chemotherapy followed by postoperative intraperitoneal (IP) chemotherapy."2.67Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program. ( Kiyabu, M; Laine, L; Leichman, CG; Leichman, L; Muggia, FM; Radin, R; Ray, M; Silberman, H; Spears, CP; Stain, S, 1992)
"Histology was squamous cell carcinoma in 6 patients and undifferentiated carcinoma in the remaining 33 patients."2.67Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases. ( Banis, K; Daniilidis, J; Dimitriadis, A; Fountzilas, G; Kalogera-Fountzila, A; Kosmidis, P; Makrantonakis, P; Nicolaou, A; Sombolos, K; Sridhar, KS, 1991)
" The present study compared the pharmacokinetic profiles of intravenous and intra-hepatic arterial infusions of folinic acid in patients with colorectal liver metastases (n = 6) who were being treated with weekly regional infusions of 5-FU."2.67A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid. ( Anderson, JH; Cooke, TG; Kerr, DJ; McArdle, CS; Setanoians, A, 1992)
" in 15' x 5 days) every 4 weeks (Arm A), or to 5-FU alone at the same dosage (Arm B)."2.67Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer). ( Aitini, E; Barni, S; Beretta, A; Beretta, GD; Cesana, B; Comella, G; Cozzaglio, L; Cristoni, M; Labianca, R; Pancera, G, 1991)
" Patients were treated with 5-fluorouracil given at a dosage of 4 gm/m2 over a 24-hour period every 2 weeks."2.67High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. ( Anthony, S; Atkins, JN; Brockschmidt, J; Case, D; Grote, TH; Muss, HB; O'Rourke, M; Schnell, FM; Stanley, V; West, JH, 1991)
"BACKGROUND Gastric cancer metastasis to the appendix is a rare condition that might present with symptoms of acute appendicitis or remain asymptomatic and be diagnosed incidentally."2.66Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review. ( Aburahmah, M; Alhadid, D; Almana, H; AlShammari, A, 2020)
"Choriocarcinoma is an aggressive malignancy of trophoblastic tissue, typically of gestational etiology."2.66Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature. ( Boyce, J; Cole, JT; Tawagi, K, 2020)
"Thirty-two patients with untreated advanced colorectal carcinoma received high-dose methotrexate pretreatment followed sequentially by 5-fluorouracil (5-FU)."2.66High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals. ( Ajani, JA; Bedikian, AY; Kanojia, MD, 1989)
" The LT 5-FU was given at a dosage of 750 mg/m2 every 2 weeks for 18 months or until progression."2.66Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. ( Bleiberg, H; Buyse, M; Dalesio, O; Gerard, A; Gignoux, M; Goffin, JC; Michel, J; Pector, JC; Roussel, A; Samana, G, 1989)
"Eighty-two patients with colo-rectal cancers (29 colon and 53 rectum) were admitted and underwent radical resection from January 1982 to June 1984."2.66[Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial]. ( Wan, DS, 1988)
"Doxifluridine is an active agent in colorectal cancer."2.66A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma. ( Alberto, P; Cavalli, F; Germano, G; Joss, R; Kaplan, S; Martz, G; Mermillod, B; Spati, B; Weber, W, 1988)
" During the past eleven years, we have used postoperative chemotherapy in three ways over three different periods: in the earliest period, short-term combined chemotherapy (STCC) was used, in the middle period, intermittent long-term combined chemotherapy (ILTCC) was used in combination with immunotherapy for a randomized group, and in the latest period, when continuous long-term combined chemotherapy (CLTCC) with immunotherapy was employed."2.66[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy]. ( Hashizume, Y; Ichihashi, T; Iida, S; Kimoto, H; Kobayashi, H; Sato, H; Shimizu, J; Tsunamura, Y; Watanabe, Y; Yamada, T, 1985)
"Ten of the gastric cancer patients (29%) had partial responses."2.66Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach. ( Ahmed, S; Alvarez, CA; Cazap, EL; Estevez, RA; Gisselbrecht, C; Hannois, A; Lagarde, C; Schein, PS; Smith, FP; Woolley, PV, 1986)
" Alpha-2 interferon, alone or in combination with 5-FU, is ineffective in advanced colorectal cancer."2.66Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer. ( Blomgren, H; Cedermark, B; Clark, PI; Fallenius, A; Kurschel, E; Lundell, G; Niederle, N; Ohman, U; Reznek, RH; Slevin, ML, 1987)
" day 1, 2, 23 and 24) was applied with the same schedule and dosage of radiation."2.65The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer. ( Dujmović, I; Kolarić, K; Roth, A, 1984)
"Patients with advanced colorectal cancer and no prior chemotherapy were randomized to six treatment regimens: A) fluorouracil (FU) alone; B) FU + hydroxyurea (HU); C) semustine (SE) + dacarbazine (DA); D) FU + HU alternating with SE + DA; E) SE + razoxane (RA); F) mitomycin (MI) + DA."2.65Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278). ( Engstrom, PF; Klaassen, DJ; MacIntyre, JM; Mittelman, A, 1984)
"In well differentiated squamous cell carcinoma, a marked positive effect was obtained in 48."2.65[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer]. ( Bidiak, IP; Kiseleva, ES; Pitskhelauri, VG; Trakhtenberg, AKh; Zholkiver, KI, 1984)
"Three hundred and eleven cases of rectal cancer received treatment according to the protocol of a cooperative randomized study."2.65[Effectiveness of combined and complex treatment of patients with operable cancer of the rectum]. ( Aliev, BM; Barsukov, IuA; Bondar', GV; Dvoĭrin, VV; Knysh, VI, 1984)
"Although chemotherapy of pancreatic cancer is a developing field, clinically meaningful responses correlated with improved patient survival can be obtained with existing regimens."2.65Chemotherapy of pancreatic carcinoma. ( Schein, PS; Smith, FP; Zimmerman, SE, 1981)
"The Southeastern Cancer Study Group has evaluated 5-fluorouracil administered intravenously weekly at a dosage of 600 mg."2.65A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma. ( Bartolucci, AA; Hemstreet, G; Hester, M; Smalley, RV, 1981)
" The polychemotherapy was given as a high dosage intermittent stosstherapy with 3 infusions at intervals of a week for 3 years."2.64[The combined treatment of bronchial carcinoma (author's transl)]. ( Karrer, K; Pridun, N, 1975)
"Ninety-two women with advanced breast cancer were allocated at random to receive either cytotoxic or endocrine treatment."2.64Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer. ( Baum, M; Forbes, J; Jones, V; Priestman, T, 1977)
"originates in the stomach."2.64Gastric cancer: current status of treatment. ( Carter, SK; Comis, RL, 1977)
"route."2.64A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma. ( Bruckner, HW; Hahn, RG; Moertel, CG; Schutt, AJ, 1975)
" A total dosage of 17-23 g."2.64[Use of ftorafur for the treatment of 3d-4th stage]. ( Gutman, EKh; Osman, VI; Plaude, RK; Purinia, IZh; Tabachnik, BI, 1975)
"Among 2636 patients with stage III colon cancer treated with FOLFOX, MMR status was available for 2501."2.58Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. ( Alberts, SR; Folprecht, G; Goldberg, RM; Julie, C; Laurent-Puig, P; Le Malicot, K; Meyers, JP; Mini, E; Sargent, DJ; Shi, Q; Sinicrope, FA; Smyrk, TC; Tabernero, J; Taieb, J; Van Laethem, JL; Zaanan, A; Zawadi, A, 2018)
"Locally advanced pancreatic cancer (LAPC) is an emerging entity lacking in level III evidence-based recommendations for its treatment."2.58Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment? ( de Liguori Carino, N; McNamara, MG; O'Reilly, DA; Pihlak, R; Radhakrishna, G; Siriwardena, AK; Valle, JW, 2018)
"Gastric cancer has a fatality-to-case ratio of 0."2.55The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction. ( Amlashi, FG; Blum Murphy, M; Bozkurt, M, 2017)
"The objective of the treatment of colorectal cancer patients with unresectable liver metastases should be clearly defined at the outset."2.53Unresectable liver metastases in colorectal cancer: review of current strategies. ( Pellerin, O; Pernot, S; Pointet, AL; Sueur, B; Taieb, J; Voron, T, 2016)
"Pancreatic cancer is one of the deadliest cancers, ranking fourth among cancer-related deaths."2.53Dilemma of first line regimens in metastatic pancreatic adenocarcinoma. ( Assi, T; El Rassy, E; Ghosn, M; Ibrahim, T; Kattan, J; Kourie, HR, 2016)
"When paclitaxel plus platinum was compared with platinum plus 5-fluorouracil, the hazard ratios (95% CrI) in the entire, squamous cell carcinoma, and adenocarcinoma population were 0."2.52Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer. ( Hsu, CH; Huang, TC; Lin, CC; Tu, YK, 2015)
"One of them was well differentiated tubular adenocarcinoma which occupied in mucosal layer."2.52Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature. ( Chino, O; Kazuno, A; Kumaki, N; Makuuchi, H; Ozawa, S; Sakai, I; Shimada, H; Tamayama, T; Yamamoto, S; Yasuda, S, 2015)
"Solitary adrenal metastasis of rectal cancer is comparatively rare condition and it is difficult to be diagnosed because it doesn't have any characteristic symptoms."2.52[A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER]. ( Fukuda, H; Iida, S; Iizuka, J; Ikeda, T; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Toda, N, 2015)
"Sigmoid colon cancer was found on a pre-operative CT scan."2.52[A Case of Sigmoid Colon Cancer with Metastasis to the Uterus]. ( Arimitsu, H; Chibana, T; Chou, A; Ikeda, A; Kainuma, O; Kobayashi, R; Nabeya, N; Nagata, M; Souda, H; Takiguchi, N; Tokoro, Y; Tonooka, T; Yamamoto, H; Yanagibashi, H, 2015)
"Despite advances in the treatment of gastric cancer, it remains the world's second highest cause of cancer death."2.50Treatment options in patients with metastatic gastric cancer: current status and future perspectives. ( Bilici, A, 2014)
"A 48-year-old man with colorectal cancer and right inguinal lymph node metastasis had previously undergone radiotherapy and chemotherapy (uracil/tegafur/leucovorin) after a colostomy in another hospital before being referred to us."2.50[Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review]. ( Aihara, T; Fukuda, S; Iino, C; Mikami, T; Sakamoto, J; Sawaya, M; Tanaka, M; Tono, H; Yamagata, R; Yoshida, K, 2014)
"Treatment of locally advanced pancreatic cancer is palliative, based on chemotherapy and according to response, chemoradiotherapy can be applied."2.49Locally advanced pancreatic cancer. ( Huber, KE; Oikonomopoulos, GM; Saif, MW; Syrigos, KN, 2013)
"Metastatic pancreatic cancer is a rapidly fatal disease with few therapeutic options."2.49First-line treatment for advanced pancreatic cancer. ( Kim, R; Kothari, N; Saif, MW, 2013)
"Capecitabine is an orally administered prodrug that converts preferentially to 5-FU within tumors, resulting in enhanced concentrations of 5-FU in tumor tissue."2.49Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy. ( Endo, A; Nakashima, R; Takahashi, N; Tanabe, K; Yoshida, Y, 2013)
"What are the colorectal cancer prognostic factors which would guide the chemotherapy? TNM classification, number of examined lymph nodes, MSI status, and presence or not of a perforation or a perinervous, lymphatic or venous invasion is recognized prognostic factors."2.48[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?]. ( Brezault, C; Chaussade, S; Coriat, R; Esch, A; Perkins, G, 2012)
"For cT2 N0 esophageal cancer patients, the benefit of neoadjuvant therapy is still unclear."2.48Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging. ( Brock, MV; Franco, N; Hooker, CM; How, R; Hulbert, A; Lee, S; Prevas, H; Shin, J; Yang, SC; Zhang, JQ, 2012)
"Capecitabine is a prodrug of 5-fluorouracil, more easily administered by mouth; its transformation in 5-fluorouracil is performed in the liver."2.47Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report. ( Bagli, L; Drudi, F; Fantini, M; Gianni, L; Nicoletti, S; Possenti, C; Ravaioli, A; Sintini, M; Tamburini, E; Tassinari, D, 2011)
"Subacute cutaneous lupus erythematosus is an uncommon dermatosis characterised by a non-scarring, annular photo-distributed dermatosis associated with anti-Ro/SSA antibodies."2.47[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review]. ( Bagot, M; Cosnes, A; Duong, TA; Gantzer, A; Ortonne, N; Regnier, S; Wolkenstein, P, 2011)
"Gastric cancer is the fourth most common malignancy worldwide with Japan, Korea, Taiwan, China, Mongolia and many countries in South America and eastern Europe, as well as parts of the Middle East, contributing to the majority of cases."2.47A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. ( Ajani, JA; Blum, M; Suzuki, A, 2011)
"Keywords for the search were: "rectal cancer", "preoperative radiotherapy", "phase II-III", "preoperative chemotherapy", "adjuvant chemotherapy" and "surgery"."2.47[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies]. ( Bosset, JF; Créhange, G; Maingon, P, 2011)
"A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen."2.46Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. ( Bozkurt, MT; Cirak, Y; Degirmenci, M; Demir Piskin, G; Durusoy, R; Gorumlu, G; Karabulut, B; Karaca, B; Sanli, UA; Tunali, D; Uslu, R, 2010)
"In colorectal cancer, increased response rates are achieved by cetuximab and panitumumab within standard chemotherapy schedules, but not in chemoradiation regimens."2.46Cetuximab and chemoradiation for rectal cancer--is the water getting muddy? ( Glynne-Jones, R; Harrison, M; Mawdsley, S, 2010)
"We report a case of renal tubular acidosis (RTA) secondary to capecitabine, oxaliplatin, and cetuximab administration in a 63-year-old woman with liver metastasis from colon carcinoma who had partial treatment response."2.46Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. ( Meirovitz, A; Sonnenblick, A, 2010)
"Metastatic pancreatic cancer is often one of the most challenging malignancies a medical oncologist faces."2.46Palliative chemotherapy for pancreatic malignancies. ( Mehta, SP, 2010)
"A 47-year-old man who was diagnosed as Crohn's disease at the age of 27 became aware of a mass on the forehead."2.45[Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease]. ( Hayashi, N; Hayashi, Y; Hiramatsu, N; Iijima, H; Ito, H; Kondo, J; Nishida, T; Takehara, T; Tsuji, S; Tsujii, M; Tsutsui, S; Yamamoto, K, 2009)
"The median age at diagnosis of colorectal cancer is during the seventh decade, and the incidence of the disease increases continuously with age."2.45Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use. ( Belda, C; Casado, E; Castro, JD; Feliu, J; González-Barón, M; Sereno, M, 2009)
"Pancreatic cancer is the fourth leading cause of cancer death in the United States."2.45Medical management of pancreatic adenocarcinoma. ( Cunha, JE; Fernandes, Gdos S; Freitas, D; Hoff, PM, 2009)
"Data on colorectal cancer in HIV-positive patients are limited."2.44FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature. ( Bearz, A; Berretta, M; Berretta, S; Del Ben, C; Di Benedetto, F; Martellotta, F; Simonelli, C; Spina, M; Tirelli, U, 2008)
"Treatment with capecitabine lead to clinical amelioration."2.44Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature. ( Bergonzi, P; Fasola, G; Minisini, AM; Pauletto, G, 2007)
"Pancreatic cancer is a devastating disease with a poor prognosis for most patients."2.44The case for routine use of adjuvant therapy in pancreatic cancer. ( Kennedy, EP; Yeo, CJ, 2007)
"Approximately 84% of patients with gastric cancer will have advanced disease and median survival of these patients without chemotherapy is only 3-4 months."2.44Chemotherapy of advanced gastric cancer. ( López-Brea, MF; Rivera, F; Vega-Villegas, ME, 2007)
"A new era in the treatment of advanced pancreatic cancer commenced a decade ago with the advent of gemcitabine as a standard of care."2.44Cytotoxic therapy for advanced pancreatic adenocarcinoma. ( Abou-Alfa, GK; O'Reilly, EM, 2007)
" Dosing of S-1 is different between Western and Asian populations due to differences in metabolism by CYP2A6."2.44Medical treatment for advanced gastroesophageal adenocarcinoma. ( Ajani, JA; Cen, P, 2007)
"Pancreatic cancer is one of the major causes of cancer death."2.44Neoadjuvant and adjuvant strategies for pancreatic cancer. ( Ghaneh, P; Neoptolemos, JP; Raraty, M; Smith, R; Tudor-Smith, C, 2008)
"Treatment of rectal cancer over the last two decades has evolved with changes in techniques of surgery and radiation based on national and international trials."2.44Total mesorectal excision and management of rectal cancer. ( Phang, PT; Pinsk, I, 2007)
"Gemcitabine has been a standard treatment for advanced pancreatic cancer since it was shown a decade ago to result in a superior clinical benefit response and survival compared with bolus 5-fluorouracil (5-FU)."2.44Pancreatic cancer--is the wall crumbling? ( Chua, YJ; Zalcberg, JR, 2008)
"If almost all colorectal cancers (CRC) correspond to the same histopathological type (adenocarcinoma), molecular biology allowed the identification of two different molecular mechanisms of colorectal carcinogenesis: chromosomal instability characterized by recurrent allelic losses on chromosomes 17, 5, 18, 8 and 22 that contribute to the inactivation of tumor suppressor genes, and genetic instability characterized by the instability of microsatellite loci due to an alteration of DNA mismatch repair leading to the accumulation of mutations in genes involved in the control of cell cycle and apoptosis."2.43[Molecular biology in clinical cancer research: the example of digestive cancers]. ( Laurent-Puig, P; Lièvre, A, 2005)
"We relate 2 cases reports about rectal cancer and pregnancy."2.43[Management of rectal cancer in pregnant women]. ( Benouna, J; Classe, JM; Dravet, F; Dupré, PF; Mahé, MA; Pigeau, H; Pioud, R, 2005)
"Capecitabine is an oral prodrug of 5-fluorouracil, which is converted to 5-fluorouracil by three sequential enzymatic reactions."2.43Capecitabine in carcinoma of the pancreas. ( Neoptolemos, JP; Smith, DB, 2006)
"Treatment of localized gastric cancer relies primarily on surgical intervention, although growing evidence suggests that the addition of chemoradiation may improve disease-free intervals and overall survival."2.43Molecular markers for gastric adenocarcinoma: an update. ( Anderson, C; Kim, J; Nijagal, A, 2006)
"The rare finding of heterotopic ossification in a case of primary rectal adenocarcinoma is described along with a review of the literature."2.42Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism. ( Gottfried, MR; Jones, R; Kypson, AP; Morphew, E; Seigler, HF, 2003)
"Assessment of response to therapy of pancreatic cancer has been a difficult challenge."2.42Developments in the systemic therapy of pancreatic cancer. ( el-Rayes, BF; Philip, PA; Shields, AF; Vaitkevicius, V, 2003)
"Selected patients with inflammatory breast cancer have the potential for long-term survival."2.42Ten-year outcome after combined modality therapy for inflammatory breast cancer. ( Bertsch, H; Fox, K; Glick, J; Harris, EE; Schultz, D; Solin, LJ, 2003)
"Gemcitabine has replaced 5-fluorouracil-based chemotherapy as the standard of care."2.42New perspectives in the management of pancreas cancer. ( Haller, DG, 2003)
"The late diagnosis of pancreatic cancer, at a locally advanced and metastatic stage explains in part its poor prognosis."2.41[Gemcitabine and pancreatic cancer]. ( Azria, D; Prost, P; Ychou, M, 2002)
"Gemcitabine is a new fluorine-substituted cytarabine compound."2.41Clinical update of gemcitabine in pancreas cancer. ( Au, E, 2000)
"Selected elderly patients with colon cancer can receive the same benefit from fluorouracil-based adjuvant therapy as their younger counterparts, without a significant increase in toxic effects."2.41A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. ( Francini, G; Goldberg, RM; Haller, DG; Jacobson, SD; Labianca, R; Macdonald, JS; Sargent, DJ; Seitz, JF; Shepherd, LE, 2001)
"A case of AFP producing early gastric cancer successfully treated with a small dose of CDDP and 5-FU therapy administered intermittedly is reported with a review of the literature."2.41[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy]. ( Aoki, T; Fujimitsu, Y; Koyanagi, Y; Moritani, M; Niido, T; Shinohara, M; Tsuchida, A, 2001)
"Most patients diagnosed with gastric cancer in the United States and the Western World will either present with advanced disease or have recurrence after surgery, requiring discussions of chemotherapy."2.41Chemotherapy options for gastric cancer. ( Fuchs, CS; Meyerhardt, JA, 2002)
"Pancreatic cancer is one of the deadliest malignancies and is fatal in more than 95% of affected individuals."2.41Management of locally advanced adenocarcinoma of the pancreas. ( Ryan, DP; Willett, CG, 2002)
"Advanced extramammary Paget's disease is also adenocarcinoma of the skin."2.40[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature]. ( Yamazaki, N, 1997)
"Patients with advanced colorectal cancer can only benefit from these important advances, however, if a truly multidisciplinary approach to patient care is adopted which requires integration of the roles of the surgeon, medical oncologist and radiotherapist."2.40The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon. ( Neoptolemos, JP; Rougier, P, 1997)
"Irinotecan or CPT11 is a topoisomerase 1 inhibitor."2.40[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials]. ( Peeters, M; Van Cutsem, E, 1998)
"Irinotecan treated patients lived for significantly longer than those on 5FU: median time of survival was 10."2.40[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials]. ( Ducreux, M; Mitry, E; Rougier, P, 1998)
"Pancreatic cancer is widely regarded by medical personnel and the lay public as one of the most dreaded of all diagnoses."2.40Practical recommendations for the management of adenocarcinoma of the pancreas. ( Sporn, JR, 1999)
"Five-year survival rates were 57% for squamous cell carcinoma, 63% for adenocarcinoma, and 33% for melanoma."2.40Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. ( Klas, JV; Madoff, RD; Rothenberger, DA; Wong, WD, 1999)
"This article describes two cases of colorectal cancer in adolescents and reviews the literature regarding this rare condition."2.40Colorectal cancer in adolescents. ( Renaut, AJ; Shankar, A; Taylor, I; Whelan, J, 1999)
"Both gastric and pancreatic cancer remain leading causes of cancer death in the United States and worldwide."2.40Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer. ( Leach, SD; Lowy, AM, 1999)
"Locally advanced, fungating breast cancers pose particularly difficult management problems for which intra-arterial drug delivery may be appropriate in carefully, selected cases."2.39Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature. ( Bufill, JA; Grace, WR; Neff, R, 1994)
"Eighty percent of the patients had squamous cell carcinoma and 20% had adenocarcinoma."2.39Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma. ( Bates, BA; Bernard, SA; Detterbeck, FC; Qaqish, BF; Tepper, JE, 1996)
" Thus, we should perform effective adjuvant therapies in combination with surgery, in order to completely prevent these two types of cancer relapse."2.39[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas]. ( Furukawa, H; Imaoka, S; Ishikawa, O; Iwanaga, T; Kabuto, T; Matayoshi, Y; Nakaizumi, A; Ohigashi, H; Sasaki, Y; Uehara, H, 1996)
"The pharmacokinetic advantage of a novel system to noninvasively isolate the hepatic venous outflow and infuse high doses of chemotherapy (doxorubicin or 5-FU) is discussed and compared with intravenous infusion and intra-arterial infusion without hepatic venous detoxification."2.39Isolated liver perfusion for liver metastases: pharmacokinetic advantage? ( Dixon, K; Ravikumar, TS, 1996)
"5-Fluorouracil (5-FU) is a chemotherapy drug that treats several cancers; however, it causes severe adverse effects and multidrug resistance."1.91Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase. ( Ganesan, K; Gong, G; Tsim, KWK; Xiong, Q; Zheng, Y, 2023)
"Poorly cohesive cells-gastric cancer (PCC-GC) represents distinct features within the GC spectrum."1.91Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer. ( Baek, JH; Cho, M; Kang, BW; Kang, H; Kim, JG; Kwon, OK; Park, JY; Park, KB; Seo, AN, 2023)
"Conventional therapy for colorectal cancer often involves the use of 5-fluorouracil as a chemotherapeutic agent."1.91In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells. ( Dehelean, C; Ilia, I; Ionita, I; Macasoi, I; Pinzaru, I; Susan, M; Susan, R, 2023)
"A total of 554 patients with pancreatic cancer of all stages were screened, and 73 patients treated with Gem-Nab and 48 patients treated with Gem-Ox in the palliative first-line setting were identified and included in this analysis."1.91Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis. ( Gantschnigg, A; Greil, R; Huemer, F; Schlick, K; Seymer, A; Weiss, L, 2023)
"From 2016 to 2020, of 1551 pancreatic cancer patients, 615 received palliative-intent chemotherapy."1.72Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry. ( Ananda, S; Burge, M; Clarke, K; Gibbs, P; Jennens, R; Lee, B; Lipton, L; Michael, M; Nikfarjam, M; Pattison, S; Santucci, J; Shapiro, J; Tacey, M; Thomson, B; Wong, R; Zielinski, R, 2022)
"Colorectal cancer is one of the most common cancers in the world."1.62Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report. ( Akkuş, E; Gürbüz, M; Utkan, G, 2021)
"• Margin-negative resection rate of pancreatic cancer following FOLFIRINOX therapy did not differ among each resectability (67-73%, p = 0."1.62CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. ( Byun, JH; Hong, SM; Jang, JK; Kang, JH; Kim, HJ; Kim, JH; Kim, KP; Kim, SC; Lee, MG; Lee, SS; Seo, DW; Son, JH; Yoo, C, 2021)
"Gemcitabine monotherapy was given to 13% (41/326) of patients and nab-paclitaxel/gemcitabine to 10% (33/326), with a median of two (IQR 3-5) and three (IQR 3-5) cycles respectively."1.62Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort. ( Besselink, MG; Blomjous, JG; Bollen, TL; Bosscha, K; Brada, LJ; Bruijnen, RC; Busch, OR; Creemers, GJ; Daams, F; de Hingh, IH; de Meijer, VE; de Vos-Geelen, J; de Vries, JJJ; Festen, S; Hermans, JJ; Jan de Groot, D; Kerver, ED; Liem, MS; Los, M; Meijerink, MR; Mekenkamp, LJ; Mohammad, NH; Molenaar, IQ; Nederend, J; Nio, CY; Patijn, GA; Patuleia, SIS; Polée, MB; Pruijt, JF; Renken, NS; Rombouts, SJ; Schouten, TJ; Stommel, MWJ; van Dam, R; van der Leij, C; van Leeuwen, MS; van Lienden, KP; van Santvoort, HC; Verweij, ME; Vulink, A; Walma, MS; Wessels, FJ; Willem de Groot, J; Wilmink, JW, 2021)
"Advanced, unresectable pancreatic cancer is often treated with either gemcitabine plus nab-paclitaxel (Gem/NabP) or FOLFIRINOX, although these regimens have never been compared in a head-to-head trial."1.62Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. ( Bates, SE; Conroy, T; Fojo, T; Juzyna, B; Mutetwa, T; Nadkarni, G; Park, YA; Polak, P; Sigel, C; Sigel, K; Wisnivesky, JP; Ychou, M; Yeh, C; Zhou, M, 2021)
"KRas is frequently mutated in pancreatic cancers."1.62GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals. ( Abrams, SL; Akula, SM; Candido, S; Cervello, M; Cocco, L; Duda, P; Falzone, L; Gizak, A; Libra, M; Martelli, AM; McCubrey, JA; Meher, AK; Montalto, G; Rakus, D; Ratti, S; Ruvolo, P; Steelman, LS, 2021)
"Pancreatic cancer is the 8th commonest cancer and the 5th commonest cause of cancer-related death in Australia, with a 9% average 5-year survival."1.62Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. ( Ashrafi-Zadeh, A; Chan, DL; Chua, TC; Clarke, S; Diakos, C; Gill, A; Hruby, G; Jamieson, NB; Kneebone, A; Maloney, S; Mittal, A; Nahm, CB; Pavlakis, N; Samra, JS; Wijetunga, AR, 2021)
"Patients with locally advanced pancreatic cancer (LAPC) are increasingly treated with FOLFIRINOX, resulting in improved survival and resection of tumors that were initially unresectable."1.62Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms. ( Besselink, MG; Bosscha, K; Brada, LJH; Bruijnen, RC; Busch, OR; Daamen, LA; de Hingh, IH; de Meijer, VE; de Vries, JJJ; Festen, S; Liem, MLS; Los, M; Mohammad, NH; Patijn, GA; Polée, MB; Quintus Molenaar, I; Stommel, MWJ; van Dam, RM; van Lienden, KP; van Roessel, S; van Santvoort, HC; Walma, MS; Wessels, FJ; Wilmink, HW; Yung Nio, C, 2021)
"We obtained 93 pancreatic cancer specimens (tumor and adjacent nontumor tissues) from patients who underwent surgery and gemcitabine chemotherapy and analyzed them by immunohistochemistry."1.56ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells. ( Brabletz, T; Bronze, MS; Cui, X; Ding, K; Edil, BH; Fernandez-Zapico, ME; Fung, KA; Houchen, CW; Li, M; Li, YP; Liu, M; Postier, RG; Stemmler, MP; Tian, X; Yang, J; Yang, Z; Zhan, H; Zhang, Y; Zhou, Z, 2020)
"Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells."1.56Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020)
"We demonstrated in this study that dose escalation using IMRT in combination with platin-based chemotherapy as a definitive treatment for esophageal carcinoma is safe and results in higher loco-regional and control survival when compared to previously reported data."1.56Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients. ( Carrère, N; Dalmasso, C; Guimbaud, R; Izar, F; Lusque, A; Modesto, A; Moyal, E; Rives, M; Vieillevigne, L, 2020)
"Cutaneous metastases from colorectal cancer are extremely rare and generally appear several years after diagnosis or resection of the primary colorectal tumor."1.56Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report. ( Cheng, Q; Liao, L; Pei, F; Ye, S; Zhu, G, 2020)
"The prognosis of patients with advanced gastric cancer remains unsatisfactory, highlighting the need for improved therapeutic strategies."1.56FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer. ( Cao, D; Du, T; Jiang, X; Li, H; Song, C; Sun, Q; Yan, D; Yang, Y; Yuan, B; Zhang, S, 2020)
" No toxic death was observed."1.56Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX. ( Bengrine, L; Fumet, JD; Ghiringhelli, F; Granconato, L; Hennequin, A; Palmier, R; Vincent, J, 2020)
"Here, we report the case of a Lynch syndrome PDA patient with an exceptional response to a single cycle of pembrolizumab immunotherapy."1.56Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma. ( Khan, GN; Patil, NR, 2020)
"Esophageal cancer is increasingly common and carries a poor prognosis."1.56Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. ( Bateman, A; Byrne, JP; Grace, BL; Iveson, T; Jackson, A; Kelly, JJ; Noble, F; Pucher, PH; Rahman, SA; Rees, C; Underwood, TJ; Walker, RC, 2020)
"Patients with PM from colorectal cancer and PCI >20 that were treated with CRS and HIPEC experience a one year longer and doubled overall survival compared with open-close/debulking patients."1.56Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. ( Artursson, S; Birgisson, H; Cashin, P; Enblad, M; Ghanipour, L; Graf, W, 2020)
"The patient had locally advanced rectal cancer with widespread contact with the sacrum, and preoperative radiochemotherapy (S-1 100 mg/day plus radiotherapy 50 Gy/25 Fr)was performed."1.56[A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy]. ( Ichikawa, J; Koreeda, N; Nishiki, M; Noritomi, T; Okamoto, T; Ryu, S; Sannomiya, H; Sato, K; Shin, Y; Yamana, I; Yanagisawa, J; Yoshida, Y, 2020)
"Primary systemic therapy in resectable pancreatic cancer is currently under investigation."1.51Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer. ( Joseph, NE; Marsh, RW; Polish, A, 2019)
"Vulvar metastasis of colorectal cancer (CRC) and acquired resistance to cetuximab is a very rare phenomenon."1.51Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report. ( Ni, X; Qiang, W; Wu, Q; Zhang, C; Zhao, J, 2019)
"Most patients had disease progression as the best response to treatment (75."1.51Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine? ( Costa, FP; Faria, LDBB; Fernandes, GS; Girardi, DM; Hoff, PMG; Teixeira, MC, 2019)
"From our established gastric cancer database, patients with pathological stage II and III gastric cancer who received adjuvant chemotherapy after D2 gastrectomy at Zhongshan Hospital of Fudan University were analyzed."1.51The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study. ( Cheng, X; Cui, Y; Ji, Y; Jiang, H; Li, W; Liu, F; Liu, TS; Shen, Z; Sun, Y; Tang, C; Wang, X; Wang, Y; Yu, S; Yu, Y, 2019)
"Organoids were derived from resected gastric cancer tumors (huTGOs) or normal stomach tissue collected from sleeve gastrectomies (huFGOs)."1.51An Organoid-Based Preclinical Model of Human Gastric Cancer. ( Ahmad, S; Biesiada, J; Chakrabarti, J; Chang, J; Hawkins, J; Helmrath, M; Holokai, L; Mahe, M; Medvedovic, M; Nowacki, LM; Shroyer, N; Steele, NG; Sundaram, N; Wang, J; Zavros, Y, 2019)
"A 35-year-old woman was diagnosed with rectal cancer with metastasis to the liver."1.51Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report. ( Ouyang, Y; Peng, T; Tong, K, 2019)
"Pathologists assess rectal cancers that have responded significantly to neoadjuvant therapy more thoroughly."1.51Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation. ( Avila, K; Chow, OS; Chu, P; Garcia-Aguilar, J; Keskin, M; Patil, S; Shia, J; Smith, DD; Smith, JJ; Widmar, M, 2019)
"Distant metastasis still remained a major concern in pCR patients following nCRT and TME."1.51Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors. ( Chi, P; Huang, Y; Lin, H; Lu, X; Sun, Y; Wu, X; Zhang, Y, 2019)
"Aiming to address the issue of poor bioavailability of most anti-tumor medicines against colorectal cancer, we developed a targeted anticancer nanocarrier using biocarriers able to both bind and easily release their load in a controlled manner."1.51Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer. ( Costache, M; Galateanu, B; Georgiana Nitu, S; Ginghina, O; Hudita, A; Iovu, H; Negrei, C; Radu, IC; Shtilman, M; Tanasa, EV; Tsatsakis, A; Velonia, K; Zaharia, C, 2019)
"Irinotecan was administered whenever initial serum bilirubin was <1."1.51Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma. ( Almohamad, W; Biondani, P; Chebib, A; Gumus, Y; Haydar, M; Karaboué, A; Krimi, S; Morère, JF; Teyar, N; Ulusakarya, A, 2019)
"Peritoneal carcinomatosis (PC) from colorectal cancer is associated with poor prognosis."1.51Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study. ( Burnett, A; Cloutier, AS; Dubé, P; Gervais, MK; Lecompte, MA; Sideris, L; Trabulsi, N; Trilling, B, 2019)
"After few days, despite of this dose reduction, he experienced life-threatening adverse events such as mucositis G3, diarrhea G3, neutropenia G4, thrombocytopenia G4, and hyperbilirubinemia G3 according to Common Terminology Criteria for Adverse Events v 5."1.51A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant. ( Ciardiello, D; Ciardiello, F; Conzo, G; Coppola, N; De Falco, V; De Vita, F; Giunta, EF; Marinaccio, A; Martinelli, E; Napolitano, S; Natalicchio, MI; Troiani, T; Vietri, MT; Vitale, P; Vitiello, PP; Zanaletti, N, 2019)
"Cardiotoxicity is an important side effect in patients receiving chemotherapy and the application of anthracycline drugs for gastric cancer treatment is uncommon."1.51Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. ( Bai, Y; Gao, L; Jin, X; Wu, S, 2019)
"Sarcopenia was defined as SMI ≤38."1.51Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer. ( Block, C; Gorsuch, K; Gupta, D; Hill, D; Vashi, PG; Wan, L, 2019)
"But it is rare in adults."1.51[Intussusception Caused by Colon Cancer in Pregnancy]. ( Jung, YJ; Kim, CL; Kim, K; Kim, TO; Ko, M; Sim, HC, 2019)
"Adjuvant chemotherapy for gastric cancer, particularly stage III, improves survival after curative D2 gastrectomy."1.51Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. ( Bae, WK; Cho, SH; Chung, IJ; Hwang, EC; Hwang, JE; Jeong, O; Kim, H; Park, YK; Ryu, SY; Shim, HJ, 2019)
"Atypical features of Posterior reversible encephalopathy syndrome (PRES) (diffusion restriction, involvement of corpus callosum & white matter tracts along posterior limbs of internal capsule) were seen in a patient after oxaliplatin administration (FOLFOX- 4 regimen)."1.51Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer. ( Jiji, V; Prahladan, A; Ramachandran, K; Roshni, S; Sen, A; Venugopal, M, 2019)
"Long-term outcomes of older esophageal cancer patients (70 y and above) selected for treatment with neoadjuvant chemoradiotherapy followed by surgery or definitive chemoradiotherapy were comparable with the outcomes of their younger counterparts."1.48Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer. ( Aleman, BMP; Grootscholten, C; Sikorska, K; Snaebjornsson, P; van der Kaaij, RT; van Dieren, JM; van Sandick, JW; van Werkhoven, E; Voncken, FEM, 2018)
"Melatonin has antitumor activity via several mechanisms including its anti-proliferative and pro-apoptotic effects."1.48Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro. ( Bejarano, I; Espino, J; Pariente, JA; Pariente, R; Rodríguez, AB, 2018)
"Data were analyzed from a prospective pancreatic cancer database."1.48Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy. ( Chabot, JA; Hecht, EM; Kluger, MD; Rashid, MF; Rosario, VL; Schrope, BA; Steinman, JA, 2018)
"For advanced rectal cancer with involved or threatened mesorectal fascia (MRF), current standard is pre-operative long course chemoradiotherapy (PLCRT) with either capecitabine or 5-fluorouracil (5-FU)."1.48Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients. ( Chiang, CL; Lee, FAS; Lee, SF; Poon, CM; Tung, SY; Wong, FCS; Wong, YW, 2018)
"Mismatch repair status in pancreatic cancer patients is not only a prognostic indicator but also a potential guiding factor for the use of 5-fluorouracil-based adjuvant chemotherapy."1.48Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer. ( Liang, C; Liang, D; Meng, Q; Ni, Q; Shi, S; Xu, J; Yu, X; Zhang, B, 2018)
" Dosing and completion of prescribed chemotherapy were assessed on the subset of patients who received all therapy at MSK."1.48Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. ( Cercek, A; Crane, CH; Garcia-Aguilar, J; Gollub, MJ; Gonen, M; Guillem, JG; Nash, GM; Paty, PB; Reidy, DL; Roxburgh, CSD; Saltz, LB; Segal, NH; Seier, K; Shia, J; Smith, JJ; Stadler, ZK; Strombom, P; Temple, LKF; Vakiani, E; Varghese, A; Weiser, MR; Wu, AJ; Yaeger, R, 2018)
"Colon cancer is common in the elderly, but owing to under representation in clinical trials, the benefit of standard therapies is uncertain in this age group."1.48Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer. ( Aghmesheh, M; Brungs, D; Carolan, M; Clingan, P; de Souza, P; Ranson, M; Rose, J, 2018)
"All cases of locally advanced gastric cancer treated with the XELOX or DOS regimen were reviewed retrospectively."1.48Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. ( Cheng, X; Cui, YH; Hou, J; Ji, Y; Liu, FL; Liu, TS; Shen, ZB; Sun, YH; Wang, Y, 2018)
"Indiana University Simon Cancer Center pancreatic cancer database was used to identify patients with metastatic PDAC, treated with FOLFIRINOX and had tissue available for DNA sequencing."1.48Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX. ( Gbolahan, O; Hancock, BA; O'Neil, BH; Radovich, M; Sehdev, A; Shahda, S; Stanley, M; Wan, J; Wu, HH, 2018)
"The predictive role of biomarkers in colon cancer is still being defined."1.48The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer. ( Chouhan, H; Moore, JW; Sammour, T; Thomas, ML, 2018)
"Anal canal cancer occasionally accompanies extramammary Paget disease."1.48Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report. ( Hirose, S; Hyodo, I; Kawai, H; Moriwaki, T; Sato, M; Suganuma, D; Tajima, H; Uchida, Y; Watanabe, R; Yamada, T; Yamamoto, Y; Yamaura, M, 2018)
"MMR-D pancreatic cancer have been reported to respond to checkpoint inhibitor therapy."1.48Acquired resistance to immunotherapy in MMR-D pancreatic cancer. ( Diaz, LA; Hellmann, MD; Hu, ZI; O'Reilly, EM; Shia, J; Stadler, ZK; Vyas, M; Wolchok, JD, 2018)
"Systemic EGFRi may increase dry eye signs as well as decrease CEBD and CNFD."1.48Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial. ( Adán, A; Castellà, C; Eixarch, A; Reguart, N; Saint-Jean, A; Sainz-de-la-Maza, M; Sánchez-Dalmau, B, 2018)
"Patients with rectal cancer treated with chemoradiotherapy and radical surgery from 2003 to 2015 (N = 222) were included."1.46Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy. ( Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Tanaka, T; Watanabe, T, 2017)
"Distal resection margin (≤5 vs >5 mm) did not show any significant difference in cumulative incidence of locoregional recurrence (P=."1.46Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis. ( Bae, JM; Jang, HS; Jeong, S; Kim, SH; Lee, JH; Lee, JW; Nam, TK; Song, JH; Sung, S, 2017)
"Of 216 stage IIIB cervical cancer patients, 114 of them had no LTI and 72 had LTI."1.46Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion. ( Katanyoo, K, 2017)
"Blood examinations showed disseminated intravascular coagulation(DIC)at the end of the second-line chemotherapy."1.46Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation. ( Kichiraku, T; Kotanagi, H; Kotanagi, K; Kudoh, K; Masuda, A; Miyazawa, H; Munakata, M; Muto, O; Ouchi, S; Sakata, Y; Satoyoshi, R; Sawada, T; Yamagata, K, 2017)
"We report a rare case of breast carcinoma metastatic to the left mandibular condyle in a 55-year-old Japanese woman, who visited our department for a dental check-up prior to chemotherapy."1.46Metastasis in the mandibular condyle: a case report. ( Dodo, M; Hirakawa, H; Kato, Y; Koseki, T; Kumagai, M, 2017)
"To investigate the association between polymorphisms of DNA repair genes and xenobiotic with acute adverse effects in locally advanced rectal cancer patients treated with neoadjuvant radiochemotherapy."1.46Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy. ( Agolli, L; Borro, M; Bracci, S; De Sanctis, V; Di Nardo, F; Enrici, RM; Falco, T; Gentile, G; Maglio, M; Minniti, G; Nicosia, L; Osti, MF; Simmaco, M; Valeriani, M, 2017)
"The most common sites of metastases were liver (63%) and peritoneum (22%)."1.46Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study. ( Cheung, WY; Gill, S; Ho, MY; Kennecke, HF; Lim, HJ; Renouf, DJ, 2017)
"Perineural invasion (PNI) in colon cancer (CC) has been associated with poorer prognosis even in stage II disease (T3-4 N0 M0)."1.46Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer. ( Baixauli, J; Beorlegui, C; Cienfuegos, JA; Hernández-Lizoáin, JL; Martínez, P; Rodríguez, J; Rosenstone, S; Sola, JJ, 2017)
"Methods Twenty-one patients with gastric cancer (including sixteen with advanced/recurrent gastric cancer and five with poor general condition) underwent chemo-radiotherapy, for whom the therapeutic efficacy, toxicity and survival period were analysed."1.46Usefulness of chemoradiotherapy for inoperable gastric cancer. ( Hoya, Y; Mitsumori, N; Nakayoshi, T; Okamoto, T; Sekine, H; Taki, T; Watanabe, A; Yanaga, K, 2017)
"Rectal cancer is a malignant disease requiring multidisciplinary management."1.46Management of rectal cancer: the 2016 French guidelines. ( Bridoux, V; Brouquet, A; de Chaisemartin, C; Kirzin, S; Lakkis, Z; Lefevre, JH; Maggiori, L; Manceau, G; Panis, Y, 2017)
"Locally advanced unresectable pancreatic cancer (LAPC) historically portends a poor prognosis."1.46Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes? ( Bahary, N; Bednar, F; Hogg, ME; Ocuin, LM; Steve, J; Winters, S; Zeh, HJ; Zenati, MS; Zureikat, AH, 2017)
"Peritoneal metastasis is common in gastric cancer."1.46Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready? ( Chan, DY; Chee, CE; Nga, ME; Phua, JN; Shabbir, A; So, JB; Soh, TI; Syn, NL; Yap, R; Yong, WP, 2017)
"Both patients presented with colorectal cancer with synchronous liver metastasis."1.46A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases. ( Aydin, N; Berber, E; Dural, C; Okoh, AK; Taskin, HE; Yazici, P; Yigitbas, H, 2017)
"For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response."1.46The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. ( Bowman, CR; Dorrington, MS; Kaye, P; Madhusudan, S; Mumtaz, E; Pang, V; Parsons, SL; Reece-Smith, AM; Saunders, JH; Soomro, I, 2017)
"A total of 198 patients with rectal cancer underwent preoperative endoscopic assessments after chemoradiotherapy."1.46Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer. ( Fukayama, M; Hata, K; Ishihara, S; Kawai, K; Kiyomatsu, T; Morikawa, T; Nozawa, H; Watanabe, T, 2017)
"AFP-PGC patients had more liver metastases than non-AFP-PGC patients (p < 0."1.46The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma. ( Bozkaya, Y; Demirci, NS; Doğan, M; Erdem, GU; Yazıcı, O; Zengin, N, 2017)
"Currently, metastatic colorectal cancer is treated as a homogeneous disease and only RAS mutational status has been approved as a negative predictive factor in patients treated with cetuximab."1.46Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies. ( Bibeau, F; Del Rio, M; Emile, JF; Gongora, C; Martineau, P; Mollevi, C; Robert, J; Roger, P; Selves, J; Tubiana-Mathieu, N; Vie, N; Ychou, M, 2017)
"Pancreatic cancer has become the third leading cause of cancer death with minimal improvements in outcome for over 40 years."1.46BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. ( Bailey, P; Biankin, AV; Brody, JR; Chang, DK; Laheru, D; Pishvaian, MJ; Wolfgang, CL, 2017)
"Type of esophageal cancer was adenocarcinoma in 213 patients (80%) and squamous cell carcinoma in 46 patients (17%)."1.43Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience. ( Bhatia, S; Martenson, JA; Miller, RC; Quevedo, JF; Schomas, DA; Sio, TT; Stauder, MC; Wilson, ZC, 2016)
"Metastatic and refractory gastric cancer (GC) are associated with a poor prognosis; therefore, the identification of prognostic factors and chemosensitivity markers is extremely important."1.43Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients. ( Altan, B; Asao, T; Bai, T; Bao, P; Hara, K; Ide, M; Kimura, A; Kogure, N; Kuwano, H; Mochiki, E; Nishiyama, M; Ogata, K; Oyama, T; Suzuki, M; Toyomasu, Y; Yokobori, T, 2016)
"RanBPM expression in human gastric cancer tissue samples was analyzed using real-time polymerase chain reaction."1.43Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance. ( Feng, YI; Gao, X; Ji, J; Ji, KE; Jia, Y; Jiang, WG; Satherley, LK; Shao, S; Sun, PH; Ye, L, 2016)
"Patients with resectable oesophageal cancer are treated with neoadjuvant chemoradiotherapy (nCRT) followed by surgery within 3-8 weeks."1.43Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. ( Creemers, GJ; Kathiravetpillai, N; Koëter, M; Luyer, MD; Nieuwenhuijzen, GA; Rutten, HJ; van der Sangen, MJ, 2016)
"The histological diagnosis was tubular adenocarcinoma (tub2-1), int, INF a, pMP, ly0, v0, pDM0, pPM0, R0."1.43[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab]. ( Aomatsu, N; Dozaiku, T; Hanno, H; Hirakawa, T; Hirooka, T; Iwauchi, T; Kawamura, M; Morimoto, J; Nakazawa, K; Nishii, T; Takayanagi, S; Takeda, O; Takeuchi, K; Uchima, Y; Yukawa, Y, 2016)
"Gastric cancer is considered the fourth most common cancer and second most common cause of cancerrelated mortalities worldwide."1.43Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer. ( Esmaeilpour, K; Haghighi, S; Kasbkar, H; Yasaei, M, 2016)
"Febrile neutropenia was not reported."1.43Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. ( Caparello, C; Falcone, A; Fornaro, L; Lencioni, M; Musettini, G; Pasquini, G; Petrini, I; Vasile, E; Vivaldi, C, 2016)
"For patients with metastatic pancreatic cancer, FOLFIRINOX (fluorouracil [5-FU], leucovorin [LV], irinotecan [IRI], and oxaliplatin) has shown improved survival rates compared with gemcitabine but with significant toxicity, particularly in patients with a high tumor burden."1.42Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. ( Bekaii-Saab, T; Blazer, M; Bloomston, M; Ellison, EC; Goldberg, RM; Muscarella, P; Phillips, G; Reardon, J; Schmidt, C; Williams, TM; Wu, C; Wuthrick, E, 2015)
"Sarcopenia is a significant predictor of DLT in oesophago-gastric cancer patients undergoing neo-adjuvant chemotherapy."1.42Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. ( Brammer, K; Catton, JA; James, EJ; Parsons, SL; Randhawa, N; Tan, BH; Welch, NT, 2015)
" By exclusion the pseudo-obstruction was attributed to a toxic oxaliplatin-induced autonomic neuropathy which slowly improved during months of follow-up."1.42A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity. ( Bleecker, JD; Pauwels, W; Vandamme, M, 2015)
"For patients with locally advanced rectal cancer, higher radiation dose may contribute to the improvement of both LC and disease-free survival, without significantly increasing the incidence of acute and long-term complications compared with adjuvant chemoradiotherapy alone."1.42Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer. ( Fu, S; Huang, G; Li, P; Lu, JJ; Peng, L; Tey, J; Xiong, F; Yang, Z; Zhang, Q, 2015)
" Oxaliplatin in combination with intravenous 5-FU plus leucovorin (LV; modified [m]FOLFOX6) or capecitabine (XELOX) improves tolerability compared with 5-FU/cisplatin regimen."1.42Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study. ( André, T; Bachet, JB; Chibaudel, B; Cohen, R; de Gramont, A; Hentic, O; Louvet, C; Samalin, E; Soularue, É; Tournigand, C; Zaanan, A, 2015)
" Most adverse events were mild (grade 1-2) (Common Terminology Criteria for Adverse Events, version 3."1.42Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer. ( Kumita, S; Mine, T; Murata, S; Onozawa, S; Sakamoto, A; Sugihara, F; Ueda, T; Yamaguchi, H; Yasui, D, 2015)
"In recent decades, the management of rectal cancer has been significantly improved by optimizing the surgical treatment with the total mesorectal excision and the development of neoadjuvant radiotherapy with or without chemotherapy."1.42[Preoperative chemoradiotherapy for rectal cancer: experience from one centre]. ( Bednarek, C; Bosset, JF; Cerda, T; Guimas, V; Lepinoy, A; Lescut, N; Schipman, B, 2015)
"025) in the toxic group (n = 12) compared to the non-toxic group (n = 19)."1.42Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study. ( Bowen, JM; Game, PA; Hussey, DJ; Irvine, T; Karapetis, CS; Keefe, DM; Kristaly, K; Smith, L; Tan, H; Thompson, SK; Tsykin, A; Watson, DI; White, I, 2015)
"The bleak prognosis associated with pancreatic cancer (PDAC) drives the need for the development of novel treatment methodologies."1.42Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer. ( Guillen, KP; Harrison, RG; Kurkjian, C; Restuccia, A, 2015)
"In Europe, pancreatic cancer (PC) accounts for approximately 2."1.42Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study. ( André, T; Ball, DE; Bapat, B; Kaye, JA; Smyth, EN, 2015)
"Metastasis of colorectal cancer (CRC) in an adrenal gland develops in 1."1.42[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava]. ( Andreĭtseva, OI; Gritsiuta, AI; Kalinin, DV; Kharazov, AF; Vishnevskiĭ, AV; Zhavoronkova, OI, 2015)
"Patients with gastric cancer who undergo diagnostic laparoscopy, preoperative chemoradiation, and gastrectomy have a high frequency of obtaining an R0 resection and excellent OS rates."1.42Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. ( Ajani, J; Badgwell, B; Blum, M; Chiang, YJ; Das, P; Estrella, J; Fournier, K; Mansfield, P; Matamoros, A, 2015)
"The authors conclude that multiple synchronous neoplasms can be treated with individualized chemotherapeutic protocol with good efficacy and few adverse reactions."1.42[Individualized therapy of synchronous ovarian and colon cancers with lymph]. ( Bishr, AM; Deme, D; Nizar, J; Telekes, A, 2015)
"Stage III colon cancer is currently treated as an entity with a unified therapeutic principle."1.42A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites. ( Deng, G; He, J; Ma, J; Pei, H; Shen, H; Wu, X; Zeng, S; Zhang, S; Zhang, Y, 2015)
"Colon cancer in pregnancy is uncommon."1.42Chemotherapeutic treatment of colorectal cancer in pregnancy: case report. ( Al-Khatani, K; Al-Mohaisen, F; Makoshi, Z; Perrott, C, 2015)
"Primary rectal cancer patients with synchronous distant metastases between September 2001 and August 2011 were enrolled."1.42Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2015)
"Stable disease and further disease progression were achieved in 36 and 14 patients, respectively."1.42Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer. ( Kim, YT; Lee, SH; Paik, WH; Park, JM; Ryu, JK; Song, BJ, 2015)
"The human gastric cancer BGC-823 cells were infected with Cx43-IRES2-EGFP recombinant adenovirus vector."1.42Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis. ( Hu, X; Li, Y; Liu, D; Liu, W; Shi, G; Sun, X; Wang, T; Wu, J; Yue, X; Zhang, X; Zhao, Y; Zhou, H, 2015)
"Pancreatic cancer is the fourth leading cause of cancer related death with median survival ranging from 3 to 6 months for metastatic disease."1.42Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country. ( Jabbar, AA; Zahir, MN, 2015)
"Locally advanced rectum cancer patients experience good results with surgery and adjuvant concurrent chemoradiation."1.42Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand. ( Boonyawan, K; Chansriwong, P; Dangprasert, S; Darunikorn, P; Dhanachai, M; Jiarpinitnun, C; Pattaranutaporn, P; Puataweepong, P; Sitathanee, C; Swangsilpa, T, 2015)
"Colon cancer is a frequently occurring primary malignant tumor."1.42Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma. ( Cai, S; Hu, J; Xu, Y, 2015)
"The SCAN pancreatic cancer workgroup aimed to develop Singapore Cancer Network (SCAN) clinical practice guidelines for systemic therapy for pancreatic adenocarcinoma in Singapore."1.42Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma. ( , 2015)
"After disease progression, a second line based on FOLFIRI-aflibercept was started achieving an initial partial response followed by a long-lasting disease stability with a good tolerability."1.42[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case]. ( Aroldi, F; Zaniboni, A, 2015)
"Even in cases of peritoneal recurrence of colon cancer, aggressive resection may improve the prognosis in some cases."1.42[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report]. ( Hakamada, K; Miura, T; Nakayama, Y, 2015)
"This was a rare case of rectal cancer with submucosal invasion that showed recurrence in the bone and lymph nodes 78 months after the additional resection."1.42[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report]. ( Amikura, K; Asayama, M; Fukuda, T; Ishikawa, H; Kawashima, Y; Kazama, S; Kurozumi, M; Mori, Y; Nishimura, Y; Nishizawa, Y; Sakamoto, H; Takano, M; Takenoya, T; Tanaka, Y, 2015)
"Adverse events seen with chemotherapy consisted of grade 2 leukopenia in 1 patient, but there were no cases of delayed administration or dosage reduction due to grade 2 neurotoxicity."1.42Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery. ( Arimitsu, H; Hirano, A; Koda, K; Kosugi, C; Matsuo, K; Shiragami, R; Shuto, K; Suzuki, M; Tanaka, K; Yamazaki, M; Yasuda, H, 2015)
"Berberine is an alkaloid isolated from the Chinese herbal medicine Huanglian, and has long been used as an antibiotic."1.40Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo. ( Cai, Y; Huang, P; Jiang, W; Luo, R; Shi, Y; Sun, Y; Xia, Q, 2014)
"Case 1 was a 61-year-old man with squamous cell carcinoma of the urethra that directly invaded into the perineal skin."1.40Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma. ( Arai, Y; Itoh, J; Kaiho, Y; Kimura, S; Mitsuzuka, K; Saito, H; Tanaka, T; Yamada, S; Yamamuro, T; Yamashita, S, 2014)
"After 4 weeks, dysphagia scores improved by at least 1 point in 67% of patients in group 1 versus 93% in group 2 (p=0."1.40Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer. ( Archambeaud, I; Landi, B; Lepère, C; Lièvre, A; Mitry, E; Rougier, P; Touchefeu, Y, 2014)
"Knockdown of DAP3 was conducted in gastric cancer cell lines to investigate its impact on cell growth, migration, adhesion and invasion."1.40Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. ( Hargest, R; Ji, J; Ji, K; Jia, Y; Jiang, WG; Ye, L; Zhang, L, 2014)
"Advanced pancreatic cancer remains a lethal disease with no standard treatment beyond first-line palliative chemotherapy."1.40Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma. ( Ajouz, H; Elias, E; Faraj, W; Haydar, A; Khalife, M; Mukherji, D; Saleh, A; Shamseddine, A; Temraz, S; Yakan, AS, 2014)
" Severe toxic reactions to 5-FU have been associated with decreased levels of dihydropyrimidine dehydrogenase (DPD) enzyme activity."1.40A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach. ( Diasio, RB; Lee, AM; McConnell, K; Offer, SM; Relias, V; Saif, MW, 2014)
"However, the number of long-term esophageal cancer survivors has been increasing due to advances in early detection and therapy."1.40Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer. ( Dasanu, CA; Nandy, N, 2014)
"The presented patient with stage IV rectal cancer and liver metastases was in a unique situation linked to its inclusion in a reversed treatment and the use of neoadjuvant chemotherapy alone."1.40Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer. ( Gervaz, P; Mentha, G; Morel, P; Naiken, SP; Roth, A; Rubbia-Brandt, L; Thomopoulos, T; Toso, C, 2014)
"The role of autophagy in pancreatic cancer is still not clear."1.40Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs. ( Bläuer, M; Hashimoto, D; Hirota, M; Ikonen, NH; Laukkarinen, J; Sand, J, 2014)
"Borderline resectable pancreatic cancer is best treated by multimodality therapy."1.40Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm? ( Christians, KK; Erickson, B; Evans, DB; George, B; Kelly, T; Mahmoud, A; Ritch, P; Thomas, JP; Tsai, S; Wang, H; Wiebe, L, 2014)
"Hepatic resection of metastatic colorectal cancer (CRC) has become the treatment of choice for patients after resection of the primary CRC."1.40Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases. ( Araki, K; Asao, T; Fujii, T; Kubo, N; Kuwano, H; Suzuki, H; Tsukagoshi, M; Tsutsumi, S; Wada, S; Watanabe, A, 2014)
" This treatment should be considered regardless of patients' age alone, but consideration should be given to the capacity of patients to tolerate adverse events."1.40Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study. ( Bedenne, L; Bouvier, AM; Faivre, J; Hamza, S; Lepage, C; Rollot, F, 2014)
"Abdominal pain was the most frequent symptom (36."1.40Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients. ( Bai, L; Guo, XC; Mao, ZY; Su, D; Wang, LJ; Zhang, TT, 2014)
" In vivo pellet coating led to reduced drug bioavailability and enhanced drug accumulation at colon (179."1.40Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment. ( Bose, A; Elyagoby, A; Wong, TW, 2014)
"DCF has strong antitumor activity for esophageal cancer and may confer survival benefits when used as preoperative chemotherapy."1.40Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. ( Baba, H; Baba, Y; Ishimoto, T; Iwagami, S; Iwatsuki, M; Nagai, Y; Watanabe, M; Yoshida, N, 2014)
"Radiotherapy for advanced rectal cancer is an important treatment to reduce local recurrence."1.40Late complications after proctectomy in rectal cancer patients who underwent radiotherapy. ( Jung, SH; Kim, JH; Kim, SH, 2014)
"Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine."1.40Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients. ( Agolli, L; Bracci, S; De Sanctis, V; Falco, T; Masoni, L; Maurizi Enrici, R; Osti, MF; Valeriani, M, 2014)
"Secondary surgery of metastasized gastric cancer may be justified in selected cases without progression under induction chemotherapy."1.40Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. ( Friess, HM; Novotny, AR; Reim, D; Schuhmacher, C, 2014)
"Treatment of HCT-116 and Caco-2 colon cancer cells with the hypoxia mimic CoCl2 induced the formation of cells with larger cell and nuclear size (PGCCs), while the cells with normal morphology were selectively eliminated."1.40CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer. ( Aranda, E; De la Haba-Rodríguez, JR; Hernandez, V; Jimenez, C; Lopez-Pedrera, C; Lopez-Sánchez, LM; Martinez, A; Muñoz-Castañeda, JR; Peñarando, J; Rodriguez-Ariza, A; Valverde, A, 2014)
"Postoperative complications were graded according to the Clavien-Dindo classification."1.40Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer. ( Berkel, AE; Klaase, JM; van der Palen, J; Woutersen, DP, 2014)
"Capecitabine is an oral prodrug to 5-fluorouracil and is commonly used in the treatment of advanced breast, colon and stomach cancer."1.40Capecitabine induced colitis. ( Grin, A; Grover, SC; Maggo, G, 2014)
"Lung cancer is one of the leading causes of cancer-related death in developed countries."1.40SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer. ( Feng, Y; Lu, W; Zhang, M; Zuo, Y, 2014)
"Pancreatic cancer is a lethal disease and its prognosis remains dismal."1.40First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward. ( Psyrri, A; Ramfidis, VS; Saif, MW; Syrigos, KN, 2014)
"Locally advanced rectal cancers are currently treated with neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery, but stratification of risk and final outcomes remain suboptimal."1.40Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy. ( Chen, TJ; Hsing, CH; Lee, SW; Lee, YY; Li, CF; Lin, CY; Lin, LC; Sheu, MJ; Wu, TF, 2014)
"However, the esophageal cancer recurred, and subtotal esophagectomy was performed in January 2011."1.40[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy]. ( Kigawa, G; Matsubara, T; Matsumiya, A; Mizukami, H; Nemoto, H; Saito, M; Tanaka, J; Tate, G; Umemoto, T, 2014)
"Capecitabine is an established treatment alternative to intravenous 5-fluorouracil (5-FU) for patients with rectal cancer receiving chemoradiotherapy."1.40Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. ( Beijnen, JH; Cats, A; Dewit, L; Meulendijks, D; Schellens, JH; Tomasoa, NB; van Tinteren, H, 2014)
"We examined the outcomes of transanal endoscopic microsurgery excisions with entry into the peritoneal cavity and compared them with those that did not to address our hypothesis that entry is safe with no ill infectious or oncological consequences."1.40Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe? ( D'Andrea, AP; Frenkel, JL; Greenleaf, CE; Marks, JH, 2014)
"Radiotherapy (RT) planning of gastric cancer is important because of the low radiation tolerance of surrounding critical organs."1.40Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy. ( Adas, YG; Aktas, C; Akyurek, S; Andrieu, MN; Atakul, T; Dirican, B; Ergocen, S; Gokce, SC; Hicsonmez, A; Yilmaz, S, 2014)
"Computed tomography showed intussusception caused by a large tumor in the pelvis and absence of distant metastases."1.40Intussusception due to rectal adenocarcinoma in a young adult: a case report. ( Fujiwara, T; Inada, R; Kishimoto, H; Kondo, Y; Mori, Y; Nagasaka, T; Toshima, T, 2014)
"The study included 405 gastric cancer patients who underwent curative gastrectomy with D2 lymph node dissection and received adjuvant therapy between January 2008 and July 2009."1.40Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study. ( Bae, JM; Choi, MG; Kang, WK; Kim, S; Lee, J; Lee, JH; Lee, SJ; Lim, DH; Lim, HY; Park, JO; Park, SH; Park, YS; Sohn, TS, 2014)
"Docetaxel and cisplatin in combination with fluorouracil (DCF) regimen is accepted to be one of the standard regimens in the treatment of advanced gastric cancer."1.40Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer. ( Bilici, A; Demir, N; Dikilitas, M; Oven Ustaalioglu, BB; Selcukbiricik, F; Yildiz, O, 2014)
"Two patients presented with brain metastases, while one demonstrated lymphangitic spread to lungs."1.40A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma. ( Calkins, SM; Cinar, P; Kelley, RK; Venook, AP, 2014)
"We report a case of rectal cancer, which was successfully treated with radical resection and neoadjuvant chemoradiotherapy."1.40[Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer]. ( Ami, K; Ando, M; Arai, K; Gokita, K; Hayasaka, J; Imai, K; Kitazume, A; Kondou, M; Okamoto, E; Shibayama, T; Takagi, K; Tamura, A; Tei, S; Watanabe, A, 2014)
"Herein, we present a case of advanced rectal cancer surgically resected after chemotherapy."1.40[Surgical resection after chemotherapy for advanced rectal cancer - report of a case]. ( Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Minagawa, M; Nogami, H; Sakata, J; Shimada, Y; Suda, K; Wakai, T, 2014)
"The patient declined surgery for recurrence so radiotherapy was planned."1.40[Irradiation with carbon ions for locally recurrent rectal cancer]. ( Akita, H; Fujino, S; Fujiwara, Y; Fukata, T; Gotoh, K; Kishi, K; Marubashi, S; Miyoshi, N; Motoori, M; Noura, S; Ohue, M; Sakon, M; Sugimura, K; Takahashi, H; Yano, M, 2014)
"Metastatic gastric cancer is uncommon, and metastasis of colorectal cancer to the stomach is extremely rare."1.40[A case of metastatic gastric cancer originating from transverse colon cancer]. ( Doi, S; Kan, K; Maruyama, H; Murata, K; Nakaguchi, K; Nakano, K; Nushijima, Y; Okamura, S; Sugimoto, K, 2014)
"Six months after surgery, recurrence was detected in the para-aortic lymph node."1.40[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy]. ( Egawa, T; Ito, Y; Kemmochi, T; Mihara, K; Nagashima, A; Nishiya, S; Yamashiro, N, 2014)
"The aim is to evaluate the preliminary efficacy and side effects of paclitaxel, 5-fluorouracil, and leucovorin intravenous chemotherapy in combination with cisplatin hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) as postoperative adjuvant therapy for patients of locally advanced gastric cancer (GC) at high risk for recurrence after curative resection."1.40Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer. ( Chen, S; Deng, Q; Jing, S; Li, J; Li, X; Ma, S; Tang, R; Wu, K; Wu, Z; Zheng, Z, 2014)
"We examined 120 stage II colon cancer patients."1.39Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision. ( Barbazza, R; Bonin, S; Donada, M; Pettirosso, D; Stanta, G, 2013)
"Borderline resectable pancreatic cancer remains an area that requires multi-disciplinary approach."1.39Advancements in the management of pancreatic cancer: 2013. ( Saif, MW, 2013)
"A total of 128 patients with gastric cancer who underwent gastrectomy, followed by adjuvant chemotherapy consisting of epirubicin, cisplatin or oxaliplatin, leucovorin, and 5-fluorouracil, according to a defined schedule, were divided into three groups according to the number of chemotherapy cycles: Group I (<6 cycles); Group II (6 cycles); and Group III (>6 cycles)."1.39Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis. ( Bai, Y; Gao, J; Gong, YF; Jiang, B; Liu, F; Yuan, HH; Zhang, WJ; Zhang, WY, 2013)
"Ninety-five patients with esophageal cancer were retrospectively analyzed."1.39Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis. ( Domagk, D; Domschke, W; Heinzow, HS; Kucharzik, T; Meister, T; Seifert, H; Tsepetonidis, S; Wolters, H, 2013)
"The survival rates of esophageal cancer treated with DCRT in North West of Iran is poor; therefore, early detection and improved treatment methods, with clinical trials are a high priority."1.39Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran. ( Ghojazadeh, M; Jangjoo, AG; Mirinezhad, SK; Mohammadzadeh, M; Naseri, AR; Nasiri, B; Seyednezhad, F; Somi, MH, 2013)
"Almost all gastric cancers are adenocarcinomas, which have considerable heterogeneity among patients."1.39Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil. ( Boussioutas, A; Chua, C; Das, K; Deng, N; Feng, Z; Flotow, H; Goh, LK; Guan, YK; Ivanova, T; Lee, M; Lei, Z; Lim, TK; Manesh, S; Ngo, A; Ooi, CH; Pattison, S; Rozen, SG; So, JB; Tan, E; Tan, IB; Tan, P; Teh, BT; Wu, J; Zhang, S; Zouridis, H, 2013)
"Postoperative complications have had occurred in 12."1.39[Immediate results of complex treatment of resectable rectal neoplasms of distal localization]. ( Basheev, VKh; Bondar', GV; Sovpel', IV; Sovpel', OV; Zolotukhin, SÉ, 2013)
"Patients with advanced gastric cancer receiving chemotherapy were retrospectively collected, and divided into two groups."1.39Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer. ( Huang, XE; Qian, YD; Wang, L; Xiang, J; Xu, HQ; Xu, X, 2013)
"Management of locally advanced rectal cancer is complex because curative treatment routinely involves administration of surgery, chemotherapy, and radiation."1.39Evolving role of neoadjuvant therapy in rectal cancer. ( Schrag, D, 2013)
" Simultaneous heterozygous UGT1A1 28 and UGT1A1 6 polymorphisms may produce higher exposure to SN-38 and a higher risk of adverse effects related to irinotecan."1.39Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms. ( Ge, FJ; Lin, L; Liu, ZY; Sharma, MR; Wang, Y; Xu, JM, 2013)
"Because the gastric cancer was HER2-positive, she was treated with trastuzumab plus capecitabine plus cisplatin(XP)chemotherapy as third-line treatment."1.39[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment]. ( Fuyuki, A; Hata, Y; Kanoshima, K; Kuriyama, H; Kuwabara, H; Matsuura, T; Murata, Y; Taniguchi, R; Tomeno, W; Uchiyama, T, 2013)
"A total of 507 patients with rectal cancer underwent RT at HKL."1.39Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience. ( Lau, FN; Lee, WC; Phua, VC; Yusof, MM, 2013)
"Eighteen patients with rectal cancer and synchronous liver metastases, who had undergone laparoscopic colorectal resection and simultaneous treatment for liver metastases, were retrospectively reviewed."1.39The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy. ( Chen, F; Chen, K; Ding, XM; Hu, BS; Leng, JJ; Tan, HM; Tan, JW; Zhu, Z, 2013)
"DNA from 143 esophageal cancer patients, 63 receiving neoadjuvant therapy and 80 receiving primary surgery, was analyzed for the following polymorphisms: the GSTM1 null, GSTT1 null, and GSTP1 Ile105Val (rs16953) in glutathione S-transferase (GST) family, 2 in thymidylate synthase (TS) gene, and the ERCC1 Asn118Asn (rs11615), ERCC1 C8092A (rs3212986), XPD/ERCC2 Asp312Asn (rs1799793), and XPD/ERCC2 Lys751Gln (rs13181) of the nucleotide excision repair pathway."1.39ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy. ( Alfieri, R; Amadori, A; Ancona, E; Basso, D; Boldrin, E; Cagol, M; Castoro, C; Cavallin, F; Rumiato, E; Ruol, A; Saggioro, D, 2013)
"Fecal incontinence was assessed by patient self-reported data without the use of a validated score."1.39Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer. ( Buchner, S; Dinnewitzer, A; Jäger, T; Nawara, C; Öfner, D; Wolfgang, H, 2013)
"Clinical data of 311 node-negative gastric cancer patients who underwent potentially curative gastrectomy with more than 15 lymph nodes resected, from January 2002 to December 2006, were analyzed retrospectively."1.39Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer. ( Deng, JY; Liang, H; Wang, XN; Xue, Q; Zhang, RP, 2013)
"Most (90%) patients with brain metastases were diagnosed within 24 months of surgery."1.39Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. ( Ajani, JA; Bhutani, MS; Blum, MA; Campagna, MC; Correa, AM; Hofstetter, WL; Komaki, R; Lee, JH; Maru, DM; Rice, DC; Skinner, H; Sudo, K; Swisher, S; Taketa, T; Wadhwa, R; Weston, B, 2013)
"MC was found in 12."1.39Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma. ( de Hingh, IH; de Wilt, JH; Hugen, N; Lemmens, VE; Nagtegaal, ID; Pruijt, JF; Radema, SA; Verhoeven, RH, 2013)
"Of all patients operated for rectal cancer, 27."1.39Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications. ( Fietkau, R; Gock, M; Klar, E; Klautke, G; Prall, F; Rau, B; Schiffmann, L; Wedermann, N, 2013)
"Capecitabine (CA) is an orally administered fluoropyrimidine carbamate which is preferentially converted to active 5-FU and is one of the agents used instead of FU in such cases."1.39Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma? ( Isikli, L; Yoney, A, 2013)
"However, the role of Nrf2 in gastric cancer (GC) remains incompletely understood."1.39Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer. ( Feng, XS; Gao, SG; Hu, XF; Peng, XQ; Wang, XS; Yang, YT; Yao, J, 2013)
"Time to recurrence (TTR) was the primary end point of the study, Kaplan-Meier curves and log-rank tests were used to assess the association between timing of the AC and TTR."1.39Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care. ( Barzi, A; Lenz, HJ; Sadeghi, S; Senagore, A; Shabihkhani, M; Thara, E; Yang, D; Yu, S, 2013)
"The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4."1.39[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy]. ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013)
"A 69-year-old man diagnosed with lower rectal cancer was referred to our hospital."1.39[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer]. ( Fujiwara, Y; Gotoh, K; Ishikawa, O; Kishi, K; Marubashi, S; Motoori, M; Noura, S; Ohigashi, H; Ohue, M; Shingai, T; Sueda, T; Takahashi, H; Tomita, Y; Yano, M, 2013)
"Synchronous gastric and pancreatic cancers represent a very rare association."1.39Double pancreatic and gastric adenocarcinomas: a rare association. ( Cuenod, CA; Dubreuil, O; Fabre, M; Kourie, HR; Landi, B; Markoutsaki, N; Palazzo, L; Rahmi, G; Rougier, P; Roussel, H; Taieb, J; Van der Stiegel, M, 2013)
"Twenty patients with esophageal cancer were treated with trimodal therapy (CRT plus surgery) and underwent [(18)F]FDG-PET/CT scans both before (pre-CRT) and after (post-CRT) CRT."1.39Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy. ( Chen, W; D'Souza, WD; Feigenberg, S; Kim, G; Kligerman, S; Lu, M; Lu, W; Suntharalingam, M; Tan, S, 2013)
"Patients with small residual tumors (≤3 cm) radiologically staged ycT0-2N0 were treated by transanal endoscopic microsurgery."1.39Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution. ( Bianchi, R; Gama-Rodrigues, J; Habr-Gama, A; Lynn, PB; Perez, RO; Proscurshim, I; São Julião, GP, 2013)
"We report on an 86-year-old woman with colon cancer with liver metastasis who was treated with 5-fluorouracil, folinic acid, and bevacizumab."1.39Cervical extravasation of bevacizumab. ( Boudou-Rouquette, P; Brezault, C; Chaussade, S; Coriat, R; Dhooge, M; Dréanic, J; Goldwasser, F; Mir, O; Perkins, G, 2013)
"To assess the outcome of esophageal cancer according to therapeutic strategy."1.39[Esophageal cancer: outcome according to therapeutic strategy]. ( Capitain, O; Cellier, P; Denis, F; Girault, S; Hamy, A; Mahé, MA; Mesgouez-Nebout, N; Paumier, A; Poirier, AL; Rousseau, D, 2013)
"Patients who had squamous cell carcinoma (SCC) or adenocarcinoma (AC) were treated in four referral centers in the north-east Netherlands with definitive chemoradiotherapy (dCRT) or radiotherapy (dRT) between 1996 and 2008."1.39Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands. ( Beukema, JC; Burgerhof, JG; Hospers, GA; Langendijk, JA; Muijs, CT; Mul, VE; Muller, K; Paardekooper, G; Plukker, JT; Smit, JK; Timmer, PR; van Dijk, BA; Woutersen, D, 2013)
"A total of 93 Stage II-III rectal cancer patients were genotyped using peripheral blood samples."1.38X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients. ( Anido, U; Balboa, E; Barros, F; Bernardez, B; Carracedo, A; Duran, G; Gomez, A; Lamas, MJ; Lopez, R; Rana-Diez, P, 2012)
"5-Fluorouracil (5-FU) has a significant antineoplastic activity and has been used for the management of various malignant neoplasms."1.38Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. ( Çağdaş, M; Çalık, AN; Çeliker, E; Güzelburç, Ö; Velibey, Y, 2012)
"Patients with resected pancreatic cancer (PC) have a poor prognosis."1.38Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience. ( Gill, S; Kim, C; Owen, D, 2012)
" SERMS are a safe and effective intervention in dysphagic patients undergoing neoadjuvant chemotherapy for esophageal cancer."1.38Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. ( Gilani, SQ; Jain, PK; Pellen, MG; Razack, A; Sabri, S, 2012)
"Patients with locally unresectable pancreatic cancer (AJCC stage III) have a median survival of 10-14 months."1.38Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. ( Allen, PJ; Bickenbach, KA; Brennan, MF; D'Angelica, MI; Dematteo, RP; Fong, Y; Gonen, M; Goodman, K; Jarnagin, WR; O'Reilly, E; Tang, LH, 2012)
"To study the efficacy of low-dose-rate californium-252 ((252)Cf) neutron intracavitary afterloading radiotherapy (RT) combined with external pelvic RT for treatment of cervical cancer."1.38Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer. ( Lin, S; Liu, JR; Pan, SD; Xu, HD; Yue, JH; Zhang, M, 2012)
"The prognosis of stage IVB cervical cancer is generally poor."1.38Outcomes and toxicities for the treatment of stage IVB cervical cancer. ( Hwang, JH; Kang, S; Kim, JY; Lim, MC; Park, SY; Seo, SS, 2012)
"Survival for patients with pancreatic cancer remains poor."1.38Intensity-modulated radiotherapy for pancreatic adenocarcinoma. ( Abelson, JA; Chang, DT; Chung, M; Fisher, GA; Ford, JM; Koong, AC; Kunz, P; Minn, AY; Murphy, JD; Norton, JA; Poultsides, GA; Visser, BC, 2012)
"ACA in locally advanced cervical cancer had poorer response rate from treatment and also used longer time to achieve CR than SCC."1.38Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. ( Katanyoo, K; Manusirivithaya, S; Sanguanrungsirikul, S, 2012)
"In spite of advances in rectal cancer surgery and the use of preoperative 5-fluorouracil-(5-FU) based chemoradiotherapy (CRT) in stage II and III disease distant metastases still occur in about 35-40% of the patients."1.38Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life. ( Brade, J; Gencer, D; Hofheinz, RD; Hofmann, WK; Horisberger, K; Kienle, P; Kripp, M; Post, S; Welzel, G; Wenz, F; Wieneke, J, 2012)
"One 67 gastric cancer patients with cT2-4 or TanyN1-3M0 between January 2006 and December 2007 were included."1.38Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. ( Dong, B; Du, H; Ji, J; Jia, Y; Liu, Y; Tang, L; Wu, A; Yuan, P, 2012)
"Tegafur is a 5-fluorouracil (5-FU) prodrug widely used outside the United States to treat colorectal cancer as well as cancers of the head and neck."1.38Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin. ( Hurwitz, HI; McManus, TJ; Peer, CJ; Petros, WP, 2012)
"An analysis of 162 rectal cancer patients who underwent curative surgery between 2005 and 2010."1.38Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer. ( Contu, PC; Damin, DC; Ferreira, PR; Kliemann, LM; Rosito, MA; Schwartsmann, G; Tarta, C, 2012)
"Pancreatic cancer has a dismal prognosis."1.38Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer. ( Dicheva, BM; Eggermont, AM; Hop, WC; Koning, GA; Seynhaeve, AL; Ten Hagen, TL; van Dekken, H; van der Zee, JA; van Eijck, CH, 2012)
"A 31-year-old man with sigmoid colon cancer with concomitant simultaneous multiple liver metastases had received FOLFIRI (leucovorin, fluorouracil and irinotecan) and FOLFOX6 (leucovorin, fluorouracil and oxaliplatin) after an ordinary sigmoidectomy."1.38Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. ( Kawahara, H; Kitamura, H; Onda, S; Saito, R; Toyama, Y; Ushigome, T; Watanabe, K; Yanaga, K; Yanagisawa, S; Yoshida, S, 2012)
"One hundred and twenty-eight advanced gastric cancer patients receiving first-line paclitaxel plus capecitabine in Peking University Cancer Hospital from December 2006 to October 2010 were enrolled in the study."1.38Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine. ( Gao, J; Li, Y; Lu, Z; Shen, L; Yu, J, 2012)
"After matching, only CEA and metastasectomy, but not CCRT, were independent prognostic factors."1.38Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer. ( Chang, SC; Chen, WS; Jiang, JK; Lan, YT; Lee, LK; Lin, CC; Lin, JK; Lin, TC; Liu, JH; Teng, HW; Tzeng, CH; Wang, HS; Yang, SH; Yen, CC, 2012)
"A total of 31 patients with advanced gastric cancer was included."1.38The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer. ( Bilici, A; Ercan, S; Gumus, M; Orcun, A; Seker, M; Ustaalioglu, BB; Yilmaz, BE, 2012)
"Irinotecan was given as a combined regimen for median 6 cycles (range, 3-12) and as a single agent for median 3 cycles (range, 1-10)."1.38Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer. ( Akyol, M; Bayoglu, IV; Can, A; Demir, L; Dirican, A; Erten, C; Kucukzeybek, Y; Medeni, M; Somali, I; Tarhan, MO, 2012)
"Unresectable pancreatic cancer (UPC) has low survival."1.38Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation. ( Golden, DW; Liauw, SL; Minsky, BD; Novak, CJ, 2012)
" Recently, fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) demonstrated their superiority in first-line therapy."1.38Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study. ( Chauffert, B; Gentil, J; Ghiringhelli, F; Lorgis, V, 2012)
"Standard treatment for locally advanced rectal cancer (cT3/4 and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil) followed by radical surgical resection."1.38MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. ( Fabian, P; Gombosova, J; Kocakova, I; Nekvindova, J; Radova, L; Sana, J; Slaby, O; Svoboda, M; Vyzula, R, 2012)
"A 71 years old Italian man had type 3 gastric cancer of the greater curvature."1.38Local recurrence of gastric cancer after total gastrectomy: an unusual presentation. ( Amato, B; Cardin, F; Lorenzetti, R; Martella, B; Militello, C; Terranova, C, 2012)
"Several factors may influence pancreatic cancer resistance, and expression of ATP-binding cassette transport proteins is one of the major mechanisms of drug resistance."1.37Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil. ( Grube, M; Guitton, J; Hübner, T; Jedlitschky, G; Köck, K; Kowalczyk, DW; Kroemer, HK; Lerch, MM; Mayerle, J; Mews, S; Nambaru, PK; Payen, L; Rimmbach, C; Ritter, CA; Rosskopf, D; Sendler, M; Weiss, FU, 2011)
"Gastric cancer is the third most common cancer worldwide and the second leading cause of cancer deaths."1.37Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer. ( Abou-Alfa, GK; Al-Olayan, A; Kelsen, D; Lowery, M; Naghy, M; Power, D; Saliba, T; Shah, MA; Shamseddine, A; Smyth, E, 2011)
"Between 1997 and 2007, 94 patients with esophageal cancer were treated with chemoradiation in our institute."1.37Chemoradiation for esophageal cancer: institutional experience with three different regimens. ( Aleman, BM; Boot, H; Cats, A; Courrech Staal, EF; Jansen, EP; van Coevorden, F; van Sandick, JW; van Velthuysen, ML, 2011)
"Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease."1.37Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin. ( Peters, GJ; Schneiders, FL; van den Berg, HP; van der Vliet, HJ; Verheul, HM, 2011)
"Fatigue was a prominent long-lasting symptom in these patients."1.37Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer. ( Aarstad, AK; Aarstad, HJ; Hjermstad, MJ; Hurmuzlu, M; Viste, A, 2011)
"Forty-four patients with rectal cancer treated with 5-FU-based preoperative CRT were prospectively enrolled in this study."1.37Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer. ( Choi, J; Choi, SH; Hur, H; Kang, J; Keum, KC; Kim, H; Kim, NK; Lee, KY; Lee, MY; Min, BS; Shin, SJ, 2011)
"We studied 26 gastric cancer patients with lymph node metastasis who underwent gastric resection at the Korea University Guro Hospital from Feb 2007 to July 2008."1.37Metastatic lymph node targeted chemosensitivity test for gastric cancer. ( Jang, YJ; Kim, CS; Kim, JH; Kim, SJ; Mok, YJ; Park, SH; Park, SS, 2011)
"Human colon cancer HT-29 cells were transduced with a pLPCX expression retroviral vector containing green fluorescent protein and neomycin resistance genes."1.37A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor. ( Ding, Y; Jin, H; Sun, Y; Wang, J; Yang, Z; Zhang, S, 2011)
"Patients with rectal cancer, candidates to receive pCRT, were enrolled in a multicenter prospective observational trial."1.37Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study. ( Amato, A; Capirci, C; Cuicchi, D; De Paoli, A; Del Bianco, P; Efficace, F; Nitti, D; Pucciarelli, S; Serpentini, S, 2011)
"Three patients (20%) had grade 3-4 dysphagia in weeks 3-4 and were continued on intravenous fluids and pain medications."1.37Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer. ( Ad, VB; Bar-Ad, V; Both, S; Hwang, WT; Metz, J; O'Dwyer, P; Plastaras, J; Thukral, A, 2011)
"Obesity is a risk factor for the development of esophageal malignancy."1.37Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity. ( Mathew, J; Odell, JA; Stauffer, JA, 2011)
"When capecitabine and melatonin were combined, a well-differentiated pancreatic adenocarcinoma was observed in 10% of animals."1.37Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer. ( Arjona, A; Montilla, P; Muntané, J; Padillo, J; Perea, D; Ruiz-Rabelo, J; Túnez, I; Vázquez, R, 2011)
"Patients with locally advanced rectal cancer treated with neoadjuvant therapy can safely undergo laparoscopic proctectomy with a low rate of complications."1.37Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up. ( Cone, MM; Diggs, BS; Herzig, DO; Lu, KC; Oommen, SC; Rea, JD, 2011)
"Adjuvant chemotherapy in rectal cancer is not well defined."1.37Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer. ( Alfonso, R; Corona, J; Custodio, A; de las Heras, M; Dıaz-Rubio, E; Ortega, L; Puente, J; Rodriguez, L; Sanchez, JC; Sastre, J, 2011)
"Patients with metastatic colorectal cancers have poor outcomes."1.37Changing management and survival in patients with stage IV colorectal cancer. ( Ng, S; O'bichere, A; Platell, C; Tebbutt, N, 2011)
" The incidences of grade 3 or 4 adverse events and grade 2 or greater histopathological sinusoidal injury were significantly higher in the SVI ≥ +30% than in the SVI < +30% group."1.37Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. ( Arai, T; Kobayashi, S; Koike, J; Koizumi, S; Makizumi, R; Miura, K; Miyajima, N; Nakano, H; Otsubo, T; Sakurai, J; Shimamura, T; Yamada, K, 2011)
"Patients with mucinous rectal cancer experienced a lower rate of T-downstaging after PCRT and had a poorer prognosis than did patients with nonmucinous cancer."1.37Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. ( Kim, CW; Kim, JC; Kim, JH; Kim, TW; Lim, SB; Shin, US; Yoon, SN; Yoon, YS; Yu, CS, 2011)
"Next, we showed that nine human colon cancer cell lines established from primary tumors or metastases expressed OX1R mRNA and underwent important apoptosis on orexin-A challenge."1.37Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis. ( Bedossa, P; Descatoire, V; El Firar, A; Fasseu, M; Henin, D; Laburthe, M; Lehy, T; Paradis, V; Rouyer-Fessard, C; Voisin, T; Walker, F, 2011)
"Pelvic schwannomas are rare; it is even more rare for a pelvic schwannoma to occur concurrently with a colon cancer."1.37Synchronous colonic adenocarcinoma and pelvic schwannoma. ( Bai, J; Kleyser-Sugrue, K; Nerenstone, SR; Welch, JP, 2011)
" Despite widespread concern about the successful performance of this procedure following neoadjuvant chemoradiotherapy (NACR) treatment, we hypothesized that safe and effective MIE could be performed in this setting."1.37Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy. ( Ben-David, K; Cendan, JC; Grobmyer, SR; Hochwald, SN; Rossidis, G; Sarosi, GA; Zlotecki, RA, 2011)
"We retrospectively evaluated 333 rectal cancer patients who received preoperative CRT followed by surgery with curative intent between January 2000 and December 2006."1.37Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection. ( Kim, CW; Kim, JC; Kim, KH; Lim, SB; Yang, SS; Yoon, SN; Yoon, YS; Yu, CS, 2011)
"Patients with dMMR colon cancers have reduced rates of tumor recurrence, delayed TTR, and improved survival rates, compared with pMMR colon cancers."1.37DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. ( Allegra, C; Foster, NR; Gallinger, S; Kim, GP; Labianca, R; Marsoni, S; Monges, G; Moore, MJ; Sargent, DJ; Sinicrope, FA; Thibodeau, SN; Yothers, G, 2011)
"The most commonly used schedules are 5-FU in combination with CDDP with or without epirubicin (ECF) or docetaxel (TCF) in treatment of MGA patients (pts), independently of HER status."1.37Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment. ( Abbas, F; Adenis, A; Afchain, P; Aparicio, T; Bécouarn, Y; Bouché, O; Desseigne, F; Dorval, E; Edeline, J; Guimbaud, R; Kramar, A; Mitry, E; Romano, O; Samalin, E; Thézenas, S; Ychou, M, 2011)
"It is said that disseminated carcinomatosis of the bone marrow has a poor prognosis, but we were able to obtain a good response in this case by chemotherapy."1.37[Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia]. ( Abiko, S; Gotoh, J; Higashiyama, A; Kawamura, A; Kawamura, N; Kudo, M; Meguro, J; Nagasako, T; Takano, M; Tamaki, T; Tanino, M; Yamamoto, Y; Yonekawa, M, 2011)
"Metastatic colorectal cancer has a low cure rate."1.37Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer. ( Afonso, S; Afonso, V; Stefano, E; Viani, G, 2011)
"The finding that some rectal cancers respond to neoadjuvant chemoradiation is broadening new surgical options for the treatment of some of these tumors that, until now, required a total mesorectal excision."1.37Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings? ( Arbea, L; Aristu, J; Baixauli, J; Beorlegui, C; Hernandez-Lizoain, JL; Pastor, C; Sola, J; Subtil, JC, 2011)
" In combination with gemcitabine, median survival was further prolonged."1.37An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine. ( Bhattacharyya, M; Eddouadi, A; Francis, J; Halldén, G; Lemoine, NR, 2011)
"Gemcitabine alone was given to 60 (38%) patients, and gemcitabine with high-dose infusional fluorouracil (5-FU) with (n = 25) or without (n = 39) oxaliplatin was given to 64 (40%) patients."1.37Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials. ( Cheng, AL; Hsu, C; Hsu, CH; Kuo, SH; Kuo, YH; Tien, YW; Yang, SH, 2011)
"In two patients with locally invasive pancreatic cancer, the pancreatic blood supply was altered under angiographic guidance, and an intra-arterial catheter with a subcutaneous port was left in place for the administration of 5-fluorouracil (5-FU) 1,000 mg/m(2)."1.37Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer. ( Anai, H; Hasegawa, M; Kichikawa, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T, 2011)
"Two years later, he was diagnosed for rectal cancer and bilateral lung metastases by TBLB."1.37[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis]. ( Amagasa, H; Ami, K; Ando, M; Arai, K; Fukuda, A; Ganno, H; Kurokawa, T; Nagahama, T; Nakamura, M; Okada, Y; Tei, S; Watayo, Y, 2011)
"A total of 107 patients with advanced gastric cancer treated in our hospital from December 2005 to November 2008 were included in this retrospective analysis."1.37[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis]. ( Ge, FJ; Li, SS; Lin, L; Liu, JZ; Liu, LJ; Wang, Y; Xu, JM; Zhao, CH, 2011)
" Docetaxel, cisplatin, 5-fluorouracil (DCF) is effective, but highly toxic regimen for advanced cases."1.36The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma. ( Abali, H; Budakoglu, B; Güler, T; Odabaşi, H; Oksüzoğlu, B; Ozdemir, NY; Uncu, D; Zengin, N, 2010)
"Advanced gastric cancer (AGC) rarely presents with disseminated intravascular coagulation (DIC) at the time of diagnosis before treatment with no current standard chemotherapy (CTx) regimen."1.36Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis. ( Hamaguchi, T; Hirashima, Y; Kato, K; Nakajima, TE; Okita, NT; Shimada, Y; Shirao, K; Takahari, D; Takashima, A; Yamada, Y, 2010)
"Capecitabine is an oral fluoropyrimidine that was designed to allow selective activation in tumour tissues, thus reducing toxicity."1.36Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. ( Ahmad, A; Gounaris, I, 2010)
"Patients with histologically proven gastric cancer and measurable metastatic disease received docetaxel 75 mg/m(2) as a 1-h intravenous infusion on day 1, and oral etoposide 50 mg/m(2) once daily on days 1-5, every 3 weeks until disease progression or unacceptable toxicities."1.36Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens. ( Alici, S; Benekli, M; Buyukberber, S; Camci, C; Coskun, U; Dane, F; Gumus, M; Kalender, ME; Kaya, AO; Ozturk, B; Sevinc, A; Uncu, D; Yaman, E; Yildiz, R, 2010)
"Capecitabine was administrated 1,650 mg/m(2)/day, 7 days/week."1.36Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer. ( Aygerinos, K; Baltatzis, G; Bamias, A; Beroukas, K; Boskos, CS; Dimopoulos, MA; Korkolis, D; Lamproglou, I; Liacos, C; Papasavvas, P; Stoupa, E; Terpos, E, 2010)
"The treatment of locally advanced pancreatic cancer varies enormously both within the UK and internationally."1.36Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment. ( Brewster, AE; Crosby, TD; Hudson, E; Hurt, C; Iqbal, N; Joseph, G; Mort, D; Mukherjee, S, 2010)
"Biopsied lung tumor was diagnosed as tubular adenocarcinoma, and CK7(+)/CK20(+)/Cdx-2(-)."1.36Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report. ( Arai, M; Asakage, M; Endo, J; Furukawa, Y; Muto, Y; Nozawa, H; Oka, T; Yamada, Y, 2010)
"Microsatellite instability was observed in all VCMsh2 strains and limited to the intestinal mucosa."1.36An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents. ( Bronson, RT; Clark, AB; Edelmann, W; Fan, K; Hou, H; Jelicks, L; Kucherlapati, MH; Kucherlapati, R; Kunkel, TA; Lee, K; Li, H; Lipkin, M; Nguyen, AA; Rosulek, A; Yang, K, 2010)
"Of 100 patients with locally advanced rectal cancer, 32 were clinically staged as T3N0M0."1.36Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment? ( Ceccarelli, C; Cola, B; Cuicchi, D; Di Fabio, F; Di Tullio, P; Iacopino, B; Lecce, F; Lombardi, R; Martoni, A; Minni, F; Neri, S; Pini, S; Pinto, C; Taffurelli, M; Tardio, ML; Ugolini, G, 2010)
"We established 2 HIF-1alpha knockdown gastric cancer cell lines in order to clarify the role of HIF-1alpha in chemo-resistance against 5-FU."1.36HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy. ( Hashiguchi, K; Hiraki, M; Kai, K; Kitajima, Y; Miyazaki, K; Nakamura, J; Noshiro, H, 2010)
"The BGC-823 gastric cancer cell line was incubated for 48 h with 0."1.36Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells. ( Chen, XM; Huang, ZG; Wang, ZR; Zhang, DW; Zhang, X; Zhu, FS, 2010)
"Using a comprehensive esophageal cancer database, we identified patients who underwent esophagectomy between 1994 and 2008."1.36Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. ( Hoffe, S; Karl, R; Kelley, S; Marcovalerio, M; McLoughlin, J; Meredith, KL; Shah, N; Siegel, EM; Turaga, KK; Weber, JM, 2010)
"Borderline resectable pancreatic cancer is an emerging stage of disease defined by computed tomogrpahy criteria, patient (Katz type B), or disease characteristics (Katz type C)."1.36Management of borderline resectable pancreatic cancer. ( Christians, K; Evans, DB; Lal, A, 2010)
"Capecitabine is an anticancer agent, prodrug of 5 fluorouracil (5-FU) administered orally and with a narrow therapeutic index."1.36[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency]. ( Bontemps, H; Coursier, S; Emptoz, J; Guillermet, A; Martelet, S; Villier, C, 2010)
"Pre-operative chemoradiation in low rectal cancer is not associated with a higher incidence of peri-operative complications and its benefits may include reduction local recurrence."1.36Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers. ( Fan, JF; Law, WL; Lim, YK; Liu, R; Lo, OS; Poon, JT, 2010)
"In patients with stage IV colorectal cancer, liver metastases exhibit a better histological response than primary tumors to OCFL neoadjuvant chemotherapy."1.36Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. ( Andres, A; Gervaz, P; Majno, P; Mentha, G; Morel, P; Roth, A; Rubbia-Brandt, L, 2010)
"The risk of venous thromboembolism has been reported to increase when receiving bevacizumab."1.36Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab. ( Doi, T; Fuse, N; Ikematsu, H; Kaneko, K; Koike, K; Kojima, T; Minashi, K; Mochizuki, S; Ohtsu, A; Tahara, M; Yano, T; Yoshino, T, 2010)
"Adjuvant chemo-radiation for gastric cancer is a standard at our institution and has resulted in few relapses and an interesting median survival."1.36Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. ( Aftimos, PG; Chahine, GY; El Helou, JA; Ghosn, MG; Nasr, DI; Nasr, EA; Nasr, FL; Noun, RJ, 2010)
"We report a case of acute interstitial pneumonitis and respiratory failure occurring in a 69-year-old, previously healthy patient receiving FOLFOX regimen plus cetuximab for colon cancer."1.36Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy. ( Chang, SC; Lai, JI; Lai, YC; Lin, PC; Wang, WS, 2010)
"298 patients with inoperable cancer of the esophagus were identified (16."1.36Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer. ( Belka, C; Ganswindt, U; Haimerl, W; Hölzel, D; Niyazi, M; Schmidt, M; Wolf, M; Zehentmayr, F, 2010)
"Patients with locally advanced pancreatic cancer (LAPC) are most commonly managed with chemotherapy or concurrent chemoradiotherapy (CRT), which may or may not include non-involved regional lymph nodes in the clinical target volume."1.36Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. ( Dickinson, C; Green, MM; Jackson, AS; Jain, P; Price, PM; Saleem, A; Taylor, MB; Valle, J; Watkins, GR; Whitfield, GA, 2010)
"Colorectal cancer is one of the leading malignancies in the world."1.36Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer. ( Fu, ZX; Shen, W; Tu, JK; Wang, XH, 2010)
"To compare the efficacy, time to disease progression (TTP), overall survival (OS) and toxicity of FOLFOX6 and TLF regimens for advanced gastric cancer."1.36[Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer]. ( Deng, YM; Li, LL; Xian, HB; Yu, HB, 2010)
"Eighty five patients with advanced gastric cancer accepted oxaliplatin/5-FU-based chemotherapy as first-line chemotherapy were investigated."1.36[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy]. ( Jiang, J; Jiang, T; Li, QF; Liang, J; Lü, HY; Song, SA; Sun, YY; Yao, RY, 2010)
"Blood test showed severe disseminated intravascular coagulation (DIC)."1.36[mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report]. ( Doi, M; Okamoto, Y; Shinozaki, K; Yamauchi, M, 2010)
"Aprepitant is a very active antiemetic drug for the prevention of delayed nausea and vomiting induced by mFOLFOX6 regimen."1.36[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case]. ( Abe, T; Hachiro, Y; Kunimoto, M, 2010)
"Goblet cell carcinoid of the large intestine is a rare neoplasm, usually located in ascending colon and rectum."1.36Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report. ( Erkasap, S; Ihtiyar, E; Karakaş, BR; Paşaoğlu, O; Yaşar, FN, 2010)
"Patients with nonmetastatic distal rectal cancer treated by neoadjuvant chemoradiation therapy, including 50."1.36Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. ( Gama-Rodrigues, J; Habr-Gama, A; Kessler, H; Marks, J; Perez, RO; Wynn, G, 2010)
" A protocol-defined prohibitive adverse event occurred in 4 patients (6%), including 2 treatment-associated deaths."1.36Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. ( Chen, HX; Christos, P; Hamilton, A; Horvath, L; Kindler, HL; Matulich, D; Ocean, AJ; Polite, B; Sparano, JA, 2010)
" Using the indwelling catheter-port system with the unification of the pancreatic blood supply, we initially conducted an arterial infusion of weekly high-dose 5-FU (1,000 mg/m2/qw) combined with systemic gemcitabine (1,000 mg/m2/qw)."1.36[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report]. ( Anai, H; Hasegawa, M; Kichikawa, K; Maeda, S; Masada, T; Morimoto, K; Nakajima, Y; Nishiofuku, H; Sakaguchi, H; Sho, M; Sueyoshi, S; Tamamoto, T; Tanaka, T; Yamamoto, K, 2010)
"It is important to understand that gastric cancer diagnosed poorly differentiated adenocarcinoma pathologically sometimes occurs duodenal invasion and obstructive jaundice."1.36[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy]. ( Fukuda, S; Hiraki, S; Kawaoka, T; Matsukuma, S; Nagashima, A, 2010)
"A colonoscopy revealed primary rectal cancer."1.36[A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy]. ( Danno, K; Imaoka, S; Inatome, J; Kagara, N; Kanoh, T; Kim, C; Kimura, Y; Monden, T; Nakamura, H; Nakano, Y; Ohnishi, T; Taniguchi, H; Tono, T; Tsukao, Y; Watanabe, A, 2010)
"Colonoscopy detected an advanced rectal cancer."1.36[A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy]. ( Hirakawa, K; Inoue, T; Kubo, N; Maeda, K; Muguruma, K; Murata, A; Nagahara, H; Noda, E; Ohira, M; Tanaka, H; Yamada, N, 2010)
"Local therapy for early rectal cancer is a valid alternative to the classical radical operation, which has a higher morbidity and mortality rate."1.35Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience. ( Baldarelli, M; Bartolacci, S; Grillo Ruggeri, F; Guerrieri, M; Lezoche, E; Mantello, G; Organetti, L, 2008)
"However, G-CSF-producing colorectal cancer (CRC) has never been reported in the English literature."1.35Granulocyte-colony stimulating factor producing rectal cancer. ( Akamo, Y; Funahashi, H; Ochi, N; Sakamoto, M; Satoh, M; Sawai, H; Takahashi, H; Takayama, S; Takeyama, H; Wakasugi, T; Yasuda, A, 2008)
"Patients with localized esophageal cancer (LEC) have diverse outcomes (post-therapy pathologic response, disease-free survival [DFS], and overall survival [OS]) after preoperative chemoradiation (P-CTRT), dictated also by inherent molecular heterogeneity."1.35Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus. ( Ajani, JA; Arora, R; Bhutani, MS; Correa, AM; Hofstetter, WL; Izzo, JG; Javeri, H; Lee, JH; Liao, Z; Maru, D; McAleer, MF; Swisher, SG, 2008)
"In patients with metastatic colorectal cancer (mCRC), several prognostic factors such as performance status (PS), number of metastatic sites, carcinoembryonic antigen (CEA), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) have been reported."1.35Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer. ( Asaka, M; Boku, N; Fukutomi, A; Hironaka, S; Machida, N; Onozawa, Y; Taku, K; Yamazaki, K; Yasui, H; Yoshino, T, 2008)
"Locally advanced rectal cancer is frequently treated with neoadjuvant chemoradiotherapy to reduce local recurrence and possibly improve survival."1.35A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. ( Armstrong, J; Beddy, D; Fennelly, D; Gibbons, D; Hyland, JM; Lim, C; Moriarty, M; Sheahan, K; White, A; Winter, DC, 2008)
"Gemcitabine is a pyrimidine antimetabolite with activity in a number of cancers."1.35Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer. ( Cornfeld, D; Lansigan, F; Saif, MW; Shaib, W; Syrigos, K, 2008)
"We report a patient with pancreatic cancer, challenged with maintaining the international normalized ratio (INR) with gemcitabine-capecitabine combination, and later with gemcitabine monotherapy with concomitant warfarin, as well as, a brief review of the literature."1.35Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer. ( Saif, MW; Wasif, N, 2008)
"Two fatal cases of interstitial pneumonitis rapidly evolving to pulmonary fibrosis are reported here."1.35Fatal pneumonitis induced by oxaliplatin. ( Arévalo Lobera, S; Azkue Gabilondo, M; Basterretxea Badiola, L; Egaña Otaño, L; Elejoste Echeberría, I; La Casta Muñoa, A; Melé Olivé, M; Sagastibeltza Mariñelarena, N, 2008)
"Capecitabine is an oral prodrug of 5-fluorouracil (5-FU) chemotherapy and is licensed for the treatment of breast and gastrointestinal cancers."1.35Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion. ( Kolluri, RB; Raouf, S; Tipples, K, 2009)
"While hiccups are usually benign, severe attacks may lead to exhaustion, eating difficulties, and affect quality of life."1.35Severe hiccups during chemotherapy: corticosteroids the likely culprit. ( Gilbar, P; McPherson, I, 2009)
"104 patients with advanced gastric cancers were treated with capecitabine-based chemotherapy regimens from Sept."1.35[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. ( Li, J; Li, Y; Lu, M; Shen, L; Xiao, Y; Zhang, J; Zhang, XD, 2009)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent commonly used in a number of solid malignancies, including colorectal cancer."1.35A case of 5-fluorouracil-induced acute psychosis. ( Alabsi, E; Fakih, M; Fora, A, 2009)
"Forty patients with rectal cancer underwent 5-fluorouracil based chemoradiotherapy followed by curative surgery."1.35Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues. ( Inoue, Y; Kusunoki, M; Miki, C; Saigusa, S; Tanaka, K; Toiyama, Y; Yokoe, T, 2009)
"Patients with locally advanced rectal cancer undergoing preoperative radiotherapy have disparity in pathological tumor regression."1.35[Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma]. ( Ding, PR; Lin, JZ; Pan, ZZ; Wan, DS; Zeng, ZF, 2009)
"Twenty-two specimens of colorectal cancer were collected."1.35[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues]. ( Chen, G; Fu, LW; Liang, YJ; Qiu, HB; Yuan, SQ; Zhang, LY; Zhou, ZW, 2009)
"We experienced this AFP-producing gastric cancer in which CR was possible by FLEP."1.35[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case]. ( Fujii, M; Funada, T; Kaiga, T; Kanamori, N; Kochi, M; Takahashi, T; Takayama, T, 2009)
"A clinical finding was Stage IV gastric cancer of poorly differentiated adenocarcinoma."1.35[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy]. ( Akabane, H; Hanamoto, T; Kita, K; Kuji, M; Miyagi, H; Nakano, S; Oikawa, F; Shomura, H; Takahashi, M; Yanagida, N, 2009)
" Administration of 30 mg/kg CS-706 from Day 7 combined with a single intravenous treatment of 10 mg/kg cisplatin on Day 7 completely regressed the tumors in all tumor-bearing mice examined, whereas only in 1 of 10 mice tumor was regressed with cisplatin treatment."1.35CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents. ( Fujiwara, K; Hanai, M; Inoue, S; Ishida, S; Kimura, T; Kurakata, S; Senzaki, M; Yada, A, 2008)
"Fifty-eight advanced gastric cancer patients with previous chemotherapy were enrolled into the study."1.35The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma. ( Akbulut, H; Boruban, MC; Buyukcelik, A; Demirkazik, A; Icli, F; Onur, H; Sencan, O; Senler, FC; Yalcin, B, 2008)
"Therefore, ERUS-/MRI-staged T3N0 rectal cancer patients should continue to receive preoperative CMT."1.35cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. ( Aristu, JJ; Coco, C; Díaz-González, JA; Guillem, JG; Hernandez-Lizoain, JL; Jeong, SY; Leon, R; Minsky, BD; Nitti, D; Pucciarelli, S; Riedel, ER; Rodriguez-Bigas, MA; Valentini, V; Wong, WD, 2008)
"5-fluorouracil was given as continuous infusion 350 mg/m(2)/day five times weekly, and RHT (BSD-2000 system) was applied twice a week within 1 h after radiotherapy."1.35Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer. ( Buecklein, V; Duehmke, E; Issels, RD; Milani, V; Pazos, M; Rahman, S; Schaffer, M; Schaffer, P; Tschoep, K; Wilkowski, R, 2008)
"The standard adjuvant therapy for rectal cancer is 5-fluorouracil (5-FU) often combined with radiotherapy."1.35A case of 5-fluorouracil-induced peripheral neuropathy. ( De Bleecker, JL; Pauwels, WJ; Werbrouck, BF, 2008)
" There was no toxic death, but 1 patient had long-term complications."1.35The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute. ( Avraham, R; Ayala, H; Luna, K; Marc, W; Tamar, S; Yakir, R, 2008)
"The tumor caused rectosigmoid intussusception and then it prolapsed out through the anus."1.35Rectal prolapse as initial clinical manifestation of colon cancer. ( Chen, CW; Hsiao, CW; Jao, SW; Wu, CC, 2008)
"Capecitabine (Xeloda) is an oral 5-fluorouracil pro-drug used in the treatment of two of the commonest cancers: breast and colorectal."1.35Capecitabine-associated coronary vasospasm: a case report. ( Papadopoulos, CA; Wilson, H, 2008)
"Neoadjuvant treatment modalities for esophageal cancer were developed to improve local tumor control as well as to reduce lymph node metastases and distant metastases in patients with locally advanced esophageal cancer."1.34Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. ( Baldus, SE; Bollschweiler, E; Dienes, HP; Hölscher, AH; Izbicki, JR; König, A; Mueller, RP; Prenzel, KL; Schneider, PM; Schnickmann, C; Schröder, W, 2007)
"Syndrome of DPD deficiency manifests as diarrhea, stomatitis, mucositis, and neurotoxicity and in some cases death."1.34DPYD*2A mutation: the most common mutation associated with DPD deficiency. ( Diasio, RB; Ezzeldin, H; Saif, MW; Sellers, S; Vance, K, 2007)
"Among the patients with T3/T4 gastric cancer, postoperative oral fluorouracil treatment was effective in those who were pAkt-positive."1.34Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy. ( Ikeguchi, M; Katano, K; Murakami, D; Osaki, T; Saito, H; Tatebe, S; Tsujitani, S, 2007)
"Resection of locally recurrent rectal cancer (LRRC) after curative resection represents a difficult problem and a surgical challenge."1.34Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience. ( Asoglu, O; Emek, E; Igci, A; Kapran, Y; Karanlik, H; Kecer, M; Muslumanoglu, M; Ozmen, V; Parlak, M, 2007)
"50 patients diagnosed as advanced gastric cancer were administered continuous infusion of 5-FU (300 mg/m(2)/day, x 14 days) and intermittent infusion of CDDP (3 mg/m(2)/day, day 1-5 and 8-12) before surgery."1.34[Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer]. ( Koda, K; Miyazaki, M; Oda, K; Seike, K; Takano, S; Takiguchi, N, 2007)
"Here, we report the case of a sigmoid colon cancer patient with initially unresectable hepatic metastases showing a prolonged survival (6."1.34[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases]. ( Gega, M; Hashimoto, A; Ikeuchi, H; Kuno, T; Noda, M; Oshima, T; Tanaka, K; Tsukamoto, K; Yagyuu, T; Yamamura, T; Yanagi, H; Yoshikawa, R, 2007)
"Two human colon cancer cell lines (HCT-15 and HT-29) were treated with 5-FU and celecoxib, alone and in combination."1.34Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. ( Bae, YM; Chun, WJ; Lim, YJ; Rhee, JC, 2007)
"5-fluorouracil (5FU) has traditionally been the drug of choice in combination with radiation therapy."1.34Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma. ( Amichetti, M; Caraul, B; Casula, G; Deidda, MA; Dessì, M; Farci, D; Farigu, R; Lay, GC; Maxia, L; Murtas, R; Orrù, S, 2007)
"Endoscopic findings showed Type 3 gastric cancer with pyloric stenosis."1.34[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil]. ( Ninomiya, M; Nishizaki, M; Sasaki, H; Takakura, N; Yamada, E, 2007)
"He was diagnosed as advanced sigmoid colon cancer which invaded the rectal colon (Ra) and prostate (SI, N 0, P 0, H 0, M (-), cStage IIIa)."1.34[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery]. ( Maezawa, K; Mizukami, H; Nemoto, H; Sanada, Y; Sasaya, S; Yoshizawa, Y, 2007)
"After 10 years, second primary cancer (seven cases) became as important an issue as recurrence of primary gastric cancer (six cases)."1.34Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute. ( Chung, HC; Jeung, HC; Kim, BS; Moon, YW; Noh, SH; Rha, SY; Roh, JK; Yoo, NC, 2007)
"To study the effects of two specific cyclooxygenase inhibitors (SCI), rofecoxib and celecoxib, combined with chemotherapeutic drugs 5-Fu, DDP and VP-16 on gastric cancer cell line BGC-823, and to evaluate whether specific cyclooxygenase inhibitors can be used as a synergetic agent in chemotherapy."1.34[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro]. ( Chen, XM; Feng, JX; Wang, YJ; Zhang, X; Zhu, FS, 2007)
"121 locally advanced middle-low rectal cancer patients were treated with preoperative radiotherapy or chemoradiotherapy followed by surgery after rest of 4 to 6 weeks."1.34[Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer]. ( Cao, WG; Che, JF; Jin, YN; Li, H; Ma, T; Xi, WQ; Xu, HP; Zhao, R, 2007)
" We have applied goshajinkigan (TJ 107) for a case of advanced colon cancer with mFOLFOX 6, and experienced a reduction in numbness, the adverse effect of LOHP."1.34[A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer]. ( Chisato, N; Ebisawa, Y; Kono, T; Mamiya, K; Mamiya, N; Satomi, M, 2007)
"Advanced pancreatic cancer has a poor prognosis."1.34[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. ( Di, LJ; Gong, JF; Jin, ML; Li, J; Shen, L; Zhang, XD, 2007)
"Colon cancer is c-kit positive and responsive to the specific tyrosine kinase inhibitor imatinib."1.34Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation. ( Chalkiadakis, G; Kanakis, I; Karamanos, NK; Kletsas, D; Mavroudis, D; Roussidis, AE; Stahtea, XN; Tzanakakis, GN, 2007)
"Familial Mediterranean Fever is a chronic hereditary disease which is relatively prevalent in the Middle East and is associated with recurrent episodes of serosal, synovial or cutaneous inflammations."1.34Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever. ( Brenner, B; Purim, O; Sulkes, A, 2007)
"101 patients with cervical cancer FIGO IB1-IVB underwent chemoradiation after transperitoneal laparoscopic staging."1.34Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging. ( Bischoff, A; Budach, V; Füller, J; Köhler, C; Marnitz, S; Roth, C; Schneider, A; Wendt, T, 2007)
"In order to develop a model of liver metastasis of human gastrointestinal cancer cells, we examined the potential of 10 human colon and stomach cancer cell lines (HT-29, WiDr, HCT-116, HCT-15, HCC-2998, MKN7, MKN28, MKN45, MKN74 and St-4) to form liver metastases in nude mice."1.34Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells. ( Ishizu, K; Makuuchi, H; Sadahiro, S; Sunose, N; Tsuruo, T; Yamazaki, K; Yamori, T, 2007)
"The standard management of rectal cancer continues to be defined by the results of randomized, clinical trials exploring the optimal timing and use of adjuvant chemotherapy and radiation therapy in relation to surgery."1.34Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal. ( Chao, M; Fong, A; Gibbs, P; Jones, IT; Kipp, D; Lim, L; McLaughlin, S; Millar, JL; Rezo, A; Shapiro, J, 2007)
"Treatment with capecitabine and erlotinib in gemcitabine-refractory patients was associated with an overall objective radiologic response rate of 10% and a median survival duration of 6."1.34Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer. ( Blaszkowsky, LS; Clark, JW; Enzinger, PC; Fuchs, CS; Kulke, MH; Kwak, EL; Lawrence, C; Meyerhardt, JA; Muzikansky, A; Ryan, DP; Zhu, AX, 2007)
"In one matched gastric cancer sample pair, the serial analysis of gene expression (SAGE) experiment was conducted to compare the gene expression profiles between cancerous and adjacent tissues."1.34Upregulated expression of S100A6 in human gastric cancer. ( Dong, H; Gao, HJ; Han, JS; Jiang, CL; Wu, JX; Wu, YL; Xiao, HS; Yang, YQ; Zhang, LJ; Zhang, QH; Zhu, ZG, 2007)
" The adverse effect included grade 3 or grade 4 leukopenia in 12."1.34[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers]. ( Bai, P; Li, XG; Ma, SK; Wu, LY; Zhang, R; Zhang, WH, 2007)
" 60Co gamma-irradiation or 6MVX-ray with conventional fraction were used for radiotherapy with a total volume dosage of 55-70 Gy."1.34[Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus]. ( Han, JQ; Li, XQ; Liang, RX; Liu, Q; Qu, FS; Sun, YH; Yan, TX, 2007)
"Capecitabine has shown efficacy in treatment of metastatic pancreatic cancer."1.34Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? ( Diasio, R; Johnson, M; Kang, SP; Ledbetter, L; Saif, MW; Steg, A, 2007)
" The dosage of FOLFOX 4 was reduced after three courses due to neutropenia and diarrhea."1.34[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy]. ( Fujisawa, M; Ishibiki, Y; Ishiyama, S; Kitabatake, T; Kojima, K; Machida, M; Nakayama, Y; Nitta, S; Ono, S; Shinjou, K; Urao, M, 2007)
"Surgery was performed for sigmoid colon cancer on September 29, 2004."1.34[A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy]. ( Akamatsu, M; Katamoto, T; Matsubara, S; Nakata, W; Ohata, K; Ohmae, T; Tsuji, Y, 2007)
"We report two cases of advanced low rectal cancer, with preoperative chemo-radiation therapy leading to a complete histological response."1.34[Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response]. ( Fujita, H; Jida, M; Kubo, M; Maeda, H; Mizuta, M; Shirakawa, K; Sogabe, O; Udaka, T; Waki, N, 2007)
"AI of human gastric cancer xenografts in nude mice was significantly increased to (9."1.34[Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA]. ( Gu, Y; Li, T; Tang, LD; Yang, JK; You, SF; Zhao, AG; Zhao, HL, 2007)
"For inoperable pancreatic cancer, the goals of treatment are to palliate symptoms and prolong life."1.34Inoperable pancreatic cancer: standard of care. ( Benson, AB; Small, W; Wahl, AO; Wisinski, KB, 2007)
"The major clinical problem was the deep venous thrombosis related to the central venous catheter, which occurred in 5 patients (17%)."1.33Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. ( Cantore, M; Caudana, R; Fiorentini, G; Lombardi, M; Mambrini, A; Nicoli, N; Pennucci, C; Rabbi, C; Sanguinetti, F; Zamagni, D, 2005)
"3%), no toxic death, and only one grade 3 neutropenia (4."1.33Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients. ( Artru, P; Atlan, D; Bouché, O; Dahan, L; Lledo, G; Mitry, E; Nguyen, T; Richard, K; Ries, P; Rougier, P; Seitz, JF, 2005)
"Most patients (95%) had histology of squamous cell carcinoma."1.33Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan. ( Inoue, T; Kawaguchi, A; Kodaira, T; Maebayashi, K; Mitsuhashi, N; Nakamura, K; Ogawa, K; Shinoda, A; Teshima, T; Toita, T; Uno, T, 2005)
" 5-FU serum concentrations were higher at night time and the peak concentration of 5-FU was obtained at 3 a."1.33[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report]. ( Hatakeyama, K; Muneoka, K; Shirai, Y; Wakai, T; Yokoyama, N, 2005)
"Patients with rectal cancer treated by preoperative chemoradiation showed a surprisingly low rate of micrometastasis detection (7%), even in high-risk patients (T3 and T4 tumors)."1.33Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy. ( Coelho Siqueira, SA; Gama-Rodrigues, JJ; Habr-Gama, A; Kiss, DR; Nishida Arazawa, ST; Perez, RO; Rawet, V, 2005)
" After three cycles of chemotherapy over a 10-week period, the patient's dosage requirements returned to her baseline level (before treatment with 5-fluorouracil and leucovorin had started)."1.33Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy. ( Davis, DA; Fugate, SE, 2005)
"Complete response (no residual tumour, TRG 1) was seen in 7% of the patients (3/44) and total or major regression (TRG 1-3) in 73% of the patients (32/44) treated with 50-Gy chemoradiation."1.33Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. ( Jantunen, I; Juhola, M; Kairaluoma, M; Kellokumpu, I; Vironen, J, 2005)
"An HCT-8 colorectal cancer cell line was used and a high concentration of 5-Fluorouracid (5-FU) was introduced at the beginning to induce drug resistance, then the concentration of 5-FU was increased in gradients."1.33Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line. ( Bu, LM; Han, Y; Ji, X; Liu, CY; Wang, ZH, 2005)
"Treatment of locally advanced pancreatic cancer with high-dose radiotherapy has not been curative, and can be difficult to tolerate."1.33Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas. ( Abbruzzese, JL; Crane, CH; Delclos, ME; Evans, DB; Ho, L; Tamm, EP; Wolff, RA; Wong, AA; Xiong, HQ, 2005)
"5-Fluorouracil (5-FU) has demonstrated activity against colorectal cancer, leading to apoptosis of neoplastic cells."1.33Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells. ( Ashktorab, H; Dawkins, FW; Larbi, D; Mohamed, R; Smoot, DT, 2005)
"Male breast cancer is very rare, especially inflammatory breast cancer, which is an aggressive, rapidly proliferating manifestation of primary breast carcinoma."1.33Inflammatory breast cancer in a male. ( Choueiri, MB; El Saghir, NS; El-Hajj, II; Otrock, ZK; Tawil, AN, 2005)
"Intersphincteric resection of low rectal tumors is a surgical technique extending rectal resection into the intersphincteric space."1.33Technique and long-term results of intersphincteric resection for low rectal cancer. ( Feil, W; Hölbling, N; Holzer, B; Novi, G; Renner, K; Rosen, HR; Schiessel, R; Urban, M, 2005)
"We tested the hypothesis that rectal tumors are most responsive to neoadjuvant therapy if they possess p53 and/or caspase 8 activity."1.33Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways. ( Coppola, D; Kelley, ST; Marcet, J; Yeatman, T, 2005)
"The use of chemoradiotherapy for pancreatic cancer has been advocated for its potential ability to downstage locally advanced tumors."1.33Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas. ( Adhoute, X; Béllannée, G; Brunet, R; Collet, D; Laurent, C; Masson, B; Rault, A; Sa Cunha, A; Vendrely, V, 2005)
"Pseudomembranous colitis is frequently associated with antibiotics and more rarely with chemotherapeutic agents such as 5-fluorouracil."1.33Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil. ( Aranda Aguilar, E; de la Haba Rodríguez, JR; Gómez España, MA; Méndez Vidal, MJ; Morales Chamorro, R; Rubio Pérez, MJ; Serrano Blanch, R, 2005)
"Twenty-two patients with localized esophageal cancer suitable for curative chemoradiation therapy and 24 patients suitable for palliative therapy were enrolled."1.33Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin. ( Burmeister, BH; Burmeister, EA; Gotley, DC; Harvey, JA; Mark Smithers, B; Thomas, J; Thomson, DB; Walpole, ET, 2005)
"The role of second-line chemotherapy in gastric cancer is not yet established."1.33Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy. ( Köster, W; Müller, C; Stahl, M; Wilke, H, 2005)
"HDRBT is safe and beneficial for local control in the radical treatment of patients with esophageal cancer."1.33The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy. ( Burtin, P; Corns, R; David, M; Devic, S; Evans, M; Faria, S; Mayrand, S; Parent, J; Szego, P; Vuong, T, 2005)
"Capecitabine is an oral prodrug to 5-fluorouracil (5-FU)."1.33Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma. ( Hoeffding, LD; Jakobsen, A; Lindebjerg, J; Nielsen, JN, 2005)
"To investigate the effect and feasibility of concurrent radiation and chemotherapy combined with endorectal brachytherapy in T3 rectal cancer with complete pathologic remission as end point."1.33Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost. ( Bisgaard, C; Hansen, JW; Jakobsen, A; Lindebjerg, J; Mortensen, JP; Rafaelsen, SR, 2006)
"A 54-year-old woman who had ascending colon cancer with multiple liver and lung metastases underwent rt."1.33[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11]. ( Fujii, Y; Kobayashi, T; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T, 2005)
"She was diagnosed with advanced cecal cancer with simultaneous multiple liver metastases."1.33[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy]. ( Fujio, N; Fukuda, Y; Ihara, T; Koyama, I; Osugi, H; Takatori, H; Tsukazaki, T; Tsukazaki, Y, 2005)
"Patients who had rectal cancer with a distal margin within 6 cm of the anal verge had the anus included in the field of radiotherapy (Group A, n = 26)."1.33Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency. ( Chao, MW; Gibbs, P; Hiscock, R; Lim, JF; Tjandra, JJ, 2006)
" As adverse effects of the following systemic chemotherapy, three patients had grade 3 anemia and one had grade 3 leukopenia."1.33[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination]. ( Bamba, T; Hanyu, T; Hatakeyama, K; Ishikawa, T; Kanda, T; Kosugi, S; Makino, S; Ohashi, M; Sakamoto, K; Tanabe, T; Yajima, K, 2005)
" We dosed 6 cycles of FEC chemotherapy (CPA 800 mg, EPI 80 mg, 5-FU 750 mg/body x 1 cycle)."1.33[A case of breast cancer detected by MRI mammography after Hollywood syndrome]. ( Amano, S; Enomoto, K; Kitajima, A; Matsuo, S; Negishi, N; Nemoto, N; Oinuma, T; Sakurai, K, 2005)
"Twenty pretreatment biopsy samples from rectal cancer patients and their paired, post-CRT surgical specimens (n = 17) were analyzed."1.33Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. ( El-Hajjar, D; Geradts, J; Groth, J; Iyer, R; Javle, M; Lawrence, D; Watwe, V, 2005)
"The type of genomic instability could influence the prognosis of CRC, in particular in stages II and III."1.33Microsatellite instability and colorectal cancer prognosis. ( Barana, D; Benatti, P; Di Gregorio, C; Gafà, R; Guerzoni, L; Lanza, G; Losi, L; Maestri, I; Maffei, S; Marino, M; Menigatti, M; Oliani, C; Pedroni, M; Ponti, G; Ponz de Leon, M; Roncari, B; Roncucci, L; Rossi, G; Santini, A; Scarselli, A, 2005)
"Fifty-two patients with resectable esophageal cancers (cT2-4, Nx, and M0) received neoadjuvant radiochemotherapy (cisplatin, 5-5-fluorouracil, 36 Gy) followed by transthoracic en bloc esophagectomy."1.33High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer. ( Baldus, SE; Bollschweiler, E; Brabender, J; Dienes, HP; Hoelscher, AH; Ling, FC; Metzger, R; Moenig, S; Mueller, RP; Neiss, S; Schneider, PM; Warnecke-Eberz, U; Xi, H, 2005)
"Celecoxib was initiated in the diet at 100 ppm (equivalent to 20 mg/kg/d p."1.33Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. ( Blanquicett, C; Buchsbaum, DJ; Carpenter, MD; Chhieng, DC; Diasio, RB; Eloubeidi, M; Johnson, MR; Russo, S; Saif, MW; Sellers, JC; Vickers, SM, 2005)
"To evaluate the treatment outcome of radiotherapy combined with cis-diammine-glycolatoplatinum (nedaplatin) plus 5-fluorouracil (5-FU) for esophageal cancer."1.33Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study. ( Igaki, H; Nakagawa, K; Nakamura, N; Ohtomo, K; Sasano, N; Shiraishi, K; Tago, M; Yamashita, H, 2006)
"Patients with bilobar colorectal cancer metastases to the liver present a unique problem in terms of resection."1.33Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved. ( Chaudhury, PK; Horton, PJ; Martinie, JB; Metrakos, P; Rochon, C; Tzimas, GN; Znajda, TL, 2006)
"Progressive respiratory failure developed in a 68 year-old female who was treated with single-agent oxaliplatin for colorectal cancer."1.33Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. ( Colomer, R; Fabregat, MB; Merino, BQ; Puig, J; Soy, E; Yagüe, XH, 2005)
"This study is the first to evaluate esophageal cancer treatment with a pharmacogenetic paradigm and its application of pharmacogenetic analysis to multiple genes in each drug action pathway as a means of developing a more accurate and consistent risk prediction model."1.33Pharmacogenetics in esophageal cancer. ( Ajani, JA; Chiang, SS; Lu, C; Wu, X, 2005)
"One hundred fifteen patients with rectal cancer were treated with oral 5-fluorouracil or Tegafur with preoperative radiotherapy, surgery, and intraoperative electron beam radiation therapy to identify potential pre- and on-treatment characteristics that might be of prognostic value for disease outcome."1.33Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. ( Alvarez, E; Calvo, FA; Cortés, J; Del Valle, E; Díaz-González, JA; García-Sabrido, JL; Gómez-Espí, M; Muñoz-Jiménez, F, 2006)
"5-Fluorouracil is an antineoplastic antimetabolite responsible for a variety of cutaneous reactions."1.33Chronic cutaneous lupus flare induced by systemic 5-fluorouracil. ( Bessis, D; Guillot, B; Kluger, N, 2006)
"To describe oncocytic change in rectal cancers that have been treated with chemoradiation before surgery."1.33Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy. ( Chetty, R; Rouzbahman, M; Serra, S, 2006)
"We report here the case of a coma with a favorable outcome following 5FU chemotherapy."1.33[Coma following chemotherapy: is 5FU implicated? Discussion about on case-report]. ( Heluwaert, F; Hilleret, MN; Martin, C; Martin, D; Santre, C, 2006)
"Stage II-III rectal cancer patients received 2 cycles of bolus 5-FU (425 mg/m2) and leucovorin (LV) (20 mg/m2) on days 1-5 q3w followed by oral capecitabine (800 mg/m2 bid) continuously during pelvic radiotherapy (total 50."1.33Capecitabine chemoradiation for rectal cancer after curative surgery. ( Bajetta, E; Beretta, E; Buzzoni, R; Di Bartolomeo, M; Dognini, G; Ferrario, E; Mancin, M; Mariani, L; Valvo, F, 2006)
"Cyclin D1 ASODN could increase the chemosensitivity to 5-FU, MTX, CDDP in cells."1.33Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells. ( Chen, JH; Han, GX; Shuai, XM; Wang, GB, 2006)
"Adjuvant CRT for gastric cancer, even with conformal RT, is associated with significant toxicity."1.33Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases. ( Brierley, J; Cummings, B; Kassam, Z; Kim, J; Knox, JJ; Lockwood, G; Moore, M; O'brien, C; Oza, A; Ringash, J; Siu, L; Swallow, C; Wong, R, 2006)
"The clinical diagnosis of multiple pyogenic granulomas was confirmed by histological examination."1.33Multiple periungual pyogenic granulomas following systemic 5-fluorouracil. ( Cooray, P; Curr, N; Gin, D; Murugasu, A; Saunders, H; Schwarz, M, 2006)
"Thus, patients with a DPD deficiency are at risk of developing severe 5-FU-associated toxicity."1.33Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency. ( Baek, JH; Hong, YJ; Kim, DH; Kim, JG; Kim, SN; Lee, KB; Sohn, SK, 2006)
"Seven patients with gastric cancer were treated with IMRT."1.33Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques. ( Chmura, SJ; Farrey, K; Garofalo, MC; Heimann, R; Jani, AB; Milano, MT; Rash, C, 2006)
"Eligible patients had prostate cancer with clinical evidence of invasion through the prostatic capsule or into the seminal vesicles without evidence of nodal or distant metastasis."1.33Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024. ( Crawford, ED; Faulkner, J; Noble, MJ; O'Rourke, TJ; Quick, DP; Smalley, SR; Stephens, RL; Swanson, GP; Thompson, IM; Weiss, GR, 2006)
"Twenty-five chemonaive patients with AGC have been treated with FOLFIRI regimen consisting of irinotecan 180 mg/m(2) over 30 min on day 1 combined with leucovorin 200 mg/m(2) over 2 h followed by 5-fluorouracil 400 mg/m(2) as bolus and 600 mg/m(2) as a 22-hour infusion on day 1 and 2."1.33Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy. ( Alacacioglu, A; Oztop, I; Somali, I; Tarhan, O; Yaren, A; Yilmaz, U, 2006)
"HCT116 colon cancer cells were treated with docetaxel, flavopiridol, and 5-FU in several different administrative schedules in vitro, either sequentially or simultaneously."1.33Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil. ( Becerra, CR; Frenkel, EP; Fu, YC; Guo, J; Tripathy, D; Verma, UN; Zhou, AW, 2006)
"Human pancreatic cancer cells HPAF-II and Capan-1, and endothelial cells HMEC-1 and HUVEC were used in this study."1.33Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting. ( Campbell, RB; Kalra, AV, 2006)
"Although patients with locally advanced pancreatic cancer (LAPC) have an extremely poor prognosis, they are a heterogeneous group."1.33Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation. ( Abbruzzese, JL; Crane, CH; Das, P; Delclos, ME; Evans, DB; Gould, MS; Guha, S; Janjan, NA; Krishnan, S; Palla, S; Rana, V; Varadhachary, G; Wolff, RA, 2006)
" After that his general condition recovered, and two cycles of neoadjuvant chemotherapy (NAC) by irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) therapy were performed on an outpatient basis."1.33[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)]. ( Fukada, T; Hasegawa, A; Hashimoto, R; Hayashi, T; Kametaka, H; Kawano, H; Koyama, T; Seike, K; Tanaka, H; Yasuno, K, 2006)
"Forty-two patients with invasive breast carcinoma received 4 cycles of anthracycline based neoadjuvant chemotherapy."1.33Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study. ( Arslan, M; Demiray, M; Ercan, I; Evrensel, T; Gokgoz, S; Manavoglu, O; Saraydaroglu, O; Ulukaya, EE, 2006)
"As leukopenia was seen after the first cycle, the administration doses were reduced and GTX has been continued for a total 13 cycles."1.33[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine]. ( Fukuhara, T; Honda, K; Kobayashi, N; Kojima, Y; Kushihata, F; Tanaka, H, 2006)
"An advanced colon cancer of the cecum was found with a colonoscopy."1.33[A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. ( Handa, R; Iijima, S; Kato, T; Kikkawa, N; Kurokawa, E; Miyake, Y; Oshima, K; Oshima, S; Yamamoto, H, 2006)
" Resection of liver metastases from SBA combined with neoadjuvant and adjuvant chemotherapy can result in extended disease-free survival and should undergo further investigation."1.33Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report. ( Eigenbrod, T; Klebl, F; Kullmann, F, 2006)
"In patients with locally advanced rectal cancer located 3-6 cm from anal verge who are traditionally treated with abdominoperineal resection, preservation of anal sphincter after preoperative chemoradiation therapy plus complete rectal excision with coloanal anastomosis is feasible and is associated with acceptable morbidity and no mortality."1.32Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis. ( Fernández, R; Gutiérrez De La Barrera, M; Hernández-Pacheco, F; Labastida, S; Luna-Pérez, P; Rodríguez-Ramírez, S, 2003)
"The prognosis and QOL of unresectable pancreatic cancer are very poor."1.32[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1]. ( Endo, W; Fujito, T; Goda, F; Hojo, S; Maeura, Y; Matsuyama, J; Yamazaki, K; Yano, Y, 2003)
"A remission of lymph node metastasis was accurately shown by rES in 17/19 cases (90%) and by CT in 10/12 cases (83%)."1.32[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?]. ( Becker, H; Füzesi, L; Ghadimi, BM; Jakob, C; Langer, C; Liersch, T; Markus, PM; Müller, D; Siemer, A, 2003)
"Adenocarcinoma of the female urethral diverticulum is rare and has been treated by surgery and/or radiation."1.32Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy. ( Awakura, Y; Fukuyama, T; Itoh, N; Maeno, A; Nonomura, M, 2003)
"Human esophageal cancer cells NEC and human lung adenocarcinoma cells GLC were cultured and then inoculated into the wells."1.32[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells]. ( Huang, J; Jiao, SC; Lu, SX; Sun, Y, 2003)
"Drugs pharmacokinetic control is a usual practice in case of flat continuous infusions."1.32[Modeling 5-FU clearance during a chronomodulated infusion]. ( Chevalier, V; Chevrier, R; Chollet, P; Cure, H; Kwiatkowski, F; Richard, D, 2003)
"These data in a heavily pretreated patient population confirm that oxaliplatin is safe when used as a single agent or with a variety of FU-based regimens as salvage therapy in patients with advanced colorectal cancer."1.32Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer. ( Clark, JW; Gococo, KO; Haller, DG; Kardinal, CG; Kemeny, NE; Lenz, HJ; Mitchell, EP; Ramanathan, RK, 2003)
" At both institutions, concurrent chemotherapy consisted of a continuous infusion of 5-fluorouracil (5-FU) at a dosage of 1500 mg/m(2)/week."1.32The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer. ( Birnbaum, EH; Chandra, A; Crane, CH; Delclos, ME; Feig, BW; Fleshman, JW; Janjan, NA; Kodner, IJ; Lin, EH; Lockett, MA; Myerson, RJ; Phan, T; Picus, J; Read, TE; Singh, AK; Skibber, JM; Thames, HD, 2003)
" Furthermore, he was administered tegafur/uracil (400 mg/day) 5 days weekly as pharmacokinetic modulating chemotherapy (PMC)."1.32[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy]. ( Baba, Y; Hayashi, S; Ishikawa, T; Kamimura, T; Nomura, K; Oota, H; Yoshida, T, 2003)
" Pharmacokinetic modulating chemotherapy (PMC) was performed after the operation."1.32[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy]. ( Futamura, N; Matsutomo, M; Sakamoto, K; Tateyama, K; Yasumura, M, 2003)
"3R allele in colorectal cancer was subdivided into around half by the SNP, indicating its commonness among Japanese."1.32Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene. ( Kawakami, K; Watanabe, G, 2003)
"Case 1 A 40-year-old female with gastric cancer located in the MULE area underwent total gastrectomy with D3 lymph node dissection on June 2, 1989."1.32[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection]. ( Arai, K; Horiguchi, S; Iwasaki, Y; Katayanagi, S; Matsumoto, H; Miyamoto, H; Nishioka, K; Takahashi, K; Yamaguchi, T, 2003)
"We report a case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP."1.32[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. ( Akiyama, N; Arai, F; Funakoshi, K; Inayoshi, J; Kato, T; Motoyama, H; Tasaki, A, 2003)
" After the operation, weekly bolus of 5-fluorouracil combined with levofolinate was carried out."1.32[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil]. ( Inoue, M; Jingu, K; Nakajima, Y; Ochiai, T, 2004)
"Endoscope and CT scan revealed type 3 gastric cancer with paraaortic lymph nodal metastasis."1.32[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU]. ( Fujita, K; Gotoh, M; Hirata, I; Hongo, H; Katsu, K; Kawabe, S; Ohta, S; Takiuchi, H, 2004)
"Under a diagnosis of advanced ileocecal colon cancer with metastases to Virchow's and the paraaortic lymph nodes, ileocecal resection was performed."1.32[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy]. ( Kathou, T; Maruyama, H; Mio, H; Sekiya, M; Yamada, T, 2004)
"A 58-year-old man who had colon cancer with liver and multiple lung metastases underwent ileocecal resection on May 10, 2002."1.32[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11]. ( Fujii, M; Kasakura, Y; Kobayashi, M; Kochi, M; Morishita, Y; Sato, K; Takayama, T, 2004)
" He was treated with pharmacokinetic modulating chemotherapy (PMC) and low-dose CPT-11."1.32[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11]. ( Aihara, T; Fukuhara, A; Kouno, T; Murayama, M; Nakagawa, K; Nakamura, E; Niida, M; Nishimoto, Y; Nozaki, H; Syouda, S; Watanabe, Y; Yagyu, T; Yasuoka, H, 2004)
"Rare reports of intestinal obstruction have been confined to the stiff plastic and stainless-steel stents."1.32A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex). ( Ho, HS; Ong, HS, 2004)
"We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin."1.32[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. ( Aoki, T; Ichimiya, H; Kato, K; Katsumata, K; Okada, K; Wakana, Y, 2004)
"Human colon cancer cells were implanted s."1.32Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer. ( El-Salhy, M, 2004)
"Capecitabine was given at 1,600 mg/m(2)/day in two divided doses, 5 days per week, concurrently with radiotherapy."1.32Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. ( Ben-Josef, E; Bossenberger, T; Burmeister, J; El-Rayes, BF; McDermott, P; Philip, PA; Shields, AF; Vaishampayan, U; Vaitkevicius, V, 2004)
"Sigmoidectomy was performed for sigmoid colon cancer in 1991."1.32[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy]. ( Beppu, T; Doi, K; Egami, H; Ishiko, T; Morinaga, H; Nakagawa, M; Sugiyama, S; Tanaka, H; Yamane, T, 2004)
"For synchronous liver metastases from rectal cancer, after extirpation of the primary lesion, a transcatheter arterial embolization was postoperatively performed 3 times at 6-month intervals."1.32[Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report]. ( Ishimaru, S; Kanayama, T, 2004)
"Mitomycin and cisplatin were highly effective to prevent peritoneal carcinomatosis (direct application immediately after tumor cell transfer - 1 (st) treatment group)."1.32[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis]. ( Fenske, A; Hribaschek, A; Krüger, S; Lippert, H; Meyer, F; Pross, M; Ridwelski, K, 2004)
"Stage 0 rectal cancer disease is associated with excellent long-term results irrespective of treatment strategy."1.32Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. ( Campos, FG; Gama-Rodrigues, J; Habr-Gama, A; Kiss, DR; Nadalin, W; Perez, RO; Ribeiro, U; Sabbaga, J; Silva e Sousa, AH, 2004)
"The use of neoadjuvant chemotherapy for pancreatic cancer has been advocated for its potential ability to optimize patient selection for surgical resection and to downstage locally advanced tumors, especially for patients with Stage IV b (Japan criteria)."1.32[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics]. ( Hirano, H; Ikuma, H; Imai, T; Kadowaki, S; Mitsui, Y; Miyashita, K; Murata, T; Nakamura, T; Nobuoka, Y; Tanigawa, K; Taoka, H; Umino, W; Yamashita, M; Yoshimine, S, 2004)
"After surgical resection of colon cancer, he suffered a multiple liver metastasis."1.32[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery]. ( Hayashi, T; Ishiwatari, H; Kato, J; Kogawa, T; Miyanishi, K; Niitsu, Y; Oku, T; Takada, K; Takahashi, M; Takanashi, K; Takayama, T, 2004)
"Human HCT116 colon cancer cells were stably transfected with the sense or antisense FPGS cDNA or blank (control)."1.32Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Moskovitz, DN; Novakovic, P; Smirnakis, F; Sohn, KJ; Yates, Z, 2004)
"We performed radio-frequency ablation (RFA) therapy combined with intra-arterial chemotherapy for a 71-year old female gastric cancer patient with liver metastasis."1.32[A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy]. ( Imaizumi, H; Kamei, K; Kosaka, T; Nakano, Y; Takashima, S; Ueno, K; Usami, K, 2004)
"Twenty patients with advanced gastric cancer received biweekly regimen of CF/5-FU/PTX (200 mg/m(2) of CF, intravenous infusion for 2 h, day 1; 500 mg/m(2) of 5-FU, intravenous injection, day 1; 1 500 mg/m(2) of 5-FU, intravenous infusion for 46 h, day 1, 2; 90 mg/m(2) of PTX, intravenous infusion for 3 h,day 1)."1.32[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer]. ( Feng, JF; Lu, JW; Sun, XF, 2004)
"Surgical specimens were assessed for rectal cancer regression grade."1.32Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade. ( Cunningham, C; Dodds, E; George, BD; Jones, AC; Mortensen, NJ; Warren, BF; Wheeler, JM, 2004)
"Drug resistance and toxic side effects are major limiting factors in the clinical use of antineoplastic chemotherapy."1.31Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2. ( Aulmann, M; Dihlmann, S; Eisold, S; Linnebacher, M; Ridder, R; Ryschich, E; Schlehofer, JR; Schmidt, J; von Knebel Doeberitz, M, 2002)
"Objective responses in colorectal cancer patients were: 1st-line MdG (22 assessable): PR=36%, NC=32%, PD=32%."1.31A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer. ( Cheeseman, SL; Chester, JD; Dent, JT; Joel, SP; Richards, FJ; Seymour, MT; Wilson, G, 2002)
"Capecitabine (Xeloda) is a new orally administered fluoropyrimidine carbamate that was rationally designed to exert its effect by tumor-selective activation."1.31Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. ( Cho, MJ; Kim, JS; Song, KS; Yoon, WH, 2002)
"This report shows a case of advanced gastric cancer that responded to low-dose 5-FU plus CDDP."1.31[A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP]. ( Baba, H; Endo, K; Ikeda, Y; Ishio, T; Kawamoto, K; Kohnoe, S; Okamura, T; Toh, Y; Yamamoto, M, 2002)
"We report a case of inoperable gastric cancer with multiple liver metastases, which responded significantly to the short-term administration of TS-1 following intravenous FMP therapy."1.31[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization]. ( Chinzei, T; Okada, Y; Tasaka, K; Tomofuji, Y, 2002)
"We treated a patient with unresectable rectal cancer with multiple liver, pulmonary and lymph node metastases that responded remarkably to pharmacokinetic modulating chemotherapy (PMC)."1.31[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy]. ( Chiba, M; Hayashi, K; Inaba, Y; Kamio, Y; Koyama, M; Ohe, S; Watabe, S, 2002)
"These results suggest that colon cancer cells with microsatellite instability are more sensitive to 5-FU, whereas more resistant to CDDP."1.31Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines. ( Chen, XX; Huang, Q; Lai, MD; Zhang, YL, 2002)
" We examined the response of three human colon tumors to TRAIL alone and in combination with chemotherapy, using SCID mice engrafted with intact patient surgical specimens."1.31Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice. ( Hylander, BL; Naka, T; Repasky, EA; Rustum, YM; Sugamura, K; Widmer, MB, 2002)
"Six patients with gastric cancer, stage IIIA to IV, received intraabdominal cisplatin (CDDP) at laporotomy."1.31[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion]. ( Kagawa, R; Nakayama, N; Sakata, S; Tada, M; Yamaguchi, T, 2002)
" Administration of modified pharmacokinetic modulating chemotherapy (PMC) using Leucovorin (intravenous infusion of 5-FU, 600 mg/m2/24 hours; oral administration of UFT, Taiho Pharmaceutical Co."1.31[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin]. ( Hatada, T; Inoue, Y; Kobayashi, M; Kusunoki, M; Miki, C; Ojima, E, 2002)
"Compared with adenocarcinoma, squamous cell carcinoma might be a favorable target for 5-FU-based chemotherapy in the treatment of nonsmall-cell lung cancer."1.31Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues. ( Koga, T; Ninomiya, S; Takeo, S; Yano, T, 2002)
"Ovarian metastasis is frequent."1.31Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case. ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002)
"Twenty-four patients with gastric cancers who underwent the intraoperative systemic chemotherapy were taken as controls."1.31[Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer]. ( Chen, D; Lai, Y; Peng, B; Xiao, Q; Zhang, S, 2001)
"112 cases of fresh human gastric cancer samples were obtained for drug sensitivity testing using MTT."1.31[Study on the chemosensitivity test of human gastric cancer using the MTT assay]. ( Chen, J; Chen, Z; Hu, J; Mao, Y; Yan, L; Zou, L, 2001)
"5-Fluorouracil (5-FU) is a drug of standard use in chemotherapy of colon carcinoma."1.31Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil. ( Cordel, S; Goupille, C; Hallouin, F; Le Pendu, J; Meflah, K, 2000)
" Although various dosage regimens of FP therapy have been investigated, there has been a certain limit to the response rate achieved by this therapy, and new protocols have been explored."1.31[Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective]. ( Ashizawa, T; Katsumata, K; Koyanagi, Y; Majima, T; Mori, M; Murohashi, T; Nagashima, K; Sumi, T; Takahashi, S; Yamamoto, K; Yamashita, S, 2000)
"We report a case of unresectable rectal cancer in a 53-year-old male treated with chemoradiation."1.31[Long-term complete response in a case of unresectable rectal cancer following chemoradiation]. ( Musha, N; Oka, K; Saito, H; Sando, N; Sasaki, M; Setu, M; Setu, Y; Sunami, E, 2000)
"Preoperative chemoradiation for pancreatic cancer is associated with low rates of hepatic toxicity and biliary stent-related complications."1.31Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents. ( Abbruzzese, JL; Crane, CH; Evans, DB; Hudec, WA; Janjan, NA; Lahoti, S; Lee, JE; Lenzi, R; Pisters, PW; Raijman, I; Rich, TA; Wolff, RA, 2000)
"It is possible to cure oesophageal cancer with chemo-radiotherapy and selective oesophagectomy, and achieve organ preservation in the majority of long term survivors."1.31Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation. ( Lim, JT; Wilson, KS, 2000)
"5-Fluorouracil (5-FU) was given as a bolus (500-1000 mg/m2/day) during the first and last weeks of RT in 22 patients, whereas continuous 5-FU (225 mg/m2/day) was given to 3 patients."1.31Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results. ( Latona, C; Paulino, AC, 2000)
"5-fluorouracil (5-FU) was given 200 mg/day for 26 days orally."1.31[A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy]. ( Nashimoto, A; Tanaka, O; Yabusaki, H, 2000)
"Data on 45 patients with colorectal cancer were analyzed."1.31Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas. ( Hinoshita, E; Kinukawa, N; Kuwano, M; Maehara, Y; Sugimachi, K; Taguchi, K; Tsuneyoshi, M; Uchiumi, T, 2000)
"Lymph node metastasis was not present."1.31[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report]. ( Iesato, H; Morishita, Y; Nakagami, K; Ohwada, S; Ohya, T; Sasaki, T; Sugitani, K; Takahashi, T; Yokomori, T, 2000)
"In the patients with squamous cell carcinoma, 100 mg/m2 of cisplatin was infused intravenously, followed immediately by five consecutive daily administrations of 5-fluorouracil, 1,000 mg/m2/day, each infused intravenously over 24 hr."1.31Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors. ( Kim, GE; Kim, SN; Kim, SW; Park, TK; Suh, CO, 2000)
"We report a case of advanced rectal cancer accompanied by unresectable liver metastasis in which remission has been achieved for 7 years."1.31[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective]. ( Baba, H; Kikunaga, H; Matsudo, A; Miura, H; Morisue, A; Nakai, H; Osakabe, Y; Sotome, K; Takao, M, 2000)
"Gemcitabine (dFdC) is a prodrug that undergoes metabolism by cytidine deaminase to form an inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU)."1.31Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites. ( Delauter, BJ; Egorin, MJ; Plunkett, W; Ramanathan, RK; Stover, LL; Zamboni, WC; Zuhowski, EG, 2000)
"The oestrogen receptor positive breast cancer cell lines (MCF-7, T47D) demonstrated an increased level of HSP 27 and 70 expression compared with oestrogen receptor negative cell lines (BT20, HBL100)."1.31Heat shock protein expression in human tumours grown in severe combined immunodeficient mice. ( Katoh, M; Koninkx, J; Schumacher, U, 2000)
"A 67-year-old female with rectal cancer and multiple liver metastases underwent low anterior resection by total mesorectal excision (TME), cholecystectomy and hepatic arterial cannulation in June 1995."1.31[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)]. ( Kusunoki, M; Noda, M; Yamamura, T; Yanagi, H; Yoshikawa, R, 2001)
"Two patients were diagnosed with large rectal tumors and localized prostate cancer."1.31External beam radiotherapy for synchronous rectal and prostatic tumors. ( Kapp, DS; King, C; Siu, W; Terris, MK; Wren, SM, 2001)
"Preoperative chemoradiotherapy for gastric cancer can be delivered safely and is well tolerated."1.31A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. ( Ajani, JA; Feig, BW; Janjan, N; Lowy, AM; Mansfield, PF; Pisters, PW; Rich, TA, 2001)
" This is the first report of non-invasive monitoring of toxic 5-FU metabolites in normal human tissues."1.31Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment. ( Griffiths, JR; Howe, FA; Lofts, F; McIntyre, DJ; McSheehy, PM; Nicholson, G; Noordhuis, P; Peters, GJ; Price, NM; Rodrigues, LM; Smid, K; Stubbs, M; Wadsworth, P, 2001)
" Because no data are available for patients with severe renal failure, the pharmacokinetic parameters of 5-FU and its catabolites were determined for a patient with colorectal carcinoma and end-stage renal disease on maintenance hemodialysis therapy."1.31Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. ( Bommer, J; Göggelmann, C; Hull, WE; Rengelshausen, J; Schwenger, V; Walter-Sack, I, 2002)
" We report three cases of advanced gastric cancer treated using TS-1 in combination with a low-dose of cisplatinum (CDDP) that well responded."1.31[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum]. ( Gomi, T; Kanaya, S; Katayama, T; Momoi, H; Ohtoshi, M; Tamaki, N; Wada, Y, 2002)
"Human colon cancer cell lines LS174T and LiM6 were plated on plastic, on hepatocyte-derived ECM or on stromal ECM and in the presence of the antimetabolite 5-fluorouracil (5-FU)."1.31Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines. ( Brill, S; Halpern, Z; Khaikin, M; Kouniavsky, G; Papa, M; Zippel, D; Zvibel, I, 2002)
"Ten patients with invasive distal rectal cancer (six T2, four T3) were treated with preoperative radiotherapy (3600-5040 cGy) with or without 5-fluorouracil based chemotherapy."1.31Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers. ( Cohen, AM; Guillem, JG; Minsky, BD; Paty, PB; Quan, SH; Ruo, L, 2002)
"A 59-year-old man with colon cancer was diagnosed as having a local recurrence of the disease, forming a huge intra pelvic tumor, accompanied by pulmonary metastasis 16 months after hemicolectomy."1.30[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin]. ( Masumoto, N; Nakamura, M; Nakano, S; Niho, Y; Tabata, H; Takasaki, S, 1997)
"Advanced gastric cancer was found in 12 cases (operation performed in 9 cases and 7 cases resectable) and recurrent in 5 cases."1.30[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer]. ( Katsumata, K; Kohno, M; Koyanagi, Y; Moriwaki, R; Ohno, M; Shibata, K; Tadatomo, H; Yamamoto, K; Yamashita, S, 1997)
"We reported two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil (5-FU), cisplatin (CDDP) and cytarabine (Ara-C), 5-FU (300-350 mg/body) was given by continuous intravenous infusion."1.30[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine]. ( Hizawa, Y; Itoh, J; Munakata, A; Saitoh, S; Satoh, T; Tamura, Y; Tsushima, K; Yamada, Y, 1997)
"Cranial dystonia is usually idiopathic but may be caused by trauma or medications."1.30Focal dystonia after chemotherapy: a case series. ( Brashear, A; Siemers, E, 1997)
" The mean total dosage was 6."1.30[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine]. ( Baba, H; Kohnoe, S; Matsuoka, H; Morita, M; Saito, T; Seo, Y; Taketomi, A; Tomoda, H, 1997)
"Trimodality treatment for esophageal cancer may provide long-term survival in some patients regardless of their pCR status."1.30Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus. ( Bernard, SA; Detterbeck, FC; Egan, TM; Jones, DR; Parker, LA; Tepper, JE, 1997)
"Eighty-eight patients with cancer of the esophagus ineligible for surgery were entered in the study between 1986 and 1993."1.30Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients. ( Auperin, A; Dhermain, F; Ducreux, M; Elias, D; Girinsky, T; Kac, J; Marsiglia, H; Randrianarivelo, H; Rougier, P, 1997)
"About one-third of patients with gastric cancer are unresectable at the time of diagnosis."1.30Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer. ( Cho, JY; Chung, HC; Kim, BS; Kim, CB; Kim, JH; Min, JS; Noh, SH; Park, JO; Rha, SY; Roh, JK; You, NC, 1997)
"This suggested that the therapy for a breast cancer patient with distant metastasis must be considered according to the region of recurrence."1.30[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer]. ( Ayabe, H; Hara, S; Hashizume, S; Itoyanagi, N; Oka, T; Shinguu, H; Tagawa, Y; Tooyama, H; Tou, K; Tsuji, H; Yamamoto, S; Yamazumi, K, 1997)
"A 57-year-old man suffering from gastric cancer with esophageal invasion and liver and paraaortic lymph nodes metastases was treated with continuous 5-FU injection and intra-hepatic arterial infusion of low-dose cisplatin following non-curative surgery."1.30[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin]. ( Oka, M; Ueno, T, 1997)
"Mitomycin C suppository was significantly less toxic compared with intravenous delivery, and higher rectal tissue concentrations were observed from 10 to 30 minutes (P < 0."1.30Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer. ( Ackerman, D; Galandiuk, S; Hofmeister, A; LaRocca, R; Lewis, RK; Myers, SR; Paris, KJ; Pokorny, RM; Wrightson, WR, 1997)
"We reported a case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate (MTX) and 5-fluorouracil (5-FU) sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil."1.30[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil]. ( Kamei, M; Kawabata, H; Matsuda, K; Nishioka, M; Sasahara, K; Uchida, Y, 1998)
"Twenty-nine patients with advanced colorectal cancer were divided into four groups, 3 days, 5 days, 7 days, and 10 days."1.30[Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern]. ( Kaibara, N; Kurayoshi, K; Makino, M; Taniguchi, T; Yamane, N, 1998)
"An advanced gastric cancer patient with T3N1M0 successfully underwent a curatively total gastrectomy combined with distal pancreatectomy and lymphnode dissection following ELF-P combined chemotherapy."1.30[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case]. ( Kamiyama, H; Kawashima, K; Koike, N; Morishita, Y; Ogawa, T; Ohwada, S; Sato, Y; Takeyoshi, I, 1998)
"Treatment of colorectal cancers is based on surgery and the prognosis is determined by the locoregional or metastatic tumor spread."1.30[How I treat colorectal cancer. I. Prevention and adjuvant treatment]. ( Bours, V; Fillet, G; Jerusalem, G, 1998)
"Then, 23 cases with local relapsed prostate cancer and two cases with endocrine-resistant prostate cancer received chemotherapy."1.30[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer]. ( Deguchi, T; Kawada, Y; Kuriyama, M; Nakano, M; Shinoda, I; Takahashi, Y; Takeuchi, T; Yamamoto, N; Yasuda, M; Yoh, M, 1998)
"The patient was diagnosed to have gastric cancer (T3 N3 M0 P3, Stage IV b)."1.30[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival]. ( Horimi, T; Morita, S; Takahashi, I; Takamatsu, M; Takasaki, M; Tsuji, A, 1998)
" These high 5-FU levels disappeared with an apparent elimination half-life (tl/2,beta) of 5."1.30Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. ( Brown, N; Covington, W; Ho, DH; Huo, YY; Kuritani, J; Lassere, Y; Pazdur, R, 1998)
"For advanced pancreatic cancer, there is no typical chemotherapy regimen non single chemotherapeutic agent."1.30[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis]. ( Kobayashi, A; Yamaguchi, M, 1998)
"This study included seven cases of pancreatic cancer considered unresectable."1.30[Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?]. ( Alexandre, M; Bousquet, J; Chipponi, J; Cure, H; Pezet, D; Slim, K; Verrelle, P, 1998)
"5-Fluorouracil is an S-phase-specific, synthetic pyrimidine antimetabolite, which is used as a cytostatic agent for a variety of malignant lesions, either singly or in multidrug regimens."1.30Supraventricular arrhythmia: a complication of 5-fluorouracil therapy. ( Ahmad, M; Aziz, SA; Iqbal, K; Jalal, S; Mohi-ud-Din, K; Tramboo, NA, 1998)
"In group 3, invasive squamous cell carcinoma and adenocarcinoma developed in one rat each."1.30Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats. ( Mori, M; Muto, T; Nagawa, H; Seto, Y; Tsuruo, T, 1999)
"An 80-year-old woman with metastatic bone cancer from ascending colon showed a remarkable response to combination therapy of 5-FU and radiation."1.30[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report]. ( Masuda, M; Nakamura, N; Nakanishi, K; Okamoto, E; Satoh, M; Takeuchi, T; Tanihata, H; Terada, M; Ueno, Y; Yoshikawa, H, 1999)
"In stade II and III breast cancer, neoadjuvant chemotherapy with FEC-HD obtains an important histological response with an acceptable toxicity."1.30[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer]. ( Arnoud, L; Belichard, C; Coudert, B; Darut-Jouve, A; Guerrin, J; Jolimoy, G, 1999)
"A total of 22 patients with primary colorectal cancer who underwent surgical treatment were examined for chemosensitivity with iable tumor samples using the Histoculture Drug Response Assay (HDRA)."1.30Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer. ( Hayashi, H; Imaseki, H; Isono, K; Nakajima, K; Ochiai, T; Shimada, H; Suzuki, T; Takayama, W; Takeda, A, 1999)
"Invest, 101: 344-352, 1998) to suppress pancreatic cancer cell growth and increase cytotoxic actions of cisplatinum."1.30Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes. ( Arber, N; Beger, HG; Danenberg, KD; Danenberg, PV; Korc, M; Kornmann, M, 1999)
" There were two EBRT dosage groups: Low EBRT, 23."1.30Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels. ( Abrams, RA; Cameron, JL; Chakravarthy, A; Grochow, LB; Haulk, TL; Hruban, RH; Lillemoe, KD; Ord, S; Pitt, HA; Sohn, TA; Yeo, CJ; Zahurak, ML, 1999)
"Fifty-three patients with localized esophageal cancer received concurrent chemoradiotherapy followed by brachytherapy."1.30High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. ( Dokiya, T; Oki, Y; Yorozu, A, 1999)
"Pancreatic cancer is one of the most common tumor of the gastrointestinal tract."1.30[Contribution of gemcitabine in the treatment of advanced pancreatic cancer]. ( Brunet, R; Fonck, M, 1999)
"The role in colorectal cancer is less clear, although there are some reports that suggest a benefit."1.30Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer. ( Clingan, P; Horsell, KW; King, DW; Merten, S; Morris, DL, 1999)
"Local control of esophageal cancer is excellent following neoadjuvant chemotherapy and radiation therapy."1.30Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy. ( Adelstein, DJ; Becker, M; Chidel, MA; Kupelian, PA; Rice, TW; Suh, JH, 1999)
"The surgical treatment of colorectal cancer (CRC) in elderly patients (age 70 years or older) has improved, but data on adjuvant and palliative chemotherapy tolerability and benefits in this growing population remain scarce."1.30Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. ( Cunningham, D; Norman, A; Parikh, B; Popescu, RA; Ross, PJ, 1999)
"In contrast, in group B, 9 had tubular adenocarcinomas (well or moderately differentiated) and 3 non-solid or diffuse-type poorly differentiated adenocarcinomas and there was only one solid-type tumor."1.30Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy. ( Ishihara, S; Kato, Y; Kitagawa, T; Nakajima, T; Ninomiya, Y; Yanagisawa, A, 1999)
"A 64-year-old man with unresectable esophageal cancer (A3, N1, M0) was treated with concurrent chemoradiotherapy."1.30[A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy]. ( Inoue, H; Ise, H; Matsumoto, G; Matsuo, S; Suzuki, N, 1999)
"The prognosis of node negative breast cancer patients was mainly associated with tumor size."1.30[Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients]. ( Han, Q; Shen, Z; Yu, L, 1997)
"The high sensitivity rate (HSR) of breast carcinoma cells to 5-fluorouracil (5-Fu), mitomycin (MMC), cisplatin (DDP), adriamycin(ADM), methotrexate(MTX), vincristin(VCR), vepesid(VP-16), taxol, and vindesine(VDS) were 57."1.30[Chemosensitivity test for 170 human breast carcinoma samples]. ( Chen, Z; Fei, H; He, Z; Liu, S; Shen, Z; Yuan, J, 1998)
"The another patient was 61 years old rectum cancer patient with lung and hepatic metastasis (stage V)."1.29[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home]. ( Hayashi, K, 1994)
"We reported a case of gastric cancer with peritoneal dissemination, which was successfully treated by neoadjuvant chemotherapy and partial gastrectomy."1.29[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy]. ( Ikeda, K; Shibata, N; Tamai, M, 1995)
" Low drug dosages (relative to the sensitivity of in vivo NMR) or rapid drug elimination create the additional problem of data sparsity where a pharmacokinetic model cannot be fitted individually."1.29Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach. ( Bachert, P; Port, RE; Schlemmer, HP, 1994)
"This report concerns four patients with brain metastases from breast carcinoma treated initially by systemic chemotherapy."1.29[Chemotherapy in the treatment of brain metastases of breast cancers]. ( Bastit, P; Chevallier, B; Couteau, C, 1994)
"In ten multiple metastatic brain tumors, three complete responses, two partial responses, one minor response and four non-responses were observed on MRI."1.29[Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat ( Hagiwara, Y; Kanayama, T; Kobayashi, H; Koezuka, M; Miyawaki, Y; Nakagawa, H; Tokiyoshi, K; Tsuruzono, K; Yamada, M, 1994)
"A 67-year-old man with advanced gastric cancer with multiple liver metastases was treated by a new combination chemotherapy using 5-FU, THP and MMC (FTM)."1.29[A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)]. ( Kusano, F; Maekawa, N; Sakai, Y; Sasaki, N; Tajiri, K; Tazawa, J; Yamamoto, C, 1994)
"We described a case of advanced gastric cancer with multiple liver metastases, who was placed on neoadjuvant chemotherapy using CDDP and 5-FU (FP therapy) with a marked reduction in tumor load."1.29[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases]. ( Igarashi, S; Kurosu, Y; Mori, K; Niki, M; Nishimura, G; Oohara, M; Osada, H; Takamoto, Y; Tsuzuki, H; Ueda, H, 1994)
"levamisole/5-FU) treatment."1.29Enhancement of antitumor effects of combined chemoimmunotherapy. ( Fowler, WC; Gerçel-Taylor, C; Taylor, DD; Weese, JL, 1993)
"The second patient had advanced gastric cancer with carcinomatosis."1.29[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports]. ( Furuya, Y; Hamabe, Y; Ku, Y; Nakamura, T; Saitoh, Y; Yamamoto, K, 1994)
"A 51-year-old female with inoperable gastric cancer and with infiltration of pancreatic tail diagnosed by abdominal CT was treated with leucovorin (LV) and 5-fluorouracil (5-FU)."1.29[Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)]. ( Inamura, Y; Kanemitsu, T; Koike, A; Kojima, T; Matsumoto, K; Miwa, M; Nagata, H; Naruse, T; Ohiwa, Y; Suzumura, K, 1993)
"A 58-year-old woman with colon cancer, who had received oral 5-FU over 17 months after right hemicolectomy, was diagnosed as having a recurrence of the disease with multiple pulmonary metastasis."1.29[A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a]. ( Hirata, Y; Ichiki, Y; Kanaya, S; Nakamura, M; Nakano, S; Niho, Y, 1993)
"The energy metabolism of FM3A tumors in C3H mice following radiotherapy (20 Gy or 40 Gy), 5-fluorouracil compound (UFT) chemotherapy or radiotherapy (20 Gy) combined with UFT was investigated by in vivo 31P-MR spectroscopy on day 2 after treatment."1.29Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT). ( Ohkubo, M, 1993)
"5-Fluorouracil was given every 3 weeks by 5-day continuous chronomodulated venous infusion (CMVI) with peak 5-FU delivery at 4 a."1.29Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma. ( Adam, R; Bertheault-Cvitkovic, F; Bismuth, H; Brienza, S; Itzhaki, M; Lévi, F; Misset, JL; Soussan, S, 1993)
" A tolerable dosage regimen was radiation at 45 Gy with 4 days of 5-FU plus leucovorin during the first week and 3 days during the last week with postradiation chemotherapy."1.29Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. ( Burch, PA; Cha, SS; Gunderson, LL; Mailliard, JA; Martenson, JA; McKenna, PJ; Moertel, CG, 1994)
"A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with cis-diamminedichloroplatinum (CDDP) is reported."1.29[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP]. ( Hayashi, H; Iwashita, R; Miyauchi, H; Miyoshi, H; Mochizuki, R; Nakagohri, T; Takeuchi, H; Tsunoda, Y; Ueda, K, 1994)
"Fifty-three patients with advanced colorectal cancer were given single oral doses of 5'-DFUR, 400 mg/body, preoperatively to assess the pharmacokinetics of 5'-DFUR in the patients with colorectal cancer and to investigate schedules for 5'-DFUR treatment."1.29[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer]. ( Hanyu, F; Hayashi, T; Igarashi, T; Suzuki, M; Watanabe, K; Yoshida, K, 1994)
" 5-Fluorouracil is given in a dosage of 1000 mg/m2/day as a continuous 24-hour infusion for 4 days."1.29Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer. ( Cellini, N; Coco, C; De Franco, A; Magistrelli, P; Mattana, C; Netri, G; Picciocchi, A; Roncolini, G; Valentini, V; Vecchio, FM, 1994)
"To evaluate the effect of the oral fluoropyrimidines, tegafur and uracil (UFT) and 5-fluorouracil (5-FU), a pharmacodynamic analysis was conducted using a nude mouse system and patients."1.29A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer. ( Hishinuma, S; Ikeda, T; Inada, T; Kotake, K; Koyama, Y; Kubota, T; Ogata, Y; Ozawa, I; Shimizu, H, 1993)
"A 59-year-old woman with advanced gastric cancer was treated with continuous 5-fluorouracil infusion for thirty-five days."1.29Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions. ( Kano, Y; Sasagawa, M; Seki, T; Suda, K, 1993)
"This case suggested that respiratory failure due to lymphangitis carcinomatosis can be a treatable condition."1.29Respiratory failure due to pulmonary lymphangitis carcinomatosis. ( Fujita, J; Kubo, A; Takahara, J; Takigawa, K; Yamagishi, Y; Yamaji, Y, 1993)
"An experience with an advanced gastric cancer patient with metastases to bilateral breasts, uterus, abdominal lymph nodes, bilateral axillary and supraclavicular lymph nodes, and bone marrow, responded extremely well to an FAP combined chemotherapy as reported here."1.29[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy]. ( Azuma, T; Doihara, H; Kirihara, Y; Miyahara, E; Ohashi, R; Sakamoto, N; Soga, H; Takiyama, W; Tanada, M; Yokoyama, N, 1993)
"This metastatic model of human stomach cancer shows that locally growing and metastatic tumors may have different chemosensitivities, and provides the opportunity to test both with various treatment regimens."1.29Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice. ( Furukawa, T; Hoffman, RM; Kitajima, M; Kubota, T; Kuo, TH; Watanabe, M, 1993)
"In a 63-year-old male patient with gastric cancer having multiple liver metastases, the metastatic lesions responded well to postoperative staggered intraarterial infusion therapy with MTX and 5-FU."1.29[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU]. ( Adachi, A; Nakano, Y; Ota, Y; Shirafuji, T; Yamaguchi, H; Yoshida, K, 1993)
"The patient was a 44-year-old male with gastric cancer accompanied by pancreatic invasion and metastasis to the periaortic lymph nodes."1.29[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP]. ( Kobayashi, O; Motohashi, H; Okada, K; Okugawa, T; Rino, Y; Sairenji, M, 1993)
"5-Fluorouracil was given concurrently by continuous infusion at a dose of 300 mg m-2 day-1."1.29Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms. ( Abbruzzese, JL; Buchholz, DJ; Cleary, KR; Evans, OB; Lee, JE; Rich, TA, 1995)
"The palliative effects on dysphagia of radiotherapy (RT) and chemotherapy (CT) were evaluated retrospectively and compared with the effect of the self-expanding stent, evaluated in the prospective study."1.29Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment. ( Albertsson, M; Cwikiel, M; Cwikiel, W, 1996)
"Patients with inflammatory breast cancer have a high risk of developing a local recurrence and/or distant metastases."1.29Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy. ( Arriagada, R; Fontaine, F; Le Chevalier, T; Mouriesse, H; Spielmann, M; Thomas, F; Tursz, T, 1995)
"The proliferation of MCF-7, human breast cancer cell line, was stimulated by testosterone and estradiol."1.29Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell. ( Fujikura, T; Ideyama, Y; Kudoh, M; Mori, M; Nanya, T; Shikama, H; Susaki, Y, 1996)
"Three women with breast carcinoma were treated with combination chemotherapy, including cyclophosphamide, 5-fluorouracil, and methotrexate, after mastectomy."1.29Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma. ( Kramer, N; Leitner, SP; Michaelson, RA; Rosenstein, ED, 1996)
"Irinotecan and etoposide were combined using the (d x 5)2 i."1.29Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996)
"We conclude that inoperable esophageal cancer can be treated successfully by radiotherapy with a curative intent."1.28[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases]. ( Calais, G; Chauvet, B; Geara, F; Le Floch, O; Reynaud-Bougnoux, A, 1990)
"As a prerequisite four human breast cancer cell lines (MDA-MB-231, MCF-7, T-47-D and ZR-75-1) were characterized with regard to oestrogen and progesterone receptor content, modal chromosome number and proliferation kinetics depending on the number of passages in culture."1.28Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity. ( Bernhardt, G; Birnböck, H; Reile, H; Schönenberger, H; Spruss, T, 1992)
"Thirty patients with advanced colorectal cancer were treated preoperatively by combined regional radiofrequency hyperthermia and 5-FU."1.28[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies]. ( Wu, GR, 1992)
"Twenty patients with rectal cancer underwent the preoperative regimen that consisted of 3,000 cGy delivered in 10 fractions over 12 days with concomitant 5-fluorouracil and mitomycin-C."1.28Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma. ( Broadwater, JR; Gocio, JC; Hutchins, LF; Klimberg, VS; Lang, NP; Langston, JD; Maners, A; Westbrook, KC, 1992)
"Seven consecutive advanced ovarian cancer patients presented with massive ascites (5 with pleural effusion)."1.28[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations]. ( Fujimoto, I; Hasumi, K; Masubuchi, K; Shimizu, Y; Tatsuki, Y; Yamauchi, K, 1992)
"Hypertriglyceridemia was maintained within acceptable levels, without adjusting the treatment plan, by an appropriate diet and gemfibrosil administration."1.28Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report. ( Berruti, A; Dogliotti, L; Gorzegno, G; Tampellini, M; Vitetta, G, 1992)
"A 60-year-old woman with gastric cancer had undergone partial gastrectomy in September 1989."1.28Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate. ( Hosokawa, T; Kajiwara, T; Ogawa, K; Otani, Y, 1992)
"A dosage form comprising 5-fluorouracil (5-FU, 25 mg/ml) adsorbed on a suspension of micronized charcoal (100 mg/ml) 2-5 microns in diameter, adsorbing 5-FU in aqueous solution was studied for intratumor treatment of mammary carcinoma in animal experiments."1.28Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles. ( Amdidouche, D; Bonhomme, L; Faure, E; Fredj, G; Guisteau, D; Mathieu, MC; Naveau, S, 1992)
"Mitomycin C was given on Day 1 (dose: 15 mg/m2 i."1.28Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer. ( Dobrowsky, W, 1992)
"We reported a case of metastatic liver cancer from rectal carcinoma, which was successfully treated by systemic continuous 5-Fluorouracil and intermittent Mitomycin C chemotherapy."1.28[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy]. ( Noguchi, S; Shibata, N, 1992)
"Determined by clonogenic assay in human colon cancer HT-29 cells, the cell survivals for AZT, 10 microM, dipyridamole, 5 microM, and methotrexate (MTX), 0."1.28Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. ( Taniki, T; Weber, G; Zhen, YS, 1992)
"The records of patients with esophageal cancer who were treated with a combined modality therapy were reviewed to determine the effects of simultaneously administered chemotherapy and radiotherapy (RT) at sites of recurrence and the relationship between treatment outcome and clinicopathologic variables."1.28Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery . ( Denham, JW; Devitt, PG; Gill, PG; Jamieson, GG; Olweny, C; Yeoh, E, 1992)
"A clone of human gastric cancer cells (AGS-6) and the parental line (AGS-P) from which it was isolated were used in cell survival studies to determine whether pretreatment for 24, 48 or 72h with alpha-difluoromethylornithine (DFMO, 5mM) would increase the cell's sensitivity to 5-Fluorouracil (5FU), Adriamycin (Adria), 1-(2-chloroethyl)-3-(4-methyl cyclohexyl)-1-nitrosourea (MeCCNU), or Bleomycin (Bleo)."1.28Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro. ( Barranco, SC; Ford, PJ; Ho, BY; Koester, SK; Reumont, KJ; Townsend, CM, 1990)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."1.28Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma. ( Coia, LR; Engstrom, PF; Hanks, GE; Paul, AR; Stafford, PM, 1991)
"Twenty-two advanced consecutive thyroid cancer patients with varying histologies were treated with the so called BAP regime which consisted of bleomycin (B) 30 mg a day for three days, adriamycin (A) 60 mg/m2 iv in day 5, and cisplatinum (P) 60 to mg/m2 iv in day 5."1.28Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. ( Busnardo, B; Casara, D; De Besi, P; Fiorentino, MV; Girelli, ME; Nacamulli, D; Simioni, N; Toso, S; Zorat, P, 1991)
"Radiation myelitis is a rare but serious complication of radiation therapy."1.28Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix. ( Berman, ML; Bloss, JD; DiSaia, PJ; Hyden, EC; Manetta, A; Mannel, RS; Walker, JL, 1991)
"A case of relapsing breast carcinoma presenting with acute visual loss secondary to choroidal metastases is described."1.28Choroidal metastases as a presenting sign after 24 years of a primary breast cancer. ( Baheti, D; Consul, S; Gupta, R, 1991)
"Presence of hepatomegaly emerged as the more significant (P = 0."1.28Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy. ( Ducreux, M; Elias, D; Lasser, PH; Lumbroso, J; Pignon, JP; Rougier, P; Ruffie, P; Tigaud, JM, 1991)
"Eighty-three rats with isolated colon cancer underwent total colectomy; 40 of these rats with no metastases were randomized into two groups: surgery alone or surgery plus 5-FU (5 mg/kg body weight/day) for 5 days after surgery."1.28Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy. ( Ballet, F; Delelo, R; Herve, JP; Nordlinger, B; Panis, Y; Puts, JP, 1991)
"Feasibility of utilizing human gastric cancers as first transplant generation xenografts in nude mice for determining tumor sensitivity to chemotherapeutic agents was demonstrated by applying subrenal capsule (SRC) assay."1.28Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy. ( Akiyama, S; Ito, A; Ito, K; Kondo, K; Satta, T; Takagi, H; Watanabe, T; Yamauchi, M, 1991)
"A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor characterized by S3 (invasion of the pancreas), N3, P0 and H0."1.28[A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)]. ( Azuma, S; Furuta, T; Kawata, R; Kunieda, K; Miya, K; Saji, S; Sugiyama, Y; Takao, H; Tanemura, H; Umemoto, T, 1991)
"Only two of them bore colonic cancer."1.28Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases. ( Fujita, S; Kusunoki, M; Sakanoue, Y; Shoji, Y; Utsunomiya, J; Yamamura, T; Yanagi, H, 1991)
"Pericarditis and cardiac arrhythmias developed, but the patient did not have cardiac tamponade."1.28Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter. ( Cathcart-Rake, WF; Mowery, WE, 1991)
"Consequently, secondary biliary cirrhosis developed, requiring orthotopic liver transplantation."1.28[Ectasing cholangitis and secondary biliary cirrhosis following intra-arterial hepatic chemotherapy. Treatment by liver transplantation]. ( Chapuis, Y; Gaudric, M; Houssin, D; Louvel, A; Pitre, J; Vigouroux, C, 1991)
"Forty-four patients with advanced gastric cancer were treated with a combination including 5-fluorouracil, 4-epi-doxorubicin and mitomycin C."1.28Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer. ( Kolarić, K; Luetić, J; Roth, A; Zupanc, D, 1990)
" This was deemed due to the small dosage and a short duration of 5'-DFUR."1.28[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum]. ( Harada, T; Hirano, M; Kikkawa, H; Masuda, S; Matsu, T; Saito, H; Sakatoku, M; Tatsuzawa, T, 1990)
" The tumor pool of free 5FU in those human tumors that trapped 5FU was determined to have a half-life of 0."1.28Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. ( Albright, MJ; Atkinson, D; Barker, PB; el-Tahtawy, A; King, M; Ong, R; Presant, CA; Ring, R; Servis, KL; Wolf, W, 1990)
"The prognosis of unresectable advanced gastric cancer is extremely poor."1.28Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen. ( Chung, HC; Kim, BS; Lee, JT; Lee, KB; Lee, SI; Min, JS; Park, YJ; Roh, JK, 1990)
"Fourteen samples of epithelial ovarian cancer were studied; chemosensitivity in vitro was examined by clonogenic assay, and DNA content was measured by static cytometry."1.28Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results. ( Carenza, L; Giovagnoli, MR; Prosperi Porta, R; Rulli, G, 1990)
"Of 25 patients with squamous cell carcinoma, 13 underwent esophagectomy."1.28Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma. ( Daniel, TM; Hahn, SS; Harkins, BJ; Stewart, FM, 1989)
"5'-Deoxy-5-fluorouridine (DFUR), whether or not combined with (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) was pursued in BDF1 mice from both a pharmacokinetic viewpoint, following a single oral dose administration, and an anticancer viewpoint, following 5 daily oral doses in mice inoculated subcutaneously with adenocarcinoma 755 tumor cells."1.28Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels. ( De Clercq, E; Hoshi, A; Iigo, M; Nakajima, Y; Nishikata, K; Odagiri, H; Okudaira, N, 1989)
" 5-fluorouracil (5-FU) with a daily dosage of 1 g/m2/day was given continuously for 5 consecutive days at 3-week intervals."1.28Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy. ( Herrmann, R; Hohenberger, P; Räth, U; Schlag, P, 1989)
"Fluorouracil (Adrucil) has been used for more than 20 years to treat metastatic colorectal carcinoma and has provided significant palliation of symptoms to some patients."1.28Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil. ( Joseph, RR; Treat, J, 1989)
" Other adverse sequelae, such as abdominal pain, were manageable with medication."1.28Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study. ( Blessing, JA; Homesley, HD; Walton, LA, 1989)
"Retreatment of patients with colon cancer and liver metastases by hepatic arterial infusion of fluorodeoxyuridine and mitomycin C can result in significant prolongation of survival in patients with response to this treatment."1.27Effective retreatment of patients with colorectal cancer and liver metastases. ( Chuang, VP; Mavligit, G; Patt, YZ; Peters, RE; Wallace, S, 1983)
"Although both patients with hepatocellular cancer and the patient with a soft tissue sarcoma responded to the regimen, only 1 of 38 patients with adenocarcinoma had a favourable response."1.27Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer. ( Cedermark, BJ; Gunven, P; Hammarberg, C, 1983)
"Laboratory experiments using breast cancer cells in long-term tissue culture revealed that tamoxifen is cytotoxic, estrogen stimulates the growth of ER-positive cells and can rescue cells from tamoxifen's effect, and sequential MTX/5-FU is synergistic in rapidly growing breast cancer cells."1.27Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer. ( Allegra, JC, 1983)
"One partial remission out of 7 cases of stomach cancer was obtained, and its duration was 40 weeks."1.27[Clinical trial on the effect of tegafur (SF-SP)]. ( Akazawa, S; Futatsuki, K; Hattori, M; Ishibashi, I; Kanda, Y; Sendai, H; Shimada, S, 1984)
"Thirty patients with advanced gastric cancer were treated with a combination chemotherapy consisting of adriamycin 20-30 mg/m2 iv day 1 q3wks, mitomycin C 2."1.27[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Okada, Y; Usui, N, 1983)
"The sensitivity of two human pancreatic adenocarcinomas (Capan-1 and Capan-2) to heat and heat combined with chemotherapy was studied using xenografts of the tumors in the foot of athymic nude mice."1.27Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy. ( Cahan, A; Fogh, J; Fortner, JG; Shiu, MH, 1983)
"Tegafur was administered orally in two or three divided doses."1.27Phase I evaluation of oral tegafur. ( Bedikian, AY; Bodey, GP; Burgess, MA; Valdivieso, M, 1983)
"Three rectal cancer patients with partial response (PR) were obtained by oral administration of 800-1200 mg/day of SF-SP."1.27[The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients]. ( Endo, S; Furukawa, R; Katsumi, S; Mukae, S; Sato, T; Sekine, S; Watanabe, I; Watanabe, S, 1984)
"Spontaneous metastasis of highly metastatic variants, B16 melanoma BL-6 and colon adenocarcinoma 26 NL-22, was examined."1.27Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis. ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984)
"5-fluorouracil that was less active in the used therapeutic doses did not cause similar changes in the LSA levels."1.27[Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents]. ( Bassalyk, LS; Kozlov, AM; Novikov, AM; Sof'ina, ZP, 1984)
"Melphalan (L-PAM) was compared to (C) cyclophosphamide, (M) methotrexate, and (F) 5-fluorouracil (CMF) in 413 patients with advanced ovarian carcinoma."1.27Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer. ( Bauer, M; Brodovsky, HS; Elson, PJ; Horton, J, 1984)
"Eighty-four patients with advanced gastric cancer treated in four centres in Scotland between June 1980 and December 1982 were reviewed following treatment with 5-fluorouracil, adriamycin and mitomycin-C (FAM)."1.27Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C. ( Allan, SG; Calman, KC; Carter, DC; Cunningham, D; Hutcheon, AW; Kaye, SB; McArdle, CS; Sangster, G; Smyth, JF; Soukop, M, 1984)
" Although the dosage of the anticancer chemotherapy was quite small, this treatment may have promoted the regression of the tumor in conjunction with activated antitumor immunity of the host."1.27[A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy]. ( Furuta, K; Hara, K; Kiyomitsu, Y; Nakazaki, S; Shinoda, M; Watanabe, K; Yajima, K; Yasuda, S; Yokoyama, T, 1984)
"Tumor metastasis was examined after iv inoculation of highly metastatic variants of mouse tumors."1.27Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors. ( Hori, K; Kawabata, H; Naganuma, K; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984)
"Twenty-one patients with advanced gastric cancer were treated with a combination chemotherapy of adriamycin and 5-fluorouracil (AF)."1.27[Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer]. ( Ezaki, K; Horikoshi, N; Ikeda, K; Inagaki, J; Inoue, K; Miyamoto, H; Nakada, H; Ogawa, M; Usui, N, 1983)
"Chemoradiotherapy was recommended to 40 pancreatic cancer patients following exploratory and palliative operations."1.27[Chemoradiation treatment of pancreatic cancer]. ( Barkanov, AI; Itin, AB, 1985)
"The prognosis of bile duct cancer is still poor."1.27[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]. ( Arnold, W; Bartels, E; Schmeck, HJ; Viets, CH, 1986)
"Mitomycin C (10 mg/m2) was administered as a bolus injection on day 2."1.27Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy. ( Coia, LR; Engstrom, PF; Paul, A, 1987)
"The majority of patients (78%) had squamous cell carcinoma."1.27Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University. ( al-Sarraf, M; Cummings, G; Ensley, JF; Kelly, J; Kish, JA; LoRusso, P; Tapazoglou, E, 1988)
"The chemosensitivity of human colorectal cancer was studied in relation to the biological features of the tumor using a human tumor/nude mouse in-vivo system."1.27Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice. ( Yamada, K, 1987)
"For the response of advanced gastric cancer to chemotherapy in the National Cancer Center Hospital, the combined use of UFT and Mitomycin C gave the highest rate, 46%."1.27Radiation therapy for advanced gastric cancer. ( Akine, Y; Egawa, S; Hijikata, J; Kajiura, Y; Kitagawa, T; Ogino, T; Tsukiyama, I; Yamashita, K, 1988)
"All of the gallbladders had significant arteritis, with narrowing or occlusion of lumina or necrosis of vessel walls."1.27Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump. ( Dakhil, SR; Housholder, DF; Marymont, JV; Travers, H, 1985)
"Nine patients had squamous cell carcinoma, two adenocarcinoma, and two large cell carcinoma."1.27[Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung]. ( Kikuchi, K; Ogata, T, 1986)
" The drug sensitivity of the cultured cancer cells was investigated with a colony forming assay, and a dose-response curve was obtained for the time-dependent anticancer drug."1.27[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment]. ( Maeda, T, 1986)
"A 55-year-old woman with gastric cancer underwent laparotomy and was found to have an unresectable tumor at the MC region, characterized by S3 (invasion into the pancreas), N3, P0, H0, Borrmann-II and moderately differentiated tubular adenocarcinoma."1.27[Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report]. ( Ando, T; Azuma, S; Furuta, T; Kawata, R; Ohashi, H; Saji, S; Shimokawa, K; Suzuki, M; Tanemura, H; Tsuya, H, 1987)
"Of the 77 patients who had squamous cell carcinoma, 62 received definitive treatment for disease confined to the esophagus and regional nodes."1.27Esophageal carcinoma: modest benefits from combined modality therapy. ( Carlson, RW; Goffinet, DR; Hancock, SL; Mark, JB, 1987)
"A 65-year-old man with gastric cancer showing multiple liver metastases was treated with recombinant interferon-gamma (KW-2202) and 5-fluorouracil (5-FU)."1.27[A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU]. ( Hisatsugu, T; Katano, M; Kitajima, Y; Sato, S; Uchida, Y; Yamamoto, H, 1987)
"A 75-year-old man with gastric cancer metastatic to the liver was treated by combined administration of Tegafur (800 mg/body/day), 5-fluorouracil (300 mg/body/day) and Mitomycin C (hepatic arterial infusion of 20 mg/body and intravenous infusion of 8 mg/body)."1.27[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C]. ( Ito, T; Nehashi, Y; Sasaki, J; Sasaki, Y, 1988)
"Fluorodeoxyuridylate (FdUMP) was assayed by isotope dilution of [3H]FdUMP binding to bacterial TS; free and total TS was determined by [3H]FdUMP binding; and deoxyuridylate (dUMP) was assayed by conversion to [14C]thymidylate."1.27Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil. ( Berne, M; Bernstein, L; Frösing, R; Gustavsson, BG; Hayes, AA; Spears, CP, 1988)
" At these dosage levels, diarrhea was not a limiting toxicity."1.27High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer. ( Arnold, DJ; Balcueva, EP; Dimitrov, NV; Scholnik, AP; Schwenke, P; Suhrland, LG; Walker, WS, 1988)
"However, it is unfortunate that colorectal cancer screening in young patients is difficult because of the low rates of precancerous states (4%)."1.27Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. ( Astre, C; Domergue, J; Ismail, M; Joyeux, H; Pujol, H; Saint-Aubert, B; Solassol, C, 1988)
"32 cases of colon cancer were given I/V 5-fluorouracil for at least one year."1.27Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital. ( Chia, KB; Chua, EJ; Khor, TH; Sethi, VK; Tan, BC; Tan, TM, 1987)
"Patients with metastatic breast carcinoma and similar presentations should be considered for prophylactic therapy with allopurinol and hydration before chemotherapy."1.27Fatal acute tumor lysis syndrome with metastatic breast carcinoma. ( Coonley, CJ; Dyer, MC; Stark, ME, 1987)
"In most cases of metastatic gastric cancer, treatment with cytostatic drugs seems to be justified."1.27[Chemotherapy of metastatic gastric cancer--x-ray follow-up]. ( Hofmann-Preiss, K; Theobaldy, S; Walter, M, 1987)
"Fifty-seven patients with esophageal cancer were treated with curative intent between January 1979 and June 1985."1.27Comparison of three treatment strategies for esophageal cancer within a single institution. ( Bae, Y; Burdakin, J; Jacobsen, G; Lewis, J; Richmond, J; Seydel, HG, 1987)
"Allopurinol has been shown to ameliorate the myelotoxicity of 5-fluorouracil (5-FU) given as an infusion."1.27Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule. ( Ahmann, FR; Garewal, H, 1986)
" Of the 66 patients with colorectal carcinoma, 44 had not been previously treated with cytostatics and 22 were resistant to previous chemotherapy with 5-FU given either as a single agent or combined with other drugs."1.27Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update. ( Chollet, P; Goldschmidt, E; Machover, D; Mathé, G; Misset, JL; Schwarzenberg, L; Vanden-Bulcke, JM, 1985)
"A 61-year-old man with double colon cancers and a solitary hepatic metastasis underwent right hemicolectomy and catheterization of the proper hepatic artery in April 1979."1.27[A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy]. ( Itoh, J; Koyama, K; Masuda, T; Narisawa, T, 1985)
"At present hyperthermia shows great promise when combined with other modalities."1.27[Clinical application of local hyperthermia combined with antineoplastic agents]. ( Ishiwata, J; Iwamoto, S; Koike, M; Maeda, Y; Masuda, T; Sasaki, T; Takeshita, Y; Tanaka, Y, 1985)
"5-Fluorouracil treatments resulted in a dose-dependent inhibition of tumor growth under the two examined schedules (five daily doses and three doses every 4 days) when administered either i."1.275-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice. ( Frei, E; Goldin, A; Mantel, N; VanWinkle, TJ; Zimmerman, RJ, 1986)
"The Southwest Oncology Group conducted a pilot study in patients who had had total clinical resection of cancer of the colon and had a high risk of recurrence (Duke's C); the purpose of the study was to determine the toxic effects of intra-arterial chemotherapy combined with hepatic radiotherapy, in anticipation of their potential use in an adjuvant groupwide protocol."1.27Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study. ( Boyer, C; Janaki, L; McCracken, JD; Oishi, N; Weatherall, TJ, 1985)
" This study demonstrates that sequential MTX and 5-FU in this dosage and schedule is ineffective in NSCCL."1.27Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung. ( Ponder, BA; Slevin, ML; Wood, CD; Wrigley, PF, 1985)
" The mean half-life of 5-FU in the isolated circuit was 18."1.27Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion. ( Abramson, IS; Andrews, PA; Howell, SB; Murphy, MP; Stemmer, EA; Wile, AG, 1985)
"For stage I and II gastric cancer, radical gastrectomy and postoperative immunotherapy for 3 months would be the best treatment."1.27Immunochemosurgery for gastric cancer. ( Kim, JP, 1985)
"Patients with squamous cell carcinoma or good performance status were somewhat more likely to respond."1.27Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer. ( Einstein, AB; Rudolph, RH; Weiden, PL, 1985)
"Phosphorylating activity in squamous cell carcinoma of the lung was similar to that in adenocarcinomas."1.26Metabolism of 5-fluorouracil in various human normal and tumor tissues. ( Fujii, S; Maehara, Y; Nagayama, S; Nakamura, H; Okazaki, H; Shirasaka, T, 1981)
"Other nonneoplastic gastrointestinal disorders showed an 18% abnormal CSAp titer frequency, of which more than half bordered the upper limit of normalcy."1.26Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer. ( Goldenberg, DM; Nelson, MO; Pant, KD; Shochat, D, 1982)
"Regional arterial infusion of high doses of anti-cancer drugs combined with direct hemoperfusion was done in 12 patients with malignancies of the urinary tract."1.26Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract. ( Harada, T; Nishizawa, O; Ohmura, H; Tsuchida, S, 1982)
"Sixteen patients with advanced colo-rectal cancer were treated with the combination methyl-CCNU, vincristin, 5-fluorouracil and streptozotocin (MOF-Strepto)."1.26[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma]. ( Cavalli, F; Sessa, C; Togni, P; Varini, M, 1982)
"In the total 70 cases including those of undifferentiated carcinoma and adenocarcinoma, the 3-year and 5-year actual survival rates were 75."1.26Analysis of the results of our combined therapy for maxillary cancer. ( Inoue, S; Konno, A; Togawa, K, 1980)
"5-Fluorouracil (5-FU) is an effective anti-tumor drug, which has been used both as a single agent and in combination with other chemotherapeutic agents for the treatment of tumors such as breast and colorectal carcinoma."1.26Metabolic and distribution studies with radiolabeled 5-fluorouracil. ( Ghanbarpour, A; Shani, J; Siemsen, JK; Vine, E; Wolf, W; Young, D, 1982)
" Dose-response relationships of 3 triple-drug combinations and their component agents were explored, allowing the relative contributions of single agents in each combination to be assessed."1.26Experimental combination and single-agent chemotherapy in human lung-tumour xenografts. ( Jones, JM; Peckham, MJ; Shorthouse, AJ; Steel, GG, 1982)
"Breast tumors are known to be heterogeneous with respect to estrogen receptor status, and the low complete remission rate may be related to this biochemical heterogeneity."1.26A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer. ( Allegra, JC; Bland, KI; Richman, SP; Wittliff, JL; Woodcock, TM, 1982)
" The group of long term administration of FT-207 and CQ included many patients with good response."1.26[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer]. ( Fukuda, O; Inoue, S; Maeyama, M; Nakayama, M; Tajima, C; Tokunaga, T, 1982)
"Of the 31 patients with stomach cancer who were evaluable for response and had had no previous chemotherapy, 12 (39%) achieved complete or partial remission."1.26Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas. ( Bennetts, RW; Heifetz, LJ; Jones, RD; Karlin, DA; Mahal, PS; Stroehlein, JR, 1982)
" Gastrointestinal and hematologic toxic effects were mild and infrequent."1.26High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule. ( Campbell, TN; House, BA; Howell, SB; Pfeifle, C, 1982)
"For the diffuse invasive type of gastric cancer, the changes in the X-ray finding such as stiffness and poor elasticity of gastric wall and malignant relief were also taken into consideration for the judgement."1.26[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer]. ( Chin, F; Hirasawa, H; Isono, K; Kimura, M; Kouzu, T; Okuyama, K; Onoda, S; Ryu, M; Sato, H; Satoh, H; Tounosu, N; Yamamoto, Y, 1982)
"Pre-treatment with the anabolic steroid nandrolone decanoate (ND) increases the LD50 of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) and 5-Fluorouracil (FU) in NMRI mice."1.26Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours. ( Bibby, MC; Double, JA; Mughal, MA, 1981)
"Two patients with advanced rectal cancer, women aged 73 and 49 years, have survived more than nine years with chemotherapy only and no surgical removal of the disease foci."1.26Long-term survivors with nonresectable advanced carcinoma of the rectum. ( Fukuda, I; Iwanaga, T; Koyama, H; Otani, T; Taniguchi, H, 1981)
"A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin."1.26Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III. ( Drago, JR; Worgul, TJ, 1981)
" This route-dependent pharmacokinetic profile is consistent with the reported absence of myelosuppression in prolonged infusion and may be related to the resultant lower levels of 5-FUra achieved in bone marrow."1.26Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. ( Baker, LH; Buroker, TR; Fraile, RJ; Horwitz, J; Vaitkevicius, VK, 1980)
"After confirming the presence of gastric cancer, 1-n-hexylcarbamoyl-5-fluorouracil (HCFU), a derivative of 5-fluorouracil, was given to the dogs orally as capsules at a daily dose of 5 or 10 mg/kg body weight."1.26Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine. ( Aoyagi, M; Hirashima, T; Hirota, T; Kawachi, T; Matsukura, N; Sugimura, T; Takasugi, T; Uchida, E; Ushio, K; Yoshida, S, 1980)
"A group of patients with metastatic breast cancer treated by a distinct drug regimen is analyzed with special respect to clinical and psychological problems."1.26[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)]. ( Fernholz, HJ; Frik, W; Nüvemann, M, 1976)
"Three patients with metastatic breast carcinoma who had untreated locally advanced primary tumors were treated initially with combination chemotherapy followed by hygienic mastectomy."1.26Mastectomy as an adjunct to combination chemotherapy. ( Aisner, J; Elias, EG; Morris, D; Wiernik, PH, 1978)
"Eighty-four previously untreated patients with metastatic adenocarcinoma of the large intestine received intravenous ftorafur at a dosage of 2."1.26Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study. ( Buroker, T; Groppe, C; Guy, G; Heilbrun, L; Hoogstraten, B; McCracken, J; Padilla, F; Quagliana, J; Vaitkevicius, VK, 1979)
"Fifteen patients with advanced gastric cancer were treated with the combination of Ftorafur, Adriamycin and mitomycin-C (FAM II)."1.26A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma. ( Haller, DG; Hoth, DF; MacDonald, JS; Rosenoff, S; Schein, PS; Smythe, T; Woolley, PV, 1979)
"Successful heterotransplantation of ovarian cancer in the mouse mutant, nude is described, with serial transmission, in one case to date."1.26Heterologous growth of human ovarian cancer. A new in vivo testing system. ( Davy, M; Johannessen, JV; Mossige, J, 1977)
"Cell free supernatants from human breast tumors produce less total phosphorylation than murine tumors and some specimens produce only monophosphates whereas others produce mono-, di and triphosphates."1.26Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors. ( Ardalan, B; Cooney, D; Macdonald, JS; Schein, PS, 1979)
"Two patients with generalized ovarian cancer may be cured."1.26Chemotherapy of ovarian cancer. ( Dimitriades, M; Midoulas, N; Panopoulos, C; Papadimitriou, GC; Razis, DV, 1978)
"Soft tissue metastases may be more responsive than bony lesions."1.26Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate. ( Bergreen, PW; Buell, GV; Saiers, JH; Saiki, JH, 1978)
"In additional 13 cases with gastric cancer, the active 5-FU concentrations in the regional lymph nodes were determined."1.26Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer. ( Cho, K; Fujita, Y; Majima, S; Morisawa, K; Nakao, E; Nishioka, B; Takahashi, T; Ueda, T; Watanabe, S, 1978)
"Two young women with cancer of the pancreas are described."1.26Cancer of the pancreas in young adults. ( Butterfield, D; Hobbs, JB; Kune, GA; Sali, A, 1978)
"A series of 156 patients with gastric cancer during a 15-year period were reviewed retrospectively to determine the effectiveness of combined surgery and adjuvant chemotherapy."1.26The treatment of gastric cancer with combined surgical resection and chemotherapy. ( Cruz, AB; Franz, JL, 1977)
"Seventeen patients with metastatic breast carcinoma were treated with a combination of 5-fluorouracil, methotrexate, vincristine, cyclophosphamide and prednisone."1.25Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma. ( Blom, J; Stutz, FH; Tormey, DC, 1973)

Research

Studies (4,932)

TimeframeStudies, this research(%)All Research%
pre-1990924 (18.73)18.7374
1990's900 (18.25)18.2507
2000's1421 (28.81)29.6817
2010's1466 (29.72)24.3611
2020's221 (4.48)2.80

Authors

AuthorsStudies
Rewcastle, GW1
Atwell, GJ1
Baguley, BC1
Calveley, SB1
Denny, WA1
Nambaru, PK1
Hübner, T1
Köck, K1
Mews, S1
Grube, M1
Payen, L1
Guitton, J1
Sendler, M1
Jedlitschky, G1
Rimmbach, C1
Rosskopf, D1
Kowalczyk, DW1
Kroemer, HK1
Weiss, FU1
Mayerle, J4
Lerch, MM3
Ritter, CA1
Lin, LW1
Lai, PS1
Chen, YY4
Chen, CY2
Hadj Bachir, E1
Poiraud, C1
Paget, S1
Stoup, N1
El Moghrabi, S1
Duchêne, B1
Jouy, N1
Bongiovanni, A1
Tardivel, M1
Weiswald, LB2
Vandepeutte, M1
Beugniez, C1
Escande, F1
Leteurtre, E1
Poulain, L2
Lagadec, C1
Pigny, P1
Jonckheere, N1
Renaud, F1
Truant, S1
Van Seuningen, I2
Vincent, A1
Catenacci, DVT2
Othman, MS1
Al-Bagawi, AH1
Obeidat, ST1
Fareid, MA1
Habotta, OA1
Moneim, AEA1
Giommoni, E3
Lavacchi, D1
Tirino, G1
Fornaro, L6
Iachetta, F1
Pozzo, C5
Satolli, MA3
Spallanzani, A1
Puzzoni, M1
Stragliotto, S1
Sisani, M1
Formica, V2
Giovanardi, F2
Strippoli, A1
Prisciandaro, M1
Di Donato, S1
Pompella, L1
Pecora, I1
Romagnani, A1
Fancelli, S1
Brugia, M1
Pillozzi, S1
De Vita, F12
Antonuzzo, L2
Garnier, J2
Magallon, C1
Ewald, J3
Palen, A1
Marchese, U3
Delpero, JR8
Turrini, O6
Högner, A1
Al-Batran, SE17
Siveke, JT5
Lorenz, M6
Bartels, P1
Breithaupt, K4
Malfertheiner, P1
Homann, N10
Stein, A2
Gläser, D1
Tamm, I1
Hinke, A5
Vogel, A1
Thuss-Patience, P6
Gebauer, F1
Damanakis, AI1
Popp, F1
Quaas, A1
Kütting, F2
Lutz, K1
Held, S1
Deuß, B1
Göser, T1
Waldschmidt, D1
Bruns, C1
Assenat, E2
de la Fouchardière, C7
Portales, F4
Ychou, M26
Debourdeau, A1
Desseigne, F8
Iltache, S1
Fiess, C1
Mollevi, C3
Mazard, T3
Su, YY2
Chiu, YF1
Li, CP4
Yang, SH9
Lin, J2
Lin, SJ1
Chang, PY2
Chiang, NJ3
Shan, YS4
Ch'ang, HJ1
Chen, LT12
Rogers, JE1
Wang, X13
Trail, A1
Ajani, JA43
Quesada, S1
Samalin, E8
Thezenas, S4
Khellaf, L1
Mourregot, A2
Adenis, A9
Yoshida, R1
Mizuno, D1
Suemori, K1
Miyauchi, S3
Iga, N1
Uno, F2
Kawai, H2
Ishizaki, M2
Nishi, H1
Yamashita, K4
Lalonde, CS1
Wang, L16
Quigley, B1
Patel, P3
Maithel, SK5
El-Rayes, BF11
Akce, M1
Lee, LD1
Pozios, I1
Liu, V1
Nachbichler, SB1
Böhmer, D1
Kamphues, C1
Beyer, K1
Bruns, CJ8
Kreis, ME1
Seeliger, H2
Moore, JL1
Kumar, S3
Santaolalla, A1
Patel, PH1
Kapiris, M1
Van Hemelrijck, M1
Maisey, N2
Hill, M5
Lagergren, J1
Gossage, JA4
Kelly, M1
Chaudry, A2
Allum, WH10
Baker, CR1
Cunningham, D57
Davies, AR1
Zaibet, S1
Hautefeuille, V4
Auclin, E3
Lièvre, A5
Tougeron, D9
Sarabi, M2
Gilabert, M4
Wasselin, J1
Edeline, J3
Artru, P12
Bechade, D3
Morin, C1
Ducoulombier, A1
Taieb, J22
Pernot, S6
Meneses-Medina, MI1
Gervaso, L1
Cella, CA1
Pellicori, S1
Gandini, S1
Sousa, MJ1
Fazio, N6
Hochster, HS8
Alexander, HR2
Janssen, QP4
van Dam, JL2
Doppenberg, D2
Prakash, LR3
van Eijck, CHJ3
Jarnagin, WR4
O' Reilly, EM1
Paniccia, A3
Besselink, MG7
Katz, MHG6
Tzeng, CD3
Wei, AC3
Zureikat, AH5
Groot Koerkamp, B3
Chiu, TJ1
Chiu, SC2
Hsueh, SW1
Bai, LY1
Cheng, FM1
Chuang, SC1
Chan, DC1
Yen, CJ2
Peng, CM2
Chen, JS5
Chou, WC1
Zheng, S2
Hu, C1
Lin, H2
Li, G4
Xia, R1
Zhang, X12
Su, D3
Li, Z3
Zhou, Q1
Chen, R2
Moussa, O1
Bhogal, RH1
Malietzis, G1
Fribbens, C1
Starling, N7
Gerlinger, M1
Watkins, D4
Chau, I19
Rao, S7
Matsumura, K2
Yamamura, K1
Miyamoto, H7
Hara, Y1
Oda, E1
Akahoshi, S1
Yoshida, K11
Yuki, H1
Motohara, T2
Sakamoto, K5
Komohara, Y1
Beppu, T3
Elias, R1
Cockrum, P3
Surinach, A3
Wang, S5
Chul Chu, B1
Shahrokni, A1
Canton, C1
Boussari, O1
Boulin, M1
Le Malicot, K7
Dahan, L6
Lopez, A1
Lepage, C10
Bachet, JB16
Mehta, R1
Frakes, J2
Kim, J5
Nixon, A1
Liu, Y10
Howard, L1
Martinez Jimenez, ME1
Carballido, E1
Imanirad, I2
Sanchez, J2
Dessureault, S1
Xie, H2
Felder, S2
Sahin, I2
Hoffe, S4
Malafa, M2
Kim, R4
Kim, G2
Wainberg, Z2
Temraz, S5
Nassar, F1
Hammoud, MS2
Mukherji, D6
O'Reilly, EM12
Dbouk, H1
Farhat, F2
Charafeddine, M4
Faraj, W3
Khalifeh, MJ1
Abou-Alfa, GK4
Shamseddine, A8
Kamposioras, K1
Papaxoinis, G2
Dawood, M1
Appleyard, J1
Collinson, F1
Lamarca, A2
Ahmad, U1
Hubner, RA2
Wright, F1
Pihlak, R2
Damyanova, I1
Razzaq, B1
Valle, JW8
McNamara, MG2
Anthoney, A7
Ng, M1
Chen, S5
Ong, WS1
Balachander, A1
Seet, A1
Yeong, J1
Sutiman, N1
Lim, TKH1
Lee, B2
Guo, YA1
Leong, WF1
Lee, SS5
Lam, J1
Choo, SP3
Skanderup, AJ1
Biswas, SK1
Tai, D1
Chowbay, B2
Garcia-Aguilar, J7
Patil, S4
Gollub, MJ4
Kim, JK1
Yuval, JB1
Thompson, HM1
Verheij, FS1
Omer, DM1
Lee, M3
Dunne, RF1
Marcet, J4
Cataldo, P3
Polite, B2
Herzig, DO3
Liska, D1
Oommen, S3
Friel, CM2
Ternent, C1
Coveler, AL2
Hunt, S2
Gregory, A1
Varma, MG2
Bello, BL1
Carmichael, JC1
Krauss, J1
Gleisner, A2
Paty, PB10
Weiser, MR5
Nash, GM3
Pappou, E1
Guillem, JG10
Temple, L1
Wei, IH1
Widmar, M2
Lin, S4
Segal, NH2
Cercek, A3
Yaeger, R2
Smith, JJ4
Goodman, KA6
Wu, AJ4
Saltz, LB6
Campoverde, LE1
Batalini, F1
Bulushi, Y1
Bullock, A1
Shimano, R1
Kotake, M2
Ida, A1
Hashimoto, M3
Saito, H13
Sawada, K1
Oshima, M1
Hada, M1
Kato, Y6
Oyama, K3
Hara, T3
Inaki, N1
Janjigian, YY7
Van Cutsem, E29
Muro, K12
Hyung, WJ3
Molena, D1
Marcovitz, M1
Ruscica, D1
Robbins, SH1
Negro, A1
Tabernero, J15
Dos Santos, M1
Lequesne, J1
Leconte, A1
Corbinais, S2
Parzy, A1
Guilloit, JM1
Varatharajah, S1
Brachet, PE1
Dorbeau, M1
Vaur, D1
Le Gallic, C1
Castera-Tellier, M1
Galais, MP2
Clarisse, B1
Yu, KH3
Park, J3
Mittal, A2
El Dika, I1
Epstein, AS2
Ilson, DH10
Kelsen, DP20
Ku, GY2
Li, J20
Park, W3
Varghese, AM1
Chou, JF2
Capanu, M5
Cooper, B1
Bartlett, A1
McCarthy, D1
Sangar, V1
McCarthy, B1
Klein-Brill, A1
Amar-Farkash, S1
Lawrence, G1
Collisson, EA1
Aran, D1
Kato, A1
Naitoh, I1
Naiki-Ito, A1
Hayashi, K4
Okumura, F1
Fujita, Y5
Sano, H1
Nishi, Y1
Miyabe, K1
Inoue, T9
Hirano, A2
Takada, H1
Yoshida, M4
Hori, Y1
Natsume, M1
Kato, H9
Takahashi, S6
Kataoka, H2
Breakstone, R1
Almhanna, K4
Raufi, A1
Beard, RE1
Leonard, KL1
Renaud, J1
Kastura, M1
Dionson, S1
Wood, R1
Sturtevant, A1
Dipetrillo, T4
Olszewski, A1
Safran, H11
Möhring, C1
Timotheou, A1
Mańczak, A1
Sadeghlar, F1
Zhou, T3
Mahn, R1
Bartels, A1
Monin, M1
Toma, M1
Feldmann, G1
Brossart, P1
Köksal, M1
Sarria, GR1
Giordano, FA1
Lingohr, P1
Jafari, A1
Kalff, JC1
Strassburg, CP1
Gonzalez-Carmona, MA1
Crane, CH17
Ellsworth, SG2
Reyngold, M2
Shi, Q6
Meyers, J1
Herman, JM7
Chuong, M1
Wolpin, BM5
Ahmad, S2
Marsh, R1
Schwartz, L1
Behr, S1
Frankel, WL2
Collisson, E1
Leenstra, J1
Williams, TM3
Vaccaro, G1
Venook, A3
Meyerhardt, JA10
Ecker, BL2
Court, CM1
Tao, AJ1
D'Angelica, MI2
Drebin, JA2
Gonen, M6
Pan, H3
Pan, J1
Wu, J6
Zhu, Z5
Hou, Q1
Wang, B5
Li, C5
Liu, L3
Gong, W1
Chai, J1
Guo, H3
Jia, Y5
Santucci, J1
Tacey, M1
Thomson, B1
Michael, M10
Wong, R7
Shapiro, J4
Jennens, R1
Clarke, K1
Pattison, S2
Burge, M2
Zielinski, R1
Nikfarjam, M1
Ananda, S1
Lipton, L1
Gibbs, P5
Marschner, N1
Hegewisch-Becker, S5
Reiser, M1
von der Heyde, E1
Bertram, M1
Hollerbach, SH1
Kreher, S1
Wolf, T1
Binninger, A1
Chiabudini, M1
Kaiser-Osterhues, A1
Jänicke, M1
Gong, J3
Thomassian, S1
Kim, S16
Gresham, G1
Moshayedi, N1
Ye, JY1
Yang, JC1
Jacobs, JP1
Lo, S1
Nissen, N1
Gaddam, S1
Tighiouart, M1
Osipov, A1
Hendifar, A1
Hamad, A2
Crossnohere, N1
Ejaz, A2
Tsung, A1
Pawlik, TM8
Sarna, A1
Santry, H1
Wills, C2
Cloyd, JM1
Zhou, B1
Mai, Z1
Ye, Y3
Song, Y2
Zhang, M4
Yang, X2
Xia, W1
Qiu, X1
Aparicio, T13
Bouché, O24
Etienne, PL8
Barbier, E3
Mineur, L7
Desgrippes, R2
Guérin-Meyer, V3
Hocine, F1
Martin, J1
Le Brun-Ly, V1
Cretin, J2
Desramé, J3
Rinaldi, Y3
Cany, L1
Falandry, C2
Lefevre, LB1
Marous, M1
Terrebonne, E6
Mosser, L1
Turpin, J1
Turpin, A1
Bauguion, L1
Reichling, C1
Van den Eynde, M2
Carola, E10
Hiret, S1
Kroupová, J1
Hanuš, J1
Štěpánek, F1
Sochacka-Ćwikła, A1
Mączyński, M1
Czyżnikowska, Ż1
Wiatrak, B1
Jęśkowiak, I1
Czerski, A1
Regiec, A1
Ramaswamy, A1
Bhargava, P3
Srinivas, S1
Kannan, S1
Bhandare, M1
Chaudhari, V1
Mantri, A1
Kapoor, A1
Das, S1
Booma, N1
Chaugule, D1
Shrikhande, SV1
Ostwal, V1
Tang, JL1
Zhang, B6
Xu, JP1
Qi, L1
Xin, D1
Wang, BZ1
Tian, YT1
Li, Y20
Huang, J4
Zhou, R1
Li, L5
Xi, S1
Zhang, Y10
Liu, Z1
Zeng, D1
Sun, H2
Shi, M3
Bin, J1
Liao, Y1
Liao, W1
Wang, T5
Li, X10
Zhai, J1
Shen, L13
Chen, Q2
Cui, SP1
Wang, D3
Lang, R1
Sarradin, V1
Betrian, S1
Chaltiel, L1
Brac De La Perriere, C1
Delord, JP2
Zeng, H2
Wang, C5
Song, LY1
Jia, SJ1
Zeng, X1
Liu, Q4
Tao, J4
Joseph, MX3
Vaudreuil, A3
Dahiya, M3
Eilers, D3
Gürler, F3
Güven, DC3
Aydemir, E3
Sütçüoğlu, O3
İnci, BK3
Arık, Z3
Yalçın, Ş9
Özdemir, N6
Özet, A3
Yazıcı, O4
Saif, A3
Verbus, E3
Erickson, B4
Kamgar, M3
Tsai, S5
Evans, D4
Hernandez, JM3
Hall, WA3
Chiang, CH3
Chiu, JH1
Ma, KS1
Chen, BS1
Luan, YZ1
Cheng, TC1
Hsieh, CL1
Dayyani, F1
Macarulla, T3
Johnson, A1
Wainberg, ZA4
Fong, ZV1
Verdugo, FL1
Fernandez-Del Castillo, C7
Ferrone, CR8
Allen, JN6
Blaszkowsky, LS8
Clark, JW15
Parikh, AR1
Ryan, DP19
Weekes, CD2
Hong, TS11
Wo, JY8
Lillemoe, KD12
Qadan, M3
Sisic, L2
Crnovrsanin, N1
Nienhueser, H1
Jung, JO1
Schiefer, S1
Haag, GM3
Bruckner, T2
Schneider, M2
Müller-Stich, BP1
Büchler, MW18
Schmidt, T2
Gong, G1
Zheng, Y2
Ganesan, K1
Xiong, Q1
Tsim, KWK1
Goetze, TO1
Hofheinz, RD18
Gaiser, T2
Schmalenberg, H7
Strumberg, D4
Goekkurt, E3
Angermeier, S1
Zander, T1
Kopp, HG1
Pink, D3
Siegler, G1
Schenk, M1
Galizia, G5
Maiello, E5
Bechstein, WO2
Elshafei, M1
Loose, M1
Sookthai, D1
Brulin, T1
Pauligk, C9
Lamarre, N1
Sgouros, J1
Gkoura, S1
Spathas, N1
Tzoudas, F1
Karampinos, K1
Miaris, N1
Visvikis, A2
Dessypris, N1
Mauri, D2
Aravantinos, G5
Theodoropoulos, I1
Stamoulis, G1
Samantas, E4
Hingorani, M1
Goody, R1
Bozas, G1
Zahid, K1
Mitton, DJ1
Jain, P3
Wong, V1
Roy, R3
Fu, Q2
Chen, Y11
Huang, D3
Guo, C1
Xiao, W2
Xue, X2
Zhang, Q7
Gao, S1
Que, R1
Shen, Y3
Bai, X1
Liang, T1
Nicolais, LM1
Caron, M1
Verdini, N1
Fitzgerald, TL1
Lei, Y1
Chen, W3
Tian, X2
Wei, J3
Shen, JP1
Yousef, AM1
Zeineddine, FA1
Zeineddine, MA1
Tidwell, RS1
Beaty, KA1
Scofield, LC1
Rafeeq, S1
Hornstein, N1
Lano, E1
Eng, C6
Matamoros, A2
Foo, WC1
Uppal, A1
Scally, C1
Mansfield, P2
Taggart, M1
Raghav, KP1
Overman, MJ3
Fournier, K2
Procaccio, L1
Merz, V3
Fasano, M1
Vaccaro, V1
Pretta, A1
Noventa, S1
Giordano, G1
Zichi, C1
Pinto, C6
Zecchetto, C2
Barsotti, G1
Milella, M4
Scartozzi, M3
Zaniboni, A4
Spadi, R1
Casalino, S1
Bergamo, F3
De Toni, C1
Melisi, D4
Lonardi, S6
Xu, Y7
Tang, Q1
Ding, N1
Zhang, T2
Luo, H2
Mangieri, CW1
Valenzuela, CD1
Solsky, IB1
Erali, RA1
Pardee, T1
Lima, CMSR2
Howerton, R1
Clark, CJ1
Shen, P2
Kunos, CA1
Piekarz, R1
Collins, JM1
Kinsella, TJ2
Baek, JH7
Kang, BW2
Kang, H1
Cho, M1
Kwon, OK1
Park, JY2
Park, KB1
Seo, AN1
Kim, JG7
Pratap, A1
Qualman, A1
Garrett, H1
The, E1
Chauhan, A1
Idrovo, JP1
Cheng, L1
Wani, S1
Meguid, RA1
Meng, X1
Susan, M1
Macasoi, I1
Pinzaru, I1
Dehelean, C1
Ilia, I1
Susan, R1
Ionita, I1
Schlick, K1
Gantschnigg, A1
Seymer, A1
Huemer, F1
Greil, R4
Weiss, L1
Chi, XJ1
Song, YB1
Liu, DH1
Wei, LQ1
Zhao, AR1
An, X4
Feng, ZZ1
Lan, XH1
Lv, YM1
Li, HJ2
Lan, D1
He, HM1
Singhal, R1
Rogers, SC1
Lee, JH23
Ramnaraign, B1
Fabregas, JC1
Thomas, RM1
Hughes, SJ2
Nassour, I1
Hitchcock, K1
Russell, K1
Kayaleh, O1
Turk, A1
Zlotecki, R1
DeRemer, DL1
George, TJ3
Pillarisetty, VG1
Koh, WJ2
Zhen, DB1
Park, JO20
King, GG1
Sham, JG1
Hannan, LM1
Mann, GN1
Baker, KK1
Redman, MW1
Swanson, PE2
Chiorean, EG4
Whiting, SH1
Tasnim, S1
Sudarshan, M2
Zhang, J12
Han, G3
Tang, J2
Guo, F1
Li, W8
Xie, L1
Xu, H1
Tian, Y3
Pan, L1
Shu, Y3
Ma, L2
Chen, X2
Almeida Junior, JC1
Helal-Neto, E1
Pinto, SR1
Dos Santos, SN1
Bernardes, ES1
Al-Qahtani, M1
Nigro, F1
Alencar, LMR1
Ricci-Junior, E1
Santos-Oliveira, R1
Endo, Y3
Kitago, M1
Aiura, K1
Shinoda, M3
Yagi, H1
Abe, Y1
Oshima, G1
Hori, S3
Nakano, Y5
Itano, O1
Fukada, J1
Masugi, Y1
Kitagawa, Y1
Jia, AY1
Narang, A1
Safar, B2
Zaheer, A1
Murphy, A1
Azad, NS1
Gearhart, S1
Fang, S1
Efron, J2
Warczynski, T1
Hacker-Prietz, A2
Meyer, J2
Sunde, B1
Klevebro, F3
Johar, A1
Johnsen, G3
Jacobsen, AB3
Glenjen, NI2
Friesland, S3
Lindblad, M2
Ajengui, A1
Lundell, L3
Lagergren, P1
Nilsson, M3
Sahu, KK1
Pandey, D1
Mishra, AK1
O'Shea, J1
McGregor, B1
Tran, NH1
Sahai, V1
Griffith, KA5
Nathan, H2
Kaza, R1
Cuneo, KC1
Shi, J2
Kim, E1
Sonnenday, CJ1
Cho, CS1
Lawrence, TS3
Zalupski, MM10
Philip, PA15
Buyse, ME1
Alistar, AT1
Rocha Lima, CM1
Luther, S1
Pardee, TS1
Lin, C4
Verma, V2
Lazenby, A2
Ly, QP2
Berim, LD1
Schwarz, JK2
Madiyalakan, M1
Nicodemus, CF1
Hollingsworth, MA2
Meza, JL2
Are, C2
Padussis, J1
Grem, JL11
Opattova, A1
Horak, J1
Vodenkova, S1
Kostovcikova, K1
Cumova, A1
Macinga, P1
Galanova, N1
Rejhova, A1
Vodickova, L1
Kozics, K1
Turnovcova, K1
Hucl, T1
Sliva, D1
Vodicka, P2
Borg, D1
Sundberg, J1
Brun, E1
Kjellén, E2
Petersson, K1
Hermansson, M1
Johansson, J1
Eberhard, J1
Johnsson, A5
Polish, A1
Joseph, NE1
Marsh, RW1
Gaszynski, R1
Gray, A1
Merrett, N1
Pointet, AL3
Pozet, A1
Trouilloud, I5
Lourenco, N2
Locher, C5
Williet, N2
Soularue, E2
Le Roy, B1
Legué, LM1
van Erning, FN1
Bernards, N1
Lemmens, VEPP1
de Hingh, IHJT2
Creemers, GJ6
Wu, G1
Baine, MJ1
Zhao, N2
Li, S4
Sundar, R1
Ng, A1
Zouridis, H2
Padmanabhan, N1
Sheng, T1
Zhang, S8
Lee, MH3
Ooi, WF1
Qamra, A1
Inam, I1
Hewitt, LC1
So, JB3
Koh, V1
Nankivell, MG1
Langley, RE6
Rozen, SG2
Yong, WP3
Grabsch, HI3
Tan, P2
Tsang, ES1
Spratlin, J1
Cheung, WY3
Kim, CA2
Kong, S1
Gill, S4
Mahalingam, D1
Wilkinson, GA1
Eng, KH1
Fields, P1
Raber, P1
Moseley, JL1
Cheetham, K1
Coffey, M1
Nuovo, G1
Kalinski, P1
Arora, SP1
Fountzilas, C2
Liu, M5
Yang, J3
Cui, X1
Zhou, Z5
Zhan, H1
Ding, K1
Yang, Z9
Fung, KA1
Edil, BH4
Postier, RG1
Bronze, MS1
Fernandez-Zapico, ME1
Stemmler, MP1
Brabletz, T1
Li, YP1
Houchen, CW1
Li, M4
Igarashi, H1
Taniguchi, H10
Nosho, K1
Ishigami, K1
Koide, H1
Mitsuhashi, K1
Okita, K1
Takemasa, I3
Imai, K5
Nakase, H1
Jiang, Z2
Hou, Z1
Liu, W3
Wang, H12
Hammel, P6
Fabienne, P1
Metges, JP1
Andre, T27
Louvet, C35
El Hajbi, F1
Faroux, R3
Guimbaud, R8
Lecomte, T8
Rebischung, C3
Tournigand, C15
Cros, J2
Kay, R1
Hamm, A1
Gupta, A1
El Hariry, I1
Bang, YJ19
Lee, KH11
Chiu, CF2
Kim, JS16
Shim, HJ5
Rau, KM1
Choi, HJ5
Oh, DY16
Belanger, B1
Mukherjee, S4
Boland, PM2
Gosain, R1
Attwood, K1
Tan, W1
Khushalani, N2
Iyer, R2
Fiori, E1
Crocetti, D1
Lamazza, A1
DE Felice, F3
Tarallo, M1
Sterpetti, AV1
Mingoli, A1
Sapienza, P1
DE Toma, G1
Wen, F2
Zheng, H5
Zhang, P2
Zhou, J3
Chen, H2
Zhou, K1
Li, Q5
Bi, F1
Farren, MR1
Sayegh, L1
Ware, MB1
Chen, HR1
Liang, Y1
Krasinskas, A1
Zaidi, M1
Sarmiento, JM1
Kooby, D1
El-Rayes, B2
Shaib, W2
Lesinski, GB1
Law, HC1
Lagundžin, D1
Clement, EJ1
Qiao, F1
Wagner, ZS1
Krieger, KL1
Costanzo-Garvey, D1
Caffrey, TC1
DiMaio, DJ1
Grandgenett, PM1
Cook, LM1
Fisher, KW1
Yu, F3
Woods, NT1
Lof, S1
Korrel, M1
van Hilst, J1
Alseidi, A1
Balzano, G12
Boggi, U1
Butturini, G3
Casadei, R1
Dokmak, S1
Edwin, B1
Falconi, M2
Keck, T1
Malleo, G4
de Pastena, M1
Tomazic, A1
Wilmink, H1
Zerbi, A9
Abu Hilal, M1
Qiang, W1
Wu, Q2
Ni, X1
Zhang, C1
Zhao, J2
Brown, J1
Liepa, AM1
Bapat, B2
Madhwani, S1
Lorenzen, S9
García-Foncillas, J3
Candrilli, SD1
Kaye, JA2
Lee, MC1
Chen, YK1
Hsu, YJ1
Lin, BR1
Alhadid, D1
AlShammari, A1
Almana, H1
Aburahmah, M1
Jain, A2
Roviello, G4
Roviello, F2
Mini, E8
Wen, L1
Yang, S3
Li, P3
Wang, Q2
Kaspo, B1
Fan, H1
Hu, J5
Rosati, G8
Galli, F2
Cantore, M8
Banzi, M1
Zampino, MG5
Mattioli, R2
Cardellino, GG2
Ronzoni, M5
Di Bartolomeo, M4
Tamberi, S1
Marchetti, P2
Rimassa, L1
Corsi, D1
Bochicchio, AM3
Artioli, F1
Labianca, R11
Rulli, E1
Bilancia, D1
Bregni, G1
Lordick, F21
Herrmann, K1
Barbour, AP2
Walpole, ET3
Mai, GT1
Barnes, EH1
Watson, DI6
Ackland, SP3
Martin, JM1
Finch, R1
Karapetis, CS4
Shannon, J2
Nott, LM1
Varma, S1
Marx, G1
Falk, GL2
Gebski, V4
Oostendorp, M1
Wilson, K2
Thomas, J7
Lampe, G1
Zalcberg, JR5
Simes, J2
Smithers, BM6
Archid, R2
Zieker, D2
Weinreich, FJ1
Hönes, F1
Königsrainer, A5
Quintanilla-Martínez, L1
Reymond, MA1
Solass, W1
Nakajima, TE4
Yamaguchi, K6
Boku, N10
Hyodo, I6
Mizusawa, J1
Hara, H3
Nishina, T6
Sakamoto, T3
Shitara, K2
Shinozaki, K4
Katayama, H2
Nakamura, S4
Terashima, M1
Ganschow, P1
Hofmann, L1
Stintzing, S4
Heinemann, V11
Angele, M2
Werner, J4
Schulz, C2
Scherr, AL1
Jassowicz, A1
Pató, A1
Elssner, C1
Ismail, L1
Schmitt, N1
Hoffmeister, P1
Neukirch, L1
Gdynia, G1
Goeppert, B1
Schulze-Bergkamen, H2
Jäger, D13
Köhler, BC1
Chase, L1
Lomnicki, S1
Karrison, T1
de Wilton Marsh, R1
Rampurwala, MM1
Narula, S1
Alpert, L1
Setia, N1
Xiao, SY1
Hart, J1
Siddiqui, UD1
Peterson, B1
Moore, K1
Kipping-Johnson, K1
Markevicius, U1
Gordon, B2
Allen, K1
Racette, C1
Maron, SB1
Liao, CY1
Polite, BN2
Kindler, HL3
Turaga, K1
Prachand, VN1
Roggin, KK1
Ferguson, MK2
Posner, MC3
Wei, L1
Chen, J8
Wen, J1
Wu, D2
Ma, X2
Chen, Z7
Petito, LC1
García-Albéniz, X3
Logan, RW1
Howlader, N1
Mariotto, AB1
Dahabreh, IJ1
Hernán, MA1
Modesto, A1
Dalmasso, C1
Lusque, A1
Vieillevigne, L1
Izar, F1
Moyal, E1
Carrère, N1
Rives, M1
Launay, S1
Moureau-Zabotto, L4
Poizat, F2
Giovannini, M8
Yamano, T1
Kubo, S1
Tomita, N1
Kolla, BC1
Petersen, A1
Chengappa, M1
Gummadi, T1
Ganesan, C1
Gaertner, WB1
Blaes, A1
Loi, M1
Magallon-Baro, A1
Suker, M2
Van Eijck, C1
Hoogeman, M1
Nuyttens, JJ2
Perri, G1
Prakash, L1
Caravati, A1
Varadhachary, GR3
Fogelman, D3
Pant, S2
Koay, EJ1
Herman, J2
Maggino, L2
Kim, M1
Ikoma, N2
Tzeng, CW3
Salvia, R3
Lee, JE15
Bassi, C9
Golan, T2
Barenboim, A2
Lahat, G2
Nachmany, I2
Goykhman, Y2
Shacham-Shmueli, E3
Halpern, N2
Brazowski, E2
Geva, R2
Wolf, I2
Goldes, Y1
Ben-Haim, M1
Klausner, JM2
Lubezky, N2
Wu, S2
Turner, JR2
Blangero, Y1
Rabilloud, M1
Laurent-Puig, P7
Ecochard, R1
Subtil, F2
Laurent-Badr, Q1
Barbe, C1
Brugel, M1
Volet, J1
Grelet, S1
Desot, E1
Botsen, D2
Deguelte, S1
Pitta, A1
Abdelli, N1
Brasseur, M1
De Mestier, L1
Neuzillet, C2
Sugarbaker, PH6
Nishikawa, Y1
Hoshino, N1
Horimatsu, T3
Funakoshi, T2
Hida, K1
Sakai, Y4
Muto, M3
Nakayama, T4
Probst, EA1
Smith, AL1
Abad, JD1
Park, H2
Jin, RU1
Wang-Gillam, A10
Suresh, R2
Rigden, C1
Amin, M1
Tan, BR3
Pedersen, KS1
Lim, KH2
Trikalinos, NA1
Acharya, A1
Copsey, ML1
Navo, KA1
Morton, AE1
Gao, F2
Lockhart, AC3
Scarabel, L1
Garziera, M1
Fortuna, S1
Asaro, F1
Toffoli, G1
Geremia, S1
Liao, L1
Cheng, Q1
Zhu, G1
Pei, F1
Ye, S2
Tintelnot, J1
Binder, M1
Knorrenschild, JR1
Kretzschmar, A7
Ettrich, T1
Lindig, U2
Jacobasch, L1
Nilsson, S1
Bokemeyer, C9
Michelakos, T2
Cai, L2
Villani, V1
Sabbatino, F2
Kontos, F2
Yamada, T13
Neyaz, A1
Taylor, MS2
Deshpande, V3
Kurokawa, T3
Ting, DT3
Warshaw, AL4
Ferrone, S1
Sakai, D1
Sugimoto, N1
Tamura, T4
Esaki, T4
Denda, T5
Okuda, H2
Satoh, T7
Tsushima, T2
Makiyama, A2
Tsuda, T2
Hosokawa, A5
Kuramochi, H1
Tokunaga, S5
Moriwaki, T3
Yasui, H4
Ishida, H6
Tsuji, A9
Otsu, S1
Shimokawa, H1
Baba, E3
Sato, M8
Matsumoto, S5
Ozaki, Y2
Tamagawa, H1
Goto, M4
Kadowaki, S4
Fujii, H1
Koh, Y1
Yamazaki, K7
Hironaka, S3
Kishimoto, J1
Pan, CH1
Otsuka, Y3
Sridharan, B1
Woo, M1
Leiton, CV1
Babu, S1
Torrente Gonçalves, M1
Kawalerski, RR1
K Bai, JD1
Chang, DK4
Biankin, AV2
Scampavia, L1
Spicer, T1
Escobar-Hoyos, LF1
Shroyer, KR1
Taghizadeh, H1
Unseld, M1
Schmiderer, A1
Djanani, A1
Wilthoner, K1
Buchinger, D1
Prager, GW1
Frampton, JE1
Taibi, A1
Lo Dico, R1
Kaci, R1
Naneix, AL1
Mathonnet, M1
Pocard, M1
Yan, D3
Sun, Q1
Du, T1
Cao, D1
Yang, Y4
Yuan, B1
Li, H7
Jiang, X1
Song, C1
Colombo, PE1
Quenet, F2
Alric, P1
Neron, M1
Rouanet, P3
Carrier, G1
Wu, AA1
Bever, KM1
Ho, WJ1
Fertig, EJ1
Niu, N1
Zheng, L3
Parkinson, RM1
Durham, JN1
Onners, B1
Ferguson, AK1
Wilt, C1
Ko, AH7
Laheru, DA5
Anders, RA1
Thompson, ED1
Sugar, EA2
Jaffee, EM3
Le, DT2
Begg, SKS1
Birnbaum, DJ1
Mino-Kenudson, M1
Wellner, UF1
Schilling, O1
Castillo, CF1
Liss, AS1
Fumet, JD1
Vincent, J2
Bengrine, L1
Hennequin, A1
Granconato, L1
Palmier, R1
Ghiringhelli, F4
Cao, C2
Parikh, P1
Moezardalan, K1
Anantharaman, A1
Azarm, A1
Lai, J1
Khemissa Akouz, F1
Wahiba, B1
Louafi, S2
Gratet, A1
Miglianico, L1
Laharie, H1
Bouhier Leporrier, K1
Thirot Bidault, A2
Texereau, P1
Coriat, R9
Gouttebel, MC1
Malka, D5
Gürbüz, M1
Akkuş, E1
Utkan, G1
Nicolle, R1
Blum, Y1
Duconseil, P1
Vanbrugghe, C1
Brandone, N1
Roques, J1
Bigonnet, M1
Gayet, O1
Rubis, M1
Elarouci, N1
Armenoult, L1
Ayadi, M1
de Reyniès, A1
Grandval, P1
Garcia, S1
Canivet, C1
Bournet, B1
Buscail, L2
Moutardier, V5
Iovanna, J1
Dusetti, N1
Patil, NR1
Khan, GN1
Ye, L4
Hines, OJ2
Pishvaian, MJ3
He, AR1
Hwang, JJ1
Smaglo, BG1
Kim, SS3
Weinberg, BA1
Weiner, LM9
Marshall, JL4
Brody, JR2
Fu, X2
Chang, L1
Hui, D1
Jia, R1
Liu, N3
Zhang, H6
Han, Z1
Liu, H9
Zhu, H2
Bhutiani, N1
Zheng, Q4
Pandit, H1
Shi, X1
Yu, Y5
Pulliam, ZR1
Tan, M2
Martin, RCG1
Pazderová, N1
Urbán, V1
Makovník, M1
Macák, D1
Janega, P1
Chovanec, M1
Rejleková, K1
Mardiak, J1
Mego, M1
Pucher, PH1
Rahman, SA1
Walker, RC1
Grace, BL1
Bateman, A2
Iveson, T9
Jackson, A1
Rees, C2
Byrne, JP3
Kelly, JJ3
Noble, F4
Underwood, TJ4
Dotan, E2
Cardin, DB1
Lenz, HJ14
Messersmith, W1
O'Neil, B1
Cohen, SJ9
Denlinger, CS2
Shahda, S2
Astsaturov, I1
Kapoun, AM1
Brachmann, RK1
Uttamsingh, S1
Stagg, RJ1
Weekes, C1
Tang, W1
Ren, L2
Liu, T3
Ye, Q1
Wei, Y3
He, G1
Lin, Q2
Wang, M4
Liang, F1
Cui, Y2
Xu, J11
Kim, BH1
Kim, K16
Jang, JY9
Kwon, W2
Kim, H14
Lee, KB6
Chie, EK10
Choi, YJ5
Byun, Y1
Kang, JS1
Kim, HS8
Han, Y4
Paik, WH2
Lee, SH11
Ryu, JK2
Kim, YT3
Lee, K2
Jang, JK1
Byun, JH2
Kang, JH5
Son, JH1
Kim, JH26
Kim, HJ20
Yoo, C1
Kim, KP3
Hong, SM1
Seo, DW2
Kim, SC3
Lee, MG2
Pourghasemian, M1
Danandeh Mehr, A1
Molaei, M1
Habibzadeh, A1
Zeidan, YH2
Kreidieh, M2
Khalifeh, I2
Turfa, R2
Kattan, J6
Alqasem, K2
Amarin, R2
Al Awabdeh, T2
Deeba, S2
Jamali, F2
Mohamad, I2
Elkhaldi, M2
Daoud, F2
Al Masri, M2
Dabous, A2
Hushki, A2
Jaber, O2
Khoury, C1
El Husseini, Z2
Al Darazi, M2
Geara, F3
Birgisson, H1
Enblad, M1
Artursson, S1
Ghanipour, L1
Cashin, P1
Graf, W5
Ettrich, TJ1
Perkhofer, L1
Decker, T3
Hoffmann, T1
Hebart, HF1
Herrmann, T4
Hannig, CV1
Büchner-Steudel, P1
Güthle, M1
Hermann, PC1
Berger, AW1
Seufferlein, T3
Granata, V3
Fusco, R3
Palaia, R3
Belli, A1
Petrillo, A6
Izzo, F3
Koizumi, M3
Shinji, S2
Matsuda, A2
Yokoyama, Y4
Takahashi, G1
Iwai, T2
Takeda, K4
Hara, K4
Yoshida, H4
Foster, L1
Satyadas, T1
Siriwardena, A1
Song, J2
Xu, B1
Boyce, J1
Tawagi, K1
Cole, JT1
Hagen, ER1
Cleary, RK1
Hue, JJ1
Sugumar, K1
Bingmer, K1
Ammori, JB1
Winter, JM3
Hardacre, JM3
Walma, MS2
Brada, LJ1
Patuleia, SIS1
Blomjous, JG1
Bollen, TL1
Bosscha, K2
Bruijnen, RC2
Busch, OR3
Daams, F1
van Dam, R1
Festen, S2
Jan de Groot, D1
Willem de Groot, J1
Mohammad, NH3
Hermans, JJ2
de Hingh, IH4
Kerver, ED1
van Leeuwen, MS1
van der Leij, C1
Liem, MS1
van Lienden, KP2
Los, M3
de Meijer, VE2
Meijerink, MR1
Mekenkamp, LJ1
Nederend, J2
Nio, CY1
Patijn, GA2
Polée, MB2
Pruijt, JF2
Renken, NS1
Rombouts, SJ1
Schouten, TJ1
Stommel, MWJ2
Verweij, ME1
de Vos-Geelen, J2
de Vries, JJJ2
Vulink, A1
Wessels, FJ2
Wilmink, JW4
van Santvoort, HC2
Molenaar, IQ1
Evrard, C1
Hajbi, FE1
Fiore, FD1
Malicot, KL1
Bibeau, F7
Zaanan, A9
Sokol, H1
Chibaudel, B3
Pierre, S1
Gonzalez, D2
Ishiguro, M1
Takenaka, R1
Ogura, K1
Hiratsuka, A1
Takeda, H3
Kawai, D1
Tsugeno, H1
Fujiki, S1
Okada, H1
Sekigami, Y1
Harrison, J1
Catalano, O1
Miwa, K3
Oki, E5
Enomoto, M1
Ihara, K1
Ando, K2
Fujita, F4
Tominaga, M2
Mori, S1
Nakayama, G2
Shimokawa, M2
Saeki, H5
Baba, H10
Mori, M15
Akagi, Y1
Runkel, M1
Verst, R1
Spiegelberg, J1
Fichtner-Feigl, S2
Hoeppner, J2
Glatz, T2
Nishiki, M1
Yoshida, Y7
Ryu, S1
Ichikawa, J1
Shin, Y1
Sannomiya, H1
Koreeda, N1
Yamana, I1
Sato, K4
Okamoto, T3
Yanagisawa, J1
Noritomi, T1
Dreyfuss, AD1
Barsky, AR1
Wileyto, EP1
Eads, JR2
Kucharczuk, JC1
Williams, NN1
Karasic, TB1
Metz, JM4
Ben-Josef, E7
Plastaras, JP2
Wojcieszynski, AP1
Sohal, DPS2
Duong, M1
Ahmad, SA1
Gandhi, NS1
Beg, MS1
Wade, JL1
Guthrie, KA3
Lowy, AM5
Barrak, D1
Desale, S1
Yoon, JJ1
Dugan, MM1
Kodavanti, PP1
Sampah, ME1
Shah, MA9
Bodoky, G9
Starodub, A1
Yip, D5
Bendell, J2
Thai, D1
He, J3
Bigness, A1
Sahin, IH1
Laskowitz, D1
Sigel, K1
Zhou, M1
Park, YA4
Mutetwa, T1
Nadkarni, G1
Yeh, C1
Polak, P1
Sigel, C1
Conroy, T13
Juzyna, B2
Fojo, T1
Wisnivesky, JP1
Bates, SE2
Gani, C2
Lamprecht, U2
Ziegler, A1
Moll, M1
Gellermann, J1
Heinrich, V1
Wenz, S1
Fend, F1
Bitzer, M3
Zips, D1
Mitachi, K1
Ariake, K1
Shima, H1
Sato, S6
Miura, T6
Maeda, S3
Ishida, M2
Mizuma, M1
Ohtsuka, H1
Kamei, T1
Igarashi, K1
Unno, M1
Marthey, L3
Abdallah, R1
Mas, L2
Francois, E7
Saint, A1
Cunha, AS4
Vienot, A1
Ksontini, F1
Forestier, J2
Fabiano, E1
Leroy, F1
Li, K2
He, X3
Tong, S1
Jooste, V1
Bouvier, AM2
Abrams, SL1
Akula, SM1
Meher, AK1
Steelman, LS1
Gizak, A1
Duda, P1
Rakus, D1
Martelli, AM1
Ratti, S1
Cocco, L1
Montalto, G1
Cervello, M1
Ruvolo, P1
Libra, M1
Falzone, L1
Candido, S1
McCubrey, JA1
Wijetunga, AR1
Chua, TC3
Nahm, CB1
Pavlakis, N2
Clarke, S4
Chan, DL1
Diakos, C1
Maloney, S1
Ashrafi-Zadeh, A1
Kneebone, A4
Hruby, G1
Jamieson, NB2
Gill, A1
Samra, JS1
Fuchs, CS15
Bhagia, P1
Adelberg, D1
Qin, SK2
Zarkavelis, G1
Koliou, GA1
Papadopoulou, K1
Batistatou, A1
Pazarli, E1
Tryfonopoulos, D1
Tsipoura, A1
Bobos, M1
Psyrri, A2
Makatsoris, T4
Petraki, C1
Pectasides, D4
Fountzilas, G10
Pentheroudakis, G6
Aomatsu, N2
Maeda, K7
Uchima, Y2
Matsutani, S1
Tsujio, G1
Okada, T1
Kurihara, S1
Nishii, T2
Tachimori, A1
Ikeda, K4
Takeuchi, K5
Rovers, KP1
Bakkers, C1
Nienhuijs, SW1
Burger, JWA1
Creemers, GM1
Thijs, AMJ1
Brandt-Kerkhof, ARM1
Madsen, EVE1
van Meerten, E1
Tuynman, JB1
Kusters, M2
Versteeg, KS1
Aalbers, AGJ1
Kok, NFM1
Buffart, TE1
Wiezer, MJ1
Boerma, D1
de Reuver, PR1
Bremers, AJA1
Verheul, HMW1
Kruijff, S1
de Groot, DJA1
Witkamp, AJ1
van Grevenstein, WMU1
Koopman, M4
Lahaye, MJ1
Kranenburg, O1
Fijneman, RJA1
van 't Erve, I1
Snaebjornsson, P3
Hemmer, PHJ1
Dijkgraaf, MGW1
Punt, CJA2
Tanis, PJ1
Le, VH1
Franko, J1
Paz, BI1
Singh, G1
Fakih, M3
Chung, V4
Abdel-Rahman, O1
King, K1
Scarfe, A2
Ou, FS1
Hall, NC1
Bekaii-Saab, T9
Fruth, B1
Twohy, E1
Meyers, MO1
Boffa, DJ1
Mitchell, K2
Niedzwiecki, D14
Noonan, A1
Thurmes, PJ1
Venook, AP7
Park, SJ1
Joo, I1
Han, JK1
Brada, LJH1
Daamen, LA1
van Roessel, S1
van Dam, RM1
Liem, MLS1
Yung Nio, C1
Wilmink, HW1
Quintus Molenaar, I1
Allen, CJ1
Pointer, DT1
Blumenthaler, AN1
Mehta, RJ1
Hoffe, SE4
Minsky, BD22
Smith, GL1
Blum, M3
Mansfield, PF7
Das, P5
Ajani, J6
Dineen, SP1
Fleming, JB5
Badgwell, BD1
Pimiento, JM1
Machover, D7
Almohamad, W2
Castagné, V1
Desterke, C1
Gomez, L1
Gaston-Mathé, Y1
Boucheix, C1
Goldschmidt, E7
Gratiaux, J1
Gossery, C1
Rezzag-Mahcene, C1
Visseaux, L1
Slimano, F2
Lutsyk, M1
Awawda, M1
Gourevich, K1
Ben Yosef, R1
Watts, K1
Madi, A1
Palles, C1
Maughan, TS3
Kaplan, R1
Al-Tassan, NA1
Kerr, R1
Kerr, D4
Gray, V1
West, H1
Houlston, RS1
Escott-Price, V1
Cheadle, JP1
Shu, C1
Wang, R1
Wen, H1
Tian, Z1
Wu, X9
Gou, G1
Erdoğan, MK1
Ağca, CA1
Aşkın, H1
Caron, B1
Reimund, JM1
Ben Abdelghani, M3
Sondag, D1
Noirclerc, M2
Duclos, B1
Kurtz, JE2
Nguimpi-Tambou, M1
Botta, GP1
Kato, S4
Patel, H2
Fanta, P1
Lee, S11
Okamura, R1
Kurzrock, R1
Na, D1
Chae, J1
Cho, SY2
Kang, W1
Lee, A1
Min, S1
Kang, J3
Kim, MJ3
Choi, J2
Lee, W1
Shin, D1
Min, A1
Kim, YJ6
Kim, TY16
Suh, YS1
Kong, SH1
Lee, HJ4
Kim, WH4
Im, SA15
Yang, HK4
Lee, C5
Kim, JI2
Garza-Treviño, EN1
Martínez-Rodríguez, HG1
Delgado-González, P1
Solís-Coronado, O1
Ortíz-Lopez, R1
Soto-Domínguez, A1
Treviño, VM1
Padilla-Rivas, GR1
Islas-Cisneros, JF1
Quiroz-Reyes, AG1
Said-Fernández, SL1
Sędłak, K1
Rawicz-Pruszyński, K1
Mlak, R1
Gęca, K1
Skórzewska, M2
Pelc, Z1
Małecka-Massalska, T1
Polkowski, WP1
Grieb, BC1
Agarwal, R2
Pijnappel, EN1
Dijksterhuis, WPM1
van der Geest, LG1
de Groot, JWB1
Homs, MYV2
van Laarhoven, HWM1
Makino, S4
Takahashi, H6
Haraguchi, N3
Nishimura, J3
Hata, T5
Matsuda, C1
Ikenaga, M3
Murata, K5
Yamamoto, H11
Doki, Y7
Mizushima, T5
Leong, T7
Haustermans, K3
Miller, D1
Zalcberg, J5
Boussioutas, A2
Findlay, M4
O'Connell, RL1
Verghis, J1
Willis, D2
Kron, T1
Crain, M1
Murray, WK1
Swallow, C2
Darling, G1
Pelzer, U2
Blanc, JF6
Cubillo, A3
Von Hoff, DD2
Wan, Y1
Solem, CT1
Botteman, MF1
de Jong, FA2
Squire, T1
Buchanan, G1
Rangiah, D1
Davis, I1
Chua, YJ7
Rich, T1
Elsaleh, H4
Ishihara, S7
Kawai, K4
Tanaka, T20
Kiyomatsu, T3
Hata, K5
Nozawa, H6
Morikawa, T2
Watanabe, T10
Lamb, YN1
Scott, LJ2
Bozkurt, M2
Amlashi, FG1
Blum Murphy, M1
Sadahiro, S6
Suzuki, T10
Tanaka, A1
Okada, K6
Saito, G1
Miyakita, H1
Ogimi, T1
Nagase, H1
Illerhaus, G2
Martens, UM1
Stoehlmacher, J4
Luley, KB1
Prasnikar, N1
Egger, M1
Probst, S3
Messmann, H1
Moehler, M14
Fischbach, W1
Hartmann, JT15
Mayer, F1
Höffkes, HG1
Koenigsmann, M1
Arnold, D5
Kraus, TW1
Grimm, K1
Berkhoff, S1
Post, S5
Jäger, E10
Bechstein, W1
Ronellenfitsch, U1
Mönig, S1
Du, C1
Peng, Y1
Yao, Y3
Zhao, Y10
Cao, L1
Zhu, WG1
Gu, J3
Idasiak, A1
Galwas-Kliber, K1
Behrendt, K1
Wziętek, I1
Kryj, M1
Stobiecka, E1
Chmielik, E1
Suwiński, R2
Sanford, NN1
Catalano, PJ6
Enzinger, PC9
King, BL1
Bueno, R1
Martin, NE1
Mamon, HJ7
Abrams, TA2
Meyer, G2
Schrag, D6
Schröder, W3
Antonios, A1
Gharios, J1
Tohme, C1
Li, SS3
Guan, QY1
Meng, G1
Chang, XF1
Wei, JW1
Wang, P3
Kang, B1
Xu, JJ1
Chen, HY1
Nakayama, N4
Hirashima, Y5
Fujita, M4
Asayama, M2
Moriyama, I1
Nakashima, K1
Kitamura, H2
Yoshimura, K2
Wang, Y14
Yang, L8
Yin, D1
Sung, S1
Kim, SH17
Nam, TK3
Jeong, S1
Jang, HS3
Song, JH1
Lee, JW5
Bae, JM4
Takayoshi, K1
Kusaba, H1
Uenomachi, M1
Mitsugi, K1
Makiyama, C1
Uchino, K1
Shirakawa, T2
Shibata, Y1
Shinohara, Y1
Inadomi, K1
Tsuchihashi, K1
Arita, S1
Ariyama, H1
Akashi, K1
Park, JJ1
Hajj, C1
Shi, W2
Zhang, Z8
Cuaron, JJ1
Lowery, MA2
Patel, M3
Kurkjian, C2
Hemphill, B1
Flores, M1
Thompson, D1
Hernandez-Aragues, I2
Baniandrés-Rodríguez, O2
Avilés-Izquierdo, JA1
Vilas-Boas, PT2
Oumrani, S1
Guillaumot, MA1
Brieau, B1
Oudjit, A1
Léandri, C1
Brezault, C4
Chaussade, S4
Casadaban, L1
Maker, AV1
Cinar, P2
Voncken, FEM1
van der Kaaij, RT2
Sikorska, K2
van Werkhoven, E1
van Dieren, JM2
Grootscholten, C1
van Sandick, JW4
Aleman, BMP1
Hirsch, D1
Sasaki, T17
Ito, Y7
Ohue, M3
Kanemitsu, Y1
Kobatake, T1
Ito, M2
Moriya, Y1
Saito, N2
Ruff, P2
Lakomy, R1
Prausova, J2
van Hazel, GA2
Moiseyenko, VM6
Soussan-Lazard, K1
Dochy, E1
Magherini, E1
Papamichael, D4
Davuluri, R1
Jiang, W2
Fang, P1
Xu, C1
Komaki, R11
Gomez, DR1
Welsh, J1
Cox, JD5
Hsu, CC3
Lin, SH2
Pariente, R1
Bejarano, I1
Rodríguez, AB1
Pariente, JA1
Espino, J1
Bascoul-Mollevi, C3
Gourgou, S2
Raoul, JL13
Douillard, JY7
Bedenne, L12
Francis, SR1
Orton, A1
Thorpe, C1
Stoddard, G1
Lloyd, S1
Anker, CJ1
Markovina, S1
Youssef, F1
Roy, A2
Aggarwal, S2
Khwaja, S2
DeWees, T1
Tan, B2
Myerson, RJ5
Chang, DT3
Parikh, PJ3
Olsen, JR2
Kluger, MD1
Rashid, MF1
Rosario, VL1
Schrope, BA1
Steinman, JA1
Hecht, EM1
Chabot, JA3
Mazzone, M1
Finisguerra, V1
Prenen, H4
Abramov, M1
Bondarenko, I1
Shparyk, Y1
Gorbunova, V5
Hontsa, A1
Otchenash, N1
Alsina, M2
Lazarev, S1
Feliu, J4
Elme, A2
Esko, V1
Abdalla, K1
Verma, U1
Benedetti, F1
Aoyama, T3
Mizuguchi, H2
Makris, L1
Payette, E1
Sarker, S1
Chalchal, H1
Lloyd, MA1
Turkington, R1
Griffiths, E1
O'Donovan, M1
O'Neill, JR1
Mercer, S1
Parsons, SL5
Fitzgerald, RC1
Song, DJ1
Xu, ZL1
Xie, SP1
Hu, JH1
Tepper, JE10
Ye, X3
Swanson, RS3
Haller, DG20
Dragovich, T1
Alberts, SR11
Bjarnason, GA4
Willett, CG17
Gunderson, LL19
Goldberg, RM20
Ilson, D3
O'Reilly, E3
Ciombor, K1
Berg, DJ1
Meyerhardt, J1
Mayer, RJ13
Ikemura, M1
Hashida, T1
Meyers, JP2
Smyrk, TC4
Julie, C2
Zawadi, A1
Folprecht, G6
Van Laethem, JL7
Sargent, DJ8
Sinicrope, FA6
Lal, H1
Yadav, P1
Jena, R1
Jain, M1
Moussallem, T1
Lim, C2
Osseis, M1
Esposito, F1
Lahat, E1
Fuentes, L1
Salloum, C1
Azoulay, D2
Katanyoo, K2
Mizandari, M1
Paksashvili, N1
Kikodze, N1
Azrumelashvili, T1
Pantsulaia, I1
Shanava, K1
Janikashvili, N1
Chikovani, T1
Muto, O1
Munakata, M2
Yamagata, K1
Masuda, A1
Kotanagi, K1
Kichiraku, T1
Satoyoshi, R1
Kudoh, K1
Sawada, T5
Miyazawa, H1
Ouchi, S1
Kotanagi, H1
Sakata, Y6
Siena, S2
Rivera, F5
Peeters, M7
Koukakis, R1
Demonty, G1
Köhne, CH13
Lee, SF1
Chiang, CL1
Lee, FAS1
Wong, YW1
Poon, CM1
Wong, FCS1
Tung, SY1
Dodo, M1
Kumagai, M1
Hirakawa, H1
Koseki, T1
Tseng, MSF1
Ng, IWS1
Leong, YH1
Leong, CN1
Cheong, WK1
Tey, JCS1
Sönnichsen, R1
Hennig, L1
Blaschke, V1
Winter, K5
Körfer, J1
Hähnel, S1
Monecke, A1
Wittekind, C4
Jansen-Winkeln, B1
Thieme, R1
Gockel, I1
Grosser, K1
Weimann, A1
Kubick, C1
Wiechmann, V1
Aigner, A1
Bechmann, I1
Kallendrusch, S1
Radyk, MD1
Burclaff, J1
Willet, SG1
Mills, JC1
Lund, K1
Olsen, CE1
Wong, JJW1
Olsen, PA1
Solberg, NT1
Høgset, A1
Krauss, S5
Selbo, PK1
Bruckner, HW15
Gurell, D1
Hirschfeld, A1
Yamada, Y15
Gamoh, M3
Iwanaga, I2
Yuki, S4
Shimodaira, H2
Nakamura, M9
Yamaguchi, T16
Ohori, H2
Kobayashi, K8
Tsuda, M3
Kobayashi, Y3
Miyamoto, Y2
Shimada, K2
Sato, A2
Morita, S8
Komatsu, Y8
Ishioka, C4
Conde-Montero, E1
Suárez-Fernández, R1
Liang, D1
Shi, S1
Liang, C1
Meng, Q1
Ni, Q1
Yu, X1
Hyun, HB1
Moon, JY1
Cho, SK1
Park, Y1
Paik, JH1
Kim, SW8
Watanabe, S3
Kariya, K1
Morita, A2
Cremolini, C8
Antoniotti, C2
Aprile, G5
Masi, G10
Grande, R1
Tonini, G5
Mescoli, C3
Coltelli, L1
Salvatore, L8
Corsi, DC3
Lupi, C2
Gemma, D1
Dell'Aquila, E1
Marmorino, F1
Di Fabio, F5
Mancini, ML1
Marcucci, L1
Fontanini, G2
Zagonel, V1
Boni, L2
Falcone, A14
Palmisano, A1
Esposito, A2
Di Chiara, A1
Ambrosi, A4
Passoni, P16
Slim, N5
Fiorino, C2
Albarello, L1
Di Muzio, N3
Calandrino, R3
Rosati, R1
Del Maschio, A1
De Cobelli, F1
Chu, NS1
Wu, IC1
Chin, YY1
Bonucci, M1
Pastore, C1
Ferrera, V1
Fiorentini, C1
Fabbri, A1
Zykova, T1
Zhu, F2
Lim, DY1
Yao, K1
Roh, E1
Yoon, SP1
Kim, HG4
Bae, KB1
Wen, W1
Shin, SH2
Nadas, J1
Ma, W1
Bode, AM1
Dong, Z1
Jin, Z3
Hartgers, ML1
Sanhueza, CT1
Shubert, CR1
Truty, MJ2
Muppa, P1
Nagorney, DM7
Hassan, M1
Mahipal, A2
Kato, T16
Bando, H1
Yoshino, T3
Kagawa, Y2
Iwamoto, S3
Emi, Y4
Touyama, T1
Kotaka, M1
Sakisaka, H1
Yamanaka, T1
Kanazawa, A1
Gouveia, HS1
Lopes, SO1
Faria, AL1
Mayanagi, S1
Kashiwabara, K1
Honda, M1
Oba, K3
Kanda, M2
Maeda, H5
Hamada, C1
Sakamoto, J5
Saji, S6
Yoshikawa, T3
Roxburgh, CSD1
Strombom, P1
Temple, LKF1
Stadler, ZK2
Seier, K1
Reidy, DL1
Varghese, A1
Shia, J7
Vakiani, E2
Kim, SM1
An, JY1
Lee, J17
Sohn, TS6
Antonoff, M1
Jaramillo, S1
Sagebiel, T1
Murphy, MB1
Iveson, TJ5
Kerr, RS1
Saunders, MP6
Cassidy, J6
Hollander, NH1
Haydon, A1
Glimelius, B26
Harkin, A1
Allan, K1
McQueen, J1
Scudder, C1
Boyd, KA1
Briggs, A1
Waterston, A1
Medley, L1
Wilson, C2
Ellis, R1
Essapen, S2
Dhadda, AS1
Harrison, M7
Falk, S9
Raouf, S3
Olesen, RK1
Propper, D2
Bridgewater, J4
Azzabi, A1
Farrugia, D1
Webb, A6
Hickish, T9
Weaver, A1
Gollins, S4
Wasan, HS2
Paul, J3
Qi, F1
Zheng, Z2
Yan, Q1
Liu, J8
Zhang, G2
Usón Junior, PLS1
Rother, ET1
Maluf, FC1
Bugano, DDG1
Kondoh, C1
Komori, A1
Narita, Y2
Ura, T4
Ando, M4
Rombouts, AJM1
Hugen, N2
Verhoeven, RHA1
Elferink, MAG1
Poortmans, PMP1
Nagtegaal, ID5
de Wilt, JHW1
Wawok, P1
Polkowski, W2
Richter, P1
Szczepkowski, M3
Olędzki, J2
Wierzbicki, R4
Gach, T1
Rutkowski, A3
Dziki, A1
Kołodziejski, L1
Sopyło, R2
Pietrzak, L3
Kryński, J2
Wiśniowska, K2
Spałek, M1
Pawlewicz, K1
Polkowski, M1
Kowalska, T1
Paprota, K2
Jankiewicz, M2
Radkowski, A1
Chalubińska-Fendler, J1
Michalski, W2
Bujko, K4
Walston, S1
Salloum, J1
Grieco, C1
Wuthrick, E3
Diaz, DA1
Barney, C1
Manilchuk, A1
Schmidt, C2
Dillhoff, M2
MacGregor, TP1
Carter, R5
Gillies, RS1
Findlay, JM1
Kartsonaki, C1
Castro-Giner, F1
Sahgal, N1
Wang, LM1
Chetty, R3
Maynard, ND1
Cazier, JB1
Buffa, F1
McHugh, PJ1
Tomlinson, I1
Middleton, MR4
Sharma, RA2
Dhir, M1
Zenati, MS2
Singhi, AD1
Bahary, N3
Hogg, ME2
Zeh, HJ2
Petrioli, R6
Nardone, V1
Rosellini, P2
Multari, AG2
Conca, R3
Aieta, M2
Desai, GS1
Pande, P1
Shah, RC1
Jagannath, P1
Jones, CM1
Adams, R3
Downing, A1
Glynne-Jones, R8
Hawkins, M1
Sebag-Montefiore, D3
Gilbert, DC1
Muirhead, R1
Brungs, D1
Aghmesheh, M1
de Souza, P1
Carolan, M1
Clingan, P2
Rose, J1
Ranson, M2
Jang, BS1
Park, HJ3
Huang, KW1
Yang, PC1
Pua, U1
Kim, MD2
Li, SP2
Qiu, YD1
Song, TQ1
Liang, PC1
Tin, AW1
Smith, E1
Hepworth, R1
Walker, J1
Wilson, D3
Wadd, N2
Pokorny, AMJ1
Chin, VT1
Nagrial, AM1
Chantrill, LA1
Cortellini, A1
Cannita, K2
Parisi, A1
Venditti, O1
Lanfiuti Baldi, P2
De Berardis, B1
Vicentini, R2
Vicentini, V1
Verna, L1
Porzio, G1
Ficorella, C2
Erstad, DJ1
Sojoodi, M1
Ghoshal, S1
Razavi, AA1
Graham-O'Regan, KA1
Bardeesy, N1
Lanuti, M1
Caravan, P1
Tanabe, KK1
Fuchs, BC1
Cheng, X2
Cui, YH1
Hou, J2
Ji, Y3
Sun, YH3
Shen, ZB2
Liu, FL2
Liu, TS3
Álvarez-Gallego, R1
Muñoz, M1
Pond, G1
Perea, S1
Sánchez, G1
Martin, M2
Rodríguez-Pascual, J2
Garralda, E1
Vega, E1
de Vicente, E2
Quijano, Y2
Muñoz, C1
Ugidos, L1
Toledo, RA1
Hidalgo, M2
Ahmed, F1
Kumari, S1
Kondapi, AK1
Schwarz, L1
Vernerey, D1
Tuech, JJ1
Michel, P7
Mondaca, S1
Margolis, M1
Sanchez-Vega, F1
Jonsson, P1
Riches, JC1
Hechtman, JF1
Tuvy, Y1
Berger, MF1
Yu, K2
Goldberg, Z1
Desai, A1
Solit, DB1
Schultz, N1
Sehdev, A2
Gbolahan, O1
Hancock, BA1
Stanley, M1
Wan, J1
Wu, HH1
Radovich, M1
O'Neil, BH3
Jiang, ZC1
Chi, Y2
Takada, S1
Sagawa, T4
Fujikawa, K1
Tahatsu, K1
Fukai, Y1
Hashishita, H1
Takahashi, Y3
Endo, M3
Nakache, R1
Rosen, G1
Isakov, O1
de Liguori Carino, N1
O'Reilly, DA1
Siriwardena, AK1
Radhakrishna, G1
Kao, CT1
Aziz, M1
Kasi, A1
Girardi, DM1
Faria, LDBB1
Teixeira, MC1
Costa, FP1
Hoff, PMG1
Fernandes, GS1
Tfayli, A2
Assi, H1
Makki, I1
Nassif, S1
Signorovitch, JE1
Yang, H1
Patterson-Lomba, O1
Xiang, CQ1
Ung, B1
Parisi, M1
Athauda, A1
Mohammed, K1
Tait, D6
Aitken, K1
Cao, Y1
Yu, L4
Lin, L4
Kim, WR1
Han, YD1
Min, BS5
Touchefeu, Y3
Cohen, R3
Gornet, JM5
Nguyen, S5
Azzedine, A3
Phelip, JM4
Chapelle, N1
Sefrioui, D1
Lucidarme, O2
Levache, CB2
Desauw, C1
Brocard, F1
Breysacher, G3
Lagasse, JP1
Di Fiore, F3
Dupuis, OJM1
Aleba, A1
Singh, N2
Wong, E1
Riffat, F1
Zambetti, M4
Montemurro, F2
Morandi, P1
Zamagni, C1
Brandes, AA1
Bisagni, G4
Cagossi, K1
Bengala, C2
Gori, S3
Iannacone, C1
Stell, A1
Gianni, L3
Chakrabarti, S1
Sara, J1
Lobo, R1
Eiring, R1
Finnes, H1
Mitchell, J1
Hartgers, M1
Okano, A1
Halfdanarson, T1
Grothey, A1
Chouhan, H1
Sammour, T1
Thomas, ML1
Moore, JW1
Rhoades, K1
Smith, B1
Honaker, MD1
Druzhkova, I1
Ignatova, N1
Prodanets, N1
Kiselev, N1
Zhukov, I1
Shirmanova, M1
Zagainov, V1
Zagaynova, E1
Yu, S4
Tang, C1
Jiang, H1
Sun, Y6
Shen, Z3
Liu, F7
Lin, HY2
Kuo, WT1
Hsu, CW1
Yamaura, M1
Watanabe, R1
Hirose, S3
Tajima, H1
Uchida, Y4
Suganuma, D1
Yamamoto, Y7
Hu, ZI1
Hellmann, MD1
Wolchok, JD1
Vyas, M1
Diaz, LA2
Saint-Jean, A1
Reguart, N1
Eixarch, A1
Adán, A1
Castellà, C1
Sánchez-Dalmau, B1
Sainz-de-la-Maza, M1
Narjoux, G1
Clarenne, J1
Azzouz, B1
Zeller, PS1
Que, WC1
Huang, YF1
Lin, XY1
Lan, YQ1
Gao, XY1
Wang, XL1
Wu, RP1
Du, B1
Huang, XB1
Qiu, HQ1
Zhong, DT1
Steele, NG1
Chakrabarti, J1
Wang, J12
Biesiada, J1
Holokai, L1
Chang, J2
Nowacki, LM1
Hawkins, J1
Mahe, M2
Sundaram, N1
Shroyer, N1
Medvedovic, M1
Helmrath, M1
Zavros, Y1
Watson, S1
Ferraz, JM1
Lefevre, M1
Colin, D1
Svrcek, M1
Meurisse, A1
Kim, TH8
Lee, IJ1
Lee, CG2
Lee, YC3
Kim, JW3
Borelli, B1
Pietrantonio, F2
Maish, WN1
Nguyen, LK1
Ngu, C1
Bennett, G1
Pranavan, G1
Vogl, UM1
Andalibi, H1
Klaus, A1
Vormittag, L1
Schima, W1
Heinrich, B1
Kafka, A1
Winkler, T1
Öhler, L1
Raufi, AG1
Manji, GA1
Peng, T1
Ouyang, Y1
Tong, K1
Soveri, LM1
Lamminmäki, A1
Hänninen, UA1
Karhunen, M1
Bono, P1
Osterlund, P6
Matsumoto, I2
Kamei, K2
Omae, K2
Suzuki, S4
Matsuoka, H3
Mizuno, N1
Ozaka, M2
Ueno, H6
Kobayashi, S5
Uesugi, K1
Kobayashi, M7
Todaka, A1
Fukutomi, A3
Ito, A2
Takata, R1
Matsuo, T1
Kimura, T3
Otsuka, K1
Ishii, S1
Tokiwa, S1
Tanji, S1
Sugimura, J1
Omori, S1
Obara, W1
Setola, SV1
Albino, V1
Piccirillo, M2
Grimm, R1
Paganini, G1
Chiriacò, G1
Aoto, K1
Inoue, N1
Kono, K2
Margalit, O1
Mamtani, R1
Kopetz, S4
Yang, YX2
Lawrence, YR1
Abu-Gazala, S1
Reiss, KA1
Aderka, D1
Giantonio, B4
Boursi, B1
Chow, OS3
Keskin, M1
Smith, DD3
Avila, K3
Chu, P1
Rezkallah, KNM1
Ahmed, A1
Patel, S3
Kozma, K1
Roca-Lema, D1
Martinez-Iglesias, O1
Fernández de Ana Portela, C1
Rodríguez-Blanco, A1
Valladares-Ayerbes, M3
Díaz-Díaz, A1
Casas-Pais, A1
Prego, C1
Figueroa, A1
Jia, B1
Du, X1
Dai, G3
Zeng, M1
Wen, K1
Zhu, Y5
Feng, L1
Ramanathan, RK7
McDonough, SL1
Hingorani, SR1
Lacy, J4
Kortmansky, JS3
Thumar, J1
Shields, AF9
Behl, D1
Mehan, PT1
Gaur, R1
Seery, T1
Su, X1
Xiao, H1
Chen, C2
Wang, G3
Sasson, A1
Hahn, SM1
Kazlauskas, A1
Darinskas, A1
Meškys, R1
Tamašauskas, A1
Urbonavičius, J1
Fan, Z2
Song, N1
Han, M1
Yan, M1
Guo, LH1
Jihui, J1
Liu, S2
Ichikawa, N1
Homma, S1
Hattori, M2
Kamiizumi, Y1
Omori, K1
Nomura, M3
Yokota, R1
Koike, M2
Kon, H1
Ishizu, H2
Hirose, K1
Kuraya, D1
Ishikawa, T6
Murata, R1
Iijima, H2
Kawamata, F1
Yoshida, T4
Ohno, Y1
Minagawa, N1
Takahashi, N4
Taketomi, A3
Mirakhur, B1
Lu, X1
Huang, Y11
Chi, P1
Radu, IC1
Hudita, A2
Zaharia, C1
Galateanu, B2
Iovu, H1
Tanasa, EV1
Georgiana Nitu, S1
Ginghina, O2
Negrei, C2
Tsatsakis, A1
Velonia, K1
Shtilman, M1
Costache, M2
Massih, SA1
Kanso, M1
Renz, P1
Wegner, RE1
Hasan, S1
Brookover, R1
Finley, G1
Monga, D1
Raj, M1
McCormick, J1
Kirichenko, A1
Cleary, JM1
Horick, NK1
McCleary, NJ1
Yurgelun, MB1
Azzoli, CG1
Rubinson, DA1
Brooks, GA1
Chan, JA1
Goyal, L2
Ng, K1
Savarese, DMF1
Graham, C1
Fitzpatrick, B1
Gibb, KA1
Boucher, Y1
Duda, DG1
Jain, RK1
Rangelova, E1
Wefer, A1
Persson, S2
Valente, R1
Tanaka, K11
Orsini, N1
Segersvärd, R1
Arnelo, U1
Del Chiaro, M1
Kang, YK17
Cho, H1
Lu, B2
Lu, C3
Sun, Z2
Qu, C1
Hua, Z1
Tong, R1
Ozaki, K1
Hayashi, H7
Ikuta, Y2
Masuda, T4
Akaboshi, S1
Ogata, K2
Matumoto, K1
Ogawa, K6
Kamio, T1
Takamori, H2
Pouypoudat, C1
Buscail, E1
Cossin, S1
Cassinotto, C2
Smith, D10
Marty, M1
Dupin, C1
Laurent, C4
Dabernat, S1
Chiche, L1
Vendrely, V6
Ulusakarya, A1
Teyar, N1
Karaboué, A1
Haydar, M1
Krimi, S1
Biondani, P2
Gumus, Y1
Chebib, A1
Morère, JF2
Bradley, CA1
Kourie, H1
Gaujoux, S1
Bruzzi, M1
Sauvanet, A1
El-Hajjar, A1
Vaillant, JC3
Pietrasz, D3
Han, C1
Pang, Q1
Sun, X3
Zhang, W6
Lin, Y1
Ge, X1
Ni, W1
Chang, X1
Liang, J4
Deng, L1
Wang, W3
Xiao, Z1
Buettner, S1
Beumer, BR1
Addeo, P2
Bachellier, P2
Bali, MA1
Boone, BA1
Frakes, JM1
Grose, D1
Hosein, PJ1
Javed, AA1
Khan, K2
Margonis, GA1
McCarter, MD1
McKay, CJ2
Mellon, EA1
Moorcraft, SY2
Okada, KI1
Peters, NA1
Rabl, H4
Samra, J1
Tinchon, C1
van Tienhoven, G1
van Veldhuisen, E1
Weiss, MJ2
Yamaue, H4
Burnett, A1
Lecompte, MA1
Trabulsi, N1
Dubé, P1
Gervais, MK1
Trilling, B1
Cloutier, AS1
Sideris, L1
Xu, X6
De Falco, V1
Natalicchio, MI1
Napolitano, S1
Coppola, N1
Conzo, G1
Martinelli, E2
Zanaletti, N1
Vitale, P1
Giunta, EF1
Vietri, MT1
Vitiello, PP1
Ciardiello, D1
Marinaccio, A1
Ciardiello, F5
Troiani, T1
Wagner, AD3
Mauer, M1
Marreaud, S2
Caballero, C1
Mueller, L1
Moehler, MH1
Martens, U1
Rha, SY14
Cats, A11
Tokunaga, M1
Vollmer, CM1
Behrman, SW1
Allegrini, V1
Aversa, J1
Ball, CG1
Barrows, CE1
Berger, AC2
Cagigas, MN1
Christein, JD2
Dixon, E2
Fisher, WE1
Freedman-Weiss, M1
Guzman-Pruneda, F1
Hollis, RH1
House, MG1
Kent, TS1
Kowalsky, SJ1
Salem, RR2
Schmidt, CR1
Seykora, TF1
Zheng, R1
Dickson, PV1
Mochizuki, Y1
Harada, H2
Oyama, J1
Michi, Y1
Kuroshima, T1
Kugimoto, T1
Huffman, BM1
Yadav, S1
McWilliams, RR1
Halfdanarson, TR1
Das, M1
Hajjar, AH1
Eid, R1
Haddad, FG1
Kourie, HR3
Kadakia, KC1
Worrilow, WM1
Coley, H1
Salem, ME1
Jin, X2
Bai, Y4
Gao, L3
Vreeland, TJ1
McAllister, F1
Javadi, S1
Fogelman, DR1
Ho, L4
Varadhachary, G4
Aloia, TA3
Vauthey, JN8
Kim, MP1
Vashi, PG1
Gorsuch, K1
Wan, L1
Hill, D1
Block, C1
Gupta, D1
Ko, M1
Sim, HC1
Kim, CL1
Jung, YJ1
Kim, TO1
Hwang, JE1
Bae, WK2
Hwang, EC1
Jeong, O1
Ryu, SY1
Park, YK3
Cho, SH4
Chung, IJ4
Bala, A1
Panditharadyula, SS1
Borg, C5
Mantion, G2
Boudghène, F1
Mornex, F10
Azria, D5
Balosso, J5
François, Y1
Rio, E1
Roullet, B2
Spaëth, D1
Quero, L2
Lakkis, Z4
Coudert, M1
Ionescu-Goga, M1
Tanang, A1
Sen, A1
Jiji, V1
Roshni, S1
Prahladan, A1
Venugopal, M1
Ramachandran, K1
Marchegiani, G2
Viviani, E1
Nessi, C1
Ciprani, D1
Landoni, L1
Casetti, L1
Tuveri, M1
Paiella, S1
Casciani, F1
Sereni, E1
Binco, A1
Bonamini, D1
Secchettin, E1
Auriemma, A1
Simionato, F1
D'Onofrio, M1
Huang, M3
Cai, Y3
Xiao, J3
Lan, P3
Hu, H1
Ling, J1
Peng, J3
Chen, D3
Kang, L1
Ren, D3
Lin, F1
Zheng, J3
Deng, Y5
Neely, D1
Ong, J1
Patterson, J1
Kirkpatrick, D1
Skelly, R1
Cabau, M1
Luc, G2
Belleanne, G1
Sa Cunha, A3
Collet, D3
Bajetta, E10
Buzzoni, R6
Ferrario, E3
Valvo, F3
Mariani, L6
Dotti, KF1
Formisano, B1
Gevorgyan, A2
Grassi, P1
Li, PF1
Geng, M1
Cao, YC1
Yin, YC1
Donada, M3
Bonin, S3
Barbazza, R1
Pettirosso, D1
Stanta, G3
Kripp, M4
Rosowski, J1
Saif, MW28
Oikonomopoulos, GM1
Huber, KE1
Syrigos, KN6
Kothari, N1
Skoura, E1
Nichols, RC1
Zaiden, RA1
Awad, ZT1
Asbun, HJ1
Huh, S1
Ho, MW1
Mendenhall, NP1
Morris, CG1
Hoppe, BS1
Pluschnig, U4
Schoppmann, SF4
Preusser, M2
Datler, P2
Asari, R2
Ba-Ssalamah, A4
Schwameis, K2
Birner, P2
Zacherl, J4
Hejna, M5
Uronis, HE2
Bendell, JC7
Altomare, I1
Blobe, GC4
Hsu, SD2
Morse, MA7
Pang, H2
Zafar, SY1
Conkling, P1
Favaro, J1
Arrowood, CC1
Cushman, SM1
Meadows, KL1
Brady, JC1
Nixon, AB1
Hurwitz, HI8
Vañó-Galván, S1
Longo, F1
Grillo, E1
Jaén, P1
Cohn, AL4
Maurel, J6
Nowara, E1
Sastre, J4
Chuah, BYS1
Kopp, MV1
Sakaeva, DD1
Mitchell, EP2
Dubey, S2
Hei, YJ1
Galimi, F1
McCaffery, I2
Pan, Y1
Loberg, R1
Cottrell, S1
Mol, L1
van Gils, CW1
Ottevanger, PB1
Punt, CJ7
van Dijk, TH1
Tamas, K2
Beukema, JC2
Beets, GL1
Gelderblom, AJ1
de Jong, KP1
Rutten, HJ4
van de Velde, CJ7
Wiggers, T2
Hospers, GA3
Havenga, K2
Gordon, MA1
Gundacker, HM1
Benedetti, J3
Macdonald, JS41
Baranda, JC1
Levin, WJ1
Blanke, CD9
Elatre, W1
Weng, P1
Zhou, JY1
Press, MF1
Sohal, DP1
Sun, W5
Giantonio, BJ2
Ginsberg, G1
Kochman, ML1
Teitelbaum, UR1
Harlacker, K1
Heitjan, DF1
Feldman, MD1
O'Dwyer, PJ10
Garcia-Carbonero, R1
Sobrero, A10
Tejpar, S1
Gladkov, O1
Davidenko, I2
Salazar, R5
Vladimirova, L1
Cheporov, S1
Burdaeva, O1
Samuel, L2
Bulavina, I1
Potter, V1
Chang, YL1
Lokker, NA1
Zhang, WY1
Zhang, WJ1
Yuan, HH1
Gao, J2
Gong, YF1
Jiang, B1
Alici, S2
Buyukberber, S5
Alkis, N2
Benekli, M4
Ozkan, M4
Bilici, A4
Demirci, U2
Karaca, H3
Arpaci, E2
Gumus, M5
Altunbas, M1
Dane, F4
Turk, HM1
Berindan-Neagoe, I1
Braicu, C1
Pileczki, V1
Cojocneanu Petric, R1
Miron, N1
Balacescu, O1
Iancu, D1
Ciuleanu, T2
Heinzow, HS1
Seifert, H1
Tsepetonidis, S1
Wolters, H1
Kucharzik, T1
Domschke, W1
Domagk, D1
Meister, T1
Iwasa, S2
Mayahara, H2
Brodowicz, T1
Ciuleanu, TE1
Radosavljevic, D2
Vrbanec, D1
Plate, S1
Mrsic-Krmpotic, Z1
Dank, M3
Purkalne, G1
Messinger, D1
Zielinski, CC1
Saridaki, Z1
Lambrodimou, G1
Kachris, S1
Makrantonakis, P2
Boukovinas, I2
Polyzos, A9
Anagnostopoulos, A1
Athanasiadis, A6
Stoltidis, D1
Georgoulias, V9
Souglakos, J6
Nakai, T1
Okuno, K1
Kitaguchi, H1
Ishikawa, H4
Yamasaki, M4
Carrato, A9
Popov, I3
Gaspà, L1
Valladares, M1
Rougier, P37
Gog, C1
Reichardt, P6
Wils, J8
Pignatti, F1
Biertz, F1
Hendlisz, A4
Golfinopoulos, V1
Deleporte, A1
Paesmans, M3
Mansy, HE1
Garcia, C1
Annemans, L1
Vandeputte, C1
Maetens, M1
Borbath, I1
Dresse, D1
Houbiers, G1
Fried, M1
Awada, A1
Piccart, M2
Laethem, JL1
Flamen, P2
Rudek, MA1
Connolly, RM1
Hoskins, JM1
Garrett-Mayer, E2
Jeter, SC1
Armstrong, DK1
Fetting, JH1
Stearns, V1
Wright, LA1
Zhao, M1
Watkins, SP1
McLeod, HL2
Davidson, NE1
Wolff, AC1
Aichler, M2
Elsner, M1
Ludyga, N1
Feuchtinger, A1
Zangen, V1
Maier, SK1
Balluff, B1
Schöne, C1
Hierber, L1
Braselmann, H1
Meding, S1
Rauser, S1
Zischka, H1
Aubele, M1
Schmitt, M1
Feith, M5
Hauck, SM1
Ueffing, M1
Langer, R8
Kuster, B1
Zitzelsberger, H1
Höfler, H6
Walch, AK1
Haller, B1
Schuster, T2
Luley, K2
Bichev, D4
Schumacher, G2
Waddell, T1
Okines, AF5
Frances, A1
Okines, C1
Wotherspoon, A8
Saffery, C3
Middleton, G5
Wadsley, J2
Ferry, D3
Mansoor, W1
Crosby, T3
Coxon, F3
Waters, J2
Slater, S2
Peckitt, C4
Barbachano, Y7
Chung, HC17
Salman, P1
Oh, SC5
Kurteva, G1
Volovat, C2
Sawaki, A4
Celik, I2
Götte, H1
Melezínková, H1
Xia, Q2
Luo, R1
Huang, P1
Shi, Y1
Yuan, ST1
Wang, FL2
Liu, YH2
Liu, SG1
Li, YQ1
Liu, XB1
Li, WH1
Yu, J3
Zhang, JD1
de Amuriza-Chicharro, N1
Gastalver-Martín, C1
Cortijo-Cascajares, S1
Ferrari-Piquero, JM1
Hurt, CN1
Staffurth, J1
Ray, R1
Bashir, N1
Bridgewater, JA1
Geh, JI2
Blazeby, J1
Maughan, T1
Griffiths, G1
Shridhar, R3
Weber, JM2
Chuong, MD1
Karl, RC2
Meredith, K2
Ozerkan, T1
Aydemir Sezer, U1
Deliloglu Gurhan, İ1
Gulce İz, S1
Hasirci, N1
Khanna, A1
Reece-Smith, AM2
Cunnell, M1
Madhusudan, S4
Thomas, A2
Bowrey, DJ1
Al-Tonbary, Y1
Darwish, A1
El-Hussein, A1
Fouda, A1
Barsukov, YA1
Gordeyev, SS1
Tkachev, SI1
Fedyanin, MY2
Perevoshikov, AG1
Mirinezhad, SK2
Somi, MH2
Seyednezhad, F1
Jangjoo, AG2
Ghojazadeh, M2
Mohammadzadeh, M2
Naseri, AR2
Nasiri, B2
Wu, XY2
Huang, XE3
You, SX1
Lu, YY2
Cao, J2
Yu, DF1
Wu, FR1
Lei, Z1
Tan, IB2
Das, K1
Deng, N1
Chua, C1
Feng, Z1
Guan, YK1
Ooi, CH1
Ivanova, T1
Ngo, A1
Manesh, S1
Tan, E1
Teh, BT1
Goh, LK1
Lim, TK1
Flotow, H1
Bondar', GV3
Basheev, VKh1
Zolotukhin, SÉ1
Sovpel', IV1
Sovpel', OV1
Elezkurtaj, S1
Moser, L1
Budczies, J1
Müller, AJ1
Bläker, H1
Buhr, HJ4
Dietel, M1
Kruschewski, M1
Musio, D2
Bulzonetti, N2
Guarnaccia, R1
Caiazzo, R2
Bangrazi, C1
Raffetto, N1
Tombolini, V3
Zhu, J5
Gu, W2
Lian, P3
Sheng, W2
Cai, G3
Shi, D3
Cai, S4
Xu, HQ1
Qian, YD1
Xiang, J2
Mitry, E12
Dalban, C1
Seitz, JF17
Turki, H1
Lepère, C3
Vaillant, JN2
Landi, B5
El Bouzidi, L1
Mahiou-Leddet, V1
Bun, SS1
Larhsini, M1
Abbad, A1
Markouk, M1
Fathi, M1
Boudon, M1
Ollivier, E1
Bekkouche, K1
Todaro, M1
Orlando, V1
Cicero, G5
Caccamo, N1
Meraviglia, S1
Stassi, G1
Dieli, F1
Cooper, AB2
Katz, MH5
Gerber, N1
Bains, MS1
Rizk, N1
Rusch, VW1
Trusilova, EV1
Besova, NS2
Bagrova, SG1
Gorbunova, VA2
Stilidi, IS1
Nered, SN1
Tang, R6
Sang, Y1
Hu, Q1
Du, Z1
Zhou, Y2
Ahn, JS4
Jeon, JR1
Yoo, HS1
Park, TK2
Park, CK5
Sinn, DH1
Paik, SW1
Miyata, H3
Sugimura, K2
Takahashi, T15
Kurokawa, Y2
Nakajima, K4
Takiguchi, S3
Xu, JM4
Ge, FJ3
Liu, ZY1
Sharma, MR1
Strimpakos, AS3
Loupakis, F8
Yang, D4
Wakatsuki, T1
Bohanes, P1
Schirripa, M4
Benhaim, L1
Graziano, F4
Ruzzo, A2
Lucchesi, S1
Murata, Y1
Matsuura, T1
Kanoshima, K1
Kuwabara, H2
Fuyuki, A1
Tomeno, W1
Taniguchi, R1
Uchiyama, T1
Kuriyama, H1
Hata, Y1
Oh, SY13
Kim, MC3
Kim, KH3
Chen, SS1
Yang, XC1
Chi, F1
Yu, WZ1
Wang, ZB1
Ning, FL1
Yu, ZS1
Hao, YZ1
Li, ML1
Wang, F7
Geng, DZ1
Liu, LH1
Dong, XJ1
Peng, XZ1
Ji, CX1
Lee, DW2
Park, ST1
Park, JS7
Lee, HN2
Shirmohamadi, M1
Seyednejad, F1
Lee, WC2
Yusof, MM1
Lau, FN1
Phua, VC1
Turner, ES1
Ilhan-Mutlu, A1
Püspök, A1
Buyse, M10
Lichinitser, M5
Cascinu, S13
Zaucha, R1
Moiseyenko, V4
Cai, Z1
Ke, J1
Yuan, R1
Tan, JW1
Tan, HM1
Hu, BS1
Chen, K1
Ding, XM1
Leng, JJ1
Chen, F1
Morita, M2
Tsuda, Y1
Hidaka, G1
Kasagi, Y1
Kawano, H2
Otsu, H1
Kimura, Y3
Kusumoto, T1
Maehara, Y9
Murphy, CC1
Incalcaterra, JR1
Albright, HW1
Correa, AM7
Swisher, SG9
Hofstetter, WL4
Huddart, RA1
Hall, E2
Hussain, SA1
Jenkins, P1
Rawlings, C1
Tremlett, J1
Crundwell, M1
Adab, FA1
Sheehan, D1
Syndikus, I1
Hendron, C1
Lewis, R1
Waters, R1
James, ND1
Rumiato, E1
Cavallin, F2
Boldrin, E1
Cagol, M2
Alfieri, R2
Basso, D1
Castoro, C2
Ancona, E3
Amadori, A1
Ruol, A3
Saggioro, D1
Shin, SJ8
Russo, AL1
Borger, DR2
Szymonifka, J2
Liang, WY1
Kwak, EL6
Zhu, AX8
Berger, DL2
Cusack, JC2
Haigis, KM1
Ilyas, S1
Wasif, K1
Bao, Q1
Schwarz, B2
Zhao, L3
Mysliwietz, J2
Ellwart, J1
Renner, A2
Hirner, H1
Niess, H2
Camaj, P3
Gros, S1
Izbicki, J1
Jauch, KW4
Nelson, PJ3
Donnelly, ED1
Refaat, T1
Gentile, M1
Herskovic, A7
Boyle, J1
Helenowski, I1
Rademaker, A2
Lurain, J1
Schink, J1
Singh, D1
Strauss, JB1
Small, W5
Habr-Gama, A12
Sabbaga, J3
Gama-Rodrigues, J11
São Julião, GP6
Proscurshim, I5
Bailão Aguilar, P2
Nadalin, W5
Perez, RO11
Dinnewitzer, A1
Jäger, T1
Nawara, C1
Buchner, S1
Wolfgang, H1
Öfner, D5
Xue, Q1
Wang, XN1
Deng, JY1
Zhang, RP1
Liang, H1
Gurzu, S1
Jung, I3
Comsulea, M1
Kadar, Z1
Azamfirei, L1
Molnar, C1
Kim, SE1
Cole, PD1
Cho, RC1
Ly, A1
Ishiguro, L1
Sohn, KJ2
Croxford, R2
Kamen, BA1
Kim, YI5
Ky, V1
Hav, M1
Berrevoet, F2
Troisi, RI2
Ferdinande, L1
Monsaert, E1
Vanderstraeten, E1
De Bosschere, K1
Van Damme, N1
Laurent, S2
Geboes, K1
Wadhwa, R2
Taketa, T1
Sudo, K2
Campagna, MC1
Blum, MA1
Skinner, H1
Bhutani, MS2
Weston, B1
Maru, DM2
Rice, DC1
Swisher, S4
Kochi, M4
Akiyama, Y2
Aoki, T6
Hagiwara, K1
Hironaka, K1
Teranishi, F1
Osuka, F1
Takeuchi, M1
Fujii, M7
Nakajima, T5
Verhoeven, RH1
Radema, SA1
Lemmens, VE2
de Wilt, JH1
Schiffmann, L3
Wedermann, N1
Gock, M1
Prall, F4
Klautke, G3
Fietkau, R10
Rau, B1
Klar, E1
Oh, D1
Huh, SJ2
Nam, H1
Choi, JY1
Kim, BT1
Hashash, JG1
Proksell, S1
Regueiro, MD1
Martin-Richard, M3
Gallego, R4
Pericay, C4
Garcia Foncillas, J1
Queralt, B1
Casado, E2
Barriuso, J2
Iranzo, V1
Juez, I1
Visa, L1
Saigi, E3
Barnadas, A4
Oranratanaphan, S1
Khemapech, N1
Yao, Z1
Yuan, Y3
Yao, S1
Fan, CW1
Chen, T2
Shang, YN1
Gu, YZ1
Zhang, SL2
Lu, R1
OuYang, SR1
Zhou, X2
Meng, WT1
Hu, JK2
Lu, Y3
Sun, XF2
Bu, H1
Zhou, ZG2
Mo, XM1
Lee, KW6
Park, SR4
Park, YI3
Khosravan, R2
Lin, X3
Lee, SY3
Roh, EJ1
Valota, O1
Lechuga, MJ3
Chao, D3
Chen, WC1
Thirkill, CE1
Lee, AG1
Joseph, R1
Dasanu, CA4
Madbouly, KM1
Abbas, KS1
Hussein, AM1
Guindalini, RS1
Mak, MP1
Takahashi, TK1
Testa, L1
Dzik, C1
Abdul-Jalil, KI1
Sheehan, KM1
Kehoe, J1
Cummins, R1
O'Grady, A1
McNamara, DA1
Deasy, J2
Breathnach, O1
Grogan, L2
O'Neill, BD1
Faul, C1
Parker, I1
Kay, EW1
Hennessy, BT1
Gillen, P1
Kaira, K2
Sunose, Y2
Ohshima, Y1
Ishioka, NS1
Arakawa, K1
Ogawa, T3
Sunaga, N1
Shimizu, K3
Tominaga, H2
Oriuchi, N1
Itoh, H2
Nagamori, S2
Kanai, Y2
Yamaguchi, A1
Segawa, A1
Ide, M3
Oyama, T3
Takeyoshi, I4
Sclafani, F1
Gonzalez de Castro, D2
Cervantes, A7
Eltahir, Z2
Oates, J16
Han, S1
Lee, CW1
Trevino, JG1
Sarosi, GA2
Ye, Z1
Xi, W1
Ma, T4
Mahaseth, H1
Brutcher, E1
Kauh, J2
Hawk, N1
Kooby, DA2
Landry, J4
Mirza, A2
Pritchard, S1
Welch, I1
Dunne, PD1
McArt, DG1
Blayney, JK1
Kalimutho, M1
Greer, S1
Srivastava, S1
Ong, CW2
Arthur, K1
Loughrey, M1
Redmond, K1
Longley, DB3
Salto-Tellez, M3
Johnston, PG5
Van Schaeybroeck, S1
Chang, W2
Gao, X2
Du, Y1
Tan, X1
Fan, X1
Zhou, W1
Fu, C1
Cao, G1
Yoney, A2
Isikli, L2
Hu, XF1
Yao, J1
Gao, SG1
Wang, XS1
Peng, XQ1
Yang, YT1
Feng, XS1
Unal, OU3
Oztop, I7
Unek, IT3
Yilmaz, AU1
Shabihkhani, M1
Thara, E1
Senagore, A1
Sadeghi, S1
Barzi, A2
Ueda, A2
Yoshita, H2
Mihara, H1
Ando, T4
Kajiura, S2
Fujinami, H1
Nishikawa, J1
Minemura, M1
Terada, M2
Kobayashi, T5
Horikawa, N2
Yabushita, K3
Note, M2
Sugiyama, T5
Tseng, YD1
Napolitano, BN1
Ancukiewicz, M3
Shimada, H5
Nagata, M2
Cho, A1
Takiguchi, N3
Kainuma, O2
Soda, H1
Ikeda, A2
Nabeya, Y2
Yajima, S1
Itami, M1
Tran Cao, HS1
Pisters, PW13
Wolff, RA15
Abbruzzese, JL26
Evans, DB20
Abbott, DE1
Curtis, NJ1
Bailey, IS2
Itoh, J3
Mitsuzuka, K1
Kimura, S1
Yamamuro, T1
Yamashita, S4
Yamada, S4
Kaiho, Y1
Arai, Y4
Wu, H2
He, YL1
Xu, JB1
Cai, SR1
Ma, JP1
Chen, CQ1
Zhang, XH1
Zhan, WH1
Reni, M15
Cattaneo, GM2
Cereda, S12
Castoldi, R1
Longobardi, B1
Bettinardi, V1
Gianolli, L1
Gusmini, S1
Staudacher, C7
Archambeaud, I1
Chen, KT2
Devarajan, K1
Milestone, BN1
Cooper, HS3
Denlinger, C1
Meyer, JE2
Hoffman, JP11
Tatli, AM1
Uysal, M1
Goksu, SS1
Gunduz, S1
Arslan, D1
Ozdogan, M1
Hiraki, M2
Ohtsuka, M1
Shiomi, H1
Uemura, M1
Hayashi, T8
Isohashi, F1
Yoshioka, Y1
Ji, K1
Zhang, L9
Hargest, R1
Ji, J5
Jiang, WG2
Greenhalf, W4
Ghaneh, P7
Neoptolemos, JP13
Palmer, DH3
Cox, TF2
Lamb, RF1
Garner, E1
Campbell, F2
Mackey, JR1
Costello, E4
Moore, MJ9
McDonald, AC5
Tebbutt, NC6
Goldstein, D9
Dervenis, C8
Deakin, M2
Charnley, RM2
Lacaine, F4
Scarfe, AG2
Halloran, CM3
Oláh, A5
Jackson, R2
Rawcliffe, CL4
Scarpa, A2
Stiekema, J1
Trip, AK1
Jansen, EP7
Boot, H9
Ponz, OB1
Verheij, M5
Endo, A1
Nakashima, R1
Tanabe, K3
Rodriguez-Bigas, MA4
Chang, GJ1
Skibber, JM3
You, YN1
Munsell, MF1
Clemons, MV1
Kopetz, SE1
Garrett, CR1
Shureiqi, I1
Delclos, ME6
Krishnan, S3
Di Lauro, L4
Vici, P2
Belli, F1
Tomao, S1
Fattoruso, SI1
Arena, MG1
Pizzuti, L1
Giannarelli, D1
Paoletti, G2
Barba, M1
Sergi, D1
Maugeri-Saccà, M1
Zhao, F1
Yi, C1
You, KY1
Peng, HH1
Gao, YH3
Chen, L5
Zhou, GQ1
Chang, H1
Du, XJ1
Xiao, L1
Zeng, ZF4
Wen, BX1
Liu, MZ1
Ubink, I1
van der Sluis, P1
Schipper, M1
Reerink, O1
Voest, E1
Borel-Rinkes, I1
Wijrdeman, H1
Vleggaar, F1
Agterof, M1
Overkleeft, E1
Siersema, P1
van Hillegersberg, R2
Lolkema, MP2
Berger, AK1
Weber, TF1
Springfeld, C2
Vasudev, E1
Shellito, PC4
Ajouz, H1
Haydar, A1
Yakan, AS1
Saleh, A1
Elias, E1
Khalife, M1
Zemelka, T1
Barone, C8
Schlichting, M1
Heighway, J1
Eggleton, SP1
Srimuninnimit, V1
Lee, AM1
Offer, SM1
McConnell, K1
Relias, V1
Diasio, RB8
Kadota, T1
Osuga, T1
Ogawa, H1
Kitami, M1
Ishimura, M1
Shigaki, Y1
Nakajima, E1
Nakata, S1
Kadota, C1
Hirano, S1
Ikura, Y1
Iwai, Y1
Ueno, N3
Ojima, E3
Nakano, T7
Kanamoto, A1
Sasaki, S1
Sueda, T1
Noura, S2
Shingai, T1
Gotoh, K2
Motoori, M2
Kishi, K4
Marubashi, S3
Fujiwara, Y8
Ohigashi, H4
Yano, M3
Tomita, Y2
Ishikawa, O5
Furukawa, H6
Fukunaga, M1
Munakata, S1
Kawabata, R1
Nakata, K2
Yamamoto, T4
Kawase, T2
Ohzato, H1
Torii, Y1
Kato, R2
Minami, Y1
Hasegawa, K4
Fujii, T5
Udagawa, Y1
Hirata, K11
Nagata, N1
Okuyama, Y1
Andoh, H1
Takahashi, K9
Hazama, S3
Mishima, H5
Mochinaga, K1
Tsuchiya, T2
Nagasaki, T3
Arai, J1
Tominaga, T4
Yamasaki, N2
Matsumoto, K3
Miyazaki, T4
Nanashima, A2
Tsukamoto, K2
Nagayasu, T2
Nolan, L1
Bateman, AC1
Sharland, DM1
Rees, CN1
Bateman, AR1
Nandy, N1
Palmer, D1
Cox, T2
Stocken, DD6
O'Reilly, D1
Robinson, BA1
Karapetis, C2
Sand, J2
Izbicki, JR4
Lind, PA4
Sumpter, K4
Hollywood, E1
Reidy-Lagunes, DL1
Temple, LK3
Bichard, D1
Limat, S2
Lorgis, V2
Berthou, J1
Orry, D1
Ortega-Deballon, P1
Facy, O1
Heyd, B1
Rat, P1
Nerich, V2
Ladoire, S1
Pere-Verge, D2
Martel-Lafay, I1
Chapet, S2
Sobhani, I3
Pezet, D4
Dousset, B1
Jouve, JL2
Maillard, E3
Gao, W1
Zeng, F1
Kong, LX1
Naiken, SP1
Toso, C1
Rubbia-Brandt, L3
Thomopoulos, T1
Roth, A8
Mentha, G3
Morel, P3
Gervaz, P4
Chen, FW1
Egbert, BM1
Swetter, SM1
Sarin, KY1
Bosset, JF7
Calais, G4
Maingon, P4
Stojanovic-Rundic, S1
Bensadoun, RJ1
Bardet, E2
Beny, A2
Ollier, JC2
Bolla, M1
Marchal, D1
Klein, V1
Giralt, J1
Clavère, P1
Glanzmann, C1
Cellier, P2
Collette, L3
Alkhateeb, A1
Zubritsky, L1
Kinsman, B1
Leitzel, K1
Campbell-Baird, C1
Ali, SM1
Connor, J1
Lipton, A1
Akiyoshi, T1
Ueno, M2
Fukunaga, Y1
Nagayama, S2
Fujimoto, Y1
Konishi, T4
Kawabe, H1
Tomizawa, G1
Yabuhita, K1
Ruf, C1
Thomusch, O1
Goos, M2
Makowiec, F2
Ruf, G2
Hu, DL1
Guo, XD1
Sun, ZN1
Zhao, YM1
Yu, H2
Lei, H1
Xie, C1
Zhong, Y2
Chan, SL1
Chan, ST1
Chan, EH1
He, ZX1
Aoyama, F1
Hiyoshi, M2
Sawaguchi, A1
Shoji, H2
Morizane, C4
Hiraoka, N1
Kondo, S2
Ohno, I1
Shimizu, S3
Mitsunaga, S1
Ikeda, M8
Okusaka, T9
Barrueco, N1
Such Díaz, A1
Sáez de la Fuente, J1
Escobar, I1
Kim, GJ2
Koshy, M2
Hanlon, AL2
Horiba, MN1
Edelman, MJ1
Burrows, WM1
Battafarano, RJ1
Suntharalingam, M2
Hashimoto, D1
Bläuer, M1
Hirota, M1
Ikonen, NH1
Laukkarinen, J1
Qiu, MZ5
Wei, XL1
Zhang, DS4
Jin, Y2
Zhou, YX1
Wang, DS2
Ren, C2
Bai, L2
Luo, HY4
Wang, ZQ6
Wang, FH6
Li, YH11
Yang, DJ1
Xu, RH10
Van Loon, K1
Zhang, XT2
Chu, YP1
Gong, JF3
Miranda, MB1
Gencer, D2
Hochhaus, A9
Merx, K1
Qin, S1
Xu, R1
Bu, L2
Piao, Y1
Babacan, T1
Turkbeyler, IH1
Dag, MS1
Dilli, I1
Balakan, O1
Altundag, K4
Petrelli, F1
Coinu, A1
Borgonovo, K1
Cabiddu, M1
Ghilardi, M1
Barni, S3
Christians, KK2
Mahmoud, A1
Ritch, P4
Thomas, JP2
Wiebe, L1
Kelly, T1
George, B2
Jin, J4
Li, YX1
Ren, H2
Fang, H1
Wang, SL1
Liu, YP2
Wang, WH1
Yu, ZH2
Song, YW1
Liu, XF1
Kondratska, K1
Kondratskyi, A1
Yassine, M1
Lemonnier, L1
Lepage, G1
Morabito, A1
Skryma, R1
Prevarskaya, N1
Kojouharov, BM1
Brackett, CM1
Veith, JM1
Johnson, CP1
Gitlin, II1
Toshkov, IA1
Gleiberman, AS1
Gudkov, AV1
Burdelya, LG1
Dirican, A4
Kucukzeybek, Y4
Alacacioglu, A4
Varol, U3
Aksun, S1
Bayoglu, IV4
Demir, L4
Coban, E2
Sutcu, R1
Tarhan, MO4
Esnaola, NF1
Chaudhary, UB1
O'Brien, P2
Camp, ER1
Thomas, MB1
Cole, DJ1
Montero, AJ2
Hoffman, BJ1
Romagnuolo, J1
Orwat, KP1
Marshall, DT1
Karakhanova, S2
Mosl, B2
Harig, S5
von Ahn, K1
Fritz, J1
Schmidt, J9
Bazhin, AV2
Faron, M1
Chirica, M1
Tranchard, H1
Balladur, P1
de Gramont, A26
Afchain, P5
Paye, F1
Watkins, DJ1
Webb, J2
Brown, G5
Suzuki, H5
Asao, T6
Tsutsumi, S5
Wada, S1
Araki, K2
Kubo, N2
Watanabe, A5
Tsukagoshi, M1
Kuwano, H10
Patel, K1
Iacobuzio-Donahue, CA1
Gormley, PE1
Kern, SE1
Cunningham, SC2
Marks, E2
Yu, Z2
Yu, JK1
Fang, XF1
Shen, H3
Hamza, S1
Rollot, F1
Faivre, J1
Yeh, YS1
Huang, ML1
Chang, SF1
Chen, CF1
Hu, HM1
Wang, JY2
Ma, ZJ1
Guo, XC1
Mao, ZY1
Wang, LJ1
Zhang, TT1
Sonoda, H2
Shimizu, T3
Mekata, E1
Tani, T3
Tokuda, Y1
Arakura, F1
Uhara, H1
Yoon, HH2
Mahoney, MR2
Nelson, GD1
Nair, SG1
Thibodeau, SN3
Deng, W1
Wang, QW1
Lu, M5
Lu, ZH4
Suarez Martinez-Falero, B1
Gillmore, R2
Bose, A1
Elyagoby, A1
Wong, TW1
Dorth, JA1
Pura, JA1
Palta, M1
D'Amico, TA3
Czito, BG5
Watanabe, M8
Baba, Y2
Yoshida, N1
Ishimoto, T1
Nagai, Y2
Iwatsuki, M1
Iwagami, S1
Dong, L2
Lou, XP1
Miao, JH1
Lu, P1
Chang, ZW1
Han, ZF1
Miyamoto, M1
Kirii, Y1
Takagi, H6
Miyamoto, S3
Li, T5
Jia, X1
Liu, B5
Wan, X1
Lang, J1
Daniel, ES1
Guerrieri, M2
Faragher, I1
Jung, SH3
Etienne-Grimaldi, MC1
Mahamat, A1
Chazal, M1
Olschwang, S1
Gaub, MP1
Formento, JL2
Formento, P1
Sudaka, A1
Boige, V6
Abderrahim-Ferkoune, A1
Benchimol, D1
Houry, S3
Faucheron, JL1
Letoublon, C2
Gilly, FN1
Lasser, P9
Pradere, B1
Penault-Llorca, F2
Milano, G3
Matsumoto, T2
Hasegawa, S4
Okoshi, K2
Yamada, M5
Kawada, K1
Costa, C1
Shen, J1
Sanchez, JJ2
Qian, X1
Zou, Z1
Gimenez-Capitan, A1
Yue, G1
Guan, W1
Rosell, R4
Hoshino, S2
Aisu, N2
Naito, M2
Tanimura, S1
Mogi, A1
Tamura, K4
Yamashita, Y9
Cai, X2
Fang, JM1
Xue, P2
Song, WF2
Gu, HL2
Yang, HY2
Wang, LW4
Hur, H4
Kim, NK18
Baik, SH5
Lee, KY10
Koom, WS4
Ahn, JB9
Roxburgh, P1
Lumsden, GR1
Harden, S1
Sweeting, L1
James, A1
Crellin, A3
Morrison, R2
Evans, TR3
Osti, MF2
Agolli, L2
Bracci, S2
Masoni, L1
Valeriani, M2
Falco, T2
De Sanctis, V2
Maurizi Enrici, R1
van Bunderen, CC1
de Weger, VA1
Griffioen-Keijzer, A1
Ren, G1
Xia, T1
Miura, JT1
Johnston, FM1
Eastwood, D1
Turaga, KK2
Gamblin, TC1
Freilich, J1
Fulp, WJ1
Yue, B1
Holmes, HM1
des Bordes, JK1
Parker, NH1
Shiovitz, S1
Bertagnolli, MM1
Renfro, LA1
Nam, E1
Foster, NR4
Dzieciatkowski, S1
Luo, Y1
Lao, VV1
Monnat, RJ1
Emond, MJ1
Maizels, N1
Warren, RS1
Grady, WM2
Honjo, S1
Scott, AW1
Skinner, HD1
Stroehlein, J1
Johnson, RL1
Song, S2
Bozkurt, O2
Ozaslan, E2
Baldane, S1
Berk, V3
Inanc, M3
Duran, AO2
Dikilitas, M2
Er, O1
Luo, NQ1
Zhang, ZH2
Ma, Y2
Mongan, AM1
Kalachand, R1
King, S1
O'Farrell, NJ1
Power, D2
Ravi, N2
Muldoon, C1
O'Byrne, K1
Reynolds, JV6
Sio, TT1
Wilson, ZC1
Stauder, MC1
Bhatia, S3
Martenson, JA7
Quevedo, JF1
Schomas, DA1
Miller, RC5
Tashiro, J1
Yamaguchi, S4
Ishii, T1
Suzuki, A4
Kondo, H1
Morita, Y2
Koyama, I4
Guo, Mg2
zhong Di, J1
Thind, G1
Johal, B1
Follwell, M1
Kennecke, HF2
Novotny, AR1
Reim, D1
Friess, HM1
Schuhmacher, C3
Senatore, FJ1
Ynson, ML1
Jiang, Y5
Mackley, HB1
Kimchi, ET1
Gusani, N1
Kaifi, J1
Staveley-O'Carroll, KF1
Belani, CP3
Xie, S1
He, L1
Xu, W1
Qin, Z1
Combs, SE1
Habermehl, D1
Kessel, KA1
Bergmann, F1
Naumann, P1
Debus, J5
Okabe, T2
Hoshino, K2
Richter, I2
Dvořák, J4
Bartoš, J2
Takada, T3
Sutoh, T1
Morita, H2
Yajima, R2
Thaler, J7
Petersen, LN2
Blons, H1
Emile, JF4
Lopez-Sánchez, LM1
Jimenez, C1
Valverde, A1
Hernandez, V1
Peñarando, J1
Martinez, A2
Lopez-Pedrera, C1
Muñoz-Castañeda, JR1
De la Haba-Rodríguez, JR1
Aranda, E7
Rodriguez-Ariza, A1
Berkel, AE1
Woutersen, DP1
van der Palen, J2
Klaase, JM1
Han, K1
Maia, M1
Lowe, J1
Sersch, MA1
Allison, DE1
Grey, A1
Cooper, A1
McNeil, C1
O'Toole, S1
Thompson, J4
Grimison, P1
Maggo, G1
Grover, SC1
Grin, A1
Yoon, C2
Park, DJ2
Schmidt, B2
Thomas, NJ1
Kim, TS1
Cohen, DJ2
Yoon, SS1
Ischenko, I1
Krebs, S1
Jäckel, C1
Blum, H1
Ellwart, JW1
Silcocks, P1
Valle, J4
Ross, P4
Roques, T1
Corrie, P2
Robinson, A2
McAdam, K1
Eatock, M2
Evans, J1
Archer, C2
Garcia-Alonso, A1
Nicolson, M8
Steward, W2
Shaw, V1
Naisbitt, D1
Rawcliffe, C1
Nanson, G1
Neoptolemos, J1
Tassone, P1
Yu, R2
Szado, T1
Garg, A1
Donehower, RC5
Tjulandin, S5
Deptala, A1
Nirni, S1
Lakshmaiah, K1
Zhu, M1
Anderson, A1
Oliner, KS1
Loh, E1
Takahashi, M5
Niwa, K2
Ishiyama, S2
Sugimoto, K3
Komiyama, H1
Yaginuma, Y1
Kojima, Y2
Okuzawa, A1
Tomiki, Y1
Chao, TH1
Chang, GR1
Chen, WY1
Chen, PL1
Mao, FC1
Vargas, GM1
Parmar, AD1
Sheffield, KM1
Tamirisa, NP1
Brown, KM1
Riall, TS3
Erten, C2
Somali, I3
Can, A2
Akyol, M3
Yildiz, Y2
Koyuncu, B1
Koca, D1
Yılmaz, U5
Swellengrebel, HA1
Bosch, SL1
Vincent, AD1
Dewit, LG1
Verwaal, VJ3
Marijnen, CA2
Alcindor, T5
Ades, S3
Aloraini, A1
van Huyse, M1
Asselah, J2
David, M2
Frechette, D1
Brisson, S1
Thirlwell, M1
Ferri, L2
Sa-Cunha, A1
Gauthier, M3
Cueff, A1
Manfredi, S3
Solub, D1
Lécaille, C2
Carbonnel, F1
Rudloff, U1
Langan, RC1
Mullinax, JE1
Beane, JD1
Steinberg, SM6
Beresnev, T1
Webb, CC1
Walker, M1
Toomey, MA2
Schrump, D1
Pandalai, P1
Stojadinovic, A1
Avital, I2
Nam, JK1
Park, JK4
Min, do S1
Kuh, HJ2
Lu, W3
Zuo, Y1
Feng, Y2
Ishikawa, K4
Nakamatsu, K1
Shiraishi, O1
Yasuda, T2
Nishimura, Y4
Ramfidis, VS1
De Stefano, A1
Moretto, R1
Bucci, L1
Pepe, S2
Romano, FJ1
Cella, AC1
Attademo, L1
Rosanova, M1
De Falco, S1
Fiore, G1
Raimondo, L1
De Placido, S4
Carlomagno, C4
Lemstrová, R1
Souček, P1
Melichar, B5
Mohelnikova-Duchonova, B1
Battisti, S1
Guida, FM1
Pagliara, E1
Zobel, BB1
Santini, D2
Spratlin, JL1
Armstrong, DE1
Ghosh, S1
Mulder, KE1
Tejani, MA2
ter Veer, A1
Milne, D1
Ottesen, R1
Benson, AB15
Shibata, S2
Skibber, J3
Weiser, M3
Wilkinson, N1
Lee, YY1
Li, CF2
Lin, CY3
Lee, SW3
Sheu, MJ2
Lin, LC2
Chen, TJ2
Wu, TF1
Hsing, CH2
Akgun, Z1
Saglam, S2
Yucel, S2
Gural, Z1
Balik, E2
Cipe, G1
Yildiz, S1
Kilickap, S1
Okyar, A1
Kaytan-Saglam, E1
Shimada, Y10
Sameshima, S2
Ina, K3
Sugihara, K5
Fiteni, F2
Jary, M2
Monnien, F1
Nguyen, T4
Beohou, E1
Demarchi, M1
Dobi, E1
Fein, F3
Cleau, D2
Fratté, S3
Bonnetain, F10
Pivot, X2
Lv, F1
Liu, X3
Jin, M1
Miki, Y3
Hosono, M1
Nagahara, H2
Hirakawa, K4
Shimatani, Y1
Nemoto, H2
Tate, G1
Umemoto, T2
Matsubara, T2
Mizukami, H2
Saito, M2
Kigawa, G1
Matsumiya, A1
Tanaka, J6
Donahue, TR1
Nguyen, AH1
Moughan, J2
Tatishchev, S1
Toste, P1
Farrell, JJ1
Kandioler, D1
Zwrtek, R1
Kappel, S1
Wolf, B1
Mittlböck, M1
Kührer, I1
Wrba, F1
Kalikaki, A1
Politaki, H1
Apostolaki, S1
Papadimitraki, E1
Georgoulia, N1
Tzardi, M2
Mavroudis, D6
Voutsina, A1
Yao, X1
Fischbach, NA1
Stein, S1
Doddamane, I1
Karimeddini, D1
Lambertz, A1
Klink, CD1
Schmitz, D1
Pich, A1
Feher, K1
Bremus-Köbberling, E1
Neumann, UP1
Junge, K1
Rose, PG1
Java, JJ1
Whitney, CW2
Stehman, FB1
Lanciano, R3
Thomas, GM2
Meulendijks, D1
Dewit, L1
Tomasoa, NB1
van Tinteren, H3
Beijnen, JH1
Schellens, JH2
McNamara, MJ1
Adelstein, DJ10
Bodmann, JW1
Greskovich, JF1
Ives, DI4
Mason, DP3
Murthy, SC4
Rice, TW9
Saxton, JP5
Sohal, D1
Stephans, K1
Rodriguez, CP4
Videtic, GM6
Rybicki, LA5
Lindner, K1
Borchardt, C1
Schöpp, M1
Bürgers, A1
Stock, C1
Hussey, DJ5
Haier, J3
Hummel, R3
Velut, G1
Mary, F2
Wind, P2
Schwameis, M1
Schober, A1
Schörgenhofer, C1
Kulinna-Cosentini, C1
Laggner, A1
Röggla, M1
Jilma, B1
Kaytan Saglam, E1
Asoglu, O2
Yamaner, S1
Bugra, D1
Oral, EN1
Kizir, A1
Kapran, Y2
Sakar, B1
Akyuz, A1
Gulluoglu, M1
Cienfuegos, JA2
Rotellar, F1
Baixauli, J6
Beorlegui, C3
Sola, JJ5
Arbea, L4
Pastor, C6
Arredondo, J3
Hernández-Lizoáin, JL7
Marks, JH1
Frenkel, JL1
Greenleaf, CE1
D'Andrea, AP1
Chander, S2
McKendrick, J6
MacKay, JR2
Steel, M1
Hicks, R1
Heriot, A2
Cooray, P3
Jefford, M2
Bressel, M1
McClure, B3
Ngan, SY6
Motschmann, M1
Jütting, U1
Luber, B1
Becker, K11
Ott, K8
Siewert, JR10
Walch, A1
Fang, Y1
Wang, XT1
Dan, X1
Sun, LL1
Yildiz, I1
Muslu, U1
Cokmert, S1
Karabulut, B2
Uslu, R2
Adas, YG1
Andrieu, MN1
Hicsonmez, A1
Atakul, T1
Dirican, B1
Aktas, C1
Yilmaz, S1
Akyurek, S1
Gokce, SC1
Ergocen, S1
Ahlgren, J2
Patel, N1
Simmens, S1
Akin, E1
Bishop, C1
Kirkel, D1
Siegel, P1
Schuck, S1
Guebre-Xabiher, H1
Siegel, R1
Dong, CX1
Fu, JF1
Ye, XY1
Li, XF1
Zhong, X1
Abali, H3
Vural, M1
Oksuzoglu, B4
Civelek, B1
Oguz, D1
Bostanci, B1
Yalcin, B2
Zengin, N5
Xu, N4
Schaeffer, DF1
Yoshida, EM1
Inada, R1
Nagasaka, T2
Toshima, T3
Mori, Y2
Kondo, Y1
Kishimoto, H1
Fujiwara, T3
Ress, AL1
Stiegelbauer, V1
Schwarzenbacher, D1
Deutsch, A1
Perakis, S1
Ling, H1
Ivan, C1
Calin, GA1
Rinner, B1
Gerger, A1
Pichler, M2
Yamahsita, S1
Matsuda, Y1
Kishino, T1
Kushima, R1
Kato, K10
Igaki, H2
Tachimori, Y1
Osugi, H4
Nagino, M3
Ushijima, T2
Iino, C1
Mikami, T1
Sawaya, M1
Aihara, T2
Yamagata, R1
Tono, H1
Tanaka, M5
Fukuda, S3
Ries, P3
Boucher, E2
Holck, S1
Nielsen, HJ1
Hammer, E1
Christensen, IJ1
Larsson, LI1
Blüml, A1
Cermáková, E1
Urbanec, M1
Sitorová, V1
Ryška, A1
Sirák, I2
Buka, D1
Ferko, A1
Petera, J2
Lunardi, G2
Inno, A1
Magarotto, R1
Duranti, S1
Messa, MG1
Mucchino, C1
Cirillo, M2
Chen, HM1
Lin, JK8
Chen, WS3
Jiang, JK5
Lan, YT2
Lin, CC4
Teng, HW2
Osawa, T2
Sano, T3
Shimizu, Y4
Senda, Y1
Yamaura, H1
Inaba, Y3
Larsen, AC1
Holländer, C1
Duval, L1
Schønnemann, K1
Achiam, M1
Pfeiffer, P13
Yilmaz, MK1
Thorlacius-Ussing, O1
Bæksgaard, L1
Ladekarl, M1
Sie, C1
Ansar, A1
Michael, MZ2
Van der Hoek, M1
Blazer, M2
Wu, C3
Phillips, G1
Muscarella, P1
Reardon, J3
Ellison, EC1
Bloomston, M4
el Aziz, LM1
Pardini, B1
Rosa, F1
Naccarati, A1
Vymetalkova, V1
di Gaetano, C1
Buchler, T1
Novotny, J1
Matullo, G1
Lee, SJ4
Park, SH18
Lim, DH6
Park, YS18
Lim, HY10
Choi, MG1
Kang, WK17
Eisterer, W2
De Vries, A2
Koplmüller, R1
Tschmelitsch, J3
Schmid, R2
Kapp, K1
Lukas, P3
Sedlmayer, F1
Höfler, G1
Gnant, M3
Wang, CC1
Liang, JT3
Tsai, CL1
Chen, YH1
Lin, YL1
Shun, CT2
Cheng, JC2
Perez, K3
Sikov, W3
Vrees, M2
Klipfel, A2
Shah, N3
Schechter, S1
Oldenburg, N1
Pricolo, V2
Rosati, K2
Selcukbiricik, F1
Demir, N1
Oven Ustaalioglu, BB1
Yildiz, O1
Misirlioglu, HC1
Coskun-Breuneval, M1
Kucukpilakci, B1
Ugur, VI1
Elgin, Y1
Demirkasimoglu, T1
Kara, SP1
Ozgen, A1
Sanri, E1
Guney, Y1
Fernández-Esparrach, G1
Ayuso-Colella, JR1
Bombí, JA1
Conill, C3
Cuatrecasas, M1
Delgado, S2
Ginés, A2
Miquel, R1
Pagés, M2
Pineda, E1
Pereira, V1
Sosa, A1
Reig, O1
Victoria, I1
Feliz, L1
María de Lacy, A1
Castells, A1
Burkholder, I1
Boni, C7
Massuti, B3
Pimentel, FL1
Cohn, A2
Follana, P1
Clemens, M2
Richards, DA1
Ecstein-Fraisse, E1
Hitier, S1
Lin, JZ3
Luo, JL1
Cai, MY1
Cai, PQ1
Kong, LH3
Liu, GC1
Tang, JH1
Chen, G5
Pan, ZZ7
Ding, PR4
Kong, J1
Wu, Y3
Xu, E1
Lai, M1
Dupont-Gossard, AC1
Thirot-Bidault, A2
Lobry, C1
Asnacios, A1
Manet-Lacombe, S1
Dubreuil, O2
Cools-Lartigue, J1
Jones, D1
Spicer, J1
Zourikian, T1
Rousseau, M1
Eckert, E1
Vanhuyse, M1
Ferri, LE3
Breugom, AJ1
van Gijn, W1
Muller, EW1
Berglund, Å9
van den Broek, CBM1
Fokstuen, T4
Gelderblom, H1
Kapiteijn, E1
Leer, JWH1
Marijnen, CAM1
Martijn, H2
Meershoek-Klein Kranenbarg, E1
Påhlman, L9
Putter, H3
Roodvoets, AGH1
Rutten, HJT1
Steup, WH1
van de Velde, CJH1
Sheen, YT1
Lin, CP1
Sheen, MC1
Tan, BH1
Brammer, K1
Randhawa, N1
Welch, NT1
James, EJ1
Catton, JA1
Namikawa, T1
Munekage, E1
Kitagawa, H2
Hanazaki, K1
Calkins, SM1
Kelley, RK1
Vandamme, M1
Pauwels, W1
Bleecker, JD1
Stashkevych, M1
Khomutov, E1
Dumanskiy, Y1
Matviyenko, A1
Zinkovych, I1
Zhang, N1
Derouet, MF1
Liu, G3
Darling, GE1
Berdov, BA2
Erygin, DV1
Nevol'skikh, AA1
Titova, LN1
Zamulaeva, IA1
Kondrashova, LM1
Xu, CD1
Neofytou, K2
Giakoustidis, A1
Smyth, EC2
Mudan, S2
Izumi, H2
Touge, H1
Igishi, T1
Makino, H3
Nishii-Ito, S1
Takata, M2
Nakazaki, H1
Ueda, Y3
Kodani, M1
Kurai, J1
Yanai, M1
Tanaka, N14
Nirodi, CS1
Shimizu, E2
Li, ZY2
Li, ZW1
Sun, YS1
Ji, JF3
Ferrandina, G1
Gambacorta, A1
Gallotta, V1
Smaniotto, D1
Fagotti, A1
Tagliaferri, L1
Foti, E1
Fanfani, F1
Autorino, R1
Scambia, G1
Valentini, V7
Zhao, HY1
Chen, GY2
Li, XL2
Feng, JF3
Shi, MQ1
Cheng, Y2
Ma, LX1
Zhang, YP2
Gu, CP1
Song, XQ1
Zhou, D1
Poulsen, LØ1
Qvortrup, C4
Yilmaz, M5
Falkmer, U1
Sorbye, H1
Ritch, PS4
Erickson, BA1
McDonnell, EI1
Santos, DD1
Faris, JE1
Murphy, JE1
Kang, SY1
Ahn, MS1
Song, GW1
Choi, YW1
Lee, HW2
Jeong, SH1
Cho, YK2
Han, SU2
Sheen, SS1
Han, JH1
Choi, JH3
Tey, J2
Peng, L2
Fu, S2
Huang, G2
Xiong, F2
Lu, JJ2
Okabe, H3
Ihaya, T1
Kichikawa, K3
Ohashi, Y4
Yuan, F1
Shi, H1
Cai, Q1
Ghasemi, Z1
Dinarvand, R1
Mottaghitalab, F1
Esfandyari-Manesh, M1
Sayari, E1
Atyabi, F1
Strobel, O1
Kozak, MM1
von Eyben, R1
Pai, J1
Vossler, SR1
Limaye, M1
Jayachandran, P1
Anderson, EM1
Shaffer, JL1
Longacre, T1
Pai, RK1
Koong, AC3
Baba, K1
Oshita, A1
Kohyama, M1
Inoue, S6
Kuroo, Y2
Nakamura, H4
Sugiyama, Y4
Tazaki, T2
Sasaki, M5
Imamura, Y2
Daimaru, Y2
Ohdan, H1
Nakamitsu, A2
Ojima, H1
Fukuchi, M1
Sakai, M1
Sohda, M1
Ieta, K1
Saito, K2
Sano, A1
Yokobori, T2
Inose, T1
Nakajima, M2
Riera Knorrenschild, J1
Pohl, M1
Bassermann, F2
Helbig, U1
Weißinger, F2
Schnoy, E1
Stocker, G2
Rüschoff, J2
Eisenmenger, A1
Karapanagiotou-Schenkel, I2
Rizvi, SM1
Sarwani, N1
El-Deiry, WS4
Scheulen, ME1
Jassem, J1
Vynnychenko, I2
Tamura, A2
Ami, K2
Hayasaka, J1
Takagi, K1
Okamoto, E2
Kitazume, A1
Kondou, M1
Gokita, K1
Tei, S2
Arai, K8
Shibayama, T1
Suda, K2
Kameyama, H1
Sakata, J1
Nogami, H1
Minagawa, M1
Kosugi, S2
Koyama, Y3
Wakai, T2
Miyoshi, N1
Fukata, T1
Fujino, S1
Akita, H1
Sakon, M2
Nushijima, Y2
Nakano, K2
Nakaguchi, K3
Kan, K1
Maruyama, H3
Doi, S1
Okamura, S4
Tomihara, H1
Hama, N2
Wada, H2
Tomokuni, A1
Tomimaru, Y1
Asaoka, T1
Kawamoto, K2
Eguchi, H1
Nagano, H2
Jeongho, M1
Hatanaka, N1
Odagiri, K1
Honmyo, N1
Inoue, M6
Irei, T1
Tanemura, M1
Mihara, K1
Yamashiro, N1
Nishiya, S1
Kemmochi, T1
Egawa, T1
Nagashima, A3
Ryschich, E2
Hartwig, W1
Francini, E2
Marrelli, D1
Fiaschi, AI2
Laera, L1
Rossi, G3
Bianco, V1
Brozzetti, S1
Hentic, O3
Murata, S1
Onozawa, S1
Sugihara, F1
Sakamoto, A1
Ueda, T3
Yamaguchi, H5
Yasui, D1
Mine, T1
Kumita, S1
Rosso, E1
Fuchshuber, P2
Oussoultzoglou, E1
De Blasi, V1
Simone, G2
Belletier, C1
Dufour, P2
Lescut, N1
Lepinoy, A1
Schipman, B1
Cerda, T1
Guimas, V1
Bednarek, C1
Neumann, JH1
Jung, A4
Kirchner, T3
McDonald, AM1
Dulaney, CR1
López-Araujo, J1
Posey, JA1
Keene, KS2
Heslin, MJ1
Wood, TE1
Jacob, R1
Rateesh, S1
Shekar, K1
Naidoo, R1
Mittal, D1
Bhaskar, B1
Nicosia, L1
Gentile, G1
Di Nardo, F1
Minniti, G1
Maglio, M1
Borro, M1
Simmaco, M1
Enrici, RM1
Endo, S3
Okuyama, M2
Hiraoka, K1
Konishi, K4
Kim, C4
Nakagawa, T2
Nishikawa, K1
Nishijima, J2
Bowen, JM1
White, I1
Smith, L1
Tsykin, A1
Kristaly, K1
Thompson, SK2
Tan, H1
Game, PA1
Irvine, T1
Keefe, DM1
Argilés, G1
Benson, A2
Guillén Ponce, C1
Macpherson, IR1
Wagner, A1
Luigi Garosi, V1
Grunert, J1
Kordes, S1
Klümpen, HJ1
Weterman, MJ1
Richel, DJ1
Treese, C1
von Winterfeld, M1
Dogan, Y2
Schmidt, SC1
Daum, S3
Thuss-Patience, PC6
Hassan, AS1
Naicker, M1
Yusof, KH1
Wan Ishak, WZ1
Hacibekiroglu, I1
Kodaz, H1
Erdogan, B1
Turkmen, E1
Esenkaya, A1
Uzunoglu, S1
Cicin, I1
Gaduputi, V1
Tariq, H1
Ihimoyan, A1
Guillen, KP1
Restuccia, A1
Harrison, RG1
Smyth, EN1
Ball, DE1
Johnson, E1
Viste, A3
Myrnäs, T1
Szabo, E1
Tsai, JA2
Vishnevskiĭ, AV1
Andreĭtseva, OI1
Kharazov, AF1
Gritsiuta, AI1
Kalinin, DV1
Zhavoronkova, OI1
Lastoria, S3
Yhim, HY1
Kim, SY12
Cho, IS1
Lee, KT3
Lee, WS1
Lee, SI4
Park, MR1
Park, SG1
Han, HS2
Choi, YS1
Lee, NR1
Song, EK3
Yim, CY1
Lopes-Ramos, C1
Koyama, FC1
Salim, AC1
Bettoni, F1
Asprino, PF1
França, GS1
Parmigiani, RB1
Galante, PA1
Camargo, AA1
Illum, H1
Wang, DH1
Dowell, JE1
Hittson, WJ1
Torrisi, JR1
Huerta, S1
Vanhoecke, B1
Bateman, E1
Mayo, B1
Vanlancker, E1
Stringer, A1
Thorpe, D1
Keefe, D1
Gakis, G1
Morgan, TM1
Daneshmand, S1
Keegan, KA1
Todenhöfer, T1
Mischinger, J1
Schubert, T1
Zaid, HB1
Hrbacek, J1
Ali-El-Dein, B1
Clayman, RH1
Galland, S1
Olugbade, K1
Rink, M1
Fritsche, HM1
Burger, M1
Chang, SS1
Babjuk, M1
Thalmann, GN1
Stenzl, A1
Efstathiou, JA1
Yanai, H1
Yahara, N1
Furuya, T1
Murakami, T1
Shimokawa, Y1
Sugihara, S1
Gariboldi, MB2
Taiana, E1
Bonzi, MC1
Craparotta, I1
Giovannardi, S1
Mancini, M1
Monti, E2
Teufel, A2
Gerken, M1
Hartl, J1
Itzel, T1
Stroszczynski, C1
Schlitt, HJ2
Hofstädter, F1
Klinkhammer-Schalke, M1
Zhao, Q3
Qiao, X1
Shi, G3
Xu, Q3
Li, R1
Yang, P1
Wiecha, C1
Kunzmann, R1
Heger, U1
Weichert, W2
Stange, A2
Blank, S2
Grenacher, L1
Badgwell, B1
Estrella, J1
Chiang, YJ1
Gronnier, C1
Lebreton, G1
Brigand, C1
Mabrut, JY1
Bail, JP1
Meunier, B2
Mariette, C7
Korytova, LI1
Sandalevskaya, AG1
Krasnikoval, VG1
Korytov, OV1
Meshechkin, AV1
Volovat, SR1
Negru, SM1
Danciu, M1
Scripcariu, V1
Deme, D1
Bishr, AM1
Nizar, J1
Telekes, A1
Wen, B1
Huang, R1
Peng, H1
Dong, J1
Zeng, Z1
Gao, Y1
Kim, ST7
Marks, EI1
Brennan, M4
Lam, JY1
McConnell, YJ2
Rivard, JD1
Temple, WJ2
Mack, LA2
Ma, J2
Deng, G1
Pei, H1
Zeng, S1
Makielski, RJ1
Lubner, SJ1
Mulkerin, DL1
Traynor, AM1
Groteluschen, D1
Eickhoff, J1
LoConte, NK1
Park, IJ3
Kim, DY10
Kim, HC6
Kim, HR4
Kang, SB2
Choi, GS3
Oh, ST4
Lim, SB8
Kim, JC8
Oh, JH7
Lee, WY4
Lee, JB1
Yu, CS8
Tseng, CL1
Chen, JC1
Wu, YC1
Fang, HW1
Lin, FH1
Tang, TP1
Makoshi, Z1
Perrott, C1
Al-Khatani, K1
Al-Mohaisen, F1
Nanda, RH1
Van De Voorde, L1
Janssen, L1
Larue, R1
Houben, R1
Buijsen, J1
Sosef, M1
Vanneste, B1
Schraepen, MC1
Berbée, M1
Lambin, P1
Fan, WH1
Li, LR2
Wu, XJ4
Wan, DS7
Park, JM2
Song, BJ1
Badiyan, SN1
Lee, AY1
Menias, CO1
Strasberg, SM1
Hawkins, WG1
Linehan, DC1
Martínez-Lago, N1
Vieito-Villar, M1
Vidal-Insua, Y1
Padin-Iruegas, ME1
Vazquez-Rivera, F1
Candamio-Folgar, S1
Lopez-Lopez, R1
Chang, KH1
Kelly, NP1
Duff, GP1
Condon, ET1
Waldron, D1
Coffey, JC1
Wu, Z1
Ma, S1
Jing, S1
Deng, Q1
Wu, K1
Vargas, A2
Montironi, C1
Buxó, E2
Ho, MY1
Renouf, DJ1
Lim, HJ1
Messager, M2
Chaudry, MA1
Umemura, A1
Nitta, H1
Sasaki, A1
Takahara, T2
Hasegawa, Y1
Wakabayashi, G1
Marcet, JE1
Cataldo, PA1
Kumar, AS1
Coutsoftides, T1
Hunt, SR1
Stamos, MJ1
Ternent, CA1
Fichera, A1
Dietz, DW2
Rödel, C3
Graeven, U1
Hohenberger, W8
Hothorn, T1
Ghadimi, M1
Wolff, HA2
Lang-Welzenbach, M1
Raab, HR1
Ströbel, P2
Staib, L3
Wilhelm, M1
Grabenbauer, GG2
Hoffmanns, H1
Lindemann, F1
Schlenska-Lange, A1
Sauer, R7
Liersch, T8
Fleming, GF1
Neureiter, D1
Kemmerling, R1
Folwaczny, M1
Ning, Y1
Sebio, A1
Stremitzer, S1
Sunakawa, Y1
Matsusaka, S4
Yamauchi, S1
Ruffier-Loubière, A1
Janoray, G1
de Calan, L1
Dumont, P4
Dorval, É3
Orain, I1
De Divitiis, C1
Cassata, A1
Nasti, G1
Ottaiano, A2
Nappi, A1
Barretta, ML1
Iaffaioli, RV2
Jiang, DM1
Raissouni, S1
Mercer, J1
Kumar, A2
Goodwin, R1
Heng, DY1
Tang, PA1
Doll, C1
MacLean, A1
Powell, E1
Price-Hiller, J1
Monzon, J1
Vickers, MM1
Huang, TC1
Hsu, CH4
Tu, YK1
Bronsert, P1
Schäfer, M1
Kulemann, B1
Marjanovic, G1
Sick, O1
Hopt, UT1
Zirlik, K1
Osumi, H1
Yoshio, T1
Chin, K3
Ogura, M2
Kumekawa, Y1
Suenaga, M3
Shinozaki, E3
Morishige, K1
Ishiyama, A1
Hirasawa, T1
Tsuchida, T1
Fujisaki, J1
Igarashi, M1
Mizunuma, N3
Wagner, M2
Regenet, N1
Innominato, P1
D'Haens, G2
Bennouna, J3
Ducreux, M22
Latini, L1
Staines, H1
Oum'Hamed, Z1
Dressler, H1
Studeny, M1
Capdevila, J2
Piro, G1
Giacopuzzi, S3
Bencivenga, M1
Carbone, C1
Verlato, G3
Frizziero, M1
Zanotto, M1
Mina, MM1
Santoro, R1
Zanoni, A3
De Manzoni, G3
Tortora, G1
Schneider, CC1
Fischer, N1
Bühler, S1
Venturelli, S1
Berger, A1
Burkard, M1
Kirschniak, A1
Bachmann, R1
Glatzle, J1
Cho, HM1
Shim, BY1
Baek, JY2
Yoon, MS1
Jeong, JU1
Jeong, BK1
Zhu, B1
Wu, JR1
Zhou, XP1
Liu, D2
Zhou, H1
Yue, X1
Hu, X3
Zahir, MN1
Jabbar, AA1
Deniz, K1
Nitsche, U1
Wenzel, P1
Braren, R1
Holzapfel, K1
Schlitter, AM1
Stöß, C1
Kong, B1
Esposito, I1
Erkan, M1
Michalski, CW1
Friess, H8
Kleeff, J1
Goto, R1
Kurihara, M4
Ochenduszko, S1
Puskulluoglu, M1
Konopka, K1
Fijorek, K1
Urbanczyk, K1
Budzynski, A1
Matlok, M1
Lazar, A2
Sinczak-Kuta, A1
Pedziwiatr, M1
Krzemieniecki, K1
Yamamoto, S6
Kumaki, N1
Makuuchi, H4
Ozawa, S1
Chino, O1
Kazuno, A1
Yasuda, S5
Tamayama, T1
Sakai, I1
Ghorani, E1
Wong, HH1
Hewitt, C1
Calder, J1
Basu, B1
Serrano, JJ1
Fernández, C2
Ramirez, C1
Ortega, L2
García-Paredes, B1
Corona, J2
Alfonso, R2
Córdoba, S2
Díaz-Rubio, E7
LoConte, N1
Tempero, MA4
Walker, EJ1
Kate Kelley, R1
Lewis, S1
Chang, WC1
Kantoff, E2
Vannier, MW1
Catenacci, DV1
Mayer, B1
Sander, S2
Paschke, S1
Henne-Bruns, D3
Link, KH4
Kornmann, M5
Ikeda, T2
Iida, S2
Toda, N1
Fukuda, H4
Takagi, T4
Iizuka, J1
Kondo, T2
Stoller, R1
Kemeny, M1
Krishnamurthi, S3
Su, YB1
Ocean, A1
Mehrotra, B1
Henderson, C1
Sun, GP1
Lu, HS1
Zhong, MZ2
Zhang, HL1
Yu, SY1
Hu, XH1
Wang, JJ2
Zhou, JT1
Guo, ZQ3
Guan, ZG1
Zhu, D1
Qin, C1
Niu, W1
Qin, X1
Altan, B1
Mochiki, E1
Toyomasu, Y1
Kogure, N1
Kimura, A1
Bai, T4
Bao, P1
Suzuki, M9
Nishiyama, M4
Lavau-Denes, S1
Gargot, D2
Gasmi, M2
Adhoute, X2
Khemissa, F1
Provençal, J1
Legoux, JL2
Charneau, J1
Chone, L1
Serra-Aracil, X1
Ocaña-Rojas, J1
Mora-López, L1
Dotor, E2
Casalots, A2
Pisa, A1
Rupinski, M1
Malinowska, M2
Mroz, A1
Wyrwicz, L2
Kwon, HY1
Kim, IK1
Sohn, SK9
Darunikorn, P1
Puataweepong, P1
Dhanachai, M1
Dangprasert, S1
Swangsilpa, T1
Sitathanee, C1
Jiarpinitnun, C1
Pattaranutaporn, P1
Boonyawan, K1
Chansriwong, P1
Charpentier, KP1
Mantripragada, K1
Miner, T3
Kuritzky, B1
Apor, E1
Bishop, K1
Luppe, D1
Davis, EJ1
Kim, EJ1
Ruch, JM1
McDonnell, KJ1
Jung, M3
Keum, KC3
Lim, JS1
Hong, SP1
Kim, TI3
Roh, JK11
Oh, SK1
Kim, HW1
Kang, DH1
Choi, CW3
Choi, YY1
Lim, HK1
Goo, JJ1
Choi, SY1
Shin, DY1
Choi, YH1
Lee, HR4
Na, II2
Yuh, YJ1
Kim, BS15
Kang, HJ3
Kuribara, T1
Ichikawa, T1
Kaneko, S1
Osa, K1
Ueda, M4
Asanuma, K1
Kishimoto, Y1
Iai, A1
Houssany, S1
Renner, J1
Boutonnet, M1
Peigne, V1
Soler, C1
Sasaki, H4
Kaneto, H1
Iida, T1
Naganawa, Y1
Satoh, S2
Shimizu, H2
Sasaki, K9
Konishi, Y1
Kon, S1
Bussolati, G1
Nardon, E2
Annaratone, L1
Chiaravalli, AM1
Capella, C1
Hoefler, G1
Beumer, JH1
Negrea, L1
Holleran, JL2
Strychor, S1
Meropol, NJ9
Han, P1
He, Y1
Zhao, C1
Yang, W2
Shan, M1
Yang, C1
Weng, M1
Cui, B1
Shen, G1
Vargo, CA1
Gulati, M1
Cohen, SA1
Yu, M1
Gourgioti, G1
Wirtz, R2
Raptou, G1
Gkakou, C1
Kotoula, V1
Karavasilis, V1
Kalogeras, KT1
Cho, MS1
Renehan, AG1
Malcomson, L1
Emsley, R1
Maw, A1
Myint, AS1
Rooney, PS1
Susnerwala, S2
Blower, A1
Wilson, MS1
Scott, N2
O'Dwyer, ST1
Biffi, R3
Maibach, R4
Hayoz, S1
Thierstein, S1
Brauchli, P2
Bernhard, J5
Stupp, R3
Andreoni, B1
Renne, G1
Crosta, C1
Morant, R3
Chiappa, A2
Luca, F1
Huber, O2
Goldhirsch, A6
de Braud, F6
Roth, AD5
Chae, YS2
Park, SY3
Li, TT1
Li, FP1
Hu, YF1
Mou, TY1
Lin, T1
Li, GX1
Li, D3
Crane, C2
Regine, WF8
Abrams, RA9
Liu, C3
Chang, P1
Freedman, GM1
Winter, KA6
Guha, C2
Orlandi, A1
Calegari, MA1
Martini, M1
Cocomazzi, A1
Bagalà, C1
Indellicati, G1
Zurlo, V1
Basso, M2
Cassano, A3
Larocca, LM1
Cashin, PH1
Mahteme, H3
Spång, N1
Syk, I1
Frödin, JE3
Torkzad, M1
Aroldi, F1
Alexandersson von Döbeln, G1
Wang, N1
Hatlevoll, I1
Lind, P2
Note, H1
Ariga, T2
Suzuki, K4
Kobayashi, H5
Sawada, N1
Kanada, Y1
Senba, Y1
Yoshioka, T4
Sato, Y7
Miyazaki, A1
Natsume, T2
Matsuzaki, H1
Tanaka, H9
Maruyama, T3
Nakayama, Y2
Hakamada, K1
Tokoro, Y1
Tonooka, T1
Souda, H1
Chibana, T1
Kobayashi, R1
Arimitsu, H2
Yanagibashi, H1
Chou, A1
Nabeya, N1
Takenoya, T1
Takano, M3
Nishizawa, Y1
Fukuda, T1
Kazama, S1
Amikura, K1
Kurozumi, M1
Kawashima, Y2
Tanaka, Y4
Sakamoto, H1
Kakuta, S1
Takayama, W2
Kou, T1
Satou, M1
Sugaya, M1
Cai, H1
Zheng, W1
Tong, M1
Ao, L1
Hong, G1
Guan, Q1
Guo, Z1
Prithviraj, GK1
Jiang, K2
Zhao, X1
Chen, DT1
Strosberg, J1
Campos, T1
Shibata, D2
Price, TJ2
Ferraro, DA1
Wong, N1
Veillard, AS1
Hall, M4
Sjoquist, KM1
Strickland, A2
Varma, SC1
Young, R1
Underhill, C4
Shannon, JA2
Ganju, V2
Wild, AT1
Dholakia, AS1
Moningi, S1
Rosati, LM1
Assadi, RK1
Saeed, AM1
Tran, PT1
Wolfgang, CL7
Ford, E1
Grossman, SA1
Kosugi, C1
Koda, K2
Yamazaki, M2
Shuto, K2
Matsuo, K3
Shiragami, R1
Yasuda, H2
Blum Murphy, MA1
Qiao, W1
Mewada, N1
Elimova, E1
Takashi, T1
Phan, A1
Baker, J1
Fernandez, LM2
Figueiredo, MN1
Buchpiguel, CA2
Geetha, P1
Sivaram, AJ1
Jayakumar, R1
Gopi Mohan, C1
Magnante, AL1
Benevento, I1
Nahas, SC3
Rizkallah Nahas, CS1
Sparapan Marques, CF1
Ribeiro, U5
Cotti, GC1
Imperiale, AR1
Capareli, FC1
Chih Chen, AT1
Hoff, PM6
Cecconello, I1
Lynn, PB2
Jorge, JM1
Hackert, T1
Ulrich, A1
Gao, K1
Liang, Q1
Zhao, ZH1
Li, YF3
Wang, SF1
Shao, S1
Sun, PH1
Satherley, LK1
Ji, KE1
Feng, YI1
Neuman, T1
Olszanski, AJ1
Davey, M1
Cheng, JD2
Lebenthal, A1
Burtness, BA3
Scott, WJ1
Astsaturov, IA1
Bupathi, M1
Ahn, DH1
Ciombor, KK1
Stephens, JA1
Goldstein, DA1
Mazzola, R1
Ferrera, G1
Cucchiara, T1
Figlia, V1
Gueci, M1
Sciumè, F1
Di Paola, G1
Scibetta, N1
Lo Casto, A1
Pappalardo, MP1
Lagalla, R1
Alongi, F1
Stein, SM1
James, ES1
Cong, X1
Staugaard, C1
Indukala, D1
Boustani, AM1
Patel, V1
Cha, CH1
Chang, B1
Ion, RM1
Stan, M1
Nikitovic, D1
Hayes, AW1
Spandidos, DA1
Tsatsakis, AM1
Ur Rehman, SS1
Lim, K1
Li, ZZ1
Zhang, ZC1
He, MM2
Ren, J1
Shao, JY1
Frankel, P1
Lim, D1
Yeon, C1
Leong, L7
Chao, J1
Ruel, N1
Luevanos, E1
Koehler, S1
Chung, S1
Lau, SC1
Fakih, MG6
Wang, ZX2
Yang, XL1
Zhou, ZW3
Zhan, YQ3
Yu, T1
Cao, XL1
Wu, GJ1
Zhao, G1
Jia, WW1
Xiao, G1
Kathiravetpillai, N1
Koëter, M1
van der Sangen, MJ2
Luyer, MD1
Nieuwenhuijzen, GA3
Cravioto-Villanueva, A1
Cavazos, M1
Luna-Perez, P4
Martinez-Gomez, H1
Ramirez, ML1
Solorzano, J1
Montiel, H1
Esquivel, J2
Sinclair, R1
Navidi, M1
Griffin, SM1
Osawa, H2
Ohta, K1
Chang, JY3
Sainakham, M1
Manosroi, A1
Abe, M1
Manosroi, W1
Manosroi, J1
Jung, SM1
Kim, TW18
Yoon, YS3
Yukawa, Y1
Kawamura, M1
Takeda, O1
Hanno, H1
Takayanagi, S1
Hirooka, T2
Dozaiku, T1
Hirakawa, T1
Iwauchi, T1
Morimoto, J1
Nakazawa, K2
Kouyama, M1
Yabuta, Y1
Shirai, A1
Uzuhashi, K1
Al-Fakeeh, A1
Mulla, N1
Doerksen, T1
Al-Ruzug, I1
Santos, F1
Aydin, D1
Sendur, MA1
Kefeli, U1
Ustaalioglu, BB2
Aydin, O1
Yildirim, E1
Isik, D1
Ozcelik, M1
Surmeli, H1
Oyman, A1
Isik, S1
Sener, N1
Ercelep, O1
Odabas, H2
Aliustaoglu, M1
Inukai, M1
Tanioka, H1
Nasu, J3
Okajima, M1
Yamaguchi, Y3
Fassan, M1
Lampis, A1
Hahne, JC1
Rugge, M2
Nankivell, M1
Langley, R1
Ghidini, M3
Braconi, C1
Valeri, N1
Xie, X1
Ruan, Z1
Li, F1
Kalaitzakis, E1
Havre, RF1
Willemoe, GL1
Meisner, S1
Song, XL1
Kang, HK1
Jeong, GW1
Ahn, KY1
Jeong, YY1
Kang, YJ1
Cho, HJ1
Moon, CM1
Nagashima, K2
Ikezawa, N1
Hamaguchi, T6
Honma, Y1
Takashima, A4
Okita, N1
Daibo, K1
Mera, T1
Naito, K1
Yasumoto, K1
Kamigaki, T2
Goto, S2
Cramer, HM1
Ibrahim, AA1
Younger, AE1
Murono, K1
Yasuda, K2
Otani, K1
Nishikawa, T3
Douglas, K1
Villaflor, VM1
Ahn, PH1
Machtay, M1
Anne, PR2
Cognetti, D1
Keane, WM1
Dicker, AP2
Axelrod, RS1
Cho, JY5
Kang, A1
Shames, DS2
Wang, Z4
Hao, J1
Paget-Bailly, S1
Mathieu, P1
Lamfichekh, N1
Sakek, N1
Jacquin, M1
Foubert, A1
Stanisavljević, L1
Myklebust, MP1
Leh, S1
Dahl, O5
De Pasquale, MD1
Mastronuzzi, A1
De Sio, L1
Serra, A1
Grimaldi, C1
Chinali, M1
Giordano, U1
Nakakura, EK1
Wang, ZJ1
Kim, GE2
Corvera, CU1
Harris, HW1
Kirkwood, KS1
Hirose, R1
Hecht, M1
Büttner-Herold, M1
Erlenbach-Wünsch, K1
Haderlein, M1
Croner, R1
Grützmann, R1
Hartmann, A1
Distel, LV1
Motton, M1
Casella, F2
Weindelmayer, J2
Ambrosi, E1
Di Leo, A2
Vassiliadis, A1
Ricci, F1
Chopitea, A4
González, I2
A-Cienfuegos, J1
Martínez, P2
Rodriguez, J7
Herbst, A1
Kalinski, T1
Qin, J1
Benedix, F1
Franke, S1
Wartman, T1
Halangk, W2
Kolligs, FT1
Haghighi, S1
Kasbkar, H1
Esmaeilpour, K1
Yasaei, M1
Supaadirek, C1
Pesee, M1
Thamronganantasakul, K1
Thalangsri, P1
Krusun, S1
Supakalin, N1
Uchida, T1
Abe, N1
Ito, K8
Matsuda, K5
Fujinaga, A1
Martin-Romano, P1
Diaz-Gonzalez, JA4
Iragorri, Y1
Martínez-Regueira, F1
Ponz-Sarvise, M1
Subtil, JC3
Cano, D1
Ceniceros, L1
Legaspi, J1
Hernandez, JL2
Nasierowska-Guttmejer, A1
Kosakowska, E1
Zwoliński, J1
Winiarek, M1
Kuśnierz, J1
Zając, L1
Bednarczyk, M1
Tarnowski, W1
Paśnik, K1
Radziszewski, J1
Partycki, M1
Bęczkowska, K1
Styliński, R1
Bury, P1
Lewicka, M1
Ciseł, B1
Mielko, J1
Danek, A1
Nawrocki, G1
Kępka, L1
Due, SL1
Bastian, I1
Ding, GQ1
Sukocheva, OA1
Astill, DS1
Vat, L1
Gepfner-Tuma, I1
Maderer, A1
Ruessel, J1
Wilke, H12
Rafiyan, MR1
Schmoll, HJ5
Kullmann, F2
von Weikersthal, LF2
Weusmann, J1
Kanzler, S2
Schimanski, CC4
Otte, M1
Schollenberger, L1
Koenig, J1
Galle, PR8
Zhuang, RY1
Yu, YY1
Shen, KT1
Zhao, NQ1
Qin, Q1
Boubaya, M1
Benallaoua, M1
Baumgaertner, I2
des Guetz, G2
Rosenstone, S1
Ansari, N1
Solomon, MJ1
Fisher, RJ1
Mackay, J3
Burmeister, B2
Ackland, S2
Joseph, D9
McLachlan, SA2
Taki, T1
Hoya, Y1
Nakayoshi, T1
Sekine, H1
Mitsumori, N1
Yanaga, K2
Hokuto, D1
Nomi, T1
Yamato, I1
Obara, S1
Kawaguchi, C2
Kanehiro, H1
Nakajima, Y12
Pasquini, G1
Vasile, E3
Caparello, C1
Vivaldi, C1
Musettini, G1
Lencioni, M3
Petrini, I1
Häussler, U1
Bösmüller, H1
Clasen, S1
Götz, M1
Malek, NP1
Plentz, RR1
Sueur, B1
Pellerin, O1
Voron, T1
Gemici, C1
Yaprak, G1
Batirel, HF1
Ilhan, M1
Mayadagli, A1
Keane, FK1
Sánchez Cendra, C1
Juez Martel, I1
Gutierrez Abad, D1
Braiteh, FS1
Firdaus, I1
Lewis, N1
Anderson, DM1
Arrowsmith, E2
Schwartz, JD1
Hsu, Y1
Péron, J2
Roy, P5
Gourgou-Bourgade, S3
Stanbury, T1
Roche, L1
Ozenne, B1
Van Der Kraak, L1
Goel, G2
Ramanan, K1
Kaltenmeier, C1
Normolle, DP1
Freeman, GJ1
Tang, D1
Nason, KS1
Davison, JM1
Luketich, JD3
Dhupar, R1
Lotze, MT1
Fattouh, K1
Collet-Benzaquen, D1
Provensal, AM1
Castillo, C2
Combemale, P1
de la Fouchardière, A1
Manceau, G1
Bridoux, V1
Brouquet, A1
Kirzin, S1
Maggiori, L1
de Chaisemartin, C2
Lefevre, JH1
Panis, Y3
Bezborodova, OA1
Nemtsova, ER1
Gevorkov, AR1
Boyko, AV1
Venediktova, JB1
Alekseenko, IV1
Kostina, MB1
Monastyrskaya, GS1
Sverdlov, ED1
Khmelevskiy, EV1
Yakubovskaya, RI1
Kalpande, S1
Pandya, J1
Sharma, T1
Ghadban, T1
Dibbern, JL1
Reeh, M1
Miro, JT1
Tsui, TY1
Wellner, U1
Güngör, C1
Vashist, YK1
Ålgars, A1
Sundström, J1
Lintunen, M1
Jokilehto, T1
Kytölä, S1
Kaare, M1
Vainionpää, R1
Orpana, A2
Ristimäki, A1
Carpen, O1
Ristamäki, R2
DeWitt, JM1
Murthy, SK1
Ardhanari, R1
DuVall, GA1
Wallner, G1
Litka, P1
Daugherty, C1
Fowers, K1
Antunes, C1
Zappa, M1
Bednar, F1
Steve, J1
Winters, S1
Ocuin, LM1
Chen, M1
Hack, SP1
Bruey, JM1
Phan, S1
Axilbund, J1
Dalton, WB1
Laheru, D6
Watkins, S1
Chu, D2
Cravero, K1
Button, B1
Kyker-Snowman, K1
Waters, I1
Gocke, CD1
Lauring, J1
Park, BH1
McDonough, S1
Cardin, D1
Hui, L1
Seery, TE1
Dy, IA1
Al Baghdadi, T1
Hendifar, AE1
Doyle, LA1
Chan, DY1
Syn, NL1
Yap, R1
Phua, JN1
Soh, TI1
Chee, CE1
Nga, ME1
Shabbir, A1
Allegra, CJ7
Pogue-Geile, KL1
Yothers, G4
Sugiyama, K2
Tajika, M1
Ghosn, M6
Ibrahim, T2
Assi, T2
El Rassy, E2
Sánchez-Velázquez, P1
Moosmann, N3
Töpel, I1
Piso, P2
Clancy, TE1
Mancias, JD1
Rosenthal, MH1
Balogoun, R1
Mulot, C1
Saban-Roche, L1
Perkins, G3
Luc Van Laethem, J1
Laurent Puig, P1
Hall, PS1
Lord, SR1
Collinson, M1
Marshall, H1
Jones, M1
Lowe, C1
Howard, H1
Swinson, D1
Velikova, G1
Dent, J1
Cheeseman, S1
Last, K1
Seymour, MT6
Kondo, J2
Maeda, Y6
Nisimura, T1
Nagashima, Y1
Morita, K1
Setoguchi, M1
Sakata, K3
Fujisaki, S1
Takashina, M1
Tomita, R1
Sakurai, K2
Takayama, T7
Minoji, T1
Kitahara, T1
Hamano, R1
Yanagisawa, T1
Fukuchi, N2
Ebisui, C2
Yokouchi, H3
Kinuta, M2
Ohishi, K1
Yigitbas, H1
Yazici, P1
Taskin, HE1
Okoh, AK1
Dural, C1
Aydin, N1
Berber, E2
Nazim, UM1
Rasheduzzaman, M1
Lee, YJ3
Seol, DW1
Fernandez, E2
Cacheux, W1
Frossard, JL1
Koessler, T1
Abou, M1
Moniez, M1
Puppa, G1
Staib, F1
Göhler, T1
Hebart, H1
Heike, M4
Neise, M1
Rudi, J2
Geer, T2
Dingeldein, G1
Lang, C1
Ehscheidt, P1
Flohr, T1
Josten, KM1
Karthaus, M1
Schmittel, A1
Wierecky, J1
Boller, E1
Indorf, M1
Wörns, MA1
El Karak, F1
Zhang, F1
Zhang, JG1
Qu, J1
Prasad, C1
Wei, ZJ1
Viaud, J1
Brac, C1
Le Pabic, E1
Leconte, B2
Bodère, A1
Pracht, M1
Le Sourd, S1
Saunders, JH1
Bowman, CR1
Pang, V1
Dorrington, MS1
Mumtaz, E1
Soomro, I1
Kaye, P1
Voncken, FE1
Fukayama, M1
Bozkaya, Y1
Doğan, M1
Erdem, GU1
Demirci, NS1
Del Rio, M4
Vie, N2
Selves, J1
Roger, P1
Gongora, C4
Robert, J2
Tubiana-Mathieu, N3
Martineau, P4
Bailey, P1
Hu, S1
Yue, J1
Xue, L1
Hwang, WS1
Chao, TY2
Lin, SF1
Chung, CY1
Chang, YF1
Chen, PM5
Chiou, TJ4
Bruin, S1
van Slooten, G1
Becerra, CR3
Verma, UN2
Tran, HT1
Tavana, D1
Williams, NS1
Frenkel, EP2
Ballonoff, A1
Kavanagh, B1
McCarter, M1
Kane, M1
Pearlman, N1
Nash, R1
Shah, RJ1
Raben, D1
Schefter, TE1
Greenberg, JA1
Herndon, JE3
Steele, GD1
Mayer, R2
Bleday, R1
Agostini, M3
Pasetto, LM2
Pucciarelli, S8
Terrazzino, S2
Bedin, C2
Galdi, F1
Friso, ML7
Urso, E4
Leon, A2
Lise, M9
Nitti, D12
Kakolyris, S5
Ardavanis, A1
Ziras, N7
Varthalitis, I3
Amarantidis, K2
Tsousis, S2
Vamvakas, L6
Vardakis, N2
Baldarelli, M1
Organetti, L1
Grillo Ruggeri, F1
Mantello, G1
Bartolacci, S1
Lezoche, E1
Lin, SS1
Tai, CJ1
Lee, WR1
Chu, JS1
Wang, KH1
Jeung, HC11
Yoo, NC3
Noh, SH10
Zaluski, J3
Valvere, V3
Peschel, C7
Wenczl, M2
Goker, E2
Cisar, L1
Wang, K1
Bugat, R7
Bullarddunn, K1
Yang, GY1
Pendyala, L4
Toth, K3
Andrews, C1
Rustum, YM11
Ross, ME2
Levea, C1
Puthillath, A1
Park, YM1
Rajput, A1
Lindebjerg, J3
Spindler, KL1
Ploen, J3
Jakobsen, A5
Vikram, B2
Fujita, T2
Berretta, M2
Di Benedetto, F1
Bearz, A2
Simonelli, C1
Martellotta, F1
Del Ben, C1
Berretta, S2
Spina, M1
Tirelli, U2
Yasuda, A1
Ochi, N2
Sakamoto, M2
Takayama, S2
Wakasugi, T1
Funahashi, H1
Sawai, H1
Satoh, M2
Akamo, Y2
Takeyama, H2
Izzo, L1
Pietrasanta, D1
Izzo, P1
Caputo, M1
Di Cello, P1
Meloni, P1
Bolognese, A1
Ngeow, JY1
Prakash, KM1
Quek, ST1
Ehrenberg, R1
Hickmann, L1
Vick, B1
Urbanik, T1
Berger, MR2
Schad, A1
Weber, A1
Heeger, S2
Woei Chung, L1
Liao, YM1
Hsieh, CY1
Javeri, H1
Arora, R1
Liao, Z4
McAleer, MF1
Maru, D2
Izzo, JG1
Matsubara, J3
Takahari, D5
Okita, NT4
Shirao, K6
Gustafsson, SB1
Lindgren, T1
Jonsson, M1
Jacobsson, SO1
Warchoł, R1
Szymański, L1
Seichter, A1
Kalofonos, HP5
Bamias, A5
Koutras, A1
Papakostas, P3
Basdanis, G3
Karina, M1
Misailidou, D1
Pisanidis, N1
Economopoulos, T2
Papadimitriou, C2
Skarlos, DV2
Stavropoulos, M2
Bafaloukos, D1
Kardamakis, D2
Karanikiotis, C1
Vourli, G3
Hart, LL1
Childs, BH1
Hainsworth, JD5
Wong, L1
Fehrenbacher, L1
Abubakr, Y1
Schwartzberg, L1
Hedrick, E1
Gosens, MJ1
Moerland, E1
Lemmens, VP1
Rutten, HT1
Tan-Go, I1
van den Brule, AJ1
Lee, JL6
Zang, DY3
Ryoo, BY5
Shin, DB10
Ryu, MH5
Chang, HM9
Min, YJ1
Braendengen, M1
Tveit, KM6
Birkemeyer, E1
Frykholm, G3
Wiig, JN2
Byström, P6
Dietrich, D2
Scheithauer, W16
Gerber, D1
Ruhstaller, T3
Schüller, J2
Saletti, P7
Bauer, J2
Figer, A3
Pestalozzi, BC2
Mingrone, W1
Stemmer, SM1
Kornek, GV7
Koeberle, D3
Herrmann, R7
Hofheinz, R6
Rethwisch, V2
Clemens, MR1
Mahlberg, R1
Fritz, M1
Seipelt, G3
Sievert, M1
Atmaca, A5
Brell, JM1
Krishnamurthi, SS1
Javle, M4
Saltzman, J1
Wollner, I2
Pelley, R1
Dowlati, A1
Kantharaj, BN1
Schluchter, MD1
Rath, L1
Ivy, SP1
Remick, SC1
Frustaci, S2
Talamini, R2
Lombardi, D1
Fratino, L1
Lleshi, A1
Bonanno, S1
Spartà, D1
Palmucci, S1
Hizawa, K1
Nagata, Y2
Taniguchi, M2
Nakamori, M2
Iida, M1
Sanz-Sánchez, T1
Jiménez-Ayala, B1
Borbujo, JM1
Gartner, EM1
Pan, Q1
Brewer, GJ1
Henja, GF1
Merajver, SD2
Button, MR1
Morgan, CA1
Croydon, ES1
Roberts, SA3
Crosby, TD4
Comella, P8
Massidda, B3
Filippelli, G2
Farris, A4
Natale, D1
Barberis, G1
Maiorino, L4
Palmeri, S4
Cannone, M2
Condemi, G1
Rosenthal, DI2
Landry, JC1
Sigurdson, ER4
Spitz, FR1
Granci, V2
Kramar, A3
Boissière-Michot, F1
Thirion, A1
Hwang, J2
Lee, SR1
Yang, DH1
Kim, YK1
Lee, JJ4
Trojan, J3
Lubomierski, N1
Lehnert, T1
Engels, K1
Zeuzem, S1
Wen, S2
Morris, J4
Abaza, MS1
Bahman, AM1
Al-Attiyah, RJ1
Tatokoro, M1
Kawakami, S1
Yonese, J1
Fujii, Y2
Okubo, Y1
Takeshita, H1
Komai, Y1
Ishikawa, Y1
Fukui, I2
Wilson, PM1
Fazzone, W1
LaBonte, MJ1
Deng, J2
Neamati, N2
Ladner, RD1
Lawson, JD1
Staley, C2
Zeng, SY1
Li, LY1
Shu, KY1
Pan, M1
Li, HP1
Luo, B1
Caponigro, F2
Lacombe, D1
Twelves, C3
Govaerts, AS1
Milano, A2
Rong, J1
Lin, TY1
Zhai, LZ1
Chiarion-Sileni, V2
Innocente, R2
Cavina, R1
Corti, L1
Pigozzo, J1
Del Bianco, P3
Fumagalli, U1
Santoro, A1
Marti, JL1
Hiotis, SP1
Donahue, B2
Ryan, T2
Newman, E4
Bollschweiler, E8
Metzger, R10
Drebber, U3
Baldus, S2
Vallböhmer, D6
Kocher, M2
Hölscher, AH7
Chen, CW2
Wang, WM1
Su, YC2
Wu, JY1
Hsieh, JS1
Seo, Y2
Willis, J1
Stellato, TA1
Siegel, CT1
Harpp, D1
Willson, JK1
Gibbons, J1
Sanabria, JR1
Schulak, JP1
Kunoki, N1
Nishiyama, R1
Ryuzaki, H1
Oonishi, M1
Uno, A1
Ogawa, M9
Ogihara, A1
Moriyama, M2
Sou, K1
Kinukawa, N2
Machida, N1
Onozawa, Y2
Taku, K2
Asaka, M3
Recchia, F5
Candeloro, G3
Necozione, S3
Bratta, M2
Bisegna, R2
Rea, S5
Beddy, D1
Hyland, JM1
Winter, DC2
White, A1
Moriarty, M1
Armstrong, J1
Fennelly, D1
Gibbons, D1
Sheahan, K1
Gu, Y2
Haghighat, P1
Conti, JA4
Kendall, TJ1
Armstrong, TA1
Papa-Adams, A1
Packham, G1
Primrose, JN2
Benyon, RC1
Iredale, JP1
Garrido, M1
Bustos, M1
Orellana, E1
Madrid, J1
Galindo, H1
Sánchez, C1
Pimentel, F1
Guzmán, S1
Ibáñez, L1
Butte, JM1
Alvarez, M1
Besa, P1
Wang, ZH3
Guo, J2
Li, CZ1
Sheng, LJ1
Zhou, DG1
Wang, QC1
Zhang, EN1
Jurado, JM1
Pajares, B1
Olmos, D1
Sevilla, I1
Alba, E1
Fisher, GA5
Kuo, T3
Ramsey, M1
Schwartz, E1
Rouse, RV1
Cho, CD2
Halsey, J2
Sikic, BI2
Lansigan, F1
Cornfeld, D1
Syrigos, K6
Wasif, N1
Almeyda, R1
Capper, J1
Seol, YM1
Song, MK1
Kim, GH1
Shin, HJ2
Song, GA1
Chung, JS2
Cho, GJ2
Bertolini, F2
Chiara, S1
Antognoni, P1
Dealis, C1
Zironi, S7
Malavasi, N2
Scolaro, T1
Depenni, R2
Jovic, G1
Sonaglio, C1
Rossi, A2
Luppi, G8
Conte, PF5
Konski, A5
Sigurdson, E3
Spies, S1
Yu, JQ1
Wahl, A1
Stryker, S1
Cheng, Z1
Feng, CN1
Sugae, T1
Yaguchi, T1
Kajikawa, M1
Nakayama, S1
Takase, T1
Inokawa, Y1
Tsushima, Y1
Harada, A1
Arévalo Lobera, S1
Sagastibeltza Mariñelarena, N1
Elejoste Echeberría, I1
Melé Olivé, M1
Egaña Otaño, L1
Basterretxea Badiola, L1
La Casta Muñoa, A1
Azkue Gabilondo, M1
Ishihama, H1
Chida, M1
Araki, O1
Karube, Y1
Seki, N1
Tamura, M1
Umezu, H1
Honma, K1
Masawa, N1
Miyoshi, S1
Hatlova, J1
Vosmik, M1
Zoul, Z1
Tycova, V1
Lesko, M1
Hajduch, M1
Dunst, J5
Rudat, V1
Wulf, J1
Budach, W2
Hoelscher, T1
Reese, T3
Mose, S1
Roedel, C1
Zuehlke, H1
Chaput, U1
Terris, B1
Nobili, S2
Checcacci, D1
Filippelli, F1
Del Buono, S1
Mazzocchi, V1
Mazzei, T3
Twombly, R1
Honda, T3
Shimoda, T2
Lorizzo, K1
Radice, D1
Boselli, S1
Ariu, L1
Nolè, F3
Magni, E2
Ardito, R1
Minchella, I1
Rocca, A2
Di Meglio, G1
Squadroni, M1
Cartwright, T2
Kuefler, P1
Hyman, W2
Berger, M2
Richards, D3
Vukelja, S1
Nugent, JE1
Ruxer, RL1
Boehm, KA3
Asmar, L3
Sandoval, A1
Lee, JT2
Ahn, SJ1
Lee, YL1
Yoo, J1
Ahn, BC1
Ha, JH1
Ota, K4
Kurita, S1
Nishimura, M2
Kamei, Y1
Ariyoshi, Y1
Kataoka, K1
Murakami, M1
Oyama, A1
Hoshino, A1
Amo, H1
Fanning, DM1
Prichard, RS1
Roche-Nagle, G1
McNamara, D1
Le Scodan, R3
Partensky, C5
Mercier, C3
Valette, PJ4
Scoazec, JY4
Asiyanbola, B1
Choti, MA2
Swartz, M1
Schulick, RD3
Cameron, JL11
Morak, MJ1
van der Gaast, A4
Incrocci, L2
van Dekken, H2
Jeekel, J4
Hop, WC3
Kazemier, G2
van Eijck, CH3
Minashi, K2
Nihei, K2
Kagami, Y3
Gunnlaugsson, A2
Anderson, H3
Fernebro, E2
Berglund, K1
Ekelund, M1
Holm, T1
Kang, BM1
Jun, SH1
Hayashi, Y3
Nishida, T4
Yamamoto, K11
Tsutsui, S1
Hiramatsu, N1
Tsujii, M1
Tsuji, S1
Ito, H4
Takehara, T1
Hayashi, N5
Baize, N1
Abakar-Mahamat, A1
Mounier, N1
Berthier, F1
Caroli-Bosc, FX2
Wolff, K2
Wein, A9
Reulbach, U3
Männlein, G2
Brückl, V1
Meier, C1
Ostermeier, N2
Schwab, SA1
Horbach, T1
Hahn, EG4
Boxberger, F4
Lin, RB1
Fan, NF1
Wang, XJ1
Oya, M1
Muto, T6
Konishi, F3
Hatake, K2
Jung, JY1
Kwon, JH2
Song, HH1
Kim, I1
Lee, KS7
Lee, JA1
Adinin, R1
Lin, E5
Morris, JS1
Norman, AR7
Hawkins, R1
Harper, P4
Seymour, M4
Kortman, GA1
Mekenkamp, L1
Ligtenberg, MJ1
Hoogerbrugge, N1
Antonini, NF1
van Krieken, JH3
Ravizza, R1
Molteni, R1
Marras, E1
Perletti, G1
Gou, HY1
Han, JS2
Li, SM1
Yang, R1
Qiao, J1
Lorusso, V3
Casaretti, R3
Putzu, C1
Leo, S2
Roselli, M1
Mancarella, S3
Greco, E2
Vessia, G1
Sandomenico, C2
Franco, L1
Kwon, HC10
Lee, DM2
Roh, MS2
Kim, DC1
Park, KJ2
Novarino, A2
Chiappino, I1
Giacobino, A2
Bellone, G2
Rahimi, F1
Milanesi, E1
Bertetto, O1
Ciuffreda, L2
Chayahara, N1
Yamamori, M1
Kadowaki, Y1
Okuno, T1
Miki, I1
Nishisaki, H2
Maeda, T4
Inoue, Y8
Okumura, K1
Azuma, T3
Kasuga, M1
Sakaeda, T1
Hirai, M1
Kozuch, P4
Malamud, S3
Wasserman, C1
Homel, P2
Mirzoyev, T2
Grossbard, M2
Yilmaz, G1
Oztürk, B2
Akyürek, N1
Yildiz, R3
Tonyali, O1
Coşkun, U4
Bitik, B1
Kalpakci, Y1
Altan, E1
Dogan, E1
Johansson, B2
Nygren, P3
Pedersen, D1
Letocha, H1
Fukui, T2
Takano, J1
Fujishima, S1
Otake, S2
Orii, T1
Sato, T8
Sasaki, Y8
Nishise, S1
Kawata, S1
Takamura, H1
Osawa, S1
Iwaizumi, M1
Hamaya, Y1
Takagaki, K1
Nishino, M1
Kodaira, C1
Muramatsu, A1
Futami, H1
Furuta, T4
Ikuma, M1
Kemeny, N13
D'Angelica, M1
Jarnagin, W1
Haviland, D1
Dematteo, R1
Fong, Y3
Jin, C1
Yao, L1
Long, J1
Fu, DL1
Yu, XJ1
Yang, F1
Ni, QX1
Schønnemann, KR2
Jensen, HA5
Jensen, BY1
Larsen, O1
Benson, M2
Lüpfert, C2
Kurek, R2
Baselga, J2
Hill, A7
Liu, JF1
Jamieson, GG7
Wu, TC1
Zhu, GJ1
Drew, PA1
Fluge, Ø1
Carlsen, E1
Myrvold, HE1
Vonen, B1
Podhorny, N1
Bjerkeset, O1
Eide, TJ1
Halvorsen, TB2
Milicević, M2
Radosević-Jelić, Lj2
Pino, MS1
Gelibter, A3
Sperduti, I4
De Marco, S2
Nuzzo, C1
Bria, E3
Carpanese, L1
Ruggeri, EM4
Carlini, P5
Cognetti, F7
Saha, AK1
Sutton, C1
Rotimi, O1
Dexter, S1
Sue-Ling, H1
Sarela, AI1
Kim, MA2
Kim, TM2
Kim, DW7
Heo, DS6
Lee, KU2
Choe, KJ2
Tipples, K1
Kolluri, RB1
Gilbar, P1
McPherson, I1
Milla, P1
Airoldi, M2
Weber, G2
Drescher, A1
Jaehde, U1
Cattel, L1
Richter, SN1
Nadai, M1
Palumbo, M1
Palù, G1
Stieler, J2
Roll, L1
Hilbig, A1
Dörken, B4
Riess, H3
Oettle, H4
Martinez-Balibrea, E1
Martínez-Cardús, A1
Musulén, E1
Manzano, JL1
Plasencia, C1
Abad, A6
Gold, DG1
Haddock, MG5
Quevedo, F1
Donohue, JH5
Kobayashi, N2
Hata, N1
Yokoyama, S2
Shinada, T1
Shirakabe, A1
Mizuno, K2
Vaidya, KS1
Kim, EL1
Welch, DR1
Chen, SP1
Wu, CC2
Lin, SZ1
Kang, JC1
Su, CC2
Chen, YL1
Lin, PC2
Pang, CY1
Harn, HJ1
Angitapalli, R1
Litwin, AM2
Kumar, PR1
Nasser, E1
Lombardo, J1
Mashtare, T1
Wilding, GE1
Mogck, U1
Schuch, G2
Kramer, M1
Jaeger, E2
Ehninger, G1
Gómez Portilla, A1
Cendoya, I1
Olabarría, I1
Martínez de Lecea, C1
Gómez Martínez de Lecea, C1
Gil, A1
Martín, E1
Muriel, J1
Magrach, L1
Romero, E1
Lirola, A1
Guede, N1
Moraza, N1
Kvadatze, M1
Valdovinos, M1
Larrabide, I1
Ruiz de Alegría, N1
Fernández, JL1
Rua, O1
Ulibarrena, MA1
Dinter, D1
Lukan, N1
Sereno, M1
Castro, JD1
Belda, C1
González-Barón, M2
Dalzell, JR1
Samuel, LM2
Kim, BG2
Rho, MH1
Kim, YH10
Rho, MS1
Jeong, JS1
Zouhairi, ME1
Venner, A1
Charabaty, A1
Schuette, K1
Link, H2
Koehne, CH1
Gruenwald, V1
Stahl, M7
Huebner, G1
Bonfill, T1
Darnell, A1
Bombardó, J1
Jhawer, M2
Coit, D2
Qin, LX1
Klimstra, D4
Tang, L3
Rognone, A4
Nicoletti, R9
Mazza, E2
Arcidiacono, PG2
Di Carlo, V9
Villa, E9
Garajová, I1
Svoboda, M2
Slabý, O2
Kocáková, I2
Fabian, P2
Kocák, I1
Vyzula, R2
Fetterly, G1
Zwiebel, JA1
Espinoza-Delgado, I1
Litwin, A2
Egorin, MJ2
Hristov, B1
Reddy, S3
Hruban, RH8
Swartz, MJ3
Kemp, C1
Markman, M2
Brady, M1
Hutson, A1
Berek, JS2
Salah-Eldin, MA1
Ebrahim, MA1
AL-Ashry, MS1
Wexner, S2
Zhao, R3
Cruz-Correa, M1
Berho, M3
Yau, T1
Chong, G1
Viret, F4
Guiramand, J2
Lelong, B4
Zhou, LY1
Shan, ZZ1
You, JL1
Kim, DH6
Wang-Chesebro, A1
Weinberg, V1
Pouliot, J1
Chen, LM1
Speight, J1
Littell, R1
Hsu, IC1
Desai, S1
Simeone, D1
Greenson, JK2
Francis, IR1
Hampton, J1
Colletti, L1
Chang, AE1
Yin, A1
Freitas, D1
Fernandes, Gdos S1
Cunha, JE1
Dembinski, JL1
Vizio, B1
Brondino, G1
Addeo, A1
Prati, A1
Campra, D1
Fronda, GR1
Kabra, N1
Li, B2
Yeatman, T2
Coppola, D2
Okines, A1
Allum, W1
Riddell, A1
Stavridi, F1
Ashley, S3
Iio, A1
Nakagawa, Y2
Naoe, T1
Tanigawa, N2
Akao, Y1
Lee, GW2
Jeong, CY1
Pena Alvarez, C1
Suh Oh, HJ1
Sáenz de Miera Rodríguez, A1
García Arroyo, FR1
Covela Rúa, M1
Salgado Boquete, L1
López Clemente, PM1
Constenla Figueiras, M1
Lim, JY2
Oh, KJ1
Choi, SH9
Tansley, S1
Gibbons, S1
Märten, A5
Ose, J2
Abel, U3
Münter, MW2
Adler, G2
Gress, T1
Lartigau, E2
Chang, PA1
Li, JJ1
Pan, F1
Bian, ZH1
Zou, L2
He, JM1
Liang, HJ1
Girard, N2
Hattangadi, JA1
Yeap, BY1
Degirmenci, M1
Karaca, B2
Gorumlu, G1
Durusoy, R1
Demir Piskin, G1
Bozkurt, MT1
Cirak, Y1
Tunali, D1
Sanli, UA1
Sica, G3
Bonfili, P1
Lou, F1
Zhu, YH1
Pan, HM1
Yoshifuku, K1
Deguchi, K1
Kurono, Y1
Sun, ZJ1
Sun, MZ1
Ai, CH1
Lu, XL1
Zheng, YF1
Yang, BF2
Dong, DL1
Curran, D2
Kimura, M4
Takatsuka, Y3
Toi, M1
Abe, R2
Koyama, H5
Takashima, S5
Nomura, Y4
Miura, S1
Kimijima, I1
Tashiro, H1
You, DD1
Lee, HG2
Heo, JS7
Choi, DW3
Huh, JW4
Thiebot, T1
Henno, S1
Falize, L1
Bretagne, JF2
Koizumi, W4
Tanabe, S3
Azuma, M1
Ishido, K1
Nishimura, K3
Nakatani, K1
Higuchi, K2
Katada, C2
Geissler, M3
Raedle, J1
Ebert, MP2
Flieger, D2
Hoehler, T1
Saltz, L11
Dai, H1
Xiao, Y1
Zhang, XD4
Chakrabarty, S1
Dong, NN1
Wang, MY1
Liu, ZF1
Jensen, BV3
Nielsen, SE1
Keldsen, N2
Bjerregaard, B2
Mejer, J1
Larsen, FO1
Teng, KY2
Ruan, DY2
Chen, XQ1
He, YJ6
Hyspler, R1
Krcmová, L1
Urbánek, L1
Kalábová, H1
Kasparová, M1
Solichová, D1
Fora, A1
Alabsi, E1
Grenader, T1
Goldberg, A1
Gabizon, A1
Ozdemir, NY2
Budakoglu, B2
Uncu, D5
Güler, T1
Odabaşi, H1
Malamos, N1
Adamou, A1
Kalbakis, K4
Papakotoulas, P2
Kouroussis, C1
Karvounis, N2
Christophyllakis, C1
Farhat, FS1
Chahine, GY2
Younes, FC1
Nasr, FL2
Mroue, RM1
Ghosn, MG2
Tsikitis, VL1
Larson, DW1
Poola, VP1
Nelson, H1
Wolff, BG2
Pemberton, JH1
Cima, RR1
Grimminger, P1
Hoffmann, A1
Schulte, C1
Schneider, PM6
Brabender, J6
Kersting, S1
Konopke, R1
Dittert, D1
Distler, M1
Rückert, F1
Gastmeier, J1
Baretton, GB3
Saeger, HD2
Ponti, G2
Mendiola, C1
Vaz, MA1
Hashmi, S1
Bell, D1
Tardío, JC1
Nájera, L1
Alemany, I1
Martín, T1
Castaño, A1
Pérez-Regadera, JF1
Fernández-Peralta, AM1
Daimiel, L1
Nejda, N1
Iglesias, D1
Medina Arana, V1
González-Aguilera, JJ1
Jansen, EPM1
Dubbelman, R3
Kuboki, Y1
Ichimura, T1
Matsueda, K1
Ren, DN1
Kim, IY1
Koh, SB1
Chang, SJ1
Eom, M1
Yi, SY1
Seong, SH1
Bronner, MP1
Cho, MY1
Yokoe, T2
Saigusa, S2
Toiyama, Y3
Miki, C5
Kusunoki, M8
Feng, F3
Jiang, WQ3
Yuan, SQ1
Liang, YJ1
Fu, LW1
Qiu, HB1
Zhang, LY2
Xiang, XJ4
Karampeazis, A1
Kouroussis, Ch2
Iott, MJ1
Corsini, MM2
Zhong, B1
Tucker, S1
Cheng, J1
Szynglarewicz, B1
Matkowski, R1
Halon, A1
Lacko, A1
Stepien, M1
Forgacz, J1
Pudelko, M1
Kornafel, J1
Itoh, S1
Harimoto, N1
Tsujita, E1
Sugimachi, K4
Gion, T1
Stenning, SP3
Bancewicz, J1
Clark, PI2
Chansky, K2
Christman, KL1
Hundahl, SA3
Issell, BF3
Van Veldhuizen, PJ1
Budd, GT4
Kim, SG2
Kim, DK1
Jang, JS1
Maindrault-Goebel, F3
Lledo, G8
Bennamoun, M4
Mabro, M6
Flesch, M5
Dupuis, O3
Colin, P4
Larsen, AK1
Küronya, Z1
Bodrogi, I1
Lövey, J1
Plótár, V1
Manninger, S1
Pápai, Z1
Choi, M1
Heilbrun, LK7
Venkatramanamoorthy, R2
Lawhorn-Crews, JM1
Malik, I4
Hussein, F1
Bush, D1
Alqaisi, M1
Bernal, P2
Byrd, J2
Garberoglio, C1
Iwahashi, M2
Takifuji, K1
Hotta, T1
Higashiguchi, T1
Oku, Y1
Nasu, T1
Fareed, KR1
Ilyas, M1
Kaye, PV1
Soomro, IN1
Lobo, DN1
Doi, T5
Takiuchi, H3
Ohtsu, A6
Henningsen, N1
Hapfelmeier, A1
Hois, S1
Plaschke, S1
Keller, G2
Marsh, Rde W1
Siddiqui, T1
Mendenhall, WM3
Zlotecki, RA2
Grobmyer, S1
Hochwald, S1
Chang, M1
Larson, B1
King, J1
Sprenger, T3
Rothe, H3
Homayounfar, K2
Beissbarth, T2
Ghadimi, BM3
Becker, H6
Gounaris, I1
Ahmad, A2
Kalender, ME1
Sevinc, A1
Camci, C1
Kaya, AO1
Yaman, E1
Cuilliere-Dartigues, P1
Guilloux, A1
Parc, Y1
Tiret, E1
Dumont, S1
Gayet, B1
Validire, P1
Fléjou, JF1
Duval, A1
Praz, F1
Nishigami, K1
Kawami, H1
Spindler, KG1
Andersen, RF1
Jensen, LH1
Harper, PG7
Dunn, J1
Tudur-Smith, C1
West, J1
Adab, F1
Leonard, P1
Ostrowski, J1
Boskos, CS1
Liacos, C1
Korkolis, D1
Aygerinos, K1
Lamproglou, I1
Terpos, E1
Stoupa, E1
Baltatzis, G1
Beroukas, K1
Papasavvas, P1
Dimopoulos, MA2
Damast, S1
Ho, AY1
Montgomery, L1
Fornier, MN2
Ishill, N1
Elkin, E1
Beal, K1
McCormick, B1
Qin, H1
Hudson, E1
Hurt, C1
Mort, D1
Brewster, AE2
Iqbal, N1
Joseph, G1
Lee, JK2
Wilkowski, R3
Boeck, S3
Ostermaier, S1
Herbst, M1
Flentje, M2
Miethe, S2
Boettcher, HD1
Scholten, T1
Rau, HG1
Buechner-Steudel, P2
Behrens, R2
Fahlke, J2
Behl, S1
Kuss, O2
Kleber, G2
Fleig, WE2
Wang, TS1
Ding, QQ1
Guo, RH1
Sun, J2
Lu, KH1
You, SH1
Ge, HM1
Shu, YQ1
Liu, P1
Kanamori, N1
Kaiga, T1
Funada, T1
Natsuizaka, M1
Tsuyuguchi, M1
Nagasako, T2
Kawamura, N2
Kudo, M2
Tsuda, I1
Meguro, J2
Dose-Schwarz, J1
Tiling, R1
Avril-Sassen, S1
Mahner, S1
Lebeau, A1
Weber, C1
Schwaiger, M1
Jänicke, F1
Untch, M1
Avril, N1
Hebbar, M3
Kockler, L1
Huang, C1
Zhang, XM2
Tavaluc, RT1
Hart, LS2
Dicker, DT2
Muto, Y1
Endo, J1
Asakage, M1
Oka, T2
Furukawa, Y1
Arai, M1
Otrock, ZK2
Barada, WM1
Sawaya, RA1
Saab, JF1
Bazarbachi, AA1
Kucherlapati, MH1
Nguyen, AA1
Clark, AB1
Hou, H1
Rosulek, A1
Yang, K2
Fan, K1
Lipkin, M1
Bronson, RT1
Jelicks, L1
Kunkel, TA1
Kucherlapati, R1
Edelmann, W1
Paiva, CE1
Paiva, BS1
Garita, R1
Michelin, OC1
Sharma, S1
Abhyankar, V1
Burgess, RE1
Infante, J1
Trowbridge, RC1
Tarazi, J1
Tortorici, M1
Robles, RL1
Sym, SJ2
Yook, JH3
Collins, A1
Robles-Jara, C1
Robles-Medranda, C1
Wente, MN2
Rötzer, I1
Decker-Baumann, C1
Sala-Vila, A1
Folkes, J1
Calder, PC1
Kim, JY3
Rhee, PL2
Kim, DS2
Yun, H2
Cho, YB3
Yun, SH4
Chun, HK3
Ha, SW5
Bati, Y1
Akboru, H1
Unsal, M1
Rego, RL1
Le, M1
O'Connell, MJ17
Windschitl, H1
Petty, RD2
Murray, GI1
MacDonald, G1
O'Kelly, T1
Loudon, M1
Binnie, N1
Aly, E1
McKinlay, A1
Gilbert, F1
Semple, S1
Collie-Duguid, ES1
Albain, KS1
Barlow, WE1
Ravdin, PM1
Farrar, WB1
Burton, GV1
Ketchel, SJ1
Cobau, CD1
Levine, EG1
Ingle, JN1
Pritchard, KI1
Lichter, AS1
Schneider, DJ1
Abeloff, MD2
Henderson, IC2
Muss, HB3
Green, SJ1
Lew, D1
Livingston, RB6
Martino, S1
Osborne, CK1
Lombardi, R1
Cuicchi, D2
Iacopino, B1
Neri, S1
Tardio, ML1
Ceccarelli, C2
Lecce, F1
Ugolini, G1
Pini, S2
Di Tullio, P1
Taffurelli, M1
Minni, F1
Martoni, A3
Cola, B1
Saunders, M2
Uña, E1
Bargagli, G1
Lazzi, S1
Pascucci, A1
Bellan, C1
Martellucci, I1
Lorenzi, B1
Francini, G5
Moen, I1
Tronstad, KJ1
Kolmannskog, O1
Salvesen, GS1
Reed, RK1
Stuhr, LE1
Nakamura, J1
Kitajima, Y3
Kai, K1
Hashiguchi, K1
Noshiro, H1
Miyazaki, K3
Iida, A2
Yoshidome, H1
Kaneko, T2
Mishima, T1
Miyazaki, M4
Miyamoto, A1
Tsujie, M3
Yasui, M1
Hirao, M1
Fujitani, K1
Nakamori, S3
Tsujinaka, T3
Kita, K1
Nakano, S6
Akabane, H1
Yanagida, N1
Shomura, H1
Hanamoto, T1
Kuji, M1
Oikawa, F1
Miyagi, H1
Takada, J1
Kenno, S1
Hamada, H4
Katsuki, Y1
Go, SI1
Simianu, VV1
Zyromski, NJ1
Nakeeb, A1
Kim, LG1
Kong, HH1
Low, LY1
Iacopetta, B4
Soong, R2
Callister, MD1
Farnell, MB1
Kang, SH1
Moon, HS1
Sung, JK1
Lee, BS1
Jeong, HY1
Catania, C1
Pelosi, G1
Spitaleri, G1
Noberasco, C1
Maggioni, A1
Trifirò, G1
Toffalorio, F1
Vigna, PD1
De Pas, T1
Orphanos, GS1
Stavrou, NG1
Picolos, MK1
Kim, CW4
Shin, US2
Jung, KY1
Yoon, SN3
Eiermann, W1
Semiglazov, V2
Manikhas, A1
Lluch, A1
Vazquez, F1
Byakhow, M1
Climent, MA1
Ciruelos, E1
Ojeda, B1
Mansutti, M1
Bozhok, A1
Baronio, R1
Feyereislova, A3
Barton, C1
Valagussa, P3
Okugawa, Y1
Zhu, FS2
Chen, XM2
Huang, ZG1
Wang, ZR1
Zhang, DW1
Njiaju, UO1
Truica, CI1
Meredith, KL1
Siegel, EM1
McLoughlin, J1
Marcovalerio, M1
Kelley, S1
Karl, R1
Manuyakorn, A1
Paulus, R1
Farrell, J1
Dawson, NA1
Tze, S1
Cheung-Lau, G1
Reber, H1
Seligson, DB1
Horvath, S1
Kurdistani, SK1
Dawson, DW1
Dahlqvist, C1
Fremault, A1
Carrasco, J1
Colinet, B1
Kanagavel, D1
Pokataev, IA1
Tryakin, AA1
Bazin, IS2
Narimanov, MN1
Yakovleva, ES1
Garin, AM3
Tjulandin, SA2
García-Montesinos-De la Peña, M1
Oteiza-López, L1
Aldunate-Calvo, S1
Gómez-Sánchez, MJ1
Sáenz-Bañuelos, JJ1
Tihista-Jiménez, JA1
Lal, A1
Christians, K1
Rodriguez, W1
Garin, A1
Lang, I3
Falcon, S1
Helsby, NA1
Lo, WY1
Thompson, P3
Laking, GR1
Paczos, TA1
Ackers, S1
Odunsi, K1
Lele, S2
Mhawech-Fauceglia, P1
Mawdsley, S3
Ishii, H5
Furuse, J2
Ohkawa, S1
Hamamoto, Y1
Nakamura, K5
Jørgensen, JT1
Hongoh, S1
Nomoto, T1
Kawakami, M2
Hanai, K1
Inatsuchi, H1
Terachi, T1
Ejlertsen, B2
Mouridsen, HT2
Jensen, MB2
Andersen, J2
Andersson, M2
Kamby, C2
Knoop, AS1
Viganò, MG3
Aldrighetti, L2
Vidaurreta, M1
Sánchez-Muñoz, R1
Veganzones, S1
Rafael, S1
Gutiérrez, M1
de-la-Orden, V1
Arroyo, M1
Cerdán, FJ1
Maestro de las Casas, ML1
Seront, E1
Marot, L1
Coche, E1
Gala, JL1
Sempoux, C2
Humblet, Y4
Guo, JF1
Wu, F1
Xing, H1
Zhu, GY1
Nie, XY1
Vilgelm, AE1
Washington, MK1
Prassolov, VS1
Zaika, AI1
Dalla Chiesa, M1
Tomasello, G1
Buti, S1
Rovere, RK1
Brighenti, M1
Lazzarelli, S1
Donati, G1
Passalacqua, R3
Rullier, A1
Capdepont, M1
Bioulac-Sage, P1
Rullier, E2
Sonnenblick, A2
Meirovitz, A1
Coursier, S1
Martelet, S1
Guillermet, A1
Emptoz, J1
Villier, C1
Bontemps, H1
Allegrini, G5
Fontana, E2
Granetto, C3
Mentuccia, L1
Andreuccetti, M2
Cortesi, E3
Merlano, M1
Sogabe, S1
Takano, H2
Kawamoto, Y1
Nakatsumi, H1
Uehata, Y1
Ye, ZB1
Zhu, ZG2
Lim, YK1
Law, WL1
Liu, R2
Poon, JT1
Fan, JF1
Lo, OS1
Spigel, DR2
Greco, FA4
Meluch, AA1
Lane, CM1
Farley, C1
Gray, JR1
Clark, BL1
Burris, HA3
Mehta, SP1
Taura, M1
Fukuda, R1
Suico, MA1
Eguma, A1
Koga, T2
Shuto, T2
Morino-Koga, S1
Kai, H1
Dikken, JL1
Bakker, B1
Hartgrink, HH2
Kranenbarg, EM1
Peeters, KC1
Kurose, A1
Takatori, E1
Traganos, F2
Darzynkiewicz, Z1
Sawai, T2
McCollum, D1
Hecht, JR5
Pillai, M1
Gollard, R1
Heim, W1
Swan, F1
Patel, R2
Dreiling, L1
Mo, M1
Boccia, RV1
Cosgriff, TM1
Headley, DL1
Badarinath, S1
Dakhil, SR3
Raftery, L1
Calvo, BF1
Chakravarthy, AB1
Ivanova, A1
Myers, MO1
Chan, E2
Wise, PE1
Caskey, LS1
Bernard, SA4
Sanoff, HK2
Beretta, GD4
Tondulli, L1
De Pellegrin, A1
Decorti, G1
Jung, K1
Christiansen, H1
Conradi, LC2
Lo, SS1
Khorana, AA1
Simon, S1
Kiefer, G1
Rajasenan, K1
Hantel, A1
Shayne, M1
Schmotzer, A1
Tran, B1
Yovino, S1
Poppe, M1
Jabbour, S1
David, V1
Garofalo, M1
Pandya, N1
Alexander, R1
Hanna, N2
Andres, A2
Majno, P1
Promkan, M1
Katopodis, O1
Kentepozidis, N1
Giassas, S1
Rovithi, M1
Bozionelou, V1
Andersen, M1
Vestermark, LW2
Hess, V2
Pratsch, S1
Potthast, S1
Lee, L1
Winterhalder, R3
Widmer, L3
Cescato, C1
Lohri, A1
Jost, L1
Stillhart, P1
Pestalozzi, B1
Trikudanathan, G1
Uehara, K2
Ishiguro, S2
Nishio, H1
Ebata, T1
Kokuryo, T1
Tsunoda, N1
Igami, T1
Sugawara, G1
Fukaya, M1
Hill, ME5
Campbell, A1
Culler, K1
Zalupski, M2
Hejna, G1
Harris, W1
Hoffman, J4
Talamonti, M2
Cooper, H3
Avallone, A3
Delrio, P2
Pecori, B1
Tatangelo, F2
Marone, P2
Aloi, L1
Iaffaioli, VR1
Scala, D1
Iodice, G1
Budillon, A2
Joon, DL1
Jayamoham, J1
Spry, N3
Harvey, J3
Di Iulio, J1
Milner, A1
Mann, GB1
Spanos, CP1
Syrakos, T1
Ogata, S1
Ozeki, Y1
Nakanishi, K2
Tanaka, F2
Mio, T1
Hiroi, S1
Tominaga, S1
Aida, S1
Kawai, T3
Mochizuki, S1
Kojima, T4
Fuse, N2
Ikematsu, H1
Yano, T3
Tahara, M2
Kaneko, K2
Koike, K2
Gallagher, M2
Whittington, R3
Gilligan, D1
Beadman, C1
Ripley, RT1
Davis, JL1
Kemp, CD1
Jeong, EK1
Jeon, HM1
Kim, CH1
Kang, HS1
Hurmuzlu, M2
Øvrebø, K1
Monge, OR1
Smaaland, R1
Wentzel-Larsen, T1
Paduch, R1
Kandefer-Szerszeń, M1
Piersiak, T1
Aftimos, PG1
Nasr, EA1
Nasr, DI1
Noun, RJ1
El Helou, JA1
Lai, HS1
Cheng, KW1
Van Huysse, J1
Vandenbossche, B1
Sainz-Barriga, M1
Vinci, A1
Ricciardi, S1
Bocchetti, T1
Rogiers, X1
de Hemptinne, B1
Jauhri, M1
Negi, A1
Smyth, E1
Lowery, M1
Al-Olayan, A1
Naghy, M1
Saliba, T1
Kelsen, D8
Kelly, P1
Appleyard, V1
Murray, K1
Paulin, F1
Lamont, D1
Baker, L2
Suttie, S1
Exon, D1
Thompson, A2
Lai, JI1
Wang, WS3
Lai, YC1
Chang, SC2
Schultheis, B1
Riebeling, J1
Allali, M1
Bergmann, U1
Kummer, G1
Sendler, U1
Tannapfel, A2
Sendler, A3
Napoli, C1
Landini, I1
Morganti, M1
Cianchi, F1
Valanzano, R1
Tonelli, F1
Cortesini, C1
Courrech Staal, EF1
Aleman, BM1
van Velthuysen, ML1
van Coevorden, F1
Maleux, G1
Lambert, B1
Vannoote, J1
De Keukeleire, K1
Verslype, C2
Defreyne, L1
Delatte, P1
Delaunoit, T3
Personeni, N1
Schneiders, FL1
van den Berg, HP1
Peters, GJ7
Verheul, HM1
van der Vliet, HJ1
Engelman, JA1
Sahani, DV1
Lisovsky, M2
Wolf, M2
Zehentmayr, F1
Niyazi, M1
Ganswindt, U1
Haimerl, W1
Schmidt, M2
Hölzel, D1
Belka, C1
Besch, S1
Mönig, SP3
Baldus, SE5
Specht, K4
Piperdi, M1
McDade, TP1
Shim, JK1
Piperdi, B1
Kadish, SP1
Sullivan, ME1
Whalen, GF1
Tseng, JF1
Li, HM1
Chen, XF1
Xie, KC1
Huang, Q4
Davies, L1
Lewis, WG1
Arnold, DT1
Escofet, X1
Blackshaw, G1
Gwynne, S1
Evans, M3
Appadurai, I1
Laurence, V1
Tobias, J1
Blackman, G1
Meyer, T1
Goodchild, K1
Collis, C1
Nonaka, K3
Sha, S1
Yamanaka, N1
Son, JY1
Shin, JW1
Wang, JH2
Raghavendran, HR1
Son, CG1
Astier, A1
Takemura, M2
Morimura, K1
Kishida, S1
Dietlein, M1
Alakus, H2
Jackson, AS1
Watkins, GR1
Whitfield, GA1
Green, MM1
Taylor, MB1
Dickinson, C1
Price, PM1
Saleem, A1
Tanoue, Y1
Mounier-Boutoille, H1
Boisdron-Celle, M6
Cauchin, E1
Galmiche, JP1
Morel, A4
Gamelin, E11
Matysiak-Budnik, T1
Unger, KR1
Romney, DA1
Koc, M2
Moskaluk, CA1
Foley, EF1
Rich, TA21
Kim, HK5
Ko, BM1
Hong, SJ1
Moon, JH1
Lee, JS12
Lee, MS3
Toujima, S2
Ashley, SE1
Turner, A1
Redmond, KJ1
Ahn, J1
Penney, R1
Kaley, K1
Marshall, MB1
Cupini, S2
Ciarlo, A1
Del Monte, F1
Amoroso, D1
Sensi, E1
Bartholomeusz, D1
Devitt, PG4
Lamb, PJ1
Ruszkiewicz, AR1
Konings, IR1
van der Wijk, LJ1
de Jongh, FE1
Eskens, FA1
Sleijfer, S1
Omuro, Y3
Kulikov, E1
Hill, J1
Lehle, M1
Ahn, JY1
Stathopoulos, GP3
Batziou, C1
Trafalis, D1
Koutantos, J1
Batzios, S1
Stathopoulos, J1
Legakis, J1
Armakolas, A1
Savva-Bordalo, J1
Ramalho-Carvalho, J1
Pinheiro, M1
Costa, VL1
Rodrigues, A4
Dias, PC1
Veiga, I1
Machado, M1
Teixeira, MR1
Henrique, R1
Jerónimo, C1
Aarstad, HJ1
Aarstad, AK1
Hjermstad, MJ1
Gubanski, M1
Kadar, L1
Karlberg, I1
Flygare, P1
Padbury, R1
Gallinger, S3
Doi, R1
Buckels, JA1
Chen, YB2
Sun, XW2
Xu, DZ2
Guan, YX2
Feng, XY1
Wolthuis, AM2
Penninckx, F2
Ectors, N1
D'Hoore, A2
Taylor, NJ1
Makris, A2
Ah-See, ML1
Beresford, MJ1
Stirling, JJ1
d'Arcy, JA1
Collins, DJ1
Padhani, AR2
Monjazeb, AM1
Riedlinger, G1
Aklilu, M1
Geisinger, KR1
Mishra, G1
Isom, S1
Clark, P1
Levine, EA1
Blackstock, AW2
Wiegel, T2
Kreuser, ED3
Kron, M2
Baumann, W2
Shen, W1
Tu, JK1
Wang, XH1
Fu, ZX1
Yukawa, K2
Schauer, MC1
Holzmann, B1
Peiper, M1
Knoefel, WT1
Theisen, J1
Husein-ElAhmed, H1
Aneiros-Fernandez, J1
Arias-Santiago, S1
Naranjo-Sintes, R1
Hong, YS3
Yun, T2
Jeong, SY4
Choi, HS3
Chang, HJ6
Jung, KH4
Velenik, V4
Oblak, I4
Anderluh, F4
Fantini, M1
Tassinari, D1
Nicoletti, S1
Possenti, C1
Drudi, F1
Sintini, M1
Bagli, L1
Tamburini, E1
Ravaioli, A1
Atar, A1
Korkmaz, ME1
Ozin, B1
Lee, MY2
Brændengen, M1
Bruheim, K1
Cvancarova, M1
Jang, YJ1
Park, SS2
Kim, SJ2
Kim, CS1
Mok, YJ3
Lagares-Garcia, J1
Cataldo, T1
McNulty, B1
Shipley, J1
Anderson, E1
Khurshid, H1
Oconnor, B1
Oldenburg, NB1
Radie-Keane, K1
Husain, S1
Cattan, S2
Chauffert, B4
Yu, HB1
Xian, HB1
Deng, YM1
Li, LL1
Murad-Regadas, SM1
Regadas, FS1
Rodrigues, LV1
Crispin, FJ1
Kenmoti, VT1
Fernandes, GO1
Buchen, G1
Monteiro, FC1
Fischer von Weikersthal, L2
Schalhorn, A3
Stauch, M2
Quietzsch, D5
Maubach, PA1
Lambertz, H1
Oruzio, D2
Schlag, R1
Weigang-Köhler, K1
Vehling-Kaiser, U3
Schulze, M3
Truckenbrodt, J1
Goebeler, M1
Mittermüller, J2
Bosse, D1
Szukics, B1
Grundeis, M1
Zwingers, T1
Giessen, C2
Chang, MH1
Lee, IK1
Si, Y1
Woo, IS1
Li, QF1
Yao, RY1
Lü, HY1
Jiang, J1
Sun, YY1
Song, SA1
Jiang, T1
Ebara, T1
Saito, J2
Shioya, M3
Sakurai, H3
Xanthakis, I1
Samelis, G2
Xiros, N1
Kosmidis, P4
Christodoulou, C2
Linardou, H1
Skondra, M1
Wernroth, L1
Larsson, A1
Einarsson, R1
Tagawa, T1
Honda, S1
Hidaka, S1
Baird, R1
Biondo, A1
Chhaya, V1
McLachlan, J1
Karpathakis, A1
Rahman, S2
Pantling, AZ1
Mamidanna, R1
Newman, G1
Manifold, DK1
Hale, PC1
Burmeister, BH7
Thomas, JM1
Burmeister, EA2
Harvey, JA2
Thomson, DB2
Gotley, DC3
Yamauchi, M2
Okamoto, Y2
Doi, M1
Jin, H1
Ding, Y1
Kang, MF1
Luo, MQ1
Dong, CM1
Kang, EJ2
Park, KH3
Choi, IK4
Seo, JH5
Shin, SW4
Xia, LP1
Wu, PH1
Xia, JC1
Guan, ZZ1
Guo, GF1
Zeng, YX1
Belli, C2
Longoni, S2
Fugazza, C3
Brioschi, M1
Madajewicz, S2
Waterhouse, DM1
Khan, MQ1
Higby, DJ1
Leichman, CG6
Malik, SK1
Hentschel, P1
Gill, JF1
Nicol, SJ1
Ababneh, Y1
Verpoort, K1
Musch, R1
Soeling, U1
Maintz, C1
Siebler, J4
Efficace, F2
Serpentini, S2
Capirci, C1
De Paoli, A2
Amato, A1
Thukral, A1
Metz, J2
Hwang, WT1
O'Dwyer, P2
Plastaras, J1
Both, S1
Bar-Ad, V1
Ad, VB1
Drullinsky, P1
Sugarman, SM1
D'Andrea, G1
Gilewski, T1
Lake, D1
Traina, T1
Wasserheit-Lieblich, C1
Sklarin, N1
Atieh-Graham, D1
Mills, N1
Troso-Sandoval, T1
Seidman, AD1
Yuan, J2
Norton, L3
Hudis, C3
Paillas, S1
Boissière, F1
Denouel, A1
Causse, A1
Denis, V2
Vezzio-Vié, N1
Marzi, L1
Cortijo, C1
Ait-Arsa, I1
Askari, N1
Pourquier, P1
Teke, Z1
Nessar, G1
Kiremitci, S1
Aksoy, E1
Elbir, OH1
Abe, T3
Hachiro, Y1
Kunimoto, M1
Liu, LJ2
Zhao, CH2
Liu, JZ2
Li, ZQ1
Stauffer, JA1
Mathew, J1
Odell, JA1
Chi, KC1
Lamas, MJ1
Duran, G1
Gomez, A1
Balboa, E1
Anido, U1
Bernardez, B1
Rana-Diez, P1
Lopez, R1
Carracedo, A1
Barros, F1
Ihtiyar, E1
Paşaoğlu, O1
Erkasap, S1
Karakaş, BR1
Yaşar, FN1
Ruiz-Rabelo, J1
Vázquez, R1
Arjona, A1
Perea, D1
Montilla, P1
Túnez, I1
Muntané, J1
Padillo, J1
Wynn, G1
Marks, J2
Kessler, H1
Cone, MM1
Lu, KC1
Rea, JD1
Diggs, BS1
Oommen, SC1
Park, KS1
Lefkowitz, RA1
Robinson, E3
Ogata, Y6
Shirabe, K2
Hasegawa, H4
Sadanaga, N2
Samura, H2
Kitazono, M1
Yamamoto, M6
Morikita, T1
Inomata, M3
Kakeji, Y3
Shirouzu, K2
de Campos-Lobato, LF1
Stocchi, L1
da Luz Moreira, A1
Geisler, D1
Lavery, IC1
Fazio, VW1
Kalady, MF1
Amonkar, SJ1
Cain, HJ1
Hughes, T1
Hemming, JD1
Browell, DA1
Çalık, AN1
Çeliker, E1
Velibey, Y1
Çağdaş, M1
Güzelburç, Ö1
Ocean, AJ1
Christos, P1
Horvath, L1
Hamilton, A1
Matulich, D1
Chen, HX1
Sparano, JA5
Hirst, J1
Barbour, A1
Stokes, JB1
Nolan, NJ1
Stelow, EB1
Walters, DM1
Weiss, GR2
de Lange, EE1
Adams, RB1
Bauer, TW1
Custodio, A1
Sanchez, JC1
Rodriguez, L1
Puente, J1
de las Heras, M2
Nishiofuku, H2
Anai, H3
Sueyoshi, S3
Morimoto, K1
Masada, T1
Sho, M3
Tamamoto, T2
Hasegawa, M2
Sakaguchi, H2
Shimobayashi, T1
Inatsugi, N1
Yoshikawa, S1
Uchida, H1
Kuge, H1
Yokotani, T1
Yamaoka, K1
Inagaki, M2
Matsuoka, M1
Tatsumi, K1
Saraya, T1
Otsuji, T1
Yamochi, Y1
Yamanishi, K1
Enomoto, Y1
Nonomura, A1
Ota, T1
Toma, T1
Ohira, G1
Uesato, M1
Akutsu, Y1
Kono, T2
Matsubara, H1
Kawaoka, T1
Matsukuma, S1
Hiraki, S1
Kanoh, T1
Ohnishi, T1
Danno, K1
Tsukao, Y1
Inatome, J1
Kagara, N1
Tono, T1
Monden, T1
Imaoka, S4
Murata, A2
Noda, E1
Muguruma, K2
Yamada, N2
Ohira, M1
Okubo, K1
Yoshioka, S1
Asukai, K1
Nakanishi, M1
Maekawa, T2
Kashiwazaki, M1
Konishi, M2
Yano, K1
Fujimoto, T2
Platell, C2
Ng, S1
O'bichere, A1
Tebbutt, N1
Luo, W1
Liao, WJ2
Huang, YT1
Wen, Q1
Zhou, MQ1
Chai, H1
Tian, R1
Tang, H1
Miura, K2
Nakano, H2
Sakurai, J1
Koizumi, S2
Arai, T5
Shimamura, T1
Makizumi, R1
Yamada, K2
Miyajima, N1
Otsubo, T1
Koike, J1
Kidera, Y1
Ueda, S2
Okamoto, W1
Okamoto, I1
Fumita, S1
Yonesaka, K1
Makimura, C1
Okamoto, K3
Kiyota, H1
Tsurutani, J1
Yoshinaga, M1
Fujiwara, K3
Yamazoe, Y1
Moriyama, K1
Tsubaki, M2
Chiba, Y2
Nishida, S1
Nakagawa, K5
Hazard, L1
Jones, K1
Shaban, A1
Anker, C1
Scaife, C1
Weis, J1
Mulvihill, S1
Gordon, VL1
Harding, GA1
Czaykowski, P1
Smith, C1
Kist, J1
Sun Myint, A1
Haylock, B1
Wise, M1
Neupane, R1
Dougal, M2
Lloyd, A1
Topham, C3
Devries, AF3
Schaberl-Moser, R2
Zitt, M1
Kapp, KS1
Fastner, G1
Keil, F1
Jäger, R1
Offner, F1
Chun, CL1
Eisenstat, S1
Dormady, S1
Lombard, C1
Triadafilopoulos, G1
Advani, PP1
Lustig, R1
Konski, AA3
Khan, A1
Compton, S1
Yeo, SG3
Park, JW4
Sohn, DK3
Hass, HG3
Dietzfelbinger, H1
Klein, S1
Zellmann, K1
Abenhardt, W1
Puchtler, G1
Kappauf, H1
Haberl, C2
Adamo, V1
Franchina, T1
Minciullo, PL1
Pace, E1
Colonese, F1
Ricciardi, GR1
Saitta, S1
Ferraro, M1
Spatari, G1
Gangemi, S1
O'Donovan, TR1
O'Sullivan, GC2
McKenna, SL1
Han, SW6
Park, JH3
Yoon, SM2
Lee, YS2
Park, EK1
Miyashiro, I1
Sasako, M3
Nashimoto, A7
Kinoshita, T2
Kobayashi, O2
Aksoy, S4
Oksuzoglu, BC1
Aslan, N1
Bleckmann, A1
Schirmer, M1
Jo, P1
Middel, P1
Ghadimi, MB1
Rachakonda, PS1
Panzram, B1
Buechler, M1
Hemminki, K1
Kumar, R2
Yan, SK1
Dai, WX1
Liu, XR1
Zhang, WD1
Owen, D1
Pohlen, U2
Berger, G2
Ritz, JP1
Holmer, C1
Coban, I1
Kneuertz, PJ1
Kauh, JS1
Sarmiento, J1
Staley, CA2
Volkan Adsay, N1
Renaud, S1
Santelmo, N1
Falcoz, PE1
Massard, G1
Choi, IJ4
Kim, CG2
Oshima, A1
Michalowski, A1
Green, JE1
Precetti, FA1
Prieto, Mde C1
Pietrantonio, A1
González, B1
Latiano, T1
Aschele, C9
Garufi, C5
Bochicchio, A1
Giaquinta, S3
Torri, V2
Bardelli, A1
Gion, M1
Chang, BW1
Bhangu, A1
Tiramula, R1
Fioravanti, A1
Orlandi, P1
Di Desidero, T1
Canu, B1
Frumento, P3
Di Paolo, A3
Danesi, R6
Bocci, G2
Zhang, XL1
Shi, HJ1
Cui, SZ1
Tang, YQ1
Ba, MC1
Voisin, T1
El Firar, A1
Fasseu, M1
Rouyer-Fessard, C1
Descatoire, V1
Walker, F1
Paradis, V1
Bedossa, P1
Henin, D1
Lehy, T1
Laburthe, M1
Enzo, MV1
Briarava, M1
Maretto, I1
Toppan, P3
Min, JJ1
Eich, HT1
Stepien, A1
Zimmermann, C1
Hellmich, M1
Hölscher, A1
Müller, RP2
McCaffrey, R1
Bahtiyar, M1
Kohorn, EI1
Chambers, JT1
Schwartz, PE1
Chambers, SK1
Vázquez-Mazón, F1
Ramos, FJ1
Countouriotis, AM1
Ruiz-Garcia, A1
Wei, G1
Tursi, JM2
Guillen-Ponce, C3
Moore, M4
Germond, C1
Berg, W2
Chen, BL2
Jalava, T2
Lebwohl, D2
Meinhardt, G2
Laurent, D2
Trarbach, T3
Major, P1
Lloyd-Salvant, K1
Pendergrass, K1
Nogué, M1
Salud, A2
Vicente, P1
Arriví, A1
Roca, JM1
Losa, F1
Ponce, J1
Safont, MJ1
Guasch, I1
Moreno, I1
Ruiz, A1
Leibold, T1
Akhurst, TJ1
Chessin, DB2
Yeung, HW1
Macapinlac, H2
Riedel, E1
Mazumdar, M1
Wong, WD4
Larson, SM1
Bai, J1
Kleyser-Sugrue, K1
Nerenstone, SR1
Welch, JP1
Ben-David, K1
Rossidis, G1
Grobmyer, SR1
Cendan, JC1
Hochwald, SN1
Rodriguez, NA1
Ascaso, FJ1
Teo, M1
Swan, NC1
McDermott, RS1
Abrams, R1
Gavoille, C2
Komaki, RU1
Wu, TT7
Strassburg, J1
Ruppert, R1
Ptok, H1
Maurer, C1
Junginger, T3
Merkel, S2
Hermanek, P1
Hodul, P1
Klapman, J1
Centeno, B1
Helm, J1
Valone, T1
Springett, G1
Koucky, K1
Konturek, PC1
Albrecht, H1
Busse, D1
Golcher, H1
Schildberg, C1
Janka, R1
Neurath, MF1
Yang, SS1
Scarpa, M1
Zanchettin, G1
Bécouarn, Y5
Khemissa-Akouz, F1
Delbaldo, C2
Montoto-Grillot, C1
Thompson, LC3
Shepherd, SF1
O'Mahony, MS1
Parmar, M1
Gantzer, A1
Regnier, S1
Cosnes, A1
Ortonne, N1
Wolkenstein, P1
Bagot, M1
Duong, TA1
Negri, FV2
Bozzetti, C1
Ardizzoni, A4
Lagrasta, C1
Crafa, P2
Silini, EM1
Xie, T1
Li, DR1
Mao, NQ1
Liu, DS1
Zuo, CT1
Huang, DM1
Zhao, WY1
Chen, DY1
Qi, Q1
Li, JH1
Jiang, HR1
Garant, A1
Des Groseilliers, S1
Martin, L2
Ferland, É1
Vuong, T2
Mamon, H1
Pellen, MG1
Sabri, S1
Razack, A1
Gilani, SQ1
Jain, PK1
Marsoni, S2
Monges, G3
Kim, GP1
Allegra, C4
Hongo, K1
Tsuno, NH1
Shuno, Y1
Kaneko, M1
Sunami, E4
Kitayama, J2
Nagawa, H7
Kim, BC1
Cionini, L2
Cordio, S4
Artale, S1
Tagliagambe, A1
Ambrosini, G1
Rosetti, P1
Bonetti, A2
Negru, ME1
Tronconi, MC2
Silvano, G1
Chiaulon, G1
Gallo, M1
Norman, G1
Rice, S1
Spackman, E1
Stirk, L1
Danso-Appiah, A1
Suh, D1
Palmer, S1
Eastwood, A1
Werner Kraus, T1
Bruch, HP1
Noack, F1
Altmannsberger, HM2
Rezzonico, S1
Cappio, S1
Doglioni, C2
Pederson, AW1
Salama, JK1
Witt, ME1
Stenson, KM1
Blair, EA1
Vokes, EE3
Haraf, DJ2
Abbas, F1
Romano, O2
Mayes, PA1
Dolloff, NG1
Daniel, CJ1
Liu, JJ1
Kuribayashi, K1
Allen, JE1
Jee, DI1
Dorsey, JF1
Liu, YY1
Brown, JM1
Furth, EE1
Klein, PS1
Sears, RC1
Nishihara, C1
Kuratsukuri, K1
Kawashima, H1
Nakatani, T2
Wilson, BJ1
Schatton, T1
Zhan, Q1
Gasser, M1
Saab, KR1
Schanche, R1
Waaga-Gasser, AM1
Gold, JS1
Murphy, GF1
Frank, MH1
Frank, NY1
Pera, M2
Montagut, C2
Iglesias, M1
Reig, A1
Balagué, C1
Pétriz, L1
Momblan, D1
Bellmunt, J2
Hollis, D5
Kennecke, H1
Berry, S2
Zhou, C1
Tankel, K1
Easaw, J1
Post, J1
Hay, J1
Catalano, V3
Galluccio, N1
Canestrari, E1
Vincenzi, B1
Bencardino, K1
Ricci, V2
Manzoni, M1
Danova, M1
Magnani, M1
Yoh, T1
Yamamichi, K1
Oishi, M2
Iwaki, R1
Motohiro, T1
Kobunai, T2
Nozawa, K2
Iinuma, H2
Horie, H1
Ikeuchi, H3
Eshima, K1
Edden, Y1
Wexner, SD2
Wolff, R2
von Gall, C1
Weitz, J1
Haberkorn, U2
Zalinski, S1
Farges, O1
Kawashima, R1
Abei, M2
Fukuda, K4
Murata, T3
Wakayama, M2
Seo, E2
Hasegawa, N1
Obata, Y1
Yokoyama, KK2
Jeanneret, LA1
Schneider, MP1
Troxler, S1
Bugnon, O1
Lüthi, F1
Kuramitsu, Y1
Murakami, K5
Ryozawa, S1
Taba, K1
Kaino, S1
Sakaida, I1
Bojic, M1
Thallinger, CM1
Maresch, J1
Higashiyama, A1
Abiko, S1
Gotoh, J1
Tamaki, T1
Yonekawa, M1
Kawamura, A1
Tanino, M1
Tse, VC1
Ng, WT2
Lee, V1
Lee, AW1
Chua, DT1
Chau, J1
McGhee, SM1
Zhang, D2
Takigawa, N1
Tanimoto, Y1
Ichihara, E1
Hotta, K2
Tabata, M1
Tanimoto, M1
Kiura, K3
Thomas, CR5
Medich, D2
Pigazzi, A1
Kang, MK2
Kim, MS1
Leite, D1
Kater, FR1
Afonso, S2
Viani, G1
Afonso, V1
Stefano, E1
Iqbal, S2
Chang, RY1
Potmesil, M1
Chandra, A2
Utate, M1
Hiotis, S1
Pachter, LH1
Hochster, H4
Muggia, F2
Assaf, E1
Verlinde-Carvalho, M1
Grenier, J1
Sellam, Z1
Pouessel, D1
Bouaita, L1
Tayar, C1
Paul, M1
Culine, S1
Cihan, Ş1
Babacan, NA1
Rothmann, F1
Blau, I1
Schwaner, I1
Grothoff, M1
Grieser, C1
Martijnse, IS1
Dudink, RL1
Vermeer, TA1
West, NP1
van Lijnschoten, I1
Quirke, P1
Meng, H1
Zhou, G1
Xue, Z1
De Jesus-Acosta, A1
Oliver, GR1
Blackford, A1
Kinsman, K1
Flores, EI1
Wilfong, LS1
Cosgrove, D1
Chung, K2
Créhange, G3
Sakamoto, E1
Maeda, A1
Tojima, Y1
Omiya, N1
Ishizuka, N1
Nakao, A2
Goto, H1
Xenidis, N1
Chelis, L1
Chamalidou, E1
Dimopoulos, P1
Michailidis, P1
Tentes, A1
Deftereos, S1
Karanikas, M1
Karayiannakis, A1
Lin, LS1
DiCarlo, B1
Dao, KM1
Wang, HJ1
Elashoff, R1
Ryba, N1
Bang, SM7
Amini, A1
Sanati, H1
Sola, J1
Aristu, J3
Rai, K1
Tsushima, M1
Kudo, K2
Mizuta, M2
Yonei, T1
Yamadori, I1
Bhattacharyya, M1
Francis, J1
Eddouadi, A1
Lemoine, NR1
Halldén, G1
Verhage, RJ1
van der Horst, S1
van der Sluis, PC1
McCleod, M1
Shipley, DL1
Barnes, EK1
Infante, JR1
Mohammed, TA1
Dennie, T1
Holen, KD2
Serra, S2
Kennedy, E1
Gujral, DM1
Hawkins, MA1
Leonulli, BG1
Shumaker, GC1
Khandelwal, P2
Smith, DA1
Neubauer, MA3
Mehta, N1
Watkins, DL1
Zhang, K1
Yassine, MR1
Ferrarotto, R1
Pathak, P1
Agarwal, A1
Overman, M1
Wong, NS1
Fernando, NH3
Honeycutt, W4
Madoff, RD2
Pan, SY1
Chen, QQ1
Gao, XP1
Ocvirk, J1
Music, M1
Bracko, M1
Edhemovic, I1
Brecelj, E1
Kropivnik, M1
Omejc, M1
Al-Niaimi, F1
Lyon, C1
Van Hazel, G5
Wong, A4
Gilberg, F1
Latkauskas, T1
Pauzas, H1
Gineikiene, I1
Janciauskiene, R1
Juozaityte, E2
Saladzinskas, Z1
Tamelis, A1
Pavalkis, D1
Baldi, GG1
Tuzi, A1
Brunetti, IM1
Ricci, S1
Dai, ZK1
Yang, XS1
Yu, LM1
Crea, F1
Paolicchi, E1
Farrar, WL1
Zhang, RX1
Narang, AK1
Azzopardi, N1
Ternant, D1
Piller, F1
Gouilleux-Gruart, V1
Vignault-Desvignes, C1
Watier, H1
Paintaud, G1
Sbitti, Y1
Essaidi, I1
Debbagh, A1
Kadiri, H1
Oukabli, M1
Moussaid, Y1
Slimani, K1
Fetohi, M1
Elkaoui, H1
Albouzidi, A1
Mahi, M1
Ali, AA1
Ichou, M1
Errihani, H1
Warnecke-Eberz, U3
Grimminger, PP1
Chen, LC1
Wu, YH1
Liu, IH1
Ho, CL1
Chang, CH1
Lan, KL1
Ting, G1
Lee, TW1
Shien, JH1
Egashira, A1
Toyama, T1
Ohga, T1
Kohakura, F1
Higashi, H5
Kohnoe, S4
Engels, B1
Tournel, K1
Everaert, H1
Hoorens, A1
Sermeus, A1
Christian, N1
Storme, G1
Verellen, D1
De Ridder, M1
Kuo, YH1
Tien, YW1
Hsu, C1
Kuo, SH1
Cheng, AL6
Leichman, LP3
Goldman, BH1
Bohanes, PO1
Billingsley, KG1
Corless, CL1
Gold, PJ1
Benedetti, JK4
Danenberg, KD7
Bayraktar, UD1
Bayraktar, S1
Hosein, P1
Chen, E2
Koniaris, LG1
Rocha-Lima, CM1
Chasen, M2
Marcus, V2
Hickeson, M2
Artho, G2
Thirlwell, MP3
Maréchal, R2
Vos, B1
Polus, M1
Demetter, P1
Demols, A1
Franchimont, D1
Verset, G1
Van Houtte, P1
Van de Stadt, J1
Ren, JH1
Cui, CX1
Li, JL1
Wang, JW1
Balachandran, A1
Bhosale, P1
Abdalla, EK1
Abbruzzese, J1
Chopin-Laly, X1
Charnsangavej, C5
Devun, F1
Bousquet, G1
Biau, J1
Herbette, A1
Roulin, C1
Berger, F1
Sun, JS1
Robine, S1
Dutreix, M1
Martínez-Monge, R3
Moreno, M1
Ramos, LI1
Nuñez, J1
Cambeiro, M1
Gaztañaga, M1
Abu-Ghanem, S1
Novik, EF1
Abu-Ghanem, Y1
Man, S1
Shelef, I1
Bouchbika, Z1
Kouto, H1
Baruch-Hennequin, V1
Munoz, N1
Cojean-Zelek, I1
Houdart, R1
Valleur, P1
Maylin, C1
Hennequin, C2
Yu, C1
Zhu, W1
Chung, HJ1
Tabe, Y1
Suto, T1
Werner, D1
Steinmetz, K1
Esch, A1
Scotté, M1
Hamidou, H1
Paillot, B2
Michot, F1
Bickenbach, KA1
Tang, LH2
Goodman, K1
Brennan, MF3
Dematteo, RP1
Allen, PJ1
Semrau, R1
Herzog, SL1
Damodaran, S1
Bellavia, T1
Sait, SN1
Wang, ES1
Wetzler, M1
Khushalani, NI2
Chakravarty, T1
Briere, TM1
Beddar, AS1
Mok, H1
Reed, VK1
Xu, HD1
Pan, SD1
Yue, JH1
Liu, JR1
Wahba, HA1
El-Hadaad, HA1
Roshdy, S1
Rose, MG1
Perkal, MF1
Chao, HH1
Hwang, JH1
Lim, MC1
Seo, SS1
Kang, S1
Jiang, R1
Bellot, GL1
Tan, WH1
Tay, LL1
Koh, D1
Lau, PC1
Zheng, SF1
Yu, SC1
Koh, CE1
Bu, ZD1
Wu, AW1
Zhang, LH2
Zong, XL1
Zhang, XP1
Li, JY1
Hu, Y2
Abelson, JA1
Murphy, JD1
Minn, AY1
Chung, M4
Ford, JM4
Kunz, P1
Norton, JA1
Visser, BC1
Poultsides, GA1
Shintani, Y1
Funakoshi, Y1
Matsumura, A1
Ohta, M3
Okumura, M1
Ide, Y1
Watayo, Y1
Amagasa, H1
Ganno, H1
Fukuda, A1
Nagahama, T3
Okada, Y4
Bruera, G1
Giuliante, F2
Nuzzo, G2
Antonucci, A1
Ricevuto, E1
Kauppi, JT1
Oksala, N1
Salo, JA1
Helin, H1
Karhumäki, L1
Kemppainen, J1
Sihvo, EI1
Räsänen, JV1
Zanow, J1
Leistner, Y1
Ludewig, S1
Rauchfuss, F1
Settmacher, U2
Heintges, T1
Stoll, C1
Modest, DP1
Neumann, J1
Kim, YW2
Noh, SI1
Yeh, TS1
Button, P1
Sirzén, F1
Ferte, C1
Bourgeois, V1
Peugniez, C1
Lindet, C1
Ladrat, L1
Triboulet, JP4
Cho, YH1
Hong Lee, M1
Yoo, MW1
Bang, HY1
Yoon, SY2
Milandri, C5
Magli, A1
Ben Aharon, I1
Purim, O2
Kundel, Y1
Brenner, R1
Gordon, N1
Sulkes, A4
Brenner, B3
Kim, GM1
Nam, BH1
Inal, A2
Kaplan, MA3
Kucukoner, M2
Isikdogan, A3
Gong, L1
Lou, JY1
Zhang, JW1
Peng, ZL1
Zhang, JQ1
Hooker, CM1
Brock, MV1
Shin, J1
How, R1
Franco, N1
Prevas, H1
Hulbert, A1
Yang, SC2
Sanguanrungsirikul, S1
Manusirivithaya, S1
Burtness, B3
Mintzer, D2
Ruth, K1
Tuttle, H1
Sylvester, J1
Kim, SD1
Lee, HY1
Shim, JW1
Baek, SH1
Zabel, BA1
Bae, YS1
Wang, PL1
Cheng, YB1
Kuerban, G1
Chang, YY1
Vietor, NO1
George, BJ1
Yoon, DH1
Wieneke, J1
Kienle, P1
Welzel, G1
Brade, J1
Horisberger, K2
Wenz, F3
Hofmann, WK1
Tikidzhieva, A1
Benner, A1
Michel, S1
Formentini, A2
Dippold, W2
von Knebel Doeberitz, M2
Kloor, M1
DU, JP1
Li, SJ1
Zhai, LP1
Yang, XY1
Wu, ZT1
Martin, ST1
Heneghan, HM1
Gasent Blesa, JM1
Garde Noguera, J1
Laforga Canales, JB1
Giner Bosch, V1
Alberola, A1
Soler Tortosa, M1
Peris Godoy, M1
Sanchez, JL1
Provencio Pulla, M1
Alberola Candel, V1
Harder, J1
Ihorst, G1
Buechler, P1
Kloeppel, G1
Röcken, C2
Endlicher, E1
Reinacher-Schick, A1
Schmoor, C1
Connolly, S1
Scott, P1
Cochrane, D1
Harte, R1
Dong, B1
Du, H1
Yuan, P1
Wu, A1
Bedford, MR1
Anathhanam, S1
Saleh, D1
Hickson, A1
McGregor, AK1
Boyle, K1
Burke, D2
Winkler, J1
Zipp, L1
Knoblich, J1
Zimmermann, F1
Carpenter, WR1
Meyer, AM1
Qaqish, B1
Weiner, BJ1
Kanzaki, M1
Wada, J1
Nakatsuka, A1
Teshigawara, S1
Inoue, K9
Terami, T1
Katayama, A1
De Hertogh, G1
Fieuws, S1
Yi, JH1
Yim, DS1
Schönekaes, K2
Rübe, C2
Sulkowski, U2
Preusser, P4
Prott, FJ2
Willich, N3
Dewdney, A2
Liu, YW1
Qiu, F2
Zhan, ZY1
Feng, M1
Yan, J1
Zhao, JG1
Xiong, JP3
Mutyala, V1
Bains, S1
Patil, C1
Madhavarao, B1
Maggiulli, E1
Broggi, S1
Gianolini, S1
Salvetti, C1
Di Muzio, NG1
Kim, KK1
Lange, TS1
Singh, RK1
Brard, L1
Moore, RG1
Matsutani, T1
Sasajima, K1
Yokoyama, T2
Matsushita, A1
Hirakata, A1
Takao, Y1
Umakoshi, M1
Hayakawa, T1
Hosone, M1
Uchida, E2
Radziwon-Balicka, A1
Medina, C1
O'Driscoll, L1
Treumann, A1
Bazou, D1
Inkielewicz-Stepniak, I1
Radomski, A1
Jow, H1
Radomski, MW1
Chang, KJ3
Reid, T1
Senzer, N1
Pinto, H1
Chak, A1
Soetikno, R1
Tsuji, Y3
Nagase, M2
Miyata, Y1
Mizutani, N1
Hashigaki, S1
Short, M1
Halkett, G1
Reece, W2
Borg, M1
Zissiadis, Y1
Márquez, E1
Rodríguez, E1
Pascual, J1
Guo, M1
Gradishar, WJ1
Perez, EA3
Sledge, GW1
Utsunomiya, T1
Utsunomiya, H1
Peer, CJ1
McManus, TJ1
Petros, WP2
Bleiberg, H9
Vandebroek, A1
Deleu, I1
Vergauwe, P2
Rezaei Kalantari, H1
Efira, A1
Seshimo, K1
Ikeda, H6
Yamamura, M1
Kodera, M1
Fujita, H5
Shibagaki, K1
Takita, K1
Nishie, M1
Iwakawa, K1
Smalley, SR4
Estes, NC4
Goldman, B1
Jessup, JM5
Stemmermann, GN2
Gómez-Martín, C1
Gil-Martín, M1
Núñez, JA1
Puig, M1
Damin, DC1
Rosito, MA1
Contu, PC1
Tarta, C1
Ferreira, PR1
Kliemann, LM1
Schwartsmann, G1
Bauer, KM1
Lambert, PA1
Hummon, AB1
van der Zee, JA1
Dicheva, BM1
Seynhaeve, AL1
Koning, GA1
Eggermont, AM2
Ten Hagen, TL1
Goyer, P1
Benoist, S1
Hajjam, ME1
Penna, C2
Nordlinger, B7
Zafar, SF1
Orsucci, D1
Pizzanelli, C1
Alì, G1
Calabrese, R1
Ricci, G1
Lenzi, P1
Petrozzi, L1
Moretti, P1
Siciliano, G1
Treska, V1
Safranek, J1
Lysak, D1
Mirka, H1
Skalicky, T1
Slauf, F1
Hes, O1
Shatz, M1
Menendez, D1
Resnick, MA1
Phillips, BE1
Tubbs, RR1
Plesec, T1
Kofoed, SC1
Lundsgaard, M1
Ellemann, AC1
Svendsen, LB1
Dellas, K1
Richter, M1
Park, DH1
Lee, SK1
Kim, MH1
Han, DJ1
Capitain, O2
Asevoaia, A1
Poirier, AL2
Florschütz, A1
Mantovani-Löffler, L1
Kneba, M1
Glanemann, M1
Schlattmann, P1
Gahn, B1
Sung, EZ1
Arasaradnam, RP1
Jarvie, EM1
James, S1
Goodyear, SJ1
Borman, RA1
Snead, D1
Sanger, GJ1
Nwokolo, CU1
Toyama, Y1
Ushigome, T1
Watanabe, K3
Onda, S1
Saito, R2
Yoshida, S6
Kawahara, H2
Yanagisawa, S1
Przyborek, M1
Schleucher, N3
Vanhoefer, U5
Lu, Z1
Rottenberg, Y1
Kadouri, L1
Wygoda, M1
Rivkind, A1
Vainer, GW1
Peretz, T1
Hubert, A1
Guo, WJ2
Wang, AY1
Levy, A1
Chargari, C1
Huguet, F2
Védrine, L1
Deutsch, E1
Verbeke, CS1
Unek, T1
Akman, T2
Atilla, K1
Ellidokuz, H1
Bora, S1
Sarioglu, S1
Glockzin, G1
von Breitenbuch, P1
Lee, LK1
Lin, TC4
Wang, HS3
Yen, CC3
Liu, JH3
Tzeng, CH3
Krstovski, N1
Dokmanovic, L1
Lazic, J1
Rodic, P1
Paripovic, L1
Janic, D1
Schneider, BJ1
Hayman, JA1
Chang, AC1
Orringer, MB5
Pickens, A1
Pan, CC1
Urba, SG6
Arias, F1
del Moral-Avila, R1
Gómez-Millán, J1
Jiménez, E1
Wals, A2
Tisaire, JL1
Alcantara, MP1
Margolin, DA1
Cai, F1
Lecumberri, E1
Clerc, A1
Dupertuis, YM1
Pichard, C1
Ayez, N1
Alberda, WJ1
Burger, JW1
Dwarkasing, RS1
Willemssen, FE1
Verhoef, C1
Kwak, JY1
Jang, SJ1
Ismael, G1
Hegg, R1
Muehlbauer, S1
Heinzmann, D1
Lum, B1
Kim, SB1
Pienkowski, T1
Jackisch, C1
Iqbal, MS1
Hardman, J1
Ercan, S1
Seker, M1
Yilmaz, BE1
Orcun, A1
Martinez-Lapiscina, EH1
Erro, ME1
Cabada, T1
Tuñón, T1
Medeni, M1
Ambrosy, AP1
Kunz, PL1
Witteles, RM1
Flaherty, AM1
Peddi, PF1
Lubner, S1
McWilliams, R1
Picus, J5
Sorscher, SM2
Menias, C1
Linehan, D1
Rousseau, B1
Rebours, V1
Bengrine-Lefèvre, L1
Lévy, P1
Raymond, E6
Ruszniewski, P2
Golden, DW1
Novak, CJ1
Liauw, SL1
Ryu, KW1
Quaroni, L1
Casson, AG2
Kim, YB2
Choi, JJ1
Lee, I2
Cho, JH1
Niu, J1
Mims, MP1
Pavlidis, N4
Gentil, J1
Tsuruta, Y1
Takamori, S1
Shishikura, Y1
Schroeder, C1
von Weyhern, CH1
Weinmann, M1
Bamberg, M1
Berger, B1
Hoffmann, K4
Bartsch, D1
Klein, J1
Mansmann, U2
Capussotti, L1
Kunz, R1
Uguen, T1
Tchoundeu, B1
Chattopadhyay, S1
Mondal, SK1
Saha, A1
Manna, A1
Kundu, SK1
Yoshimi, K1
Hashimoto, T2
Niwa, Y1
Serikawa, T1
Kuramoto, T1
Cho, NY1
Park, JG2
Kang, GH1
Nagashima, T2
Niiro, M1
Hirayama, K1
Date, S1
Okihara, K1
Mukaisho, K1
Truong, TG1
Jones, KA1
Dito, E1
Ong, A1
Nakamura, Y4
Weinreich, J1
Schott, TC1
Königsrainer, I1
Küper, M1
Schott, H1
Bilici, M1
Cetin, B2
Ekinci, AS1
Cayir, K2
Yetisyigit, T1
Tekin, SB1
Eroglu, C1
Turhal, S1
Salman, T1
Schwartzman, AD1
Sethi, R1
Smith, R2
Focan, C3
Kreutz, F1
Graas, MP1
Longrée, L1
Focan-Henrard, D1
Demolin, G1
Moeneclaey, N1
Rostom, Y1
Zaghloul, H1
Khedr, G1
El-Shazly, W1
Abd-Allah, D1
Clavier, JB1
Antoni, D2
Atlani, D1
Schumacher, C1
Noel, G1
Tufan, G1
Stevenson, L1
Middleton, GW1
Evans, L1
Ford, D1
Plummer, C1
Blazeby, JM2
Griffin, M4
Eatock, MM2
Bampton, CL1
Strickland, AH3
Swieboda-Sadlej, A1
Nanayakkara, N1
Sun, YN1
Zhong, ZD1
Bass, MB1
Adewoye, AH1
Francis, WP1
Ho, T1
Xuan, Y1
Lee, G1
Shim, W1
Yun, J1
Ham, IH1
Helbling, D1
Gautschi, O1
Bosman, F1
Gloor, B1
Burkhard, R2
Madlung, A1
Rauch, D1
Borner, M1
Baertschi, D1
Yan, P1
Benhattar, J2
Leibundgut, EO1
Bougel, S1
Markoutsaki, N1
Roussel, H1
Rahmi, G1
Van der Stiegel, M1
Palazzo, L1
Fabre, M1
Cuenod, CA1
Liang, JW1
Zhou, ZX1
Hu, JJ1
Zhao, P2
Yu, DS1
Wang, GP1
Sana, J1
Gombosova, J1
Nekvindova, J1
Radova, L1
Martella, B1
Cardin, F1
Lorenzetti, R1
Terranova, C1
Amato, B1
Militello, C1
Pioche, M1
Aguero Garcete, G1
Lépilliez, V1
Nozières, C1
Lombard-Bohas, C1
Saurin, JC1
Hong, J1
Cho, EK7
Park, YH5
Lee, WK3
Schmutz, JL1
Trechot, P1
Krug, S1
Michl, P1
Olszewski, AJ1
Grossbard, ML3
Chung, MS1
Chalasani, SB1
Kozuch, PS1
Hernando-Requejo, O1
García-García, E1
Morelli, P1
Rubio, C1
López-Ríos, F1
Muro, A1
López, U1
Prados, S1
Bérille, J1
Tan, S1
Kligerman, S1
Feigenberg, S1
D'Souza, WD1
Knox, JJ5
Bianchi, R1
Mayr, M1
Schulte, N1
Belle, S1
Krause, A1
Schmid, RM1
Mulcahy, M1
Obel, J1
Rocha-Lima, CS1
Iwata, T1
Hanada, S1
Toda, M1
Reis-Filho, JS1
Waddell, TS1
Noor, D1
Stenning, S2
Sharif, S1
Petrelli, NJ6
Lopa, SH1
Wolmark, N7
Salmenkylä, S1
Kouri, M2
Pukkala, E1
Luukkonen, P1
Hyöty, M1
Pääkkönen, M1
Mäkelä, J1
Mustonen, H1
Järvinen, HJ1
Naito, Y2
Fukushima, H1
Takano, T1
Derbel, O1
Penet, AS1
Stella, M1
Méeus, P1
Orlandini, F1
Pérol, M1
Murakami, N2
Morota, M1
Sumi, M2
Itami, J1
Dréanic, J1
Mir, O1
Boudou-Rouquette, P1
Dhooge, M1
Goldwasser, F2
Lee, MA1
Choi, IS2
Rousseau, D1
Denis, F1
Girault, S1
Paumier, A1
Hamy, A1
Mahé, MA2
Mesgouez-Nebout, N1
Smit, JK1
Muijs, CT1
Burgerhof, JG1
Paardekooper, G1
Timmer, PR1
Muller, K1
Woutersen, D1
Mul, VE1
van Dijk, BA1
Langendijk, JA1
Plukker, JT3
Pasini, F1
Zhao, E1
Andalib, A1
Shankaran, V1
Mummy, D1
Koepl, L1
Blough, D1
Yim, YM1
Yu, E2
Ramsey, S1
Klaver, YL1
Morris, DL4
Huang, DZ1
Yan, Z1
Zhuang, ZX1
Wan, HP1
Deng, T1
Zheng, RS1
Hu, CH1
Wang, ML1
Meng, JC1
Ba, Y1
Guan, Z1
Liang, L1
Graves, CA2
Camphausen, K2
Parameswaran, R1
Titcomb, DR1
Blencowe, NS1
Berrisford, RG1
Wajed, SA1
Streets, CG1
Hollowood, AD1
Krysztopik, R1
Barham, CP1
Anter, AH1
Abdel-Latif, RM1
Kilic, D1
Yalman, D1
Aksu, G1
Atasoy, BM1
Igdem, S1
Dincbas, FO1
Korbakis, D1
Fragoulis, EG1
Scorilas, A1
Tian, YF1
Lee, HH1
Shiue, YL1
Huang, HY1
Pan, HY1
Chen, SH2
Pacelli, F1
Sanchez, AM1
Covino, M1
Tortorelli, AP1
Bossola, M1
Gambacorta, MA3
Doglietto, GB1
Chen, YN1
Tan, BB1
Zhao, XF1
Jiao, ZK1
Zhang, ZD1
Chang, SL1
Shi, MM1
Xiong, YL1
Jia, XS1
Wang, EH1
Suresh, AV1
Manikhas, G1
Rogowski, W1
Huang, X1
Wu, B1
Warner, D1
Jain, R1
Bossi, P2
Perrone, F1
Miceli, R1
Cantù, G2
Orlandi, E1
Fallai, C1
Locati, LD2
Cortelazzi, B1
Quattrone, P2
Potepan, P1
Licitra, L2
Pilotti, S2
Wood, MD1
Zaki, BI1
Gordon, SR1
Sutton, JE1
Gui, J1
Bubis, JA1
Dragnev, KH1
Rigas, JR1
Hwang, JA1
Hong, SH1
Ono, CR1
Lynn, P1
Grosso, F1
Mandalà, M1
Maglione, V1
Berretta, L1
Mariani, N1
Rossi, M1
Piovano, PL1
Drago, D1
Summa, M1
Franzone, P1
Musante, F1
Spinoglio, G1
Musola, M1
Cassandrini, PA1
Venturini, M1
Ritchim, P1
Charkrabandhu, T1
Jongraksat, W1
Pucci, F4
Camisa, R2
Bui, S1
Galdy, S1
Leonardi, F1
Anselmi, E1
Losardo, PL1
Roncoroni, L1
Dell'abate, P1
Vigil, C1
Yaremko, BP1
Palma, DA1
Erickson, AL1
Pierce, G1
Malthaner, RA1
Inculet, RI1
Dar, AR1
Rodrigues, GB1
Luján, J1
García De Burgos, F1
Jordán, A1
García, M1
Reyes, F1
Espinosa, MD1
Mirjolet, JF2
Didelot, C2
Barberi-Heyob, M3
Merlin, JL3
Truter, EJ1
Santos, AS1
Els, WJ1
Hartung, G3
Samel, S3
Pichlmeier, U1
Hehlmann, R4
Queisser, W4
Balart, J2
Capellà, G1
de los Inocentes, RM1
de Andrés, J1
Ares, C1
Craven-Bartle, J1
Lluís, F1
Crucitta, E1
De Lucia, L2
Del Gaizo, F1
Lannelli, A1
Tafuto, S1
Buzzi, F2
De Cataldis, G1
Eisold, S1
Dihlmann, S1
Linnebacher, M1
Aulmann, M1
Schlehofer, JR1
Ridder, R1
Vitoratos, N1
Salamalekis, E1
Makrakis, E1
Creatsas, G1
Iizuka, R1
Kakihara, N2
Matsumura, H1
Takenaka, A2
Gagnadoux, F1
Roiron, C1
Carrie, E1
Monnier-Cholley, L1
Lebeau, B2
Ahn, JH2
Bahng, H1
Kang, WC1
Kim, WK2
Lee, KD1
Liu, TW2
Wu, CW2
Tiu, CM1
Liu, JM2
Chung, TR2
Whang-Peng, J2
Cheeseman, SL1
Joel, SP1
Chester, JD1
Wilson, G1
Dent, JT1
Richards, FJ1
Pignon, JP4
Merouche, Y1
Berthault-Cvitkovic, F1
Luboinski, M1
Ezenfis, J1
Clavero-Fabri, MC2
McInnes, A1
Blackie, R1
Raby, N1
Fullarton, GM1
Soukop, M6
Algar Algar, FJ1
Alvarez Kindelán, A1
Fuentes Vaamonde, E1
Salvatierra Velázquez, A1
Baamonde Laborda, C1
López Pujol, FJ1
Mohiuddin, M5
Marks, G1
Mashino, K1
Inoue, H3
Matsukuma, A2
Kawaguchi, H1
Kusumoto, H2
Haraguchi, M1
Bazarbashi, S1
Rahal, M1
Raja, MA1
El Weshi, A1
Pai, C1
Ezzat, A2
Ajarim, D1
Memon, M1
Al Fadda, M1
Görgülü, S1
Oğuz, E1
Zor, A1
Zor, U1
Gürdoğan, M1
Tezel, T1
Price, T1
Nehls, O4
Klump, B2
Arkenau, HT3
Greschniok, A1
Gregor, M2
Porschen, R3
Elomaa, I3
Repo, H1
Joensuu, H3
Carraro, S1
Roca, EL1
Cartelli, C1
Rafailovici, L1
Castillo Odena, S1
Wasserman, E1
Gualdrini, U1
Huertas, E1
Barugel, M1
Ballarino, G1
Rodriguez, MC1
Masciangioli, G1
Cho, MJ1
Song, KS1
Yoon, WH1
Sutter, T1
Zühlke, H1
Kölling-Schlebusch, K1
Frings, S2
Leonard, GD1
Zhuang, SH1
Ishio, T1
Endo, K1
Ikeda, Y1
Toh, Y1
Okamura, T2
Tasaka, K1
Tomofuji, Y1
Chinzei, T1
Takizawa, M1
Hirano, M2
Uno, Y1
Kikuchi, T1
Asaumi, Y1
Kikkawa, H2
Koyama, M2
Watabe, S1
Ohe, S1
Kamio, Y1
Chiba, M1
Rassu, PC1
Cassinelli, G1
Ronzitti, F1
Bronzino, P1
Stanizzi, T1
Casaccia, M1
Rothenberg, ML3
Seay, TE2
George, CS1
Tanaka, MS1
Giguere, JK1
Pruitt, BT1
Di Martino, N3
Orditura, M5
Cosenza, A1
Del Genio, A1
Catalano, G12
Chen, XX1
Lai, MD1
Zhang, YL1
Lauria, R1
De Laurentiis, M1
Arpino, G1
Massarelli, E1
Ferrara, C1
Vernaglia Lombardi, A1
Costanzo, R1
Bianco, AR3
Shiah, HS1
Jan, CM1
Calvo, E2
Cortés, J3
González-Cao, M1
Aramendía, JM1
Fernández-Hidalgo, O2
Martín-Algarra, S2
Salgado, JE1
de Irala, J2
Brugarolas, A2
Naka, T1
Sugamura, K1
Hylander, BL1
Widmer, MB1
Repasky, EA1
Mercier, M1
Rath, GK1
Sharma, DN1
Shukla, NK1
Maraveyas, A1
O'Boyle, C1
Cowen, M1
Kern, M1
Hoepffner, N1
Neuhaus, P3
Sugita, M1
Togo, S1
Miura, Y2
Akiyama, H1
Kunisaki, C1
Hatada, T2
Mohri, T1
Jacot, W1
Lemanski, C1
Senesse, P2
Prost, P2
Delard, R1
Masson, B2
Dubois, JB2
Waters, JS2
Lofts, F3
Norman, A9
Kim, WS6
Tsavaris, N7
Kosmas, C5
Gennatas, K1
Vadiaka, M3
Skopelitis, E1
Xila, V1
Rokana, S2
Margaris, E1
Zografos, G1
Papastratis, G2
Kouraklis, G1
Aquino, A1
Prete, SP1
Balduzzi, A2
Fossile, E1
Torino, F1
Bonmassar, L1
Di Giacomo, A1
Cappelletti, D1
Cardillo, A1
Graziani, G1
Miyanari, N1
Mori, T8
Yasuno, M1
Happich, K1
Schirner, I1
Brueckl, WM2
Mace, AD1
Lale, AM1
Capper, JW1
Emig, M1
Pilz, L2
Willeke, F2
Bex, A1
Otto, T1
Lümmen, G1
Rübben, H1
Kempin, S1
Gutierrez, J2
Wilson, E1
Lowery, C1
Diasio, R2
Yamada, H2
Ichikawa, W1
Uetake, H1
Shirota, Y2
Nihei, Z1
Hirayama, R1
Rebollo, J1
Vincent, M1
Ho, C1
Tomiak, A1
Winquist, E1
Whiston, F1
Stitt, L1
Kjaer, M1
Skovsgaard, T1
Linné, T2
Boussard, B2
Oulid-Aïssa, D1
Pyrhönen, S3
Tigaud, JM5
Brunet, R6
Jacob, JH2
Levoir, D1
Taamma, A1
Cvitkovic, E5
Violette, S1
Festor, E1
Pandrea-Vasile, I1
Mitchell, V1
Adida, C1
Dussaulx, E1
Lacorte, JM1
Chambaz, J1
Lacasa, M1
Lesuffleur, T1
Kagawa, R1
Sakata, S1
Tada, M1
Saguchi, T1
Murayama, C2
Salman, HS1
Cynamon, J1
Jagust, M1
Bakal, C1
Rozenblit, A3
Kaleya, R3
Negassa, A1
Wadler, S10
Huguier, M3
Ochiai, T5
Maruyama, M5
Ebuchi, M4
Takashima, I1
Natsui, S1
Sakoma, T1
Katsumoto, Y2
Maruyama, K2
Furukawa, J2
Nagai, K2
Maruyama, N2
Sue, F1
Souma, I1
Izawa, H1
Sakita, I1
Kanai, T2
Kouro, T1
Schüll, B1
Ulrich-Pur, H1
Schmid, K1
Raderer, M3
Haider, K2
Kwasny, W4
Depisch, D7
Schneeweiss, B2
Lang, F1
Ninomiya, S1
Takeo, S1
Vannozzi, F1
Amadori, D3
Del Tacca, M4
Garin, L1
Blanchot, J1
Le Guilcher, P1
Rodríguez-Ramírez, S1
Hernández-Pacheco, F1
Gutiérrez De La Barrera, M1
Fernández, R2
Labastida, S3
Mehta, VK2
Cho, C1
Jambalos, C1
Poen, J2
Koong, A1
Lin, A1
Bastidas, JA1
Young, H2
Dunphy, EP1
Fisher, G2
Xiao, Q1
Peng, B1
Lai, Y1
Akbulut, H2
Altuntas, F1
Akbulut, KG1
Ozturk, G1
Cindoruk, M1
Unal, E1
Icli, F2
Jüngert, B1
Brueckl, V1
Hautmann, M1
Niki, T1
Hamano, K1
Okutani, T1
Hirohata, S1
Nakashima, T2
Yasutake, K1
Kawaguchi, K1
Sashikata, T1
Kypson, AP1
Morphew, E1
Jones, R2
Gottfried, MR2
Seigler, HF4
Yang, TS3
Chiang, JM2
Hsieh, PS2
Yeh, CY2
Changchien, CR2
Kerr, DJ5
McArdle, CS5
Ledermann, J1
Taylor, I3
Sherlock, DJ1
Schlag, PM1
Buckels, J2
Mayer, D1
Cain, D1
Stephens, RJ1
Papagikos, M1
Janjan, NA9
Feig, B3
Hung, A1
Delclos, M2
Cleary, K1
Myerson, R3
Zobeiri, I1
Birnbaum, E1
Dietz, D1
Fleshman, J1
Kodner, I1
Ratkin, G3
Terrosu, G1
Cedolini, C1
Bresadola, V1
Baccarani, U1
Uzzau, A1
Signor, M1
Fongione, S1
Buffoli, A1
Iop, A1
Vigevani, E1
Sacco, C1
Cartei, G2
Bresadola, F1
Bar Sela, G1
Tsalic, M1
Gaitini, D1
Steiner, M2
Haim, N4
Black, CA1
Ensley, JF2
Gennatas, C2
Dardoufas, C1
Mouratidou, D2
Pouli, A1
Androulakis, G1
Philippakis, M1
Voros, D1
Batalis, T1
Besbeas, S1
Hatzistylianos, G1
Katsos, J1
Komporozos, V1
Legakis, N1
Mallas, H1
Peros, G1
Photopoulos, A1
Pisiotis, C1
Polymeneas, G1
Retalis, G1
Samanidis, L1
Smyrniotis, V1
Stamatiadis, A1
Vasiliou, J1
Andreadis, H1
Papadimitriou, J1
Bermann, A1
Rettig, K2
Strohmeyer, G1
Kawashima, M1
Nakagohri, T2
Ogino, T3
Maru, Y1
Yoshino, M2
Kaneyasu, Y3
Okawa, T3
Yajima, M1
Nakabayashi, M1
Seshimo, A2
Kameoka, S2
Aomi, S1
Mitsuhashi, N2
Loesch, DM1
Canfield, VA1
Parker, GA1
Hynes, HE2
Ellis, PG1
Ferri, WA1
Robert, NJ2
Catalano, P1
Rao, MS1
Lin, JC1
Jan, JS1
Hsu, CY1
Jiang, RS1
Wang, WY1
Sawada, M1
Ono, Y1
Fukushima, M5
Fujito, T1
Goda, F1
Matsuyama, J1
Hojo, S1
Yano, Y2
Endo, W1
Maeura, Y1
Nakagoe, T1
Yamaguchi, E1
Tsuji, T2
Shibasaki, S1
Yasutake, T1
Ayabe, H2
Krenn, V1
Okabe, S2
Tanami, H1
Fukahara, T1
Udagawa, M1
Ootsukasa, S1
Maruyama, S2
Murase, N2
Yamashita, H4
Siefker-Radtke, AO1
Gee, J1
Daliani, D1
Millikan, RE1
Pisters, LL1
Gérard, JP5
Chapet, O2
Nemoz, C1
Romestaing, P3
Coquard, R1
Barbet, N2
Atlan, D2
Adeleine, P1
Freyer, G3
Grinev, MV1
Beech, DJ1
Madan, AK1
Aliabadi-Wahle, S1
Hays, AN1
Long, WP1
Carrat, F1
Mal, F3
Beerblock, K7
Cady, J4
Vaitkevicius, V4
Langer, C1
Jakob, C3
Müller, D1
Siemer, A1
Markus, PM1
Füzesi, L3
Harris, EE1
Schultz, D1
Bertsch, H1
Fox, K1
Glick, J2
Solin, LJ4
Lorvidhaya, V2
Chitapanarux, I1
Sangruchi, S1
Lertsanguansinchai, P1
Kongthanarat, Y1
Tangkaratt, S1
Visetsiri, E1
Magnin, V2
Giovannini, MH1
Bardou, VJ2
Alzieu, C1
Arora, A1
Potter, J1
Hosie, KB1
Gilbert, JA1
Downes, M1
Lakin, G1
Pemberton, G1
Timms, K1
Young, A1
Stanley, A1
Stein, DE1
Mahmoud, NN2
Rose, DG1
Isenberg, GA1
Goldstein, SD1
Mitchell, E2
Fry, RD2
Awakura, Y2
Nonomura, M2
Itoh, N1
Maeno, A1
Fukuyama, T2
Mo, B1
Pater, A1
Gutzler, F1
Steinmann, S2
Boehme, M1
Raeth, U1
Stremmel, W1
Malik, IA1
Aziz, Z1
Murad, AM3
Guimarães, RC2
Aragão, BC2
Rodrigues, VH1
Scalabrini-Neto, AO2
Padua, CA1
Moore, FC1
Fujii, R1
Picozzi, VJ2
Kozarek, RA1
Traverso, LW3
Yan, L1
Mao, Y2
Kelm, J1
Ahlhelm, F1
Weissenbach, P1
Schliesing, P1
Regitz, T1
Deubel, G1
Engel, C1
Kleinberg, L2
Knisely, JP2
Heitmiller, R1
Zahurak, M2
Salem, R2
Heath, EI2
Forastiere, AA5
Cohen, V1
Panet-Raymond, V1
Sabbaghian, N1
Morin, I1
Batist, G1
Rozen, R1
Makower, D1
Fehn, K1
Landau, L1
Wissel, P1
Versola, M1
Mani, S1
Bonnefoi, H1
Biganzoli, L2
Mauriac, L1
Cufer, T1
Schaefer, P2
Atalay, G1
Lortholary, A2
Delozier, T2
Monnier, A3
Bourgeois, H1
Bougnoux, P1
Riffaud, JCh1
Besson, D1
Lotz, V1
Yeo, CJ9
Shibata, T2
Noguchi, T3
Kikuchi, R1
Oka, Y2
Toyoda, H1
Okada, S5
Saini, A1
Jodrell, D1
Ross, PJ3
Denham, JW5
Steigler, A1
Kilmurray, J1
Wratten, C1
Lamb, DS3
Delaney, G1
Christie, D1
Jamieson, G1
Walpole, E2
Gokel, Y1
Paydas, S1
Ishikura, S1
Jiao, SC1
Lu, SX1
Duffour, J1
Debrigode, C1
Bressolle, F1
Pinguet, F1
Bading, JR1
Yoo, PB1
Fissekis, JD1
Alauddin, MM1
D'Argenio, DZ1
Conti, PS1
Kwiatkowski, F1
Chevalier, V1
Chevrier, R1
Richard, D1
Cure, H3
Chollet, P8
Chachoua, A1
Speyer, J2
Escalon, J1
Zeleniuch-Jacquotte, A1
Correale, P3
Messinese, S2
Marsili, S3
Ceciarini, F1
Pozzessere, D1
Sabatino, M1
Cerretani, D2
Pellegrini, M1
Di Palma, T1
Neri, A1
Calvanese, A1
Pinto, E2
Giorgi, G2
Benchekroun, A1
Nouini, Y1
Zannoud, M1
Kasmaoui, el H1
Jira, H1
el Alj, HA1
Ghaemmaghami, F1
Behtash, N1
Yarandi, F1
Moosavi, A1
Modares, M1
Toogeh, G1
Khanafshar, N1
Cocconi, G4
Gamboni, A1
Gasperoni, S4
Rodinò, C2
Porrozzi, S1
Di Costanzo, F6
Canaletti, R2
Melissas, J1
Schoretsanitis, G1
Daskalakis, M1
Tsiftsis, DD1
Achille, E1
Colbert, N1
Boaziz, C1
Piedbois, P4
Boutan-Laroze, A1
Kemeny, NE1
Gococo, KO1
Kardinal, CG3
Vaishampayan, U3
Jain, V2
Adsay, V2
Day, J1
Tokunaga, T2
Sumimura, J1
Yoshidome, K1
Fujita, S4
Tsuji, K2
Oota, F1
Tsuboyama, N1
Nagai, I1
Micke, O2
Bruns, F1
Kurowski, R1
Horst, E1
Hausler, JW1
Schäfer, U1
Birnbaum, EH3
Feig, BW3
Singh, AK1
Lin, EH1
Fleshman, JW3
Thames, HD2
Kodner, IJ3
Lockett, MA1
Phan, T2
Read, TE3
Nesbitt, JC1
Lahoti, S3
Martin, F3
Putnam, JB6
Smythe, WR2
Vaporciyan, AA3
Walsh, GL3
Roth, JA11
Penna, Ch1
Claude, L2
Brickell, K1
Porter, D1
An, FS1
Huang, JQ1
Xie, YT1
Rong, TH1
Chen, ZH1
Feng, B1
Gunel, N1
Onuk, E1
Yilmaz, E1
Bayram, O1
Yamac, D1
Cihan, A1
Ucan, B1
Yildirim, Y1
Celenkoglu, G1
Ozkan, S1
Nomura, K1
Hayashi, S2
Oota, H1
Kamimura, T1
Kim, DJ1
Suh, JH2
Cho, YS1
Shin, SK1
Kang, JK1
Cassinello, J2
Escudero, P1
Marcos, F2
Pujol, E2
Pérez-Carrión, R1
Colmenarejo, A3
González del Val, R1
Valero, J1
Oruezábal, MJ1
Guillem, V1
García, I1
Arcediano, A2
Marfà, X2
Noh, JH4
Jung, CW4
Im, YH5
Park, K6
Park, CH4
Günther, K1
Dimmler, A1
Rödel, F1
Bittorf, BR1
Matzel, KE1
Papadopoulos, T1
Gambardella, A1
Miyake, H1
Takamura, K1
Tashiro, S2
Nakazato, H1
Koike, A3
Baba, S1
Mai, M1
REITEMEIER, RJ14
MOERTEL, CG34
KNOCK, FE3
BRENNAN, MJ1
TALLEY, RW3
DRAKE, EH2
VAITKEVICIUS, VK16
POZNANSKI, AK1
BRUSH, BE1
CHANG, WW1
BUERGER, L1
DESBERG, D1
TANNO, V1
MCBRIDE, TJ1
NOBLE, LC1
CARR, MA1
HULL, K1
OLESON, JJ1
BLACKBURN, CM1
SHERLOCK, P1
CHAN, DP1
HO, JH1
WOO, AW1
HART, GD1
CENTARO, A1
GASPARRI, F1
MAIJNELLI, M1
PERITI, P2
GOLLIN, FF1
ANSFIELD, FJ2
VERMUND, H2
WATSON, EC1
HELSPER, JT1
DEMOSS, EV1
RIEHL, JL1
BROWN, WJ1
MCCAFFERY, JF1
CAMMACK, KV1
CHILDS, DS6
COLBY, MY3
HOLBROOK, MA7
CRESSY, NL2
SCHELL, HW2
MCALISTER, WH1
FLOCH, MH1
HELLMAN, L1
HAHN, RG12
WILSON, WL1
DELAGARZA, JG1
Giannakakis, T1
Gouveris, P2
Dimitrakopoulos, A1
Karadima, D1
Papalambros, E2
Margaris, H1
Tsipras, H1
O'Connell, M2
Cooke, E2
Jantscheff, P1
Terracciano, L1
Lowy, A2
Glatz-Krieger, K1
Grunert, F1
Micheel, B1
Brümmer, J1
Laffer, U3
Metzger, U2
Rochlitz, C1
Reszka, R1
Lucas, S1
Futamura, N1
Matsutomo, M1
Yasumura, M1
Tateyama, K1
Hu, YC1
Komorowski, RA1
Graewin, S1
Hostetter, G1
Kallioniemi, OP1
Pitt, HA2
Ahrendt, SA1
Dittler, HJ1
Helmberger, H1
Busch, R5
Kollmannsberger, C5
Fink, U4
Kawakami, K2
Watanabe, G1
Araneo, M1
Frager, D1
Marino, J1
DeGregorio, P1
Mortazabi, F1
Firoozi, K1
Jindal, K1
Kulke, MH4
Earle, CC4
Stuart, K3
Catarius, KJ1
Winkelmann, J1
Foo, K1
Lim Joon, D2
Weih, L1
Ngan, S1
Thomas, R1
Mariani, G1
Giaccon, G1
Mastore, M1
Goldberg, M2
Farma, J1
Lampert, C1
Colarusso, P2
Coia, L3
Frucht, H1
Goosenberg, E1
Beard, M1
Semiglazov, VF1
Maksimov, SIa1
Semiglazov, VV1
Kosnikov, AG1
Bai, YR1
Wu, GH1
Wu, XD1
Zhou, RH1
Lu, DQ1
Maruyama, KT1
Ishigami, H1
Kikkawa, N4
Iijima, S3
Handa, R2
Naoi, Y1
Oshima, S2
Kurokawa, E2
Shimizu, J2
Masutani, S3
Imamura, H1
Tatsuta, M2
Yura, M1
Saeki, N1
Kitamura, S1
Tomotsu, K1
Takamura, M1
Okamoto, N1
Maruta, M2
Masumori, K1
Nishioka, K1
Iwasaki, Y5
Katayanagi, S2
Matsumoto, H1
Horiguchi, S1
Balmaña, J1
Rius, X1
Gallen, M2
Navarro, S1
Arcusa, A1
Gallardo, E1
Brunet, J1
Kremser, C2
Judmaier, W2
Hein, P1
Griebel, J2
Lim, JT2
Truong, PT1
Berthelet, E1
Pai, H1
Joe, H1
Wai, E1
Larsson, S1
Kader, HA1
Weinerman, B1
Olivotto, IA1
Sørbye, H5
Oechsle, K2
Honecker, F2
Käfer, G1
Kanz, L5
Funakoshi, K1
Tasaki, A1
Inayoshi, J1
Arai, F1
Motoyama, H1
Akiyama, N3
Mezawa, S2
Homma, H2
Akiyama, T3
Kogawa, K1
Kida, M2
Murase, K2
Iyama, S3
Al-Sukhun, S1
Soulen, R1
Weaver, D1
Levin, K1
Forman, JD1
Morton, RF1
Williamson, SK3
Findlay, BP1
Pitot, HC2
Coleman, TA1
Redger, CD1
Hamill, RL1
Dainer, P1
Shibata, K3
Kikkawa, F1
Suzuki, Y4
Terauchi, M1
Kajiyama, H1
Ino, K1
Mizutani, S2
Antón, A3
Marcuello, E1
Massutti, B1
Fenández-Martos, C1
Huarte, L1
Balcells, M3
Han, JY2
Lee, DH2
Kim, HY2
Kim, EA1
Ju, SY1
Shin, EH1
Sorio, C1
Moore, PS1
Ennas, MG1
Tecchio, C1
Bonora, A1
Sartoris, S1
Balzarini, P1
Grigolato, P1
Assersohn, L1
Ward, C1
Larsson, B1
Sundin, A1
Khamis, H1
Gibson, MK3
Abraham, SC1
Heitmiller, RF2
Heath, E1
Forastiere, A4
Samuel, J1
Flood, TP1
Agbemadzo, B1
Renta, V1
Mullai, N1
Osafo, DC1
Holloway, N1
Cohen, JA1
Tekuzman, G1
Engin, H1
Turker, A1
Barista, I1
Gullu, I1
Guler, N2
Ozisik, Y1
Kars, A2
Furusawa, J1
Mizumati, T1
Iizuka, K1
Imamura, M5
Yamaki, T1
Yasuda, M3
Hansson, J1
Saenger, J1
Leible, M1
Seelig, MH1
Tajima, T1
Saitoh, T1
Jingu, K1
Rigatos, SK2
Potamiannou, A1
Tsiakopoulos, I1
Androulakis, N3
Jaeger, D1
Hahnfeld, S1
Rummel, MJ1
Rost, A1
Orth, J1
Knuth, A4
Hong, TJ1
Cohen, DP1
Tyler, DS5
Anscher, MS4
Ludwig, KA2
Mantyh, C2
Spector, NL1
Ertel, PJ1
Mangum, SG1
Hahn, P1
Eifel, PJ5
Morris, M3
Levenback, C1
Grigsby, PW5
Cooper, J3
Rotman, M2
Gershenson, D2
Mutch, DG3
Yumuk, PF1
Abacioglu, U1
Caglar, H1
Sengoz, M1
Turhal, NS1
Guba, M1
Koehl, GE1
Doenecke, A1
Steinbauer, M1
Wagner, C1
Frank, E1
Geissler, EK1
Ford, HE1
Mulligan, ED1
Dunne, B2
Keeling, N2
Ohta, S1
Kawabe, S1
Gotoh, M1
Hirata, I1
Katsu, K1
Hongo, H1
Fujita, K1
Tsuchida, A2
Hayashida, Y1
Takagi, M1
Kawakita, H1
Kubouchi, T1
Kinoshita, M1
Kataba, Y1
Mio, H1
Sekiya, M1
Kathou, T1
Morishita, Y6
Kasakura, Y2
Yagyu, T2
Murayama, M2
Nakamura, E1
Nozaki, H1
Niida, M1
Yasuoka, H1
Nishimoto, Y1
Watanabe, Y6
Syouda, S1
Kouno, T1
Fukuhara, A1
Berkey, BA1
Gaspar, LE5
Yeh, KH5
Wan, JP1
Lin, CS1
Liu, CC1
Tsamandas, AC1
Ravazoula, P1
Zolota, V1
Salakou, S1
Tepetes, K1
Kalogeropoulou, C1
Tsota, I1
Kourelis, T1
Karavias, D1
Scopa, CD1
Bonikos, DS1
Petsas, T1
White, JD1
Junor, EJ1
McGarva, J1
McManners, J1
Holland, IS1
Soung, YH1
Park, WS1
Cho, YG1
Kim, CJ1
Seo, SH1
Nam, SW1
Yoo, NJ1
Lee, JY1
Clavijo, J1
Gomez-de-Segura, IA1
Gomez-García, L1
Vallejo-Cremades, MT1
Sanchez, M1
de Miguel, E1
Ho, HS1
Ong, HS1
Dzik-Jurasz, A1
Hedley, D3
Oza, A3
Siu, LL3
Pond, GR4
Katsumata, K3
Ichimiya, H1
Wakana, Y1
Whitehead, RP2
Ardalan, B7
Goodwin, JW1
Balcerzak, SP3
Samlowski, WE1
Shore, S1
Zumstein, L1
Willer, A2
Weisser, A1
Gnad, U1
Saussele, S2
Kreil, S2
El-Salhy, M1
Milano, MT2
Chmura, SJ2
Garofalo, MC3
Rash, C2
Roeske, JC1
Connell, PP1
Kwon, OH1
Jani, AB2
Heimann, R2
McDermott, P1
Burmeister, J1
Bossenberger, T1
Fossati, R1
Boffi, L1
Scatizzi, M1
Tardio, B1
Mastrodonato, N1
Banducci, S1
Consani, G1
Pancera, G2
Wu, WC1
Chen, SC2
Chuang, WL1
Chen, VM1
Thrift, KM1
Morel-Kopp, MC1
Jackson, D1
Ward, CM1
Flower, RL1
Walsh, G3
Lynch, PM6
Smythe, R3
Vaporciyan, A2
Faust, J1
Cohen, DS2
Nivers, R2
Joh, JW1
Park, YJ2
Nam, HR1
Ahn, YC1
Suganuma, T1
Terauchi, R1
Shikina, A1
Aozasa, S1
Utsunomiya, K1
Fujino, K2
Hase, K1
Hildebrandt, B1
Wust, P1
Dräger, J1
Lüdemann, L1
Sreenivasa, G1
Tullius, SG1
Amthauer, H1
Felix, R1
Ghielmini, M1
Martinoli, S2
Clerici, M1
Cetta, F1
Savelli, V1
Guarnieri, A1
Sai, H1
Mitsumori, M1
Yamauchi, C1
Araki, N2
Okumura, S1
Hiraoka, M1
Takanashi, K2
Machida, T5
Katsuki, S1
Di Cosimo, S1
Malaguti, P1
Pellicciotta, M1
Terzoli, E3
Yu, ZW1
Dong, XS1
Yao, XQ1
Yin, XH1
Fu, SB1
Ema, T1
Sakurai, Y7
Uraguchi, T1
Imazu, H1
Ochiai, M1
Funabiki, T1
Steffens, F1
Bathe, OF1
Dowden, S1
Sutherland, F1
Butts, C1
Bigam, D1
Walley, B1
Ruether, D1
Ernst, S1
Janjan, N2
Songun, I2
Tesselaar, ME2
Kranenbarg, EK1
de Vries, JE2
Wils, JA5
van der Bijl, J2
Shibata, SI1
Pezner, R1
Doroshow, JH7
Chow, WA1
Leong, LA1
Margolin, KA1
McNamara, MV1
Morgan, RJ2
Raschko, JW1
Somlo, G2
Tetef, ML1
Yen, Y1
Synold, TW1
Wagman, L1
Vora, N1
Carroll, M1
Longmate, J1
Kuehr, T1
Rapoport, BL1
Daniel, F1
Jacobs, C1
Davidson, N1
Carmichael, J2
Kamoshida, S2
Shiogama, K1
Matsuyama, A1
Shimomura, R1
Inada, K1
Tsutsumi, Y2
Zanke, C1
Hohl, H1
Adami, B1
Schroeder, M3
Klein, O2
Höhler, T2
Eisendrath, P1
Legendre, H1
Pector, JC3
De Becker, D1
Ishiyama, T2
Nakamura, T9
Inazawa, K1
Kasai, M1
Nozaki, T1
Kawamura, S1
Sawamura, N1
Hiraga, H1
Fukuda, Y4
Fujio, N3
Mayumi, K1
Ihara, T3
Terakura, M1
Takatori, H3
Tsukazaki, T3
Tsukazaki, Y3
Yavuzsen, T1
Yaren, A2
Tarhan, O2
Sagol, O2
Coker, A1
Alakavuklar, M1
Smith, RE2
Colangelo, L2
Wieand, HS14
Begovic, M2
Tamaru, N1
Hishikawa, Y2
Ejima, K1
Nagasue, N2
Muramatsu, M1
Koji, T2
Harada, O1
Sasamoto, M1
Shimaya, S1
Sugiyama, S2
Ishiko, T2
Doi, K2
Nakagawa, M1
Morinaga, H2
Yamane, T2
Egami, H2
Kanayama, T4
Ishimaru, S1
Voelter, V2
Choi, N1
Park, SD1
Lynch, T1
Wright, C2
Wain, J1
Donahue, D1
Mathisen, D1
Hiller, L1
Geh, I1
Yu, SJ1
Joh, YH1
Hribaschek, A2
Pross, M2
Ridwelski, K2
Meyer, F1
Fenske, A1
Krüger, S1
Lippert, H2
Sasson, AR1
Wetherington, RW1
Ross, EA1
Freedman, G3
Pingpank, JF1
Eisenberg, BL4
Birtle, AJ1
Newby, JC1
Harland, SJ3
Silva e Sousa, AH2
Campos, FG3
Kiss, DR3
Taoka, H1
Hirano, H1
Mitsui, Y1
Umino, W1
Nobuoka, Y1
Yamashita, M1
Tanigawa, K1
Yoshimine, S1
Imai, T2
Miyashita, K1
Ikuma, H1
Miyanishi, K2
Takada, K2
Oku, T1
Ishiwatari, H1
Kogawa, T1
Kato, J5
Niitsu, Y4
Morio, A1
Futagawa, T1
Oh, T1
Yamazaki, A1
Konno, H2
Benavides, M2
García-Alfonso, P1
Cobo, M1
Muñoz-Martín, A1
Gil-Calle, S1
Carabantes, F1
Villar, E1
Graupera, J1
Pérez-Manga, G3
Maish, M1
Erasmus, JJ1
Bresalier, R1
Munden, RF1
Rice, D1
Taillier, G1
Elmiger, R1
Gerster, JC1
Imdahl, A1
Schöffel, U1
Hopf, UT1
Elkiran, ET1
Beyazit, Y1
Robb, WB1
Naughton, P1
Walsh, TN2
Tanimoto, K1
Shimokuni, T1
Ukon, K1
Tsujimoto, H1
Kawahara, K2
Hiyama, K1
Nikkuni, K1
Nagahashi, M1
Nishimura, A2
Kawachi, Y2
Arsène, D1
Paitel, JF1
Buecher, B3
Kaminsky, MC1
Milan, C1
Anastasopoulos, D1
Mellou, S1
Detsi, I1
Tsiakalos, G1
Pateli, A1
Klouvas, G2
Papadimitriou, A1
Bonnen, M1
Rodriguez-Bigas, M2
Pop, C1
Nica, R1
Vlaicu, R1
Vinereanu, D1
Aust, DE2
Meyer, W2
Schwabe, W1
Häusler, P1
Smirnakis, F1
Moskovitz, DN1
Novakovic, P1
Yates, Z1
Lucock, M1
Luciani, F1
Spada, M1
De Milito, A1
Molinari, A1
Rivoltini, L1
Montinaro, A1
Marra, M1
Lugini, L1
Logozzi, M1
Lozupone, F1
Federici, C1
Iessi, E1
Parmiani, G1
Arancia, G3
Belardelli, F1
Fais, S1
Brasiūnas, V1
Brasiūniene, B1
Barauskas, G1
Goto, A2
Szanto, J2
Padi, E1
Bükki, J1
Biakhov, M1
Zuber, E1
Jacques, C2
Stanclift, RM1
Gilson, SD1
Kosaka, T3
Imaizumi, H2
Usami, K1
Ueno, K2
Fujiwara, H1
Sonoyama, T1
Ichikawa, D1
Sakakura, C1
Itoi, H1
Otsuji, E2
Hagiwara, A1
Yamagishi, H1
Mitsuishi, Y1
Kishida, T1
Yoshitani, S1
Kuroda, M1
Yokoi, M1
Tamesa, T1
Mori, N1
Tangoku, A1
Oka, M2
Tokuuye, K4
Al-Khatib, H1
Burgart, L1
Cera, PJ1
Flynn, PJ4
Finch, TR1
Levitt, R3
Windschitl, HE5
Knost, JA3
Tschetter, LK7
Garay, CA1
Gurtler, J1
Kennedy, P1
Brandt, DS1
Polikoff, J1
Wertheim, M1
Shumaker, G1
Hallman, D1
Burger, B1
Gupta, S3
Sando, K1
Ito, T4
Mikata, S1
Ide, H1
Michiura, T1
Kainuma, S2
Yamanaka, H2
Iwase, K2
Ishibashi, S1
Nishimura, H2
Mizusawa, H1
Stevens, CW1
Yao, JC2
Allen, PK1
Mau-Holzmann, UA1
Kolb, H1
Reichenmiller, HE1
Riess, O1
Schömig, E1
Lee, KE1
Chung, CW1
Lu, JW2
Suardi, S1
Lo Vullo, S1
Oggionni, M1
Olmi, P1
Pierotti, MA1
Gnad-Vogt, U1
Presicci, PF1
Veronesi, G1
D'Aiuto, M1
Spaggiari, L1
Russo, V1
Pasetto, L1
Marino, F1
Wheeler, JM1
Dodds, E1
Warren, BF2
Cunningham, C1
George, BD1
Jones, AC1
Mortensen, NJ1
Repp, M1
Kingreen, D1
Hennesser, D1
Micheel, S1
Scholz, C1
Alter, P1
Herzum, M1
Schaefer, JR1
Maisch, B1
Hirohashi, Y1
Sumi, K1
Matsuyama, S1
Ikemoto, T1
Nishioka, M2
Yawata, Y1
Terashima, Y3
Ikushima, H1
Shimada, M1
Flandin, I1
Kubas, A1
Khodri, M1
Wautot, V1
Mazeron, R1
Gohongi, T2
Iida, H5
Nakai, R2
Gunji, N2
Akine, Y2
Orii, K3
Haller, D3
Ugai, H1
Todoroki, T2
Matsuzaki, Y2
Fiorentini, G7
Caudana, R4
Piazza, E2
Comella, G7
Ceravolo, C3
Miserocchi, L3
Mambrini, A6
Del Freo, A2
Zamagni, D4
Rabbi, C3
Marangolo, M4
Dinçer, M1
Holcroft, CA1
Kvols, LK6
Pennucci, C1
Sanguinetti, F1
Lombardi, M2
Nicoli, N1
Liu, WB1
Xu, XQ1
Zhao, YR1
Schneider, S1
Uchida, K2
Yochim, J1
Salonga, D3
Chen, P1
Tsao-Wei, D1
Groshen, S4
Hoelscher, AH3
Danenberg, PV6
Richard, K1
Toita, T3
Uno, T3
Kodaira, T2
Shinoda, A1
Maebayashi, K1
Kawaguchi, A1
Teshima, T2
Chen, CC1
Lee, RC1
Kanou, Y1
Ooshima, H1
Kawase, J1
Kudou, J2
Mizuno, Y2
Sekikawa, K2
Ohki, S2
Ohshima, T1
Fukushima, T1
Kanazawa, M1
Takenoshita, S1
Muneoka, K1
Shirai, Y1
Yokoyama, N3
Hatakeyama, K2
Nishida Arazawa, ST1
Rawet, V1
Coelho Siqueira, SA1
Gama-Rodrigues, JJ1
Schattner, M1
Akhurst, T1
Kanemitsu, K1
Chikamoto, A1
Nakahara, O1
Hiraoka, T2
Ikeda, O1
Imuta, M1
Feyerherd, P1
Ludwig, K2
Foitzik, T1
Coward, J1
Joshi, MB1
Conlon, DH1
Salonga, DS1
Harpole, DH3
Sumitsuzi, A1
Kamohara, H1
Kuwahara, N1
Feld, R1
Nematollahi, M1
Mazeron, JJ1
Knaebel, HP1
Seiler, C1
Lindel, K3
Schmitz-Winnenthal, H1
Fritz, S2
Goldschmidt, H1
Krempien, R1
Diehl, V1
Colucci, G6
Thaler, W1
Dejaco, H1
Marsoner, H1
Grones, A1
Davis, DA1
Fugate, SE1
Penberthy, DR2
Shepard, RC1
Jones, RS2
Manzano, H1
Chirivella, I1
Matano, E1
Bianco, R1
Infusino, S1
Damiano, V1
Simeone, E1
Diadema, MR1
Lieto, E2
Castellano, P1
Vironen, J1
Juhola, M1
Kairaluoma, M1
Jantunen, I1
Kellokumpu, I1
Seule, M1
Steiner, B1
Bauer, I1
Freund, M1
Schuff-Werner, P1
Jankilevich, G1
Mermershtain, W2
Gluzman, A1
Gusakova, I1
Walfish, S1
Cohen, Y5
Ariad, S1
Park, KW1
Veronese, ML1
Berlin, J5
Shults, J1
Davis, L2
Ismail, AS1
Quinn, MG1
Wright, MA1
Ernst, A1
Kao, V1
Parr, A2
Grollman, F3
Kirsch, IR1
Hokita, S1
Xi, H2
Mueller, RP3
Dienes, HP3
Brivio, F1
Fumagalli, L1
Fattori, L1
Nespoli, L1
Denova, M1
Sargenti, E1
Nespoli, A1
Ryu, BY1
Choi, SJ1
Hu, MJ1
Wu, YL2
Qiao, MM1
Fu, H1
Bu, LM1
Ji, X1
Liu, CY1
Fisher, R2
Schache, D1
Rischin, D2
Hehr, T2
Schleicher, J1
Jehle, EC1
Boehlke, I1
Mauer, AM1
Kraut, EH1
Krauss, SA1
Ansari, RH1
Kasza, K1
Szeto, L1
Bazan, V1
Agnese, V1
Corsale, S1
Calò, V1
Valerio, MR1
Latteri, MA1
Vieni, S1
Grassi, N1
Dardanoni, G1
Tomasino, RM1
Gebbia, N5
Russo, A2
Wong, AA1
Tamm, EP1
Xiong, HQ1
Bonetto, E5
Oliani, C3
Galli, L4
Bordonaro, R5
Passardi, A2
Choi, EY1
Ki Lee, W1
Henri, M1
Latulippe, JF1
Heyen, F1
Dubé, S1
Eimermacher, A1
Menges, M1
Gracien, E1
Duyster, J1
Lersch, C2
von Delius, S1
Hennig, M1
Bredenkamp, R1
Zagon, IS1
Jaglowski, JR1
Verderame, MF1
Smith, JP5
Leure-Dupree, AE1
McLaughlin, PJ1
Ramnath, N1
Intengan, ME1
Slocum, HK2
Smith, PF1
Stewart, CC1
Hoffman, JL1
Javle, MM2
Berdzik, J2
Creaven, PJ3
Shirakusa, T1
Dong, PD1
O'Connor, JK1
Sause, WT1
Hazard, LJ1
Belnap, LP1
Noyes, RD1
Nudelman, IL1
Fuko, V1
Geller, A1
Fenig, E1
Lelchuk, S1
Ooka, M1
Okajima, S1
Shindo, H1
Tonouchi, A1
Yamamori, H1
Ashktorab, H1
Dawkins, FW1
Mohamed, R1
Larbi, D1
Smoot, DT1
Brugge, WR1
Sahani, D1
Brachtel, EF1
Dai, MS1
Felici, A1
Gamucci, T1
Pollera, CF1
Fariello, AM1
Moscetti, L2
Adami, E1
Moody, JS1
Russo, SM2
Sung, WJ1
Kim, TB1
Jung, HY2
Yu, W2
Skopelitis, H1
Kopterides, P1
Kopteridis, P1
Loukeris, D1
Sigala, F1
Zorbala-Sypsa, A1
Felekouras, E1
Panucci, MG2
Lee, SN1
Park, DK1
Takezako, Y1
Choueiri, MB1
Tawil, AN1
El-Hajj, II1
El Saghir, NS1
Dobelbower, R1
Lipsitz, S2
Sischy, B3
Smith, TJ2
Kawakami, H1
Isobe, K1
Aruga, T1
Saisho, H2
Kawata, T1
Fulfaro, F1
Bajardi, E1
Intrivici, C1
Vuolo, G1
Carli, AF1
Caraglia, M1
Del Prete, S1
Nikolic-Tomasevic, Z2
Jelic, S2
Filipovic-Ljeskovic, I1
Tomasevic, Z2
Mitomi, T1
Noto, T1
Kumada, K1
Hiki, Y1
Yamakawa, T1
Amano, T1
Oki, S1
Otani, Y3
Oka, H1
Takemiya, S1
Nishiyama, K1
Yamamura, T5
Tsuchiya, S2
Ogawa, N3
Oman, M1
Lundqvist, S1
Gustavsson, B3
Hafström, LO1
Naredi, P1
Okur, A1
Kantarci, M1
Akgun, M1
Alper, F1
Onbas, O1
Bessell, JR1
Tsai, JY1
Iannitti, D1
Berkenblit, A1
Akerman, P2
Nadeem, A1
Rathore, R1
Harrington, D1
Roye, D1
Barnett, JM1
Maia, C1
Kim, SR1
Pistevou-Gompaki, K1
Kouloulias, V1
Papaloukas, C1
Eleftheriadis, D1
Andronikidis, I1
Eleftheriadis, N1
Bitzilekis, D1
Schiessel, R3
Novi, G1
Holzer, B1
Rosen, HR1
Renner, K1
Hölbling, N1
Feil, W1
Urban, M1
Dimri, K1
Balachandran, P1
Lal, P1
Sikora, SS1
Rastogi, N1
Saxena, R1
Datta, NR1
Ayyagari, S1
Kapoor, VK1
Kelley, ST1
Bakouboula, B1
Morel, O1
Douchet, MP1
Chauvin, M1
Wakelee, HA1
Advani, RH1
Fodor, MB1
Chao, Y5
Cabral Filho, S1
Majlis, A4
Assadourian, S1
Ho, WM1
Ma, B1
Mok, T1
Yeo, W1
Lai, P1
Lim, R1
Koh, J2
Wong, YY1
King, A1
Leow, CK1
Chan, AT1
Bhandary, S1
Prasad, GN1
Shenoi, SD1
Morgan-Meadows, S1
Mulkerin, D1
Berlin, JD4
Bailey, H1
Saphner, T2
Jumonville, A1
Hansen, R5
Ahuja, H1
McFarland, T1
Kamoshita, N2
Makita, F2
Aiba, M1
Tokiniwa, H1
Ohwada, S4
Rault, A1
Béllannée, G1
Abdel-Latif, MM1
O'Riordan, JM1
Kelleher, D1
Morales Chamorro, R1
Serrano Blanch, R1
Méndez Vidal, MJ1
Gómez España, MA1
Rubio Pérez, MJ1
de la Haba Rodríguez, JR1
Aranda Aguilar, E1
Mark Smithers, B1
Smeenk, HG1
de Castro, SM1
Jeekel, JJ1
Erdmann, J1
Gouma, DJ2
Barletta, E1
Fiore, F1
Daniele, B1
D'Angelo, R1
Ferrari, E1
Formato, R1
Tortoriello, A1
Turitto, G1
Bruni, GS1
Pignata, S1
Beresford, M1
Richman, P1
Stott, D1
Osborne, M1
Ashford, R1
Grainger, J1
Al-Jabbour, J1
Talbot, I1
Mitchell, IC2
Meyrick Thomas, J1
Livingstone, JI2
McCue, J1
MacDonald, P1
Northover, JA1
Windsor, A1
Novell, R1
Wallace, M1
Harrison, RA2
Müller, C3
Köster, W1
Christofferson, E1
Le, QT1
Ho, A1
Greco, R1
Norton, J1
Yang, GP1
Kokkinakis, DM1
Neuner, RD1
Maciá-Escalante, S1
Molina-Garrido, MJ1
Carrato-Mena, A1
von Borstel, R1
Szego, P1
Parent, J1
Mayrand, S1
Corns, R1
Burtin, P2
Faria, S1
Devic, S1
Lin, YC2
Chang, HK1
Hsueh, S1
Tsai, CS1
Lo, YF1
Hwang, TL1
Chen, MF2
McDermott, U1
Galligan, L1
Allen, W1
Wilson, T1
Nielsen, JN1
Hoeffding, LD1
Machiels, JP1
Duck, L1
Honhon, B1
Coster, B1
Coche, JC1
Scalliet, P1
Aydin, S1
Kerger, J1
Remouchamps, V1
Canon, JL1
Van Maele, P1
Gilbeau, L1
Kirkove, C1
Octave-Prignot, M1
Baurain, JF1
Kartheuser, A1
Ahmed, M1
Lukyanov, AN1
Torchilin, V1
Tournier, H1
Schneider, AN1
Goldberg, SN1
Mortensen, JP2
Bisgaard, C1
Hansen, JW1
Rafaelsen, SR1
Matsuoka, T3
Morikage, N1
Kuga, T1
Wei, Q1
Ewald, P3
Bekesch, M1
Sarbia, M2
Stein, HJ2
Vanni, B1
Aschelter, AM2
Zappalà, AR1
Nisticò, C2
Martus, P1
Papadoupolos, T1
Klimpfinger, M1
Raab, R1
Cusnir, M1
Burdick, RK1
Van Echo, DA1
Moesinger, R1
Guo, JC1
Zhao, YP1
Liao, Q2
Ayav, A1
Habib, N1
Jiao, LR1
Lebray, P1
Elias, D8
Falk, SJ2
Hong, CW1
Ehrsson, H1
Baltesgard, L1
Øgreid, D1
Starkhammar, H4
Wallin, I1
Lim, JF1
Tjandra, JJ2
Hiscock, R1
Chao, MW2
Dos Santos, JG3
Sava, C1
Tres, A1
Coombes, RC3
Crivellari, D2
Marchet, A3
Sanchez, E1
Bliss, JM2
Homewood, J1
Couvreur, ML4
Baron, B3
Woods, E1
Emson, M1
Hickey, H1
Dunn, JA2
Lorchel, F1
Buffet, J1
Bosset, M1
Chaigneau, L2
Servagi, S1
Jatoi, A2
Murphy, BR1
Nikcevich, DA2
Fitch, TR1
Rowland, KM1
Gul, M1
Duzenli, A1
Bircan, M1
Cander, B1
Kocak, S1
Ozdemir, K1
Innis, M1
Sandiford, N1
Shenoy, RK1
Prussia, PR1
Zbar, A1
O'Rourke, MA1
Frontiera, MS1
Jackson, DV1
Eloubeidi, MA1
Russo, S2
Steg, A2
Thornton, J1
Fiveash, J1
Carpenter, M1
Blanquicett, C2
Johnson, MR2
Bamba, T1
Kanda, T1
Ohashi, M1
Hanyu, T1
Yajima, K2
Tanabe, T3
Kitajima, A1
Amano, S1
Enomoto, K1
Matsuo, S2
Negishi, N1
Oinuma, T1
Nemoto, N1
Shiba, Y1
Umekita, N3
Noda, K2
Kitamura, M5
Pigeau, H1
Dupré, PF1
Benouna, J1
Classe, JM1
Pioud, R1
Dravet, F1
Mackay, HJ1
Billingsley, K1
Smith, A1
Yeung, R1
Croitoru, M1
Stathopoulos, JG1
Xynotroulas, JP1
Dimou, E1
Watwe, V1
Lawrence, D2
Groth, J1
El-Hajjar, D1
Geradts, J1
Dobelbower, MC1
Raisch, KP1
Seay, LL1
Clemons, LK1
Suter, S1
Posey, J2
Bonner, JA1
Benatti, P1
Gafà, R1
Barana, D1
Marino, M1
Scarselli, A1
Pedroni, M1
Maestri, I1
Guerzoni, L1
Roncucci, L1
Menigatti, M1
Roncari, B1
Maffei, S1
Santini, A1
Losi, L1
Di Gregorio, C1
Ponz de Leon, M1
Lanza, G1
Neiss, S1
Ling, FC1
Moenig, S1
Cedermark, B2
Bentzen, SM1
Grönberg, H1
Hultborn, R1
Albertsson, M5
Lee, JN1
Aparicio, J1
Fernandez-Martos, C1
Vincent, JM1
Maestu, I1
Llorca, C1
Busquier, I1
Campos, JM1
Perez-Enguix, D1
Malani, AK1
Gupta, C1
Rangineni, S1
Gupta, V1
Taylor, JR2
Hollis, DR3
Sutherland, S2
Buchsbaum, DJ1
Eloubeidi, M1
Vickers, SM1
Chhieng, DC1
Carpenter, MD1
Sellers, JC1
Tago, M1
Nakamura, N2
Shiraishi, K1
Sasano, N1
Ohtomo, K1
Ambrosini-Spaltro, A1
Salvi, F1
Betts, CM1
Frezza, GP1
Piemontese, A1
Del Prete, P1
Baldoni, C1
Foschini, MP1
Viale, G2
Horton, PJ1
Chaudhury, PK1
Znajda, TL1
Martinie, JB1
Rochon, C1
Tzimas, GN1
Metrakos, P1
González Vela, JL1
Sánchez Guillén, JM1
Treviño Aguirre, SA1
Hernández Barajas, D1
Brito Villanueva, WO1
Cárdenas Estrada, E1
González Guerrero, JF1
Yagüe, XH1
Soy, E1
Merino, BQ1
Puig, J1
Fabregat, MB1
Colomer, R1
Medarova, Z1
Pham, W1
Kim, Y1
Moore, A2
Cho, HK1
Lee, ES1
Shim, CK1
Chung, SJ1
Kim, DD1
Marshall, J3
Haluszka, O1
Engstrom, P4
Watson, JC1
Eisenberg, D1
McGarrity, E1
Chiang, SS2
Gallego-Plazas, J1
Calvo, FA1
García-Sabrido, JL1
Gómez-Espí, M1
Del Valle, E1
Muñoz-Jiménez, F1
Alvarez, E1
Ohsugi, H1
Seong, J1
Cho, CW1
Lee, Y1
Han, SH1
Zhou, ZF1
Yin, BJ1
Liu, DL1
Zhu, LJ1
Pan, LX1
Mantyh, CR1
Yu, D2
Clary, BM4
Pappas, TN4
El-Khoueiry, AB1
Kluger, N1
Bessis, D1
Guillot, B1
Rouzbahman, M1
Matono, S1
Yamana, H1
Sugiura, T2
Mizuno, H1
Hoki, M1
Souma, Y1
Ozawa, H1
Kanou, T1
Nakamori, Y1
Giordano, KF1
Stella, PJ1
Foster, N1
Mailliard, JA7
Arveux, P1
Girault, C1
Kalykaki, A2
Samonis, G1
Varette, C6
Bergenfeldt, M1
Dongiovanni, V1
Spinnler, MT1
Ardine, M1
Carneiro, BA1
Kaminer, L1
Eldibany, M1
Sreekantaiah, C1
Kaul, K1
Locker, GY1
Heluwaert, F1
Santre, C1
Martin, C2
Hilleret, MN1
Martin, D3
Yau, K1
Price, P1
Pillai, RG1
Aboagye, E1
Kaur, T1
Khanduja, KL1
Kaushik, T1
Kaushik, G1
Gupta, R2
Gupta, NM1
Vaiphei, K1
Beretta, E1
Mancin, M1
Dognini, G1
Rades, D1
Tribius, S1
Yekebas, EF1
Bahrehmand, R1
Wildfang, I1
Kilic, E1
Muellerleile, U1
Gross, E1
Schild, SE2
Alberti, W1
Shuai, XM1
Han, GX1
Wang, GB1
Chen, JH1
Engles, JM1
Quarless, SA1
Mambo, E1
Ishimori, T1
Wahl, RL1
Weissenberger, C1
Otto, F1
Barke, A1
Henne, K1
von Plehn, G1
Rein, A1
Bartelt, S1
Henke, M1
Forshaw, MJ2
Chrystal, K2
Cheong, K2
Atkinson, S1
Botha, A1
Mason, RC4
Vincitore, M1
Michelini, A1
Sheehan, S1
Burge, ME1
Jackson, DP1
Anthoney, DA1
Halstead, F1
Hirota, T2
Kodaira, S4
Kassam, Z1
Lockwood, G1
O'brien, C1
Brierley, J1
Siu, L1
Cummings, B3
Ringash, J1
Sengul, N1
Woodhouse, S1
Arrigain, S1
Xu, M1
Larach, JA1
Ahn, BK1
Weiss, EG1
Nogueras, JJ1
Valencia Julve, J1
Alonso Orduña, V1
Escó Barón, R1
López-Mata, M1
Méndez Villamón, A1
Ould-Kaci, M1
Breau, JL1
Morvan, F3
Serio, G1
Pederzoli, P5
Iacono, C2
Pulica, C1
Capelli, P1
Torri, T3
Pacetti, P2
Pagani, M1
Alvarez, JV1
López, MJ1
Segovia, F1
Filipovich, E1
Castro, IG1
Mediema, BE1
Curr, N1
Saunders, H1
Murugasu, A1
Schwarz, M1
Gin, D1
Li, QS1
Zhang, XQ1
Li, DP1
Sheng, XG1
Du, XL1
Song, QQ1
Jeon, SB1
Wöhlke, M1
Barten, M2
Kim, SN2
Hong, YJ1
Contreras, J1
Macías, J1
Fortes, I1
Rivas, D1
González, P1
Herruzo, I1
Moreno-Vega, AL1
Fuentes-Pradera, J1
Gordón-Santiago, Mdel M1
Vargas-Machuca, JC1
Orel, NF1
Borisova, TA1
Markovich, AA1
Zaguzina, NN1
Zhang, YS1
Zhu, LF1
Weng, XS1
Corporaal, S1
Smit, WM1
Russel, MG1
Legdeur, MC1
Abraham, J1
Brewster, A1
Hardwick, R1
Havard, T1
Lewis, W1
Askill, C1
Manson, J1
Williamst, GT1
Court, J1
Farrey, K1
Crozier, JE1
McKee, RF1
Angerson, WJ1
Anderson, JH2
Horgan, PG1
McMillan, DC1
Roof, KS1
Coen, J1
Lynch, TJ2
Fidias, P1
Choi, NC4
Melloni, G1
Bandiera, A1
Carretta, A1
Ciriaco, P1
Arrigoni, G1
Zannini, P1
Chateau, MC1
Borrelly, C1
Guida, C1
Cascini, LG1
Morrica, B1
Parisi, V1
Gebbia, V8
Verderame, F2
Ferraù, F2
Callari, A1
Caruso, M2
Tirrito, ML1
Valenza, R3
Borsellino, N2
Tralongo, P2
Chen, JZ1
Luo, RC1
Skare, NG1
Vinholes, J1
Lago, S1
Pecego, R1
Carlone, N1
Manni, A1
Aitini, E3
Etzel, CJ1
Amos, CI1
Milas, L2
Hittelman, WN1
Karpeh, MS1
Coit, DG1
Klimstra, DS1
Bossard, N1
Renouf, D1
Abbrederis, K1
Roethling, N2
Swanson, GP1
Faulkner, J1
Noble, MJ1
Stephens, RL5
O'Rourke, TJ1
Quick, DP1
Thompson, IM1
Crawford, ED4
Thompson, JN1
Scarffe, JH3
Lofts, FJ3
Smith, DB2
Verma, M1
Weeden, S1
Ferrero, JM2
Chamorey, E2
Oudard, S1
Dides, S1
Lesbats, G2
Cavaglione, G1
Nouyrigat, P1
Foa, C1
Kaphan, R1
McCoy, S1
Patel, T1
Cobb, PW2
Yost, KJ1
Spreafico, A1
Johnson, CD1
Tan, MT1
Stipa, F1
De Salvo, GL1
Fabris, G1
Ferraro, B1
Bruttocao, A1
Aurilio, G1
Vecchione, L1
Harashima, K1
Nonaka, T1
Jia, JH1
Zhang, MX1
Zhou, YB1
Zhang, RM1
Yu, XP1
Okamoto, R4
Kandabashi, K1
Sasaki, E1
Nakagawa, S1
Yabusaki, H4
Saigenji, K1
Choi, W1
Cogdell, D1
Hamilton, SR1
Qiu, XH1
Zhang, SQ1
Chen, ZM1
Kobayashi, D1
Honda, I2
Kagawa, S1
Tokunaga, N1
Nishizaki, M2
Teraishi, F1
Gouchi, A1
Matsuoka, J1
Chujo, M1
Kawano, Y2
Miyawaki, M1
Imakiire, T1
Hayashita, Y1
Kwon, JM1
Park, BB2
Han, MJ1
Radosevic-Jelic, L1
Daban, A1
Gundling, F1
Fuchs, M1
Nowak, L1
Hoffmann, E1
Schepp, W1
Zhou, AW1
Fu, YC1
Tripathy, D1
Closon-Dejardin, MT1
Untereiner, M1
Leduc, B1
Mackiewicz, R1
Movsas, B2
Diratzouian, H1
Hanlon, A1
Stein, J2
Kister, D1
Eisenberg, B2
Kendal, WS1
Jonker, D2
Stern, H1
Moyana, T1
Blaszkowsky, L3
Battu, S2
Kolodziej, M1
Rousey, SR1
Pluenneke, RE1
Perrine, G1
Mull, S1
Ilegbodu, D1
Wang, HP1
Lee, JM1
Yang, CH1
Lin, JT3
Haraguchi, Y1
Ueno, S1
Sakamoto, F1
Toyoyama, H1
Ikeda, N2
Kamikado, C1
Aikou, T1
Tsuchiya, M1
Takita, W1
Koshino, H1
Kurihara, A1
Kaneko, H2
Teramoto, T2
Strojan, P2
Zakotnik, B1
Chun, JH1
Lisi, V1
Peramiquel, L1
Dalmau, J1
Puig, L1
Roé, E1
Fernández-Figueras, MT1
Alomar, A1
Dawson, SJ1
Biagi, J1
Foo, KF1
Hui, A1
Milner, AD1
Thomas, RJ1
Kalra, AV1
Campbell, RB1
Constenla, M3
Fodor, M4
Voznyi, E3
Risse, ML1
Gotlib, V1
Khaled, S1
Lapko, I1
Mar, N1
Agelaki, S1
Kotsakis, AP1
Gioulbasanis, J1
Tsetis, D1
Sfakiotaki, G1
Chatzidaki, D1
Rana, V1
Gould, MS1
Palla, S1
Guha, S1
Oeda, M1
Sanada, Y2
Wada, Y6
Mizuiri, H1
Shigematsu, H1
Cho, CH2
Shyr, Y1
Beauchamp, RD2
Chakravarthy, B1
Prenzel, KL1
König, A1
Schnickmann, C1
Yokoi, K2
Ishikawa, N1
Seya, T2
Horiba, K1
Kanazawa, Y2
Ohkawa, K2
Kudoh, H2
Yoshioka, M1
Tajiri, T2
Honma, H1
Fukada, T1
Yasuno, K1
Koyama, T1
Seike, K2
Kametaka, H1
Hashimoto, R1
Hasegawa, A1
de Geus-Oei, LF1
Ruers, TJ1
Leer, JW2
Corstens, FH1
Oyen, WJ1
da Silva, RG1
Demiray, M1
Ulukaya, EE1
Arslan, M1
Gokgoz, S1
Saraydaroglu, O1
Ercan, I1
Evrensel, T1
Manavoglu, O1
Minisini, AM1
Pauletto, G1
Bergonzi, P1
Fasola, G1
Sadighi, S1
Mohagheghi, MA1
Montazeri, A1
Sadighi, Z1
Schoppmeyer, K2
Wiedmann, M2
Liebmann, A1
Hauss, J1
Mossner, J2
Caca, K2
Witzigmann, H1
Hildebrandt, G1
Anderson, C1
Nijagal, A1
Noguchi, H1
Kitajima, M4
Konishi, N1
Sato, G2
Nagaoka, I1
Futagawa, S1
Rojas Llimpe, FL2
Mutri, V2
Giannetta, L1
Funaioli, C2
Berardi, R2
Longobardi, C2
Piana, E1
Martoni, AA2
Ezzeldin, H1
Vance, K1
Sellers, S1
Popov, IP1
Kecmanovic, D1
Borojevic, N1
Micev, MT1
Kezic, I1
Siefker-Radtke, A1
González-González, JJ1
Sanz-Alvarez, L1
Marqués-Alvarez, L1
Navarrete-Guijosa, F1
Martínez-Rodríguez, E1
Cho, BC2
Cheong, JH1
Kelsey, CR2
Honda, K1
Fukuhara, T2
Kushihata, F1
Abe, S3
Okuda, T3
Koo, DH1
Miyake, Y1
Oshima, K1
Zu, Y1
Kennedy, EP1
Hwang, SJ1
Lee, SD1
Sin, CH1
Nam, SH1
Mottolese, M2
Orlandi, G1
Merola, R1
Buglioni, S2
Di Benedetto, A1
Pinnarò, P1
Perracchio, L1
Venturo, I1
Cianciulli, A1
Hughes, MA2
Frassica, DA2
Younes, F1
Moukadem, W1
Nasr, F1
Chahine, G1
Wydmański, J1
Poltorak, S1
Maka, B1
Miszczyk, L1
Wolny, E1
Bielaczyc, G1
Zajusz, A1
Fritschi, L1
Jensen, SA1
Vilmar, A2
Sørensen, JB2
Kraus-Tiefenbacher, U1
Leitner, A1
Grobholz, R1
Kähler, G1
Murakami, D1
Tsujitani, S3
Osaki, T1
Katano, K1
Tatebe, S1
Ikeguchi, M2
Valenti, V1
Diaz-Gonzalez, J1
Beunza, JJ1
Alvarez-Cienfuegos, JA1
Borget, I1
Aupérin, A2
Abbas, M1
Mousseau, M2
Cassan, P1
Stremsdoerfer, N1
Nasca, S2
Queuniet, AM1
Ozyiğit, T1
Buğra, Z1
Lahans, T1
Kabeya, K1
Neri, B3
Pantaleo, P1
Grifoni, R1
Paoletti, C1
Rotella, V1
Pantalone, D1
Taddei, A1
Mercatelli, A2
Tonelli, P1
Diculescu, M1
Hoepffner, NM1
Sailer, V1
Chick, J1
Brock, K1
Albert, D1
Morgan, B1
Berry, DP1
Blanshard, K1
Price, D1
Bower, G1
Steward, WP1
Qayyum, A1
Mujtaba, I1
Ogino, S1
Kawasaki, T6
Loda, M1
Vega-Villegas, ME1
López-Brea, MF1
Karanlik, H1
Muslumanoglu, M1
Igci, A1
Emek, E1
Ozmen, V1
Kecer, M1
Parlak, M1
Cambray i Amenós, M1
Navarro García, M1
Martí Ragué, J1
Pareja Fernández, L1
Pera Fábregas, J1
Grau Cat, J1
Navarro Ferrando, JT1
Mate Sanz, JL1
Ribera Santasusana, JM1
Zuccaro, G3
Vargo, JJ1
Dumot, JA1
Carroll, MA1
Saggio, G1
Cesta, A1
Amiconi, G1
Blasio, AD1
Manza, SG1
Rusin, B1
Ferris, AM1
Takano, S1
Oda, K1
Oshima, T1
Noda, M3
Kuno, T2
Hashimoto, A2
Gega, M1
Yagyuu, T1
Yoshikawa, R3
Yanagi, H4
Minami, K1
Kameda, A1
Tsutani, Y1
Miyahara, E2
Noso, Y1
Dolinsky, CM1
Mick, R1
Whittington, RW1
Rosato, EF1
Dupont, J1
Seo, BG1
Viteri, A1
Muñoz, A1
Rubio, I1
Barceló, R2
Martínez-Bueno, A1
Carrera, S1
López-Vivanco, G1
Piessen, G1
Briez, N1
Yanagisawa, Y1
Maruta, F1
Iinuma, N1
Ishizone, S1
Koide, N1
Nakayama, J1
Miyagawa, S2
Pintoffl, JP1
Meisinger, I1
Horger, M1
Lim, YJ1
Rhee, JC1
Bae, YM1
Chun, WJ1
Isacoff, WH1
Bendetti, JK1
Barstis, JJ1
Jazieh, AR1
Sur, HY1
Sung, HJ1
Jeen, YT1
Chun, HJ1
Gaffney, DK2
Miller, B1
Ryu, J1
Avizonis, V1
Fromm, M1
Greven, K1
Enzinger, P1
Lawrence, C2
Norwood, AA1
Tucci, M1
Benghuzzi, H1
Caron, P1
Seiter, K2
Malik, Z1
Mickle, M1
Mulcahy, MF1
Chen, YW1
Yen, SH2
Chen, SY1
Huang, PI1
Shiau, CY1
Liu, YM1
Kaminski, A1
Giuliani, F3
Cartenì, G1
Manzione, L3
Romito, S1
Tchekmedyian, S1
Hu, E1
Chan, D1
Amado, RG1
Nabhan, C1
Ragam, A1
Samuels, B1
Milton, DT1
Prasad, L1
Hooberman, A1
Hartsell, W2
Anthony, A1
Weisman, R1
Bitran, JD5
Anderson, SE1
Bains, M1
Hummer, A1
Ostwald, C1
Lay, GC1
Caraul, B1
Dessì, M1
Orrù, S1
Murtas, R1
Deidda, MA1
Farigu, R1
Farci, D1
Maxia, L1
Casula, G1
Amichetti, M1
Feisthammel, J1
Tampellini, M3
Brizzi, MP1
Bitossi, R1
Alabiso, I1
Sculli, CM1
Chiusa, L1
Papotti, M1
Dogliotti, L2
Kuo, LJ1
Liu, MC1
Jian, JJ1
Horng, CF1
Cheng, TI1
Chen, CM1
Fang, WT1
Chung, YL1
Nielsen, D1
Iversen, A1
Vejlø, C1
Yamada, E2
Ninomiya, M1
Takakura, N2
Yoshizawa, Y1
Sasaya, S1
Maezawa, K1
Rodriguez-Blanco, I1
Ginarte Val, M1
Peteiro, C1
Toribio, J1
Jen, YM2
Di Maggio, G1
Di Cristina, L1
Agueli, R1
Russo, P1
Riechelmann, RP1
Townsley, CA1
Chin, SN1
Moon, YW2
Hoshina, K1
Kobayashi, I2
Kurita, M1
Shida, D1
Shinkai, H1
Miyashita, M1
Paran, H1
Edelstein, E1
Klein, B1
Gutman, M1
Wang, YJ1
Feng, JX1
Cao, WG1
Xi, WQ1
Xu, HP1
Che, JF1
Jin, YN1
Zhang, HG1
Zhang, YJ1
Song, SP1
Chu, DT1
Yang, ZY1
Hong, X1
Lu, L1
Zhang, CH1
Kotasek, D1
Davies, T1
Briasoulis, E1
Fatouros, M1
Roukos, DH1
Van Krieken, HH1
Mulder, NH3
Carstens, H1
Takeuchi, S3
Hentrich, M1
Seroneit, T1
Marabotti, C1
Awad, L3
Köberle, D1
Borner, MM4
Rufibach, K1
Wernli, M2
Leslie, M1
Maehara, S1
Makino, I1
Imamura, S1
Aso, M1
Katoh, H1
Cobo, F1
De Celis, G1
Pereira, A1
Latorre, X1
Pujadas, J1
Albiol, S1
Sharma, SP1
Choi, MY1
Lauwers, GY2
Hur, C1
Chung, DC1
Mitchell, P1
Beale, P2
Friedlander, M1
White, S1
Nishino, Y1
Yamaura, G1
Ohtsuka, K1
Kakudo, Y1
Chiba, N1
Sakayori, M1
Murakawa, Y2
Shibata, H2
Mamiya, N1
Mamiya, K1
Satomi, M1
Chisato, N1
Ebisawa, Y1
Bartelink, H2
Nelson, JW1
Chino, JP1
Clough, RW1
Di, LJ1
Jin, ML1
Shi, YX1
Mortimer, J2
Kocha, W2
Zhong, LX1
Tao, QS1
Tang, XM1
Iyer, RV1
Gibbs, J1
Kuvshinoff, B1
Kepner, J1
Soehnlein, N1
Stahtea, XN1
Roussidis, AE1
Kanakis, I1
Tzanakakis, GN1
Chalkiadakis, G1
Kletsas, D1
Karamanos, NK1
Deeks, ED1
Suehisa, H1
Toyooka, S1
Uchida, A1
Soh, J1
Ouchida, M1
Date, H1
Sanghera, P1
Ho, K1
Muscroft, T1
Hartley, A1
Wrzesinski, SH1
McGurk, ML1
Donovan, CT1
Ferencz, TM1
Desai, SP1
Knol, JA1
Huang, EH1
McGinn, CJ1
Millis, R1
Jean, M1
Kennedy, T2
Marnitz, S1
Köhler, C1
Roth, C1
Füller, J1
Bischoff, A1
Wendt, T1
Schneider, A2
Budach, V1
Lee, WB1
Sy, HM1
Filip, DJ1
Grossniklaus, HE1
Thomsen Lønborg, J1
Mård, D1
Astrup Jensen, S1
Allendorf, JD1
Lauerman, M1
Bill, A1
DiGiorgi, M1
Goetz, N1
Remotti, H1
Schrope, B1
Sherman, W1
Fine, RL1
Terzi, C1
Canda, AE1
Atila, K1
Sonmez, D1
Fuzun, M1
Gorken, IB1
Obuz, F1
Eigenbrod, T1
Klebl, F1
Ishizu, K1
Sunose, N1
Tsuruo, T5
Yamori, T3
Nikaido, T1
Araki, H1
Chiba, H1
Jung, GR1
Kim, KJ1
Choi, CH1
Lee, TB1
Han, SI1
Han, HK1
Lim, SC1
Suttie, SA1
Park, KG1
Smith, TA1
Merlin, F1
Prochilo, T1
Kildani, B2
Tucci, A1
Ferrari, S1
D'Adda, P1
Kuebler, JP2
Robinson, B1
Hua, D2
Huang, ZH2
Deng, JZ1
Katia, D1
Zilembo, N1
Ardizzoia, A1
Marini, G1
Schieppati, G1
Pinotti, G1
Palazzo, S1
Fagnani, D1
Reguzzoni, G1
Agostana, B1
Duro, M1
Botta, M1
Mozzana, R1
Mantovani, G1
Torres, MA1
Jhingran, A1
Levenback, CF1
Bodurka, DC1
Ramondetta, LM1
Hirakawa, M1
Son, HJ1
Isaksson, B1
Almström, M1
Albiin, N1
Permert, J1
Fang, WJ1
Zhang, XC1
Yu, LF1
Bao, HY1
Shi, GM1
Huang, S1
Siperstein, AE1
Ballem, N1
Parikh, RT1
Schippinger, W1
Samonigg, H1
Thödtmann, R1
Jagoditsch, M1
Steger, GG1
Jakesz, R3
Herbst, F1
Hofbauer, F1
Wohlmuth, P1
Ruotsalainen, T1
Korpela, R1
Saxelin, M1
Ollus, A1
Valta, P1
Schinzari, G1
D'Argento, E1
Trigila, N1
Astone, A2
Lim, L1
Chao, M1
Millar, JL2
Kipp, D1
Rezo, A1
Fong, A1
Jones, IT1
McLaughlin, S1
van de Schoot, L1
Romme, EA1
van Lijnschoten, G1
van Driel, OJ1
Cen, P1
Majno, PE1
Giostra, E1
Terraz, S1
Allal, AS1
Wolfson, AH1
Crook, W1
Krishan, A1
Markoe, AM1
Lucci, JA1
Coco, C5
Cosimelli, M3
Bellavita, R1
Morganti, AG1
La Torre, G1
Trodella, L1
Genovesi, D3
Portaluri, M1
Maurizi-Enrici, R1
Barbera, F1
Maranzano, E1
Lupattelli, M1
Ibele, AR1
Koplin, SA1
Slaughenhoupt, BL1
Kryger, JV1
Friedl, A1
Lund, DP1
Shin, H1
Tudor-Smith, C1
Raraty, M1
Jung, EJ2
Pinsk, I1
Phang, PT1
Jeffery, M1
Schulz, J1
Soufi-Mahjoubi, R1
Barrueco, J2
Muzikansky, A1
Sujendran, V1
Wheeler, J1
Baron, R1
Maynard, N1
Ohara, T1
Okuda, Y1
Suzuki, N3
Kiguchi, K1
Ishizuka, B1
Tavares-Bello, R1
Law, CC1
Fu, YT1
Chau, KK1
Choy, TS1
So, PF1
Wong, KH1
Perez-Staub, N1
Yang, YQ1
Zhang, LJ1
Dong, H1
Jiang, CL1
Wu, JX1
Xiao, HS1
Gao, HJ1
Zhang, QH1
Peignaux, K1
N'guyen, TD1
Mirabel, X1
Marchal, C1
Verrelle, P2
Bai, P1
Zhang, R1
Li, XG1
Ma, SK1
Wu, LY1
Zhang, WH1
Han, JQ1
Liang, RX1
Qu, FS1
Yan, TX1
Li, XQ1
Rakhit, A1
Fettner, SH1
Brennscheidt, U1
Wang, HZ1
Wang, HB1
Gao, H1
Kang, SP1
Ledbetter, L1
Johnson, M1
McLean, SR1
Shousha, S1
Francis, N1
Lim, A1
Eccles, S1
Nathan, M1
Brock, CS1
Palmieri, C1
Mitsuno, M1
Ide, T1
Ohtaka, K1
Senzaki, M1
Ishida, S1
Yada, A1
Hanai, M1
Kurakata, S1
Min, JS6
Fujisawa, M1
Ono, S1
Nitta, S1
Shinjou, K1
Machida, M1
Kitabatake, T1
Ishibiki, Y1
Urao, M1
Kojima, K2
Armbrust, T1
Sobotta, M1
Grabbe, E1
Ramadori, G1
Xue, YW1
Han, JG1
Li, BX1
Salvagni, S1
Tagliaferri, P1
Crocicchio, F1
Mari, E1
Kim, KS1
Choi, JS1
Cha, SH1
Torrisi, R1
Ghisini, R1
Bottiglieri, L1
Veronesi, P1
Luini, A1
Orlando, L1
Colleoni, M3
De Greve, J1
Braumann, D2
Joosens, E1
Müller, L1
Janssens, J1
Reimer, P1
Späth-Schwalbe, E1
Wilke, HJ1
Van Den Brande, J1
Debois, M1
Bethe, U1
Caputo, G1
Condorelli, S1
Germano, D1
Mattina, M1
Amadio, P1
Reggiardo, G2
Tomimatsu, H1
Akamatsu, M1
Nakata, W1
Ohmae, T1
Ohata, K1
Matsubara, S1
Katamoto, T1
Udaka, T1
Jida, M1
Waki, N1
Kubo, M1
Sogabe, O1
Shirakawa, K1
Fanti, S1
Castellucci, P1
Sperandi, F1
Furuta, S1
Sunagawa, R1
Inaba, K1
Isogaki, J1
Komori, Y1
Uyama, I1
Zhao, AG1
Yang, JK1
You, SF1
Zhao, HL1
Tang, LD1
Lim, T1
Kim, KM1
Wisinski, KB1
Wahl, AO1
Sencan, O1
Buyukcelik, A1
Boruban, MC1
Demirkazik, A1
Senler, FC1
Onur, H1
Francis, P1
Crown, J2
Balil, A1
Nordenskjöld, B2
Vorobiof, D1
Dolci, S1
Jamin, S1
Bendahmane, B1
Gelber, RD2
Castiglione-Gertsch, M2
Piccart-Gebhart, M1
Horger, MS1
Koppenhöfer, U1
Brunner, TB1
Rupp, A1
Melzner, W1
Ballardini, M1
Orlandi, M1
Guadagni, S2
Fu, SY1
Leon, R1
Aristu, JJ1
Riedel, ER1
Balteskard, L2
Tveit, K2
Heikkilä, R1
Garmo, H1
Copois, V1
Bec, N1
Robert, B1
Fraslon, C1
Conseiller, E1
Molina, F1
Larroque, C1
Koutras, AK1
Gerolymos, MK1
Kontogeorgou, E1
Iconomou, G1
Tsiata, E1
Chrysanthopoulos, C1
Tai, BC1
Soo, RA1
Han, HC1
Ng, SS1
Tan, WL1
Zeps, N1
Baratta, A1
Gorin, RJ1
Costa, R1
Kogo, M1
Yoneyama, K1
Imawari, M1
Kiuchi, Y1
Lee, KC1
Calzolari, F1
Tison, C1
Giampalma, E1
Cecconetto, L1
Golfieri, R1
Yonemori, K1
Takesako, Y1
Rosemurgy, A1
Luzardo, G1
Bowers, C1
Zervos, E1
Al-Saadi, S1
Carroll, R1
Chheda, H1
Carey, L1
Goldin, S1
Grundy, S1
Kudryk, B1
Zwiebel, B1
Black, T1
Briggs, J1
Chervenick, P1
Berdah, JF1
Teissier, E1
Codoul, JF1
Badetti, JL1
Hébert, C1
Mari, V1
Ogreid, D1
Kook, MC1
Lee, JR1
Cho, SJ1
Tsunoda-Shimizu, H1
Hamaoka, T1
Tsugawa, K3
Yagata, H1
Kikuchi, M1
Kimmick, GG1
Cirrincione, C1
Duggan, DB1
Bhalla, K2
Robert, N1
Berry, D1
Lemke, S1
Winer, E1
Touboul, E3
Tepper, J1
Krasna, MJ1
Reed, CE1
Goldberg, R1
Kiel, K1
Willett, C1
Sugarbaker, D1
Ette, C1
Kudrimoti, MR1
Fromm, ML1
Lieuw-a-Fa, M1
Peringa, J1
Leeksma, O1
Terpstra, W1
Seller, S1
Santoro, L1
Zorzino, L1
Dell'Orto, P1
Sonzogni, A1
Monfardini, L1
Milani, V1
Pazos, M1
Issels, RD2
Buecklein, V1
Tschoep, K1
Schaffer, P1
Duehmke, E1
Schaffer, M1
Paik, YH1
Lee, DK1
Yoon, DS1
Gorbounova, VA1
Biakhov, MY1
Granov, DA1
Hossain, AM1
Blatter, J1
Kaiser, C1
Ma, D1
Tani, M1
Kawai, M1
Miyazawa, M1
Hirono, S1
Ina, S1
Nishioka, R1
Uchiyama, K2
Werbrouck, BF1
Pauwels, WJ1
De Bleecker, JL1
Katoh, S1
Ohno, T2
Kataoka, M1
Tanaka, E1
Harima, Y1
Hollerbach, S1
Wilhelm, G1
Derigs, HG1
Grossmann, J1
von Moos, R1
Heitzmann, F1
Terraciano, L1
Neuweiler, J1
Bieri, G1
Rust, C1
Toepfer, M1
Li, LH1
Zhu, JD1
Ohaki, Y1
Trindade, F1
Haro, R1
Fariña, MC1
Requena, L1
Kadikoylu, G1
Yavasoglu, I1
Barutca, S1
Meydan, N1
Bolaman, Z1
Sasada, T1
Denno, R4
Kanai, M2
Mizukami, Y1
Kohno, S1
Takabayashi, A2
Viel, E2
Demarchi, MF1
Legat, C1
Stein, U1
Thiery-Vuillemin, A1
Yakir, R1
Luna, K1
Marc, W1
Tamar, S1
Avraham, R1
Ayala, H1
Hsiao, CW1
Jao, SW1
Ishiyama, H1
Hayakawa, K1
Heudel, P1
You, B1
Glehen, O1
Vie, B1
Innominato, PF1
Bjarnason, G1
Coens, C1
Tumolo, S1
Genet, D1
Bottomley, A1
Giacchetti, S1
Lévi, F5
Laessig, D1
Haas, M1
Golf, A1
Mundt, P1
Mochmann, HC1
Ebhardt, H1
Zeitz, M1
Duchmann, R1
Pauschinger, M1
Seung, SK1
Smith, JW1
Ross, HJ1
Papadopoulos, CA1
Wilson, H2
Walko, CM1
Delva, R4
Jacob, J1
Merrouche, Y3
Piot, G3
Chen, XZ1
Gou, HF1
Chen, ZX1
Chen, JP1
Kristensen, B1
Cold, S1
Edlund, P1
Ewertz, M1
Lindman, H1
Bergh, J1
Saadati, H1
Bouillet, T2
Hiro, J1
Pennathur, A1
Landreneau, RJ1
Ward, J1
Christie, NA1
Schuchert, M1
Cooper, K1
Land, SR1
Keam, B1
Ham, HS1
Gorgun, B2
Goplerud, DR1
Watne, AL2
Thompson, JP1
Dockerty, MB1
Symmonds, RE1
Hayles, AB1
Brindley, GV1
Bonnet, JD1
Brocard, H1
Akoun, G1
Turpin, G1
Gendre, JP1
Rhodes, EG1
Boesen, EA1
Corringham, RE1
Matthews, KB1
Tuddenham, EG1
Kernoff, PB1
Steffensrud, S1
Erichsen, H1
Røysland, P1
Klepp, R1
Klepp, O1
Wünsch, E1
Petersen, H1
Ahmed, NK1
Jones, BG1
Fielding, JW1
Newman, CE1
Howell, A1
Brookes, VS2
Wright, J1
Abolfathi, A1
Penman, E1
Marks, V1
Deppe, G4
Cohen, CJ3
Gazet, JC1
Spears, CP5
Shahinian, AH1
Moran, RG1
Heidelberger, C2
Corbett, TH2
Okazaki, H1
Shirasaka, T10
Fujii, S1
Pant, KD1
Shochat, D1
Nelson, MO1
Goldenberg, DM2
Villacorte, D1
Heck, D1
Corbett, T1
Habeshaw, T1
Adam, JS1
Kirk, J1
Harada, T3
Ohmura, H1
Nishizawa, O1
Tsuchida, S2
Dimitriadis, K1
Boutis, L1
Tavantzis, J1
Bouchoris, N1
Koukourikos, S1
Hatzigogos, K1
Safarini, S1
Houghton, JA17
Houghton, PJ15
Kolarić, K3
Dujmović, I1
Beals, SP1
Lucas, RJ1
Bukowski, RM11
Schacter, LP1
Groppe, CW4
Hewlett, JS4
Weick, JK7
Togni, P1
Sessa, C2
Varini, M1
Cavalli, F2
Gahbauer, R2
Rodriquez-Antunez, A1
Hermann, R1
Smith, FP10
Rustgi, VK1
Schertz, G1
Woolley, PV11
Schein, PS17
Theodors, A2
Waddell, WR2
Gerner, RE1
Reich, MP1
Patt, YZ2
Peters, RE1
Chuang, VP1
Wallace, S2
Mavligit, G1
Oberfield, RA4
Karakousis, CP1
Kauppila, A1
Jänne, O1
Kujansuu, E1
Vihko, R1
Taylor, RE2
Smith, IE2
Ford, HT1
Bryant, BM1
Casey, AJ1
Smyth, JF2
Miller, TP3
McMahon, LJ1
Karrer, K2
Pridun, N2
Denck, H1
Konno, A1
Togawa, K1
Grozea, PN1
Carlin, DA1
Young, D2
Vine, E1
Ghanbarpour, A1
Shani, J2
Siemsen, JK1
Wolf, W3
Sordillo, PP2
Magill, GB2
Avni, A1
Haikin, H1
Feuchtwanger, MM1
Sacks, M1
Naggan, L1
Sarov, B1
Sarov, I1
Shorthouse, AJ1
Jones, JM1
Steel, GG1
Peckham, MJ2
Schwarzenberg, L6
Tourani, JM2
Michalski, B2
Hayat, M2
Dorval, T6
Misset, JL8
Delouche, C1
Brochon, D1
Fraioli, JP1
Jasmin, C2
Maral, R2
Mathe, G5
Allegra, JC2
Woodcock, TM1
Richman, SP4
Bland, KI1
Wittliff, JL1
Kitade, F1
Sakuramoto, K1
Okajima, K1
Cedermark, BJ3
Gunven, P1
Hammarberg, C1
Brooks, JL1
Ryan, JA1
Bauermeister, DE1
von der Maase, H2
Magnusson, K1
Sveinsson, T1
Iigo, M16
Kuretani, K6
Hoshi, A15
Komatubara, S1
Teramoto, S1
Tatsumura, T2
Murakami, A1
Fujisawa, T1
Chorba, T1
Orenstein, JM1
Harisiadis, L1
Moody, T1
Burton, T1
Schulof, RS1
Futatsuki, K3
Shimada, S2
Kanda, Y4
Ishibashi, I2
Sendai, H1
Akazawa, S4
Cunningham, J1
Purvis, J1
DeWys, WD1
Begg, CB1
Brodovsky, H1
Creech, R1
Khandekar, J1
Smith, BJ2
Ashford, RF2
Bakowski, M1
Hellman, K1
Newton, K1
Phillips, R1
Lambert, J1
Peters, N1
Higgins, GA2
Amadeo, JH2
Smith, DE4
Humphrey, EW1
Keehn, RJ2
McElhinney, J1
McCaughan, JJ1
Murphy, GP2
Slack, NH1
Mittelman, A7
Velez-Garcia, E1
Vogel, CL1
Marcial, V1
Ketcham, A1
Bartolucci, A1
Smalley, R1
Lopez, M3
Perno, CF1
Papaldo, P1
Presant, CA3
Denes, AE1
Bartolucci, AA4
Coates, AS1
Tattersall, MH4
Swanson, C1
Fox, RM3
Raghavan, D1
Engstrom, PF10
MacIntyre, JM2
Klaassen, DJ3
Kiseleva, ES1
Pitskhelauri, VG1
Trakhtenberg, AKh1
Bidiak, IP1
Zholkiver, KI1
Knysh, VI2
Aliev, BM1
Dvoĭrin, VV1
Barsukov, IuA1
Sparsø, BH1
Kristensen, D1
Christiansen, J1
Damgaard Nielsen, SA1
Hebjørn, M1
Andersen, B1
Sternberg, CN1
Cheng, EW1
Malcolm, A1
Johnson, DH2
Burnett, LS1
Jones, HW1
Jolivet, J3
Giroux, L1
Laurin, S1
Gruber, J1
Bettez, P1
Band, PR1
Schutt, AJ12
Rubin, J8
Creagan, ET1
Inagaki, J2
Horikoshi, N4
Ezaki, K2
Usui, N2
Nakada, H4
Naito, E1
Fuse, Y1
Yorioka, S1
Kodama, T1
Takino, T1
Shimono, M1
Shiu, MH2
Cahan, A1
Fogh, J1
Fortner, JG2
Kingsnorth, AN1
Russell, WE1
McCann, PP1
Diekema, KA1
Malt, RA1
Bedikian, AY4
Bodey, GP7
Valdivieso, M7
Burgess, MA2
Friedman, MA2
Carter, SK9
Kimura, K1
Hannigan, J1
Wakui, A3
Taguchi, T4
Burk, K1
Gropp, C2
Rodeck, G1
Logothetis, CJ5
Samuels, ML5
von Eschenbach, AC2
Trindade, A3
Ogden, S2
Grant, C2
Johnson, DE3
Hakuta, Y1
Ashizawa, I1
Nakazima, K1
Akiyama, J2
Sagara, Y1
Takeda, Y2
Boulis-Wassif, S1
Gerard, A3
Loygue, J1
Camelot, D1
Duez, N6
Sekine, S1
Katsumi, S1
Mukae, S1
Furukawa, R1
Watanabe, I2
Panettiere, FJ3
Haas, C1
McDonald, B1
Costanzi, JJ5
Athens, J1
Oishi, N5
Chen, TT4
Sampi, K1
Fujiki, T1
Izuno, O2
Suda, Y2
Urata, M1
Yanagawa, T1
Yura, Y1
Nitta, T1
Lönn, U4
Lönn, S4
Nosoh, Y1
Yoshinaka, K1
Yamaguchi, M2
Toge, T3
Niimoto, M3
Hattori, T4
Satomi, Y3
Senga, Y1
Fukuda, M1
Nakahashi, M2
Ohshima, H1
Furuhata, A2
Douglass, HO8
Lavin, PT5
Goudsmit, A1
Paul, AR6
Lagomarsino Caprino, MC1
De Vecchis, L2
Popoli, P1
Abderhalden, RT1
Zimmerman, SE1
Naganuma, K3
Kawabata, H3
Oh-Hara, T1
Tsukagoshi, S5
Shlemkevich, MP2
Shiian, DN4
Phillips, RK1
Quill, DS1
Dudley, HA1
Ibuka, T2
Ishiwata, J3
Satomi, T2
Shehata, WM2
Meyer, RL2
Krause, RJ1
Jazy, FK2
Cormier, WJ2
Kozlov, AM1
Novikov, AM1
Bassalyk, LS1
Sof'ina, ZP1
Kihara, K4
Kusuyama, H1
Washizuka, M2
Vogl, SE1
Brodovsky, HS2
Bauer, M1
Horton, J2
Elson, PJ1
Babaian, RJ1
Carter, DC2
Allan, SG1
Kaye, SB3
Sangster, G1
Calman, KC2
Hutcheon, AW1
Epelbaum, R2
Waldhorn, RE1
Tsou, E1
Kerwin, DM1
Heim, ME2
Swoboda, M1
Pahlke, W1
Edler, L3
Bicker, U1
Horner-Vallet, D1
Cappelaere, P2
Delobelle, A1
Depadt, G2
Madelain, M1
Demaille, A1
Droz, JP8
Kac, J3
Spielmann, M2
Crespon, B1
Ley, G1
Zimmermann, P1
Theodore, C6
Chavy, A1
Shildt, RA1
Kennedy, PS1
Athens, JW1
O'Bryan, RM3
Shapiro, CM3
Shapiro, RA1
Shah, A1
MacDonald, WC1
Tashiro, K1
Masuda, F4
Ohishi, Y1
Schulz, A1
Kracht, J1
Brenner, HJ1
Bibi, C1
Chaitchik, S2
Gerbie, MV1
Desser, RK2
Schifeling, D1
Kozloff, MF2
Robin, E2
Recant, W1
Michel, A2
Rochman, H1
Billings, AA2
Haas, CD1
Mansfield, CM1
Considine, B1
Gattoni, F1
Mazzoni, R1
Moro, E1
Frontini, L2
Uslenghi, C1
Hoskins, RB1
Cohen, AC1
Kaufman, S2
Wood, WC3
Carey, RW7
Khankhanian, N1
McBride, CM1
McMurtrey, MJ1
Hashimoto, I1
Sawada, Y1
Mikami, J1
Yoshimoto, M1
Nishidai, H1
Nakanishi, Y1
Kashi, Y1
Kuwayama, H1
Eastwood, GL1
Kohashi, E1
Niederle, N4
Kurschel, E2
Schmidt, CG1
Furuta, K2
Nakazaki, S1
Kiyomitsu, Y1
Hori, K1
Gnatyshak, AI2
Bertoldi, I1
Cavaleri, V1
D'Avena, C1
Mangialardi, N1
Chirletti, P1
Castro, JR1
Saunders, WM1
Quivey, JM1
Chen, GT1
Collier, JM1
Woodruff, KH1
Lyman, JT1
Twomey, P2
Frey, C2
Phillips, TL1
Yoshizawa, H1
Kanazawa, K3
Okamura, Y1
Kajiwara, T2
Anderson, JM1
Conroy, JF3
Roda, PI1
Brodsky, I2
Kahn, SB1
Bulova, SI1
Pequignot, E1
Hanna, WT1
Regester, RF1
Murphy, WM1
Chang, YC1
Falkson, G7
Tormey, DC6
Crowley, J1
Blokhina, NG3
Sorokina, GA1
Sugimori, H1
Jimi, S1
Watanabe, E1
Morita, T2
Shigyo, R1
Toyota, Y1
Tsukamoto, N1
Matsuyama, T1
Taki, I1
Ornitz, R1
Rogers, C1
Chang, BK1
Gutman, R1
Takai, S1
Mazzucco, G1
Fornari, G1
Monga, G1
Havemann, K1
Fukuda, O1
Tajima, C1
Nakayama, M1
Maeyama, M1
Recent, W1
DeLuca, SA1
Castronovo, FP1
Rhea, JT1
Lerner, H1
Marcovitz, E1
Zaren, H1
Underwood, DA1
Tsai, AR1
Yiannikas, J1
Heupler, FA1
Narisawa, T2
Sano, M3
Pouillart, P8
Bretaudeau, B1
Palangie, T7
Jouve, M5
Garcia-Giralt, E5
Asselain, B1
Sakuramoto, T1
Vaughn, CB4
Maniscalco-Greb, E1
Lockhard, C1
Groshko, G2
Enochs, K1
Duffin, H1
Demitrish, M1
Schabel, FM1
Skipper, HE1
Trader, MW1
Laster, WR1
Griswold, DP1
Choy, DS1
Newman, H1
Vieta, J1
Jochimsen, PR1
Brady, P1
Chinn, BJ1
Daversa, GC1
Parzuchowski, JS1
White, DR1
Richards, F2
Cooper, MR2
Spurr, CL1
Chlebowski, RT5
Silverberg, I2
Pajak, T1
Weiner, J2
Kardinal, C1
Bateman, JR6
Woods, RL2
Levi, JA4
Brodie, GN1
Torti, FM1
McCracken, JD5
Ray, P1
Saiki, JH2
Rivkin, SE4
Rossof, AH1
Moore, TN1
Keehn, R1
Elliott, D1
Higgins, G1
Chapman, JL1
Garland, M1
Pederson, B1
Demitrish, MM1
Chinn, B2
Ward, D2
Brady, PR1
Howell, SB4
Wung, WE1
Taetle, R1
Hussain, F1
Romine, JS1
Hazel, JJ1
Huggins, M1
Maksymiuk, A1
MacFarlane, JK1
Wheeler, TK2
Edelstyn, GA2
Bates, TS1
Brinkley, D2
Evans, RG2
Kitchen, G1
MacRae, KD2
Nicol, NT1
Spittle, M1
Chuang, V1
Haynie, TP1
Trux, F1
Olson, M1
Cruz, AB5
Leichman, L8
Helmkamp, BF1
Beecham, JB1
Wandtke, JC1
Keys, H1
Levine, AW1
Donegan, WL1
Irwin, M1
Quarles, JM1
Morris, NG1
Leibovitz, A1
Ausman, RK2
Caballero, GA2
Quebbeman, E3
Ausman, DC1
Smalley, RV3
Scogna, DM1
Malmud, LS1
Cowen, DM1
Siegerstetter, J1
Janik, AC1
Double, JA6
Granov, AM1
Borisov, AE1
Plotkin, LL1
Zemlianoĭ, VP1
Shelukhin, AP1
Karlin, DA3
Stroehlein, JR1
Bennetts, RW1
Jones, RD1
Heifetz, LJ1
Mahal, PS1
Kukleta, JF1
Altorfer, J1
Akovbiantz, A1
Gasser, RW2
Schmalzl, F2
Campbell, TN1
Pfeifle, C1
House, BA1
Calabro-Jones, PM1
Byfield, JE1
Ward, JF1
Sharp, TR1
Gota, CH1
Chan, KK1
Weiner, JM2
Block, JB1
Mughal, T1
Goold, MA1
Phillips, RH1
MacKay, IS1
Tice, AJ1
Tampier, C1
Zamorano, R1
Sato, H2
Satoh, H1
Isono, K2
Onoda, S1
Okuyama, K1
Tounosu, N1
Chin, F1
Kouzu, T1
Ryu, M1
Hirasawa, H1
Matsumura, Y1
Komiyama, S1
Makishima, K1
Hiroto, I1
Beckley, S1
Wajsman, Z2
Maeso, E1
Pontes, E1
Murphy, G2
Dworken, HJ1
Botti, RE1
Hemstreet, G1
Hester, M1
Revazova, ES1
Horno Gimeno, M1
Savrin, RA1
Martin, EW1
Wolberg, WH1
Morin, J1
Tokuzen, R1
Aroney, RS2
Dalley, DN2
Chan, WK1
Bell, DR1
Rosi, DR1
Nogeire, C1
Brown, B1
Ali, M1
Ewer, M1
Samuels, M1
Halpren, J1
Brufman, G1
Shnider, B1
Biran, S1
Jacobs, AJ2
Bruckner, H3
Giuliani, FC1
Zirvi, KA3
Kaplan, NO1
Goldin, A2
Ando, N2
Goldobenko, GV1
Lycev, VA1
Sidorcenkov, VO1
Gapanjuk, ON1
Aleksanjan, AZ1
Baranec, GV1
Schmitz, R6
Hüper, J2
Pichlmayr, R2
Frytak, S1
Weiland, LH1
Livstone, E1
Spiro, H1
Knowlton, A1
Kalser, M1
Barkin, J1
Lessner, H1
Mann-Kaplan, R1
Ramming, K1
Douglas, HO2
Thomas, P1
Nave, H1
Bateman, J1
Lokich, J3
Brooks, J2
Chaffey, J1
Corson, JM1
Zamcheck, N1
Novak, JW1
Bibby, MC4
Mughal, MA1
Fukuda, I1
Iwanaga, T4
Otani, T1
Drago, JR7
Worgul, TJ1
Efimov, GA1
Ushakov, IuM1
Amasaki, H1
Antonelli, D1
Beker, B1
Barzilay, J1
Payne, JE1
Meyer, JH1
Macpherson, JG1
Nelson, DS1
Walls, RS1
Pheils, MT1
Goldman, LB5
Gershwin, ME6
Fraile, RJ1
Baker, LH6
Buroker, TR2
Horwitz, J1
Schmitz, CA2
Richlmayr, R1
Remington, JH1
Sobel, SH1
Savlov, ED1
Ward, A1
Sherlock, D1
Matsukura, N1
Aoyagi, M1
Kawachi, T1
Hirashima, T1
Takasugi, T1
Ushio, K1
Sugimura, T1
Piver, MS4
Barlow, JJ5
Späti, B2
Jungi, WF1
Mayr, AC2
Hammer, B1
Senn, HJ2
Lei, D1
Castaño-Almendral, A1
Brunner, KW2
Martz, G2
Obrecht, P1
Melchert, F1
Rhomberg, W1
Hoth, DF2
Levin, B11
Echtermeyer, V1
Benz, C2
Schoenberg, M1
Choti, M1
Cadman, E2
Smythe, T3
Ueno, W3
Hoth, D2
Smith, F1
Boiron, M2
Gisselbrecht, C3
Lagarde, C2
Ichiki, AT1
Israelsen, KL1
Sonoda, T2
Collmann, IR1
Maroda, SJ1
Phillips, JO1
Caravella, LP1
Burns, JA1
Zangmeister, M1
Schuurman, B1
Sirovich, I1
Heuff, G1
van der Wilt, CL2
Beelen, RH1
Meyer, S1
Neubauer, BL1
Best, KL1
Counts, DF1
Goode, RL1
Hoover, DM1
Jones, CD1
Sarosdy, MF1
Shaar, CJ1
Tanzer, LR1
Merriman, RL1
Yuasa, C1
Toko, T1
Takeda, S3
Unemi, N2
Kuroda, Y4
Tsuji, M2
Demachi, H2
Stéphan, F1
Etienne, MC1
Wallays, C1
Clergue, F1
Bufill, JA1
Grace, WR1
Neff, R1
Testa, A3
Latteri, M2
Bajardi, G1
Mastrandrea, G1
Cipolla, C2
Pischedda, G1
Curto, G2
Cannata, G1
Turrisi, AT1
Highley, MS2
Parnis, FX1
Trotter, GA1
Houston, SJ1
Penson, RT1
Daliani, DD1
Eisenberg, PD1
Weems, J1
Lord, R1
Fueger, R1
Chevallier, B4
Roche, H4
Fumoleau, P3
Kerbrat, P2
Genot, JY1
Fargeot, P2
Olivier, JP2
Fizames, C1
Jacquet, P1
Averbach, AM1
Stephens, AD1
Hoshima, M1
Mugitani, T1
Koishi, K1
Masuyama, M1
Miyata, K2
Ozaki, M2
Ooshima, I1
Kinoshita, H1
Takeda, A2
Yoshimura, S2
Shouko, T1
Koizumi, T1
Mori, K2
Osaku, M1
Watahiki, Y1
Hojyo, M1
Kosaka, A1
Maruo, H1
Hyogo, H1
Kido, S1
Matsuda, M2
Matsuura, M2
Nakajima, N2
Maeshiro, T2
Awane, Y2
Terada, J1
Mizuno, I2
Mohri, N2
Inagaki, H1
Manabe, T2
Kondo, K5
Akiyama, S4
Nonami, T1
Kasai, Y2
Hibi, K2
Gardin, G1
Rosso, R8
Campora, E1
Repetto, L1
Naso, C1
Canavese, G1
Catturich, A1
Corvò, R1
Guenzi, M1
Pronzato, P1
Yudelman, I1
Nussbaum, M1
Beattie, E1
Figueredo, AT2
Fawcet, SE1
Molloy, DW1
Dobranowski, J1
Paulseth, JE1
Cleary, KR7
Buchholz, DJ4
Fenoglio, CJ3
Collier, C1
Sahmoud, T4
Fiorentino, M1
Stevens, J1
Rosato, F2
Barbot, D3
Biermann, W3
Cantor, R2
Dubrow, RA2
Meterissian, SH1
Roubein, LD2
Lepek, KJ1
Murray, D2
O'Brien, M5
Gill, PG4
Devitt, P1
Yeoh, E4
Hamilton, CS3
Adachi, Y5
Sakino, I1
Konishi, J1
Funahashi, S1
Yo, R1
Iso, Y1
Ayabe, K1
Foutzilas, G1
Markantonakis, P1
Mylonakis, N2
Bacoyannis, C1
Zisiadis, A1
Sobolos, K1
Kohara, N1
Kitaoka, F1
Komuta, K2
Motojima, K1
Kanematsu, T1
Jannot, MC1
Yeaton, P1
Pauwels, O1
DePrez, C1
Astruc, J1
Chazottes, E1
Kruczynski, A1
Kiss, R1
Ryan, MB1
Natrajan, G1
Gould, P1
Kimura, O1
Kurayoshi, K2
Sugezawa, A1
Makino, M2
Kaibara, N3
Hisatomi, K1
Nagafuchi, Y1
Ohsato, K1
Molina Esquivel, J1
Vargas Sandoval, G1
Rodríguez del Rincón, E1
Velázquez López, J1
Fontana, T1
Noviello, MR1
Egami, I1
Onda, M1
Tonusin, A1
Sukthomya, W1
Changwiwit, W1
Nimmolrat, A1
Loganzo, F1
Maslak, P1
Lai, L1
de Oliveira, AR1
Schwartz, GK3
Blundell, ML1
Altorki, NK1
Albino, AP1
Turk, PS1
Belliveau, JF1
Darnowski, JW1
Weinberg, MC1
Leenen, L1
Wanebo, HJ1
Rosen, H4
Sebesta, C4
Roos, G1
Stenram, U3
Héry, M1
Gedouin, D1
Goudier, MJ2
Jacquin, JP1
Plat, F2
Cabarrot, E1
Serin, D2
Namer, M2
Wada, K1
Iijima, Y1
Hirota, Y1
Hongo, J1
Nicolaides, C2
Briassoulis, E1
Sirott, M1
Heelan, R2
Keresztes, R1
Kallinowski, F1
Eble, MJ1
Wannenmacher, M1
Herfarth, C1
Dorval, ED1
Regimbeau, C2
Picon, L2
Bérard, H1
Reeder, LB1
Hoffman, PC2
Drinkard, LC1
Naunheim, KS2
Petruska, PJ1
Roy, TS2
Schlueter, JM2
Baue, AE2
Sørensen, P1
Edal, AL1
Madsen, EL1
Fenger, C1
Poulsen, MR1
Petersen, OF1
Wiseman, CL1
Girvin, GW1
Matsumoto, GH1
Bates, DM1
Garcia, JM1
Clyde, JC1
Lin, PH1
Knopf, K1
Redei, I1
Green, F1
Scher, R3
Ellis, PA1
Talbot, DC2
Nicolson, MC2
Priest, K1
Margolin, K5
Raschko, J1
Sorich, J1
Akman, S5
Vasilev, S1
Algan, O1
Coia, LR10
Keller, SM2
Schultheiss, TE1
Hanks, GE2
Horii, H1
Imai, J1
Watanabe, C1
Ishiyama, M1
Takada, O1
Kawamura, T1
Hasebe, K1
Chari, RS1
Russell, L1
Hathorn, J1
Cao, Z1
You, Z1
Zhou, S1
Shinohara, K1
Zabudkin, AF1
Bukhteev, SV1
Bernhard, H1
Jäger-Arand, E1
Bernhard, G1
Riemann, JF1
Meyer zum Büschenfelde, KH1
Ajao, OG1
Grillo, IA1
Malatani, T1
al Shehri, MY1
Mochizuki, F2
Tomioka, K1
Sato, F1
Yamagata, T1
Nagakawa, Y1
Kobari, Y1
Iwai, S1
Shibata, N3
Tamai, M2
Bolli, E1
Saccomanno, S1
Mondini, G1
Guglielmi, A3
Ligas, B1
Connio, M1
Mori, A1
Espinosa, E2
García-Girón, C1
Chacon, I1
Garrido, P1
Sauter, ER1
Cohen, AM11
Enker, WE5
Frankel, J4
Kodama, S1
Yanase, T1
Ikarashi, H1
Kazama, Y1
Fried, G1
Tsalik, M1
Stein, M2
Dale, J1
Romani, R1
Umehara, Y1
Okubo, T1
Sano, Y1
Sakamoto, R1
Tsuchiya, Y3
Nagato, Y1
Moriyama, R1
Mizumoto, K1
Furumoto, T1
Kawamura, Y1
Katoh, K1
Jablonski, KA1
Port, RE2
Schlemmer, HP2
Bachert, P2
Keilholz, L1
Dworak, O1
Köckerling, F2
Rexroth, G1
Scotland, V1
Boyce, HW1
Nicolson, V3
Garcia, P1
Gravalos, C1
Tusquets, I1
Font, A1
Perez, G1
Cortés-Funes, H3
Fabregat, X1
Morise, K2
Kusugami, K1
Iwase, H1
Horiuchi, Y1
Kuroiwa, A1
Suga, S1
Kumai, K1
Matsumoto, M3
Kitazaki, M1
Noma, M1
Ota, M1
Ban, K1
Masuda, K1
Shida, H1
Shchepotin, IB1
Shabahang, M1
Nauta, RJ1
Buras, RR1
Brenner, RV1
Evans, SR1
Couteau, C1
Bastit, P1
Braly, PS1
Blessing, JA3
Homesley, HD2
Averette, H1
Fanning, J1
Ladd, C1
Hilgers, RD1
Caudry, M3
Bonnel, C3
Floquet, A1
Marsault, C1
Quétin, P1
Pujol, J1
Maton, O1
Dujols, JP1
Caudry, Y1
Skawinski, P1
Weese, JL4
Agarwal, P1
Litwin, S4
Watts, P2
Chen, YC2
Chen, BR1
Lee, WJ2
Lee, PH2
Wang, CH1
Wang, TH1
Nakai, Y1
Furuse, K1
Asakawa, M2
Fukuoka, M1
Niitani, H2
Johnson, PW2
Hall, MR1
Wrigley, PF3
Slevin, ML4
Empereur, S1
Fagot, D1
Forgue-Lafitte, E1
Chastre, E1
Zimber, A1
Mester, J1
Gespach, C1
Costa, MJ1
Stewart, G1
Goodnight, JE1
Kabuto, T3
Kameyama, M2
Hiratsuka, M2
Kimura, F1
Sugaya, J1
Sejima, T1
Takano, Y1
Kiriyama, M2
Tomita, F2
Kita, I1
Yamamoto, O1
Sakai, S1
Shiraishi, T1
Hosoda, Y1
Shirato, M1
Seki, T2
Hirama, K1
Mikami, Y1
Nishi, T1
Konn, M1
Satoh, Y1
Une, Y2
Fujisawa, J1
Uchino, J2
Sasson, Z1
Morgan, CD1
Thomas, G2
MacKenzie, B1
Platts, ME1
Theodossiou, C1
Kroog, G1
Ettinghausen, S1
Tolcher, A1
Cowan, K1
O'Shaughnessy, J1
Chen, TB1
Huzak, M1
Macura, S1
Vuk-Pavlović, S1
Loehrer, PJ3
Harry, D1
Weinerman, BH1
MacCormick, RE1
Comande, S1
Buccellato, C1
Khansur, T1
Allred, C1
Tavassoli, M1
Tamaki, Y1
Touno, T2
Shin, E1
Wright, CD2
Mathisen, DJ3
Wain, JC3
Grillo, HC3
Hilgenberg, AD2
Moncure, AC2
Daly, M1
Logan, DL2
Mansi, J2
Nash, A1
Sacks, N1
Ford, H1
Bradley, C1
Selby, P1
Buswell, L1
Recht, A1
Clark, J3
Ravikumar, T1
Busse, PM1
Coleman, CN1
Semmler, W1
Hohenberger, P2
Schlag, P3
Lorenz, WJ1
van Kaick, G1
Gao, Z1
Meng, FH1
Nakagawa, H3
Koezuka, M1
Miyawaki, Y1
Tokiyoshi, K1
Hagiwara, Y2
Tsuruzono, K1
Villar-Grimalt, A2
Belón, J2
Jimeno, JM1
Candel, MT1
García de Paredes, ML1
Colajori, E1
Carrillo Hernández, JF1
Ernesto de Obaldía Castillo, G1
Ramírez Ortega, C1
Frías Mendivil, M1
Pardo, M1
Bernstein, M1
Villamil, A1
Davidson, G1
Erlichman, C5
Motoyama, M1
Imaoka, T1
Ichihara, N1
Hirai, K1
Ashikaga, K1
Kimura, C1
Kuroda, H2
Ono, M2
Kusano, F1
Yamamoto, C1
Maekawa, N1
Sasaki, N1
Tajiri, K1
Tazawa, J1
Fassas, AB1
Gattani, AM1
Morgello, S1
Yit, CC1
Das, NP1
Krook, JE12
Poplin, EA2
Khanuja, PS1
Kraut, MJ1
Herskovic, AM1
Lattin, PB1
Cummings, G2
Kinzie, JL1
Steiger, Z1
Shibata, J3
Aiba, K1
Minowa, S1
Tsuzuki, H1
Niki, M1
Ueda, H1
Takamoto, Y1
Oohara, M1
Igarashi, S4
Osada, H1
Nishimura, G3
Kurosu, Y1
Wakasugi, H2
Yokota, M1
Furukawa, M1
Mukuta, T1
Funakoshi, A1
Long, HJ1
Nelimark, RA1
Su, JQ1
Garneau, SC1
Poon, MA4
Kugler, JW2
Blitzer, PH1
Dosoretz, DE1
Katin, MJ1
Rubenstein, JH1
Harwin, WN1
Raymond, MG1
Teufel, TE1
Seidenstein, L1
Mangano, MM1
Salenius, SA1
Budman, DR2
Korzun, AH2
Younger, J2
Hart, RD1
Ellerton, JA1
Ferree, CR1
Bélanger, K1
Yelle, L1
Guévin, R1
Potvin, M2
Wilson, J1
Rudinskas, L1
Latreille, J1
Dionne, J1
Gagné, L1
Ucar, A1
Reddy, R1
Livingstone, AS1
Markoe, A1
Schwade, J1
Donofrio, K1
Weese, J1
Solin, L1
Weiner, L1
Paul, A2
Hanks, G1
Teshima, K1
Yamagata, S2
Sugawa, T1
Kubo, H1
Sugimoto, O2
Nakajima, H1
Yamabe, T1
Kaga, S1
Kano, A1
Saitoh, A1
Kikuchi, H4
Tsushima, K3
Narita, N1
Suematsu, T1
Kawabata, S1
Kodama, I1
Koufuji, K1
Aoyagi, K1
Maruiwa, M1
Ohta, J1
Kumegawa, H1
Egeli, R1
Arma, S1
Aeberhard, P1
Barras, JP1
Müller, W1
Castiglione, M1
Schroeder, R1
Roux, FX5
Brasnu, D5
Devaux, B1
Chabardes, E1
Schwaab, G1
Laccourreye, O2
Menard, M2
Janot, F2
Bertrand, J1
Steele, G3
Posner, M3
Busse, P2
Cady, B2
Stone, M2
Jenkins, R1
Osteen, R1
Taylor, DD1
Gerçel-Taylor, C1
Fowler, WC2
Okayasu, T2
Cullinan, SA4
McAtee, N3
Murphy, RF3
Hamilton, JM6
Balis, F2
Steinberg, S1
Arbuck, SG4
Setser, A1
Jordan, E1
Chen, A2
Weidmann, B1
Teipel, A1
Ritzi, EM1
Pyo, S1
Swain, SM1
Honig, SF1
Wolf, GT1
Esclamado, RM1
McLaughlin, PW1
Thornton, AF1
Graham, RA2
Atkins, MB1
Karp, DD1
Wazer, DE3
Hackford, AW2
Fedeli, A3
Fuhrman, GM1
Ota, DM4
Furuya, Y2
Ku, Y1
Hamabe, Y1
Saitoh, Y2
Navarro-Carola, E1
Demuynck, B6
Soubrane, D2
Grangé, JD3
Krulik, M11
Kajanti, M1
Meyer, HJ1
Berns, T3
Achterrath, W1
Knipp, H1
Harstrick, A3
Köhne-Wömpner, CH1
Schöffski, P4
Murase, M2
Kodera, Y1
Kiriyama, K1
Nagata, H1
Ohiwa, Y1
Miwa, M2
Inamura, Y1
Suzumura, K1
Kanemitsu, T1
Naruse, T1
Miyazaki, N1
Ohkura, H2
Kajimura, N1
Okazaki, N4
Sobrero, AF1
Guglielmi, AP1
Mori, AM1
Melioli, GG1
Bertino, JR6
Takamura, A1
Horio, K1
Ohta, T2
Yamano, M1
Sawaguchi, Y1
Ichiki, Y1
Hirata, Y1
Kanaya, S2
Niho, Y4
John, WJ3
Neefe, JR1
Cantrell, J1
Smith, M1
O'Reilly, SE1
Gelmon, KA1
Onetto, N1
Parente, J1
Rubinger, M1
Page, RA1
Plenderleith, IH1
Ohkubo, M1
Barbe, L1
Lesur, G1
Turner, L1
Dupont, C1
Coggia, M1
Dupuy, P1
Dorra, M1
Koide, T1
Kawai, Y2
Takeshige, K1
Bertheault-Cvitkovic, F1
Soussan, S1
Brienza, S2
Adam, R1
Itzhaki, M1
Bismuth, H1
Koyama, S2
Tsujimoto, M1
Kitagawa, M2
Kagamimori, S1
Griffon, G1
Weber, B2
Chen, JA1
Garton, GR1
Martin, JK4
McIlrath, DC3
Cha, SS2
Kerr, IG1
Doyle, N1
Macdonald, M1
Sone, M1
Earle, JD2
Foley, JF6
McKenna, PJ2
Twito, DI3
Burch, PA2
Miyoshi, H1
Tsunoda, Y1
Takeuchi, H1
Ueda, K1
Mochizuki, R1
Miyauchi, H1
Iwashita, R1
Kaizer, L1
Fine, S3
Minsky, B1
Cohen, A2
Enker, W1
Guillem, J3
Conti, J1
Rustamov, IR1
Dzhulbekov, KI1
Igarashi, T2
Hanyu, F1
Picciocchi, A2
Magistrelli, P1
Roncolini, G1
Netri, G1
Mattana, C2
Cellini, N3
De Franco, A1
Vecchio, FM1
Blumenstein, B1
Saiers, JH2
Coltman, CA5
Hurteloup, P1
Tomio, L1
Zorat, PL1
Paccagnella, A1
Segati, R1
Loreggian, L1
Lora, O1
Favaretto, A1
Fede, A1
Liebes, L1
Schwartz, EL1
Dutcher, JP2
Wang, FS1
Chang, YM2
Wallace, HJ1
Greer, BE1
Cain, J1
Stelzer, KJ1
Russell, KJ1
Tamimi, HK1
Figge, DC1
Russell, AH1
Griffin, TW1
Hoff, SJ1
Stewart, JR1
Sawyers, JL1
Murray, MJ1
Merrill, WH1
Adkins, RB2
Cooper, SG1
Bonaventura, A1
Joseph, DJ2
Stewart, JF1
Rustum, Y4
Herrera, L5
Creaven, P3
Grison, X1
Zittoun, J3
Metzger, G3
Richaud, J1
Lotz, JP4
Hannoun, L3
Marquet, J3
Morton, CL3
Adkins, DA2
Rahman, A3
Kase, S2
Kubota, T7
Takeuchi, T4
Furukawa, T4
Ishibiki, K3
Suganuma, Y1
Oguro, A1
Torii, T1
Ishikawa, A1
Ozawa, M1
Toyama, K1
Yeung, RS1
Kowalyshyn, MJ1
Tanemura, H5
Tanaka, S3
Oshita, H1
Asano, M2
Kaneda, N1
Kumazawa, I1
Murren, JR1
Ganpule, S1
Papac, R1
Son, YH1
Peschel, RE1
Durivage, H1
Buzaid, AC2
Lamb, L1
Makuch, R1
Hait, WN1
Inada, T4
Ozawa, I1
Hishinuma, S1
Kotake, K1
Najjar, TA1
Slomiany, BL1
Drake, J1
Chisena, T1
Cysyk, R1
Kano, Y1
Sasagawa, M1
Laufman, LR4
Collier, MA1
Sullivan, BA1
McKinnis, RA1
Clendennin, NJ1
Guaspari, A1
Brenckman, WD3
Fleming, TR10
Taylor, SA1
Dohden, K1
Ohmura, K1
Neu, IS2
Samandas, N1
Owen, W1
Dussek, J1
Barker, S1
Darnton, SJ4
Allen, SM2
Edwards, CW1
Matthews, HR3
Xing, FY1
Liu, WH1
Dong, W1
Gu, BW1
Okazaki, K2
Naito, H1
Wu, JT1
Tamura, S1
Shiozaki, H1
Miyata, M1
Kido, Y1
Pazdur, R7
Gomez, J1
Bready, B1
Hudes, GR1
Kitson, J1
Walczak, J3
Peddada, AV1
Harvey, JC1
Anderson, PJ1
Davidson, W1
Kagan, AR1
Atiq, OT1
Tong, W1
Trochanowski, B1
Toomasi, F1
Fell, S2
Haynes, H4
Katz, HJ1
Wiernik, PH5
Fujita, J1
Yamagishi, Y1
Kubo, A1
Takigawa, K1
Yamaji, Y1
Takahara, J1
Brockmann, WP1
Sommer, K1
Steiner, P1
Hübener, KH1
Kornek, G4
Schulz, F1
Kimmel, DW2
Carstensen, JM1
Burcharth, F1
Bobbio-Pallavicini, E1
Porta, C2
Moroni, M2
Spaghi, A2
Casagranda, I1
Nastasi, G2
Nozue, M1
Koike, N2
Kawamoto, T1
Toko, K1
Sindou, T1
Kondou, T1
Mun, Y1
Nithou, M1
Takiyama, W2
Sakamoto, N1
Ohashi, R1
Kirihara, Y1
Doihara, H1
Tanada, M2
Soga, H1
Komatsu, T1
Ookubo, K1
Chan, A1
Langevin, J1
Khoo, R2
Cummings, BJ2
Keane, TJ2
O'Sullivan, B2
Wong, CS2
Catton, CN2
Schnall, S1
Glees, J1
Kalnicki, S2
Dalton, J3
Chesser, MR3
Mandeli, J2
Janus, C2
Beuzeboc, P4
Livartowski, A1
Valone, FH1
Gandara, DR2
Luce, JA1
Wall, S1
Braham, N1
George, M1
Letvak, L1
Perez-Tamayo, C3
Snady, H3
Lehrer, D1
Harpaz, N1
Suh, C1
Park, KC1
Kim, HT1
Wozniak, AJ1
Blumenstein, BA1
Boileau, M1
Fletcher, WS3
Kuo, TH2
Hoffman, RM1
Ota, Y1
Shirafuji, T1
Adachi, A2
Okugawa, T1
Rino, Y1
Sairenji, M1
Motohashi, H1
Delfau, S2
Maisani, JE3
Zarba, JJ1
Basile, M1
Mahjoubi, M2
Benahmed, M1
Armand, JP1
Laurie, JA4
Tangen, CM2
Ungerleider, JS1
Emerson, WA1
Glick, JH1
Evans, OB1
Maddox, AM1
Spiridonidis, CH1
Leach, SD2
Klostergaard, J1
Leroux, ME1
Hsu, HA1
Hsi, BP1
Siddik, ZH1
Danhauser, LL1
Tomasovi, SP1
Yumoto, Y1
Kawase, K1
Narimatsu, A1
Okada, O1
Yagihashi, A2
Yamamitsu, S4
Colozza, M1
Mosconi, AM2
Anastasi, P2
de Angelis, V1
Giansanti, M1
Mercati, U1
Aristei, C1
Latini, P1
Tonato, M1
Pierga, JY2
Dieras, V3
Paraiso, D1
Scholl, SM2
Bates, BA1
Detterbeck, FC2
Qaqish, BF1
Cohen, H2
Laine, L4
Crookes, P3
Silberman, H4
Baranda, J3
Garcia, Y1
Marcell, A1
Karall, M2
Peterson, RF1
Berenberg, JL2
McClure, S1
Chapman, RA2
Eyre, HJ1
Solanki, D1
Gagliano, R1
Fornasiero, A3
Gignoux, M2
de Leonardis, V1
Romano, S2
Andreoli, F2
Pernice, LM1
Bruno, L1
Borrelli, D1
Valeri, A1
Fabbroni, S1
Intini, C1
Cini, G2
Cwikiel, M1
Cwikiel, W1
Stuschke, M2
Walz, MK2
Molls, M1
Fett, W1
Makoski, HB1
Breuer, N1
Schmidt, U1
Niebel, W1
Sack, H1
Eigler, FW1
Seeber, S3
Schnall, SF1
Stryker, SJ1
Kiel, KD1
Shaw, JM1
Ujiki, GT1
Poticha, SM1
Ikegami, H1
Nishikawa, H2
Yokota, S2
Tachibana, T1
Higashino, K1
Tangen, C1
Hutchins, LF3
Natale, RB1
Guy, JT1
Savarese, DM1
Gordon, J1
Smith, TW1
Litofsky, NS1
Licho, R1
Ragland, R1
Recht, L1
Mansi, JL2
Glees, JP1
Dalgleish, AG1
Knight, MJ1
Kung, SP1
Hsieh, RK2
Fan, S2
Wei, CH1
Carey, PD1
Farrer, C1
Gordon, A1
Sommers, SS1
Pearce, S1
Monson, JR1
Guillou, PJ2
Maurer, U1
Härle, M1
Jungius, KP1
Thomas, F1
Arriagada, R1
Mouriesse, H1
Le Chevalier, T3
Fontaine, F1
Tursz, T1
Hsu, WL1
Shueng, PW1
Wu, CJ1
Liu, HS1
Hwang, JM1
Witham, M1
Harnett, PR1
Tagliaventi, M1
Mazzocchi, B1
Bella, M2
Donati, D1
Acito, L2
Maggian, P1
Angiona, S3
Ahmed, FY1
Watson, M4
Hill, AS1
O'Brien, ME1
Evans, TC1
Carducci, MA1
Zahurak, ML2
Grochow, LB3
Babu, KG2
Raud, C1
Kumaraswamy, SV1
Lalitha, N2
Beitler, JJ2
Camacho, M2
Levine, B1
Giannopoulos, A1
Bacoyiannis, C1
Papadimas, V1
Kalahanis, N1
Karatzas, G1
Sakelaropoulos, N1
Archimandritis, A1
Papachristodoulou, A1
Malacarne, P3
Maestri, A1
Takechi, T2
Satake, H1
Uchida, J1
Fujioka, A1
Karpeh, M1
Schwartz, G1
Gerdes, H1
Lightdale, C2
Botet, J5
Lauers, G1
Quan, V1
Bassot, V2
Laccourreye, L1
Naudo, P1
Guichard, M1
Noonan, N1
Hollywood, D1
Kelly, A2
Hennessy, TP1
Marsh, RD1
Chu, NM1
Bewsher, C1
Copeland, EM4
Kurimoto, H1
Ono, K2
Fuku, A1
Muchmore, JH2
Preslan, JE1
George, WJ1
Cerottini, JP1
Saraga, E1
Metthez, G1
Givel, JC2
Ardiet, JM1
Sentenac, I1
Chauvet, B1
Reynaud-Bougnoux, A1
Le Floch, O1
Kumagai, N1
Serizawa, H1
Iwabuchi, N1
Watanabe, N2
Hamada, Y1
Tsuchimoto, K1
Morinaga, S1
Xiao, S1
Christie, DR1
Bull, CA1
Langlands, AO1
Poorter, RL2
Bakker, PJ2
Huizing, MT1
Taat, CW2
Rietbroek, RC1
Rauws, EA1
Veenhof, CH4
Petrov, VP1
Perekhodov, SN1
Lazarev, GV1
Cohen, L1
Hendrickson, FR2
Lennox, AJ1
Kroc, TK1
Hatcher, MA1
Bennett, BR1
Gleissner, B1
Hilgenfeld, RU1
Thiel, E1
Magnien, F1
Lapprand, M1
Oddes, B1
Nose, H2
Nakasuka, H1
Nakayama, H1
Nagahama, H2
Rasheshyam, D1
Bouleuc, C1
Azzouzi, K1
See, J1
Esteso, A1
Avenin, D1
Izrael, V3
Pagani, O1
Cummings, F2
Browne, M1
Akerley, W1
Wanebo, H1
Weitberg, A2
Cole, B1
Bigley, J1
Beitz, J2
Darnowski, J1
Werner, A1
Bender, E1
Mahaffey, W1
McKeating, J1
Marrangoni, A1
Katoh, A2
Cripps, MC1
Andersen, JS1
Portenoy, RK1
Green, MR2
Tarassoff, PG1
Brown, TD1
Casper, ES2
Storniolo, AM1
Kudoh, M1
Susaki, Y1
Ideyama, Y1
Nanya, T1
Shikama, H1
Fujikura, T1
Fockens, P1
Bartelsman, JF1
Moreau, S2
Zylberait, D1
Majello, E1
Pezzella, G1
Giuseppe, S1
Giotta, F1
Riccardi, F1
Fortunato, S1
Kok, TC3
Splinter, TA2
Spry, NA1
Walker, QJ1
Stock, E1
Orenberg, EK1
Yu, NY1
Kanekal, S1
Brown, DM1
Windsor, AC1
Somers, SS1
Hassan, S1
Macadam, R1
Sadek, SA1
Ragnhammar, P1
Blomgren, H2
Gonda, T1
Hojo, I1
Fukunari, H1
Grossi, F1
Tixi, L2
Sanchez, W1
Alvarado, I1
Wagener, DJ6
Hoogenraad, WJ1
Lusinchi, A4
Taal, BG3
de Graeff, A1
Amos, EH1
McCarty, PJ1
Gage, JO1
Emlet, JL1
Lowrey, GC1
Peterson, CA1
Amos, WR1
Nakaizumi, A1
Uehara, H1
Matayoshi, Y1
Jacobson, J1
Panella, TJ1
Ron, IG2
Lotan, A1
Inbar, MJ1
Rosenstein, ED1
Kramer, N1
Leitner, SP1
Michaelson, RA1
Tan, EH1
Ang, PT2
Bushunow, PW1
Kirkwood, J1
Skarlatos, J1
Kosma, L1
Koukourakis, M1
Zambatis, C1
Kapsoritakis, A1
Mouder, N1
Yannakakis, D1
Kubo, Y1
Kurita, A1
Saeki, T1
Goey, SH1
Gratama, JW1
Ward, U1
Mertelsmann, RH1
Osterwalder, B2
Verweij, J2
Stoter, G2
Palmieri, G2
Nicollela, D1
Ianniello, GP1
Montella, M1
Frasci, G1
Perna, M1
Kikuyama, M1
Murohisa, G1
Suzuki, F1
Tsugiki, M1
Souda, K1
Yoshimi, T1
Van Laar, JA1
Smid, K3
Kuiper, CM1
Pinedo, HM3
Joffe, JK1
Hughes, M1
Wardley, A1
Meehan, M1
Rigg, A1
Gore, M1
Moore, H1
Rath, U2
Oliver, I1
Svensson, C2
Ravikumar, TS2
Dixon, K1
Ebie, N1
Millikan, K1
Murthy, AK1
Griem, K1
Recine, DC1
Doolas, A1
Taylor, S2
Sporn, JR2
Slater, D1
Cohen, N1
Greenberg, BR1
Schneider, HJ1
Sampson, SA1
Andreyev, HJ2
Tilsed, JV1
Clarke, PA1
Yamazaki, N1
Takasaki, S1
Masumoto, N2
Tabata, H1
Onodera, H1
Nishitai, R1
Maetani, S1
Dimpfl, T1
Stumpfe, M1
Baltzer, J1
Genz, T1
Deeb, LS1
Yamout, BI1
Shamseddine, AI1
Shabb, NS1
Uthman, SM1
Ohno, M2
Moriwaki, R1
Kohno, M1
Tadatomo, H1
Koyanagi, Y3
Takayanagi, N1
Anakura, T1
Ostkamp, K1
Wagner, W1
Pötter, R1
Moriuchi, S1
Kaba, SE1
Kyritsis, AP1
Hess, K1
Yung, WK1
Mercier, R1
Dakhil, S1
Jaeckle, KA1
Levin, VA1
Lucchi, E1
Favre, R1
Hyams, DM1
Mamounas, EP1
Petrelli, N2
Rockette, H3
Jones, J3
Deutsch, M1
Wickerham, L1
Fisher, B2
Kitao, Y1
Yasuoka, R1
Miyagaki, T1
Ekström, K1
Hoffman, K1
Sjödén, PO1
Haglund, U1
Enander, LK1
Sellström, H1
Heuman, R1
Shanahan, F1
Qian, C1
Kocha, WI4
Graham, M2
Chan, AK1
Wong, AO1
Langevin, JM1
Jenken, DA1
Heine, JA1
Buie, WD1
Johnson, DR1
Yoshimori, M2
Weiden, PL3
Thompson, T2
Stain, S2
Casagrande, Y1
Vignoud, J1
Le Bail, N2
Grann, A2
Bass-Loeb, J1
Lefranc, JP1
Blondon, J1
Buffat, L1
Deniaud, E1
Belkacémi, Y1
Benmiloud, M1
Huart, J1
Laugier, A1
Schlienger, M1
Martino, RL1
Morrell, LM2
Dandekar, NP1
Dalal, AV1
Tongaonkar, HB1
Kamat, MR1
Petroni, GR1
Vaughn, DJ2
Holroyde, C1
Nuamah, I1
Armstead, B1
Graiff, C1
Nelli, P1
Vicario, G1
Sgarbossa, G1
Pancheri, F1
Manente, P1
Okabo, S1
Shimoju, K1
Sakurazawa, K1
Yabata, E1
Saitoh, S2
Tamura, Y2
Hizawa, Y1
Munakata, A2
Raghunathan, K1
Schmitz, JC1
Priest, DG1
Kumagai, K1
Ueki, K1
Inoki, C1
Orino, I1
Ueki, M2
MacLeod, C1
Moylan, E1
Piazza, GA1
Rahm, AK1
Finn, TS1
Fryer, BH1
Stoumen, AL1
Pamukcu, R1
Ahnen, DJ1
Lin, P1
Ichikawa, A1
Baker, P1
Beger, H2
Link, K2
Büchler, M1
Brashear, A1
Siemers, E1
Chung, YS1
Nakata, B2
Onoda, N2
Sowa, M2
Oikawa, I3
Mukaiya, M3
Hiraike, N1
Takasaka, H2
Katsuramaki, T2
Yamashiro, K1
Tomoda, H1
Saito, T2
Miura, M2
Yamazaki, S1
Ikeyama, S1
Taki, S1
Ishikawa, M1
Yogita, S1
Kamm, YL1
Lerner-Tung, MB1
Chang, AY1
Ong, LS1
Kreiser, D1
Blijham, GH1
Sakamoto, S3
Iwama, T1
Tsukada, K1
Sagara, T1
Murakami, S3
Kudo, H2
Okayasu, I1
Jones, DR1
Egan, TM1
Parker, LA1
Konovalova, NP1
Volkova, LM1
Tat'ianenko, LV1
Kotel'nikova, RA1
Iakushchenko, TN1
Kagiia, T1
Street, JC1
Alfieri, AA1
Koutcher, JA1
Wender, DB1
Schroeder, G2
Ghosh, C1
Kirschling, RJ1
Kamthan, AG2
Morris, JC1
Mandeli, JP1
Leben, D1
Cooperman, A2
Lu, J1
Rakovitch, E1
Fyles, AW1
Pintilie, M1
Leung, PM1
Girinsky, T1
Marsiglia, H1
Dhermain, F1
Randrianarivelo, H1
Proulx, GM1
Daley, W1
Athanassiadou, P1
Athanassiades, P2
Petrakakou, E1
Zerva, C1
Mavrikakis, M1
Murray, CL1
Ford, WJ1
Swenson, KK1
Heros, D1
Sperduto, PW1
von Schlippe, M1
Becker, M3
Larto, MA1
Kirby, TJ1
Koka, A1
Tefft, M1
Irwin, JF1
Waterfield, W1
Poussin-Rosillo, H1
Sardi, A1
Hejna, MH1
Weinlaender, G1
Vorbeck, F1
Fiebiger, WC1
You, NC1
Kim, CB1
Fushiki, H1
Hidaka, T1
Fujimura, M1
Yamakawa, Y1
Izumi, R1
Fujita, A2
Takabatake, H1
Tagaki, S1
Sekine, K2
Kudo, T2
Kuwahara, H1
Takamatsu, S3
Sugano, N2
Hiddemann, W1
Sugawara, T1
Omodei Zorini, C1
Deffontaines, D1
Scholl, S1
Hara, S1
Hashizume, S1
Itoyanagi, N1
Tagawa, Y1
Tsuji, H2
Shinguu, H1
Tou, K1
Tooyama, H1
Yamazumi, K1
Okawa, MK1
Kokubo, N1
Karasawa, K1
Fukuhara, N1
Toda, J1
Kuroda, C1
Matsumoto, N1
Ueno, T2
Liang, S1
Koshiji, M1
Taketani, S3
Hioki, K3
Ikehara, S4
Murotani, M1
Iihara, K1
Takami, M1
Kitada, M1
Tsukahara, Y1
Niinobu, T1
Hanada, M1
Nose, T1
Yuasa, Y1
Miki, H2
Noguchi, S2
Tazaki, N1
Kida, T1
Pace, R1
Giunta, S1
Gallà, DA1
Silecchia, GF1
Franchi, F3
Narduzzi, C1
Kawabata, K1
Nio, Y3
Padhani, A1
Prendiville, J1
Massey, A1
Popescu, R1
Pokorny, RM1
Wrightson, WR1
Lewis, RK1
Paris, KJ1
Hofmeister, A1
LaRocca, R1
Myers, SR1
Ackerman, D1
Galandiuk, S1
O'Hagan, S1
Diamond, T1
Landreaneau, RJ1
Day, R1
Ferson, PF1
Keenan, RJ1
Seeger, J1
Lembersky, B2
Dresler, C1
Kahn, M1
Fitzgibbons, RJ3
Shepherd, L1
Vukov, AM1
Figueredo, A1
Konda, B1
Look, KY1
Valea, FA1
McGehee, R1
Manetta, A2
Webster, KD1
Andersen, WA1
Frassineti, GL1
Vinci, M1
Caroti, C1
Ciferri, E1
Verdi, E1
Sasahara, K1
Kamei, M1
Surico, N1
Ribaldone, R1
Warzelhan, J1
Byram, D1
Bell, R1
Bond, R1
Vaughan, S1
McLennan, R1
Lim-Joon, M1
Wada, M1
Longo, GS2
Izzo, J1
Tong, WP1
Zielinski, Z1
Gorlick, R2
Chou, TC1
Pfreundner, L2
Baier, K1
Schwab, F1
Willner, J1
Bratengeier, K2
Feustel, H2
Fuchs, KH1
Rossi, BM2
Nakagawa, WT2
Novaes, PE1
Filho, WD1
Lopes, A2
Ojugo, AS1
McSheehy, PM2
Stubbs, M2
Alder, G1
Bashford, CL1
Maxwell, RJ1
Leach, MO1
Judson, IR1
Griffiths, JR2
Friedrich, M1
Daniel, PT1
Benter, T1
Bauer, B1
Dietz, R1
Kimoto, M1
Mure, T1
Onuma, E1
Iki, K1
Tadaoka, Y1
Majima, T2
Kawasaki, S1
Kubozoe, T1
Tsunoda, T2
Kajihara, K1
Akama, F1
Ninomiya, H1
Shigeta, K1
Sano, I1
Iwasaki, K1
Yokomori, T2
Iesato, H2
Ouya, T1
Blumenson, LE1
Flett, MQ1
Propert, KJ1
Trump, D1
Wilding, G1
Hudes, G1
Burch, P1
Keller, A1
Loehrer, P1
Shinohara, N1
Demura, T1
Toyoda, K1
Kashiwagi, A1
Ohmuro, H1
Ohzono, S1
Koyanagi, T1
Mantini, G1
Barbaro, B1
Cogliandolo, S1
Ambesi-Impiombato, F1
Tedesco, M1
Miles, JS1
Fu, J1
Banerjee, D1
Jhanwar, S1
Cailleux, PE1
Alleaume, C1
Maillet, ML1
Sire, M1
Person-Joly, MC1
Maigre, M1
Maillart, P1
Fety, R1
Dumesnil, Y1
Geslin, J1
Gesta, P1
Danquechin-Dorval, E1
Larra, F1
Chen, CL1
Marczell, A4
Karner, J2
Salem, G1
Greiner, R1
Burger, D1
Stöger, F1
Ritschel, J1
Kovats, E1
Vischer, HM1
Donegan, J1
Reed, C1
Yamane, N1
Taniguchi, T1
Duley, JA1
Nethersell, AB1
Kawashima, K1
Kamiyama, H1
Stein, ME1
Drumea, K1
Yarnitsky, D1
Benny, A1
Tzuk-Shina, T1
Casucci, D1
Gulino, A1
Frati, L1
Sanz-Altamira, PM1
Ferrante, K1
Jenkins, RL1
Lewis, WD1
Huberman, MS2
Stuart, KE1
Bozec, L1
Bierling, P1
Fromont, P1
Debat, P1
Bours, V1
Jerusalem, G1
Fillet, G1
Nüsslein, S1
Katalinic, A1
Lu, JD1
Kim, RY2
Iba, T1
Yagi, Y1
Kidokoro, A1
Ishi, K1
Koyatsu, J1
Sumi, S2
Kidouchi, K1
Yamamoto, N1
Deguchi, T1
Kuriyama, M1
Yoh, M1
Nakano, M1
Kawada, Y1
Shinoda, I1
Steyn, RS1
Vijeyasingam, R1
Cullen, MH3
Burke, SJ1
Percarpio, BA1
Knight, DC1
Kwasnik, EM1
Belsanti, V1
Marzola, M2
Corgna, E1
Sdrobolini, A3
Figoli, F3
Algeri, R2
Ujiie, S1
Kanamaru, R3
Crawley, C1
Takasaki, M3
Takamatsu, M1
Horimi, T3
Takahashi, I3
Peters, HD1
Possinger, K2
Hietschold, SM1
Pincemaille, B1
Besançon, C1
Balme, B1
Devaux, Y1
Thomas, L1
Scher, RM1
Provins, S1
Ho, DH1
Covington, W1
Brown, N1
Huo, YY1
Lassere, Y1
Kuritani, J1
de Souza, PM1
Gansl, R1
Sousa, AH1
Kobayashi, A1
Caujolle, C1
Gastaud, P1
Montoya, ML1
Demarquay, JF1
Delmont, JP1
Kuniyasu, T1
Tabuchi, Y1
Mullany, S1
Svingen, PA1
Kaufmann, SH1
Lozac'h, P1
Topart, P1
Volant, A1
Gonzales, A1
Lu, K1
Harrison, LB1
Mychalczak, B1
Anderson, L1
White, C1
Fisher, BJ1
Perera, FE1
Bauman, GS1
Taylor, M1
Vincent, MD1
Plewes, EA1
Engel, CJ1
Stitt, LW1
Navarro, M2
Herait, P3
Aebi, S2
Fink, D1
Gordon, R1
Fink, JL1
Cheshire, PJ4
Stewart, CF1
Hallman, JD1
Lutz, L1
Luo, X1
Park, HC1
Yoon, HJ1
Choi, YM1
Cho, KS1
Lindner, H1
Dikken, C1
Sitzia, J1
Goswitz, MS1
Raijman, I4
Lenzi, R3
Cripps, C2
Goel, R2
Oza, AM1
Skillings, JR1
Kerr, I1
Germond, CJ1
Maroun, JA2
Franssen, E1
Dulude, H1
Ginsberg, R1
Pajak, TF1
Sheahan, DG1
Gunderson, L1
Estes, N1
Okamoto, M1
Kasetani, H1
Kaji, R1
Goda, H1
Ohe, G1
Bold, RJ1
Takashima, T1
Bousquet, J1
Slim, K1
Alexandre, M1
Chipponi, J1
Suwa, H1
Hosotani, R2
Okino, T1
Monden, K1
Arii, S1
Kogire, M3
Ohshio, G1
Fukumoto, M1
Ferry, DR2
Aziz, SA1
Tramboo, NA1
Mohi-ud-Din, K1
Iqbal, K1
Jalal, S1
Ahmad, M1
Bavisotto, LM1
Patel, NH1
Althaus, SJ1
Coldwell, DM1
Nghiem, HV1
Storer, B1
Au, E3
Seow-Choen, F2
Soo, KC2
Low, CH2
Chng, HC1
Ng, BK2
Gil-Delgado, M1
de Gramond, A1
Khayat, D1
Valencak, J1
Weinländer, G1
Fiebiger, W1
Miholic, J1
Seto, Y2
Masamune, R1
Kunii, Y1
Djordjevic, B1
Lange, CS1
Schwartz, MS1
Ueno, Y1
Yoshikawa, H1
Tanihata, H1
Masuda, M1
Matsuda, T1
Mabuchi, K2
Kitaoka, H1
Hirata, N1
Kitaoka, U1
Kawabata, Y1
Yano, S2
Ohishi, T1
Darut-Jouve, A1
Coudert, B1
Jolimoy, G1
Belichard, C1
Arnoud, L1
Guerrin, J2
Duan, C1
Leng, A1
Serravezza, G1
Lelli, G1
Nicolella, G1
Brandi, M1
Kimura, H1
Corral, P1
Rodríguez-Coria, D1
Goldblum, J1
Medendorp, SV1
Pimentel, R1
Gitlin, L1
Sabaawy, HE1
Farley, T1
Ahmed, T2
Feldman, E2
Abraham, NG2
Bender, H1
Bangard, N1
Metten, N1
Bangard, M1
Mezger, J1
Schomburg, A1
Biersack, HJ1
Khalil, A2
Seoud, M2
Kahwaji, S2
Taher, A1
Bizri, AR1
Medawar, W2
Ibrahim, K1
Habbal, Z1
Klas, JV1
Rothenberger, DA1
Kissel, J1
Zaers, J1
Bellemann, ME1
Strauss, LG1
Brix, G2
Warner, E1
Jensen, JL1
Khoo, KE1
Kerr, IA1
Fields, AL2
Hrincu, A1
Fushida, S2
Taniguchi, K2
Bando, E2
Michiwa, Y1
Fujimura, T2
Yonemura, Y2
Pegram, M1
Hsu, S1
Lewis, G1
Pietras, R1
Beryt, M1
Sliwkowski, M1
Coombs, D1
Baly, D1
Kabbinavar, F1
Slamon, D1
Sause, W1
Bundy, BN1
Malfetano, JH1
Hannigan, EV1
Clarke-Pearson, DL1
Liao, SY1
Mamounas, E1
Wieand, S1
Bear, HD2
Atkins, JN2
Song, K1
Sabaawy, HM1
Quan, S1
Kancherla, R1
Masaki, T1
Partyka, S1
Dumas, P2
Baek, HJ1
Kim, YC1
Shim, YM1
Kim, CM1
Zo, JI1
Shankar, A1
Renaut, AJ1
Whelan, J1
Blot, E1
Marie, I1
Delastre, O1
Cailleux, N1
Lévesque, H1
Courtois, H1
Kuriyama, S1
Mitoro, A1
Tsujinoue, H1
Toyokawa, Y1
Okamoto, S1
Fukui, H2
Funahashi, Y1
Koyanagi, N1
Sonoda, J1
Kitoh, K1
Yoshimatsu, K1
Imaseki, H1
Asato, Y1
Yoshimi, F1
Ono, H1
Amemiya, R1
Miya, T1
Goya, T1
Ohnuma, S1
Takenami, K1
Hosoya, Y1
Kitoh, Y1
Kobayashi, E1
Okabe, R1
Fujimura, A1
Arber, N1
Beger, HG1
Korc, M1
Chakravarthy, A2
Sohn, TA1
Haulk, TL1
Ord, S1
Streeter, OE1
Martz, KL1
Delrowe, JD1
Asbell, SO1
Salter, MM1
Roach, M1
Doidy, L1
Sabourin, JC1
Bonvalot, S1
Nabai, H1
Mohindra, R1
Mehregan, D1
Waller, CF1
von Lintig, F1
Daskalakis, A1
Musahl, V1
Lange, W1
Damle, S1
Wolf, E1
Kito, T1
Okabayashi, K1
Mehran, R1
Maroun, J1
Crepeau, A1
Iwata, R1
Ido, T1
Gamo, M1
Evrard, A1
Cuq, P1
Ciccolini, J1
Vian, L1
Cano, JP1
Hürny, C2
Otani, S1
Iwagaki, H1
Jikuhara, A1
Tagashira, H1
Nagao, A1
Isozaki, H1
Hizuta, A1
Skradis, A1
Kolar, C1
Kolath, J1
Anderson, J1
Lawson, T1
Talmadge, J1
Gmeiner, WH1
Yorozu, A1
Dokiya, T2
Oki, Y1
Allen, DC1
Fon, LJ1
McAleer, JJ1
Irwin, ST1
Keizer, HJ1
Hermans, J2
Klementschitsch, P1
Sakukawa, R1
Saiki, I1
Shapiro, JD1
Harold, N1
Takimoto, C1
Vaughn, D1
Liewehr, D1
Monahan, B1
Lash, A1
Flemming, D1
Behan, K1
Quinn, M1
Morrison, G1
Yamamoto, W1
Hanaoka, H1
Matsukawa, M1
Jones, SE1
McIntyre, K1
Mennel, R1
Orr, D1
Kirby, R1
Agura, E1
Duncan, L1
Roque, T1
Regan, D1
Schuster, M1
Dimitrov, N1
Garrison, L1
Lange, M1
Fata, F2
Viens, P1
Janvier, M1
Fabbro, M1
Labat, JP1
Linassier, C1
Audhuy, B1
Feuilhade, F1
Costa, B1
Rousseau, F1
Guillot, A1
Jacquemier, J1
Oka, S2
Kondo, A1
Maeta, M1
Gravina, A1
Faranda, A1
Comis, S2
O'Byrne, KJ1
Propper, DJ1
Braybrooke, JP1
Bates, NP1
Taylor, MA1
Madigan, D1
Ganesan, TS1
Harris, AL2
Silva, RR1
Martignoni, G1
Gasparini, G2
Baldelli, AM1
Giuliodori, L1
Agostinelli, R1
Paulino, AC2
Keppen, MD1
Dalton, RJ2
Gerstner, JB1
Jancewicz, MT1
Ebbert, LP1
Fonck, M2
Grogan, M1
Melamed, I1
Wong, FL1
Pearcey, RG1
Joseph, PK1
Portelance, L1
Crook, J1
Jones, KD1
Horsell, KW1
Merten, S1
King, DW1
Levitt, M1
House, A1
Robbins, P2
Vieceli, G1
Marchiori, E1
Chidel, MA1
Kupelian, PA1
Antonuzzo, A1
Brunetti, I1
Pfanner, E2
Conte, P2
Lutz, MP1
Königer, M1
Muche, R1
Ellenrieder, V1
Steinkamp, M1
Gress, TM1
Bensmaine, MA1
Lucas, V1
Dupont-André, G1
Nomura, E1
Sako, S1
Otani, M1
Wakahara, M1
Ooshita, H1
Kanno, A1
Suhara, T1
Nakata, T1
Saitou, S1
Takata, N1
Harada, K1
Yoshinaka, I1
Maeda, M1
Hargraves, K1
Curley, S1
Popescu, RA1
Parikh, B1
Tocchi, A1
Lepre, L1
Costa, G1
Liotta, G1
Mazzoni, G1
Agostini, N1
Miccini, M1
Larzillière, I1
Brandissou, S1
Breton, P1
Lingoungou, A1
Ramain, JP1
Harnois, C1
Oyaizu, H1
Ikebukuro, K2
Tokunaga, R2
Ganser, A1
Wiese, KH1
Rambusch, E1
de Vries, MJ1
Hanauske, A1
Sasaki, J3
Tanaka, O3
Tsutsui, M1
Fukuzawa, S1
Cordel, S1
Goupille, C1
Hallouin, F1
Meflah, K1
Le Pendu, J1
Ninomiya, Y1
Yanagisawa, A1
Kitagawa, T2
Taieb, S1
Vaillant, E1
Pommier, P1
Bonvoisin, S1
Morignat, E1
Page, C1
Beidler, DR1
Wicha, MS1
Núñez, G1
Carr, JA1
Ajlouni, M1
Wong, D2
Velanovich, V1
Danikas, D1
Theodorou, SJ1
Arvanitis, ML1
Zinterhofer, LM1
Rienzo, AA1
Petroianu, A1
Cabral, LO1
Carpi, A2
Frassoldati, A2
Mosconi, A1
Borrini, A1
Buzzi, P1
Kucuk, O1
Pandya, KJ1
Skeel, RT3
Peracchia, A1
Bonavina, L1
Via, A1
Incarbone, R1
Farczádi, E1
Kaszás, I1
Benyó, I1
Bodnár, Z1
Szlobodnyik, J1
Szende, B1
Turnbull, AD1
Sullivan, D1
Stockman, J1
Blumgart, LH1
Klinkenbijl, JH1
van Pel, R1
Arnaud, JP3
Gonzalez, DG1
de Wit, LT1
Hennipman, A1
Thirion, P1
Haddad, E1
Gogas, H1
Sasano, H1
Ohi, R1
Imaizumi, M2
Shineha, R1
Shibuya, D1
Matsumoto, G1
Ise, H1
Müller, HH2
Schratter-Sehn, A1
Krauss, G1
Locker, G1
Ashizawa, T1
Sumi, T1
Murohashi, T1
Minari, Y1
Itakura, M1
Yamasawa, K1
Musha, N2
Sando, N2
Setu, Y1
Setu, M1
Oka, K2
Hudec, WA1
Talamini, MA1
Kaufman, HS1
Canto, MI1
Topazian, M1
Olukayode, K1
Gambiez, L1
Denimal, F1
Karoui, M1
Dewailly, V1
Pruvot, FR1
Quandalle, P1
Han, Q1
Takenoue, T2
Koyama, K3
Dickie, G1
Hodge, R1
Morton, K1
Wilson, KS1
Minatoya, T1
Ajisaka, H1
Iwatani, Y1
Iwasaki, T1
Sinmaru, H1
Takeuchi, I2
Idezuki, Y2
Hohya, I1
Nihei, T1
Colonna, M1
Bellaïche, A1
Parc, R1
Ukarapol, N1
Wongsawasdi, L1
Singhavejsakul, J1
Alexander, EP1
Lipman, T1
Harmon, J1
Wadleigh, R1
Takeda, N1
Ishihata, R1
James, RD1
Karasek, P1
Jandik, P1
Alakl, M1
Gruia, G1
Daly, JM1
Deuffic, S1
Pelissier, E1
Favre, JP1
Jaeck, D1
Fourtanier, G1
Grandjean, JP1
Marre, P1
Israel, ZH1
Lossos, A1
Barak, V1
Soffer, D1
Siegal, T1
Arthur, DW1
Schmidt-Ullrich, RK1
Friedman, RB1
Kachnic, LA2
Amir, C1
Hackney, MH1
Lawrence, W3
Levy-Piedbois, C1
Durand-Zaleski, I1
Juhel, H1
Schmitt, C1
Bellanger, A1
Janinis, J1
Skarlos, D1
Papagianopoulos, P1
Aki, Z1
Kotiloğlu, G1
Ozyilkan, O1
Fan, FS1
Toki, J1
Bergmann-Leitner, ES1
Abrams, SI1
Lavrenkov, K1
Kawahara, M2
Takii, Y1
Teng, HC1
Hung, HC1
King, KL1
Chi, KH1
Chang, FY1
He, Z1
Fei, H1
Latona, C1
Kawamura, K1
Tasaki, K1
Takenaga, K1
Sakiyama, S1
Tagawa, M1
Hochmuth, K1
Collette, M1
Yoshimasu, T1
Oura, S1
Maebeya, S1
Tanino, H1
Bessho, T1
Arimoto, J1
Sakurai, T1
Matsuyama, K1
Suzuma, T1
Hirai, I1
Unno, J1
Shirozaki, T1
Arai, S2
Okuyama, H1
Hayashida, N1
Kouda, S1
Tadokoro, M1
Ishikou, T1
Touda, J1
Kajiwara, M1
Midgley, RS1
Marshall, ME1
O'Rourke, M2
Barnett, TC1
Olmeo, N1
Cavicchi, F1
Contu, A1
Hinoshita, E1
Uchiumi, T1
Taguchi, K1
Tsuneyoshi, M1
Kuwano, M1
Westermann, AM1
Swart, M1
Craanen, M1
Gerritsen, WR1
Wientjes, MG1
Gan, Y1
Au, JL1
Ducreux, MP1
Lacave, AJ1
Planker, M1
Santos, JG1
Bodenstein, H1
Kin, R1
Nishimoto, N1
Hirai, T1
Kamata, T1
Nakamoto, A1
Onishi, I1
Takeda, T1
Koyasaki, N1
Kanno, M1
Shinkawa, H1
Wada, N1
Naka, S1
Yasuhara, H1
Kuroda, T1
Nojiri, T1
Nagao, T1
Nagao, K1
Kawasaki, H1
Matsunaga, T1
Nakagawa, N1
Yabana, T1
Yasojima, T1
Furuhata, T1
Hata, F1
Yovine, A1
Hsu, KC1
Chang, TC1
Oh, CM1
Bleeker, WA1
Otter, R1
Cornalba, G1
Smerieri, F1
Paradiso, J1
Kiefer, L1
McCart, JA1
Puhlmann, M1
Libutti, SK1
Bartlett, DL1
Feng, J1
Zheng, X1
Dai, A1
Alektiar, KM1
Zelefsky, MJ1
Powell, B1
Grieu, F1
Menso, L1
Nukui, Y1
Kwok, QS1
Banerji, U1
Townsend, ER1
Homerin, M1
Hmissi, A1
Hendler, D1
Haag, C2
Lingenfelser, T1
Baronius, W2
Hempel, V2
Ezekiel, G1
Walfisch, S1
Di Paolo, AD1
Innocenti, F1
Melosi, A1
Battistoni, M1
Barsanti, G1
Ahmed, S2
Du, W2
Arlauskas, P1
Gordon, C1
Kellogg, C1
Kim, CD1
Um, SH1
Jacobson, JL1
Modiano, M1
Moore, DF1
Schroder, LE1
Nita, ME1
Ono-Nita, SK1
Tsuno, N1
Tominaga, O1
Nakagami, K1
Sugitani, K1
Ohya, T1
Fukutomi, K1
Ohkuma, K1
Hisano, C1
Kaji, Y1
McGrath, P1
Strodel, WE1
Suh, CO1
Talamonti, MS1
Harbison, SP1
Stiller, GD1
Henry, DH1
Fisher, SA1
Kikunaga, H1
Sotome, K1
Morisue, A1
Matsudo, A1
Nakai, H1
Takao, M1
Osakabe, Y1
Miura, H1
Momono, S1
Iwata, S1
Taki, Y1
Waddell, BE1
Lee, RJ1
Weber, TK1
András, C1
Csiki, Z1
Gál, I1
Takács, I1
Antal, L1
Szegedi, G1
Delauter, BJ1
Stover, LL1
Zuhowski, EG1
Plunkett, W1
Zamboni, WC1
Noh, JK1
Kastl, S1
Brunner, T1
Herrmann, O1
Riepl, M1
Grabenbauer, G1
Klein, P1
Peyrat, JP1
Abecassis, J1
Millon, R1
David, JS1
Gueugniaud, PY1
Hepp, A1
Gaussorgues, P1
Petit, P1
Hess, KR2
Korman, LT1
Zahurek, ML1
O'Reilly, S1
Hurwitz, H2
Katoh, M1
Koninkx, J1
Schumacher, U1
Hasuike, Y1
Nishisho, I1
Ukei, T1
Oozato, H1
Lammering, G1
Hartmann, KA1
Frenken, M1
Aryus, B1
Döker, R1
Ulrich, B1
Iwamoto, M1
Niiya, F1
Ikeda, S1
Nagata, S1
Odou, E1
Hayabuchi, N1
Ida, K1
Kamiya, T1
Gilles, V1
Molitor, JL1
Ratanatharathorn, V1
Sirachainan, E1
Jirajarus, M1
Sirilerttrakul, S1
Eckel, F1
Lippl, F1
Assmann, G1
Schulte-Frohlinde, E1
Rauch, DP1
Maurer, CA1
Pampallona, S1
Ludwig, CU2
Debernardis, D1
Tunesi, G1
Maley, F1
Ott, MJ1
Ryan, D1
Benoit, R1
Grobost, O1
Chalmet, P1
Knegt, PP1
Ah-See, KW1
vd Velden, LA1
Kerrebijn, J1
Rotholtz, N1
Pisano, M1
Kaplan, E1
Secic, M1
Coucke, P1
Pikarsky, A1
Weiss, E1
Haie-Meder, C1
Lhommé, C1
de Crevoisier, R2
Morice, P1
Resbeut, M1
Kamiya, N1
Asano, S1
Shinya, F1
Turrisi, A1
Iannettoni, M1
Strawderman, M1
Furuyama, JI1
Hashimoto-Tamaoki, T1
Gerhardt, P1
Schnirer, II1
Putnam, J1
Feng, C1
Paty, PP1
Löhr, JM1
Breslin, TM1
Harbison, DB1
Jean, ME1
Dackiw, AP1
Motegi, M1
Sasamoto, H1
Wada, W1
Raina, V1
Gujral, S1
Matsuno, S1
Boffi, B1
Francesconi, D1
Mazzanti, R1
Medi, F1
Siliani, L1
Tarquini, R1
Moretti, R1
Gneiting, T1
Kreczy, A1
Pfeiffer, KP1
Shaw, JE1
Manning, MA1
Lauve, AD1
Neifeld, JP1
Moore, MB1
Aloia, T1
Sporn, T1
Linoila, I1
Backus, HH1
Dukers, DF1
van Groeningen, CJ2
Vos, W1
Bloemena, E1
Wouters, D1
van Riel, JM1
Giaccone, G2
Siu, W1
Kapp, DS1
Wren, SM1
King, C1
Terris, MK1
Sekikawa, T1
Tsukui, H1
Kina, S1
Kawahara, T2
Kishida, Y1
Yakumaru, K1
Kagami, H1
Kamiya, K1
Baba, M1
Oota, M1
Shouji, T1
Igarashi, A1
Eguchi, T1
Imai, S1
McNevin, MS1
Gross, EK1
Whiteford, HM1
Lewis, JL1
Mueller, HH1
Mattes, E1
Gassel, HJ1
Schramm, H1
Staib-Sebler, E1
Vetter, G1
Heinrich, S1
Jan, YY1
Liau, CT1
Gibbs, JF1
Cao, S1
Aoki, Y1
Tsuneki, I1
Onaitis, MW1
Noone, RB1
Hartwig, M1
Morse, M1
Jowell, P1
McGrath, K1
Clary, B1
Tyler , DS1
Frykholm, GJ1
Katai, H1
Domenge, C1
Wibault, P2
Koscielny, S1
Bobin, S1
Luboinski, B1
Eschwege, F2
Bourhis, J1
Kovàcs, G1
Saghatchian, M1
Fizazi, K1
Borel, C2
Ruffié, P2
De Filippis, S1
Rosselli, M1
Pompili, PL1
Koo, WH1
Chua, EJ2
Hoe, M1
Petit, T1
Ghnassia, JP1
Rodier, JF1
Escande, A1
Mors, R1
Haegelé, P1
Mahyar-Roemer, M1
Roemer, K1
Schache, DJ1
Bell, A1
Selle, F1
Shelton, CH1
Minasi, JS1
Lew, JI1
Gooding, WE1
Safatle-Ribeiro, AV1
Hundt, A1
Sturm, J2
Knoll, MR1
Petryk, M2
Evans, A1
Cooperman, AM1
Hammerman, H1
Siegel, J1
Stark, B1
Bank, S1
Nesbitt, J1
Martin, FD1
Staren, ED1
Iwamura, T1
Appert, HE1
Howard, JM2
Ratkin, GA1
Kuranaga, N1
Shinomiya, N1
Mochizuki, H1
Böhm, B1
Helfritzsch, H1
Thiele, M1
Altendorf-Hofmann, A1
Scheele, J1
Archer, VR1
Mulholland, PJ1
Virkkunen, P1
Kohno, H1
Kimoto, T1
Dhar, DK1
Kubota, H1
Tachibana, M1
Reading, DM1
Gunn, IF1
Green, MD2
McLaughlin, SJ1
Pedersen, JS1
McGinty, J1
Parda, D1
Karlovits, S1
Davis, C1
Caushaj, P1
D'Agnano, I1
Vasselli, S1
Perrone Donnorso, R1
D'Angelo, C1
Brenna, A1
Benevolo, M1
Zupi, G4
Yamashita, A1
Maruo, K1
Shirota, K1
Baz, DV1
Bofill, JS1
Nogueira, JA1
Lestuzzi, C1
Picano, E1
Meneguzzo, N1
Kammori, M1
Haniuda, N1
Takubo, K2
Endo, H1
Kaminishi, M1
Sunouchi, K1
Higuchi, Y1
Tsurita, G1
Zhan, M1
Jacobson, SD1
Shepherd, LE1
Boz, G1
Rossi, C1
Tosolini, G1
Trovò, MG1
Pories, WJ1
Hillard, J1
Wiley, AL3
Youngblood, R1
McIntyre, DJ1
Howe, FA1
Rodrigues, LM1
Wadsworth, P1
Price, NM1
Nicholson, G1
Noordhuis, P1
Mulligan, E2
Goffre, B1
Zerbib, F1
Saric, J1
Kuhn, R1
Boltze, C1
Allman, D1
Boyer, M1
Jahn, M1
Schmiegel, WH1
Vieitez, JM1
Weitzel, C1
Dencausse, Y1
Dietzler, P1
Bambach, M1
Wojatschek, C1
Lindemann, H1
Qeisser, W1
Heydon, K1
Eifel, P1
Toukairin, H1
Kure, N1
Tamamori, Y1
Nishino, H1
Nishihara, T1
Varvarigos, N1
Kamaradou, H1
Kourti, A1
Papavasiliou, ED1
Papaioannou, H1
Migdalis, IN1
Galanis, C1
Almond, J1
Fernandez-Cruz, L1
Pap, A1
Spooner, D1
Zoetmulder, FA1
Fuwa, N1
Kano, M1
Shikama, N1
Matsumoto, A1
Kamata, M1
Furutani, K1
Tatibana, H1
Raouf, A1
Evoy, D1
Carton, E1
Sweeney, E1
Cristofanilli, M1
Buzdar, AU1
Sneige, N1
Smith, T1
Wasaff, B1
Ibrahim, N1
Booser, D1
Rivera, E1
Murray, JL1
Valero, V1
Singletary, ES1
Hunt, K1
Strom, E1
McNeese, M1
Stelling, C1
Hortobagyi, GN1
Zotter, H1
Schwinger, W1
Kerbl, R1
Urban, C1
Smolle Juettner, FM1
Hinterleitner, T1
Wong, NA1
Brett, L1
Stewart, M1
Leitch, A1
Dunlop, MG1
Lessells, AM1
Jodrell, DI1
White, RR1
Paulson, EK1
Baillie, J1
Branch, MS1
Jowell, PS1
McGrath, KM1
Kresl, JJ1
Henning, GT1
Donohue, J1
Pitot, H1
Nagorney, D1
Baglan, KL1
Frazier, RC1
Huang, RR1
Martinez, AA1
Robertson, JM1
Virik, K1
Ryder, K1
Cowling, M1
Deng, Z1
Lou, X1
Hua, B1
Wang, A1
Caliò, E1
Seminara, P2
Aronne, T1
Sbaffi, E1
Pagani Guazzugli Bonaiuti, V1
Gargano, L1
Escourrou, J1
Pages, P1
Moreau, J1
Faure, P1
Moritani, M1
Fujimitsu, Y1
Shinohara, M1
Niido, T1
Duffaud, F1
Ville, E1
Laugier, R1
Huang, KC1
Cheng, YM1
Hsu, HC1
Wang, SM1
Ford, J1
Edelstein, PS1
Vierra, M1
Bastidas, AJ1
de Wit, R1
Greim, G1
van der Born, K1
Wanders, J1
de Boer, RF1
Peng, ZH1
Xing, TH1
Qiu, GQ1
Tang, HM1
Hsieh, YC1
Miller, LL1
Yee, LK2
Schuler, B1
Chen, AP1
Chabuk, C1
Grabenc, M1
Takimoto, CH1
Kouvatseas, G1
Giannoulis, E1
Androulakis, I1
Rengelshausen, J1
Hull, WE1
Schwenger, V1
Göggelmann, C1
Walter-Sack, I1
Bommer, J1
Zeuli, M1
Di Costanzo, E1
Paoloni, FP1
Cherubini, R1
Abushullaih, S1
Saad, ED1
Munsell, M1
Lim, KC1
Dunlop, DJ1
Koufos, C1
Gomi, T1
Ohtoshi, M1
Tamaki, N1
Momoi, H1
Katayama, T1
Lamont, EB1
Lauderdale, DS1
Schilsky, RL1
Christakis, NA1
Planting, A2
Baujat, B1
Maindrault, F1
Nagata, T1
Kouniavsky, G1
Khaikin, M1
Zvibel, I1
Zippel, D1
Brill, S1
Halpern, Z1
Papa, M1
Honegger, H1
Hanselmann, S1
Müller, S1
Wada, I1
Craig, G1
Nair, S1
Law, A1
Gallagher, J1
Ellison, N1
Bernath, A1
Craipeau, C1
Massacesi, C1
Pistilli, B1
Valeri, M1
Lippe, P1
Rocchi, MB1
Cellerino, R1
Piga, A1
Jang, WI1
Ballo, MT1
Mason, K1
Wong, AB1
Nguyen, Q1
Kouloulias, VE2
Nikita, KS2
Kouvaris, JR2
Uzunoglu, NK2
Golematis, VC1
Papavasiliou, CG1
Vlahos, LJ2
Adamek, HE1
Yachida, S1
Fukushima, N1
Matsuno, Y1
Kosuge, T1
Hirohashi, S1
Ohsawa, T1
Inokuma, S1
Hoshino, T1
Daijo, H1
Davies, MM1
Carnochan, P1
Glover, C1
Kaur, S1
Allen-Mersh, TG1
Shih, CH1
Ruo, L1
Quan, SH1
Spott, C1
Bozzetti, F1
Andreola, S1
Baratti, D1
Stani, SC1
Spinelli, P1
Vaishampayan, UN1
Levin, KJ1
Proulx, G1
Nava, H2
Bodnar, L1
Klippenstein, D1
Smith, J1
Nava, E1
Smith, P1
Greco, W1
Douglass, H1
Paradiso, A1
Ranieri, G1
Silvestris, N1
Costa, A1
De Lena, M1
Leone, A1
Vallejo, C1
Lacava, J1
Calvilio, J1
Escribano, A1
de Castro, J1
Sánchez, ME1
Mata, A1
García Grande, A1
Mateo, A1
González Barón, M1
Joo, HJ1
Yi, JW1
Kim, MW1
Ohta, Y1
Takemura, S1
Kawasaki, M1
de O Ferreira, F1
Ferrigno, R1
David Filho, WJ1
Nishimoto, IN1
Vieira, RA1
Golematis, BC2
Mystakidou, K1
Bergevin, PR2
Patwardhan, VC1
Weissman, J1
Lee, SM1
Barone, RM1
Starichkov, MS2
Nivinskaia, MM1
Bychkov, MB2
Lichinitser, MR1
Chebotareva, LI1
Prostman, TJ1
Lanzotti, VJ2
Thomas, DR1
Holoye, PY1
Boyle, LE1
Smith, TL1
Israel, L2
Depierre, A1
Stevenson, DL1
Mikhailidis, DP1
Gillett, DS1
Xynos, FP1
Hartwich, G2
Neidhardt, B2
Black, K1
Hanna, SS1
Langer, B1
Jirsch, DW1
Rider, WD1
Zeitoun, P2
Lamy, P1
Lamaze, R1
Tutton, PJ1
Barkla, DH1
Young, RC1
Chabner, BA1
Hubbard, SP1
Fisher, RI1
Bender, RA1
Anderson, T4
Simon, RM1
Canellos, GP1
DeVita, VT1
Pazianos, AG1
Salzman, FA1
Stein, TP1
Hargrove, WC1
Miller, EE1
Wallace, HW1
Buzby, GP1
Mullen, JL1
Friedman, M1
Cassidy, M1
Levine, M1
Phillips, T1
Spivack, S1
Resser, KJ1
Goffin, JC2
Maurer, RE4
Volm, M2
Faufmann, M1
MAttern, J2
Wayss, K2
Wasserman, TH1
Hanley, J3
Carbone, PP3
Sych, F1
Habs, M1
Schmähl, D1
McCaffrey, JA1
Polio, J1
Clouse, ME1
Hamilton, T1
Merrin, CE1
Nüvemann, M1
Fernholz, HJ1
Frik, W1
Bernath, AM1
Cohen, MH2
Ihde, DC2
Fossieck, BE1
Matthews, MJ1
Minna, JD2
Grady, ED1
Nolan, TR1
Crumbley, AJ1
Rosen, AR1
Breuel, HP1
Douwes, F1
Bähre, M1
San Luis, T1
Emrich, D1
Seligman, M1
Greenstreet, RL1
Morris, D1
Aisner, J3
Elias, EG3
Reynolds, RD1
O'Dell, S1
Möschl, P1
Lubec, G1
Awrich, A1
Klotz, JH1
Minton, JP1
Hill, GJ4
Aust, JB3
Grage, TB2
Multhauf, PM1
Shoemaker, JP1
Dagher, RK1
Golubeva, VA1
Osipov, NE1
Bukharova, IK1
Priestman, T1
Baum, M1
Jones, V1
Forbes, J1
Alyea, EP1
Dees, JE1
Glenn, JF1
Abdallah, AM1
Bell, G1
Diggs, CH1
Smyth, AC1
Kim, PN2
Ratanatharathron, V1
Wojtaszak, B2
Terz, JJ2
Horsley, JS3
Brown, PW2
Romero, C1
Tanneberger, S1
Kingston, RD1
Ellis, DJ1
Powell, J1
Waterhouse, JA1
Hurst, MD1
Smith, JA1
Klahr, C1
Smith, LF2
Buroker, T3
Dindogru, A1
DeMattia, M1
Groth, C1
Bunn, PA1
Nugent, JL1
Eddy, JL1
Groppe, C2
McCracken, J2
O'Bryan, R1
Panettiere, F1
Coltman, C1
Bottomley, R1
Bonnet, J2
Thigpen, T1
Hoogstraten, B2
Heilbrun, L2
Chauvergne, J1
Berlie, J1
Clavel, B1
Gary-Bobo, J2
Brulé, G1
Klein, T1
Pommatau, E1
Carton, M1
Voznyĭ, EK2
Borisov, VI1
Perevodchikova, NI2
Babaian, LA1
Vaarik, KhM1
Woll, J1
Carbone, P1
Hestorff, R1
Sardoff, L1
Padilla, F1
Guy, G1
Quagliana, J1
Belt, RJ1
Stephens, R1
Schaefer, J1
Arnold, H1
Drings, P1
Geldmacher, J1
Kredel, L1
Mayer, M1
von Oldershausen, HF1
Rösch, W1
Wahrendorf, J1
Vassilopoulos, PP1
Shingleton, WW1
Jubert, AV1
Moss, SE2
Rosenoff, S1
Rake, MO2
Mallinson, CN1
Cocking, JB1
Cwynarski, MT1
Fox, CA1
Wass, VJ1
Diffey, BL1
Jackson, GA1
Kessinger, MA1
Lemon, HM2
Comis, RL4
Davy, M1
Mossige, J1
Johannessen, JV1
Cooney, D1
Eckels, DD2
Salas, H1
Butler, TP1
Solomon, A1
White, LA1
Perry, MC2
Kennedy, BJ2
Weiss, RB1
Lee, YT2
Hartman, HA1
Kessinger, A1
Stone, SP1
Eckels, D1
Palmer, JM1
Staab, R1
Livingston, R1
Wolma, FJ1
Kelly, JP1
Hannam, TW1
Giles, GR1
Soloway, MS2
Shippel, RM1
Ikard, M1
Yakushiji, M1
Ide, K1
Rowling, J1
West, C1
Rózewicki, S1
Rzepka, I1
Górski, H1
Cifuentes de Castro, L1
Lee, PW1
Tomomatsu, H1
Morita, N1
Nagai, T1
Shiwaku, Y1
Shingami, T1
Nakao, Y1
Shimokawahara, H1
Hashimoto, S2
Yunoki, K1
Kutzner, J1
Kempf, P1
Brückner, R1
Rohwedder, JJ1
Sagastume, E1
Khwaja, TA1
Yokoyama, M1
Himori, T1
Dimitriades, M1
Papadimitriou, GC1
Razis, DV1
Panopoulos, C1
Midoulas, N1
Buell, GV1
Bergreen, PW1
Krein, BM1
Eckert, M1
Gerassimidis, T1
Schultess, F1
Hammann, J1
Beck, I1
Hishinuma, H1
Majima, S1
Nakao, E1
Morisawa, K1
Cho, K1
Nishioka, B2
Fischetti, MR1
Weitzman, SA1
Kelley, RM1
Sohier, WD1
DiBenedetto, J1
Moayeri, H1
Evans, JT1
Richardson, RL1
Shulman, SF1
Oldham, RK1
Heppner, GH1
Dexter, DL1
DeNucci, T1
Miller, FR1
Calabresi, P2
Davis, S1
Buscaglia, MD1
Brown, I1
Ward, HW1
Kune, GA1
Hobbs, JB1
Butterfield, D1
Sali, A1
Fichardt, T1
Sandison, AG2
Hillcoat, BL1
McCulloch, PB1
Ehsan, MH1
Rosenfeld, JM1
Nakamura, A2
Bates, IS1
Spittle, H1
Wheeler, T1
Serrou, B1
Sancho-Garnier, H1
Plagne, R1
Metz, R1
Pujol, H2
Block, NL1
Camuzzi, F1
Stover, B1
Claflin, A1
Troner, M1
Politano, VA1
Didolkar, MS1
van Eden, EB2
Mittelman, JA1
Bakemeier, RF1
Cohen, D1
Yron, I1
Grover, NB1
Weiss, DW1
MacFadyen, BV1
Dudrick, SJ3
Souchon, EA1
Watson, P1
Nevin, JE2
Hoffman, AA1
Inoguchi, T1
Yamasaki, I1
Yazuka, K1
Kita, T1
Kuwano, K1
Piver, S1
Chung, WS1
Lee, FT1
Vongtama, V2
Fugmann, RA1
Anderson, JC1
Stolfi, RL1
Martin, DS3
Grage, TD1
Metter, GE2
Cornell, GN1
Strawitz, JG1
Frelick, RW1
Kaufman, JH1
Franz, JL1
Bixenman, WW1
Nicholls, JV1
Warwick, OH1
Malkasian, GD2
Decker, DG2
Jorgensen, EO2
Morgan, DF1
Busuttil, RW1
Li, MC1
Ross, ST1
Reuter, HJ1
Gehan, E1
Abisatov, KhA1
Khan, SV1
Murphy, S1
Huguley, CM1
Belpomme, D1
Huguenin, P1
Morin, P1
Gautier, H1
Laparre, C1
Baron, A1
Collier, D1
Lowitz, BB1
Kane, RD1
Mickey, DD1
Paulson, DF2
Ikram, H1
Plaude, RK1
Osman, VI1
Tabachnik, BI1
Purinia, IZh1
Gutman, EKh1
Merrin, C1
Etra, W1
Baumgartner, G1
Dowell, KE1
Armstrong, DM1
Ingis, DA1
Farmer, RG1
Kas'ianenko, IV1
Horsley, S1
Donaldson, M1
Lovett, WL1
Ruffner, BW1
Regelson, W1
Otis, PT1
Armentrout, SA1
Melnick, I1
Baggerly, JT1
Landes, R1
Easley, CA1
Lee, FJ1
Håkansson, L2
Dahn, I1
Huldt, B1
Tropé, C1
Dencker, H1
Seifert, P1
Reed, ML2
Frank, S1
Richter, K1
Ehrhart, H1
Penning, W1
Meister, P1
Schmidt, D1
Götz, A1
Schimmel, DH1
Julien, PJ1
Gamsu, G1
Schulman, S2
Thorp, GW1
Kirsner, JB1
Rosenberg, IH1
Nichols, M1
Vyas, AC1
Hamilin, R1
Gottlieb, JA3
Freireich, EJ3
Delikaris, PG1
Haritopoulos, NK1
Setakis, NG1
Schifeling, DJ1
Dobelbower, RR3
Merrick, HW3
Bernhardt, G1
Reile, H1
Birnböck, H1
Spruss, T1
Schönenberger, H1
Monma, K1
Sakaki, N1
Tabata, I1
Gazdar, AF3
Beck, H1
Zunino, F1
Capranico, G1
Smith, FW1
Heys, SD1
Evans, NT1
Roeda, D1
Gvozdanovic, D1
Eremin, O1
Mallard, JR1
Sugimoto, Y2
Ohe, Y2
Nishio, K2
Ohmori, T2
Morikage, T1
Saijo, N2
Wu, GR1
Kiyabu, M2
Chandrasoma, P1
Miyama, T1
Hirata, T1
Mafune, K1
Hiraishi, M1
Fielding, LP1
Hittinger, R1
Grace, RH2
Fry, JS1
Paik, S1
Koh, E1
Garten, L1
Gray, R2
Byrd, DR3
Connelly, JH1
Ames, FC3
Laidman, PJ1
Gebauer, K1
Trotter, J1
Vering, A1
Michel, RT1
Mitze, M1
Stegmüller, M1
Bender, HG1
Colofiore, J2
Sawyer, R1
Warszawski, N1
Bohndorf, W1
Nishikata, K3
Daemen, T1
Regts, J1
Morselt, H1
Scherphof, GL1
Hemmingsson, A1
Nyman, R1
Lottsfeldt, JL1
Fevold, KL1
Williams, LG5
Loftin, SK1
Dayan, A1
Luzi Fedeli, S2
Klimberg, VS1
Langston, JD1
Maners, A1
Gocio, JC1
Lang, NP1
Westbrook, KC1
Broadwater, JR1
Broder, LE1
Sridhar, KS2
Selawry, OS2
Charyulu, KN1
Rao, RK1
Saldana, MJ1
Lenz, C1
Ray, M1
Muggia, FM2
Radin, R1
Omura, K1
Ishida, F1
Matsu, T2
Brinkmann, J1
Breier, B1
Tatsuki, Y1
Fujimoto, I2
Yamauchi, K1
Hasumi, K2
Masubuchi, K2
Berruti, A1
Gorzegno, G1
Vitetta, G1
Ober, H1
Ebina, T1
Hosokawa, T1
Kaufman, DS1
Eliseo, R1
Convery, K1
Pisansky, TM1
Schaid, DJ1
Loprinzi, CL1
Schray, MF1
Schomberg, PJ1
Bonhomme, L1
Mathieu, MC1
Amdidouche, D1
Faure, E1
Guisteau, D1
Fredj, G1
Naveau, S1
Pfeffel, F1
Wiltschke, C1
Funovics, J1
Rosvold, E1
Schilder, R1
DiFino, SM1
Banerjee, TK2
Heim, WJ1
Ozols, RF1
de Mulder, PH1
Burghouts, JT2
Dobrowsky, W2
Ammarguellat, H1
Benhamed, M1
Laplaige, P1
Goldberg, J1
Kunimura, T1
Morohoshi, T1
Taguchi, S1
Hatta, Y1
Saito, Y1
Niwa, M1
Maruyama, Y1
Ishizuka, K1
Hasegawa, T1
Ogoshi, K1
Percarpio, B1
Bitterman, J1
Sabbath, K1
Alfano, F1
Ruszkowski, R1
Bowen, J1
Jimeno, J1
Cruz-Hernández, J1
Nishiyama, T1
Sasagawa, T1
Tanikawa, T1
Katayama, Y1
Kawakami, Y1
Terunuma, M1
Ravaud, A1
Bussières, E2
Lagarde, P1
Costa, P1
Wiseberg, J1
McCulloch, W1
Petruska, P1
Andrus, CH1
Johnson, FE1
Peters, T1
Byhardt, RW1
Order, S1
Gallagher, MJ1
Pederson, J1
Wong, SW1
Martz, K1
al-Sarraf, M3
Brindle, J1
Byhardt, R1
Emami, B1
Gray, BN1
Anderson, JE1
Burton, MA1
Codde, J1
Morgan, C1
Klemp, P1
Schuricht, A1
Zhen, YS1
Taniki, T1
Meadows, LM1
Lindley, C1
Ozer, H1
Olweny, C1
Carey, P1
Wajima, T1
Mukhopadhyay, P1
Rausa, L1
Ingria, F1
Spatafora, G1
Zerillo, G1
Cimino, A1
Pastorello, T1
Ferrara, P1
Van Ginckel, R1
Distelmans, W1
De Brabander, M1
Callens, M1
Janssens, B1
Jagers, E1
Wouters, L1
De Coster, R1
Janssen, PA1
Hook, CC1
Scheithauer, BW1
Forsyth, PA1
Rodriguez, M1
Marks, LB1
Halperin, EC1
Prosnitz, LR1
Ross, M1
Vredenburgh, JJ1
Rosner, GL1
Peters, W1
Hughes, LL1
Luengas, J1
Perry, DJ1
Goutsou, M1
Modeas, C1
Muchmore, E1
Rege, V1
Chahinian, AP1
Hirsh, V1
Poiesz, B1
Sbalzarini, G1
Pandolfi, C1
Labadini, A1
Kao, GD1
Altermatt, HJ1
Gebbers, JO1
Laissue, JA1
Natali, M1
Carpano, S1
Conti, EM1
Barranco, SC1
Townsend, CM1
Ho, BY1
Reumont, KJ1
Koester, SK1
Ford, PJ1
Chu, E1
Zinn, S1
Boarman, D1
Denham, J1
Jones, AM1
Stafford, PM1
Daniilidis, J1
Kalogera-Fountzila, A1
Nicolaou, A1
Banis, K1
Dimitriadis, A1
Sombolos, K1
De Besi, P1
Busnardo, B1
Toso, S1
Girelli, ME1
Nacamulli, D1
Simioni, N1
Casara, D1
Zorat, P1
Fiorentino, MV1
Riechman, B1
Reichman, B2
Bromberg, J2
Grinblatt, DL1
Lovett, D1
Wong, J1
Buckley, M1
Murray, P2
Setanoians, A1
Cooke, TG1
Fleischer, AB1
O'Keefe, EJ1
Schaldenbrand, JD1
Siders, DB1
Zainea, GG1
Thieme, ET1
Saikawa, Y1
Nishibori, H1
Beretta, A1
Cesana, B1
Cozzaglio, L1
Cristoni, M1
Walker, SJ1
Steel, A1
Codacci-Pisanelli, G1
Codacci-Pisanelli, M1
Ferri, GM1
Grieco, A1
Pagani, V1
Bloss, JD1
DiSaia, PJ1
Mannel, RS1
Hyden, EC1
Walker, JL1
Berman, ML1
Kuwa, K1
Kasahara, N1
Consul, S1
Baheti, D1
Ahmann, FR2
Garewal, HS1
Yin, MB1
Miyamoto, T1
Mochinaga, N1
Fragu, P1
Fabri, MC1
Papadopoulos, S1
Halpern, S1
Prade, M1
Dougherty, J1
Casper, E1
Vinciguerra, V1
Rosenbluth, R1
Jordá, E1
Galan, A1
Betlloch, I1
Ramon, D1
Revert, A1
Torres, V1
Lumbroso, J4
Lasser, PH1
Russell, SA1
Wilkinson, MJ1
Ostick, DG1
Vukelja, SJ1
Bonner, MW1
McCollough, M1
Gaule, DA1
Fanucchi, PJ1
Keeling, JH1
Nakajima, S1
Honda, R1
Bonomi, P2
Gale, M1
Rowland, K2
Taylor, SG1
Purl, S1
Phillips, A1
Kittle, CF2
Warren, W2
Tsai, CM2
Perng, RP2
Kramer, BS3
Piantadosi, S1
Puts, JP1
Herve, JP1
Delelo, R1
Ballet, F1
Atabek, U1
Gionfra, T1
Gandolfo, G1
Ameglio, F1
Cornia, E1
Bacchi, M2
Bartolucci, R2
McBride, C1
Boddie, A1
Jackson, DE2
Roh, M1
Hohn, D1
Goodman, A1
Zukerberg, LR1
Nikrui, N1
Scully, RE1
Josui, K1
Arisawa, Y1
Suto, A1
Abe, O2
Satta, T1
Azuma, S3
Kawata, R3
Miya, K1
Kunieda, K1
Takao, H1
Kakizaki, K1
Yamauchi, H1
Thompson, PI1
Deasy, NP1
Thuraisingham, RC1
Raber, MN2
Faintuch, J2
Sumrall, C1
Frost, P1
Sleijfer, DT1
Grond, J1
Verschueren, RC1
Ellis, GK1
Green, S1
Rivkin, S1
Sakanoue, Y1
Shoji, Y1
Utsunomiya, J1
Balis, FM1
Sorensen, JM1
Sartor, O1
Goldstein, LJ1
Hoshino, M1
Satou, N1
Pastor, MC1
Carles, J2
Ribelles, N2
Oller, B1
Armengol, M1
Salva, A1
Ribas, M1
Armstrong, JG1
Ziegler, LD1
Kroll, SS1
Case, D1
Brockschmidt, J1
Schnell, FM1
Grote, TH1
West, JH1
Anthony, S1
Stanley, V1
DeCaprio, JA1
Gonin, R1
Bonadonna, G3
Valtonen, M1
Guarnaccia, S1
Pais, V1
Grous, J1
Spirito, N1
Bach, A1
Goodman, P1
Cathcart-Rake, WF1
Mowery, WE1
Mies, C1
Ernst, F1
Hentschel, E1
Kimler, BF1
Collins, RT1
Beart, RW3
Kubista, TP1
Meyers, WC1
Bagshawe, KD1
Sharma, K1
Southall, PJ1
Boden, JA1
Boxer, GM1
Patridge, TA1
Antoniw, P1
Pedley, RB1
Falliers, CJ1
Mutch, RS1
Hutson, PR1
Leigh, JE2
Pfeifle, DM1
Slavik, M1
LeClair, JM1
Falchuk, ZM1
Bothe, A1
Lagadec, B2
Gonzalez-Canali, G2
Willems, G1
Delvaux, G1
Moliterni, A1
Ferrari, L1
Solano, V1
Pitre, J1
Houssin, D1
Louvel, A1
Vigouroux, C1
Gaudric, M1
Chapuis, Y1
Bromberg, C1
Leonetti, C2
Malorni, W2
Greco, C2
Formisano, G2
Ceci, G1
Colozza, MA1
De Lisi, V1
Lottici, R1
Saito, D2
Miyamoto, K1
Rothman, H1
Cantrell, JE1
Difino, S1
Fryer, J1
Fonte, CE1
Cardello, F1
Parnes, HL1
Abrams, JS1
Tait, N1
Minford, J1
Allen, SL1
Duggan, D1
Berdel, WE2
Danhauser-Riedl, S1
Steinhauser, G1
Rastetter, J1
Siegmund, R1
Illiger, HJ1
Klee, M1
Rieche, K1
Mainzer, K1
Günzl, C1
Lewerenz, B1
Koizumi, J1
Shiraishi, H1
Hori, M2
Urba, S2
Takasugi, BJ1
Zupanc, D1
Luetić, J1
Lepage, E1
Ishibashi, O1
Paris, P1
Seydel, HG2
Stablein, DM1
Kinzie, JJ1
Thomas, PR1
Szinai, I1
Veres, Z1
Szabolcs, A1
De Clercq, E5
Sakatoku, M1
Tatsuzawa, T1
Masuda, S1
Kashani-Sabet, M1
Haedicke, K1
Scanlon, KJ1
Gridelli, C1
Airoma, G1
Balestrino, M1
Bisogno, A1
Incoronato, P1
Nyce, J1
Klann, RC1
Holbrook, CT1
Cheson, BD3
Moriguchi, S1
Sznol, M1
Reboul, F1
Cullinan, S1
Norris, BD1
Barlow, JF1
Chilvers, CE1
Beretta, G1
Rutten, A1
Wickerham, DL1
Redmond, C1
Fisher, ER1
Davies, RJ1
Robidoux, A1
Evans, WK2
Shepherd, FA2
Rusthoven, J1
Stewart, DJ1
Aitken, SE1
Slapak, CA1
Browne, MJ1
Curt, G1
Cummings, FJ2
Wiemann, M1
Morris, DM1
Gross, DC1
Edwards, J1
Teshima, H2
Denz, H1
Gisin, H1
Obrecht, JP1
Goudie, MJ1
Silver, R1
Costanza, M1
Rice, MA1
Wood, W1
Servis, KL1
el-Tahtawy, A1
Albright, MJ1
Barker, PB1
Ring, R1
Atkinson, D1
Ong, R1
King, M1
Porile, JL1
Olopade, OI1
Laudonio, N2
Erba, E1
D'Incalci, M1
Delanian, S1
Abensour, L1
Radparvar, S4
Germain, G2
Pennington, J1
Dieudonne, P1
Dumont, MA1
Wainer, IW2
Jadaud, P1
Kamiyama, T1
Satou, Y1
Sano, F1
Nojima, T1
Ryan, B1
McMurtrey, M1
DeCaro, L1
Mountain, C1
Clark, JL1
Barcewicz, P1
Nava, HR1
Goodwin, PS1
van Heerden, JA1
Skotinkova, OI1
Sergeeva, NS1
Moroz, IA1
Sviridova, IK1
Pelevina, II1
Prosperi Porta, R1
Rulli, G1
Giovagnoli, MR1
Carenza, L1
Goya, N2
Yanagisawa, H1
Nakamura, R2
Toma, H2
Wereldsma, JC1
Bruggink, ED1
Meijer, WS1
Roukema, JA1
van Putten, WL1
Multhauf, P2
Litchfield, T2
Carr, B4
Bertrand, M4
Goldberg, D4
Blayney, D2
Barkanov, AI1
Itin, AB1
Wright, JC1
Schmeck, HJ1
Bartels, E1
Viets, CH1
Arnold, W1
Yoshimoto, J1
Ochi, J1
Tanahashi, T1
Nanba, K1
Saegusa, M1
Hara, M1
Akagi, T1
Obama, T1
Kunitomo, K1
Kawahito, M1
Komi, N1
Kerr, GR1
Arnott, SJ1
Gohji, K1
Kamidono, S1
Burke, P1
Stulc, J1
Emrich, LJ3
Inoue, F1
Takeda, I1
Miyake, M1
Mimura, H1
Orita, K1
Teder, H1
Erichsen, C2
Christensson, PI2
Jönsson, PE2
LoRusso, P2
Tapazoglou, E1
Kish, JA1
Kelly, J1
Jacobsson, B1
Elias, L1
Crissman, HA1
Smith, RA1
Stubblefield, GC1
Reagan, MT1
Birsic, W1
D'Oro, L1
Charoensiri, S1
Lele, SB2
Sawyer, RC1
Derby, S1
Salvia, B1
Hottenrott, C2
Pedani, F1
Brando, V1
Gabriele, P1
Giordano, C1
Everson, LK3
Vaughn, C1
Chapman, J1
Maniscalco, B1
Reznik, S1
Piper, D1
Kac, JL1
Muff, NS2
Shetabi, H2
Stutz, FH2
Eiesland, H1
Mitani, K1
Rios, AA1
Ende, K1
Edwards, C1
Faintuch, JS2
Saks, S1
Gutterman, JU1
Stewart, FM1
Harkins, BJ1
Hahn, SS1
Daniel, TM1
Dembo, A1
DePetrillo, A1
Pringle, J1
Ackerman, I1
Bryson, P1
Balogh, J1
Osborne, R1
Rosen, B1
Fyles, A1
Hallissey, MT2
Ward, LC1
Hockey, MS1
Arima, S1
Futami, K1
Shimura, H1
Morimoto, T1
Monden, A1
Nylen, U1
Winblad, G1
Araki, E2
Ogasawara, H1
Itoh, T1
Furukohri, N1
Baba, T1
Okudaira, N1
Odagiri, H1
Zanea-Wangler, E1
Kesseler, J1
Ploss, HJ1
Romanini, A1
Russello, O1
Nicolin, A1
Sidibe, S2
Ishitsuka, H1
Ohkawa, T1
Misaki, O1
Inglis, R1
Kirkowa-Reimann, M1
Otsuka, S1
Tsubuku, Y1
Kenmizaki, H1
Tatekawa, I1
Soga, K1
Turuya, T1
Toshima, M1
Shibasaki, K1
Matugi, H1
Kawai, C1
Asakura, H1
Kelly, KA1
Urata, A1
Rubin, JR1
Marschke, RF2
Marquet, RL1
Niemiec, TR1
Senekjian, EK1
Montag, AG1
Weeks, A1
Gravel, D1
Grem, J1
Chun, HG1
Lupera, H1
Lapleige, P1
Zelkowitz, RS1
Posner, MR1
Weitberg, AB1
Wang, QL1
de Quay, N1
Cuttat, JF1
Tevaearai, H1
Chapuis, G1
Albe, X1
Vassilakos, P1
Rak, J1
Kuśnierczyk, H1
Strzadała, L1
Kłosiewicz, S1
Radzikowski, C1
Christiansen, NP1
Abdi, EA1
Hanson, J1
Harbora, DE1
Young, DG1
McPherson, TA1
Mukaiyama, T1
Kuraishi, Y1
Hazelton, BJ1
Molinaro, P1
Lafleur, F1
Blum, RH2
Kanojia, MD2
Cricca, A1
Guaraldi, M1
Pannuti, F1
Kuske, RR1
Perez, CA1
Lovett, RD1
Galakatos, AE1
Camel, HM1
Kao, MS1
Redman, BG1
Kinzie, J1
Dalesio, O3
Roussel, A1
Samana, G1
Michel, J1
Bognel, C1
Grandjouan, S1
Obertop, H1
Temsch, EM1
Petzl, DH1
Sinha, PP2
Goudeau, P1
Boman, BM1
Dickinson, R1
Presgrave, P1
Levi, J1
Milliken, S1
Woods, R1
Saiga, T1
Kashu, I1
Tabuchi, K1
Midorikawa, O1
Donadieu, S1
Chodkiewicz, JL1
Laccourreye, H2
Köhler, L1
Mennigen, R1
Eypasch, E1
Blöchl, H1
Schröder, U1
McElhinney, RS3
McCormick, JE3
Atassi, G3
Pratesi, G3
Radacic, M3
Treat, J2
Falchuk, SC1
Tremblay, C1
Spielman, M1
Rouesse, J1
Sevin, D1
Hines, JD2
Spiess, JL1
Giroski, P1
Carter, SG1
Stydnicki, KA2
Morgan, ED2
Collier, M2
Knick, VB2
Duch, DS2
Mullin, R2
Ferone, R2
Flanagan, B2
Odujinrin, O2
Ludwig, H1
Liang, CL1
Hsu, H1
Wirtanen, GW2
Stephenson, JA1
Ramirez, G3
Demets, D1
Joseph, RR1
Higashi, Y1
Andoh, M1
Kitahara, S1
Horiuchi, S1
Oshima, H1
Tjandra, J1
Tsukiyama, I1
Kajiura, Y1
Egawa, S1
Hijikata, J1
Pincus, M1
Faber, LP1
Pan, XY1
Li, FQ1
Yu, RJ1
Xie, GF1
Zhao, LY1
Mira, JG1
Taylor, SL1
Madejewicz, S1
Plager, J1
Soloman, J1
Huan, S1
Singhakowinta, A1
Samal, B1
Lokich, JJ2
Ahlgren, JD3
Gullo, JJ1
Philips, JA1
Fryer, JG1
Walton, LA1
Hatch, TR1
Fuchs, EF1
Oster, MW1
Panasci, L1
Wang, GT1
Holl, E1
Zänker, KS1
Lange, J1
Malet-Martino, MC1
Faure, F1
Vialaneix, JP1
Palevody, C1
Hollande, E1
Martino, R1
Flippin, TA1
Langston, HD1
Prather, JL1
Scott, DI1
Monk, MR1
Sanchez, JD1
Phelps, CD1
Miller, DM1
Alberto, P1
Mermillod, B1
Germano, G1
Kaplan, S1
Weber, W3
Joss, R1
Ayoub, J1
Audet-Lapointe, P1
Méthot, Y1
Beaulieu, R1
Chemaly, R1
Cormier, A1
Déry, JP1
Drouin, P1
Gauthier, P1
Kimoto, H1
Tsunamura, Y1
Ichihashi, T1
Hashizume, Y1
Sertoli, MR2
Bruzzone, M2
Rubagotti, A2
Bentivoglio, G1
Conio, A1
Pescetto, G1
Marymont, JV1
Travers, H1
Housholder, DF1
Kido, C1
Hayakawa, M1
Iizuka, A1
Inagaki, T1
Nakura, E1
Ohno, R1
Tunekawa, H1
Kikuchi, K2
Ogata, T1
Vance, RB1
Weiss, GB1
Weiss, KD1
Torrance, PM3
Furusaka, T1
Kida, A1
Yokode, Y1
Tomita, H1
Axelson, JA1
Clark, RH1
Dimitrov, NV2
Yamanaka, A1
Shaw, MT1
Shaw, MK1
La Ciura, P1
La Grotta, G1
Nigra, E1
Comandone, A1
Grecchi, G1
Leria, G1
Calciati, A1
Guimaraes dos Santos, J1
Kim, JP2
Nadal, JC1
Stablein, D1
Tominaga, J1
Kunieda, E1
Shigematsu, N1
Bjerkeset, T1
Fjøsne, HE1
Watase, M1
Umeshita, K1
Shimano, T1
Monden, M1
Okamura, J1
Claycomb, CL1
Berkovic, M1
Pasterz, R1
Savaraj, N1
Burgess, M1
Zhero, SV1
Ganina, KP1
Kitano, M1
Shimokawa, K2
Tsuya, H1
Ohashi, H2
Fieck, JM1
Lam, WK2
So, SY2
Kung, TM1
Sham, MK1
Ip, M2
Yashige, H1
Inazawa, J1
Nishigaki, H1
Horiike, S1
Taniwaki, M1
Misawa, S1
Sadamoto, Y1
Haruma, K1
Tokumo, K1
Sumii, K1
Kajiyama, G1
Furue, H1
Nakao, I1
Hancock, SL1
Goffinet, DR1
Carlson, RW1
Mark, JB1
Scott, KW1
Williams, SD2
Nichols, CR1
Katano, M1
Hisatsugu, T1
Cantor, RJ1
Weiss, SM1
Rosato, FE1
Mergenthaler, HG1
Binsack, T1
Wilmanns, W1
Komatsumoto, M1
Hamada, J1
Takeichi, N1
Hosokawa, M1
Onitsuka, S1
Nakazawa, H1
Misu, Y1
Shikata, J1
Kozakai, M1
Marée, D1
Nehashi, Y1
Haghbin, M1
Hinson, J1
de Insausti, CL1
Gutiérrez, LE1
Hayano, K1
Hattori, S1
Quebbeman, EJ2
Cantwell, BM1
Gustavsson, BG3
Berne, M2
Frösing, R3
Bernstein, L1
Hayes, AA1
Iosi, F1
Kienzle, HF1
Wilhelm, S1
Frich, JC1
Wilson, JF1
Ball, AS1
Mann, CV1
Clifton, MA1
Baker, WN1
Goode, AW1
Mehta, MP1
Shahabi, S1
Jacobson, G1
Nordgren, CE1
Shiotani, M1
Honda, H1
Nishi, O1
Baumgart, J1
Zhukovskaya, NV1
Anisimov, VN1
Zakem, MH1
Mortimer, JE1
Higano, C1
Scholnik, AP1
Arnold, DJ1
Walker, WS1
Schwenke, P1
Suhrland, LG2
Balcueva, EP1
Loiseau, JP1
Carlsson, G1
deGraaf, SS1
Rodman, JR1
Elhakim, T1
Goodman, PJ1
Brownlee, RW1
Laufman, L1
Hansen, RM3
Davis, HL2
Zaentz, SD1
Schiferl, EA1
Ousley, JL1
Pogodzinski, AE1
Trump, DL1
Lacave, A1
Fabre, A1
Chodkiewicz, JP1
Domergue, J1
Ismail, M1
Astre, C1
Saint-Aubert, B1
Joyeux, H1
Solassol, C1
Roldan, GE1
Ilstrup, DM1
Hayashi, R1
Kurata, A1
Planting, AS1
Eibl-Eibesfeldt, B1
Storz, V1
Kummermehr, J1
Moynihan, T1
Beatty, P1
Ausman, R2
Chitambar, C1
Vukelich, M1
Kita, M1
Sethi, VK1
Chia, KB1
Khor, TH1
Tan, BC1
Tan, TM1
Liu, LY1
Hong, WJ1
Hou, YJ1
Yao, ZH1
Wu, AR1
Jack, A1
McMurdo, DF1
Blijham, G1
Splinter, T1
Frick, J1
Trave, F2
Milliron, S1
Baroni, M1
Krzeczowski, KA1
Roach, R1
Segal, M1
Vandenbulcke, JM2
Fourtillan, JB1
Bacoyiannes, H1
Kontoyiannes, D1
Cazap, EL1
Estevez, RA2
Alvarez, CA1
Hannois, A1
Thomson, D1
Gill, G1
Omura, GA3
Graham, SD1
Walker, A1
Cox, EB1
Laszlo, J1
Berry, WR1
Cazap, E1
Marantz, A1
Wilcosky, T1
Hunt, TM1
Windle, R1
Walach, N1
Horn, Y1
Welling, RE1
Gelman, RS1
Falkson, CI1
Wolter, JM1
Stark, ME1
Dyer, MC1
Coonley, CJ1
Nitenberg, G1
Reznek, RH1
Lundell, G1
Fallenius, A1
Ohman, U1
Burger, AJ1
Mannino, S1
Theobaldy, S1
Hofmann-Preiss, K1
Walter, M1
Smith, JB2
Ghayad, PY2
Dhabuwala, CB2
Drelichman, A2
Pierce, JM2
Galligioni, E1
Canobbio, L1
Fassio, T1
Vaccher, E1
Lo Re, G1
Veronesi, A1
Kavanagh, JJ1
Copeland, L1
Roberts, WS1
Purvis, JD1
Yamaizumi, Z1
Nishimura, S1
Richmond, J1
Bae, Y1
Lewis, J1
Burdakin, J1
Jacobsen, G1
Wile, A1
Smolin, M1
Almersjö, O2
Waldenström, J1
Insler, MS1
Helm, CJ1
Quilty, PM1
Berne, MH1
Spears, PC1
Gez, E1
Yablonsky-Peretz, T1
Weshler, Z1
Garewal, H1
Li, XT1
Li, PY1
Nishimawari, K1
Shinde, SR1
Shaha, PB1
Shetty, PA1
Henderson, A1
Ahuja, RK1
Simanovsky, M1
Feldman, MI1
Urabe, T1
Burkes, R1
Paul, K1
DeBoer, G1
Büyükünal, E1
Berkarda, N1
Serdengeçti, S1
Derman, U1
Berkarda, B1
Kikuchi, Y2
Kizawa, I1
Oomori, K1
Kasimis, BS1
Miller, JB1
Kaneshiro, CA1
Forbes, KA1
Moran, EM1
Speyer, JL1
Dubin, N1
Wernz, JC1
Roses, D1
Sanger, J1
Jett, JR1
Brunk, FS1
Brechot, JM1
Ameille, J1
de Fenoyl, O1
Rochemaure, J1
Hagin, GD1
Sugimoto, M1
Wakabayashi, Y1
Vanden-Bulcke, JM1
Glass, A1
Aabo, K1
Hald, I1
Hørbov, S1
Dombernowsky, P1
Hansen, HH1
Sørensen, HM1
Lundvall, F1
Nielsen, NC1
Sørensen, BL1
Swierz, J1
Dinse, GE1
Davis, TE1
Creech, RH1
Arseneau, JC1
Greenspan, EM1
Pagano, M1
Aogauchi, R1
Tsubota, N1
Yamashita, C1
Yoshikawa, K1
Ishii, N1
Hirahara, K1
Aoki, S1
Sekiguchi, I2
Tamada, T2
Nishida, M1
Yu, DY1
Jewell, LD1
Murray, CJ1
Thomson, AB1
Abe, F1
Shibuya, K1
Ashizawa, J1
Horinishi, H1
Ishizuka, M1
Umezawa, H1
Pasmantier, MW1
Coleman, M1
Silver, RT1
Ballard, WP1
Asakawa, H1
Otawa, H1
Parker, EF1
Marks, RD1
Kratz, JM1
Chaikhouni, A1
Warren, ET1
Bartles, DM1
Yoshida, A1
Noda, H1
Kitamura, O1
Takemori, Y1
Fujiwara, M1
Weber-Stadelmann, W1
Fuller, AF1
Krane, IM1
Budzik, GP1
Donahoe, PK1
Takeshita, Y1
Ohwada, M1
Shiba, E1
Terasawa, T1
Wada, A1
Becker, T1
Caballero, G1
Jenkins, D1
Blake, D1
Tangen, L1
Schulte, W1
Zimmerman, RJ1
VanWinkle, TJ1
Mantel, N1
Frei, E2
Kinami, Y1
Miyazaki, I1
Weatherall, TJ1
Janaki, L1
Boyer, C1
August, DA1
Ottow, RT1
Gianola, FJ1
Schneider, PD1
Catton, GE1
Wu, YF2
Ellison, NM1
Servi, RJ1
Fischer, HP1
Leone, B1
Rabinovich, M1
Ferrari, CR1
Boyer, J1
Rosso, H1
Strauss, E1
Zhen, ZA1
Shao, JK1
Zhen, HD1
Han, ZH1
Wood, CD1
Ponder, BA1
Manaka, RC1
Cohen, JL2
Wile, AG1
Stemmer, EA1
Andrews, PA1
Murphy, MP1
Abramson, IS1
Kalser, MH1
Ellenberg, SS1
Chiuten, DF2
Bedikian, A2
Shepard, KV1
Sweet, DL1
Yap, SH1
Wobbes, T1
van Dam, FE1
Hillen, HF1
Hoogendoorn, GJ1
Scheerder, H1
van der Vegt, SG1
Einhorn, LH1
Hui, SL1
Pennington, K1
Nobile, MT1
Tagarelli, G1
Miller, A1
Loo, TL1
Benvenuto, JA1
Einstein, AB1
Rudolph, RH1
Luce, JK1
Sorokina, EA1
Hellriegel, W1
Tancini, G1
Haslam, JB1
Cavanaugh, PJ1
Stroup, SL1
Basso, A1
Wrbka, E1
Sandeman, TF1
Pettavel, J1
Morgenthaler, F1
Fain, WR1
Conn, JH1
Chavez, CM1
Navashin, SM1
Fomina, IP1
Osokina, LI1
Zharikov, AA1
Witte, S1
Hindringer, B1
Papaioannou, AN1
Murray-Lyon, IM1
Parsons, VA1
Blendis, LM1
Dawson, JL1
Laws, JW1
Williams, R1
Limber, GK1
King, RE1
Silverberg, SG1
Sakker, S1
Ware, CC1
Macfayden, BV1
Burrows, JH1
Tucker, WG1
Dendy, PP1
DeKernion, JB2
Resnick, MI1
Persky, L2
Resnick, ML1
Yagoda, A1
Jato, J1
Windheuser, JJ1
Smith, FE1
Lane, M1
Hudgins, PT1
Tashima, CK1
Morrow, LB1
Burrow, GN1
Kaplan, SR1
Mulrow, PJ1
Kühböck, J1
Pokorny, D1
Steinbach, K1
Eggerth, G1
Rutledge, F4
Rottenberg, VI1
Bergsagel, DE1
Ferguson, E1
Obi, LJ1
Man, B1
Kraus, L1
Pikielny, S1
Korfsmeier, KH1
Furnari, S1
Pavone-Macaluso, M1
Veroux, G1
Mattea, E1
Speckhard, ME1
Hurley, JD1
Fetherston, WC1
Grueninger, AJ1
Wharton, JT1
Belousova, AK1
Moskalik, KG1
Kozlov, AP1
Akimov, AA1
Moertel, C1
van der Merwe, AM2
van Dyk, JJ2
Falkson, HC2
Faulkner, SL1
Reynolds, VH1
Hattori, N1
Ono, T1
Aran, M1
Bilge, N1
Ozman, M1
Gailani, S2
Leone, L2
Sugawara, H1
Harata, T1
Yamaguchi, O1
Savran, VR1
Galt, RM2
Oester, YT2
Sylvester, R1
Andrews, JT1
Cox, KR1
Hare, WS1
McConchie, IH1
Goepfert, H1
Jesse, RH1
Lindberg, RD1
Grover, FL1
Webb, MJ1
Donovan, JF1
Kaslow, RA1
Wisch, N1
Glass, JL1
Carr, DT1
Lee, RE1
Holland, JF2
Burningham, R1
Larsen, V1
Franksson, C1
Bergstrand, A1
Ljungdahl, I1
Magnusson, G1
Nordenstam, H1
Larsen, RR1
Montminy, L1
Cerruti, FR1
Ammon, J1
Hermann, HJ1
Janssen, B1
Schmidt, L1
Günther, W1
Moroz, LV2
Karev, NI1
Nordman, E1
Kauppinen, C1
Skarin, AT1
Tandon, RN1
Bunnell, IL1
Cooper, RG1
Blom, J1
Roberts, GA1
Nagel, GA1
Dana, M1
Spigel, SC1
Ellert, J1
Creasey, WA1
Kovach, JS1
Tully, TE1
Shafer, RB1
Chawla, PL1
Sekiya, S1
Takamizawa, H1
Ahmann, DL1
Bisel, HF1
Dines, DE1
Burdette, WJ1
Miller, E1
Burns, BC1
Soffar, S1
Colby, M1
Tubaro, E1
Bulgini, MJ1
Molina, C1
Cheminat, JC1
Passemard, N1
Adam, J1
Ermolenko, AS1
Tarasova, GV1
Nelson, RS1
Lanza, FL1
Syrkin, AB1
Benson, J1
Labelle, E1
Lleander, VC1
Goldstein, G1
Pershin, MP1
Chumakina, SI1
Gunka, II1
Pantophel, AM1
Steklenev, NA1
Zirin, MA1
Grjaznova, IN1
Shain, AA1
Pecherskaja, BG1
Saveliev, NP1
Bashirova, NG1
Kuzmin, VP1
Budarina, EM1
Svedencov, EP1
Phateeva, KV1
Iunusmetov, IR1
Silitrin, NP1
Shklovskii, GS1
Balas, AN1
Ushivceva, AE1
Gordan, GS1
Wessler, S1
Avioli, LV1
Kanzawa, F1
Jacobs, EM1
Reeves, WJ1
Wood, DA1
Pugh, R1
Braunwald, J1
From, P1
Morrissey, WJ1
Sams, J1
Minami, T2
Pugh, RP1
Cassidy, FR1
Marshall, GJ1
Irwin, LE1
Krant, MJ1
Shnider, BI1
Matias, PI1
Baxter, D1
Hillemand, P1
Roux, M1
Muller, JM1
Bernard, HJ1
Delavierre, P1
Braun-Falco, O1
Lukacs, I1
Chevrel, B1
Chevrel, JP1
Sheehe, PR1
Graham, S1
Vinhafs, JC1
Ferreira, AJ1
Neyazaki, T1
Seki, Y1
Egawa, N1
Suzuki, C1
Tugarinov, OA1
Smolianskaia, AZ1
Klein, E1
Konovalova, AL1
Bengmark, S1
Brix, M1
Börjesson, B1
Hafström, L1
Olsson, A1
Mitchell, MS1
DeConti, RC1
Serpick, AA1
Edwards, AJ1
Rowland, GF1
Sumner, MR1
Hurd, CM1
Milonov, BV1
Kosarev, VA1
Nikiforov, AM1
Rowe, DS1
Barrett, O2
Reboul, AR1
Lewest, G1
Herter, FP1
Mulcare, RJ1
McCarthy, JG1
Gump, FE1
Ukai, M1
Buckley, K1
Wheeler, B1
Nadler, SH1
Abasov, IT1
Nadzharov, AG1
Bernard, E1
Goolsby, CD1
Daly, JW1
Skinner, OD1
Gibbs, CE1
Kaufman, JJ1
Kaneshiro, W1
Roux, F1
Chakravorty, RC1
Sarkar, SK1
Mukerji, B1
Topolnicki, W1
Lee, TC1
Lowenfels, AN1
Rohmans, M1
Bourgeois, C1
Plecha, FR1
Clarkson, B1
Ohkita, T1
O'Connor, A1
Sullivan, RD1
Zurek, WZ1
Traldi, A1
Morini, A1

Clinical Trials (448)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Pazopanib With 5-Fluorouracil, Leucovorin and Oxaliplatin (FLO) as 1st-line Treatment in Advanced Gastric Cancer; a Randomized Phase-II-study of the Arbeitsgemeinschaft Internistische Onkologie[NCT01503372]Phase 275 participants (Actual)Interventional2011-11-30Completed
Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patient[NCT04617457]Phase 2150 participants (Anticipated)Interventional2021-10-10Recruiting
A Phase II Randomized Study of Induction Chemotherapy Followed by Concurrent Chemo-radiotherapy in Locally Advanced Pancreatic Cancer[NCT01867892]Phase 286 participants (Anticipated)Interventional2013-06-30Enrolling by invitation
An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers[NCT06135896]Phase 298 participants (Anticipated)Interventional2023-12-10Not yet recruiting
Phase I Study of Pre-operative Capecitabine and Lenvatinib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT02935309]Phase 120 participants (Actual)Interventional2016-10-14Completed
A Phase II Multicenter Randomized Trial Evaluating 3-year Disease Free Survival in Patients With Locally Advanced Rectal Cancer Treated With Chemoradiation Plus Induction or Consolidation Chemotherapy and Total Mesorectal Excision or Non-operative Managem[NCT02008656]Phase 2358 participants (Actual)Interventional2013-11-30Active, not recruiting
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Neoadjuvant-Adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Patients With Resectable Gastric and Gastroesophageal Junction Cancer (GC/GEJC)[NCT04592913]Phase 3958 participants (Actual)Interventional2020-11-17Active, not recruiting
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)[NCT04736485]Phase 267 participants (Anticipated)Interventional2021-06-28Active, not recruiting
Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response[NCT03033927]74 participants (Actual)Observational2017-01-24Active, not recruiting
Evaluation of Exceptional Responders With Solid Tumor Cancer[NCT02555735]250 participants (Anticipated)Observational2015-10-31Enrolling by invitation
Preoperative Extended Chemotherapy vs. Chemotherapy Plus Hypofractionated Radiation Therapy for Borderline Resectable Adenocarcinoma of the Head of the Pancreas[NCT02839343]Phase 2126 participants (Actual)Interventional2016-12-31Active, not recruiting
A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia[NCT03207724]Phase 116 participants (Actual)Interventional2017-10-16Completed
A Randomized Multicenter Phase II/III Study Comparing 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced Resectable Adenocarcinoma of the Esophagogastreal Junction or the Stomac[NCT01216644]Phase 2/Phase 3716 participants (Actual)Interventional2010-08-31Completed
Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy[NCT01362127]Phase 2181 participants (Actual)Interventional2006-10-31Completed
A Phase II Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients With Borderline Resectable Pancreatic Cancer[NCT01661088]Phase 225 participants (Actual)Interventional2011-06-30Completed
A Phase III Multicenter Open-label Randomized Trial to Evaluate Efficacy and Safety of Folfirinox (FFX) Versus Combination of CPI-613 With Modified Folfirinox (mFFX) in Patients With Metastatic Adenocarcinoma of the Pancreas[NCT03504423]Phase 3528 participants (Actual)Interventional2018-11-09Completed
Phase II, Randomized, Controlled, Clinical Trial Exploring Efficacy and Safety of ERY001 (L-asparaginase Encapsulated in Red Blood Cells) in Association With Gemcitabine or FOLFOX4 in Second-line Therapy for Patients With Progressive Metastatic Pancreatic[NCT02195180]Phase 2141 participants (Actual)Interventional2014-07-31Completed
A Randomized, Open Label Phase 3 Study of MM-398, With or Without 5-Fluorouracil and Leucovorin, Versus 5 Fluorouracil and Leucovorin in Patients With Metastatic Pancreatic Cancer Who Have Failed Prior Gemcitabine-based Therapy[NCT01494506]Phase 3417 participants (Actual)Interventional2011-11-30Completed
Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers[NCT00524186]Phase 123 participants (Actual)Interventional2007-05-31Terminated (stopped due to PI left institute)
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma[NCT02366819]Phase 436 participants (Anticipated)Interventional2014-12-11Recruiting
Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors[NCT01928290]Phase 267 participants (Actual)Interventional2013-11-08Completed
Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma[NCT03409848]Phase 297 participants (Actual)Interventional2018-03-01Completed
Chemotherapy and Irreversible Electroporation (IRE) in the Treatment of Advanced Pancreatic Adenocarcinoma[NCT03484299]Phase 120 participants (Anticipated)Interventional2018-05-30Recruiting
Study of Avastin in Combination With Chemotherapy for the First Line Treatment of RAS Mutant Unresectable Colorectal Liver-limited Metastases[NCT01972490]Phase 4241 participants (Actual)Interventional2013-10-31Completed
Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma[NCT03503630]Phase 244 participants (Actual)Interventional2018-07-20Active, not recruiting
TRICC-C: A Multicenter, Randomized, Phase II Trial: BIBF 1120 vs. Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)[NCT01362361]Phase 254 participants (Actual)Interventional2011-06-30Completed
A Prospective, Open-Label, Single-Arm and Multicentre Phase II Study to Explore the Efficacy and Safety of Neoadjuvant Cadonilimab Plus Chemotherapy Following Short-Course Radiotherapy in Middle and Lower Locally Advanced Rectal Cancer[NCT05792735]Phase 227 participants (Anticipated)Interventional2023-04-11Recruiting
Rationale and Design of a Prospective, Multicenter Phase Ⅱ Clinical Trial of Safety and Efficacy Evaluation of Long Course Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.[NCT04911517]Phase 250 participants (Anticipated)Interventional2021-06-01Recruiting
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma[NCT02562716]Phase 2147 participants (Actual)Interventional2016-01-06Completed
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT02545504]Phase 3432 participants (Actual)Interventional2015-10-13Completed
Preoperative Radiochemotherapy With Concurrent Deep Regional Hyperthermia for Locally Advanced Rectal Cancer. A Prospective Phase II Trial[NCT02353858]Phase 278 participants (Actual)Interventional2012-08-31Completed
Sintilimab Plus Chemotherapy and Radiotherapy for Patients With Inoperable Pancreatic Cancer: a Single-arm, Exploratory, Phase II Trial[NCT06050317]Phase 225 participants (Anticipated)Interventional2023-08-18Recruiting
Patient Reported Outcomes Following Cancer of the Rectum[NCT04936581]200 participants (Anticipated)Observational2021-09-01Recruiting
A Phase 3, Randomized, Double-blind Clinical Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy as First-line Treatment in Participants With HER2 Negative, Previously Untreated, Unresectable or Metastatic Gastric Orgastroe[NCT03675737]Phase 31,579 participants (Actual)Interventional2018-11-08Active, not recruiting
A Phase II, Single-arm Clinical Trial of Administration of Cisplatin and 5- Fluorouracil With Afatinib as First-line Therapy in Patients With Inoperable Gastric or Gastroesophageal Junction Cancer[NCT01743365]Phase 255 participants (Actual)Interventional2013-02-11Completed
Perioperative Systemic Therapy and Cytoreductive Surgery With HIPEC Versus Upfront Cytoreductive Surgery With HIPEC Alone for Isolated Resectable Colorectal Peritoneal Metastases: a Multicentre, Open-label, Parallel-group, Phase II-III, Randomised Superio[NCT02758951]Phase 2/Phase 3358 participants (Anticipated)Interventional2017-06-01Recruiting
Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer[NCT01333033]Phase 2257 participants (Actual)Interventional2011-07-31Completed
UCSD Profile Related Evidence Determining Individualized Cancer Therapy (UCSD PREDICT)[NCT02478931]10,000 participants (Anticipated)Observational2013-09-05Recruiting
A Randomized Phase II Trial of Perioperative Chemoimmunotherapy Verses Perioperative Chemoimmunotherapy Plus Preoperative Chemoradiation for Locally Advanced Gastric (G) or Gastroesophageal Junction (GEJ) Adenocarcinoma[NCT05161572]Phase 2152 participants (Anticipated)Interventional2021-09-28Recruiting
MAgnetic Resonance Imaging Guided LAteral Lymph Node Dissection in Lower REctal Cancer - A Multicenter, Prospective, Registry Study (MALAREC)[NCT04850027]268 participants (Anticipated)Observational [Patient Registry]2021-01-01Recruiting
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study[NCT05277766]Phase 145 participants (Anticipated)Interventional2022-11-21Recruiting
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Combined With Sintilimab in Gastric Cancer With Peritoneal Metastasis[NCT05648487]Phase 246 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Clinical Study of CT and MR in Staging and Prediction of Response in Patients With Gastric Cancer[NCT04028375]400 participants (Anticipated)Observational2019-09-01Recruiting
A Prospective Multicenter Study With 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Limited Metastatic or Extensive Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction[NCT00849615]Phase 2252 participants (Actual)Interventional2009-02-28Completed
Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial[NCT06121700]Phase 255 participants (Anticipated)Interventional2023-01-01Recruiting
Adjuvant Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) During Laparoscopic Resection in High-risk Gastric Cancer Patients: A Multicentre Phase-I Study (the PIPAC-OPC4 Study)[NCT04047004]Phase 120 participants (Actual)Interventional2020-03-11Completed
Preoperative Hyperfractionated Radiotherapy Versus Combined Radiochemotherapy for Patients With Locally Advanced Rectal Cancer: a Phase III Randomized Trial.[NCT01814969]Phase 3260 participants (Anticipated)Interventional2014-03-31Recruiting
A Multinational, Randomized, Double-blind Study, Comparing the Efficacy of Aflibercept Once Every 2 Weeks Versus Placebo in Patients With Metastatic Colorectal Cancer (MCRC) Treated With Irinotecan / 5-FU Combination (FOLFIRI) After Failure of an Oxalipla[NCT00561470]Phase 31,226 participants (Actual)Interventional2007-11-30Completed
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy[NCT01285557]Phase 3361 participants (Actual)Interventional2011-04-14Terminated (stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.)
A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus 5-Fluorouracil (5-FU)/Leucovorin (CF) With or Without Cetuximab (C225) After Curative Resection for Patients With Stage III Colon Cancer[NCT00079274]Phase 33,397 participants (Actual)Interventional2004-02-29Completed
Induction Chemotherapy With Folfoxiri Plus Cetuximab and Maintenance With Cetuximab or Bevacizumab Therapy in Unresectable Kras Wild-type Metastatic Colorectal Cancer Patients[NCT02295930]Phase 2143 participants (Actual)Interventional2011-10-31Completed
Temozolomide and Irinotecan Consolidation in Patients With MGMT Silenced, Microsatellite Stable Colorectal Cancer With Persistence of Minimal Residual Disease in Liquid Biopsy After Standard Adjuvant Chemotherapy: the ERASE-TMZ Study[NCT05031975]Phase 235 participants (Anticipated)Interventional2022-05-02Recruiting
Resectable Pancreatic Adenocarcinoma Neo-Adjuvant FOLF(IRIN)OX-based CHEmotherapy - A Multicenter, Randomised Phase II Trial (PANACHE01-PRODIGE48 Study)[NCT02959879]Phase 2160 participants (Anticipated)Interventional2017-03-01Recruiting
A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT00515411]Phase 2111 participants (Actual)Interventional2006-10-23Completed
A Phase 2, Open-Label, Multi-Center Study to Assess Safety and Efficacy of Second/Third-Line Treatment With NAB®-Paclitaxel (ABI-007) In Combination With Epigenetic Modifying Therapy Of CC-486, Or Immunotherapy of Durvalumab (MEDI4736), Or As Monotherapy [NCT02250326]Phase 2240 participants (Actual)Interventional2015-01-07Completed
Non-interventional Observational Post-authorization Study to Assess Clinical and Patient Reported Outcomes With Nab-paclitaxel in Combination With Gemcitabine in Routine Clinical Practice Treating Pancreatic Cancer (TRUST)[NCT02670746]44 participants (Actual)Observational2015-10-01Terminated (stopped due to Due to slow recruitment study is being terminated.)
Multicenter Non-interventional Study to Investigate Safety, Tolerability and Efficacy of Nab-paclitaxel in Clinical Routine Treatment of First-line Pancreatic Cancer Patients[NCT02555813]317 participants (Actual)Observational2015-05-08Completed
A Phase III, Randomized, Open-Label, Multi-Center, Safety and Efficacy Study to Evaluate Nab-Paclitaxel (Abraxane®) as Maintenance Treatment After Induction With Nab-Paclitaxel Plus Carboplatin in Subjects With Squamous Cell Non-Small Cell Lung Cancer (NS[NCT02027428]Phase 3427 participants (Actual)Interventional2014-02-11Completed
Phase II: First Line Treatment by FOLFIRINOX for Patients With a Rectum Cancer With Synchronous Non Resectable Metastasis[NCT01674309]Phase 265 participants (Actual)Interventional2012-04-30Completed
National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer[NCT01940497]Phase 3240 participants (Actual)Interventional2013-11-15Completed
S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma[NCT01959139]Phase 1/Phase 2126 participants (Actual)Interventional2014-01-23Active, not recruiting
A Phase 1 Study of Hypofractionated Stereotactic Radiotherapy and Concurrent HIV Protease Inhibitor Nelfinavir as Part of a Neoadjuvant Regimen in Patients With Locally Advanced Pancreatic Cancer[NCT01068327]Phase 146 participants (Actual)Interventional2007-11-05Completed
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer[NCT01191697]Phase 237 participants (Actual)Interventional2011-02-28Active, not recruiting
A Phase II/III Study Comparing Simultaneous Integrated Boost (SIB) Intensity Modulated Radiation Therapy (IMRT) With S1 Based SIB-IMRT Followed by Adjuvant Chemotherapy With S1 in Elderly Patients With Esophageal or Esophagogastric Cancer (3JECROG-P01)[NCT02979691]Phase 2/Phase 3350 participants (Anticipated)Interventional2016-10-31Completed
Therapeutic Efficacy and Safety of Concurrent FOLFIRINOX Plus HIFU for Locally Advanced/Borderline Resectable Pancreatic Cancer: A Prospective Single-center, Single-arm, Investigator-initiated, Open-labeled, Exploratory Clinical Trial[NCT05262452]60 participants (Anticipated)Interventional2021-08-09Recruiting
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL[NCT02205047]Phase 2171 participants (Anticipated)Interventional2015-07-15Active, not recruiting
Phase 2b, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease[NCT00865709]Phase 2198 participants (Actual)Interventional2009-03-31Completed
Preoperative Chemosensitivity Testing as Predictor of Treatment Benefit in Adjuvant Stage III Colon Cancer: PePiTA Trial[NCT00994864]235 participants (Actual)Interventional2009-11-30Completed
REAL 3 : A Randomised Open-labelled Multicentre Trial of the Efficacy of Epirubicin, Oxaliplatin and Capecitabine (EOX) With or Without Panitumumab in Previously Untreated Advanced Oesophago-gastric Cancer[NCT00824785]Phase 3574 participants (Actual)Interventional2008-05-31Terminated (stopped due to Lack of efficacy)
A Single Arm, Open Label, Exploratory Study of Pemetrexed and S-1 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT03843853]Phase 20 participants (Actual)Interventional2019-05-01Withdrawn (stopped due to cooperation terminated)
A Single Arm, Open Label, Exploratory Study of Pemetrexed and TAS-102 in Combination With Bevacizumab in Patients Who Have Progressed After Standard Second Line Therapy[NCT04683965]Phase 227 participants (Anticipated)Interventional2021-01-01Active, not recruiting
Approximation to the Therapeutic Individualization in Patients With Locally Advanced Gastric and Gastroesophageal Cancer Through Modelling and Generation of Predictive Gene Signatures[NCT02454673]121 participants (Actual)Observational2013-09-30Completed
An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease[NCT00400179]Phase 31,053 participants (Actual)Interventional2005-05-31Completed
PATHOS Tradeoffs in Patient Decision Making About Rectal Cancer Treatment: Benefits Compared to Quality Of Life.[NCT04925154]192 participants (Anticipated)Observational [Patient Registry]2021-12-13Recruiting
A Phase 1 Study Of Sunitinib Malate In Combination With Cisplatin/Capecitabine Or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer[NCT00555620]Phase 176 participants (Actual)Interventional2008-05-31Completed
Prospectively Defining Metastatic Pancreatic Ductal Adenocarcinoma Subtypes by Comprehensive Genomic Analysis[NCT02869802]190 participants (Anticipated)Observational2016-10-06Recruiting
Phase I/II Study of Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer[NCT00889187]Phase 1/Phase 210 participants (Actual)Interventional2009-12-31Terminated (stopped due to Excess toxicity was identified intraoperatively)
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy[NCT04281511]238 participants (Actual)Observational [Patient Registry]2019-04-03Completed
Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab[NCT00827671]Phase 212 participants (Actual)Interventional2009-03-31Terminated (stopped due to Experimental treatment not feasible due to high rate of drop out)
A Phase I/II Study of Bevacizumab, Erlotinib and 5-fluorouracil With Concurrent External Beam Radiation Therapy in Locally Advanced Rectal Cancer[NCT00307736]Phase 1/Phase 232 participants (Actual)Interventional2006-05-31Completed
A Randomized, Open-label Phase II Study Evaluating the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab as First-line Therapy in Subjects With Metastatic Colorectal Cancer.[NCT00439517]Phase 2302 participants (Actual)Interventional2007-02-28Completed
The Outcome After Operation for Pancreatic and Periampullary Tumors in Greeland Inuit.[NCT05595811]2,326 participants (Actual)Observational1999-01-01Completed
Postoperative and Long-term Survival in Relation to Life-expectancy After Pancreatic Surgery in Elderly Patients[NCT04893408]1,556 participants (Actual)Observational2010-01-01Completed
Non Inferiority Multicenter Phase III Randomized Trial Comparing Preoperative Chemotherapy Only to Chemotherapy Followed by Chemoradiotherapy for Locally Advanced Resectable Rectal Cancer (Intergroup FRENCH-GRECCAR- PRODIGE)[NCT03875781]Phase 3540 participants (Anticipated)Interventional2019-06-05Recruiting
Early Evaluation of Chemosensitivity for Low-risk Stage II/III Rectal Cancer[NCT03666442]Phase 261 participants (Actual)Interventional2018-06-01Completed
Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy[NCT04749108]Phase 2/Phase 31,075 participants (Anticipated)Interventional2021-11-26Recruiting
A Multicenter, Prospective, Randomized Clinical Trial to Investigate the Combined Modality Therapy for Locally Advanced Mid/Low Rectal Cancer.[NCT03042000]1,200 participants (Anticipated)Interventional2017-02-28Not yet recruiting
FOUR ARMS PHASE III CLINICAL TRIAL FOR T3-T4 RESECTABLE RECTAL CANCER COMPARING PRE-OPERATIVE PELVIC IRRADIATION TO PRE-OPERATIVE IRRADIATION COMBINED WITH FLUOROURACIL AND LEUCOVORIN WITH OR WITHOUT POST-OPERATIVE ADJUVANT CHEMOTHERAPY[NCT00002523]Phase 31,011 participants (Actual)Interventional1993-04-30Completed
Multicenter Phase II Study of Preoperative Chemoradiotherapy With CApecitabine Plus Temozolomide in Patients With MGMT Silenced and Microsatellite Stable Locally Advanced RecTal Cancer: the CATARTIC Trial[NCT05136326]Phase 221 participants (Anticipated)Interventional2021-12-01Recruiting
Complete Pathologic Response Rectal Cancers EYSAC.1 Study[NCT03351959]1,000 participants (Anticipated)Observational2018-01-01Recruiting
Maintenance Treatment With S-1 Versus Observation After First-line Chemotherapy in Patients With Advanced Gastric Cancer: a Randomized Phase II Study[NCT03701373]Phase 2200 participants (Anticipated)Interventional2016-01-01Recruiting
Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320]Phase 2200 participants (Actual)Interventional2015-10-05Active, not recruiting
Phase 2 Study of Neoadjuvant Modified FOLFIRINOX in Patients With Borderline Resectable Pancreas Adenocarcinoma[NCT02749136]Phase 244 participants (Actual)Interventional2016-05-31Completed
The Identification, Validation and Implementation of Molecular Markers to Predict Response to Fluorouracil-based Adjuvant Chemotherapy in Stage III Colorectal Cancer Patients - Prospective Clinical Observational Study[NCT03127111]300 participants (Anticipated)Observational2022-12-01Not yet recruiting
Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer: An Open, Multi-centered, Randomize Controlled Phase 3 Trial.[NCT03970694]Phase 349 participants (Actual)Interventional2019-05-11Terminated (stopped due to Significant differences in conversion rate as well as R0 resection rate between the two groups.)
Adjuvant Treatment of Fully Resected Stage III Colon Cancer With FOLFOX-4 Versus FOLFOX-4 Plus Cetuximab[NCT00265811]Phase 32,559 participants (Actual)Interventional2005-11-30Completed
Ancillary Study of miR-31-3p and miR-31-5p Expression Levels in Patients Enrolled in the PETACC-8 Study, and of the Predictive Role of miR-31-3p Expression Level on Clinical Outcomes of Patients Treated With Cetuximab[NCT03362684]Phase 31,808 participants (Actual)Interventional2005-11-30Completed
Biomarker Validation Study of Linear Quantification of CD3 Positive Cells in Localized Colorectal Carcinomas, Based on the Cohort of Patient Included in PETACC8 International Phase III Trial (NCT00265811)[NCT02364024]856 participants (Actual)Observational2005-11-30Completed
A Phase Ib/II Trial of Capeox Regimen Combined With Sintilimab and Bevacizumab in First-line Treatment for Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma[NCT05640609]Phase 1/Phase 257 participants (Anticipated)Interventional2023-03-10Recruiting
A Double-blind, Randomised, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-line Therapy in Patients With Advanced Gastric Cancer[NCT00548548]Phase 3774 participants (Actual)Interventional2007-09-30Completed
A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, an[NCT00719550]Phase 1/Phase 2130 participants (Actual)Interventional2009-02-28Completed
Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial[NCT00941655]Phase 315 participants (Actual)Interventional2009-07-22Completed
Phase II/III Trial of CPT-11/5-FU/l-LV (FOLFIRI) Versus CPT-11/TS-1 (IRIS) as Second Line Chemotherapy of Unresectable Colorectal Cancer[NCT00284258]Phase 2/Phase 3426 participants (Actual)Interventional2006-01-31Completed
Docetaxel, Cisplatin and Fluorouracil Combination in the Neoadjuvant Treatment of Locally Advanced Gastric Adenocarcinoma : Phase II Clinical Study[NCT00343239]Phase 259 participants (Actual)Interventional2006-06-30Completed
[NCT00477711]Phase 241 participants (Actual)Interventional2007-03-31Completed
[NCT02870036]Phase 1243 participants (Anticipated)Interventional2016-10-31Recruiting
Strategy Phase III Intergroup Study for Chemotherapy of the Metastatic or Locally Advanced Cancers of the Stomach[NCT00374036]Phase 3416 participants (Anticipated)Interventional2005-06-30Completed
PET/MR-imaging and Circulating Tumour Cells to Evaluate the Response of Chemotherapy in Patients With Gastroesophageal Junction Cancer[NCT02433301]23 participants (Actual)Observational2015-04-30Completed
5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial[NCT01500993]Phase 3401 participants (Actual)Interventional2002-03-31Completed
A Randomized Phase II Study of Docetaxel in Combination With Oxaliplatin With or Without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease[NCT00382720]Phase 2275 participants (Actual)Interventional2006-09-30Completed
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using Magnetic Resonance Guided Radiotherapy Linear Accelerator:A Prospective Phase 2 Trial[NCT05338866]58 participants (Anticipated)Observational2022-01-01Enrolling by invitation
KCSP Trial of cONsolidation Chemotherapy for Locally Advanced Mid or Low Rectal Cancer After neoadjUvant Concurrent chemoraDiothErapy: A Multicenter, Randomized Controlled Trial (KONCLUDE Trial)[NCT02843191]Phase 3358 participants (Anticipated)Interventional2016-12-31Recruiting
The Utility of Circulating Tumour Cells and Plasma microRNA Detection to Predict the Response to Treatment in Patients With Esophageal Adenocarcinoma[NCT02812680]200 participants (Anticipated)Observational2016-06-30Active, not recruiting
A Phase II Study of Erlotinib in Combination With Capecitabine as First-line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)[NCT00816868]Phase 262 participants (Actual)Interventional2009-01-31Completed
Lapatinib Versus Lapatinib With Capecitabine as Second-line Treatment in Her2-Overexpressing Metastatic Gastro-Esophageal Cancer: A Randomized Phase II Trial[NCT01145404]Phase 276 participants (Anticipated)Interventional2010-06-30Terminated (stopped due to Changes of SoC for third line therapy resulting in poor recruitment)
A Clinical Trial Using Electrochemotherapy With Bleomycin for the Treatment of Non-metastatic Unresectable Pancreatic Cancer[NCT03225781]1 participants (Actual)Interventional2017-07-01Terminated (stopped due to Logistic reasons)
Technical Feasibility of Modified Early Post-Operative Intraperitoneal Chemotherapy (mEPIC)[NCT05913674]Phase 225 participants (Anticipated)Interventional2023-07-31Not yet recruiting
Rectal Microbiome Variability Among Rectal Cancer Cohorts Including Complete Clinical Responders, Pathologic Responders, and Early Recurrence[NCT04223102]40 participants (Anticipated)Interventional2020-02-18Active, not recruiting
A Prospective Multicenter Randomized Controlled Trial of the Clinical Efficacy of Neoadjuvant Therapy Based on Organoids Drug Sensitivity Versus Empirical Neoadjuvant Therapy in the Treatment of Advanced Rectal Cancer[NCT05352165]192 participants (Anticipated)Interventional2023-01-01Not yet recruiting
Timing of Rectal Cancer Response to Chemoradiation[NCT00335816]Phase 2248 participants (Anticipated)Interventional2008-08-31Active, not recruiting
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by 4 Cycles XELOX Pre- a Delayed TME Compared With 6 Cycles XELOX post-a Regular Timing TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized, Open-Label Trial[NCT03038256]Phase 2244 participants (Anticipated)Interventional2018-01-31Recruiting
Translational Validation Study to Examine KFO179-1 Biomarker Scores for the Prediction and Prognosis of Advanced Primary Resectable Rectal Cancer Stages UICC II-IV, With a 5-FU-based Standard Radiochemotherapy Followed by Total Mesorectal Excision.[NCT03034473]200 participants (Actual)Interventional2011-08-31Active, not recruiting
Organ Preservation in Locally Advanced Rectal Cancer by Radiochemotherapy Followed by Consolidation Chemotherapy. A Prospective Phase II Pilot Trial of the German Rectal Cancer Study Group[NCT03561142]Phase 294 participants (Anticipated)Interventional2018-06-15Recruiting
Prospective Randomised Multicenter Phase-III-study: Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil Plus Oxaliplatin Versus Preoperative Radiochemotherapy and Adjuvant Chemotherapy With 5-Fluorouracil for Locally Advanced Rect[NCT00349076]Phase 31,256 participants (Actual)Interventional2006-07-31Completed
An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma[NCT03694262]Phase 230 participants (Actual)Interventional2019-07-19Completed
Phase II Study of Optimum Design of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal Cancer[NCT02938195]Phase 250 participants (Anticipated)Interventional2016-01-31Recruiting
[NCT02445209]Phase 356 participants (Actual)Interventional2010-09-30Completed
A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer[NCT01198392]Phase 3270 participants (Anticipated)Interventional2008-09-30Recruiting
A Prospective,Randomized Control Trial of Intraoperative Intraportal Chemotherapy (5-FU and Oxaliplatin) Combined With Adjuvant Chemotherapy to Prevent Liver Metastasis in Patients Receiving Curative Colorectal Cancer Resection.[NCT01972503]Phase 4300 participants (Anticipated)Interventional2008-06-30Recruiting
Randomized Study of Classic vs Simplified Leucovorin Calcium and Fluorouracil With or Without Irinotecan in Patients Aged At Least 75 Years With Advanced Colorectal Cancer[NCT00303771]Phase 3282 participants (Actual)Interventional2003-06-30Completed
Determination of Microbiological Factors Associated With Poor Response to Neoadjuvant Therapy in Rectal Cancers: Focus on Cyclomodulin-producing Escherichia Coli[NCT04103567]220 participants (Anticipated)Interventional2020-01-14Recruiting
A Randomised Phase-III Study Comparing Cytoreductive Surgery Plus Intraperitoneal Chemotherapy Versus Modern Systemic Chemotherapy in Colorectal Peritoneal Carcinomatosis.[NCT01524094]Phase 349 participants (Actual)Interventional2003-06-30Completed
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903)[NCT04138212]Phase 3456 participants (Anticipated)Interventional2019-10-22Recruiting
Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma[NCT01376453]Phase 118 participants (Actual)Interventional2011-06-30Completed
A Phase I/II Study of Docetaxel, 5-Fluorouracil and Oxaliplatin (D-FOX) in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction[NCT00526110]Phase 1/Phase 298 participants (Actual)Interventional2004-08-31Completed
Study of the Value of the PET/CT in Evaluating the Response of Distal Rectal Cancer to Neoadjuvant Chemoradiation Therapy[NCT00254683]Phase 2100 participants (Anticipated)Interventional2005-09-30Recruiting
Phase II Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer[NCT01523457]Phase 275 participants (Actual)Interventional2011-10-31Completed
Assessment of Cardiorespiratory Fitness and Lung Function in Lung Cancer Patients Undergoing Neoadjuvant Cancer Therapy and Role of Prehabilitation in Preventing Associated Decline[NCT05636969]25 participants (Anticipated)Observational2023-02-01Not yet recruiting
A Pilot Study in Gastric Cancer of Assignment to Postoperative Chemoradiation or Chemotherapy Based Upon Surgical Lymph Node Assessment After Preoperative Chemotherapy, With Gene Assay as Correlate of Biologic Response[NCT03515941]Early Phase 16 participants (Actual)Interventional2018-06-22Terminated (stopped due to The PI has decided to close the study due to the outdated study design.)
Induction Chemotherapy for Locally Advanced Esophageal Cancer: A Phase II Study[NCT03110926]Phase 240 participants (Anticipated)Interventional2017-06-19Active, not recruiting
Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer[NCT00381706]Phase 2245 participants (Actual)Interventional2006-09-15Completed
A Randomized, Phase II, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Onartuzumab (MetMAb) In Combination With 5-Fluorouracil, Folinic Acid, And Oxaliplatin (mFOLFOX6) In Patients With Metastatic HER2-Negative G[NCT01590719]Phase 2123 participants (Actual)Interventional2012-07-31Completed
A Phase II/III Randomized Controlled Study of Neoadjuvant FOLFOX6 Treatment With or Without Radiation Compared to 5-Fu Based Chemoradiation in Treating Patients With Resectable Rectal Cancer[NCT01211210]Phase 2/Phase 3495 participants (Actual)Interventional2010-06-30Active, not recruiting
Total Mesorectal Excision(TME) With Lateral Lymph Node Dissection Versus TME After Neoadjuvant Chemo-radiotherapy of Lower Rectal Cancer With Suspected Local Lymph Node Metastasis[NCT03587480]250 participants (Anticipated)Interventional2018-12-17Recruiting
A Randomised Trial of Preoperative Radiotherapy for Stage T3 Adenocarcinoma of Rectum[NCT00145769]Phase 3326 participants (Actual)Interventional2001-07-31Completed
Randomized, Placebo-Controlled, Double-Blind Phase 2 Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product(IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach[NCT01246960]Phase 2168 participants (Actual)Interventional2011-04-30Completed
Validation of the French Version of the Low Anterior Resection Syndrome (LARS) Score for Measuring Bowel Dysfunction After Sphincter-preserving Surgery Among Rectal Cancer Patients[NCT03569488]1,100 participants (Anticipated)Observational2020-01-24Recruiting
A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer[NCT00573131]Phase 2137 participants (Actual)Interventional2008-01-31Terminated (stopped due to OncoGel did not show any impact on overall tumor response)
Chemotherapy-based Split Stereotactic Body Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: Study Protocol of a Prospective, Single-arm Phase II Trial[NCT04289792]Phase 227 participants (Anticipated)Interventional2020-05-09Recruiting
A Randomized, Phase III, Multicenter, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With 5-Fluorouracil, Folinic Acid, and Oxaliplatin (mFOLFOX6) in Patients With Metastatic HER2-Negative,[NCT01662869]Phase 3564 participants (Actual)Interventional2012-11-30Completed
Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients With Metastatic Pancreatic Cancer After Prior Chemotherapy[NCT01658943]Phase 2137 participants (Actual)Interventional2012-08-31Completed
Phase 1 Study of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and Electrostatic PIPAC (ePIPAC) With Paclitaxel for Peritoneal Carcinomatosis - PIPAC2 Study[NCT05395910]Phase 136 participants (Anticipated)Interventional2022-10-31Recruiting
A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin, and Oxaliplatin (mFOLFOX6) Every Two Weeks With Bevacizumab to the Same Regimen Without Bevacizumab for the Treatment of Patients With Resected Stages II and III Carcinoma [NCT00096278]Phase 32,710 participants (Actual)Interventional2004-09-15Completed
BEV-IP: Perioperative Chemotherapy With Bevacizumab in Patients Undergoing Cytoreduction and Intraperitoneal Chemoperfusion for Colorectal Carcinomatosis[NCT02399410]Phase 260 participants (Actual)Interventional2015-12-31Active, not recruiting
Risk of Acute Kidney Injury in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intra-peritoneal Chemotherapy[NCT04941625]150 participants (Anticipated)Observational2018-02-23Recruiting
A Phase I/II Study of Weekly Intravenous Oxaliplatin in Combination With Oral Daily Capecitabine and Radiation Therapy in the Neoadjuvant Treatment of Rectal Cancer[NCT00086931]Phase 1/Phase 237 participants (Actual)Interventional2003-09-30Completed
Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study[NCT02114359]Phase 3111 participants (Actual)Interventional2014-02-28Completed
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)[NCT01917552]Phase 3870 participants (Anticipated)Interventional2013-08-19Recruiting
Phase III Trial of S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer[NCT01671449]Phase 3338 participants (Actual)Interventional2012-12-31Completed
MRI Simulation-guided Boost in Short-course Preoperative Radiotherapy (SCPRT) Followed by Consolidation Chemotherapy Versus Long Course Chemoradiation for Unresectable Rectal Cancer[NCT03714490]Phase 2200 participants (Anticipated)Interventional2018-10-23Recruiting
Resource-Sparing Curative Treatment for Rectal Cancer[NCT01459328]Phase 3350 participants (Anticipated)Interventional2009-09-30Recruiting
Gemcitabine Plus Capecitabine Versus Gemcitabine Alone In Advanced Pancreatic Cancer. A Randomized Phase III Trial[NCT00030732]Phase 3319 participants (Actual)Interventional2001-06-30Completed
Capecitabine And Gemcitabine In Patients With Advanced Or Metastatic Biliary Tract Cancer, A Multicenter Phase II Trial[NCT00073905]Phase 244 participants (Actual)Interventional2003-04-30Completed
A Multicenter, Randomised Phase II Trial on the Therapy of Advanced Gastric Cancer or Adenocarcinoma of the Esophagogastric Junction in Patients Older Than 65 Years With Specific Regard of Quality of Life and Pharmacogenetic Risk Profile[NCT00737373]Phase 2143 participants (Actual)Interventional2007-08-31Completed
A Phase I, Open-Label, Non-Randomized, Dose-Escalating Safety, Tolerability and Pharmacokinetic Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors[NCT02454062]Phase 1120 participants (Actual)Interventional2013-03-31Completed
Phase I Study of PS-341 (VELCADE) in Combination With 5FU/LV Plus Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00098982]Phase 116 participants (Actual)Interventional2004-09-30Completed
Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial[NCT02604615]Phase 360 participants (Anticipated)Interventional2014-10-31Recruiting
Prospective Study to Analyze the Predictive Role of Factors Implicated in the Signaling Pathway of ERCC1 in Response to Treatment With Neoadjuvant Radiochemotherapy in Patients With Esophageal Cancer[NCT00953511]80 participants (Actual)Interventional2009-08-31Completed
A Study of ZD1839 (Iressa) in Combination With Oxaliplatin, 5-Fluorouracil (5-FU) and Leucovorin (LV) in Advanced Solid Malignancies (Phase I) and Advanced Colorectal Cancers (Phase II)[NCT00025142]Phase 20 participants Interventional2001-07-31Completed
A Phase II Study of Capecitabine and Oxaliplatin (XELOX) in Adenocarcinoma of the Small Bowel and Ampulla of Vater[NCT00354887]Phase 231 participants (Actual)Interventional2004-11-30Completed
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer. A Pan-European Prospective Multicenter Double Single Arm Cohort Study.[NCT06068023]400 participants (Anticipated)Observational2023-07-01Recruiting
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Combination in Microsatellite Stable (MSS), MGMT Silenced Metastatic Colorectal Cancer (mCRC): the MAYA Study[NCT03832621]Phase 2135 participants (Actual)Interventional2019-03-25Completed
A Phase I Study Of Hepatic Arterial Infusion With Floxuridine And Dexamethasone In Combination With Intravenous Oxaliplatin Plus 5-Fluorouracil And Leucovorin In Patients With Unresectable Hepatic Metastases From Colorectal Cancer[NCT00008294]Phase 10 participants Interventional2000-08-31Completed
Phase 1 Study of Postoperative Capecitabine With Concurrent Radiation in Elderly With Stage II/III Rectal Cancer[NCT01268943]Phase 118 participants (Actual)Interventional2010-11-30Completed
Randomized, Placebo Controlled, Phase II Trial, on the Effect of an Oral Supplement,TK3 (Tryptophan and Thiamine) on the Quality of Life and Chemotherapy Tolerance in Cancer Patients With Advanced Disease.[NCT03341286]Phase 2140 participants (Anticipated)Interventional2017-11-30Not yet recruiting
A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study)[NCT00407186]Phase 3788 participants (Actual)Interventional2007-01-11Active, not recruiting
A Pilot Study to Test the Feasibility of the Combination of Gemcitabine and Anti-PD1 Monoclonal Antibody (CT-011) in the Treatment of Resected Pancreatic Cancer[NCT01313416]Phase 22 participants (Actual)Interventional2012-09-30Terminated (stopped due to Drug supply issues)
Impact of Widths After Gastric Tube Reconstruction on Quality of Life for Patients With Esophagogastric Cancers[NCT01911832]Phase 360 participants (Anticipated)Interventional2012-03-31Recruiting
Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study[NCT04776590]Phase 230 participants (Anticipated)Interventional2021-01-28Recruiting
A Randomized, Multicenter, Double Blind, Phase II Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable Esophageal Squamous Cell Carcinoma[NCT05213312]Phase 2/Phase 390 participants (Anticipated)Interventional2022-06-01Recruiting
Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma(cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial[NCT03001596]264 participants (Actual)Interventional2017-01-31Completed
Phase II-III Study of an Optimized LV-5FU-Oxaliplatin Strategy in Metastatic Colorectal Cancer. Optimox2 Study. C02-2[NCT00274872]Phase 2/Phase 3600 participants (Anticipated)Interventional2004-01-31Active, not recruiting
Phase II Study Evaluating the Interest of the Re-introduction of Pemetrexed and Platinum (Cisplatin or Carboplatin) With Prolonged Angiogenic Blocking by Bevacizumab in Non Squamous Non Small Cell Lung Cancer of Advanced Stage.[NCT01705184]Phase 2120 participants (Actual)Interventional2012-12-31Completed
Randomized Phase III Study of 5-FU Continuous Infusion (5-FUci) Versus CPT-11 Plus CDDP (CP) Versus S-1 Alone (S-1) in Advanced Gastric Cancer (JCOG9912)[NCT00142350]Phase 3690 participants Interventional2000-11-30Completed
Apatinib Plus XELOX Regime as Neoadjuvant Therapy in Locally Advanced Gastric Cancer Patients With Lymph Node Metastasis[NCT03229096]Phase 235 participants (Anticipated)Interventional2017-02-01Recruiting
A Phase III Multicenter Randomized Clinical Trial Comparing Gemcitabine Alone Or In Combination With Capecitabine For The Treatment Of Patients With Advanced Pancreatic Cancer[NCT00032175]Phase 3508 participants (Anticipated)Interventional2002-04-30Completed
Efficacy and Tolerance of RADIOEMBOLIZATION for Patients With Unresectable Intrahepatic Cholangiocarcinoma With Tumor Progression After First-line Therapy[NCT01383746]Phase 1/Phase 25 participants (Actual)Interventional2011-10-31Terminated (stopped due to Not enough inclusion)
Induction Chemotherapy, Preoperative Radiochemotherapy, Consolidation Chemotherapy, Operation and Adjuvant Chemotherapy in the Treatment of Locally Advanced Rectal Cancer- OIGIT 5-01 Phase II Trial[NCT01489332]Phase 260 participants (Anticipated)Interventional2011-10-31Recruiting
Maintenance of Chemotherapy Following Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer[NCT01613469]Phase 25 participants (Actual)Interventional2011-08-31Terminated (stopped due to Re-eval of patient population)
Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies[NCT02648711]Phase 141 participants (Actual)Interventional2015-10-31Terminated (stopped due to Company decision)
A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer[NCT01187212]Phase 2195 participants (Actual)Interventional2010-08-31Completed
Open-label Randomized Multicentre Phase IIIb Trial Comparing Parenteral Substitution Versus Best Supportive Nutritional Care in Patients With Pancreatic Cancer Receiving 2nd Line Chemotherapy[NCT01362582]Phase 332 participants (Actual)Interventional2010-03-31Terminated
Phase III Comparison of Adjuvant Chemoendocrine Therapy With CAF and Concurrent or Delayed Tamoxifen to Tamoxifen Alone in Postmenopausal Patients With Involved Axillary Lymph Nodes and Positive Receptors[NCT00929591]Phase 31,558 participants (Actual)Interventional1989-05-31Completed
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertu[NCT03272477]Phase 2257 participants (Actual)Interventional2017-10-05Active, not recruiting
A Prospective Multicenter Open-label, Randomized Phase II Study of Pembrolizumab in Combination With Neoadjuvant EC-Paclitaxel Regimen in HER2-negative Inflammatory Breast Cancer.[NCT03515798]Phase 281 participants (Anticipated)Interventional2018-07-24Recruiting
A Multicenter, Randomized, Open-label, Phase II Trial Aiming to Evaluate the Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2 Positive Breast Cancer Patients[NCT03571633]Phase 290 participants (Anticipated)Interventional2018-08-06Recruiting
Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients[NCT01428414]Phase 2100 participants (Anticipated)Interventional2011-08-31Active, not recruiting
A Phase II Trial of Dose Escalated Proton Beam Therapy or Photon Therapy for Resectable and Unresectable Esophageal Cancer[NCT03234842]Phase 20 participants (Actual)Interventional2017-10-30Withdrawn (stopped due to non-accrual)
T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System[NCT02662348]Phase 16 participants (Anticipated)Interventional2016-02-29Enrolling by invitation
A Phase I/II Trial of Preoperative Oxaliplatin, Docetaxel, and Capecitabine With Concurrent Radiation Therapy in Localized Carcinoma of the Esophagus or Gastroesophageal Junction[NCT00193128]Phase 1/Phase 259 participants (Actual)Interventional2004-04-30Completed
Chemotherapy Administered Every 2 Weeks With or Without a Single Injection of Pegfilgrastim as First or Second-Line Treatment in Subjects With Locally Advanced or Metastatic Colon Cancer[NCT00094809]Phase 2252 participants (Actual)Interventional2003-02-01Completed
A Dose Escalating (Phase I) Study Looking at the Biomodulation of Capecitabine by Docetaxel and Gemcitabine in Patients With Advanced Pancreas Cancer[NCT00320749]Phase 121 participants (Actual)Interventional2005-12-31Completed
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547]Phase 220 participants (Anticipated)Interventional2019-01-31Not yet recruiting
Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma[NCT00215644]Phase 272 participants (Actual)Interventional2005-08-31Completed
Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases[NCT01095523]Phase 20 participants (Actual)Interventional2010-01-14Withdrawn
Phase 1b Trial of 5-fluorouracil, Leucovorin, Irinotecan in Combination With Temozolomide (FLIRT) and Bevacizumab for the First-line Treatment of Patients With MGMT Silenced, Microsatellite Stable Metastatic Colorectal Cancer.[NCT04689347]Phase 118 participants (Anticipated)Interventional2021-01-01Recruiting
Open-label, Multicenter, Phase II Study Of First-line Biweekly Irinotecan, Oxaliplatin And Infusional 5-FU/LV (FOLFOXIRI) In Combination With Bevacizumab In Patients With Metastatic Colorectal Cancer[NCT01163396]Phase 257 participants (Actual)Interventional2007-07-31Completed
A Phase II Study Assessing Efficacy and Safety of TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated Metastatic Colorectal Cancer[NCT03517618]Phase 241 participants (Actual)Interventional2014-07-05Completed
Development of a Prospective Clinicobiological Database in Metastatic Digestive Cancers[NCT03978078]200 participants (Anticipated)Interventional2016-09-12Recruiting
Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.[NCT05687617]Phase 230 participants (Anticipated)Interventional2022-12-15Recruiting
A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination With a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients With HER2-positive Advanced Gastric Cancer[NCT01041404]Phase 3584 participants (Actual)Interventional2005-09-30Completed
Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer[NCT02004769]Phase 267 participants (Actual)Interventional2013-11-30Completed
Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks[NCT02852096]600 participants (Anticipated)Interventional2015-11-30Recruiting
Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy:Prospective Observational Study.[NCT02250209]Phase 240 participants (Anticipated)Interventional2014-07-31Recruiting
A Retrospective Study for Evaluation of Real-world Efficacy and Safety of Ramucirumab Plus Paclitaxel in Patients With Locally-advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04192734]1,063 participants (Actual)Observational2019-12-18Completed
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System[NCT05165602]30 participants (Anticipated)Observational2022-01-01Not yet recruiting
A Phase 1B/2 Study of Trastuzumab, Bevacizumab With Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy (TREAZURE)[NCT05640830]Phase 1/Phase 247 participants (Anticipated)Interventional2023-01-01Recruiting
Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study[NCT03024450]98 participants (Actual)Observational [Patient Registry]2012-01-31Completed
Cytoreductive Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy and Systemic Chemotherapy in Gastric Cancer With Regional Peritoneal Metastasis, a Multicenter and Single-arm Phase III Study[NCT03023436]Phase 3220 participants (Anticipated)Interventional2016-01-31Recruiting
A Phase I Study of the Efficacy and Safety of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors[NCT05707910]Phase 19 participants (Anticipated)Interventional2023-02-10Recruiting
A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer[NCT01396707]Phase 255 participants (Actual)Interventional2011-06-30Completed
A Prospective Study for Real-world Data (RWD) of Ramucirumab Plus Paclitaxel in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04915807]222 participants (Anticipated)Observational [Patient Registry]2021-06-30Not yet recruiting
A Phase II Study of Adjuvant Chemotherapy of S-1 With Oxaliplatin in Gastric Cancer at Stage IIIB/ IV (AJCC 6th) After D2 Resection[NCT02191566]Phase 28 participants (Actual)Interventional2015-05-31Terminated (stopped due to The patient's study enrollment was too low.)
European Study Group For Pancreatic Cancer - Trial 3[NCT00058201]Phase 31,030 participants (Anticipated)Interventional2001-07-31Completed
A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.[NCT02736552]Phase 30 participants (Actual)Interventional2016-03-31Withdrawn
Preoperative Radiochemotherapy With IMRT - Simultaneous Integrated Boost in Locally Advanced Rectal Cancer - BISER[NCT02268006]Phase 250 participants (Anticipated)Interventional2014-01-31Recruiting
Essai Randomise Comparant Deux Stategies De Chimiotherapie Dans Les Cancers Pancreatiques Avances: LV5FU2 Simplifie + Cisplatine Suivi de Gemcitabine, Versus Gemcitabine Suivi de LV5FU2 Simplifie + Cisplatine en Can de Progression[NCT00303758]Phase 3202 participants (Actual)Interventional2005-10-31Completed
Prospective Randomized Controlled Trial of Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy[NCT03734952]537 participants (Anticipated)Interventional2023-05-01Recruiting
A Multicenter, Randomized Phase II Trial of Avastin Plus Gemcitabine Plus 5FU/Folinic Acid (A + FFG) vs. Avastin Plus Oxaliplatin Plus 5FU/Folinic Acid (A + FOLFOX 4) as Therapy for Patients With Metastatic Colorectal Cancer[NCT00192075]Phase 284 participants (Actual)Interventional2003-06-30Completed
Follow up and Functional Outcome of Organ Saving Treatment in Patients With Good Response to Neo-adjuvant (Chemo)Radiation for Rectal Cancer[NCT02278653]100 participants (Anticipated)Observational [Patient Registry]2014-03-31Active, not recruiting
Diagnostic Value of Novel MR Imaging Techniques for the Primary Staging and Restaging of Rectal Cancer[NCT01721785]307 participants (Actual)Observational2012-10-31Completed
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer[NCT00100841]Phase 266 participants (Actual)Interventional2004-11-30Completed
Preoperative Combined Radiochemotherapy for Patients With Newly Diagnosed, Primary Operable and Locally Advanced Rectal Carcinoma (cT3, Nx, M0) of the Lower and Middle Rectum[NCT00297141]Phase 260 participants (Actual)Interventional2004-10-31Completed
Preoperative Induction Chemotherapy in Combination With Bevacizumab Followed by Combined Chemoradiotherapy in Locally Advanced Rectal Cancer With High Risk of Recurrence- Phase II Pilot Study With Preoperative Administration of Capecitabine (Xeloda), Oxal[NCT01434147]Phase 225 participants (Actual)Interventional2011-10-31Completed
A Phase III Study of Pre and Post Chemoradiation 5-FU vs. Pre and Post Chemoradiation Gemcitabine for Postoperative Adjuvant Treatment of Resected Pancreatic Adenocarcinoma[NCT00003216]Phase 3518 participants (Anticipated)Interventional1998-07-31Completed
Phase II Clinical Trial of Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer[NCT01022541]Phase 247 participants (Actual)Interventional2006-06-30Completed
Randomized Trial of Adjuvant Chemotherapy With Cisplatin Followed by Oral Fluorouracil (UFT) in Serosa-positive Gastric Cancer (JCOG9206-2)[NCT00147147]Phase 3280 participants Interventional1993-01-31Completed
A Study of 18F-FLT Positron Emission Tomography (PET)/Computed Tomography Imaging in Pediatrics With Myeloproliferative Neoplasms[NCT03121599]3 participants (Actual)Interventional2017-06-11Terminated (stopped due to Delayed study materials, poor recruitment)
A Study of 18F-FLT Positron Emission Tomography/Computed Tomography (PET/CT) Imaging in Cases of Prefibrotic/Early Primary Myelofibrosis (PMF) and Essential Thrombocythemia (ET)[NCT03116542]21 participants (Anticipated)Interventional2017-05-07Recruiting
Usefulness of Cell-free DNA Quantification With Fluorescent Assay in Response Evaluation of Palliative Chemotherapy[NCT05227950]100 participants (Anticipated)Observational [Patient Registry]2022-01-01Recruiting
A Randomized, Double-blind, Placebo-controlled, Phase III Study of Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo in Patients With Previously Treated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00056446]Phase 3855 participants (Actual)Interventional2003-01-31Completed
A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo[NCT00056459]Phase 31,168 participants (Actual)Interventional2003-02-28Completed
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) Functional CTCs Using EPIDROP[NCT05346536]63 participants (Anticipated)Interventional2022-06-16Recruiting
A Phase II Study Of Paclitaxel-Based Chemoradiotherapy Regimen With Selective Surgical Salvage For Resectable Locoregionally Advanced Carcinoma Of The Esophagus[NCT00069953]Phase 243 participants (Actual)Interventional2003-09-30Completed
Pre- and Postoperative Incidence and Prognostic Implication of Positive Peritoneal Lavage and Circulating Tumor DNA in Patients With Pancreatic Cancer[NCT05400681]200 participants (Anticipated)Observational [Patient Registry]2020-08-01Recruiting
Randomized Phase II/III Trial Comparing Folririnox Association [Oxaliplatin / Irinotecan / LV5FU2] Versus Gemcitabine in First Line of Chemotherapy in Metastatics Pancreas Cancers Patients[NCT00112658]Phase 2/Phase 3342 participants (Actual)Interventional2004-11-30Completed
Evaluation of the Effect of Ocoxin-Viusid® Nutritional Supplement in the Life Quality in Patients Diagnosed With Advanced Pancreatic Adenocarcinoma. Phase II[NCT03717298]Phase 230 participants (Actual)Interventional2018-10-30Completed
1911GCCC:Two Parallel, Single-arm, Open Label, Phase 2 Trials of Galeterone Alone or Galeterone Combined With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma Refractory to Standard Chemotherapy[NCT04098081]Phase 258 participants (Anticipated)Interventional2019-12-12Recruiting
Roux-en-Y Gastric Bypass Versus Loop Gastrojejunostomy for Malignant Gastric Outlet Obstruction[NCT05986890]16 participants (Anticipated)Interventional2023-08-17Recruiting
Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma[NCT04662112]Phase 1/Phase 240 participants (Actual)Interventional2021-06-15Active, not recruiting
Phase I Study of Low Kilovoltage Intraoperative Radiation for Patients With Resectable Pancreatic Adenocarcinoma[NCT02599662]Phase 112 participants (Anticipated)Interventional2015-01-31Recruiting
Pharmacotyping of Patient-derived Pancreatic Cancer Organoids From Endoscopic Ultrasound-guided Biopsy as a Tool for Predicting Oncological Response[NCT05196334]88 participants (Actual)Observational2021-07-01Active, not recruiting
A Phase III, Open Label, Multicentre Randomised Clinical Study Comparing Acelarin (NUC-1031) With Gemcitabine in Patients With Metastatic Pancreatic Carcinoma[NCT03610100]Phase 2/Phase 3328 participants (Anticipated)Interventional2015-12-31Suspended (stopped due to Suspended to recruitment following TSC review on efficacy and toxicities)
An Open Single-center Phase II Clinical Study of Fruquintinib Combined With Chemotherapy in Patients With Liver Metastases From Pancreatic Cancer[NCT05168527]Phase 230 participants (Anticipated)Interventional2021-09-03Recruiting
Phase II Trial of Infusional 5 FLUOROURACIL, LEUCOVORIN, OXALIPLATIN AND IRINOTECAN (FOLFIRINOX) in First Line Treatment of Advanced Biliary Tract Cancers[NCT03291899]Phase 232 participants (Anticipated)Interventional2017-01-03Recruiting
Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529]Phase 228 participants (Anticipated)Interventional2021-03-01Recruiting
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer: The SMART Study[NCT04276857]27 participants (Anticipated)Interventional2024-01-01Not yet recruiting
Phase II Study of Neoadjuvant Folfirinox Chemotherapy Followed by Pembrolizumab Followed by Surgery for Patients With Localized, Resectable Adenocarcinoma of the Pancreas[NCT05132504]Phase 230 participants (Anticipated)Interventional2022-08-31Recruiting
A Multicenter, Open-label, ExploRatory Platform Trial to EValuate ImmunOtherapy Combinations With Chemotherapy for the Treatment of Patients With PreviousLy UnTreated MetastatIc Pancreatic AdenOcarciNoma (REVOLUTION)[NCT04787991]Phase 145 participants (Anticipated)Interventional2021-08-09Active, not recruiting
A Phase II Trial of Flouro-Gem as a First Line Treatment of Metastatic Adenocarcinoma of the Pancreas (GEFLUPAN)[NCT04769414]Phase 248 participants (Actual)Interventional2021-02-20Completed
A Phase II Study of Induction Consolidation and Maintenance Approach for Patients With Advanced Pancreatic Cancer[NCT01488552]Phase 1/Phase 260 participants (Actual)Interventional2011-11-30Completed
An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX[NCT03450018]Phase 1/Phase 230 participants (Anticipated)Interventional2019-01-10Recruiting
Clinical Efficacy of QingyiHuaji Optimized Formula Combined With Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer: a Prospective, Multicenter, Randomized Controlled Clinical Study[NCT05840341]Phase 3306 participants (Anticipated)Interventional2023-05-01Recruiting
An Open-label, Single-centre, Single-arm Phase II Study of Capecitabine Combined With Oxaliplatin and Irinotecan (Xeloxiri) as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma[NCT01558869]Phase 237 participants (Actual)Interventional2012-04-30Completed
Randomized Phase II Trial Evaluating the Efficacy of a Sequential Treatment Gemcitabine Plus Nab-paclitaxel (Gembrax) Followed by Folfirinox Versus Folfirinox Alone in Patients Treated in First Metastatic Line Pancreatic Cancer[NCT05065801]Phase 2162 participants (Anticipated)Interventional2022-01-30Recruiting
Phase II Study to Assess the Interest of a Sequential Treatment With Gemcitabine/Nab-paclitaxel (GEMBRAX) and Then FOLFIRINOX Followed by Stereotactic Magnetic Resonance-guided Adaptive Radiotherapy in Patients With Locally Advanced Pancreatic Cancer[NCT04570943]Phase 2103 participants (Anticipated)Interventional2020-12-15Recruiting
Survival Rate and Treatment Cost in Patients With Pancreatic Cancer With the Advent of New Chemotherapeutic Agents in Korea: An Analysis Using NHIS Database and K-PaC Registry Focusing on the Newest One, Liposomal Irinotecan[NCT04984174]54,000 participants (Anticipated)Observational2021-08-04Recruiting
A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma[NCT03943667]Phase 3211 participants (Actual)Interventional2019-05-23Completed
A Study of Preoperative FOLFIRINOX For Potentially Curable Pancreatic Cancer[NCT03167112]Phase 220 participants (Anticipated)Interventional2017-07-03Recruiting
Drug Treatment for Bowel Cancer: Making the Best Choices When a Milder Treatment is Needed[NCT00070213]Phase 3460 participants (Actual)Interventional2003-09-30Completed
Aflibercept and 5-FU vs. FOLFOX as 1st Line Treatment for Elderly or Frail Elderly Patients With Metastatic Colorectal Cancer[NCT03530267]Phase 2124 participants (Actual)Interventional2018-09-28Active, not recruiting
PAXG Out in the Country[NCT04480268]Phase 4175 participants (Anticipated)Interventional2020-07-08Recruiting
Sequential FDG-PET (Positron Emission Tomography) and Induction Chemotherapy in Locally Advanced Adenocarcinoma of the Esophagogastric Junction (AEG): The Heidelberg Imaging Program in Cancer of the Oesophago-gastric Junction During Neoadjuvant Treatment:[NCT01271322]Phase 20 participants Interventional2010-10-31Terminated
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer[NCT00114231]Phase 290 participants (Actual)Interventional2006-05-31Completed
Low-dose Versus Standard-dose Capecitabine Adjuvant Chemotherapy for Chinese Elderly Patients With Stage II/III Colorectal Cancer: A Randomized, Phase 3 Non-inferiority Study[NCT02316535]Phase 3710 participants (Anticipated)Interventional2014-11-30Recruiting
A Phase II Study of 5-Fluorouracil, Bevacizumab (Avastin), and Radiation in the Preoperative or Adjuvant Treatment of Patients With Stage II / III Rectal Cancer[NCT00308516]Phase 266 participants (Actual)Interventional2006-03-31Completed
Multi Center, Open Label, Single Arm Trial Evaluating Panitumumab in Combination With FOLFIRI Therapy Following First Line FOLFOX and Bevacizumab Treatment of Metastatic Colorectal Cancer[NCT00411450]Phase 2116 participants (Actual)Interventional2006-11-30Completed
Effect of Topical Diclofenac on Clinical Outcome in Breast Cancer Patients Treated With Capecitabine: A Randomized Controlled Trial.[NCT05641246]Phase 266 participants (Anticipated)Interventional2022-12-08Active, not recruiting
A Multi-center, II Phase,Randomized Controlled Clinical Study of Capecitabine Metronomic Chemotherapy After Gemcitabine Plus Capecitabine Standard Adjuvant Therapy for Stage II/III Pancreatic Cancer[NCT03959150]Phase 2/Phase 3231 participants (Anticipated)Interventional2020-01-05Recruiting
Oxaliplatin (NSC-266046) Plus Protracted Infusion 5-Fluorouracil And Radiation For Potentially Curable Esophageal Cancer: A Phase II Trial With Molecular Correlates[NCT00086996]Phase 298 participants (Actual)Interventional2004-09-30Completed
A Phase II Study of Neoadjuvant Chemotherapy With Modified FOLFOX6 Regimen and Effects of Tumor Regression in Locally Advanced Gastric Cancer[NCT02226380]Phase 275 participants (Anticipated)Interventional2013-10-31Recruiting
A Phase III Study Comparing Adjuvant Chemotherapy Consisting of Capecitabine/Oxaliplatin vs Surgery Alone in Patients With Stage II (T1N2, T2N1, T3N0), IIIa (T2N2, T3N1, T4NO), and IIIb (T3N2) Gastric Adenocarcinoma[NCT00411229]Phase 31,035 participants (Actual)Interventional2006-06-30Completed
A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resecti[NCT01935778]Phase 3286 participants (Anticipated)Interventional2013-10-02Recruiting
The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial[NCT03607656]Phase 2/Phase 3270 participants (Actual)Interventional2018-06-08Completed
A Validation Study of Relationships Among Genomic Gene Expression Profile, Prognosis and Prediction of Adjuvant Chemotherapy Benefit With Capecitabine and Oxaliplatin in Gastric Cancer Stage II and III (6th AJCC) Patients After D2 Surgery Using a Phase 3 [NCT03403296]640 participants (Actual)Observational2016-07-13Completed
Phase III Multicenter Randomized Controlled Trial of Adjuvant Chemoradiotherapy vs Chemotherapy for Radical Resected Advanced Gastric Carcinoma Concurrent With Lymph Node Metastasis and Lymphovascular Invasion[NCT03680261]Phase 3556 participants (Anticipated)Interventional2018-10-01Not yet recruiting
A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)[NCT04793932]Phase 2261 participants (Anticipated)Interventional2020-11-03Recruiting
Feasibility Study of Intraperitoneal Paclitaxel With Oxaliplatin and Capecitabine in Patients With Advanced Gastric Cancer[NCT01739894]Phase 220 participants (Anticipated)Interventional2013-01-31Recruiting
Phase II Study of the Combination of Cetuximab, Capecitabine, and Oxaliplatin With Out Without Bevacizumab as Initial Therapy for Metastatic Colorectal Cancer[NCT00321100]Phase 223 participants (Actual)Interventional2006-04-12Terminated (stopped due to Enrollment closed 10/15/2008 based on data about KRAS.)
Total Neoadjuvant Therapy in Rectal Cancer Treatment[NCT04747951]Phase 4280 participants (Anticipated)Interventional2020-10-30Recruiting
A Single Arm, Phase II Study of TNFerade™ Biologic Gene Therapy + Radiation + 5-FU and Cisplatin in Locally Advanced, Resectable, Esophageal Cancer[NCT00051480]Phase 20 participants InterventionalCompleted
A Phase II Study Of Sunitinib In Combination With Irinotecan, L-leucovorin, And 5-Fluorouracil In Patients With Unresectable Or Metastatic Colorectal Cancer[NCT00668863]Phase 271 participants (Actual)Interventional2008-05-31Completed
Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Pilot Study[NCT05396326]Phase 120 participants (Anticipated)Interventional2022-06-01Not yet recruiting
Neoadjuvant Transcatheter Arterial Chemoinfusion and Embolism (TACiE) for Patients With Locally Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction: a Prospective, Phase 2, Single Arm Trial.[NCT05346874]Phase 237 participants (Anticipated)Interventional2022-06-01Not yet recruiting
Multicenter, Open Lable Phase II Study to Evaluate the Safety and Efficacy of a Perioperative Chemotherapy With Docetaxel, Cisplatin and Capecitabine in Patients With Gastric Adenocarcinoma, Adenocarcinoma of the Gastro-esophageal Junction or the Distal E[NCT00865982]Phase 250 participants (Anticipated)Interventional2008-09-30Active, not recruiting
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis[NCT03079427]Phase 2101 participants (Actual)Interventional2017-05-15Completed
A Phase III, Randomized Open-Label Study to Compare the Pharmacokinetics, Efficacy, and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-Positive Early Breast Cancer (EBC)[NCT00950300]Phase 3596 participants (Actual)Interventional2009-10-16Completed
Neoadjuvant Therapy With Trastuzumab and Chemotherapy and the Resultant Pathologic Complete Response Observed in HER2 Positive Breast Cancer;a Systematic Review[NCT05931042]1,209 participants (Actual)Observational2023-06-01Completed
A Prospective, Phase II Study of Percutaneous Endoscopic Gastrostomy Before Definitive Concurrent Chemoradiation Therapy in Patients With Esophageal Squamous Cell Carcinoma[NCT04380480]Phase 263 participants (Actual)Interventional2020-02-01Completed
A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres[NCT00450203]Phase 2/Phase 31,103 participants (Anticipated)Interventional2007-10-31Recruiting
A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junctio[NCT00583674]Phase 2171 participants (Actual)Interventional2007-12-31Completed
Neoadjuvant Radiotherapy and Capecitabine With or Without Panitumumab in Patients With Advanced, K-ras Unmutated Rectal Cancer. A Randomized Multicenter Phase II Trial[NCT00814619]Phase 268 participants (Actual)Interventional2008-11-30Completed
A Phase I Study of Capecitabine, Cisplatin and Imatinib in Patients With Unresectable or Metastatic Gastric Cancer.[NCT00601510]Phase 138 participants (Actual)Interventional2007-11-30Completed
A Phase III Study of Chemotherapy and Chemoradiotherapy With or Without Algenpantucel-L (HyperAcute®-Pancreas) Immunotherapy in Subjects With Surgically Resected Pancreatic Cancer[NCT01072981]Phase 3722 participants (Actual)Interventional2010-04-30Completed
A Phase II Study of Algenpantucel-L (HyperAcute Pancreas) Cancer Vaccine in Subjects With Surgically Resected Pancreatic Cancer[NCT00569387]Phase 273 participants (Actual)Interventional2007-12-31Completed
A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma[NCT02465736]Phase 3610 participants (Anticipated)Interventional2015-07-31Recruiting
Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors[NCT03863145]Early Phase 190 participants (Anticipated)Interventional2022-06-14Recruiting
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma[NCT00752570]Phase 2144 participants (Actual)Interventional2008-11-30Completed
A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330]Phase 260 participants (Actual)Interventional2007-02-28Completed
Capecitabine as Radiosensitising Agent in Neoadjuvant Treatment of Locally Advanced Resectable Rectal Cancer[NCT01152710]Phase 257 participants (Actual)Interventional2004-06-30Completed
A Pilot Study Using Neoadjuvant Proton Beam Radiation Therapy and Chemotherapy for Marginally Resectable Carcinoma of the Pancreas[NCT00763516]8 participants (Actual)Interventional2009-02-28Completed
Preoperative Radiotherapy With Capecitabine and Bevacizumab in Locally Advanced Rectal Cancer: CRAB Phase II Study[NCT00842686]Phase 260 participants (Anticipated)Interventional2009-01-31Active, not recruiting
Prospective Randomized Phase III Study of Concurrent Capecitabine and Radiotherapy With or Without Oxaliplatin as Adjuvant Treatment for Stage II and III Rectal Cancer[NCT00714077]570 participants (Anticipated)Observational2008-04-30Recruiting
A Study Using Photon/Proton Beam Radiation Therapy and Chemotherapy for Unresectable Carcinoma of the Pancreas[NCT00685763]13 participants (Actual)Interventional2008-03-31Completed
Phase I Study of Preoperative Concurrent Chemo-radiation With Capecitabine in Elderly Rectal Cancer Patients[NCT01584544]Phase 124 participants (Actual)Interventional2011-01-31Completed
Phase I Study of Chemoradiation Therapy With Epitope Peptide Vaccine Therapy in Treating Patients With Unresectable, Advanced or Recurrent Esophageal Cancer[NCT00632333]Phase 19 participants (Anticipated)Interventional2008-02-29Recruiting
A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538]Phase 1/Phase 245 participants (Actual)Interventional2010-02-28Completed
A Phase I/II Trial of Docetaxel and Oxaliplatin in Patients With Advanced Gastric Cancer[NCT00533533]Phase 1/Phase 268 participants (Anticipated)Interventional2006-01-31Completed
Long-term Results of Plasma Epstein-Barr Virus DNA Monitoring In Nasopharyngeal Carcinoma After Curative Treatment[NCT03973723]441 participants (Actual)Observational2011-08-01Completed
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer[NCT04409860]120 participants (Anticipated)Interventional2020-05-26Recruiting
A Phase II Trial of Eloxatin in Combination With 5-Fluorouracil and Leucovorin in Patients With Advanced Colorectal Carcinoma[NCT00004102]Phase 20 participants Interventional1999-01-31Completed
Proteomic Approach Using Matrix-assisted Laser Desorption/Ionization Tandem Time-of-flight (MALDI-TOF/TOF) of Tumor Response in Rectal Carcinoma After Radiochemotherapy[NCT00855946]46 participants (Actual)Observational2009-05-31Completed
MRI for Response Evaluation After Chemoradiation for Locally Advanced Rectal Cancer[NCT04790227]50 participants (Anticipated)Observational2022-01-31Not yet recruiting
Vitro 3D Drug Sensitivity Detection of Micro Tumor (PTC) Combined With Tumor Whole Exon (WES) Sequencing Technology to Guide Postoperative Adjuvant Treatment Strategy and Prognosis of Colorectal Cancer[NCT05424692]200 participants (Anticipated)Interventional2021-09-01Recruiting
A Randomized Phase III Trial of Three Different Regimens of CPT-11 Plus 5-Fluorouracil and Leucovorin Compared to 5-Fluorouracil and Leucovorin in Patients With Advanced Adenocarcinoma of the Colon and Rectum[NCT00003594]Phase 31,691 participants (Actual)Interventional1998-10-31Completed
XELOX III. Capecitabine (Xeloda) in Combination With Oxaliplatin (Eloxatin) as First-line Treatment of Patients With Advanced or Metastatic Colorectal Cancer. A Randomized Phase II Study[NCT00212615]Phase 2/Phase 3116 participants (Actual)Interventional2004-02-29Completed
Phase II Trial of Weekly Carboplatin-Paclitaxel Adjuvant Chemotherapy After Intensity Modulated Extended-field Chemoradiation in the Treatment of Locally Advanced Cervical Cancer With Para-aortic Positive Nodes[NCT04016142]Phase 221 participants (Actual)Interventional2020-07-15Active, not recruiting
Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression[NCT02309658]Phase 250 participants (Actual)Interventional2013-09-30Completed
A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY[NCT00002631]Phase 3298 participants (Anticipated)Interventional1995-06-30Completed
A Clinical Trial to Evaluate Postoperative Immunotherapy and Postoperative Systemic Chemotherapy in the Management of Resectable Colon Cancer[NCT00427570]Phase 30 participants Interventional1977-09-30Completed
"Radical External Beam Chemoradiation in Patients With Rectal Cancer: a Wait-and-see Approach"[NCT03001362]48 participants (Anticipated)Interventional2015-03-31Recruiting
Prediction of Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.[NCT02439086]20 participants (Anticipated)Interventional2015-09-30Not yet recruiting
Phase II Trial Of Gemcitabine, 5-Fluorouracil, And Leucovorin In Patients With Measurable Unresectable Or Metastatic Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, Ampulla Of Vater) And Gallbladder Carcinoma[NCT00009893]Phase 242 participants (Actual)Interventional2001-05-31Completed
A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681]Phase 26 participants (Actual)Interventional2014-09-30Terminated (stopped due to lack of funding)
Phase II Study of Docetaxel and Capecitabine as 1st Line Therapy for Patients With Locally Advanced or Metastatic Gastric Cancer[NCT00142038]Phase 280 participants Interventional2004-03-31Completed
Randomized Phase 3 Study of Xelox(Capecitabine Plus Oxaliplatin) Followed by Maintenance Capecitabine or Observation in Patients With Advanced Gastric Adenocarcinoma[NCT02289547]Phase 3184 participants (Anticipated)Interventional2015-05-31Recruiting
OGF & Gemcitabine: Novel Treatment for Pancreatic Cancer Phase I, A Safety and Toxicity Study[NCT00783172]Phase 14 participants (Actual)Interventional2009-01-31Terminated (stopped due to Problems with IRB)
Randomized Phase II-III Trial of Post-operative Treatment of Pancreatic Adenocarcinoma: Gemcitabine Versus PEFG Followed by Radiochemotherapy With Concomitant Continuous Infusion of 5-fluorouracil[NCT00960284]Phase 2/Phase 3102 participants (Actual)Interventional2003-06-30Completed
Mono-Center Phase ǀ Study on Dose Escalation of Stereotactic Body Radiotherapy (SBRT) Treating Pancreatic Cancer Patients With CyberKnife[NCT02716207]16 participants (Actual)Interventional2016-03-31Completed
3D-printing Template-assisted CT-guided I125 Seed Implantation and Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer:A Prospective Multicenter Cohort Study[NCT03964064]100 participants (Anticipated)Interventional2019-06-11Recruiting
Randomized Phase 2 Study Comparing Pathological Responses on Colorectal Cancer Metastases After Preoperative Treatment Combining Bevacizumab With FOLFOX or FOLFIRI[NCT01858649]Phase 260 participants (Actual)Interventional2013-05-31Completed
Randomised Phase 2 Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors[NCT01858662]Phase 24 participants (Actual)Interventional2014-01-31Terminated (stopped due to due to poor recrutment)
Effects of Different Treatment for Anorectal Function of Patients With Rectal Cancer: a Study Protocol for a Prospective, Observational, Controlled, Multicentre Study[NCT05671809]402 participants (Anticipated)Observational [Patient Registry]2023-01-01Not yet recruiting
A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia[NCT00040859]Phase 248 participants (Actual)Interventional2002-09-30Completed
A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin / 5-FU/ Leucovorin With Bevacizumab, or Cetuximab (C225), or With the Combination of Bevacizumab and Cetuximab for Patients With Untreated Metastatic Adenocarcinoma of the Colon or Rectum[NCT00265850]Phase 32,334 participants (Actual)Interventional2005-11-30Completed
A Phase II Study Of Docetaxel And Capecitabine In Patients With Measurable Metastatic Adenocarcinoma Of The Stomach And Gastroesophageal Junction[NCT00054457]Phase 246 participants (Actual)Interventional2003-09-30Completed
A Phase II Study to Assess Efficacy and Safety of Capecitabine and Irinotecan Plus Bevacizumab Followed by Capecitabine and Oxaliplatin Plus Bevacizumab or the Reverse Sequence in Patients With Metastatic Colorectal Cancer[NCT02119026]Phase 2120 participants (Actual)Interventional2011-02-28Completed
Surgery Outcome Treated by Neo-adjuvant Chemotherapy FOLFOXIRI Regimen in Colorectal Cancer With Liver-limited Synchronous Metastases[NCT05362825]89 participants (Anticipated)Observational2022-02-18Recruiting
A Phase II Study of OSI-774 (Tarceva) in Combination With Oxaliplatin and Capecitabine in Previously Treated Patients With Stage IV Colorectal Cancer[NCT00123851]Phase 232 participants Interventional2003-03-31Completed
International Registry on Cholangiocarcinoma Treatment[NCT01920503]40 participants (Anticipated)Observational [Patient Registry]2013-07-31Recruiting
Morbidity In Open Versus Minimally Invasive Hybrid Esophagectomy[NCT03035071]26 participants (Actual)Interventional2010-05-01Completed
Assessment of a Robotic Distal Gastrectomy on Non-inferiority of N2 Area Nodal Dissection for Clinical Stage II or III Gastric Cancer[NCT02572050]Phase 287 participants (Anticipated)Interventional2015-10-31Recruiting
The Clinical Efficacy of Patient-derived Organoid-based Drug Sensitive Neoadjuvant Chemotherapy Versus Traditional Neoadjuvant Chemotherapy in Advanced Gastric Cancer: a Prospective Multi-center Randomized Controlled Study[NCT05351398]54 participants (Anticipated)Observational2022-04-30Not yet recruiting
The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma.[NCT00674167]Phase 221 participants (Actual)Interventional2007-05-31Active, not recruiting
A RANDOMISED, CONTROLLED TRIAL OF PRE- AND POST-OPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER[NCT00002615]Phase 3500 participants (Anticipated)Interventional1994-06-30Completed
An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction.[NCT01234324]Phase 2171 participants (Actual)Interventional2010-10-31Completed
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma[NCT04999332]Phase 258 participants (Anticipated)Interventional2021-12-10Recruiting
Prospective Observational Study of Patients With Locally Advanced Gastric Cancer Treated With Perioperative Chemotherapy and Surgery[NCT01633203]61 participants (Actual)Observational2010-08-31Completed
Docetaxel-based Chemoradiotherapy Plus Periradiation Chemotherapy in R0 Gastric Cancer[NCT02640898]500 participants (Anticipated)Interventional2015-12-31Recruiting
A Phase II Study of PN-401, 5-FU and Leucovorin in Unresectable or Metastatic Adenocarcinoma of the Stomach[NCT00004233]Phase 265 participants (Actual)Interventional2001-02-28Completed
Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score Through Registration[NCT02781285]1,500 participants (Anticipated)Observational [Patient Registry]2014-12-31Recruiting
Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly[NCT02992886]Phase 268 participants (Actual)Interventional2016-09-30Completed
PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer[NCT04301557]Phase 225 participants (Anticipated)Interventional2020-07-31Recruiting
Surgical Treatment and Molecular Marker Exploration of Locally Recurrent Colorectal Cancer[NCT06114420]500 participants (Anticipated)Observational2023-01-30Recruiting
Estudo Randomizado de Fase II Com Capecitabina Versus 5-Fluorouracil/Leucovorin em Bolus Associados à Radioterapia no Tratamento Neoadjuvante de câncer de Reto Localmente avançado: INCAGI004.[NCT03428529]Phase 2/Phase 363 participants (Actual)Interventional2011-01-12Completed
Preoperative Radiotherapy With or Without Concurrent Chemotherapy (5-Fluorouracil and Leucovorin) in T3-4 Rectal Cancers - Randomized Trial[NCT00296608]Phase 3762 participants (Actual)Interventional1993-04-30Completed
Evaluation of Individual Radiosensitivity of Cancer Patients to be Treated by Radiotherapy or Radiochemotherapy Per-operative[NCT02797405]97 participants (Actual)Interventional2016-10-31Terminated (stopped due to Withdrawal of analysis study Partner.)
A Phase I Study Of ZD1839 (Iressa) In Combination With Irinotecan, Leucovorin, And 5-Fluorouracil In Previously Untreated, Stage IV Colorectal Cancer[NCT00026364]Phase 122 participants (Actual)Interventional2001-11-30Completed
A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) Combined Albumin Binding Paclitaxel, Cisplatin in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma.[NCT04460066]Phase 1/Phase 270 participants (Anticipated)Interventional2020-11-18Active, not recruiting
Cetuximab (Erbitux®), Capecitabine and Radiotherapy in Neoadjuvant Treatment of Patients With Locally Advanced Resectable Rectal Cancer: A Phase II Pilot Study[NCT00689702]Phase 243 participants (Actual)Interventional2007-02-28Active, not recruiting
Open Label, Randomized Multicentre Phase II/III Study of Docetaxel in Combination With Cisplatin (CDDP) or Docetaxel in Combination With 5-Fluorouracil (5-FU) and CDDP Compared to the Combination of CDDP and 5-FU in Patients With Metastatic or Locally Rec[NCT00290966]Phase 2/Phase 3610 participants Interventional1998-10-31Completed
Lateral Pelvic Lymph Node Dissection After Neoadjuvant Chemo-radiation for Preoperative Enlarged Lateral Nodes in Advanced Low Rectal Cancer: a Phase III Randomized Controlled Trial[NCT02614157]51 participants (Actual)Interventional2016-05-31Terminated (stopped due to The enrollment was too low)
Prospective Randomized Clinical Trial on Delay Phenomenon Utility in Preventing Oesophagogastric Anastomotic Dehiscence After Ivor-Lewis Esophagectomy. Pilot Study.[NCT02432794]44 participants (Actual)Interventional2015-05-31Completed
Coala-T-CBD Study: A Study of the Effect of Hemp-CBD on the Severity and Duration of Chemotherapy-Induced Peripheral Neuropathy in Patients Receiving Neurotoxic Chemotherapy for Non-Metastatic Breast, Uterine, Pancreatic, and Colorectal Cancer and All Sta[NCT04398446]Phase 256 participants (Actual)Interventional2020-05-27Active, not recruiting
A Phase II Trial of Infusional 5-Fluorouracil (5-FU), Calcium Leucovorin (LV), Mitomycin-C (Mito-C), and Dipyridamole (D) in Patients With Locally Advanced Unresected Pancreatic Adenocarcinoma[NCT00003018]Phase 254 participants (Actual)Interventional1997-09-30Completed
A Phase I/II Study Of COX-2 Inhibitor, CELEBREX (CELECOXIB), And Chemoradiation In Patients With Locally Advanced Cervical Cancer[NCT00023660]Phase 1/Phase 284 participants (Actual)Interventional2001-08-31Completed
A Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Irinotecan, Leucovorin, and 5-Fluorouracil in Subjects With Metastatic Colorectal Cancer[NCT00111761]Phase 243 participants (Actual)Interventional2002-07-31Completed
A Prospective, Single-arm Study of Simultaneous Modulated Accelerated Radiotherapy Combined With S-1/DDP for Elderly Esophageal Squamous Cell Carcinoma.[NCT02606916]Phase 242 participants (Actual)Interventional2015-07-31Completed
Taxotere-Cisplatin-5FU (TCF) Versus Taxotere-Cisplatin (TC) Versus Epirubicin-Cisplatin-5FU (ECF) as Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial[NCT00004873]Phase 20 participants Interventional1999-08-31Completed
Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib as Adjuvant Therapy for Lung and Esophageal Cancers, Thymic Neoplasms, Thoracic Sarcomas, and Malignant Pleural Mesotheliomas[NCT01143545]Phase 110 participants (Actual)Interventional2010-12-07Terminated (stopped due to Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.)
Prospective, Randomised and Multi-centric Therapy Optimisation Study for Examining the Influence of Surgical Staging on the Oncological Results for Patients With Cervix Carcinoma of the FIGO Stages IIB-IV After Chemoradiation[NCT01049100]250 participants (Anticipated)Interventional2009-04-30Recruiting
A Clinical Trial Comparing 5-Fluorouracil (5-FU) Plus Leucovorin (LV) and Oxaliplatin With 5-FU Plus LV for the Treatment of Patients With Stages II and III Carcinoma of the Colon[NCT00004931]Phase 32,472 participants (Anticipated)Interventional2000-02-29Completed
A Prospective Phase II Study of Prophylactic TPO Combined With Bone Marrow-Sparing Intensity-Modulated Radiotherapy to Reduce Platelet Inhibition in Patients With Esophageal Cancer Undergoing Concurrent Chemoradiotherapy[NCT05944809]Phase 227 participants (Anticipated)Interventional2023-07-15Not yet recruiting
The Influence of Probiotics on Vancomycin-Resistant Enterococcus[NCT00591474]8 participants (Actual)Interventional2007-12-31Terminated (stopped due to Participant lost to followup)
Phase Ⅱ Clinical Study of RALOX or CAPOX Combined With Bevacizumab in the First-line Treatment of Advanced Colorectal Cancer[NCT03813641]Phase 2100 participants (Anticipated)Interventional2019-01-28Recruiting
Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer[NCT02833753]Phase 114 participants (Actual)Interventional2016-07-31Completed
Randomized Study of Adjuvant Radiochemotherapy After Surgery Versus Radiochemotherapy Alone in Patients With Locally Advanced Esophageal Cancer[NCT00416858]Phase 340 participants (Anticipated)InterventionalCompleted
Irinotecan Combined With Infusional 5-FU/Folinic Acid or Capecitabine and the Role of Celecoxib in Patients With Metastatic Colorectal Cancer[NCT00064181]Phase 386 participants (Actual)Interventional2003-05-31Completed
Concurrent EUS-guided Intra-tumour Injection of OncoSil (32P) With Chemotherapy in Locally Advanced Pancreatic Carcinoma.[NCT05131776]Phase 2/Phase 320 participants (Anticipated)Interventional2021-11-01Recruiting
Protocole de Phase II: Etude de Faisabilite de L'Oxaliplatine en Association Chimio-Radiotherapie Concomitante Dans le Traitement Des Cancers du Pancreas Localement Avances Non Resecables[NCT00275119]Phase 20 participants Interventional2003-11-30Active, not recruiting
A Prospective, Phase Ⅱ Study of S-1 Plus Moderately Hypofractionated Conformal Radiation for Esophageal Squamous Cell Carcinoma[NCT03660449]Phase 258 participants (Actual)Interventional2017-10-01Completed
A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer[NCT00003118]Phase 356 participants (Actual)Interventional1997-10-31Completed
Monitoring Efficacy of Radiotherapy Based on Next Generation Sequencing Liquid Biopsy Technique in Lung Cancer and Esophageal Cancer: a Prospective Study[NCT04014465]150 participants (Anticipated)Observational2019-02-01Recruiting
Different Radiation Dose of Neoadjuvant Chemoradiation Followed By Surgery in Treating Patients With Locally Advanced, Resectable Thoracic Esophageal Cancer[NCT03381651]144 participants (Anticipated)Interventional2018-02-22Recruiting
Neoadjuvant Immunotherapy (PD-1 / PD-L1) Combined With Chemotherapy for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma: a Single Center, Prospective, Open, One Arm Exploratory Clinical Study[NCT05028231]46 participants (Anticipated)Observational2021-06-05Recruiting
Phase II Study of Adjuvant Gemcitabine Started One Week After Laparoscopic[NCT01045941]Phase 20 participants (Actual)InterventionalWithdrawn (stopped due to The study was never initiated)
A Phase II Trial of Postoperative Proton Radiotherapy With Concomitant Chemotherapy for Patients With Resected Pancreatic Adenocarcinoma[NCT01553019]Phase 22 participants (Actual)Interventional2011-10-31Completed
A Phase II Study of Docetaxel and Epirubicin Combination in Patients With Advanced Gastric Cancer.[NCT00375999]Phase 234 participants (Actual)Interventional2006-09-30Completed
Phase II Study Of Radiotherapy And Capecitabine As Pre-Operative Treatment In Patients With Colorectal Cancer[NCT00075556]Phase 20 participants Interventional2002-01-31Active, not recruiting
First Line Infusional 5-Fluorouracil, Folinic Acid and Oxaliplatin for Metastatic Colorectal Cancer or Loco-Regional Recurrency - Role of Chronomodulated Delivery Upon Survival - A Multicenter Randomized Phase III Trial[NCT00003287]Phase 3554 participants (Anticipated)Interventional1998-03-31Completed
FOcUs on Colorectal CAncer oUtcomes: Long-Term Study[NCT03965325]300 participants (Anticipated)Observational2019-06-07Recruiting
[NCT02748772]Phase 3148 participants (Anticipated)Interventional2016-01-31Recruiting
Clinical Trial Of Safety Of Robot-assisted Thoracic Approach Verus Open Transthoracic Esophagectomy in Esophageal Cancer.[NCT04652180]108 participants (Anticipated)Interventional2020-11-06Recruiting
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors[NCT00001579]Phase 150 participants Interventional1997-06-30Completed
A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas[NCT00005926]Phase 250 participants Interventional2000-06-30Completed
09.017 - A Phase I Study of Tolfenamic Acid With Gemcitabine and Radiation in Patients With Locally Advanced or Metastatic Pancreatic Cancer Requiring Definitive or Palliative Radiation Therapy[NCT02159248]Phase 10 participants (Actual)Interventional2014-03-31Withdrawn (stopped due to The study closed prior to enrolling any participants.)
A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase[NCT00248404]Phase 1/Phase 2155 participants (Anticipated)Interventional2005-09-30Completed
An Open-labeled Study to Evaluate Efficacy of Combining Erbitux Plus Concurrent Chemo-radiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)[NCT00815308]Phase 255 participants (Actual)Interventional2009-01-31Completed
A Randomized, Controlled Phase II Clinical Trial of Fruquintinib Combined With Raltitrexed Versus Fruquintinib Monotherapy in Patients With Advanced Colorectal Cancer Who Had Failed Second-line or Above Standard Chemotherapy[NCT04582981]Phase 2136 participants (Anticipated)Interventional2020-09-28Recruiting
Standard Palliative Care Versus Standard Palliative Care Plus Polychemotherapy (CVD-Protocol) in the Second-Line Therapy of Distant Metastasized Malignant Melanoma[NCT00226473]Phase 4200 participants Interventional2001-09-30Recruiting
Efficacy of the Oncoxin-Viusid® Nutritional Supplement on the Quality of Life of Patients With Advanced or Metastatic Ovarian Epithelial Cancer. Clinical Trial Phase II.[NCT03562897]Phase 240 participants (Actual)Interventional2018-10-25Completed
TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.[NCT04392479]Phase 3202 participants (Anticipated)Interventional2020-09-02Active, not recruiting
A Prospective Clinical Trial of Improving the Treatment of Thoracic Esophageal Cancer[NCT01137123]Phase 3301 participants (Actual)Interventional2010-04-30Completed
A Multicenter Observational and Feasibility Study of Excision of Superficially Invasive Squamous Cell Carcinoma (SISCCA) of the Anal Canal and Perianus in HIV-Infected Persons[NCT02437851]Phase 216 participants (Actual)Interventional2015-04-30Active, not recruiting
CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment[NCT00122772]Phase 3601 participants (Actual)Interventional2005-11-30Completed
Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters[NCT00603408]Phase 25 participants (Actual)Interventional2007-12-31Terminated (stopped due to Study was discontinued due to lack of accrual.)
Effect of a Low Residue Diet in Comparison to the Dietary Recommendations From the INCan: A Randomized Clinical Trial to Assess Malnutrition, Gastrointestinal Toxicity and Quality of Life of Advanced Cervical Cancer Patients (IB2-IVA)[NCT03100409]137 participants (Actual)Interventional2017-02-01Terminated (stopped due to The study was closed prematurely because the interim analysis found that subjects in the experimental group had less gastrointestinal toxicity.)
Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer[NCT01561586]Phase 3374 participants (Anticipated)Interventional2012-03-31Recruiting
A Clinical Trial to Assess the Relative Efficacy of 5-FU + Leucovorin, 5-FU + Levamisole, and 5-FU + Leucovorin + Levamisole in Patients With Dukes' B and C Carcinoma of the Colon[NCT00425152]Phase 32,151 participants (Actual)Interventional1989-07-31Completed
A Clinical Trial to Evaluate the Postoperative Portal Vein Infusion of 5-Fluorouracil and Heparin in Patients With Resectable Adenocarcinoma of the Colon[NCT00427310]Phase 31,158 participants (Actual)Interventional1984-03-31Completed
Prediction of Benefit From Adjuvant Chemotherapy for pT1N1 Gastric Cancer: A Pilot Retrospective Multicenter Cohort Study[NCT03485105]1,000 participants (Anticipated)Observational2017-11-01Active, not recruiting
MicroOrganoSphere Drug Screen to Lead Care (MODEL) Precision Oncology Pilot Trial in Colorectal Cancer (CRC)[NCT05189171]180 participants (Anticipated)Observational2022-10-25Recruiting
Short-term Effects of Laparoscopic-assisted Small-incision Surgery Versus Conventional Laparotomy in Treatment of Resectable Colorectal Liver Metastasis[NCT02350166]Phase 340 participants (Anticipated)Interventional2013-11-30Recruiting
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial[NCT02969473]Phase 2120 participants (Anticipated)Interventional2010-10-31Active, not recruiting
A Prospective Single-arm Phase Ⅱ Study of Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma[NCT04844385]Phase 283 participants (Anticipated)Interventional2021-02-20Recruiting
Genetic Variants and the Efficacy or Severe Adverse Reactions of CPT-11 Based Regimens in mCRC[NCT01282658]200 participants (Anticipated)Observational2010-11-30Recruiting
A Prospective Random Assignment Trial to Study Operative Debulking and Systemic Chemotherapy With or Without Intra-and Peri-Operative Intraperitoneal Chemotherapy for Subjects With Peritoneal Carcinomatosis From Low Grade Gastrointestinal Adenocarcinoma[NCT00052962]Phase 330 participants (Actual)Interventional2003-01-31Completed
A Randomized, Placebo-controlled, Double-blind Multicenter Phase II Study to Investigate the Protectivity and Efficacy of Metformin Against Steatosis in Combination With FOLFIRI and Cetuximab in Subjects With First-line Palliative Treated, KRAS-Wild-Type,[NCT01523639]Phase 28 participants (Actual)Interventional2012-04-30Terminated (stopped due to Prematurely due to slow recruitment (07/08/2013). Newly defined study end=LPLV=05/11/2013. ABCSG guaranteed completed treatment period for ethical reasons.)
A Phase II Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, Panitumumab and External Beam Radiation, in Patients With Localized, Non-Metastatic Pancreatic Adenocarcinoma[NCT01130701]Phase 20 participants (Actual)Interventional2010-05-31Withdrawn (stopped due to Study never went beyond FDA application for an IND #. FDAA required institutional DSMC which this institution then lacked.)
Phase 2 Prospective Randomized Double Blind Trial Comparing Metastasectomy Plus Sulindac Versus Metastasectomy Alone in Patients With Stage IV Colorectal Cancer[NCT01856322]Phase 23 participants (Actual)Interventional2013-04-30Terminated (stopped due to The trial was prematurely closed due to lack of accrual.)
Development of Quantitative Imaging Biomarkers for Evaluating Sarcoma Patients[NCT02579980]32 participants (Actual)Interventional2015-10-31Completed
Evaluation of Antibody-dependent Cell Cytotoxicity (ADCC) Against Gastric Cancer Cells[NCT02078362]30 participants (Anticipated)Observational2013-09-30Recruiting
A Randomized Phase III Trial of Postoperative Chemotherapy or Chemo-radiotherapy for Locally Advanced Gastric Cancer After D2 Resection[NCT03601988]Phase 3408 participants (Anticipated)Interventional2018-07-28Recruiting
Comparative Study on the Efficacy of Lobaplatin and Paclitaxel in the Treatment of Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy[NCT04808466]Phase 2231 participants (Anticipated)Interventional2021-09-18Recruiting
Aromatase Inhibitors Plus Metronomic Capecitabine in Treatment of Patients With Recurrent or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer[NCT04942899]Phase 270 participants (Anticipated)Interventional2023-08-30Not yet recruiting
A Pilot Study- Prevention of Capecitabine Induced Hand and Foot Syndrome[NCT01291628]10 participants (Anticipated)Interventional2012-01-31Not yet recruiting
Phase I Trial of Dose Escalated IMRT to the Para-aortic Nodes With Concurrent Cisplatin and Amifostine in Locally Advanced Cervical Cancer[NCT00137358]Phase 10 participants (Actual)InterventionalWithdrawn (stopped due to unable to obtain funding to conduct study)
Phase III Study Comparing Neoadjuvant Chemotherapy With Carboplatin and Paclitaxel Followed by Standard Therapy, With Standard Therapy Alone in Women With Cervical Cancer and Para Aortic Positive Lymph Node.[NCT03534713]Phase 3310 participants (Anticipated)Interventional2020-07-17Recruiting
A Pilot Study Investigating Preoperative Proton Radiotherapy for Retroperitoneal Sarcoma[NCT00901836]2 participants (Actual)Interventional2009-05-31Terminated (stopped due to Study closed due to feasability)
A Randomized Crossover Trial Comparing Oral Capecitabine and Intravenous Fluorouracil + Folinic Acid (Nordic FU/FA Regimen) for Patient Preference in Colorectal Cancer[NCT00212589]Phase 360 participants Interventional2002-12-31Completed
A Phase I-II Study of Capecitabine and Oxaliplatin in Chemotherapy-Naive and Thymidylate Synthase Inhibitor Pretreated Advanced or Metastatic Colorectal Cancer[NCT00004187]Phase 1/Phase 20 participants Interventional1999-06-30Completed
Phase II Study of High-dose (86 Gy)Intensity Modulated Radiotherapy and Concurrent Paclitaxel and Cisplatin in Locoregionally Advanced Esophageal Cancer[NCT03535207]50 participants (Anticipated)Interventional2018-04-01Recruiting
Phase I Trial of Radiation Dose Escalation With Concurrent Weekly Cisplatin and Paclitaxel in Patients With Esophageal Cancer[NCT03082586]31 participants (Actual)Interventional2016-11-20Completed
A Prospective, Randomized, Phase III Trial of FLAC (5-Fluorouracil, Leucovorin, Adriamycin, Cytoxan) Chemotherapy With GM-CSF (Granulocyte-Macrophage Colony-Stimulating Factor) Versus PIXY 321 in Advanced Breast Cancer[NCT00001338]Phase 365 participants Interventional1993-06-30Completed
Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606]Phase 158 participants (Actual)Interventional1999-04-30Completed
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348]Early Phase 15 participants (Actual)Interventional2011-11-01Terminated (stopped due to Slow, insufficient accrual.)
A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer[NCT00001428]Phase 265 participants Interventional1995-02-28Completed
A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer[NCT02311361]Phase 1/Phase 265 participants (Actual)Interventional2015-03-25Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Event-free Survival

Defined as time from randomization to the first documentation of event where events considered are 1) disease progression, per RECIST, prior to surgery, 2) surgery with R2 resection, 3) recurrent disease following surgery, or 4) death due to any cause. Will be estimated using the method of Kaplan-Meier in each arm and compared between treatment groups using the log-rank test. The correlation between pathologic complete response (pCR) status and event-free survival time will be assessed by Cox model with landmark approach. (NCT02839343)
Timeframe: 4 years and 7 months

InterventionMonths (Median)
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)15.0
Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)10.2

Incidence of Adverse Events Assessed Per Common Terminology Criteria for Adverse Events (CTCAE) Version 4 and the Patient-Reported Outcomes Version of the CTCAE

Overall adverse event rates will be compared between treatment groups using Chi-square test (or Fisher's exact test if the data in contingency table is sparse). (NCT02839343)
Timeframe: 1 year

InterventionParticipants (Count of Participants)
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)66
Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)55

Overall Survival (OS) Rate

Defined as the percentage of patients who are alive at 18 months after randomization divided by the total number of evaluable patients in each arm. An evaluable patient is defined as any patient who signed informed consent, deemed eligible by central review and received any protocol-defined treatment. 95% confidence interval will be estimated based on standard method. Chi-squared test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare 18 month OS rates among treatment arms. OS within each arm will be summarized by Kaplan-Meier method. Median, 1-year and 2-year rates will be estimated based on Kaplan-Meier curves. (NCT02839343)
Timeframe: 18 months

Interventionpercentage of patients (Number)
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)64.6
Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)47.3

Pathologic Complete Rate (pCR) Rate

Defined as the percentage of patients in whom a pCR was confirmed by histopathologic review of the surgical specimen. Chi-square test (or Fisher's exact test if the data in contingency table is sparse) will be used to compare pCR resection rate between two treatment arms. Sensitivity analysis will be conducted among patients in cohort 1) and cohort 2). The association between pCR rate and OS/progression free survival (PFS) will be assessed by log-rank test and Cox model. (NCT02839343)
Timeframe: 24 months

Interventionpercentage of patients (Number)
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)0
Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)11

Residual Tumor (R)0 Resection Rate

Defined as the percentage of patients in whom an achieved R0 resection was achieved during surgery. (NCT02839343)
Timeframe: 24 months

Interventionpercentage of patients (Number)
Arm 1 (mFOLFIRINOX + Surgery + FOLFOX)49
Arm 2 (mFOLFIRINOX + Radiation + Surgery + FOLFOXx)35

Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.

Chireac tumour regression grade (NCT01362127)
Timeframe: Therapy followed in 14-16 weeks before surgery. After surgery the patients will be followed until 60 weeks after completed therapy.

InterventionParticipants (Count of Participants)
Radiochemotherapy22
Chemotherapy7

Safety of Respective Neoadjuvant Therapies.

Safety profile of carrying out radical surgery after respective neoadjuvant therapy. (NCT01362127)
Timeframe: Five years follow up

InterventionParticipants (Count of Participants)
Radiochemotherapy79
Chemotherapy81

HRQOL and Swallowing Function

The European Organisation for Research and Treatment of Cancer (EORTC) core questionnaire QLQ-C30 and disease specific questionnaires (QLQ-OES24/OG25). All items included in the questionnaires are analysed and also separate analysis of dysphagia questionnaires for oesophageal cancer were used, both clinically and psychometrically validated. All questions have four response alternatives (1, not at all; 2:a little, 3: quite a bit, 4: very much), except global scales which comprise seven response alternatives from poor to excellent. Questionnaire responses were transformed lineraly into scores ranging from 0 to 100 according to the EORTC scoring manual. A higher score indicates either more symotoms or better function, depending on the question. (NCT01362127)
Timeframe: Entry study up to Five years follow up

,
Interventionunits on a scale (Mean)
Mean global QoLDysphagia score all
Chemotherapy6931
Radiochemotherapy6727

Median Overall Survival Time

To estimate overall survival as a function of time from study enrollment. (NCT01661088)
Timeframe: up to 2 years

Interventionmonths (Median)
Study Treatment24.4

Median Progression-free Survival Time

To estimate progression-free survival as a function of time from study enrollment. Progression is defined as at least a 20% increase in the LD (longest diameter) of the primary lesion or the appearance of one or more new lesions (NCT01661088)
Timeframe: up to 2 years

Interventionmonths (Median)
Study Treatment13.1

The Percentage of Patients That Underwent an R0 Resection

To determine the frequency of achieving an R0 resection using a neoadjuvant regimen of FOLFIRINOX followed by IMRT concurrent with fixed dose rate (FDR)-gemcitabine in patients with borderline resectable pancreatic cancer. R0 resection indicates a microscopically margin-negative resection, in which no gross or microscopic tumor remains in the primary tumor bed. (NCT01661088)
Timeframe: 6 months

Interventionpercentage of patients (Number)
Study Treatment52

Overall Response Rate (ORR)

Defined as the rate of Complete Response (CR) plus Partial Response (PR): Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least 30% decrease in the sum of diameters of target lesions; (NCT03504423)
Timeframe: 38 months

InterventionParticipants (Count of Participants)
CPI-613, mFolfirinox104
Folfirinox90

Overall Survival (OS)

Defined as the duration from the date of randomization to the date of death from any cause (NCT03504423)
Timeframe: 38 months

Interventionmonths (Median)
CPI-613, mFolfirinox11.10
Folfirinox11.73

Progression Free Survival (PFS)

"Defined as the duration from the date of randomization to the date of progressive disease or death from any cause.~Progressive Disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must have also demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered progression." (NCT03504423)
Timeframe: 38 months

Interventionmonths (Median)
CPI-613, mFolfirinox7.82
Folfirinox7.98

Objective Response Rate

The objective response rate was a secondary efficacy endpoint of the study and was defined by the percentage of patients in the study population with a best overall response of Complete Response (CR) or Partial Response (PR) as assessed by the investigator. Best overall response was defined per RECIST (version 1.1) recorded from randomization until progression or end of study. RECIST (v 1.1) criteria does not require confirmation of response, but an additional, more stringent analysis was also conducted, with designation of CR (or PR) requiring confirmation of response at least 4 weeks following the initial assessment of CR (or PR). Stable disease (SD) required an assessment of SD at least 6 weeks after starting treatment. Subjects with insufficient data for response classification were classified as Not Evaluable for best overall response, and as a non-responder for objective response, in the ITT population. Treatment groups are as indicated for the primary outcome of OS. (NCT01494506)
Timeframe: Assessment every 6 weeks after initial response; Day 1 to data cut off of 14 Feb 2014; maximum time on study 25 months.

Interventionpercentage with confirmed response (Number)
MM-398 Arm A (Mono Therapy Comparison)3.31
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)0.67
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison7.69
5-FU + Leucovorin (Combo Therapy Comparison)0.84

Overall Survival

"Overall survival was the primary efficacy endpoint of the study and was defined as the time from the date of patient randomization to the date of death or the date the patient was last known to be alive. OS was summarized by Kaplan-Meier methodology for each treatment group. Pairwise treatment group comparisons were carried out using unstratified log rank analyses on the ITT population. Hazard ratio estimates are from Cox regression analysis.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: From randomization to death; until the data cut off 14 Feb 2014. The maximum time in follow up was 25 months.

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)4.9
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)4.2
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison6.1
5-FU + Leucovorin (Combo Therapy Comparison)4.2

Percentage of Patients With Clinical Benefit Response

"Composite measure based on patient-reported pain (per VAS), patient-reported pain medication, KPS, and weight. Clinical benefit is indicated by either:~(a) improvement in pain (less pain intensity with stable or decreased pain medication; or less pain medication with stable or decreased pain intensity) with stable or improved KPS; or (b) improvement in KPS with stable or improved pain.~With stable for KPS and pain, clinical benefit may be indicated with an observation of positive weight change.~Clinical benefit response (CBR) was classified weekly and a patient was considered a clinical benefit responder if clinical benefit was observed and maintained over a 4 week period." (NCT01494506)
Timeframe: Randomization to treatment discontinuation.The maximum time in follow up was 25 months

Interventionpercentage of participants with CBR (Number)
MM-398 Arm A (Mono Therapy Comparison)14
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)13
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison14
5-FU + Leucovorin (Combo Therapy Comparison)12

Percentage of Patients With Tumor Marker (CA 19-9) Response

Tumor marker response (TMR) was evaluated by the change in CA19-9 serum levels. Response was defined as a decrease of 50% of CA19-9 in relation to the baseline level at least once during the treatment period. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months

Interventionpercent of participants with TMR (Number)
MM-398 Arm A (Mono Therapy Comparison)23.6
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)11.4
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison28.9
5-FU + Leucovorin (Combo Therapy Comparison)8.6

Progression Free Survival

"Progression-free survival was defined as the time from the date of randomization to the date of disease progression, or death (any cause) on or prior to the clinical cutoff date, whichever occurred earlier. Participants who did not have disease progression or had not died were censored at the date of the last tumor assessment. Patients with two or more consecutive missing response assessments prior to a visit with documented progression (or death) were censored at the last date of tumor assessment when the patient was documented to be progression free. PFS was summarized using Kaplan-Meier methods.~The comparison of Arm C is based only on patients who were randomized under the 3-arm version of the protocol. Consequently, the 5-FU+Leucovorin (Combo Therapy Comparison) group is a subset of all patients randomized to 5-FU+Leucovorin, which is the Mono Therapy Comparison control and contains patients randomized under both the 2-arm and 3-arm versions of the protocol." (NCT01494506)
Timeframe: Randomization until disease progression or death from any cause; Until the data cut off of 14 Feb 2014. The maximum time in follow up was 25 months.

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)2.7
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)1.6
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison3.1
5-FU + Leucovorin (Combo Therapy Comparison)1.5

Time to Treatment Failure

Time from randomization to discontinuation of treatment for any reason, including disease progression, treatment toxicity or death. (NCT01494506)
Timeframe: Randomization to treatment discontinuation (any cause). The maximum time in follow up was 25 months

Interventionmonths (Median)
MM-398 Arm A (Mono Therapy Comparison)1.7
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)1.4
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison2.3
5-FU + Leucovorin (Combo Therapy Comparison)1.4

EORTC-QLQ-C30

This patient recorded outcome consists of 15 subscales in 3 independent domains: global health-related quality of life (HRQoL), functional scales (cognitive, emotional, physical, role and social functioning), and symptom scales (appetite loss, constipation, diarrhea, dyspnea, fatigue, insomnia, nausea and vomiting, and pain). For each subscale, patients were classified as improved, worsened or stable. Improvement is indicated by achievement of subscale score at least 10% improved from baseline and maintained for at least 6 weeks. Worsened is indicated by subscale score at least 10% worse than baseline. Stable is indicated by neither improvement nor worsened. Achievement of improvement prior to worsening was classified as improvement. (NCT01494506)
Timeframe: Baseline to treatment discontinuation every 6 weeks; The maximum time in follow up was 25 months

,,,
Interventionpercent of patients in category (Number)
Global Health Status: ImprovedGlobal Health Status: StableGlobal Health Status: WorsenedPhysical Functioning: ImprovedPhysical Functioning: StablePhysical Functioning: WorsenedRole Functioning: ImprovedRole Functioning: StableRole Functioning: WorsenedEmotional Functioning:ImprovedEmotional Functioning:StableEmotional Functioning:WorsenedCognitive Functioning:ImprovedCognitive Functioning:StableCognitive Functioning:WorsenedSocial Functioning:ImprovedSocial Functioning:StableSocial Functioning:WorsenedFatigue:ImprovedFatigue:StableFatigue:WorsenedNausea and Vomiting:ImprovedNausea and Vomiting:StableNausea and Vomiting:WorsenedPain:ImprovedPain:StablePain:WorsenedDyspnoea:ImprovedDyspnoea:StableDyspnoea:WorsonedInsomnia:ImprovedInsomnia:StableInsomnia:WorsenedAppetite Loss:ImprovedAppetite Loss:StableAppetite Loss:WorsenedConstipation:ImprovedConstipation:StableConstipation:WorsenedDiarrhoea:ImprovedDiarrhoea: StableDiarrhoea: WorsenedFinancial Difficulties: ImprovedFinancial Difficulties: StableFinancial Difficulties: Worsened
5-FU + Leucovorin (Arm B) (Mono Therapy Comparison)114148113752103952859336425211434611305964252103753669244494764252463344583916731
5-FU + Leucovorin (Combo Therapy Comparison)124444114049113753958337444911474212335444651114049568255494654649467304583907426
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison173845104149153252204634114841133454142066133255273439751421834481145441356316395585141
MM-398 Arm A (Mono Therapy Comparison)103157102961629661032561232541126621318695375820305010474494348938531347394355965142

Pharmacokinetic Measurements of Total Irinotecan

Plasma concentration-time data for MM-398 will be analyzed using population pharmacokinetic methods. (NCT01494506)
Timeframe: 6 weeks after first study drug administration

,
InterventionTotal irinotecan = ug/L; SN38= ug/L (Geometric Mean)
Total Irinotecan-CavgTotal Irinotecan-CmaxTotal SN38-CavgTotal SN38-Cmax
MM-398 + 5-FU + Leucovorin(Arm C) Combo Therapy Comparison2120.0028460.000.682.58
MM-398 Arm A (Mono Therapy Comparison)2550.0040550.000.823.93

Clinical Benefit Rate

"Clinical benefit rate is the percentage of combined patients who have achieved complete response (CR), partial response (PR), and stable disease (SD)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters~SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)33
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Duration of Response

Time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)5.8
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)10.5

Number of Participants With an Objective Response

"Objective response (defined as complete response (CR) + partial response (PR) by RECIST 1.1 criteria)~CR: Disappearance of all target lesions, non-target lesions, and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm.~PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters." (NCT01928290)
Timeframe: Through completion of treatment (estimated to be 4 months)

InterventionParticipants (Count of Participants)
Arm A: FOLFIRINOX (HER2-negative)25
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)22

Overall Survival (OS)

Overall survival is defined as the time interval from date of diagnosis to date of death from any cause. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)15.5
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)19.6

Progression Free Survival

Duration of time from start of treatment to time of progression or death, whichever occurs first. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.4
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.8

Time to Progression (TTP)

Duration of time from start of treatment to time of progression. Progression is defined as At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (NCT01928290)
Timeframe: Through 1 year after completion of treatment (median follow-up 16.2 months - 95% CI 4.7-42.5 months)

Interventionmonths (Median)
Arm A: FOLFIRINOX (HER2-negative)8.0
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)13.9

Toxicity and Tolerability (Arm A and Arm B) as Measured by the Number of Participants With Grade 3 or Higher Adverse Events

(NCT01928290)
Timeframe: 30 days after completion of treatment (estimated to be 5 months)

,
Interventionparticipants (Number)
AnemiaFebrile neutropeniaAnal FistulaDiarrheaHematemesisNauseaPeripheral ischemiaVomitingFatigueLaparoscopy surgeryPainSepsisLung infectionPneumoniaHypernatremiaNeutrophil count decreasedPlatelet count decreasedAnorexiaDehydrationHypokalemiaBack painPeripheral sensory neuropathySyncopeDyspneaPleural embolismSkin infectionThromboembolic eventAbdominal painEnterocolitisHemorrhoidsG-tube infectionNeutropenic entercolitisAlkaline phosphatase increased
Arm A: FOLFIRINOX (HER2-negative)1214121341111111933411211114000000
Arm B: FOLFIRINOX & Trastuzumab (HER2-positive)000502010000000800020010000111111

Disease-free Survival From the Time of R0 or R1 Resection.

Disease-free survival (DFS) is calculated for patients who undergo surgical resection (R0/R1). DFS will be measured from the date of surgical resection to date of first documentation of recurrence (loco-regional or distant) or death due to any cause. Patients last known to be alive and free of disease will be censored at date of last contact. (NCT02562716)
Timeframe: Up to 4 years

InterventionMonths (Median)
mFOLFIRINOX ->Surg ->mFOLFIRINOX10.9
Gem/Nab-P ->Surg ->Gem/Nab-P14.2

Number of Participants With a Response Following Preoperative Chemotherapy, Including Confirmed and Unconfirmed, Complete and Partial Response, Per RECIST 1.1.

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT02562716)
Timeframe: Up to 6 months post registration (and within 2 to 4 weeks after the last dose of Cycle 3 preoperative chemotherapy.).

InterventionParticipants (Count of Participants)
mFOLFIRINOX ->Surg ->mFOLFIRINOX5
Gem/Nab-P ->Surg ->Gem/Nab-P10

Number of Patients Achieving R0 Resection After Preoperative Chemotherapy.

R0 resection classification is defined as macroscopically complete tumor removal with negative microscopic surgical margins (bile duct, pancreatic parenchyma, and superior mesenteric artery margins). (NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).

InterventionParticipants (Count of Participants)
mFOLFIRINOX ->Surg ->mFOLFIRINOX34
Gem/Nab-P ->Surg ->Gem/Nab-P28

Number of Patients Going to Surgery for Resection After Preoperative Chemotherapy.

(NCT02562716)
Timeframe: Up to 8 months post registration (and within 4 to 8 weeks after the last dose of Cycle 3 preoperative chemotherapy).

InterventionParticipants (Count of Participants)
mFOLFIRINOX ->Surg ->mFOLFIRINOX40
Gem/Nab-P ->Surg ->Gem/Nab-P33

Overall Survival (OS)

OS is the length of time between protocol registration and patient death (NCT02562716)
Timeframe: Up to 4 years for the estimates of median overall survival. Up to 2 years for Statistical Analysis 1 and 2, comparing the observed 2-year overall survival (OS) to the null hypothesis of 40%, in each arm.

InterventionMonths (Median)
mFOLFIRINOX ->Surg ->mFOLFIRINOX23.2
Gem/Nab-P ->Surg ->Gem/Nab-P23.6

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

Only adverse events that are possibly, probably or definitely related to preoperative and postoperative chemotherapy are reported. (NCT02562716)
Timeframe: Duration of treatment and follow up until death or 4 years post registration.

,
InterventionParticipants (Number)
Abdominal infectionAcute kidney injuryAlanine aminotransferase increasedAllergic reactionAnemiaAnorexiaAspartate aminotransferase increasedBiliary tract infectionBlood bilirubin increasedColonic perforationConstipationDehydrationDiarrheaDysesthesiaDyspneaFallFatigueFebrile neutropeniaHepatobiliary disorders - Other, specifyHyperglycemiaHypertensionHypoalbuminemiaHypoglycemiaHypokalemiaHypomagnesemiaHyponatremiaInfections and infestations - Other, specifyInfusion related reactionInsomniaLeukocytosisLung infectionLymphocyte count decreasedMucositis oralMyocardial infarctionNauseaNeutrophil count decreasedNon-cardiac chest painPancreatitisPapulopustular rashPeripheral motor neuropathyPeripheral sensory neuropathyPlatelet count decreasedPneumonitisRectal hemorrhageRespiratory failureSepsisSkin infectionThromboembolic eventVomitingWeight lossWhite blood cell decreased
Gem/Nab-P->Surg->Gem/Nab-P0120401131103010320211112210102210117101032111200006
mFOLFIRINOX->Surg->mFOLFIRINOX1031422010018101401200030211011001311010153000112221

Objective Response Rate (ORR)

ORR was defined as the percentage of participants who achieve a complete response (CR) or partial response (PR) as assessed by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. CR was defined as the disappearance of all target lesions and disappearance of all non-target lesions and normalization of tumor marker level. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT02545504)
Timeframe: Up to 135.4 weeks at the time of final analysis

Interventionpercentage of participants (Number)
Andecaliximab + mFOLFOX650.5
Placebo + mFOLFOX641.1

Overall Survival (OS)

OS was defined as the time interval from the date of randomization to death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of final analysis: 19.43 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 19.45 months

Interventionmonths (Median)
Andecaliximab + mFOLFOX612.52
Placebo + mFOLFOX611.76

Percentage of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal product, which does not necessarily have a causal relationship with the treatment. TEAEs are events in a given study period that meet any of the following criteria: Any AE with onset date of on or after andecalizimab/placebo start date and no later than 30 days after permanent discontinuation of all study treatment (andecaliximab/placebo and chemotherapy) or Any AEs with onset date of on or after the andecaliximab/placebo start date and no later than 55 days after permanent discontinuation of andecaliximab/placebo or AEs leading to discontinuation of andecaliximab/placebo. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum:161.7 weeks) plus 30 to 55 days

Interventionpercentage of participants (Number)
Andecaliximab + mFOLFOX699.1
Placebo + mFOLFOX699.5

Progression-free Survival (PFS)

PFS was defined as the interval of time from the date of randomization to the earlier of the first documentation of definitive disease progression or death from any cause. (NCT02545504)
Timeframe: Andecaliximab + mFOLFOX6 median follow-up at the time of the final analysis: 18.64 months; Placebo + mFOLFOX6 median follow-up at the time of the final analysis: 18.74 months

Interventionmonths (Median)
Andecaliximab + mFOLFOX67.46
Placebo + mFOLFOX67.06

Percentage of Participants With Clinically Relevant Treatment-emergent Laboratory Abnormalities

Treatment-emergent laboratory abnormalities were graded per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03 where 0=None, 1=Mild, 2=Moderate, 3=Severe, 4=Potentially Life Threatening. Treatment-emergent laboratory abnormalities are defined as values that increase at least 1 toxicity grade from baseline at any post-baseline time point, up to 30 days after the last dose of all study treatment, or 55 days after the last dose of andecaliximab/placebo for participants who permanently discontinued all study treatments. If the relevant baseline laboratory value is missing, then any abnormality of at least Grade 1 was considered treatment-emergent. (NCT02545504)
Timeframe: First dose date up to the last dose date (maximum: 161.7 weeks) plus 30 to 55 days

,
Interventionpercentage of participants (Number)
HematologySerum ChemistryCoagulation
Andecaliximab + mFOLFOX694.491.77.4
Placebo + mFOLFOX689.592.93.3

Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)8.0
Placebo + Chemotherapy (FP or CAPOX Regimen)5.7

Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)8.3
Placebo + Chemotherapy (FP or CAPOX Regimen)5.6

Duration of Response (DOR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

DOR was defined as the time from first documented evidence of a confirmed Complete Response (CR) or Partial Response (PR) until progressive disease (PD) or death, whichever occurred first. Per RECIST 1.1 as assessed by BICR, CR was the disappearance of all target lesions and PR was ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD. PD was defined as ≥20% increase in the SOD of target lesions according to RECIST 1.1. In addition to the relative increase of 20%, the SOD must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. DOR for participants who had not progressed or died at the time of analysis was censored at the date of the last tumor assessment. DOR was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)10.9
Placebo + Chemotherapy (FP or CAPOX Regimen)5.8

Number of Participants Who Discontinued Study Treatment Due To an Adverse Event (AE)

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE is presented. (NCT03675737)
Timeframe: Up to 33.7 months

InterventionParticipants (Count of Participants)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)257
Placebo + Chemotherapy (FP or CAPOX Regimen)204

Number of Participants Who Experienced an Adverse Event (AE)

An AE was defined as any untoward medical occurrence, in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants with at least one AE is presented. (NCT03675737)
Timeframe: Up to 36.7 months

InterventionParticipants (Count of Participants)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)776
Placebo + Chemotherapy (FP or CAPOX Regimen)771

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionPercentage of Participants (Number)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)51.3
Placebo + Chemotherapy (FP or CAPOX Regimen)42.0

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionPercentage of Participants (Number)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)52.1
Placebo + Chemotherapy (FP or CAPOX Regimen)42.6

Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

ORR was defined as the percentage of the participants who had a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the baseline SOD) according to RECIST 1.1 as assessed by BICR. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionPercentage of Participants (Number)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)60.6
Placebo + Chemotherapy (FP or CAPOX Regimen)43.0

Overall Survival (OS) in All Participants

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)12.9
Placebo + Chemotherapy (FP or CAPOX Regimen)11.5

Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)13.0
Placebo + Chemotherapy (FP or CAPOX Regimen)11.4

Overall Survival (OS) In Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

OS was defined as the time from randomization to death due to any cause. Participants without documented death at the time of the analysis were censored at the date of the last follow-up. OS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 45.9 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)15.7
Placebo + Chemotherapy (FP or CAPOX Regimen)11.8

Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in All Participants

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)6.9
Placebo + Chemotherapy (FP or CAPOX Regimen)5.6

Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)6.9
Placebo + Chemotherapy (FP or CAPOX Regimen)5.6

Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR) in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10

PFS was defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 as assessed by BICR, PD was defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of ≥5 mm. The appearance of ≥1 new lesions was also considered PD. PFS was estimated using the product-limit (Kaplan-Meier) method for censored data. (NCT03675737)
Timeframe: Up to 49.5 months

InterventionMonths (Median)
Pembrolizumab + Chemotherapy (FP or CAPOX Regimen)8.1
Placebo + Chemotherapy (FP or CAPOX Regimen)5.6

Complete Pathological Response (pCR) of PET/CT Non-responders

The primary endpoint of this study is the percentage of PET/CT non-responders within each induction treatment group reporting a pCR. A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Non-Responder17.95
CP Non-Responder20

pCR Compared Among Non-responders Between Induction Treatment Arms if Treatment Regimens Are Found to be Efficacious

"A Complete Pathological Response (pCR) is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor. A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.>~>>>~>~>>> Among the patients who completed induction therapy and did not respond, the percentage of patients reporting a pCR in each arm were compared." (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Regimen Non-Responders17.95
CP (Carboplatin + Paclitaxel + Radiation) Non-Responders20

pCR Compared Between Induction Treatment Arms Among PET/CT Responders

"A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as>~>>~>>~>> measured by maximum standardized uptake value (SUVmax). A pCR is defined as having no tumor found on pathology review at surgery in all resected lymph nodes and tissue. All tissues sampled must have NO viable tumor." (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of participants with a pCR (Number)
FOLFOX Responder40.28
CP (Carboplatin + Paclitaxel + Radiation) Responder14.06

PET/CT Response Between Treatment Arms

A PET/CT response to induction therapy is defined as metabolic activity of the tumor decreasing by >=35%, as measured by maximum standardized uptake value (SUVmax). (NCT01333033)
Timeframe: Up to 5 years

Interventionpercentage of patients with a response (Number)
FOLFOX Regimen64.86
CP (Carboplatin + Paclitaxel + Radiation)56.14

Progression Free Survival (PFS) Among PET/CT Non-responders Within Each Induction Treatment Group

"A non-responder was defined as having a PET/CT SUV (standard uptake value) decrease of less than 35% after induction.~Among the patients who completed induction therapy and did not respond, the progression free survival in each arm were compared. PFS will be measured from study entry until documented progression or death from any cause. PFS will be estimated using the method of Kaplan and Meier." (NCT01333033)
Timeframe: Up to 5 years

Interventionmonths (Median)
FOLFOX Regimen Non-ResponderNA
CP Non-Responder33.4

Overall Objective Response Rate (ORR) Based on the Tumor Assessment by the Independent Review Committee (IRC) as Per Response Evaluation Criteria in Solid Tumours (RECIST) Criteria

"The overall ORR was the percentage of evaluable participants who achieved complete response [CR] or partial response [PR] according to RECIST criteria version 1.0.~CR reflected the disappearance of all tumor lesions (with no new tumors)~PR reflected a pre-defined reduction in tumor burden~Tumors were assessed by the IRC using Computerized Tomography (CT) scans or Magnetic Resonance Imaging (MRI) scans; and an observed response was confirmed by repeated imaging after 4 - 6 weeks." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 06 May 2010 (approximately 30 months)

Interventionpercentage of participants (Number)
Placebo/FOLFIRI11.1
Aflibercept/FOLFIRI19.8

Overall Survival (OS)

"Overall Survival was the time interval from the date of randomization to the date of death due to any cause. Once disease progression was documented, participants were followed every 2 months for survival status, until death or until the study cutoff date, whichever came first. The final data cutoff date for the analysis of OS was the date when 863 deaths had occurred (07 February 2011).~OS was estimated using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model." (NCT00561470)
Timeframe: From the date of the first randomization until the study data cut-off date, 07 February 2011 (approximately three years)

Interventionmonths (Median)
Placebo/FOLFIRI12.06
Aflibercept/FOLFIRI13.50

Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

"PFS was the time interval from the date of randomization to the date of progression, or death from any cause if it occurs before tumor progression is documented. To evaluate disease progression, copies of all tumor imaging sets were systematically collected and assessed by the IRC.~PFS was analyzed using the Kaplan-Meier method, and the Hazard Ratio was estimated using the Cox Proportional Hazard Model.~The analysis for PFS was performed as planned when 561 deaths (OS events) had occurred." (NCT00561470)
Timeframe: From the date of the first randomization until the occurrence of 561 OS events, 06 May 2010 (approximately 30 months)

Interventionmonths (Median)
Placebo/FOLFIRI4.67
Aflibercept/FOLFIRI6.90

Immunogenicity Assessment: Number of Participants With Positive Sample(s) in the Anti-drug Antibodies (ADA) Assay and in the Neutralizing Anti-drug Antibodies (NAb) Assay

Serum samples for immunogenicity assessment were analyzed using a bridging immunoassay to detect ADA. Positive samples in the ADA assay were further analyzed in the NAb assay using a validated, non-quantitative ligand binding assay. (NCT00561470)
Timeframe: Baseline, every other treatment cycle, 30 days and 90 days after the last infusion of aflibercept/placebo

,
Interventionparticipants (Number)
At least one positive sample in the ADA assayAt least one positive sample in the NAb assay
Aflibercept/FOLFIRI81
Placebo/FOLFIRI182

Number of Participants With Adverse Events (AE)

"All AEs regardless of seriousness or relationship to study treatment, spanning from the first administration of study treatment until 30 days after the last administration of study treatment, were recorded, and followed until resolution or stabilization.~The number of participants with all treatment emergent adverse events (TEAE), serious adverse events (SAE), TEAE leading to death, and TEAE leading to permanent treatment discontinuation are reported." (NCT00561470)
Timeframe: From the date of the first randomization up to 30 days after the treatment discontinuation or until TEAE was resolved or stabilized

,
Interventionparticipants (Number)
Treatment-Emergent Adverse Event (TEAE)Serious TEAETEAE leading to DeathTEAE causing permanent treatment discontinuation
Aflibercept/FOLFIRI60629437164
Placebo/FOLFIRI5921982973

Duration of Response (DR)

Duration of response was defined as the time (in months) from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin5.1
5FU+Cisplatin4.2

Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3

An AE was any untoward medical condition that occurred in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

InterventionParticipants (Count of Participants)
S-1+Cisplatin157
5FU+Cisplatin78

Overall Response Rate (ORR): Percentage of Participants With Overall Response

ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) based on the Investigator review of the images and application of Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to less than (<) 10 millimeter (mm). PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionpercentage of participants (Number)
S-1+Cisplatin34.7
5FU+Cisplatin19.8

Overall Survival (OS)

OS was defined as the time from randomization to the date of death for the ITT population. Participants who did not die were censored at the date last known to be alive. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From the date of randomization until disease progression or death, cut-off date: 15 August 2014 (approximately 40 months)

Interventionmonths (Median)
S-1+Cisplatin7.5
5FU+Cisplatin6.6

Progression-free Survival (PFS)

PFS was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Disease Progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, where any of the 3 criteria have been met: 1) at least 20% increase in the sum of diameters of the target lesions, taking as reference the smallest sum on study, including the baseline sum, 2) Progression in no-target lesion(s), 3) appearance of new lesion(s) Participants who were alive with no PD were censored at the date of the last tumor assessment. Participants who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of randomization until disease progression or death, cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin4.4
5FU+Cisplatin3.9

Time to Treatment Failure (TTF)

TTF was defined as the time from date of randomization until date of PD (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Participates who were still on study treatment at the time of the analysis were censored at the last date the participants was known to be on treatment. (NCT01285557)
Timeframe: From date of randomization until disease progression, cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin4.2
5FU+Cisplatin3.8

Time to Tumor Response (TTR)

TTR was defined as the time (in months) from the date of randomization to the date of first observation of response (PR or CR) (whichever status was recorded first). TTR was assessed based on investigator assessment utilizing RECIST 1.1. CR was defined as the disappearance of all target or non-target lesions. Any pathological lymph nodes for target lesions or all lymph nodes for non-target lesions were non-pathological morphologically that was reduced in size in short axis to <10 mm. PR was defined as target lesions with at least 30% decrease in the sum of diameters, taking baseline sum diameters as reference. Analysis was performed by using Kaplan-Meier method. (NCT01285557)
Timeframe: From date of first study medication until cut-off date: 07 March 2014 (approximately 34.7 months)

Interventionmonths (Median)
S-1+Cisplatin1.8
5FU+Cisplatin1.9

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)

AE was defined as any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily had to have a causal relationship with the use of the study medication. A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs that developed or worsened or became serious during on-treatment period (from first dose of study medication up to 30 days of last study medication [maximum duration: 35.7 months]). (NCT01285557)
Timeframe: From first dose of study medication up to 30 days of last study medication (maximum duration: 35.7 months)

,
InterventionParticipants (Count of Participants)
TEAETESAE
5FU+Cisplatin11131
S-1+Cisplatin21463

Disease-free Survival (Arms A and D: Mutant KRAS Patients)

"A secondary endpoint for this study was to investigate the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A67.1
Mutant KRAS Arm D65.0

Disease-free Survival (Arms A and D: Wild-type KRAS Patients)

"The primary endpoint for this study was to compare the disease-free survival (DFS) in patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint.~Disease-free survival is defined as the time from randomization until tumor recurrence or death, whichever is first. Estimated by the method of Kaplan and Meier." (NCT00079274)
Timeframe: At 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A74.6
Wild-type KRAS Arm D71.5

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Mutant KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event-free rates (percentage) are report below for mutant KRAS patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Mutant KRAS Arm A87.9
Mutant KRAS Arm D82.7

Overall Survival as Measured by the 3-year Event-free Rate (Arms A and D: Wild-type KRAS Patients)

Evidence of death from any cause within 3 years counted as events in the time to event- Kaplan Meier analysis of overall survival for patients with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). Participants treated according to Arms B, C, E, and F treatment schedules received treatment which included irinotecan hydrochloride and therefore were not analyzed for this endpoint. The 3-year event free rates (percentage) are reported below for Wild-type KRAS Patients. (NCT00079274)
Timeframe: Up to 3 years

Interventionpercentage of participants (Number)
Wild-type KRAS Arm A87.3
Wild-type KRAS Arm D85.6

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Mutant KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS mutant (or KRAS-nonevaluable) and randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Mutant KRAS Arm A55.6
Mutant KRAS Arm D72.3

Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3) (Arms A and D: Wild-type KRAS Patients)

The maximum grade for each type of toxicity will be recorded for each patient with stage III colon cancer who are KRAS wild-type randomized to one of two treatment regimens: 1) oxaliplatin, leucovorin calcium, and fluorouracil (Arm A) or 2) oxaliplatin, leucovorin calcium, fluorouracil and cetuximab (Arm D). The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below. (NCT00079274)
Timeframe: Assessed up to 8 years

Interventionpercentage of patients (Number)
Wild-type KRAS Arm A51.1
Wild-type KRAS Arm D73.3

6 Month Progression Free Survival (PFS)

"Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as accurate and appropriate" (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months

Interventionpercentage of paticipants (Mean)
Arm A, - Modified DCF63
ARM B - Parent DCF With G-CSF53
Arm C - Modified DCF+ Trastuzumab73

Overall Survival

Overall survival measured in months (NCT00515411)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 43 months

Interventionmonths (Median)
Arm A, - Modified DCF18.8
ARM B - Parent DCF With G-CSF12.6
Arm C - Modified DCF+ Trastuzumab24.9

Dose Intensity Per Week of CC-486

Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

Interventionmg/ week (Mean)
Nab-Paclitaxel + CC-486 Combination Arm716.66

Dose Intensity Per Week of Durvalumab

Dose intensity was the cumulative dose divided by the dosing period in weeks). (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

Interventionmg/week (Mean)
Nab-Paclitaxel + Durvalumab Combination Arm279.96

Dose Intensity Per Week of Nab-Paclitaxel

Dose intensity was the cumulative dose divided by the dosing period in weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

Interventionmg/m^2/week (Mean)
Nab-Paclitaxel + CC-486 Combination Arm54.73
Nab-Paclitaxel + Durvalumab Combination Arm57.18
Nab-Paclitaxel Alone58.61

Kaplan Meier Estimate of Overall Survival (OS)

Overall survival was defined as the time in months between randomization/treatment assignment and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off, whichever was earlier. Participants who were lost to follow-up prior to the end of the study or who were withdrawn from the study were censored at the time of last contact. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; participants were followed for overall survival up to 30 months

InterventionMonths (Median)
Nab-Paclitaxel + CC-486 Combination Arm8.1
Nab-Paclitaxel + Durvalumab Combination Arm10.1
Nab-Paclitaxel Alone17.0

Kaplan Meier Estimate of Progression-Free Survival (PFS) as Assessed by the Investigator

Progression-free survival was defined as the time in months from the date of randomization/assignment to the date of disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria documented by computed tomography (CT) scan, not including symptomatic deterioration, or death (any cause) on or prior to the clinical cut-off date, which ever occurred earlier. Participants who did not have disease progression and had not died, regardless of whether they were discontinued from treatment, were censored at the date of last tumor assessment, on or prior to the clinical cut-off date that the participant was progression free. Progressive Disease was defined as at least a 20% increase in the sum of diameters of target lesions from nadir. (NCT02250326)
Timeframe: From date of first dose of IP to DP; up to data cut-off date of 30 August (Aug) 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 December (Dec) 2017 for Durva + nab-paclitaxel; participants were followed for PFS for up to 18 months

Interventionmonths (Median)
Nab-Paclitaxel + CC-486 Combination Arm3.2
Nab-Paclitaxel + Durvalumab Combination Arm4.5
Nab-Paclitaxel Alone4.2

Percentage of Participants Who Achieved a Best Overall Response of Complete Response or Partial Response According to RECIST V 1.1 Criteria

Overall Response was defined as percentage of participants who achieved a radiologic confirmed complete response or partial response according to RECIST V 1.1 criteria and compared with baseline among all tumor assessments, where baseline was the last CT obtained prior to or on Day 1 of treatment. Per RECIST V 1.1 criteria, a CR is defined as a disappearance of all target lesions; a PR is defined as having at least a 30% decrease in the sum of diameters of target lesions from baseline. Responses were evaluated every 6 weeks. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

Interventionpercentage of participants (Number)
Nab-Paclitaxel + CC-486 Combination Arm13.6
Nab-Paclitaxel + Durvalumab Combination Arm27.8
Nab-Paclitaxel Alone16.3

Percentage of Participants Who Achieved a Complete Response (CR), Partial Response (PR) or Stable Disease (SD) According to RECIST V 1.1 Criteria

"Disease control rate was defined as the percentage of participants who had a CR, PR or SD during the course of the study, according to RECIST version 1.1 criteria, as evaluated by the investigator. RECIST Version 1.1 criteria is defined as follows:~Complete Response is the disappearance of all target lesions;~Partial Response is at least a 30% decrease in the sum of diameters of target lesions from baseline;~Stable Disease is neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. Responses were evaluated every 6 weeks." (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

InterventionPercentage of Participants (Number)
Nab-Paclitaxel + CC-486 Combination Arm65.4
Nab-Paclitaxel + Durvalumab Combination Arm70.9
Nab-Paclitaxel Alone67.5

Percentage of Participants Who Discontinued Study Treatment

The discontinuation rate was defined as the percentage of participants who had study drug discontinued and was assessed throughout the conduct of the study. (NCT02250326)
Timeframe: Up to 30 Aug 2017 for nab-paclitaxel and CC-486 + nab-paclitaxel and 23 Dec 2017 for Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

Interventionpercentage of participants (Number)
Nab-Paclitaxel + CC-486 Combination Arm100.0
Nab-Paclitaxel + Durvalumab Combination Arm80.8
Nab-Paclitaxel Alone96.2

Number of Participants With Treatment Emergent Adverse Events (TEAEs) During the Entire Treatment Period

TEAEs were defined as any adverse event or serious adverse event that occurred or worsened on or after the day of the first dose of the IP through 28 days after the last dose of IP for Arms A and C or up to 90 days after the last dose for Arm B, and those SAEs made known to the investigator at any time thereafter that are suspected of being related to IP. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs were graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild l intervention/therapy required Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Death. (NCT02250326)
Timeframe: TEAEs were collected up to 4 weeks after receiving last dose of IP for nab-paclitaxel and CC-486 + nab-paclitaxel, and up to 90 days after the last IP dose for Durva + nab-paclitaxel; TEAEs were collected up to 86.1 weeks

,,
InterventionParticipants (Count of Participants)
TEAESerious TEAEGrade (GR) 3/4 TEAEGrade 3 or HigherTreatment Related TEAETreatment Related Serious TEAETreatment Related GR 3 or Higher TEAETEAE With Action to Reduce/Interrupt IPTreatment-Related to Reduce or Interrupt IPTEAE with Action Taken to Withdraw IPTEAE with Fatal OutcomeTreatment Related TEAE with Fatal Outcome
Nab-Paclitaxel + CC-486 Combination Arm793048497411324936840
Nab-Paclitaxel + Durvalumab Combination Arm7837535571173257329124
Nab-Paclitaxel Alone78294747685253827831

Percentage of Participants With Study Drug Dose Reductions

A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

InterventionPercentage of Participants (Number)
Nab-Paclitaxel
Nab-Paclitaxel Alone10.1

Percentage of Participants With Study Drug Dose Reductions

A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

InterventionPercentage of Participants (Number)
Nab-PaclitaxelCC-486
Nab-Paclitaxel + CC-486 Combination Arm10.120.3

Percentage of Participants With Study Drug Dose Reductions

A dose reduction occurred when the dose assigned at a visit was lower than the dose assigned at the previous visit. Dose reductions were typically caused by clinically significant laboratory abnormalities and/or TEAEs or toxicities. (NCT02250326)
Timeframe: Up to 16 Jan 2017 for CC-486 + nab-paclitaxel and up to 23 Dec 2017 for nab-paclitaxel and Durva + nab-paclitaxel; maximum treatment duration = 82.1 weeks, 52.6 weeks and 66.1 weeks for nab-paclitaxel, CC-486 + nab-paclitaxel and Durva + nab-paclitaxel

InterventionPercentage of Participants (Number)
Nab-PaclitaxelDurvalumab (Reductions Not Allowed per Protocol)
Nab-Paclitaxel + Durvalumab Combination Arm14.10.0

Kaplan-Meier Estimate for Duration of Response Over the Entire Study

Duration of overall response was measured from the time criteria were first met for CR/PR until the first date the recurrent or progressive disease (PD) was radiologically documented. Participants who did not have PD after the response were censored on the date of last tumor assessment. If a participant died before PD, the participant was censored on the date of death. (NCT02027428)
Timeframe: Between Day 1 of the Induction Period through to the date of disease progression or death; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study.

Interventionmonths (Median)
Nab-Paclitaxel + BSC: Induction + Maintenance5.95
BSC: Induction + Maintenance4.60

Kaplan-Meier Estimate of Overall Survival (OS) From Randomization Into Maintenance

Overall survival was defined as the duration in months between randomization and death from any cause. Participants who were still alive as of the clinical cut-off date had their OS censored at the date of last contact or clinical cut-off (01 August 2019 whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: From the date of randomization to death from any cause; up to 01 August 2019; survival follow up was 55.89 months

Interventionmonths (Median)
Nab-Paclitaxel + Best Supportive Care (BSC)17.61
Best Supportive Care (BSC)12.16

Kaplan-Meier Estimate of Overall Survival (OS) Over Entire Study

Overall survival was defined as the time in months from Day 1 of treatment for the Induction part to death from any cause. Subjects who were alive at the time of analysis had their OS censored at the date or last contact of 01 August 2019, whichever was earlier. The last contact date was the date of the last record in the database, or if the subject was lost to follow-up, the last known date that the subject was alive. (NCT02027428)
Timeframe: Between Day 1 of treatment in the Induction Part to death from any cause; up to 01 August 2019; survival follow up was 55.89 months

Interventionmonths (Median)
Nab-Paclitaxel + BSC: Induction + Maintenance20.57
BSC: Induction + Maintenance15.05

Kaplan-Meier Estimate of Progression-Free Survival (PFS) From Randomization Into Maintenance

Progression-free survival is defined as the time in months from the date of randomization to the date of disease progression based on the investigator's assessment according to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 criteria (documented by computerized axial tomography [CT scan], not including symptomatic deterioration) or death (any cause) on or prior to 01 Aug 2019. RECIST 1.1 Definition: - Complete response (CR) -disappearance of all target lesions; - Partial response (PR) -at least a 30% decrease in the sum of diameters of target lesions from baseline - Stable disease (SD) -neither sufficient shrinkage to qualify for partial response (PR) nor sufficient increase of lesions to qualify for progressive disease (PD) - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir, and/or the appearance of new lesions. (NCT02027428)
Timeframe: From the date of randomization to the date of disease progression or death of any cause; up to data cut off date of 15 September 2017; up to 27.6 months

Interventionmonths (Median)
Nab-Paclitaxel + Best Supportive Care (BSC)3.12
Best Supportive Care (BSC)2.60

Kaplan-Meier Estimate of Progression-Free Survival (PFS) Over Entire Study

PFS was defined as the time in months from Day 1 of treatment for the Induction part to the date of disease progression according to RECIST 1.1 criteria (documented by CT-scan, not including symptomatic deterioration) or death (any cause) on or prior to 01 August 2019, whichever occurred earlier. RECIST 1.1 Definition: - Progressive Disease (PD) - At least a 20% increase in the sum of diameters of target lesions from nadir; the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of new lesions is also considered progression. (NCT02027428)
Timeframe: Between Day 1 of the Induction Part through to the date of disease progression or death; up to 01 August 2019; the maximum treatment duration was 234.1 weeks for entire study

Interventionmonths (Median)
Nab-Paclitaxel + BSC: Induction + Maintenance6.47
BSC: Induction + Maintenance5.55

Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) In Maintenance Beyond the Response in Induction

Overall response in the maintenance period was defined as the percentage of participants who showed an improvement in best overall response from stable disease (SD) or partial response (PR) during Induction to a Complete Response (CR) or PR during Maintenance according to RECIST 1.1 criteria and confirmed in no less than 28 days. Evaluation takes as reference the lesion measurement or status at the last tumor assessment before randomization to Maintenance. The 95% CI was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. - Stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for progressive disease. (NCT02027428)
Timeframe: For the induction period the maximum treatment was 19 weeks for the maintenance period the maximum treatment was 150 weeks.

Interventionpercentage of participants (Number)
Nab-Paclitaxel + BSC: Induction + Maintenance9.6
BSC: Induction + Maintenance3.0

Percentage of Participants Who Achieved a Confirmed Overall Response of Complete Response or Partial Response (Overall Response Rate) Over Entire Study

Overall response was defined as the percentage of participants with a confirmed assessment of complete response (CR) or partial response (PR) according to RECIST 1.1 criteria and confirmed in no less than 28 days. The 95% confidence interval (CI) was calculated using Clopper-Pearson method. RECIST 1.1 Definition: - Complete response-disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - Partial response-at least a 30% decrease in the sum of diameters of target lesions from baseline. (NCT02027428)
Timeframe: Day 1 of treatment in the induction period and subsequent anticancer therapy, death or discontinuation up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

Interventionpercentage of participants (Number)
Nab-Paclitaxel + BSC: Induction + Maintenance69.1
BSC: Induction + Maintenance57.6

Percentage of Participants Who Achieved Disease Control (Disease Control Rate) by Investigator Assessment During Induction and Over the Entire Study

Disease control rate was defined as the percentage of participants who had radiologic CR, PR or SD for >= 6 weeks according to RECIST 1.1 criteria as determined by the investigator. Only participants with a confirmed CR/PR are included in this summary. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. RECIST 1.1 Definition: - CR- disappearance of all target lesions; any pathological lymph nodes (whether target or non target) must have reduction in short axis to < 10 mm. - PR- at least a 30% decrease in the sum of diameters of target lesions from baseline; - SD- neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for PD. The 95% CI was calculated using Clopper-Pearson method. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 induction through maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

Interventionpercentage of participants (Number)
All Participants - Induction47.9
Nab-Paclitaxel + BSC: Induction + Maintenance99.3
BSC: Induction + Maintenance100.0

Time to Confirmed Response During Induction and Over the Entire Study

Time to confirmed complete or partial response (CR/PR) is defined as the time from day 1 of treatment in Induction to the first occurrence of confirmed CR/PR. Two timeframes are offered: - Time to confirmed response within the Induction timeframe. - Time to Confirmed Response Over the Entire Study, i.e. the time from Day 1 of treatment in Induction to the first occurrence of confirmed CR/PR any time during the study. Only participants with a confirmed CR or PR are included in this summary. (NCT02027428)
Timeframe: Induction is from Day 1 to a maximum treatment time of 19 weeks; entire study from Day 1 Induction through Maintenance up to PD; up to 01 August 2019; maximum treatment duration was 234.1 weeks for entire study

Interventionmonths (Median)
All Participants - Induction1.446
Nab-Paclitaxel + BSC: Induction + Maintenance1.478
BSC: Induction + Maintenance1.413

Participants With Treatment-Emergent Adverse Events (TEAEs) in the Induction Period

TEAE in the Induction part is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and on or before the day of randomization for subjects who entered into the Maintenance part, or, for subjects who did not enter into the Maintenance part, before the treatment discontinuation date plus 28 days or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate Grade, 3 = Severe Grade, 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: Day 1 of Induction up to Week 23 (maximum treatment in Induction plus 4 weeks if not continuing into Maintenance)

,,
InterventionParticipants (Count of Participants)
TEAESerious TEAESeverity Grade 3/4 TEAESeverity Grade 3 or higher TEAETreatment-related (trt-related) TEAETrt-related serious TEAETEAE-study drug dose reduced or interruptedTrt-related TEAE-dose reduced or interruptedTEAE-study drug withdrawnTrt-related TEAE-study drug withdrawnTEAE-outcome of deathTrt-related TEAE-outcome of death
All Participants - Induction419177337340408823413015535327
TEAE Specific to CarboplatinNANANANA394732912365329NA6
TEAE Specific to Nab-PaclitaxelNANANANA407803402925534NA7

Participants With Treatment-Emergent Adverse Events (TEAEs) Over the Entire Study

TEAE over entire study is defined as any adverse event (AE) with an onset on or after Day 1 of treatment for the Induction part, and before the treatment discontinuation date plus 28 days, or any serious AE which occurred thereafter but was determined to be related to any study drug by the investigator. The severity of AEs was graded based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 and the scale: Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life threatening, Grade 5 = Death. Relation to study drug was determined by the investigator. (NCT02027428)
Timeframe: From Day 1 up to 01 August 2019; (maximum treatment length plus 28 days); the maximum treatment duration was 234.1 weeks for entire study

,,,,,,,
InterventionParticipants (Count of Participants)
TEAESerious TEAESeverity Grade 3/4 TEAESeverity Grade 3 or higher TEAETreatment-related (trt-related) TEAETrt-related serious TEAETEAE-study drug dose reduced or interruptedTrt-related TEAE-dose reduced or interruptedTEAE-study drug withdrawnTrt-related TEAE- study drug withdrawnTEAE-outcome of deathTrt-related TEAE-outcome of death
BSC: Induction + Maintenance6221484861852450120
BSC: TEAE Specific to BSCNANANANA101000NA0
BSC: TEAE Specific to CarboplatinNANANANA587453710NA0
BSC: TEAE Specific to Nab-PaclitaxelNANANANA618524510NA0
Nab-Paclitaxel + BSC: Induction + Maintenance1305410810912922115107221840
Nab-Paclitaxel + BSC: TEAE Specific to BSCNANANANA181170202NA0
Nab-Paclitaxel + BSC: TEAE Specific to CarboplatinNANANANA12316958511NA0
Nab-Paclitaxel + BSC: TEAE Specific to Nab-PaclitaxelNANANANA129221131042218NA0

Actual Dose of Trastuzumab Administered

Actual dose (mg) administered = (sum over all cycles of actual dose received [mg] divided by number of cycles). Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)

Interventionmg (Mean)
Trastuzumab (Vial): Adjuvant599.7
Trastuzumab (Vial): Neoadjuvant600.00
Trastuzumab (SID): Adjuvant593.3
Trastuzumab (SID): Neoadjuvant595.9

Disease-Free Survival (DFS) Using Mammography

DFS was defined as the time from the first treatment to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Kaplan-Meier estimates were used for analysis. Participants who were disease-free were censored at the data cut off date. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

InterventionMonths (Median)
Trastuzumab (Vial): AdjuvantNA
Trastuzumab (Vial): NeoadjuvantNA
Trastuzumab (SID): AdjuvantNA
Trastuzumab (SID): NeoadjuvantNA

Duration of Treatment With Trastuzumab

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up last dose of trastuzumab (up to approximately 1 year)

Interventiondays (Mean)
Trastuzumab (Vial): Adjuvant346
Trastuzumab (Vial): Neoadjuvant352.2
Trastuzumab (SID): Adjuvant340.1
Trastuzumab (SID): Neoadjuvant351.9

Overall Survival (OS)

Overall survival was defined as the time from the first treatment to death from any cause. Kaplan-Meier estimates were used for analysis. Participants who did not die were censored on the date they were last known to be alive. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)

InterventionMonths (Median)
Trastuzumab (Vial): AdjuvantNA
Trastuzumab (Vial): NeoadjuvantNA
Trastuzumab (SID): AdjuvantNA
Trastuzumab (SID): NeoadjuvantNA

Percentage of Participants Who Died

Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to death due to any cause (up to approximately 4.5 years)

InterventionPercentage of Participants (Number)
Trastuzumab (Vial): Adjuvant5.2
Trastuzumab (Vial): Neoadjuvant4.5
Trastuzumab (SID): Adjuvant0.0
Trastuzumab (SID): Neoadjuvant5.26

Percentage of Participants Who Received Concomitant Medications

(NCT01940497)
Timeframe: Screening (Day -28 to -1) up to 2.5 years

InterventionPercentage of Participants (Number)
Trastuzumab (Vial)100
Trastuzumab (SID)100

Percentage of Participants With Event (Local, Regional or Distant Recurrence, Contralateral Breast Cancer or Death) Using Mammography

A participant was considered as disease free if the participant was free from local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first). Percentage of participants with event at the cut off date were reported. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to local, regional or distant recurrence, contralateral breast cancer or death due to any cause (whichever occurred first [up to approximately 4.5 years])

InterventionPercentage of Participants (Number)
Trastuzumab (Vial): Adjuvant18.5
Trastuzumab (Vial): Neoadjuvant33.3
Trastuzumab (SID): Adjuvant6.6
Trastuzumab (SID): Neoadjuvant11.1

Percentage of Participants With Pathological Complete Response (pCR) (Neoadjuvant Groups Only) Using Mammography

In the neoadjuvant setting, the activity of two sequential drug regimens, doxorubicin-containing chemotherapy followed by paclitaxel or docetaxel chemotherapy in combination with trastuzumab, was assessed as the percentage of participants with pCR in breast and nodes using mammography. pCR was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after preoperative treatment. Data for this outcome measure were analyzed and reported only for neoadjuvant groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 24 weeks

InterventionPercentage of Participants (Number)
Trastuzumab (Vial): Neoadjuvant40.9
Trastuzumab (SID): Neoadjuvant15.8

Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm. (NCT01940497)
Timeframe: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)

InterventionPercentage of Participants (Number)
Trastuzumab (Vial): Adjuvant98.9
Trastuzumab (Vial): Neoadjuvant100.0
Trastuzumab (SID): Adjuvant89.1
Trastuzumab (SID): Neoadjuvant95.2

Percentage of Health Care Professionals (HCPs) by Response to Health Care Professional Questionnaire (HCPQ)

Percentage of HCPs providing responses to various questions related to overall ease of study drug administration was reported in different categories, where categories indicate all possible responses to such questions. (NCT01940497)
Timeframe: After at least 4 participants completed 5 cycles of adjuvant treatment (1 cycle = 21 days; maximum up to 1 year)

,
InterventionPercentage of HCPs (Number)
Specialization: OncologistSpecialization: Specialist nurseSpecialization: OtherSpecialization: MissingPersonally administered/supervised: AlwaysPersonally administered/supervised: SometimesPersonally administered/supervised: NeverIf 'Never', who administered: Specialist nurseSyringe prepared at: PharmacySyringe prepared at: Oncology wardSyringe prepared at: MissingTime to fill syringe: less than (<) 5 minutesTime to fill syringe: 6-10 minutesTime to fill syringe: 11-15 minutesTime to fill syringe: UnknownTotal time for vial administration: <3 minutesTotal time for vial administration: <5 minutesTotal time for vial administration: 6-15 minutesTime to prepare SID: <5 minutesTime to prepare SID: 6-10 minutesTime to prepare SID: 11-15 minutesTime to prepare SID: 16-20 minutesTime to prepare SID: >20 minutesTotal time for SID administration: <3 minutesTotal time for SID administration: <5 minutesTotal time for SID administration: 6-15 minutesInjection site: Irritation: A lotInjection site: Irritation: A fewInjection site: Irritation: NoneInjection site: Bruising: A fewInjection site: Bruising: NoneInjection site: Infection: NoneFever,shivering,flu-like,rash,swelling:A fewFever,shivering,flu-like,rash,swelling:NoneTime at hospital for administration: <2 hoursTime at hospital for administration: >2, <3 hoursTime at hospital for administration: >3, <4 hoursTime at hospital for administration: >4 hoursTime at hospital for administration: MissingAnxiety to participants: NoneAnxiety to participants: A fair amountEase of vial administration: NoneEase of vial administration: A fair amountEase of vial administration: A lotSubcutaneous route may simplify management: YesSubcutaneous route may simplify management: NoWould recommend SID to intravenous route: YesWould recommend SID to intravenous route: NoWould recommend subcutaneous route to medics: YesWould recommend subcutaneous route to medics: NoWould recommend subcutaneous to medics:MissingConvenience of using SID by participants: YesConvenience of using SID by participants: NoConvenience of using SID by participants: Missing
HCPs: Trastuzumab (SID)16.076.08.00.048.048.04.04.0NANANANANANANANANANA72.014.04.02.08.026.030.044.04.036.060.010.090.0100.014.086.044.034.012.010.00.090.010.0NANANA100.00.096.04.090.08.02.096.04.00.0
HCPs: Trastuzumab (Vial)17.369.211.51.940.451.97.77.755.840.43.867.313.55.813.51.959.638.5NANANANANANANANA1.946.251.97.792.3100.015.484.644.223.123.17.71.982.717.35.838.555.894.25.896.23.8100.00.00.094.20.05.8

Percentage of Participants by Response to Patient Satisfaction Questionnaire (PSQ)

"Participants were asked the following 5 questions: (1) Following the first injection given by the physician/nurse and training on how to use the SID, I felt comfortable injecting the study drug by myself; (2) The SID was convenient and easy to use; (3) I am confident giving myself an injection in the thigh with the SID; (4) Taking all things into account, I find self-administration using the SID satisfactory; (5) If given the opportunity, I would choose to continue self-injecting the study drug using the SID at home. Response to each question was recorded as either of the following options: Unknown, Strongly Disagree, Disagree, Unsure, Agree, Strongly Agree. Percentage of participants who provided responses to above questions was reported. Data for this outcome measure were analyzed and reported only for Trastuzumab (SID) arm." (NCT01940497)
Timeframe: After at least 14 cycles (1 cycle = 21 days; maximum up to 1 year)

InterventionPercentage of Participants (Number)
Comfortable: UnknownComfortable: Strongly DisagreeComfortable: DisagreeComfortable: UnsureComfortable: AgreeComfortable: Strongly AgreeConvenient: UnknownConvenient: Strongly DisagreeConvenient: DisagreeConvenient: UnsureConvenient: AgreeConvenient: Strongly AgreeConfident: UnknownConfident: Strongly DisagreeConfident: DisagreeConfident: UnsureConfident: AgreeConfident: Strongly AgreeSatisfactory: UnknownSatisfactory: Strongly DisagreeSatisfactory: DisagreeSatisfactory: UnsureSatisfactory: AgreeSatisfactory: Strongly AgreeWould continue: UnknownWould continue: Strongly DisagreeWould continue: DisagreeWould continue: UnsureWould continue: AgreeWould continue: Strongly Agree
Trastuzumab (SID)0.00.00.06.74053.30.00.00.06.733.3600.00.00.06.740.053.30.00.00.06.733.3600.00.013.36.72060

Objective Tumor Response Rate (Confirmed and Unconfirmed, Complete and Partial)

"Objective tumor response rate (complete response, unconfirmed complete response, partial response, unconfirmed partial response) in patients with measurable disease were assessed in each arm and compared between arms using Chi-squared test.~Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions" (NCT01959139)
Timeframe: Up to 3 years

Interventionpercent of participants (Number)
Phase II: mFOLFIRINOX45
Phase II: mFOLFIRINOX + PEGPH2033

Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOX

"Assess safety of mFOLFIRINOX in combination with PEGPH20 and select the optimal dose of PEGPH20 for the Phase II portion.~MTD of PEGPH20 in combination with mFOLFORINOX was evaluated by testing decreasing doses of PEGPH20 from 3mcg/kg on Day 1 and Day 3/4, to 3mcg/kg on Day 1 only and to 1.6 mcg/kg on Day 1 only.~MTD reflects the highest dose that had a dose-limiting toxicity (DLT) rate of ≤ 17%. DLTs were defined as treatment regimen related: grade ≥ 3 non-hematologic toxicity; grade 4 absolute neutrophil count (ANC) anemia or thrombocytopenia; grade 4 ANC lasting > 7 days; grade ≥ 3 febrile neutropenia; grade ≥ 3 elevation of aspartate aminotransferase (AST)/alanine aminotransferase (ALT), total bilirubin, and creatinine; delay in starting the 2nd cycle of mFOLFIRINOX by > 2 weeks due to drug related toxicity.~DLT were graded using the NCI CTCAE version 4. Note: the third and lowest dose level was not reached." (NCT01959139)
Timeframe: 2 cycles of 14 days

Interventionug/kg (Number)
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/40
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 13
All Phase 1 Participants3

Phase II: Overall Survival

"Time from date of registration to date of death due to any cause. Participants last known to be alive are censored at date of last contact.~Assessed using the logrank test." (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years

Interventionmonths (Median)
Phase II: mFOLFIRINOX14.4
Phase II: mFOLFIRINOX + PEGPH207.7

Progression Free Survival (PFS) (Phase II)

Time from date of registration to date of first documentation of progression or symptomatic deterioration or death due to any cause. Participants last known to be alive without report of progression are censored at date of last contact. (NCT01959139)
Timeframe: From date of registration to date of death due to any cause, assessed up to 3 years

Interventionmonths (Median)
Phase II: mFOLFIRINOX6.2
Phase II: mFOLFIRINOX + PEGPH204.3

Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs

"Adverse Events (AEs) are reported by CTCAE Version 4.0. Only adverse events that are possibly, probably or definitely related to study drug are reported.~Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living e.g. bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.~Grade 4: Life-threatening consequences; urgent intervention indicated.~Grade 5: Death related to adverse event" (NCT01959139)
Timeframe: Duration of treatment and follow up until death or 3 years post registration

,,,
InterventionParticipants (Number)
Abdominal painAcute kidney injuryAlanine aminotransferase increasedAlkaline phosphatase increasedAnemiaAnorexiaArthralgiaAscitesAspartate aminotransferase increasedBlood bilirubin increasedCreatinine increasedDehydrationDepressionDiarrheaEsophagitisFatigueFebrile neutropeniaGallbladder obstructionGastrointestinal disorders - Other, specifyGeneral disorders and admin site conditions- OtherGeneralized muscle weaknessHyperglycemiaHypertensionHypokalemiaHyponatremiaHypophosphatemiaHypotensionInfections and infestations - Other, specifyInfusion related reactionLeukocytosisLung infectionLymphocyte count decreasedMucositis oralMyalgiaNauseaNeutrophil count decreasedPainParesthesiaPeripheral motor neuropathyPeripheral sensory neuropathyPeritoneal infectionPlatelet count decreasedPortal vein thrombosisPulmonary hypertensionResp, thoracic and mediastinal disorders - OtherSepsisSkin infectionSmall intestine infectionSpasticityThromboembolic eventVentricular tachycardiaVomitingWeight lossWhite blood cell decreased
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 and Day 3/4011000000101010201000001100000001110000000000100000100
Phase I: mFOLFIRINOX + PEGPH20, 3 ug/kg on Day 1 Only001100001001000100000001101000000000000201000000000100
Phase II: mFOLFIRINOX1000420000171100610011113100102110084111202011100011812
Phase II: PEGPH20 + mFOLFIRINOX3032231101040121110010310431001104421230015131001111501002

Median Duration of Response (DOR)

DOR is defined as the time from date of first documented confirmed objective response to date of first documented progressive disease (PD). Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).

Interventionmonths (Median)
Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine14.9

Median Overall Survival

Overall survival based on the Kaplan-Meier method is defined as the time from randomization to death. Participants alive are censored at the last date of contact (including lost-to-follow-up) or at the date of withdrawal of consent, if relevant. (NCT01191697)
Timeframe: 23.2 months (IQR: 11.0 - 46.9 months ).

Interventionmonths (Median)
Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine23.2

Median Progression Free Survival (PFS)

PFS is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy. Per RECIST 1.1 for target lesions: PD is at least a 20% increase in sum LD, taking as reference the smallest sum on study with at least 5 mm absolute increase. For non-target lesions, progression-free means no new lesions or unequivocal progression on existing non-target lesions or not evaluated. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow up of 23.2 months (IQR: 11.0 - 46.9 months ).

Interventionmonths (Median)
Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine14.0

Objective Response Rate (ORR)

ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. (NCT01191697)
Timeframe: Patients received a median of 19 cycles of therapy (Interquartile range (IQR): 8 - 34.5 cycles). Median duration of follow-up of 23.2 months (IQR: 11.0 - 46.9 months ).

Interventionpercentage of patients (Number)
Trastuzumab, Bevacizumab, Oxaliplatin and Capecitabine81

Duration of Response

Duration of Response was defined as the time from date of first response (Complete Response (CR) or Partial Response (PR)) to the date when Progressive Disease (PD) was first documented or to the date of death, whichever occurred first according to Response Evaluation Criteria in Solid Tumors (RECIST). Subjects still having CR or PR and alive at the time of analysis were censored at their last date of tumor evaluation. CR was defined as disappearance of tumor lesions, PR as a decrease of at least 30% and PD as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks

Interventionmonths (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX67.5
Matching Placebo + mFOLFOX66.7

Overall Response

Overall response of a subject was defined as the best tumor response (Complete Response (CR) or Partial Response (PR)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

Interventionparticipants (Number)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX645
Matching Placebo + mFOLFOX661

Overall Survival (OS)

Overall Survival (OS) was defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact. (NCT00865709)
Timeframe: From randomization of the first subject until 33 months later.

Interventiondays (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6535
Matching Placebo + mFOLFOX6552

Progression-Free Survival (PFS)

Progression-free Survival (PFS) was defined as the time from date of randomization to disease progression or death due to any cause, whichever occurred first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.1
Matching Placebo + mFOLFOX68.7

Time to Progression (TTP)

Time to progression (TTP) was defined as the time from date of randomization to disease progression. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation. Disease progression was defined as an increase of at least 20% in the sum of tumor lesions sizes. (NCT00865709)
Timeframe: From randomization of the first subject until 23 months later, assessed every 8 weeks.

InterventionMonths (Median)
Sorafenib (Nexavar, BAY43-9006) + mFOLFOX69.2
Matching Placebo + mFOLFOX69.0

Duration of Response (DR)

Duration of response was defined as the time from date of first confirmed response (CR or PR) to date of first progressive disease (PD) or death. Per the RECIST criteria, definitions were as follows: CR was the disappearance of all target lesions for at least 4 weeks, PR was at least a 30% decrease in the sum of the longest diameter of target lesions, and PD was at least a 20% increase in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient was randomized).

InterventionMonths (Median)
S-1/Cisplatin6.5
5-FU/Cisplatin5.8

Median Survival

Survival was defined as the time from the date of randomization to the time of death (from any cause) for each patient. (NCT00400179)
Timeframe: The cutoff date for survival analysis was 07 March 2008 (12 months after last patient randomized).

InterventionMonths (Median)
S-1/Cisplatin8.6
5-FU/Cisplatin7.9

Overall Response Rate (ORR)

The proportion of patients with objective evidence of complete response (CR) or partial response (PR) based on tumor response assessments. Per the Response Evaluation Criteria in Solid tumors (RECIST), CR was defined as the disappearance of all target lesions for at least 4 weeks, and PR was defined as at least a 30% decrease in the sum of the longest diameter of target lesions. (NCT00400179)
Timeframe: Data cutoff was 07 March 2008 (12 months after last patient randomized).

InterventionPercentage of patients in each group (Number)
S-1/Cisplatin29.1
5-FU/Cisplatin31.9

Progression-free Survival (PFS)

The time from randomization to date of first documented PD or date of death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of first documented PD, date of death, or until data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

InterventionMonths (Median)
S-1/Cisplatin4.8
5-FU/Cisplatin5.5

Time to Treatment Failure (TTF)

The time from randomization to date of permanent discontinuation of S-1 or 5-FU, first documented PD, or death, whichever occurred first. (NCT00400179)
Timeframe: From date of randomization until date of permanent discontinuation of S-1 or 5-FU, first documented PD, death, or data cutoff on 07 March 2008 (12 months after last patient randomized), whichever came first.

InterventionMonths (Median)
S-1/Cisplatin3.8
5-FU/Cisplatin3.8

Duration of Response (DR)

DR defined as time from start of first documented objective tumor response (CR or PR) to first documented objective tumor progression or death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15

Interventionmonths (Median)
SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^214.1
SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^26.3
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^210.5
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^25.9
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^26.3

Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)

Any DLT event in Cycle 1: Grade (GR) 3/4 nausea, vomiting, or diarrhea despite anti-emetics, anti-diarrheals; GR 3 nonhematological toxicity for greater than or equal to (≥)7 days (except alopecia, skin or hair discoloration, hyperamylasemia, or hyperlipasemia without other clinical evidence of pancreatitis and asymptomatic hyperuricemia); GR 4 nonhematological toxicity; GR 4 neutropenia ≥7 days or thrombocytopenia; GR ≥3 febrile neutropenia or neutropenic infection; GR 3 thrombocytopenia ≥7 days; any treatment-related toxicity having >3 consecutive CAP or SU missed doses per cycle; delayed toxicity recovery >14 days. (NCT00555620)
Timeframe: Baseline up to Day 21

Interventionparticipants (Number)
SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^21
SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^20
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^23
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22
SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^22
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20

Percentage of Participants With Objective Response

Percentage of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as ≥30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions. (NCT00555620)
Timeframe: Baseline, Day 21 of every even-numbered cycle up to 15 months

Interventionpercentage of participants (Number)
SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^216.7
SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^242.9
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^246.7
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^243.5
SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^245.5

Progression-Free Survival (PFS)

PFS defined as time from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. (NCT00555620)
Timeframe: Baseline up to Month 15

Interventionmonths (Median)
SU 37.5 mg, CIS 60 mg/m^2, CAP 1600 mg/m^23.2
SU 37.5 mg, CIS 60 mg/m^2, CAP 2000 mg/m^26.6
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^26.4
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^28.0
SU 37.5 mg, OXA 110 mg/m^2, CAP 2000 mg/m^22.8
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^25.5

Area Under the Curve From Time 0 to 24 Hours Postdose (AUC [0-24]) for SU, SU012662, and Total Drug (SU + SU012662)

Area under the plasma concentration-time curve from time 0 to 24 hours postdose (0-24), also considered the AUC between doses at steady state. (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

,,
Interventionnanogram hours per milliliter (ng*hr/mL) (Mean)
AUC (0-24) SU011248AUC (0-24) SU012662AUC (0-24) total drug (SU011248+SU012662)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^28443211163
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^29023271230
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^214205241944

Area Under the Curve From Time Zero to 12 Hours [AUC (12)] for CAP, 5'DFCR, 5'DFUR, and 5-FU

AUC (12) = Area under the plasma concentration versus time curve from time zero (predose) to the extrapolated time 12 hours postdose. It is obtained from AUC (0 - last) plus AUC (last - 12) (NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng*hr/mL (Mean)
CAP (n = 1, 4, 9)5'DFCR (n = 1, 7, 10)5'DFUR (n = 1, 6, 10)5-FU (n = 1, 5, 10)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^22543515522155221299
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^288651009110291842
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2266370874822353

Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)]: CAP, 5'DFCR, 5'DFUR, and 5-FU

AUC (0 - ∞) = Area under the plasma concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - ∞). It is obtained from AUC (0 - t) plus AUC (t - ∞). (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng*hr/mL (Mean)
CAP (n = 1, 4, 10)5'DFCR (n = 1, 7, 10)5'DFUR (n = 1, 6, 10)5-FU (n = 1, 5, 9)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2748092007770386
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^28069114679099489
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2282888535703285

Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for CAP

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

,,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2755513532
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^273738213
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^228993157

AUClast for 5-FU

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

,,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2355688
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2506854
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2291350

AUClast for 5'DFCR

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

,,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2128158614
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2112299776
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^280286464

AUClast for 5'DFUR

Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast) (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose) and Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours)

,,
Interventionng*hr/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^288558500
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2895110017
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^256584829

Cmax of 5-fluorouracil (Metabolite of CAP, 5-FU)

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2176552
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2495866
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^2165153

Cmax of 5'-Deoxy-5-fluorocytidine (Metabolite of CAP, 5'DFCR)

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^248005500
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^280178036
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^233522267

Cmax of 5'-Deoxy-5-fluorouridine (Metabolite of CAP, 5'DFUR)

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^240106259
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^2716610082
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^228912074

Cmax of CAP

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^2700020491
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^21168116276
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^220511989

Cmin of 5-FU

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.00.0
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.80.0
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^20.00.0

Cmin of 5'DFCR

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^211.150.5
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^255.600.00
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^213.00.00

Cmin of 5'DFUR

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.033.5
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^234.40.0
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22.40.0

Cmin of CAP

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionng/mL (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^224.832.0
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.00.0
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^20.00.0

Maximum Observed Plasma Concentration (Cmax) of SU, SU012662 (Metabolite of SU), and Total Drug (SU + SU012662)

(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

,,
Interventionnanograms per milliliter (ng/mL) (Mean)
Cmax SU011248Cmax SU012662Cmax total drug (SU011248+SU012662)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^240.114.053.9
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^246.516.662.4
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^269.723.793.0

Minimum Observed Plasma Trough Concentration (Cmin) of SU, SU012662, and Total Drug (SU + SU012662)

(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

,,
Interventionng/mL (Mean)
Cmin SU011248Cmin SU012662Cmin total drug (SU011248+SU012662)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^229.011.941.6
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^230.211.141.8
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^249.218.768.5

t1/2 for 5-FU

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.80.6
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.60.6
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^21.21.1

t1/2 for 5'DFCR

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.70.7
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.80.8
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^21.01.1

t1/2 for 5'DFUR

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.70.6
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.70.7
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^21.01.0

t1/2 for CAP

Plasma decay half-life is the time measured for the plasma concentration to decrease by one half. (NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Mean)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^20.30.4
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.40.4
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^20.30.5

Time to Reach Maximum Observed Plasma Concentration (Tmax) for SU, SU012662, and Total Drug (SU + SU012662)

(NCT00555620)
Timeframe: Day 14 of Cycle 1 (predose and 2, 4, 6, 8, 10, and 24 hours postdose)

,,
Interventionhour (hr) (Median)
Tmax SU011248Tmax SU012662Tmax total drug (SU011248+SU012662)
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^24.09.04.0
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^28.06.06.0
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^28.08.08.0

Tmax for 5-FU

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Median)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^24.50.4
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.60.5
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22.03.0

Tmax for 5'DFCR

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Median)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^24.30.4
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.60.5
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22.03.0

Tmax for 5'DFUR

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Median)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^24.50.4
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.80.5
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22.03.0

Tmax for CAP

(NCT00555620)
Timeframe: Day 1 of Cycle 1 (0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose); Day 14 of Cycle 1 (predose and 0.25, 0.5, 1, 2, 3, 4, 8, and 10 hours postdose)

,,
Interventionhr (Median)
Cycle 1, Day 1Cycle 1, Day 14
SU 25 mg, CIS 80 mg/m^2, CAP 2000 mg/m^24.30.3
SU 25 mg, OXA 110 mg/m^2, CAP 2000 mg/m^20.50.4
SU 37.5 mg, OXA 110 mg/m^2, CAP 1600 mg/m^22.02.0

Dose Limiting Toxicity (DLT) [Phase I]

DLT occurring within 3 weeks of the start of chemoradiation therapy was defined as: Grade 3 non-hematologic or hematologic toxicity requiring interruption of >7 days (d) of chemo or >3d chemoradiation; Grade 4 non-hematologic; Grade 4 neutropenia or thrombocytopenia; Treatment-related death; Delays in surgery >3 weeks due to treatment-related toxicity. A 30% increase in any surgical complication rate beyond those previously established rates (readmission rate: 16%; pancreatic fistula/intra-abdominal abscess/infection rate: 27%, major intra-abdominal bleeding requiring return to OR: 1.6%, delayed gastric emptying: 4.4%, and superficial wound infection rate: 8%) was also considered a DLT. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy

Interventionpatients with DLT (Number)
Phase 1 Cohort 1: Photon Rad (30 Gy/12 Days)+Capecitabine0
Phase I Cohort 2: Photon Rad (25 Gy/11 Days)+Capecitabine0
Phase I Cohort 3: Photon Rad (25 Gy/5 Days)+Capecitabine0

Neoadjuvant Short-Course Photon Radiation Therapy Maximum Tolerated Dose (MTD) [Phase I]

Neoadjuvant short-course photon radiation therapy MTD in combination with capecitabine 825 mg/m2 orally BID for ten consecutive weekdays, beginning on the morning of the first day of radiation therapy is determined by the number of patients who experience a dose limiting toxicity (DLT). See subsequent primary outcome measure for the DLT definition. The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If none of 3 initial patients or only 1 of 6 patients have a DLT on dose level 3 then 6 additional patients are treated at this dose. If during this expansion, the rate of DLT exceeds 30% then the next lower dose level is declared the MTD. If no DLTs are observed, the MTD is not reached. (NCT00889187)
Timeframe: within 3 weeks of the start of chemoradiation therapy

InterventionGy per fraction (Number)
All Phase I: Photon Rad+CapecitabineNA

Maximum Tolerated Dose (MTD) of Erlotinib When Administered in Combination With 5-fluorouracil (5-FU), Bevacizumab, and External Beam Radiation Therapy

MTD of Erlotinib was determined using a traditional 3 + 3 dose escalation scheme of three dose levels (50,100,150mg). Successive cohorts of 3-6 patients were enrolled into dose escalation cohorts for 14 day cycles. MTD reflects the highest dose of Erlotinib that had ≤1 out of 6 patients with Dose-Limiting Toxicity (DLT) at the highest dose level below the maximally administered dose. The maximally administered dose is the first dose that causes DLT in >33% of patients. DLT was defined as: Any grade 4 neutropenia, Any grade 3 thrombocytopenia, or Any ≥ grade 3 non-hematologic toxicity that results in greater than 7 days interruption in therapy. (NCT00307736)
Timeframe: 3 years

Interventionmg (Number)
5-FU, Bevacizumab, Erlotinib and Radiation100

Pathologic Complete Response

The number of subjects who achieved a pathologic complete response as determine by pathologist, following completion of the study therapy. Pathologic complete response represents the absence of residual invasive disease in the rectum and in the regional lymph nodes. (NCT00307736)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Completed Study Therapy9
Underwent Resection10
Treated at MTD7

Percentage of Participants With Disease-free Survival

Summary of disease free survival at 1, 2, and 3 years. Disease free survival is the length of time after primary treatment for cancer ends that the participant survives without any clinical signs or symptoms of that cancer. The data is shown of the percentage of participants still in disease free survival at one, two, and three years. (NCT00307736)
Timeframe: 1, 2, 3 years

Interventionpercentage of participants (Number)
1 Year2 Years3 Years
5-fluorocuracil, Bevacizumab, Erlotinib and Radiation93.483.475.5

Post-operative Complications After Resection of Rectal Cancers Following Preoperative 5-FU, Bevacizumab, Erlotinib, and External Beam Radiation Therapy.

Surgical morbidity following R0 resection with one of the following procedures: abdominal perineal resection, low anterior resection, and low anterior resection with coloanal anastomosis. (NCT00307736)
Timeframe: 3 years

Interventionparticipants (Number)
anastomotic leaksintra-abdominal infectionwound infectionspulmonary embolussmall bowel obstructionurinary obstruction/retentionfever
Surgery, 5-fluorocuracil, Bevacizumab, Erlotinib and Radiation4221151

Summary of Grade 3 or Greater Toxicity

"Summary of grade 3 or greater toxicity by grade and type. All adverse events were evaluated using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.~Grade 3: Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care activities of daily living.~Grade 4 Life-threatening consequences; urgent intervention indicated." (NCT00307736)
Timeframe: 3 years

,
Interventionparticipants (Number)
LymphopeniaDiarrhea w/o prior colostomyHypophosphatemiaRash: acne/acneiformALT-SGPTAST-SGOTCardiac-ischemiaColitisDehydrationFatigueFebrile neutropeniaHypertensionHyperuricemiaHypokalemiaHyponatremiaMuco/stomatitis (symptom) oral cavityMuco/stomatitis by exam-oral cavityProteinuriaRadiation dermatitisRash/desquamationRectum-pain
Grade 31663211111101011111111
Grade 4500000000010100000000

Best Overall Response (BOR)

"BOR defined as percentage of subjects, whose BOR was either (confirmed) complete response (CR) or partial response (PR), relative to the number of subjects belonging to the study population of interest. CR defined as Disappearance of all target lesions plus disappearance of all non-target lesions & without appearance of any new lesions; confirmed minimum 4 weeks later. PR defined as At least 30% reduction in the SOLD of target lesions plus no significant change in non-target lesions to qualify for either CR or PD without appearance of new lesions; confirmed minimum 4 weeks later" (NCT00439517)
Timeframe: Evaluations were performed every 8 weeks until disease progression, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionpercentage of participants (Number)
UFOX + Cetuximab37.5
FOLFOX4 + Cetuximab51.3

Overall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionmonths (Median)
UFOX + Cetuximab12.9
FOLFOX4 + Cetuximab15.5

Overall Survival (OS)

Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whatever is earlier. (NCT00439517)
Timeframe: Time from randomization to death or last known to be alive, reported between day of first patient randomised, Feb 2007, until cut off date, 31 Aug 2011

Interventionmonths (Median)
UFOX + Cetuximab16.8
FOLFOX4 + Cetuximab18.4

Progression-free Survival (PFS)

Duration from randomization until progression or death due to any cause. Only deaths within 12 weeks of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment. Response and progression were assessed by the Investigators using response evaluation criteria in solid tumors (RECIST) 1.0 criteria (NCT00439517)
Timeframe: Time from randomization to disease progression, death, or last tumor assessment reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionmonths (Median)
UFOX + Cetuximab6.6
FOLFOX4 + Cetuximab8.2

Safety - Number of Patients Experiencing Any Adverse Event

Please refer to Adverse Events section for details of individual serious adverse events and other adverse events (NCT00439517)
Timeframe: Time from first dose up to 30 days after last dose of study treatment, reported between day of first patient randomised, Feb 2007, until cut off date, 30 Jun 2009

Interventionparticipants (Number)
UFOX + Cetuximab151
FOLFOX4 + Cetuximab149

QOL EuroQuol-5D (EQ-5D) Health Outcome Questionnaire

The EQ-5D questionnaire is a measure of health status that provides a simple descriptive profile and a single index value. The optional part of the questionnaire was not applied. The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The 5 items are combined to generate health profiles. These profiles were converted to a continuous single index score using a one to one matching. The lowest possible score is -0.59 and the highest is 1.00, higher scores on the EQ-5D represent a better QOL. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

,
Interventionscores on a scale (Least Squares Mean)
BaselineCycle 3Cycle 6
FOLFOX4 + Cetuximab0.7340.7580.771
UFOX + Cetuximab0.7470.7820.758

QOL Therapy Preference Questionnaire (TPQ)

TPQ was used to investigate which features of chemotherapy treatment are the most relevant in ensuring patient satisfaction. The most essential characteristics of a cancer medication are shown at baseline and at cycle 3, along with percentage of subjects selecting that characteristic. (NCT00439517)
Timeframe: at baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. All cycles were 4 weeks long unless dosing delays

,
Interventionpercentage of participants (Number)
Baseline: Does not increase your risk of infectionBaseline: Does not interfere with daily activitiesBaseline: Does not make you vomitBaseline: Does not give you diarrheaCycle 3: Does not increase your risk of infectionCycle 3: Does not interfere with daily activitiesCycle 3: Does not make you vomitCycle 3: Does not give you diarrhea
FOLFOX4 + Cetuximab16151451511104
UFOX + Cetuximab1817491510415

Quality of Life (QOL) Functional Assessment of Cancer Therapy-Colorectal (FACT-C)

"All of the single-item measures of the FACT-C are assessed on ordinal response categories ranging from 0=Not at all to 4=Very much. For scoring purposes the response scores are reversed on negatively phrased questions. The principle for scoring the sub-scales is the same in all cases: subscale score = (Sum of items × Number of items in the subscale) / numbers of items answered. The lowest possible total score is 0 and the highest is 136. A high scale score represents a high QOL." (NCT00439517)
Timeframe: At baseline, at every first day of every third cycle during active - treatment, and at final tumor assessment , reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009. Cycles were 4 weeks long unless dosing delays

,
Interventionscores on a scale (Least Squares Mean)
BaselineCycle 3Cycle 6
FOLFOX4 + Cetuximab96.4595.8994.70
UFOX + Cetuximab98.2295.4194.75

Treatment Impact on Social Daily Living and Health Care Resource Utilization

Non-protocol medical care visits and consultations (NCT00439517)
Timeframe: From randomisation until final visit, reported between day of first patient randomised, Feb 2007, until cut-off date, 30 Jun 2009

,
Interventionvisits or consultations (Number)
Emergency room visitHospital oupatient clinic visitPractice visitHome visitGeneral Practitioner consultationSpecialist consultationNurse consultationOther consultation
FOLFOX4 + Cetuximab26351591301248412318
UFOX + Cetuximab3440711565621519

Duration of Response

Duration of response during first line therapy is defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first line therapy. This was only be calculated for participants who achieved a best overall response of CR or PR. Participants who did not progress or die after they had a confirmed response were censored at the date of their last tumor measurement or last follow up for progression of disease during first line therapy. Median duration of response was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization to the end of study, up to 26 months

Interventionmonths (Median)
Bevacizumab7.1
Placebo5.8

Overall Survival

The primary efficacy endpoint for this study was overall survival (time to death), defined as the time between randomization and the date of death irrespective of the cause of death. Patients for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive. Median survival was estimated by the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until death, up to 26 months

Interventionmonths (Median)
Bevacizumab12.1
Placebo10.1

Progression-free Survival

Progression-free survival (PFS) is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first. Patients who neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow up for progression of disease. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression or death, up to 26 months.

Interventionmonths (Median)
Bevacizumab6.7
Placebo5.3

Progression-free Survival During First-line Therapy

Progression-free survival (PFS) during first-line therapy is defined as the time between randomization and the date of first documented disease progression or death, whichever occurs first and only if it occurs no later than 28 days after last confirmed intake of any study medication and only if it occurs before the start of non-study antineoplastic treatment. Participants who did not progress or die in this interval or were lost to follow-up were censored at the date of the last tumor assessment within this time window. Median PFS was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until 28-days after the last study treatment was administered, up to 26 months.

Interventionmonths (Median)
Bevacizumab6.9
Placebo5.4

Time to Disease Progression

Time to progression is defined as the time from randomization to the first occurrence of progressive disease (PD). PD was assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria and defined as at least a 20% increase in the sum of the longest diameter of target lesions, or appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions. Patients with no PD at study completion (including those who died before PD) were censored at the date of the last tumor assessment. Median time to PD was estimated using the Kaplan-Meier method. (NCT00548548)
Timeframe: From randomization until disease progression; assessed every 6 weeks for the first year and every 12 weeks thereafter, up to 26 months.

Interventionmonths (Median)
Bevacizumab7.0
Placebo5.6

Participants With a Best Overall Response of Complete or Partial Response

Best overall response during first-line therapy is defined as the occurrence of either a confirmed complete (CR) or a partial (PR) best overall response, as determined by the RECIST criteria. CR is defined as the disappearance of all target and non-target lesions and PR is defined as at least a 30% decrease in the sum of the longest diameter of target lesions and no new or progression of non-target lesions, or the disappearance of all target lesions and persistence of one or more non-target lesion(s). (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.

,
Interventionparticipants (Number)
RespondersNon-responders
Bevacizumab143168
Placebo111186

Participants With Adverse Events

The intensity of Adverse Events (AEs) was graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 3.0 on a five-point scale from Grade 1 (Mild) to Grade 5 (Death). A serious AE (SAE) was defined as any event that is fatal, life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is medically significant or requires intervention to prevent one or other of the outcomes listed above. (NCT00548548)
Timeframe: From randomization until 3 months after last dose (up to 26 months)

,
Interventionparticipants (Number)
Any Adverse eventSerious AEGrade 3/4/5 AEGrade 5 AEDeaths not due to Progression
Bevacizumab3801342931831
Placebo3771372942529

Participants With Disease Control

Disease control for participants with measurable disease was defined as a complete response (CR), partial response (PR) or stable disease (SD) for 6 weeks or longer, as determined by the RECIST criteria. For participants without measurable disease, disease control was defined as no disease progression for ≥ 6 weeks. (NCT00548548)
Timeframe: From randomization until the end of study, up to 26 months.

,
Interventionparticipants (Number)
Participants with Disease ControlParticipants without Disease Control
Bevacizumab30087
Placebo271116

12 Months Disease Free Survival (DFS)

Participants who were alive and disease free at 12 months. DFS was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response was disappearance of all target lesions. Partial response was at least a 30% decrease in target lesions. Progression was at least a 20% increase in target lesions and stable disease is neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. (NCT00941655)
Timeframe: 12 months

InterventionParticipants (Count of Participants)
Surgery + HIPEC + Systemic Chemotherapy2
Systemic Chemotherapy Alone0

Median Blood Loss During Surgery

Blood loss during surgery is related to complexity of the operation and via that to the stage of disease (more tumor to be cytoreduced, more blood loss). (NCT00941655)
Timeframe: Day 1

Interventionml (Median)
Surgery + HIPEC + Systemic Chemotherapy650

Median Duration of Cytoreduction Surgery and Heated Intraperitoneal Chemotherapy (HIPEC)

Time it takes to perform this complex surgery and HIPEC to reduce tumor burden overall in this disease. (NCT00941655)
Timeframe: up to 12 hours

Interventionhours (Median)
Surgery + HIPEC + Systemic Chemotherapy10.1

Median Hospital Stay After Initial Surgery

Recuperation period following complex surgery for this disease. (NCT00941655)
Timeframe: 1-10 weeks

InterventionDays (Median)
Surgery + HIPEC + Systemic Chemotherapy17

Number of Participants With Serious and Non-Serious Adverse Events

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v3.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT00941655)
Timeframe: Date treatment consent signed to date off study, approximately, 40.5 months

InterventionParticipants (Count of Participants)
Surgery + HIPEC + Systemic Chemotherapy8
Systemic Chemotherapy Alone5

Completeness of Cytoreduction (CCR) Score

CCR is assessed by Sugarbaker's criteria. CCR-0 is no residual tumor. CCR-1 is no residual nodules greater than 2.5 mm in diameter, CCR-2 is no residual nodules greater than 25 mm, and CCR-3 is residual nodules greater than 25 mm. (NCT00941655)
Timeframe: Day 1

InterventionScores on a scale (Number)
Patient 1Patient 2Patient 3Patient 4Patient 5Patient 6Patient 7Patient 8
Surgery + HIPEC + Systemic Chemotherapy00020000

Gillys Stage Before and After Surgery

Gillys stage measures the completeness of the cytoreduction and is recorded before and after surgery. It is used to classify disease burden and determine prognosis. Stage 0 is no macroscopic signs of disease, stage 1 is nodules >5mm in one part of the abdomen, stage 2 is nodules >5 mm throughout the abdomen, stage 3 is nodules 5mm to 2 cm, and stage 4 is nodules < 2 cm. (NCT00941655)
Timeframe: Day 1

InterventionStage (Number)
Patient 1 Before SurgeryPatient 1 After SurgeryPatient 2 Before SurgeryPatient 2 After SurgeryPatient 3 Before SurgeryPatient 3 After SurgeryPatient 4 Before SurgeryPatient 4 After SurgeryPatient 5 Before SurgeryPatient 5 After SurgeryPatient 6 Before SurgeryPatient 6 After SurgeryPatient 7 Before SurgeryPatient 7 After SurgeryPatient 8 Before SurgeryPaitent 8 After Surgery
Surgery + HIPEC + Systemic Chemotherapy0010003100001030

Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I

Time between the first day of treatment and the date of death. (NCT00941655)
Timeframe: 12 weeks up to 3 years

InterventionMonths (Number)
Patient #1Patient #2Patient #4Patient #6Patient #7Patient #9Patient #11Patient #15
Surgery + HIPEC + Systemic Chemotherapy1911114145120

Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm II

Time between the first day of treatment and the date of death (NCT00941655)
Timeframe: 12 weeks up to 3 years

InterventionMonths (Number)
Patient #3Patient #5Patient #8Patient #10Patient #12Patient #13Patient #14
Systemic Chemotherapy Alone176100080

Best Overall Response Rate (ORR)

"Percentage of partial and complete responses, according to WHO criteria:~Complete Response: Disappearance of all known disease, determined by 2 observations not less than 4 weeks apart.~Partial Response: Decrease by at least 50% of the diameters of all measurable lesions, determined by 2 observations not less than 4 weeks apart." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months

Interventionpercentage of participants (Number)
(TE) Taxotere and Eloxatin23.1
(TEF) Taxotere, Eloxatin and 5-fluorouracil46.6
(TEX) Taxotere, Eloxatin and Xeloda25.6

Overall Survival (OS)

The number of months measured from the date of randomization to the date of death due to any cause. (NCT00382720)
Timeframe: up to a maximum of 36 months

Interventionmonths (Median)
(TE) Taxotere and Eloxatin8.97
(TEF) Taxotere, Eloxatin and 5-fluorouracil14.59
(TEX) Taxotere, Eloxatin and Xeloda11.30

Time to Progression

"The number of months measured from the day of randomization to the first tumor progression according to World Health Organization (WHO) criteria evaluation of cancer response, or death from any cause.~WHO Criteria for Progressive Disease: ≥ 25% increase in the size of at least one bidimensionally or unidimensionally measurable lesion." (NCT00382720)
Timeframe: every 8 weeks up to a maximum of 36 months

InterventionMonths (Median)
(TE) Taxotere and Eloxatin4.50
(TEF) Taxotere, Eloxatin and 5-fluorouracil7.66
(TEX) Taxotere, Eloxatin and Xeloda5.55

Maximum Tolerated Dose (MTD)

MTD is the highest dose at which 1 or fewer dose limiting toxicities (DLT's) are observed in 6 patients. DLT defined as any non-hematologic grade III/IV or neutropenia-associated (infection or fever treated in the hospital) toxicity attributable to this therapy. Response evaluated after two 14-day treatments of Docetaxel, 5-Fluorouracil and Oxaliplatin (One cycle = 28 days). (NCT00526110)
Timeframe: 28 days

Interventionmg/m^2 (Number)
Phase I50

Median Overall Survival

Overall survival was defined as the time from the start of treatment until death or last follow-up. Kaplan-Meier curve was used to estimate overall survival. (NCT00526110)
Timeframe: Up to 30 months

Interventionmonths (Median)
Phase II11.1

Progression Free Survival

Progression Free Survival (PFS) defined as the time from the first study drug administration until the first day of radiological and/or symptomatic disease progression is documented, or the start of further anticancer therapy or death from any cause, whichever occurs first. Kaplan-Meier curve was used to estimate PFS. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesion. (NCT00526110)
Timeframe: Assessed from baseline to 30 months

Interventionmonths (Median)
Phase II6.5

Objective Response Rate

Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST 1.1 by independent radiology review) at 8 week intervals in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
MPC Modified FOLFIRINOX35.1
LAPC Modified FOLFIRINOX17.2

Overall Survival

Overall survival will be determined in patients with metastatic disease and in patients with locally advanced disease. (NCT01523457)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
MPC Modified FOLFIRINOX81
LAPC Modified FOLFIRINOX100

Progression Free Survival

The primary objective of this study is to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a dose-attenuated modification of FOLFIRINOX. Tumour response was determined according to RECIST 1.1 by independent radiology review. (NCT01523457)
Timeframe: 24 weeks

Interventionpercentage of participants (Number)
MPC Modified FOLFIRINOX54
LAPC Modified FOLFIRINOX97

Rate of Resection in Patients With Locally Advanced Disease

The rate of surgical resection in the cohort of patients with locally advanced disease will be determined. (NCT01523457)
Timeframe: 24 weeks

Interventionparticipants (Number)
TotalUnresectableBorderline
LAPC Modified FOLFIRINOX1367

Toxicity

Toxicities will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) 4.0. Rates of grade 3 and 4 toxicities will be compared to historical controls. MPC and LAPC are combined because they were given the exact same medication. The study aimed to compare this dosage with historical dosage, so this comparison is the most appropriate. (NCT01523457)
Timeframe: 24 weeks

,
Interventionparticipants (Number)
NeutropeniaThrombocytopeniaAnaemiaFebrile neutropeniaDiarrheaFatigueAlanine aminotransferase (ALT) increasedThromboembolic eventPeripheral sensory neuropathyVomiting
LAPC Modified FOLFIRINOX5222440001
MPC Modified FOLFIRINOX4521853321

Median Time to Recurrence

Disease recurrence will be defined as radiographic tumor evidence detected by surveillance imaging. Confirmation of recurrence by biopsy will be at the discretion of the treating physician. This study closed early on June 18, 2020. It was earlier than one planned because of the lack of accrual. (NCT03515941)
Timeframe: From the end of completion of assigned therapy, subjects undergo follow-up every 3 months for a total of 36 months(planned) after the date of surgery or until the study closure

Interventionmonths (Median)
Arm 1: Adjuvant ChemotherapyNA
Arm 2: Adjuvant ChemoradiationNA

Number of Participants Who Complete the Recommended Therapy From Each Arm

The number of patients who complete the recommended therapy will be counted for each arm. (NCT03515941)
Timeframe: From date of assigned therapy up to 17 weeks

InterventionParticipants (Count of Participants)
Arm 1: Adjuvant Chemotherapy3
Arm 2: Adjuvant Chemoradiation2

Overall Survival in Patients With Adenocarcinoma

Overall survival (OS) was defined as the time from study entry to death of any cause. The median OS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)11.6
Arm B: Adenocarcinoma (IC + Cetuximab)8.6
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)11.8

Progression-free Survival in Patients With Adenocarcinoma

Progression free survival (PFS) was defined as the time from study entry to progression or death of any cause. The median PFS with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)7.1
Arm B: Adenocarcinoma (IC + Cetuximab)4.9
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)6.8

Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with adenocarcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionpercentage of participants (Number)
Arm A: Adenocarcinoma (ECF + Cetuximab)61
Arm B: Adenocarcinoma (IC + Cetuximab)45
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)54

Time to Treatment Failure in Patients With Adenocarcinoma

Time to treatment failure (TTF) was measured from study entry until documented progression, death resulting from any cause, or end of protocol therapy because of unacceptable toxicity. The median TTF with 95% CI was estimated using the Kaplan Meier method. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionmonths (Median)
Arm A: Adenocarcinoma (ECF + Cetuximab)5.6
Arm B: Adenocarcinoma (IC + Cetuximab)4.3
Arm C: Adenocarcinoma (FOLFOX + Cetuximab)6.7

Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma

Response was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria: Complete Response (CR): disappearance of all target lesions; Partial Response (PR) 30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions; Stable Disease (SD): small changes that do not meet above criteria. Overall tumor response is the total number of CR and PRs in participants with squamous cell carcinoma who have received at least one cycle of therapy. (NCT00381706)
Timeframe: Up to 2 years post-treatment

Interventionpercentage of participants (Number)
Arm A: Squamous Cell Carcinoma (ECF + Cetuximab)67
Arm B: Squamous Cell Carcinoma (IC + Cetuximab)13
Arm C: Squamous Cell Carcinoma (FOLFOX + Cetuximab)60

Duration of Response

Duration of response was defined using RECIST v. 1.1 criteria as the time from the date criteria were met for the first objectively recorded CR or PR until the first date criteria for PD were met or death from any cause. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. Participants who were not known to have died and who did not have PD were censored at the date of the last tumor assessment prior to the date of any subsequent systemic anticancer therapy. (NCT01246960)
Timeframe: Time of first response to measured PD (up to Month 23.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX67.4
Placebo and mFOLFOX65.8

Number of Participants With Treatment-Emergent Anti-Ramucirumab Antibodies

Participants with treatment-emergent anti-ramucirumab antibodies were participants with a 4-fold increase (2 dilution increase) in immunogenicity titer over baseline titer, or participants who tested negative at baseline and positive post-baseline (at titer of ≥1:20). (NCT01246960)
Timeframe: Months 1, 2, 4, 6, and 8

Interventionparticipants (Number)
Ramucirumab and mFOLFOX60
Placebo and mFOLFOX61

Overall Survival (OS)

OS was defined as the time from randomization to death due to any cause. OS was censored at the date of the last follow-up visit for participants who were alive or lost to follow-up. (NCT01246960)
Timeframe: Randomization to date of death from any cause (up to Month 28.3)

Interventionmonths (Median)
Ramucirumab and mFOLFOX611.7
Placebo and mFOLFOX611.5

Percentage of Participants Achieving an Objective Response (Objective Response Rate)

The percentage of participants who achieved a best overall response of partial response (PR) or complete response (CR) is reported. Response was defined using RECIST, v. 1.1 criteria. CR was the disappearance of all lesions and pathological lymph node reduction in the short axis to <10 mm. PR was a ≥30% decrease in the sum of the diameters of target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved was CR or PR/number of participants treated)*100. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 23.0)

Interventionpercentage of participants (Number)
Ramucirumab and mFOLFOX645.2
Placebo and mFOLFOX646.4

Progression-Free Survival (PFS)

PFS was defined using Response Evaluation Criteria in Solid Tumors [RECIST version (v.) 1.1] as the time from randomization to the first observation of progressive disease (PD) or death due to any cause, whichever came first. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 millimeters (mm); the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. If a participant did not have a baseline disease assessment, PFS time was censored at the randomization date, regardless of whether or not PD or death was observed. Participants not known to have died or have objective PD were censored at the last post-baseline radiological assessment date. (NCT01246960)
Timeframe: Randomization to measured PD or date of death from any cause (up to Month 25.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX66.4
Placebo and mFOLFOX66.7

Time to Disease Progression (TTP)

TTP was defined using RECIST v. 1.1 as the time from study randomization to the first date of PD. PD was a ≥20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of ≥5 mm; the appearance of ≥1 new lesions or unequivocal progression of non-target lesions. TTP was censored at the date of last adequate tumor assessment if death was due to causes other than PD. (NCT01246960)
Timeframe: Randomization to measured PD (up to Month 25.0)

Interventionmonths (Median)
Ramucirumab and mFOLFOX68.7
Placebo and mFOLFOX67.1

Number of Participants With Adverse Events (AEs)

Reported are the number of participants who had ramucirumab/placebo-related: AEs, serious AEs (SAEs), AEs based on common terminology criteria for adverse events (CTCAE) ≥Grade 3, AEs = CTCAE Grade 5, as well as, AEs leading to treatment discontinuation and AEs resulting in death. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module. (NCT01246960)
Timeframe: Baseline through study completion (up to Month 28.3)

,
Interventionparticipants (Number)
Any Ramucirumab/Placebo-Related AEAny Ramucirumab/Placebo-Related SAEAny Ramucirumab/Placebo-Related ≥Grade 3 AEAny Ramucirumab/Placebo-Related Grade 5 AEAny AE Leading to Treatment DiscontinuationAny AE with Outcome of Death
Placebo and mFOLFOX6641233352
Ramucirumab and mFOLFOX66410360185

Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT

"Per the Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and by Spiral CT assessment:~Complete Response (CR) is the disappearance of all target lesions; Partial Response (PR) is a >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR" (NCT00573131)
Timeframe: Screening and Week 12

Interventionpercentage of patients (Number)
Group 112.5
Group 220.0

Overall Survival

From date of registration to date of death due to any cause. Patients last known to be alive are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years

Interventionmonths (Median)
mFOLFOX6.7
MK2206 and Selumetinib3.9

Progression-free Survival

From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact. (NCT01658943)
Timeframe: Up to 3 years

Interventionmonths (Median)
mFOLFOX2.0
MK2206 and Selumetinib1.9

Number of Patients With Grade 3 Through Grade 5 Adverse Events That Are Related to Study Drug

Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT01658943)
Timeframe: Up to 3 years

,
InterventionParticipants (Number)
Abdominal painAlanine aminotransferase increasedAlkaline phosphatase increasedAnemiaAnorexiaAspartate aminotransferase increasedBlood bilirubin increasedCognitive disturbanceDehydrationDevice related infectionDiarrheaEdema faceEncephalopathyErythema multiformeErythrodermaFatigueGeneralized muscle weaknessHepatic failureHyperglycemiaHypertensionHypokalemiaHypomagnesemiaHyponatremiaHypophosphatemiaHypotensionHypoxiaLeft ventricular systolic dysfunctionLung infectionLymphocyte count decreasedMucositis oralMulti-organ failureNauseaNeoplasms benign, malignant and unspecifiedNeutrophil count decreasedPlatelet count decreasedRash acneiformRash maculo-papularSkin infectionSoft tissue infectionStevens-Johnson syndromeSyncopeVomitingWeight lossWhite blood cell decreased
mFOLFOX10021010114000080012111010018103041000000312
MK2206 and Selumetinib04231301604111171175104111110410200571111100

Objective Response Rate

Confirmed response (CR) is two or more objective statuses of CR a minimum of four weeks apart documented before progression or symptomatic deterioration. Partial response (PR) is two or more objective statuses of PR or better a minimum of four weeks apart documented before progression or symptomatic deterioration. Unconfirmed CR is one objective status of CR documented before progression or symptomatic deterioration but not qualifying as CR or PR. Unconfirmed PR is one objective status of PR documented before progression or symptomatic deterioration but not qualifying as CR, PR or unconfirmed CR. (NCT01658943)
Timeframe: Up to 3 years

,
Interventionparticipants (Number)
Partial ResponseUnconfirmed Partial ResponseStable/No responseIncreasing diseaseSymptomatic DeteriorationAssessment Inadequate
mFOLFOX41142936
MK2206 and Selumetinib01123426

Disease-free Survival

Where events are defined as recurrence, second primary cancer, or death from any cause (NCT00096278)
Timeframe: 3 years

Interventionpercentage of patients (Number)
Arm 1: Oxaliplatin + Leucovorin + 5-Fluorouracil75.5
Arm 2: Oxaliplatin + Leucovorin + 5-Fluorouracil + Bevacizumab77.4

Survival

Percentage of patients who did not experience an event where events are defined as death from any cause. (NCT00096278)
Timeframe: 5 years

Interventionpercentage of patients (Number)
Arm I (mFOLFOX6)77.6
Arm II (Bevacizumab, mFOLFOX6)78.7

Number of Participants With Overall Response

Overall response rate defined as Complete Response (CR), disappearance of all target lesions; or Partial Response (PR), at least a 30% decrease in sum of longest diameter (LD) of target lesions, taking as reference the baseline sum LD, assessed by Response Evaluation Criteria in Solid Tumors (RECIST) Committee [JNCI 92(3):205-216, 2000]. In addition to a baseline scan, confirmatory scans for those deemed to have achieved a PR or CR. (NCT00354887)
Timeframe: Every 9 weeks from treatment initiation and confirmatory images 6 weeks or more after initial responses

Interventionparticipants (Number)
Participants with CRParticipants with PR
Oxaliplatin + Capecitabine312

Dose Related Toxicity

dose related toxicity is defined as follows:1. WBC damage >= grade 3; granular cell decrease >= grade 3; hemoglobin >= grade 2; platelet >= grade 2;SGPT/SGOT elevation >= grade 2; ALP >= grade 2; GGT >= grade 2; Tbil >= grade 2;renal function damage: BUN/Cr elevation >= grade 2;Non-gradular cell decreased fever >= grade 2;nausea/vomiting >= grade 2; fatigue >= grade 3; weight loss >= grade 3;gastritis >= grade 3; dairrea >= grade 3; abdominal pain >= grade 3; pancreatitis >= grade 2; upper gastrointestinal bleeding >= grade 2;other toxic reaction >= grade 3;KPS < 50 during the treatment (NCT01268943)
Timeframe: up to 9 weeks

Interventionevent (Number)
1000mg1
1200mg0
1400mg0
1500mg3

Disease-Free Survival (DFS)

Defined as the interval between the start date of treatment and the date of occurrence of progressive disease or death from any cause. (NCT00193128)
Timeframe: 18 months

Interventionmonths (Median)
Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2)16.3

Overall Survival (OS)

Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00193128)
Timeframe: 36 months

Interventionmonths (Median)
Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2)24.1

Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in Their Surgical Specimen Following Surgery

The absence of any residual tumor cells in a histologic evaluation of a tumor specimen following surgery is defined as a complete pathologic response (NCT00193128)
Timeframe: 18 months

InterventionParticipants (Count of Participants)
Oxaliplatin/Docetaxel/Capecitabine/Radiation (Cohort 2)24

Antibiotic Use Due to Febrile Neutropenia

Antibiotic use during any of the first 4 cycles of treatment due to febrile neutropenia. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)2
Placebo8

Dose Delay or Reduction Due to Neutropenia

Dose delay or reduction in chemotherapy doses due to neutropenia (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)5
Placebo26

Dose Delay or Reduction for Any Reason

Dose delay or reduction in chemotherapy dose during the first 4 cycles for any reason (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)41
Placebo53

Febrile Neutropenia

Febrile neutropenia, Defined as a temperature ≥ 38.2 °C on a given day, with an ANC < 1.0 x 10^9/L recorded on the same day or the next day, during any of the first 4 cycles of treatment. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)3
Placebo10

Grade 3 or 4 Neutropenia

Grade 3 or 4 neutropenia, defined as an absolute neutrophil count (ANC) < 1 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)16
Placebo51

Grade 4 Neutropenia

Grade 4 neutropenia, defined as an absolute neutrophil count (ANC) <0.5 x 10^9/L, in any of the first four cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)13
Placebo17

Hospitalization Due to a Neutropenia-Related Event

Hospitalization because of a neutropenia-related event during the first 4 cycles of treatment (NCT00094809)
Timeframe: First 4 cycles of neutropenia (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)7
Placebo9

Objective Tumor Response

Objective tumor response (complete or partial) at the end of treatment, defined as a reduction of at least 50% in the area of all measurable lesions (partial response) or disappearance of all measurable or evaluable disease without the development of new lesions (complete response) on computed tomographic (CT) or other scanning. (NCT00094809)
Timeframe: First 4 cycles of treatment (8 weeks)

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)34
Placebo37

Progression-Free Survival

Kaplan-Meier estimate of the median time to disease progression or death (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment

InterventionDays (Median)
Pegfilgrastim (Neulasta)318
Placebo322

Survival

Death from any cause through the end of the follow-up period (NCT00094809)
Timeframe: Up to 24 months after first four cycles of treatment

InterventionParticipants (Number)
Pegfilgrastim (Neulasta)47
Placebo49

Common Toxicities

The NCI Common Terminology Criteria for Adverse Events version 3.0 was used for adverse event reporting and toxicity grading. (NCT00320749)
Timeframe: Weekly up to 24 weeks

Interventionpercent of patients (Number)
leukopenianeutropeniafatigue
Capecitabine, Docetaxel, Gemcitabine292925

Maximum Tolerated Dose (MTD)

MTD will be the dose at which 1 or fewer patients (≤ 1/6) experiences a DLT during the first or second cycle with the next higher dose having at least 2/3 or 2/6 patients experiencing Dose Limiting Toxicities (DLT). (NCT00320749)
Timeframe: Weekly up to 24 weeks

Interventionmg/m^2 (Number)
docetaxelgemcitabinecapecitabine
Capecitabine, Docetaxel, Gemcitabine36750625

Therapeutic Response

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. (NCT00320749)
Timeframe: every 8 weeks, up to 24 weeks

Interventionpercent of patients (Number)
Partial ResponseComplete ResponseStable Disease
Capecitabine, Docetaxel, Gemcitabine11072

Duration of Objective Response Assessed by Independent Review Committee

Objective response was defined as having a CR or a PR. Response assessment was performed using modified WHO criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: >50% decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. Duration of objective response was defined as time from first appearance of CR or PR to time of PD (PD: >25% increase in one or more lesions, or appearance new lesions) or death. Duration of objective response was to be assessed using Kaplan-Meier analysis. (NCT00215644)
Timeframe: From first documented objective response to PD or death due to any cause (up to approximately 3 years)

Interventionmonths (Median)
Epirubicin, Cisplatin, Capecitabine (ECX)+MatuzumabNA
ECX OnlyNA

Overall Survival (OS)

OS was defined as the duration from randomization to death (due to any cause). OS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline until death due to any cause (up to approximately 3 years)

Interventionmonths (Median)
Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab9.4
ECX Only12.2

Percentage of Participants With Objective Response Assessed by Independent Review Committee

Objective response was defined as having a complete response (CR) or a partial response (PR). Response assessment was performed using modified World Health Organization (WHO) criteria. CR: disappearance of all index and non-index lesions, without appearance of any new lesion. PR: greater than (>) 50 percent (%) decrease from baseline in sum of product of diameters of index lesions, without appearance of any new lesion. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)

Interventionpercentage of participants (Number)
Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab31
ECX Only58

Progression-Free Survival

PFS was defined as the time from randomization to the first documentation of PD or to death due to any cause, whichever occurred first. PD: >25% increase in one or more lesions, or appearance new lesions. PFS was estimated using Kaplan-Meier analysis. (NCT00215644)
Timeframe: Baseline up to PD or death due to any cause (up to approximately 3 years)

Interventionmonths (Median)
Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab4.8
ECX Only7.1

Best Overall Change From Baseline in European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) Score

EORTC QLQ-C30 included GHS/QoL, functional scales (physical, role, cognitive, emotional, social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, financial difficulties). Most questions from EORTC QLQ-C30 were a 4-point scale (1/Not at All to 4/Very Much), except Items 29-30, which comprise GHS scale and were a 7-point scale (1/Very Poor to 7/Excellent). For this instrument, GHS/QOL was linearly transformed and ranged 0-100, where lower scores indicate poorer functioning (e.g., worsening) and higher scores indicate better functioning (e.g., improvement). EORTC QLQ-C30 GHS/QoL score at baseline and best overall change from baseline (throughout study) are reported. (NCT00215644)
Timeframe: Baseline (Day 1), Post Baseline (Up to 3 Years)

,
Interventionunits on a scale (Mean)
BaselinePost-Baseline
ECX Only67.9-10.0
Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab53.30.0

Body Weight (Kilograms [kg]) at BL

(NCT01041404)
Timeframe: BL

Interventionkg (Median)
Fluoropyrimidine/Cisplatin (FP)60
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)61

Duration of Response

The median time, in months, of the duration of response. Participants were censored at the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionmonths (Median)
Fluoropyrimidine/Cisplatin (FP)4.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)6.9

Duration of Response - Percentage of Participants With an Event

Duration of response was defined for responders as the time from the date on which the CR or PR was first recorded to the date on which PD is first noted. Participants were censored on the date of death, the date of last tumor measurement, the last date in study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)80.0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)71.9

Overall Survival - Time to Event

The median time, in months, from the date of randomization to the date of an OS event. Participants were censored at the last date tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionmonths (Median)
Fluoropyrimidine/Cisplatin (FP)11.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)13.8

Overall Survival (OS) - Percentage of Participants With an Event

OS was defined as the time from the date of randomization to the date of death due to any cause. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: Baseline (BL), Days 1, 8, 15, 22, 43, 64, 85, 106, 127, and every 21 days until the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)62.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)56.8

Percentage of Participants With Clinical Benefit

Clinical benefit was defined as stable disease (SD), CR, or PR for 6 weeks or longer as determined by RECIST. For TLs, SD was defined as neither sufficient shrinkage to qualify for PR, nor sufficient increase to qualify for PD, taking as a reference the smallest SLD recorded since treatment had started. For NTLs, SD was defined as a persistence of one or more NTLs and/or maintenance of tumor marker levels above the normal limits. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)69.3
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)78.9

Percentage of Participants With Confirmed Complete Response (CR) or Partial Response (PR) Determined by Response Evaluation Criteria in Solid Tumors (RECIST)

For TLs, a CR was defined as the disappearance of all TLs and a PR was defined as at least a 30% decrease in the SLD of the TLs, taking as a reference the baseline SLD. For NTLs, a CR was defined as the disappearance of all NTLs and normalization of tumor marker levels. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)34.5
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)47.3

Progression-Free Survival - Time to Event

The median time, in months, from the date of randomization to the date of a PFS event. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionmonths (Median)
Fluoropyrimidine, Cisplatin5.5
Trastuzumab, Fluoropyrimidine, Cisplatin6.7

Progression-Free Survival (PFS) - Percentage of Participants With an Event

PFS was defined as the time from the date of randomization to the date of the first documentation of progressive disease (PD) or date of death, whichever occurs first. For target lesions (TL), PD was defined as at least a 20 percent (%) increase in the sum of the longest diameter (SLD) of TLs, taking as a reference the smallest SLD recorded since the treatment started, or the appearance of one or more lesions. For non-target lesions (NTL), PD was defined as an unequivocal progression of existing NTLs. Participants were censored at the last date of tumor measurement, the last date in the study drug log, or the date of last follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)81.0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)76.9

Steady State Trastuzumab Area Under the Concentration (AUC)

Individual steady state predicted exposure, as assessed by median AUC (measured as mg multiplied by [*] day per liter [L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. Individual steady state AUC was calculated using all available PK samples from all timepoints. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Interventionmg*day/L (Median)
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)1030

Time to Progression - Time to Event

The median time, in months, from the date of randomized to the date of a TTP event. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionmonths (Median)
Fluoropyrimidine/Cisplatin (FP)5.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)7.1

Time to Progression (TTP) - Percentage of Participants With an Event

TTP was defined as the time from the date of randomization and the date of the first occurrence of PD. Participants were censored at the last date of tumor assessment, the last date in the study drug log, or the last date of follow-up. (NCT01041404)
Timeframe: BL, Days 43, 85, and 127, and every 21 days thereafter until disease progression or the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

Interventionpercentage of participants (Number)
Fluoropyrimidine/Cisplatin (FP)74.1
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)70.7

Trastuzumab Maximum Serum Concentration (Cmax)

Median Cmax (measured as mg/L) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Interventionmg/L (Median)
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)128

Trastuzumab Minimum Serum Concentration (Cmin)

Median Cmin (measured as milligrams per liter [mg/L]) calculated for all treated participants using the nominal dosage schedule administered as an IV infusion. (NCT01041404)
Timeframe: Predose and end of infusion on Days 1, 8, 15, and 64, and predose on Days 22 and 106

Interventionmg/L (Median)
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)23.0

EORTC Quality of Life Questionnaire-Stomach Cancer Specific (QLQ STO22) Questionnaire Scores

The QLQ-STO22 is a gastric cancer quality of life questionnaire. There are 22 questions concerning disease, treatment related symptoms, side effects, dysphagia, nutritional aspects, and questions about the emotional problems of gastric cancer (dysphagia, pain, reflux, eating restrictions, anxiety, dry mouth, body image, and hair loss). The questions are grouped into five scales and 4 single items which are related to the symptoms of the disease. Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer). A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

,
Interventionscores on a scale (Mean)
Dysphagia Scale: BL (n=276,287)Dysphagia Scale: Week 4 (n=234,250)Dysphagia Scale: Week 7 (n=181,220)Dysphagia Scale: Week 10 (n=176,203)Dysphagia Scale: Week 13 (n=152,183)Dysphagia Scale: Week 16 (n=120,165)Dysphagia Scale: Week 19 (n=114,143)Dysphagia Scale: Week 22 (n=79,143)Dysphagia Scale: Week 25 (n=64,124)Dysphagia Scale: Week 28 (n=47,111)Dysphagia Scale: Week 31 (n=45,95)Dysphagia Scale: Week 34 (n=37,87)Dysphagia Scale: Week 37 (n=29,64)Dysphagia Scale: Week 40 (n=24,55)Dysphagia Scale: Week 43 (n=12,43)Dysphagia Scale: Week 46 (n=14,42)Dysphagia Scale: Week 49 (n=10,36)Dysphagia Scale: Week 52 (n=8,30)Dysphagia Scale: Week 55 (n=6,24)Dysphagia Scale: Week 58 (n=6,21)Dysphagia Scale: Week 61 (n=4,17)Dysphagia Scale: Week 64 (n=3,20)Dysphagia Scale: Week 67 (n=4,16)Dysphagia Scale: Week 70 (n=3,14)Dysphagia Scale: Week 73 (n=3,12)Dysphagia Scale: Week 76 (n=3,8)Dysphagia Scale: Week 79 (n=3,9)Dysphagia Scale: Week 82 (n=2,6)Dysphagia Scale: Week 85 (n=2,6)Dysphagia Scale: Week 88 (n=2,6)Dysphagia Scale: Week 91 (n=2,4)Dysphagia Scale: Week 94 (n=2,6)Dysphagia Scale: Week 97 (n=1,5)Dysphagia Scale: Week 100 (n=1,4)Dysphagia Scale: Week 103 (n=1,4)Dysphagia Scale: Week 106 (n=1,4)Dysphagia Scale: Week 109 (n=1,4)Dysphagia Scale: Week 112 (n=1,5)Dysphagia Scale: Week 115 (n=1,4)Dysphagia Scale: Week 118 (n=1,5)Dysphagia Scale: Week 121 (n=1,5)Dysphagia Scale: Week 124 (n=1,5)Dysphagia Scale: Week 127 (n=1,3)Dysphagia Scale: Week 130 (n=0,3)Dysphagia Scale: Week 133 (n=1,3)Dysphagia Scale: Week 136 (n=0,2)Dysphagia Scale: Week 139 (n=0,2)Dysphagia Scale: Week 142 (n=0,2)Dysphagia Scale: Week 145 (n=0,1)Dysphagia Scale: Final Visit (n=157,159Pain Scale: BL (n=276,287)Pain Scale: Week 4 (n=234,250)Pain Scale: Week 7 (n=181,219)Pain Scale: Week 10 (n=176,203)Pain Scale: Week 13 (n=152,183)Pain Scale: Week 16 (n=120,165)Pain Scale: Week 19 (n=114,143)Pain Scale: Week 22 (n=79,143)Pain Scale: Week 25 (n=64,124)Pain Scale: Week 28 (n=47,111)Pain Scale: Week 31 (n=45,95)Pain Scale: Week 34 (n=37,87)Pain Scale: Week 37 (n=29,64)Pain Scale: Week 40 (n=24,55)Pain Scale: Week 43 (n=12,43)Pain Scale: Week 46 (n=14,42)Pain Scale: Week 49 (n=10,36)Pain Scale: Week 52 (n=8,30)Pain Scale: Week 55 (n=6,24)Pain Scale: Week 58 (n=6,21)Pain Scale: Week 61 (n=4,17)Pain Scale: Week 64 (n=3,20)Pain Scale: Week 67 (n=4,16)Pain Scale: Week 70 (n=3,14)Pain Scale: Week 73 (n=3,12)Pain Scale: Week 76 (n=3,8)Pain Scale: Week 79 (n=3,9)Pain Scale: Week 82 (n=2,6)Pain Scale: Week 85 (n=2,6)Pain Scale: Week 88 (n=2,6)Pain Scale: Week 91 (n=2,6)Pain Scale: Week 94 (n=2,6)Pain Scale: Week 97 (n=1,5)Pain Scale: Week 100 (n=1,4)Pain Scale: Week 103 (n=1,4)Pain Scale: Week 106 (n=1,4)Pain Scale: Week 109 (n=1,4)Pain Scale: Week 112 (n=1,5)Pain Scale: Week 115 (n=1,4)Pain Scale: Week 118 (n=1,5)Pain Scale: Week 121 (n=1,5)Pain Scale: Week 124 (n=1,5)Pain Scale: Week 127 (n=1,3)Pain Scale: Week 130 (n=0,3)Pain Scale: Week 133 (n=1,3)Pain Scale: Week 136 (n=0,2)Pain Scale: Week 139 (n=0,2)Pain Scale: Week 142 (n=0,2)Pain Scale: Week 145 (n=0,1)Pain Scale: Final Visit (n=157,160)Reflux Symptoms Scale: BL (n=275,287)Reflux Symptoms Scale: Week 4 (n=234,250)Reflux Symptoms Scale: Week 7 (n=180,220)Reflux Symptoms Scale: Week 10 (n=176,203)Reflux Symptoms Scale: Week 13 (n=152,182)Reflux Symptoms Scale: Week 16 (n=120,165)Reflux Symptoms Scale: Week 19 (n=114,165)Reflux Symptoms Scale: Week 22 (n=79,143)Reflux Symptoms Scale: Week 25 (n=64,124)Reflux Symptoms Scale: Week 28 (n=47,111)Reflux Symptoms Scale: Week 31 (n=45,95)Reflux Symptoms Scale: Week 34 (n=45,95)Reflux Symptoms Scale: Week 37 (n=29,64)Reflux Symptoms Scale: Week 40 (n=24,55)Reflux Symptoms Scale: Week 43 (n=12,42)Reflux Symptoms Scale: Week 46 (n=14,42)Reflux Symptoms Scale: Week 49 (n=10,36)Reflux Symptoms Scale: Week 52 (n=8,30)Reflux Symptoms Scale: Week 55 (n=6,24)Reflux Symptoms Scale: Week 58 (n=6,21)Reflux Symptoms Scale: Week 61 (n=4,17)Reflux Symptoms Scale: Week 64 (n=3,20)Reflux Symptoms Scale: Week 67 (n=4,16)Reflux Symptoms Scale: Week 70 (n=3,13)Reflux Symptoms Scale: Week 73 (n=3,12)Reflux Symptoms Scale: Week 76 (n=3,8)Reflux Symptoms Scale: Week 79 (n=3,9)Reflux Symptoms Scale: Week 82 (n=2,6)Reflux Symptoms Scale: Week 85 (n=2,6)Reflux Symptoms Scale: Week 88 (n=2,6)Reflux Symptoms Scale: Week 91 (n=2,4)Reflux Symptoms Scale: Week 94 (n=2,6)Reflux Symptoms Scale: Week 97 (n=1,5)Reflux Symptoms Scale: Week 100 (n=1,4)Reflux Symptoms Scale: Week 103 (n=1,4)Reflux Symptoms Scale: Week 106 (n=1,4)Reflux Symptoms Scale: Week 109 (n=1,4)Reflux Symptoms Scale: Week 112 (n=1,5)Reflux Symptoms Scale: Week 115 (n=1,4)Reflux Symptoms Scale: Week 118 (n=1,5)Reflux Symptoms Scale: Week 121 (n=1,5)Reflux Symptoms Scale: Week 124 (n=1,5)Reflux Symptoms Scale: Week 127 (n=1,3)Reflux Symptoms Scale: Week 130 (n=0,3)Reflux Symptoms Scale: Week 133 (n=1,3)Reflux Symptoms Scale: Week 136 (n=0,2)Reflux Symptoms Scale: Week 139 (n=0,2)Reflux Symptoms Scale: Week 142 (n=0,2)Reflux Symptoms Scale: Week 145 (n=0,1)Reflux Symptoms Scale: Final Visit (n=1,5)Eating Restrictions (ER) Scale: BL (n=276,287)ER Scale: Week 4 (n=234,250)ER Scale: Week 7 (n=181,220)ER Scale: Week 10 (n=176,203)ER Scale: Week 13 (n=152,183)ER Scale: Week 16 (n=120,165)ER Scale: Week 19 (n=114,143)ER Scale: Week 22 (n=79,143)ER Scale: Week 25 (n=64,124)ER Scale: Week 28 (n=47,111)ER Scale: Week 31 (n=45,95)ER Scale: Week 34 (n=37,87)ER Scale: Week 37 (n=29,64)ER Scale: Week 40 (n=24,55)ER Scale: Week 43 (n=12,43)ER Scale: Week 46 (n=14,42)ER Scale: Week 49 (n=10,36)ER Scale: Week 52 (n=8,30)ER Scale: Week 55 (n=6,24)ER Scale: Week 58 (n=6,21)ER Scale: Week 61 (n=4,17)ER Scale: Week 64 (n=3,20)ER Scale: Week 67 (n=4,16)ER Scale: Week 70 (n=3,14)ER Scale: Week 73 (n=3,12)ER Scale: Week 76 (n=3,8)ER Scale: Week 79 (n=3,9)ER Scale: Week 82 (n=2,6)ER Scale: Week 85 (n=2,6)ER Scale: Week 88 (n=2,6)ER Scale: Week 91 (n=2,4)ER Scale: Week 94 (n=2,6)ER Scale: Week 97 (n=1,5)ER Scale: Week 100 (n=1,4)ER Scale: Week 103 (n=1,4)ER Scale: Week 106 (n=1,4)ER Scale: Week 109 (n=1,4)ER Scale: Week 112 (n=1,5)ER Scale: Week 115 (n=1,4)ER Scale: Week 118 (n=1,5)ER Scale: Week 121 (n=1,5)ER Scale: Week 124 (n=1,5)ER Scale: Week 127 (n=1,3)ER Scale: Week 130 (n=0,3)ER Scale: Week 133 (n=1,3)ER Scale: Week 136 (n=0,2)ER Scale: Week 139 (n=0,2)ER Scale: Week 142 (n=0,2)ER Scale: Week 145 (n=0,1)ER Scale: Final Visit (n=157,160)Anxiety Scale: BL (n=276,287)Anxiety Scale: Week 4 (n=234,250)Anxiety Scale: Week 7 (n=181,220)Anxiety Scale: Week 10 (n=176,203)Anxiety Scale: Week 13 (n=152,183)Anxiety Scale: Week 16 (n=120,165)Anxiety Scale: Week 19 (n=114,143)Anxiety Scale: Week 22 (n=79,143)Anxiety Scale: Week 25 (n=64,124)Anxiety Scale: Week 28 (n=47,111)Anxiety Scale: Week 31 (n=45,95)Anxiety Scale: Week 34 (n=37,87)Anxiety Scale: Week 37 (n=29,64)Anxiety Scale: Week 40 (n=24,55)Anxiety Scale: Week 43 (n=12,43)Anxiety Scale: Week 46 (n=14,42)Anxiety Scale: Week 49 (n=14,42)Anxiety Scale: Week 52 (n=8,30)Anxiety Scale: Week 55 (n=6,24)Anxiety Scale: Week 58 (n=6,21)Anxiety Scale: Week 61 (n=4,17)Anxiety Scale: Week 64 (n=3,20)Anxiety Scale: Week 67 (n=4,16)Anxiety Scale: Week 70 (n=3,14)Anxiety Scale: Week 73 (n=3,12)Anxiety Scale: Week 76 (n=3,8)Anxiety Scale: Week 79 (n=3,9)Anxiety Scale: Week 82 (n=2,6)Anxiety Scale: Week 85 (n=2,6)Anxiety Scale: Week 88 (n=2,6)Anxiety Scale: Week 91 (n=2,4)Anxiety Scale: Week 94 (n=2,6)Anxiety Scale: Week 97 (n=1,5)Anxiety Scale: Week 100 (n=1,4)Anxiety Scale: Week 103 (n=1,4)Anxiety Scale: Week 106 (n=1,4)Anxiety Scale: Week 109 (n=1,4)Anxiety Scale: Week 112 (n=1,5)Anxiety Scale: Week 115 (n=1,4)Anxiety Scale: Week 118 (n=1,5)Anxiety Scale: Week 121 (n=1,5)Anxiety Scale: Week 124 (n=1,5)Anxiety Scale: Week 127 (n=1,3)Anxiety Scale: Week 130 (n=0,3)Anxiety Scale: Week 133 (n=1,3)Anxiety Scale: Week 136 (n=0,2)Anxiety Scale: Week 139 (n=0,2)Anxiety Scale: Week 142 (n=0,2)Anxiety Scale: Week 145 (n=0,2)Anxiety Scale: Final Visit (n=157,160)Dry Mouth: BL (n=274,287)Dry Mouth: Week 4 (n=232,249)Dry Mouth: Week 7 (n=180,219)Dry Mouth: Week 10 (n=176,203)Dry Mouth: Week 13 (n=152,183)Dry Mouth: Week 16 (n=120,165)Dry Mouth: Week 19 (n=113,143)Dry Mouth: Week 22 (n=79,143)Dry Mouth: Week 25 (n=64,124)Dry Mouth: Week 28 (n=47,111)Dry Mouth: Week 31 (n=45,95)Dry Mouth: Week 34 (n=37,87)Dry Mouth: Week 37 (n=29,64)Dry Mouth: Week 40 (n=23,55)Dry Mouth: Week 43 (n=12,43)Dry Mouth: Week 46 (n=14,42)Dry Mouth: Week 49 (n=10,36)Dry Mouth: Week 52 (n=8,30)Dry Mouth: Week 55 (n=6,24)Dry Mouth: Week 58 (n=6,21)Dry Mouth: Week 61 (n=4,17)Dry Mouth: Week 64 (n=3,20)Dry Mouth: Week 67 (n=4,16)Dry Mouth: Week 70 (n=3,14)Dry Mouth: Week 73 (n=3,12)Dry Mouth: Week 76 (n=3,8)Dry Mouth: Week 79 (n=3,9)Dry Mouth: Week 82 (n=2,6)Dry Mouth: Week 85 (n=2,6)Dry Mouth: Week 88 (n=2,6)Dry Mouth: Week 91 (n=2,4)Dry Mouth: Week 94 (n=2,6)Dry Mouth: Week 97 (n=1,5)Dry Mouth: Week 100 (n=1,4)Dry Mouth: Week 103 (n=1,4)Dry Mouth: Week 106 (n=1,4)Dry Mouth: Week 109 (n=1,4)Dry Mouth: Week 112 (n=1,5)Dry Mouth: Week 115 (n=1,4)Dry Mouth: Week 118 (n=1,5)Dry Mouth: Week 121 (n=1,5)Dry Mouth: Week 124 (n=1,5)Dry Mouth: Week 127 (n=1,3)Dry Mouth: Week 130 (n=0,3)Dry Mouth: Week 133 (n=1,3)Dry Mouth: Week 136 (n=0,2)Dry Mouth: Week 139 (n=0,2)Dry Mouth: Week 142 (n=0,2)Dry Mouth: Week 145 (n=0,1)Dry Mouth: Final Visit (n=157,157)Taste: BL (n=275,286)Taste: Week 4 (n=234,249)Taste: Week 7 (n=179,217)Taste: Week 10 (n=176,200)Taste: Week 13 (n=151,181)Taste: Week 16 (n=119,165)Taste: Week 19 (n=113,143)Taste: Week 22 (n=79,143)Taste: Week 25 (n=64,124)Taste: Week 28 (n=47,111)Taste: Week 31 (n=45,95)Taste: Week 34 (n=37,87)Taste: Week 37 (n=28,64)Taste: Week 40 (n=24,55)Taste: Week 43 (n=12,43)Taste: Week 46 (n=14,42)Taste: Week 49 (n=9,36)Taste: Week 52 (n=8,30)Taste: Week 55 (n=6,24)Taste: Week 58 (n=6,21)Taste: Week 61 (n=4,17)Taste: Week 64 (n=3,20)Taste: Week 67 (n=4,16)Taste: Week 70 (n=3,14)Taste: Week 73 (n=3,12)Taste: Week 76 (n=3,8)Taste: Week 79 (n=3,9)Taste: Week 82 (n=2,6)Taste: Week 85 (n=2, 6)Taste: Week 88 (n=2,6)Taste: Week 91 (n=2,4)Taste: Week 94 (n=2,6)Taste: Week 97 (n=1,5)Taste: Week 100 (n=1,4)Taste: Week 103 (n=1,4)Taste: Week 106 (n=1,4)Taste: Week 109 (n=1,4)Taste: Week 112 (n=1,5)Taste: Week 115 (n=1,4)Taste: Week 118 (n=1,5)Taste: Week 121 (n=1,5)Taste: Week 124 (n=1,5)Taste: Week 127 (n=1,3)Taste: Week 130 (n=0,3)Taste: Week 133 (n=1,3)Taste: Week 136 (n=0,2)Taste: Week 139 (n=0,2)Taste: Week 142 (n=0,2)Taste: Week 145 (n=0,1)Taste: Final Visit (n=157,158)Body Image: BL (n=272,286)Body Image: Week 4 (n=233,249)Body Image: Week 7 (n=180,219)Body Image: Week 10 (n=175,203)Body Image: Week 13 (n=152,182)Body Image: Week 16 (n=119,165)Body Image: Week 19 (n=114,140)Body Image: Week 22 (n=79,143)Body Image: Week 25 (n=64,124)Body Image: Week 28 (n=47,111)Body Image: Week 31 (n=45,95)Body Image: Week 34 (n=37,87)Body Image: Week 37 (n=29,64)Body Image: Week 40 (n=24,55)Body Image: Week 43 (n=12,43)Body Image: Week 46 (n=14,42)Body Image: Week 49 (n=10,36)Body Image: Week 52 (n=8,30)Body Image: Week 55 (n=6,24)Body Image: Week 58 (n=6,21)Body Image: Week 61 (n=4,17)Body Image: Week 64 (n=3,20)Body Image: Week 67 (n=4,16)Body Image: Week 70 (n=4,14)Body Image: Week 73 (n=3,12)Body Image: Week 76 (n=3,8)Body Image: Week 79 (n=3,9)Body Image: Week 82 (n=2,6)Body Image: Week 85 (n=2,6)Body Image: Week 88 (n=2,5)Body Image: Week 91 (n=2,4)Body Image: Week 94 (n=2,6)Body Image: Week 97 (n=1,5)Body Image: Week 100 (n=1,4)Body Image: Week 103 (n=1,4)Body Image: Week 106 (n=1,4)Body Image: Week 109 (n=1,4)Body Image: Week 112 (n=1,5)Body Image: Week 115 (n=1,4)Body Image: Week 118 (n=1,5)Body Image: Week 121 (n=1,5)Body Image: Week 124 (n=1,5)Body Image: Week 127 (n=1,3)Body Image: Week 130 (n=0,3)Body Image: Week 133 (n=1,3)Body Image: Week 136 (n=0,2)Body Image: Week 139 (n=0,2)Body Image: Week 142 (n=0,2)Body Image: Week 145 (n=0,1)Body Image: Final Visit (n=157,159)Hair Loss: BL (n=64,76)Hair Loss: Week 4 (n=68,71)Hair Loss: Week 7 (n=65,82)Hair Loss: Week 10 (n=75,78)Hair Loss: Week 13 (n=66,80)Hair Loss: Week 16 (n=53,72)Hair Loss: Week 19 (n=50,56)Hair Loss: Week 22 (n=38,54)Hair Loss: Week 25 (n=24,49)Hair Loss: Week 28 (n=20,39)Hair Loss: Week 31 (n=17,26)Hair Loss: Week 34 (n=13,24)Hair Loss: Week 37 (n=12,16)Hair Loss: Week 40 (n=11,13)Hair Loss: Week 43 (n=5,9)Hair Loss: Week 46 (n=5,13)Hair Loss: Week 49 (n=4,7)Hair Loss: Week 52 (n=3,4)Hair Loss: Week 55 (n=2,6)Hair Loss: Week 58 (n=2,3)Hair Loss: Week 61 (n=1,2)Hair Loss: Week 64 (n=1,4)Hair Loss: Week 67 (n=1,4)Hair Loss: Week 70 (n=1,2)Hair Loss: Week 73 (n=1,5)Hair Loss: Week 76 (n=1,3)Hair Loss: Week 79 (n=1,4)Hair Loss: Week 82 (n=1,1)Hair Loss: Week 85 (n=1,1)Hair Loss: Week 88 (n=1,2)Hair Loss: Week 91 (n=1,1)Hair Loss: Week 94 (n=1,2)Hair Loss: Week 97 (n=1,2)Hair Loss: Week 100 (n=1,2)Hair Loss: Week 103 (n=1,1)Hair Loss: Week 106 (n=1,1)Hair Loss: Week 109 (n=0,2)Hair Loss: Week 112 (n=1,3)Hair Loss: Week 115 (n=1,2)Hair Loss: Week 118 (n=1,3)Hair Loss: Week 121 (n=1,2)Hair Loss: Week 124 (n=1,2)Hair Loss: Week 127 (n=1,1)Hair Loss: Week 130 (n=0,1)Hair Loss: Week 133 (n=1,1)Hair Loss: Final Visit (n=61,60)
Fluoropyrimidine/Cisplatin (FP)18.711.810.98.58.810.29.510.06.96.66.43.95.43.74.62.44.41.40.03.72.80.02.80.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA15.429.721.619.417.016.017.019.215.811.311.212.612.213.814.913.015.511.79.49.75.64.22.84.22.80.05.62.80.04.28.30.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA24.718.314.812.812.612.812.011.39.05.66.67.47.26.17.97.44.82.22.85.60.02.83.72.83.70.03.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA15.327.420.618.817.516.017.820.815.511.613.913.410.612.513.59.710.911.75.28.39.74.20.08.32.85.62.85.64.24.24.28.30.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA23.847.542.040.638.235.732.935.831.725.227.429.123.127.229.630.626.220.023.631.520.48.35.611.13.77.40.011.111.111.111.111.15.60.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA41.524.524.024.623.523.223.922.419.016.110.612.69.912.68.711.19.516.712.55.611.18.30.08.30.00.00.00.00.016.70.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA24.017.220.720.121.819.920.424.519.010.912.18.16.38.38.35.64.87.44.211.111.18.311.18.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA25.330.932.630.730.128.929.130.728.722.423.425.218.923.020.827.821.416.716.716.711.18.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA31.015.120.125.121.822.228.323.320.213.926.715.77.78.312.16.726.70.011.116.716.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.00.00.00.00.00.0NA0.023.0
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)16.612.512.810.69.09.18.87.86.85.36.87.57.36.55.22.92.24.43.73.20.73.32.83.24.62.82.53.71.91.90.01.92.22.80.00.00.00.00.02.20.00.00.00.00.00.05.65.60.017.027.021.820.117.516.215.916.315.114.414.014.612.513.811.89.710.19.58.64.56.35.49.68.36.59.75.27.46.95.65.62.15.68.36.38.36.34.210.04.28.310.08.38.311.113.912.58.38.30.026.816.916.015.413.512.914.410.610.69.79.610.19.310.99.39.06.66.58.16.55.32.63.96.34.37.91.43.75.60.00.00.00.00.00.00.02.80.00.00.04.40.06.77.40.00.00.00.00.00.018.323.921.119.017.417.015.115.513.612.911.312.510.99.59.57.06.08.19.35.26.05.48.310.46.59.05.25.62.84.24.24.24.26.76.36.34.24.23.34.26.75.01.70.08.35.60.04.20.00.022.848.243.839.338.237.537.134.932.829.226.928.427.828.226.325.123.325.927.428.221.725.523.918.827.028.727.833.325.924.114.822.222.231.116.722.219.416.722.219.420.015.617.822.218.518.516.711.116.70.040.923.923.326.925.021.123.420.516.312.110.811.29.69.47.36.24.86.510.08.314.311.86.78.311.913.920.811.15.60.05.60.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.023.617.924.824.025.325.223.822.619.615.914.713.09.67.87.97.07.94.67.84.24.80.01.74.20.02.80.00.05.60.05.60.05.66.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.020.331.931.727.928.428.228.125.022.422.620.119.318.018.219.415.515.913.916.716.715.913.718.314.616.727.837.525.916.711.16.716.716.713.38.38.316.78.36.716.76.76.76.6711.10.011.116.70.016.70.030.425.016.419.120.120.423.621.422.218.414.510.316.712.512.83.75.19.58.30.00.016.70.00.00.06.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.019.4

European Organisation For the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ C-30) Questionnaire Scores

EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score equals (=) better level of functioning or greater degree of symptoms. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

,
Interventionscores on a scale (Mean)
Global Health Status: BL (n=274,287)Global Health Status: Week 4 (n=235,249)Global Health Status: Week 7 (n=180,220)Global Health Status: Week 10 (n=176,202)Global Health Status: Week 13 (n=152,182)Global Health Status: Week 16 (n=121,165)Global Health Status: Week 19 (n=114,143)Global Health Status: Week 22 (n=78,143)Global Health Status: Week 25 (n=64,124)Global Health Status: Week 28 (n=47,111)Global Health Status: Week 31 (n=45,95)Global Health Status: Week 34 (n=36,87)Global Health Status: Week 37 (n=29,64)Global Health Status: Week 40 (n=23,55)Global Health Status: Week 43 (n=12,43)Global Health Status: Week 46 (n=13,42)Global Health Status: Week 49 (n=9,36)Global Health Status: Week 52 (n=7,29)Global Health Status: Week 55 (n=5,24)Global Health Status: Week 58 (n=5,21)Global Health Status: Week 61 (n=4,17)Global Health Status: Week 64 (n=3,20)Global Health Status: Week 67 (n=4,17)Global Health Status: Week 70 (n=3,14)Global Health Status: Week 73 (n=3,12)Global Health Status: Week 76 (n=3,8)Global Health Status: Week 79 (n=3,9)Global Health Status: Week 82 (n=2,5)Global Health Status: Week 85 (n=2,6)Global Health Status: Week 88 (n=2,6)Global Health Status: Week 91 (n=2,4)Global Health Status: Week 94 (n=2,6)Global Health Status: Week 97 (n=1,5)Global Health Status: Week 100 (n=1,4)Global Health Status: Week 103 (n=1,3)Global Health Status: Week 106 (n=1,4)Global Health Status: Week 109 (n=1,4)Global Health Status: Week 112 (n=1,5)Global Health Status: Week 115 (n=1,4)Global Health Status: Week 118 (n=1,5)Global Health Status: Week 121 (n=1,5)Global Health Status: Week 124 (n=1,5)Global Health Status: Week 127 (n=1,3)Global Health Status: Week 130 (n=0,3)Global Health Status: Week 133 (n=1,3)Global Health Status: Week 136 (n=0,2)Global Health Status: Week 139 (n=0,2)Global Health Status: Week 142 (n=0,2)Global Health Status: Week 145 (n=0,1)Global Health Status: Final Visit (n=158,160)Physical Functioning: BL (n=276,287)Physical Functioning: Week 4 (n=235,250)Physical Functioning: Week 7 (n=181,220)Physical Functioning: Week 10 (n=174,201)Physical Functioning: Week 13 (n=151,183)Physical Functioning: Week 16 (n=121,165)Physical Functioning: Week 19 (n=114,143)Physical Functioning: Week 22 (n=79,143)Physical Functioning: Week 25 (n=64,124)Physical Functioning: Week 28 (n=47,110)Physical Functioning: Week 31 (n=45,95)Physical Functioning: Week 34 (n=37,87)Physical Functioning: Week 37 (n=29,64)Physical Functioning: Week 40 (n=24,55)Physical Functioning: Week 43 (n=12,43)Physical Functioning: Week 46 (n=14,42)Physical Functioning: Week 49 (n=10,36)Physical Functioning: Week 52 (n=8,30)Physical Functioning: Week 55 (n=6,24)Physical Functioning: Week 58 (n=6,21)Physical Functioning: Week 61 (n=4,17)Physical Functioning: Week 64 (n=3,20)Physical Functioning: Week 67 (n=4,17)Physical Functioning: Week 70 (n=3,14)Physical Functioning: Week 73 (n=3,12)Physical Functioning: Week 76 (n=3,8)Physical Functioning: Week 79 (n=3,9)Physical Functioning: Week 82 (n=2,6)Physical Functioning: Week 85 (n=2,6)Physical Functioning: Week 88 (n=2,6)Physical Functioning: Week 91 (n=2,4)Physical Functioning: Week 94 (n=2,6)Physical Functioning: Week 97 (n=1,5)Physical Functioning: Week 100 (n=1,4)Physical Functioning: Week 103 (n=1,4)Physical Functioning: Week 106 (n=1,4)Physical Functioning: Week 109 (n=1,4)Physical Functioning: Week 112 (n=1,5)Physical Functioning: Week 115 (n=1,4)Physical Functioning: Week 118 (n=1,5)Physical Functioning: Week 121 (n=1,5)Physical Functioning: Week 124 (n=1,5)Physical Functioning: Week 127 (n=1,3)Physical Functioning: Week 130 (n=0,3)Physical Functioning: Week 133 (n=1,3)Physical Functioning: Week 136 (n=0,2)Physical Functioning: Week 139 (n=0,2)Physical Functioning: Week 142 (n=0,2)Physical Functioning: Week 145 (n=0,1)Physical Functioning: Final Visit (n=158,161)Role Functioning: BL (n=276,287)Role Functioning: Week 4 (n=234,250)Role Functioning: Week 7 (n=181,220)Role Functioning: Week 10 (n=176,202)Role Functioning: Week 13 (n=152,182)Role Functioning: Week 16 (n=121,165)Role Functioning: Week 19 (n=114,143)Role Functioning: Week 22 (n=79,142)Role Functioning: Week 25 (n=64,124)Role Functioning: Week 28 (n=47,110)Role Functioning: Week 31 (n=45,95)Role Functioning: Week 34 (n=37,87)Role Functioning: Week 37 (n=29,64)Role Functioning: Week 40 (n=24,55)Role Functioning: Week 43 (n=12,43)Role Functioning: Week 46 (n=14,42)Role Functioning: Week 49 (n=10,36)Role Functioning: Week 52 (n=8,30)Role Functioning: Week 55 (n=6,24)Role Functioning: Week 58 (n=6,21)Role Functioning: Week 61 (n=4,17)Role Functioning: Week 64 (n=3,20)Role Functioning: Week 67 (n=4,17)Role Functioning: Week 70 (n=3,14)Role Functioning: Week 73 (n=3,12)Role Functioning: Week 76 (n=3,8)Role Functioning: Week 79 (n=3,9)Role Functioning: Week 82 (n=2,6)Role Functioning: Week 85 (n=2,6)Role Functioning: Week 88 (n=2,6)Role Functioning: Week 91 (n=2,4)Role Functioning: Week 94 (n=2,6)Role Functioning: Week 97 (n=1,5)Role Functioning: Week 100 (n=1,4)Role Functioning: Week 103 (n=1,4)Role Functioning: Week 106 (n=1,4)Role Functioning: Week 109 (n=1,4)Role Functioning: Week 112 (n=1,5)Role Functioning: Week 115 (n=1,4)Role Functioning: Week 118 (n=1,5)Role Functioning: Week 121 (n=1,5)Role Functioning: Week 124 (n=1,5)Role Functioning: Week 127 (n=1,3)Role Functioning: Week 130 (n=0,3)Role Functioning: Week 133 (n=1,3)Role Functioning: Week 136 (n=0,2)Role Functioning: Week 139 (n=0,2)Role Functioning: Week 142 (n=0,2)Role Functioning: Week 145 (n=0,1)Role Functioning: Final Visit (n=158,161)Emotional Functioning: BL (n=276,287)Emotional Functioning: Week 4 (n=235,250)Emotional Functioning: Week 7 (n=180,220)Emotional Functioning: Week 10 (n=176,202)Emotional Functioning: Week 13 (n=152,183)Emotional Functioning: Week 16 (n=121,165)Emotional Functioning: Week 19 (n=114,143)Emotional Functioning: Week 22 (n=79,143)Emotional Functioning: Week 25 (n=64,124)Emotional Functioning: Week 28 (n=47,111)Emotional Functioning: Week 31 (n=45,95)Emotional Functioning: Week 34 (n=37,87)Emotional Functioning: Week 37 (n=29,64)Emotional Functioning: Week 40 (n=24,55)Emotional Functioning: Week 43 (n=12,43)Emotional Functioning: Week 46 (n=14,42)Emotional Functioning: Week 49 (n=10,36)Emotional Functioning: Week 52 (n=8,29)Emotional Functioning: Week 55 (n=6,24)Emotional Functioning: Week 58 (n=6,21)Emotional Functioning: Week 61 (n=4,17)Emotional Functioning: Week 64 (n=3,20)Emotional Functioning: Week 67 (n=4,17)Emotional Functioning: Week 70 (n=3,14)Emotional Functioning: Week 73 (n=3,12)Emotional Functioning: Week 76 (n=3,8)Emotional Functioning: Week 79 (n=3,9)Emotional Functioning: Week 82 (n=2,6)Emotional Functioning: Week 85 (n=2,6)Emotional Functioning: Week 88 (n=2,6)Emotional Functioning: Week 91 (n=2,4)Emotional Functioning: Week 94 (n=2,6)Emotional Functioning: Week 97 (n=1,5)Emotional Functioning: Week 100 (n=1,4)Emotional Functioning: Week 103 (n=1,4)Emotional Functioning: Week 106 (n=1,4)Emotional Functioning: Week 109 (n=1,4)Emotional Functioning: Week 112 (n=1,5)Emotional Functioning: Week 115 (n=1,4)Emotional Functioning: Week 118 (n=1,5)Emotional Functioning: Week 121 (n=1,5)Emotional Functioning: Week 124 (n=1,5)Emotional Functioning: Week 127 (n=1,3)Emotional Functioning: Week 130 (n=0,3)Emotional Functioning: Week 133 (n=1,3)Emotional Functioning: Week 136 (n=0,2)Emotional Functioning: Week 139 (n=0,2)Emotional Functioning: Week 142 (n=0,2)Emotional Functioning: Week 145 (n=0,1)Emotional Functioning: Final Visit (n=158,161)Cognitive Functioning: BL (n=276,287)Cognitive Functioning: Week 4 (n=235,250)Cognitive Functioning: Week 7 (n=180,220)Cognitive Functioning: Week 10 (n=176,202)Cognitive Functioning: Week 13 (n=152,183)Cognitive Functioning: Week 16 (n=121,165)Cognitive Functioning: Week 19 (n=114,143)Cognitive Functioning: Week 22 (n=79,143)Cognitive Functioning: Week 25 (n=64,124)Cognitive Functioning: Week 28 (n=47,111)Cognitive Functioning: Week 31 (n=45,95)Cognitive Functioning: Week 34 (n=37,87)Cognitive Functioning: Week 37 (n=29,64)Cognitive Functioning: Week 40 (n=24,55)Cognitive Functioning: Week 43 (n=12,43)Cognitive Functioning: Week 46 (n=14,42)Cognitive Functioning: Week 49 (n=10,36)Cognitive Functioning: Week 52 (n=8,29)Cognitive Functioning: Week 55 (n=6,24)Cognitive Functioning: Week 58 (n=6,21)Cognitive Functioning: Week 61 (n=4,17)Cognitive Functioning: Week 64 (n=3,20)Cognitive Functioning: Week 67 (n=4,17)Cognitive Functioning: Week 70 (n=3,14)Cognitive Functioning: Week 73 (n=3,12)Cognitive Functioning: Week 76 (n=3,8)Cognitive Functioning: Week 79 (n=3,9)Cognitive Functioning: Week 82 (n=2,6)Cognitive Functioning: Week 85 (n=2,6)Cognitive Functioning: Week 88 (n=2,6)Cognitive Functioning: Week 91 (n=2,4)Cognitive Functioning: Week 94 (n=2,6)Cognitive Functioning: Week 97 (n=1,5)Cognitive Functioning: Week 100 (n=1,4)Cognitive Functioning: Week 103 (n=1,4)Cognitive Functioning: Week 106 (n=1,4)Cognitive Functioning: Week 109 (n=1,4)Cognitive Functioning: Week 112 (n=1,5)Cognitive Functioning: Week 115 (n=1,4)Cognitive Functioning: Week 118 (n=1,5)Cognitive Functioning: Week 121 (n=1,5)Cognitive Functioning: Week 124 (n=1,5)Cognitive Functioning: Week 127 (n=1,3)Cognitive Functioning: Week 130 (n=0,3)Cognitive Functioning: Week 133 (n=1,3)Cognitive Functioning: Week 136 (n=0,2)Cognitive Functioning: Week 139 (n=0,2)Cognitive Functioning: Week 142 (n=0,2)Cognitive Functioning: Week 145 (n=0,1)Cognitive Functioning: Final Visit (n=158,161)Social Functioning: BL (n=276,286)Social Functioning: Week 4 (n=235,250)Social Functioning: Week 7 (n=179,220)Social Functioning: Week 10 (n=176,202)Social Functioning: Week 13 (n=152,183)Social Functioning: Week 16 (n=180,165)Social Functioning: Week 19 (n=114,143)Social Functioning: Week 22 (n=79,143)Social Functioning: Week 25 (n=64,124)Social Functioning: Week 28 (n=47,111)Social Functioning: Week 31 (n=45,95)Social Functioning: Week 34 (n=37,87)Social Functioning: Week 37 (n=29,64)Social Functioning: Week 40 (n=24,55)Social Functioning: Week 43 (n=12,43)Social Functioning: Week 46 (n=14,42)Social Functioning: Week 49 (n=10,36)Social Functioning: Week 52 (n=8,29)Social Functioning: Week 55 (n=6,24)Social Functioning: Week 58 (n=6,21)Social Functioning: Week 61 (n=4,17)Social Functioning: Week 64 (n=3,20)Social Functioning: Week 67 (n=4,17)Social Functioning: Week 70 (n=3,14)Social Functioning: Week 73 (n=3,12)Social Functioning: Week 76 (n=3,8)Social Functioning: Week 79 (n=3,9)Social Functioning: Wek 82 (n=2,6)Social Functioning: Week 85 (n=2,6)Social Functioning: Week 88 (n=2,6)Social Functioning: Week 91 (n=2,4)Social Functioning: Week 94 (n=2,6)Social Functioning: Week 97 (n=1,5)Social Functioning: Week 100 (n=1,4)Social Functioning: Week 103 (n=1,4)Social Functioning: Week 106 (n=1,4)Social Functioning: Week 109 (n=1,4)Social Functioning: Week 112 (n=1,5)Social Functioning: Week 115 (n=1,4)Social Functioning: Week 118 (n=1,5)Social Functioning: Week 121 (n=1,5)Social Functioning: Week 124 (n=1,5)Social Functioning: Week 127 (n=1,3)Social Functioning: Week 130 (n=0,3)Social Functioning: Week 133 (n=1,3)Social Functioning: Week 136 (n=0,2)Social Functioning: Week 139 (n=0,2)Social Functioning: Week 142 (n=0,2)Social Functioning: Week 145 (n=0,1)Social Functioning: Final Visit (n=158,161)Fatigue: BL (n=276,287)Fatigue: Week 4 (n=235,250)Fatigue: Week 7 (n=181,220)Fatigue: Week 10 (n=176,201)Fatigue: Week 13 (n=152,183)Fatigue: Week 16 (n=121,165)Fatigue: Week 19 (n=114,143)Fatigue: Week 22 (n=79,143)Fatigue: Week 25 (n=64,124)Fatigue: Week 28 (n=47,110)Fatigue: Week 31 (n=45,95)Fatigue: Week 34 (n=37,87)Fatigue: Week 37 (n=29,64)Fatigue: Week 40 (n=24,55)Fatigue: Week 43 (n=12,43)Fatigue: Week 46 (n=14,42)Fatigue: Week 49 (n=10,36)Fatigue: Week 52 (n=8,30)Fatigue: Week 55 (n=6,24)Fatigue: Week 58 (n=6,21)Fatigue: Week 61 (n=4,17)Fatigue: Week 64 (n=3,20)Fatigue: Week 67 (n=4,17)Fatigue: Week 70 (n=3,14)Fatigue: Week 73 (n=3,12)Fatigue: Week 76 (n=3,8)Fatigue: Week 79 (n=3,9)Fatigue: Week 82 (n=2,6)Fatigue: Week 85 (n=2,6)Fatigue: Week 88 (n=2,6)Fatigue: Week 91 (n=2,4)Fatigue: Week 94 (n=2,6)Fatigue: Week 97 (n=1,5)Fatigue: Week 100 (n=1,4)Fatigue: Week 103 (n=1,4)Fatigue: Week 106 (n=1,4)Fatigue: Week 109 (n=1,4)Fatigue: Week 112 (n=1,5)Fatigue: Week 115 (n=1,4)Fatigue: Week 118 (n=1,5)Fatigue: Week 121 (n=1,5)Fatigue: Week 124 (n=1,5)Fatigue: Week 127 (n=1,3)Fatigue: Week 130 (n=0,3)Fatigue: Week 133 (n=1,3)Fatigue: Week 136 (n=0,2)Fatigue: Week 139 (n=0,2)Fatigue: Week 142 (n=0,2)Fatigue: Week 145 (n=0,1)Fatigue: Final Visit (n=158,160)Nausea & Vomiting: BL (n=276,287)Nausea & Vomiting: Week 4 (n=235,250)Nausea & Vomiting: Week 7 (n=181,220)Nausea & Vomiting: Week 10 (n=176,201)Nausea & Vomiting: Week 13 (n=121,183)Nausea & Vomiting: Week 16 (n=121,165)Nausea & Vomiting: Week 19 (n=114,143)Nausea & Vomiting: Week 22 (n=79,143)Nausea & Vomiting: Week 25 (n=64,124)Nausea & Vomiting: Week 28 (n=47,110)Nausea & Vomiting: Week 31 (n=45,95)Nausea & Vomiting: Week 34 (n=37,87)Nausea & Vomiting: Week 37 (n=29,64)Nausea & Vomiting: Week 40 (n=24,55)Nausea & Vomiting: Week 43 (n=12,43)Nausea & Vomiting: Week 46 (n=14,42)Nausea & Vomiting: Week 49 (n=10,36)Nausea & Vomiting: Week 52 (n=8,30)Nausea & Vomiting: Week 55 (n=6,24)Nausea & Vomiting: Week 58 (n=6,21)Nausea & Vomiting: Week 61 (n=4,17)Nausea & Vomiting: Week 64 (n=3,20)Nausea & Vomiting: Week 67 (n=4,17)Nausea & Vomiting: Week 70 (n=3,14)Nausea & Vomiting: Week 73 (n=3,12)Nausea & Vomiting: Week 76 (n=3,8)Nausea & Vomiting: Week 79 (n=3,9)Nausea & Vomiting: Week 82 (n=2,6)Nausea & Vomiting: Week 85 (n=2,6)Nausea & Vomiting: Week 88 (n=2,6)Nausea & Vomiting: Week 91 (n=2,4)Nausea & Vomiting: Week 94 (n=2,6)Nausea & Vomiting: Week 97 (n=1,5)Nausea & Vomiting: Week 100 (n=1,4)Nausea & Vomiting: Week 103 (n=1,4)Nausea & Vomiting: Week 106 (n=1,4)Nausea & Vomiting: Week 109 (n=1,4)Nausea & Vomiting: Week 112 (n=1,5)Nausea & Vomiting: Week 115 (n=1,4)Nausea & Vomiting: Week 118 (n=1,5)Nausea & Vomiting: Week 121 (n=1,5)Nausea & Vomiting: Week 124 (n=1,5)Nausea & Vomiting: Week 127 (n=1,3)Nausea & Vomiting: Week 130 (n=0,3)Nausea & Vomiting: Week 133 (n=1,3)Nausea & Vomiting: Week 136 (n=0,2)Nausea & Vomiting: Week 139 (n=0,2)Nausea & Vomiting: Week 142 (n=0,2)Nausea & Vomiting: Week 145 (n=0,1)Nausea & Vomiting: Final Visit (n=158,161)Pain: BL (n=276,287)Pain: Week 4 (n=235,250)Pain: Week 7 (n=181,220)Pain: Week 10 (n=176,202)Pain: Week 13 (n=152,183)Pain: Week 16 (n=121,165)Pain: Week 19 (n=114,143)Pain: Week 22 (n=79,143)Pain: Week 25 (n=64,124)Pain: Week 28 (n=47,111)Pain: Week 31 (n=45,95)Pain: Week 34 (n=37,87)Pain: Week 37 (n=29,64)Pain: Week 40 (n=24,55)Pain: Week 43 (n=12,43)Pain: Week 46 (n=14,42)Pain: Week 49 (n=10,36)Pain: Week 52 (n=8,30)Pain: Week 55 (n=6,24)Pain: Week 58 (n=6,21)Pain: Week 61 (n=4,17)Pain: Week 64 (n=3,20)Pain: Week 67 (n=4,17)Pain: Week 70 (n=3,14)Pain: Week 73 (n=3,12)Pain: Week 76 (n=3,8)Pain: Week 79 (n=3,9)Pain: Week 82 (n=2,6)Pain: Week 85 (n=2,6)Pain: Week 88 (n=2,6)Pain: Week 91 (n=2,4)Pain: Week 94 (n=2,6)Pain: Week 97 (n=1,5)Pain: Week 100 (n=1,4)Pain: Week 103 (n=1,4)Pain: Week 106 (n=1,4)Pain: Week 109 (n=1,4)Pain: Week 112 (n=1,5)Pain: Week 115 (n=1,4)Pain: Week 118 (n=1,5)Pain: Week 121 (n=1,5)Pain: Week 124 (n=1,5)Pain: Week 127 (n=1,3)Pain: Week 130 (n=0,3)Pain: Week 133 (n=1,3)Pain: Week 136 (n=0,2)Pain: Week 139 (n=0,2)Pain: Week 142 (n=0,2)Pain: Week 145 (n=0,1)Pain: Final Visit (n=158,161)Dyspnoea: BL (n=274,281)Dyspnoea: Week 4 (n=232,249)Dyspnoea: Week 7 (n=181,217)Dyspnoea: Week 10 (n=176,198)Dyspnoea: Week 13 (n=151,182)Dyspnoea: Week 16 (n=121,165)Dyspnoea: Week 19 (n=113,143)Dyspnoea: Week 22 (n=79,143)Dyspnoea: Week 25 (n=63,124)Dyspnoea: Week 28 (n=47,110)Dyspnoea: Week 31 (n=45,95)Dyspnoea: Week 34 (n=36,87)Dyspnoea: Week 37 (n=29,64)Dyspnoea: Week 40 (n=24,55)Dyspnoea: Week 43 (n=12,43)Dyspnoea: Week 46 (n=14,42)Dyspnoea: Week 49 (n=10,36)Dyspnoea: Week 52 (n=8,30)Dyspnoea: Week 55 (n=6,24)Dyspnoea: Week 58 (n=6,21)Dyspnoea: Week 61 (n=4,17)Dyspnoea: Week 64 (n=3,20)Dyspnoea: Week 67 (n=4,17)Dyspnoea: Week 70 (n=3,14)Dyspnoea: Week 73 (n=3,12)Dyspnoea: Week 76 (n=3,8)Dyspnoea: Week 79 (n=3,9)Dyspnoea: Week 82 (n=2,6)Dyspnoea: Week 85 (n=180,6)Dyspnoea: Week 88 (n=2,6)Dyspnoea: Week 91 (n=2,4)Dyspnoea: Week 94 (n=2,6)Dyspnoea: Week 97 (n=1,5)Dyspnoea: Week 100 (n=1,4)Dyspnoea: Week 103 (n=1,4)Dyspnoea: Week 106 (n=1,4)Dyspnoea: Week 109 (n=1,4)Dyspnoea: Week 112 (n=1,5)Dyspnoea: Week 115 (n=1,4)Dyspnoea: Week 118 (n=1,5)Dyspnoea: Week 121 (n=1,5)Dyspnoea: Week 124 (n=1,5)Dyspnoea: Week 127 (n=1,3)Dyspnoea: Week 130 (n=0,3)Dyspnoea: Week 133 (n=1,3)Dyspnoea: Week 136 (n=0,2)Dyspnoea: Week 139 (n=0,2)Dyspnoea: Week 142 (n=0,2)Dyspnoea: Week 145 (n=0,1)Dyspnoea: Final Visit (n=157,160)Insomnia: BL (n=276,285)Insomnia: Week 4 (n=234,248)Insomnia: Week 7 (n=181,219)Insomnia: Week 10 (n=175,200)Insomnia: Week 13 (n=152,183)Insomnia: Week 16 (n=120,164)Insomnia: Week 19 (n=113,143)Insomnia: Week 22 (n=79,143)Insomnia: Week 25 (n=64,124)Insomnia: Week 28 (n=47,110)Insomnia: Week 31 (n=45,94)Insomnia: Week 34 (n=37,87)Insomnia: Week 37 (n=29,63)Insomnia: Week 40 (n=24,55)Insomnia: Week 43 (n=12,43)Insomnia: Week 46 (n=13,42)Insomnia: Week 49 (n=10,36)Insomnia: Week 52 (n=8,30)Insomnia: Week 55 (n=6,24)Insomnia: Week 58 (n=6,21)Insomnia: Week 61 (n=4,17)Insomnia: Week 64 (n=3,20)Insomnia: Week 67 (n=4,17)Insomnia: Week 70 (n=3,14)Insomnia: Week 73 (n=3,12)Insomnia: Week 76 (n=3,8)Insomnia: Week 79 (n=3,9)Insomnia: Week 82 (n=2,6)Insomnia: Week 85 (n=2,6)Insomnia: Week 88 (n=2,6)Insomnia: Week 91 (n=2,4)Insomnia: Week 94 (n=2,6)Insomnia: Week 97 (n=1,5)Insomnia: Week 100 (n=1,4)Insomnia: Week 103 (n=1,4)Insomnia: Week 106 (n=1,4)Insomnia: Week 109 (n=1,4)Insomnia: Week 112 (n=1,5)Insomnia: Week 115 (n=1,4)Insomnia: Week 118 (n=1,5)Insomnia: Week 121 (n=1,5)Insomnia: Week 124 (n=1,5)Insomnia: Week 127 (n=1,3)Insomnia: Week 130 (n=0,3)Insomnia: Week 133 (n=1,3)Insomnia: Week 136 (n=0,2)Insomnia: Week 139 (n=0,2)Insomnia: Week 142 (n=0,2)Insomnia: Week 145 (n=0,1)Insomnia: Final Visit (n=157,160)Appetite Loss: BL (n=275,286)Appetite Loss: Week 4 (n=235,250)Appetite Loss: Week 7 (n=180,216)Appetite Loss: Week 10 (n=176,201)Appetite Loss: Week 13 (n=151,183)Appetite Loss: Week 16 (n=121,165)Appetite Loss: Week 19 (n=114,141)Appetite Loss: Week 22 (n=79,143)Appetite Loss: Week 25 (n=64,124)Appetite Loss: Week 28 (n=47,109)Appetite Loss: Week 31 (n=45,95)Appetite Loss: Week 34 (n=37,87)Appetite Loss: Week 37 (n=29,64)Appetite Loss: Week 40 (n=24,55)Appetite Loss: Week 43 (n=12,43)Appetite Loss: Week 46 (n=14,42)Appetite Loss: Week 49 (n=9,36)Appetite Loss: Week 52 (n=8,30)Appetite Loss: Week 55 (n=6,24)Appetite Loss: Week 58 (n=6,21)Appetite Loss: Week 61 (n=4,17)Appetite Loss: Week 64 (n=3,20)Appetite Loss: Week 67 (n=4,17)Appetite Loss: Week 70 (n=3,14)Appetite Loss: Week 73 (n=3,12)Appetite Loss: Week 76 (n=3,8)Appetite Loss: Week 79 (n=3,9)Appetite Loss: Week 82 (n=2,6)Appetite Loss: Week 85 (n=2,6)Appetite Loss: Week 88 (n=2,6)Appetite Loss: Week 91 (n=2,4)Appetite Loss: Week 94 (n=2,6)Appetite Loss: Week 97 (n=1,5)Appetite Loss: Week 100 (n=1,4)Appetite Loss: Week 103 (n=1,4)Appetite Loss: Week 106 (n=1,4)Appetite Loss: Week 109 (n=1,4)Appetite Loss: Week 112 (n=1,5)Appetite Loss: Week 115 (n=1,4)Appetite Loss: Week 118 (n=1,5)Appetite Loss: Week 121 (n=1,5)Appetite Loss: Week 124 (n=1,5)Appetite Loss: Week 127 (n=1,3)Appetite Loss: Week 130 (n=0,3)Appetite Loss: Week 133 (n=1,3)Appetite Loss: Week 136 (n=0,2)Appetite Loss: Week 139 (n=0,2)Appetite Loss: Week 142 (n=0,2)Appetite Loss: Week 145 (n=0,1)Appetite Loss: Week Final Visit (n=156,161)Constipation: BL (n=276,285)Constipation: Week 4 (n=235,247)Constipation: Week 7 (n=179,220)Constipation: Week 10 (n=175,203)Constipation: Week 13 (n=152,183)Constipation: Week 16 (n=121,165)Constipation: Week 19 (n=114,143)Constipation: Week 22 (n=78,143)Constipation: Week 25 (n=64,124)Constipation: Week 28 (n=47,111)Constipation: Week 31 (n=45,95)Constipation: Week 34 (n=37,86)Constipation: Week 37 (n=29,64)Constipation: Week 40 (n=24,55)Constipation: Week 43 (n=12,43)Constipation: Week 46 (n=14,42)Constipation: Week 49 (n=10,36)Constipation: Week 52 (n=8,29)Constipation: Week 55 (n=6,24)Constipation: Week 58 (n=6,21)Constipation: Week 61 (n=4,17)Constipation: Week 64 (n=3,20)Constipation: Week 67 (n=4,17)Constipation: Week 70 (n=3,14)Constipation: Week 73 (n=3,12)Constipation: Week 76 (n=3,8)Constipation: Week 79 (n=3,9)Constipation: Week 82 (n=2,6)Constipation: Week 85 (n=2,6)Constipation: Week 88 (n=2,6)Constipation: Week 91 (n=2,4)Constipation: Week 94 (n=2,6)Constipation: Week 97 (n=1,5)Constipation: Week 100 (n=1,4)Constipation: Week 103 (n=1,4)Constipation: Week 106 (n=1,4)Constipation: Week 109 (n=1,4)Constipation: Week 112 (n=1,5)Constipation: Week 115 (n=1,4)Constipation: Week 118 (n=1,5)Constipation: Week 121 (n=1,5)Constipation: Week 124 (n=1,5)Constipation: Week 127 (n=1,3)Constipation: Week 130 (n=0,3)Constipation: Week 133 (n=1,3)Constipation: Week 136 (n=0,2)Constipation: Week 139 (n=0,2)Constipation: Week 142 (n=0,2)Constipation: Week 145 (n=0,1)Constipation: Final Visit (n=158,160)Diarrhoea: BL (n=276,283)Diarrhoea: Week 4 (n=234,246)Diarrhoea: Week 7 (n=180,220)Diarrhoea: Week 10 (n=174,202)Diarrhoea: Week 13 (n=152,183)Diarrhoea: Week 16 (n=120,165)Diarrhoea: Week 19 (n=114,143)Diarrhoea: Week 22 (n=78,143)Diarrhoea: Week 25 (n=64,124)Diarrhoea: Week 28 (n=47,111)Diarrhoea: Week 31 (n=45,95)Diarrhoea: Week 34 (n=37,87)Diarrhoea: Week 37 (n=29,64)Diarrhoea: Week 40 (n=24,55)Diarrhoea: Week 43 (n=12,42)Diarrhoea: Week 46 (n=14,42)Diarrhoea: Week 49 (n=10,36)Diarrhoea: Week 52 (n=8,29)Diarrhoea: Week 55 (n=6,24)Diarrhoea: Week 58 (n=6,21)Diarrhoea: Week 61 (n=4,17)Diarrhoea: Week 64 (n=3,20)Diarrhoea: Week 67 (n=4,17)Diarrhoea: Week 70 (n=3,14)Diarrhoea: Week 73 (n=3,12)Diarrhoea: Week 76 (n=3,8)Diarrhoea: Week 79 (n=3,9)Diarrhoea: Week 82 (n=2,6)Diarrhoea: Week 85 (n=2,6)Diarrhoea: Week 88 (n=2,6)Diarrhoea: Week 91 (n=2,4)Diarrhoea: Week 94 (n=2,6)Diarrhoea: Week 97 (n=1,5)Diarrhoea: Week 100 (n=1,4)Diarrhoea: Week 103 (n=1,4)Diarrhoea: Week 106 (n=1,4)Diarrhoea: Week 109 (n=1,4)Diarrhoea: Week 112 (n=1,5)Diarrhoea: Week 115 (n=1,4)Diarrhoea: Week 118 (n=1,5)Diarrhoea: Week 121 (n=1,5)Diarrhoea: Week 124 (n=1,5)Diarrhoea: Week 127 (n=1,3)Diarrhoea: Week 130 (n=0,3)Diarrhoea: Week 133 (n=1,3)Diarrhoea: Week 136 (n=0,2)Diarrhoea: Week 139 (n=0,2)Diarrhoea: Week 142 (n=0,2)Diarrhoea: Week 145 (n=0,1)Diarrhoea: Final Visit (n=157,160)Financial Difficulties: BL (n=274,286)Financial Difficulties: Week 4 (n=234,249)Financial Difficulties: Week 7 (n=178,220)Financial Difficulties: Week 10 (n=175,202)Financial Difficulties: Week 13 (n=151,181)Financial Difficulties: Week 16 (n=120,165)Financial Difficulties: Week 19 (n=113,143)Financial Difficulties: Week 22 (n=78,142)Financial Difficulties: Week 25 (n=63,124)Financial Difficulties: Week 28 (n=45,111)Financial Difficulties: Week 31 (n=45,94)Financial Difficulties: Week 34 (n=36,87)Financial Difficulties: Week 37 (n=29,64)Financial Difficulties: Week 40 (n=24,55)Financial Difficulties: Week 43 (n=12,43)Financial Difficulties: Week 46 (n=14,42)Financial Difficulties: Week 49 (n=10,35)Financial Difficulties: Week 52 (n=8,29)Financial Difficulties: Week 55 (n=6,24)Financial Difficulties: Week 58 (n=6,21)Financial Difficulties: Week 61 (n=4,17)Financial Difficulties: Week 64 (n=3,20)Financial Difficulties: Week 67 (n=4,17)Financial Difficulties: Week 70 (n=3,14)Financial Difficulties: Week 73 (n=3,12)Financial Difficulties: Week 76 (n=3,8)Financial Difficulties: Week 79 (n=3,9)Financial Difficulties: Week 82 (n=2,6)Financial Difficulties: Week 85 (n=2,6)Financial Difficulties: Week 88 (n=2,6)Financial Difficulties: Week 91 (n=2,4)Financial Difficulties: Week 94 (n=2,6)Financial Difficulties: Week 97 (n=1,5)Financial Difficulties: Week 100 (n=1,4)Financial Difficulties: Week 103 (n=1,4)Financial Difficulties: Week 106 (n=1,4)Financial Difficulties: Week 109 (n=1,4)Financial Difficulties: Week 112 (n=1,5)Financial Difficulties: Week 115 (n=1,4)Financial Difficulties: Week 118 (n=1,5)Financial Difficulties: Week 121 (n=1,5)Financial Difficulties: Week 124 (n=1,5)Financial Difficulties: Week 127 (n=1,3)Financial Difficulties: Week 130 (n=0,3)Financial Difficulties: Week 133 (n=1,3)Financial Difficulties: Week 136 (n=0,2)Financial Difficulties: Week 139 (n=0,2)Financial Difficulties: Week 142 (n=0,2)Financial Difficulties: Week 145 (n=0,1)Financial Difficulties: Final Visit (n=158,160)
Fluoropyrimidine/Cisplatin (FP)55.361.060.962.363.860.861.065.168.072.069.670.866.162.072.975.068.572.676.776.779.277.875.077.880.677.877.883.383.383.383.383.383.383.383.383.383.383.383.383.383.383.383.3NA83.3NANANANA53.278.976.079.378.280.279.878.880.785.886.285.686.385.784.485.687.688.788.385.686.791.795.693.397.897.895.695.693.3100.0100.0100.0100.0100.0100.0100.0100.0100.093.3100.0100.0100.0100.0100.0NA100.0NANANANA72.173.267.470.970.273.472.071.174.781.380.582.283.381.679.980.682.181.785.480.677.883.383.383.388.988.983.383.391.7100.091.791.7100.083.383.3100.0100.0100.083.3100.0100.083.383.3100.0NA100.0NANANANA63.575.480.581.382.982.683.182.285.988.286.085.788.583.983.681.982.188.386.576.485.695.810095.897.294.4100.097.295.895.8100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0NA100.0NANANANA75.186.986.085.785.688.282.884.285.985.986.587.088.388.583.388.989.385.091.794.491.791.7100.091.7100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0NA100.0NANANANA79.572.472.173.174.572.772.774.479.383.383.081.584.785.185.487.586.985.087.586.188.991.794.495.894.4100.094.494.4100.091.791.7100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0NA100.0NANANANA68.136.337.134.435.332.933.033.130.022.224.122.022.821.823.619.420.619.416.718.516.78.37.413.911.17.47.47.40.05.60.00.00.011.10.00.011.10.00.00.00.00.00.00.0NA0.0NANANANA40.415.016.616.916.412.814.214.210.38.63.53.74.52.94.22.81.23.32.10.00.00.00.00.00.00.05.60.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA14.924.917.814.513.412.013.614.215.010.78.212.212.211.518.816.713.113.36.32.88.30.05.60.00.05.65.65.60.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA27.412.412.112.714.611.315.415.313.912.79.210.410.210.39.719.411.96.712.55.65.616.70.08.30.00.011.10.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA20.027.222.121.919.814.715.317.114.815.19.910.49.08.013.913.97.710.012.516.711.18.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA21.935.231.527.226.724.724.526.919.012.014.211.111.712.613.95.64.83.70.00.05.68.30.08.30.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA35.322.920.619.019.216.714.613.512.07.37.810.45.411.58.38.34.83.34.25.611.18.30.00.00.00.00.00.016.716.70.00.00.00.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA19.010.99.18.710.56.68.17.36.07.35.75.95.45.76.98.34.810.08.311.111.116.711.116.711.111.122.211.10.00.00.016.716.70.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA10.027.323.623.621.522.523.120.619.716.417.015.610.213.822.216.716.716.78.316.711.116.711.116.711.111.111.111.116.716.716.716.716.70.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA26.6
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)54.960.960.561.963.661.963.864.967.868.570.072.070.670.673.673.876.671.373.873.872.570.072.568.568.167.769.460.079.273.679.279.278.385.475.077.177.175.072.975.075.081.772.272.272.266.766.766.766.753.179.679.579.380.280.580.781.583.684.883.785.485.185.888.289.991.992.089.293.191.491.091.093.392.991.190.092.690.095.695.698.397.897.396.796.798.395.097.393.396.094.796.093.393.395.693.393.393.3100.073.873.976.173.374.375.174.675.879.782.479.781.182.281.582.186.886.588.084.488.289.787.387.590.286.980.681.381.580.691.794.491.7100.090.0100.0100.0100.095.893.383.386.790.090.088.988.988.983.383.383.3100.068.773.177.980.281.280.581.982.484.084.885.585.785.486.386.787.887.591.488.288.588.990.786.389.289.382.987.584.383.391.790.395.888.991.787.587.589.691.795.093.890.095.090.0100.088.991.795.895.895.8100.074.385.786.386.586.885.786.887.687.487.488.090.088.791.491.591.591.792.689.791.090.591.293.391.291.783.383.381.588.991.794.495.894.490.095.891.795.895.893.395.896.796.796.7100.088.994.4100.0100.0100.0100.080.072.074.175.176.776.377.579.580.180.280.278.980.781.882.784.186.984.782.285.487.390.285.885.386.980.681.385.280.688.988.991.791.790.095.8100.091.795.896.795.896.7100.096.783.394.4100.0100.0100.0100.0100.071.434.234.534.133.233.732.829.426.725.123.222.219.719.818.617.113.814.517.214.416.414.417.215.016.716.718.118.529.611.19.311.17.411.111.119.413.916.717.825.017.817.813.314.818.514.822.222.222.211.137.615.719.718.916.414.714.513.912.28.26.58.87.56.84.81.22.80.95.02.13.20.04.22.92.41.40.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.019.825.117.916.114.413.312.412.813.212.212.011.811.312.210.38.96.76.510.08.37.14.96.74.94.89.78.39.32.80.02.84.20.03.38.30.00.00.03.30.03.33.30.00.05.65.60.00.00.00.025.413.411.810.811.313.713.511.912.19.410.39.19.610.44.86.25.64.65.68.36.33.98.35.97.18.38.37.416.75.65.68.35.60.00.08.38.38.36.78.36.76.76.711.111.111.116.716.716.733.318.323.623.320.418.018.917.720.017.015.913.314.913.411.110.39.39.57.47.88.39.57.810.09.89.511.18.311.111.111.15.60.05.66.78.30.00.00.06.70.06.76.70.00.011.111.10.00.00.00.024.633.833.631.329.428.427.925.120.716.711.613.09.610.99.77.05.66.510.010.04.80.08.35.97.15.64.20.05.65.611.10.05.60.00.08.38.30.00.00.00.00.00.00.011.111.10.00.00.00.033.521.520.217.615.115.815.414.510.010.29.66.34.710.47.97.07.15.610.36.96.35.95.05.94.811.14.23.716.70.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.020.010.712.214.211.912.012.910.39.66.24.84.95.74.23.02.41.63.72.34.24.80.03.32.03.32.00.00.00.00.00.00.00.00.00.00.00.00.06.70.00.00.06.70.00.00.00.00.00.00.010.029.327.723.923.322.724.422.424.922.321.623.424.523.423.619.418.320.020.718.122.223.516.717.619.019.425.025.922.216.716.725.016.720.016.78.316.716.713.316.713.313.313.311.111.10.00.00.00.00.027.9

Pain Intensity Scores as Assessed By Visual Analog Scale (VAS)

"The participant assessed their pain on a 0 to 100 millimeter (mm) horizontal VAS. The left-hand extreme of the line equals 0 mm, and is described as no pain and the right-hand extreme equals 100 mm as unbearable pain. A negative change indicated improvement." (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

,
Interventionmm (Mean)
BL (n=275,284)Week 4 (n=234,249)Week 7 (n=181,219)Week 10 (n=174, 202)Week 13 (n=152,181)Week 16 (n=121,165)Week 19 (n=114,142)Week 22 (n=79,141)Week 25 (n=64,124)Week 28 (n=47,111)Week 31 (n=45,95)Week 34 (n=37,86)Week 37 (n=29,64)Week 40 (n=24,54)Week 43 (n=12,43)Week 46 (n=14,41)Week 49 (n=10,36)Week 52 (n=8,30)Week 55 (n=6,24)Week 58 (n=6,20)Week 61 (n=4,17)Week 64 (n=3,20)Week 67 (n=4,17)Week 70 (n=3,13)Week 73 (n=3,10)Week 76 (n=3,8)Week 79 (n=3,9)Week 82 (n=2,6)Week 85 (n=2,6)Week 88 (n=2,6)Week 91 (n=2,4)Week 94 (n=2,6)Week 97 (n=1,5)Week 100 (n=1,4)Week 103 (n=1,4)Week 106 (n=1,4)Week 109 (n=1,4)Week 112 (n=1,5)Week 115 (n=1,4)Week 118 (n=1,5)Week 121 (n=1,5)Week 124 (n=1,4)Week 127 (n=1,3)Week 130 (n=0,3)Week 133 (n=1,3)Week 136 (n=0,2)Week 139 (n=0,2)Week 142 (n=0,2)Week 145 (n=0,1)Final visit/withdrawal (n=157,161)
Fluoropyrimidine/Cisplatin (FP)21.114.611.114.511.314.015.413.312.78.68.79.415.516.412.616.17.25.82.34.75.32.01.51.31.01.71.00.01.00.50.50.50.00.00.00.00.00.00.00.00.00.00.0NA0.0NANANANA23.8
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)17.913.313.812.912.212.812.015.111.012.312.510.710.98.87.27.46.56.93.33.87.26.88.91.316.512.95.94.86.35.77.55.80.20.36.57.87.34.25.83.83.24.56.35.75.06.08.07.515.021.9

Percentage of Participants With a Change in Analgesic Medication During the Study

Analgesic medications were recorded throughout the study until disease progression. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

,
Interventionpercentage of participants (Number)
Taking any analgesic medicationDiscontinued at least 1 medicationDecreased dose of at least 1 medicationNo change in any medicationIncreased dose or added at least 1 medication
Fluoropyrimidine/Cisplatin (FP)29.05.90.35.517.2
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)29.31.70.37.120.1

Percentage of Participants With Change From Baseline in Body Weight by Percentage Change in Weight

Change in body weight was categorized as an increase of greater than (>)5 percent (%), no change (plus or minus [±]5%), decrease of >5-10%, or a decrease of >10% from BL to the end of study. Time windows were applied in order to assign visits to weight measurements, and the lowest post-screening value recorded was used for the analysis. The percentage change in weight from screening was summarized over time. (NCT01041404)
Timeframe: BL, Days 1, 22, 43, 64, 85, 106, 127, and every 21 days until disease progression of the end of study, 1 year after the cut-off date for the 2nd interim efficacy analysis

,
Interventionpercentage of participants (Number)
Increase >5%No change (±5%)Decrease >5-10%Decrease >10%
Fluoropyrimidine/Cisplatin (FP)1.551.628.218.7
Trastuzumab + Fluoropyrimidine/Cisplatin (FP + H)1.150.527.221.2

Duration of Response

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG12.7
A + FOLFOX 47.9

Duration of Response - A+FOLFOX4 - Avastin Subgroup

The duration of a complete response (CR) or partial response (PR) was defined as the time from first objective status assessment of CR or PR to the first time of progression or death as a result of any cause. (NCT00192075)
Timeframe: date of first response until the first date of documented progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A + FOLFOX 4 - Avastin Subgroup5.2

Overall Survival

Overall survival is the duration from enrollment to death. For patients who are alive, overall survival is censored at the last contact. (NCT00192075)
Timeframe: randomization to the date of death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG20.6
A + FOLFOX 419.7

Progression-Free Survival

Defined as the time from randomization to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.5

Progression-Free Survival - Avastin Subgroup

Defined as the time from date of first dose to the first observation of disease progression, or death due to any cause. (NCT00192075)
Timeframe: randomization to the first date of progression or death from any cause (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup11.5

Time to Progressive Disease

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG8.6
A + FOLFOX 49.7

Time to Progressive Disease - Avastin Subgroup

Defined as the time from study enrollment to the first date of disease progression. Time to disease progression was censored at the date of death if death was due to other cause. (NCT00192075)
Timeframe: randomization to the date of first documented disease progression or death due to disease under study, whichever comes first (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

Interventionmonths (Median)
A+FFG - Avastin Subgroup13.7
A + FOLFOX 4 - Avastin Subgroup13.8

Survival at 12 Months and 24 Months - Avastin Subgroup

Percentage of participants who were alive at 12 months and 24 months. (NCT00192075)
Timeframe: randomization to the date of death from any cause (up to 24 months)

,
Interventionpercentage of participants alive (Number)
12-Month Survival24-Month Survival
A + FOLFOX 4 - Avastin Subgroup83.366.7
A+FFG - Avastin Subgroup75.650.4

Toxicity - Avastin Subgroup

Includes all Grade 3-4 hematologic toxicities and all non-hematologic toxicities with either >=1 Grade 4 or >=2 Grade 3 adverse events (NCT00192075)
Timeframe: every cycle (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Neutropenia (Grade 3)Neutropenia (Grade 4)Thrombocytopenia (Grade 3)Thrombocytopenia (Grade 4)Leukopenia (Grade 3)Leukopenia (Grade 4)Anemia (Grade 3)Anemia (Grade 4)Febrile neutropenia (Grade 3)Febrile neutropenia (Grade 4)Diarrhea (Grade 3)Diarrhea (Grade 4)Small intestinal obstruction (Grade 3)Small intestinal obstruction (Grade 4)Fatigue (Grade 3)Fatigue (Grade 4)Cerebral infarction (Grade 3)Cerebral infarction (Grade 4)Hyperglycemia (Grade 3)Hyperglycemia (Grade 4)Dehydration (Grade 3)Dehydration (Grade 4)Deep vein thrombosis (Grade 3)Deep vein thrombosis (Grade 4)Myocardial infarction (Grade 3)Myocardial infarction (Grade 4)Subdural hematoma (Grade 3)Subdural hematoma (Grade 4)Perirectal abscess (Grade 3)Perirectal abscess (Grade 4)Hypoxia (Grade 3)Hypoxia (Grade 4)
A + FOLFOX 4 - Avastin Subgroup51000000100110200000102002000000
A+FFG - Avastin Subgrouup35103100001010000000000000001000

Tumor Response - Avastin Subgroup

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 4 - Avastin Subgroup18981710
A+FFG - Avastin Subgroup000111161

Tumor Response by Response Evaluation Criteria In Solid Tumors (RECIST)

Response using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response=disappearance of all target lesions; Partial Response=30% decrease in sum of longest diameter of target lesions; Progressive Disease=20% increase in sum of longest diameter of target lesions; Stable Disease=small changes that do not meet above criteria. (NCT00192075)
Timeframe: baseline to measured progressive disease (every 7-8 weeks for 2 cycles, monthly for 3 months, every other month for 6 months, then every 3 months up to 4.4 years)

,
Interventionparticipants (Number)
Complete Response (CR)Partial Response (PR)Overall Response Rate (CR+PR)Stable Disease (SD)Disease Control Rate (CR+PR+SD)Progressive DiseaseUnknown
A + FOLFOX 421517163372
A+FFG1342125143

Progression Free Survival Rate

(NCT00100841)
Timeframe: From randomization to the first documented disease progression

Interventionmonths (Median)
Treatment (Combination Chemotherapy)9.6

Severe Adverse Event (SAE) Rate

The primary objective is to evaluate safety in all treated patients specifically the rate of serious adverse events which were defined as grade 5 events, grade 4 hemorrhage or thrombosis or bowel perforation (NCT00100841)
Timeframe: The duration of the study

Interventionparticipants (Number)
Grade 5 DeathGrade 4 venous thrombosis
Treatment (Combination Chemotherapy)22

Overall Survival (1-year Rate Reported)

One-year survival estimate is reported. Survival time is defined as time from registration to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at date of last contact. This analysis was planned to occur when all patients had been potentially followed for 1 year. On the basis of a 1-year survival rate of 60% from the Radiation Therapy Oncology Group (RTOG) esophageal database, 38 analyzable patients with a 1-year survival rate of 77.5% or better was needed for this trial to be deemed promising enough for development of a Phase III protocol (type I error of 0.05 and type II error of 0.20). (NCT00069953)
Timeframe: From registration to date of death or last follow-up. Analysis occurs after all patients have been potentially followed for 1 year.

Interventionpercentage of participants (Number)
ChemoRT and Selective Surgery71

3-Year Disease-free Survival

The primary endpoint was 3-year disease-free survival (DFS). Evidence of local recurrence, distant metastasis, or death from any cause within 3 years counted as events in the time-to-event Kaplan-Meier analysis of disease-free survival. (NCT00114231)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery)88.2

Local Recurrence Rate

The local recurrence rate (percentage) is defined as the percentage of patients who had local recurrence as initial sites of failure at the end of follow-up. (NCT00114231)
Timeframe: Up to 5 years

Interventionpercentage of patients (Number)
Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery)4

R0 Resection Rate (Negative Margin Rate)

The rate (percentage) of patients with negative resection margins after undergoing local excision is reported below. (NCT00114231)
Timeframe: At time of surgery

Interventionpercentage of patients (Number)
Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery)98.7

Rate of Pathologic Complete Response of the Primary Tumor

The rate (percentage) of patients with pathologic complete response (pCR) is reported below. Pathologic response will be determined by comparing tumor width and stage in the surgical specimen with the same parameters as determined by pre-CRT ERUS: PATHOLOGIC COMPLETE RESPONSE (pCR): no residual tumor. (NCT00114231)
Timeframe: Up to 5 years

Interventionpercentage of patients (Number)
Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery)44

Morbidity and Mortality Rate

Morbidity and mortality after neoadjuvant cheoradiotherapy and local excision. (NCT00114231)
Timeframe: Up to 30 days

Interventionpercentage of patients (Number)
MortalityMorbidity
Treatment (Capecitabine, Oxaliplatin, Radiotherapy, Surgery)610

Disease-Free Survival (DFS), The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment

The Proportion of Patients Predicted to be Alive Without Evidence of Disease Recurrence 24 Months After Completion of Protocol Treatment (NCT00308516)
Timeframe: 24 months

Interventionpercentage of participants (Number)
Preoperative 5FU/Radiation/Bevacizumab85
Postoperative 5FU/Radiation/Bevacizumab97

Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death

Overall Survival (OS) is defined ad the Length of time, in months, that patients were alive from their first date of protocol treatment until death. (NCT00308516)
Timeframe: 24 months

Interventionmonths (Median)
Preoperative 5FU/Radiation/BevacizumabNA
Postoperative 5FU/Radiation/BevacizumabNA

Best Response During Second-Line Treatment

"Objective response rate is defined as the percentage of participants with a best response of complete response or partial response based on investigator review of scans using modified RECIST criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no post-baseline radiographic tumor assessment(s) were considered non-responders.~CR: disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or PD and no new lesions." (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionpercentage of participants (Number)
Wild-type KRAS23
Mutant KRAS16

Duration of Response

Duration of response is defined as the time from the date of first response to the date of first progression of disease during second-line treatment (as evaluated by the investigator) or death (if the death was due to disease progression but not detected earlier) in the subset of participants who responded (CR or PR, as evaluated by the investigator). Duration of response was analyzed using Kaplan-Meier methods; participants who responded but did not progress while on study were censored at the date of last tumor assessment. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS29
Mutant KRAS23

Overall Survival

Overall survival is defined as as the number of days from Study Day 1 to the date of death due to any cause. Overall survival was analyzed using the Kaplan-Meier method; participants who were lost to follow-up or who had not died at the end of the study (52 weeks after the last participant was enrolled) were censored at the date of last contact. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS50
Mutant KRAS31

Progression-free Survival Time

Progression-free survival time was defined as the time from Study Day 1 to the date of disease progression (based on investigator assessment) or the date of death due to any cause. Participants who terminated from the study early (eg, prior to disease progression due to fully withdrawn informed consent) were censored at their last tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS26
Mutant KRAS19

Time to Progression

Time to progression is defined as the time from study Day 1 to the date of observed disease progression. Time to progression was analyzed using Kaplan-Meier methods; participants who did not have disease progression were censored at the date of last evaluable tumor assessment. (NCT00411450)
Timeframe: From Study Day 1 until the data cut-off date of 2 January 2009; median follow-up time was 39 weeks, with a maximum of 93 weeks.

Interventionweeks (Median)
Wild-type KRAS26
Mutant KRAS17

Time to Response

Time to response of second-line treatment is defined as the time from study Day 1 to the date of first documentation of CR or PR, calculated for those participants with an objective tumor response of CR or PR. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS9.1
Mutant KRAS9.3

Time to Treatment Failure

Time to failure of second-line treatment is defined as the time from study Day 1 to the date of the earliest of the following events: end of second-line therapy due to any reason except for complete response and curative surgery; progressive disease; or death due to any cause. Time to treatment failure was analyzed using Kaplan-Meier methods; participants who did not discontinue second-line treatment or discontinue due to complete response or curative surgery, who were still alive, and who did not have disease progression were censored at the date of the last contact. (NCT00411450)
Timeframe: Tumor response was assessed at Weeks 9, 17, 25, and 33, and once every 12 weeks thereafter until the end of second-line treatment; maximum time on treatment was 77 weeks.

Interventionweeks (Median)
Wild-type KRAS19
Mutant KRAS15

Disease Control Rate at Weeks 17 and 25

The percentage of participants whose best response was either a complete or partial response or stable disease, based on modified RECIST criteria as assessed by the investigator. Stable diease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD of target lesions and no progression of existing non-target lesions and no new lesions, or, the persistence of 1 or more non-target lesions not qualifying for either CR or PD if no target lesions were identified at Baseline. (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercentage of participants (Number)
Week 17Week 25
Mutant KRAS5858
Wild-type KRAS6464

Number of Participants Who Developed Antibodies to Panitumumab

The immunogenicity of panitumumab was evaluated using 2 different screening immunoassays for the detection of anti-panitumumab antibodies: an acid dissociation bridging enzyme-linked immunosorbent assay (ELISA; detecting high-affinity antibodies) and a Biacore® biosensor immunoassay (detecting both high and low-affinity antibodies). When either of the 2 screening assays yielded a positive result, that particular sample was subjected to an in vitro bioassay for the detection of neutralizing antibodies. (NCT00411450)
Timeframe: Prior to first dose and 28 days after the last dose of second-line treatment

Interventionparticipants (Number)
Binding antibody positiveNeutralizing antibody positive
Panitumumab Plus FOLFIRI10

Number of Participants With Adverse Events

The severity of adverse events (AEs) was graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0, except for panitumumab related skin toxicities, where Grade 1 = Mild AE; Grade 2 = Moderate AE; Grade 3 = Severe AE; Grade 4 = Life-threatening or disabling AE; Grade 5 = Death related to AE. The relationship of each adverse event to the panitumumab and/or FOLFIRI regimen was assessed by the investigator. A serious adverse event was defined as an adverse event that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

Interventionparticipants (Number)
Any adverse eventGrade 3 or higher adverse eventPanitumumab-related adverse eventsChemotherapy-related adverse events≥ grade 3 panitumumab-related adverse events≥ grade 3 chemotherapy-related adverse eventsSerious adverse eventsSerious panitumumab-related adverse eventsSerious chemotherapy-related adverse eventsLife-threatening adverse eventsEnded second-line treatment due to adverse eventsEnded panitumumab due to adverse eventsEnded FOLFIRI due to adverse eventsDeath due to adverse eventsPanitumumab infusion reactionsDeaths during study
Panitumumab Plus FOLFIRI115941071125665461524181820288271

Number of Participants With Grade 4 Laboratory Toxicities

Laboratory toxicities were graded according to CTCAE version 3. (NCT00411450)
Timeframe: From the first dose date to 30 days after the last dose date. The median time frame is 4.5 months.

Interventionparticipants (Number)
AnemiaNeutropeniaHypomagnesaemiaHypokalemiaHypocalcaemiaHyperbilirubinaemia
Panitumumab Plus FOLFIRI148131

Objective Response Rate at Weeks 17 and 25

Objective response rate is defined as the percentage of participants with a best response of complete response or partial response. Disease assessments were based on investigator review of scans using modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria. A complete or partial response was confirmed no less than 4 weeks after the criteria for response were first met. Participants with no radiographic tumor assessment(s) at Week 17 or 25 were considered non-responders. Complete Response (CR): disappearance of all target and non-target lesions and no new lesions. Partial Response (PR): At least a 30% decrease in the size of target lesions with no progression of non-target lesions (defined as a ≥ 25% increase in lesion size) and no new lesions, or, the disappearance of all target lesions but persistence of 1 or more non-target lesions not qualifying for either CR or progressive disease (PD) and no new lesions. (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercentage of participants (Number)
Week 17Week 25
Mutant KRAS1414
Wild-type KRAS2022

Progression-free Survival Rate at Weeks 17 and 25

"The progression-free survival rate is defined as the Kaplan-Meier (KM) estimator of progression-free survival at Week 17 and Week 25 reported as the probability of being event (disease progression or death)-free. Tumor assessments were evaluated by the investigator according to modified RECIST criteria.~PD: At least a 20% increase in the size of target lesions since the treatment started or at least a 25% increase in the size of non-target lesions and the lesion(s) measure ≥ 10 mm, or the appearance of any new lesions. Participants who withdraw from the study prior to completion of Week 17 or 25 radiographic tumor assessments were censored at the last evaluable tumor assessment." (NCT00411450)
Timeframe: Week 17 and Week 25

,
Interventionpercent probability (Number)
Week 17Week 25
Mutant KRAS5541
Wild-type KRAS6752

Overall Survival

Measured from time of registration to death, or last contact date (NCT00086996)
Timeframe: 0-5 years

Interventionmonths (Median)
Chemo Plus RT, Surgery, Chemo28.3

Pathological Complete Response

Complete pathologic response assessed after chemoradiotherapy and surgery, defined as no evidence of residual disease on path review. Patients who did not receive surgery are assumed to have not responded. (NCT00086996)
Timeframe: 10-16 weeks after beginning study treatment

Interventionparticipants (Number)
Chemo Plus RT, Surgery, Chemo26

Progression-free Survival

measured from date of registration to time of first documentation of progression by Response Evaluation Criteria in Solid Tumors (RECIST), death, or last contact date. (NCT00086996)
Timeframe: 0-3 years

Interventionmonths (Median)
Chemo Plus RT, Surgery, Chemo19.7

Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug

Only adverse events that are possibly, probably or definitely related to study drug are reported. (NCT00086996)
Timeframe: Up to 3 years

InterventionParticipants (Number)
Adult respiratory distress syndrome (ARDS)AnorexiaCNS cerebrovascular ischemiaCalcium, serum-low (hypocalcemia)Cardiac troponin T (cTnT)Cardiac-ischemia/infarctionChyle or lymph leakageConfusionCoughCreatinineDehydrationDiarrheaDistention/bloating, abdominalDysphagia (difficulty swallowing)Dyspnea (shortness of breath)EsophagitisFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever in absence of neutropenia, ANC lt1.0x10e9/LFistula, GI - Oral cavityGastrointestinal-Other (Specify)Glucose, serum-high (hyperglycemia)Heartburn/dyspepsiaHemoglobinHypotensionHypoxiaInf (clin/microbio) w/Gr 3-4 neuts - LungInf w/normal ANC or Gr 1-2 neutrophils - BloodInf w/normal ANC or Gr 1-2 neutrophils - LungInf w/normal ANC or Gr 1-2 neutrophils - Perit cavInf w/normal ANC or Gr 1-2 neutrophils - WoundInfection with unknown ANC - BloodInfection with unknown ANC - Lung (pneumonia)Infection with unknown ANC - WoundLeak (including anastomotic), GI - EsophagusLeukocytes (total WBC)LymphopeniaMood alteration - anxietyMucositis/stomatitis (clinical exam) - EsophagusMucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (functional/symp) - EsophagusMucositis/stomatitis (functional/symp) - Oral cavMuscle weakness, not d/t neuropathy - body/generalNauseaNecrosis, GI - StomachNeutrophils/granulocytes (ANC/AGC)Obstruction, GI - EsophagusPain - Abdomen NOSPain - Pain NOSPericardial effusion (non-malignant)PlateletsPleural effusion (non-malignant)Pneumonitis/pulmonary infiltratesPotassium, serum-low (hypokalemia)Pulmonary/Upper Respiratory-Other (Specify)Renal failureSVT and nodal arrhythmia - Atrial fibrillationSVT and nodal arrhythmia - Sinus tachycardiaSkin breakdown/decubitus ulcerSodium, serum-low (hyponatremia)Stricture/stenosis (incl anastomotic), EsophagusSyncope (fainting)Thrombosis/thrombus/embolismTyphlitis (cecal inflammation)VomitingWeight lossWound complication, non-infectious
Chemo Plus RT, Surgery, Chemo4151211111131214331411113141612314121121011452111111114233431211521217131

Overall Survival

Follow-up for survival to be done at 3 month intervals for 2 years, then 6 month intervals for up to 5 years from study registration (NCT00321100)
Timeframe: From dose of first study drug to last timepoint known to be alive (median follow-up for all patients was 25.9 months)

Interventionmonths (Median)
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab18
Cetuximab, Oxaliplatin, Capecitabine42.5

Time to Progression (TTP)

"Per Response Evaluation Criteria In Solid Tumors (RECISTv1.0) assessed by CT, MRI, x-ray scan:~Complete response (CR): Disappearance of all lesions Partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL Stable disease (SD): Neither PR, PD, or CR Progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion" (NCT00321100)
Timeframe: every 6-9 weeks; from dose of first study drug to event

Interventionmonths (Median)
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab8.7
Cetuximab, Oxaliplatin, Capecitabine14.4

Objective Response Rate (ORR)

"Objective response rate calculated by the proportion of overall response: CR+PR. Patients were categorized by one of the following (1-4 per RECISTv1.0 criteria on CT, MRI, x-ray; 4-9 considered failure to respond/disease progression):~complete response (CR): Disappearance of all lesions~partial response (PR): >=30% decrease in the sum of the longest diameter of target lesions (SoL); from baseline SoL~stable disease (SD): Neither PR, PD, or CR~progressive disease (PD): >=20% increase in the SoL; from smallest SoL. Or appearance of new lesion~early death from malignant disease~early death from toxicity~early death from other cause~9) unknown (not assessable, insufficient data)" (NCT00321100)
Timeframe: every 6-9 weeks; from date of first study drug dose until off treatment date (median of 8 cycles; range <1-19)

,
InterventionParticipants (Count of Participants)
Overall responseComplete responsePartial responseStable disease
Cetuximab, Oxaliplatin, Capecitabine8173
Cetuximab, Oxaliplatin, Capecitabine, Bevacizumab4137

Apparent Oral Clearance (CL/F) of Sunitinib

Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed. Clearance was estimated from population pharmacokinetic (PK) modeling. Drug clearance is a quantitative measure of the rate at which a drug substance is removed from the blood. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI32.9

Clearance of Irinotecan

CL is calculated as dose divided by AUC 0-∞ (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL/hour (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI23.0

Duration of Response (DR)

DR is defined as the time from the first objective documentation of complete or partial response that is subsequently confirmed to the first documentation of disease progression or to death due to any cause, whichever occurs first. The definition of censorship is the same as PFS. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.3

Percentage of Participants Who Presented Objective Response: Objective Response Rate (ORR)

ORR is defined as the percentage of participants with best overall response of either a confirmed complete (CR) or partial response (PR) relative to the number of participants in FAS. Based on the response evaluation criteria in solid tumors (RECIST), CR is defined as the disappearance of all target lesions and PR is defined as a greater than or equal to 30% decrease in the sum of the longest dimensions of the target lesion. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionpercentage of participants (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI36.6

Plasma Concentration at Steady State (Css) of 5-FU

Concentration at 22 hour post start of 5-FU infusion were to be used as Css if 5-FU concentrations suggested steady state at 22 hours time point. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI650

Progression-Free Survival (PFS)

"PFS is defined as the time from the date of enrollment to the date of the first documentation of objective tumor progression or death due to any cause, whichever occurs first.~PFS data was censored on the day following the date of the last tumor assessment documenting absence of progressive disease for patients who 1) were given anti-tumor treatment other than the study treatment prior to observing objective tumor progression; 2) were removed from the study prior to documentation of objective tumor progression; and 3) were ongoing at the time of the analysis." (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

Interventionweeks (Median)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI28.9

Terminal Phase Elimination Half-life (t1/2) of Irinotecan

Terminal phase half-life of irinotecan was calculated as ln 2/ kel. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI5.36

Volume of Distribution at Steady State (Vss) of Irinotecan

Vss was calculated using following equation: CL x mean residence time (MRT), where MRT = the area under the first moment curve from zero time to infinity (AUMC 0-∞)/AUC 0-∞- (infusion time/2), AUMC 0-∞ = the area under the first moment curve from zero time to time t (AUMC t)+ ((t x Ct*)/ kel) + (Ct* / kel^2), AUMC t is calculated using the linear trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

InterventionL (Mean)
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI160

Area Under the Plasma Concentration Versus Time Curve From Time 0 to 24 Hours Postdose (AUC 0-24) of Sunitinib

AUC 0-24 was determined using the Linear/Log trapezoidal method. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Sunitinib AUC 0-24SU012662 AUC 0-24Total (sunitinib + SU0122662) AUC 0-24
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI11613461507

Area Under the Plasma Concentration Versus Time Curve From Time 0 to the Time of the Last Measurable Concentration (AUC Last) and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Infinity (AUC ∞) of Irinotecan

"AUC last of irinotecan and its metabolite SN-38 were calculated using the Linear/Log trapezoidal method.~AUC∞ of irinotecan was calculated using following equation; AUC last+(C*t/kel), where Ct* is the estimated concentration at the time of the last quantifiable concentration, kel is terminal phase rate constant that is estimated as the absolute value of the slope of a linear regression during the terminal phase of the natural-logarithm (ln) transformed concentration-time profile." (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng.h/mL (Mean)
Irinotecan AUC lastIrinotecan AUC ∞SN-38 AUC last
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI1310013800274

Maximum Observed Plasma Concentration (Cmax) and Predose Concentration (Ctrough) of Sunitinib.

Plasma concentrations were assessed at predose, 2, 4, 6, 8, and 24 hours postdose and Cmax and Ctrough of sunitinib, its metabolite SU012662, and the total (sunitinib + SU0122662) were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Sunitinib CmaxSunitinib CtroughSU012662 CmaxSU012662 CtroughTotal (sunitinib + SU0122662) CmaxTotal (sunitinib + SU0122662) Ctrough
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI54.341.815.811.370.053.1

Maximum Observed Plasma Concentration (Cmax) of Irinotecan

Plasma samples were assessed at prior to initiation of irinotecan (and l-leucovorin) infusion, 1, 2 (predose for 5-FU bolus), 4, 8, and 24 hours after initiation of irinotecan infusion, and Cmax of irinotecan and its metabolite SN-38 were determined. (NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionng/mL (Mean)
Irinotecan CmaxSN-38 Cmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI196325.1

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and Grade 3 or Higher Adverse Events According to Common Terminology Criteria (CTCAE).

Any untoward medical occurrence in a patient who received study drug was considered an adverse event (AE), without regard to possibility of causal relationship. Treatment-emergent adverse events (TEAE): those which occurred or worsened after baseline. An adverse event resulting in any of the following outcomes, or deemed to be significant for any other reason, was considered to be a serious adverse event (SAE): death; initial or prolonged inpatient hospitalization; a life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. (NCT00668863)
Timeframe: Up to 11 cycles (1 cycle = 6 weeks)

InterventionParticipants (Number)
Treatment emergent adverse eventsSerious adverse eventsCTCAE grade 3 or 4 adverse eventsCTCAE grade 5 adverse events
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI7132701

Time to Reach Maximum Plasma Concentration (Tmax) of Irinotecan

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Irinotecan tmaxSN-38 tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI24

Time to Reach Maximum Plasma Concentration (Tmax) of Sunitinib

(NCT00668863)
Timeframe: Cycle 1 Day 15

Interventionhours (Mean)
Sunitinib TmaxSU012662 TmaxTotal (sunitinib + SU0122662) Tmax
Sunitinib 37.5 mg (Schedule 4/2) + FOLFIRI646

Area Under the Concentration-Time Curve From 0 to 21 Days (AUC21d) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 7 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in days multiplied by micrograms per milliliters (d*μg/mL). (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventiond*μg/mL (Mean)
Herceptin IV + Chemotherapy2056
Herceptin SC + Chemotherapy2268

AUC21d of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). Values were extrapolated beyond Day 15 to produce the area over the full 21-day cycle. The AUC21d value at Cycle 12 was calculated from trastuzumab concentration-time profiles using standard non-compartmental PK methods, averaged among all participants, and expressed in d*μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventiond*μg/mL (Mean)
Herceptin IV + Chemotherapy2179
Herceptin SC + Chemotherapy2610

Cmax of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). The Cmax during Cycle 12 was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy230
Herceptin SC + Chemotherapy166

Event-Free Survival (EFS)

Protocol-defined events included disease recurrence or progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. EFS was estimated by Kaplan-Meier analysis and defined as the time from randomization to the first protocol-defined event. (NCT00950300)
Timeframe: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

Interventionmonths (Median)
Herceptin IV + ChemotherapyNA
Herceptin SC + ChemotherapyNA

Maximum Serum Concentration (Cmax) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). The Cmax during Cycle 7 was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy221
Herceptin SC + Chemotherapy149

Number of Participants With Ctrough of Trastuzumab >20 μg/mL After Surgery

Pre-dose samples were obtained after surgery (Cycle 13). The number of participants who had an observed Ctrough >20 μg/mL was reported. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventionparticipants (Number)
Herceptin IV + Chemotherapy216
Herceptin SC + Chemotherapy227

Number of Participants With Ctrough of Trastuzumab >20 μg/mL Prior to Surgery

Pre-dose samples were obtained prior to surgery (Cycle 8). The number of participants who had an observed Ctrough >20 μg/mL was reported. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventionparticipants (Number)
Herceptin IV + Chemotherapy232
Herceptin SC + Chemotherapy227

Observed Ctrough of Trastuzumab After Surgery

Pre-dose samples were obtained after surgery (Cycle 13). The observed Ctrough was recorded, averaged among all participants, and expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy62.1
Herceptin SC + Chemotherapy90.4

Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery

Pre-dose samples were obtained prior to surgery (Cycle 8). The observed Ctrough was recorded, averaged among all participants, and expressed in micrograms per milliliter (μg/mL). (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy57.8
Herceptin SC + Chemotherapy78.7

Overall Survival (OS)

OS was estimated by Kaplan-Meier analysis and defined as the time from randomization to death from any cause. (NCT00950300)
Timeframe: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

Interventionmonths (Median)
Herceptin IV + ChemotherapyNA
Herceptin SC + ChemotherapyNA

Percentage of Participants Who Died

The percentage of participants who died at any time during the study was reported. (NCT00950300)
Timeframe: Continuously during treatment (up to 12 months); at Months 1, 3, 6 from last dose of Cycle 18 (cycle length of 21 days); then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

Interventionpercentage of participants (Number)
Herceptin IV + Chemotherapy14.5
Herceptin SC + Chemotherapy13.6

Percentage of Participants Who Experienced a Protocol-Defined Event

Protocol-defined events included disease recurrence/progression (local, regional, distant, contralateral) or death from any cause. Imaging was performed at specified visits for up to 5 years after last dose. Thereafter, participants were followed for survival only. The percentage of participants who experienced a protocol-defined event at any time during the study was reported. (NCT00950300)
Timeframe: Screening; Day 1 of Cycle 18 (cycle length of 21 days); and Months 6, 12, 24, 36, 48, 60 from last dose of Cycle 18; then every 6 months until withdrawal for any reason (up to approximately 87 months overall)

Interventionpercentage of participants (Number)
Herceptin IV + Chemotherapy33.3
Herceptin SC + Chemotherapy32.7

Percentage of Participants With Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.0, Among Those With Measurable Disease at Baseline

Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to less than (<) 10 millimeters (mm) with no prior assessment of progressive disease (PD). PR was defined as greater than or equal to (≥) 30% decrease from Baseline in sum diameter (SD) of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. The percentage of participants with overall response of CR or PR at the end of neoadjuvant treatment was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: Tumor assessments at Baseline; on Day 1 of Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months overall)

Interventionpercentage of participants (Number)
Herceptin IV + Chemotherapy88.8
Herceptin SC + Chemotherapy87.2

Percentage of Participants With Pathological Complete Response (pCR)

Participants were evaluated following eight cycles of treatment and after surgery to assess for pCR, defined as absence of neoplastic invasive cells in the breast according to pathologist examination. The percentage of participants with pCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)

Interventionpercentage of participants (Number)
Herceptin IV + Chemotherapy40.7
Herceptin SC + Chemotherapy45.4

Percentage of Participants With Total Pathological Complete Response (tpCR)

Participants were evaluated following eight cycles of treatment and after surgery to assess for tpCR, defined as absence of neoplastic invasive cells in the breast and axillary lymph nodes according to pathologist examination. The percentage of participants with tpCR was reported, and the 95% CI for one-sample binomial was constructed using the Pearson-Clopper method. (NCT00950300)
Timeframe: After surgery following eight cycles of Herceptin + chemotherapy (approximately 6 months from Baseline)

Interventionpercentage of participants (Number)
Herceptin IV + Chemotherapy34.2
Herceptin SC + Chemotherapy39.2

Predicted Ctrough of Trastuzumab After Surgery

Predicted Ctrough at pre-dose after surgery (Cycle 13) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy51.7
Herceptin SC + Chemotherapy80.6

Predicted Ctrough of Trastuzumab Prior to Surgery

Predicted Ctrough at pre-dose prior to surgery (Cycle 8) was determined on the basis of a population PK model from Study BP22023 (NCT00800436). The mean predicted Ctrough was expressed in μg/mL. (NCT00950300)
Timeframe: Pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventionμg/mL (Mean)
Herceptin IV + Chemotherapy51.4
Herceptin SC + Chemotherapy80.3

Time of Maximum Serum Concentration (Tmax) of Trastuzumab Prior to Surgery

PK samples were obtained prior to surgery (Cycle 7). The Tmax during Cycle 7 was recorded, averaged among all participants, and expressed in days. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 7; on Days 2, 4, 8, 15 of Cycle 7; pre-dose (0 hours) on Day 1 of Cycle 8 (cycle length of 21 days)

Interventiondays (Mean)
Herceptin IV + Chemotherapy0.05
Herceptin SC + Chemotherapy4.12

Time to Response According to RECIST Version 1.0, Among Those With Measurable Disease at Baseline

Tumor response was assessed using RECIST version 1.0. CR was defined as disappearance of all target lesions and short-axis reduction of any pathological lymph nodes to <10 mm with no prior assessment of PD. PR was defined as ≥30% decrease from Baseline in SD of target lesions with no prior assessment of PD. PD was defined as ≥20% relative increase and ≥5 mm of absolute increase in the SD of target lesions, taking as reference the smallest SD recorded since treatment started; or appearance of 1 or more new lesions. Time to response was defined as the time from first dose of study medication to the first assessment of CR or PR, which was the date the response was first documented by objective evidence, among participants with an overall response of CR or PR. (NCT00950300)
Timeframe: Tumor assessments at Baseline; on Day 1 Cycles 3, 5, 7 (cycle length of 21 days); and at time of surgery following eight cycles of chemotherapy (approximately 6 months overall)

Interventionweeks (Median)
Herceptin IV + Chemotherapy6.14
Herceptin SC + Chemotherapy6.14

Tmax of Trastuzumab After Surgery

PK samples were obtained after surgery (Cycle 12). The Tmax during Cycle 12 was recorded, averaged among all participants, and expressed in days. (NCT00950300)
Timeframe: Pre-dose (0 hours) and at end of 30-minute infusion (Herceptin IV only) on Day 1 of Cycle 12; on Days 2, 4, 8, 15 of Cycle 12; pre-dose (0 hours) on Day 1 of Cycle 13 (cycle length of 21 days)

Interventiondays (Mean)
Herceptin IV + Chemotherapy0.06
Herceptin SC + Chemotherapy4.08

Number of Participants With ADAs Against Recombinant Human Hyaluronidase (rHuPH20)

"Participants in the Herceptin SC arm provided PK samples for evaluation of anti-rHuPH20 antibodies. The number of participants with Treatment-induced ADAs and Treatment-enhanced ADA against rHuPH20 (an excipient unique to the SC formulation) at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)." (NCT00950300)
Timeframe: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18

Interventionparticipants (Number)
Treatment-induced ADATreatment-enhanced ADA
Herceptin SC + Chemotherapy4913

Number of Participants With Anti-Drug Antibodies (ADAs) Against Trastuzumab

"Participants provided PK samples for evaluation of anti-trastuzumab antibodies. The number of participants with Treatment-induced ADAs and Treatment-enhanced ADA against trastuzumab at any time during or after treatment was reported. Treatment-induced ADA = a participant with negative or missing Baseline ADA result(s) and at least one positive post-Baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at Baseline who has one or more post Baseline titer results that are at least 0.60 titer unit greater than the Baseline titer result (four-fold increase of titer)." (NCT00950300)
Timeframe: Baseline; pre-dose (0 hours) on Day 1 of Cycles 2, 5, 13, 18 (cycle length of 21 days); and Months 3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60 from last dose of Cycle 18

,
Interventionparticipants (Number)
Treatment-induced ADAsTreatment-enhanced ADA
Herceptin IV + Chemotherapy282
Herceptin SC + Chemotherapy461

Median Progression-Free Survival (PFS)

Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date

Interventionsurvival time in months (Median)
1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin6.97

Median Survival

Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date

Interventionsurvival time in months (Median)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti10.51

Response Rate

The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year

Interventionpercentage of participants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti41.7

To Assess the Safety and Tolerability of the Combination of Bevacizumab, Oxaliplatin and Capecitabine in Patients With Previously Untreated Metastatic Esophagogastric Adenocarcinoma

Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days

Interventionparticipants (Number)
1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti56

Cumulative Incidence of grade3+ Bowel Perforation, Grade 3+ Bleeding (Ocurring Withing 1 Years) and grade4+ Nonhematologic Acute Adverse Events (Limited to Within 90 Days of Treatment Start)

(NCT00685763)
Timeframe: 1 year following the completion of radiation therapy

Interventionparticipants (Number)
Proton Radiation and Chemotherapy0

Number of Participants Experienced Dose Limited Toxicity

Dose related toxicity is defined as follows:1. luecopenia > grade 2; granular cell decrease > grade 2; anemia > grade 1; platelet > grade 1;SGPT/SGOT elevation > grade 1; ALP > grade 1; GGT > grade 1; Tbil > grade 1;renal function damag > grade 2;Non-gradular cell decreased fever > grade 1;nausea/vomiting > grade 1; fatigue > grade 2; weight loss > grade 2;gastritis > grade 2; dairrea > grade 2; abdominal pain > grade 2; upper gastrointestinal bleeding > grade 1;other toxic reaction > grade 2;KPS < 50 during the treatment (NCT01584544)
Timeframe: up to 7 weeks from start of the treatment

Interventionparticipants (Number)
1000mg0
1200mg1
1350mg1
1500mg0
1650mg1

Number of Participants With Intrahepatic Disease Progression After Treatment With Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment6

Number of Participants With Intrahepatic Recurrence After Partial Hepatectomy With Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.

InterventionParticipants (Count of Participants)
Treatment1

Number of Participants With Post-operative Complications After Partial Hepatectomy After Antecedent Combination Low-dose Radiotherapy and Gemcitabine-cisplatin.

Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy

InterventionParticipants (Count of Participants)
Treatment1

Overall Survival

Survival time will be defined as the time from registration to death. Time to event distributions will be estimated using the Kaplan-Meier method. Overall Survival (OS) will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab29.0
Arm B: FOLFOX or FOLFIRI + Cetuximab30.0

Progression-free Survival (PFS)

PFS will be measured from study entry until first documented progression or death from any cause. Time to event distributions will be estimated using the Kaplan-Meier method. PFS will be compared between Arm A and Arm B. (NCT00265850)
Timeframe: Up to 5 years post-treatment

Interventionmonths (Median)
Arm A: FOLFOX or FOLFIRI + Bevacizumab10.6
Arm B: FOLFOX or FOLFIRI + Cetuximab10.5

Duration of Response

"Duration of overall response was measured from the time that measurement criteria are met for complete response (CR) or partial response (PR) (whichever status was recorded first) until the onset of progression. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date).~Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV244.0
B: XELOX + BEV Followed by XELIRI + BEV315

Efficacy Duration of Disease Control by Tumor Assessment (CT/MRI/Clinical Examination)

The primary variable was duration of disease control (DDC) and was defined as the sum of progression free survival intervals during first line and second line treatment (= time from the beginning of first line treatment until onset of progression during second line treatment). Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). (NCT02119026)
Timeframe: screening, every 8 to 9 weeks until progression, at end of treatment (other than progression), every 3 months until progression, death or up to 24 months (whatever comes first)

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV373.00
B: XELOX + BEV Followed by XELIRI + BEV370.00

First Line Progression Free Survival (PFS)

The first line PFS was defined as the progression free survival interval during first line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced. If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements. (NCT02119026)
Timeframe: at progression of disease (PD) in first line therapy or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV241
B: XELOX + BEV Followed by XELIRI + BEV280

Overall Response Rate (Number of Participants With Response)

The rate of overall response was measured as the response rate from randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

InterventionParticipants (Count of Participants)
A: XELIRI + BEV Followed by XELOX + BEV32
B: XELOX + BEV Followed by XELIRI + BEV36

Overall Survival of XELIRI Plus Bevacizumab and XELOX Plus Bevacizumab

Overall survival was measured as the time from the randomization date to the date of death. Patients without death date were censored at the date of the last tumor assessment (exception: availability of validated information about a later exitus date or a prolonged survival - in such a case the date of the follow-up assessment was either defined as the exitus date or replaced the last tumor assessment date) or the date of refusal. (NCT02119026)
Timeframe: date of death or date of last tumor assessment (28d safety f-u) in patients without death

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV593.0
B: XELOX + BEV Followed by XELIRI + BEV643

Second Line PFS

"The second line PFS was defined as the progression free survival interval during second line treatment. Patients without progression at the last tumor assessment date during their study participation were censored at this last tumor assessment date (exception: availability of validated information about a later onset of progression or a longer progression free interval - in such a case the date of the follow-up assessment was either defined as the onset of progression or replaced the last tumor assessment date). Missing onset of progression data because of refusal or because of death was replaced.~If several response evaluations for a patient showed progressive disease (PD), the time to PD was assessed by using the first of these measurements." (NCT02119026)
Timeframe: at progression of disease (PD) in second line therapy or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV129
B: XELOX + BEV Followed by XELIRI + BEV155

Time to Response

Time to overall response was measured from the time of randomization until the day of documented complete response (CR) or partial response (PR) (whichever status is recorded first). Patients without response were censored at the date of the last tumor assessment, the date of death or the date of refusal. (NCT02119026)
Timeframe: at the day of documented complete or partial response or at 28 days safety follow-up in cases without PD

Interventiondays (Median)
A: XELIRI + BEV Followed by XELOX + BEV185.0
B: XELOX + BEV Followed by XELIRI + BEV178.0

Tumour Assessments (Based on RECIST Criteria) in 1st-line

Best response in first line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up

,
Interventionparticipants (Number)
Progressive Disease (PD)Stable Disease (SD)Partial Response (PR)Complete Response (CR)
A: XELIRI + BEV Followed by XELOX + BEV421262
B: XELOX + BEV Followed by XELIRI + BEV123300

Tumour Assessments (Based on RECIST Criteria) in 2nd-line

Best response in second line was based on the tumor assessments (based on RECIST criteria) for target lesions and assessed by CT scans, MRI scans, X-ray, bone scan and clinical examination: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter (sum LD) of target lesions; Progressive Disease (PD), >= 20% increase in the sum of the LD of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started. (NCT02119026)
Timeframe: Baseline, every 8-9 weeks, 28d Safety follow-up

,
Interventionparticipants (Number)
Progressive Disease (PD)Stable Disease (SD)Partial Response (PR)Complete Response (CR)Not available (NA)
A: XELIRI + BEV Followed by XELOX + BEV711608
B: XELOX + BEV Followed by XELIRI + BEV813201

Number of Participants Who Died (Part 2)

The number of participants in Part 2 who died during the study. (NCT00111761)
Timeframe: From enrollment until last contact. Maximum follow-up was 16 months.

Interventionparticipants (Number)
Panitumumab With FOLFIRI6

Number of Participants With an Objective Tumor Response (Part 2)

Objective tumor response (complete or partial) in Part 2 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI8

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 1)

The number of participants with grade 3 or grade 4 diarrhea in Part 1 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL11

Number of Participants With Grade 3 or Grade 4 Diarrhea (Part 2)

The number of participants with grade 3 or grade 4 diarrhea in Part 2 of the study. Grading of diarrhea followed the grading scale in Version 2.0 of the National Cancer Institute Common Toxicity Criteria (NCI CTC). (NCT00111761)
Timeframe: Until disease progression (median 47 weeks)

InterventionParticipants (Number)
Panitumumab With FOLFIRI6

Number of Participants With Objective Tumor Response (Part 1)

Objective tumor response (complete or partial) in Part 1 of the study, based on Response Evaluation Criteria in Solid Tumors (RECIST), where complete response = disappearance of all target lesions, partial response = ≥30% reduction in lesion size, progressive disease = ≥20% increase in tumor size; otherwise stable disease. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionParticipants (Number)
Panitumumab With IFL9

Progression-free Survival Time (Part 1)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 1 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL24.3

Progression-free Survival Time (Part 2)

Kaplan-Meier estimate of median time from enrollment to death or disease progression in Part 2 of the study. Participants who had not progressed and had not died were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI41.1

Survival Time (Part 1)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

Survival Time (Part 2)

Kaplan-Meier estimate of the median time from enrollment to death from any cause. Participants who did not die on study were censored at their last contact date. (NCT00111761)
Timeframe: From enrollment until death. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With IFL73.1

Time to Disease Progression (Part 1)

Kaplan-Meier estimate of the median time from the first dose of study drug to disease progression or death if due to disease progression (whichever comes first) in Part 1 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until disease progression or death. Maximum follow-up time was 25 months.

Interventionweeks (Median)
Panitumumab With IFL35.0

Time to Disease Progression (Part 2)

Kaplan-Meier estimate of median time from the first dose of study drug to first observed disease progression or death if the death was due to disease progression (whichever comes first) in Part 2 of the study. Participants who had not progressed or died for reasons other than disease progression were censored at their last disease assessment date. (NCT00111761)
Timeframe: From enrollment until death or diease progression. Maximum follow-up time was 16 months.

Interventionweeks (Median)
Panitumumab With FOLFIRI47.3

Time to Initial Objective Tumor Response (Part 1)

Median time to first observed objective tumor response (complete or partial) among responders in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

Interventionweeks (Median)
Panitumumab With IFL5.9

Time to Treatment Failure (Part 1)

Kaplan-Meier estimate of the median time from the date of first dose of panitumumab or chemotherapy to the date the decision was made to end treatment for any reason in Part 1 of the study. (NCT00111761)
Timeframe: Until disease progression (median 35 weeks) or 48 weeks, whichever occurred first

InterventionWeeks (Median)
Panitumumab With IFL24.3

Overall Survival

(NCT00375999)
Timeframe: One year

Interventionmonth (Median)
Treatment Group13.4

Number of Participants With K-ras Gene Mutation

DNA was extracted from tumor specimens.Screened for the presence of KRAS codon 12 and 13 mutations using a PCR clamping and melting curve technique. PCR amplification of the wild-type KRAS sequence was suppressed in this process by the incorporation in the reaction mix of a locked nucleic-acid oligomer16 spanning codons 12 and 13 of the KRAS gene. Post-PCR hybridization and melting curve analysis using fluorescently tagged oligonucleotides incorporated in the original PCR reaction permitted the identification and discrimination of distinct KRAS codon 12 and 13 missense mutations. (NCT00815308)
Timeframe: 07/29/2010-09/30/2010

Interventionparticipants (Number)
Cetuximab, Concurrent Chemo-radiotherapy53

Number of Participants With Overall Response Rate (RR)

The overall response rate was defined as the numbers of patients with a complete response (CR) or partial response (PR). CR was defined as no target lesion at follow-up computed tomography scan and barium swallow examination 3-6 weeks after completion of chemo-radiation. PR was defined at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. (NCT00815308)
Timeframe: 1 to 3 month after therapy

Interventionparticipants (Number)
Cetuximab, Concurrent Chemo-radiotherapy44

Number of Participants With Toxicity

All patients were regularly monitored for possible adverse events, which were graded according to National Cancer Institute Common Toxicity Criteria version 3.0. (NCT00815308)
Timeframe: Every week during treatment and 1 month after therapy

Interventionparticipants (Number)
Cetuximab, Concurrent Chemo-radiotherapy55

Number of Participants With Medical Toxicities

The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting. All detailed information regarding serious and other adverse events are listed in the Adverse Event module of these results. (NCT00603408)
Timeframe: 30 days post surgery (week 17-18)

Interventionparticipants (Number)
Cisplatin + Radiation + Recommended Surgery5

Number of Participants With Surgical Complications

(NCT00603408)
Timeframe: 30 days post surgery (week 17-18)

Interventionparticipants (Number)
Cisplatin + Radiation + Recommended Surgery0

Overall Survival Rate (OS)

OS = Time from registration until death from any cause (NCT00603408)
Timeframe: Until study was terminated (23.5 months)

Interventionpercentage of participants (Number)
Cisplatin + Radiation + Recommended Surgery100

Overall Response

"Complete response: disappearance of all target lesions, non-target lesions, and normalization of tumor marker level~Partial response: at least a 30% decrease in the sum of the longest diameter (LD) of the target lesions taking as reference the baseline sum LD~Stable disease: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as references the smallest sum LD since the treatment started,~Progressive disease: at least a 20% increase in the sum of the LD of the target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions, appearance of one more new lesions, or unequivocal progression of existing non-target lesions." (NCT00603408)
Timeframe: At the time of surgery (week 13)

Interventionparticipants (Number)
Complete responsePartial responseStable diseaseProgressive disease
Cisplatin + Radiation + Recommended Surgery2300

Number of Participants With an Adverse Event

Here is the number of participants with an adverse event. For a detailed list of adverse events see the adverse event module. (NCT00052962)
Timeframe: 2003-2008

InterventionParticipants (Number)
Arm 1 Surgery + Post op Chemotherapy7
Arm 2 Surgery + CHPP6

Local Failure

Local failure will be assessed radiographically using endoscopy with biopsy, CT scan, and a positron emission computed tomography-CT scan. which was defined as persistence /recurrence of the tumor in the radiation therapy field. (NCT03082586)
Timeframe: 15 months

InterventionParticipants (Count of Participants)
Arm 1: Radiochemotherapy 10
Arm 2: Radiochemotherapy 21
Arm 3: Radiochemotherapy 31
Arm 4: Radiochemotherapy 40
Arm 5: Radiochemotherapy 50
Arm 6: Radiochemotherapy 60

Number of Dose Limiting Toxicities (DLTs) Occurring in Participants

The DLTs were defined as grade >/=4 esophatitis, any other grade >/=3 nonhematological toxicity (except nausea and vomiting), or grade >/=4 hematological toxicity lasting more than 7 days, which are possibly, probably, or definitely associated with protocol treatment occurring during and after completion of the HFRT boost treatment. (NCT03082586)
Timeframe: 15 months

Interventiondose limiting toxicity (Number)
Arm 1: Radiochemotherapy 10
Arm 2: Radiochemotherapy 20
Arm 3:Radiochemotherapy 30
Arm 4: Radiochemotherapy 41
Arm 5: Radiochemotherapy 50
Arm 6: Radiochemotherapy 62

Number of Participants With Serious and Non-Serious Adverse Events

Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.

InterventionParticipants (Count of Participants)
1/Intravenous (IV) Tetrahydrouridine (THU)2

Frequency and Severity of Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0

[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions

Interventionadverse events (Number)
Day 1 Adverse EventsDay 2, Grade 2 HypoalbuminemiaDay 2, Grade 3 AnemiaDay 3 Adverse EventsDay 4 Adverse EventsDay 5 Adverse Events
1/Intravenous (IV) Tetrahydrouridine (THU)011000

Radiation Dosimetry Estimates of 5-fluoro-2'-Deoxycytidine (FdCyd) in Humans

Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year

InterventionmSv/MBq (Mean)
AdrenalsBrainBreastsGallbladder wallLower large intestine wallSmall intestineStomach wallUpper large intestine wallHeart wallKidneysLiverLungsMuscleOvariesPancreasRed marrowOsteogenic cellsSkinSpleenTestesThymusThyroidUrinary bladder wallUterus
1/Intravenous (IV) Tetrahydrouridine (THU)1.838.171.034.052.522.131.902.041.105.266.021.821.161.571.631.141.718.651.691.031.128.237.961.63

Tumor to Background Ratios (TBRs) of Target Lesions at 4 Time Points After Injection

Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection

InterventionTBR ratio (Number)
Pt 1 L. Parotid adenosquam. cell ca at 9 minPt 1 L. Parotid adenosquam. cell ca at 32 minPt 1 L. Parotid adenosquam. cell ca at 56 minPt 1 L. Parotid adenosquam. cell ca at 2 hrsPt 2 R. Parapharyngeal Spindle Cell Ca at 9 minPt 2 R. Parapharyngeal Spindle Cell Ca at 32 minPt 2 R. Parapharyngeal Spindle Cell Ca at 56 minPt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrsPt 3 Non-small Cell Lung Ca at 9 minPt 3 Non-small Cell Lung Ca at 32 minPt 3 Non-small Cell Lung Ca at 56 minPt 3 Non-small Cell Lung Ca at 2 hrsPt 4 Non-small Cell Lung Ca at 9 minPt 4 Non-small Cell Lung Ca at 32 minPt 4 Non-small Cell Lung Ca at 56 minPt 4 Non-small Cell Lung Ca at 2 hrsPt 5 Hepatocellular Ca at 9 minPt 5 Hepatocellular Ca at 32 minPt 5 Hepatocellular Ca at 56 minPt 5 Hepatocellular Ca at 2 hrs
1/Intravenous (IV) Tetrahydrouridine (THU)1.41.51.51.61.91.71.71.61.41.41.51.72.42.11.62.0NANANANA

Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)

Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02311361)
Timeframe: Date treatment consent signed to date off study, approximately 18 months and 4 days for Cohort 1/Dose Level A1, 23 months and 29 days for Cohort 2/Dose Level A2, 32 months and 19 days for Cohort C/Dose Level C1, and 44 months and 18 days for Cohort C/Dose

InterventionParticipants (Count of Participants)
Durvalumab + 8 Gray (Gy) in 1 Fraction14
Durvalumab +5 Gy in 5 Fractions10
Durvalumab +Tremelimumab + 8 Gy in 1 Fraction19
Durvalumab +Tremelimumab +5 Gy in 5 Fractions20

Overall Survival

Amount of time participants survived after therapy. (NCT02311361)
Timeframe: From study entry to death or date of last contact, whichever occurs first, up to 2 years of follow-up

InterventionMonths (Median)
Cohort A Dose Level A13.3
Cohort A Dose Level A29.0
Cohort C Dose Level C12.1
Cohort C Dose Level C24.2

Percentage of Participants With 6-month Overall Survival

Participants who survived at least 6 months after therapy. (NCT02311361)
Timeframe: 6 month

Interventionpercentage of participants (Number)
Cohort A Dose Level A126
Cohort A Dose Level A258
Cohort C Dose Level C112
Cohort C Dose Level C240

Progression Free Survival (PFS)

PFS is the defined as the median amount of time subject survives without disease progression after treatment. Progression is assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions). NOTE: While RECIST Progressive Disease (PD) will be noted and recorded the immune-related (IR) RECIST criteria will be applied to determine discontinuation of study treatment. For modified Immune-Related Response Criteria (irRC), only target and measurable lesions are taken into account. (NCT02311361)
Timeframe: From study entry to disease progression, death or date of last contact, whichever occurs first, an average of 6 months

InterventionMonths (Median)
Cohort A Dose Level A11.7
Cohort A Dose Level A22.5
Cohort C Dose Level C10.9
Cohort C Dose Level C22.3

Number of Adverse Events in Each Cohort With Grade 1 Through 5 Related to Study Drug

Adverse Events (AEs) are reported by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Grade 1=Mild, Grade 2= Moderate, Grade 3 = Severe, Grade 4 = Life-threatening, and Grade 5 = Fatal. (NCT02311361)
Timeframe: Participants were assessed from the start of study treatment at Cycle 1 then after every cycle (1 cycle = 28 days) of protocol treatment until 30 days after they were taken off treatment, approximately 4.0 months.

,,,
InterventionAdverse events (Number)
Grade 1 Abdominal painGrade 1 Alanine aminotransferase increasedGrade 1 Alkaline Phosphatase increasedGrade 1 AnemiaGrade 1 AnorexiaGrade 1 Atrial fibrillationGrade 1 Aspartate aminotransferase increasedGrade 1 Back painGrade 1 Blood bilirubin increasedGrade 1 CoughGrade 1 Creatinine increasedGrade 1 DiarrheaGrade 1 DizzinessGrade 1 Dry mouthGrade 1 DysgeusiaGrade 1 Endocrine disorders,Other, Elevated T3, T4Grade 1 Eye disorders - decr. in near vision,bilatGrade 1 - FatigueGrade 1 FeverGrade 1 HeadacheGrade 1 Hemorrhoidal hemorrhageGrade 1 HoarsenessGrade 1 HyperglycemiaGrade 1 - HyperkalemiaGrade 1 HyperuricemiaGrade 1 HypoalbuminemiaGrade 1 HypocalcemiaGrade 1 - HyponatremiaGrade 1 HypothyroidismGrade 1 Infusion related reactionGrade 1 Lymphocyte count decreasedGrade 1 MucositisGrade 1 Musculoskeletal & connective tissueGrade 1 NauseaGrade 1 Neutrophil count decreasedGrade 1 PainGrade 1 Platelet count decreasedGrade 1 PruritisGrade 1 Rash maculo-papularGrade 1 Serum amylase increasedGrade 1 - Skin/subc tissue disorder - Night sweatsGrade 1 Skin/subc tissue disorder - RashGrade 1 Skin/subc tissue - PsoriasisGrade 1 Skin/subc tissue disorder - ItchingGrade 1 Skin/subc tissue disorder-Skinpeeling handGrade 1 VertigoGrade 1 VomitingGrade 1 Weight lossGrade 1 White blood cell decreasedGrade 2 Abdominal painGrade 2 AnemiaGrade 2 AnorexiaGrade 2 Autoimmune disorderGrade 2 DiarrheaGrade 2 DysgeusiaGrade 2 Endocrine disorders - TSH elev-HypothyroidGrade 2 FatigueGrade 2 Fecal incontinenceGrade 2 FeverGrade 2 Gastroesophageal reflux diseaseGrade 2 HyperglycemiaGrade 2 HypoalbuminemiaGrade 2 HypothyroidismGrade 2 HypophosphatemiaGrade 2 Infusion related reactionGrade 2 Lymphocyte count decreasedGrade 2 MalaiseGrade 2 NauseaGrade 2 Neutrophil count decreasedGrade 2 Platelet count decreasedGrade 2 Rash maculo-papularGrade 2 Weight lossGrade 2 White blood cell countGrade 3 AnemiaGrade 3 AnorexiaGrade 3 ColitisGrade 3 DehydrationGrade 3 DiarrheaGrade 3 FatigueGrade 3 HyperthyroidismGrade 3 Lymphocyte count decreasedGrade 3 NauseaGrade 3 Serum amylase increasedGrade 3 VomitingGrade 4 Lymphocyte count decreased
Cohort A Dose Level A101031010000001000110100000020015000002100000000001030000000000001070000000000000030000
Cohort A Dose Level A2002300000001000012120000000000200310001100011010040100100010100000190000002000000070000
Cohort C Dose Level C1000900101001001100100120000300170030072101101101010900201200010101150021001200001060102
Cohort C Dose Level C2152931611117100007100001151412261021113323100000417110214105010010003023121203123311182022

Tumor Response Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Measured by Computed Tomography (CT) and Magnetic Resonance Imaging (MRI)

Progressive disease (PD): >=20% increase in sum of longest diameter (LD) of target lesion(s), taking as reference smallest sum LD recorded since treatment started. Complete response (CR): disappearance of all target lesions. Partial response (PR): >=30% decrease in sum of LD of target lesion(s), taking as reference baseline sum LD. Stable disease (SD): neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD. (NCT02311361)
Timeframe: At screening then every 8 weeks until disease progression or patient is taken off the trial, whichever comes first, approximately 6 months.

,,,
InterventionParticipants (Count of Participants)
Complete ResponsePartial ResponseStable DiseaseProgressive Disease
Cohort A Dose Level A10134
Cohort A Dose Level A20044
Cohort C Dose Level C10026
Cohort C Dose Level C201510

Reviews

283 reviews available for fluorouracil and Adenocarcinoma, Basal Cell

ArticleYear
Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature.
    Chinese clinical oncology, 2022, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Fluorouracil

2022
Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis.
    Cancer treatment reviews, 2022, Volume: 104

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Cytoreduction Surgical Pro

2022
MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer.
    Future oncology (London, England), 2022, Volume: 18, Issue:20

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Tri

2022
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
    European journal of medical research, 2022, Nov-09, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Chemotherapy, Adjuvan

2022
Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
    Cancer treatment reviews, 2023, Volume: 113

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro

2023
Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm.
    Oncology, 2023, Volume: 101, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso

2023
A phase II study of neoadjuvant liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in pancreatic adenocarcinoma.
    Future oncology (London, England), 2023, Volume: 19, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2023
Missed Gastric Cancer Metastasis to the Appendix: Case Report and Literature Review.
    The American journal of case reports, 2020, Jan-05, Volume: 21

    Topics: Adenocarcinoma; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Appendiceal

2020
Chemotherapy for patients with unresectable or metastatic small bowel adenocarcinoma: a systematic review.
    International journal of clinical oncology, 2020, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil;

2020
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Drugs, 2020, Volume: 80, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; DNA Topoisomerases, Type I; Fluorouracil; Humans; Irinotecan;

2020
Primary colon adenocarcinoma with choriocarcinoma differentiation: a case report and review of the literature.
    Journal of medical case reports, 2020, Nov-16, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Choriocarcinoma; Colon; Femal

2020
Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:6

    Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Antineoplastic Combined Chemotherapy Proto

2021
HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.
    Current treatment options in oncology, 2021, 08-23, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C

2021
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma.
    Drugs, 2017, Volume: 77, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; Fluorou

2017
The role of chemotherapy in unresectable or metastatic adenocarcinoma of the stomach and gastroesophageal junction.
    Minerva chirurgica, 2017, Volume: 72, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop

2017
Best practices for the treatment of metastatic pancreatic adenocarcinoma: the therapeutic landscape in 2017.
    Chinese clinical oncology, 2017, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil

2017
A network meta-analysis of the short-term efficacy of five chemotherapy regimens based on cisplatin and fluorouracil for esophagogastric junctional adenocarcinoma.
    Experimental & molecular medicine, 2017, 09-29, Volume: 49, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Disease

2017
Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials.
    JAMA oncology, 2018, Mar-01, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brai

2018
Adenocarcinoma located at a Meckel's Diverticulum: A case report and literature review.
    Journal of cancer research and therapeutics, 2017, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colonoscopy; Fema

2017
Gastroesophageal Cancer During Pregnancy: a Case Report and Review of the Literature.
    Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoradiotherapy; Do

2019
Meta-analysis of Modified FOLFIRINOX Regimens for Patients With Metastatic Pancreatic Cancer.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum

2018
Pancreaticoduodenectomy with Replaced Common Hepatic Artery and Portal Vein Reconstruction in Primary Carcinoma Duodenum: a Case Report and Literature Review.
    Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Aged; Angioplasty; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2019
Metastatic pancreatic ductal adenocarcinoma: diagnosis and treatment with a view to the future.
    Internal medicine journal, 2018, Volume: 48, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Drug C

2018
Irreversible Electroporation in pancreatic ductal adenocarcinoma: Is there a role in conjunction with conventional treatment?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Electroporation;

2018
Non-α-fetoprotein-producing adrenal hepatoid adenocarcinoma: A case report and literature review.
    Medicine, 2018, Volume: 97, Issue:39

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenal Glands; alpha-Fetoproteins; Antineoplastic Combined

2018
Metastatic Urachus Neoplasia: A Case Report and Review of the Current Literature.
    Clinical genitourinary cancer, 2019, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cystectomy; Fatal Outcome; Fl

2019
Neoadjuvant Treatment for Pancreatic Cancer.
    Seminars in oncology, 2019, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Duct

2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis.
    Journal of the National Cancer Institute, 2019, 08-01, Volume: 111, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and

2019
Long-term survival of an elderly patient with advanced gastric cancer after combination therapy: a case report and literature review.
    BMC cancer, 2019, May-16, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Protocols; Combined Modality Therapy; Cr

2019
Role of Nuclear Factor Erythroid 2-Related Factor 2 (NRF-2) Mediated Antioxidant Response on the Synergistic Antitumor Effect of L-Arginine and 5-Fluro Uracil (5FU) in Breast Adenocarcinoma.
    Current pharmaceutical design, 2019, Volume: 25, Issue:14

    Topics: Adenocarcinoma; Animals; Antioxidants; Arginine; Breast Neoplasms; Fluorouracil; Humans; NF-E2-Relat

2019
Small intestinal adenocarcinoma: rarely considered, often missed?
    Postgraduate medical journal, 2013, Volume: 89, Issue:1050

    Topics: Adenocarcinoma; Aged; Capsule Endoscopy; Celiac Disease; Chemotherapy, Adjuvant; Cystic Fibrosis; Do

2013
Locally advanced pancreatic cancer.
    JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase

2013
First-line treatment for advanced pancreatic cancer.
    JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Tri

2013
Second-line therapy in pancreatic cancer.
    JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2013
Adenocarcinoma of the colon in children: case series and mini-review of the literature.
    Hematology/oncology and stem cell therapy, 2013, Volume: 6, Issue:1

    Topics: Abdomen; Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Barium Sulfate;

2013
Which is false: oxaliplatin or fluoropyrimidine? An analysis of patients with KRAS wild-type metastatic colorectal cancer treated with first-line epidermal growth factor receptor monoclonal antibody.
    Cancer science, 2013, Volume: 104, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2013
Capecitabine induces both cardiomyopathy and multifocal cerebral leukoencephalopathy.
    International heart journal, 2013, Volume: 54, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cardiomyopathies; Colorectal Neoplasm

2013
[A case of early colorectal cancer with synchronous multiple liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2013
Systemic treatment for inoperable pancreatic adenocarcinoma: review and update.
    Chinese journal of cancer, 2014, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin

2014
Polychemotherapy or gemcitabine in advanced pancreatic cancer: a meta-analysis.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Tri

2014
Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
    World journal of gastroenterology, 2014, Apr-14, Volume: 20, Issue:14

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cisplatin; Clinical Trials

2014
Disseminated intravascular coagulation as clinical manifestation of colorectal cancer: a case report and review of the literature.
    The Netherlands journal of medicine, 2014, Volume: 72, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De

2014
[Penile metastasis from rectal carcinoma: a case report and literature review].
    Zhonghua nan ke xue = National journal of andrology, 2014, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura

2014
Adenocarcinoma of the ampulla of Vater: what treatment options are available?
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2015, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2015
Role of solute carrier transporters in pancreatic cancer: a review.
    Pharmacogenomics, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Deoxycytidine; Drug Resistance, Neoplasm; Fluorouracil; Gemcitabine; Humans; Membran

2014
[Disappearance of a gastric lesion following modified FOLFOX6 chemotherapy in a patient with metastatic colorectal cancer: a case report and literature review].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Ma

2014
Review on adjuvant chemotherapy for rectal cancer - why do treatment guidelines differ so much?
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Chemotherapy, Adjuvant; Disease-

2015
[Molecular pathology of colorectal cancer].
    Der Pathologe, 2015, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Algorithms; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Colorectal

2015
Dark Agouti rat model of chemotherapy-induced mucositis: establishment and current state of the art.
    Experimental biology and medicine (Maywood, N.J.), 2015, Volume: 240, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluor

2015
Second-Line Therapy for Endometrial Cancer: The Need for Better Options.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-01, Volume: 33, Issue:31

    Topics: Adenocarcinoma; Amines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials

2015
Systematic review and network meta-analysis: neoadjuvant chemoradiotherapy for locoregional esophageal cancer.
    Japanese journal of clinical oncology, 2015, Volume: 45, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio

2015
Resection of a Submucosal Tumor-Like Superficial Carcinoma in Middle Thoracic Esophagus Concomitant with Mucosal Adenocarcinoma and Submucosal Squamous Cell Carcinoma: A Case Report and Review of Literature.
    The Tokai journal of experimental and clinical medicine, 2015, Sep-20, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2015
[A CASE OF SOLITARY ADRENAL TUMOR METASTASIZED FROM RECTAL CANCER].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2015, Volume: 106, Issue:3

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antineoplastic Combined Chemotherapy P

2015
[A Case of Pathologically Complete Response of a Rectal Cancer after Preoperative Treatment with mFOLFOX6 and Radiation Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura

2015
[A Case of Sigmoid Colon Cancer with Metastasis to the Uterus].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2015
[A Case of Descending Colon Adenocarcinoma with Neuroendocrine Differentiation Successfully Treated with FOLFIRI plus Bevacizumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Camptothe

2016
Borderline resectable pancreatic cancer.
    Cancer letters, 2016, Jun-01, Volume: 375, Issue:2

    Topics: Adenocarcinoma; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Therapy; Pancreatect

2016
Adjuvant and Neoadjuvant Therapy for Pancreatic Cancer.
    Surgical oncology clinics of North America, 2016, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Clinical

2016
Nanoliposomal irinotecan plus fluorouracil and folinic acid: a new treatment option in metastatic pancreatic cancer.
    Expert review of anticancer therapy, 2016, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pa

2016
Development of nanoliposomal irinotecan (nal-IRI, MM-398, PEP02) in the management of metastatic pancreatic cancer.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-Free Survival;

2016
Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
    Discovery medicine, 2016, Volume: 21, Issue:117

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, T

2016
Small bowel adenocarcinoma of the jejunum: a case report and literature review.
    World journal of surgical oncology, 2016, Jul-04, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Delay

2016
Unresectable liver metastases in colorectal cancer: review of current strategies.
    Minerva chirurgica, 2016, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2016
Dilemma of first line regimens in metastatic pancreatic adenocarcinoma.
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin

2016
FOLFOX-4 regimen with concomitant highly active antiretroviral therapy in metastatic colorectal cancer HIV-infected patients: a report of five cases and review of the literature.
    Cancer investigation, 2008, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highl

2008
Capecitabine-induced oromandibular dystonia: a case report and literature review.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Asian People; Brain Stem; Capecitabine; Deoxycytidi

2008
[A case of alpha-fetoprotein-producing gastric cancer with hepatic metastasis successfully treated with combination chemotherapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:10

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2008
An update on biochemotherapy of advanced gastric and gastroesophageal adenocarcinoma.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2008, Volume: 6, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ca

2008
[Modified FOLFOX6 was effective for advanced adenocarcinoma with unknown origin in a patient with Crohn's disease].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Crohn Disease; Fluorouracil; Humans;

2009
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2009
The addition of bevacizumab to fluoropyrimidine, irinotecan and oxaliplatin-based therapy improves survival for patients with metastatic colorectal cancer (CRC): combined analysis of efficacy.
    Acta chirurgica Iugoslavica, 2008, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2008
Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-10, Volume: 27, Issue:17

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri

2009
The European contribution to "Sugarbaker's protocol" for the treatment of colorectal peritoneal carcinomatosis.
    Revista espanola de enfermedades digestivas, 2009, Volume: 101, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2009
Chemotherapy for colorectal cancer in the elderly: Whom to treat and what to use.
    Cancer treatment reviews, 2009, Volume: 35, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2009
The spectrum of 5-fluorouracil cardiotoxicity.
    Anti-cancer drugs, 2009, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arr

2009
Small bowel adenocarcinoma.
    Current treatment options in oncology, 2008, Volume: 9, Issue:4-6

    Topics: Adenocarcinoma; Age of Onset; Animals; Antimetabolites, Antineoplastic; Disease Models, Animal; Fema

2008
[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2008, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adju

2008
Medical management of pancreatic adenocarcinoma.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2009, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Agents; Black People; Capecitabine; Deoxycytidine; Diabe

2009
Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant

2010
Review of adjuvant radiochemotherapy for resected pancreatic cancer and results from Mayo Clinic for the 5th JUCTS symposium.
    International journal of radiation oncology, biology, physics, 2009, Oct-01, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Chemoth

2009
[Therapy in gastric cancer. From an oncological perspective].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2009, Volume: 80, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2009
Diagnosis and management of pancreatic cancer.
    Minerva gastroenterologica e dietologica, 2009, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Chemotherapy, Adjuvant; Cholangiog

2009
[Neoadjuvant chemotherapy and pancreatoduodenectomy for locally advanced colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Flu

2009
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2010
Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature.
    International journal of clinical oncology, 2010, Volume: 15, Issue:4

    Topics: Acidosis, Renal Tubular; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
Palliative chemotherapy for pancreatic malignancies.
    The Surgical clinics of North America, 2010, Volume: 90, Issue:2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2010
Evolving pharmacotherapeutic strategies for small bowel adenocarcinoma.
    Expert opinion on pharmacotherapy, 2010, Volume: 11, Issue:10

    Topics: Adenocarcinoma; Camptothecin; Clinical Trials as Topic; Fluorouracil; Humans; Intestinal Neoplasms;

2010
[A case of poorly differentiated adenocarcinoma of the rectum with disseminated carcinomatosis of the bone marrow successfully treated with mFOLFOX-6/bevacizumab].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2010, Volume: 107, Issue:7

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2010
[Recent developments of pharmacogenomics in the treatment of colorectal cancers].
    Annales pharmaceutiques francaises, 2010, Volume: 68, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Biotr

2010
Toxic encephalopathy in elderly patients during treatment with capecitabine: literature review and a case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2011, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Cap

2011
[Histologic assessment of treatment effect of preoperative chemoradiation in patients presenting with resectable pancreatic adenocarcinoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2011, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2011
[A case of long-term survival after resection for postoperative solitary adrenal metastasis from esophageal adenocarcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Aged; Antimetabolites, Antineoplastic; Antin

2010
Metastatic pancreatic cancer: old drugs, new paradigms.
    Current opinion in oncology, 2011, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic

2011
[Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
    Annales de dermatologie et de venereologie, 2011, Volume: 138, Issue:5

    Topics: Adenocarcinoma; Aged; Antibodies, Antinuclear; Antibodies, Monoclonal; Antibodies, Monoclonal, Human

2011
Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Health technology assessment (Winchester, England), 2011, Volume: 15 Suppl 1

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Capecitabine; Cisplatin; C

2011
A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.
    Future oncology (London, England), 2011, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap

2011
[A case of effective neoadjuvant chemoradiotherapy with capecitabine for locally advanced sigmoid colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Capecitabine; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Humans; Male;

2011
[Preoperative radiochemotherapy for rectal cancer: forecasting the next steps through ongoing and forthcoming studies].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2011, Volume: 15, Issue:6-7

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop

2011
[Chemotherapy and rectal cancer].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2011, Volume: 15, Issue:6-7

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop

2011
[Is there alternative to FOLFOX adjuvant chemotherapy for stage III colorectal cancer patients?].
    Presse medicale (Paris, France : 1983), 2012, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Choice Behav

2012
Inoperable pancreatic adenocarcinoma rendered complete remission by high-intensity focused ultrasound concurrent with gemcitabine-capecitabine chemotherapy: case report and topic review.
    Journal of digestive diseases, 2012, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cap

2012
Neoadjuvant chemoradiation therapy is beneficial for clinical stage T2 N0 esophageal cancer patients due to inaccurate preoperative staging.
    The Annals of thoracic surgery, 2012, Volume: 93, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dia

2012
Oxaliplatin-induced hepatocellular injury and ototoxicity: a review of the literature and report of unusual side effects of a commonly used chemotherapeutic agent.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2012, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer.
    The British journal of surgery, 2012, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Chemotherapeutic strategies in advanced or metastatic pancreatic adenocarcinoma.
    American journal of clinical oncology, 2014, Volume: 37, Issue:2

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2014
New biomarkers and targets in pancreatic cancer and their application to treatment.
    Nature reviews. Gastroenterology & hepatology, 2012, Volume: 9, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma in Situ; Carcinoma, Pan

2012
Addisonian crisis secondary to bilateral adrenal metastases in rectal carcinoma: report of a rare case and literature review.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2

    Topics: Addison Disease; Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Capecitab

2013
Management of diabetes and pancreatic cancer.
    Oncology nursing forum, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2012
Oxaliplatin-induced thrombotic thrombocytopenic purpura: case report and literature review.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-01, Volume: 30, Issue:31

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2012
Multiorgan failure in a patient treated with the 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan regimen.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Duodenal Neoplasms; Fe

2013
New developments in pancreatic cancer treatment.
    Minerva gastroenterologica e dietologica, 2012, Volume: 58, Issue:4

    Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Du

2012
Histological complete response after neoadjuvant XELOX in advanced gastric carcinoma.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:123

    Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Biopsy

2013
The role of the FOLFIRINOX regimen for advanced pancreatic cancer.
    Current oncology reports, 2013, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top

2013
Combined-modality therapy for rectal cancer using irinotecan.
    Oncology (Williston Park, N.Y.), 2002, Volume: 16, Issue:5 Suppl 5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials as Top

2002
[Primary adenocarcinoma of the appendix. Case report and review of the literature].
    Minerva chirurgica, 2002, Volume: 57, Issue:5

    Topics: Adenocarcinoma; Adult; Appendectomy; Appendiceal Neoplasms; Appendicitis; Cecal Neoplasms; Chemother

2002
[Gemcitabine and pancreatic cancer].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Adenocarcinoma; Analgesia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro

2002
[Gemcitabine-based combinations in inoperable pancreatic cancers].
    Bulletin du cancer, 2002, Volume: 89 Spec No

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati

2002
Heterotopic ossification in rectal cancer: Rare finding with a novel proposed mechanism.
    Journal of surgical oncology, 2003, Volume: 82, Issue:2

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Bone Morphogenetic Protein 2; Bone Morphogen

2003
Past and present treatment of pancreatic adenocarcinoma: chemotherapy as a standard treatment modality.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 20

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabin

2002
Outpatient weekly neoadjuvant chemotherapy followed by radiotherapy for advanced nasopharyngeal carcinoma: high complete response and low toxicity rates.
    British journal of cancer, 2003, Jan-27, Volume: 88, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2003
Developments in the systemic therapy of pancreatic cancer.
    Cancer investigation, 2003, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2003
Ten-year outcome after combined modality therapy for inflammatory breast cancer.
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci

2003
Older patients with colon cancer: is adjuvant chemotherapy safe and effective?
    Journal of the American Geriatrics Society, 2003, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Female; Fluorouracil; Humans; Leuco

2003
Adjuvant therapy for pancreatic adenocarcinoma: what have we learned since 1985?
    International journal of radiation oncology, biology, physics, 2003, Volume: 56, Issue:4 Suppl

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical T

2003
Sigmoidoduodenal fistula as a rare complication of colonic carcinoma: report of a case.
    Surgery today, 2003, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colonic Neoplasms; Duodenal Diseases; Fluorouracil; Hu

2003
[Chemoradiation in pancreatic carcinoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2003, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M

2003
Pancreatic cancer.
    Clinical evidence, 2003, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil

2003
New perspectives in the management of pancreas cancer.
    Seminars in oncology, 2003, Volume: 30, Issue:4 Suppl 11

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2003
Focus on gastric cancer.
    Cancer cell, 2004, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cadheri

2004
The development and application of functional nuclear magnetic resonance to in vivo therapeutic anticancer research: 2002 Sir Godfrey Hounsfield lecture delivered at the President's Day, Manchester.
    The British journal of radiology, 2004, Volume: 77, Issue:916

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biliary Tract; Biomarkers; Fluorouracil; Forecastin

2004
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplat

2004
Factors affecting postoperative course and survival after en bloc resection for esophageal carcinoma.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2004
Neoadjuvant treatment of oesophageal adenocarcinoma.
    Minerva chirurgica, 2004, Volume: 59, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2004
[Chemoradiation for pancreatic adenocarcinoma].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2004, Volume: 8 Suppl 1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2004
Colonic rupture in a patient on combination chemotherapy for metastasized carcinoma of the esophagogastric junction. Case report and review of the literature.
    Onkologie, 2005, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Diseases; Cisplatin; Colonic D

2005
[Clinical role of interleukin-2 in the surgical treatment of liver metastasis due to colon adenocarcinoma].
    Minerva chirurgica, 2004, Volume: 59, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Combined

2004
Role of post-operative chemoradiation in resected gastric cancer.
    Journal of surgical oncology, 2005, Jun-01, Volume: 90, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura

2005
The treatment of colorectal carcinoma: standard chemotherapy and beyond.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:9

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2004
Systemic therapy for pancreatic cancer.
    Seminars in radiation oncology, 2005, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2005
[Molecular biology in clinical cancer research: the example of digestive cancers].
    Revue d'epidemiologie et de sante publique, 2005, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Alleles; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agen

2005
Role of adjuvant therapy in the management of pancreatic cancer.
    Advances in surgery, 2005, Volume: 39

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Can

2005
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2006
Radiation and chemoradiation therapy for esophageal adenocarcinoma.
    Journal of surgical oncology, 2005, Dec-01, Volume: 92, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2005
[Management of rectal cancer in pregnant women].
    Bulletin du cancer, 2005, Volume: 92, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Case Management; Cesarean Section; Chemotherapy, Adjuv

2005
The role of bevacizumab as first-line therapy for colon cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2005
Adjuvant therapy of resected gastric cancer is necessary.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil

2005
Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe?
    Cancer investigation, 2006, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Col

2006
Target practice: figuring out which, when, and why to use systemic therapies for metastatic colon cancer.
    Cancer investigation, 2006, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; DNA; DNA Topoiso

2006
Current state of adjuvant therapy in resected pancreatic adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Modality

2006
Major combined electrolyte deficiency during therapy with low-dose cisplatin, 5-fluorouracil and interferon alpha: report on several cases and review of the literature [ISRCTN62866759].
    BMC cancer, 2006, May-10, Volume: 6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcium; Cisplatin; Combined Modalit

2006
Capecitabine in carcinoma of the pancreas.
    Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:12

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2006
Paraneoplastic neurological syndromes and breast cancer. Regression of paraneoplastic neurological sensorimotor neuropathy in a patient with metastatic breast cancer treated with capecitabine: a case study and mini-review of the literature.
    Breast cancer research and treatment, 2007, Volume: 105, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxycytidine

2007
Molecular markers for gastric adenocarcinoma: an update.
    Molecular diagnosis & therapy, 2006, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2006
Urachal carcinoma: surgical and chemotherapeutic options.
    Expert review of anticancer therapy, 2006, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cispla

2006
[Complications of surgical resection of esophageal cancer].
    Cirugia espanola, 2006, Volume: 80, Issue:6

    Topics: Adenocarcinoma; Age Factors; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Endosc

2006
The case for routine use of adjuvant therapy in pancreatic cancer.
    Journal of surgical oncology, 2007, Jun-01, Volume: 95, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Chemotherapy, Adjuv

2007
Chemotherapy of advanced gastric cancer.
    Cancer treatment reviews, 2007, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2007
Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?
    Current opinion in oncology, 2007, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Flu

2007
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) for patients with advanced pancreatic cancer: the ghost regimen.
    Cancer letters, 2007, Oct-18, Volume: 256, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic;

2007
Adjuvant therapy for pancreatic cancer: to treat or not to treat?
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu

2007
Cytotoxic therapy for advanced pancreatic adenocarcinoma.
    Seminars in oncology, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Tria

2007
Docetaxel: in gastric cancer.
    Drugs, 2007, Volume: 67, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do

2007
Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc

2008
Medical treatment for advanced gastroesophageal adenocarcinoma.
    Current opinion in gastroenterology, 2007, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecit

2007
Neoadjuvant and adjuvant strategies for pancreatic cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxycytidin

2008
Total mesorectal excision and management of rectal cancer.
    Expert review of anticancer therapy, 2007, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Anastomosis, Surgical; Antineoplastic Agents; Combined Modality Therapy; Disease Man

2007
Adjuvant therapy in pancreatic cancer: a critical appraisal.
    Drugs, 2007, Volume: 67, Issue:16

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Che

2007
Pancreatic cancer--is the wall crumbling?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Drug Ad

2008
The chemotherapy of prostatic adenocarcinoma.
    Annals of internal medicine, 1980, Volume: 92, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop

1980
Possibilities and limitations of the cytostatic treatment of gastrointestinal carcinoma.
    Hepato-gastroenterology, 1982, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combination; Es

1982
Intra-arterial chemotherapy for palliation of fungating breast cancer. A case report and review of the literature.
    American journal of clinical oncology, 1994, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Female;

1994
Preoperative chemoradiation for adenocarcinoma of the pancreas: excessive toxicity of prophylactic hepatic irradiation.
    International journal of radiation oncology, biology, physics, 1995, Nov-01, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bilirubin; Combined Modality Therapy; Fatal Outcome; Fe

1995
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1994
Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy.
    Cancer investigation, 1995, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; BCG Vacci

1995
Cerebral demyelination with 5-fluorouracil and levamisole.
    Cancer investigation, 1994, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Diseases; Colorec

1994
Adjuvant therapy for colon adenocarcinoma: current status of clinical investigation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5 Suppl 3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Chemotherapy, Adjuvant;

1994
Current approaches to multimodality management of advanced pancreatic cancer.
    Hepato-gastroenterology, 1993, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri

1993
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
    International journal of radiation oncology, biology, physics, 1993, Aug-01, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

1993
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
The use of mitomycin in esophageal cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1993
Mitomycin therapy in gastric cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1993
Adjuvant therapy for resectable gastric adenocarcinoma: preoperative and postoperative chemotherapy trials.
    The Journal of infusional chemotherapy, 1995,Summer, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Protocols; Clinical Trials a

1995
Concurrent radiation therapy and chemotherapy followed by esophagectomy for localized esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1996
Chemotherapy of adenocarcinoma of the pancreas.
    Seminars in oncology, 1996, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Antineoplastic Agents, Horm

1996
[Cancer of the anal canal].
    Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1990, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

1990
Locoregional chemotherapy for adjuvant treatment of colorectal adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluor

1996
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 1995, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1995
[Adjuvant therapies in combination with pancreatectomy for carcinoma of the pancreas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Therapy;

1996
[Sequential methotrexate and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1996
[A case of alpha-fetoprotein-producing pancreatic carcinoma--review of 41 cases reported in Japan].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1996, Volume: 93, Issue:12

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Combined Modalit

1996
Isolated liver perfusion for liver metastases: pharmacokinetic advantage?
    Surgical oncology clinics of North America, 1996, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents;

1996
[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Sch

1997
Meningeal carcinomatosis as the presenting manifestation of gastric adenocarcinoma.
    The American journal of gastroenterology, 1997, Volume: 92, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car

1997
Combined modality treatment with accelerated radiotherapy and chemotherapy in patients with locally advanced inoperable carcinoma of the pancreas: results of a feasibility study.
    British journal of cancer, 1997, Volume: 75, Issue:4

    Topics: Adenocarcinoma; Aged; Antidotes; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease

1997
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
    No shinkei geka. Neurological surgery, 1997, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla

1997
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Fall, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin

1996
The need for a multidisciplinary approach in the treatment of advanced colorectal cancer: a critical review from a medical oncologist and surgeon.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1997, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col

1997
Clinical experience with gemcitabine in pancreatic carcinoma.
    Oncology (Williston Park, N.Y.), 1997, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Drug Evalu

1997
Chemotherapy in advanced pancreatic adenocarcinoma.
    Cancer treatment reviews, 1998, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents;

1998
Treatment of advanced and metastatic pancreatic cancer.
    Frontiers in bioscience : a journal and virtual library, 1998, Nov-01, Volume: 3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis

1998
Preoperative chemoradiation strategies for localized adenocarcinoma of the pancreas.
    Journal of hepato-biliary-pancreatic surgery, 1998, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr

1998
[Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam

1998
[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec

1998
[Irinotecan in combination for colon cancer].
    Bulletin du cancer, 1998, Volume: Spec No

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C

1998
Practical recommendations for the management of adenocarcinoma of the pancreas.
    Drugs, 1999, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Combined Modality Ther

1999
Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo

1999
Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes.
    Cancer, 1999, Apr-15, Volume: 85, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
External beam radiotherapy for pelvic node recurrence after curative resection of colon cancer: report of a case.
    Japanese journal of clinical oncology, 1999, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colectomy; Colonic Neopla

1999
Colorectal cancer in adolescents.
    Annals of the Royal College of Surgeons of England, 1999, Volume: 81, Issue:2

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colon; Colore

1999
[Adenocarcinoma of the exocrine pancreas: management and therapeutic hopes].
    La Revue de medecine interne, 1999, Volume: 20, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Case-Control Studies; Chemotherapy, Adjuvant; Clini

1999
Adjuvant/neoadjuvant chemoradiation for gastric and pancreatic cancer.
    Oncology (Williston Park, N.Y.), 1999, Volume: 13, Issue:10 Suppl 5

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Combined Modality Therapy; Fluorour

1999
In situ standardised AgNOR analysis: a simplified method for routine use to determine prognosis and chemotherapy efficiency in colorectal adenocarcinoma.
    Micron (Oxford, England : 1993), 2000, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fluorouracil; Humans; Nuclear

2000
Survival impact of chemotherapy in patients with colorectal metastases confined to the liver: a re-analysis of 1458 non-operable patients randomised in 22 trials and 4 meta-analyses. Meta-Analysis Group in Cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1999
Adenocarcinoma at the esophageal gastric junction arising in an 11-year-old girl.
    Pathology international, 1999, Volume: 49, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Child; Cisplatin; Esophagectomy; Esophagogastric Ju

1999
[Chemotherapy, combined radiochemotherapy and new therapeutic approaches in adenocarcinoma of the pancreas].
    Journal de chirurgie, 1999, Volume: 136, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1999
[Adjuvant intra-arterial chemotherapy after curative resection of liver metastasis from colorectal cancer. Results of a pilot study in 30 patients].
    Chirurgie; memoires de l'Academie de chirurgie, 1999, Volume: 124, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Female; F

1999
Colonic carcinoma: a case report in a child and review literature.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2000, Volume: 83, Issue:2

    Topics: Abdominal Pain; Adenocarcinoma; Biopsy, Needle; Child; Colectomy; Colonic Neoplasms; Fluorouracil; F

2000
[New combination therapies for gastrointestinal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colorectal

2000
Adjuvant therapy of colorectal cancer.
    Hospital practice (1995), 2000, May-15, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chemotherapy, Cancer,

2000
Current status of and future prospects for the medical management of adenocarcinoma of the exocrine pancreas.
    Journal of clinical gastroenterology, 2000, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Flu

2000
Clinical update of gemcitabine in pancreas cancer.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com

2000
The treatment of pancreatic cancer.
    Annales chirurgiae et gynaecologiae, 2000, Volume: 89, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biopsy; Carcinoma, Pancreatic Ductal; Chemotherapy,

2000
[Concomitant radiochemotherapy in cancer of the cervix uteri: modifications of the standards].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2000, Volume: 4 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2000
[Palliative therapy of pancreatic adenocarcinoma].
    Zeitschrift fur Gastroenterologie, 2001, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Fluorouracil; Ge

2001
Neoadjuvant strategies for pancreatic cancer.
    Oncology (Williston Park, N.Y.), 2001, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo

2001
Treatment of metastatic pancreatic adenocarcinoma: a comprehensive review.
    The Surgical clinics of North America, 2001, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto

2001
Irinotecan-induced dysarthria.
    Journal of the National Cancer Institute, 2001, Sep-19, Volume: 93, Issue:18

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Proto

2001
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
    The New England journal of medicine, 2001, Oct-11, Volume: 345, Issue:15

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2001
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
    The New England journal of medicine, 2001, Oct-11, Volume: 345, Issue:15

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2001
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
    The New England journal of medicine, 2001, Oct-11, Volume: 345, Issue:15

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2001
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.
    The New England journal of medicine, 2001, Oct-11, Volume: 345, Issue:15

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2001
Neoadjuvant chemoradiation therapy in patients with surgically treated esophageal cancer.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2001
[A case of gastric cancer with multiple liver metastases that were completely responsive to hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Epirub

2001
[A case of AFP producing early gastric cancer successfully treated with small dose CDDP and 5-FU (PF) therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:13

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug

2001
Early appendiceal adenocarcinoma. A review of the literature with special reference to optimal surgical procedures.
    Journal of gastroenterology, 2002, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Appendiceal Neoplasms; Fluorouracil; Humans; Japan;

2002
Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center.
    Cancer, 2002, Apr-01, Volume: 94, Issue:7

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic

2002
Chemotherapy options for gastric cancer.
    Seminars in radiation oncology, 2002, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2002
[Chemotherapy for the patients with esophageal cancer].
    Nihon Geka Gakkai zasshi, 2002, Volume: 103, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Ce

2002
A comprehensive update on the use of chemotherapy for metastatic pancreatic adenocarcinoma.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow D

2002
Management of locally advanced adenocarcinoma of the pancreas.
    Hematology/oncology clinics of North America, 2002, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2002
Progress report. Cytotoxic therapy for gastrointestinal carcinoma.
    Gut, 1976, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Bleomycin; Carcinoma,

1976
An aggressive approach to prostatic cancer.
    The Journal of urology, 1977, Volume: 118, Issue:1 Pt 2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Castration; Cortisone; Cyclophosphamide; Diethylstilbes

1977
Individual cell biology: basis and prospects for a rational cancer chemotherapy.
    Archiv fur Geschwulstforschung, 1977, Volume: 47, Issue:8

    Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cell Cycle; Chromosome Aberrations; Cyclophospham

1977
Chemotherapy of pancreatic cancer.
    Seminars in oncology, 1979, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour

1979
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.
    Cancer treatment reviews, 1975, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Drug Therapy, Combination; Female; F

1975
[Systemic chemotherapy in metastatic colorectal adenocarcinomas].
    Gastroenterologie clinique et biologique, 1992, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Fem

1992
The value of adjuvant therapy after radical surgery for colorectal cancer.
    Annals of medicine, 1992, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

1992
Treatment of gastrointestinal and renal adenocarcinomas with interferon-alpha.
    Biotherapy (Dordrecht, Netherlands), 1992, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Inter

1992
Aggressive therapy for cancer of the pancreas. Does it help?
    Gastroenterology clinics of North America, 1990, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Care; Palliative Car

1990
Skin reactions to radiotherapy--a spectrum resembling erythema multiforme: case report and review of the literature.
    Cutis, 1992, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Erythema Multiforme; Female; Flu

1992
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
    Journal of the American Academy of Dermatology, 1991, Volume: 25, Issue:5 Pt 2

    Topics: Adenocarcinoma; Aged; Drug Eruptions; Fluorouracil; Humans; Infusions, Intravenous; Male; Photosensi

1991
Vaginal adenosis and clear cell carcinoma after 5-fluorouracil treatment for condylomas.
    Cancer, 1991, Oct-01, Volume: 68, Issue:7

    Topics: Adenocarcinoma; Adult; Condylomata Acuminata; Female; Fluorouracil; Humans; Vaginal Diseases; Vagina

1991
Levamisole in the adjuvant treatment of colon cancer.
    Clinical pharmacy, 1991, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne

1991
Chemotherapy and radiation therapy before transhiatal esophagectomy for esophageal carcinoma.
    The Annals of thoracic surgery, 1990, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1990
Clinical trial with 5-fluorouracil and leucovorin.
    Journal of chemotherapy (Florence, Italy), 1990, Volume: 2 Suppl 1

    Topics: Adenocarcinoma; Breast Neoplasms; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination;

1990
5-Fluorouracil plus levamisole: effective adjuvant treatment for colon cancer.
    Important advances in oncology, 1990

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemistry, Clinical; Colonic Neoplas

1990
[Combination radiotherapy and chemotherapy in cancer of the pancreas. Review of the literature and prospects].
    Bulletin du cancer, 1990, Volume: 77, Issue:3

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Pancreatic Neoplasms; Prognosis; Ra

1990
Management of colorectal cancer.
    Comprehensive therapy, 1990, Volume: 16, Issue:11

    Topics: Adenocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Hu

1990
Update in cancer chemotherapy, Part III: Lung cancer, Part 1.
    Journal of the National Medical Association, 1985, Volume: 77, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Bleomycin; Carcinoma; C

1985
Pancreatic cancer in 1988. Possibilities and probabilities.
    Annals of surgery, 1988, Volume: 208, Issue:5

    Topics: Adenocarcinoma; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Lymphatic

1988
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru

1989
[5-Fluorouracil, adriamycin, and mitomycin C (FAM) combination chemotherapy in adenocarcinoma of the parotid gland].
    Gan no rinsho. Japan journal of cancer clinics, 1989, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin;

1989
Biochemical mechanisms in colon xenografts: thymidylate synthase as a target for therapy.
    Investigational new drugs, 1989, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Neoplasm Transplantation; Thymidyl

1989
Phase I/II study of definitive radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) for advanced or recurrent gynecologic malignancies. Preliminary report.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C

1989
Low-dose continuous infusion 5-fluorouracil and cisplatin: phase II evaluation in advanced colorectal carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1989
[Neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma. Preliminary results].
    Chirurgie; memoires de l'Academie de chirurgie, 1989, Volume: 115, Issue:6

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

1989
In vivo potentiation of 5-fluorouracil by leucovorin in murine colon carcinoma.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1988, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Animals; Carcinoma; Colonic Neoplasms; Disease Models, Animal; Drug Synergism; Femal

1988
Carcinoma-associated hemolytic-uremic syndrome in a patient receiving 5-fluorouracil-adriamycin-mitomycin C combination chemotherapy.
    Oncology, 1988, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasm

1988
[Current views of the treatment of non-microcellular carcinoma of the lungs].
    Wiadomosci lekarskie (Warsaw, Poland : 1960), 1985, Jun-01, Volume: 38, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyc

1985
Chemotherapy in advanced ovarian cancer.
    Geriatrics, 1973, Volume: 28, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Cystadenocarcinoma; Cystadeno

1973
Genitourinary-tract problems of the aged male.
    Journal of the American Geriatrics Society, 1974, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Age Factors; Aged; Cyclophosphamide; Cyproterone; Diethylstilbestrol; Fluorouracil;

1974
The role of chemotherapy in the treatment of lung cancer.
    Seminars in oncology, 1974, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Alkylating Agents; Antineoplastic Agents; Bleomycin; Carcinoma, Small Cell; Carcinom

1974
The chemical therapy of breast cancer.
    Seminars in oncology, 1974, Volume: 1, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Cyclophosphamide; Doxorubicin;

1974
Proceedings: Non-hormonal cytotoxic agents in the treatment of prostatic adenocarcinoma.
    Cancer, 1973, Volume: 32, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Aniline Compounds; Bone Neoplasms; Cyclophosphamide; Evaluation St

1973
A review of chemotherapy in gastric cancer.
    Cancer, 1974, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Chlorambucil; Chromomycins; Cyclophosphamide; Cyt

1974
An assessment of massive-dose chemotherapy of malignant disease.
    Canadian Medical Association journal, 1971, Jan-09, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo

1971
[Molecular basis of the relation between the cytotoxic effect of antineoplastic compounds and the cell cycle phase].
    Voprosy onkologii, 1972, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adrenocorticotropic Hormone; Alkylating Agents; Androgens; Animals; Antibiotics, Ant

1972
[Use of optical quantum generators (lasers) in oncology].
    Voprosy onkologii, 1972, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Basal Cell; Carcinom

1972
Obstacles to the improvement of radiotherapy of rectal cancer.
    Proceedings of the Royal Society of Medicine, 1973, Volume: 66, Issue:12

    Topics: Adenocarcinoma; Animals; Cyclophosphamide; Fluorouracil; Humans; Laparotomy; Lymphography; Methods;

1973
Nonhormonal chemotherapy of endometrial adenocarcinoma: a review.
    Cancer, 1974, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Cyclophosphamide; Drug Evaluation; Drug Therapy

1974
Recent advances in pancreatic cancer.
    The Surgical clinics of North America, 1974, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Angiography; Antigens, Neoplasm; Biopsy; Carcinoembryonic Antigen; Endoscopy; Evalua

1974
Current progress in the management of cancer. A collective review.
    Plastic and reconstructive surgery, 1969, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Angiography; Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Chem

1969
The metabolism and pharmacology of 5-fluorouracil.
    Journal of surgical oncology, 1971, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Alopecia; Animals; Breast Neoplasms; Carbon Isotopes; Cell Division; Chromosome Aber

1971
Chemotherapy of ovarian cancer with melphalan.
    Clinical obstetrics and gynecology, 1968, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Ascites; Carcinoma; Cyclophosphamide; Female; Fluorouracil; Humans; Injections, Intr

1968

Trials

1532 trials available for fluorouracil and Adenocarcinoma, Basal Cell

ArticleYear
Pazopanib with 5-FU and oxaliplatin as first line therapy in advanced gastric cancer: A randomized phase-II study-The PaFLO trial. A study of the Arbeitsgemeinschaft Internistische Onkologie AIO-STO-0510.
    International journal of cancer, 2022, 03-15, Volume: 150, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Fema

2022
Study protocol of an open-label, single arm phase II trial investigating the efficacy, safety and quality of life of neoadjuvant chemotherapy with liposomal irinotecan combined with Oxaliplatin and 5-fluorouracil/Folinic acid followed by curative surgical
    BMC cancer, 2021, Nov-18, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Femal

2021
Sequential first-line treatment with nab-paclitaxel/gemcitabine and FOLFIRINOX in metastatic pancreatic adenocarcinoma: GABRINOX phase Ib-II controlled clinical trial.
    ESMO open, 2021, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine

2021
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study.
    British journal of cancer, 2022, Volume: 126, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum

2022
Impact of G-CSF Prophylaxis on Chemotherapy Dose-Intensity, Link Between Dose-Intensity and Survival in Patients with Metastatic Pancreatic Adenocarcinoma.
    The oncologist, 2022, 07-05, Volume: 27, Issue:7

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Granulocyte

2022
Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
    The oncologist, 2022, 08-05, Volume: 27, Issue:8

    Topics: Adenocarcinoma; Capecitabine; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm

2022
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects.
    International journal of cancer, 2022, 08-01, Volume: 151, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Fluorour

2022
Organ Preservation in Patients With Rectal Adenocarcinoma Treated With Total Neoadjuvant Therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 08-10, Volume: 40, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Dis

2022
Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR).
    BMC cancer, 2022, May-12, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; D

2022
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
    Cancer, 2022, 08-01, Volume: 128, Issue:15

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.
    JAMA oncology, 2022, 09-01, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Flu

2022
Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma.
    Scientific reports, 2022, Sep-02, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2022
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2023, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2023
Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma.
    BMJ open, 2022, 11-14, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cost-Benefit Analysis; Do

2022
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2023, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM.
    International journal of cancer, 2023, 07-01, Volume: 153, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri

2023
Sintilimab Plus Modified FOLFIRINOX in Metastatic or Recurrent Pancreatic Cancer: The Randomized Phase II CISPD3 Trial.
    Annals of surgical oncology, 2023, Volume: 30, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Fluorouracil; Human

2023
Efficacy of Systemic Chemotherapy in Patients With Low-grade Mucinous Appendiceal Adenocarcinoma: A Randomized Crossover Trial.
    JAMA network open, 2023, 06-01, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Appendiceal Neoplasms; Colorectal

2023
Comparison of survival for metastatic pancreatic cancer patients treated with CPI-613 versus resected borderline-resectable pancreatic cancer patients.
    Journal of surgical oncology, 2023, Volume: 128, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Neoadjuvant Th

2023
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as an adjuvant therapy for ctDNA-positive gastric and gastroesophageal junction adenocarcinoma: a protocol for a randomized, controlled, multicenter phase II clinical trial (EXPL
    Frontiers in immunology, 2023, Volume: 14

    Topics: Adenocarcinoma; Clinical Trials, Phase II as Topic; Esophagogastric Junction; Fluorouracil; Humans;

2023
Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
    Radiation oncology (London, England), 2019, Aug-19, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2019
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial).
    The British journal of surgery, 2019, Volume: 106, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adj

2019
Phase 2 Trial of Neoadjuvant FOLFIRINOX and Intensity Modulated Radiation Therapy Concurrent With Fixed-Dose Rate-Gemcitabine in Patients With Borderline Resectable Pancreatic Cancer.
    International journal of radiation oncology, biology, physics, 2020, 01-01, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Chemoradiothe

2020
A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
    Future oncology (London, England), 2019, Volume: 15, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Female; Flu

2019
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarcinoma.
    American journal of clinical oncology, 2019, Volume: 42, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemoth

2019
Palliative short-course hypofractionated radiotherapy followed by chemotherapy in esophageal adenocarcinoma: the phase II PALAESTRA trial.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2020
Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 01-01, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2020
Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 124

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa

2020
Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
    Cancer science, 2020, Volume: 111, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia

2020
Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
    Targeted oncology, 2020, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2020
Resection or Stenting in the Treatment of Symptomatic Advanced Metastatic Rectal Cancer: A Dilemma.
    Anticancer research, 2019, Volume: 39, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2019
Patient-based cost-effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4-year prospective randomised phase II study.
    European journal of cancer care, 2020, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; China; Co

2020
Predictive Impact of Mucinous Tumors on the Clinical Outcome in Patients with Poorly Differentiated, Stage II Colon Cancer: A TOSCA Subgroup Analysis.
    The oncologist, 2020, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop

2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Esophageal Neo

2020
Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Follow-U

2020
Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.
    JAMA network open, 2020, 02-05, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2020
Efficacy of Oxaliplatin/5-Fluorouracil/Capecitabine-Cetuximab Combination Therapy and Its Effects on K-Ras Mutations in Advanced Colorectal Cancer.
    Medical science monitor : international medical journal of experimental and clinical research, 2020, Feb-16, Volume: 26

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2020
Daily dose to organs at risk predicts acute toxicity in pancreatic stereotactic radiotherapy.
    Acta oncologica (Stockholm, Sweden), 2020, Volume: 59, Issue:8

    Topics: Abdominal Pain; Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols;

2020
FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    JAMA oncology, 2020, 08-01, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Esophageal Ne

2020
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
    BMC cancer, 2020, Jun-01, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pr

2020
Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 135

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2020
A Phase II Study of Allogeneic GM-CSF-Transfected Pancreatic Tumor Vaccine (GVAX) with Ipilimumab as Maintenance Treatment for Metastatic Pancreatic Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Moda

2020
Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIR
    European journal of cancer (Oxford, England : 1990), 2020, Volume: 136

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2020
A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-01, Volume: 26, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA1 P

2020
The JPJDF has Synergistic Effect with Fluoropyrimidine in the Maintenance Therapy for Metastatic Colorectal Cancer.
    Recent patents on anti-cancer drug discovery, 2020, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Double-B

2020
Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma.
    Annals of surgical oncology, 2020, Volume: 27, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Deoxycyti

2020
Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 10-15, Volume: 26, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine

2020
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2020, 09-20, Volume: 38, Issue:27

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal

2020
Short-course radiation followed by mFOLFOX-6 plus avelumab for locally-advanced rectal adenocarcinoma.
    BMC cancer, 2020, Sep-01, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin

2020
Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
    International journal of cancer, 2021, 03-15, Volume: 148, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2021
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma.
    Radiation oncology (London, England), 2020, Oct-07, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological

2020
PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2021
Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    BMC cancer, 2021, Jan-05, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2021
Efficacy of Perioperative Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
    JAMA oncology, 2021, 03-01, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluorouracil

2021
Phase III Study to Evaluate Efficacy and Safety of Andecaliximab With mFOLFOX6 as First-Line Treatment in Patients With Advanced Gastric or GEJ Adenocarcinoma (GAMMA-1).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-20, Volume: 39, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2021
Deep regional hyperthermia with preoperative radiochemotherapy in locally advanced rectal cancer, a prospective phase II trial.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2021, Volume: 159

    Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Hyperthermia; Neoadjuvant Therapy; Neoplasm

2021
KEYNOTE-859: a Phase III study of pembrolizumab plus chemotherapy in gastric/gastroesophageal junction adenocarcinoma.
    Future oncology (London, England), 2021, Volume: 17, Issue:22

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2021
Perioperative Systemic Therapy vs Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Alone for Resectable Colorectal Peritoneal Metastases: A Phase 2 Randomized Clinical Trial.
    JAMA surgery, 2021, 08-01, Volume: 156, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cap

2021
Randomized Phase II Study of PET Response-Adapted Combined Modality Therapy for Esophageal Cancer: Mature Results of the CALGB 80803 (Alliance) Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 09-01, Volume: 39, Issue:25

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2021
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.
    Annals of surgical oncology, 2017, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap

2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysis.
    British journal of cancer, 2017, May-09, Volume: 116, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
    JAMA oncology, 2017, Sep-01, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Pre-operative hyperfractionated concurrent radiochemotherapy for locally advanced rectal cancers: a phase II clinical study.
    The British journal of radiology, 2017, Volume: 90, Issue:1074

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fr

2017
A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma.
    International journal of clinical oncology, 2017, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-F

2017
A Phase II Study of the c-Met Inhibitor Tivantinib in Combination with FOLFOX for the Treatment of Patients with Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction, or Stomach.
    Cancer investigation, 2017, Aug-09, Volume: 35, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2017
Postoperative Chemoradiotherapy After Local Resection for High-Risk T1 to T2 Low Rectal Cancer: Results of a Single-Arm, Multi-Institutional, Phase II Clinical Trial.
    Diseases of the colon and rectum, 2017, Volume: 60, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Colectomy

2017
Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial.
    Journal of geriatric oncology, 2018, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combin

2018
Health-related quality of life results from the PRODIGE 5/ACCORD 17 randomised trial of FOLFOX versus fluorouracil-cisplatin regimen in oesophageal cancer.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 84

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma,

2017
Improved Metastasis- and Disease-Free Survival With Preoperative Sequential Short-Course Radiation Therapy and FOLFOX Chemotherapy for Rectal Cancer Compared With Neoadjuvant Long-Course Chemoradiotherapy: Results of a Matched Pair Analysis.
    International journal of radiation oncology, biology, physics, 2017, 10-01, Volume: 99, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
A phase III trial comparing oral S-1/cisplatin and intravenous 5-fluorouracil/cisplatin in patients with untreated diffuse gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, Sep-01, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2017
Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Nov-10, Volume: 35, Issue:32

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
S-1 and irinotecan plus bevacizumab versus mFOLFOX6 or CapeOX plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer (TRICOLORE): a randomized, open-label, phase III, noninferiority trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2018, 03-01, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2018
Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial.
    JAMA oncology, 2018, Apr-01, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2018
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Bevacizum

2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial.
    The Lancet. Oncology, 2018, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2018
Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study.
    Medical science monitor : international medical journal of experimental and clinical research, 2018, Apr-03, Volume: 24

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Disease-Free Sur

2018
Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2018, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2018
Preoperative radiotherapy and local excision of rectal cancer: Long-term results of a randomised study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2018, Volume: 127, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Combined Mo

2018
Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma.
    Scientific reports, 2018, 05-08, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease-Fre

2018
FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Annals of surgical oncology, 2018, Volume: 25, Issue:7

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcin

2018
Docetaxel, oxaliplatin, 5FU, and trastuzumab as first-line therapy in patients with human epidermal receptor 2-positive advanced gastric or gastroesophageal junction cancer: Preliminary results of a phase II study.
    Medicine, 2018, Volume: 97, Issue:20

    Topics: Adenocarcinoma; Administration, Intravenous; Adult; Antineoplastic Agents; Antineoplastic Combined C

2018
Dynamic Angiogenic Switch as Predictor of Response to Chemotherapy-Bevacizumab in Patients With Metastatic Colorectal Cancer.
    American journal of clinical oncology, 2019, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2019
Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E

2019
Ki67 and P53 in Relation to Disease Progression in Metastatic Pancreatic Cancer: a Single Institution Analysis.
    Pathology oncology research : POR, 2019, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Di

2019
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2019
FOLFIRINOX as induction treatment in rectal cancer patients with synchronous metastases: Results of the FFCD 1102 phase II trial.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 104

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2018
Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.
    European journal of cancer (Oxford, England : 1990), 2018, Volume: 105

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2018
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F

2019
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F

2019
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F

2019
Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST).
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 107

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; F

2019
FOLFIRINOX for locally advanced pancreatic cancer: Results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2019, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2019
Diffusion kurtosis imaging and conventional diffusion weighted imaging to assess electrochemotherapy response in locally advanced pancreatic cancer.
    Radiology and oncology, 2019, 01-19, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Deoxycytidi

2019
The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer.
    Investigational new drugs, 2019, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2019
Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer.
    Technology in cancer research & treatment, 2019, 01-01, Volume: 18

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2019
Phase IB/II Randomized Study of FOLFIRINOX Plus Pegylated Recombinant Human Hyaluronidase Versus FOLFIRINOX Alone in Patients With Metastatic Pancreatic Adenocarcinoma: SWOG S1313.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019, 05-01, Volume: 37, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations

2019
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2019, Volume: 132

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2019
Preoperative FOLFOX in resectable locally advanced rectal cancer can be a safe and promising strategy: the R-NAC-01 study.
    Surgery today, 2019, Volume: 49, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2019
Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
    Journal of geriatric oncology, 2019, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2019
FOLFOX plus ziv-aflibercept or placebo in first-line metastatic esophagogastric adenocarcinoma: A double-blind, randomized, multicenter phase 2 trial.
    Cancer, 2019, 07-01, Volume: 125, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doub

2019
Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma.
    The Journal of international medical research, 2019, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Carcinoma, S

2019
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol.
    BMC cancer, 2019, Apr-29, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2019
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction aden
    BMC cancer, 2019, May-24, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Ag

2019
Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2019
Neoadjuvant Chemotherapy With mFOLFOXIRI Without Routine Use of Radiotherapy for Locally Advanced Rectal Cancer.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2019
Chronomodulated capecitabine and adjuvant radiation in intermediate-risk to high-risk rectal cancer: a phase II study.
    American journal of clinical oncology, 2014, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2014
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Fre

2014
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
    The oncologist, 2013, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2013
Comparison of treatment outcome in metastatic colorectal cancer patients included in a clinical trial versus daily practice in The Netherlands.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2013
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, May-01, Volume: 19, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2013
FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colo
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2013
Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer.
    Breast cancer research and treatment, 2013, Volume: 139, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Deoxyc

2013
Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2013
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar

2013
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antin

2013
Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
    The Lancet. Oncology, 2013, Volume: 14, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Annals of surgical oncology, 2013, Volume: 20, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2013
Phase II study of concomitant chemoradiotherapy with local hyperthermia and metronidazole for locally advanced fixed rectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2013, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
Phase II study of pemetrexed as second or third line combined chemotherapy in patients with colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2013
A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
    Radiation oncology (London, England), 2013, May-29, Volume: 8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com

2013
A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma.
    Oncology research, 2013, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2013
Combination of cisplatin/S-1 in the treatment of patients with advanced gastric or gastroesophageal adenocarcinoma: Results of noninferiority and safety analyses compared with cisplatin/5-fluorouracil in the First-Line Advanced Gastric Cancer Study.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:17

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2013
Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004).
    International journal of radiation oncology, biology, physics, 2013, Oct-01, Volume: 87, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
Better outcome of XELOX chemotherapy in patients with advanced intestinal-type adenocarcinoma of the ampulla of Vater.
    The Tohoku journal of experimental medicine, 2013, Volume: 231, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Agents; Antineoplastic Combined Chemot

2013
Evaluation of Outcomes in Patients With Carcinoma of the Cervix Treated With Concurrent Radiation and Cisplatin Versus Cisplatin/5-FU Compared With Radiation Alone.
    American journal of clinical oncology, 2015, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

2015
Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management?
    Diseases of the colon and rectum, 2013, Volume: 56, Issue:10

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot

2013
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas

2013
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2013
Characteristics and treatment outcomes of patients with malignant transformation arising from mature cystic teratoma of the ovary: experience at a single institution.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2013
Phase I study of sunitinib plus capecitabine/cisplatin or capecitabine/oxaliplatin in advanced gastric cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2013
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2013
Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 110, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxycytidin

2014
Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    International journal of radiation oncology, biology, physics, 2013, Dec-01, Volume: 87, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Blood Vessels; Capecitabine; Chemoradiotherap

2013
Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.
    Journal of the National Cancer Institute, 2014, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2014
Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial.
    International journal of radiation oncology, biology, physics, 2014, Feb-01, Volume: 88, Issue:2

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Docetaxel, oxaliplatin, and capecitabine combination chemotherapy for metastatic gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2014
Adding preoperative radiotherapy plus cetuximab to perioperative chemotherapy for resectable esophageal adenocarcinoma: a single-center prospective phase II trial.
    The oncologist, 2014, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2014
Phase I/II study of neoadjuvant bevacizumab, erlotinib and 5-fluorouracil with concurrent external beam radiation therapy in locally advanced rectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2014, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2014
FOLFOX4 with cetuximab vs. UFOX with cetuximab as first-line therapy in metastatic colorectal cancer: The randomized phase II FUTURE study.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Prospective phase II trial of second-line FOLFIRI in patients with advanced colorectal cancer including analysis of UGT1A1 polymorphisms: FLIGHT 2 study.
    Anticancer research, 2014, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A

2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A

2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A

2014
Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Chemotherapy, A

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Feb-20, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. Fédération Francophone de Cancérologie Digestive 0308.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Elevation in multiple serum inflammatory biomarkers predicts survival of pancreatic cancer patients with inoperable disease.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; C-Rea

2014
A phase II study of triweekly paclitaxel and capecitabine combination therapy in patients with fluoropyrimidine-platinum-resistant metastatic gastric adenocarcinoma.
    Journal of cancer research and therapeutics, 2013, Volume: 9 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2013
Mitomycin C and capecitabine in pretreated patients with metastatic gastric cancer: a multicenter phase II study.
    Journal of cancer research and clinical oncology, 2014, Volume: 140, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2014
Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2015, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2015
Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer.
    World journal of gastroenterology, 2014, Jan-28, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv

2014
Phase 2 trial of induction gemcitabine, oxaliplatin, and cetuximab followed by selective capecitabine-based chemoradiation in patients with borderline resectable or unresectable locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2014, Mar-15, Volume: 88, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2014
Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
    Radiation oncology (London, England), 2014, Mar-07, Volume: 9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2014
Influence of interferon-alpha combined with chemo (radio) therapy on immunological parameters in pancreatic adenocarcinoma.
    International journal of molecular sciences, 2014, Mar-07, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Che

2014
The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jun-01, Volume: 20, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Comparison of short-term efficacy and safety of TIROX and DCF regimens for advanced gastric cancer.
    The Journal of international medical research, 2014, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Docet

2014
A phase I and pharmacokinetic study of capecitabine in combination with radiotherapy in patients with localised inoperable pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Cohort Studies; De

2014
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Annals of surgical oncology, 2014, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Gastroenterology, 2014, Volume: 147, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2014
Phase I dose escalation study of capecitabine and erlotinib concurrent with radiation in locally advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2014
Safety and efficacy of second-line treatment with folinic acid, 5-fluorouracil and irinotecan (FOLFIRI) in combination of panitumumab and bevacizumab for patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
    The AAPS journal, 2014, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2014
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
    The AAPS journal, 2014, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2014
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
    The AAPS journal, 2014, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2014
Lower exposure and faster clearance of bevacizumab in gastric cancer and the impact of patient variables: analysis of individual data from AVAGAST phase III trial.
    The AAPS journal, 2014, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2014
CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Adenocarcinoma; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotti

2014
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Capecitabine;

2014
A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer.
    British journal of cancer, 2014, Aug-12, Volume: 111, Issue:4

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2014
Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    The Lancet. Oncology, 2014, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2014
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
    Journal of surgical oncology, 2014, Volume: 110, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2014
Systemic therapy for advanced appendiceal adenocarcinoma: an analysis from the NCCN Oncology Outcomes Database for colorectal cancer.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms;

2014
Neoadjuvant chronomodulated capecitabine with radiotherapy in rectal cancer: a phase II brunch regimen study.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; Deoxycyt

2014
A phase 3 non-inferiority study of 5-FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as second-line chemotherapy for metastatic colorectal cancer: updated results of the FIRIS study.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2015
S-1 monotherapy as second line chemotherapy in advanced gastric cancer patients previously treated with cisplatin/infusional fluorouracil.
    International journal of clinical and experimental pathology, 2014, Volume: 7, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Disease-Free Survival; Drug Combinati

2014
Neoadjuvant capecitabine, bevacizumab and radiotherapy for locally advanced rectal cancer: results of a single-institute Phase I study.
    Journal of radiation research, 2014, Volume: 55, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Bevacizumab; Capecitabine; Deoxycytidine; F

2014
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study.
    The Journal of thoracic and cardiovascular surgery, 2014, Volume: 148, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; Biomarkers, Tumor; Ca

2014
Phase II Study of Modified FOLFOX6 With Bevacizumab in Metastatic Gastroesophageal Adenocarcinoma.
    American journal of clinical oncology, 2017, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols

2017
A phase II trial of induction epirubicin, oxaliplatin, and fluorouracil, followed by surgery and postoperative concurrent cisplatin and fluorouracil chemoradiotherapy in patients with locoregionally advanced adenocarcinoma of the esophagus and gastroesoph
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
Adjuvant chemoradiotherapy after D2 resection in gastric cancer: a single-center observational study.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2015
Phase II trial evaluating the feasibility of interdigitating folfox with chemoradiotherapy in locally advanced and metastatic rectal cancer.
    British journal of cancer, 2014, Nov-11, Volume: 111, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2014
Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2014
Predictive biomarkers for the efficacy of cetuximab combined with cisplatin and capecitabine in advanced gastric or esophagogastric junction adenocarcinoma: a prospective multicenter phase 2 trial.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati

2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati

2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati

2014
Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (Fédération Francophone de Cancérologie Digestive, Féd
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Nov-01, Volume: 32, Issue:31

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplati

2014
Blood neutrophil-lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Disea

2014
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2014
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2015
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    International journal of radiation oncology, biology, physics, 2014, Dec-01, Volume: 90, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2014
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    International journal of radiation oncology, biology, physics, 2014, Dec-01, Volume: 90, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2014
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    International journal of radiation oncology, biology, physics, 2014, Dec-01, Volume: 90, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2014
Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
    International journal of radiation oncology, biology, physics, 2014, Dec-01, Volume: 90, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2014
Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2014
Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2015
Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Acetamides; Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic

2014
Clinical study of nimotuzumab combined with chemotherapy in the treatment of late stage gastric cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
    International journal of oncology, 2015, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chem

2015
Chemoradiation with concomitant boosts followed by radical surgery in locally advanced cervical cancer: long-term results of the ROMA-2 prospective phase 2 study.
    International journal of radiation oncology, biology, physics, 2014, Nov-15, Volume: 90, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma

2014
Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung (C-TONG0807): an open-label, single arm, multicenter phase II study.
    Medicine, 2015, Volume: 94, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers; Capecitabine; China

2015
Dose-dense biweekly docetaxel combined with 5-fluorouracil as first-line treatment in advanced gastric cancer: a phase II trial.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2015
Phase II study on hepatic arterial infusion chemotherapy using percutaneous catheter placement techniques for liver metastases from colorectal cancer (JFMC28 study).
    Asia-Pacific journal of clinical oncology, 2015, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2015
Phase II Study of Docetaxel, Nedaplatin, and 5-Fluorouracil Combined Chemotherapy for Advanced Esophageal Cancer.
    Annals of surgical oncology, 2015, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2015
Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2015
Clinical Benefit and Health-Related Quality of Life Assessment in Patients Treated with Cisplatin/S-1 Versus Cisplatin/5-FU: Secondary End Point Results From the First-Line Advanced Gastric Cancer Study (FLAGS).
    Journal of gastrointestinal cancer, 2015, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2015
Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
    British journal of cancer, 2015, Mar-17, Volume: 112, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex; CD8-Positi

2015
Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2015
Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.
    European journal of cancer (Oxford, England : 1990), 2015, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2015
Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2015
Morbidity and mortality after surgery for cancer of the oesophagus and gastro-oesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2015
Electrochemotherapy in locally advanced pancreatic cancer: Preliminary results.
    International journal of surgery (London, England), 2015, Volume: 18

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antineoplas

2015
Phase I dose escalation trial of nitroglycerin in addition to 5-fluorouracil and radiation therapy for neoadjuvant treatment of operable rectal cancer.
    Surgery, 2015, Volume: 158, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2015
Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction.
    The American journal of the medical sciences, 2015, Volume: 349, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2015
[Immediate results of combined therapy for local recurrences of rectal cancer].
    Voprosy onkologii, 2015, Volume: 61, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2015
The efficacy and safety of hepatic arterial infusion of oxaliplatin plus intravenous irinotecan, leucovorin and fluorouracil in colorectal cancer with inoperable hepatic metastasis.
    Journal of chemotherapy (Florence, Italy), 2016, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2016
Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy.
    Radiation oncology (London, England), 2015, Jun-04, Volume: 10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2015
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
    Cancer chemotherapy and pharmacology, 2015, Volume: 76, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2015
Surgery with versus without preoperative concurrent chemoradiotherapy for mid/low rectal cancer: an interim analysis of a prospective, randomized trial.
    Chinese journal of cancer, 2015, Jun-10, Volume: 34, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cana

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
    The Lancet. Oncology, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2015
Chemotherapy is effective for stage I gastric cancer in patients with synchronous esophageal cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin;

2016
A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Carcinoembryonic antigen has prognostic value for tumor downstaging and recurrence in rectal cancer after preoperative chemoradiotherapy and curative surgery: A multi-institutional and case-matched control study of KROG 14-12.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2015, Volume: 116, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoem

2015
Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer.
    BMC cancer, 2015, Sep-09, Volume: 15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2015
Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Disease-Fre

2015
Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant;

2016
A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma.
    Pancreas, 2016, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin;

2016
Stratified Survival Analysis After Adjuvant Chemotherapy of Colon Cancer Reveals a Benefit for Older Patients.
    Anticancer research, 2015, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2015
Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Nov-20, Volume: 33, Issue:33

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Dis

2015
S-1 plus cisplatin versus fluorouracil plus cisplatin in advanced gastric or gastro-esophageal junction adenocarcinoma patients: a pilot study.
    Oncotarget, 2015, Oct-27, Volume: 6, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2015
Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer.
    Annals of surgery, 2016, Volume: 263, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem

2016
Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001-02).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2016
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total
    BMC cancer, 2015, Oct-23, Volume: 15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiothera

2015
Watch and wait policy after preoperative radiotherapy for rectal cancer; management of residual lesions that appear clinically benign.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot

2016
FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Advanced Pancreatic Cancer: A Brown University Oncology Research Group Phase I Study.
    American journal of clinical oncology, 2016, Volume: 39, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Disease-Free

2016
A Phase II Study of Biweekly Cisplatin, Fixed-Dose-Rate Gemcitabine and Infusional 5-Fluorouracil in Patients With Metastatic Pancreatic and Biliary Cancers.
    American journal of clinical oncology, 2018, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2018
A Randomized Phase 2 Study of Neoadjuvant Chemoradiaton Therapy With 5-Fluorouracil/Leucovorin or Irinotecan/S-1 in Patients With Locally Advanced Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2015, Dec-01, Volume: 93, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi

2015
A phase II trial of modified FOLFOX6 as first-line therapy for adenocarcinoma of an unknown primary site.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2016
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape

2016
A phase II study of preoperative mFOLFOX6 with short-course radiotherapy in patients with locally advanced rectal cancer and liver-only metastasis.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 118, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2016
Preoperative versus postoperative docetaxel-cisplatin-fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
RECQ1 A159C Polymorphism Is Associated With Overall Survival of Patients With Resected Pancreatic Cancer: A Replication Study in NRG Oncology Radiation Therapy Oncology Group 9704.
    International journal of radiation oncology, biology, physics, 2016, Mar-01, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Chemoradiotherapy; Deoxycytidine; Female; F

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: A randomised trial.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 53

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfu

2016
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction;

2016
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction;

2016
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction;

2016
A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Disease-Free Survival; Esophageal Neoplasms; Esophagogastric Junction;

2016
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, Volume: 118, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose

2016
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
    British journal of cancer, 2016, Mar-01, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy

2016
Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
    International journal of radiation oncology, biology, physics, 2016, Mar-01, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Dose Fracti

2016
A Phase I/II Study of Docetaxel, Oxaliplatin, and Fluorouracil (D-FOX) Chemotherapy in Patients With Untreated Locally Unresectable or Metastatic Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    American journal of clinical oncology, 2018, Volume: 41, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogast

2018
Consolidation chemotherapy during neoadjuvant chemoradiation (CRT) for distal rectal cancer leads to sustained decrease in tumor metabolism when compared to standard CRT regimen.
    Radiation oncology (London, England), 2016, Feb-24, Volume: 11

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Consolidation Chemotherapy; Double-B

2016
Disease Control, Survival, and Toxicity Outcome After Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: A Single-Institution Experience.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2016
Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci

2016
Impact of Organ-Preserving Strategies on Anorectal Function in Patients with Distal Rectal Cancer Following Neoadjuvant Chemoradiation.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:4

    Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Chemoradiotherapy; Fecal Incontin

2016
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
    American journal of clinical oncology, 2017, Volume: 40, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Fr

2017
Modified irinotecan and infusional 5-fluorouracil (mFOLFIRI) in patients with refractory advanced pancreas cancer (APC): a single-institution experience.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2016
Final analysis of a phase II study of modified FOLFIRINOX in locally advanced and metastatic pancreatic cancer.
    British journal of cancer, 2016, Mar-29, Volume: 114, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2016
Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients with Metastatic Gastroesophageal Adenocarcinoma.
    Oncology, 2016, Volume: 90, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2016
The Efficacy of Adjuvant FOLFOX6 for Patients With Gastric Cancer after D2 Lymphadenectomy: A Propensity Score-matched Analysis.
    Medicine, 2016, Volume: 95, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China; Femal

2016
A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma.
    Medical oncology (Northwood, London, England), 2016, Volume: 33, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2016
Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-
    BMJ open, 2016, 06-02, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabi

2016
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 08-10, Volume: 34, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer.
    American journal of clinical oncology, 2018, Volume: 41, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Squamous Cel

2018
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
    The oncologist, 2016, Volume: 21, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2016
LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:12

    Topics: AC133 Antigen; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Co

2016
Does the addition of oxaliplatin to preoperative chemoradiation benefit cT4 or fixed cT3 rectal cancer treatment? A subgroup analysis from a prospective study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Digestive S

2016
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program.
    BMC cancer, 2016, 08-31, Volume: 16

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2016
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora

2016
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora

2016
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora

2016
Impact of Preoperative Radiotherapy on Anastomotic Leakage and Stenosis After Rectal Cancer Resection: Post Hoc Analysis of a Randomized Controlled Trial.
    Diseases of the colon and rectum, 2016, Volume: 59, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Anastomosis, Surgical; Anastomotic Leak; Antineoplastic Agents; Chemora

2016
Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04).
    Annals of surgery, 2017, Volume: 265, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Chemoradiotherapy; Colectomy; Disease-Free Survival; Do

2017
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2016, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2016
An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma.
    Oncotarget, 2016, Dec-13, Volume: 7, Issue:50

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam

2016
EUS-guided paclitaxel injection as an adjunctive therapy to systemic chemotherapy and concurrent external beam radiation before surgery for localized or locoregional esophageal cancer: a multicenter prospective randomized trial.
    Gastrointestinal endoscopy, 2017, Volume: 86, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2017
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
    JAMA oncology, 2017, May-01, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biomar

2017
Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial.
    JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazo

2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers

2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers

2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers

2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
    JAMA oncology, 2017, Apr-01, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers

2017
Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2017, 04-01, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chemotherapy

2017
Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
    Journal of the National Cancer Institute, 2017, Volume: 109, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetu

2017
A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO).
    British journal of cancer, 2017, Feb-14, Volume: 116, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2017
Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
    Journal of cancer research and clinical oncology, 2017, Volume: 143, Issue:6

    Topics: Adenocarcinoma; Administration, Cutaneous; Administration, Oral; Adult; Aged; Aged, 80 and over; Ant

2017
Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
    Anti-cancer drugs, 2008, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dr

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, R

2008
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Pr

2008
Preoperative capecitabine and accelerated intensity-modulated radiotherapy in locally advanced rectal cancer: a phase II trial.
    American journal of clinical oncology, 2008, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy

2008
Glutathione S-transferase P1 Ile105Val polymorphism is associated with haematological toxicity in elderly rectal cancer patients receiving preoperative chemoradiotherapy.
    Drugs & aging, 2008, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil;

2008
Modified CAPOX (capecitabine plus oxaliplatin) regimen every two weeks as second-line treatment in patients with advanced colorectal cancer previously treated with irinotecan-based frontline therapy: a multicenter phase II study.
    Oncology, 2008, Volume: 74, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2008
Mobilized CD34+ cells as a biomarker candidate for the efficacy of combined maximal tolerance dose and continuous infusional chemotherapy and G-CSF surge in gastric cancer.
    Cancer letters, 2008, Nov-08, Volume: 270, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Biomark

2008
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2008
Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2008, Nov-01, Volume: 72, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Ch

2008
A phase i study of bolus 5-fluorouracil and leucovorin combined with weekly paclitaxel (FLTAX) as first-line therapy for advanced gastric cancer.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2008
A randomised phase III trial of adjuvant radio-chemotherapy comparing Irinotecan, 5FU and Leucovorin to 5FU and Leucovorin in patients with rectal cancer: a Hellenic Cooperative Oncology Group Study.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2008
Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jul-20, Volume: 26, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer.
    British journal of cancer, 2008, Aug-19, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Capecitabi

2008
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com

2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com

2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com

2008
Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN.1.3.001.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Aug-01, Volume: 26, Issue:22

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Analgesics; Antineoplastic Com

2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2008
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2008
A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2009
A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer.
    Investigational new drugs, 2009, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols

2009
Randomised trial comparing biweekly oxaliplatin plus oral capecitabine versus oxaliplatin plus i.v. bolus fluorouracil/leucovorin in metastatic colorectal cancer patients: results of the Southern Italy Cooperative Oncology study 0401.
    Journal of cancer research and clinical oncology, 2009, Volume: 135, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2009
Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297.
    International journal of radiation oncology, biology, physics, 2008, Sep-01, Volume: 72, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2008
Prognostic significance of TRAIL-R1 and TRAIL-R3 expression in metastatic colorectal carcinomas.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2008
Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer.
    Journal of Korean medical science, 2008, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2008
[Concurrent chemoradiotherapy versus radiotherapy in advanced cervical carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2008, Volume: 27, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Brachytherap

2008
An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acid

2009
Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2009
Phase I/II trial of induction chemotherapy followed by concurrent chemoradiotherapy and surgery for locoregionally advanced pancreatic cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2008
Alternating XELFOX and XELFIRI in patients with metastatic colorectal cancer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

2008
A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2009, Volume: 63, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; C

2009
[Preliminary study of biweekly regimen of docetaxel, oxaliplatin, 5-fluorouracil and leucovorin for advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2008
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Nov-01, Volume: 14, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2008
Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
    International journal of radiation oncology, biology, physics, 2009, Feb-01, Volume: 73, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2009
Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo

2008
Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2008
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2008
Combination therapy with mitomycin C (NSC-26980), 5-fluorouracil (NSC-19893), and cytosine arabinoside (NSC-63878) for advanced cancer in man.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Colorectal

1972
Histopathological response to preoperative chemoradiation for resectable pancreatic adenocarcinoma: the French Phase II FFCD 9704-SFRO Trial.
    American journal of clinical oncology, 2008, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility

2008
Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial.
    Annals of surgery, 2008, Volume: 248, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemo

2008
A phase I trial of 5-fluorouracil with cisplatin and concurrent standard-dose radiotherapy in Japanese patients with stage II/III esophageal cancer.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2009
Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: the CORGI-L Study.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2009
Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2009
Weekly high-dose 5-fluorouracil as a 24-h infusion and sodium folinic acid (AIO regimen) plus irinotecan in patients with locally advanced nonresectable and metastatic adenocarcinoma or squamous cell carcinoma of the oesophagus: a phase II trial.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2009
A phase II study of 5-fluorouracil/leucovorin in combination with paclitaxel and oxaliplatin as first-line treatment for patients with advanced gastric cancer.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2008
Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
    Oncology reports, 2009, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec

2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec

2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec

2009
Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Jun-01, Volume: 27, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec

2009
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer.
    British journal of cancer, 2009, Jan-27, Volume: 100, Issue:2

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 8

2009
Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop

2009
Oxaliplatin, 5-fluorouracil, and leucovorin as second-line treatment for advanced pancreatic cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Female;

2009
Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptot

2009
Phase II trial of erlotinib and capecitabine for patients with previously untreated metastatic colorectal cancer.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2009
An explorative randomised phase II study of sequential chemotherapy in advanced upper gastrointestinal cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2010
Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
Effect of multiple-phase regional intra-arterial infusion chemotherapy on patients with resectable pancreatic head adenocarcinoma.
    Chinese medical journal, 2009, Feb-05, Volume: 122, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Gemcitabine

2009
Phase II study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first-line therapy in patients with non-resectable gastric cancer.
    British journal of cancer, 2008, Sep-16, Volume: 99, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2008
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
    British journal of cancer, 2008, Sep-16, Volume: 99, Issue:6

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2008
A preliminary study on the postoperative survival of patients given aspirin after resection for squamous cell carcinoma of the esophagus or adenocarcinoma of the cardia.
    Annals of surgical oncology, 2009, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Carcinoma, Squamous C

2009
Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Antirheumatic Agents; Chemotherapy,

2009
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers.
    Oncology, 2009, Volume: 76, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2009
Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity.
    Anti-cancer drugs, 2009, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Chemotherapy

2009
Second-line therapy in refractory pancreatic cancer. results of a phase II study.
    Onkologie, 2009, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox

2009
Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2009
Phase II trial of capecitabine and oxaliplatin in patients with adeno- and undifferentiated carcinoma of unknown primary.
    Onkologie, 2009, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2009
Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.
    American journal of clinical oncology, 2009, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2009
Outcome of upfront combination chemotherapy followed by chemoradiation for locally advanced pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Cisplatin; Combined Modality Therapy; Deo

2009
A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, May-01, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2009
Phase II study of capecitabine plus cisplatin in patients with gastric cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C

2009
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine.
    Chinese journal of integrative medicine, 2009, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Co

2009
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
    British journal of cancer, 2009, Jun-02, Volume: 100, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2009
Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.
    Investigational new drugs, 2010, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidine; D

2010
Oxaliplatin combined with continuous infusion of 5-fluorouracil as first-line chemotherapy in patients with metastatic or recurrent gastric adenocarcinoma.
    Chemotherapy, 2009, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2009
A randomized multicentre phase II trial comparing adjuvant therapy in patients with interferon alpha-2b and 5-FU alone or in combination with either external radiation treatment and cisplatin (CapRI) or radiation alone regarding event-free survival - CapR
    BMC cancer, 2009, May-26, Volume: 9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl

2009
Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Feasibility

2009
Chemoradioimmunotherapy in locally advanced pancreatic and biliary tree adenocarcinoma: a multicenter phase II study.
    Pancreas, 2009, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabin

2009
[Oxaliplatin combined with ELF regimen in the treatment of patients with advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro

2009
Quality of life of palliative chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction treated with irinotecan combined with 5-fluorouracil and folinic acid: results of a randomised phase III trial.
    Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2009, Volume: 18, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2009
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
    Breast cancer (Tokyo, Japan), 2010, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Ax

2010
Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
    International journal of cancer, 2010, Jan-01, Volume: 126, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2010
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2010
[FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
[Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2009
A randomized study comparing short-time infusion of oxaliplatin in combination with capecitabine XELOX(30) and chronomodulated XELOX(30) as first-line therapy in patients with advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
    Breast cancer research and treatment, 2010, Volume: 119, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

2010
Role of low dose capecitabine combined to irinotecan in advanced and metastatic gastric cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2010
Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Journal of gastroenterology and hepatology, 2009, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2009
Mature results from a phase II trial of postoperative concurrent chemoradiotherapy for poor prognosis cancer of the esophagus and gastroesophageal junction.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009, Volume: 4, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2009
Postoperative chemoradiotherapy in gastric cancer--a phase I-II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma

2010
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies

2010
[Efficacy of FORFIRI regimen on oxaliplatin-based chemotherapy-failed advanced colorectal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2009
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
    Critical reviews in oncology/hematology, 2010, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2010
A phase II study of intra-arterial chemotherapy of 5-fluorouracil, cisplatin, and mitomycin C for advanced nonresectable gastric cancer.
    Anti-cancer drugs, 2009, Volume: 20, Issue:10

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2009
Association between histological type of tumour growth and patient survival in t2-t3 lymph node-negative rectal cancer treated with sphincter-preserving total mesorectal excision.
    Pathology oncology research : POR, 2010, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2010
Phase II trial of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) chemotherapy in patients with advanced biliary tree cancers.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2010
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2009
S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach.
    American journal of clinical oncology, 2010, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema

2010
A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined

2010
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Dec-01, Volume: 27, Issue:34

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2009
[Epirubicin combined with DDP and 5-Fu for treatment of advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A

2009
Using 18F-fluorodeoxyglucose positron emission tomography to monitor clinical outcomes in patients treated with neoadjuvant chemo-radiotherapy for locally advanced pancreatic cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Monitori

2010
A phase I study of capecitabine, irinotecan, celecoxib, and radiation as neoadjuvant therapy of patients with locally advanced rectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2010
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    The Lancet. Oncology, 2009, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2009
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    The Lancet. Oncology, 2009, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2009
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    The Lancet. Oncology, 2009, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2009
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.
    The Lancet. Oncology, 2009, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2009
CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Cell Cycle; Cisplatin; Cyclin D1; DNA R

2009
A phase II trial of neoadjuvant capecitabine combined with hyperfractionated accelerated radiation therapy in locally advanced rectal cancer.
    American journal of clinical oncology, 2010, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2010
Induction chemotherapy with docetaxel, 5-FU and CDDP (DFP) for advanced gastric cancer.
    Anticancer research, 2009, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2009
Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2009
Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine/cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer--a multi-centre randomis
    British journal of cancer, 2009, Dec-01, Volume: 101, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2009
Gemcitabine, oxaliplatin and 5-FU in advanced bile duct and gallbladder carcinoma: two parallel, multicentre phase-II trials.
    British journal of cancer, 2009, Dec-01, Volume: 101, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Deoxy

2009
Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

2010
Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2010
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov

2009
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov

2009
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov

2009
Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period.
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov

2009
A phase I study of axitinib (AG-013736) in combination with bevacizumab plus chemotherapy or chemotherapy alone in patients with metastatic colorectal cancer and other solid tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant

2010
Neoadjuvant docetaxel, capecitabine and cisplatin (DXP) in patients with unresectable locally advanced or metastatic gastric cancer.
    Annals of surgical oncology, 2010, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2010
Endoscopic chemotherapy with 5-fluorouracil in advanced gastric cancer.
    Journal of gastrointestinal cancer, 2010, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Endoscopy, Digestive System; Fluorou

2010
An open label randomized multicentre phase IIIb trial comparing parenteral substitution versus best supportive nutritional care in subjects with pancreatic adenocarcinoma receiving 5-FU plus oxaliplatin as 2nd or higher line chemotherapy regarding clinica
    BMC cancer, 2009, Nov-27, Volume: 9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cachexia; Fluorouracil;

2009
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2009, Dec-19, Volume: 374, Issue:9707

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

2009
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2010
Thymidine phosphorylase expression in metastatic sites is predictive for response in patients with colorectal cancer treated with continuous oral capecitabine and biweekly oxaliplatin.
    Anti-cancer drugs, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2010
A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
    American journal of clinical oncology, 2010, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dose-Resp

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER
    Lancet (London, England), 2010, Jan-30, Volume: 375, Issue:9712

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring

2010
Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-20, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2010
Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; CA-19-9 Antigen; Ca

2010
Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Cancer, 2010, May-01, Volume: 116, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast

2010
A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.
    Chinese journal of cancer, 2010, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2010
Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2011
Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2010
[Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
    Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery, 2010, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-01, Volume: 28, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2010
A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2010
A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Boronic Acids;

2010
A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Oncology, 2010, Volume: 78, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2010
Second-line chemotherapy with capecitabine (Xeloda) and docetaxel (Taxotere) in previously treated, unresectable adenocarcinoma of pancreas: the final results of a phase II trial.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Capeci

2010
Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2010
Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2010, Volume: 95, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2010
A phase I study of the biomodulation of capecitabine by docetaxel and gemcitabine (mGTX) in previously untreated patients with metastatic adenocarcinoma of the pancreas.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine;

2011
Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma.
    Journal of surgical oncology, 2010, Jun-01, Volume: 101, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Female; Fl

2010
Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after three-dimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Grou
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy

2011
Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas.
    Cancer chemotherapy and pharmacology, 2011, Volume: 67, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2011
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Prospective randomized trial evaluating mandatory second look surgery with HIPEC and CRS vs. standard of care in patients at high risk of developing colorectal peritoneal metastases.
    Trials, 2010, May-25, Volume: 11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chemotherapy

2010
Technical feasibility of laparoscopic total mesorectal excision for patients with low rectal cancer after concurrent radiation and chemotherapy with bevacizumab plus FOLFOX.
    Surgical endoscopy, 2011, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Hematology/oncology and stem cell therapy, 2010, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-10, Volume: 28, Issue:23

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents, Alkylating; Colorectal Neoplasms; Emboliza

2010
Influence of neoadjuvant chemoradiation on the number and size of analyzed lymph nodes in esophageal cancer.
    Annals of surgical oncology, 2010, Volume: 17, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2010
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer.
    Journal of surgical oncology, 2010, Aug-01, Volume: 102, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2010
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized, phase II/III REAL-3 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Sep-01, Volume: 28, Issue:25

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherap

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    The Lancet. Oncology, 2010, Volume: 11, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Feasibility study of sentinel lymph node biopsy in esophageal cancer with conservative lymphadenectomy.
    Surgical endoscopy, 2011, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Aged; Antimony; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

2011
The addition of pravastatin to chemotherapy in advanced gastric carcinoma: a randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2010, Volume: 46, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
    Lancet (London, England), 2010, Aug-28, Volume: 376, Issue:9742

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2012
Treatment of colorectal cancer with and without bevacizumab: a phase III study.
    Oncology, 2010, Volume: 78, Issue:5-6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Ant

2010
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2010, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F

2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc

2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc

2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc

2010
Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.
    JAMA, 2010, Sep-08, Volume: 304, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc

2010
No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2011
A phase I study of docetaxel, oxaliplatin, & capecitabine (DOC) as first-line therapy of patients with locally advanced or metastatic adenocarcinoma of stomach and GE junction.
    Cancer investigation, 2010, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2010
Adjuvant chemoradiotherapy of advanced resectable rectal cancer: results of a randomised trial comparing modulation of 5-fluorouracil with folinic acid or with interferon-α.
    British journal of cancer, 2010, Oct-12, Volume: 103, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Combined Chemotherapy Pro

2010
Preoperative chemoradiation with cetuximab, irinotecan, and capecitabine in patients with locally advanced resectable rectal cancer: a multicenter Phase II study.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Radiation oncology (London, England), 2010, Sep-29, Volume: 5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine;

2010
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Radiation oncology (London, England), 2010, Sep-29, Volume: 5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine;

2010
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Radiation oncology (London, England), 2010, Sep-29, Volume: 5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine;

2010
Long-term results from a randomized phase II trial of neoadjuvant combined-modality therapy for locally advanced rectal cancer.
    Radiation oncology (London, England), 2010, Sep-29, Volume: 5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine;

2010
Late patient-reported toxicity after preoperative radiotherapy or chemoradiotherapy in nonresectable rectal cancer: results from a randomized Phase III study.
    International journal of radiation oncology, biology, physics, 2011, Nov-15, Volume: 81, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Diagnostic

2011
Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer.
    International journal of radiation oncology, biology, physics, 2012, Jan-01, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplas

2012
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
    Gut, 2010, Volume: 59, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2010
Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2011
Irinotecan/fluorouracil/leucovorin or the same regimen followed by oxaliplatin/fluorouracil/leucovorin in metastatic colorectal cancer.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2010
An explorative study on the clinical utility of baseline and serial serum tumour marker measurements in advanced upper gastrointestinal cancer.
    Oncology reports, 2010, Volume: 24, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacolog

2010
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
Is concurrent radiation therapy required in patients receiving preoperative chemotherapy for adenocarcinoma of the oesophagus? A randomised phase II trial.
    European journal of cancer (Oxford, England : 1990), 2011, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2011
[Weekly irinotecan plus capecitabine as a second-line chemotherapy for advanced gastric cancer: an analysis of 21 cases].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; D

2010
Multicenter, randomized phase II trial of bevacizumab plus folinic acid, fluorouracil, gemcitabine (FFG) versus bevacizumab plus folinic acid, fluorouracil, oxaliplatin (FOLFOX4) as first-line therapy for patients with advanced colorectal cancer.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2012
Efficacy and safety of irinotecan-based chemotherapy for advanced colorectal cancer outside clinical trials: an observational study.
    Onkologie, 2010, Volume: 33, Issue:12

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2010
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
    Clinical breast cancer, 2010, Dec-01, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2010
[Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclon

2010
A Phase Ib pharmacokinetic study of the anti-angiogenic agent CKD-732 used in combination with capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer patients who progressed on irinotecan-based chemotherapy.
    Investigational new drugs, 2012, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplas

2012
Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-01, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience.
    Surgery today, 2011, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Pathologic complete response after neoadjuvant treatment for rectal cancer decreases distant recurrence and could eradicate local recurrence.
    Annals of surgical oncology, 2011, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin

2011
Normalization of T cell receptor repertoire diversity in patients with advanced colorectal cancer who responded to chemotherapy.
    Cancer science, 2011, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Case-Cont

2011
Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2012
Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2011
Preoperative oxaliplatin, capecitabine, and external beam radiotherapy in patients with newly diagnosed, primary operable, cT₃NxM0, low rectal cancer: a phase II study.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2011
Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy;

2012
A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2011
Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Mar-10, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
Randomized phase 3 trial comparing preoperative and postoperative chemoradiotherapy with capecitabine for locally advanced rectal cancer.
    Cancer, 2011, Aug-15, Volume: 117, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2011
Weekly cisplatin therapy compared with triweekly combination chemotherapy as concurrent adjuvant chemoradiation therapy after radical hysterectomy for cervical cancer.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group tri
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2011, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2011
Thymidylate synthase as a prognostic biomarker for locally advanced rectal cancer after multimodal treatment.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2011
A gene expression signature of acquired chemoresistance to cisplatin and fluorouracil combination chemotherapy in gastric cancer patients.
    PloS one, 2011, Feb-18, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cluster Analysis; Drug Re

2011
Phase II study of panitumumab, oxaliplatin, 5-fluorouracil, and concurrent radiotherapy as preoperative treatment in high-risk locally advanced rectal cancer patients (StarPan/STAR-02 Study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols;

2011
Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.
    British journal of cancer, 2011, Apr-12, Volume: 104, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2011
Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2011, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2011
Neoadjuvant and adjuvant chemotherapy of cervical cancer: mature results of the phase 2 PBM-PFU protocol.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2011, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Adenosq

2011
A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2012
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2011
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, May-20, Volume: 29, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Che

2011
Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study.
    The oncologist, 2011, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Annals of surgical oncology, 2011, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho

2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Annals of surgical oncology, 2011, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho

2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Annals of surgical oncology, 2011, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho

2011
Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial.
    Annals of surgical oncology, 2011, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Coho

2011
A Phase II study of a paclitaxel-based chemoradiation regimen with selective surgical salvage for resectable locoregionally advanced esophageal cancer: initial reporting of RTOG 0246.
    International journal of radiation oncology, biology, physics, 2012, Apr-01, Volume: 82, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2012
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
    The New England journal of medicine, 2011, May-12, Volume: 364, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial.
    Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2011
[Comparison between the effects of irinotecan or oxaliplatin combined with capecitabine in the treatment of advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Campto

2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad

2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad

2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad

2011
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jul-10, Volume: 29, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Rad

2011
A randomized phase II trial of two different 4-drug combinations in advanced pancreatic adenocarcinoma: cisplatin, capecitabine, gemcitabine plus either epirubicin or docetaxel (PEXG or PDXG regimen).
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2012
Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2012
A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003.
    Cancer, 2011, Jun-15, Volume: 117, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Combined Moda

2011
Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Survival and quality of life of patients with resected pancreatic adenocarcinoma treated with adjuvant interferon-based chemoradiation: a phase II trial.
    Annals of surgical oncology, 2011, Volume: 18, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2011
A phase II trial of neoadjuvant chemoradiation and local excision for T2N0 rectal cancer: preliminary results of the ACOSOG Z6041 trial.
    Annals of surgical oncology, 2012, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2012
Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
    British journal of cancer, 2011, Aug-09, Volume: 105, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cohort St

2011
T3+ and T4 rectal cancer patients seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen.
    Annals of surgical oncology, 2012, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2012
Preoperative radiotherapy combined with capecitabine chemotherapy in Chinese patients with locally advanced rectal cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011, Volume: 15, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv

2011
Phase II trial of neoadjuvant chemotherapy with XELOX plus bevacizumab for locally advanced rectal cancer.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2011
Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer.
    Oncology, 2011, Volume: 80, Issue:5-6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
    British journal of cancer, 2011, Sep-06, Volume: 105, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise

2011
Adjuvant capecitabine chemotherapy using a tailored-dose strategy in elderly patients with colon cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy

2012
Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study.
    Clinical advances in hematology & oncology : H&O, 2011, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2011
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine

2011
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2011
Identification of a biomarker profile associated with resistance to neoadjuvant chemoradiation therapy in rectal cancer.
    Annals of surgery, 2011, Volume: 254, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2011
[Efficacy of trsatuzumab (Herceptin) combined with FOLFIRI regimen in the treatment of HER2-positive advanced gastric cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2011, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2011
Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study.
    Radiation oncology (London, England), 2011, Aug-31, Volume: 6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2011
Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers

2012
Initial results of a randomized controlled trial comparing clinical and pathological downstaging of rectal cancer after preoperative short-course radiotherapy or long-term chemoradiotherapy, both with delayed surgery.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2012, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Drug Administrat

2012
Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Aged; Algorithms; Antimetabolites, Antineoplastic; Capecitabine; Celecoxib; Colorect

2012
Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Oct-01, Volume: 17, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2011
A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: a Japanese experience.
    Surgery today, 2011, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2011
Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer.
    International journal of radiation oncology, biology, physics, 2012, May-01, Volume: 83, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Disease-Free Survival; Dose Fract

2012
S0356: a phase II clinical and prospective molecular trial with oxaliplatin, fluorouracil, and external-beam radiation therapy before surgery for patients with esophageal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Dec-01, Volume: 29, Issue:34

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2011
Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2012
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2012
Phase II clinical study on the modified DCF regimen for treatment of advanced gastric carcinoma.
    Chinese medical journal, 2011, Volume: 124, Issue:19

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2011
Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
    International journal of radiation oncology, biology, physics, 2012, Jun-01, Volume: 83, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2012
Phase 2 study of capecitabine and irinotecan combination chemotherapy (modified XELIRI regimen) in patients with advanced gastric cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2011
Intensity-modulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Disease

2012
Combination of irinotecan and 5-fluorouracil with radiation in locally advanced rectal adenocarcinoma.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi

2012
Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2012
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.
    Lancet (London, England), 2012, Jan-28, Volume: 379, Issue:9813

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
FOLFIRI chemotherapy in patients with advanced non resectable esophageal or junctional adenocarcinoma: a pilot study.
    Journal of chemotherapy (Florence, Italy), 2011, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P

2011
Comparative analysis of the efficacy and safety of chemotherapy with oxaliplatin plus fluorouracil/leucovorin between elderly patients over 65 years and younger patients with advanced gastric cancer.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2012, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Fr

2012
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial.
    Annals of surgical oncology, 2012, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot

2012
The combination of docetaxel, cisplatin, and 5-fluorouracil in advanced gastric cancer: a single-institution experience.
    Anti-cancer drugs, 2012, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2012
A randomized phase II trial of S-1-oxaliplatin versus capecitabine-oxaliplatin in advanced gastric cancer.
    European journal of cancer (Oxford, England : 1990), 2012, Volume: 48, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2012
High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Feas

2012
Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Neoplasma, 2012, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2012
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Drug R

2012
Microsatellite instability and Beta2-Microglobulin mutations as prognostic markers in colon cancer: results of the FOGT-4 trial.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; beta 2-Microglobulin; Biomarke

2012
Phase II trial of concomitant neoadjuvant chemotherapy with oxaliplatin and capecitabine and intensity-modulated radiotherapy (IMRT) in rectal cancer.
    Journal of gastrointestinal cancer, 2012, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape

2012
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer.
    British journal of cancer, 2012, Mar-13, Volume: 106, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum.
    British journal of cancer, 2012, Apr-24, Volume: 106, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetax

2012
Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, May-10, Volume: 30, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antibodies, Monoclonal; Antibodies, Monoclonal, H

2012
A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma.
    Anti-cancer drugs, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2012
Characterisation of rectal motion during neo-adjuvant radiochemotherapy for rectal cancer with image-guided tomotherapy: implications for adaptive dose escalation strategies.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiot

2012
Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
    Gastrointestinal endoscopy, 2012, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2012
Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable fo
    British journal of cancer, 2012, May-22, Volume: 106, Issue:11

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2012
First-line sunitinib plus FOLFIRI in Japanese patients with unresectable/metastatic colorectal cancer: a phase II study.
    Cancer science, 2012, Volume: 103, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Camptothe

2012
Impact of gemcitabine chemotherapy and 3-dimensional conformal radiation therapy/5-fluorouracil on quality of life of patients managed for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2013, Jan-01, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Fema

2013
A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103).
    Breast cancer research and treatment, 2012, Volume: 134, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Ch

2012
A phase II randomized study of combined infusional leucovorin sodium and 5- FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer.
    Acta gastro-enterologica Belgica, 2012, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Ant

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Jul-01, Volume: 30, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; Female;

2012
A phase I, dose-finding study of sunitinib combined with cisplatin and 5-fluorouracil in patients with advanced gastric cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cohort Studi

2013
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2013, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Ant

2013
Concurrent chemoradiation of metastases with capecitabine and oxaliplatin and 3D-CRT in patients with oligometastatic colorectal cancer: results of a phase I study.
    Radiation oncology (London, England), 2012, Jun-09, Volume: 7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2012
Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Surgery, 2012, Volume: 152, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2012
Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2012
Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO){dagger}.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2012
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.
    Investigational new drugs, 2013, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplasti

2013
Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chem

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.
    JAMA, 2012, Jul-11, Volume: 308, Issue:2

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy

2012
Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer.
    Investigational new drugs, 2013, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2013
Multicenter phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2013, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Deoxy

2013
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial.
    The Lancet. Oncology, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Multi-institutional experience with FOLFIRINOX in pancreatic adenocarcinoma.
    JOP : Journal of the pancreas, 2012, Sep-10, Volume: 13, Issue:5

    Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptot

2012
Phase 3 trial of postoperative chemotherapy alone versus chemoradiation therapy in stage III-IV gastric cancer treated with R0 gastrectomy and D2 lymph node dissection.
    International journal of radiation oncology, biology, physics, 2012, Dec-01, Volume: 84, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Disease-Free Survival; Female; F

2012
Open-label, multicenter, randomized phase III trial of adjuvant chemoradiation plus interferon Alfa-2b versus fluorouracil and folinic acid for patients with resected pancreatic adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012, Nov-20, Volume: 30, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem

2012
A phase I trial of nab-paclitaxel, gemcitabine, and capecitabine for metastatic pancreatic cancer.
    Cancer chemotherapy and pharmacology, 2012, Volume: 70, Issue:6

    Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Albumins; Antineoplastic Combined Chemotherapy Proto

2012
Phase I - II study to assess the feasibility and activity of the triple combination of 5-fluorouracil/folinic acid, carboplatin and irinotecan (CPT-11) administered by chronomodulated infusion for the treatment of advanced colorectal cancer. Final report
    Pathologie-biologie, 2013, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2013
Docetaxel-based preoperative chemoradiation in localized gastric cancer: impact of pathological complete response on patient outcome.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisp

2013
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2013
A phase II study of bevacizumab, oxaliplatin, and capecitabine in patients with previously untreated metastatic colorectal cancer: a prospective, multicenter trial of the Korean Cancer Study Group.
    American journal of clinical oncology, 2014, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2013
Effect of portal vein chemotherapy on liver metastasis after surgical resection of colorectal cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Catheters, Indwelling; Colorectal Neoplasms; Fluoro

2012
A randomized phase II study of biweekly irinotecan monotherapy or a combination of irinotecan plus 5-fluorouracil/leucovorin (mFOLFIRI) in patients with metastatic gastric adenocarcinoma refractory to or progressive after first-line chemotherapy.
    Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2013
Phase I study of oxaliplatin in combination with gemcitabine, irinotecan, and 5-fluorouracil/leucovorin (G-FLIE) in patients with metastatic solid tumors including adenocarcinoma of the pancreas.
    Journal of gastrointestinal cancer, 2013, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycyti

2013
A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.
    American journal of clinical oncology, 2014, Volume: 37, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-01, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2013
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
    BMC cancer, 2012, Dec-10, Volume: 12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabin

2012
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc

2013
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc

2013
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc

2013
Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer: a phase 2 study.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canc

2013
Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jan-20, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi

2013
Does preoperative radiotherapy with postoperative chemotherapy increase acute side-effects and postoperative complications of total mesorectal excision? Report of the randomized Finnish rectal cancer trial.
    Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society, 2012, Volume: 101, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co

2012
Preoperative short-course concurrent chemoradiation therapy followed by delayed surgery for locally advanced rectal cancer: a phase 2 multicenter study (KROG 10-01).
    International journal of radiation oncology, biology, physics, 2013, May-01, Volume: 86, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Dose Fractionation,

2013
Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2013
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy for peritoneal recurrence of colorectal and appendiceal peritoneal carcinomatosis following prior primary cytoreduction.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Appendiceal Neoplasms; Chemotherapy, Adjuvant; Chemoth

2013
[A phase II prospective randomized controlled trial of weekly paclitaxel combined with S-1 or fluorouracil for advanced gastric carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea;

2012
Phase II trial of first-line chemoradiotherapy with intensity-modulated radiation therapy followed by chemotherapy for synchronous unresectable distant metastases rectal adenocarcinoma.
    Radiation oncology (London, England), 2013, Jan-07, Volume: 8

    Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Combined Modality Therapy; Deoxycytidi

2013
Prognostic significance of serum levels of vascular endothelial growth factor and insulin-like growth factor-1 in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    Chemotherapy, 2012, Volume: 58, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Enzyme-Linked I

2012
Assessment and comparison of recovery after open and minimally invasive esophagectomy for cancer: an exploratory study in two centers.
    Annals of surgical oncology, 2013, Volume: 20, Issue:6

    Topics: Activities of Daily Living; Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemoth

2013
The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial.
    Medical oncology (Northwood, London, England), 2013, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2013
Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer.
    British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm

2013
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
    British journal of cancer, 2013, Feb-19, Volume: 108, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Camp

2013
Clinical relevance of positron emission tomography/computed tomography-positive inguinal nodes in rectal cancer after neoadjuvant chemoradiation.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2013, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Disease-F

2013
Long-term results of preoperative 5-fluorouracil-oxaliplatin chemoradiation therapy in locally advanced rectal cancer.
    Anticancer research, 2013, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise

2013
High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
    Onkologie, 2002, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do

2002
Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks in advanced colorectal carcinoma: a randomised study by the Southern Italy Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Camptot

2002
Nephrotoxicity of heptaplatin: a randomized comparison with cisplatin in advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2002, Volume: 50, Issue:2

    Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protoc

2002
A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cis

2002
Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2002
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2002
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2002
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2002
A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2002
A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma.
    Chemotherapy, 2002, Volume: 48, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2002
Oxaliplatin, fluorouracil and leucovorin for advanced biliary system adenocarcinomas: a prospective phase II trial.
    British journal of cancer, 2002, Sep-23, Volume: 87, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2002
Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3-T4 unresectable rectal cancer: a phase II IATTGI study.
    International journal of radiation oncology, biology, physics, 2002, Oct-01, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase I trial evaluating the concurrent combination of radiotherapy and capecitabine in rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2002
Phase II trial of 5-fluorouracil plus eniluracil in patients with advanced pancreatic cancer: a Southwest Oncology Group study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; D

2002
Preoperative chemoradiotherapy for squamous cell carcinoma and adenocarcinoma of the esophagus: a phase II study.
    Chest, 2002, Volume: 122, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2002
Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2002
A phase I study of weekly docetaxel, 24-hour infusion of high-dose fluorouracil/leucovorin and cisplatin in patients with advanced gastric cancer.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2002
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study.
    Oncology, 2002, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Phase I study of gemcitabine in combination with cisplatin, 5-fluorouracil and folinic acid in patients with advanced esophageal cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2002
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil and cisplatin.
    Pancreas, 2002, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Female; Fluor

2002
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2002
A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle

2002
Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease

2002
Adding weekly irinotecan to high-dose 5-fluorouracil and folinic acid (HD-5-FU/FA) after failure for first-line HD-5-FU/FA in advanced colorectal cancer--a phase II study.
    Anti-cancer drugs, 2002, Volume: 13, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Phase II study of repeated single 24-hour infusion of low-dose 5-fluorouracil for palliation in symptomatic hormone-refractory prostate cancer.
    Urologia internationalis, 2002, Volume: 69, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antimetabolites, Antineoplastic; Drug

2002
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2002
Irinotecan combined with bolus 5-fluorouracil and folinic acid Nordic schedule as first-line therapy in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Nee

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Capecit

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Dec-01, Volume: 20, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2002
Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2002
Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols

2003
Phase II trial of preoperative 3D conformal radiotherapy, protracted venous infusion 5-fluorouracil, and weekly CPT-11, followed by surgery for ultrasound-staged T3 rectal cancer.
    International journal of radiation oncology, biology, physics, 2003, Jan-01, Volume: 55, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined

2003
Biweekly bolus 5-fluorouracil and leucovorin plus oxaliplatin in pretreated patients with advanced colorectal cancer: a dose-finding study.
    Anti-cancer drugs, 2003, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2003
Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial.
    Lancet (London, England), 2003, Feb-01, Volume: 361, Issue:9355

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch

2003
Early results from a phase I/II radiation dose-escalation study with concurrent amifostine and infusional 5-fluorouracil chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
    Seminars in oncology, 2002, Volume: 29, Issue:6 Suppl 19

    Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Combined Modality Therapy; Cytoprotecti

2002
Preoperative chemoradiotherapy in cancer of the thoracic esophagus.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2003, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2003
Etoposide, doxorubicin and cisplatin alternating with 5-fluorouracil, doxorubicin and high-dose methotrexate in patients with advanced adenocarcinoma of the stomach or the gastroesophageal junction.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

2002
Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2003
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni

2003
Intraoperative and conformal external-beam radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic carcinoma.
    Cancer, 2003, Mar-01, Volume: 97, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu

2003
A phase II trial of weekly paclitaxel, 5-fluorouracil, and leucovorin as first-line treatment for metastatic breast cancer.
    Breast cancer research and treatment, 2003, Volume: 77, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea

2003
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
    Onkologie, 2003, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Doc

2003
Investigation into the usefulness and adverse events of CDDP, 5-fU and dl-leucovorin (PFL-therapy) for advanced colorectal cancer.
    Journal of medical and dental sciences, 2002, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisp

2002
Preoperative concurrent chemoradiotherapy in locally advanced rectal cancer with high-dose radiation and oxaliplatin-containing regimen: the Lyon R0-04 phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-15, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2003
Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; B

2003
Neoadjuvant preoperative chemoradiation in patients with pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2003, Apr-01, Volume: 55, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2003
Comparison of a 48-hour infusion of 5-fluorouracil without folinic acid with 24-hour folinic acid/5-fluorouracil in patients with metastatic colorectal cancer refractory to bolus folinic acid/5-fluorouracil. A prospective cohort study.
    Chemotherapy, 2003, Volume: 49, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colorec

2003
Prospective evaluation of efficacy and toxicity of 5-fu and folinic acid (Mayo Clinic regimen) in patients with advanced cancer of the gallbladder.
    American journal of clinical oncology, 2003, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gallbladder Neoplasms; Humans

2003
Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
    American journal of clinical oncology, 2003, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2003
Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer.
    International journal of radiation oncology, biology, physics, 2003, Jun-01, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2003
A pilot study of edrecolomab (Panorex, 17-1A antibody) and capecitabine in patients with advanced or metastatic adenocarcinoma.
    Cancer investigation, 2003, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigen

2003
An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.
    European journal of cancer (Oxford, England : 1990), 2003, Volume: 39, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

2003
Phase II multicentre study of docetaxel plus 5-fluorouracil in patients with anthracycline-pretreated metastatic breast cancer.
    British journal of cancer, 2003, Jun-02, Volume: 88, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

2003
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
    British journal of cancer, 2003, Jun-16, Volume: 88, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Efficacy of chemoradiotherapy on pain relief in patients with intrapelvic recurrence of rectal cancer.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther

2003
Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms

2003
Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Jul-15, Volume: 21, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2003
A novel biweekly pancreatic cancer treatment schedule with gemcitabine, 5-fluorouracil and folinic acid.
    British journal of cancer, 2003, Jul-21, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox

2003
Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chi-Squar

2003
First-line chemotherapy with 5-FU and platinum for advanced and recurrent cancer of the cervix: a phase II study.
    Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology, 2003, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

2003
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Confidence I

2003
Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Chi-S

2003
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin

2003
Oxaliplatin with weekly bolus 5-fluorouracil and leucovorin in pretreated advanced colorectal cancer patients: a phase II study.
    Chemotherapy, 2003, Volume: 49, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy.
    International journal of radiation oncology, biology, physics, 2003, Sep-01, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Austria; CA-19-9 Antige

2003
Long-term outcome of phase II trial evaluating chemotherapy, chemoradiotherapy, and surgery for locoregionally advanced esophageal cancer.
    International journal of radiation oncology, biology, physics, 2003, Sep-01, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2003
[A prospective study of combined chemoradiotherapy followed by surgery in the treatment of esophageal carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2003, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2003
Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
    Yonsei medical journal, 2003, Aug-30, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant;

2003
Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Clinical colorectal cancer, 2003, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2003
Postoperative chemoradiotherapy for gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2003, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Follow

2003
Irinotecan plus leucovorin-modulated 5-fluorouracil I.V. bolus every other week may be a suitable therapeutic option also for elderly patients with metastatic colorectal carcinoma.
    British journal of cancer, 2003, Sep-15, Volume: 89, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2003
Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up.
    International journal of colorectal disease, 2004, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Administration, Oral; Aged; Antimetabolites, Antineoplastic;

2004
Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study.
    Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm

2003
Analysis of surgical salvage after failure of primary therapy in rectal cancer: results from Intergroup Study 0114.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2003
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2003, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2003
Biweekly low-dose sequential gemcitabine, 5-fluorouracil, leucovorin, and cisplatin (GFP): a highly active novel therapy for metastatic adenocarcinoma of the exocrine pancreas.
    Cancer investigation, 2003, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin

2003
A phase II study of modified deGramont 5-fluorouracil, leucovorin, and oxaliplatin in previously treated patients with metastatic colorectal cancer.
    Cancer investigation, 2003, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2003
Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation.
    British journal of cancer, 2003, Oct-20, Volume: 89, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2003
Survival following intensive preoperative combined modality therapy with paclitaxel, cisplatin, 5-fluorouracil, and radiation in resectable esophageal carcinoma: a phase I report.
    The Journal of thoracic and cardiovascular surgery, 2003, Volume: 126, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2003
[The modern organ- and function-sparing surgical treatment in oncology].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2003, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci

2003
Intensity modulated radiation therapy and chemotherapy for locally advanced pancreatic cancer: results of feasibility study.
    World journal of gastroenterology, 2003, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fea

2003
Treatment of oesophageal cancer with preoperative chemoradiotherapy may increase operative mortality.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2003
Endoscopic response predicts for survival and organ preservation after primary chemoradiotherapy for esophageal cancer.
    International journal of radiation oncology, biology, physics, 2003, Dec-01, Volume: 57, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2003
Protracted infusional 5-fluorouracil plus high-dose folinic acid combined with bolus mitomycin C in patients with gastrointestinal cancer: a phase I/II dose escalation study.
    British journal of cancer, 2003, Dec-01, Volume: 89, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2003
Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study.
    American journal of clinical oncology, 2003, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caff

2003
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jan-01, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2004
Usefulness of preoperative chemoradiation in locally advanced cervical carcinoma.
    Gynecologic and obstetric investigation, 2004, Volume: 57, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2004
Irinotecan (CPT-11) in metastatic colorectal cancer patients resistant to 5-fluorouracil (5-FU): a phase II study.
    Methods and findings in experimental and clinical pharmacology, 2003, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Alopecia; Camptothecin; Chemotherapy, Adjuvant; Colorectal

2003
Randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP, 5-FU and dl-leucovorin for advanced colorectal cancer.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2004
A Phase II study of weekly irinotecan and capecitabine in patients with previously treated non-small cell lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-01, Volume: 9, Issue:16 Pt 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2003
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2004
Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.
    British journal of cancer, 2004, Jan-26, Volume: 90, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2004
Prophylactic hepatic arterial infusion chemotherapy for the prevention of liver metastasis in patients with colon carcinoma: a randomized control trial.
    Cancer, 2004, Feb-01, Volume: 100, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chi-Square Distribution; Colectomy; Colonic Neoplasms;

2004
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; D

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Feb-15, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

2004
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
    International journal of radiation oncology, biology, physics, 2004, Mar-01, Volume: 58, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2004
Nordic 5-fluorouracil/leucovorin bolus schedule combined with oxaliplatin (Nordic FLOX) as first-line treatment of metastatic colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2003
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-01, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach

2004
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-01, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach

2004
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-01, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach

2004
Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Mar-01, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Brach

2004
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
    Clinical colorectal cancer, 2004, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Circadian Rhythm; Colorectal Neoplasms; Fluorouracil; Humans;

2004
Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi

2004
A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Dose-Res

2004
Pegylated liposomal doxorubicin in combination with mitomycin C, infusional 5-fluorouracil and sodium folinic acid. A phase-I-study in patients with upper gastrointestinal cancer.
    British journal of cancer, 2004, May-17, Volume: 90, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholangiocarcinoma; Dox

2004
Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti

2004
Randomized trial of intraportal and/or systemic adjuvant chemotherapy in patients with colon carcinoma.
    Journal of the National Cancer Institute, 2004, May-19, Volume: 96, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2004
Patterns of failure in gastric carcinoma after D2 gastrectomy and chemoradiotherapy: a radiation oncologist's view.
    British journal of cancer, 2004, Jul-05, Volume: 91, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas

2004
Regional pelvic hyperthermia as an adjunct to chemotherapy (oxaliplatin, folinic acid, 5-fluorouracil) in pre-irradiated patients with locally recurrent rectal cancer: a pilot study.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2004, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combine

2004
Gemcitabine (GEM), 5-fluorouracil (5-FU) and folinic acid (FA) in patients with different gastroenteric malignancies.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox

2004
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma.
    Cancer, 2004, Jul-01, Volume: 101, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

2004
Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma.
    BMC cancer, 2004, Jul-10, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cause of

2004
Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Jul-15, Volume: 22, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2004
Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin;

2004
Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer.
    BMC cancer, 2004, Jul-16, Volume: 4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2004
Irinotecan plus folinic acid/continuous 5-fluorouracil as simplified bimonthly FOLFIRI regimen for first-line therapy of metastatic colorectal cancer.
    BMC cancer, 2004, Jul-20, Volume: 4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2004
Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2004
Gemcitabine combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced carcinoma of the pancreas.
    Chemotherapy, 2004, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2004
Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01.
    Journal of the National Cancer Institute, 2004, Aug-04, Volume: 96, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer.
    British journal of cancer, 2004, Sep-13, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
First-line chemotherapy with irinotecan plus capecitabine for advanced colorectal cancer.
    Oncology, 2004, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2004
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
    International journal of radiation oncology, biology, physics, 2004, Sep-01, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2004
Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
    Japanese journal of clinical oncology, 2004, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic C

2004
Enhanced induction of apoptosis in lung adenocarcinoma after preoperative chemotherapy with tegafur and uracil (UFT).
    Surgery today, 2004, Volume: 34, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2004
Weekly irinotecan (CPT-11) in 5-FU heavily pretreated and poor-performance-status patients with advanced colorectal cancer.
    Medical oncology (Northwood, London, England), 2004, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Cam

2004
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Nov-01, Volume: 22, Issue:21

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

2004
Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion.
    International journal of colorectal disease, 2005, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colonic Neoplasm

2005
Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer.
    International journal of clinical oncology, 2004, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2004
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2004
Phase I study of hyperfractionated radiation therapy with protracted 5-fluorouracil infusion in patients with locally advanced pancreatic cancer.
    Oncology, 2004, Volume: 67, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation; Drug Ad

2004
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Cancer, 2005, Jan-01, Volume: 103, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2005
Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-01, Volume: 22, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2004
Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen.
    American journal of clinical oncology, 2004, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2004
Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004, Dec-15, Volume: 22, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2004
Irinotecan and capecitabine as second-line treatment after failure for first-line infusional 24-h 5-fluorouracil/folinic acid in advanced colorectal cancer: a phase II study.
    Anti-cancer drugs, 2005, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2005
Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-20, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2005
Concurrent RT with 5-FU/epirubicin and cisplatin or irinotecan for locally advanced upper GI adenocarcinoma.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemother

2004
Irinotecan, epirubicin, and capecitabine in metastatic adenocarcinomas: preliminary results of a phase I study.
    Oncology (Williston Park, N.Y.), 2004, Volume: 18, Issue:14 Suppl 1

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents,

2004
Gemcitabine versus FLEC regimen given intra-arterially to patients with unresectable pancreatic cancer: a prospective, randomized phase III trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
    Journal of chemotherapy (Florence, Italy), 2004, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2004
Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma.
    The oncologist, 2005, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Duodenal Neoplas

2005
Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
    British journal of cancer, 2005, Mar-14, Volume: 92, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2005
How accurate is magnetic resonance imaging in restaging rectal cancer in patients receiving preoperative combined chemoradiotherapy?
    Diseases of the colon and rectum, 2005, Volume: 48, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2005
[Trial of outpatient anti-cancer chemotherapy with infusion of 5-FU and cisplatin for advanced gastric and colorectal cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; C

2005
5-fluorouracil intra-arterial infusion combined with systemic gemcitabine for unresectable pancreatic cancer.
    Pancreas, 2005, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
Intensified concurrent chemoradiotherapy with 5-fluorouracil and irinotecan as neoadjuvant treatment in patients with locally advanced rectal cancer.
    British journal of cancer, 2005, Apr-11, Volume: 92, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined

2005
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Apr-01, Volume: 23, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2005
Phase III trial of postoperative cisplatin, interferon alpha-2b, and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma -- CapRI: study protocol [ISRCTN62866759].
    BMC cancer, 2005, Apr-12, Volume: 5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin; Clinic

2005
Phase I trial of oxaliplatin in combination with cisplatin, protacted-infusion fluorouracil, and radiotherapy in advanced esophageal and gastroesophageal carcinoma.
    International journal of radiation oncology, biology, physics, 2005, May-01, Volume: 62, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2005
A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients.
    British journal of cancer, 2005, May-09, Volume: 92, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; D

2005
Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2005
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
    British journal of cancer, 2005, May-23, Volume: 92, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neopl

2005
A phase II and pharmacologic study of fluorouracil given by a 1-hour infusion daily for 5 days with leucovorin and interferon alpha-2a in adenocarcinoma of the large bowel.
    Oncology reports, 2005, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Color

2005
Phase II study of paclitaxel and carboplatin in advanced gastric cancer previously treated with 5-fluorouracil and platinum.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carbo

2005
Promising results of a cooperative group phase II trial of preoperative chemoradiation for locally advanced rectal cancer (TROG 9801).
    Diseases of the colon and rectum, 2005, Volume: 48, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Dose Fractionation, Radia

2005
Adjuvant chemoradiation using 5-fluorouracil/folinic acid/cisplatin with or without paclitaxel and radiation in patients with completely resected high-risk gastric cancer: two cooperative phase II studies of the AIO/ARO/ACO.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2005
Phase II trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2005
Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.
    The Lancet. Oncology, 2005, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2005
Salvage chemotherapy with irinotecan and cisplatin in patients with metastatic gastric cancer failing both 5-fluorouracil and taxanes.
    Anti-cancer drugs, 2005, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2005
Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer.
    British journal of cancer, 2005, Jun-20, Volume: 92, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagog

2005
Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial.
    British journal of cancer, 2005, Jun-20, Volume: 92, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam

2005
S-phase modulation by irinotecan: pilot studies in advanced solid tumors.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2005
Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; DNA, Neoplasm; Drug Administrati

2005
Treatment of rectal cancer by chemoradiation followed by surgery: analysis and early clinical outcome in 66 patients.
    The Israel Medical Association journal : IMAJ, 2005, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem

2005
Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2006
Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer.
    Oncology, 2005, Volume: 68, Issue:2-3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A

2005
Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
    Investigational new drugs, 2005, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy

2005
Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma.
    Oncology, 2005, Volume: 68, Issue:2-3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2005
A phase II study of epirubicin, cisplatin and capecitabine combination chemotherapy in patients with metastatic or advanced gastric cancer.
    Oncology, 2005, Volume: 68, Issue:4-6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2005
A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282.
    International journal of radiation oncology, biology, physics, 2005, Aug-01, Volume: 62, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2005
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
Fluoropyrimidine therapy: hyperbilirubinemia as a consequence of hemolysis.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr

2005
Phase I/II trial of intraperitoneal 5-Fluorouracil with and without intravenous vasopressin in non-resectable pancreas cancer.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2005
Phase I study of docetaxel, capecitabine, and carboplatin in metastatic esophagogastric cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area

2005
Multicenter phase II study of oral capecitabine plus irinotecan as first-line chemotherapy in advanced colorectal cancer: a Korean Cancer Study Group trial.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant

2005
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2005
Liver resection after irinotecan, 5-fluorouracil, and folinic acid for patients with unresectable colorectal liver metastases: a multicenter phase II study by the Cancer Therapeutic Research Group.
    Medical oncology (Northwood, London, England), 2005, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma.
    Oncology, 2005, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2005
Second-line intra-arterial chemotherapy in advanced pancreatic adenocarcinoma.
    Frontiers in bioscience : a journal and virtual library, 2006, Jan-01, Volume: 11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2006
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2005, Oct-01, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy;

2005
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2005, Oct-01, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy;

2005
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2005, Oct-01, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy;

2005
Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2005, Oct-01, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality Therapy;

2005
Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2005
Randomised phase II study of standard versus chronomodulated CPT-11 plus chronomodulated 5-fluorouracil and folinic acid in advanced colorectal cancer patients.
    European journal of cancer (Oxford, England : 1990), 2006, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2006
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Carcinoma; Carcinom

2005
A phase I dose escalation study of continuous oral capecitabine in combination with oxaliplatin and pelvic radiation (XELOX-RT) in patients with locally advanced rectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2006
Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic A

2006
Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial.
    Digestive surgery, 2005, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chi-Square Distributi

2005
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2006
Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemot

2005
Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Dec-01, Volume: 23, Issue:34

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therapy; Deox

2005
A multicenter phase II study of "adjuvant" irinotecan following resection of colorectal hepatic metastases.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Bio

2005
Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2005
Epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study.
    Anti-cancer drugs, 2006, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2006
Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Acta oncologica (Stockholm, Sweden), 2005, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2005
Phase II study of epirubicin, cisplatin, and capecitabine for advanced biliary tract adenocarcinoma.
    Cancer, 2006, Jan-15, Volume: 106, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2006
FOLFOX alternated with FOLFIRI as first-line chemotherapy for metastatic colorectal cancer.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2005
Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Age

2005
[Effectiveness of 5-fluoruracil and vinorelbine in patients who had received multi-treatments for metastatic breast cancer].
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Female; Flu

2005
Clinical pharmacokinetics of oxaliplatin and 5-fluorouracil administered in combination with leucovorin in Korean patients with advanced colorectal cancer.
    Journal of cancer research and clinical oncology, 2006, Volume: 132, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Creatini

2006
Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil.
    Anti-cancer drugs, 2006, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2006
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Feb-01, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2006
A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer.
    Oncology, 2006, Volume: 70, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2006
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2006
Longitudinal quality of life study in patients with metastatic gastric cancer. Analysis modalities and clinical applicability of QoL in randomized phase II trial in a digestive oncology.
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2005
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncolog
    British journal of cancer, 2006, Mar-27, Volume: 94, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2006
Phase II trial alternating FOLFOX-6 and FOLFIRI regimens in second-line therapy of patients with metastatic colorectal cancer (FIREFOX study).
    Cancer investigation, 2006, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo

2006
A phase II study of capecitabine plus 3-weekly oxaliplatin as first-line therapy for patients with advanced gastric cancer.
    British journal of cancer, 2006, Apr-10, Volume: 94, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2006
Epoetin alfa improves survival after chemoradiation for stage III esophageal cancer: final results of a prospective observational study.
    International journal of radiation oncology, biology, physics, 2006, Jun-01, Volume: 65, Issue:2

    Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squ

2006
Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Apr-20, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2006
A phase I and II study of 2-weekly irinotecan with capecitabine in advanced gastroesophageal adenocarcinoma.
    British journal of cancer, 2006, May-08, Volume: 94, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2006
Significance of histologic type of primary lesion and metastatic lymph nodes as a prognostic factor in stage III colon cancer.
    Diseases of the colon and rectum, 2006, Volume: 49, Issue:7

    Topics: Adenocarcinoma; Alkylating Agents; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic

2006
Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Fe

2006
Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2006
Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2006
Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Jun-01, Volume: 24, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2006
Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer.
    British journal of cancer, 2006, May-22, Volume: 94, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2006
[Study on efficacy and toxicity of new combined regimen "taxoter + cisplatin + 5-fluorouracil" in disseminated and locally-spread stomach cancer. Comparative analysis of tolerance and efficacy in patients younger and older than 65 years].
    Advances in gerontology = Uspekhi gerontologii, 2006, Volume: 18

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2006
Pilot study of preoperative combined modality treatment for locally advanced operable oesophageal carcinoma: toxicities and long-term outcome.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplas

2006
Symptomatic responses to neoadjuvant chemotherapy for carcinoma of the oesophagus and oesophagogastric junction: are they worth measuring?
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2006, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2006
Biweekly oxaliplatin, raltitrexed, 5-fluorouracil and folinic acid combination chemotherapy during preoperative radiation therapy for locally advanced rectal cancer: a phase I-II study.
    British journal of cancer, 2006, Jun-19, Volume: 94, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2006
Raltitrexed plus levofolinic acid and bolus/continuous infusion 5-fluorouracil on a biweekly schedule for elderly patients with advanced colorectal carcinomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17 Suppl 7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2006
[Efficacy of Avastin in combination with irinotecan for metastatic colorectal cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2006, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2006
Phase II multicenter trial of docetaxel, epirubicin, and 5-fluorouracil (DEF) in the treatment of advanced gastric cancer: a novel, safe, and active regimen.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2006, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel;

2006
Regional combined with systemic chemotherapy in unresectable biliary tract cancers: a phase II study.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary

2003
Randomised trial of gemcitabine versus flec regimen given intra-arterially for patients with unresectable pancreatic cancer.
    Journal of experimental & clinical cancer research : CR, 2003, Volume: 22, Issue:4 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2003
A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2006
Feasibility of preoperative combined radiation therapy and chemotherapy with 5-fluorouracil and cisplatin in potentially resectable pancreatic adenocarcinoma: The French SFRO-FFCD 97-04 Phase II trial.
    International journal of radiation oncology, biology, physics, 2006, Aug-01, Volume: 65, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2006
Erythropoietin-alfa during neoadjuvant chemotherapy for locally advanced esophagogastric adenocarcinoma.
    The Annals of thoracic surgery, 2006, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Anemia; Antineoplastic Combined Chemotherapy Protocols;

2006
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 59, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin

2007
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
    The New England journal of medicine, 2006, Jul-06, Volume: 355, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2006
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Cancer, 2006, Aug-15, Volume: 107, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2006
Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: a Southwest Oncology Group study.
    Investigational new drugs, 2006, Volume: 24, Issue:6

    Topics: Acetates; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Proto

2006
Quality of life assessment in advanced pancreatic adenocarcinoma: results from a phase III randomized trial.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2006, Volume: 6, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2006
Complications, functional outcome and quality of life after intensive preoperative chemoradiotherapy for rectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2006, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D

2006
The synchronization of chemotherapy to circadian rhythms and irradiation in pre-operative chemoradiation therapy with hyperthermia for local advanced rectal cancer.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2006, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chronotherapy; Combined Modality Therapy; Fem

2006
A phase II study of combined chemotherapy with methotrexate, 5-fluorouracil, and low-dose cisplatin (MFP) for histologically diffuse-type advanced and recurrent gastric cancer (KDOG9501).
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2006, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2006
[Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2006, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca

2006
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2007
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2007
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2007
Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2007
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Chemotherapy with preoperative radiotherapy in rectal cancer.
    The New England journal of medicine, 2006, Sep-14, Volume: 355, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Oct-01, Volume: 24, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Phase II trial of preoperative chemoradiation with a hyperfractionated radiation boost in locally advanced rectal cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2006
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2006
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
    Clinical genitourinary cancer, 2006, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2006
Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2007
Gemcitabine, oxaliplatin and weekly high-dose 5-FU as 24-h infusion in chemonaive patients with advanced or metastatic pancreatic adenocarcinoma: a multicenter phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres

2007
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
Capecitabine as a radiosensitizing agent in neoadjuvant treatment of locally advanced resectable rectal cancer: prospective phase II trial.
    Croatian medical journal, 2006, Volume: 47, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2006
A phase II trial of docetaxel plus capecitabine in patients with previously treated non-small cell lung cancer.
    Japanese journal of clinical oncology, 2006, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma

2006
A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation.
    Pharmacogenetics and genomics, 2006, Volume: 16, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2006
A phase I/II trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer.
    Investigational new drugs, 2007, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Celecoxib; Cisplatin; Combined Modality Therapy;

2007
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Nov-01, Volume: 24, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; D

2006
Phase II trial of capecitabine and oxaliplatin (CAPOX) plus cetuximab in patients with metastatic colorectal cancer who progressed after oxaliplatin-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
Phase II study of preoperative paclitaxel/cisplatin with radiotherapy in locally advanced esophageal cancer.
    International journal of radiation oncology, biology, physics, 2007, Feb-01, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy

2007
Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF).
    BMC cancer, 2006, Dec-05, Volume: 6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do

2006
Radiochemotherapy followed by gemcitabine and capecitabine in extrahepatic bile duct cancer: a phase I/II trial.
    American journal of clinical oncology, 2006, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi

2006
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
    International journal of radiation oncology, biology, physics, 2007, Mar-15, Volume: 67, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Capecitabine

2007
Impact of interferon-alpha in combined chemoradioimmunotherapy for pancreatic adenocarcinoma (CapRI): first data from the immunomonitoring.
    Journal of immunotherapy (Hagerstown, Md. : 1997), 2007, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality

2007
Results of adjuvant radiochemotherapy for gastric adenocarcinoma in Slovenia.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; F

2007
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
    American journal of clinical oncology, 2007, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2007
The tolerance and efficacy of preoperative chemoradiotherapy followed by gastrectomy in operable gastric cancer, a phase II study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2007, Volume: 82, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Female; Fluorouracil; Gastrectomy; Hum

2007
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.
    British journal of cancer, 2007, Mar-26, Volume: 96, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
Cost-effectiveness analysis of first-line chemotherapies in metastatic colorectal cancer. Results of the Fédération Francophone de Cancérologie Digestive (FFCD) 9601 randomized trial.
    Oncology, 2006, Volume: 71, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2006
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study.
    British journal of cancer, 2007, Apr-10, Volume: 96, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Colorec

2007
A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as first-line treatment in patients with advanced biliary cancers.
    Investigational new drugs, 2007, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract

2007
Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Mar-20, Volume: 25, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Austral

2007
The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2008
A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-1

2007
Preoperative radio-chemotherapy (RT-CT) in rectal cancer. Prospective study with postoperative RT-CT control group.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2007, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Amputation, Surgical; Antimetabolites, Antineoplastic; Colostomy; Combined Modality

2007
Oral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients.
    The oncologist, 2007, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Dis

2007
A phase II trial of accelerated multimodality therapy for locoregionally advanced cancer of the esophagus and gastroesophageal junction: the impact of clinical heterogeneity.
    American journal of clinical oncology, 2007, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2007
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
    Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2008
Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Denmark;

2007
A phase II study of oxaliplatin with low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFOX-4) as first line therapy for patients with advanced gastric cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; D

2007
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
    Onkologie, 2007, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Do

2007
Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, May-01, Volume: 25, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dipy

2007
A phase II study of biweekly dose-intensified oral capecitabine plus irinotecan (bXELIRI) for patients with advanced or metastatic gastric cancer.
    British journal of cancer, 2007, May-21, Volume: 96, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128.
    International journal of radiation oncology, biology, physics, 2007, Sep-01, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2007
Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
Differences in toxicity across gender in patients treated with chemoradiation for rectal cancer.
    Australasian radiology, 2007, Volume: 51, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2007
Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols;

2007
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2007
Combined modality chemoradiation in elderly oesophageal cancer patients.
    British journal of cancer, 2007, Jun-18, Volume: 96, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2007
Irinotecan with 5-FU/FA in advanced biliary tract adenocarcinomas: a multicenter phase II trial.
    American journal of clinical oncology, 2007, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biliary Tract Neoplasms; Camptothecin; Female; F

2007
Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:7

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2007
Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Cancer, 2007, Sep-15, Volume: 110, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2007
[A randomized trial of irinotecan plus fuorouracil and leucovorin with thalidomide versus without thalidomide in the treatment for advanced colorectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2007
Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer.
    British journal of cancer, 2007, Aug-20, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytidine; Disea

2007
Preoperative chemoradiotherapy with capecitabine and oxaliplatin in locally advanced rectal cancer. A phase I-II multicenter study of the Dutch Colorectal Cancer Group.
    Annals of surgical oncology, 2007, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2007
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2007
Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution

2007
Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution

2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E

2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E

2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E

2007
Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-01, Volume: 25, Issue:22

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; E

2007
A phase I-II study of postoperative capecitabine-based chemoradiotherapy in gastric cancer.
    International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2007
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-20, Volume: 25, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2007
A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2007
A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study.
    Annals of surgical oncology, 2007, Volume: 14, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct N

2007
A phase II study of preoperative capecitabine and radiation therapy in patients with rectal cancer.
    American journal of clinical oncology, 2007, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combi

2007
A phase I study of docetaxel, oxaliplatin, and capecitabine in patients with metastatic gastroesophageal cancer.
    American journal of clinical oncology, 2007, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squam

2007
Postoperative chemoradiotherapy in gastric cancer -- a Phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy.
    British journal of cancer, 2007, Sep-17, Volume: 97, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2007
Dose-intense PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) in advanced pancreatic adenocarcinoma: a dose-finding study.
    Cancer investigation, 2007, Volume: 25, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin

2007
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
    Cancer, 2007, Nov-01, Volume: 110, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Diseases; Colonic Neop

2007
Thymidylate synthase and thymidine phosphorylase gene expression as predictive parameters for the efficacy of 5-fluorouracil-based adjuvant chemotherapy for gastric cancer.
    World journal of gastroenterology, 2007, Oct-07, Volume: 13, Issue:37

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Chemotherapy, Adjuvant; Female; Fluor

2007
Feasibility of sequential therapy with FOLFIRI followed by docetaxel/cisplatin in patients with radically resected gastric adenocarcinoma. A randomized phase III trial.
    Oncology, 2006, Volume: 71, Issue:5-6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2006
Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment.
    International journal of radiation oncology, biology, physics, 2008, Jan-01, Volume: 70, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Carcinoma,

2008
Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2008
A Phase II trial of oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX4) as first-line chemotherapy in advanced colorectal cancer: a China single-center experience.
    Cancer investigation, 2007, Volume: 25, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Colorectal Neopl

2007
A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2007
Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases.
    British journal of cancer, 2007, Oct-22, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2007
A highly active and tolerable neoadjuvant regimen combining paclitaxel, carboplatin, 5-FU, and radiation therapy in patients with stage II and III esophageal cancer.
    Annals of surgical oncology, 2008, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

2008
Are increased tumor aneuploidy and heightened cell proliferation along with heterogeneity associated with patient outcome for carcinomas of the uterine cervix? A combined analysis of subjects treated in RTOG 9001 and a single-institution trial.
    International journal of radiation oncology, biology, physics, 2008, Jan-01, Volume: 70, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2008
Randomized, multicenter, phase IIb study of preoperative chemoradiotherapy in T3 mid-distal rectal cancer: raltitrexed + oxaliplatin + radiotherapy versus cisplatin + 5-fluorouracil + radiotherapy.
    International journal of radiation oncology, biology, physics, 2008, Feb-01, Volume: 70, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2008
A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2007
Phase II study of low-dose paclitaxel and cisplatin as a second-line therapy after 5-fluorouracil/platinum chemotherapy in gastric cancer.
    Journal of Korean medical science, 2007, Volume: 22 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2007
Toxicity profile and efficacy of oral capecitabine as adjuvant chemotherapy for Chinese patients with Stage III colon cancer.
    Diseases of the colon and rectum, 2007, Volume: 50, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Ch

2007
FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study.
    Cancer, 2007, Dec-15, Volume: 110, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Stud

2007
Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
    Annals of surgery, 2007, Volume: 246, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Digestive System Surgical Procedures; Disease

2007
Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Nov-01, Volume: 25, Issue:31

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality

2007
A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita

2008
[Clinical observation on treatment of 34 advanced gastric carcinoma patients by chemotherapy of DCF regimen combined with Fuzheng Hewei Decoction].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2007
Aberrant methylation of p16 predicts candidates for 5-fluorouracil-based adjuvant therapy in gastric cancer patients.
    Journal of gastroenterology, 2007, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Signet Ring Cel

2007
Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

2008
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
    British journal of cancer, 2008, Jan-15, Volume: 98, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; E

2008
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neo

2008
Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemot

2008
Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
    World journal of gastroenterology, 2007, Dec-14, Volume: 13, Issue:46

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal

2007
Phase II trial of a biweekly regimen of fluorouracil and leucovorin plus irinotecan in patients with previously untreated advanced gastric cancer.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Journal of the National Cancer Institute, 2008, Jan-16, Volume: 100, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo

2008
Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial.
    British journal of cancer, 2008, Jan-29, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2008
Esophageal cancer. A prospective phase II study of concomitant-boost external-beam chemoradiation with a top-up endoluminal boost.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

2008
Prognostic factors in patients with advanced pancreatic adenocarcinoma treated with intra-arterial chemotherapy.
    Pancreas, 2008, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

2008
[Comparative study on treatment of advanced colorectal cancer by Aidi injection combined with FOLFOX4 regimen and by FOLFOX4 regimen alone].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2007, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2007
A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2008
Phase II study of irinotecan plus leucovorin and bolus 5-fluorouracil as first- or second-line chemotherapy in patients with advanced gastric or esophageal-gastric junction adenocarcinoma.
    Journal of chemotherapy (Florence, Italy), 2007, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Esophagea

2007
Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:80

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera

2007
32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: a randomized trial.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2008, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Pancreatic Neoplasms; Phospho

2008
Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study.
    Cancer chemotherapy and pharmacology, 2008, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2008
Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2008
Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).
    Breast cancer research and treatment, 2009, Volume: 113, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2009
Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en O
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-01, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2008, Volume: 34, Issue:12

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Dr

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
    Cancer chemotherapy and pharmacology, 2008, Volume: 63, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2008
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineo

2007
A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
    Oncology, 2007, Volume: 73, Issue:1-2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplast

2007
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-20, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
    British journal of cancer, 2008, Apr-08, Volume: 98, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2008
PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) regimen as second-line therapy in patients with progressive or recurrent pancreatic cancer after gemcitabine-containing chemotherapy.
    American journal of clinical oncology, 2008, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidin

2008
A phase I trial of definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced esophageal carcinoma: Kitasato digestive disease & oncology group trial (KDOG 0501).
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2008, Volume: 87, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2008
Capecitabine, irinotecan, oxaliplatin (CAPIRINOX) and concomitant irradiation in advanced rectal cancer: the Lyon R-02-01 phase I trial.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2008, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2008
Preoperative treatment combining capecitabine with radiation therapy in rectal cancer: a GERCOR Phase II Study.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2007
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Validation of patient's self-reported social functioning as an independent prognostic factor for survival in metastatic colorectal cancer patients: results of an international study by the Chronotherapy Group of the European Organisation for Research and
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-20, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2008
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms;

2007
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms;

2007
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms;

2007
Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Bone Neoplasms;

2007
Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2008, Volume: 21, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2008
Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Surface Area; Colorec

2008
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer.
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast

2008
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.
    The Annals of thoracic surgery, 2008, Volume: 85, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2008
Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.
    BMC cancer, 2008, May-27, Volume: 8

    Topics: 3' Untranslated Regions; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols

2008
Treatment with secretin and a cholecystokinin-like peptide in patients with pancreatic cancer. A pilot study.
    Scandinavian journal of gastroenterology, 1984, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Aged; Alanine Transaminase; Alkaline Phosphatase; Amylases; Antineoplastic Combined

1984
A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group.
    Cancer, 1982, May-01, Volume: 49, Issue:9

    Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up

1982
[Chemotherapy of the non-small cell bronchogenic carcinoma].
    Onkologie, 1983, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell;

1983
The value of two combined chemoradiotherapy approaches in the treatment of inoperable esophageal cancer.
    Tumori, 1984, Feb-29, Volume: 70, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Ca

1984
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi).
    Cancer treatment reports, 1980, Volume: 64, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Clinical Trials as Topic; Drug Therapy

1980
Combined irradiation and three-drug chemotherapy in inoperable colorectal carcinoma.
    Acta radiologica. Oncology, 1982, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug

1982
A comparative clinical trial of adriamycin and 5-fluorouracil in advanced prostatic cancer: prognostic factors and response.
    The Prostate, 1983, Volume: 4, Issue:1

    Topics: Acid Phosphatase; Adenocarcinoma; Clinical Trials as Topic; Doxorubicin; Fluorouracil; Humans; Male;

1983
A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
    American journal of clinical oncology, 1983, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Drug Administration Schedu

1983
Efficacy of prolonged intermittent therapy with combined 5-FU and methyl-CCNU following resection for gastric carcinoma. A Veterans Administration Surgical Oncology, Group report.
    Cancer, 1983, Sep-15, Volume: 52, Issue:6

    Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Fluorouracil; Gastrectomy

1983
Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. A Veterans Administration Surgical Oncology Group report.
    Cancer, 1984, Jan-01, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1984
Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Seminars in oncology, 1983, Volume: 10, Issue:3 Suppl 3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Castration; Cisplatin; Clinical Tria

1983
Postmastectomy adjuvant chemotherapy with or without radiation therapy in women with operable breast cancer and positive axillary lymph nodes: the Southeastern Cancer Study Group experience.
    Breast cancer research and treatment, 1983, Volume: 3 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as

1983
5-fluorouracil, adriamycin, and BCNU (FAB) combination chemotherapy for advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 1984, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carmustine

1984
Prospective randomized reappraisal of 5-fluorouracil in metastatic colorectal carcinoma. A comparative trial with 6-thioguanine.
    Cancer, 1984, Jun-15, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Diarrhea; Female; Fluorour

1984
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Clinical T

1984
Chemotherapy of advanced colorectal carcinoma: fluorouracil alone vs. two drug combinations using fluorouracil, hydroxyurea, semustine, dacarbazine, razoxane, and mitomycin. A phase III trial by the Eastern Cooperative Oncology Group (EST: 1278).
    American journal of clinical oncology, 1984, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne

1984
[Cooperative trials of the Council of Mutual Economic Aid countries on chemoradiotherapy of lung cancer].
    Meditsinskaia radiologiia, 1984, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1984
[Effectiveness of combined and complex treatment of patients with operable cancer of the rectum].
    Voprosy onkologii, 1984, Volume: 30, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cobalt Radioisotopes; Combined Modality Thera

1984
Complications following postoperative combined radiation and chemotherapy in adenocarcinoma of the rectum and rectosigmoid. A randomized trial that failed.
    Cancer, 1984, Dec-01, Volume: 54, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M

1984
MIFA III (mitomycin-C, 5-fluorouracil, and adriamycin) chemotherapy for advanced adenocarcinoma of the pancreas.
    American journal of clinical oncology, 1984, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxo

1984
Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group.
    Cancer, 1983, Nov-15, Volume: 52, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; California; Clinical Tr

1983
Randomized study of combination chemotherapy in unresectable gastric cancer. The Gastrointestinal Tumor Study Group.
    Cancer, 1984, Jan-01, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubici

1984
Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery. Trial of the European Organization on Research and Treatment of Cancer Gastroint
    Cancer, 1984, May-01, Volume: 53, Issue:9

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colectomy; Combined Modality Therapy; Fluorouracil; Follow

1984
Drug combinations in the treatment of gastric adenocarcinoma: a randomized Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch

1984
An Eastern Cooperative Oncology Group evaluation of combinations of methyl-CCNU, mitomycin C, Adriamycin, and 5-fluorouracil in advanced measurable gastric cancer (EST 2277).
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl

1984
Preliminary research on the evaluation of some prognostic factors in a randomized study of adjuvant immunochemotherapy in colorectal adenocarcinoma.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1984, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Colonic Ne

1984
Chemotherapy of pancreatic carcinoma.
    Cancer, 1981, Mar-15, Volume: 47, Issue:6 Suppl

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Therapy, Combinat

1981
Management of patients with metastatic adenocarcinoma of unknown origin: a Southwest Oncology Group study.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Fluoroura

1983
[Biological effect of recombined leukocyte alpha-2-interferon in metastasizing colorectal cancers].
    Deutsche medizinische Wochenschrift (1946), 1984, May-18, Volume: 109, Issue:20

    Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Herpes Labialis; Humans; Hypotension

1984
Treatment of advanced gastric cancer with 5-fluorouracil versus mitomycin C.
    Journal of surgical oncology, 1982, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Clinical Trials as Topic; Female; Fluorouracil; Humans; Male; Middle Aged; Mi

1982
[Antiblastic therapy of nonadvanced colorectal cancer: preliminary results of a randomized therapeutic trial].
    Annali italiani di chirurgia, 1982, Volume: 54, Issue:1

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluo

1982
Clinical problems in radiotherapy of carcinoma of the pancreas.
    American journal of clinical oncology, 1982, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Alpha Particles; Clinical Trials as Topic; Fluorouracil; Helium; Humans; Liver Neopl

1982
[Clinical trial of cisplatin in the treatment of ovarian carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Cystadenocarcino

1982
Combination chemotherapy in advanced gastrointestinal malignancy.
    Oncology, 1980, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combinat

1980
Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate.
    Cancer, 1980, Feb-15, Volume: 45, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide

1980
Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count.
    Cancer, 1980, May-01, Volume: 45, Issue:9

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Diarrhea; Drug Therap

1980
Metastatic adenocarcinomas of unknown primary site: a randomized study of two combination-chemotherapy regimens.
    The New England journal of medicine, 1980, Jul-10, Volume: 303, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Cyclop

1980
The chemotherapy of prostatic adenocarcinoma.
    Annals of internal medicine, 1980, Volume: 92, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclop

1980
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
    Cancer, 1980, Oct-01, Volume: 46, Issue:7

    Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do

1980
Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group.
    Cancer, 1981, Jan-01, Volume: 47, Issue:1

    Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat

1981
The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy.
    Oncology, 1981, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Dru

1981
Modulation of 5-fluorouracil toxicity by allopurinol in man.
    Cancer, 1981, Sep-15, Volume: 48, Issue:6

    Topics: Adenocarcinoma; Allopurinol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorouraci

1981
Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
    Journal of the Canadian Association of Radiologists, 1981, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up

1981
Adjuvant chemotherapy with four drugs for stage 2 breast cancer.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Adenocarcinoma; Aged; Breast Neoplasms; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Co

1980
Controlled trial of adjuvant chemotherapy following curative resection for gastric cancer. The Gastrointestinal Tumor Study Group.
    Cancer, 1982, Mar-15, Volume: 49, Issue:6

    Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorouracil; Humans; L

1982
Management of pelvic complications of malignant urothelial tumors with combined intra-arterial and iv chemotherapy.
    Cancer treatment reports, 1982, Volume: 66, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug A

1982
A phase II evaluation of a 3-drug combination of cyclophosphamide, doxorubicin and 5-fluorouracil and of 5-fluorouracil in patients with advanced bladder carcinoma or stage D prostatic carcinoma.
    The Journal of urology, 1981, Volume: 125, Issue:2

    Topics: Adenocarcinoma; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin; Drug Evaluation; Drug T

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group.
    Cancer, 1981, Oct-15, Volume: 48, Issue:8

    Topics: Adenocarcinoma; Anemia; Carcinoembryonic Antigen; Female; Fluorouracil; Humans; Male; Middle Aged; N

1981
[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].
    Schweizerische medizinische Wochenschrift, 1980, Aug-16, Volume: 110, Issue:33

    Topics: Adenocarcinoma; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxypr

1980
The activity of paclitaxel in gastrointestinal tumors.
    Seminars in oncology, 1995, Volume: 22, Issue:5 Suppl 12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

1995
Combination chemotherapy of 5-fluorouracil, epidoxorubicin and mitomycin C in the palliative treatment of locally advanced and/or metastatic adenocarcinoma of the stomach.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Epir

1994
Split-course accelerated radiation therapy combined with carboplatin and 5-fluorouracil for palliation of metastatic or unresectable carcinoma of the esophagus.
    Cancer, 1995, Jan-15, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

1995
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma.
    The British journal of surgery, 1994, Volume: 81, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1994
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
    The Journal of urology, 1995, Volume: 153, Issue:5

    Topics: Adenocarcinoma; Aged; Disease Progression; Fluorouracil; Humans; Interferon-alpha; Male; Prospective

1995
Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:7

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1995
[Hepatic arterial infusion therapy for gastric liver metastasis using implanted reservoir].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluoroura

1995
[Experience in intra-hepatic-arterial chemotherapy and hepatic resection for metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1995
[Outcomes of effective treatment of cases of metastatic liver tumors by intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms;

1995
Chemotherapy rapidly alternating with twice-a-day accelerated radiation therapy in carcinomas involving the hypopharynx or esophagus: an update.
    Cancer investigation, 1995, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1995
Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod

1995
Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:11

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hu

1995
Combined modality therapy for esophageal carcinoma: preliminary results from a large Australasian multicenter study.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aust

1995
Prophylactic portal infusion chemotherapy as adjuvant therapy for the prevention of metachronous liver metastasis in colorectal cancer.
    Surgery today, 1995, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; DNA, Neoplasm; Female; Fluorouracil; H

1995
[Is radiotherapy necessary in the control of colorectal cancer?].
    Ginecologia y obstetricia de Mexico, 1995, Volume: 63

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Cobalt Radioisotopes; Colectomy; Colonic

1995
Effect of cisplatin in advanced colorectal cancer resistant to 5-fluorouracil plus (S)-leucovorin.
    Journal of cancer research and clinical oncology, 1995, Volume: 121, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1995
Induction chemotherapy and irradiation in advanced carcinoma of the cervix.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined M

1995
Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer.
    BMJ (Clinical research ed.), 1993, Mar-20, Volume: 306, Issue:6880

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop

1993
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
    Drugs, 1993, Volume: 45 Suppl 2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophospha

1993
[Usefulness of adjuvant chemotherapy with antimetabolites for cervical invasive cancer].
    Nihon Sanka Fujinka Gakkai zasshi, 1995, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Female; Fluo

1995
Is the combination of 5-fluorouracil and folinic acid effective in advanced gastric carcinoma? Results of a pilot study and review of the literature.
    Journal of chemotherapy (Florence, Italy), 1994, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1994
A phase II trial of interferon alpha-2A, 5-fluorouracil, and cisplatin in patients with advanced esophageal carcinoma.
    Cancer, 1995, May-01, Volume: 75, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1995
Intraoperative radiotherapy for primary and recurrent rectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

1995
[Treatment of acute chemically induced diarrhea by inhibition of enkephalinase. Results of a pilot study].
    Gastroenterologie clinique et biologique, 1995, Volume: 19, Issue:1

    Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Diarrhe

1995
Reversible hepatic steatosis in patients treated with interferon alfa-2a and 5-fluorouracil.
    Cancer, 1995, May-15, Volume: 75, Issue:10

    Topics: Adenocarcinoma; Colonic Neoplasms; Fatty Liver; Female; Fluorouracil; Humans; Interferon alpha-2; In

1995
Inflammatory breast cancer: 10-year follow-up of a trial of surgery, chemotherapy, and allogeneic tumor cell/BCG immunotherapy.
    Cancer investigation, 1995, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; BCG Vacci

1995
Treating esophageal cancer with a combination of chemotherapy, radiation, and excision.
    American journal of surgery, 1995, Volume: 169, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1995
Relationship of acute gastrointestinal toxicity and the volume of irradiated small bowel in patients receiving combined modality therapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intestine, Small; Leucovorin; Neopl

1995
Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
    Investigational new drugs, 1994, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran

1994
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer.
    British journal of cancer, 1995, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell;

1995
Modulation of 5-fluorouracil with high-dose leucovorin calcium: activity in ovarian cancer and correlation with CA-125 levels.
    Gynecologic oncology, 1995, Volume: 58, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; CA-125 Antigen; Drug Therapy, Combination; Female; F

1995
Management of adenocarcinoma of the esophagus with chemoradiation alone or chemoradiation followed by esophagectomy: results of sequential nonrandomized phase II studies.
    International journal of radiation oncology, biology, physics, 1995, Jun-15, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1995
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live

1995
Preoperative radiation and chemotherapy in the treatment of adenocarcinoma of the rectum.
    Annals of surgery, 1995, Volume: 221, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case

1995
[Chemotherapy against lymphatic metastases of gynecologic cancer via pelvic retroperitoneal cannulation: a preliminary report].
    Zhonghua fu chan ke za zhi, 1995, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Animals; Catheterization; Endometrial Neoplasms; Female; Fluorouracil;

1995
Treatment of advanced pancreatic cancer with 5-fluorouracil, folinic acid and interferon alpha-2A: results of a phase II trial.
    British journal of cancer, 1995, Volume: 71, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1995
5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. GLISP (Gruppo Ligure Studio Pancreas).
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1995
Preoperative high-dose radiation and chemotherapy in adenocarcinoma of the esophagus and esophagogastric junction.
    Annals of surgical oncology, 1994, Volume: 1, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso

1994
Efficacy of postoperative 5-FU, high-dose leucovorin, and sequential radiation therapy for clinically resectable rectal cancer.
    Cancer investigation, 1995, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1995
Long-term results of single course of adjuvant intraportal chemotherapy for colorectal cancer. Swiss Group for Clinical Cancer Research (SAKK)
    Lancet (London, England), 1995, Feb-11, Volume: 345, Issue:8946

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni

1995
5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
    Cancer chemotherapy and pharmacology, 1995, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1995
Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy.
    Annals of surgery, 1995, Volume: 221, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Appendicea

1995
[Preoperative radiochemotherapy in primary non-resectable rectal cancer].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1995, Volume: 171, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Female; Fluorouracil;

1995
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
    British journal of cancer, 1995, Volume: 71, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1995
Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer. A multi-institutional randomized trial.
    Cancer, 1995, Mar-15, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1995
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi

1995
[A randomized early phase II study of l-leucovorin and 5-fluorouracil in gastric cancer. l-Leucovorin and 5-FU Study Group].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Administration

1995
Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial.
    Gynecologic oncology, 1995, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Combined Chemotherapy Protoc

1995
Cisplatin, 5-fluorouracil, and ifosfamide in the treatment of recurrent or advanced cervical cancer.
    Gynecologic oncology, 1995, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1995
A randomized study of bolus fluorouracil plus folinic acid versus 21-day fluorouracil infusion alone or in association with cyclophosphamide and mitomycin C in advanced colorectal carcinoma.
    American journal of clinical oncology, 1995, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

1995
Efficacy of a new 5-fluorouracil derivative, BOF-A2, in advanced non-small cell lung cancer. A multi-center phase II study.
    Acta oncologica (Stockholm, Sweden), 1994, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Sm

1994
Double modulation of 5-fluorouracil with interferon alpha 2a and high-dose leucovorin: a phase I and II study.
    British journal of cancer, 1994, Volume: 70, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations

1994
Liver perfusion chemotherapy via both the hepatic artery and portal vein to prevent hepatic metastasis after extended pancreatectomy for adenocarcinoma of the pancreas.
    American journal of surgery, 1994, Volume: 168, Issue:4

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Combined Mod

1994
[Methotrexate/5-fluorouracil therapy in gastric cancer with peritoneal metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Drug Administration Sch

1994
5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma.
    Investigational new drugs, 1994, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

1994
A phase II survival comparison of patients with adenocarcinoma of the pancreas treated with 5-fluorouracil and calcium leucovorin versus a matched tumor registry control population.
    American journal of clinical oncology, 1994, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Leucovorin; Male; Midd

1994
Weekly levofolinic acid and 5-fluorouracil plus hydroxyurea in metastatic gastrointestinal adenocarcinomas.
    American journal of clinical oncology, 1994, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

1994
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chi-

1994
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
    International journal of radiation oncology, biology, physics, 1994, Jun-15, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1994
Phase II study with iododoxorubicin in measurable advanced colorectal adenocarcinoma. Effective rescue using weekly high-dose 5-fluorouracil (WFU). Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), Work Group of SEOM (Spanish Medical Onc
    Tumori, 1994, Apr-30, Volume: 80, Issue:2

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle

1994
[The usefulness of pre- and immediately postoperative chemotherapy in colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

1994
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery.
    The New England journal of medicine, 1994, Aug-25, Volume: 331, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Therapy, Combination

1994
Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy.
    Internal medicine (Tokyo, Japan), 1994, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Autonomic Nerve Block; Celiac Plexus; Combined Modal

1994
Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
    Gynecologic oncology, 1994, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons

1994
Radiation and chemotherapy. Treatment of localized pancreatic carcinoma.
    The Journal of the Florida Medical Association, 1994, Volume: 81, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin

1994
Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
    The New England journal of medicine, 1994, May-05, Volume: 330, Issue:18

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherap

1994
The importance of dose scheduling with mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administratio

1994
Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
    Cancer, 1994, Oct-01, Volume: 74, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Combined Modali

1994
Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum.
    International journal of radiation oncology, biology, physics, 1994, Aug-30, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1994
[Long-term administration of carmofur as a post-operative adjuvant chemotherapy for cervical adenocarcinoma. Cervical Adenocarcinoma Cooperative Research Association].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell;

1994
[Status of portal perfusion in colorectal cancer. Swiss Study Group for Clinical Cancer Research].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 1994, Volume: 65, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1994
Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Fluo

1994
Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Drug Administration Schedule; Female; Fluorouracil; Ga

1994
Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1994
Etoposide, leucovorin, 5-fluorouracil and interferon alpha-2b in elderly gastric cancer patients: a pilot study.
    Cancer chemotherapy and pharmacology, 1994, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1994
Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study.
    American journal of clinical oncology, 1994, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bi

1994
5-Fluorouracil, folinic acid, etoposide and cisplatin chemotherapy for locally advanced or metastatic carcinoma of the oesophagus.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1994
[Concomitant arterial infusion chemotherapy with tamoxifen therapy for hepatic metastases from pancreatic adenocarcinoma--a preliminary report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Inject

1993
5-fluorouracil and interferon-alpha-2a in advanced colorectal cancer. Results of two treatment schedules.
    Cancer, 1993, Dec-01, Volume: 72, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Catheters, Indwelling; Colonic Neoplasms; Drug Admin

1993
Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin, and fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1993
Further study of nebulisation chemotherapy, a new chemotherapeutic method in the treatment of lung carcinomas: fundamental and clinical.
    British journal of cancer, 1993, Volume: 68, Issue:6

    Topics: Adenocarcinoma; Administration, Inhalation; Aerosols; Aged; Animals; Bronchial Neoplasms; Carcinoma,

1993
[Comparison of the therapeutic effect of CMxMF and CAMF regimens in the management of advanced breast cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1993, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea

1993
High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 1993, Dec-01, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Follow-Up Studies; Humans; Int

1993
Phase I study of 5-fluorouracil and leucovorin by a 14-day circadian infusion in metastatic adenocarcinoma patients.
    Cancer chemotherapy and pharmacology, 1993, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Circadian R

1993
Evaluation of external-beam radiation therapy plus 5-fluorouracil (5-FU) versus external-beam radiation therapy plus hycanthone (HYC) in confined, unresectable pancreatic cancer.
    International journal of radiation oncology, biology, physics, 1994, Jan-01, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Evaluation Studies as Top

1994
A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.
    Anti-cancer drugs, 1993, Volume: 4, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; I

1993
Preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for rectal cancer.
    Cancer, 1994, Jan-15, Volume: 73, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Brachytherapy; Combined Modality Therapy; Drug Administration Schedule;

1994
Doxorubicin, mitomycin C and 5-fluorouracil in the treatment of hormone refractory adenocarcinoma of the prostate: a Southwest Oncology Group study.
    The Journal of urology, 1993, Volume: 150, Issue:2 Pt 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1993
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1993
Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.
    Cancer research, 1993, Aug-01, Volume: 53, Issue:15

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1993
Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer.
    International journal of radiation oncology, biology, physics, 1993, Aug-01, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cisplatin; Combined Modali

1993
Fluorouracil plus folinic acid in metastatic adenocarcinoma of unknown primary site suggestive of a gastrointestinal primary.
    Tumori, 1993, Apr-30, Volume: 79, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

1993
Pelvic radiotherapy with concurrent 5-fluorouracil modulated by leucovorin for rectal cancer: a phase II study.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1993, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Diarrhea; Female; Fluorouracil; Humans; Leucovorin;

1993
Large scale trial for adjuvant treatment in high risk resected colorectal cancers. Rationale to test the combination of loco-regional and systemic chemotherapy and to compare l-leucovorin + 5-FU to levamisole + 5-FU.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
5-Fluorouracil combined with the [6S]-stereoisomer of folinic acid in high doses for treatment of patients with advanced colorectal carcinoma. A phase I-II study of two consecutive regimens.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1993
Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study.
    Cancer, 1993, Oct-01, Volume: 72, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Duodenal Neoplasms;

1993
A phase II trial of mitomycin C, 5-fluorouracil and radiation therapy in the treatment of unresectable non-small cell lung cancer.
    Oncology research, 1993, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1993
A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
    Cancer research, 1993, Oct-15, Volume: 53, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1993
A randomized, double-blind trial of fluorouracil plus placebo versus fluorouracil plus oral leucovorin in patients with metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:10

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Double-Blind Method; Drug Administration Schedule; Femal

1993
Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study.
    Cancer, 1993, Jan-15, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorourac

1993
High-dose folinic acid with 5-fluorouracil bolus and continuous infusion in the treatment of advanced gastric and oesophageal adenocarcinoma.
    British journal of cancer, 1993, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Dr

1993
Phase II evaluation of recombinant alpha-2a-interferon and continuous infusion fluorouracil in previously untreated metastatic colorectal adenocarcinoma.
    Cancer, 1993, Feb-15, Volume: 71, Issue:4

    Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Administration Schedule; F

1993
Phase II trial of postoperative adjuvant intraperitoneal cisplatin and fluorouracil and systemic fluorouracil chemotherapy in patients with resected gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1993
Treatment of carcinoma of the esophagus with 5-fluorouracil and recombinant alfa-2a-interferon.
    Cancer, 1993, Mar-01, Volume: 71, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1993
[The chemoradiotherapy of advanced colorectal carcinoma--the results and toxicity in a pilot study with 44 patients].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1993, Volume: 169, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1993
A phase I-II study of epirubicin, 5-fluorouracil, and leucovorin in advanced adenocarcinoma of the stomach.
    Cancer, 1993, Apr-01, Volume: 71, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations

1993
Folinic acid does improve 5-fluorouracil activity in vivo. Results of a phase III study comparing 5-fluorouracil to 5-fluorouracil and folinic acid in advanced colon cancer patients.
    Journal of chemotherapy (Florence, Italy), 1993, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema

1993
Preoperative concurrent 5-fluorouracil infusion, mitomycin C and pelvic radiation therapy in tethered and fixed rectal carcinoma.
    International journal of radiation oncology, biology, physics, 1993, Apr-02, Volume: 25, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1993
The use of mitomycin in esophageal cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1993
Mitomycin in anal canal carcinoma.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anu

1993
Mitomycin therapy in gastric cancer.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1993
Comparison of single-agent epirubicin and 5-fluorouracil/epirubicin/mitomycin in patients with advanced adenocarcinoma of the pancreas.
    Oncology, 1993, Volume: 50 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu

1993
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
    Presse medicale (Paris, France : 1983), 1993, Jan-30, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1993
Phase I trial of a 5-day infusion of L-leucovorin plus daily bolus 5-fluorouracil in patients with advanced gastrointestinal malignancies.
    Cancer chemotherapy and pharmacology, 1993, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

1993
Survival after combined modality therapy for pancreatic cancer.
    Journal of clinical gastroenterology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1993
Cyclophosphamide, methotrexate, and 5-fluorouracil in the treatment of metastatic prostate cancer. A Southwest Oncology Group study.
    Cancer, 1993, Jun-15, Volume: 71, Issue:12

    Topics: Acid Phosphatase; Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy P

1993
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1993, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis

1993
Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1995, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

1995
Phase II evaluation of low-dose continuous 5-fluorouracil and weekly cisplatin in advanced adenocarcinoma of the stomach. A Southwest Oncology Group study.
    American journal of clinical oncology, 1995, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoc

1995
Induction chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Long-term results.
    American journal of clinical oncology, 1996, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1996
Treatment of advanced or recurrent endometrial carcinoma with combination of etoposide, cisplatin, and 5-fluorouracil: a phase II study.
    Gynecologic oncology, 1996, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati

1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati

1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati

1996
Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Cisplati

1996
Combined intraperitoneal plus intravenous chemotherapy after curative resection for colonic adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Col

1995
Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
    Annals of surgical oncology, 1995, Volume: 2, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

1995
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy.
    Annals of surgical oncology, 1995, Volume: 2, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxorubicin;

1995
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
    British journal of cancer, 1996, Volume: 73, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis

1996
Combined preoperative chemotherapy and radiotherapy in patients with locally advanced esophageal cancer. Interim analysis of a phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell;

1996
A phase II study of cisplatin, vindesine and continuously infused 5-fluorouracil in the treatment of advanced non-small-cell lung cancer. Osaka Lung Cancer Chemotherapy Study Group.
    British journal of cancer, 1996, Volume: 73, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcino

1996
Phase II study of 5-fluorouracil and folinic acid in the treatment of patients with advanced gastric cancer. A Southwest Oncology Group study.
    Cancer, 1995, Sep-01, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Infusions, Intrave

1995
A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.
    British journal of cancer, 1996, Volume: 73, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin;

1996
Treatment of advanced gastric cancer with a modified regimen of etoposide/leucovorin/5-fluorouracil.
    Cancer investigation, 1996, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations

1996
Concurrent 5-fluorouracil, daily low-dose cisplatin, and radiotherapy in stage IIIB cervical cancer. A phase II prospective study.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squa

1996
High-dose folinic acid and fluorouracil with or without ifosfamide is an inactive combination in advanced pancreatic cancer. A randomized phase II study of the Italian Oncology Group for Clinical Research (G.O.I.R.C.).
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1996
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Cancer, 1996, May-15, Volume: 77, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
    International journal of radiation oncology, biology, physics, 1996, Apr-01, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1996
Phase II clinical trial with 5-fluorouracil, recombinant interferon-alpha-2b, and cisplatin for patients with metastatic or regionally advanced carcinoma of the esophagus.
    Cancer, 1996, Jul-01, Volume: 78, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1996
Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Cancer chemotherapy and pharmacology, 1996, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

1996
Neoadjuvant therapy of high-risk gastric cancer: a phase II trial of preoperative FAMTX and postoperative intraperitoneal fluorouracil-cisplatin plus intravenous fluorouracil.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.
    The New England journal of medicine, 1996, Aug-15, Volume: 335, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
Regional chemotherapy for inoperable pancreatic carcinoma.
    Cancer, 1996, Aug-01, Volume: 78, Issue:3 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Infusi

1996
[ACNU and methyl-CCNU in combination chemotherapy for advanced gastric cancer: a randomized comparative study. Shanghai ACNU Collaborative Study Group].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1996, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chin

1996
Phase II trial of N-(phosphonacetyl)-L-aspartate (PALA), 5-fluorouracil and recombinant interferon-alpha-2b in patients with advanced gastric carcinoma.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Fluorour

1996
Clinical response to systemic combined chemotherapy with 5-fluorouracil and cisplatin (FP therapy) in patients with advanced pancreatic cancer.
    Japanese journal of clinical oncology, 1996, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1996
Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop

1996
Phase II study of 5-fluoruracil leucovorin and azidothymidine in patients with metastatic colorectal cancer.
    Journal of cancer research and clinical oncology, 1996, Volume: 122, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Adm

1996
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Body Weight; Deoxycytidine; Disease Pr

1996
Intermittent continuous infusion of 5-fluorouracil in combination with epirubicin and cisplatin in advanced gastric cancer: the importance of dose intensity.
    The Journal of infusional chemotherapy, 1996,Spring, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Respons

1996
Dual modulation of 5-fluorouracil with folinic acid and hydroxyurea in metastatic colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Spring, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1996
Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Cancer, 1996, Sep-15, Volume: 78, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplast

1996
[Neoadjuvant chemotherapy in high-grade advanced gastric cancer with protracted infusional 5-fluorouracil and consecutive low-dose cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1996
Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG)
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1996, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1996
[Arterial infusion chemotherapy for advanced gastric cancer by sequential MTX/5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Drug Ad

1996
Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients.
    Cytotechnology, 1996, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Col

1996
Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1996
Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060.
    Cancer, 1996, Nov-01, Volume: 78, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1996
Advanced colorectal carcinoma: redefining the role of oral ftorafur.
    Anti-cancer drugs, 1996, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1996
5-Fluorouracil continuous infusion in metastatic colorectal cancer.
    Annals of the Academy of Medicine, Singapore, 1996, Volume: 25, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colorectal N

1996
Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.
    American journal of clinical oncology, 1996, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1996
Hypofractionated radiotherapy with concurrent 5-fluorouracil radiosensitisation for recurrent or locally advanced colorectal cancer. A phase II study.
    International journal of colorectal disease, 1996, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modalit

1996
[Chemotherapy for peritoneal dissemination in gastric cancer under ureteral catheterization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female

1996
Interleukin 2 and interferon alpha-2a do not improve anti-tumour activity of 5-fluorouracil in advanced colorectal cancer.
    British journal of cancer, 1996, Volume: 74, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antimetabolites, Antineoplastic; Antineoplastic Age

1996
Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies.
    European journal of cancer (Oxford, England : 1990), 1996, Volume: 32A, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Digestive System Neoplasms; Drug Syner

1996
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; C

1997
A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
    British journal of cancer, 1997, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carboplati

1997
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1996
Integration of surgery in multimodality therapy for esophageal cancer.
    American journal of clinical oncology, 1997, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1997
Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin.
    American journal of clinical oncology, 1997, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis

1997
[Effects of biochemical modulation chemotherapy with CDDP and 5-FU on metastatic brain tumor from lung cancer].
    No shinkei geka. Neurological surgery, 1997, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla

1997
TPDC-FuHu chemotherapy for the treatment of recurrent metastatic brain tumors.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neop

1997
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour infusion with interferon-alpha-2a in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Cancer, 1997, Mar-15, Volume: 79, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1997
Bimonthly high dose leucovorin and 5-fluorouracil 48-hour continuous infusion in patients with advanced colorectal carcinoma. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD).
    Cancer, 1997, Mar-15, Volume: 79, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1997
A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum: a progress report of National Surgical Breast and Bowel Project Protocol R-03.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Female; Fluorouraci

1997
Progress in treating esophageal adenocarcinoma.
    Gastroenterology, 1997, Volume: 112, Issue:4

    Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; Esophageal Neoplasms; Fluorouracil; Humans; Pr

1997
A phase I/II study of external beam radiation, brachytherapy and concurrent chemotherapy in localized cancer of the esophagus (RTOG 92-07): preliminary toxicity report.
    International journal of radiation oncology, biology, physics, 1997, Feb-01, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

1997
Protracted 5-fluorouracil infusion with concurrent radiotherapy as a treatment for locally advanced pancreatic carcinoma.
    Cancer, 1997, Apr-15, Volume: 79, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro

1997
Concomitant intraarterial cisplatin, intravenous 5-flourouracil, and split-course radiation therapy for locally advanced unresectable pancreatic adenocarcinoma: a phase II study of the Puget Sound Oncology Consortium (PSOC-703).
    American journal of clinical oncology, 1997, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1997
Systemic chemotherapy for gastric carcinoma followed by postoperative intraperitoneal therapy: a final report.
    Cancer, 1997, May-01, Volume: 79, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1997
Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo

1997
Primary chemotherapy and preoperative irradiation for patients with stage II larger than 3 cm or locally advanced non-inflammatory breast cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1997, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1997
Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
    Investigational new drugs, 1996, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Female; Fluorouracil;

1996
Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Agranulocytosis; Antidotes; Antimetabolites, An

1997
A phase II study of 5-fluorouracil, leucovorin, adriamycin, and cisplatin (FLAP) for metastatic gastric and gastroesophageal junction adenocarcinoma. A Penn Cancer Clinical Trial Group and Roswell Park Cancer Institute Community Oncology Research Program
    American journal of clinical oncology, 1997, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antidotes; Antimetaboli

1997
Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma.
    American journal of clinical oncology, 1997, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phyt

1997
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci

1997
[The influence on prognosis of intraoperative chemotherapy for adenocarcinoma of gastric cardia].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1996, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Cardia; Female; Fluorouracil; Humans; Intraop

1996
Progress report. A randomized multicenter European study comparing adjuvant radiotherapy, 6-mo chemotherapy, and combination therapy vs no-adjuvant treatment in resectable pancreatic cancer (ESPAC-1).
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1997, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Clinical Protocols; Combined

1997
Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
    Cancer, 1997, Jul-01, Volume: 80, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Synergi

1997
[Combination chemotherapy of continuous infusion 5-fluorouracil and daily low-dose cisplatin in advanced gastrointestinal and lung adenocarcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms;

1997
The EORTC GI group experience with high-dose infusional 5-FU in colorectal cancer.
    The Journal of infusional chemotherapy, 1996,Summer, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

1996
The French experience with infusional 5-FU in gastric and pancreatic cancer.
    The Journal of infusional chemotherapy, 1996,Fall, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Bio

1996
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

1997
Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
    Gynecologic oncology, 1997, Volume: 66, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla

1997
Clinical benefit with cisplatin, hydroxyurea and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

1997
[Preoperative intraluminal 5-FU osmosis chemotherapy as an adjuvant to radical resection for rectal cancer].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1996, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy

1996
A phase II study of continuous infusion 5-fluorouracil (5-FU) with epirubicin and cisplatin in metastatic, hormone-resistant prostate cancer: an active new regimen.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

1997
Use of concurrent chemotherapy, accelerated fractionation radiation, and surgery for patients with esophageal carcinoma.
    Cancer, 1997, Sep-15, Volume: 80, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car

1997
Treatment of advanced pancreatic cancer with epirubicin, 5-fluorouracil and 1-leucovorin: a phase II study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Flu

1997
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
    The Journal of thoracic and cardiovascular surgery, 1997, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1997
[Clinical evaluation of intra-arterial infusion chemotherapy for advanced or recurrent cervical cancer with or without radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

1997
A phase I trial of 5-day chronomodulated infusion of 5-fluorouracil and 1-folinic acid in patients with metastatic colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 1997, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Dose-Response Re

1997
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cath

1997
Efficacy of cisplatin, 5-fluorouracil, and paclitaxel regimen for carcinoma of the esophagus.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1997
Combined-modality therapy for esophageal cancer: phase I trial of escalating doses of paclitaxel in combination with cisplatin, 5-fluorouracil, and high-dose radiation before esophagectomy.
    Seminars in oncology, 1997, Volume: 24, Issue:6 Suppl 19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1997
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin

1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin

1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin

1998
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adolescent; Adult; Aged; Aged, 80 and over; Antidotes; Antin

1998
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Cisplatin; Combined Modality Therapy; DNA-Binding Proteins; Endonucleases; Female; F

1998
Phase II trial of 5-fluorouracil and high-dose leucovorin in recurrent adenocarcinoma of the cervix: a Gynecologic Oncology Group study.
    Gynecologic oncology, 1997, Volume: 67, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1997
Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a multicentric phase II study.
    British journal of cancer, 1998, Volume: 77, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1998
Postoperative adjuvant radiotherapy and 5-fluorouracil chemotherapy for rectal carcinoma.
    Australasian radiology, 1998, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu

1998
[Sequential chemotherapy with methotrexate and 5-fluorouracil for advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

1998
Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female

1998
Continuous venous infusion 5-fluorouracil and interferon-alpha in pancreatic carcinoma.
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1998
5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889).
    American journal of clinical oncology, 1998, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Fluorouracil; H

1998
5-fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone-refractory adenocarcinoma of the prostate.
    The Prostate, 1998, Apr-01, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy

1998
Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colon

1998
High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy.
    Cancer, 1998, May-01, Volume: 82, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Dose-Response Relationship, Drug; Drug

1998
Combined intravenous and intraperitoneal chemotherapy with fluorouracil + leucovorin vs fluorouracil + levamisole for adjuvant therapy of resected colon carcinoma.
    British journal of cancer, 1998, Volume: 77, Issue:8

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neopla

1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1998
Advanced carcinoma of the pancreas: phase II study of combined chemotherapy, beta-interferon, and retinoids.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Diterpenes; Epirubicin;

1998
A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma.
    Cancer, 1998, Jun-15, Volume: 82, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ca

1998
Twice-daily fractionation of external irradiation with brachytherapy and chemotherapy in carcinoma of the cervix with positive para-aortic lymph nodes: Phase II study of the Radiation Therapy Oncology Group 92-10.
    International journal of radiation oncology, biology, physics, 1998, Jul-01, Volume: 41, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

1998
A phase II trial of cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

1998
High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
    American journal of clinical oncology, 1998, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1998
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
    British journal of cancer, 1998, Volume: 78, Issue:4

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Female; Fluorouracil; Humans; Infusions, Int

1998
Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1998
Phase I dose escalating trial of hyperfractionated pre-operative chemoradiation for locally advanced rectal cancer.
    International journal of radiation oncology, biology, physics, 1998, Aug-01, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antineoplastic Combined Chemotherapy Prot

1998
Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer.
    Lancet (London, England), 1998, Oct-31, Volume: 352, Issue:9138

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy

1998
OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Cancer, 1998, Nov-15, Volume: 83, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-F

1998
Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.
    American journal of clinical oncology, 1998, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide;

1998
Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer.
    The New England journal of medicine, 1998, Dec-31, Volume: 339, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1998
A phase II trial of preoperative mitomycin, cisplatin and 5-fluorouracil in adenocarcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti

1998
Hepatic transcatheter arterial chemoembolization alternating with systemic protracted continuous infusion 5-fluorouracil for gastrointestinal malignancies metastatic to liver: a phase II trial of the Puget Sound Oncology Consortium (PSOC 1104).
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1999
5-methyltetrahydrofolate for biochemical modulation of fluorouracil (FU) in patients with advanced colorectal cancer: a randomized phase I-II study of two different FU administration schedules.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bone Marrow Diseases; Colorectal Neopl

1998
5-fluorouracil and levofolinic acid with or without recombinant interferon-2b in patients with advanced colorectal carcinoma: a randomized multicenter study with stratification for tumor burden and liver involvement by the Southern Italy Oncology Group.
    Cancer, 1999, Feb-01, Volume: 85, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antidotes; Antineoplastic Combined Chemotherapy P

1999
[Biochemical modulation of 5-FU--effect of low dose CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin

1999
Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer.
    Hybridoma, 1999, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Feasibility St

1999
The relation between erythropoietin, hematocrit and hemoglobin in breast cancer patients on non-nephrotoxic chemotherapy.
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents,

1998
The relationship between serum levels of erythropoietin (EPO) and insulin-like growth factor-1 (ILGF-1) and hematocrit (HCT) in breast cancer patients receiving non-nephrotoxic chemotherapy.
    European journal of gynaecological oncology, 1998, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

1998
Local excision of rectal carcinoma: a safe alternative for more advanced tumors?
    Journal of surgical oncology, 1999, Volume: 70, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1999
Outpatient 5-fluorouracil, folinic acid and cisplatin in patients with advanced esophageal carcinoma.
    Acta oncologica (Stockholm, Sweden), 1999, Volume: 38, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; C

1999
[No improvement of prognosis by neoadjuvant chemotherapy alone in operable esophageal carcinoma].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1999, Volume: 175, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1999
Combination chemotherapy with granulocyte-macrophage-colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma.
    Cancer, 1999, Jun-01, Volume: 85, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relations

1999
Adjuvant (cisplatin, etoposide, and 5-fluorouracil) chemotherapy after curative resection of gastric adenocarcinomas involving the esophagogastric junction.
    American journal of clinical oncology, 1999, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1999
[Influence of preoperative on gastric cancer tissues and cells].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1997, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1997
[Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
[Treatment for advanced colorectal carcinoma with 5-fluorouracil plus low-dose leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone

1999
Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG #85-01?
    International journal of radiation oncology, biology, physics, 1999, Jul-15, Volume: 44, Issue:5

    Topics: Adenocarcinoma; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Black Pe

1999
Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy.
    Bone marrow transplantation, 1999, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin;

1999
Phase I-II study of 5-fluorouracil, recombinant interferon alpha2a, and cisplatin in combination with external beam radiation therapy followed by surgery in patients with locally advanced carcinoma of the esophagus.
    American journal of clinical oncology, 1999, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1999
Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group.
    Lancet (London, England), 1999, Jul-24, Volume: 354, Issue:9175

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Ant

1999
The role of stable disease in objective response assessment and its impact on survival in advanced colorectal cancer: is "stable disease" a homogenous response category?
    Neoplasma, 1999, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colorectal

1999
Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK)
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1999
Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG).
    European journal of cancer (Oxford, England : 1990), 1999, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1999
A pilot study of interferon alpha-2a, fluorouracil, and leucovorin given with granulocyte-macrophage colony stimulating factor in advanced gastrointestinal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; G

1999
Randomized, double-blind, placebo-controlled trial to evaluate the hematopoietic growth factor PIXY321 after moderate-dose fluorouracil, doxorubicin, and cyclophosphamide in stage II and III breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1999
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial).
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Bone Marro

1999
Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ant

1999
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
A phase II study of Tomudex alternated with methotrexate, 5-fluorouracil, leucovorin in first-line chemotherapy of metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
North Central Cancer Treatment Group Phase II study of 5-fluorouracil and high-dose levamisole for gastric and gastroesophageal cancer using survival as the primary endpoint of efficacy.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Esop

1999
Infusions of fluorouracil and leucovorin: effects of the timing and semi-intermittency of drug delivery.
    Oncology, 1999, Volume: 57, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1999
A phase II study of weekly 24-h infusion of high-dose 5-fluorouracil in advanced pancreatic cancer.
    Zeitschrift fur Gastroenterologie, 1999, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Administration Schedule; Female; Fluorou

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1999
[Neoadjuvant treatment of operable esophageal cancers].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:10

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1999
Phase II trial of the combination of paclitaxel and 5-fluorouracil in the treatment of advanced gastric cancer: a novel, safe, and effective regimen.
    American journal of clinical oncology, 1999, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analgesics; Antimetabolites, Antineoplastic; Antineoplastic

1999
Comparison of CMF (cyclophosphamide, methotrexate, and 5-fluorouracil) with a rotational crossing and a sequential intensification regimen in advanced breast cancer: a prospective randomized study.
    American journal of clinical oncology, 1999, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

1999
Phase II study of cisplatin and 5-fluorouracil in previously treated metastatic breast cancer: an Eastern Cooperative Oncology Group study (PA 185).
    Breast cancer research and treatment, 1999, Volume: 57, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl

1999
Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.
    The New England journal of medicine, 1999, Dec-30, Volume: 341, Issue:27

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group.
    Annals of surgery, 1999, Volume: 230, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

1999
Management of adenocarcinoma of unknown primary with a 5-fluorouracil-cisplatin chemotherapy regimen (CFTam).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

1999
Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colore
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2000
Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    British journal of cancer, 2000, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cispla

2000
Phase II evaluation of preoperative chemoradiation and postoperative adjuvant chemotherapy for squamous cell and adenocarcinoma of the esophagus.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207): final report.
    Cancer, 2000, Mar-01, Volume: 88, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2000
Aggressive multimodality therapy for stage III esophageal cancer: a phase I/II study.
    The Annals of thoracic surgery, 2000, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Combined Modality T

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
    Lancet (London, England), 2000, Mar-25, Volume: 355, Issue:9209

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2000
Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial.
    Annals of surgery, 2000, Volume: 231, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Di

2000
Cost-effectiveness of second-line treatment with irinotecan or infusional 5-fluorouracil in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2000
Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2000
Phase II study of weekly high dose fluorouracil in previously treated patients with metastatic colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 2000, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Sch

2000
Successful initial treatment with weekly etoposide, epirubicin, cisplatin, 5-fluorouracil and leucovorin chemotherapy in advanced gastric cancer patients with disseminated intravascular coagulation.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:3

    Topics: Acute Disease; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplati

2000
Modulation of fluorouracil by methotrexate, leucovorin, and cisplatin (M-FLP) in the treatment of advanced pancreatic cancer: a phase II study of the Italian Oncology Group for Clinical Research (GOIRC).
    American journal of clinical oncology, 2000, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2000
Sequence-dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy with lenograstim support for advanced gastric cancer: a feasibility study.
    Pharmacological research, 2000, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardia; Doxorubicin; Dr

2000
Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the Europe
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

2000
Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2000
[The clinical effect of low-dose FP (5-FU + low-dose CDDP) in patients with far advanced gastric cancer, and their quality of life].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2000
[Biweekly low-dose cisplatin and 5-fluorouracil combination chemotherapy for advanced gastrointestinal carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2000
The addition of low-dose leucovorin to the combination of 5-fluorouracil- levamisole does not improve survival in the adjuvant treatment of Dukes' C colon cancer. IKN Colon Trial Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols;

2000
Intra-arterial chemotherapy for unresectable pancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2000
Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial.
    Cancer, 2000, Jul-15, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2000
Can p53 alterations be used to predict tumour response to pre-operative chemo-radiotherapy in locally advanced rectal cancer?
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2000, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2000
Interferon-based adjuvant chemoradiation therapy improves survival after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    American journal of surgery, 2000, Volume: 179, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:16

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
    British journal of cancer, 2000, Volume: 83, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis

2000
[Adjuvant therapy of colon cancer stage C MAC. Adverse effects and efficacy in the Department of Oncology, Soroka Medical Center in the years 1991-1994].
    Harefuah, 1999, Jun-15, Volume: 136, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop

1999
Comparative pharmacokinetic analysis of 5-fluorouracil and its major metabolite 5-fluoro-5,6-dihydrouracil after conventional and reduced test dose in cancer patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo

2000
Cisplatin, cytarabine, caffeine, and continuously infused 5-fluorouracil (PACE) in the treatment of advanced pancreatic carcinoma: a phase II study.
    American journal of clinical oncology, 2000, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2000
Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
    American journal of clinical oncology, 2000, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2000
A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413).
    Investigational new drugs, 2000, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Etop

2000
The feasibility of dose escalation using concurrent radiation and 5-fluorouracil therapy following pancreaticoduodenectomy for pancreatic carcinoma.
    Journal of hepato-biliary-pancreatic surgery, 2000, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disease-Free Survival

2000
Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Oct-01, Volume: 18, Issue:19

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deo

2000
Neoadjuvant chemotherapy, radical resection with intraoperative radiation therapy (IORT): improved treatment for gastric adenocarcinoma.
    Surgery, 2000, Volume: 128, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2000
A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer.
    Annals of surgical oncology, 2000, Volume: 7, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Disea

2000
Neoadjuvant radio-chemotherapy in advanced primarilynon-resectable carcinomas of the pancreas.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2000, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Dose Fractionation, Radiation; Fluor

2000
[Short-term hypofractionated radiotherapy followed by total mesorectal excision].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2000, Volume: 176, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2000
Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2000, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; C

2000
Clinical activity and benefit of irinotecan (CPT-11) in patients with metastatic colorectal carcinoma pre-treated with fluorouracil-based chemotherapy.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2000, Volume: 83, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2000
Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Journal of experimental & clinical cancer research : CR, 2000, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Femal

2000
Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
    Oncology, 2001, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Jan-15, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamou

2001
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction.
    American journal of clinical oncology, 2001, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Comb

2001
Preoperative combined modality therapy for clinically resectable uT3 rectal adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2001, Mar-15, Volume: 49, Issue:4

    Topics: Adenocarcinoma; Anal Canal; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free

2001
Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma.
    Cancer, 2001, Apr-01, Volume: 91, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Disease Pr

2001
Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up.
    British journal of cancer, 2001, Apr-06, Volume: 84, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2001
Gemcitabine following radiotherapy with concurrent 5-fluorouracil for nonmetastatic adenocarcinoma of the pancreas.
    International journal of cancer, 2001, Apr-20, Volume: 96, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2001
Adjuvant chemotherapy for gastro-oesophageal cancer with epirubicin, cisplatin and fluorouracil: a single-centre experience.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous

2001
Phase II study of weekly 24-hour intra-arterial high-dose infusion of 5-fluorouracil and folinic acid for liver metastases from colorectal carcinomas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2001
Mitomycin C with weekly 24-h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract and periampullar carcinomas.
    Anti-cancer drugs, 2001, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Bilia

2001
Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, May-15, Volume: 19, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

2001
Neoadjuvant chemotherapy using low-dose consecutive intraarterial infusions of cisplatin combined with 5-fluorouracil for locally advanced cervical adenocarcinoma.
    Gynecologic oncology, 2001, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Endometrioid

2001
Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum.
    International journal of radiation oncology, biology, physics, 2001, Jun-01, Volume: 50, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2001
Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
    Cancer, 2001, Jun-01, Volume: 91, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2001
Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma.
    Cancer, 2001, Jun-01, Volume: 91, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2001
[Percutaneous radiotherapy plus brachytherapy and concurrent chemotherapy for patients with localized esophageal carcinoma--Radiation Oncology Group Study 9207].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2001, Volume: 177, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brachytherapy; Carcinoma, Squamous Cell; Combined M

2001
Carcinoma of an unknown primary site: a chemotherapy strategy based on histological differentiation--results of a prospective study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Differe

2001
Phase II study of epirubicin, mitomycin C, and 5-fluorouracil in hormone-refractory prostatic carcinoma.
    American journal of clinical oncology, 2001, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoembr

2001
Early toxicity from preoperative radiotherapy with continuous infusion 5-fluorouracil for resectable adenocarcinoma of the rectum: a Phase II trial for the Trans-Tasman Radiation Oncology Group.
    International journal of radiation oncology, biology, physics, 2001, Jul-15, Volume: 50, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-

2001
A pilot study of chronomodulated infusional 5-fluorouracil chemoradiation for pancreatic cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Chronotherapy; Combined Modality Therapy;

2001
Long-term survival following induction chemoradiotherapy and esophagectomy for esophageal carcinoma.
    Archives of surgery (Chicago, Ill. : 1960), 2001, Volume: 136, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

2001
A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction.
    Cancer, 2001, Jul-15, Volume: 92, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2001
Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Aug-01, Volume: 19, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy

2001
A phase I/II trial of three-dimensionally planned concurrent boost radiotherapy and protracted venous infusion of 5-FU chemotherapy for locally advanced rectal carcinoma.
    International journal of radiation oncology, biology, physics, 2001, Aug-01, Volume: 50, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colectomy; Combined

2001
Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2001, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2001
Phase II clinical trial of preoperative combined chemoradiation for T3 and T4 resectable rectal cancer: preliminary results.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fracti

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
    The New England journal of medicine, 2001, Sep-06, Volume: 345, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2001
Response shift in the perception of health for utility evaluation. an explorative investigation.
    European journal of cancer (Oxford, England : 1990), 2001, Volume: 37, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Attitude to Health;

2001
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female

2001
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female

2001
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female

2001
Randomized, controlled trial of lateral node dissection vs. nerve-preserving resection in patients with rectal cancer after preoperative radiotherapy.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Autonomic Nervous System; Disease-Free Survival; Female

2001
Radiotherapy and continuous infusion 5-fluorouracil in patients with nonresectable pancreatic carcinoma.
    International journal of radiation oncology, biology, physics, 2001, Nov-01, Volume: 51, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-01, Volume: 19, Issue:21

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2001
Adjuvant radio-chemotherapy in stage II-III rectal cancer with 24-hour infusion of high-dose 5-fluorouracil and folinic acid: evaluation of feasibility.
    Onkologie, 2001, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2001
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial.
    Lancet (London, England), 2001, Nov-10, Volume: 358, Issue:9293

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality The

2001
Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III.
    British journal of cancer, 2001, Nov-16, Volume: 85, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni

2001
Alternating chemoradiotherapy for nasopharyngeal cancer using cisplatin and 5-fluorouracil: a preliminary report of phase II study.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2001, Volume: 61, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2001
Paclitaxel in the multimodality treatment for inflammatory breast carcinoma.
    Cancer, 2001, Oct-01, Volume: 92, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2001
[Clinical study on treatment of rectal carcinoma with Chinese herbal medicine and high dose fluorouracil emulsion via rectal infusion].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1999, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Administration, Rectal; Adult; Antimetabolites, Antineoplastic; CD4-CD8 Ratio; Drug

1999
[Clinical study on treatment of mid-late stage gastric carcinoma by composite xiansu capsule combined with chemotherapy].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 1999, Volume: 19, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Caps

1999
P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection.
    International journal of cancer, 2002, Feb-01, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell D

2002
Radiotherapy, concomitant protracted-venous-infusion 5-fluorouracil, and surgery for ultrasound-staged T3 or T4 rectal cancer.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Endosonography; Fem

2001
Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2002
A phase II study of irinotecan with 5-fluorouracil and leucovorin in patients with previously untreated gastric adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2001
A phase III study of 5-fluorouracil versus 5-fluorouracil plus interferon alpha 2b versus 5-fluorouracil plus leucovorin in patients with advanced colorectal cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
    American journal of clinical oncology, 2002, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2002
Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2001
Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience.
    Cancer investigation, 2002, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil

2002
Non-infusional 5-fluorouracil, doxorubicin and cisplatin in the treatment of locally advanced or metastatic gastro-oesophageal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Progressio

2001
Raltitrexed (Tomudex) administration in patients with relapsed metastatic colorectal cancer after weekly irinotecan/5-Fluorouracil/Leucovorin chemotherapy.
    BMC cancer, 2002, Volume: 2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
Results of a randomised phase II study of cisplatin plus 5-fluorouracil versus cisplatin plus 5-fluorouracil with alpha-interferon in metastatic pancreatic cancer: an EORTC gastrointestinal tract cancer group trial.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2002
Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

2002
Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combin

2002
Phase II study of capecitabine and oxaliplatin in first- and second-line treatment of advanced or metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Apr-01, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2002
Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2002
Cytoreductive surgery combined with intraoperative chemo-hyperthermia and postoperative radiotherapy in the management of advanced pancreatic adenocarcinoma: feasibility aspects and efficacy.
    Journal of hepato-biliary-pancreatic surgery, 2001, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Feasibility Studie

2001
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Anti-cancer drugs, 2002, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2002
Preoperative chemoradiation in patients with resectable rectal cancer: results on tumor response.
    Annals of surgical oncology, 2002, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2002
Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2002
A phase II study of irinotecan alternated with a weekly schedule of high-dose leucovorin and 48-hour 5-fluorouracil infusion in patients with metastatic colorectal cancer.
    Oncology, 2002, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2002
Neoadjuvant therapy of rectal carcinoma with UFT-leucovorin plus radiotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Diseas

2002
Chemoradiation instead of surgery to treat mid and low rectal tumors: is it safe?
    Annals of surgical oncology, 2002, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu

2002
Intraoperative hyperthermia and chemoradiotherapy for inoperable pancreatic carcinoma.
    European journal of cancer care, 2002, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2002
[Chemotherapy of non-microcellular disseminated bronchial cancer (author's transl)].
    Revue francaise des maladies respiratoires, 1979, Volume: 7, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squam

1979
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
    The New England journal of medicine, 1978, Dec-07, Volume: 299, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati

1978
Adrenalectomy-oophorectomy and combined chemotherapy for carcinoma of the breast with metastases.
    Surgery, gynecology & obstetrics, 1979, Volume: 148, Issue:6

    Topics: Adenocarcinoma; Adrenalectomy; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Castration; Cli

1979
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamide.
    Cancer, 1977, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combina

1977
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
    Surgery, 1979, Volume: 85, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N

1979
[The combined treatment of bronchial carcinoma (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1975, Aug-01, Volume: 117, Issue:31

    Topics: Adenocarcinoma; Aged; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Clinical

1975
Combination modality therapy in lung cancer: a survival study showing beneficial results of AMCOF (adriamycin, methotrexate, cyclophosphamide, oncovin and 5-fluorouracil).
    Cancer, 1978, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Small Cell; Carcinoma, S

1978
Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with ftorafur, adriamycin, and cis-dichlorodiammineplatinum(II).
    Cancer treatment reports, 1978, Volume: 62, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Doxorubicin

1978
Comparative trial of endocrine versus cytotoxic treatment in advanced breast cancer.
    British medical journal, 1977, May-14, Volume: 1, Issue:6071

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Castration; Clinical Trials as Topic; Cyclo

1977
A controlled study of 5-fluorouracil versus 5-fluorouracil and methyl-CCNU in advanced gastrointestinal adenocarcinoma.
    Clinical oncology, 1977, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorourac

1977
Mitomycin-C alone and in combination with infused 5-fluorouracil to the treatment of disseminated gastrointestinal carcinomas.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Drug Therapy, Combination; Female; Fluorourac

1978
Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report.
    Archives of surgery (Chicago, Ill. : 1960), 1978, Volume: 113, Issue:2

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Administration Schedule; Drug Eval

1978
The West Midlands gastric carcinoma chemotherapy trial: planning and results.
    Clinical oncology, 1978, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Aged; Carcinoma; Clinical Trials as Topic; Disability Evaluation; Evaluation Studies

1978
Phase II trial of 5-fluorouracil plus melphalan in colorectal carcinoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Therapy, Combinat

1978
Phase II trial of 5-fluorouracil, adriamycin, and mitomycin C in advanced colorectal cancer.
    Cancer treatment reports, 1978, Volume: 62, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Blood Cell Count; Clinical Trials as Topic; Colonic Neoplasms; Doxorubi

1978
Phase II trial of ftorafur with mitomycin C versus ftorafur with methyl-CCNU in untreated colorectal cancer.
    Cancer treatment reports, 1978, Volume: 62, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Drug Ther

1978
5-fluorouracil, methyl-CCNU, adriamycin, and mitomycin C in the treatment of advanced gastric cancer.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Drug Eval

1978
5FU infusion with mitomycin-C versus 5 FU infusion with methyl-CCNU in the treatment of advanced colon cancer: a Southwest Oncology Group Study.
    Cancer, 1978, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil; Huma

1978
Chemotherapy of advanced breast cancer. Results of a controlled trial comparing two three-drug regimens.
    European journal of cancer, 1978, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Cycl

1978
Chemotherapy of advanced measurable colon and rectal carcinoma with oral 5-fluorouracil, alone or in combination with cyclophosphamide or 6-thioguanine, with intravenous 5-fluorouracil or beta-2'-deoxythioguanosine or with oral 3(4-methyl-cyclohexyl)-1(2-
    Cancer, 1978, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Clinical Trials as Topic; Colonic Neoplasms; Cyc

1978
Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial.
    Cancer, 1978, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Cyclophosphamide; Digestive System; Dox

1978
[A prospective multi-centre study of the response of metastatic gastrointestinal tumours (author's transl)].
    Deutsche medizinische Wochenschrift (1946), 1979, Aug-31, Volume: 104, Issue:35

    Topics: Adenocarcinoma; Carmustine; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestinal Neoplasms;

1979
Results of a prospective randomized study of hepatic artery infusion with 5-fluorouracil versus intravenous 5-fluorouracil in patients with hepatic metastases from colorectal cancer: A Central Oncology Group study.
    Surgery, 1979, Volume: 86, Issue:4

    Topics: Adenocarcinoma; Catheterization; Clinical Trials as Topic; Colonic Neoplasms; Female; Fluorouracil;

1979
Chemotherapy in advanced gastric cancer: a controlled, prospective, randomised multi-centre study.
    Gut, 1979, Volume: 20, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combination;

1979
Chemotherapy of pancreatic cancer.
    Seminars in oncology, 1979, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Fluorour

1979
Adriamycin, mitomycin C, and 5-fluorouracil in combination for advanced colorectal adenocarcinoma previously treated with 5-fluorouracil.
    Cancer clinical trials, 1979,Winter, Volume: 2, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Doxorubicin; Dru

1979
Comparative therapeutic trial of radiation with or without chemotherapy in pancreatic carcinoma. Gastrointestinal Tumor Study Group.
    International journal of radiation oncology, biology, physics, 1979, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Aged; Bone Marrow; Clinical Trials as Topic; Fluorouracil; Humans; Middle Aged; Panc

1979
Gastric cancer: current status of treatment.
    Journal of the National Cancer Institute, 1977, Volume: 58, Issue:3

    Topics: Adenocarcinoma; Aged; Carmustine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Ther

1977
A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group.
    Annals of surgery, 1979, Volume: 189, Issue:2

    Topics: Adenocarcinoma; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Male; Middle Aged;

1979
Adjuvant cytotoxic liver perfusion for colorectal cancer.
    The British journal of surgery, 1979, Volume: 66, Issue:12

    Topics: Adenocarcinoma; Aged; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; England; Female;

1979
Four drug combination cytotoxic chemotherapy following surgery for breast cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Administration Sched

1978
Results of a randomized trial of prophylactic chemotherapy in T3-T4 breast cancer patients previously treated by radiotherapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1978, Volume: 68

    Topics: Adenocarcinoma; Antineoplastic Agents; BCG Vaccine; Breast Neoplasms; Cyclophosphamide; Drug Adminis

1978
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms;

1976
A controlled clinical trial of fluorouracil plus imidazole carboxamide dimethyl triazeno plus vincristine plus bis-chloroethyl nitrosourea plus radiotherapy in stomach cancer.
    Medical and pediatric oncology, 1976, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazin

1976
Sequential and combination chemotherapy of advanced gastric cancer.
    Cancer, 1976, Volume: 38, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug Administration Schedul

1976
Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
    National Cancer Institute monograph, 1975, Volume: 42

    Topics: Adenocarcinoma; Alkylating Agents; Chlorambucil; Cyclophosphamide; Dactinomycin; Drug Therapy, Combi

1975
Adjuvant chemotherapy with 5-fluorouracil after surgical resection of colorectal carcinoma (COG protocol 7041). A preliminary report.
    American journal of surgery, 1977, Volume: 133, Issue:1

    Topics: Adenocarcinoma; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Prospective Studies; Rectal N

1977
Combination with 5-fluorouracil, methyl-CCNU and beta-2-deoxythioguanosine in advanced colo-rectal adenocarcinoma.
    Clinical oncology, 1977, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Deoxyribonucleosides; Drug Therapy, Combination; Fem

1977
Randomized prospective trial comparing 5-fluorouracil (NSC-19893) to 5-fluorouracil and methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
    Cancer treatment reports, 1976, Volume: 60, Issue:6

    Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Gastrointestinal Neoplasms

1976
Combination versus sequential five-drug chemotherapy in metastatic carcinoma of the breast.
    Cancer research, 1976, Volume: 36, Issue:11 Pt 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Drug Adminis

1976
A double-blind comparison of intensive course 5-flourouracil by oral vs. intravenous route in the treatment of colorectal carcinoma.
    Cancer, 1975, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Clinical Trials as Topic; Colonic Neoplasms; Evaluation Studie

1975
[Use of ftorafur for the treatment of 3d-4th stage].
    Voprosy onkologii, 1975, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation; Femal

1975
[Sequential chemotherapy based on the hypothesis of a circadian rhythm of tumor proliferation].
    La Nouvelle presse medicale, 1975, Nov-08, Volume: 4, Issue:38

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Circadian R

1975
Chemotherapy of advanced carcinoma of the prostate with 5-fluorouracil, cyclophosphamide and adriamycin.
    The Journal of urology, 1976, Volume: 115, Issue:1

    Topics: Adenocarcinoma; Aged; Alopecia; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Evalua

1976
Chemotherapy as an adjuvant to surgery for colorectal cancer.
    Annals of surgery, 1975, Volume: 181, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Colonic Neoplasms; Fluorouracil; Humans; Postoperative Care; P

1975
Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma.
    Cancer, 1975, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administratio

1975
Randomised controlled trial of adjuvant chemotherapy by portal-vein perfusion after curative resection for colorectal adenocarcinoma.
    Lancet (London, England), 1992, Aug-29, Volume: 340, Issue:8818

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Colorectal Neoplasms; Fluorouracil; Follow-Up Studies; Hepar

1992
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
    Cancer, 1992, Oct-01, Volume: 70, Issue:7

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

1992
A phase II clinical trial evaluating the use of two sequential, four-drug combination chemotherapy regimens in ambulatory bronchogenic adenocarcinoma patients.
    American journal of clinical oncology, 1992, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchog

1992
Preoperative systemic chemotherapy followed by adjuvant postoperative intraperitoneal therapy for gastric cancer: a University of Southern California pilot program.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1992
Treatment of elderly advanced gastric cancer patients with 5-fluorouracil and leucovorin combination.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Aged; Aging; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female

1992
A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas.
    Cancer, 1992, Oct-01, Volume: 70, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Fluor

1992
Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp

1992
Alpha-interferon in combination with 5-fluorouracil and leucovorin in metastatic colorectal cancer: a phase I study.
    Cancer chemotherapy and pharmacology, 1992, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Evaluation; Drug Therapy, Combination; Fluor

1992
Phase II trial of 7-day continuous 5-fluorouracil infusion in the treatment of advanced colorectal carcinoma.
    Oncology, 1992, Volume: 49, Issue:1

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule;

1992
Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; F

1992
A prospective randomized trial of continuous infusion 5-fluorouracil (5-FU) versus 5-FU plus cisplatin in patients with advanced colorectal cancer. A trial of the Spanish Cooperative Group for Digestive Tract Tumor Therapy (T.T.D.).
    American journal of clinical oncology, 1992, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1992
High-dose local irradiation plus prophylactic hepatic irradiation and chemotherapy for inoperable adenocarcinoma of the pancreas. A preliminary report of a multi-institutional trial (Radiation Therapy Oncology Group Protocol 8801).
    Cancer, 1992, Jun-01, Volume: 69, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil

1992
The value of adjuvant therapy after radical surgery for colorectal cancer.
    Annals of medicine, 1992, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus.
    The New England journal of medicine, 1992, Jun-11, Volume: 326, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
Chemotherapy with 5-fluorouracil (5-FU) and cisplatin or 5-FU, cisplatin, and vinblastine for advanced non-small cell lung cancer. A randomized phase II study of the cancer and leukemia group B.
    Cancer, 1991, Jun-15, Volume: 67, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1991
Treatment of adenocarcinoma of the cardia with synchronous chemotherapy and radiotherapy.
    The British journal of surgery, 1990, Volume: 77, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality

1990
Platinum-based chemotherapy followed by radiation therapy of locally advanced nasopharyngeal cancer. A retrospective analysis of 39 cases.
    Acta oncologica (Stockholm, Sweden), 1991, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carboplatin;

1991
Phase I trial of postoperative 5-FU, radiation therapy, and high dose leucovorin for resectable rectal cancer.
    International journal of radiation oncology, biology, physics, 1992, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Infusions, Intravenous; Leucovorin;

1992
Interferon alfa-2a and fluorouracil in the treatment of patients with advanced esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug

1992
A pharmacokinetic comparison of intravenous versus intra-arterial folinic acid.
    British journal of cancer, 1992, Volume: 65, Issue:1

    Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Intra-Arterial; Infusions, Intra

1992
Folinic acid + 5-fluorouracil (5-FU) versus equidose 5-FU in advanced colorectal cancer. Phase III study of 'GISCAD' (Italian Group for the Study of Digestive Tract Cancer).
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

1991
A phase II study of chemotherapy of metastatic colorectal carcinoma with 5-fluorouracil plus cisplatin. A Southwest Oncology Group study.
    Investigational new drugs, 1991, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1991
A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma.
    Cancer, 1991, Sep-01, Volume: 68, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Caffeine; Carboplatin;

1991
Preoperative chemotherapy (cisplatin and fluorouracil) and radiation therapy in stage III non-small-cell lung cancer: a phase II study of the Lung Cancer Study Group.
    Journal of the National Cancer Institute, 1991, Feb-20, Volume: 83, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1991
Thymopentin and interleukin-2 in combination with 5-fluorouracil and leucovorin in metastatic colorectal adenocarcinoma: preliminary results.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Femal

1991
Preliminary report of high dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer: a randomized trial of the Italian Oncology Group for Clinical Research.
    Journal of surgical oncology. Supplement, 1991, Volume: 2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr

1991
Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastatic carcinoma of unknown primary origin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1991
Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5-fluorouracil.
    The British journal of surgery, 1991, Volume: 78, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1991
Alternating weekly doxorubicin and 5-fluorouracil/leucovorin followed by weekly doxorubicin and daily cyclophosphamide in stage IV breast cancer. A Southwest Oncology Group study.
    Cancer, 1991, Sep-01, Volume: 68, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1991
Sequential combination of methotrexate (MTX), 5-fluorouracil (FU), and high-dose folinic acid (FA) in advanced colorectal cancer: double biochemical modulation?
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1991
High-dose 24-hour infusion of 5-fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association.
    American journal of clinical oncology, 1991, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Drug Evaluation; Fluorouracil; Humans; Infusions, In

1991
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug

1991
Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1991
A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
    Cancer, 1991, Jan-15, Volume: 67, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

1991
Treatment of patients with advanced colorectal cancer with cisplatin, 5-fluorouracil, and leucovorin.
    Cancer, 1991, Mar-01, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1991
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
    The New England journal of medicine, 1991, Mar-14, Volume: 324, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1991
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
    The New England journal of medicine, 1991, Mar-14, Volume: 324, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1991
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
    The New England journal of medicine, 1991, Mar-14, Volume: 324, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1991
Effective surgical adjuvant therapy for high-risk rectal carcinoma.
    The New England journal of medicine, 1991, Mar-14, Volume: 324, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1991
Levamisole in the adjuvant treatment of colon cancer.
    Clinical pharmacy, 1991, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne

1991
A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer.
    Cancer, 1991, May-15, Volume: 67, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1991
Phase I evaluation of spirogermanium and 5-fluorouracil in colorectal carcinoma.
    Investigational new drugs, 1991, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorec

1991
Hepatic artery ligation with and without portal infusion of 5-FU. A randomized study in patients with unresectable liver metastases from colorectal carcinoma. The E.O.R.T.C. Gastrointestinal Cancer Cooperative Group (G.I. Group).
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1991, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Combined Modality Therapy; Female; Fluorouracil;

1991
Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1991
Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl

1991
An early phase II study of 5-fluorouracil combined with cisplatinum as a second line chemotherapy against metastatic gastric cancer.
    Japanese journal of clinical oncology, 1991, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla

1991
Phase I/II study of cyclophosphamide, doxorubicin, fluorouracil, and leucovorin for treatment of metastatic adenocarcinoma.
    Journal of the National Cancer Institute, 1991, Jul-17, Volume: 83, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxor

1991
Tumor necrosis factor in advanced colorectal cancer: a phase II study. A trial of the phase I/II study group of the Association for Medical Oncology of the German Cancer Society.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Colorectal Neoplasms; Combined Modality Therapy; Drug Administration Schedule

1990
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial.
    Archives of surgery (Chicago, Ill. : 1960), 1990, Volume: 125, Issue:8

    Topics: Adenocarcinoma; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Humans; Infusion Pump

1990
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin.
    Cancer, 1990, May-15, Volume: 65, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Combined Chemotherapy Proto

1990
A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Combined Mo

1990
Adjuvant therapy of Dukes' A, B, and C adenocarcinoma of the colon with portal-vein fluorouracil hepatic infusion: preliminary results of National Surgical Adjuvant Breast and Bowel Project Protocol C-02.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; In

1990
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
    Cancer investigation, 1990, Volume: 8, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols;

1990
Association of bolus tetrahydropyranyl adriamycin and 120 hours continuous 5-fluorouracil infusion in patients with metastatic breast cancer.
    American journal of clinical oncology, 1990, Volume: 13 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1990
A feasibility study of intensive CAF as outpatient adjuvant therapy for stage II breast cancer in a cooperative group: CALGB 8443.
    Cancer investigation, 1990, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1990
Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.
    Archives of surgery (Chicago, Ill. : 1960), 1990, Volume: 125, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Combined Modality Therapy; Fem

1990
Adjuvant portal liver infusion in colorectal cancer with 5-fluorouracil/heparin versus urokinase versus control. Results of a prospective randomized clinical trial (colorectal adenocarcinoma trial I).
    Cancer, 1990, Feb-01, Volume: 65, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheterization, Central Venou

1990
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf

1990
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf

1990
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf

1990
Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf

1990
A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1987
[Can the occurrence of extrahepatic metastases in regional chemotherapy of the liver be prevented by adding systemic chemotherapy? A randomized multicenter study].
    Zeitschrift fur Gastroenterologie. Verhandlungsband, 1989, Volume: 24

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps

1989
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasms; Dru

1989
Activity of 5-fluorouracil, mitomycin C, and methyl CCNU in inoperable adenocarcinoma of pancreas.
    American journal of clinical oncology, 1989, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alkylating Agents; Antineoplastic Combined Chemother

1989
A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group.
    British journal of cancer, 1989, Volume: 60, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Mo

1989
Prevention of extrahepatic disease during intraarterial floxuridine of colorectal liver metastases by simultaneous systemic 5-fluorouracil treatment? A prospective multicenter study.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Inju

1989
Adjuvant chemotherapy in operable gastric cancer. 5 year follow-up of first British Stomach Cancer Group trial.
    Lancet (London, England), 1989, Mar-18, Volume: 1, Issue:8638

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy

1989
A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin.
    JAMA, 1985, Apr-12, Volume: 253, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Costs and

1985
Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Aged; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combinat

1989
Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis.
    Journal of surgical oncology, 1989, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Clinical T

1989
A phase III randomized trial of epirubicin versus 5-fluorouracil in metastatic rectal/sigmoid adenocarcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Clinical Trials as Topic; Epirubicin; Fluorouracil; Humans; Neoplasm Metastasis; Ran

1989
High-dose methotrexate and 5-fluorouracil in patients with advanced colorectal carcinoma. A randomized study of two pretreatment intervals.
    American journal of clinical oncology, 1989, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood; Clinical Trials as Topic; Col

1989
A randomized clinical trial with a weekly regimen of 5-fluorouracil with or without folinic acid in advanced gastrointestinal adenocarcinomas: a preliminary report.
    Journal of chemotherapy (Florence, Italy), 1989, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug

1989
Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1989, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Human

1989
Combined hepatic artery 5-fluorouracil and irradiation of liver metastases. A randomized study.
    Cancer, 1989, Nov-01, Volume: 64, Issue:9

    Topics: Adenocarcinoma; Blood Chemical Analysis; Colorectal Neoplasms; Combined Modality Therapy; Female; Fl

1989
[Reevaluation of intraluminal fluorouracil chemotherapy as an adjuvant to radical resection of colorectal cancer--results of a randomized trial].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1988, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy;

1988
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Prolongation of the disease-free interval in surgically treated rectal carcinoma.
    The New England journal of medicine, 1985, 06-06, Volume: 312, Issue:23

    Topics: Adenocarcinoma; Combined Modality Therapy; Drug Therapy, Combination; Female; Fluorouracil; Follow-U

1985
Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group.
    Cancer, 1985, Dec-01, Volume: 56, Issue:11

    Topics: Adenocarcinoma; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Humans; Male; Middle A

1985
Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group.
    Journal of the National Cancer Institute, 1988, Jul-20, Volume: 80, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined M

1988
A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Female; Fluorouracil; Humans; Inf

1989
Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).
    Cancer, 1986, Jan-01, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl

1986
Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin

1986
A randomized comparison of doxifluridine and fluorouracil in colorectal carcinoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Clinical Trials as Topic; Colonic Neoplasms; Female; Floxurid

1988
Efficacy of sequential cyclical hormonal therapy in endometrial cancer and its correlation with steroid hormone receptor status.
    Gynecologic oncology, 1988, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1988
[Clinical value of postoperative chemotherapy for non-small cell lung cancer--with special reference to long-term combined chemotherapy combined with immunotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Ca

1985
Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. The influence of optimum pretreatment surgical resection.
    American journal of obstetrics and gynecology, 1985, Jun-01, Volume: 152, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1985
Effect of alternating combination chemotherapy on survival of ambulatory patients with metastatic large-cell and adenocarcinoma of the lung. A Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Cl

1986
5-Methyltetrahydrofolic acid (MFH4): an effective folate for the treatment of advanced colorectal cancer with 5-FU.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1988, Volume: 110

    Topics: Adenocarcinoma; Adult; Aged; Clinical Trials as Topic; Colonic Neoplasms; Drug Therapy, Combination;

1988
Phase-III clinical trial of adjuvant FAM2 (5-FU, adriamycin and mitomycin C) vs control in resectable gastric cancer: a study of the EORTC Gastrointestinal Tract Cancer Cooperative Group.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1988, Volume: 110

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1988
Immunochemosurgery as a new approach to reasonable treatment of advanced cancer.
    Annals of the Academy of Medicine, Singapore, 1988, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Clinical Trials

1988
The Roswell Park Memorial Institute and Gastrointestinal Tumor Study Group phase III experience with the modulation of 5-fluorouracil by leucovorin in metastatic colorectal adenocarcinoma.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal

1988
Clinical experience with CF-FUra.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1988
Effective salvage therapy for refractory disseminated breast cancer with 5-fluorouracil and high-dose continuous infusion folinic acid.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cl

1988
Comparison of oral ftorafur and intravenous 5-fluorouracil in patients with advanced cancer of the stomach, colon or rectum.
    Oncology, 1986, Volume: 43, Issue:4

    Topics: Actuarial Analysis; Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid

1986
5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy in advanced adenocarcinoma of the lung: comparison of two dosage schedules.
    Cancer chemotherapy and pharmacology, 1987, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin

1987
Ifosfamide plus 5-fluorouracil for treatment of adenocarcinoma of the pancreas.
    Cancer treatment reports, 1987, Volume: 71, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1987
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 1988, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To

1988
A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1988
Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine

1988
Sequential 5-fluorouracil, methotrexate, and calcium leucovorin in metastatic colorectal cancer.
    Wisconsin medical journal, 1988, Volume: 87, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Col

1988
An EORTC Gastrointestinal Group phase III evaluation of combinations of methyl-CCNU, 5-fluorouracil, and adriamycin in advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1987
Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer.
    NCI monographs : a publication of the National Cancer Institute, 1987, Issue:5

    Topics: Adenocarcinoma; Biological Availability; Colonic Neoplasms; Fluorouracil; Hematopoiesis; Humans; Inf

1987
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne

1986
Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin;

1986
Phase II trials of 5-FU, doxorubicin, and cisplatin in advanced, measurable adenocarcinoma of the lung and stomach.
    Cancer treatment reports, 1986, Volume: 70, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic;

1986
Analysis of a prospectively randomized comparison of doxorubicin versus 5-fluorouracil, doxorubicin, and BCNU in advanced gastric cancer: implications for future studies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Clinical Tr

1986
Treatment of gastrointestinal cancer: the Southeastern Cancer Study Group experience, 1979 to 1983.
    Southern medical journal, 1986, Volume: 79, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Evalu

1986
Value of cyclophosphamide or melphalan as combined chemotherapy in hormonally unresponsive prostatic carcinoma.
    Urology, 1986, Volume: 28, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp

1986
5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Ne

1987
FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
    Cancer treatment reports, 1987, Volume: 71, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1987
Treatment of metastatic breast cancer in premenopausal women using CAF with or without oophorectomy: an Eastern Cooperative Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosph

1987
Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (trial 1) and in combination with 5-fluorouracil (trial 2) in advanced colorectal cancer.
    International journal of colorectal disease, 1987, Volume: 2, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Sched

1987
Cyclophosphamide versus 5-fluorouracil, doxorubicin, and mitomycin C (FAM') in the treatment of hormone-resistant metastatic carcinoma of the prostate: a preliminary report of a randomized trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin;

1985
A controlled evaluation of combined 5-fluorouracil, doxorubicin, and mitomycin C (FAM) for the treatment of advanced non-small-cell lung cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1985
Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275).
    Cancer, 1985, May-01, Volume: 55, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Fema

1985
Cyclophosphamide plus 5-FU versus 5-FU alone in advanced gastric carcinoma.
    Oncology, 1985, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Aged; Body Weight; Clinical Trials as Topic; Cyclophosphamide; Drug Administration S

1985
A randomized study of single agent vs combination chemotherapy in FIGO stages IIB, III and IV ovarian adenocarcinoma.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Clinical Tria

1985
A randomized comparison of cyclophosphamide, Adriamycin, and 5-fluorouracil with triethylenethiophosphoramide and methotrexate, both as sequential and as fixed rotational treatment in patients with advanced ovarian cancer.
    Cancer, 1985, Jan-01, Volume: 55, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosp

1985
The need for pilot studies and surgery-only controls in adjuvant therapy trials for large-bowel cancer.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1985, Volume: 98

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topi

1985
Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection.
    Archives of surgery (Chicago, Ill. : 1960), 1985, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Leukopenia; Male; Mid

1985
Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer.
    Lancet (London, England), 1969, Oct-25, Volume: 2, Issue:7626

    Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Gastrointestinal Neoplasms; Humans; Intestin

1969
Adrenal function in patients treated with testosterone and fluorinated pyrimidines.
    The Journal of clinical endocrinology and metabolism, 1968, Volume: 28, Issue:2

    Topics: 17-Ketosteroids; Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Glands; Adrenocorticotropic Hormon

1968
Advanced lung cancer: A clinical trial of radiotherapy plus two drug combination regimens.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1973, Nov-24, Volume: 47, Issue:46

    Topics: Adenocarcinoma; Amides; Antineoplastic Agents; Carcinoma; Carcinoma, Small Cell; Carcinoma, Squamous

1973
Current therapy approaches of the Division of Cancer Treatment with emphasis on pancreatic carcinoma.
    Journal of surgical oncology, 1974, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Animals; Carcinoma; Carcinoma, Intraductal, Noninfiltrating; Clinical Trials as Topi

1974
Effect of concomitant drug treatment on toxic and therapeutic activity of 5-fluorouracil (5-FU; NSC-19893).
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Antiemetics; Clinical Trials as Topic; Drug Antagonism; Drug Synergism; Fluorouracil

1972
A comparison of 5-fluorouracil administered by slow infusion and rapid injection.
    Cancer research, 1972, Volume: 32, Issue:12

    Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Infusions, Parenteral; Injections, I

1972
Evaluation of 6,17 alpha-dimethyl-6-dehydroprogesterone for treatment of recurrent and metastatic gynecologic malignancy.
    American journal of obstetrics and gynecology, 1974, Feb-15, Volume: 118, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Clinical Trials as Topic; Cyclophosphamide; Drug

1974
Cancer of the gastrointestinal tract. Radiation therapy.
    JAMA, 1974, Jun-03, Volume: 228, Issue:10

    Topics: Adenocarcinoma; Clinical Trials as Topic; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasm Recurr

1974
Radiotherapy plus 5-FU compared to radiotherapy alone for inoperable and unresectable bronchogenic carcinoma.
    Cancer, 1972, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Clinical Trials as Top

1972
Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinoside.
    Cancer, 1972, Volume: 29, Issue:5

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colonic Neoplasms; Cytarabine; Diabetic Ketoacidosis; Diar

1972
A controlled evaluation of 5-fluorouracil utilizing a single injection technique.
    Oncology, 1974, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Alopecia; Evaluation Studies as Topic; Fluorouracil; Gastrointestinal Diseases; Huma

1974
[Oxytetracycline, vehicle for therapeutic drugs, fluorouracil and nitrogen mustard, in the treatment of gastrointestinal tumors].
    Hospital (Rio de Janeiro, Brazil), 1970, Volume: 77, Issue:4

    Topics: Adenocarcinoma; Adult; Bile Duct Neoplasms; Clinical Trials as Topic; Drug Combinations; Esophagus;

1970
Treatment of unresectable adenocarcinomas of the stomach with a combination of 5-fluorouracil and radiation.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1968, Volume: 102, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Cobalt Isotopes; Female; Fluorouracil; Humans; Injections, Intravenous;

1968
Comparison of antimetabolites in the treatment of breast and colon cancer.
    JAMA, 1967, May-29, Volume: 200, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites; Breast Neoplasms; Child; Clinical Trials a

1967

Other Studies

3130 other studies available for fluorouracil and Adenocarcinoma, Basal Cell

ArticleYear
Potential antitumor agents. 58. Synthesis and structure-activity relationships of substituted xanthenone-4-acetic acids active against the colon 38 tumor in vivo.
    Journal of medicinal chemistry, 1989, Volume: 32, Issue:4

    Topics: Acetates; Adenocarcinoma; Animals; Chemical Phenomena; Chemistry; Chlorine; Colonic Neoplasms; Hydro

1989
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Multiple; Drug R

2011
Expression of astrocyte-elevated gene-1 indicates prognostic value of fluoropyrimidine-based adjuvant chemotherapy in resectable stage III colorectal cancer.
    Pathology international, 2021, Volume: 71, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2021
A new pancreatic adenocarcinoma-derived organoid model of acquired chemoresistance to FOLFIRINOX: First insight of the underlying mechanisms.
    Biology of the cell, 2022, Volume: 114, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fluoroura

2022
Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 12-01, Volume: 27, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fluorouracil; Hum

2021
Antitumor Activity of Zinc Nanoparticles Synthesized with Berberine on Human Epithelial Colorectal Adenocarcinoma (Caco-2) Cells through Acting on Cox-2/NF-kB and p53 Pathways.
    Anti-cancer agents in medicinal chemistry, 2022, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Animals; Apoptosis; bcl-2-Associated X Protein; Berberine; Caco-2 Cells; Caspase 3;

2022
Results of the observational prospective RealFLOT study.
    BMC cancer, 2021, Oct-08, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2021
Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
    Langenbeck's archives of surgery, 2022, Volume: 407, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Frozen Sections; Human

2022
Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing?
    Oncology, 2022, Volume: 100, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2022
Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.
    Anticancer research, 2022, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin

2022
[A Case of Metastatic Pancreatic Ductal Adenocarcinoma Successfully Treated with Modified FOLFIRINOX and Concurrent Radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2021, Volume: 48, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Hu

2021
Thymidine phosphorylase induction by ionizing radiation antagonizes 5-fluorouracil resistance in human ductal pancreatic adenocarcinoma.
    Radiation and environmental biophysics, 2022, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Cell Line, Tumor; Fluorouracil; Humans; Pancreatic Neoplasms; Radiation, Ionizing; R

2022
Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 163

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Esophageal Neoplasms

2022
Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study.
    British journal of cancer, 2022, Volume: 126, Issue:10

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
Bias and Pancreatic Cancer Reporting.
    Journal of the National Cancer Institute, 2022, 05-09, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Fluorouracil; Humans; Irinotec

2022
FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Journal of the National Cancer Institute, 2022, 05-09, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Cohort

2022
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin.
    Journal of hepato-biliary-pancreatic sciences, 2022, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans;

2022
circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway.
    Journal of experimental & clinical cancer research : CR, 2022, Feb-21, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinom

2022
Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study.
    BJS open, 2022, 01-06, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2022
Highly Advanced Colorectal Liver Metastases Successfully Treated With Fluorouracil Plus Leucovorin Monotherapy and Microwave Ablation.
    Anticancer research, 2022, Volume: 42, Issue:3

    Topics: Ablation Techniques; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, A

2022
Real-world Impact of Age at Diagnosis on Treatment Patterns and Survival Outcomes of Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    The oncologist, 2022, 06-08, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2022
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Current medical research and opinion, 2022, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Adult; Anemia; Antineoplastic Combined Chemotherapy Protocols; Atropine Derivatives;

2022
Neo-adjuvant FOLFIRINOX in borderline resectable and locally advanced pancreatic adenocarcinoma.
    Asia-Pacific journal of clinical oncology, 2022, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovorin; Mi

2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2022, Volume: 61, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Fluorouracil; Humans; In

2022
Response in
    BMJ case reports, 2022, Apr-29, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Carcinoma, Pancreatic

2022
Robotic low anterior resection of rectal metastasis from small bowel adenocarcinoma: A case report.
    Asian journal of endoscopic surgery, 2022, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Aged; Duodenal Neoplasms; Female; Fluorouracil; Humans; Keratin-20; Keratin-7; Leuco

2022
Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    JAMA network open, 2022, 06-01, Volume: 5, Issue:6

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Flu

2022
Class III β-Tubulin Expression Is of Value in Selecting nab -Paclitaxel and Gemcitabine as First-Line Therapy in Unresectable Pancreatic Cancer.
    Pancreas, 2022, 04-01, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Flavonoids;

2022
The Brown University Oncology Group Experience With FOLFOX + Nab-paclitaxel [FOLFOX-A] for Metastatic and Locally Advanced Pancreatic, BrUOG-292 and BrUOG-318.
    American journal of clinical oncology, 2022, 08-01, Volume: 45, Issue:8

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc

2022
Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?
    Journal of cancer research and clinical oncology, 2023, Volume: 149, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasm

2023
Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2022, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal;

2022
Alterations in Somatic Driver Genes Are Associated with Response to Neoadjuvant FOLFIRINOX in Patients with Localized Pancreatic Ductal Adenocarcinoma.
    Journal of the American College of Surgeons, 2022, 08-01, Volume: 235, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro

2022
Development and validation of a cancer-associated fibroblast-derived lncRNA signature for predicting clinical outcomes in colorectal cancer.
    Frontiers in immunology, 2022, Volume: 13

    Topics: Adenocarcinoma; Breast Neoplasms; Cancer-Associated Fibroblasts; Colorectal Neoplasms; Female; Fluor

2022
FKBP4 regulates 5-fluorouracil sensitivity in colon cancer by controlling mitochondrial respiration.
    Life science alliance, 2022, Volume: 5, Issue:11

    Topics: Adenocarcinoma; Carrier Proteins; Colonic Neoplasms; Copper; Electron Transport Complex IV; Fluorour

2022
Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
    European journal of cancer (Oxford, England : 1990), 2022, Volume: 174

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2022
FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world.
    International journal of cancer, 2023, 02-01, Volume: 152, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Deoxycytidine; Femal

2023
Patient Preferences for Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma.
    Pancreas, 2022, 07-01, Volume: 51, Issue:6

    Topics: Adenocarcinoma; Carbohydrates; Carcinoma, Pancreatic Ductal; Fluorouracil; Humans; Neoadjuvant Thera

2022
The role of PYCR1 in inhibiting 5-fluorouracil-induced ferroptosis and apoptosis through SLC25A10 in colorectal cancer.
    Human cell, 2022, Volume: 35, Issue:6

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Deferoxamine;

2022
Surprising efficacy twist of two established cytostatics revealed by a-la-carte 3D cell spheroid preparation protocol.
    European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2022, Volume: 180

    Topics: Adenocarcinoma; Cell Line, Tumor; Colonic Neoplasms; Cytostatic Agents; Fluorouracil; Humans; Irinot

2022
New Oxazolo[5,4-
    International journal of molecular sciences, 2022, Oct-02, Volume: 23, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Prolifera

2022
Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis.
    Journal of gastrointestinal cancer, 2023, Volume: 54, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri

2023
Perioperative treatment and biomarker analysis of LP002, an anti-PD-L1 antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer.
    Cancer medicine, 2023, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasms; Eso

2023
Expression pattern of secretory-cell-related transcriptional signatures in colon adenocarcinomas defines tumor microenvironment characteristics and correlates with clinical outcomes.
    Molecular oncology, 2023, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Cluster Analysis; Colonic Neoplasms; Fluorouracil; Humans; Tumor Microenvironment

2023
Is new risk-assessment score of venous thromboembolism for hospitalized surgical patients with borderline resectable pancreatic adenocarcinoma needed?
    Asian journal of surgery, 2023, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro

2023
5-fluorouracil with oxaliplatin and/or irinotecan for advanced sinonasal intestinal-type adenocarcinoma (ITAC).
    Bulletin du cancer, 2023, Volume: 110, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Cutaneous Intestinal Metaplasia With Adenocarcinoma Treated With Intralesional Fluorouracil.
    JAMA dermatology, 2023, 01-01, Volume: 159, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Humans; Metaplasia; Skin; Stomach Neoplasms

2023
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma.
    Turkish journal of medical sciences, 2022, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Fluorouracil;

2022
The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: A Single-Center Real-World Study.
    Pancreas, 2022, 09-01, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans;

2022
Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis.
    Journal of the American College of Surgeons, 2023, 06-01, Volume: 236, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Diseas

2023
Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective.
    Langenbeck's archives of surgery, 2023, Feb-10, Volume: 408, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophageal Neoplasms; Eso

2023
Danggui Buxue Tang potentiates the cytotoxicity of 5-fluorouracil on colorectal adenocarcinoma cells: A signaling mediated by c-Jun N-terminal kinase.
    Phytotherapy research : PTR, 2023, Volume: 37, Issue:7

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drugs, Chinese Herbal; Fluorouracil; Humans; JNK Mitogen

2023
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma.
    Cancer medicine, 2023, Volume: 12, Issue:8

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinote

2023
Incidence of Disease Recurrence in Patients With Colon and Upper Rectum Adenocarcinoma Stage II and III Receiving Adjuvant Capecitabine Monotherapy: Do Number of Chemotherapy Cycles and Relative Dose Intensity of the Drug Play a Role?
    Clinical colorectal cancer, 2023, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2023
Pathologic Tumor Regression is Associated With Improved Survival in Pancreatic Cancer.
    The American surgeon, 2023, Volume: 89, Issue:9

    Topics: Adenocarcinoma; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Fluorourac

2023
FOXM1/NCAPH activates glycolysis to promote colon adenocarcinoma stemness and 5-FU resistance.
    Anti-cancer drugs, 2023, 09-01, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Fluoro

2023
The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma.
    Cancer medicine, 2023, Volume: 12, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Continuity of Patient

2023
Ferroptosis-associated gene CISD2 suppresses colon cancer development by regulating tumor immune microenvironment.
    PeerJ, 2023, Volume: 11

    Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Ferroptosis; Fluorouracil; Humans; Tumor Microenviron

2023
A case report of typhlitis during novel use of ropidoxuridine-capecitabine-radiotherapy for treatment-naïve rectal cancer.
    Cancer chemotherapy and pharmacology, 2023, Volume: 92, Issue:2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Fem

2023
Clinical implications and chemo-sensitivity of adjuvant chemotherapy in patients with poorly cohesive cells-gastric cancer.
    Cancer chemotherapy and pharmacology, 2023, Volume: 92, Issue:4

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Oxaliplatin

2023
Targeting Glypican-1 Reverses Resistance to 5-Fluorouracil in Esophageal Adenocarcinoma Cells.
    Anticancer research, 2023, Volume: 43, Issue:8

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fluorour

2023
In Vitro Assessment of the Synergistic Effect of Aspirin and 5-Fluorouracil in Colorectal Adenocarcinoma Cells.
    Current oncology (Toronto, Ont.), 2023, 06-27, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Aspirin; bcl-2-Associated X Protein; Caspases; Colorectal Neo

2023
Comparison of gemcitabine plus oxaliplatin versus gemcitabine plus nab-paclitaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma: A single-center retrospective analysis.
    Cancer medicine, 2023, Volume: 12, Issue:16

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Gemcitabine;

2023
TRIM69: a marker of metastasis and potential sensitizer to 5-Fluorouracil and PD-1 blockers in colon adenocarcinoma.
    BMC gastroenterology, 2023, Aug-31, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Algorithms; Colonic Neoplasms; Fluorouracil; Humans; Programmed Cell Death 1 Recepto

2023
Perioperative Chemotherapy and Chemoradiotherapy for Patients With Resectable and Borderline Resectable Pancreatic Adenocarcinoma.
    Pancreas, 2023, May-01, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Pancreatic

2023
Customizing Therapy for Esophageal Cancer: CROSS vs. FLOT.
    Annals of surgical oncology, 2024, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri

2024
Colorectal Adenocarcinoma: Imaging using 5-Fluoracil Nanoparticles Labeled with Technetium 99 Metastable.
    Current pharmaceutical design, 2019, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Nanoparticles; Radiopharmaceuticals; Tec

2019
Efficacy and safety of preoperative 5-fluorouracil, cisplatin, and mitomycin C in combination with radiotherapy in patients with resectable and borderline resectable pancreatic cancer: a long-term follow-up study.
    World journal of surgical oncology, 2019, Aug-16, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2019
Mystery of neck lump: an uncommon presentation of urachal cancer.
    BMJ case reports, 2019, Aug-26, Volume: 12, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Brain Neoplasms; Diagnosis,

2019
Ganoderma Lucidum induces oxidative DNA damage and enhances the effect of 5-Fluorouracil in colorectal cancer in vitro and in vivo.
    Mutation research. Genetic toxicology and environmental mutagenesis, 2019, Volume: 845

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Division; Cell Line, Tumor; Colorecta

2019
Pathologic Response to Primary Systemic Therapy With FOLFIRINOX in Patients With Resectable Pancreatic Cancer.
    American journal of clinical oncology, 2019, Volume: 42, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cause o

2019
Port-site metastasis of pancreatic adenocarcinoma following 'successful' completion of neoadjuvant chemoradiation using FOLFIRINOX.
    ANZ journal of surgery, 2020, Volume: 90, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le

2020
Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto

2020
Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.
    Targeted oncology, 2019, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Fem

2019
Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    BMC cancer, 2019, Oct-22, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo

2019
DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial.
    European journal of cancer (Oxford, England : 1990), 2019, Volume: 123

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2019
Real-world Outcomes Among Patients Treated With Gemcitabine-based Therapy Post-FOLFIRINOX Failure in Advanced Pancreatic Cancer.
    American journal of clinical oncology, 2019, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Canada; C

2019
ZIP4 Increases Expression of Transcription Factor ZEB1 to Promote Integrin α3β1 Signaling and Inhibit Expression of the Gemcitabine Transporter ENT1 in Pancreatic Cancer Cells.
    Gastroenterology, 2020, Volume: 158, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cation Transport Proteins; Cell Line, Tumo

2020
PRDM14 promotes malignant phenotype and correlates with poor prognosis in colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2020, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adenoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation;

2020
LncRNA HAND2-AS1 inhibits 5-fluorouracil resistance by modulating miR-20a/PDCD4 axis in colorectal cancer.
    Cellular signalling, 2020, Volume: 66

    Topics: Adenocarcinoma; Animals; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug

2020
Immunologic alterations in the pancreatic cancer microenvironment of patients treated with neoadjuvant chemotherapy and radiotherapy.
    JCI insight, 2020, 01-16, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic D

2020
The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 03-01, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma,

2020
Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body or Tail on Surgical and Oncological Outcome: A Propensity-Score Matched Multicenter Study.
    Annals of surgical oncology, 2020, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

2020
Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report.
    Medicine, 2019, Volume: 98, Issue:50

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2019
Clinical management patterns of advanced and metastatic gastro-oesophageal carcinoma after fluoropyrimidine/platinum treatment in France, Germany, Spain and the United Kingdom.
    European journal of cancer care, 2020, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Analgesics, Opioid; Antiemetics; Antineoplastic Combin

2020
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
    Oncology reports, 2020, Volume: 43, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin;

2020
Perioperative chemotherapy for gastric cancer in FLOT4.
    Lancet (London, England), 2020, 01-11, Volume: 395, Issue:10218

    Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox

2020
Perioperative chemotherapy for gastric cancer in FLOT4.
    Lancet (London, England), 2020, 01-11, Volume: 395, Issue:10218

    Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox

2020
iASPP-Mediated ROS Inhibition Drives 5-Fu Resistance Dependent on Nrf2 Antioxidative Signaling Pathway in Gastric Adenocarcinoma.
    Digestive diseases and sciences, 2020, Volume: 65, Issue:10

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Movement; Drug Re

2020
Metabolic response assessment and PET-guided treatment of esophageal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2020, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Cisplatin; Docetaxel; Esophageal Neoplasms; Fluorouracil; Humans; Positron-Emission

2020
shRNA-mediated inhibition of PhosphoGlycerate Kinase 1 (PGK1) enhances cytotoxicity of intraperitoneal chemotherapy in peritoneal metastasis of gastric origin.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:4 Pt A

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Fluorou

2020
Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2021, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri

2021
Knockdown of Atg7 Induces Nuclear-LC3 Dependent Apoptosis and Augments Chemotherapy in Colorectal Cancer Cells.
    International journal of molecular sciences, 2020, Feb-07, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Beclin-1;

2020
Estimates of Overall Survival in Patients With Cancer Receiving Different Treatment Regimens: Emulating Hypothetical Target Trials in the Surveillance, Epidemiology, and End Results (SEER)-Medicare Linked Database.
    JAMA network open, 2020, 03-02, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neoplasms; Deoxycytid

2020
Tolerance and efficacy of dose escalation using IMRT combined with chemotherapy for unresectable esophageal carcinoma: Long-term results of 51 patients.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2020, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2020
Outcomes of patients with initially locally advanced pancreatic adenocarcinoma who did not benefit from resection: a prospective cohort study.
    BMC cancer, 2020, Mar-12, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox

2020
A patient-derived xenograft and a cell line derived from it form a useful preclinical model for small bowel adenocarcinoma.
    Cancer medicine, 2020, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols

2020
Impact of adjuvant chemotherapy on outcomes in appendiceal cancer.
    Cancer medicine, 2020, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2020
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer.
    Annals of surgical oncology, 2020, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema

2020
Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    Annals of surgical oncology, 2020, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le

2020
Segmental Polyposis.
    Gastroenterology, 2020, Volume: 159, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colec

2020
The area between ROC curves, a non-parametric method to evaluate a biomarker for patient treatment selection.
    Biometrical journal. Biometrische Zeitschrift, 2020, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bias; Biomarkers; Cetuximab; Colonic

2020
Time intervals to diagnosis and chemotherapy do not influence survival outcome in patients with advanced pancreatic adenocarcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2020, Volume: 52, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Mellitus; Female; Flu

2020
Peritoneal carcinomatosis of unknown primary site, a study of 25 patients over 30 years.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:10 Pt A

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms;

2020
What is causing this patient's severe pruritus?
    JAAPA : official journal of the American Academy of Physician Assistants, 2020, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen;

2020
Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
    Scientific reports, 2020, 05-29, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Binding Si

2020
Cutaneous metastasis of ascending colon cancer harboring a BRAF V600E mutation: A rare case report.
    Medicine, 2020, May-22, Volume: 99, Issue:21

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2020
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Journal of the National Cancer Institute, 2021, 02-01, Volume: 113, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Chemor

2021
An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer.
    Molecular oncology, 2020, Volume: 14, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Pancreatic Ductal; Cel

2020
First evidence for the antitumor activity of nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic biliary tract cancer.
    Cancer chemotherapy and pharmacology, 2020, Volume: 86, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxycytidi

2020
Impact of preoperative chemotherapy on the histological response of patients with peritoneal metastases from colorectal cancer according to peritoneal regression grading score (PRGS) and TRG.
    Surgical oncology, 2020, Volume: 33

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents, Immunological; Antineoplastic Combi

2020
FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer.
    Canadian journal of gastroenterology & hepatology, 2020, Volume: 2020

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2020
Distal Pancreatectomy with Celiac Axis Resection (Modified Appleby Procedure) and Arterial Reconstruction for Locally Advanced Pancreatic Adenocarcinoma After FOLFIRINOX Chemotherapy and Chemoradiation Therapy.
    Annals of surgical oncology, 2021, Volume: 28, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotec

2021
FOLFIRINOX
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2020
Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX.
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2020
Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
    Anticancer research, 2020, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino

2020
Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2021, Volume: 27, Issue:2

    Topics: Acneiform Eruptions; Adenocarcinoma; Administration, Topical; Aloe; Antineoplastic Agents; Antineopl

2021
Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer.
    EBioMedicine, 2020, Volume: 57

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bi

2020
Exceptional Response to A Single Cycle of Immunotherapy in a Lynch Syndrome Patient with Metastatic Pancreatic Adenocarcinoma.
    The American journal of case reports, 2020, Jul-13, Volume: 21

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antin

2020
Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery?
    JAMA surgery, 2020, 09-01, Volume: 155, Issue:9

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2020
Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2020,Spring, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; BRCA2 Protein; Checkpoint Kinase 2;

2020
Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2020
Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case

2020
Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
    Gut and liver, 2021, 05-15, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita

2021
CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    European radiology, 2021, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Irinot

2021
Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2020, Aug-01, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cross-Sectional Stu

2020
Patients with colorectal peritoneal metastases and high peritoneal cancer index may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2020, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Intravenous; Adolescent; Adult; Aged; Aged

2020
Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
    Annals of surgical oncology, 2020, Volume: 27, Issue:Suppl 3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Animal; Ele

2020
Even a partial pathological response is associated with lower relapse rates in patients with operable rectal cancer undergoing neoadjuvant chemotherapy.
    Journal of surgical oncology, 2021, Volume: 123, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase

2021
FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?
    ESMO open, 2020, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans;

2020
Prognostic Value of Pretreatment Serum CA199 in Patients with Locally Advanced Rectal Cancer Treated with CRT Followed by TME with Normal Pretreatment Carcinoembryonic Antigen Levels.
    Digestive surgery, 2021, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Antineoplasti

2021
Organ Preservation in the Treatment of Stage II and III Rectal Cancer.
    Diseases of the colon and rectum, 2020, Volume: 63, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Colectomy;

2020
Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer.
    American journal of surgery, 2021, Volume: 221, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2021
Treatment strategies and clinical outcomes in consecutive patients with locally advanced pancreatic cancer: A multicenter prospective cohort.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:3 Pt B

    Topics: Adenocarcinoma; Aged; Albumins; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap

2021
A Japanese Patient with Gastric Cancer and Dihydropyrimidine Dehydrogenase Deficiency Presenting with DPYD Variants.
    Acta medica Okayama, 2020, Volume: 74, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Contraindications, Drug; Dihydropyrimidine Dehydrog

2020
Intraoperative Radiation Mitigates the Effect of Microscopically Positive Tumor Margins on Survival Among Pancreatic Adenocarcinoma Patients Treated with Neoadjuvant FOLFIRINOX and Chemoradiation.
    Annals of surgical oncology, 2021, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le

2021
Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival.
    BMC surgery, 2021, Jan-13, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophagogastri

2021
[A Case of Advanced Rectal Cancer Successfully Treated with Preoperative Radiochemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2020, Volume: 47, Issue:13

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy

2020
The efficacy and safety of definitive concurrent chemoradiotherapy for non-operable esophageal cancer.
    Cancer medicine, 2021, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2021
Locally advanced rectal adenocarcinoma: Treatment sequences, intensification, and rectal organ preservation.
    CA: a cancer journal for clinicians, 2021, Volume: 71, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoembryonic

2021
Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans.
    Seminars in oncology, 2021, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouraci

2021
Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer.
    Scientific reports, 2021, 03-22, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adenosylhomocysteinase; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherap

2021
Role of FOLFIRINOX and chemoradiotherapy in locally advanced and borderline resectable pancreatic adenocarcinoma: update of the AGEO cohort.
    British journal of cancer, 2021, Volume: 124, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Stud

2021
Risk factors for sexual dysfunction after rectal cancer surgery in 948 consecutive patients: A prospective cohort study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:8

    Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Ch

2021
Chemotherapy of metastatic colon cancer in France: A population-based study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2021, Volume: 53, Issue:10

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2021
GSK-3β Can Regulate the Sensitivity of MIA-PaCa-2 Pancreatic and MCF-7 Breast Cancer Cells to Chemotherapeutic Drugs, Targeted Therapeutics and Nutraceuticals.
    Cells, 2021, 04-06, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adenylate Kinase; Antineoplastic Agents; bcl-X Protein; Berberine; Biphenyl Compound

2021
Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2021, Volume: 47, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocol

2021
AGAPP: efficacy of first-line cisplatin, 5-fluorouracil with afatinib in inoperable gastric and gastroesophageal junction carcinomas. A Hellenic Cooperative Oncology Group study.
    Acta oncologica (Stockholm, Sweden), 2021, Volume: 60, Issue:6

    Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophagogastric

2021
Multiple stage IV colorectal cancers in a patient who received multidisciplinary treatment, including chemotherapy and Japanese Kampo medicine: A case report.
    Neuropeptides, 2021, Volume: 88

    Topics: Adenocarcinoma; Aged; Bevacizumab; Colorectal Neoplasms; Drug Therapy; Fluorouracil; Humans; Japan;

2021
Chemotherapy-induced early transient increase and surge of CA 19-9 level in patients with pancreatic Adenocarcinoma
    Cancer treatment and research communications, 2021, Volume: 28

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2021
Real-world Patterns of Adjuvant Chemotherapy Following Neoadjuvant Chemoradiation for Patients With Resected Rectal Adenocarcinoma.
    American journal of clinical oncology, 2021, 08-01, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Alberta; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fem

2021
Predictors of conversion surgery in patients with pancreatic cancer who underwent neoadjuvant or palliative FOLFIRINOX treatment using baseline and follow-up CT.
    Abdominal radiology (New York), 2021, Volume: 46, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Follow-Up Studies; Hum

2021
Predicting overall survival and resection in patients with locally advanced pancreatic cancer treated with FOLFIRINOX: Development and internal validation of two nomograms.
    Journal of surgical oncology, 2021, Volume: 124, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem

2021
Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Annals of surgery, 2021, 10-01, Volume: 274, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cohort Studies; Disease-Free Surviva

2021
Pharmacologic modulation of 5-fluorouracil by folinic acid and high-dose pyridoxine for treatment of patients with digestive tract carcinomas.
    Scientific reports, 2021, 06-16, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2021
A case of palmar hypopigmentation induced by capecitabine in a gastrointestinal cancer patient.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2022, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Fluorouracil; Gastrointestinal

2022
Tumor Volume as Predictor of Pathologic Complete Response Following Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer.
    American journal of clinical oncology, 2021, 09-01, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Huma

2021
Genome-wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer.
    International journal of cancer, 2021, 11-01, Volume: 149, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cetuximab; Color

2021
The "Dextran-Magnetic Layered Double Hydroxide-Fluorouracil" Drug Delivery System Exerts Its Anti-tumor Effect by Inducing Lysosomal Membrane Permeability in the Process of Cell Death.
    Biological & pharmaceutical bulletin, 2021, Oct-01, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Azure Stains; Blotting, Western; Cell Death; Cell Line, Tumor

2021
Quercetin and Luteolin Improve the Anticancer Effects of 5-Fluorouracil in Human Colorectal Adenocarcinoma
    Nutrition and cancer, 2022, Volume: 74, Issue:2

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Luteolin; Q

2022
Survival and Predictive Factors of Chemotherapy With FOLFIRINOX as First-Line Therapy in Metastatic Pancreatic Cancer: A Retrospective Multicentric Analysis.
    Pancreas, 2021, 07-01, Volume: 50, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2021
SWI/SNF complex alterations as a biomarker of immunotherapy efficacy in pancreatic cancer.
    JCI insight, 2021, 09-22, Volume: 6, Issue:18

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Pro

2021
Predictive biomarkers for 5-fluorouracil and oxaliplatin-based chemotherapy in gastric cancers via profiling of patient-derived xenografts.
    Nature communications, 2021, 08-10, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Female;

2021
Chemosensitivity analysis and study of gene resistance on tumors and cancer stem cell isolates from patients with colorectal cancer.
    Molecular medicine reports, 2021, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; CD24 Antigen; Colorectal Neoplasms; Drug Resistance,

2021
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2022, Volume: 48, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2022
First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2021, 08-27, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leuc

2021
A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma.
    Anticancer research, 2017, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female;

2017
Does chronomodulated radiotherapy improve pathological response in locally advanced rectal cancer?
    Chronobiology international, 2017, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Circ

2017
Oncological Outcomes of Lateral Pelvic Lymph Node Metastasis in Rectal Cancer Treated With Preoperative Chemoradiotherapy.
    Diseases of the colon and rectum, 2017, Volume: 60, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Colectomy; Female; Fluorouracil;

2017
Gene expression levels of gamma-glutamyl hydrolase in tumor tissues may be a useful biomarker for the proper use of S-1 and tegafur-uracil/leucovorin in preoperative chemoradiotherapy for patients with rectal cancer.
    Cancer chemotherapy and pharmacology, 2017, Volume: 79, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

2017
5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer.
    Cancer letters, 2017, 08-01, Volume: 400

    Topics: Acetylation; Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chromatin; Colorect

2017
A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2017, Jul-01, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2017
Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
    The oncologist, 2017, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto

2017
[Multimodal therapy for gastric or gastroesophageal junction adenocarcinoma -ECF vs. FLOT].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2017, Volume: 88, Issue:6

    Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Esophageal Neoplasms; Esophagogastri

2017
Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?
    Future oncology (London, England), 2017, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Fluorouracil; Hum

2017
Revealing chemical processes and kinetics of drug action within single living cells via plasmonic Raman probes.
    Scientific reports, 2017, 05-23, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Camptothecin; Chemical Phenomena; Cisplatin

2017
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29.
    Oncology reports, 2017, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Ataxia Telangiectasia Mutated Proteins; Benzothiazo

2017
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis.
    International journal of radiation oncology, biology, physics, 2017, 07-01, Volume: 98, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Capecit

2017
Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer.
    Cancer chemotherapy and pharmacology, 2017, Volume: 80, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Beva

2017
Stereotactic body radiation vs. intensity-modulated radiation for unresectable pancreatic cancer.
    Acta oncologica (Stockholm, Sweden), 2017, Volume: 56, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco

2017
Cutaneous Drug REactions: Annular, polycyclic erythematous exanthema in an oncology patient.
    European journal of dermatology : EJD, 2017, Jun-01, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2017
Tumour growth increased following antiangiogenic interruption: the challenge of tumour evaluation.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; F

2017
Utilization and impact of adjuvant chemotherapy among patients with resected stage II colon cancer: a multi-institutional analysis.
    The Journal of surgical research, 2017, Volume: 215

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2017
Adjuvant and neoadjuvant therapy for resectable pancreatic adenocarcinoma.
    Chinese clinical oncology, 2017, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2017
Advanced Age is Not a Contraindication for Treatment With Curative Intent in Esophageal Cancer.
    American journal of clinical oncology, 2018, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2018
[Good remission under HER2 blockade in an advanced carcinoma of the oesophagogastric junction with only focal HER2 overexpression].
    Zeitschrift fur Gastroenterologie, 2017, Volume: 55, Issue:9

    Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antine

2017
Lymphocyte Nadir and Esophageal Cancer Survival Outcomes After Chemoradiation Therapy.
    International journal of radiation oncology, biology, physics, 2017, 09-01, Volume: 99, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemoradiotherapy; Esophageal Neoplasms; Fluorouracil; Hum

2017
Melatonin increases the effect of 5-fluorouracil-based chemotherapy in human colorectal adenocarcinoma cells in vitro.
    Molecular and cellular biochemistry, 2018, Volume: 440, Issue:1-2

    Topics: Adenocarcinoma; Cell Line, Tumor; Colorectal Neoplasms; Fluorouracil; Humans; Melatonin

2018
Toxicity and Outcomes in Patients With and Without Esophageal Stents in Locally Advanced Esophageal Cancer.
    International journal of radiation oncology, biology, physics, 2017, 11-15, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2017
Resection of Locally Advanced Pancreatic Cancer without Regression of Arterial Encasement After Modern-Era Neoadjuvant Therapy.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2018, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Arteries; Celiac Artery; Chemo

2018
Is There Merit for MET-Targeted Therapies in Gastroesophageal Cancer?
    JAMA oncology, 2018, 01-01, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Esophageal Neoplasms; Fluorouracil; Humans; Leucovorin; Oxal

2018
Impact of travel distance on access to treatment and survival in patients with metastatic colorectal cancer prescribed bevacizumab plus chemotherapy.
    Canadian journal of rural medicine : the official journal of the Society of Rural Physicians of Canada = Journal canadien de la medecine rurale : le journal officiel de la Societe de medecine rurale du Canada, 2017,Fall, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitab

2017
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
    The British journal of surgery, 2017, Volume: 104, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2017
Effect of Hyperglycemia on Antitumor Activity and Survival in Tumor-bearing Mice Receiving Oxaliplatin and Fluorouracil.
    Anticancer research, 2017, Volume: 37, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cell Line, T

2017
Metastatic primary seminal vesicle adenocarcinoma: management of a rare tumour with multiagent chemotherapy and hormonal therapy.
    BMJ case reports, 2017, Oct-10, Volume: 2017

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Mal

2017
Early small bowel perforation due to aflibercept.
    Drug discoveries & therapeutics, 2017, Nov-22, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2017
Comparing treatment outcomes of stage IIIB cervical cancer patients between those with and without lower third of vaginal invasion.
    Journal of gynecologic oncology, 2017, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carbopla

2017
Long-term survival in a patient with low-level inflammatory markers and liver metastasis, converted resectable by TACE.
    Immunotherapy, 2017, Volume: 9, Issue:13

    Topics: Adenocarcinoma; Adult; Biomarkers; Camptothecin; Capecitabine; Chemoembolization, Therapeutic; Colec

2017
Successful Treatment with 5-fluorouracil and Levofolinate Calcium in Advanced Gastric Cancer Patient with Disseminated Intravascular Coagulation.
    Gan to kagaku ryoho. Cancer & chemotherapy, 2017, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Disseminated Intravascular Co

2017
Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemother

2018
Outcome of neoadjuvant chemoradiation in MRI staged locally advanced rectal cancer: Retrospective analysis of 123 Chinese patients.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 2018, Volume: 117, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Capecitabine; Chemoradiotherapy; Female; Fluorouracil; Humans; Magnetic

2018
Metastasis in the mandibular condyle: a case report.
    Journal of medical case reports, 2017, Nov-16, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide;

2017
Outcomes of neoadjuvant chemoradiotherapy followed by total mesorectal excision surgery for locally advanced rectal cancer: a single-institution experience.
    Singapore medical journal, 2018, Volume: 59, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2018
Individual Susceptibility Analysis Using Patient-derived Slice Cultures of Colorectal Carcinoma.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neopl

2018
Metaplastic Cells in the Stomach Arise, Independently of Stem Cells, via Dedifferentiation or Transdifferentiation of Chief Cells.
    Gastroenterology, 2018, Volume: 154, Issue:4

    Topics: Adenocarcinoma; Animals; Biomarkers, Tumor; Cell Lineage; Cell Proliferation; Cell Transdifferentiat

2018
5-FU resistant EMT-like pancreatic cancer cells are hypersensitive to photochemical internalization of the novel endoglin-targeting immunotoxin CD105-saporin.
    Journal of experimental & clinical cancer research : CR, 2017, Dec-19, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; Endog

2017
Bevacizumab Added to Moderate-dose Chemotherapy for Refractory Uterine Cancer.
    Anticancer research, 2018, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2018
Cutaneous drug Reactions: Chemotherapy-induced hyperpigmentation.
    European journal of dermatology : EJD, 2017, Dec-01, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy

2017
Mismatch repair status as a beneficial predictor of fluorouracil-based adjuvant chemotherapy for pancreatic cancer.
    Surgery, 2018, Volume: 163, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2018
Quercetin Suppresses CYR61-Mediated Multidrug Resistance in Human Gastric Adenocarcinoma AGS Cells.
    Molecules (Basel, Switzerland), 2018, Jan-24, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferatio

2018
High expression of MMP-9 is associated with better prognosis in extrahepatic bile duct cancer patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Bile Duct Neoplasms; Bile Ducts, Extra

2018
Efficacy of low-dose 5-fluorouracil/cisplatin therapy for invasive extramammary Paget's disease.
    The Journal of dermatology, 2018, Volume: 45, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2018
Could early tumour volume changes assessed on morphological MRI predict the response to chemoradiation therapy in locally-advanced rectal cancer?
    Clinical radiology, 2018, Volume: 73, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2018
Beau's lines in nails: An indicator of recent Docetaxel and 5-FU use.
    The Kaohsiung journal of medical sciences, 2018, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetax

2018
Integrated Cancer Treatment in the Course of Metastatic Pancreatic Cancer: Complete Resolution in 2 Cases.
    Integrative cancer therapies, 2018, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Comb

2018
Targeting PRPK Function Blocks Colon Cancer Metastasis.
    Molecular cancer therapeutics, 2018, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic N

2018
Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antin

2018
Management of tumour lysis syndrome during first-line palliative chemotherapy for high-volume colorectal cancer.
    BMJ case reports, 2018, Mar-15, Volume: 2018

    Topics: Adenocarcinoma; Allopurinol; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diag

2018
Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
    Diseases of the colon and rectum, 2018, Volume: 61, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Colec

2018
Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer.
    JAMA oncology, 2018, 06-14, Volume: 4, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2018
Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis.
    Annals of surgical oncology, 2018, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2018
Tumor response after long interval comparing 5x5Gy radiation therapy with chemoradiation therapy in rectal cancer patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Carcinoma, Signet Ring

2018
Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation.
    American journal of clinical oncology, 2018, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2018
Toxicity, Tolerability, and Compliance of Concurrent Capecitabine or 5-Fluorouracil in Radical Management of Anal Cancer With Single-dose Mitomycin-C and Intensity Modulated Radiation Therapy: Evaluation of a National Cohort.
    International journal of radiation oncology, biology, physics, 2018, 08-01, Volume: 101, Issue:5

    Topics: Adenocarcinoma; Aged; Anus Neoplasms; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Coh

2018
Safety and Efficacy of Oxaliplatin Doublet Adjuvant Chemotherapy in Elderly Patients With Stage III Colon Cancer.
    Clinical colorectal cancer, 2018, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols

2018
Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution.
    World journal of surgery, 2018, Volume: 42, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy,

2018
The efficacy of combination of induction chemotherapy and irreversible electroporation ablation for patients with locally advanced pancreatic adenocarcinoma.
    Journal of surgical oncology, 2018, Volume: 118, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Chemotherapy, Adj

2018
Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma.
    Journal of geriatric oncology, 2018, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2018
Timed‑flat infusion of 5‑fluorouracil with docetaxel and oxaliplatin as first‑line treatment of gastroesophageal adenocarcinoma: A single institution experience with the FD/FOx regimen.
    Oncology reports, 2018, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2018
Orthotopic and heterotopic murine models of pancreatic cancer and their different responses to FOLFIRINOX chemotherapy.
    Disease models & mechanisms, 2018, 07-30, Volume: 11, Issue:7

    Topics: Adenocarcinoma; Allografts; Animals; Antineoplastic Combined Chemotherapy Protocols; Autografts; Car

2018
Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    BMC cancer, 2018, Jun-28, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2018
Evaluation of Antiproliferative Activity, Safety and Biodistribution of Oxaliplatin and 5-Fluorouracil Loaded Lactoferrin Nanoparticles for the Management of Colon Adenocarcinoma: an In Vitro and an In Vivo Study.
    Pharmaceutical research, 2018, Jul-16, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic Neopla

2018
Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
    Journal of visceral surgery, 2019, Volume: 156, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2019
Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy - a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study).
    BMC cancer, 2018, Jul-24, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic;

2018
Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2018, 12-15, Volume: 24, Issue:24

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2018
[Data review and analysis of 22 cases of gastric cancer associated with pregnancy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2018, Aug-23, Volume: 40, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2018
Skin Disorders and Primary Tumor Location as Prognostic Factors in Patients with Metastatic Colorectal Cancer Treated with Cetuximab and Chemotherapy
    Asian Pacific journal of cancer prevention : APJCP, 2018, Aug-24, Volume: 19, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cetuximab;

2018
Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2018, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth

2018
Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
    BMJ case reports, 2018, Sep-01, Volume: 2018

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Th

2018
Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Journal of gastrointestinal cancer, 2019, Volume: 50, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brazil; Deoxycytidine; Disease

2019
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.
    Advances in therapy, 2018, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

2018
Cisplatin Substitution with Carboplatin During Radical Chemoradiotherapy for Oesophagogastric Carcinoma: Outcomes from a Tertiary Centre.
    Anticancer research, 2018, Volume: 38, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamo

2018
C-Reactive Protein Level Predicts Survival Outcomes in Rectal Cancer Patients Undergoing Total Mesorectal Excision After Preoperative Chemoradiation Therapy.
    Annals of surgical oncology, 2018, Volume: 25, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; C-Reactive Pr

2018
Trans-Frontal Five-Fluorouracil (TraFFF): a novel technique for the application of adjuvant topical chemotherapeutic agents in sinonasal adenocarcinoma.
    BMJ case reports, 2018, Oct-24, Volume: 2018

    Topics: Adenocarcinoma; Administration, Topical; Adult; Ambulatory Care; Antimetabolites, Antineoplastic; Ch

2018
Bolus 5-fluorouracil (5-FU) In Combination With Oxaliplatin Is Safe and Well Tolerated in Patients Who Experienced Coronary Vasospasm With Infusional 5-FU or Capecitabine.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiotox

2019
The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
    Journal of surgical oncology, 2018, Volume: 118, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Australia; Chemotherapy, Adjuv

2018
Neoadjuvant Capecitabine Results in Similar Total Lymph Node Harvests as 5-Fluorouracil but an Increased Number of Lymph Nodes Containing Adenocarcinoma on Resection.
    The American surgeon, 2018, Jul-01, Volume: 84, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Colorectal

2018
E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Antigens, CD; Antineoplastic Agents; Cadherins; Colonic Neoplasms; Drug Resistance,

2019
The role of oxaliplatin in the adjuvant setting of different Lauren's type of gastric adenocarcinoma after D2 gastrectomy: a real-world study.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2019, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2019
Laparoscopic repair of bevacizumab-induced vesicovaginal fistula in metastatic colon cancer - a video vignette.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2019, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cecal Neo

2019
Anal canal adenocarcinoma with neuroendocrine features accompanying secondary extramammary Paget disease, successfully treated with modified FOLFOX6: a case report.
    BMC cancer, 2018, Nov-20, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Ca

2018
Acquired resistance to immunotherapy in MMR-D pancreatic cancer.
    Journal for immunotherapy of cancer, 2018, 11-20, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols

2018
Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
    Journal francais d'ophtalmologie, 2018, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplasti

2018
Nightmares and hallucinations with aprepitant and opium powder: a suspected drug-drug interaction.
    British journal of clinical pharmacology, 2019, Volume: 85, Issue:2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Arthr

2019
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer.
    Anti-cancer drugs, 2019, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2019
An Organoid-Based Preclinical Model of Human Gastric Cancer.
    Cellular and molecular gastroenterology and hepatology, 2019, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Proliferation; Epirubicin; Epithelium; Fluorour

2019
High-dose versus standard-dose radiation therapy for cervical esophageal cancer: Retrospective single-institution study.
    Head & neck, 2019, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2019
[The inhibition of angiogenic pathway in second line treatment of metastatic colorectal cancer.]
    Recenti progressi in medicina, 2018, Volume: 109, Issue:11

    Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Campt

2018
[Treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, right-sided colon cancer and potentially resectable liver metastases].
    Recenti progressi in medicina, 2018, Volume: 109, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas

2018
Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
    BMC cancer, 2019, Jan-08, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto

2019
Rechallenge capecitabine after fluoropyrimidine-induced cardiotoxicity in rectal cancer: A case report.
    Medicine, 2019, Volume: 98, Issue:2

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Cardiotoxicity; Combined Modal

2019
Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2019, Volume: 58, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemother

2019
[COMPLETE RESECTION OF URACHAL CARCINOMA WITH SIGMOID COLON INVASION AFTER FOLFOX CHEMOTHERAPY: A CASE REPORT].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 2018, Volume: 109, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colon, Sigmoid; Combined

2018
[A Case of Recurrent Colon Cancer with Long-Term Complete Response Treated with FOLFOX Therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2018, Volume: 45, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Flu

2018
Refining the Use of Adjuvant Oxaliplatin in Clinical Stage II or III Rectal Adenocarcinoma.
    The oncologist, 2019, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; C

2019
Variation in the Thoroughness of Pathologic Assessment and Response Rates of Locally Advanced Rectal Cancers After Chemoradiation.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2019, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; F

2019
A case of panitumumab containing chemotherapy causing interstitial lung disease: early recognition and treatment resulting in a good outcome.
    BMJ case reports, 2019, Feb-09, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged, 80 and over; Antineoplastic Agents, Immunological; An

2019
    International journal of medical sciences, 2019, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio

2019
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
    Clinical advances in hematology & oncology : H&O, 2018, Volume: 16 Suppl 17, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le

2018
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
    Clinical advances in hematology & oncology : H&O, 2018, Volume: 16 Suppl 17, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Irinotecan; Le

2018
A treatment landscape in evolution: new strategies, guidelines, and therapeutic advances for metastatic pancreatic adenocarcinoma.
    Clinical advances in hematology & oncology : H&O, 2018, Volume: 16 Suppl 17, Issue:9

    Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deo

2018
Thymidylate synthase gene polymorphism predicts disease free survival in stage II-III rectal adenocarcinoma patients receiving adjuvant 5-FU-based chemotherapy.
    Chinese clinical oncology, 2019, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Hu

2019
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
    BMC cancer, 2019, Mar-04, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line,

2019
XRCC4, which is inhibited by PFDA, regulates DNA damage repair and cell chemosensitivity.
    Journal of cellular biochemistry, 2019, Volume: 120, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cisplatin; Decanoic Acids; DNA Breaks, Do

2019
Pathological complete response may underestimate distant metastasis in locally advanced rectal cancer following neoadjuvant chemoradiotherapy and radical surgery: Incidence, metastatic pattern, and risk factors.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2019, Volume: 45, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain N

2019
Poly(3-hydroxybutyrate-CO-3-hydroxyvalerate) PHBHV biocompatible nanocarriers for 5-FU delivery targeting colorectal cancer.
    Drug delivery, 2019, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Availability; Cell Survival; Colorectal

2019
Three different polymorphisms of the DPYD gene associated with severe toxicity following administration of 5-FU: a case report.
    Journal of medical case reports, 2019, Mar-22, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Dih

2019
Survival Outcomes After Surgical Management of the Primary Tumor With and Without Radiotherapy for Metastatic Rectal Adenocarcinoma: A National Cancer Database (NCDB) Analysis.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2019
Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
    Annals of surgery, 2021, 03-01, Volume: 273, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem

2021
Perioperative FLOT: new standard for gastric cancer?
    Lancet (London, England), 2019, 05-11, Volume: 393, Issue:10184

    Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox

2019
Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma with synchronous liver metastasis after treatment with FOLFIRINOX.
    Clinical journal of gastroenterology, 2019, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Pancreatic Ductal; Fluoro

2019
FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2019, Volume: 51, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dise

2019
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinoma.
    Medicine, 2019, Volume: 98, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dise

2019
Perioperative FLOT superior to ECF/X.
    Nature reviews. Clinical oncology, 2019, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Capecitabine; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Leucovorin; Ox

2019
Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort.
    Clinics and research in hepatology and gastroenterology, 2019, Volume: 43, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studie

2019
Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
    World journal of surgical oncology, 2019, May-15, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma;

2019
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant.
    Medicine, 2019, Volume: 98, Issue:21

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant

2019
Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma.
    JAMA surgery, 2019, 08-01, Volume: 154, Issue:8

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant

2019
Metastatic gastric adenocarcinoma of the tongue with initial symptoms of glossodynia.
    Current problems in cancer, 2019, Volume: 43, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Gastric Mucosa

2019
Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.
    Clinical colorectal cancer, 2019, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2019
Combined treatment for locally advanced pancreatic cancer.
    The Lancet. Oncology, 2019, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Antihypertensive Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2019
FOLFIRINOX: a new standard of care in the adjuvant setting of resectable pancreatic adenocarcinomas.
    Future oncology (London, England), 2019, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Fluorouracil; Gemcita

2019
Optimal duration of adjuvant therapy for stage III colon cancer.
    Clinical advances in hematology & oncology : H&O, 2019, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Chem

2019
Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients.
    Cancer chemotherapy and pharmacology, 2019, Volume: 84, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2019
Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
    Pancreas, 2019, Volume: 48, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Protocols; C

2019
Sarcopenia supersedes subjective global assessment as a predictor of survival in colorectal cancer.
    PloS one, 2019, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2019
[Intussusception Caused by Colon Cancer in Pregnancy].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2019, Jun-25, Volume: 73, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscop

2019
Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
    Journal of cancer research and clinical oncology, 2019, Volume: 145, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2019
Atypical PRES with diffusion restriction or neurotoxicity- ? part of same spectrum-after oxaliplatin (FOLFOX-4 regimen) for colonic cancer.
    Current problems in cancer, 2019, Volume: 43, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura

2019
Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
    JAMA surgery, 2019, 10-01, Volume: 154, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2019
Lymph node invasion might have more prognostic impact than R status in advanced esophageal adenocarcinoma.
    American journal of surgery, 2013, Volume: 205, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Card

2013
Correlation between chemosensitivity to anticancer drugs and telomerase reverse transcriptase mRNA expression in gastric cancer.
    Diagnostic pathology, 2013, Feb-22, Volume: 8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Agents; Biomarke

2013
Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.
    BMC gastroenterology, 2013, Feb-27, Volume: 13

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; beta Catenin; Biomarkers, Tumor; CD8 Antigens

2013
Advancements in the management of pancreatic cancer: 2013.
    JOP : Journal of the pancreas, 2013, Mar-10, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2013
Proton therapy with concomitant capecitabine for pancreatic and ampullary cancers is associated with a low incidence of gastrointestinal toxicity.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Ampulla of Vater; Capecitabine; Chemoradiotherapy; Commo

2013
Modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma.
    Anticancer research, 2013, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2013
[Panitumumab-induced trichomegaly].
    Medicina clinica, 2013, Apr-20, Volume: 140, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin

2013
Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy,

2013
Impact of adjuvant chemotherapy cycles on prognosis of resectable stomach cancer: a retrospective analysis.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D

2013
Low-dose docetaxel/cisplatin - leucovorin and 46 hour infusional fluorouracil in metastatic gastric carcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Prog

2013
5-Fluorouracil potentiates the anti-cancer effect of oxaliplatin on Colo320 colorectal adenocarcinoma cells.
    Journal of gastrointestinal and liver diseases : JGLD, 2013, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Color

2013
Endoscopic ultrasound in staging esophageal cancer after neoadjuvant chemotherapy--results of a multicenter cohort analysis.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2013, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2013
Ring-enhancing lesion associated with radiation-induced liver disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2013
Postoperative treatment with docetaxel, cisplatin, and capecitabine (DCX) and chemoradiotherapy (CRT) with capecitabine for resected gastric adenocarcinoma.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; C

2015
Unresectable colorectal liver metastases: the safety and efficacy of conversion therapy using hepatic arterial infusion immunochemotherapy with 5-fluorouracil and polyethylene glycol-interferon α-2a.
    World journal of surgery, 2013, Volume: 37, Issue:8

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Disease-Free Survival;

2013
Preoperative chemosensitivity testing as Predictor of Treatment benefit in Adjuvant stage III colon cancer (PePiTA): protocol of a prospective BGDO (Belgian Group for Digestive Oncology) multicentric study.
    BMC cancer, 2013, Apr-12, Volume: 13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Belgium; Chemotherapy, Adjuvant; Col

2013
Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria.
    The Journal of pathology, 2013, Volume: 230, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Cel

2013
Berberine inhibits the growth of human colorectal adenocarcinoma in vitro and in vivo.
    Journal of natural medicines, 2014, Volume: 68, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pro

2014
Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence.
    American journal of clinical oncology, 2015, Volume: 38, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2015
[Secondary necrotizing fasciitis associated with panitumumab].
    Medicina clinica, 2013, Nov-16, Volume: 141, Issue:10

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Causal

2013
Semi-IPN chitosan/polyvinylpyrrolidone microspheres and films: sustained release and property optimisation.
    Journal of microencapsulation, 2013, Volume: 30, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Cell Line; Chitosan; Delayed-Acti

2013
Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Survival in patients treated with definitive chemo- radiotherapy for non-metastatic esophageal cancer in north- west iran.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2013
Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2013, Volume: 67, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Do

2013
Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
    Gastroenterology, 2013, Volume: 145, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bayes Theorem; Biomarkers, Tumor; Cell Line, Tumor; Clu

2013
[Immediate results of complex treatment of resectable rectal neoplasms of distal localization].
    Klinichna khirurhiia, 2013, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Case-Control Studies; Disease-Free Survival; Female; Fluorour

2013
Histopathological regression grading matches excellently with local and regional spread after neoadjuvant therapy of rectal cancer.
    Pathology, research and practice, 2013, Volume: 209, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Chi-Square Distributio

2013
Neoadjuvant-intensified treatment for rectal cancer: time to change?
    World journal of gastroenterology, 2013, May-28, Volume: 19, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2013
Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2013
Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2014, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esophagogastric Jun

2014
Cytotoxic withanolides from the leaves of Moroccan Withania frutescens.
    Pharmaceutical biology, 2013, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Chromatography, High P

2013
Chemotherapy sensitizes colon cancer initiating cells to Vγ9Vδ2 T cell-mediated cytotoxicity.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Coculture Techniques; Colonic Neoplasms; Cytotoxic

2013
Treatment of borderline resectable pancreatic cancer.
    Current treatment options in oncology, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther

2013
Outcomes of induction chemotherapy followed by chemoradiation using intensity-modulated radiation therapy for esophageal adenocarcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2014
[Results of combined treatment of patients with metastatic gastric cancer. Case study].
    Voprosy onkologii, 2013, Volume: 59, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

2013
Evolving role of neoadjuvant therapy in rectal cancer.
    Current treatment options in oncology, 2013, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Com

2013
Hepatoid adenocarcinoma of the stomach: an unusual case of elevated alpha-fetoprotein with prior treatment for hepatocellular carcinoma.
    Clinical and molecular hepatology, 2013, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Camptothec

2013
Circulating miR-200c levels significantly predict response to chemotherapy and prognosis of patients undergoing neoadjuvant chemotherapy for esophageal cancer.
    Annals of surgical oncology, 2013, Volume: 20 Suppl 3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2013
Severe irinotecan-induced toxicity in a patient with UGT1A1 28 and UGT1A1 6 polymorphisms.
    World journal of gastroenterology, 2013, Jun-28, Volume: 19, Issue:24

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protoc

2013
Pharmacogenomics in pancreatic adenocarcinoma: new data and their clinical implications.
    JOP : Journal of the pancreas, 2013, Jul-10, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Equilibrative Nucleoside Transporter

2013
Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    PloS one, 2013, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Hum

2013
[A case of HER2-positive gastric cancer successfully treated with trastuzumab plus capecitabine plus cisplatin chemotherapy as third-line treatment].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy.
    BMC cancer, 2013, Jul-22, Volume: 13

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Diseas

2013
Is neoadjuvant chemotherapy followed by radical surgery more effective than radiation therapy for stage IIB cervical cancer?
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2013, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2013
Impact of postoperative chemoradiotherapy and chemoradiotherapy alone for esophageal cancer in North-West Iran.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2013
Preoperative long course chemoirradiation in a developing country for rectal carcinoma: Kuala Lumpur hospital experience.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2013
Expanding the Lauren classification: a new gastric cancer subtype?
    Gastroenterology, 2013, Volume: 145, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Fluorouracil; Gene Expression Regulation,

2013
Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
    Anticancer research, 2013, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Cell Proli

2014
The preliminary experience in simultaneous treatment of rectal cancer and synchronous liver metastases with laparoscopy.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2013, Volume: 24, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy

2013
Multimodal treatment strategy for clinical T3 thoracic esophageal cancer.
    Annals of surgical oncology, 2013, Volume: 20, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Case

2013
Pretreatment patient comorbidity and tobacco use increase cost and risk of postoperative complications after esophagectomy at a high-volume cancer center.
    Journal of oncology practice, 2013, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Cance

2013
ERCC1 C8092A (rs3212986) polymorphism as a predictive marker in esophageal cancer patients treated with cisplatin/5-FU-based neoadjuvant therapy.
    Pharmacogenetics and genomics, 2013, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cisplatin; DNA-Binding Proteins; Endonuclease

2013
Mutational and clinical predictors of pathologic complete response in the treatment of locally advanced rectal cancer.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Adolescent; Adult; Aged; Aged, 80 and over; Anti

2014
Topical henna ameliorated capecitabine-induced hand-foot syndrome.
    Cutaneous and ocular toxicology, 2014, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Female; Fluorouracil;

2014
Stem cell-like side populations in esophageal cancer: a source of chemotherapy resistance and metastases.
    Stem cells and development, 2014, Jan-15, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; ATP Binding Cassette Transporter, S

2014
Cumulative incidence of permanent stoma after sphincter preserving low anterior resection of mid and low rectal cancer.
    Diseases of the colon and rectum, 2013, Volume: 56, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Anastomosis, Surgical; Anastomotic Leak;

2013
Effects of extended lymphadenectomy and postoperative chemotherapy on node-negative gastric cancer.
    World journal of gastroenterology, 2013, Sep-07, Volume: 19, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2013
Lethal cardiotoxicity, steatohepatitis, chronic pancreatitis, and acute enteritis induced by capecitabine and oxaliplatin in a 36-year-old woman.
    Diagnostic pathology, 2013, Sep-16, Volume: 8

    Topics: Acute Disease; Adenocarcinoma; Adult; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protoco

2013
γ-Glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate.
    British journal of cancer, 2013, Oct-15, Volume: 109, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line

2013
Cisplatin-modified de Gramont in second-line therapy for pancreatic adenocarcinoma.
    Pancreas, 2013, Volume: 42, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2013
Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
    Expert opinion on biological therapy, 2013, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2013
Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance.
    Oncology, 2013, Volume: 85, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Bridged-Ring Compounds; Chemoradiotherapy; Combined Mo

2013
Prognosis and value of adjuvant chemotherapy in stage III mucinous colorectal carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Chemotherapy, Adjuvant; Colorectal Neoplasms;

2013
Intensified neoadjuvant radiochemotherapy for rectal cancer enhances surgical complications.
    BMC surgery, 2013, Sep-30, Volume: 13

    Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

2013
Prognostic significance of tumor response as assessed by sequential 18F-fluorodeoxyglucose-positron emission tomography/computed tomography during concurrent chemoradiation therapy for cervical cancer.
    International journal of radiation oncology, biology, physics, 2013, Nov-01, Volume: 87, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Carcinoma, Squ

2013
Crohn's disease with worsening symptoms.
    Gastroenterology, 2013, Volume: 145, Issue:5

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Colectomy; Colorectal Neoplasms; Combined Mo

2013
Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer.
    Journal of chemotherapy (Florence, Italy), 2014, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Surviv

2014
Cancer-initiating cells derived from human rectal adenocarcinoma tissues carry mesenchymal phenotypes and resist drug therapies.
    Cell death & disease, 2013, Oct-03, Volume: 4

    Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Pro

2013
Paraneoplastic optic neuropathy and retinopathy associated with colon adenocarcinoma.
    Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2013, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colonoscopy; Comb

2013
A curious case of oxaliplatin-induced neurotoxicity: recurrent, self-limiting dysarthria.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2014, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat

2014
Metastatic lymph node ratio in stage III rectal carcinoma is a valuable prognostic factor even with less than 12 lymph nodes retrieved: a prospective study.
    American journal of surgery, 2014, Volume: 207, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemoradiotherapy; Colonoscop

2014
Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle.
    Anti-cancer drugs, 2014, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Genital Neoplasms, Mal

2014
The prognostic value of tumour regression grade following neoadjuvant chemoradiation therapy for rectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2014, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy;

2014
Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer.
    BMC cancer, 2013, Oct-16, Volume: 13

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Biliary Tr

2013
Autocrine extra-pancreatic trypsin 3 secretion promotes cell proliferation and survival in esophageal adenocarcinoma.
    PloS one, 2013, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Apoptosis; Autocrine Communication; Barrett Esophagus; Cell Line, Tumor; Cell Membra

2013
Efficacy and safety of docetaxel plus oxaliplatin and capecitabine in the first line treatment of advanced gastric adenocarcinoma.
    BioMed research international, 2013, Volume: 2013

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Capecitabine; Deoxycytidine; Disease-Free Survival; Docetax

2013
Modified FOLFIRINOX regimen with improved safety and maintained efficacy in pancreatic adenocarcinoma.
    Pancreas, 2013, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Campto

2013
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.
    International journal of surgical oncology, 2013, Volume: 2013

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2013
AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Jan-01, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Biomarkers, Tumor; Cell L

2014
Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma.
    Gut, 2014, Volume: 63, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2014
Can capecitabine be used instead of concurrent bolus 5-FU in postoperative chemoradiotherapy for gastric adenocarcinoma?
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine

2013
Nrf2 overexpression predicts prognosis and 5-FU resistance in gastric cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Drug Res

2013
Two-week combination chemotherapy with gemcitabine, high-dose folinic acid and 5 fluorouracil (GEMFUFOL) as first-line treatment of metastatic biliary tract cancers.
    Asian Pacific journal of cancer prevention : APJCP, 2013, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2013
Timeliness of adjuvant chemotherapy for stage III adenocarcinoma of the colon: a measure of quality of care.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2013
Non-randomized comparison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum.
    Anticancer research, 2013, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2013
Long-term monitoring of serum p53 antibody after neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: report of a case.
    Surgery today, 2014, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor;

2014
Treatment sequencing for resectable pancreatic cancer: influence of early metastases and surgical complications on multimodality therapy completion and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2014, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2014
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
    Journal of surgical oncology, 2014, Volume: 109, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemothera

2014
Docetaxel, cisplatin and 5-fluorouracil chemotherapy with concurrent radiation for unresectable advanced urethral carcinoma.
    International journal of urology : official journal of the Japanese Urological Association, 2014, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradio

2014
[Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Signet Ring Cel

2013
Chemotherapy versus self-expanding metal stent as primary treatment of severe dysphagia from unresectable oesophageal or gastro-oesophageal junction cancer.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter?
    Annals of surgical oncology, 2014, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen.
    Urologia internationalis, 2015, Volume: 94, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Immunoh

2015
Impact of stereotactic body radiotherapy on colorectal cancer with distant metastases.
    Oncology reports, 2014, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2014
Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy.
    British journal of cancer, 2014, Jan-21, Volume: 110, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Caspase 3;

2014
The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy.
    Annals of surgical oncology, 2014, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj

2014
The synergistic effects of low dose fluorouracil and TRAIL on TRAIL-resistant human gastric adenocarcinoma AGS cells.
    BioMed research international, 2013, Volume: 2013

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergis

2013
[Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2013
Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
    Onkologie, 2013, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxycytidin

2013
Modified GTX as second-line therapy for advanced pancreatic adenocarcinoma.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; D

2014
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach.
    Mayo Clinic proceedings, 2014, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Black or African American; Colonic N

2014
[A case of multiple skin metastases from cancer of the descending colon responding to FOLFIRI/cetuximab therapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Ch

2014
[A case of advanced colon cancer successfully treated with combination therapy of cetuximab and oxaliplatin, leucovorin, and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
[A case of pathological complete response with neoadjuvant mFOLFOX6 chemotherapy for advanced lower rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2013, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor

2013
ERCC1 expression and chemosensitivity in uterine cervical adenocarcinoma cells.
    Anticancer research, 2014, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferatio

2014
High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.
    Clinical lung cancer, 2014, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Sq

2014
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
    World journal of gastroenterology, 2013, Dec-28, Volume: 19, Issue:48

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2013
Second primary pancreatic adenocarcinoma three years after successfully treated index esophageal cancer.
    JOP : Journal of the pancreas, 2014, Jan-10, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad

2014
Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection.
    Annals of surgical oncology, 2014, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
Targeted delivery of 5-fluorouracil to HT-29 cells using high efficient folic acid-conjugated nanoparticles.
    Drug delivery, 2015, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biological Transport; Cell Survival; Colonic Neopla

2015
Complete pathological response (ypT0N0M0) after preoperative chemotherapy alone for stage IV rectal cancer.
    BMC surgery, 2014, Jan-17, Volume: 14

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combi

2014
Dermatomyositis associated with capecitabine in the setting of malignancy.
    Journal of the American Academy of Dermatology, 2014, Volume: 70, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Biopsy, Needle; Capecit

2014
Laparoscopic abdominosacral resection for locally advanced primary rectal cancer after treatment with mFOLFOX6 plus bevacizumab, followed by preoperative chemoradiotherapy.
    Asian journal of endoscopic surgery, 2014, Volume: 7, Issue:1

    Topics: Abdomen; Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplas

2014
Predictive value of optimal morphologic response to first-line chemotherapy in patients with colorectal liver metastases.
    Digestion, 2014, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized;

2014
Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    BMC surgery, 2014, Jan-24, Volume: 14

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2014
Colon carcinoma treated with oxaliplatin and capecitabine in a 12-year-old child.
    World journal of pediatrics : WJP, 2014, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Child; Colonic Neoplas

2014
Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, Western; Ce

2014
Establishment and biological characterization of a novel cell line derived from hepatoid adenocarcinoma originated at the ampulla of Vater.
    International journal of oncology, 2014, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Ampulla of Vater; Animals; Antimetabolites, Antineoplastic

2014
Twenty-six cases of advanced ampullary adenocarcinoma treated with systemic chemotherapy.
    Japanese journal of clinical oncology, 2014, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Cispl

2014
[Hyperammonemic encephalopathy in a patient treated with 5-fluorouracil].
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2014, Jan-01, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Antimetabolites; Fluorouracil; Humans; Hyperammonemia; Lung Neoplasms; Male; Middle

2014
The Benefit of Chemotherapy in Esophageal Cancer Patients With Residual Disease After Trimodality Therapy.
    American journal of clinical oncology, 2016, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Chemoradiotherapy; Chemotherapy, Adjuvant; Cisplati

2016
Autophagy is needed for the growth of pancreatic adenocarcinoma and has a cytoprotective effect against anticancer drugs.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:7

    Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Proliferati

2014
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2014
Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo

2014
Cetuximab-induced esophageal ulcer: the first report in literature.
    The Libyan journal of medicine, 2014, Volume: 9, Issue:1

    Topics: Abdomen, Acute; Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemother

2014
Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
    The oncologist, 2014, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemothe

2014
Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma.
    Biochimica et biophysica acta, 2014, Volume: 1843, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Calcium; Calcium Channels; Calcium Signaling; Cell

2014
Toll-like receptor-5 agonist Entolimod broadens the therapeutic window of 5-fluorouracil by reducing its toxicity to normal tissues in mice.
    Oncotarget, 2014, Feb-15, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Syn

2014
Impact of pre-angiogenic factors on the treatment effect of bevacizumab in patients with metastatic colorectal cancer.
    Medical oncology (Northwood, London, England), 2014, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Antibodies, Mono

2014
Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis.
    Journal of gastrointestinal cancer, 2014, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2014
Extracapsular lymph node involvement is associated with colorectal liver metastases and impact outcome after hepatectomy for colorectal metastases.
    World journal of surgery, 2014, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2014
Are we systematically under-dosing patients with fluorouracil?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-01, Volume: 33, Issue:7

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy

2015
Updates on first-line therapy for metastatic pancreatic adenocarcinoma.
    JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Albumins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cam

2014
Proteomic biomarker predicts therapeutical effects of oxaliplatin combining with fluoropyrimidine in metastatic gastric cancer patients by the SELDI-proteinchip platform.
    Hepato-gastroenterology, 2013, Volume: 60, Issue:127

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dise

2013
Toxicity of oxaliplatin plus fluorouracil/leucovorin adjuvant chemotherapy in elderly patients with stage III colon cancer: a population-based study.
    Annals of surgical oncology, 2014, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Colonic Neopla

2014
FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2014, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2014
Diterpenoid C of Radix Curcumae: an inhibitor of proliferation and inducer of apoptosis in human colon adenocarcinoma cells acting via inhibiting MAPK signaling pathway.
    Pharmaceutical biology, 2014, Volume: 52, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cel

2014
Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
    Cancer investigation, 2014, Volume: 32, Issue:5

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cap

2014
A complete response to mFOLFOX6 and panitumumab chemotherapy in advanced stage rectal adenocarcinoma: a case report.
    World journal of surgical oncology, 2014, Mar-26, Volume: 12

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil

2014
Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease.
    International journal of clinical oncology, 2015, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2015
Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer.
    World journal of gastroenterology, 2014, Mar-28, Volume: 20, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; China;

2014
A rare cause of susceptibility to neutropenic sepsis in a patient with metastatic pancreas cancer.
    BMJ case reports, 2014, Apr-03, Volume: 2014

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy-Ind

2014
Oral 5-fluorouracil colon-specific delivery through in vivo pellet coating for colon cancer and aberrant crypt foci treatment.
    International journal of pharmaceutics, 2014, Jul-01, Volume: 468, Issue:1-2

    Topics: Aberrant Crypt Foci; Adenocarcinoma; Adenoma; Administration, Oral; Animals; Antimetabolites, Antine

2014
Patterns of recurrence after trimodality therapy for esophageal cancer.
    Cancer, 2014, Jul-15, Volume: 120, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Anastomotic Leak; Antineoplastic Agents; Antineoplastic Combined Chemot

2014
Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2014
[A case of primary duodenal cancer recurrence successfully treated with CapeOX therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Duodena

2014
[Bevacizumab-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic colorectal cancer].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2014, Volume: 111, Issue:4

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Anticonvulsants; Antihypertensive Agents; A

2014
The safety and usefulness of neutron brachytherapy and external beam radiation in the treatment of patients with gastroesophageal junction adenocarcinoma with or without chemotherapy.
    Radiation oncology (London, England), 2014, Apr-29, Volume: 9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

2014
The role of tissue diagnosis prior to neoadjuvant chemoradiotherapy for locally advanced rectal cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2014, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot

2014
Late complications after proctectomy in rectal cancer patients who underwent radiotherapy.
    World journal of surgery, 2014, Volume: 38, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Agents; Case-C

2014
Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study.
    British journal of cancer, 2014, May-27, Volume: 110, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2014
Overcoming the challenges of primary tumor management in patients with metastatic colorectal cancer unresectable for cure and an asymptomatic primary tumor.
    Diseases of the colon and rectum, 2014, Volume: 57, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Asymptomatic Diseases; Colonos

2014
Differential effect of MMSET mRNA levels on survival to first-line FOLFOX and second-line docetaxel in gastric cancer.
    British journal of cancer, 2014, May-27, Volume: 110, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic

2014
Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients.
    International journal of clinical oncology, 2015, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Administration, Intravenous; Adult; Aged; Aged, 80 and over; Antineoplastic Combined

2015
The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer:
    European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pr

2014
Can a biomarker-based scoring system predict pathologic complete response after preoperative chemoradiotherapy for rectal cancer?
    Diseases of the colon and rectum, 2014, Volume: 57, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Biomarkers, Tumor; Biopsy; Chemoradiotherapy; Combined Modality Therapy

2014
Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients.
    International journal of colorectal disease, 2014, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit

2014
In reply to Ren et al.
    International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura

2014
IMRT with capecitabine in advanced pancreatic cancer. In regard to Passoni et al.
    International journal of radiation oncology, biology, physics, 2014, Jun-01, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura

2014
Molecular profiling in gastric cancer: examining potential targets for chemotherapy.
    Journal of surgical oncology, 2014, Volume: 110, Issue:3

    Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin

2014
Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer.
    Journal of the American College of Surgeons, 2014, Volume: 219, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2014
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.
    International journal of oncology, 2014, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blot

2014
Positive effects of oral β-glucan on mucositis and leukopenia in colorectal cancer patients receiving adjuvant FOLFOX-4 combination chemotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; b

2014
Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.
    Irish journal of medical science, 2015, Volume: 184, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2015
Long-term Treatment Outcomes for Locally Advanced Esophageal Cancer: A Single-Institution Experience.
    American journal of clinical oncology, 2016, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2016
Inferior oncological prognosis of surgery without oral chemotherapy for stage III colon cancer in clinical settings.
    World journal of surgical oncology, 2014, May-10, Volume: 12

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2014
Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma.
    World journal of surgical oncology, 2014, May-19, Volume: 12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female; Fluoro

2014
Chemoradiation with capecitabine and mitomycin-C for stage I-III anal squamous cell carcinoma.
    Radiation oncology (London, England), 2014, May-29, Volume: 9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus

2014
Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy.
    Langenbeck's archives of surgery, 2014, Volume: 399, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Esophageal Neoplasms; Female; Fluorouracil;

2014
Prognostic impact of CA 19-9 on outcome after neoadjuvant chemoradiation in patients with locally advanced pancreatic cancer.
    Annals of surgical oncology, 2014, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2014
[A case of pathological complete response of advanced rectal cancer with liver metastasis accompanied by tumor thrombus following treatment with bevacizumab/FOLFOX4 chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:5

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2014
[The combination of neoadjuvant chemoradiotherapy and epidermal growth factor receptor inhibitors in the treatment of rectal adenocarcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2014, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adj

2014
Effect of long interval between hyperthermochemoradiation therapy and surgery for rectal cancer on apoptosis, proliferation and tumor response.
    Anticancer research, 2014, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Prolife

2014
The wide gulf between stage III and stage IV colon cancer.
    The Lancet. Oncology, 2014, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C

2014
CoCl2, a mimic of hypoxia, induces formation of polyploid giant cells with stem characteristics in colon cancer.
    PloS one, 2014, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Cell Division; Cell Hypoxia; Cell Line, Tumor; Cell Shape; Cobalt; Colonic Neoplasms

2014
Prognostic factors for postoperative morbidity and tumour response after neoadjuvant chemoradiation followed by resection for rectal cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2014, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Anastomotic Leak; Antimetabolites, Anti

2014
Progression of KRAS mutant pancreatic adenocarcinoma during vemurafenib treatment in a patient with metastatic melanoma.
    Internal medicine journal, 2014, Volume: 44, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Deoxycytidine; Diseas

2014
Capecitabine induced colitis.
    Pathology, research and practice, 2014, Volume: 210, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colitis; Deoxycytidine; Fluorouracil;

2014
Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis.
    Targeted oncology, 2015, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Line, Tumor; Cell

2015
An effective 5-fluorouracil, levofolinate, and oxaliplatin therapy for recurrent breast cancer: a case report.
    Journal of medical case reports, 2014, Jun-26, Volume: 8

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma;

2014
The synergistic effect of rapamycin combined with 5-fluorouracil in BALB/cByJNarl mice bearing CT-26 tumor cells.
    Anticancer research, 2014, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell

2014
Impact of liver-directed therapy in colorectal cancer liver metastases.
    The Journal of surgical research, 2014, Volume: 191, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Catheter Ablation; Colorec

2014
Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2014
FOLFOX7 regimen in the first-line treatment of metastatic colorectal cancer.
    The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2014, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2014
Tumour regression grading after chemoradiotherapy for locally advanced rectal cancer: a near pathologic complete response does not translate into good clinical outcome.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2014, Volume: 112, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineopl

2014
Survival and recurrence patterns after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophagogastric adenocarcinoma.
    Annals of surgical oncology, 2015, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2015
FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort.
    Annals of surgical oncology, 2015, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2015
Differential protein expression and novel biomarkers related to 5-FU resistance in a 3D colorectal adenocarcinoma model.
    Oncology reports, 2014, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Chr

2014
SIRT5 facilitates cancer cell growth and drug resistance in non-small cell lung cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Wester

2014
Clinical results of definitive-dose (50 Gy/25 fractions) preoperative chemoradiotherapy for unresectable esophageal cancer.
    International journal of clinical oncology, 2015, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2015
First line treatment for metastatic pancreatic adenocarcinoma: looking for the step forward.
    JOP : Journal of the pancreas, 2014, Jul-28, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cis

2014
Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2014
Pseudocirrhosis after anti-EGFR-based neoadjuvant therapy for hepatic metastasis from colon cancer: a different point of view.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2014
Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2014
Overexpression of CPS1 is an independent negative prognosticator in rectal cancers receiving concurrent chemoradiotherapy.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carbamoyl-Phosphate Syntha

2014
Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    BMC gastroenterology, 2014, Aug-13, Volume: 14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Duct

2014
[A case of esophageal squamous cell carcinoma with an adenocarcinoma component that dedifferentiated after chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell

2014
Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
    Journal of surgical oncology, 2014, Volume: 110, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Pancreat

2014
KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer.
    PloS one, 2014, Volume: 9, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2014
Laser-induced drug release for local tumor control--a proof of concept.
    The Journal of surgical research, 2014, Volume: 192, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; beta-Cyclodextrins; Bromodeoxyuridine; Cel

2014
Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation.
    Gynecologic oncology, 2014, Volume: 135, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Car

2014
Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option.
    British journal of cancer, 2014, Oct-28, Volume: 111, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus

2014
Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer.
    Journal of experimental & clinical cancer research : CR, 2014, Sep-01, Volume: 33

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Ce

2014
Adjuvant chemotherapy by FOLFOX for gastric hepatoid adenocarcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2014, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy,

2014
Tranexamic acid and fibrinogen restore clotting in vitro and in vivo in cardiac thrombus associated hyperfibrinolysis with overt bleedings.
    Thrombosis and haemostasis, 2014, Volume: 112, Issue:5

    Topics: Adenocarcinoma; Aged; Anemia; Antifibrinolytic Agents; Antineoplastic Combined Chemotherapy Protocol

2014
Impact of perineural and lymphovascular invasion on oncological outcomes in rectal cancer treated with neoadjuvant chemoradiotherapy and surgery.
    Annals of surgical oncology, 2015, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy

2015
Transanal endoscopic microsurgery with entrance into the peritoneal cavity: is it safe?
    Diseases of the colon and rectum, 2014, Volume: 57, Issue:10

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Blood Loss, Su

2014
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy.
    Oncotarget, 2014, Aug-30, Volume: 5, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D

2014
Overcoming 5-Fu resistance of colon cells through inhibition of Glut1 by the specific inhibitor WZB117.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Drug Resi

2014
Second-line capecitabine and oxaliplatin combination for gemcitabine-resistant advanced pancreatic cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2014
Comparison of 2-dimensional and 3-dimensional conformal treatment plans in gastric cancer radiotherapy.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:17

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant; Fluorouracil; Gastrect

2014
O-MAX chemotherapy: high activity in metastatic esophagogastric adenocarcinoma and possible relation to subclinical hemolysis.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycyti

2014
Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy.
    World journal of gastroenterology, 2014, Sep-14, Volume: 20, Issue:34

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; C

2014
Hepatoid adenocarcinoma of the colon in a patient with inflammatory bowel disease.
    World journal of gastroenterology, 2014, Sep-21, Volume: 20, Issue:35

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2014
Intussusception due to rectal adenocarcinoma in a young adult: a case report.
    World journal of gastroenterology, 2014, Sep-21, Volume: 20, Issue:35

    Topics: Abdominal Pain; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; B

2014
Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer.
    Oncotarget, 2014, Sep-30, Volume: 5, Issue:18

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Caco-2 Cells; Cell Pro

2014
ZNF695 methylation predicts a response of esophageal squamous cell carcinoma to definitive chemoradiotherapy.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma,

2015
IQGAP1 in rectal adenocarcinomas: localization and protein expression before and after radiochemotherapy.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2015
[Influence of preoperative chemoradiotherapy on changes of epidermal growth factor receptor expression in patients treated by preoperative chemoradiotherapy for local advanced rectal carcinoma].
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2014, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuv

2014
Pharmacokinetics of oxaliplatin in a hemodialyzed patient: chemotherapy dose adjustment and timing of dialysis.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Dose-Response

2014
Reduced-intensity FOLFOXIRI in Treating Refractory Metastatic Colorectal Cancer: A Pilot Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2017
[Long-term survival of a patient with sigmoid colon cancer showing multiple liver metastases treated by performing partial hepatectomy, five years after achieving a complete response via hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Fluorouracil; Hepatectomy; Humans; Infusions,

2014
A nationwide retrospective study of perioperative chemotherapy for gastroesophageal adenocarcinoma: tolerability, outcome, and prognostic factors.
    Annals of surgical oncology, 2015, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2015
MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines.
    World journal of gastroenterology, 2014, Oct-28, Volume: 20, Issue:40

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor

2014
Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas.
    Annals of surgical oncology, 2015, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2015
Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
    Carcinogenesis, 2015, Volume: 36, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fema

2015
Adjuvant chemoradiation with 5-fluorouracil/leucovorin versus S-1 in gastric cancer patients following D2 lymph node dissection surgery: a feasibility study.
    Anticancer research, 2014, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity.
    World journal of surgical oncology, 2014, Nov-06, Volume: 12

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2014
Complete Neoadjuvant Treatment for Rectal Cancer: The Brown University Oncology Group CONTRE Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherap

2017
Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2014
Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation.
    World journal of gastroenterology, 2014, Nov-14, Volume: 20, Issue:42

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Chemoradiot

2014
FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience.
    Clinical colorectal cancer, 2014, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2014
MiR-22 regulates 5-FU sensitivity by inhibiting autophagy and promoting apoptosis in colorectal cancer cells.
    Cancer letters, 2015, Jan-28, Volume: 356, Issue:2 Pt B

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins;

2015
Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Annals of surgical oncology, 2015, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2015
Facial adenocarcinoma treated with intra-arterial chemotherapy.
    Journal of the American Academy of Dermatology, 2015, Volume: 72, Issue:1

    Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Facial Neoplasms; Female; Fluoro

2015
Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Capecitabine

2015
A case series of patients with HER2-overexpressed primary metastatic gastroesophageal adenocarcinoma.
    Anticancer research, 2014, Volume: 34, Issue:12

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2014
A case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity.
    Acta clinica Belgica, 2015, Volume: 70, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colecto

2015
The influence of 5-fluorouracil on activity of thymidine phosphorylase in gastric adenocarcinoma and normal adjacent tissue.
    Experimental oncology, 2014, Volume: 36, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Enzyme Activation;

2014
Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
    World journal of surgical oncology, 2014, Dec-29, Volume: 12

    Topics: Adenocarcinoma; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy Proto

2014
MiR-145 expression accelerates esophageal adenocarcinoma progression by enhancing cell invasion and anoikis resistance.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Anoikis; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cell Proliferati

2014
[Combined treatment of patients with locally advanced rectal cancer].
    Voprosy onkologii, 2014, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2014
A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectomy and hepatectomy.
    Journal of surgical oncology, 2015, Volume: 111, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatectomy; Hum

2015
Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capecitabine for locally advanced rectal cancer.
    Diseases of the colon and rectum, 2015, Volume: 58, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemo

2015
Neoadjuvant therapy for localized pancreatic cancer: support is growing?
    Annals of surgery, 2015, Volume: 261, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil;

2015
Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.
    Annals of surgery, 2015, Volume: 261, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2015
Does the timing of adjuvant chemotherapy for gastric cancer influence patient outcome?
    Acta oncologica (Stockholm, Sweden), 2015, Volume: 54, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod

2015
Adjuvant chemoradiation plus intraoperative radiotherapy versus adjuvant chemoradiation alone in patients with locally advanced rectal cancer.
    American journal of clinical oncology, 2015, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2015
Capecitabine metronomic chemotherapy inhibits the proliferation of gastric cancer cells through anti-angiogenesis.
    Oncology reports, 2015, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Administration, Metronomic; Angiogenesis Inhibitors; Animals; Antimetabolites, Antin

2015
Aptamer decorated hyaluronan/chitosan nanoparticles for targeted delivery of 5-fluorouracil to MUC1 overexpressing adenocarcinomas.
    Carbohydrate polymers, 2015, May-05, Volume: 121

    Topics: Adenocarcinoma; Animals; Aptamers, Nucleotide; Chitosan; CHO Cells; Colorectal Neoplasms; Cricetinae

2015
[After neoadjuvant therapy of pancreatic cancer the classical radiological criteria for resectability are no longer applicable].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2015, Volume: 86, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; Fluorouracil;

2015
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancer.
    Journal of clinical pathology, 2015, Volume: 68, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers, Tumor;

2015
Successful treatment of conversion chemotherapy for initially unresectable synchronous colorectal liver metastasis.
    World journal of gastroenterology, 2015, Feb-14, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2015
A case of heterogeneous sensitivity to panitumumab in cetuximab-refractory colorectal adenocarcinoma metastases.
    Cancer biology & therapy, 2015, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Campt

2015
[Efficiency of pre-operative chemoradiotherapy in treating a case of advanced rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy;

2014
[Surgical resection after chemotherapy for advanced rectal cancer - report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2014
[Irradiation with carbon ions for locally recurrent rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Heavy Io

2014
[A case of metastatic gastric cancer originating from transverse colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colon, Transverse; Col

2014
[A case report of hepatectomy for liver metastasis of colon cancer after heavy particle radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Combined Modality Ther

2014
[A case of advanced gastric cancer with liver metastasis involving curative surgery after neoadjuvant chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2014
[A case of gastric cancer showing response to first-line XP regimen after lymph node recurrence during the administration of S-1 as postoperative adjuvant chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2014, Volume: 41, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2014
Efficacy and safety of trastuzumab in combination with oxaliplatin and fluorouracil-based chemotherapy for patients with HER2-positive metastatic gastric and gastro-oesophageal junction adenocarcinoma patients: a retrospective study.
    Bulletin du cancer, 2015, Volume: 102, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2015
Feasibility and Safety of Negative-Balance Isolated Pelvic Perfusion in Patients with Pretreated Recurrent or Persistent Uterine Cervical Cancer.
    Annals of surgical oncology, 2015, Volume: 22, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2015
Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
    Oncology, 2015, Volume: 89, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2015
[Preoperative chemoradiotherapy for rectal cancer: experience from one centre].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro

2015
Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone.
    Journal of gastrointestinal cancer, 2015, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combin

2015
Use of extracorporeal membrane oxygenation for mechanical circulatory support in a patient with 5-fluorouracil induced acute heart failure.
    Circulation. Heart failure, 2015, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Cardiotoxicity; Colorectal Neoplasms; Extrac

2015
Potential Role of Single Nucleotide Polymorphisms of XRCC1, XRCC3, and RAD51 in Predicting Acute Toxicity in Rectal Cancer Patients Treated With Preoperative Radiochemotherapy.
    American journal of clinical oncology, 2017, Volume: 40, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiothera

2017
[A case of HER2-positive advanced gastric cancer successfully treated via capecitabine, cisplatin, and trastuzumab combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2015
Pre-therapy mRNA expression of TNF is associated with regimen-related gastrointestinal toxicity in patients with esophageal cancer: a pilot study.
    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2015, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2015
High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma.
    Oncology, 2015, Volume: 89, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2015
Prognostic factors and the role of adjuvant chemotherapy in post-curative surgery for Dukes B and C colon cancers and survival outcomes: a Malaysian experience.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2015
Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema

2015
A rare cause of esophagitis with crystal deposition.
    Canadian journal of gastroenterology & hepatology, 2015, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Crystallization; Esoph

2015
Annexin V-Directed Enzyme Prodrug Therapy Plus Docetaxel for the Targeted Treatment of Pancreatic Cancer.
    Pancreas, 2015, Volume: 44, Issue:6

    Topics: Adenine; Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carbon-Sulfur L

2015
Metastatic Pancreatic Adenocarcinoma Treatment Patterns, Health Care Resource Use, and Outcomes in France and the United Kingdom Between 2009 and 2012: A Retrospective Study.
    Clinical therapeutics, 2015, Jun-01, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2015
[Epinephros metastasis of colorectal cancer complicated by tumor thrombosis of inferior vena cava].
    Khirurgiia, 2015, Issue:1

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Adrenalectomy; Antineoplastic Agents; Capecitabine; Colecto

2015
Prognostic implications of thymidylate synthase gene polymorphisms in patients with advanced small bowel adenocarcinoma treated with first-line fluoropyrimidine-based chemotherapy.
    Oncology reports, 2015, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; Duodenal Neoplasms; Female; F

2015
Comprehensive evaluation of the effectiveness of gene expression signatures to predict complete response to neoadjuvant chemoradiotherapy and guide surgical intervention in rectal cancer.
    Cancer genetics, 2015, Volume: 208, Issue:6

    Topics: Adenocarcinoma; Chemoradiotherapy; Female; Fluorouracil; Gene Expression Profiling; Gene Expression

2015
Impact of perioperative chemotherapy on survival in patients with advanced primary urethral cancer: results of the international collaboration on primary urethral carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Long-Term Survival of Patient with Epstein-Barr Virus-Positive Gastric Cancer Treated with Chemotherapy: Case Report.
    Journal of gastrointestinal cancer, 2016, Volume: 47, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2016
The BH3-mimetic obatoclax reduces HIF-1α levels and HIF-1 transcriptional activity and sensitizes hypoxic colon adenocarcinoma cells to 5-fluorouracil.
    Cancer letters, 2015, Aug-10, Volume: 364, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Hypoxia; Cell Prolif

2015
Benefit of adjuvant chemotherapy in patients with T4 UICC II colon cancer.
    BMC cancer, 2015, May-20, Volume: 15

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj

2015
Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2015
Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy.
    Journal of the American College of Surgeons, 2015, Volume: 221, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2015
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2015
[Individualized therapy of synchronous ovarian and colon cancers with lymph].
    Orvosi hetilap, 2015, Jun-07, Volume: 156, Issue:23

    Topics: Abdominal Pain; Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Agents, Phytogenic;

2015
Circulating tumor cells are predictive of poor response to chemotherapy in metastatic gastric cancer.
    The International journal of biological markers, 2015, Nov-11, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Disease-Free Su

2015
Correlation of CEA but not CA 19-9 as serum biomarkers of disease activity in a case of metastatic rectal adenocarcinoma.
    Cancer biology & therapy, 2015, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; CA-19-9 Antigen;

2015
Hyperthermic intraperitoneal chemotherapy + early postoperative intraperitoneal chemotherapy versus hyperthermic intraperitoneal chemotherapy alone: assessment of survival outcomes for colorectal and high-grade appendiceal peritoneal carcinomatosis.
    American journal of surgery, 2015, Volume: 210, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2015
A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites.
    International journal of colorectal disease, 2015, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy, Adjuv

2015
Role of Adjuvant Chemotherapy in ypT0-2N0 Patients Treated with Preoperative Chemoradiation Therapy and Radical Resection for Rectal Cancer.
    International journal of radiation oncology, biology, physics, 2015, Jul-01, Volume: 92, Issue:3

    Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chem

2015
Development of lattice-inserted 5-Fluorouracil-hydroxyapatite nanoparticles as a chemotherapeutic delivery system.
    Journal of biomaterials applications, 2015, Volume: 30, Issue:4

    Topics: 3T3 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antimetabolites, Antineoplastic; Cell Li

2015
Chemotherapeutic treatment of colorectal cancer in pregnancy: case report.
    Journal of medical case reports, 2015, Jun-13, Volume: 9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female;

2015
Comparison of oncologic outcomes of metastatic rectal cancer patients with or without neoadjuvant chemoradiotherapy.
    International journal of colorectal disease, 2015, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2015
Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    Journal of surgical oncology, 2015, Volume: 111, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitab

2015
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Objective Assessment of Surgical Restaging after Concurrent Chemoradiation for Locally Advanced Pancreatic Cancer.
    Journal of Korean medical science, 2015, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Comb

2015
Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma.
    American journal of clinical oncology, 2016, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; C

2016
Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015, Volume: 17, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2015
Neoadjuvant therapy does not affect lymph node ratio in rectal cancer.
    The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2016, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; I

2016
Effect of Hyperthermic Intraperitoneal Perfusion Chemotherapy in Combination with Intravenous Chemotherapy as Postoperative Adjuvant Therapy for Advanced Gastric Cancer.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:132

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2014
Organizing pneumonia with fatal outcome after adjuvant chemotherapy with FOLFOX.
    Archivos de bronconeumologia, 2015, Volume: 51, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni

2015
Defining Eligibility of FOLFIRINOX for First-Line Metastatic Pancreatic Adenocarcinoma (MPC) in the Province of British Columbia: A Population-based Retrospective Study.
    American journal of clinical oncology, 2017, Volume: 40, Issue:6

    Topics: Activities of Daily Living; Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplas

2017
Prognostic impact of preoperative platelets to lymphocytes ratio (PLR) on survival for oesophageal and junctional carcinoma treated with neoadjuvant chemotherapy: A retrospective monocentric study on 153 patients.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2015
Modified FOLFIRINOX for Locally Advanced and Metastatic Pancreatic Cancer Patients Resistant to Gemcitabine and S-1 in Japan: A Single Institutional Experience.
    Hepato-gastroenterology, 2014, Volume: 61, Issue:131

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2014
Polymorphisms in Genes Involved in EGFR Turnover Are Predictive for Cetuximab Efficacy in Colorectal Cancer.
    Molecular cancer therapeutics, 2015, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2015
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2015, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2015
[Late complete response after long remission from treatment with FOLFIRI-aflibercept for metastatic colorectal cancer after progression to FOLFOX-bevacizumab].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot

2015
Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2015
Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2015
Pathologic Major Response After FOLFIRINOX is Prognostic for Patients Secondary Resected for Borderline or Locally Advanced Pancreatic Adenocarcinoma: An AGEO-FRENCH, Prospective, Multicentric Cohort.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2015
TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    British journal of cancer, 2015, Sep-15, Volume: 113, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Baculoviral IAP Rep

2015
Metabolic alteration--Overcoming therapy resistance in gastric cancer via PGK-1 inhibition in a combined therapy with standard chemotherapeutics.
    International journal of surgery (London, England), 2015, Volume: 22

    Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug

2015
A Retrospective Comparison of Trastuzumab Plus Cisplatin and Trastuzumab Plus Capecitabine in Elderly HER2-Positive Advanced Gastric Cancer Patients.
    Medicine, 2015, Volume: 94, Issue:34

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2015
Infection by Cx43 adenovirus increased chemotherapy sensitivity in human gastric cancer BGC-823 cells: not involving in induction of cell apoptosis.
    Gene, 2015, Dec-15, Volume: 574, Issue:2

    Topics: Adenocarcinoma; Adenoviridae; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line,

2015
Metastatic Pancreatic Carcinoma and Experience with FOLFIRINOX - a Cross Sectional Analysis From a Developing Country.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:14

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cross-Sectional

2015
Predictive Significance of VEGF and HIF-1α Expression in Patients with Metastatic Colorectal Cancer Receiving Chemotherapy Combinations with Bevacizumab.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:14

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2015
Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Pancr

2015
Safety and Efficacy of Modified FOLFIRINOX for Advanced Pancreatic Adenocarcinoma: A UK Single-Centre Experience.
    Oncology, 2015, Volume: 89, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F

2015
Nuclear PRMT1 expression is associated with poor prognosis and chemosensitivity in gastric cancer patients.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2016, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptosis; Biomarke

2016
Further evidence for preoperative chemoradiotherapy and transanal endoscopic surgery (TEM) in T2-3s,N0,M0 rectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Che

2016
In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
    Cancer research and treatment, 2016, Volume: 48, Issue:3

    Topics: Adenocarcinoma; Adenosine Triphosphate; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Anti

2016
Long Term Outcomes of Preoperative versus Postoperative Concurrent Chemoradiation for Locally Advanced Rectal Cancer: Experience from Ramathibodi Medical School in Thailand.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Fem

2015
Pneumatosis intestinalis due to 5-fluorouracil chemotherapy.
    Gastroenterologia y hepatologia, 2016, Volume: 39, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2016
Primary Adenocarcinoma with Focal Choriocarcinomatous Differentiation in the Sigmoid Colon.
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2015, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antig

2015
[Para-Aortic Lymphadenectomy and Subsequent Chemotherapy after Resection of the Primary Lesion for Poorly Differentiated Adenocarcinoma of the Sigmoid Colon - A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant;

2015
[Septic shock and Tissierella praeacuta].
    Medecine et maladies infectieuses, 2016, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cholecystectomy; Cholecystitis

2016
Specific microRNAs as novel biomarkers for combination chemotherapy resistance detection of colon adenocarcinoma.
    European journal of medical research, 2015, Dec-02, Volume: 20

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Col

2015
[mFOLFOX6 chemotherapy enabling curative resection in a patient with locally advanced duodenal adenocarcinoma and lymph node metastases].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2015, Volume: 112, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Duo

2015
A synonymous EGFR polymorphism predicting responsiveness to anti-EGFR therapy in metastatic colorectal cancer patients.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemoth

2016
A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.
    Cancer chemotherapy and pharmacology, 2016, Volume: 77, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Chemoradiotherapy; Cisplatin; Dialysis Solutions; Esoph

2016
Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colonic Neoplasms; DNA Repa

2016
Successful Completion of Adjuvant Chemotherapy in a Patient With Colon Cancer Experiencing 5-Fluorouracil-Induced Cardiac Vasospasm.
    Clinical colorectal cancer, 2016, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicit

2016
Watch-and-wait approach versus surgical resection after chemoradiotherapy for patients with rectal cancer (the OnCoRe project): a propensity-score matched cohort analysis.
    The Lancet. Oncology, 2016, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Aged; Case-Control Studies; Chemoradiotherapy, Adjuvant; Colostomy; Disease-Free Sur

2016
Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer.
    Annals of surgical oncology, 2016, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Case

2016
Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
    World journal of gastroenterology, 2015, Dec-21, Volume: 21, Issue:47

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2015
Gemcitabine versus FOLFIRINOX in patients with advanced pancreatic adenocarcinoma hENT1-positive: everything was not too bad back when everything seemed worse.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2016, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2016
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Pancreatic Adenocarcinoma.
    Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10

    Topics: Adenocarcinoma; Albumins; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin;

2015
[Efficacy and safety of antivascular drugs after anti-EFGR: aflibercept after cetuximab, a clinical case].
    Recenti progressi in medicina, 2015, Volume: 106, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colonic Neo

2015
[Successful Resection of the Peritoneal Dissemination Recurrence of Colon Cancer, Including Metastasis to the Inguinal Hernia Sac--A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Colonic Neoplasms;

2015
[Recurrence of Rectal Cancer with Submucosal Invasion in the Bone and Lymph Nodes 89 Months after Surgery--A Case Report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Camptot

2015
An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.
    Oncotarget, 2016, Feb-23, Volume: 7, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Cohort Stud

2016
Evaluation of Preoperative Chemotherapy with Modified OPTIMOX-1 Plus Bevacizumab in Patients with Advanced Rectal Cancer with Factors Contraindicative of Curative Surgery.
    Hepato-gastroenterology, 2015, Volume: 62, Issue:140

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cohort Stu

2015
Integration of in silico modeling, prediction by binding energy and experimental approach to study the amorphous chitin nanocarriers for cancer drug delivery.
    Carbohydrate polymers, 2016, May-20, Volume: 142

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chitin; Curcumin; Docetaxel;

2016
Synergistic anticancer properties of docosahexaenoic acid and 5-fluorouracil through interference with energy metabolism and cell cycle arrest in human gastric cancer cell line AGS cells.
    World journal of gastroenterology, 2016, Mar-14, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Line, T

2016
Reduced RanBPM Expression Is Associated with Distant Metastasis in Gastric Cancer and Chemoresistance.
    Anticancer research, 2016, Volume: 36, Issue:3

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Adhesion

2016
Sequential boost in neoadjuvant irradiation for T3N0-1 rectal cancer: long-term results from a single-center experience.
    Tumori, 2016, Jun-02, Volume: 2016, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Dig

2016
Impact of multicellular tumor spheroids as an in vivo‑like tumor model on anticancer drug response.
    International journal of oncology, 2016, Volume: 48, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorour

2016
Mutation profiling in chinese patients with metastatic colorectal cancer and its correlation with clinicopathological features and anti-EGFR treatment response.
    Oncotarget, 2016, May-10, Volume: 7, Issue:19

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Camptothecin; Cetuximab; Colorecta

2016
[Analysis of clinical predictive factors of pathologic complete response after neoadjuvant chemoradiotherapy in rectal cancer].
    Zhonghua yi xue za zhi, 2016, Apr-26, Volume: 96, Issue:16

    Topics: Adenocarcinoma; Chemoradiotherapy; Fluorouracil; Humans; Neoadjuvant Therapy; Radiotherapy, Intensit

2016
Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2016, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy

2016
Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) delivered via a modified perfusion system for peritoneal carcinomatosis of colorectal origin.
    Surgery today, 2016, Volume: 46, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy;

2016
The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma.
    Annals of the Royal College of Surgeons of England, 2016, Volume: 98, Issue:6

    Topics: Adenocarcinoma; Aged; Anaerobic Threshold; Antineoplastic Combined Chemotherapy Protocols; Cardiores

2016
Full-length LGR5-positive cells have chemoresistant characteristics in colorectal cancer.
    British journal of cancer, 2016, 05-24, Volume: 114, Issue:11

    Topics: Adenocarcinoma; Alternative Splicing; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Ce

2016
Potent in vivo anticancer activity and stability of liposomes encapsulated with semi-purified Job's tear (Coix lacryma-jobi Linn.) extracts on human colon adenocarcinoma (HT-29) xenografted mice.
    Drug delivery, 2016, Volume: 23, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Coix; Colon; Colonic Neoplasms; Dr

2016
Oncologic Safety of Local Excision Compared With Total Mesorectal Excision for ypT0-T1 Rectal Cancer: A Propensity Score Analysis.
    Medicine, 2016, Volume: 95, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2016
[A Case of Advanced Rectal Cancer Resected Successfully after Induction Chemotherapy with Modified FOLFOX6 plus Panitumumab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:5

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil

2016
[Surgical Resection and Adjuvant Chemotherapy with FOLFOX6 for Primary Duodenal Adenocarcinoma and Nodal Metastasis Resulted in Complete Remission].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Duodenal Neo

2016
Evaluation of Bevacizumab in Advanced Small Bowel Adenocarcinoma.
    Clinical colorectal cancer, 2017, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothec

2017
Nicotinamide N-methyltransferase enhances resistance to 5-fluorouracil in colorectal cancer cells through inhibition of the ASK1-p38 MAPK pathway.
    Oncotarget, 2016, Jul-19, Volume: 7, Issue:29

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Colorectal Neoplasms; Drug Resista

2016
Colonic perforation following endoscopic mucosal resection in a patient on bevacizumab treatment.
    Endoscopy, 2016, Volume: 48 Suppl 1

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camp

2016
Intravoxel incoherent motion diffusion-weighted imaging for monitoring chemotherapeutic efficacy in gastric cancer.
    World journal of gastroenterology, 2016, Jun-28, Volume: 22, Issue:24

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Diffusion Magnet

2016
Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2016
Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer.
    Anticancer research, 2016, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2016
Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
    Oncology, 2016, Volume: 91, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Autoantibodies; Bevacizumab; C

2016
Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2017, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2017
Transient global ventricular dysfunction in an adolescent affected by pancreatic adenocarcinoma.
    BMC pediatrics, 2016, 07-19, Volume: 16

    Topics: Adenocarcinoma; Adolescent; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Pancreatic

2016
Preoperative FOLFIRINOX for borderline resectable pancreatic cancer: Is radiation necessary in the modern era of chemotherapy?
    Journal of surgical oncology, 2016, Volume: 114, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemoradi

2016
PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.
    European journal of cancer (Oxford, England : 1990), 2016, Volume: 65

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Chemoradiother

2016
ypN0: Does It Matter How You Get There? Nodal Downstaging in Esophageal Cancer.
    Annals of surgical oncology, 2016, Volume: 23, Issue:Suppl 5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2016
Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2017, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colonic Neoplasm

2017
miR-221 Mediates Chemoresistance of Esophageal Adenocarcinoma by Direct Targeting of DKK2 Expression.
    Annals of surgery, 2016, Volume: 264, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Culture Techniques; Disease Models, A

2016
Oxaliplatin, 5Fluorouracil and Leucovorin (FOLFOX4) as First Line Chemotherapy in Elderly Patients with Advanced Gastric Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; F

2016
Outcomes of Preoperative Chemoradiotherapy and Combined Chemotherapy with Radiotherapy Without Surgery for Locally Advanced Rectal Cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:7

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci

2016
Cytomegalovirus colitis in a patient undergoing postoperative adjuvant chemotherapy for lung adenocarcinoma with uracil-tegafur.
    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy, 2016, Volume: 22, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemot

2016
Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer.
    British journal of cancer, 2016, 09-06, Volume: 115, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth

2016
Tamoxifen enhances the cytotoxicity of conventional chemotherapy in esophageal adenocarcinoma cells.
    Surgical oncology, 2016, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis;

2016
Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX).
    Oncotarget, 2016, 11-15, Volume: 7, Issue:46

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2016
Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2016, Volume: 48, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dige

2016
Perineural Invasion is a Major Prognostic and Predictive Factor of Response to Adjuvant Chemotherapy in Stage I-II Colon Cancer.
    Annals of surgical oncology, 2017, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Chemotherapy, A

2017
Usefulness of chemoradiotherapy for inoperable gastric cancer.
    Annals of the Royal College of Surgeons of England, 2017, Volume: 99, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2017
The prognosis of liver resection for patients with four or more colorectal liver metastases has not improved in the era of modern chemotherapy.
    Journal of surgical oncology, 2016, Volume: 114, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemo

2016
Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
    Oncology, 2016, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asth

2016
AFP-producing adenocarcinoma of the esophagogastric junction: report of a case with atypical immunohistochemical findings responding to palliative chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT regime).
    Zeitschrift fur Gastroenterologie, 2016, Volume: 54, Issue:10

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Esoph

2016
Radiation field size and dose determine oncologic outcome in esophageal cancer.
    World journal of surgical oncology, 2016, Oct-13, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2016
Intraoperative Radiotherapy in the Era of Intensive Neoadjuvant Chemotherapy and Chemoradiotherapy for Pancreatic Adenocarcinoma.
    American journal of clinical oncology, 2018, Volume: 41, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2018
Interstitial lung disease caused by oxaliplatin. An uncommon but not unknown complication.
    Archivos de bronconeumologia, 2017, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2017
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Journal for immunotherapy of cancer, 2016, Volume: 4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; B7-H1 Antigen; Barrett Esophagus; Biopsy; Cell Line

2016
Necrotizing Infundibular Crystalline Folliculitis (NICF) Induced by Anti-Tumoral Therapies: Report of 2 Cases.
    The American Journal of dermatopathology, 2017, Volume: 39, Issue:10

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bevacizumab; Camptothecin; Colorecta

2017
Management of rectal cancer: the 2016 French guidelines.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2017, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Capecitabine; Chemoradiotherapy; Chemoradiotherap

2017
Antitumor efficacy of combined gene and radiotherapy in animals.
    Doklady. Biochemistry and biophysics, 2016, Volume: 470, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; Combi

2016
Adenocarcinoma mimicking appendicular lump: a diagnostic dilemma-a case report.
    World journal of surgical oncology, 2016, Nov-11, Volume: 14, Issue:1

    Topics: Abdominal Abscess; Adenocarcinoma; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Appe

2016
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict chemotherapy outcomes and prognosis in patients with colorectal cancer and synchronous liver metastasis.
    World journal of surgical oncology, 2016, Nov-16, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Capecitabine; Chemo

2016
HSP90 is a promising target in gemcitabine and 5-fluorouracil resistant pancreatic cancer.
    Apoptosis : an international journal on programmed cell death, 2017, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Apoptosis; Benzoquinones; Cell Line, Tumor; Deoxycytidine; Drug Resistance, Neoplasm

2017
EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
    International journal of cancer, 2017, 02-15, Volume: 140, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chem

2017
CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    European radiology, 2017, Volume: 27, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2017
Analysis of Predictors of Resection and Survival in Locally Advanced Stage III Pancreatic Cancer: Does the Nature of Chemotherapy Regimen Influence Outcomes?
    Annals of surgical oncology, 2017, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Combined Chemotherapy Proto

2017
A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation.
    Journal of the National Comprehensive Cancer Network : JNCCN, 2016, Volume: 14, Issue:12

    Topics: Abdominal Pain; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Cells; C

2016
Conversion Surgery Post-Intraperitoneal Paclitaxel and Systemic Chemotherapy for Gastric Cancer Carcinomatosis Peritonei. Are We Ready?
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2017, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma; Deoxy

2017
Platinum-based Doublet Chemotherapy for Advanced Gastric Cancer with Disseminated Intravascular Coagulation.
    Anticancer research, 2017, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disseminated

2017
"
    World journal of gastroenterology, 2016, Dec-14, Volume: 22, Issue:46

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cecal

2016
When, What, and Why of Perioperative Treatment of Potentially Curable Pancreatic Adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017, Feb-10, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Leucov

2017
[A Case of Small Bowel Adenocarcinoma That Was Diagnosed and Treated using Laparoscopic Surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, A

2016
[CR of All Target Lesions in a Patient with Metastatic Esophageal Cancer and Generalized Weakness Treated with Systemic Chemotherapy after Nutritional Support].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcino

2016
[A Case of Advanced Rectal Cancer Resulting in a Pathologically Complete Response after Neoadjuvant Chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Deo

2016
A New Technique of Radiofrequency-assisted Ultrasound-guided Needle-localized Laparoscopic Resection of Disappearing Colorectal Liver Metastases.
    Surgical laparoscopy, endoscopy & percutaneous techniques, 2017, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Catheter Ablation

2017
Enhancement of TRAIL-induced apoptosis by 5-fluorouracil requires activating Bax and p53 pathways in TRAIL-resistant lung cancers.
    Oncotarget, 2017, Mar-14, Volume: 8, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; b

2017
Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Docetaxel; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluo

2017
Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
    Clinics and research in hepatology and gastroenterology, 2017, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Aged; Albumins; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Deoxyc

2017
Assessment of anti-cancerous potential of 6-gingerol (Tongling White Ginger) and its synergy with drugs on human cervical adenocarcinoma cells.
    Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2017, Volume: 109, Issue:Pt 2

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Catechols; Cell Cycle Checkpoints; Cell

2017
Gemcitabine as second-line chemotherapy after Folfirinox failure in advanced pancreatic adenocarcinoma: A retrospective study.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2017, Volume: 49, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Deoxycytidine; Dise

2017
The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.
    Journal of surgical oncology, 2017, Volume: 115, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2017
The prognostic and potentially predictive value of the Laurén classification in oesophageal adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy

2017
Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
    Diseases of the colon and rectum, 2017, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2017
The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
    Bosnian journal of basic medical sciences, 2017, May-20, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cis

2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies.
    European journal of cancer (Oxford, England : 1990), 2017, Volume: 76

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab

2017
BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    British journal of cancer, 2017, Apr-11, Volume: 116, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; BRCA2 Protein; Carci

2017
Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China.
    BMC gastroenterology, 2017, Mar-14, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2017
Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984.
    Diseases of the colon and rectum, 2008, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Transanal endoscopic microsurgery for the treatment of selected patients with distal rectal cancer: 15 years experience.
    Surgical endoscopy, 2008, Volume: 22, Issue:9

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survi

2008
Giant eccrine adenocarcinoma with skin and lymph node metastases: favourable response to chemotherapy.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2009, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2009
The prognostic value of lymph node metastases and tumour regression grade in rectal cancer patients treated with long-course preoperative chemoradiotherapy.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2009, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Age Factors; Aged; Chemotherapy, Adjuvant; Cohort Studies; Colectomy; Female; Fluoro

2009
Survival for patients with pancreatic cancer after addition of gemcitabine to fluorouracil chemoradiation.
    JAMA, 2008, Jun-25, Volume: 299, Issue:24

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti

2008
Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
    JAMA, 2008, Jun-25, Volume: 299, Issue:24

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycyti

2008
Granulocyte-colony stimulating factor producing rectal cancer.
    World journal of surgical oncology, 2008, Jun-29, Volume: 6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colectomy; Fatal Outcome;

2008
A case of relapsing secondary bladder adenocarcinoma after right colonic cancer.
    Nature clinical practice. Urology, 2008, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, An

2008
Bcl-x(L) and Myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells.
    World journal of gastroenterology, 2008, Jun-28, Volume: 14, Issue:24

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-X Protein; Camptothecin; Cell Line, Tumor; Cel

2008
Oxaliplatin-induced long QT syndrome in a patient with appendiceal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2009, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female

2009
Influence of induction chemotherapy and class of cytotoxics on pathologic response and survival after preoperative chemoradiation in patients with carcinoma of the esophagus.
    Cancer, 2008, Sep-15, Volume: 113, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cohort Stud

2008
Docetaxel: new indication. Metastatic gastric cancer: keep using fluorouracil-based chemotherapy. No tangible progress.
    Prescrire international, 2008, Volume: 17, Issue:95

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Drug Approval; Europe; Fluorouracil; Humans; Neoplasm Metast

2008
Cannabinoid receptor-independent cytotoxic effects of cannabinoids in human colorectal carcinoma cells: synergism with 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cannabinoid Receptor Antagonists; Can

2009
[Rectal adenocarcinoma metastasis to the facial skin--case report].
    Otolaryngologia polska = The Polish otolaryngology, 2008, Volume: 62, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Facial Neopl

2008
Thymidylate synthase genotyping is more predictive for therapy response than immunohistochemistry in patients with colon cancer.
    International journal of cancer, 2008, Oct-15, Volume: 123, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Combined Modality Therapy; DNA, Neoplasm; Female; Fl

2008
FOLFOX2 in the treatment of advanced colorectal cancer: a comparison between elderly and middle aged patients.
    Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2008
[Case of gastric cancer with isolated brain metastasis successfully managed by gamma knife radiotherapy and chemotherapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2008, Volume: 105, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cisplatin; Combined

2008
[5-Fluorouracil-induced reticular hyperpigmentation].
    Actas dermo-sifiliograficas, 2008, Volume: 99, Issue:7

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2008
Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2009, Mar-01, Volume: 73, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2009
Neoadjuvant treatment with cetuximab, 5-Fluorouracil, folinic Acid and oxaliplatin in unresectable retroperitoneal recurrent colon cancer.
    Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2008
Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma.
    Cancer, 2008, Oct-15, Volume: 113, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2008
Roscovitine synergizes with conventional chemo-therapeutic drugs to induce efficient apoptosis of human colorectal cancer cells.
    World journal of gastroenterology, 2008, Sep-07, Volume: 14, Issue:33

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms

2008
Preliminary report of multimodal treatment with ifosfamide, 5-fluorouracil, etoposide and cisplatin (IFEP chemotherapy) against metastatic adenocarcinoma of the urachus.
    International journal of urology : official journal of the Japanese Urological Association, 2008, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; F

2008
Novel opportunities for thymidylate metabolism as a therapeutic target.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Computational Biology; DN

2008
Early clinical results from chemoradiation with 5-fluorouracil and oxaliplatin for locally advanced rectal cancer.
    Clinical colorectal cancer, 2008, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohor

2008
[FOLFOX versus PLF regimen in treatment of advanced gastric adenocarcinoma].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2008, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

2008
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis

2009
Oxaliplatin/5-fluorouracil/leucovorin (FOLFOX4) regimen as an adjuvant chemotherapy in the treatment of advanced jejunal adenocarcinoma: a report of 2 cases.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2008, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female

2008
The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
    American journal of clinical oncology, 2008, Volume: 31, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Combined Mod

2008
Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemot

2008
A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Annals of surgical oncology, 2008, Volume: 15, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2008
The desmoplastic reaction surrounding hepatic colorectal adenocarcinoma metastases aids tumor growth and survival via alphav integrin ligation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-15, Volume: 14, Issue:20

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Adhesion; Cell Proliferation; Colla

2008
[Postoperative radio-chemotherapy in locally advanced gastric cancer].
    Revista medica de Chile, 2008, Volume: 136, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
'Out of blue' Lhermitte's sign: three cases due to low cumulative doses of oxaliplatin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl

2008
Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer.
    JOP : Journal of the pancreas, 2008, Nov-03, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Deoxycy

2008
Interaction between capecitabine and gemcitabine with warfarin in a patient with pancreatic cancer.
    JOP : Journal of the pancreas, 2008, Nov-03, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Aged; Blood Coagulation; Capecitabine; Cholangiopancreatography, Endoscopic Retrogra

2008
Is surgical debridement and topical 5 fluorouracil the optimum treatment for woodworkers' adenocarcinoma of the ethmoid sinuses? A case-controlled study of a 20-year experience.
    Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery, 2008, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; C

2008
Oral fluoropyrimidines (capecitabine or S-1) and cisplatin as first line treatment in elderly patients with advanced gastric cancer: a retrospective study.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

2009
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation.
    International journal of radiation oncology, biology, physics, 2009, May-01, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2009
The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer.
    Surgical oncology, 2010, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2010
[A case report of primary adenocarcinoma of small intestine successfully treated with FOLFOX].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Fluorourac

2008
Fatal pneumonitis induced by oxaliplatin.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2008, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc

2008
Comparison of 5-fluorouracil-related gene expression levels between adenocarcinomas and squamous cell carcinomas of the lung.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Dihydrouracil Dehyd

2009
Epidermal growth factor receptor as a predictor of tumor response to preoperative chemoradiation in locally advanced gastric carcinoma.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2008
[Sinusoidal obstruction syndrome induced by FOLFOX adjuvant chemotherapy].
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop

2008
Adjuvant chemoradiation for pancreatic cancer: few good data, much debate.
    Journal of the National Cancer Institute, 2008, Dec-03, Volume: 100, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri

2008
Relationships of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer.
    Oncology, 2009, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm

2009
Simplified FOLFIRI in pre-treated patients with metastatic gastric cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2009
Atypical hand-and-foot syndrome in an African American patient treated with capecitabine with normal DPD activity: is there an ethnic disparity?
    Cutaneous and ocular toxicology, 2008, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Black or African American; Capecitabine; Deox

2008
In vitro antiproliferative characteristics of flavonoids and diazepam on SNU-C4 colorectal adenocarcinoma cells.
    Journal of natural medicines, 2009, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apigenin; Cell Line, Tumor; Cell Pro

2009
Neo-adjuvant chemoradiotherapy in advanced rectal carcinoma: a note of caution.
    Irish medical journal, 2008, Volume: 101, Issue:9

    Topics: Adenocarcinoma; Fatal Outcome; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Rectal

2008
Determining pattern of recurrence following pancreaticoduodenectomy and adjuvant 5-flurouracil-based chemoradiation therapy: effect of number of metastatic lymph nodes and lymph node ratio.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dose Fractionation, Radiati

2009
A dilemma in geriatric oncology: malignant bowel obstruction in an 81-year-old man.
    Cancer treatment reviews, 2008, Volume: 34 Suppl 2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col

2008
Laparoscopic resection of extraperitoneal rectal cancer: a comparative analysis with open resection.
    Surgical endoscopy, 2009, Volume: 23, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Mod

2009
Chemotherapy for small-bowel Adenocarcinoma at a single institution.
    Surgery today, 2009, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease P

2009
Effect of HIF-1 modulation on the response of two- and three-dimensional cultures of human colon cancer cells to 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 2009, Volume: 45, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Hypoxia; Cell Proliferation; Coloni

2009
[Analysis of the diagnosis and treatment of cervical minimal deviation adenocarcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2008, Volume: 30, Issue:10

    Topics: Actins; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryoni

2008
Prognostic value of ERCC1, thymidylate synthase, and glutathione S-transferase pi for 5-FU/oxaliplatin chemotherapy in advanced colorectal cancer.
    American journal of clinical oncology, 2009, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo

2009
Coexistence Hodgkin's lymphoma and colonic adenocarcinoma: a case report.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Capecitabine; Colonic

2010
Successful treatment of primary duodenal carcinoma with bilateral adrenal metastases with docetaxel-cisplatin-5-fluorouracil regimen.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2009, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2009
[A case of primary orbital adenocarcinoma responding to chemoradiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Combined Modality

2009
[A case of elderly esophageal adenocarcinoma successfully treated with daily low-dose nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality

2009
Neoadjuvant chemotherapy and surgery for esophageal adenocarcinoma: prognostic value of circumferential resection margin and stratification of N1 category.
    Annals of surgical oncology, 2009, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2009
Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival.
    British journal of cancer, 2009, Mar-10, Volume: 100, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2009
Encephalopathy secondary to capecitabine chemotherapy: a case report and discussion.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents;

2009
Severe hiccups during chemotherapy: corticosteroids the likely culprit.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2009, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adult; Antidotes; Antiemetics; Antimetabolites, Antineoplas

2009
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
    Cancer chemotherapy and pharmacology, 2009, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colo

2009
Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy.
    International journal of cancer, 2009, Jun-15, Volume: 124, Issue:12

    Topics: Adenocarcinoma; Adenosine Triphosphatases; Adult; Aged; Aged, 80 and over; Antineoplastic Combined C

2009
Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience.
    International journal of radiation oncology, biology, physics, 2009, Sep-01, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Analysis of Variance; Carc

2009
A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2009, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Female; Fluorouracil; Heart Failure; Humans; Middle

2009
Expression of the Breast Cancer Metastasis Suppressor 1 (BRMS1) maintains in vitro chemosensitivity of breast cancer cells.
    Cancer letters, 2009, Aug-18, Volume: 281, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Doxorubici

2009
Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    American journal of clinical oncology, 2009, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Chromatography, High

2009
Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer.
    Oncology, 2009, Volume: 76, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
Alpha-fetoprotein expressing metastastic adenocarcinoma of the esophago-gastric junction responding favorably to capecitabine and oxaliplatin.
    Anti-cancer drugs, 2009, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Capecitabi

2009
Synchronous isolated adrenal metastasis from rectum adenocarcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Female; Flu

2009
Outcomes of adjuvant chemoradiation after pancreaticoduodenectomy with mesenterico-portal vein resection for adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 2010, Jan-01, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil; Human

2010
Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.
    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2009, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Etoposide; Female; Fluorouracil; Humans; Inf

2009
Lymph node harvest after proctectomy for invasive rectal adenocarcinoma following neoadjuvant therapy: does the same standard apply?
    Diseases of the colon and rectum, 2009, Volume: 52, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2009
Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
    Oncology, 2009, Volume: 76, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fl

2009
High-dose rate brachytherapy using inverse planning simulated annealing for locoregionally advanced cervical cancer: a clinical report with 2-year follow-up.
    International journal of radiation oncology, biology, physics, 2009, Dec-01, Volume: 75, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Brachytherapy; Carcinoma, Squamous Cell; Cisplatin; Female; F

2009
Gemcitabine-based combination chemotherapy followed by radiation with capecitabine as adjuvant therapy for resected pancreas cancer.
    International journal of radiation oncology, biology, physics, 2009, Dec-01, Volume: 75, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

2009
Overexpression of FADD enhances 5-fluorouracil-induced apoptosis in colorectal adenocarcinoma cells.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Animals; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Fas-Associated Death Dom

2010
Characterization and functional analysis of a slow cycling stem cell-like subpopulation in pancreas adenocarcinoma.
    Clinical & experimental metastasis, 2009, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Animals; Antigens, CD; Antimetabolites, Antineoplastic; Cell Line, Tumor; ErbB Recep

2009
Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    International journal of oncology, 2009, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CD3 Complex

2009
SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
    The Journal of biological chemistry, 2009, Jul-03, Volume: 284, Issue:27

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Colon; Colonic Neoplasms; Drug Resist

2009
Decreased expression of microRNA-143 and -145 in human gastric cancers.
    Oncology, 2009, Volume: 77, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Blotting, Western; Cell Pr

2009
Interstitial lung disease associated with oxaliplatin: description of two cases.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Antineoplastic Combined Chemot

2009
Capecitabine-induced acute myeloid leukaemia.
    The New Zealand medical journal, 2009, May-08, Volume: 122, Issue:1294

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Hu

2009
Chemosensitivity of radioresistant cells in the multicellular spheroids of A549 lung adenocarcinoma.
    Journal of experimental & clinical cancer research : CR, 2009, Jun-02, Volume: 28

    Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Ca

2009
Knockdown of focal adhesion kinase reverses colon carcinoma multicellular resistance.
    Cancer science, 2009, Volume: 100, Issue:9

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Prolife

2009
Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma.
    Cancer, 2009, Aug-15, Volume: 115, Issue:16

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Combi

2009
Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
    Japanese journal of clinical oncology, 2009, Volume: 39, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2009
Adenocarcinoma of the paranasal sinuses and nasal cavity with lung metastasis showing complete response to combination chemotherapy with docetaxel, cisplatin and 5-fluorouracil (TPF): a case report.
    Auris, nasus, larynx, 2010, Volume: 37, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Do

2010
The application of poly (glycerol-sebacate) as biodegradable drug carrier.
    Biomaterials, 2009, Volume: 30, Issue:28

    Topics: Absorbable Implants; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Cel

2009
Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2009, Volume: 35, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2009
Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2009
Postoperative chemotherapy after neoadjuvant chemoradiation and surgery for rectal cancer: is it essential for patients with ypT0-2N0?
    Journal of surgical oncology, 2009, Oct-01, Volume: 100, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2009
Complete response of an initially non-surgical adenocarcinoma of the duodenum to chemotherapy with the FOLFOX 4 regimen.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2009, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Duodenal Neoplasms; Fluoroura

2009
Current role of bevacizumab in colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2009, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2009
[Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2009
Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU.
    International journal of cancer, 2010, Feb-01, Volume: 126, Issue:3

    Topics: Adenocarcinoma; Anticarcinogenic Agents; Antimetabolites, Antineoplastic; Cell Division; Cell Line,

2010
[Impact of adjuvant chemotherapy duration on 3-year disease-free survival of colorectal carcinoma patients after radical resection].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Age Factors; Aged; Antineoplastic Combined Chemothe

2009
Intestinal permeability, vitamin A absorption, alpha-tocopherol, and neopterin in patients with rectal carcinoma treated with chemoradiation.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Aged; alpha-Tocopherol; Antimetabolites, Antineoplastic; Antioxidants; Carbohydrates

2010
A case of 5-fluorouracil-induced acute psychosis.
    Clinical colorectal cancer, 2009, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2009
Combination therapy with oxaliplatin and 5-fluorouracil in a patient with severe hepatic dysfunction associated with metastatic adenocarcinoma of the large bowel.
    Anti-cancer drugs, 2009, Volume: 20, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum

2009
The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2010
Postoperative morbidity with diversion after low anterior resection in the era of neoadjuvant therapy: a single institution experience.
    Journal of the American College of Surgeons, 2009, Volume: 209, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites,

2009
Quantitative analysis of survivin RNA expression in blood as a non-invasive predictor of response to neoadjuvant radiochemotherapy in esophageal cancer.
    Journal of surgical oncology, 2009, Nov-01, Volume: 100, Issue:6

    Topics: Actins; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Squamous Cell

2009
Complete pathological response in a patient with multiple liver metastases from colon cancer treated with Folfox-6 chemotherapy plus bevacizumab: a case report.
    Journal of hematology & oncology, 2009, Aug-06, Volume: 2

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2009
Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2009, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Non-Small-Cell Lung; Deoxy

2009
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
    Expert opinion on drug safety, 2009, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Biopsy, Fine-Needle; Capec

2009
Rectal angiosarcoma after adjuvant chemoradiotherapy for adenocarcinoma of the rectum.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Sep-20, Volume: 27, Issue:27

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fatal Outcome; Fluorouracil

2009
Association of polymorphisms MTHFR C677T and A1298C with risk of colorectal cancer, genetic and epigenetic characteristic of tumors, and response to chemotherapy.
    International journal of colorectal disease, 2010, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2010
Comparative analysis of thymidylate synthase at the protein, mRNA, and DNA levels as prognostic markers in colorectal adenocarcinoma.
    Journal of surgical oncology, 2009, Dec-01, Volume: 100, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomark

2009
Microdissection is essential for gene expression analysis of irradiated rectal cancer tissues.
    Oncology reports, 2009, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dih

2009
Sequential chemotherapy with methotrexate and 5-fluorouracil for chemotherapy-naive advanced gastric cancer with disseminated intravascular coagulation at initial diagnosis.
    Journal of cancer research and clinical oncology, 2010, Volume: 136, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2010
[Multivariate analysis of clinicopathologic factors correlated with pathological complete response following preoperative radiotherapy in rectal adenocarcinoma].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcinoembryonic An

2009
[Risk factors related to lymph node metastases after neoadjuvant therapy for locally advanced rectal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; CA-1

2009
[Correlation of chemosensitivity tested using histoculture drug response assay to expression of multidrug resistance genes and proteins in colorectal cancer tissues].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Tr

2009
[Clinical significance of a transient increase in carcinoembryonic antigen and carbohydrate antigen 19-9 in patients with metastatic colorectal cancer receiving chemotherapy].
    Ai zheng = Aizheng = Chinese journal of cancer, 2009, Volume: 28, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Ant

2009
[Metachronous metastasis from rectal adenocarcinoma to the penis--case report].
    Magyar onkologia, 2009, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2009
Combination of p53 codon 72 polymorphism and inactive p53 mutation predicts chemosensitivity to 5-fluorouracil in colorectal cancer.
    International journal of cancer, 2010, Apr-01, Volume: 126, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; bcl-2-Associated X

2010
Tumour regression grade (TRG) analyses in patients with resectable gastro-oesophageal adenocarcinomas treated with platinum-based neoadjuvant chemotherapy.
    Histopathology, 2009, Volume: 55, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2009
Preoperative chemoradiotherapy does not necessarily reduce lymph node retrieval in rectal cancer specimens--results from a prospective evaluation with extensive pathological work-up.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2010, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2010
Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecit

2010
Docetaxel combined with oral etoposide as second-line treatment for advanced gastric carcinoma after failure of platinum- and fluoropyrimidine-based regimens.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2010
Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2010
[A case of liver metastasis of rectal cancer, refractory to previous chemotherapy(5-FU/LV, irinotecan, oxaliplatin) responding to bevacizumab combined with FOLFIRI chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:10

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2009
EGF61A>G polymorphism as predictive marker of clinical outcome to first-line capecitabine and oxaliplatin in metastatic colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2010, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorecta

2010
Thymidine phosphorylase to dihydropyrimidine dehydrogenase ratio as a predictive factor of response to preoperative chemoradiation with capecitabine in patients with advanced rectal cancer.
    Journal of surgical oncology, 2010, Oct-01, Volume: 102, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant;

2010
Locoregional outcomes of inflammatory breast cancer patients treated with standard fractionation radiation and daily skin bolus in the taxane era.
    International journal of radiation oncology, biology, physics, 2010, Jul-15, Volume: 77, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brea

2010
Treatment of gastric cancer in Asia: the missing link.
    The Lancet. Oncology, 2009, Volume: 10, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2009
Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Female;

2010
Induction chemotherapy followed by chemoradiation in locally advanced pancreatic cancer: an effective and well-tolerated treatment.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials,

2010
The efficacy of frontline platinum-based combination chemotherapy in advanced adenocarcinoma of the ampulla of Vater.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Capec

2010
Expression of livin in gastric cancer and induction of apoptosis in SGC-7901 cells by shRNA-mediated silencing of livin gene.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2010, Volume: 64, Issue:5

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Apoptosis;

2010
[Complete remission with FLEP chemotherapy for multiple liver metastasis from alpha-fetoprotein-producing gastric cancer--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:11

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop

2009
[A case of primary adenocarcinoma of small intestine with multiple liver metastases successfully treated with mFOLFOX6].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2009
The combination of 5-fluorouracil plus p53 pathway restoration is associated with depletion of p53-deficient or mutant p53-expressing putative colon cancer stem cells.
    Cancer biology & therapy, 2009, Volume: 8, Issue:22

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; DNA-Binding Proteins; Drug Synergism; Elli

2009
Double primary adenocarcinomas of the jejunum and descending colon with lung metastases presenting rare immunohistochemical phenotypes: a case report.
    European journal of gastroenterology & hepatology, 2010, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2010
Bilateral phrenic nerve paralysis as a manifestation of paraneoplastic syndrome.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2010
An Msh2 conditional knockout mouse for studying intestinal cancer and testing anticancer agents.
    Gastroenterology, 2010, Volume: 138, Issue:3

    Topics: Adenocarcinoma; Adenoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

2010
Acute coronary syndrome associated with continuous 5-Fluorouracil infusion in a patient with metastatic colorectal cancer-a case report with a discussion on this clinical dilemma.
    Journal of gastrointestinal cancer, 2009, Volume: 40, Issue:3-4

    Topics: Acute Coronary Syndrome; Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2009
The effect of three lipid emulsions differing in fatty acid composition on growth, apoptosis and cell cycle arrest in the HT-29 colorectal cancer cell line.
    Clinical nutrition (Edinburgh, Scotland), 2010, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Cell Count; Cell Cycle; Cell Survival; C

2010
The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
    Medical oncology (Northwood, London, England), 2010, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Is duodenal invasion a relevant prognosticator in patients undergoing adjuvant chemoradiotherapy for distal common bile duct cancer?
    International journal of radiation oncology, biology, physics, 2010, Jul-15, Volume: 77, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antimetabolites, Antineoplastic; Chemotherapy, Ad

2010
A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma.
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2010, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2010
Prognostic effect of activated EGFR expression in human colon carcinomas: comparison with EGFR status.
    British journal of cancer, 2010, Jan-05, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Aged; Apoptosis; Cell Division; Chemotherapy, Adjuvant; Colonic Neoplasms; Combined

2010
APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
    BMC cancer, 2009, Dec-11, Volume: 9

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biomarkers, Tumor; Colorectal Neoplasms; Drug Resistan

2009
Clinically-staged T3N0 rectal cancer: is preoperative chemoradiotherapy the optimal treatment?
    Annals of surgical oncology, 2010, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2010
Sickle cell crisis in a patient receiving capecitabine chemotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Anemia, Sickle Cell; Antineoplastic Agents, Phytogenic; Capecitabine; Colonic Neopla

2010
Atypical presentation of acute neurotoxicity secondary to oxaliplatin.
    Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, 2010, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
Hyperoxia increases the uptake of 5-fluorouracil in mammary tumors independently of changes in interstitial fluid pressure and tumor stroma.
    BMC cancer, 2009, Dec-17, Volume: 9

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Volume; Dose-Response Relationship,

2009
HIF-1alpha is an unfavorable determinant of relapse in gastric cancer patients who underwent curative surgery followed by adjuvant 5-FU chemotherapy.
    International journal of cancer, 2010, Sep-01, Volume: 127, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Antimetabolites, Antineoplastic; Apoptosis;

2010
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2010
[A curative resection with the combination of portal vein branch embolization and systemic chemotherapy in a patient with synchronous multiple and bilobar colorectal liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2009
[A case of long-term survival of unresectable-advanced gastric cancer due to chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2009
[A case in which intra-arterial chemotherapy for simultaneous hepatic metastases markedly improved AFP-producing gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2009, Volume: 36, Issue:12

    Topics: Adenocarcinoma; Aged; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast

2009
[Clinical features of hypersensitivity reactions to oxaliplatin among Chinese colorectal cancer patients].
    Chinese journal of cancer, 2010, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Aged; Anaphylaxis; Anti-Allergic Agents

2010
Pancreatic cancer: progress made.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:4

    Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemo

2010
CD133 expression predicts for non-response to chemotherapy in colorectal cancer.
    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2010, Volume: 23, Issue:3

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Che

2010
Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
    Annals of surgical oncology, 2010, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2010
[A prospective study of FOLFOX7 scheme as neoadjuvant chemotherapy for stage III gastric adenocarcinoma].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 2009, Sep-01, Volume: 47, Issue:17

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2009
[Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 55, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2010
A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Neopl

2010
Hypertriglyceridemia: An underdiagnosed side effect of Capecitabine chemotherapy.
    Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Bezafibrate; Capecitabine; Cecum; Deoxycytidine; Fluorouracil

2010
Complications after sphincter-saving resection in rectal cancer patients according to whether chemoradiotherapy is performed before or after surgery.
    International journal of radiation oncology, biology, physics, 2010, Sep-01, Volume: 78, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy

2010
Gene expression profiles of epidermal growth factor receptor, vascular endothelial growth factor and hypoxia-inducible factor-1 with special reference to local responsiveness to neoadjuvant chemoradiotherapy and disease recurrence after rectal cancer surg
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Combined Modality Therapy;

2010
Rofecoxib augments anticancer effects by reversing intrinsic multidrug resistance gene expression in BGC-823 gastric cancer cells.
    Journal of digestive diseases, 2010, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplat

2010
Metastatic prostatic adenocarcinoma mimicking inflammatory breast carcinoma: a case report.
    Clinical breast cancer, 2010, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Ma

2010
Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
    Annals of surgical oncology, 2010, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che

2010
Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-10, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Deoxycytidine; Dru

2010
[Obliterative bronchiolitis with organising pneumonia following FOLFOX 4 chemotherapy].
    Revue des maladies respiratoires, 2010, Volume: 27, Issue:1

    Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemoth

2010
[Herpes simplex virus bronchopneumonitis in patient with acute respiratory failure after surgery].
    Medicina intensiva, 2010, Volume: 34, Issue:2

    Topics: Acute Disease; Acyclovir; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antiviral Agents; B

2010
Management of borderline resectable pancreatic cancer.
    Surgical oncology clinics of North America, 2010, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2010
Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?
    Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites; Antimetabolites, Antineoplastic; Aryl Hydrocarbon Hydroxylase

2010
Time to move to targeted drugs in biliary tract cancer?
    Onkologie, 2010, Volume: 33, Issue:1-2

    Topics: Adenocarcinoma; Ampulla of Vater; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineo

2010
Primary vaginal adenocarcinoma arising in vaginal adenosis after CO2 laser vaporization and 5-fluorouracil therapy.
    International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists, 2010, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Biopsy; Carcinoma in Situ; DNA, Viral; Female; Fluorouracil; Histocytochemistry; Hum

2010
Targeted HER2 treatment in advanced gastric cancer.
    Oncology, 2010, Volume: 78, Issue:1

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2010
[Complete response to M-FAP chemotherapy for multiple lung metastases after segmental resection of urachal carcinoma : a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2010, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic

2010
The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cancer, 2010, May-01, Volume: 116, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms

2010
Vascular endothelial growth factor gene polymorphisms in patients with colorectal cancer.
    Revista espanola de enfermedades digestivas, 2010, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2010
Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
    Cancer treatment reviews, 2010, Volume: 36 Suppl 1

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemot

2010
[Oxaliplatin-based regimen for the treatment of advanced or metastatic gastric/esophagogastric junction cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2009, Volume: 31, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junctio

2009
Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Pharmacological; DNA-Binding Proteins; Fluorourac

2010
Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma.
    The American journal of surgical pathology, 2010, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2010
[Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiency].
    Gastroenterologie clinique et biologique, 2010, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colorectal Neoplasms; Deoxycyti

2010
[A case of sigmoid colon cancer with lymphangitis carcinomatosa successfully treated with chemotherapies including molecular targeting drugs].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; An

2010
Impact of neoadjuvant treatment on total mesorectal excision for ultra-low rectal cancers.
    World journal of surgical oncology, 2010, Mar-26, Volume: 8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2010
TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis.
    Cancer science, 2010, Volume: 101, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line; Cell L

2010
Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2010
DNA damage detected with gammaH2AX in endometrioid adenocarcinoma cell lines.
    International journal of oncology, 2010, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Cell Line, Tumor; Cellular Senescence; Cisplatin; DNA Damage;

2010
Chemotherapy-free intervals in patients with metastatic colorectal cancer: a tale of two cities?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jun-01, Volume: 28, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free S

2010
Thymidilate synthase expression predicts longer survival in patients with stage II colon cancer treated with 5-flurouracil independently of microsatellite instability.
    Journal of cancer research and clinical oncology, 2011, Volume: 137, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv

2011
Stage II/III rectal cancer with intermediate response to preoperative radiochemotherapy: do we have indications for individual risk stratification?
    World journal of surgical oncology, 2010, Apr-13, Volume: 8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin

2010
Metastatic urachal cancer responding to FOLFOX chemotherapy.
    The Canadian journal of urology, 2010, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cystectom

2010
Intensity-modulated radiation therapy significantly improves acute gastrointestinal toxicity in pancreatic and ampullary cancers.
    International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Combined Chemothera

2011
Neoadjuvant chemotherapy in patients with stage IV colorectal cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes.
    Annals of surgical oncology, 2010, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorecta

2010
Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells.
    International journal of oncology, 2010, Volume: 36, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; C

2010
[Pathologically complete response of multiple liver metastases from rectal cancer treated with mFOLFOX6 plus bevacizumab].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2010, Volume: 107, Issue:5

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2010
Oxaliplatin plus dual inhibition of thymidilate synthase during preoperative pelvic radiotherapy for locally advanced rectal carcinoma: long-term outcome.
    International journal of radiation oncology, biology, physics, 2011, Mar-01, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2011
Anal function and intersphincteric resection.
    Diseases of the colon and rectum, 2010, Volume: 53, Issue:6

    Topics: Adenocarcinoma; Anal Canal; Antineoplastic Agents; Combined Modality Therapy; Fluorouracil; Humans;

2010
A pilot study of mRNA expressions of 5-fluorouracil pathway genes in peripheral blood mononuclear cells and tumor tissues in patients with lung adenocarcinoma.
    Lung cancer (Amsterdam, Netherlands), 2011, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Dihydrouracil Dehydrogenase (NADP);

2011
Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Japanese journal of clinical oncology, 2010, Volume: 40, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2010
Implication of necrosis-linked p53 aggregation in acquired apoptotic resistance to 5-FU in MCF-7 multicellular tumour spheroids.
    Oncology reports, 2010, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Chemical Precipitation; Drug Resistan

2010
High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study.
    World journal of surgical oncology, 2010, Jun-01, Volume: 8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2010
The importance of release of proinflammatory cytokines, ROS, and NO in different stages of colon carcinoma growth and metastasis after treatment with cytotoxic drugs.
    Oncology research, 2010, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Coculture Techniques;

2010
Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience.
    Radiation oncology (London, England), 2010, Jun-04, Volume: 5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2010
Evolution of laparoscopic left lateral sectionectomy without the Pringle maneuver: through resection of benign and malignant tumors to living liver donation.
    Surgical endoscopy, 2011, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adenoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Su

2011
Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adenoma, Villous; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin

2011
Detection of oesophageal cancer biomarkers by plasma proteomic profiling of human cell line xenografts in response to chemotherapy.
    British journal of cancer, 2010, Jul-13, Volume: 103, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Lin

2010
Acute interstitial pneumonitis in a patient receiving a FOLFOX-4 regimen plus cetuximab treated with pulse therapy.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7

    Topics: Acute Disease; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anti

2010
Neoadjuvant treatment of adenocarcinomas of the gastroesophageal junction and stomach - a feasibility trial combining cisplatin and docetaxel with either 5-fluorouracil or capecitabine.
    International journal of clinical pharmacology and therapeutics, 2010, Volume: 48, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2010
Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    International journal of cancer, 2011, Apr-15, Volume: 128, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuv

2011
Chemoradiation for esophageal cancer: institutional experience with three different regimens.
    American journal of clinical oncology, 2011, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2011
Severe toxicity of capecitabine following uncomplicated treatment with 5-fluorouracil/leucovorin.
    Medical oncology (Northwood, London, England), 2011, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Ato

2011
Case records of the Massachusetts General Hospital. Case 19-2010. A 35-year-old man with adenocarcinoma of the cecum.
    The New England journal of medicine, 2010, Jun-24, Volume: 362, Issue:25

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2010
Long-term outcome of mitomycin C- and 5-FU-based primary radiochemotherapy for esophageal cancer.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2010, Volume: 186, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2010
High pretherapeutic thymidylate synthetase and MRP-1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients.
    Journal of surgical oncology, 2010, Oct-01, Volume: 102, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, M

2010
A neoadjuvant strategy for pancreatic adenocarcinoma increases the likelihood of receiving all components of care: lessons from a single-institution database.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2010
Low dosage 5-fluorouracil increases the transfection efficiency of Ad/VEGF-A in mouse lung carcinoma cell line LA795 and inhibits tumor growth.
    Chinese journal of cancer, 2010, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proli

2010
Prognostic significance of age in the radical treatment of oesophageal cancer with surgery or chemoradiotherapy: a prospective observational cohort study.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2010
Chemoradiotherapy with or without induction chemotherapy for locally advanced pancreatic cancer: a UK multi-institutional experience.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2010
Chemotherapy-induced myelotoxicity and incidence of lung metastasis in an animal model.
    Human & experimental toxicology, 2011, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Cell Line, Tumor; Cisplatin; Colonic Ne

2011
[Selection of anticancer drug for poorly-differentiated adenocarcinoma of colorectum from the level of orotate phosphoribosyl transferase and dihydropyrimidine dehydrogenase activities in cancer tissue].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Differentiation; Colorectal Neoplasms; Dihydrourac

2010
Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2010, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Combined Mod

2010
Primary site resection is superior for incurable metastatic colorectal cancer.
    World journal of gastroenterology, 2010, Jul-28, Volume: 16, Issue:28

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2010
Lethal outcome of 5-fluorouracil infusion in a patient with a total DPD deficiency and a double DPYD and UTG1A1 gene mutation.
    British journal of clinical pharmacology, 2010, Volume: 70, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydropyrimidine Dehydrog

2010
Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression.
    International journal of radiation oncology, biology, physics, 2011, Aug-01, Volume: 80, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cape

2011
[A case of locally invasive obstructive jejunal cancer with curative resection after stenting and chemotherapy].
    The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, 2010, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Endoscopy

2010
Establishment and characterization of monoclonal 5-fluorouracil-resistant cell lines derived from human endometrial adenocarcinoma.
    International journal of oncology, 2010, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Drug Resistance, Neoplasm; Endome

2010
Adjuvant chemoradiation therapy for adenocarcinoma of the distal pancreas.
    Annals of surgical oncology, 2010, Volume: 17, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2010
Docetaxel second-line therapy in patients with advanced pancreatic cancer: a retrospective study.
    Anticancer research, 2010, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Capecitabine;

2010
Multi-modality therapy for metastatic colorectal cancer-ready for prime time?
    The American surgeon, 2010, Volume: 76, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendicitis; Colectomy; Colonoscopy

2010
Promoter methylation and large intragenic rearrangements of DPYD are not implicated in severe toxicity to 5-fluorouracil-based chemotherapy in gastrointestinal cancer patients.
    BMC cancer, 2010, Sep-01, Volume: 10

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cros

2010
Health-related quality of life in long-term survivors after high-dose chemoradiotherapy followed by surgery in esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Dose Fract

2011
Outcome standards for an organ preservation strategy in stage II and III rectal adenocarcinoma after neoadjuvant chemoradiation.
    Annals of surgical oncology, 2011, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoth

2011
Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy.
    Radiology, 2010, Volume: 257, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biop

2010
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Nov-01, Volume: 28, Issue:31

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2010
Oncolytic adenovirus mediated Survivin RNA interference and 5-fluorouracil synergistically suppress the lymphatic metastasis of colorectal cancer.
    Oncology reports, 2010, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colorectal

2010
Suppressed protein expression of the death-associated protein kinase enhances 5-fluorouracil-sensitivity but not etoposide-sensitivity in human endometrial adenocarcinoma cells.
    Oncology reports, 2010, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Apoptosis Regula

2010
Interleukin-10 and -12 predict chemotherapy-associated toxicity in esophageal adenocarcinoma.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisp

2010
Sister Mary Joseph's nodule as a metastasis of ovarian adenocarcinoma.
    International journal of dermatology, 2010, Volume: 49, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Carboplatin; Colonoscopy; Deoxycytidine;

2010
Two cases of coronary vasospasm induced by 5-fluorouracil.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2010, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Cecal Neoplasms; Coron

2010
Thymidylate synthase gene polymorphism affects the response to preoperative 5-fluorouracil chemoradiation therapy in patients with rectal cancer.
    International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemoradiotherapy; Female; Fluorouraci

2011
Metastatic lymph node targeted chemosensitivity test for gastric cancer.
    The Journal of surgical research, 2011, Volume: 171, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; An

2011
[Therapeutic effects of FOLFOX6 versus TLF regimen as the first line chemotherapy for advanced gastric cancer].
    Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2010, Volume: 30, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; Fluorou

2010
Criteria for three-dimensional anorectal ultrasound assessment of response to chemoradiotherapy in rectal cancer patients.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2011, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy,

2011
Clinical impact of K-ras mutation in colorectal cancer patients treated with adjuvant FOLFOX.
    Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
[Association between genetic polymorphisms of ERCC1, XRCC1, GSTP1 and survival of advanced gastric cancer patients treated with oxaliplatin/5-Fu-based chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:7

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2010
L-type amino-acid transporter 1 expression predicts the response to preoperative hyperthermo-chemoradiotherapy for advanced rectal cancer.
    Anticancer research, 2010, Volume: 30, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Biopsy; Cell Membrane; Fluorouracil; Humans; Hyperthermia, Induced; Lar

2010
Analysis of 5-fluorouracil-related enzymes in pulmonary neuroendocrine carcinoma: differences in biological properties compared to epithelial carcinoma.
    Clinical lung cancer, 2010, Nov-01, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Large Cell; Carcinoma, Neuroendocr

2010
Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction.
    British journal of cancer, 2011, Jan-04, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
Outcomes from chemoradiotherapy for patients with esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
[mFOLFOX6 for treatment of anal canal cancer with disseminated carcinomatosis of bone marrow--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Marrow Ne

2010
A superficial colon tumor model involving subcutaneous colon translocation and orthotopic transplantation of green fluorescent protein-expressing human colon tumor.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2011, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cecum; Cell Proliferation; Colonic Neoplas

2011
Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma.
    Asia-Pacific journal of clinical oncology, 2010, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

2010
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
    Chinese journal of cancer, 2010, Volume: 29, Issue:12

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
XELIRI or FOLFIRI as salvage therapy in advanced pancreatic cancer.
    Anticancer research, 2010, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptotheci

2010
Patient-reported outcomes after neoadjuvant chemoradiotherapy for rectal cancer: a multicenter prospective observational study.
    Annals of surgery, 2011, Volume: 253, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose Fractionation, Radiation

2011
Toxicity data for preoperative concurrent chemoradiotherapy with oxaliplatin and continuous infusion 5-fluorouracil for locally advanced esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adju

2011
Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma.
    Cancer research, 2011, Feb-01, Volume: 71, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl

2011
Hepar lobatum carcinomatosum associated with metastatic rectal carcinoma: an unusual cause of liver dysmorphy.
    Medical principles and practice : international journal of the Kuwait University, Health Science Centre, 2011, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Liver; Liver Neoplasms; Male;

2011
[Clinical usefulness of oral aprepitant for alleviation of delayed nausea and vomiting induced by mFOLFOX6--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:13

    Topics: Adenocarcinoma; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Female; Flu

2010
Esophageal adenocarcinoma after laparoscopic gastric band placement for obesity.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2011, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bariatric Surgery; Deglutition

2011
Unresectable gastric cancer with gastric outlet obstruction and distant metastasis responding to intraperitoneal and folfox chemotherapy after palliative laparoscopic gastrojejunostomy: report of a case.
    World journal of surgical oncology, 2010, Dec-20, Volume: 8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura

2010
X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.
    International journal of radiation oncology, biology, physics, 2012, Jan-01, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy;

2012
Perforated mixed carcinoid-adenocarcinoma in transverse colon and at gastroenterostomy site: case report.
    World journal of surgical oncology, 2010, Dec-22, Volume: 8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoid Tumor; Colon, Transverse;

2010
Improvement of capecitabine antitumoral activity by melatonin in pancreatic cancer.
    Pancreas, 2011, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antioxidants; Capecitabine; Cricetinae; De

2011
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
    Diseases of the colon and rectum, 2010, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma

2010
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
    Diseases of the colon and rectum, 2010, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma

2010
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
    Diseases of the colon and rectum, 2010, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma

2010
Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization.
    Diseases of the colon and rectum, 2010, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Endoscopy, Gastrointestinal; Female; Fluorouracil; Huma

2010
Laparoscopic proctectomy after neoadjuvant therapy: safety and long-term follow-up.
    Surgical endoscopy, 2011, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Digestive System Surgi

2011
Adjuvant 5-fluorouracil-induced colitis necessitating completion colectomy.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colectomy; Colitis; Fluorou

2011
Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis.
    The American journal of emergency medicine, 2012, Volume: 30, Issue:1

    Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary Angiogra

2012
Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma.
    Clinical colorectal cancer, 2010, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2010
Defining cure for esophageal cancer: analysis of actual 5-year survivors following esophagectomy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Annals of surgical oncology, 2011, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, P

2011
Risk-adapted adjuvant chemotherapy after concomitant fluoropyrimidine-radiotherapy neoadjuvant treatment for patients with resectable cT3-4 or N+ rectal cancer.
    Anti-cancer drugs, 2011, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2011
[Locally advanced pancreatic cancer successfully treated by arterial infusion chemotherapy combined with stereotactic radiotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Female; F

2010
[A surgical (right lobectomy) case of liver metastasis of colon cancer after chemotherapy using mFOLFIRI and cetuximab].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2010
[A case of duodenal invasion due to recurrent gastric cancer with obstructive jaundice treated by chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto

2010
[A case of successfully treated lower rectal cancer with both inguinal lymph nodes by chemoradiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
[A case report of advanced rectal cancer showing a pathological complete response by neo-adjuvant FOLFOX chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovor

2010
[A case report of primary adenocarcinoma of small intestine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2010
Changing management and survival in patients with stage IV colorectal cancer.
    Diseases of the colon and rectum, 2011, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antineoplastic Agents; Australia; Camptothecin; Capecit

2011
miR-20a targets BNIP2 and contributes chemotherapeutic resistance in colorectal adenocarcinoma SW480 and SW620 cell lines.
    Acta biochimica et biophysica Sinica, 2011, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Line, Tumor; Colorectal Neoplasms; Dru

2011
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
    International journal of clinical oncology, 2011, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Anti-Allergic Agents; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies

2011
Capecitabine-induced, nonneutropenic enterocolitis.
    Journal of gastrointestinal cancer, 2011, Volume: 42, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Chemotherapy, Adjuva

2011
Mir-148a improves response to chemotherapy in sensitive and resistant oesophageal adenocarcinoma and squamous cell carcinoma cells.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2011, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Su

2011
Esophageal adenocarcinoma presenting as pseudo-achalasia in a patient with juvenile polyposis syndrome: an enemy out of the blue.
    Digestive diseases and sciences, 2011, Volume: 56, Issue:7

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antin

2011
5-FU-induced hyperammonemic encephalopathy in a case of metastatic rectal adenocarcinoid successfully rechallenged with the fluoropyrimidine analog, capecitabine.
    Anticancer research, 2011, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Brain Diseases; Capecitabine; Deoxycytidine;

2011
Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Chemorad

2012
Role of interleukin-23 circulating levels increase in resected colorectal cancer before and after chemotherapy: preliminary data and future perspectives.
    Journal of cellular physiology, 2011, Volume: 226, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics.
    Autophagy, 2011, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell;

2011
Adjuvant chemoradiotherapy after curative resection for extrahepatic bile duct cancer: a long-term single center experience.
    American journal of clinical oncology, 2012, Volume: 35, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; B

2012
Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer.
    Asia-Pacific journal of clinical oncology, 2011, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineo

2011
Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2010, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2010
Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis.
    Annals of surgical oncology, 2011, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2011
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II

2011
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II

2011
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II

2011
DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials, Phase II

2011
Scan? Cure? Sure!
    The oncologist, 2011, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic

2011
A metabonomic approach to chemosensitivity prediction of cisplatin plus 5-fluorouracil in a human xenograft model of gastric cancer.
    International journal of cancer, 2010, Dec-15, Volume: 127, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplati

2010
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experience.
    American journal of clinical oncology, 2012, Volume: 35, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Aged, 80 and over; Antineoplastic Combined Chemother

2012
Hepatic arterial infusion (HAI) with PEGylated liposomes containing 5-FU improves tumor control of liver metastases in a rat model.
    Investigational new drugs, 2012, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Fluorouracil; Hepatic Ar

2012
Differential expression of ERCC1 in pancreas adenocarcinoma: high tumor expression is associated with earlier recurrence and shortened survival after resection.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2011
Mediastinal infusion with tracheal necrosis: an unusual complication of Port-a-cath devices.
    Interactive cardiovascular and thoracic surgery, 2011, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2011
[Mixed carcinoid-adenocarcinoma in transverse colon].
    Acta gastroenterologica Latinoamericana, 2010, Volume: 40, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoid Tumor; Colon, Transverse; Colonic N

2010
Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
    JOP : Journal of the pancreas, 2011, Mar-09, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic;

2011
An evaluation of whether neoadjuvant therapy delays closure of defunctioning loop ileostomy following anterior resection for rectal cancer.
    Minerva chirurgica, 2011, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast

2011
Aberrant expression of OX1 receptors for orexins in colon cancers and liver metastases: an openable gate to apoptosis.
    Cancer research, 2011, May-01, Volume: 71, Issue:9

    Topics: Adenocarcinoma; Animals; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Drug Resistan

2011
Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carb

2011
The predictive role of sequential FDG-PET/CT in response of locally advanced rectal cancer to neoadjuvant chemoradiation.
    American journal of clinical oncology, 2012, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema

2012
Neoadjuvant radiochemotherapy and surgery for advanced rectal cancer : prognostic significance of tumor regression.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2011, Volume: 187, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcin

2011
Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
    Cancer, 2011, Apr-01, Volume: 117, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Female; F

2011
Evaluation of ¹⁸F-FDG-PET for early detection of suboptimal response of rectal cancer to preoperative chemoradiotherapy: a prospective analysis.
    Annals of surgical oncology, 2011, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Fema

2011
Synchronous colonic adenocarcinoma and pelvic schwannoma.
    Connecticut medicine, 2011, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Fine-Needle; Carcinoembryoni

2011
Minimally invasive esophagectomy is safe and effective following neoadjuvant chemoradiation therapy.
    Annals of surgical oncology, 2011, Volume: 18, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Trichomegaly and poliosis of the eyelashes during cetuximab treatment of metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-20, Volume: 29, Issue:18

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agen

2011
Sustained response of adenocarcinoma of the urinary bladder to FOLFOX plus bevacizumab.
    Nature reviews. Urology, 2011, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2011
MRI-based indications for neoadjuvant radiochemotherapy in rectal carcinoma: interim results of a prospective multicenter observational study.
    Annals of surgical oncology, 2011, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
Neoadjuvant GTX chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer.
    Journal of surgical oncology, 2011, Aug-01, Volume: 104, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; CA-19-9 Antigen; Capecitabine; Deoxy

2011
Palliative first-line therapy with weekly high-dose 5-fluorouracil and sodium folinic acid as a 24-hour infusion (AIO regimen) combined with weekly irinotecan in patients with metastatic adenocarcinoma of the stomach or esophagogastric junction followed b
    Medical science monitor : international medical journal of experimental and clinical research, 2011, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
Clinical significance of pre- to post-chemoradiotherapy s-CEA reduction ratio in rectal cancer patients treated with preoperative chemoradiotherapy and curative resection.
    Annals of surgical oncology, 2011, Volume: 18, Issue:12

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabin

2011
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
    Annals of surgical oncology, 2011, Volume: 18, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

2011
HER-2 discordance between primary gastric carcinoma and paired lymph node metastasis.
    Human pathology, 2011, Volume: 42, Issue:6

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2011
[Isolation and identification of side population cells in human lung adenocarcinoma cell line A549].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; ATP-Binding Cassette Transporters; Cell Cycle; Cell

2011
[Weekly regimen of paclitaxel liposome combined with cisplatin and 5-fluorouracil continuous infusion in the treatment of advanced gastric carcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

2011
Late anastomotic dehiscence during bevacizumab therapy for patients with colorectal cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2011, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Anastomotic Leak; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemoth

2011
Short-course versus standard chemoradiation in T3 rectal cancer.
    The oncologist, 2011, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Radiation

2011
Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2012, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Weight;

2012
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
    Journal of the National Cancer Institute, 2011, Jun-08, Volume: 103, Issue:11

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Va

2011
CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
    The Journal of surgical research, 2012, Jun-15, Volume: 175, Issue:2

    Topics: AC133 Antigen; Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers,

2012
Tumor volume reduction rate after preoperative chemoradiotherapy as a prognostic factor in locally advanced rectal cancer.
    International journal of radiation oncology, biology, physics, 2012, Feb-01, Volume: 82, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2012
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, oxaliplatin and docetaxel.
    International journal of cancer, 2012, Apr-01, Volume: 130, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival;

2012
Concurrent chemotherapy and intensity-modulated radiotherapy for organ preservation of locoregionally advanced oral cavity cancer.
    American journal of clinical oncology, 2011, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Efficacy of irinotecan in combination with 5-fluorouracil (FOLFIRI) for metastatic gastric or gastroesophageal junction adenocarcinomas (MGA) treatment.
    Clinics and research in hepatology and gastroenterology, 2011, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2011
Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.
    Cancer research, 2011, Aug-01, Volume: 71, Issue:15

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Camptothecin; CD

2011
[Successful combined treatment with maximal androgen blockade (MAB), intra arterial chemotherapy and radiation for advanced prostatic ductal adenocarcinoma : report of two cases].
    Hinyokika kiyo. Acta urologica Japonica, 2011, Volume: 57, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents,

2011
ABCB5 identifies a therapy-refractory tumor cell population in colorectal cancer patients.
    Cancer research, 2011, Aug-01, Volume: 71, Issue:15

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamil

2011
Role of adjuvant chemoradiotherapy for duodenal cancer: a single center experience.
    American journal of clinical oncology, 2012, Volume: 35, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Chemoradiotherapy, Adj

2012
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer.
    BMC cancer, 2011, Jun-14, Volume: 11

    Topics: Adenocarcinoma; Aged; Alleles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineopla

2011
Gene expression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2011, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colo

2011
The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2012, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Apoptotic Protease-

2012
Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    BMC cancer, 2011, Jun-24, Volume: 11

    Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Cisplatin; Clinical Trials as Topic; Combined M

2011
Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACH
    Journal of visceral surgery, 2011, Volume: 148, Issue:3

    Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2011
EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.
    International journal of cancer, 2011, Sep-01, Volume: 129, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Animals; Antibodies, Monoclonal; Antigens, Neoplasm; Antimetabolites,

2011
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
    Revue medicale suisse, 2011, May-25, Volume: 7, Issue:296

    Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protoco

2011
Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Diseases of the colon and rectum, 2011, Volume: 54, Issue:8

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Comb

2011
Proteomic differential display analysis for TS-1-resistant and -sensitive pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry.
    Anticancer research, 2011, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Combinations;

2011
Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: experience at the Medical University of Vienna.
    Anticancer research, 2011, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2011
[Successful chemotherapy of carcinomatosis of the bone marrow with disseminated intravascular coagulation from a rectal carcinoma found by eosinophilia].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2011, Volume: 108, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Carcino

2011
Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement.
    BMC cancer, 2011, Jul-09, Volume: 11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neopl

2011
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines.
    Cancer letters, 2011, Oct-28, Volume: 309, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Ce

2011
Clinical outcomes of mild hyperthermia for locally advanced rectal cancer treated with preoperative radiochemotherapy.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2011, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adj

2011
Conversion treatment of hepatic metastases of colon adenocarcinoma by bevacizumab and FOLFOX.
    Anti-cancer drugs, 2011, Volume: 22 Suppl 2

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B

2011
Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
    Anti-cancer drugs, 2011, Volume: 22 Suppl 2

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2011
Postoperative intraperitoneal 5-fluoro-2'-deoxyuridine added to chemoradiation in patients curatively resected (R0) for locally advanced gastric and gastroesophageal junction adenocarcinoma.
    Annals of surgical oncology, 2012, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2012
5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Oncology, 2011, Volume: 80, Issue:5-6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Ch

2011
Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.
    Asian Pacific journal of cancer prevention : APJCP, 2011, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem

2011
A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Combined Chemot

2012
New approaches to the treatment of pancreatic cancer: from tumor-directed therapy to immunotherapy.
    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2011, Aug-01, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Camptothecin

2011
Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer.
    Anti-cancer drugs, 2011, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci

2011
Accuracy of endoscopic ultrasound to assess tumor response after neoadjuvant treatment in rectal cancer: can we trust the findings?
    Diseases of the colon and rectum, 2011, Volume: 54, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colonoscopy; Endosonography;

2011
A case of colorectal cancer with double-activating epidermal growth factor receptor mutations.
    Japanese journal of clinical oncology, 2011, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomark

2011
An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
    Cancer gene therapy, 2011, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival

2011
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
    Annals of surgical oncology, 2012, Volume: 19, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Ad

2012
The prognostic value of grade of regression and oncocytic change in rectal adenocarcinoma treated with neo-adjuvant chemoradiotherapy.
    Journal of surgical oncology, 2012, Volume: 105, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2012
Nonsurgical management of esophageal adenocarcinoma.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.
    Clinical colorectal cancer, 2011, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort Studies;

2011
Resolving actinic keratoses: an expected side-effect of capecitabine therapy.
    Clinical and experimental dermatology, 2012, Volume: 37, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin

2012
Outcome of second-line treatment after first-line chemotherapy with the GONO FOLFOXIRI regimen.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2012
[Anticancer effect of 5-fluorouracil combined with extract of Rosa roxburghii Tratt on human endometrial adenocarcinoma].
    Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2011, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; F

2011
An EZH2 polymorphism is associated with clinical outcome in metastatic colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study.
    Radiation oncology (London, England), 2011, Sep-28, Volume: 6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antineoplastic Agents; Chemoradiot

2011
Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?
    World journal of surgical oncology, 2011, Sep-28, Volume: 9

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto

2011
Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2012
Pharmacokinetics, dosimetry and comparative efficacy of 188Re-liposome and 5-FU in a CT26-luc lung-metastatic mice model.
    Nuclear medicine and biology, 2012, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Bone Marrow; Colonic Neoplasms; Fluorourac

2012
Inferior survival of advanced pancreatic cancer patients who received gemcitabine-based chemotherapy but did not participate in clinical trials.
    Oncology, 2011, Volume: 81, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin

2011
Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2012
Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localized pancreatic cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Loss, Surgical; Capecit

2012
Preclinical study of the DNA repair inhibitor Dbait in combination with chemotherapy in colorectal cancer.
    Journal of gastroenterology, 2012, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tu

2012
Liver metastasis from colonic adenocarcinoma presenting as nephrolithiasis: computed tomography findings.
    The Israel Medical Association journal : IMAJ, 2011, Volume: 13, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dia

2011
Postoperative chemotherapy followed by conformal concomitant chemoradiotherapy in high-risk gastric cancer.
    International journal of radiation oncology, biology, physics, 2012, Jun-01, Volume: 83, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chem

2012
Relationship between TYMS and ERCC1 mRNA expression and in vitro chemosensitivity in colorectal cancer.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carc

2011
Intra-arterial chemoinfusion prior to chemoradiotherapy with full-dose systemic gemcitabine for management of locally advanced pancreatic cancer.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemoradiotherapy; Deoxycytidine; Female; Fluoroura

2011
Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
    Anticancer research, 2011, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2011
The validation of matrix metalloproteinase-9 mRNA gene expression as a predictor of outcome in patients with metastatic gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2012
Radiotherapy: the importance of local control in pancreatic cancer.
    Nature reviews. Clinical oncology, 2011, Nov-29, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Deoxycytidine; Fluorouracil; Gemcitabine; Humans; M

2011
Definitive chemoradiotherapy in patients with esophageal adenocarcinoma: an alternative to surgery?
    Journal of surgical oncology, 2012, Jun-15, Volume: 105, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2012
Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease.
    Annals of surgical oncology, 2012, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2012
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2012, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Che

2012
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
    Clinical colorectal cancer, 2012, Volume: 11, Issue:2

    Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II a

2012
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2012, Jun-01, Volume: 83, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine;

2012
Low-dose-rate californium-252 neutron intracavitary afterloading radiotherapy combined with conformal radiotherapy for treatment of cervical cancer.
    International journal of radiation oncology, biology, physics, 2012, Jul-01, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

2012
Pathologic complete response after FOLFOX7 in a locally advanced rectal cancer.
    Journal of clinical gastroenterology, 2012, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu

2012
Outcomes and toxicities for the treatment of stage IVB cervical cancer.
    Archives of gynecology and obstetrics, 2012, Volume: 285, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Com

2012
Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2012, Volume: 102, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2012
Reliability of tumor primary cultures as a model for drug response prediction: expression profiles comparison of tissues versus primary cultures from colorectal cancer patients.
    Journal of cancer research and clinical oncology, 2012, Volume: 138, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin;

2012
Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer.
    Journal of surgical oncology, 2012, Jun-15, Volume: 105, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; F

2012
Intensity-modulated radiotherapy for pancreatic adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2012, Mar-15, Volume: 82, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; De

2012
Low dihydropyrimidine dehydrogenase correlates with prolonged survival in patients with lung adenocarcinoma treated with 5-fluorouracil.
    Anticancer research, 2011, Volume: 31, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouraci

2011
[Preoperative chemoradiation (XELOX/RT) therapy for anal canal adenocarcinoma with the metastasis to inguinal lymph node].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Capecita

2011
[A case of colon cancer with long-term survival treated by resection of recurrence on the rectum and chemotherapy for lung metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Fluorouracil; Humans; Leucov

2011
Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2012
Unusual course of an abdominal aortic aneurysm in a patient treated with chemotherapy for gastric cancer.
    Journal of vascular surgery, 2012, Volume: 55, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Aortogra

2012
Clinical evaluation of neoadjuvant chemotherapy followed by radical surgery in the management of stage IB2-IIB cervical cancer.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2012, Volume: 117, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

2012
Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer.
    Gynecologic oncology, 2012, Volume: 125, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cel

2012
A WKYMVm-containing combination elicits potent anti-tumor activity in heterotopic cancer animal model.
    PloS one, 2012, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; Antineoplastic Agents; Apoptosis; Cancer Vaccines;

2012
The clinical characteristic differences between thrombosis-related edema and lymphedema following radiotherapy or chemoradiotherapy for patients with cervical cancer.
    Journal of radiation research, 2012, Volume: 53, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2012
Oxaliplatin-related hyperammonaemic encephalopathy in a patient with colon cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2012, Volume: 14, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopl

2012
[HER-2 expression in advanced gastric cancer and its correlation with clinical features, outcome and prognosis].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2011, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2011
Intensified neoadjuvant chemoradiotherapy in locally advanced rectal cancer -- impact on long-term quality of life.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2012
Octarepeat peptides of prion are essential for multidrug resistance in gastric cancer cells.
    Journal of digestive diseases, 2012, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Cisplatin; Doxorubici

2012
A case report of 5-fluorouracil-induced coronary artery vasospasm.
    The Ulster medical journal, 2010, Volume: 79, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Coronary Vasospasm; Coronary Vessels; Fluorou

2010
Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apop

2012
Response of glutathione S-transferase Pi (GSTP1) to neoadjuvant therapy in rectal adenocarcinoma.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2012, Volume: 14, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy, Adjuvant; F

2012
Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.
    Annals of surgical oncology, 2012, Volume: 19, Issue:7

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2012
Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012, Volume: 188, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycy

2012
Postoperative chemoradiotherapy for gallbladder cancer.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2012, Volume: 188, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Chemoradiotherapy; Female; Fluorouracil; Gallbladder Neoplasms; Humans;

2012
Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation.
    Medical care, 2012, Volume: 50, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Chemoradiotherapy, Adjuvant; Colonic Neo

2012
A case of type 2 diabetes and metastatic liver cancer exhibiting hypercholesterolemia with abnormal lipoproteins.
    Internal medicine (Tokyo, Japan), 2012, Volume: 51, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure

2012
Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome.
    Annals of surgical oncology, 2012, Volume: 19, Issue:9

    Topics: Adenocarcinoma; Aged; Anastomotic Leak; Antimetabolites, Antineoplastic; Chemoradiotherapy, Adjuvant

2012
[Combined radiochemotherapy of an irresectable carcinoma of the pancreas].
    Zentralblatt fur Chirurgie, 1998, Volume: 123, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cholangiopancreat

1998
Bilateral acute ptosis leading to the diagnosis of a presumed metastatic gastric adenocarcinoma.
    Orbit (Amsterdam, Netherlands), 2012, Volume: 31, Issue:2

    Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blepharoptosis; Capec

2012
[Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2012
Tetrathiomolybdate sensitizes ovarian cancer cells to anticancer drugs doxorubicin, fenretinide, 5-fluorouracil and mitomycin C.
    BMC cancer, 2012, Apr-13, Volume: 12

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bl

2012
[A successful resected case of advanced esophageal cancer with early gastric cancer responding to neoadjuvant chemotherapy of docetaxel, CDDP and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamous Ce

2012
Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance.
    British journal of pharmacology, 2012, Volume: 167, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blood Platelets; Caco-2 Cells; Cell Cycle; Cell Pr

2012
Inadvertent severe acute kidney injury and oxaliplatin.
    International urology and nephrology, 2013, Volume: 45, Issue:1

    Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorecta

2013
Prognostic significance of tumour location after adjuvant chemoradiotherapy for periampullary adenocarcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2012, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemoradiotherapy, A

2012
Impaired death-associated protein kinase-mediated survival signals in 5-fluorouracil-resistant human endometrial adenocarcinoma cells.
    Oncology reports, 2012, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Calcium-C

2012
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012, Jun-01, Volume: 898

    Topics: Adenocarcinoma; Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy

2012
[A case of primary adenocarcinoma of small intestine responding to XELOX chemotherapy and leading to a partial metabolic response].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Fluorou

2012
Lymph node retrieval after preoperative chemoradiotherapy for rectal cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy,

2012
Comparative label-free LC-MS/MS analysis of colorectal adenocarcinoma and metastatic cells treated with 5-fluorouracil.
    Proteomics, 2012, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antioxidants; Cell Adhesion; Cell Line, Tumor; Chro

2012
Expression and prognostic significance of thymidylate synthase (TS) in pancreatic head and periampullary cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2012, Volume: 38, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; B

2012
Complete calcification of colorectal liver metastases on imaging after chemotherapy does not indicate sterilization of disease.
    Journal of visceral surgery, 2012, Volume: 149, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Camptothecin; Colo

2012
Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment.
    Neuromuscular disorders : NMD, 2012, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiomyopathies; Colo

2012
A complex oncosurgical approach to increasing the resectability of colorectal cancer metastases - a case report.
    Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2014, Volume: 158, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Emboliza

2014
The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells.
    Cancer research, 2012, Aug-15, Volume: 72, Issue:16

    Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Cell Line; Cytokines; DNA Damage; DNA, Neoplasm; D

2012
Low morbidity after palliation of obstructing gastro-oesophageal adenocarcinoma to restore swallowing function.
    Danish medical journal, 2012, Volume: 59, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Argon Plasma Coagulation; Capecitabi

2012
Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function.
    Molecular biology reports, 2012, Volume: 39, Issue:12

    Topics: Acetylcholinesterase; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita

2012
Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report.
    World journal of surgical oncology, 2012, Jun-29, Volume: 10

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2012
Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area

2012
[Expression of Bcl-w protein in human small intestinal adenocarcinoma and effect of Bcl-w siRNA on apoptosis in intestinal adenocarcinoma HuTu-80 cells].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Cell Line

2012
FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
    Pancreas, 2012, Volume: 41, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Clinical Trials, Phase

2012
Clinical and laboratory biomarkers in the management of pancreatic adenocarcinoma.
    JOP : Journal of the pancreas, 2012, Jul-10, Volume: 13, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Bevacizumab; Biomarkers; Capecitabine; Deoxycytid

2012
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, epirubicin and cisplatin (modified ECF) as adjuvant chemotherapy in resected gastric adenocarcinoma.
    Chemotherapy, 2012, Volume: 58, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Disease-Free

2012
Treatment-related morbidity and toxicity of CRS and oxaliplatin-based HIPEC compared to a mitomycin and doxorubicin-based HIPEC protocol in patients with peritoneal carcinomatosis: a matched-pair analysis.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2013
Concurrent chemoradiotherapy followed by metastasectomy converts to survival benefit in stage IV rectum cancer.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2012
Colon carcinoma in a child treated with oxaliplatin and antiangiogenic treatment regimens.
    Pediatric hematology and oncology, 2012, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2012
Self-assessment quiz: answers, critiques, and references.
    Diseases of the colon and rectum, 2012, Volume: 55, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino

2012
Colon cancer cell chemosensitisation by fish oil emulsion involves apoptotic mitochondria pathway.
    The British journal of nutrition, 2013, Apr-14, Volume: 109, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Camptothecin; Cell Lin

2013
Is restaging with chest and abdominal CT scan after neoadjuvant chemoradiotherapy for locally advanced rectal cancer necessary?
    Annals of surgical oncology, 2013, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy, Adjuvant; De

2013
Oncologically safe distal resection margins in rectal cancer patients treated with chemoradiotherapy.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2012, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2012
The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2012, Volume: 33, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc

2012
5-Fluorouracil induced hyperammonemic encephalophathy: etiopathologic correlation.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 2012, Volume: 39, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Neoplasms; Diffusion Magnetic Resonance Imagi

2012
Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

2012
Capecitabine-induced chest pain relieved by diltiazem.
    The American journal of cardiology, 2012, Dec-01, Volume: 110, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Anus Neoplasms; Calcium Channel Blockers; Cap

2012
FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts.
    World journal of gastroenterology, 2012, Sep-07, Volume: 18, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2012
Radiation dose ≥54 Gy and CA 19-9 response are associated with improved survival for unresectable, non-metastatic pancreatic cancer treated with chemoradiation.
    Radiation oncology (London, England), 2012, Sep-13, Volume: 7

    Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoma; Chemoradiotherapy

2012
Identification and characterization of stemlike cells in human esophageal adenocarcinoma and normal epithelial cell lines.
    The Journal of thoracic and cardiovascular surgery, 2012, Volume: 144, Issue:5

    Topics: Adenocarcinoma; Animals; Antigens, CD; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription F

2012
Molecular markers predict distant metastases after adjuvant chemoradiation for rectal cancer.
    International journal of radiation oncology, biology, physics, 2012, Dec-01, Volume: 84, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemoradiotherapy,

2012
Optimal therapeutic management of patients with distinct clinicopathological cancer of unknown primary subsets.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23 Suppl 10

    Topics: Adenocarcinoma; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Fluoroura

2012
Influcence of localization of primary tumor on effectiveness of 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin (FOLFIRINOX) in patients with metastatic pancreatic adenocarcinoma: a retrospective study.
    Anticancer research, 2012, Volume: 32, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2012
[A case of adenocarcinoma occurring at colostomy site 7 years after abdominoperineal resection for rectal cancer resected after preoperative mFOLFOX6 chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2012, Volume: 39, Issue:9

    Topics: Abdominal Wall; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Colost

2012
Pathological complete response and sphincter-sparing surgery after neoadjuvant radiochemotherapy with regional hyperthermia for locally advanced rectal cancer compared with radiochemotherapy alone.
    International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 2012, Volume: 28, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemoradiotherapy;

2012
First description of an uterine perforation potentially imputable to treatment with bevacizumab.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:8

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2012
Primary carcinoma of jejunum--a case report.
    Journal of the Indian Medical Association, 2012, Volume: 110, Issue:3

    Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Capecitabine; Chemothe

2012
Use of a chemically induced-colon carcinogenesis-prone Apc-mutant rat in a chemotherapeutic bioassay.
    BMC cancer, 2012, Oct-03, Volume: 12

    Topics: Adenocarcinoma; Adenomatous Polyposis Coli Protein; Animals; Antimetabolites, Antineoplastic; Azoxym

2012
Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    International journal of cancer, 2013, May-01, Volume: 132, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2013
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
    Hinyokika kiyo. Acta urologica Japonica, 2012, Volume: 58, Issue:8

    Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplasti

2012
Overexpression of forkhead box M1 transcription factor (FOXM1) is a potential prognostic marker and enhances chemoresistance for docetaxel in gastric cancer.
    Annals of surgical oncology, 2013, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor;

2013
Cytostatic activity of a 5-fluoro-2'-deoxyuridine-alendronate conjugate against gastric adenocarcinoma and non-malignant intestinal and fibroblast cell lines.
    Anticancer research, 2012, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Alendronate; Bone Density Conservation Agents; Bone Neoplasms; Cell Line; Cell Line,

2012
Prognostic analysis of patients with operable gastric cancer and tolerability to adjuvant radio-chemo-therapy.
    Neoplasma, 2013, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2013
Bimonthly regimen of high-dose leucovorin, infusional 5-fluorouracil, docetaxel, and cisplatin (modified DCF) in advanced gastric adenocarcinoma.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2013, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free

2013
Baseline nutritional status is prognostic factor after definitive radiochemotherapy for esophageal cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2014, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2014
Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor.
    Japanese journal of clinical oncology, 2013, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy

2013
HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy.
    Journal of surgical oncology, 2013, Volume: 107, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2013
Expression of pyruvate dehydrogenase kinase-1 in gastric cancer as a potential therapeutic target.
    International journal of oncology, 2013, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Blotting, Western;

2013
Double pancreatic and gastric adenocarcinomas: a rare association.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; Humans;

2013
[Clinicopathological features and prognosis of primary appendiceal adenocarcinoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2012
MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.
    Radiation oncology (London, England), 2012, Nov-20, Volume: 7

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemoradiotherapy; Combi

2012
Local recurrence of gastric cancer after total gastrectomy: an unusual presentation.
    BMC surgery, 2012, Volume: 12 Suppl 1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoth

2012
Macroscopic and histologic regression of duodenal polyposis with FOLFOX4 chemotherapy for an ileal pouch adenocarcinoma in a patient with familial adenomatous polyposis.
    Endoscopy, 2012, Volume: 44, Issue:12

    Topics: Adenocarcinoma; Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; B

2012
[Resolution of actinic keratosis with capecetabin].
    Annales de dermatologie et de venereologie, 2012, Volume: 139, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Capecitabine; Colonic Neoplasms; Deoxycytidine; Fluorou

2012
Spatial-temporal [¹⁸F]FDG-PET features for predicting pathologic response of esophageal cancer to neoadjuvant chemoradiation therapy.
    International journal of radiation oncology, biology, physics, 2013, Apr-01, Volume: 85, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamou

2013
Adjuvant therapy for intrahepatic cholangiocarcinoma: the debate continues.
    The oncologist, 2012, Volume: 17, Issue:12

    Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biomarkers

2012
Transanal endoscopic microsurgery for residual rectal cancer (ypT0-2) following neoadjuvant chemoradiation therapy: another word of caution.
    Diseases of the colon and rectum, 2013, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Aged; Anal Canal; Brazil; Chemoradiotherapy; Female; Fluorouracil; Humans; Male; Mic

2013
Solitary bulky mediastinal lymph node metastasis from colon cancer.
    Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 2013, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cell Differentiation; Chemother

2013
Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Co

2013
Concomitant occurrence of pulmonary invasive aspergillosis and Pneumocystis pneumonia during FOLFIRINOX chemotherapy for pancreatic carcinoma.
    Pancreas, 2013, Volume: 42, Issue:1

    Topics: Adenocarcinoma; Anti-Bacterial Agents; Antifungal Agents; Antineoplastic Combined Chemotherapy Proto

2013
Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis.
    BMC cancer, 2012, Dec-20, Volume: 12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; Deoxycytid

2012
Cervical extravasation of bevacizumab.
    Anti-cancer drugs, 2013, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antin

2013
Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2013, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brid

2013
[Esophageal cancer: outcome according to therapeutic strategy].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2013, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2013
Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a population-based study in the north-East Netherlands.
    Annals of surgical oncology, 2013, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2013
Neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal cancer in a single high-volume center.
    Annals of surgical oncology, 2013, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2013
Adverse events associated with bevacizumab and chemotherapy in older patients with metastatic colorectal cancer.
    Clinical colorectal cancer, 2013, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protoc

2013
Impact of adjuvant chemoradiotherapy for rectal cancer on the long-term quality of life and late side effects: a multicentric clinical evaluation by the Turkish Oncology Group.
    Asian Pacific journal of cancer prevention : APJCP, 2012, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemora

2012
Quantification and study of the L-DOPA decarboxylase expression in gastric adenocarcinoma cells treated with chemotherapeutic substances.
    Anti-cancer drugs, 2013, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Camptothecin; Cisplatin; Dopa Decarboxylase; Dose-Response Re

2013
SKP2 overexpression is associated with a poor prognosis of rectal cancer treated with chemoradiotherapy and represents a therapeutic target with high potential.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor;

2013
Improved outcomes for rectal cancer in the era of preoperative chemoradiation and tailored mesorectal excision: a series of 338 consecutive cases.
    The American surgeon, 2013, Volume: 79, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antine

2013
Fluorouracil selectively enriches stem-like cells in the lung adenocarcinoma cell line SPC.
    Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2013, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Blotting, We

2013
Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma.
    Oral oncology, 2013, Volume: 49, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Cis

2013
Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2013
Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction.
    PloS one, 2013, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradi

2013
The relationship of vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer.
    BMC cancer, 2013, Feb-01, Volume: 13

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chi-

2013
Neoadjuvant therapy and mini-invasive total mesorectal excision for rectal cancer: feasibility and outcome analysis from a single institution prospectively collected data base.
    Tumori, 2012, Volume: 98, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2012
Irinotecan during pregnancy in metastatic colon cancer.
    Tumori, 2012, Volume: 98, Issue:6

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl

2012
Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2012, Volume: 95, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; F

2012
Preliminary outcome of a treatment strategy based on perioperative chemotherapy and surgery in patients with locally advanced colon cancer.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2013, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2013
Adjuvant concurrent chemoradiation using intensity-modulated radiotherapy and simultaneous integrated boost for resected high-risk adenocarcinoma of the distal esophagus and gastro-esophageal junction.
    Radiation oncology (London, England), 2013, Feb-11, Volume: 8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Chemotherap

2013
[Angina related to 5-Fluorouracil].
    Revista espanola de cardiologia, 2002, Volume: 55, Issue:7

    Topics: Adenocarcinoma; Aged; Angina, Unstable; Antimetabolites, Antineoplastic; Chest Pain; Electrocardiogr

2002
G(1)/S but not G(0)/G(1)cell fraction is related to 5-fluorouracil cytotoxicity.
    Cytometry, 2002, May-01, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Antimetabolites; Antimetabolites, Antineoplastic; Breast Neoplasms; Bromodeoxyuridin

2002
Correlation between cell survival, clonogenic activity and micronuclei induction in DMBA-OC-1R cells treated with immunospecific albumin microspheres containing cisplatin and 5-fluorouracil.
    Cell biology international, 2002, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Albumins; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell

2002
Treatment with 5-fluorouracil enhances radiosensitivity of the human pancreatic cancer cell line MiaPaCa-2.
    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2002, Volume: 2, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Combined Modality Therapy; Fluoroura

2002
Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.
    International journal of cancer, 2002, Aug-10, Volume: 100, Issue:5

    Topics: Adenocarcinoma; Adenovirus Infections, Human; Animals; Antimetabolites, Antineoplastic; Cell Divisio

2002
Sigmoid colon cancer during pregnancy.
    European journal of obstetrics, gynecology, and reproductive biology, 2002, Aug-05, Volume: 104, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cesarean Section; Female; Flu

2002
[Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Ascitic Fluid; Drug Combinati

2002
Eosinophilic lung disease under chemotherapy with oxaliplatin for colorectal cancer.
    American journal of clinical oncology, 2002, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Ne

2002
Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:7

    Topics: Adenocarcinoma; Afferent Loop Syndrome; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin

2002
A 'modified de Gramont' regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.
    British journal of cancer, 2002, Aug-12, Volume: 87, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2002
Advanced pancreatic cancer--5 years on.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2002, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic;

2002
[Simultaneaous bilateral pulmonary metastasectomy of carcinoma of the sweat glands].
    Archivos de bronconeumologia, 2002, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Axilla; Chemotherapy, Adjuva

2002
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2002, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu

2002
Long-term results of reirradiation for patients with recurrent rectal carcinoma.
    Cancer, 2002, Sep-01, Volume: 95, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2002
Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo.
    International journal of cancer, 2002, Sep-20, Volume: 101, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Color

2002
[A case of recurrent gallbladder cancer responding to low-dose 5-FU and CDDP therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi

2002
A case of myocardial ischaemia induced by 5-fluorouracil.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2002, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Electrocardiogr

2002
Chronomodulated chemotherapy in advanced colorectal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Sep-15, Volume: 20, Issue:18

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Clinical Trials as To

2002
Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
    British journal of cancer, 2002, Sep-09, Volume: 87, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2002
Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer.
    International journal of radiation oncology, biology, physics, 2002, Oct-01, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2002
Epirubicin, Cisplatin, and protracted venous-infusion Fluorouracil in advanced esophagogastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Oct-01, Volume: 20, Issue:19

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2002
[A case of advanced gastric cancer responding to combination chemotherapy with low-dose 5-FU plus CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

2002
[Gastric cancer with multiple liver metastases, which responded significantly to oral administration of TS-1 following intravenous FMP therapy under hospitalization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combine

2002
[A case of recurrent gastric cancer that responded dramatically to docetaxel and 5'-DFUR combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr

2002
[A case of unresectable rectal cancer with liver and pulmonary metastases that responded remarkably to pharmacokinetic modulating chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Drug Administr

2002
Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines.
    World journal of gastroenterology, 2002, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2002
Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with chemotherapeutic agents on patients' colon tumors grown in SCID mice.
    Cancer research, 2002, Oct-15, Volume: 62, Issue:20

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regula

2002
Surgical resection with and without chemotherapy in oesophageal cancer.
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2002
Surgical resection with and without chemotherapy in oesophageal cancer.
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2002
Surgical resection with and without chemotherapy in oesophageal cancer.
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2002
Surgical resection with and without chemotherapy in oesophageal cancer.
    Lancet (London, England), 2002, Oct-12, Volume: 360, Issue:9340

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2002
[A case of gastric cancer with multiple liver metastases responding to combined hepatic arterial and aortic infusion chemotherapy with cisplatinum, 5-fluorouracil, and levofolinate calcium].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

2002
[A case of colon metastasis to the lung treated successfully with combined chemotherapy of CPT-11 and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administration Sc

2002
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: a case report.
    Journal of chemotherapy (Florence, Italy), 2002, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne

2002
Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer.
    Diseases of the colon and rectum, 2002, Volume: 45, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Thera

2002
[Palliative second-line treatment with oxaliplatin, gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in patients with metastatic pancreatic adenocarcinoma].
    Zeitschrift fur Gastroenterologie, 2002, Volume: 40, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Progres

2002
Adenocarcinoma of the ethmoid sinuses: a case of two primary tumours.
    The Journal of laryngology and otology, 2002, Volume: 116, Issue:9

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Ethmoid Sinus; Fluoro

2002
Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
    Cancer investigation, 2002, Volume: 20, Issue:7-8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Aged; Antimetabolites, Antineoplastic; Colonic Diseases; D

2002
Thymidylate synthase gene expression in primary colorectal cancer and metastatic sites.
    Clinical colorectal cancer, 2001, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorectal Neoplasms; Fluorourac

2001
Toxicity analysis of the 5-day bolus 5-fluorouracil/folinic acid regimen for the treatment of colorectal carcinoma from 2 randomized controlled trials: a concern about dose.
    Clinical colorectal cancer, 2002, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2002
Reg IV, a new member of the regenerating gene family, is overexpressed in colorectal carcinomas.
    International journal of cancer, 2003, Jan-10, Volume: 103, Issue:2

    Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Northern; Ca

2003
[Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcin

2002
[A case of multiple liver metastases from colon cancer successfully treated with modified pharmacokinetic modulating chemotherapy using Leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colectomy; Col

2002
[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptoth

2002
[Chemotherapy in adenocarcinomas of the pancreas].
    Gastroenterologie clinique et biologique, 2002, Volume: 26, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2002
[A case report of intra-hepatic arterial infusion of mitomycin C with degradable starch microspheres for liver metastases of sigmoid colon carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Biodegradation, Enviro

2002
[A case of metastatic vaginal tumor of rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Hysterectomy; Middle Aged;

2002
[A case of stage IV diffusely infiltrating colon cancer treated by surgical resection and chemoradiation therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Co

2002
Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues.
    International journal of clinical oncology, 2002, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; Carcin

2002
Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer.
    Clinical pharmacology and therapeutics, 2002, Volume: 72, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Chemotherapy, Adjuva

2002
Adenocarcinoid of the appendix vermiformis: complete and persistent remission after chemotherapy (folfox) of a metastatic case.
    Digestive diseases and sciences, 2002, Volume: 47, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Female; Fluor

2002
Anal sphincter preservation in locally advanced low rectal adenocarcinoma after preoperative chemoradiation therapy and coloanal anastomosis.
    Journal of surgical oncology, 2003, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antimetabolites, Antineoplastic; Col

2003
[Clinical comparison between intraoperative local arterial infusion chemotherapy and systemic venous chemotherapy of gastric cancer].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 2001, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxo

2001
Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.
    Cytokine, 2002, Nov-24, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2002
Palliative chemotherapy with gemcitabine and weekly high-dose 5-fluorouracil as 24-h infusion in metastatic biliary tract and gall bladder adenocarcinomas.
    Anti-cancer drugs, 2003, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Deoxy

2003
[A case of advanced gastric adenocarcinoma with mild elevation of serum SCC that responded remarkably to adjuvant chemotherapy of ADM, CDDP, ETP and 5-FU (ACVF)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Chemothera

2003
Chemoradiation for adenocarcinoma of the anus.
    International journal of radiation oncology, biology, physics, 2003, Mar-01, Volume: 55, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Anus Neoplasms; Carcinoma, Sq

2003
Hormone-refractory prostate cancer responding to capecitabine.
    Urology, 2003, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antimetabolites, Antineoplastic; Antineoplastic Agents,

2003
Stage IVB uterine endometrial cancer successfully salvaged by chemoradiotherapy and surgery.
    International journal of clinical oncology, 2003, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Endometrial Neoplasms;

2003
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Mar-01, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2003
[A case of advanced colon cancer responding to treatment with levofolinate combined with 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Admini

2003
[A case of advanced pancreatic cancer with multiple liver metastasis that improved remarkably with use of low-dose cisplatin and TS-1].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationshi

2003
Distal intramural spread is an independent prognostic factor for distant metastasis and poor outcome in patients with rectal cancer: a multivariate analysis.
    Annals of surgical oncology, 2003, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluoroura

2003
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience.
    The Journal of urology, 2003, Volume: 169, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Care Facilities;

2003
[Cytoreductive surgery as an alternative to palliative operations in oncology (the model of treatment of stage IV colorectal cancer)].
    Vestnik khirurgii imeni I. I. Grekova, 2002, Volume: 161, Issue:6

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

2002
Synchronous occurrence of glioblastoma multiforme and esophageal adenocarcinoma.
    The American surgeon, 2003, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carmustine; Cisplat

2003
Prognostic factor analysis in advanced gastric cancer patients treated with hydroxyurea, leucovorin, 5-fluorouracil, and cisplatin (HLFP regimen).
    Cancer investigation, 2003, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, T

2003
[Preoperative diagnostic procedures in locally advanced rectal carcinoma (> or =T3 or N+). What does endoluminal ultrasound achieve at staging and restaging (after neoadjuvant radiochemotherapy) in contrast to computed tomography?].
    Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 2003, Volume: 74, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2003
A pilot study of adjuvant intraperitoneal 5-fluorouracil using 4% icodextrin as a novel carrier solution.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2003, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Co

2003
Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma.
    Diseases of the colon and rectum, 2003, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Ch

2003
Adenocarcinoma of the female urethral diverticulum treated by multimodality therapy.
    International journal of urology : official journal of the Japanese Urological Association, 2003, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

2003
Apoptosis, 5-fluorouracil sensitivity and expression of apoptotic proteins in a human ectocervical cell carcinogenesis model using different media.
    European journal of pharmacology, 2003, Apr-25, Volume: 467, Issue:1-3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Western; Cell Line, Transforme

2003
Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma.
    International journal of clinical oncology, 2003, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy, Needle; Cell Division; Co

2003
Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma.
    American journal of surgery, 2003, Volume: 185, Issue:5

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis

2003
[Study on the chemosensitivity test of human gastric cancer using the MTT assay].
    Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, 2001, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Drug Screening Assays, Antitumor; Fem

2001
Physical training during intrahepatic chemotherapy.
    Archives of physical medicine and rehabilitation, 2003, Volume: 84, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Exercise Therapy; Fluorouracil; Forced Expiratory V

2003
Methylenetetrahydrofolate reductase polymorphism in advanced colorectal cancer: a novel genomic predictor of clinical response to fluoropyrimidine-based chemotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alleles; Antineoplastic Agents; Capecitabine; Colorectal Neoplasms; Deo

2003
The recent past and future of adjuvant therapy for pancreatic cancer.
    Annals of surgical oncology, 2003, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Tri

2003
[A case of colon cancer with liver metastases and lymph node metastases successfully treated with surgery followed by CPT-11 and 5-FU chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Camptothecin; Colo

2003
Relapse patterns after chemo-radiation for carcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2003, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2003
Chronic myeloid leukemia in a patient with colon adenocarcinoma.
    Haematologia, 2002, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Cisplatin; Colonic Neoplasms; Fluorouracil; Humans; Leukemia, Myelogenous, Chronic,

2002
[The effect of insulin on chemotherapeutic drug sensitivity in human esophageal and lung cancer cells].
    Zhonghua yi xue za zhi, 2003, Feb-10, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Drug Interactions; Esophageal Neoplasms; Etoposide

2003
Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats.
    Cancer research, 2003, Jul-01, Volume: 63, Issue:13

    Topics: Adenocarcinoma; Animals; Colorectal Neoplasms; Disease Models, Animal; Female; Fluorine Radioisotope

2003
[First-line metastatic cancer of the colon].
    Gastroenterologie clinique et biologique, 2003, Volume: 27, Issue:5 Suppl

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bio

2003
[Modeling 5-FU clearance during a chronomodulated infusion].
    Pathologie-biologie, 2003, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Cancer, Regional Perfusion; Chronothe

2003
[Ureteral adenocarcinoma in men: a case report].
    Annales d'urologie, 2003, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality

2003
Safety and toxicity analysis of oxaliplatin combined with fluorouracil or as a single agent in patients with previously treated advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Aug-01, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2003
[A case report of complete remission of liver metastases from colorectal cancer treated with continuous hepatic arterial infusion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined Modal

2003
The addition of continuous infusion 5-FU to preoperative radiation therapy increases tumor response, leading to increased sphincter preservation in locally advanced rectal cancer.
    International journal of radiation oncology, biology, physics, 2003, Sep-01, Volume: 57, Issue:1

    Topics: Academic Medical Centers; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Chemotherapy,

2003
[Cancer of the gastric antrum].
    Journal de chirurgie, 2003, Volume: 140, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; Combined Modality Therapy; Fluorourac

2003
Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports.
    British journal of cancer, 2003, Aug-18, Volume: 89, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Aged; Anticonvulsants; Antimetabolites, Antineoplastic; Breast

2003
[Effect of the change of caspase-3 activity on the neoadjuvant chemotherapy-induced apoptosis of large-intestinal carcinoma cells].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 2003, Volume: 28, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Camptothecin

2003
Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
    Neoplasma, 2003, Volume: 50, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cispl

2003
[A case of advanced gastric cancer with liver and intra-abdominal lymph node metastasis treated by hypertensive selective chemotherapy with pharmacokinetic modulating chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:8

    Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil;

2003
P27 does not predict histopathological response to radiochemotherapy in rectal cancer.
    The Journal of surgical research, 2003, Volume: 113, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Cycle Proteins

2003
Arterial infusion chemotherapy for the patient of unresectable pancreatic carcinoma with multiple liver metastases: a case report.
    The journal of medical investigation : JMI, 2003, Volume: 50, Issue:3-4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fatal Outcome; Fluo

2003
Comparison of rapid and slow intravenous administration of 5-fluorouracil in treating patients with advanced carcinoma of the large intestine.
    Cancer chemotherapy reports, 1962, Volume: 25

    Topics: Adenocarcinoma; Administration, Intravenous; Colonic Diseases; Fluorouracil; Humans; Intestinal Neop

1962
COORDINATED SURGICAL-CHEMICAL THERAPY OF CANCER.
    JAMA, 1963, Nov-09, Volume: 186

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; DNA; DNA, Neoplasm; Fluorouracil;

1963
5-FLUOROURACIL TREATMENT OF LIVER METASTASES BY CONTINUOUS HEPATIC ARTERY INFUSION VIA COURNAND CATHETER: RESULTS AND SUITABILITY FOR INTENSIVE POSTSURGICAL ADJUVANT CHEMOTHERAPY.
    Annals of surgery, 1963, Volume: 158

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Gast

1963
DISSEMINATED GEOTRICHOSIS; CASE REPORT.
    Archives of internal medicine, 1964, Volume: 113

    Topics: Adenocarcinoma; Aged; Colitis; Colonic Neoplasms; Fluorouracil; Geotrichosis; Humans; Mycoses; Patho

1964
ADENOCARCINOMA OF THE RETE TESTIS.
    The Journal of urology, 1964, Volume: 91

    Topics: Adenocarcinoma; Fluorouracil; Geriatrics; Humans; Male; Radiotherapy; Rete Testis; Surgical Procedur

1964
CHEMOTHERAPEUTIC STUDIES WITH OSTEOGENIC SARCOMA HE10734.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Carcinoma, Hepatocellular; Fl

1964
VINCRISTINE (NSC-67574) THERAPY OF ADULT PATIENTS WITH SOLID TUMORS.
    Cancer chemotherapy reports, 1964, Volume: 34

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoid Tumor; Carcinoma, Bronchogenic; Carcinoma, Squamous

1964
ACUTE GASTRITIS RESULTING FROM REGIONAL INFUSION OF AN ANTIMETABOLITE.
    Bulletin of gastrointestinal endoscopy, 1963, Volume: 9

    Topics: Adenocarcinoma; Angiography; Antimetabolites; Chemotherapy, Cancer, Regional Perfusion; Diagnosis, D

1963
A REPORT OF THE SYSTEMIC USE OF 5-FLUOROURACIL IN THE TREATMENT OF CHINESE CANCER PATIENTS.
    British journal of cancer, 1964, Volume: 18

    Topics: Adenocarcinoma; Aged; Breast Neoplasms; Carcinoma; Carcinoma, Squamous Cell; China; Fallopian Tube N

1964
PALLIATIVE MANAGEMENT OF GASTROINTESTINAL CANCER.
    Canadian Medical Association journal, 1964, May-30, Volume: 90

    Topics: Adenocarcinoma; Ascites; Deglutition Disorders; Fluorouracil; Humans; Neoplasm Metastasis; Neoplasms

1964
[PRESENT POSSIBILITIES OF CHEMOPROPHYLAXIS, COMPLEMENTARY AND PALLIATIVE CHEMOTHERAPY IN ASSOCIATION WITH SURGERY IN THE TREATMENT OF UTERINE NEOPLASMS].
    Rivista di ostetricia e ginecologia, 1964, Volume: 19

    Topics: Adenocarcinoma; Antineoplastic Agents; Aziridines; Chemoprevention; Female; Fluorouracil; Humans; Mi

1964
CLINICAL STUDIES OF COMBINED CHEMOTHERAPY AND IRRADIATION IN INOPERABLE BRONCHOGENIC CARCINOMA.
    The American journal of roentgenology, radium therapy, and nuclear medicine, 1964, Volume: 92

    Topics: Adenocarcinoma; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide; Fluo

1964
5-FLUOURACIL IN THE TREATMENT OF DISSEMINATED COLON AND RECTAL CARCINOMA.
    The New Zealand medical journal, 1964, Volume: 63

    Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Geriatrics; Neoplasm Metastasis; Pharmacology; Rect

1964
REGIONAL INTRA-ARTERIAL INFUSION OF 5-FLUOROURACIL FOR CANCER.
    Surgery, 1964, Volume: 56

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Carcinoma, Squamous Cell; Female; Fluorouracil; Glioblast

1964
ACUTE CEREBELLAR SYNDROME SECONDARY TO 5-FLUOROURACIL THERAPY.
    Neurology, 1964, Volume: 14

    Topics: Abdominal Neoplasms; Adenocarcinoma; Bone Neoplasms; Carcinoma; Carcinoma, Bronchogenic; Carcinoma,

1964
STUDIES IN THE TOXICITY AND CLINICAL APPLICATION OF 5-FLUOROURACIL.
    The Medical journal of Australia, 1964, Oct-10, Volume: 2

    Topics: Adenocarcinoma; Agranulocytosis; Biomedical Research; Diarrhea; Diverticulitis; Drug Eruptions; Fluo

1964
CLINICAL EXPERIENCE WITH PALLIATION OF METASTATIC ADENOCARCINOMA WITH 5-FLUOROURACIL CHEMOTHERAPY.
    American journal of surgery, 1964, Volume: 108

    Topics: Adenocarcinoma; Bone Neoplasms; Breast Neoplasms; Colonic Neoplasms; Dextropropoxyphene; Fluorouraci

1964
COMBINED 5-FLUOROURACIL AND SUPERVOLTAGE RADIATION THERAPY IN THE PALLIATIVE MANAGEMENT OF ADVANCED GASTROINTESTINAL CANCER: A PILOT STUDY.
    Mayo Clinic proceedings, 1964, Volume: 39

    Topics: Adenocarcinoma; Biomedical Research; Cobalt Isotopes; Drug Therapy; Fluorouracil; Gastrointestinal N

1964
EFFECTIVENESS AND TOXICITY OF PROLONGED INFUSIONS OF 5-FLUOROURACIL IN THE TREATMENT OF CANCER.
    The American journal of the medical sciences, 1965, Volume: 249

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma; Carcinoma, Sq

1965
COMPARISON OF THE EFFECTS OF CHEMOTHERAPY AND LOCAL IRRADIATION ON THE VASCULARITY OF A TRANSPLANTED MOUSE MAMMARY ADENOCARCINOMA AND A PLEOMORPHIC SARCOMA.
    Radiology, 1965, Volume: 84

    Topics: Adenocarcinoma; Angiography; Animals; Blood Vessels; Fluorouracil; Mammary Neoplasms, Animal; Mammar

1965
RECTAL MUCOSAL BIOPSY IN THE EVALUATION OF CANCER CHEMOTHERAPY.
    The American journal of the medical sciences, 1965, Volume: 249

    Topics: Adenocarcinoma; Biopsy; Cecal Neoplasms; Drug Therapy; Fluorouracil; Humans; Mucous Membrane; Neopla

1965
TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
    Radiology, 1965, Volume: 84

    Topics: Adenocarcinoma; Colonic Neoplasms; Double-Blind Method; Drug Therapy; Fluorouracil; Humans; Neoplasm

1965
COMPARISON OF 5-FLUOROURACIL (NSC-19893) AND 2'-DEOXY-5-FLUOROURIDINE (NSC-27640) IN TREATMENT OF PATIENTS WITH ADVANCED ADENOCARCINOMA OF COLON OR RECTUM.
    Cancer chemotherapy reports, 1965, Volume: 44

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Deoxyuridine; Drug Therapy; Fluorouracil;

1965
SYSTEMIC CHEMOTHERAPY FOR CNS METASTASES OF SOLID TUMORS.
    Archives of internal medicine, 1965, Volume: 115

    Topics: Adenocarcinoma; Brain Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Therapy; Floxuridine; Fluo

1965
Clinical studies with 5-fluorouracil in 47 patients.
    The American journal of the medical sciences, 1962, Volume: 244

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma; Carcinoma, Squamous Cell; Fluorourac

1962
Expression of CEACAM6 in resectable colorectal cancer: a factor of independent prognostic significance.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Oct-01, Volume: 21, Issue:19

    Topics: Adenocarcinoma; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Neoplasm; Antineo

2003
[Liposome encapsulation of cystostatic drugs and starch microspheres improve tumor targeting in locoregional therapy. An animal experiment study of CC 531 liver tumor].
    Langenbecks Archiv fur Chirurgie. Supplement. Kongressband. Deutsche Gesellschaft fur Chirurgie. Kongress, 1998, Volume: 115, Issue:Suppl I

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Delivery System

1998
[A case of multiple liver metastases from colon cancer successfully treated with pharmacokinetic modulating chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop

2003
Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Sep-15, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluorouracil;

2003
Identification and functional analysis of single nucleotide polymorphism in the tandem repeat sequence of thymidylate synthase gene.
    Cancer research, 2003, Sep-15, Volume: 63, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm

2003
Acute severe coronary spasm associated with initial first dose of 5-fluorouracil chemotherapy.
    Italian heart journal : official journal of the Italian Federation of Cardiology, 2003, Volume: 4, Issue:8

    Topics: Acute Disease; Adenocarcinoma; Chemotherapy, Adjuvant; Colonic Neoplasms; Coronary Angiography; Coro

2003
[A case of resected spinal metastasis following colectomy and hepatectomy for descending colon carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colectomy; Colo

2003
[A case of hepatic metastasis and local recurrence from rectal cancer responding to hepatic arterial infusion and systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat

2003
[A case of spinal infarction related to hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothec

2003
[A case of locally extended rectal carcinoma quickly responding to local intraarterial infusion therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

2003
[Two patients with metastatic ovarian tumor (Krukenberg's tumor) of gastric origin who underwent oophorectomy with paraaortic and intrapelvic lymph node dissection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Aorta; Camptothecin; Carcinom

2003
Preliminary results on the influence of chemoradiation on apparent diffusion coefficients of primary rectal carcinoma measured by magnetic resonance imaging.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2003, Volume: 179, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Catheterization, Central Venous; Combi

2003
Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to oxaliplatin combination chemotherapy: implications for tumor marker monitoring and guidelines.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003, Dec-01, Volume: 21, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoembryonic

2003
[A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr

2003
[A case of gastric carcinoma with multiple skin, bone, and bilateral ovary metastasis; effective treatment by chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin;

2003
Rectal adenocarcinoma with germ-cell differentiation: report of a case.
    Diseases of the colon and rectum, 2003, Volume: 46, Issue:12

    Topics: Adenocarcinoma; Adult; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Bleomycin

2003
A novel cell line and xenograft model of ampulla of Vater adenocarcinoma.
    Virchows Archiv : an international journal of pathology, 2004, Volume: 444, Issue:3

    Topics: Adenocarcinoma; Ampulla of Vater; Animals; Cell Adhesion; Common Bile Duct Neoplasms; Deoxycytidine;

2004
Uptake of 5-fluorouracil (5-FU) in peritoneal metastases in relation to the route of drug administration and tumour debulking surgery. an autoradiographic study in the rat.
    European journal of cancer (Oxford, England : 1990), 2004, Volume: 40, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Autoradiography; Colonic Neoplasms; Female

2004
Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Dec-15, Volume: 9, Issue:17

    Topics: Adenocarcinoma; Aged; bcl-2-Associated X Protein; Cisplatin; Combined Modality Therapy; Disease-Free

2003
Complete pathologic responses to preoperative chemoradiation in two patients with adenocarcinoma of the pancreas.
    Pancreas, 2004, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2004
Choroidal metastasis from adenocarcinoma of the esophagus.
    Retina (Philadelphia, Pa.), 2003, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Choroid Neoplasms

2003
Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer.
    Japanese journal of clinical oncology, 2003, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2003
[A case of parotid carcinoma with hepatic metastasis that responded remarkably to combination chemotherapy of docetaxel, cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administr

2003
[A case of advanced gastric cancer with multiple liver metastases responding completely to hepatic arterial infusion and systemic chemotherapies].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2003, Volume: 30, Issue:13

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoth

2003
Chemoembolization of rat liver metastasis with irinotecan and quantification of tumor cell reduction.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:4

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot

2004
[A case of rectal cancer with distant lymph node metastases completely responding to postoperative chemotherapy with levofolinate combined with 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female

2004
Short-time infusion of oxaliplatin (Eloxatin) in combination with capecitabine (Xeloda) in patients with advanced colorectal cancer.
    Acta oncologica (Stockholm, Sweden), 2003, Volume: 42, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

2003
Outcome of rectal and sigmoid carcinoma patients receiving adjuvant chemoradiotherapy in Marmara University Hospital.
    Journal of chemotherapy (Florence, Italy), 2003, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Chemotherapy, Adjuvant; Colectomy; Combined Modality Therap

2003
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Mar-01, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Aorta, Thoracic; Colonic Neoplasms; Deoxyr

2004
Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Cis

2004
[A case of advanced gastric cancer with DIC treated by sequential MTX and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated I

2004
[A case of gastric cancer with a synchronous hepatic metastasis responding to postoperative oral administration of UFT and intermittent intrahepatic arterial chemotherapy of 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm

2004
[A case of advanced colon cancer with metastases to both the Virchow's and the paraaortic lymph nodes that achieved complete long-term response with levofolinate.5-FU therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Colonic Neoplasms;

2004
[A case report of colon cancer with liver and lung metastases responding to combination chemotherapy with l-LV, 5-fluorouracil and CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasms; Dru

2004
[A case of highly advanced ascending colon cancer with multiple bone and liver metastases and pleuritis carcinomatosa treated with pharmacokinetic modulating chemotherapy and low-dose CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Coloni

2004
Recursive partitioning analysis of pretreatment variables of 416 patients with locoregional esophageal cancer treated with definitive concomitant chemoradiotherapy on Intergroup and Radiation Therapy Oncology Group trials.
    International journal of radiation oncology, biology, physics, 2004, Apr-01, Volume: 58, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2004
Down-regulation of thymidylate synthase expression and its steady-state mRNA by oxaliplatin in colon cancer cells.
    Anti-cancer drugs, 2004, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Blotting, Western; Calorimet

2004
The potential role of TGFbeta1, TGFbeta2 and TGFbeta3 protein expression in colorectal carcinomas. Correlation with classic histopathologic factors and patient survival.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2004, Volume: 180, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2004
Adenocarcinoma of the salivary gland? A chemo-sensitive disease.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorouracil;

2004
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
    The Journal of pathology, 2004, Volume: 202, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Carr

2004
Growth hormone protects the intestines but not the tumour from 5-fluorouracil toxicity in the short term in the rat.
    European journal of gastroenterology & hepatology, 2004, Volume: 16, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Bacterial Translocation; Body W

2004
Adjuvant chemotherapy for adenocarcinoma of the lung--is the standard of care ready for change?
    The New England journal of medicine, 2004, Apr-22, Volume: 350, Issue:17

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chem

2004
A rare life-threatening complication of migrated nitinol self-expanding metallic stent (Ultraflex).
    Surgical endoscopy, 2004, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Aged; Alloys; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther

2004
[Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

2004
5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.
    The journal of gene medicine, 2004, Volume: 6, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Pro

2004
Comparison between triple therapy with octreotide, galanin and serotonin, 5-fluorouracil/leucovorin, and sequential treatment with both, on human colon cancer.
    Oncology reports, 2004, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; C

2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer.
    International journal of radiation oncology, biology, physics, 2004, Jun-01, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Combined Modality Therap

2004
Complete remission of metastatic pancreatic cancer with cardiac involvement after gemcitabine, oxaliplatin and 46-h infusion of 5-fluorouracil/leucovorin.
    Journal of gastroenterology and hepatology, 2004, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2004
An immediate hemolytic reaction induced by repeated administration of oxaliplatin.
    Transfusion, 2004, Volume: 44, Issue:6

    Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antibody Specificity; Antigens; Antineoplastic Agents

2004
Preoperative induction of CPT-11 and cisplatin chemotherapy followed by chemoradiotherapy in patients with locoregional carcinoma of the esophagus or gastroesophageal junction.
    Cancer, 2004, Jun-01, Volume: 100, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma

2004
[A case of colon carcinoma with unresectable multiple liver metastases responding to various combined chemotherapies centering on hepatic arterial infusion therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colo

2004
Sustained complete remission of metastatic oesophageal adenocarcinoma using long-term therapy with 5-fluorouracil.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:7

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Doxorubicin; Esophageal Neoplasms; Fluorourac

2004
Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines.
    Journal of cancer research and clinical oncology, 2004, Volume: 130, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cam

2004
Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil.
    International journal of clinical oncology, 2004, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

2004
Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy.
    International journal of clinical oncology, 2004, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeuti

2004
Reversal of 5-flouroucial resistance by adenovirus-mediated transfer of wild-type p53 gene in multidrug-resistant human colon carcinoma LoVo/5-FU cells.
    World journal of gastroenterology, 2004, Jul-01, Volume: 10, Issue:13

    Topics: Adenocarcinoma; Adenoviridae; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Sub

2004
[A case of curatively resected gastric cancer through an effective response to chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration

2004
Changes in thymidylate synthase and its inhibition rate and changes in dihydropyrimidine dehydrogenase after the administration of 5-fluorouracil with cisplatin to nude mice with gastric cancer xenograft SC-1-NU.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2004, Volume: 7, Issue:2

    Topics: Adenocarcinoma; Animals; Cisplatin; Dihydrouracil Dehydrogenase (NADP); Drug Therapy, Combination; F

2004
[Mitomycin-induced hemolytic uremia syndrome].
    Deutsche medizinische Wochenschrift (1946), 2004, Jul-02, Volume: 129, Issue:27

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Do

2004
A study of radiotherapy modalities combined with continuous 5-FU infusion for locally advanced gastrointestinal malignancies.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2004, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Digestive System Surg

2004
Immunohistochemical analysis of thymidylate synthase, p16(INK4a), cyclin-dependent kinase 4 and cyclin D1 in colorectal cancers receiving preoperative chemotherapy: significance of p16(INK4a)-mediated cellular arrest as an indicator of chemosensitivity to
    Pathology international, 2004, Volume: 54, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplasti

2004
Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
    Anti-cancer drugs, 2004, Volume: 15, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Ci

2004
[A case of advanced colon cancer responding to l-LV+5-FU as neoadjuvant chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colectomy; C

2004
[Successful treatment of 5-FU intraarterial infusion on the third postoperative day for a patient with multiple liver metastases from colon cancer and high risk of liver failure].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Benzimidazoles; Colectomy; Colonic Neoplasms;

2004
[A case of advanced descending colon cancer with peritoneal dissemination responding to weekly high-dose l-leucovorin/5-fluorouracil combination therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respon

2004
Estrogen receptor-associated expression of keratinocyte growth factor and its possible role in the inhibition of apoptosis in human breast cancer.
    Laboratory investigation; a journal of technical methods and pathology, 2004, Volume: 84, Issue:11

    Topics: Adenocarcinoma; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Lin

2004
[A case of hepatic metastasis from colon cancer successfully treated with 5-FU, levofolinate (l-LV) and low-dose CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad

2004
[A successfully resected case of colorectal cancer with multiple liver metastases treated with systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Colon, Sigm

2004
[Long-term control of rectal liver metastases by hepatic arterial infusion chemotherapy of 5-fluorouracil and l-leucovorin--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru

2004
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer.
    The Annals of thoracic surgery, 2004, Volume: 78, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dise

2004
ECF in gastric cancer.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2004, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin; Fluorou

2004
[Five cytostatic substances in animal studies for prevention and treatment of experimentally induced peritoneal carcinomatosis].
    Zentralblatt fur Chirurgie, 2004, Volume: 129, Issue:4

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti

2004
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome.
    International journal of gastrointestinal cancer, 2003, Volume: 34, Issue:2-3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deox

2003
Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer.
    British journal of cancer, 2004, Oct-18, Volume: 91, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; E

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.
    Annals of surgery, 2004, Volume: 240, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

2004
[Adjuvant chemotherapy for unresectable locally advanced pancreatic cancer in light of its characteristics].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Deoxyc

2004
[A case of metastatic liver tumor from colorectal carcinoma--continued arterial infusion chemotherapy through a microcatheter located in replaced right hepatic artery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Catheters, Indwe

2004
[Bilateral shoulder-hand syndrome revealing hypothyroidism and colon carcinoma].
    Praxis, 2004, Aug-18, Volume: 93, Issue:34

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Diagnosi

2004
[Preoperative chemoradiation in esophageal cancer: experience of a single center in 102 patients].
    Zentralblatt fur Chirurgie, 2004, Volume: 129, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2004
Fluorouracil-induced neurotoxicity presenting with generalized tonic-clonic seizure.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:12

    Topics: Adenocarcinoma; Anticonvulsants; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Male; Middle

2004
Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Oct-15, Volume: 10, Issue:20

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Sq

2004
[A case of rectal cancer with multiple liver and peritoneal metastases that responded dramatically to low-dose 5-FU plus LV and CDDP combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2004
Guillain-Barré syndrome in a patient with metastatic colon cancer receiving oxaliplatin-based chemotherapy.
    Anti-cancer drugs, 2004, Volume: 15, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Guillain-Barre Syndrome; Hum

2004
Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients.
    International journal of radiation oncology, biology, physics, 2004, Nov-15, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2004
Vasospastic angina caused by 5-fluorouracil. A case report.
    Romanian journal of internal medicine = Revue roumaine de medecine interne, 2003, Volume: 41, Issue:4

    Topics: Adenocarcinoma; Aged; Angina Pectoris; Antimetabolites, Antineoplastic; Colonic Neoplasms; Coronary

2003
Thymidylate synthase, thymidine phosphorylase, dihydropyrimidine dehydrogenase expression, and histological tumour regression after 5-FU-based neo-adjuvant chemoradiotherapy in rectal cancer.
    The Journal of pathology, 2004, Volume: 204, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Combined Modality Therapy; D

2004
Effects of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate.
    Gut, 2004, Volume: 53, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Cell Survival; Colonic Neoplasms; Do

2004
Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs.
    Journal of the National Cancer Institute, 2004, Nov-17, Volume: 96, Issue:22

    Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenocarcinoma; Animals; Antineoplastic Agents; Benzimidazo

2004
Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
    Medicina (Kaunas, Lithuania), 2004, Volume: 40, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Deoxycytidine; Fem

2004
Use of cisplatin, 5-fluorouracil, and second-look laparotomy for the management of gastrointestinal adenocarcinoma in three dogs.
    Journal of the American Veterinary Medical Association, 2004, Nov-01, Volume: 225, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Dogs; Female; Fluorouracil; Gastrointesti

2004
[A case of gastric cancer patient with liver metastasis treated by radiofrequency ablation therapy combined with intra-arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheter Ablation; Cisplatin;

2004
[A case of unresectable multiple liver metastases from colon cancer successfully treated by hepatic arterial infusion chemotherapy and systemic immunotherapy (IFNANK) followed by hepatic resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms;

2004
[A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2004
[A case of disseminated tumor from cecal cancer with survival for over 5 years after twice surgical resection and systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoembryonic

2004
[Palliative surgery combined with oxaliplatin-based chemotherapy in treatment of patients with advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:11 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2004
[A case of advanced colon cancer responding completely to systemic 5-fluorouracil/l-leucovorin therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2004, Volume: 31, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colostomy;

2004
5-FU-induced acute leukoencephalopathy.
    Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:10

    Topics: Acute Disease; Adenocarcinoma; Antimetabolites, Antineoplastic; Brain Diseases; Colonic Neoplasms; F

2004
Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
    International journal of radiation oncology, biology, physics, 2004, Dec-01, Volume: 60, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot

2004
Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant.
    Onkologie, 2004, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cecal Neoplasms; Dihydropyrimidine Dehydrogenase Defic

2004
[Biweekly regimen of high dose of leucovorin, 5-fluorouracil, and paclitaxel for patients with advanced gastric cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2004, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

2004
Long-term survival after salvage surgery for colorectal lung metastases.
    The Annals of thoracic surgery, 2005, Volume: 79, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2005
Complete pathologic response following preoperative chemoradiation therapy for middle to lower rectal cancer is not a prognostic factor for a better outcome.
    Diseases of the colon and rectum, 2004, Volume: 47, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chi-Square

2004
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Long-term results of preoperative chemoradiation for distal rectal cancer correlation between final stage and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2005, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorouracil; Humans;

2005
Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
    Diseases of the colon and rectum, 2004, Volume: 47, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2004
Coronary artery spasm induced by 5-fluorouracil.
    Zeitschrift fur Kardiologie, 2005, Volume: 94, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Coronary Angiograph

2005
[Two cases of gastric cancer with multiple liver metastases responding to TS-1 with hepatic arterial infusion of CDDP following low-dose 5-FU and CDDP chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relat

2005
[A case of advanced rectal cancer responding to 5-fluorouracil based preoperative chemoradiation therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administratio

2005
Concurrent proton beam radiotherapy and systemic chemotherapy for the metastatic liver tumor of gastric carcinoma: a case report.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2005
Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma.
    Cancer, 2005, Mar-15, Volume: 103, Issue:6

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Colectomy; Colorectal Neoplasms; Dose-Response Relatio

2005
Effective gene therapy of biliary tract cancers by a conditionally replicative adenovirus expressing uracil phosphoribosyltransferase: significance of timing of 5-fluorouracil administration.
    Cancer research, 2005, Jan-15, Volume: 65, Issue:2

    Topics: Adenocarcinoma; Adenoviridae; Animals; Female; Fluorouracil; Gallbladder Neoplasms; Genetic Therapy;

2005
Common etiology of capecitabine and fluorouracil-induced coronary vasospasm in a colon cancer patient.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Coronary Vasospasm

2005
Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
    Cancer, 2005, Apr-01, Volume: 103, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Chola

2005
[Influence of chemotherapy on Th1/Th2 cytokine switching in stomach cancer patients].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2004, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

2004
Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer.
    Journal of the American College of Surgeons, 2005, Volume: 200, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc

2005
Postoperative chemoradiotherapy after surgical resection of gastric adenocarcinoma: can LV5FU2 reduce the toxic effects of the MacDonald regimen? A report on 23 patients.
    Gastroenterologie clinique et biologique, 2005, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

2005
Radiotherapy for uterine cervical cancer: results of the 1995-1997 patterns of care process survey in Japan.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo

2005
[A case of liver metastases from cecal cancer successfully treated with fluorouracil and folinic acid (UFT/LV)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cecal Neoplasms; Chemotherapy,

2005
[Pharmacokinetic modulating chemotherapy for rectal carcinoma metastases to the liver and lung--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru

2005
Lymph node micrometastasis in stage II distal rectal cancer following neoadjuvant chemoradiation therapy.
    International journal of colorectal disease, 2005, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2005
An increasingly common challenge: management of the complete responder with multi-focal metastatic colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Female; Fluoro

2005
The effects of capecitabine in Raynaud's disease: a case report.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Capecitabine; Deoxycytidine; Fluorouracil; Follow-Up Studie

2005
High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Mar-15, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2005
[A case of bilateral multiple liver metastases with distant lymph node metastases due to rectal cancer successfully treated with hepatic arterial infusion (HAI) of levofolinate (l-LV)/5-fluorouracil (5-FU) and radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr

2005
[Minutes of the 23th meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO). Amsterdam, 24-28 October 2004].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2005, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amifostine; Antineoplastic Agents, Hormonal; Antineo

2005
Increasing warfarin dosage reductions associated with concurrent warfarin and repeated cycles of 5-Fluorouracil therapy.
    Pharmacotherapy, 2005, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Anticoagulants; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Synergism;

2005
Clinical experience with chronomodulated infusional 5-fluorouracil chemoradiotherapy for pancreatic adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2005, May-01, Volume: 62, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; C

2005
Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma.
    International journal of colorectal disease, 2005, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2005
5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case.
    Journal of clinical pathology, 2005, Volume: 58, Issue:5

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopl

2005
Therapy for colorectal cancer.
    The New England journal of medicine, 2005, Apr-28, Volume: 352, Issue:17

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neoplasms

2005
Preoperative radio-chemotherapy treatment in locally advanced rectal carcinoma. Results of 8-year follow-up.
    Onkologie, 2005, Volume: 28, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Disease-Free Survival; Dose Fractionat

2005
Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Oncology reports, 2005, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2005
Synergistic effects of matrine and 5-fluorouracil on tumor growth of the implanted gastric cancer in nude mice.
    Chinese journal of digestive diseases, 2005, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Alkaloids; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogen

2005
Modulation of multidrug resistance by andrographolid in a HCT-8/5-FU multidrug-resistant colorectal cancer cell line.
    Chinese journal of digestive diseases, 2005, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Andrographis; Apoptosis; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Mu

2005
Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Gruppo Oncologico dell'Italia Meridionale (GOIM) prospective study.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2005, Volume: 16 Suppl 4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2005
Radiation dose considerations in the palliative treatment of locally advanced adenocarcinoma of the pancreas.
    American journal of clinical oncology, 2005, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2005
Complete pathologic response after chemoradiation for rectal cancer.
    Diseases of the colon and rectum, 2005, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Fluorouracil; Hu

2005
Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma.
    Cancer chemotherapy and pharmacology, 2005, Volume: 56, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Line,

2005
[Expression of metabolic enzymes of fluoropyrimidines in primary colorectal cancer and its clinical significance].
    Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2005, Jun-18, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Colorec

2005
Survival after attempted surgical resection and intraoperative radiation therapy for pancreatic and periampullary adenocarcinoma.
    International journal of radiation oncology, biology, physics, 2005, Nov-15, Volume: 63, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Chemotherapy, Adjuvant; Combined M

2005
[TS-1 treatment for progressive gastric cancer in a patient on chronic dialysis--assessment of dosage regimen by monitoring blood concentrations of therapeutic drugs (TDM)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Area Under Curve; Drug Administration Schedu

2005
[A case of metastatic submandibular lymphnode treated successfully with palliative oral (5-FU + PSK) chemotherapy in the elderly].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

2005
Apoptosis induced by aspirin and 5-fluorouracil in human colonic adenocarcinoma cells.
    Digestive diseases and sciences, 2005, Volume: 50, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Aspirin; bcl-2-Associated X Protein; Cell Line, Tu

2005
Case records of the Massachusetts General Hospital. Case 20-2005. A 58-year-old man with locally advanced pancreatic cancer.
    The New England journal of medicine, 2005, Jun-30, Volume: 352, Issue:26

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm, Abdominal; Deoxycyt

2005
Early occurrence of chylothorax related to thoracic irradiation and concomitant chemotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:4

    Topics: Adenocarcinoma; Ampulla of Vater; Antineoplastic Combined Chemotherapy Protocols; Chylothorax; Cispl

2005
Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer.
    JOP : Journal of the pancreas, 2005, Jul-08, Volume: 6, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Neuroendocrin

2005
Combined-modality neoadjuvant therapy for rectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic;

2005
Chemoradiotherapy for locally advanced pancreatic carcinoma in elderly patients.
    Oncology, 2005, Volume: 68, Issue:4-6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2005
Inflammatory breast cancer in a male.
    The New Zealand medical journal, 2005, Jul-15, Volume: 118, Issue:1218

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Cyclophospha

2005
Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 2005, Aug-01, Volume: 62, Issue:5

    Topics: Abdominal Pain; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Back Pa

2005
Unbiased estimation of tumor regression rates during chemoradiotherapy for esophageal carcinoma using CT and stereology.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2005, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

2005
Neoadjuvant chemoradiotherapy for esophageal carcinoma.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2005, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2005
Is adjuvant therapy with three-dimensional conformal irradiation combined with capecitabine (Xeloda) for gastric cancer effective?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2005, Volume: 37, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Fluorouracil; Humans;

2005
Technique and long-term results of intersphincteric resection for low rectal cancer.
    Diseases of the colon and rectum, 2005, Volume: 48, Issue:10

    Topics: Adenocarcinoma; Adenoma, Villous; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols;

2005
Anemia is the strongest prognostic factor for outcomes of 5-fluorouracil-based first-line chemotherapy in patients with advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Anemia; Disease-Free Survival; Female; Fluorouracil; Hemoglobins; Human

2006
An audit of postoperative radiotherapy after non-curative resection for cancer of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality The

2005
Tumor response to neoadjuvant chemoradiation therapy for rectal adenocarcinoma is mediated by p53-dependent and caspase 8-dependent apoptotic pathways.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers; Caspase 8; Caspases; F

2005
An observational study suggesting clinical benefit for adjuvant postoperative chemoradiation in a population of over 500 cases after gastric resection with D2 nodal dissection for adenocarcinoma of the stomach.
    International journal of radiation oncology, biology, physics, 2005, Dec-01, Volume: 63, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro

2005
[Reversible cardiogenic shock under 5-fluorouracil treatment].
    Annales de cardiologie et d'angeiologie, 2005, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Car

2005
Serpentine supravenous streaks induced by 5-fluorouracil.
    Journal of the American Academy of Dermatology, 2005, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Hyperpigmentation; Inf

2005
[Four cases of advanced colorectal cancer successfully treated with irinotecan plus 5-fluorouracil and l-leucovorin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:8

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineopla

2005
Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
    Journal of the American College of Surgeons, 2005, Volume: 201, Issue:3

    Topics: Adenocarcinoma; Algorithms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Fluorourac

2005
Activated nuclear factor-kappa B and cytokine profiles in the esophagus parallel tumor regression following neoadjuvant chemoradiotherapy.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2005, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

2005
Pseudomembranous colitis associated with chemotherapy with 5-fluorouracil.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clostridioides difficile; Dihydropyrimidine Dehydro

2005
Feasibility of chemoradiation therapy with protracted infusion of 5-fluorouracil for esophageal cancer patients not suitable for cisplatin.
    International journal of clinical oncology, 2005, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcinoma, Squamous Cell;

2005
Locally advanced pancreatic cancer treated with radiation and 5-fluorouracil: a first step to neoadjuvant treatment?
    Digestive surgery, 2005, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Digestive System Surgical Pro

2005
The reliability of lymph-node staging in rectal cancer after preoperative chemoradiotherapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2005, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2005
Second-line chemotherapy of advanced disseminated gastric cancer after cisplatin, infusional 5-fluorouracil, folinic acid (PLF): benefit dependent on progression-free interval after first-line therapy.
    Onkologie, 2005, Volume: 28, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Fe

2005
Predicting recurrence risk for synchronous primary colon cancers.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Case Management; Cecal N

2004
Current and future strategies for treating metastatic pancreatic cancer.
    Clinical advances in hematology & oncology : H&O, 2004, Volume: 2, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineop

2004
Modulation of cell cycle and gene expression in pancreatic tumor cell lines by methionine deprivation (methionine stress): implications to the therapy of pancreatic adenocarcinoma.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Blotting, Wester

2005
Patient with angina secondary to capecitabine.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:7

    Topics: Adenocarcinoma; Angina Pectoris; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothera

2005
5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:1

    Topics: Acetates; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemothe

2006
The safety and usefulness of high-dose-rate endoluminal brachytherapy as a boost in the treatment of patients with esophageal cancer with external beam radiation with or without chemotherapy.
    International journal of radiation oncology, biology, physics, 2005, Nov-01, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

2005
Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

2005
Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer.
    Cancer research, 2005, Oct-01, Volume: 65, Issue:19

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Apoptosis; Camptothecin; Cell Line, Tumor; Colorectal Neopla

2005
Immunohistochemical expression of thymidylate synthase as predictor of response to capecitabine in patients with advanced colorectal adenocarcinoma.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2005, Volume: 113, Issue:9

    Topics: Adenocarcinoma; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Humans; Immunohisto

2005
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time.
    Journal of vascular and interventional radiology : JVIR, 2005, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplasti

2005
Preoperative chemoradiation of locally advanced T3 rectal cancer combined with an endorectal boost.
    International journal of radiation oncology, biology, physics, 2006, Feb-01, Volume: 64, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bra

2006
[A case of colon cancer with multiple liver, lung and bone metastases successfully treated with combined weekly high-dose 5-FU (WHF) chemotherapy with UFT and CPT-11].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect

2005
Polymorphism at the 3'-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.
    International journal of radiation oncology, biology, physics, 2006, Mar-01, Volume: 64, Issue:3

    Topics: 3' Untranslated Regions; Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy;

2006
Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Oct-15, Volume: 11, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Calm

2005
Neoadjuvant chemoradiation to convert locally advanced pancreatic body adenocarcinoma to resectable disease.
    Clinical advances in hematology & oncology : H&O, 2003, Volume: 1, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bac

2003
[Establishment, characterization, and biological analysis of pancreatic adenocarcinoma cell strain SW1990/FU].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 2005, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Cycle; Cell Line, Tumor; Drug Resista

2005
Portal hypertension secondary to 90Yttrium microspheres: an unknown complication.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Nov-10, Volume: 23, Issue:32

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capeci

2005
Combination chemotherapy in advanced small bowel adenocarcinoma.
    Oncology, 2005, Volume: 69, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemothera

2005
[A case of cecal cancer with multiple liver metastases responding to irinotecan (CPT-11)/cisplatin (CDDP) combination therapy for elevation of CA19-9 after complete response (CR) by l-leucovorin(LV)/5-fluorouracil(5-FU) therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Camptothecin; Cecal

2005
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3 cm of the anal verge.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2006, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antimetabolites, Antineoplastic; Capecit

2006
Preoperative chemoradiation for rectal cancer causes prolonged pudendal nerve terminal motor latency.
    Diseases of the colon and rectum, 2006, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorouracil; Follow-U

2006
Cardiotoxicity resembling myocardial infarction that occurs during chemotherapy with 5-fluorouracil.
    Saudi medical journal, 2005, Volume: 26, Issue:11

    Topics: Adenocarcinoma; Adult; Chest Pain; Colonic Neoplasms; Diagnosis, Differential; Electrocardiography;

2005
Carcinoma of the jejunum with multideposit peritoneal seeding, resection and intraperitoneal chemotherapy.
    The West Indian medical journal, 2005, Volume: 54, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusions, Par

2005
[Safety and efficacy of hypotonic CDDP intraperitoneal administration for gastric cancer with peritoneal dissemination].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cisplatin; Drug Administration Schedule; Drug Therapy,

2005
[A case of breast cancer detected by MRI mammography after Hollywood syndrome].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Implants; Breast Neoplasms; C

2005
[A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2005, Volume: 32, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Camptothecin; Colorectal Neoplasms; Combined

2005
Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer.
    American journal of clinical oncology, 2005, Volume: 28, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Biopsy; Cohort Studies; Combined Modal

2005
Microsatellite instability and colorectal cancer prognosis.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Ant

2005
High cyclooxygenase-2 expression following neoadjuvant radiochemotherapy is associated with minor histopathologic response and poor prognosis in esophageal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-01, Volume: 11, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squa

2005
Thyroid metastasis from colorectal cancer: role of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography.
    Clinical colorectal cancer, 2005, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Colect

2005
Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Dec-15, Volume: 11, Issue:24 Pt 1

    Topics: 5'-Nucleotidase; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capecitabi

2005
Radiation therapy combined with cis-diammine-glycolatoplatinum (nedaplatin) and 5-fluorouracil for Japanese stage II-IV esophageal cancer compared with cisplatin plus 5-fluorouracil regimen: a retrospective study.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2006, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Cisplatin; Esophageal Ne

2006
Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy.
    Virchows Archiv : an international journal of pathology, 2006, Volume: 448, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Cell Transformation, Neopl

2006
Novel two-step resection for lesions between the middle hepatic vein and vena cava which allows the middle hepatic vein to be preserved.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2006, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

2006
Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2005, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Chemothera

2005
Concurrent oxaliplatin, capecitabine, and radiation therapy in the neoadjuvant therapy of rectal adenocarcinoma: can we get the right dose first?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2006, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Clinical Trials, Phase

2006
In vivo imaging of tumor response to therapy using a dual-modality imaging strategy.
    International journal of cancer, 2006, Jun-01, Volume: 118, Issue:11

    Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Biomarkers; Female; Fl

2006
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Combined Modality Therapy; Deoxycytidine; Femal

2005
Pharmacogenetics in esophageal cancer.
    Seminars in oncology, 2005, Volume: 32, Issue:6 Suppl 9

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Esophage

2005
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation.
    International journal of radiation oncology, biology, physics, 2006, Mar-15, Volume: 64, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2006
[A case of advanced rectal cancer responding to l-Leucovorin (LV)/5-fluorouracil( 5-FU) therapy as neoadjuvant chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis

2006
Serum CEA as a predictor for the response to preoperative chemoradiation in rectal cancer.
    Journal of surgical oncology, 2006, Feb-01, Volume: 93, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

2006
[Chronomodulated chemotherapy of oxaliplatin, 5-fluorouracil and folinic acid for advanced gastric cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2005, Volume: 27, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chronotherapy; Drug Adm

2005
Chronic cutaneous lupus flare induced by systemic 5-fluorouracil.
    The Journal of dermatological treatment, 2006, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Female; Fluorouracil; Humans; Lup

2006
Rectal adenocarcinoma with oncocytic features: possible relationship with preoperative chemoradiotherapy.
    Journal of clinical pathology, 2006, Volume: 59, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Fe

2006
Long-term survival after three-field lymph-adenectomy for an adenocarcinoma in Barrett's esophagus with metastasis to Virchow's node.
    The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi, 2006, Volume: 54, Issue:1

    Topics: Abdomen; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Ci

2006
[A case of postoperative liver metastasis from bile duct carcinoma responding to transarterial chemoembolization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Chemoembo

2006
Feasibility of 5-Fluorouracil resumption in a patient experiencing drug-induced acute Prinzmetal angina.
    Acta oncologica (Stockholm, Sweden), 2006, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Angina Pectoris, Variant; Electrocardiography; Fluorouracil; Humans; Male; Middle Ag

2006
Oxaliplatin-related acute myelogenous leukemia.
    The oncologist, 2006, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2006
[Coma following chemotherapy: is 5FU implicated? Discussion about on case-report].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cecal Neoplasms; Cecum; Coma; Fluorouracil; Humans;

2006
Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors.
    European journal of nuclear medicine and molecular imaging, 2006, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Biological Transport, Active; Cell Line, Tumor; Cell Survival; Cisplatin; Colonic Ne

2006
P53, COX-2, iNOS protein expression changes and their relationship with anti-oxidant enzymes in surgically and multi-modality treated esophageal carcinoma patients.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Blotting, Western

2006
Capecitabine chemoradiation for rectal cancer after curative surgery.
    Journal of chemotherapy (Florence, Italy), 2006, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Co

2006
Cyclin D1 antisense oligodexoyneucleotides inhibits growth and enhances chemosensitivity in gastric carcinoma cells.
    World journal of gastroenterology, 2006, Mar-21, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemoreceptor Cells; Ci

2006
Stunning and its effect on 3H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubici

2006
Anemia and long-term outcome in adjuvant and neoadjuvant radiochemotherapy of stage II and III rectal adenocarcinoma: the Freiburg experience (1989-2002).
    World journal of gastroenterology, 2006, Mar-28, Volume: 12, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protoco

2006
Neoadjuvant chemotherapy for locally advanced carcinoma of the lower oesophagus and oesophago-gastric junction.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2006, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2006
Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.
    International journal of radiation oncology, biology, physics, 2006, Jul-01, Volume: 65, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin;

2006
Effects of radiotherapy on different histopathological types of rectal carcinoma.
    Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland, 2006, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2006
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Algorithms; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic C

2006
Influence of hemoglobin levels on survival after radical treatment of esophageal carcinoma with radiotherapy.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma,

2006
Multiple periungual pyogenic granulomas following systemic 5-fluorouracil.
    The Australasian journal of dermatology, 2006, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Diagnosis, Differential; Fluorouracil; Granul

2006
[Neoadjuvant chemotherapy before radiotherapy in treatment of patients with cervical carcinoma].
    Zhonghua fu chan ke za zhi, 2006, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2006
Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum.
    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, 2006, Volume: 114, Issue:3

    Topics: Adenocarcinoma; Antigens, CD; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Ca

2006
Unpredicted severe toxicity after 5-fluorouracil treatment due to dihydropyrimidine dehydrogenase deficiency.
    The Korean journal of internal medicine, 2006, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Dihydropyrimidine De

2006
Damage assessment in gastric cancer treatment with adjuvant radiochemotherapy: calculation of the NTCP's from the differential HDV of the organs at risk.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2006
Intraventricular metastases from rectal-sigmoid adenocarcinoma.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2006, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cardiac Tamponad

2006
[Clinical observation on treatment of gastric cancer with zhijing granules: a report of 148 cases].
    Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2006, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Antineoplastic Combined Chemotherapy Protocols; Dru

2006
Capecitabine, epirubicin and cisplatin in the treatment of oesophagogastric adenocarcinoma.
    The Netherlands journal of medicine, 2006, Volume: 64, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2006
Intensity-modulated radiation therapy in the treatment of gastric cancer: early clinical outcome and dosimetric comparison with conventional techniques.
    The British journal of radiology, 2006, Volume: 79, Issue:942

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo

2006
The presence of a systemic inflammatory response predicts poorer survival in patients receiving adjuvant 5-FU chemotherapy following potentially curative resection for colorectal cancer.
    British journal of cancer, 2006, Jun-19, Volume: 94, Issue:12

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; C-Reactive Protein; Chemotherapy, Adjuvant; C

2006
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
    International journal of radiation oncology, biology, physics, 2006, Jul-15, Volume: 65, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2006
Prognostic factors and analysis of microsatellite instability in resected pulmonary metastases from colorectal carcinoma.
    The Annals of thoracic surgery, 2006, Volume: 81, Issue:6

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemother

2006
[Vascular hepatic injury following neoadjuvant treatment for a cardial adenocarcinoma].
    Gastroenterologie clinique et biologique, 2006, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Female; Fluoroura

2006
Genetic variations in radiation and chemotherapy drug action pathways predict clinical outcomes in esophageal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Aug-10, Volume: 24, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carc

2006
Capecitabine-induced cerebellar toxicity.
    Clinical colorectal cancer, 2006, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Cecal Neoplasms; Cerebellar Ata

2006
Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
    The Journal of urology, 2006, Volume: 176, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Huma

2006
[Concurrent low-dose cisplatin/5-FU chemotherapy and radiation for the recurrent gastric carcinoma--case reports].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2006
On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer.
    Annals of surgery, 2006, Volume: 244, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Pancr

2006
A pathologic complete response of rectal cancer to preoperative combined-modality therapy results in improved oncological outcome compared with those who achieve no downstaging on the basis of preoperative endorectal ultrasonography.
    Annals of surgical oncology, 2006, Volume: 13, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2006
Irinotecan combined with infusional 5-fluorouracil and high-dose leucovorin for the treatment of advanced gastric carcinoma as the first-line chemotherapy.
    Chemotherapy, 2006, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease-F

2006
[Prediction of response to neoadjuvant chemotherapy in Barrett's carcinoma by quantitative gene expression analysis].
    Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2004, Volume: 88

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cisplatin; DNA Pr

2004
Comparative proteomics of apoptosis initiation induced by 5-fluorouracil in human gastric cancer.
    The Chinese journal of physiology, 2006, Feb-28, Volume: 49, Issue:1

    Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Fluorouracil; Humans; Proteomics; Stomach Neoplasms

2006
[Clinicopathological characteristics of gastric cancer in elderly patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

2006
[A case of advanced gastric cancer responding remarkably to paclitaxel + low-dose FP therapy in a neoadjuvant setting].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2006
Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway.
    Cancer biology & therapy, 2006, Volume: 5, Issue:11

    Topics: Adenocarcinoma; Carboxylesterase; Cell Line, Tumor; Chromatin; Colonic Neoplasms; Consensus Sequence

2006
[A case of advanced gastric cancer with peritoneal metastasis that responded to paclitaxel plus 5-FU therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dr

2006
[A case of advanced gastric cancer with liver metastasis completely responding to CPT-11+low-dose 5-FU+CDDP chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:9

    Topics: Adenocarcinoma; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cardi

2006
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues.
    Oncology reports, 2006, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dihydrouracil Dehydrogenas

2006
["Iatrogenic acute coronary syndrome"--59 year old patient with adenocarcinoma of ascending colon and stenocardia while receiving adjuvant chemotherapy with 5-fluorouracil].
    Zeitschrift fur Gastroenterologie, 2006, Volume: 44, Issue:9

    Topics: Adenocarcinoma; Angina Pectoris; Chemotherapy, Adjuvant; Colon, Ascending; Colonic Neoplasms; Fluoro

2006
Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.
    Acta pharmacologica Sinica, 2006, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferati

2006
Acute proctocolitis with commencement of neoadjuvant chemoradiation for rectal cancer.
    American journal of clinical oncology, 2006, Volume: 29, Issue:5

    Topics: Acute Disease; Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dose Fractionation, Radiation;

2006
[A case of effective multidisciplinary treatment with hepatic resection for synchronous multiple liver metastases from rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Doxorubic

2006
[Case report of a liver metastasis from rectal cancer achieving complete response (CR) by a combination of intra-hepatic arterial infusion of irinotecan (CPT-11) with degradable starch microspheres (DSM) and weekly high-dose intra-hepatic arterial chemoth
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Administrat

2006
Inflammation of actinic keratoses and acral erythrodysesthesia during capecitabine treatment.
    Journal of the American Academy of Dermatology, 2006, Volume: 55, Issue:5 Suppl

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms; Deoxycytidin

2006
Development of 5-FU and doxorubicin-loaded cationic liposomes against human pancreatic cancer: Implications for tumor vascular targeting.
    Pharmaceutical research, 2006, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Blood Vessels; Cell Di

2006
Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Anti-cancer drugs, 2006, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2006
Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation.
    Cancer, 2006, Dec-01, Volume: 107, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2006
The expression profiles of orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in gastric cancer and their clinical significance.
    Oncology reports, 2006, Volume: 16, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dihydrou

2006
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop

2007
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop

2007
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop

2007
Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biop

2007
Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Annals of surgical oncology, 2007, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

2007
[Prediction of sensitivity to 5-fluorouracil (5-fu) by metabolic and target enzyme activities in colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dihydrouracil Dehydrogenas

2006
[Successful treatment of an elderly patient with advanced gastric cancer using low-doses of 5-fluorouracil, levofolinate calcium, and cis-platinum with chronomodulation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chronother

2006
[A case of advanced rectal carcinoma with multiple lung metastases responding to irinotecan combined with 5-fluorouracil and l-leucovorin (IFL) as neoadjuvant chemotherapy (NAC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2006
FDG-PET in colorectal cancer.
    Cancer imaging : the official publication of the International Cancer Imaging Society, 2006, Oct-31, Volume: 6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Clinic

2006
Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer.
    Journal of the American College of Surgeons, 2006, Volume: 203, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal

2006
Response to neoadjuvant chemotherapy in breast cancer could be predictable by measuring a novel serum apoptosis product, caspase-cleaved cytokeratin 18: a prospective pilot study.
    Cancer investigation, 2006, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neopl

2006
Evaluation of 5-fluorouracil applicability by the collagen gel droplet embedded drug sensitivity test with area under the curve analysis.
    Anti-cancer drugs, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Area Under Curve; Colorectal Neoplasms; Drug

2007
DPYD*2A mutation: the most common mutation associated with DPD deficiency.
    Cancer chemotherapy and pharmacology, 2007, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Aged; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP)

2007
Incomplete operative removal of colorectal liver metastases followed by chemotherapy decreases survival in comparison to chemotherapy alone.
    Journal of experimental & clinical cancer research : CR, 2006, Volume: 25, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cohort St

2006
Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute.
    Journal of surgical oncology, 2007, May-01, Volume: 95, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2007
[Two cases of advanced pancreas cancer treated with GTX: combined use of gemcitabine, docetaxel and capecitabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecita

2006
[Anaphylactic reaction to oxaliplatin--a case of colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:13

    Topics: Adenocarcinoma; Aged; Anaphylaxis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto

2006
Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
[A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2006, Volume: 33, Issue:12

    Topics: Adenocarcinoma; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Fluorouracil; Hepatectomy; Human

2006
Hypoxia-inducible factor-1alpha suppressing apoptosis and increasing tolerance of lung cancer cells to chemotherapy.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfam

2006
Inhibitory effect of pulmonary carcinoma by adenovirus-mediated CD/UPRT gene.
    Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban, 2006, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Adenoviridae; Bystander Effect; Cell Line, Tumor; Cell Survival; Cytosine Deaminase;

2006
Capecitabine and oxaliplatin (XELOX) for the treatment of patients with metastatic gastric cancer and severe liver dysfunction.
    The Korean journal of internal medicine, 2006, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Capecitabine; Deoxycytidine; Drug Therapy, Combination; Fluor

2006
Bio-pathologic characteristics related to chromosome 11 aneusomy and cyclin D1 gene status in surgically resected stage I and II breast cancer: Identification of an adverse prognostic profile.
    The American journal of surgical pathology, 2007, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Biomarkers,

2007
Adjuvant concurrent chemoradiation for adenocarcinoma of the distal common bile duct.
    International journal of radiation oncology, biology, physics, 2007, May-01, Volume: 68, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antimetabolites, Antineoplasti

2007
Failure to complete adjuvant chemotherapy is associated with adverse survival in stage III colon cancer patients.
    British journal of cancer, 2007, Mar-12, Volume: 96, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Coloni

2007
Adjuvant chemotherapy in elderly patients (>or=75 yr) completely resected for colon cancer stage III compared to younger patients: toxicity and prognosis.
    Medical oncology (Northwood, London, England), 2006, Volume: 23, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pr

2006
Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; DNA-

2007
Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2007
Analysis of early postoperative morbidity among patients with rectal cancer treated with and without neoadjuvant chemoradiotherapy.
    Annals of surgical oncology, 2007, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; Combined Modality Therapy; Female

2007
Left ventricular thrombus in a patient with esophageal carcinoma.
    Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology, 2007, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Diagnosis, Differential; Esophageal Neoplasms; Fluo

2007
Integrating Chinese and conventional medicine in colorectal cancer treatment.
    Integrative cancer therapies, 2007, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Combined Modality Therapy; Deoxycytidin

2007
[A retrospective study of irinotecan plus fluorouracil and l-leucovorin chemotherapy for advanced and metastatic colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplasm

2007
Effects of chemotherapy on patients with unresectable or metastatic adenocarcinoma of gallbladder.
    JPMA. The Journal of the Pakistan Medical Association, 2007, Volume: 57, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Fem

2007
Adjuvant concurrent chemoradiation for node-positive adenocarcinoma of the duodenum.
    Archives of surgery (Chicago, Ill. : 1960), 2007, Volume: 142, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Duodenal Neopl

2007
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
    Virchows Archiv : an international journal of pathology, 2007, Volume: 450, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2007
Prognostic and predictive factors after surgical treatment for locally recurrent rectal cancer: a single institute experience.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2007, Volume: 33, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Female; Fluoro

2007
[Acute promyelocytic leukemia in a patient with colon adenocarcinoma treated with fluorouracil].
    Medicina clinica, 2007, Mar-31, Volume: 128, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Leukemia,

2007
Chemoimmunotherapy in the treatment of metastatic gastric cancer.
    Anti-cancer drugs, 2007, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Antineop

2007
[Pathological evaluation of neoadjuvant chemotherapy with low-dose FP therapy for advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
[A long survival case of sigmoid colon cancer patient with initially unresectable hepatic metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Fluoroura

2007
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C

2007
Effect of time interval between surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer.
    Journal of surgical oncology, 2007, Sep-01, Volume: 96, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female

2007
Efficacy and safety of cisplatin and capecitabine in combination as first line treatment for unselected patients with advanced gastric cancer.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin

2007
Patients with locally advanced esophageal carcinoma nonresponder to radiochemotherapy: who will benefit from surgery?
    Annals of surgical oncology, 2007, Volume: 14, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2007
Modified Irinotecan/5FU/Leucovorin therapy in advanced colorectal cancer and predicting therapeutic efficacy by expression of tumor-related enzymes.
    Scandinavian journal of gastroenterology, 2007, Volume: 42, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemo

2007
Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells.
    World journal of gastroenterology, 2007, Apr-07, Volume: 13, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo

2007
A comparison of 5-fluorouracil and natural chemotherapeutic agents, EGCG and thymoquinone, delivered by sustained drug delivery on colon cancer cells.
    Biomedical sciences instrumentation, 2007, Volume: 43

    Topics: Adenocarcinoma; Antineoplastic Agents; Benzoquinones; Catechin; Cell Proliferation; Cell Survival; C

2007
Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine.
    Leukemia & lymphoma, 2007, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Fluorouracil; H

2007
Bevacizumab in the treatment of colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human

2007
The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
Liver resection after FOLFOX with bevacizumab.
    Clinical advances in hematology & oncology : H&O, 2007, Volume: 5, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2007
Anus-preservation treatment for anal cancer: retrospective analysis at a single institution.
    Journal of surgical oncology, 2007, Oct-01, Volume: 96, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro

2007
Do thymidylate synthase gene promoter polymorphism and the C/G single nucleotide polymorphism predict effectiveness of adjuvant 5-fluorouracil-based chemotherapy in stage III colonic adenocarcinoma?
    Oncology reports, 2007, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colonic Neoplasms;

2007
Phase II study of preoperative irradiation and chemotherapy with capecitabine in patients with locally advanced rectal carcinoma.
    Journal of experimental & clinical cancer research : CR, 2007, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant;

2007
Six-year stabilisation of a relapsed pelvic mass from rectal cancer after oxaliplatin-containing chemotherapy.
    Journal of cancer research and clinical oncology, 2007, Volume: 133, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

2007
Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy?
    Annals of surgical oncology, 2007, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

2007
Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2007
[A case report of highly advanced gastric cancer with ascites with long survival and improved QOL from combined chemotherapy of paclitaxel and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Drug Administration Schedul

2007
[A case of advanced colon cancer invading the rectum effectively treated with chemoradiation therapy before surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi

2007
Multiple atypical naevi after systemic 5-fluorouracil.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Aged; Back; Biopsy; Diagnosis, Differential; Fluorouracil; Humans; Male; Nevus, Pigm

2007
Images in clinical medicine. Diffuse chemoradiotherapy-related enterocolitis.
    The New England journal of medicine, 2007, Jun-14, Volume: 356, Issue:24

    Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Colon; Combined Modality Therapy

2007
Second-line chemotherapy in advanced pancreatic carcinoma: a multicenter survey of the Gruppo Oncologico Italia Meridionale on the activity and safety of the FOLFOX4 regimen in clinical practice.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2007, Volume: 18 Suppl 6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
Changing patterns of prognosticators during 15-year follow-up of advanced gastric cancer after radical gastrectomy and adjuvant chemotherapy: a 15-year follow-up study at a single korean institute.
    Annals of surgical oncology, 2007, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2007
[A case of metastatic colon cancer to paraaortic lymph nodes and liver treated successfully with oxaliplatin combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati

2007
Comparison of pretherapeutic and posttherapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy.
    American journal of clinical pathology, 2007, Volume: 128, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport

2007
Extensive colonic ischemia following treatment with bevacizumab, fluouracil and CPT-11 in a young patient with advanced adenocarcinoma of the rectum.
    The Israel Medical Association journal : IMAJ, 2007, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma

2007
[Antitumor effects of specific cyclooxygenase inhibitors combined with chemotherapeutic agents on gastric cancer cells in vitro].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Celecoxib; Cell Line, Tumor;

2007
[Evaluation of preoperative radiotherapy or chemoradiotherapy in sphincter preservation for locally advanced middle-low rectal cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2007
[Establishment of a multi drug-resistant human lung adenocarcinoma cell line and biological characteristics there of].
    Zhonghua yi xue za zhi, 2007, Apr-03, Volume: 87, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Deoxy

2007
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
    Annals of surgical oncology, 2007, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2007
Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use?
    Annals of surgical oncology, 2007, Volume: 14, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

2007
Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2007, Volume: 46, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progress

2007
Feasibility of oxaliplatin and infusional fluorouracil/leucovorin (FOLFOX4) for Japanese patients with unresectable metastatic colorectal cancer.
    Japanese journal of clinical oncology, 2007, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2007
Clinical outcomes of FOLFOX/FOLFIRI for the Japanese patients with far-advanced or recurrent colorectal cancer.
    Fukuoka igaku zasshi = Hukuoka acta medica, 2007, Volume: 98, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Peopl

2007
Oxaliplatin-induced immune hemolytic anemia: a case report and review of the literature.
    Anti-cancer drugs, 2007, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Anemia, Hemolytic, Autoimmune; Antidotes; Antimetabolites, Antineoplastic; Antineopl

2007
Capecitabine and irinotecan in advanced gastric cancer.
    The Lancet. Oncology, 2007, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Deoxycyt

2007
Microsatellite instability is frequently observed in rectal cancer and influenced by neoadjuvant chemoradiation.
    International journal of radiation oncology, biology, physics, 2007, Aug-01, Volume: 68, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Humans; Male; Microsatellite Instabilit

2007
Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
    Clinical colorectal cancer, 2007, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo

2007
A renewed call for equipoise.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Aug-10, Volume: 25, Issue:23

    Topics: Adenocarcinoma; Camptothecin; Chemotherapy, Adjuvant; Colonic Neoplasms; Disease-Free Survival; Ethi

2007
[Clinical characteristics of cancer of unknown primary (CUP)--a summary of 22 cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

2007
[A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati

2007
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.
    International journal of radiation oncology, biology, physics, 2007, Dec-01, Volume: 69, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

2007
Analysis of anal sphincter preservation rate according to tumor level and neoadjuvant chemoradiotherapy in rectal cancer patients.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2008, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
[Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Aged; Anemia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy

2007
[Efficacy of CPT-11 combined 5-FU/CF (FOLFIRI) regimen on advanced colorectal cancer].
    Ai zheng = Aizheng = Chinese journal of cancer, 2007, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic N

2007
Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
    International journal of cancer, 2007, Dec-15, Volume: 121, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apo

2007
Epidermal growth factor receptor mutation status and adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Sep-01, Volume: 25, Issue:25

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; ErbB R

2007
Neoadjuvant chemotherapy enables R0 resection of locally advanced rectal cancer in a patient with a previously irradiated pelvis.
    The British journal of radiology, 2007, Volume: 80, Issue:956

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Trans

2007
Successful desensitization to oxaliplatin with incorporation of calcium gluconate and magnesium sulfate.
    Anti-cancer drugs, 2007, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Calcium Gluconate; Drug Hyper

2007
Adjuvant chemotherapy with 5-fluorouracil in a patient with colorectal cancer and Familial Mediterranean Fever.
    Anti-cancer drugs, 2007, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Amyloidosis, Familial; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryo

2007
Stage-adjusted chemoradiation in cervical cancer after transperitoneal laparoscopic staging.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2007, Volume: 183, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carboplatin; Carcinom

2007
Metastatic esophageal adenocarcinoma presenting in the iris.
    American journal of ophthalmology, 2007, Volume: 144, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deo

2007
Prognosis of small bowel adenocarcinoma treated with Mayo or Xelox regimen: a matched case-control study from a database of 581 patients with colorectal cancer.
    Oncology reports, 2007, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Case-Cont

2007
Neoadjuvant chemotherapy and radiation for patients with locally unresectable pancreatic adenocarcinoma: feasibility, efficacy, and survival.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2008, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2008
Survivin, p53, and Ki-67 as predictors of histopathologic response in locally advanced rectal cancer treated with preoperative chemoradiotherapy.
    International journal of colorectal disease, 2008, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Digestive Syst

2008
Resection of small bowel adenocarcinoma liver metastasis combined with neoadjuvant and adjuvant chemotherapy results in extended disease-free period--a case report.
    International journal of gastrointestinal cancer, 2006, Volume: 37, Issue:2-3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A

2006
Development and characterization of a model of liver metastasis using human colon cancer HCT-116 cells.
    Biological & pharmaceutical bulletin, 2007, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptot

2007
Report of an autopsy case of colon cancer with amyotrophic lateral sclerosis.
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2007, Volume: 104, Issue:9

    Topics: Adenocarcinoma; Amyotrophic Lateral Sclerosis; Antineoplastic Combined Chemotherapy Protocols; Campt

2007
Effect of betulinic acid on anticancer drug-resistant colon cancer cells.
    Basic & clinical pharmacology & toxicology, 2007, Volume: 101, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; bcl-2-Associated X Protein; bcl-Associated Death Protein; Bet

2007
[18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
    British journal of cancer, 2007, Oct-08, Volume: 97, Issue:7

    Topics: Adenocarcinoma; Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Surviva

2007
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Combined

2007
Therapeutic efficacy of DNA-loaded PLGA microspheres in tumor-bearing mice.
    Archives of pharmacal research, 2007, Volume: 30, Issue:8

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Combined Modality Therap

2007
Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience.
    Annals of surgery, 2007, Volume: 246, Issue:4

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized;

2007
Long-term outcomes of patients with localized rectal cancer treated with chemoradiation or radiotherapy alone because of medical inoperability or patient refusal.
    Diseases of the colon and rectum, 2007, Volume: 50, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fluorourac

2007
Improved long-term outcome of surgery for advanced colorectal liver metastases: reasons and implications for management on the basis of a severity score.
    Annals of surgical oncology, 2008, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camp

2008
Colonic adenocarcinoma in a 13-year-old with cystic fibrosis.
    Journal of pediatric surgery, 2007, Volume: 42, Issue:10

    Topics: Adenocarcinoma; Adolescent; Air; Anastomosis, Surgical; Antineoplastic Combined Chemotherapy Protoco

2007
Preoperative chemoradiation followed by transanal excision for rectal cancer.
    The Journal of surgical research, 2008, Volume: 148, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

2008
Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Oct-20, Volume: 25, Issue:30

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cape

2007
Effect of neoadjuvant chemotherapy on circumferential margin positivity and its impact on prognosis in patients with resectable oesophageal cancer.
    The British journal of surgery, 2008, Volume: 95, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2008
Enzymatic activities of uridine and thymidine phosphorylase in normal and cancerous uterine cervical tissues.
    Human cell, 2007, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Carcinoma, Squamous Cell;

2007
Capecitabine-induced hand-foot syndrome and cutaneous hyperpigmentation in an elderly vitiligo patient.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2007, Volume: 21, Issue:10

    Topics: Adenocarcinoma; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplasms;

2007
Upregulated expression of S100A6 in human gastric cancer.
    Journal of digestive diseases, 2007, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Cell Cycle Proteins; Cell Line, Tumor; Dox

2007
[Efficiency and side effects of concurrent radiotherapy and chemotherapy for advanced cervical cancers].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

2007
[Clinical analysis of 108 cases with adenocarcinoma Barretts's esophagus].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2007, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Comb

2007
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
    JOP : Journal of the pancreas, 2007, Nov-09, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers; Capecitabine; Deoxycytidine; Dihydroura

2007
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
    Journal of cutaneous pathology, 2007, Volume: 34, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Densi

2007
CS-706, a novel cyclooxygenase-2 selective inhibitor, prolonged the survival of tumor-bearing mice when treated alone or in combination with anti-tumor chemotherapeutic agents.
    International journal of cancer, 2008, Mar-15, Volume: 122, Issue:6

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin

2008
[A patient with recurrent rectal cancer in whom pulmonary metastasis disappeared by FOLFOX 4 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Combined Modality Ther

2007
Chemotherapy-induced suppression to adenoma or complete suppression of the primary in patients with stage IV colorectal cancer: report of four cases.
    European journal of gastroenterology & hepatology, 2007, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Adenoma; Aged; Antineoplastic Agents; Colon; Colonic Polyps; Colonoscopy; Colorectal

2007
[Reversal effect and mechanism of arsenic trioxide on multidrug resistance of gastric carcinoma cells SGC7901].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2007, Volume: 42, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; ATP Binding Cassette Transporte

2007
Cetuximab in combination with 5-fluorouracil, leucovorin and irinotecan as a neoadjuvant chemotherapy in patients with initially unresectable colorectal liver metastases.
    Onkologie, 2007, Volume: 30, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Adjuvant

2007
[Two cases of stage IV gastric cancer who underwent total gastrectomy and achieved long-term survival by sequential chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic C

2007
[A patient with recurrent sigmoid colon cancer in whom pleural effusion and ascites resolved after FOLFOX 4 therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascites; Fluorouracil; Humans; Leuco

2007
[Two cases of advanced low rectal cancer, preoperative chemo-radiation therapy leading to complete histological response].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2007, Volume: 34, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Lymph Node Excision; M

2007
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplast

2007
Levels and expressions of orotate phosphoribosyltransferase in gastric carcinoma and normal gastric mucosa tissues.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2007, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F

2007
[Difference of gene expression profile in human gastric cancer grafted onto nude mice treated with WCA].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 2007, Volume: 32, Issue:19

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Caspase 3; Cell Line, Tumor; Ce

2007
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jan-01, Volume: 14, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Chem

2008
Inoperable pancreatic cancer: standard of care.
    Oncology (Williston Park, N.Y.), 2007, Volume: 21, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Com

2007
The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.
    European journal of cancer care, 2008, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2008
cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Jan-20, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2008
Overexpression of phosphoserine aminotransferase PSAT1 stimulates cell growth and increases chemoresistance of colon cancer cells.
    Molecular cancer, 2008, Jan-25, Volume: 7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Survival; C

2008
Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-01, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2008
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colore

2008
Sister Mary Joseph nodule: a case report.
    Cutis, 2007, Volume: 80, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo

2007
Scoring system for predicting response to chemoradiotherapy, including 5-Fluorouracil and platinum, for patients with esophageal cancer.
    Digestive diseases and sciences, 2008, Volume: 53, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

2008
Chemoradiotherapy followed by surgery in rectal cancer: improved local control using a moderately high pelvic radiation dose.
    Japanese journal of clinical oncology, 2008, Volume: 38, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Chemotherap

2008
FP therapy for controlling malignant ascites in advanced pancreatic cancer patients.
    Hepato-gastroenterology, 2007, Volume: 54, Issue:80

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; C-Reactive Pro

2007
Tumor lysis syndrome after capecitabine plus cisplatin treatment in advanced gastric cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Feb-20, Volume: 26, Issue:6

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco

2008
Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
    World journal of gastroenterology, 2008, Feb-21, Volume: 14, Issue:7

    Topics: Adenocarcinoma; Female; Fluorouracil; Gene Expression; Humans; Ki-67 Antigen; Male; Middle Aged; Neo

2008
Determining the morphological features of breast cancer and predicting the effects of neoadjuvant chemotherapy via diagnostic breast imaging.
    Breast cancer (Tokyo, Japan), 2008, Volume: 15, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carci

2008
Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
    JAMA, 2008, Mar-05, Volume: 299, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil

2008
Sepsis from liver abscesses in metastatic colorectal carcinoma after chemoimmunotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Mar-10, Volume: 26, Issue:8

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined C

2008
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
    JOP : Journal of the pancreas, 2008, Mar-08, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydropyrimidine Dehydrogenase Deficiency; D

2008
Radiochemotherapy in combination with regional hyperthermia in preirradiated patients with recurrent rectal cancer.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2008, Volume: 184, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Confidence I

2008
Sphincter-preserving operations following preoperative chemoradiation: an alternative to abdominoperineal resection for lower rectal cancer?
    World journal of surgery, 2008, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Colectomy; Female

2008
Liver metastasis as an initial recurrence has no impact on the survival of patients with resectable pancreatic adenocarcinoma.
    Langenbeck's archives of surgery, 2009, Volume: 394, Issue:2

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Cohort Studies; Combi

2009
A case of 5-fluorouracil-induced peripheral neuropathy.
    Clinical toxicology (Philadelphia, Pa.), 2008, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electromyography; Female; Fluorouracil; Humans; Low

2008
Results of concomitant chemoradiation for cervical cancer using high dose rate intracavitary brachytherapy: study of JROSG (Japan Radiation Oncology Study Group).
    Acta oncologica (Stockholm, Sweden), 2008, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy

2008
Prognostic role of p53 codon 72 polymorphism in gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy.
    Journal of cancer research and clinical oncology, 2008, Volume: 134, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Ch

2008
Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
    Journal of Nippon Medical School = Nippon Ika Daigaku zasshi, 2008, Volume: 75, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasm

2008
Hand-foot syndrome with sclerodactyly-like changes in a patient treated with capecitabine.
    The American Journal of dermatopathology, 2008, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Capecitabine; Deoxycytidine; Dose-Response Rel

2008
Chronic myeloid leukemia following the treatment of rectal adenocarcinoma.
    Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; De

2008
Intra-arterial infusion chemotherapy with 5-fluorouracil and cisplatin in advanced pancreatic cancer: a feasibility study.
    American journal of clinical oncology, 2008, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
A retrospective study of bifractionated CPT-11 with LF5FU infusion (FOLFIRI-3) in colorectal cancer patients pretreated with oxaliplatin and CPT-11 containing chemotherapies.
    American journal of clinical oncology, 2008, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, Ad

2008
The toxicity and outcomes of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected high-risk gastric cancer: results of a single institute.
    Annals of the Academy of Medicine, Singapore, 2008, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2008
Rectal prolapse as initial clinical manifestation of colon cancer.
    Zeitschrift fur Gastroenterologie, 2008, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant;

2008
Capecitabine and irinotecan as first-line treatment of advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Apr-10, Volume: 26, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms;

2008
Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer.
    Oncology, 2007, Volume: 73, Issue:3-4

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluor

2007
Capecitabine-associated coronary vasospasm: a case report.
    Emergency medicine journal : EMJ, 2008, Volume: 25, Issue:5

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Capecitabine; Coronary Vasospasm; Deoxycytid

2008
Will we ever be ready for blood level-guided therapy?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, May-01, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Body Surface Area; Colorectal Neoplasms; Drug Admin

2008
Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China.
    World journal of gastroenterology, 2008, May-07, Volume: 14, Issue:17

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Drug C

2008
Capecitabine as salvage therapy for a pancreatic cancer patient with extensive liver metastases and associated impairment of liver function.
    JOP : Journal of the pancreas, 2008, May-08, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Capecitabine; Deoxycytidine; Disease Progression; F

2008
Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
    Gastroenterologie clinique et biologique, 2008, Volume: 32, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chemotherapy, A

2008
Mechanism of resistance to chemoradiation in p53 mutant human colon cancer.
    International journal of oncology, 2008, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Blotting, Western; Colonic Neoplasms; Combined Moda

2008
Intra-arterial chemotherapy in advanced pelvic tumors.
    Archives of surgery (Chicago, Ill. : 1960), 1967, Volume: 94, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Injections, Int

1967
Ovarian and parovarian tumors in infants and children.
    American journal of obstetrics and gynecology, 1967, Apr-15, Volume: 97, Issue:8

    Topics: Adenocarcinoma; Adolescent; Child; Child, Preschool; Dysgerminoma; Female; Fluorouracil; Histocytoch

1967
Bronchial adenoma and the carcinoid syndrome.
    Annals of surgery, 1967, Volume: 165, Issue:5

    Topics: Adenocarcinoma; Adenoma; Adrenal Cortex Hormones; Bronchial Neoplasms; Carcinoid Tumor; Chlorpromazi

1967
[Attack treatment of broncho-pleuro-pulmonary cancer by polychemotherapy under the protection of phytohemagglutinin].
    Bulletins et memoires de la Societe medicale des hopitaux de Paris, 1967, Jan-27, Volume: 118, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Azirines; Betametha

1967
Disappearance of antibodies to Factor VIII in a patient with acquired haemophilia and carcinoma of the pancreas during cytotoxic therapy with fluorouracil and CCNU.
    Thrombosis and haemostasis, 1984, Oct-31, Volume: 52, Issue:2

    Topics: Adenocarcinoma; Aged; Antibodies; Antineoplastic Combined Chemotherapy Protocols; Factor VIII; Femal

1984
Enzymes of the de novo and salvage pathways for pyrimidine biosynthesis in normal colon, colon carcinoma, and xenografts.
    Cancer, 1984, Oct-01, Volume: 54, Issue:7

    Topics: Adenocarcinoma; Animals; Carboxy-Lyases; Colon; Colonic Neoplasms; Fluorouracil; Humans; Intestinal

1984
Intravascular haemolysis and renal impairment after blood transfusion in two patients on long-term 5-fluorouracil and mitomycin-C.
    Lancet (London, England), 1980, Jun-14, Volume: 1, Issue:8181

    Topics: Adenocarcinoma; Adult; Anemia, Macrocytic; Brain Edema; Disseminated Intravascular Coagulation; Fema

1980
Pancreatic somatostatinoma presenting with hypoglycaemia.
    Clinical endocrinology, 1980, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Chlorothiazide; Diazoxide; Female; Fluorouracil; Humans; Hypoglycemia; Pancre

1980
Combination chemotherapy for advanced endometrial adenocarcinoma.
    International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 1980, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone;

1980
Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas.
    Annals of the Royal College of Surgeons of England, 1980, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Infusions, I

1980
In vivo kinetics of thymidylate synthetase inhibition of 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas.
    Cancer research, 1982, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Inj

1982
Metabolism of 5-fluorouracil in various human normal and tumor tissues.
    Gan, 1981, Volume: 72, Issue:6

    Topics: Adenocarcinoma; Adenosine Triphosphate; Carcinoma, Squamous Cell; Digestive System; Fluorouracil; Ga

1981
Colon-specific antigen-p (CSAp). I. Initial clinical evaluation as a marker for colorectal cancer.
    Cancer, 1982, Sep-01, Volume: 50, Issue:5

    Topics: Adenocarcinoma; Adenoma; Antigens, Neoplasm; Carcinoembryonic Antigen; Colonic Neoplasms; Epitopes;

1982
Phosphoribosyl pyrophosphate, pool size and tissue levels as a determinant of 5-fluorouracil response in murine colonic adenocarcinomas.
    Biochemical pharmacology, 1982, Jun-01, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Resistance; Fluorouracil; Leukemia P388; Mice; Neop

1982
Weekly large fraction radiotherapy and 5 fluorouracil as a palliative treatment for large bowel carcinoma: a pilot study.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Diarrhea; Fluorouracil; Humans; Intestinal Neoplasms; Intestine, Large;

1982
Efficacy and side effects of the regional arterial infusion of anti-cancer drugs combined with direct hemoperfusion in malignancies of the urinary tract.
    The Journal of urology, 1982, Volume: 128, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Bleomycin; Carcinoma, Transitional Cell; Charcoal; Doxorubicin; Female;

1982
Elucidation of pathways of 5-fluorouracil metabolism in xenografts of human colorectal adenocarcinoma.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:6

    Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Female; Fluorouracil; Humans; Hypoxanthines

1983
Management of high bile duct carcinoma.
    The American surgeon, 1984, Volume: 50, Issue:6

    Topics: Adenocarcinoma; Adenoma, Bile Duct; Aged; Bile Duct Neoplasms; Bile Ducts; Combined Modality Therapy

1984
Phase II trial of 5-fluorouracil, adriamycin, mitomycin C, and streptozotocin (FAM-S) in pancreatic carcinoma.
    Cancer, 1982, Jul-15, Volume: 50, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Drug Therapy, Comb

1982
[The combination methyl-CCNU, vincristine, 5-fluorouracil and streptozotocin in the treatment of advanced colo-rectal adenocarcinoma].
    Schweizerische medizinische Wochenschrift, 1982, Jun-26, Volume: 112, Issue:26

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Combinations; Female; Fluorouracil; Humans; Leu

1982
Mixed beam radiotherapy and combination chemotherapy in localized pancreatic adenocarcinoma-preliminary results.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Elementary Particles;

1982
Phase II study of 5-FU, doxorubicin, and mitomycin (FAM) and chlorozotocin in advanced measureable pancreatic cancer.
    Cancer treatment reports, 1982, Volume: 66, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Evaluation; Female; Fluorouracil; Hematopoi

1982
Intermittent regional infusion of chemotherapy for pancreatic adenocarcinoma. Phase I and II pilot study.
    American journal of clinical oncology, 1982, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineop

1982
Nonsteroid antiinflammatory drugs and tamoxifen for desmoid tumors and carcinoma of the stomach.
    Journal of surgical oncology, 1983, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Anti-Inflammatory Agents; Cyclophosphamide; Drug Therapy, Combination;

1983
Effective retreatment of patients with colorectal cancer and liver metastases.
    The American journal of medicine, 1983, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Colonic Neoplasms; Drug Resistan

1983
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Modality

1983
The abdominoinguinal incision in limb salvage and resection of pelvic tumors.
    Cancer, 1984, Dec-01, Volume: 54, Issue:11

    Topics: Abdominal Muscles; Abdominal Neoplasms; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy P

1984
Treatment of advanced endometrial adenocarcinoma with a combined cytotoxic therapy. Predictive value of cytosol estrogen and progestin receptor levels.
    Cancer, 1980, Nov-15, Volume: 46, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fem

1980
Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung.
    Cancer chemotherapy and pharmacology, 1980, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Cyclophosphamide; Doxorubicin; Drug Therapy, Com

1980
[Combined chemotherapy of bronchial carcinomas (author's transl)].
    Zeitschrift fur Erkrankungen der Atmungsorgane, 1980, Volume: 155, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma,

1980
Analysis of the results of our combined therapy for maxillary cancer.
    Acta oto-laryngologica. Supplementum, 1980, Volume: 372

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell

1980
Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vindesine, and mitomycin (FEMi): a Southwest Oncology Group Study.
    Cancer treatment reports, 1982, Volume: 66, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Drug Administration Sched

1982
Metabolic and distribution studies with radiolabeled 5-fluorouracil.
    Nuklearmedizin. Nuclear medicine, 1982, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Animals; Biotransformation; Breast Neoplasms; Carcinoma, Hepatocellular

1982
Phase II trial of methyl-CCNU, vincristine, 5-fluorouracil, and streptozotocin (MOF-Strep) in patients with disseminated pancreatic carcinoma.
    American journal of clinical oncology, 1982, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Adenoma, Islet Cell; Adult; Aged; Drug Evaluation; Drug Therapy, Combination; Female

1982
Antibody pattern to human cytomegalovirus in patients with adenocarcinoma of the colon.
    Intervirology, 1981, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antibodies, Viral; Colonic Neoplasms; Cytomegalovirus; Fluorouracil; He

1981
Experimental combination and single-agent chemotherapy in human lung-tumour xenografts.
    British journal of cancer, 1982, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carc

1982
[Treatment of rectocolic and gastric adenocarcinomas with 5-fluorouracil associated with high doses of folinic acid. Results of an experimental study].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1982, Sep-16, Volume: 58, Issue:33

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Leu

1982
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.
    Breast cancer research and treatment, 1982, Volume: 2, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Drug Therapy,

1982
Clinical evaluation of preoperative combined chemotherapy with neocarzinostatin (NCS) and 5-Fluorouracil (combined NF therapy) against gastric cancer.
    Bulletin of the Osaka Medical School, 1981, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Antibiotics, Antin

1981
Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
    Journal of surgical oncology, 1983, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adult; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Drug Th

1983
Prognostic significance of hormone receptors in early recurrence of breast cancer.
    American journal of surgery, 1983, Volume: 145, Issue:5

    Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil;

1983
Potentiation of the chemotherapeutic effect of 5-fluorouracil by combination with guanosine 5'-monophosphate.
    Gan, 1983, Volume: 74, Issue:2

    Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Fluorouracil; Guanine Nucleotides; Guanosine Mon

1983
Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
    Seminars in oncology, 1983, Volume: 10, Issue:2 Suppl 2

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drug Evaluation; Drug Therapy, Combination; Estrogens

1983
[Pre- and intra-operative chemotherapy using FT-207 suppositories--with special reference to lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Small Cell; Carcinoma, Squamous Cell; Fluorouracil

1982
[New chemotherapeutic method for the treatment of tracheal and bronchial cancers--nebulization chemotherapy].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Small Cell; Carcinoma,

1983
[Transfer factor immunochemotherapy for primary lung cancer--evaluation of histologic types].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell;

1983
An atypical endocrine tumor of the lung responsive to radiation therapy and 5-fluorouracil-streptozotocin.
    Cancer, 1984, Jun-01, Volume: 53, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bombesin; Carcinoma,

1984
[Clinical trial on the effect of tegafur (SF-SP)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Capsules; Carcinoma, Intraductal, Noninfiltrating

1984
5-Fluorouracil and folinic acid: a Phase I-II trial in gastrointestinal malignancy.
    Investigational new drugs, 1984, Volume: 2, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Drug Evaluation; Female; Fluorouracil; Ga

1984
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
    Obstetrics and gynecology, 1983, Volume: 61, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap

1983
Microangiopathic hemolytic anemia, renal failure, and noncardiogenic pulmonary edema: a chemotherapy-induced syndrome.
    Cancer treatment reports, 1983, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Anemia, Hemolytic; Drug Therapy, Combination; Female; Fluorouracil; Humans; K

1983
Phase II study of ftorafur in previously untreated and treated patients with advanced colorectal cancer.
    Cancer treatment reports, 1983, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male;

1983
[Combination chemotherapy of advanced gastric cancer with adriamycin, mitomycin C, and ftorafur].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:4 Pt 2

    Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; M

1983
[Case of Borrmann III stomach cancer effectively treated by UFT therapy (co-administration of uracil and futraful)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:4 Pt 2

    Topics: Adenocarcinoma; Administration, Oral; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Male; S

1983
Sensitivity of xenografts of human pancreatic adenocarcinoma in nude mice to heat and heat combined with chemotherapy.
    Cancer research, 1983, Volume: 43, Issue:9

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cisplatin; Fluorouracil; Hot Temperature;

1983
Effects of alpha-difluoromethylornithine and 5-fluorouracil on the proliferation of a human colon adenocarcinoma cell line.
    Cancer research, 1983, Volume: 43, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Survival; Eflornithine; Fluoroura

1983
Phase I evaluation of oral tegafur.
    Cancer treatment reports, 1983, Volume: 67, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Blood Cell Count; Diarrhea; Dose-Response Relatio

1983
[Analysis of factors affecting clinical cancer chemotherapy].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Drug Evaluation; Female; Fluorouraci

1983
[Treatment of metastasizing prostatic carcinoma with DMF. Presentation of a prospective study].
    Der Urologe. Ausg. A, 1983, Volume: 22 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1983
Doxorubicin, mitomycin-C, and 5-fluorouracil (DMF) in the treatment of metastatic hormonal refractory adenocarcinoma of the prostate, with a note on the staging of metastatic prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1983, Volume: 1, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Doxorubicin; Drug Ev

1983
[A gastric cancer patient who underwent curative resection by angiotension-induced hypertension cancer chemotherapy].
    Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo

1984
[Effective cases of advanced endometrial and recurrent ovarian cancers treated with oral administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Tra

1984
[The case studies on oral administration of tegafur encapsulated with slow releasing granule (SF-SP) for three rectal patients].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Aged; Capsules; Delayed-Action Preparations; Female; Fluoroura

1984
[Combination chemotherapy of CIS-diamminedichloroplatinum (II) and fluoropyrimidine derivatives for advanced gastric cancer: a preliminary report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

1984
Effects of 5-fluorouracil and the combination of 5-fluorouracil and human leukocyte interferon on human salivary gland adenocarcinoma cell line in culture.
    International journal of oral surgery, 1984, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell Line; C

1984
Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma.
    Cancer research, 1984, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Aphidicolin; Cell Line; Colonic Neoplasms; Diterpenes;

1984
[Experimental chemotherapy of human gastrointestinal and breast cancers in nude mice and its correlation to clinical effect].
    Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:9 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

1984
[Increased cytotoxic effects of various anticancer drugs by alpha-interferon (HLBI) on human tumor xenografts in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Syner

1984
[Chemotherapy of renal cell carcinoma. 3. Single-agent therapy with FT-207 or vinblastine].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1984, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Carcinoma, Renal Cell; Female; Fluorouracil; Huma

1984
On the mechanism of cytotoxicity of fluorinated pyrimidines in four human colon adenocarcinoma xenografts maintained in immune-deprived mice.
    Cancer, 1980, Mar-15, Volume: 45, Issue:5 Suppl

    Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Female; Floxuridine; Fluorodeoxyuridylate

1980
Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas.
    Cancer clinical trials, 1980, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Drug Evaluation; Drug Therapy, Combination; Fluorouracil; Humans; Mitomycins; Nausea

1980
Spontaneous metastasis of highly metastatic variants of mouse tumors and the effect of drugs on the metastasis.
    Gan, 1984, Volume: 75, Issue:6

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms; Lymphatic Met

1984
[5-Fluorouracil treatment combined with ascorbic acid in patients with disseminated stomach cancer].
    Vrachebnoe delo, 1984, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Ascorbic Acid; Carcinoma; Combined Modality Therapy; Female; Fluorourac

1984
Experimental colon neoplasia enhanced by extract of sperm (protamine).
    Journal of the Royal Society of Medicine, 1984, Volume: 77, Issue:10

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Colonic Polyps; Dimethylhydrazines; Female; Fluorouracil

1984
[Low-dose methotrexate and sequential 5-FU treatment in advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

1984
Postoperative adjuvant irradiation and 5-fluorouracil for adenocarcinoma of the cecum. A pilot study.
    Cancer, 1984, Dec-15, Volume: 54, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Cecal Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Human

1984
[Changes in the content and composition of gangliosides of tumors as affected by chemotherapeutic agents].
    Eksperimental'naia onkologiia, 1984, Volume: 6, Issue:5

    Topics: Adenocarcinoma; Animals; Cyclophosphamide; Female; Fluorouracil; Gangliosides; Lung Neoplasms; Mamma

1984
[Chemotherapy of metastatic urothelial carcinoma. cis-Diamminedichloroplatinum combination chemotherapy for patients with decreased renal function].
    Hinyokika kiyo. Acta urologica Japonica, 1984, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell;

1984
Cisplatin, doxorubicin, and 5-FU in combination for advanced gastric cancer.
    Cancer treatment reports, 1984, Volume: 68, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

1984
Comparison of melphalan with cyclophosphamide, methotrexate, and 5-fluorouracil in patients with ovarian cancer.
    Cancer, 1984, Feb-15, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluorourac

1984
Chemotherapy of hormone-refractory carcinoma of prostate with 5-fluorouracil, adriamycin, and mitomycin C.
    Urology, 1984, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Doxorubicin; Estro

1984
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
    The British journal of surgery, 1984, Volume: 71, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Doxorubicin; D

1984
Further studies on the treatment of advanced gastric cancer by 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin C (modified FAM).
    Cancer, 1984, Nov-01, Volume: 54, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl

1984
Pulmonary veno-occlusive disease associated with microangiopathic hemolytic anemia and chemotherapy of gastric adenocarcinoma.
    Medical and pediatric oncology, 1984, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin

1984
Treatment of autochthonous rat colonic adenocarcinomas with a thioether-lysophospholipid derivative in mono- and combination chemotherapy.
    Journal of cancer research and clinical oncology, 1984, Volume: 108, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemot

1984
[5 years' results of a CMF protocol (methotrexate, cyclophosphamide, fluorouracil) of adjuvant chemotherapy in breast cancers].
    LARC medical, 1984, Volume: 4, Issue:9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mo

1984
[Treatment of advanced colonic and rectal adenocarcinoma: combination of 5-FU and high-dose folinic acid].
    Bulletin du cancer, 1983, Volume: 70, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo

1983
Remission of metastatic adenocarcinoma of the colon.
    JAMA, 1983, Nov-11, Volume: 250, Issue:18

    Topics: Adenocarcinoma; Adult; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Humans; Intestinal Poly

1983
[A clinical study (phase II) of a combination of 5-fluorouracil, vincristine and methyl CCNU in patients with advanced carcinoma of the large intestine].
    Lijecnicki vjesnik, 1983, Volume: 105, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Evaluation;

1983
Chemotherapy of advanced gastric cancer with 72-hour continuous intravenous 5-fluorouracil infusion at 2-week intervals.
    Medical and pediatric oncology, 1983, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions,

1983
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11 Suppl

    Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco

1983
First histologic findings in metastases of colorectal carcinoma following isolated liver perfusion with cytostatics.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1983, Volume: 86

    Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Humans; L

1983
Adjuvant therapy for Dukes C adenocarcinoma of colon.
    International journal of radiation oncology, biology, physics, 1983, Volume: 9, Issue:12

    Topics: Abdomen; Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Middle

1983
Malignant tumors of the vagina. Classification and approach to treatment.
    Postgraduate medicine, 1983, Volume: 73, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe

1983
Multimodality therapy of stage III adenocarcinoma of the breast.
    Journal of surgical oncology, 1983, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1983
Combined nonsimultaneous radiation therapy and chemotherapy with 5-FU, doxorubicin, and mitomycin for residual localized gastric adenocarcinoma: a Southwest Oncology Group pilot study.
    Cancer treatment reports, 1983, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Therapy, Co

1983
[A case of primary duodenal cancer. Diagnostic and therapeutic considerations].
    La Radiologia medica, 1983, Volume: 69, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug

1983
Combined modality treatment of gastric cancer.
    International journal of radiation oncology, biology, physics, 1983, Volume: 9, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Doxorubicin; Drug Therap

1983
The natural history of gastric cancer and prognostic factors influencing survival.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Liver Neoplasms; Lymphatic M

1984
[5-Fluorouracil concentration in various tissues from cancer patients after oral administration of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1984, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Breast Neoplasms; Female; Fluorouracil; Humans; M

1984
Endoscopic local injection of early gastric carcinoma with 5-fluorouracil.
    Digestive diseases and sciences, 1984, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Injections; Male

1984
[A case of advanced gastric cancer which disappeared histopathologically after short-time chemotherapy].
    Gan no rinsho. Japan journal of cancer clinics, 1984, Volume: 30, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyt

1984
Metastasis after intravenous inoculation of highly metastatic variants of mouse tumors and the effects of several antitumor drugs on the tumors.
    Gan, 1984, Volume: 75, Issue:2

    Topics: Adenocarcinoma; Age Factors; Animals; Antineoplastic Agents; Colonic Neoplasms; Doxorubicin; Fluorou

1984
[Results of combined treatment of cancer of the stomach taking into consideration tumor sensitivity to 5-fluorouracil].
    Klinicheskaia khirurgiia, 1984, Issue:5

    Topics: Adenocarcinoma; Adult; Carcinoma; Combined Modality Therapy; Female; Fluorouracil; Follow-Up Studies

1984
Chemoradiotherapeutic prevention of local recurrence after stapled anastomoses in rectal cancer.
    Scottish medical journal, 1981, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Female; Fluorouracil; Follow-Up Studies; Humans;

1981
Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1981, Volume: 79

    Topics: Adenocarcinoma; Colonic Neoplasms; Dacarbazine; Drug Resistance; Drug Therapy, Combination; Female;

1981
Renal disease after mitomycin C therapy.
    Cancer, 1981, Dec-15, Volume: 48, Issue:12

    Topics: Acute Kidney Injury; Adenocarcinoma; Adult; Aged; Blood Pressure; Blood Urea Nitrogen; Creatinine; F

1981
Phase I--II evaluation of combination cyclophosphamide, 5-fluorouracil, hexamethylmelamine, and prednisone in advanced breast cancer.
    Cancer clinical trials, 1981,Winter, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide;

1981
[Conservative treatment of primary and recurrent malignant stomach neoplasms].
    Vestnik Akademii meditsinskikh nauk SSSR, 1981, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Male

1981
[Long-term chemotherapy with FT-207 for ovarian cancer (author's transl)].
    Nihon Gan Chiryo Gakkai shi, 1981, Aug-20, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorourac

1981
Fast neutron irradiation for locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 1981, Volume: 7, Issue:11

    Topics: Adenocarcinoma; Colitis; Cost-Benefit Analysis; Energy Transfer; Esophagitis; Evaluation Studies as

1981
Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster.
    Cancer research, 1982, Volume: 42, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Disease Models, Animal

1982
[Chemotherapy of renal cell carcinoma. 1. MFC therapy].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1982, Volume: 73, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Eva

1982
Severe glomerular mesangiolysis in a patient with rectal adenocarcinoma treated with cytotoxic drugs.
    Virchows Archiv. A, Pathological anatomy and histopathology, 1982, Volume: 398, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cytarabine; Fluorescent Antibody Technique; Fluorouraci

1982
[Chemotherapy of stomach cancer].
    Zeitschrift fur Gastroenterologie, 1982, Volume: 20, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Carmustine; Cisplatin; Doxorubicin; Drug Administration Sched

1982
[Renal cell carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:6

    Topics: Adenocarcinoma; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Lung

1982
[Combined administration of futraful and esquinone for the treatment of advanced ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:7

    Topics: Adenocarcinoma; Azirines; Carbazilquinone; Drug Therapy, Combination; Female; Fluorouracil; Humans;

1982
[Clinical evaluation of Tegafur suppository in the treatment of uterine cancer--with special reference to the drug concentration in the blood, secretion from the pelvic dead space, and tissues of female genital organs].
    Igaku kenkyu. Acta medica, 1982, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorouracil; Genita

1982
Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy.
    Cancer, 1983, Feb-01, Volume: 51, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin;

1983
The effects of chemotherapy on bony metastases as measured by quantitative skeletal imaging.
    Clinical nuclear medicine, 1983, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Colonic Neoplasms; Diphosphon

1983
Gastric cancer-survival at the Pennsylvania Hospital with and without adjuvant chemotherapy.
    Journal of surgical oncology, 1983, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Drug Therapy, Combination; Female; Fluorouracil; Follow-Up Studies; Gas

1983
[Co-administration of adriamycin and 5-fluorouracil for the treatment of advanced stomach cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1983, Volume: 10, Issue:4 Pt 2

    Topics: Adenocarcinoma; Aged; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mi

1983
Coronary insufficiency and 5-fluorouracil therapy. A case report, review, and suggestion regarding mechanism.
    Cleveland Clinic quarterly, 1983,Spring, Volume: 50, Issue:1

    Topics: Adenocarcinoma; Angina Pectoris; Fluorouracil; Humans; Male; Middle Aged; Sigmoid Neoplasms

1983
[Pulmonary metastasis of renal cell carcinoma].
    Gan no rinsho. Japan journal of cancer clinics, 1983, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil;

1983
Growth inhibition of transplantable murine colon adenocarcinoma 38 by indomethacin.
    Journal of cancer research and clinical oncology, 1983, Volume: 106, Issue:1

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Indomethacin; M

1983
[Ovarian adenocarcinoma stage III and IV treated by a combination of adriamycin, cyclophosphamide, 5-fluorouracil and cis-DDP. Therapeutic role of cis-DDP in this combination].
    Bulletin du cancer, 1982, Volume: 69, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T

1982
[Chemotherapy of metastatic urothelial carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:11

    Topics: Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cisplatin; Doxorubicin; Drug Therapy, Combinatio

1982
VP-16 and adriamycin in patients with advanced breast cancer.
    American journal of clinical oncology, 1982, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neopla

1982
Concepts for controlling drug-resistant tumor cells.
    European journal of cancer, 1980, Volume: Suppl 1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Burden; Cisplatin; Cyclophosphamide; Dactinomyc

1980
Chemotherapy in gastric and oesophageal cancer.
    The Australian and New Zealand journal of surgery, 1982, Volume: 52, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Doxorubicin; Drug Therapy, Combinat

1982
Rectal adenocarcinoma treated with intra-arterial 5-fluorouracil. Prolonged remission.
    New York state journal of medicine, 1982, Volume: 82, Issue:3

    Topics: Adenocarcinoma; Female; Fluorouracil; Hepatic Artery; Humans; Injections, Intra-Arterial; Liver Neop

1982
Subacute vincristine toxicity following five consecutive daily doses.
    American journal of clinical oncology, 1982, Volume: 5, Issue:4

    Topics: Adenocarcinoma; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Fluorouracil; H

1982
Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study.
    Cancer treatment reports, 1982, Volume: 66, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointesti

1982
Doxorubicin, mitomycin, and 5-FU (DMF) in the treatment of hormone-resistant stage D prostate cancer: a preliminary report.
    Cancer treatment reports, 1982, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Bone Neoplasms; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans; Lung N

1982
Radiation therapy combined with intra-arterial 5-FU chemotherapy for treatment of localized adenocarcinoma of the pancreas: a Southwest Oncology Group Study.
    Cancer treatment reports, 1982, Volume: 66, Issue:3

    Topics: Adenocarcinoma; Cobalt Radioisotopes; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Male;

1982
Spontaneous pneumothorax in gynecologic malignancies.
    American journal of obstetrics and gynecology, 1982, Mar-15, Volume: 142, Issue:6 Pt 1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drainage; Drug Therapy,

1982
Adenocarcinoma of the colon with hepatic metastases. Fifteen-year survival.
    JAMA, 1982, May-28, Volume: 247, Issue:20

    Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Prognosis;

1982
Combinations of 5-FU, hypoxanthine and allopurinol in chemotherapy for human colon adenocarcinoma xenografts.
    Cancer treatment reports, 1982, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Hu

1982
Ex vivo hemodialysis culture system for assessing the activity of cancer chemotherapeutic agents.
    In vitro, 1982, Volume: 18, Issue:2

    Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dogs; Drug Eval

1982
Long-term, ambulatory, continuous intravenous infusion of 5-fluorouracil for the treatment of metastatic adenocarcinoma in the liver.
    Wisconsin medical journal, 1982, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Aged; Ambulatory Care; Cecal Neoplasms; Fluorouracil; Humans; Infusions, Parenteral;

1982
Advanced breast cancer with bone-only metastases: a chemotherapeutically responsive pattern of metastases.
    American journal of clinical oncology, 1982, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Dox

1982
The assessment of response of murine transplantable colon tumors to combination chemotherapy.
    Journal of cancer research and clinical oncology, 1982, Volume: 103, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Cell Line; Colonic Neoplasms; Dimethylhy

1982
[Vascular isolation and perfusion of the liver in clinical practice].
    Vestnik khirurgii imeni I. I. Grekova, 1982, Volume: 128, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Colonic Neop

1982
Phase I--II study of the combination of 5-FU, doxorubicin, mitomycin, and semustine (FAMMe) in the treatment of adenocarcinoma of the stomach, gastroesophageal junction, and pancreas.
    Cancer treatment reports, 1982, Volume: 66, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administration Sch

1982
[Juvenile carcinoma of the duodenum in two brothers (author's transl)].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1982, May-25, Volume: 71, Issue:21

    Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Fluorouracil; Humans; Lymphatic Metastasis; Male

1982
[Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil (author's transl)].
    Wiener medizinische Wochenschrift (1946), 1982, May-15, Volume: 132, Issue:9

    Topics: Adenocarcinoma; Alopecia; Candidiasis, Oral; Diarrhea; Female; Fluorouracil; Hepatomegaly; Humans; M

1982
[Autoradiographic studies on nucleic acid synthesis of human gastric cancer cells. II. Effects of 5-fluorouracil on nucleic acid synthesis of cancer cells (author's transl)].
    Nihon geka hokan. Archiv fur japanische Chirurgie, 1982, Mar-01, Volume: 51, Issue:2

    Topics: Adenocarcinoma; Aged; Cell Survival; Cells, Cultured; Female; Fluorouracil; Humans; Male; Middle Age

1982
High-dose allopurinol modulation of 5-FU toxicity: phase I trial of an outpatient dose schedule.
    Cancer treatment reports, 1982, Volume: 66, Issue:9

    Topics: Adenocarcinoma; Aged; Allopurinol; Brain Diseases; Drug Administration Schedule; Drug Evaluation; Dr

1982
Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro.
    Cancer research, 1982, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Cell Line; Cell Survival; Clone Cells; Colonic Neoplasms; Dose-Response Relationship

1982
Clinical and pharmacokinetic effects of combined warfarin and 5-flourouracil in advanced colon cancer.
    Cancer research, 1982, Volume: 42, Issue:11

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Kinetic

1982
Nasal cartilage necrosis following high-dose 5-FU: a case report.
    Cancer treatment reports, 1982, Volume: 66, Issue:10

    Topics: Adenocarcinoma; Cartilage; Female; Fluorouracil; Humans; Middle Aged; Necrosis; Nose; Pelvic Neoplas

1982
The selectivity of action of methotrexate in combination with 5-fluorouracil in xenografts of human colon adenocarcinomas.
    Molecular pharmacology, 1982, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Female; Fluorouracil; Humans; Methotr

1982
[Combined therapy of advanced gastric cancer].
    Revista medica de Chile, 1982, Volume: 110, Issue:3

    Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Methotrexate; Middle Aged; Stomach Neopla

1982
Metastatic adenocarcinoma of unknown primary site: analysis of 245 patients seen at The Johns Hopkins Hospital from 1965--1979.
    Medical and pediatric oncology, 1982, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Aged; Cyclophosphamide; Diaphragm; Doxorubicin; Female; Fluorouracil; Humans; Male;

1982
[Evaluation of the therapeutic effect of HCFU (1-hexylcarbamoyl-5-fluorouracil) on non-resectable stomach cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; F

1982
[Antitumor effect of UFT against malignant tumors of maxillary sinus--clinical and biochemical study].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1982, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Drug Therapy, Combination; Female; Fluorourac

1982
Estramustine phosphate with multiple cytotoxic agents in treatment of advanced prostatic cancer.
    Urology, 1981, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Drug Therapy, Combination; Estra

1981
Angina and anemia with marked valvular stenosis.
    Hospital practice (Hospital ed.), 1982, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Aged; Anemia, Hypochromic; Angina Pectoris; Aortic Valve Stenosis; Colon; Colonic Ne

1982
[Effect of chemotherapy on the growth of human gastrointestinal tumor strains].
    Vestnik Akademii meditsinskikh nauk SSSR, 1980, Issue:11

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Fluorouracil; Humans; Liver Neoplasms, Experimental; Mic

1980
[Experimental chemotherapy. II: Study of the cytomorphologic effects of radiation and antitumor chemotherapy on neoplastic tissue].
    Revista espanola de oncologia, 1980, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chick Embryo; Culture Techniques; Cyclophosphamide;

1980
The relationship of the possible hepatic toxicity of chemotherapeutic drugs and carcinoembryonic antigen elevation.
    Cancer, 1981, Feb-01, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Biopsy; Carcinoembryonic Antigen; Chemical and Drug Induced Liver Injury; Fluorourac

1981
Thymidylate synthetase activity and fluorouracil sensitivity of human colonic cancer and normal mucosal tissue preparations.
    Cancer, 1981, Mar-15, Volume: 47, Issue:6

    Topics: Adenocarcinoma; Colon; Colonic Neoplasms; Deoxyuracil Nucleotides; Dose-Response Relationship, Drug;

1981
Effect of 1-hexylcarbamoyl-5-fluorouracil on spontaneous mammary adenocarcinoma of mice.
    Gan, 1980, Volume: 71, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Fluorouracil;

1980
Methyl-CCNU, 6-thioguanine, and 5-fluorouracil in advanced colorectal cancer.
    Medical and pediatric oncology, 1981, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Hum

1981
5-fluorouracil, adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung.
    Cancer, 1981, Jul-01, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Drug Administration Schedule; Drug Therapy, Combination; F

1981
Vinblastine, cyclophosphamide and 5-fluorouracil (VEF) combination chemotherapy for metastatic hypernephroma.
    Oncology, 1981, Volume: 38, Issue:4

    Topics: Adenocarcinoma; Aged; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Humans; Mal

1981
Chemotherapy of advanced and recurrent endometrial carcinoma with cyclophosphamide, doxorubicin, 5-fluorouracil, and megestrol acetate.
    American journal of obstetrics and gynecology, 1981, Jun-01, Volume: 140, Issue:3

    Topics: Adenocarcinoma; Age Factors; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Drug Therapy, Com

1981
Chemotherapy of human colorectal tumor xenografts in athymic mice with clinically active drugs: 5-fluorouracil and 1-3-bis-(-2-chloroethyl)-1-nitrosourea (BCNU). Comparison with doxorubicin derivatives: 4'deoxydoxorubicin and 4'-O-methyldoxorubicin.
    International journal of cancer, 1981, Jan-15, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Doxorubicin; Fluorouracil; Humans; Mice; Mic

1981
Antitumor activity of 1-alkoxycarbonylalkylcarbamoyl-5-fluorouracil derivatives by oral administration.
    Journal of pharmacobio-dynamics, 1981, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fema

1981
[Analysis of radiobiological parameters of radiation therapy of local rectum carcinomas after preceding synchronization of the tumour cell cycle (author's transl)].
    Radiobiologia, radiotherapia, 1981, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Cell Cycle; Fluorouracil; Humans; Middle Aged; Rectal Neoplasms

1981
Studies in an animal model on the effectiveness of adjuvant chemotherapy with 5-FU and BCNU in cases of colorectal adenocarcinoma.
    Journal of cancer research and clinical oncology, 1981, Volume: 100, Issue:2

    Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluoroura

1981
Effects of nandrolone decanoate on the toxicity and anti-tumour action of CCNU and FU in murine tumours.
    British journal of cancer, 1981, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Animals; Cell Survival; Drug Therapy, Combination; Female; Fluorouracil; Lethal Dose

1981
Long-term survivors with nonresectable advanced carcinoma of the rectum.
    Diseases of the colon and rectum, 1981, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Follow-Up Studies; Humans; Middle Aged; Prognosis; Recta

1981
Triple drug chemotherapy in treatment of prostate adenocarcinoma Nb Pr A.I.-III.
    Investigative urology, 1981, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Animals; Carmustine; Cyclophosphamide; Doxorubicin; Drug Combinations; Drug Therapy,

1981
[Remote results of the treatment of colon cancer].
    Khirurgiia, 1981, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Mal

1981
Severe intoxication after combined chemotherapy of a sigma-adenocarcinoma with peptichemio and 5-fluorouracil.
    Blut, 1981, Volume: 43, Issue:5

    Topics: Adenocarcinoma; Female; Fluorouracil; Gastroenteritis; Humans; Leukopenia; Melphalan; Middle Aged; P

1981
[Effect of 5-fluorouracil (5 Fu) on growth and morphology of human ovarian clear cell carcinoma transplanted into nude mice (author's transl)].
    Nihon Gan Chiryo Gakkai shi, 1981, Aug-20, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Animals; Female; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplanta

1981
[Early cardiotoxicity of 5-fluorouracil].
    Giornale italiano di cardiologia, 1981, Volume: 11, Issue:11

    Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Male; Middle Aged; Myocarditis; Pericarditi

1981
The value of lymphocyte transformation in carcinoma of the colon and rectum.
    Surgery, gynecology & obstetrics, 1980, Volume: 150, Issue:5

    Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Lymphocyte Activa

1980
Evaluation of nonhormonal cytotoxic chemotherapy in the Nb rat prostate adenocarcinoma: autonomous tumor (18-Pr and 13-Pr).
    Cancer, 1980, Jul-15, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Ev

1980
Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion.
    Cancer research, 1980, Volume: 40, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Bone Marrow; Fluorouracil; Humans; Infusions, Parenteral; Inje

1980
Inhibition of murine colon adenocarcinomas and Lewis lung carcinoma by 1-hexylcarbamoyl-5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1980, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; In Vitro Techniques

1980
Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 2. Tumor remission following treatment with 5-FU and VCR of xenotransplanted primary human colorectal adenocarcinomas.
    Journal of cancer research and clinical oncology, 1980, Volume: 97, Issue:1

    Topics: Adenocarcinoma; Animals; Drug Therapy, Combination; Female; Fluorouracil; Humans; Male; Mice; Mice,

1980
Treatment of carcinoma of the rectum and squamous carcinoma of the anus by combination chemotherapy, radiotherapy and operation.
    Surgery, gynecology & obstetrics, 1980, Volume: 151, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans;

1980
Long term survival following chemotherapy for carcinoma of the pancreas.
    The British journal of clinical practice, 1980, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Pancreatic Neoplasms; Razoxane

1980
Chemotherapeutic study on canine gastric cancer induced by N-ethyl-N'-nitro-N-nitrosoguanidine.
    Gan, 1980, Volume: 71, Issue:3

    Topics: Adenocarcinoma; Animals; Dogs; Fluorouracil; Humans; Male; Methylnitronitrosoguanidine; Stomach Neop

1980
Melphalan, 5-fluorouracil, and medroxyprogesterone acetate in metastatic or recurrent endometrial carcinoma. Preliminary report.
    Obstetrics and gynecology, 1980, Volume: 56, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medr

1980
[Fluorouracil, mitomycin-C and adriamycin in the treatment of metastasizing gastrointestinal adenocarcinomas].
    Schweizerische medizinische Wochenschrift, 1980, Jul-08, Volume: 110, Issue:27-28

    Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans;

1980
5-fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas.
    Cancer, 1980, Nov-01, Volume: 46, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Sche

1980
[Adjuvant chemotherapy of human colorectal adenocarcinoma after growth on mice with congenital thymic dysplasia ("nude"). 1. Experiments to test the feasibility of combined chemotherapy with VCR and 5-FU (author's transl)].
    Journal of cancer research and clinical oncology, 1980, Volume: 96, Issue:3

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Mice; M

1980
Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.
    The Journal of clinical investigation, 1980, Volume: 66, Issue:5

    Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma; Cell Line; Colonic Neoplasms; Drug Administration Sched

1980
5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer.
    Annals of internal medicine, 1980, Volume: 93, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb

1980
Sequential carcinoembryonic antigen levels. A predictor of response and relapse in combination chemotherapy of advanced gastrointestinal cancer.
    Oncology, 1981, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Carcinoembryonic Antigen; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil

1981
Biochemical determinants of responsiveness to 5-fluorouracil and its derivatives in xenografts of human colorectal adenocarcinomas in mice.
    Cancer research, 1981, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; M

1981
Modulation of 5-fluorouracil metabolism and cytotoxicity by antimetabolite pretreatment in human colorectal adenocarcinoma HCT-8.
    Cancer research, 1981, Volume: 41, Issue:3

    Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; Me

1981
Punctal-canalicular stenosis related to systemic fluorouracil therapy.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1981, Volume: 99, Issue:2

    Topics: Adenocarcinoma; Adult; Breast Neoplasms; Female; Fluorouracil; Humans; Intestinal Neoplasms; Lacrima

1981
The combination 5-fluorouracil/levamisole induces enhanced rat Kupffer cell-mediated cytotoxicity in vitro against the syngeneic colon adenocarcinoma cell line CC531.
    Journal of surgical oncology, 1995, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Analysis of Variance; Animals; Cell Separation; Cells, Cultu

1995
Raloxifene (LY156758) produces antimetastatic responses and extends survival in the PAIII rat prostatic adenocarcinoma model.
    The Prostate, 1995, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adrenal Glands; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Dis

1995
[Augmentation of chemotherapeutic efficaciousness of UFT by oral l-leucovorin--l-leucovorin factors enhancing cytotoxic activity of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:13

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Colonic Neopla

1995
[A case of gastric cancer responding well to MTX/5-FU (methotrexate/5-fluorouracil) and PMUE (CDDP, MMC, UFT, etoposide) therapies upon lymphnode recurrence].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

1995
Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities.
    The American journal of medicine, 1995, Volume: 99, Issue:6

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Brain Diseases; Cecal Neoplasms; Dihydrourac

1995
Cancer recurrence following laparoscopic colectomy. Report of two patients treated with heated intraperitoneal chemotherapy.
    Diseases of the colon and rectum, 1995, Volume: 38, Issue:10

    Topics: Adenocarcinoma; Colectomy; Colonic Neoplasms; Fluorouracil; Humans; Infusions, Parenteral; Laparosco

1995
[Intra-arterial infusion chemotherapy for advanced liver metastases from lung cancer via implantable vascular access: report of six cases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplat

1995
[A case of intrahepatic infusion chemotherapy with angiotensin II human for liver metastasis from early gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure

1995
[Sclerosing cholangitis-induced biliary cyst formation: complication of hepatic artery infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:11

    Topics: Adenocarcinoma; Biliary Tract Diseases; Cholangitis, Sclerosing; Cysts; Fluorouracil; Hepatic Artery

1995
[A case of advanced gastric cancer treated effectively with neo-adjuvant chemotherapy using l-leucovorin and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Adminis

1995
[A synchronous double cancer of esophagus and stomach treated with 5-fluorouracil and consecutive low-dose cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1995
Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemo

1995
Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases.
    Cancer investigation, 1995, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Chemoth

1995
Preoperative infusional chemoradiation therapy for stage T3 rectal cancer.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Drug Administration Sched

1995
5-Fluorouracil-radiation interactions in human colon adenocarcinoma cells.
    International journal of radiation oncology, biology, physics, 1995, Jul-15, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Cell Cycle; Cell Division; Cell Survival; Colonic Neoplasms; Fluorouracil; Humans; R

1995
[Advanced gastric carcinoma with extensive lymph node metastases successfully treated by sequential methotrexate/5-fluorouracil therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro

1995
A comparative study with two administration schedules of leucovorin and 5-fluorouracil in advanced colorectal cancer.
    Journal of chemotherapy (Florence, Italy), 1995, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1995
Effective treatment of liver metastases from colon cancer with a combination of gamma-interferon and cisplatin chemotherapy: report of a case.
    Surgery today, 1995, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Cisplatin; Colectomy; Drug Therapy, Combination; Fluorouracil;

1995
Chemotherapy-induced nuclear alterations of morphologic and genomic characteristics in a human colon cancer grafted onto nude mice.
    Diseases of the colon and rectum, 1995, Volume: 38, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Camptothecin; Cell Nucleus; Chromatin; Colonic Neopl

1995
Feasibility of five courses of pre-operative chemotherapy in patients with resectable adenocarcinoma of the oesophagus or gastrooesophageal junction.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1995
A 10-year survivor with unresectable hepatic metastases from sigmoid colon carcinoma treated with regional chemotherapy.
    Surgery today, 1995, Volume: 25, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hepatic Artery; Humans

1995
[A case of liver metastasis of gastric cancer with portal vein tumor thrombosis responding to chemotherapy with 5-FU and epirubicin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Fluorouracil; Huma

1995
The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
    International journal of cancer, 1995, Feb-20, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line; Cisplatin; DNA Damage; Esophageal Neop

1995
Isolated pelvic perfusion for unresectable cancer using a balloon occlusion technique.
    Archives of surgery (Chicago, Ill. : 1960), 1993, Volume: 128, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcino

1993
Relation between the incorporation of 5-fluorouracil into liver carcinoma and normal tissue RNA at hepatic arterial administration in the rat is altered by overnight starvation.
    Journal of surgical oncology, 1993, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Animals; Fluorouracil; Hepatic Artery; Infusions, Intra-Arterial; Liver Neoplasms, E

1993
Intensive multimodality therapy for carcinoma of the esophagus and gastroesophageal junction.
    Annals of surgical oncology, 1995, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1995
Multimodality therapy for adenocarcinoma of the esophagus.
    The Annals of thoracic surgery, 1995, Volume: 59, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

1995
[Effects of 5-fluorouracil in shrinking residual gastric cancer: a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:7

    Topics: Adenocarcinoma; Aged; Fluorouracil; Gastrectomy; Humans; Male; Neoplasm, Residual; Remission Inducti

1995
[Low-dose continuous infusion therapy 5-FU and CDDP enabled terminal patients with lung and rectal cancer to remain at home].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac

1994
[Home therapy approach in cancer patients-chemotherapy (case 2-1)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac

1994
[Home therapy approach in cancer patients-chemotherapy (case 2-3)--intra-arterial infusion cancer chemotherapy for hepatic metastasis of colorectal cancer--case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21 Suppl 4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoembolization, Therapeutic

1994
New therapeutic strategies for patients with gastrointestinal malignancies using biochemical modulation of fluorouracil.
    JAMA, 1995, Jan-18, Volume: 273, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Colonic Neoplasms; Fatal

1995
[The use of endolymphatic chemotherapy in patients with metastatic stomach cancer].
    Klinicheskaia khirurgiia, 1994, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1994
Colo-rectal carcinoma in a tropical African population: an overview report.
    East African medical journal, 1994, Volume: 71, Issue:10

    Topics: Adenocarcinoma; Administration, Rectal; Adolescent; Adult; Aged; Anus Neoplasms; Ascites; Colonic Ne

1994
[Two patients with far advanced gastric cancer responding to combination chemotherapy with 5-FU and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluo

1995
[Case report of long-term survivor of advanced gastric cancer associated with peritoneal dissemination successfully treated with cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci

1995
FLEP (5-fluorouracil, leucovorin, etoposide, cisplatin) in advanced gastric cancer.
    European journal of cancer (Oxford, England : 1990), 1994, Volume: 30A, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin;

1994
[A case of meningeal carcinomatosis which occurred after treatment for recurrence of the cervical carcinoma].
    Nihon Sanka Fujinka Gakkai zasshi, 1995, Volume: 47, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combine

1995
SMS 201.995 (Sandostatin) enhances in-vitro effects of 5-fluorouracil in colorectal cancer.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Carcinoma; Colonic Neoplasms; Colorimetry; Drug Synergism; Fluorouracil; Humans; Oct

1995
[A case of advanced gastric remnant carcinoma with Virchow's metastasis treated with neoadjuvant chemotherapy (low dose CDDP + 5-FU) followed by surgical resection].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; E

1995
[A case report: postoperative recurrence of peritoneal dissemination of gastric cancer responding to sequential methotrexate and 5-FU (5-fluorouracil)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi

1995
Pharmacokinetic analysis of sparse in vivo NMR spectroscopy data using relative parameters and the population approach.
    European journal of clinical pharmacology, 1994, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Data Interpretation, Statistical; Female; Fluorou

1994
[Cardiac toxicity of 5-fluorouracil].
    Medizinische Klinik (Munich, Germany : 1983), 1994, Dec-15, Volume: 89, Issue:12

    Topics: Adenocarcinoma; Angina Pectoris; Cardiomyopathies; Cecal Neoplasms; Colonic Neoplasms; Death, Sudden

1994
Effect of 5-fluorouracil on methotrexate transport and cytotoxicity in HT29 colon adenocarcinoma cells.
    Cancer letters, 1995, Jan-27, Volume: 88, Issue:2

    Topics: Adenocarcinoma; Biological Transport; Colonic Neoplasms; Drug Administration Schedule; Drug Synergis

1995
[A case of multiple liver metastasis from remnant gastric cancer responding to leucovorin.5-FU+UFT therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1995, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Adm

1995
Antitumour activity of 5-fluorouracil, verapamil and hyperthermia against human gastric adenocarcinoma cell (AGS) in vitro.
    Surgical oncology, 1994, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modality Therap

1994
[Chemotherapy in the treatment of brain metastases of breast cancers].
    Bulletin du cancer, 1994, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; C

1994
A single institutional experience with preoperative chemoradiotherapy for stage I-III pancreatic adenocarcinoma.
    The American surgeon, 1993, Volume: 59, Issue:11

    Topics: Adenocarcinoma; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Blood Loss, Surgi

1993
Five-drug combination chemotherapy (FAPEL) for advanced gastric cancer: a pilot study.
    Journal of the Formosan Medical Association = Taiwan yi zhi, 1994, Volume: 93, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1994
The arotinoid Ro 40-8757 has antiproliferative effects in drug-resistant human colon and breast cancer cell lines in vitro.
    Cancer letters, 1994, Sep-30, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Cell Division; Colonic Neoplasms; Doxorubic

1994
Fine-needle aspiration cytology in locally advanced breast adenocarcinoma: a case with complete response to preoperative chemotherapy in association with granulomatous inflammatory reaction.
    Diagnostic cytopathology, 1994, Volume: 10, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplas

1994
[A long-survival case of unresectable liver metastasis of colon cancer by hepatic arterial intermittent multidrug infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Doxoru

1994
[A case of fistula-cancer response to arterial chemoembolization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Chemoembolization, T

1994
[A case of gastric cancer with Borrmann type 4 responding to 5-FU-MMC combined chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Fluoro

1994
[A case of metastatic breast cancer successfully treated with weekly low-dose epirubicin (EPI), cyclophosphamide (CPA), 5-fluorouracil (5-FU) and medroxyprogesterone (MPA)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cy

1994
5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation.
    The Canadian journal of cardiology, 1994, Volume: 10, Issue:8

    Topics: Acute Disease; Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lip Ne

1994
Acute arterial thrombosis in a patient with breast cancer after chemotherapy with 5-fluorouracil, doxorubicin, leucovorin, cyclophosphamide, and interleukin-3.
    Cancer, 1994, Nov-15, Volume: 74, Issue:10

    Topics: Acute Disease; Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cer

1994
Somatostatin analogue octreotide modulates metabolism and effects of 5-fluorouracil and 5-fluorouridine in human colon cancer spheroids.
    Cancer letters, 1994, Oct-28, Volume: 86, Issue:1

    Topics: Adenocarcinoma; Amino Acid Sequence; Cell Cycle; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug

1994
5-Fluorouracil, adriamycin, and mitomycin C in adenocarcinoma of the esophagus or gastroesophageal junction tumors.
    American journal of clinical oncology, 1994, Volume: 17, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Esophageal

1994
[A case of advanced gastric cancer successfully treated with resection after FEP (5-FU, epirubicin, CDDP) combined chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:15

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; D

1994
Evolution of treatment strategies for adenocarcinoma of the esophagus and gastroesophageal junction.
    The Annals of thoracic surgery, 1994, Volume: 58, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

1994
Management of advanced colorectal cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1994, Volume: 5, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1994
Drug monitoring of 5-fluorouracil: in vivo 19F NMR study during 5-FU chemotherapy in patients with metastases of colorectal adenocarcinoma.
    Magnetic resonance imaging, 1994, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; Fluorouracil; H

1994
[Effect of fagopyrum cymosum rootin on clonal formation of four human tumor cells].
    Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica, 1993, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Carcinoma, Squamous Cell; Drugs, Chinese Herbal;

1993
[Chemotherapy for metastatic brain tumors with CDDP and other agents: correlation between chemotherapeutic effects and the results of in vitro chemosensitivity tests using collagen gel-embedded culture combined with computerized image analysis in metastat
    No shinkei geka. Neurological surgery, 1994, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cispla

1994
Gastric carcinoma: curative resection and adjuvant chemotherapy.
    Archives of medical research, 1994,Spring, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Aged; Anastomosis, Roux-en-Y; Antineoplastic Combined Chemotherapy Protocols; Chemot

1994
Necrosis in a meningioma following systemic chemotherapy. Case report.
    Journal of neurosurgery, 1994, Volume: 81, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Embolizat

1994
[Effect of BOF-A2 on experimental and spontaneous metastasis model of mouse colon 26].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Body Weight; Chemotherapy, Adjuvant; Colonic Neoplas

1994
[A case of advanced gastric cancer with multiple liver metastases showing marked response to new combination chemotherapy using 5-FU, THP and MMC (FTM)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Administrati

1994
Cytotoxic effect of butein on human colon adenocarcinoma cell proliferation.
    Cancer letters, 1994, Jul-15, Volume: 82, Issue:1

    Topics: Adenocarcinoma; Cell Division; Chalcone; Chalcones; Colonic Neoplasms; Flavonoids; Fluorouracil; Hum

1994
Chemoradiotherapy of esophageal carcinoma.
    Cancer, 1994, Aug-15, Volume: 74, Issue:4

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1994
[Detection of thymidylate synthase mRNA in 5-fluorouracil resistant human colon adenocarcinoma cells].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:10

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Resistance; Fluorouracil; Humans; Polymerase Chain Reaction;

1994
[Successful neoadjuvant chemotherapy in a patient with advanced gastric cancer with multiple liver metastases].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

1994
[A case of gastric cancer completely responding to sequential methotrexate and 5-fluorouracil therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Admini

1994
[Neoadjuvant chemotherapy for elderly advanced gastric cancer: a case report of MTX/5-FU sequential therapy followed by radical gastrectomy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug A

1994
[Complete response in a case of unresectable gastric cancer treated by combined chemoimmunotherapy of MMC, 5-FU and OK-432].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

1994
Ethmoid sinus carcinomas: results and prognosis after neoadjuvant chemotherapy and combined surgery--a 10-year experience.
    Surgical neurology, 1994, Volume: 42, Issue:2

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Che

1994
Neoadjuvant therapy for unresectable pancreatic adenocarcinoma.
    Archives of surgery (Chicago, Ill. : 1960), 1993, Volume: 128, Issue:5

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Fluorouracil; Humans; Inf

1993
Enhancement of antitumor effects of combined chemoimmunotherapy.
    Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy, 1993, Volume: 13, Issue:2

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Chemotherapy, Adjuvant;

1993
Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.
    Japanese journal of cancer research : Gann, 1994, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Female; Fluorouracil; Humans; Lung; Lung Neoplasms;

1994
The syndrome of 5-fluorouracil cardiotoxicity: an elusive cardiopathy.
    Cancer, 1994, Apr-01, Volume: 73, Issue:7

    Topics: Adenocarcinoma; Angina Pectoris; Electrocardiography; Female; Fluorouracil; Heart; Heart Diseases; H

1994
Levels of viral glycoprotein reflect enhanced effectiveness of combined drug treatments.
    Life sciences, 1994, Volume: 54, Issue:13

    Topics: Adenocarcinoma; Animals; Antigens, Viral, Tumor; Antineoplastic Combined Chemotherapy Protocols; Cel

1994
Mitoxantrone, 5-FU, and leucovorin in breast cancer.
    Medical and pediatric oncology, 1994, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Adm

1994
Local excision of rectal carcinoma. Early results with combined chemoradiation therapy using 5-fluorouracil and leucovorin.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1994
Laparoscopic intestinal stomas.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anus Neoplasms; Carcinoma, Squamous Cell; Colonic Diseases; Colostomy;

1994
[Nocturnal infusion of 5-fluorouracil in advanced digestive tract cancer--two case reports].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Circadian Rhythm; Drug Administration Schedule; Eso

1994
[Toxicity of levamisole in adjuvant chemotherapy for colorectal cancer].
    La Revue de medecine interne, 1993, Volume: 14, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colorectal N

1993
[The clinical effect of chemotherapy with 5-FU and low-dose CDDP in patients with advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:7

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1994
[Efficacy of the treatment of gastric cancer as neo-adjuvant chemotherapy of 48 hour continuous intravenous infusion of 5-fluorouracil (5-FU) with leucovorin (LV)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:13

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Female; Fluo

1993
Semiautomated 14C-thymidine incorporation assay for in vitro screening of anticancer drug.
    Human cell, 1993, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Radioisotopes; Carcinoma, Signet Ring Cell; Cell Divis

1993
Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.
    Journal of the National Cancer Institute, 1993, Dec-01, Volume: 85, Issue:23

    Topics: Adenocarcinoma; Cell Cycle; Colonic Neoplasms; Drug Administration Schedule; Drug Resistance; Drug S

1993
[A case of pulmonary metastasis from colon cancer successfully treated by 5-FU combined with leucovorin and interferon alpha-2a].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fluoroura

1993
Changes of 31P-MR spectroscopy in experimental tumors following radiotherapy combined with 5-fluorouracil compound (UFT).
    The Tohoku journal of experimental medicine, 1993, Volume: 169, Issue:3

    Topics: Adenocarcinoma; Animals; Cell Division; Combined Modality Therapy; Flow Cytometry; Fluorouracil; Mag

1993
[Cardiac toxicity of 5 fluoro-uracil: a case of atrioventricular conduction disorders].
    Gastroenterologie clinique et biologique, 1993, Volume: 17, Issue:8-9

    Topics: Adenocarcinoma; Fluorouracil; Heart Block; Humans; Male; Middle Aged; Pancreatic Neoplasms

1993
[Weekly hepatic arterial infusion of high-dose 5-FU for liver metastases from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouraci

1993
[Efficacy of 48-hour infusion of 5-fluorouracil for gall bladder cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:15

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

1993
Circadian rhythm-modulated chemotherapy with high-dose 5-fluorouracil: a pilot study in patients with pancreatic adenocarcinoma.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Circadian Rhythm; Diarrhea; Dose-Response Relationship, Drug; Female; F

1993
Sequence-dependent growth-inhibitory effects of the in vitro combination of fluorouracil, cisplatin, and dipyridamole.
    Cancer chemotherapy and pharmacology, 1993, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cis

1993
Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1994
[A case of Borrmann type 4 gastric cancer responding to sequential methotrexate and 5-fluorouracil combined with CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

1994
[Local use of a drug combination consisting of fluorouracil, cyclophosphamide and silicone sorbent in patients with colonic cancer].
    Klinicheskaia khirurgiia, 1993, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Administration, Topical; Antineoplastic Combined Chemother

1993
[Study on the relationship between concentrations of 5-FU and PyNPase activity in tumor tissue during oral 5'-DFUR treatment in patients with advanced colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1994, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Fema

1994
Concomitant preoperative radiochemotherapy in operable locally advanced rectal cancer.
    Diseases of the colon and rectum, 1994, Volume: 37, Issue:2 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fluoroura

1994
A pilot study of concomitant radiation and chemotherapy in patients with locally advanced head and neck cancer.
    American journal of clinical oncology, 1993, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1993
Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance.
    Cancer research, 1993, Aug-15, Volume: 53, Issue:16

    Topics: Adenocarcinoma; Base Sequence; Colonic Neoplasms; DNA, Neoplasm; Drug Resistance; Fluorouracil; Huma

1993
Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Carboplatin; Colonic Neoplasms; Female; Fluorouracil; Humans; Male; Mid

1993
Preliminary results with neoadjuvant therapy and resection for esophageal carcinoma.
    The Annals of thoracic surgery, 1993, Volume: 56, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera

1993
Bowel rest, intravenous hydration, and continuous high-dose infusion of octreotide acetate for the treatment of chemotherapy-induced diarrhea in patients with colorectal carcinoma.
    Cancer, 1993, Sep-01, Volume: 72, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Diar

1993
Locus of the interaction among 5-fluorouracil, leucovorin, and interferon-alpha 2a in colon carcinoma cells.
    Cancer research, 1993, Sep-15, Volume: 53, Issue:18

    Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Synergism; Fluorou

1993
The modulation by L-leucovorin of 5-fluorouracil antitumor activity on human colon carcinoma cells in vitro and in vivo.
    Surgery today, 1993, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays,

1993
[A case of complete response by intermittent intra-arterial injection of 5-fluorouracil and carboplatin for liver metastases due to pancreatic cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Fluorouracil; H

1993
[Advanced breast cancer with onset of multi-organ metastases successfully treated with combined loco-regional therapies: a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Ch

1993
[A case of postoperative pulmonary metastasis of colon cancer which responded to treatment with leucovorin and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1993
A pharmacodynamic and pharmacokinetic study of fluoropyrimidines in a nude mouse system and in postoperative patients with gastric cancer.
    Surgery today, 1993, Volume: 23, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Animals; Colonic Neoplasms; Fluorouracil; Gastrectomy; Humans;

1993
Sensitivity of human colon tumor metastases to anticancer drugs in athymic (nude) mice.
    Cancer letters, 1993, Aug-16, Volume: 72, Issue:1-2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carmustine; Colonic Neoplasms; Doxorubicin; Female;

1993
Continuous 5-fluorouracil infusion causing acute gastric mucosal lesions.
    Endoscopy, 1993, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Female; Fluorouracil; Gastritis; Humans; Infusions, Parenteral; Middle Aged; Stomach

1993
Ternary complex formation and reduced folate in surgical specimens of human adenocarcinoma tissues.
    Cancer, 1993, Jan-15, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Colorectal Neoplasms; Culture Techniques; Fluorouracil; Folic Acid; Humans; Leucovor

1993
Multifocal inflammatory leukencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon.
    Acta neurologica Scandinavica, 1993, Volume: 87, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neop

1993
Histopathological findings in oesophageal carcinoma with and without preoperative chemotherapy.
    Journal of clinical pathology, 1993, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1993
[Alternative combination chemotherapy with mitomycin C, vincristine, methotrexate, 5-fluorouracil, cis-platinum and adriamycin for adenocarcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Do

1993
[Effect of preoperative FPL (5-fluorouracil, cisplatin, leucovorin) therapy on patients with primary unresectable advanced gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl

1993
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
    Cancer immunology, immunotherapy : CII, 1993, Volume: 36, Issue:3

    Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols

1993
High dose rate intraluminal radiation in a combined modality treatment plan for carcinoma of the esophagus.
    Journal of surgical oncology, 1993, Volume: 52, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinoma, Squamous C

1993
Respiratory failure due to pulmonary lymphangitis carcinomatosis.
    Chest, 1993, Volume: 103, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorouracil;

1993
Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy.
    Mayo Clinic proceedings, 1993, Volume: 68, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Hum

1993
[Metachronous liver metastases treated with repeated liver resections and chemotherapy].
    Ugeskrift for laeger, 1993, Mar-08, Volume: 155, Issue:10

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Leucovorin; Liver Neop

1993
Dependence of the thymidylate synthase inhibition rate on the interval after the last administration of tegafur in sigmoid colon cancer patients.
    Journal of surgical oncology, 1993, Volume: 52, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Colon, Sigmoid; Combined Modality Therapy; Drug Admi

1993
[A case of advanced gastric cancer responding to an FAP (5-FU, ADM, platinum compounds) combined chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplati

1993
[A case of advance colon cancer responding to sequential methotrexate and 5-fluorouracil therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati

1993
Combined modality therapy increasing local control of pancreatic cancer.
    Cancer investigation, 1993, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1993
Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1993, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1993
Differential chemosensitivity of local and metastatic human gastric cancer after orthotopic transplantation of histologically intact tumor tissue in nude mice.
    International journal of cancer, 1993, May-28, Volume: 54, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Combined Modali

1993
[A case report: multiple liver metastasis of gastric cancer responding to intraarterial infusion of MTX and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Fluoro

1993
[A patient with stage IV gastric cancer responding to combination chemotherapy with 5-FU, leucovorin and CDDP].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1993, Volume: 20, Issue:8

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio

1993
High-dose folinic acid, 5-fluorouracil bolus and infusion in advanced pancreatic adenocarcinoma: a pilot study.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1993
Rapid-fractionation pre-operative chemoradiation for malignant periampullary neoplasms.
    Journal of the Royal College of Surgeons of Edinburgh, 1995, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neoplasm Staging; Pancreatic Neoplasms

1995
Multi-chemothermoimmunotherapy for human colon adenocarcinoma in vitro.
    Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carbop

1996
[FAM as a palliative chemotherapy for gastric cancer with bone metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disseminated Intrava

1996
[Three cases of uterine cervical adenocarcinoma successfully treated by neoadjuvant chemotherapy with continuous intra-arterial infusion (cisplatin, 5-fluorouracil)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl

1996
[Study of serum CDDP concentrations in patients with advanced or recurrent adeno-or squamous cell carcinoma under combination chemotherapy of 5-FU (CIV) and low-dose CDDP (IV)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1996
Preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head.
    American journal of surgery, 1996, Volume: 171, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In

1996
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1995
Palliation of dysphagia in patients with malignant esophageal strictures. Comparison of results of radiotherapy, chemotherapy and esophageal stent treatment.
    Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

1996
Preoperative "chemoradiation" for stages II and III rectal carcinoma.
    Archives of surgery (Chicago, Ill. : 1960), 1996, Volume: 131, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

1996
Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis--a case report.
    Cancer, 1996, Jan-15, Volume: 77, Issue:2

    Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Brain Diseases; Colonic Neoplasms; Demyelinati

1996
Advanced colorectal cancer treated with combined 5-fluorouracil and folinic acid: the experience within a surgical department.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1995, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Fema

1995
[5-fluorouracil: cause of a fatal myocardial infarction in combined radiochemotherapy?].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1996, Volume: 172, Issue:5

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Antimetabolites, Antineoplastic; Fatal Outcome; Female; Flu

1996
Pattern of failure in patients with inflammatory breast cancer treated by alternating radiotherapy and chemotherapy.
    Cancer, 1995, Dec-01, Volume: 76, Issue:11

    Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic A

1995
Adenocarcinoma of the duodenum with liver metastases. Complete remission and long-term survival with 5-fluorouracil chemotherapy--a case report.
    American journal of clinical oncology, 1996, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Duodenal Neoplasms; Female; Fluorouracil; Humans; Liver Neoplasms; Remission

1996
Carcinoma colon with mandible and liver metastases.
    The British journal of oral & maxillofacial surgery, 1996, Volume: 34, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci

1996
Possible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities.
    Recenti progressi in medicina, 1996, Volume: 87, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cyclophosphamide; Dr

1996
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
    Cancer research, 1996, Jun-01, Volume: 56, Issue:11

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell

1996
Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base.
    Archives of otolaryngology--head & neck surgery, 1996, Volume: 122, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

1996
The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
    British journal of cancer, 1996, Volume: 73, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo

1996
Preoperative treatment of patients with locally advanced unresectable rectal adenocarcinoma utilizing continuous chronobiologically shaped 5-fluorouracil infusion and radiation therapy.
    Cancer, 1996, Jul-15, Volume: 78, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Antimetabolites, Antineoplastic; Cohort Studies; Combined M

1996
[A case of advanced gastric cancer with lung and liver metastasis treated by CDDP and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; C

1996
p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas.
    International journal of cancer, 1996, Jun-21, Volume: 69, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colorectal Neo

1996
[Radiotherapy of inoperable esophageal cancer. Retrospective analysis apropos of 108 cases].
    Bulletin du cancer. Radiotherapie : journal de la Societe francaise du cancer : organe de la societe francaise de radiotherapie oncologique, 1990, Volume: 77, Issue:1

    Topics: Actuarial Analysis; Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplast

1990
[A case of carcinomatous peritonitis for which combination therapy of 5-FU, leucovorin and cisplatin was effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Appendiceal Neoplasms; Cisplatin; Fl

1996
Concurrent 5-fluorouracil, mitomycin C and irradiation in locally advanced cervix cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1995, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

1995
Intermittent continuous infusion of ifosfamide and 5-fluorouracil in patients with advanced adenocarcinoma of the pancreas.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1995, Volume: 6, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1995
[Regression of 4th-stage cancer of the rectum].
    Khirurgiia, 1996, Issue:2

    Topics: Adenocarcinoma; Combined Modality Therapy; Female; Fluorouracil; Humans; Middle Aged; Rectal Neoplas

1996
Pancreatic cancer: treatment with neutron irradiation alone and with chemotherapy.
    Radiology, 1996, Volume: 200, Issue:3

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adju

1996
[Severe myalgias: an unusual undesirable effect of levamisole combined with 5-fluorouracil].
    Gastroenterologie clinique et biologique, 1996, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined

1996
Canities--reversal with chemotherapy.
    The Journal of the Association of Physicians of India, 1995, Volume: 43, Issue:8

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplasm

1995
Two cases of neurotoxicity possibly related to 5-fluorouracil and FA administration.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:2

    Topics: Adenocarcinoma; Central Nervous System Diseases; Colonic Neoplasms; Drug Interactions; Female; Fluor

1996
Inhibition of experimental liver metastasis by combined treatment with tamoxifen and interferon.
    Anti-cancer drugs, 1996, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineopl

1996
Inhibitory effect of a novel non-steroidal aromatase inhibitor, YM511 on the proliferation of MCF-7 human breast cancer cell.
    The Journal of steroid biochemistry and molecular biology, 1996, Volume: 58, Issue:2

    Topics: Adenocarcinoma; Aromatase Inhibitors; Breast Neoplasms; Cell Division; DNA; Enzyme Inhibitors; Estra

1996
5-fluorouracil and folinic acid in advanced adenocarcinoma of the esophagus or esophago-gastric junction area. Rotterdam Esophageal Tumor Study Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1996, Volume: 7, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Drug Therapy, Combination;

1996
Intratumoral chemotherapy with a sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts.
    Anti-cancer drugs, 1995, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations

1995
Paradoxical clinical deterioration despite near-complete pathological response to neoadjuvant chemotherapy for locally advanced gastro-oesophageal adenocarcinoma.
    Surgical oncology, 1995, Volume: 4, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1995
[A case of Borrmann type 4 gastric cancer successfully treated with MTX and 5-FU therapy through the hepatic artery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu

1996
Modified clearing technique to identify lymph node metastases in post-irradiated surgical specimens from rectal adenocarcinoma.
    Archives of medical research, 1996,Spring, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; Ly

1996
Preoperative radiotherapy for rectal cancer: benefits and controversies.
    Annals of surgical oncology, 1996, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Neopl

1996
Postoperative radiotherapy for locally advanced colon cancer.
    Annals of surgical oncology, 1996, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

1996
Exacerbation of rheumatoid arthritis after termination of chemotherapy for breast carcinoma.
    The Journal of rheumatology, 1996, Volume: 23, Issue:11

    Topics: Adenocarcinoma; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Breast Neoplasms; Cyclophosphamid

1996
Tumor size and origin determine the antitumor activity of cisplatin or 5-fluorouracil and its modulation by leucovorin in murine colon carcinomas.
    Cancer chemotherapy and pharmacology, 1996, Volume: 39, Issue:1-2

    Topics: Adenocarcinoma; Animals; Antidotes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Prot

1996
Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas.
    British journal of cancer, 1997, Volume: 75, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Carcinoembryonic Antigen; Chemot

1997
[A case of colon cancer with local recurrence successfully treated by systemic and local intra-arterial chemotherapy using a combination of 5-fluorouracil, interferon-alpha 2A, leucovorin and carboplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Colectomy; Colonic Neop

1997
The importance of continued endocrine treatment during chemotherapy of hormone-refractory prostate cancer.
    European urology, 1997, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocol

1997
Small intestinal cancer with extensive lymph node metastases showing complete remission by methotrexate/5-fluorouracil sequential therapy: report of a case.
    Surgery today, 1997, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1997
[Results of adjuvant chemotherapy of operated high risk cervix carcinoma].
    Geburtshilfe und Frauenheilkunde, 1996, Volume: 56, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

1996
[Clinical analysis of adjuvant chemotherapy using 5-fluorouracil, leucovorin and cis-diamminedichloroplatinum for patients with advanced and recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Chem

1997
[A case of advanced colon cancer with marked response to combination chemotherapy with 5-FU, low dose CDDP, and leucovorin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1997
[A two-year asymptomatic case with postoperative lung metastasis of sigmoid colon cancer responding to sequential methotrexate and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colon, Sigmoid; Drug Administr

1997
"Sandwich" preoperative and postoperative combined chemotherapy and radiation in tethered and fixed rectal cancer: impact of treatment intensity on local control and survival.
    International journal of radiation oncology, biology, physics, 1997, Feb-01, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Combined Mod

1997
Preliminary results of preoperative 5-fluorouracil, low-dose leucovorin, and concurrent radiation therapy for clinically resectable T3 rectal cancer.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clin

1997
Adenocarcinoma of bladder.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1997, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; C

1997
[Two cases of advanced gastric cancer effectively treated with chemotherapy of 5-fluorouracil, cisplatin and cytarabine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Administ

1997
Impact of schedule on leucovorin potentiation of fluorouracil antitumor activity in dietary folic acid deplete mice.
    Biochemical pharmacology, 1997, Apr-25, Volume: 53, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Diet; Drug Synergism; Fluor

1997
Growth inhibition and apoptotic cell death in uterine cervical carcinoma cells induced by 5-fluorouracil.
    International journal of cancer, 1997, May-16, Volume: 71, Issue:4

    Topics: Adenocarcinoma; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Squamous

1997
Carcinoma of the esophagus treated with radical chemoradiation 19 years after irradiation for recurrent breast cancer.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 1997, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Squamou

1997
Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction.
    Cancer research, 1997, Jun-15, Volume: 57, Issue:12

    Topics: 16,16-Dimethylprostaglandin E2; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis;

1997
Effect of preoperative 5-fluorouracil on apoptosis of advanced gastric cancer.
    Journal of surgical oncology, 1997, Volume: 65, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Flow Cytometry; Fluorouracil; Humans; In

1997
Focal dystonia after chemotherapy: a case series.
    Journal of neuro-oncology, 1997, Volume: 34, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Colonic Neoplasms; Doxorubicin; Dyst

1997
[Pyrimidine nucleoside phosphorylase activity, 5-fluorouracil concentration and thymidylate synthase inhibition rate in colorectal cancer after oral administration of 5'-doxifluridine].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Flo

1997
[Secondary hepatic resections in a case of sigmoid colon cancer with multiple liver metastasis (H3) after successful continuous hepatic artery infusion chemotherapy oriented by in vitro chemosensitivity test].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:8

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug

1997
Weekly chronomodulated 48 h infusion of high-dose 5-fluorouracil modulated by methotrexate and (6S)-leucovorin in advanced colorectal cancer: a phase IB study.
    Anti-cancer drugs, 1997, Volume: 8, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as

1997
Pharmacokinetics of intrapericardial administration of 5-fluorouracil.
    Cancer chemotherapy and pharmacology, 1997, Volume: 40, Issue:4

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Area Under Curve; Bre

1997
Preventive effect of 1-(2-tetrahydrofuryl)-5-fluorouracil in combination with uracil on colonic carcinogenesis induced by 1,2-dimethylhydrazine in rats.
    Cancer detection and prevention, 1997, Volume: 21, Issue:4

    Topics: 1,2-Dimethylhydrazine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Differentiatio

1997
Induction chemoradiotherapy followed by esophagectomy in patients with carcinoma of the esophagus.
    The Annals of thoracic surgery, 1997, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1997
[Inhibitory effect of the radiosensitizer AK-2123 on experimental liver metastasis and active transport of calcium ions].
    Voprosy onkologii, 1997, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Calcium Channel Blockers; Female; Fluorour

1997
In vivo and ex vivo study of metabolic and cellular effects of 5-fluorouracil chemotherapy in a mouse mammary carcinoma.
    Magnetic resonance imaging, 1997, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Cycle; Ethanolamines; Fluorouracil; Magnetic Re

1997
Combined modality therapy for stage II and stage III pancreatic carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1997
Role of mitomycin C in the development of late bowel toxicity following chemoradiation for locally advanced carcinoma of the cervix.
    International journal of radiation oncology, biology, physics, 1997, Jul-15, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Clear Cell; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplas

1997
Accelerated fractionation in esophageal cancers: a multivariate analysis on 88 patients.
    International journal of radiation oncology, biology, physics, 1997, Jul-15, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera

1997
Appendiceal carcinoma: patterns of failure following surgery and implications for adjuvant therapy.
    Journal of surgical oncology, 1997, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Appendiceal Neoplas

1997
Immunocytochemical detection of P-glycoprotein in the management of malignant effusions.
    Journal of cancer research and clinical oncology, 1997, Volume: 123, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; ATP Binding Cassette

1997
Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer.
    AJNR. American journal of neuroradiology, 1997, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Brain; Chemotherapy, Adjuva

1997
Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
    Maryland medical journal (Baltimore, Md. : 1985), 1997, Volume: 46, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemothera

1997
Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
    American journal of clinical oncology, 1997, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplasti

1997
[Evaluation of a new anti-cancer drug regimen against uterine cervical cancer in nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Camptothecin; Ca

1997
[Efficacy of systemic chemotherapy in adenocarcinoma of the lung with pleuritis carcinomatosa].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin

1997
[Cisplatin/5-fluorouracil intraperitoneal administration superior to intravenous administration for liver metastases of colonic carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:13

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl

1997
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate (PALA) is inactive in advanced pancreatic carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1997, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Ac

1997
Synergistic effects of hyperthermia in preoperative radiochemotherapy for rectal carcinoma.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Evaluatio

1997
First line protracted venous infusion fluorouracil with CisDDP or carboplatine in advanced colorectal cancer.
    La Clinica terapeutica, 1997, Volume: 148, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy;

1997
[A case of hepatic arterial infusion chemotherapy for multiple liver metastasis from breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Co

1997
[A case report of preoperative intra-arterial infusion chemotherapy for pancreatic head carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Drug Administration

1997
[Liver abscess caused by hepatic artery infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colectomy; Colonic Neoplasms; Fluorouracil; Hepatec

1997
[A case of far-advanced gastric cancer treated with continuous 5-fluorouracil injection and intrahepatic arterial infusion of low-dose cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Esophageal Neoplasm

1997
[Percutanous trans-catheter intervention for the diagnosis and treatment of malignant pericardial effusion, with a report of 50 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1996, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Catheteriz

1996
Mechanisms underlying apoptosis induced by combination of 5-fluorouracil and interferon-gamma.
    Biochemical and biophysical research communications, 1997, Nov-17, Volume: 240, Issue:2

    Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Caspase 1; Colonic Neoplasms; Cysteine Endope

1997
[Preoperative chemoradiation therapy for advanced rectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1997
[Experimental study on intraperitoneal sequential MTX/5-FU therapy for peritoneal seeding in comparison with intravenous administration].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedul

1997
[A case of stage IVb gastric cancer effectively treated by neoadjuvant chemotherapy and total gastrectomy with no residual tumor (R0)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

1997
[Long-term complete response in two cases of liver metastases from rectal and gastric cancer treated with intra-arterial infusion chemotherapy of leucovorin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1997, Volume: 24, Issue:14

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1997
5-Fluorouracil + cisplatin + mitomycin C is a relatively most effective combination against xenograft lines of human colorectal cancer.
    Anti-cancer drugs, 1997, Volume: 8, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp

1997
Suppository administration of chemotherapeutic drugs with concomitant radiation for rectal cancer.
    Diseases of the colon and rectum, 1997, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Administration, Rectal; Animals; Antibiotics, Antineoplastic; Chromatography, High P

1997
Cutaneous metastasis as a complication of hepatic intra-arterial chemotherapy.
    The Ulster medical journal, 1997, Volume: 66, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorourac

1997
[A case of advanced gastric cancer with multiple bone metastasis successfully treated by both methotrexate and 5-fluorouracil sequential therapy, and endoscopic intratumoral injection of 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Chemotherapy,

1998
Topical treatment of vaginal recurrence of endometrial carcinoma with 5-fluorouracil: case-report.
    Clinical and experimental obstetrics & gynecology, 1997, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Administration, Topical; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; B

1997
[Penetrating duodenal ulcer as a complication of a hepatic artery port catheter in hepatic metastasis of sigmoid carcinoma].
    Medizinische Klinik (Munich, Germany : 1983), 1997, Nov-15, Volume: 92, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Duodena

1997
Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Colonic Neoplasms; Dose-

1998
[3D-Ct-planned interstitial HDR brachytherapy + percutaneous irradiation and chemotherapy in inoperable pancreatic carcinoma. Methods and clinical outcome].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Brachytherapy;

1998
Radiation and chemotherapy instead of surgery for low infiltrative rectal adenocarcinoma: a prospective trial.
    Annals of surgical oncology, 1998, Volume: 5, Issue:2

    Topics: Abdomen; Adenocarcinoma; Adjuvants, Immunologic; Anal Canal; Antidotes; Antimetabolites, Antineoplas

1998
Influence of pH on the uptake of 5-fluorouracil into isolated tumour cells.
    British journal of cancer, 1998, Volume: 77, Issue:6

    Topics: Adenocarcinoma; Animals; Biological Transport; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromet

1998
Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
    British journal of cancer, 1998, Volume: 77, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Electrocardiography; Female; Fluorouracil; Heart; H

1998
[A case of advanced gastric cancer with virchow's metastasis responding remarkably to combination chemotherapy of low-dose CDDP and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Chemotherapy, Adjuvant;

1998
[A case of multiple liver metastasis of gastric cancer responding to hepatic arterial infusion chronotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Circadian Rhythm; Cisplatin; Drug Ad

1998
Preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation.
    International journal of radiation oncology, biology, physics, 1998, Mar-15, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Combined Chemotherapy Pro

1998
Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Colo

1998
[p53 and Bax protein expression as predictor of chemotherapeutic effect in gastric carcinoma].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25 Suppl 3

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Aged; Antineoplastic Combined Chemotherapy Protocols; Apo

1998
[Enhanced induction of apoptosis of human colorectal cancer cells after preoperative treatment with 5-fluorouracil its relationship to DNA ploidy pattern].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25 Suppl 3

    Topics: Adenocarcinoma; Apoptosis; Cell Cycle; Colonic Neoplasms; DNA, Neoplasm; Female; Flow Cytometry; Flu

1998
Delayed hypersensitivity to 5-fluorouracil associated with reduced dihydropyrimidine dehydrogenase (DPD) activity.
    Advances in experimental medicine and biology, 1998, Volume: 431

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Creatinine; Dihydrouracil Dehydrogenase (NADP

1998
[Advanced gastric cancer curatively resected following combined neoadjuvant chemotherapy--report of a case].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

1998
A rare event of 5-fluorouracil-associated peripheral neuropathy: a report of two patients.
    American journal of clinical oncology, 1998, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Demyelinating Diseases; Female;

1998
Irinotecan-induced immune thrombocytopenia.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1998, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; B

1998
[How I treat colorectal cancer. I. Prevention and adjuvant treatment].
    Revue medicale de Liege, 1998, Volume: 53, Issue:4

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antidotes; Antimeta

1998
[Proliferation and apoptosis before and after preoperative simultaneous radiochemotherapy of rectal carcinomas].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Biomarkers, Tumor; Biopsy; Cell Division

1998
[The intratumoral levels of thymidylate synthetase and folate in gastric and colon cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Fluoro

1998
[A case of gastric cancer with decreased dihydropyrimidine dehydrogenase activity].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:8

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Dihydrouracil Dehydrogenase (NADP); Female; F

1998
[Intraarterial chemotherapy via reservoir system for far-advanced bladder and prostate cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:9

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1998
Combined preoperative radiation and mitomycin/5-fluorouracil treatment for locally advanced rectal adenocarcinoma.
    Journal of the American College of Surgeons, 1998, Volume: 187, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Mo

1998
Advanced pancreatic cancer successfully treated with continuous infusion of 5-fluorouracil and low-dose cisplatin.
    Internal medicine (Tokyo, Japan), 1998, Volume: 37, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Cisplatin;

1998
Pre-operative sequential chemo- and radiochemotherapy in locally advanced carcinomas of the lower oesophagus and gastro-oesophageal junction.
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:5

    Topics: Adenocarcinoma; Aged; Antidotes; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous

1998
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
    European journal of cancer (Oxford, England : 1990), 1998, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Carcino

1998
[Low-dose CDDP and continuous 5-FU treatment of advanced gastric cancer with peritoneal dissemination: a case with long disease-free survival].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

1998
[Membranous lipodystrophy caused by chemotherapy].
    Annales de dermatologie et de venereologie, 1998, Volume: 125, Issue:6-7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplas

1998
Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1998, Volume: 4, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined

1998
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
    Diseases of the colon and rectum, 1998, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo

1998
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
    Diseases of the colon and rectum, 1998, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo

1998
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
    Diseases of the colon and rectum, 1998, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo

1998
Low rectal cancer: impact of radiation and chemotherapy on surgical treatment.
    Diseases of the colon and rectum, 1998, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antineoplastic Combined Chemo

1998
[Effect of combination chemotherapy of low-dose CDDP. Continuous infusion of 5-FU, and intermittent CPT-11 administration for 2 advanced pancreatic cancer cases with liver metastasis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug

1998
[Probable choroid metastasis of an esophageal adenocarcinoma that regressed with chemotherapy].
    Gastroenterologie clinique et biologique, 1998, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Choroid Neoplasms; Cisplatin;

1998
Immunohistochemical evaluation of thymidylate synthase in gastric carcinoma using a new polyclonal antibody: the clinical role of thymidylate synthase as a prognostic indicator and its therapeutic usefulness.
    Cancer, 1998, Oct-01, Volume: 83, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies; Antimetabolites, Antineoplastic; Carcino

1998
Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Cycle; Cell Survi

1998
[Adenocarcinoma of the Barrett esophagus. Apropos of 44 resected cases].
    Journal de chirurgie, 1997, Volume: 134, Issue:5-6

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic;

1997
Comparison between short or long exposure to 5-fluorouracil in human gastric and colon cancer cell lines: biochemical mechanism of resistance.
    Anti-cancer drugs, 1998, Volume: 9, Issue:7

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Drug Resistanc

1998
High dose rate intraoperative radiation therapy (HDR-IORT) as part of the management strategy for locally advanced primary and recurrent rectal cancer.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antidotes; Antimetabolites, Antineoplastic; Carcinom

1998
Preoperative radiation with concurrent 5-fluorouracil continuous infusion for locally advanced unresectable rectal cancer.
    International journal of radiation oncology, biology, physics, 1998, Sep-01, Volume: 42, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combined Modality T

1998
Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:10

    Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antineoplastic Agents; Carboplatin; Carrier Pr

1997
Potentiation of 5-fluorouracil-leucovorin activity by alpha2a-interferon in colon adenocarcinoma xenografts.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1995, Volume: 1, Issue:1

    Topics: Adenocarcinoma; Animals; Cell Division; Colonic Neoplasms; Combined Modality Therapy; Female; Fluoro

1995
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1996, Volume: 2, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl

1996
[How toxic and effective is simultaneous radiochemotherapy with hydroxyurea, 5-FU and cisplatin in cervix carcinoma?].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1998, Volume: 174, Issue:11

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1998
Patients' experiences of chemotherapy: side-effects associated with 5-fluorouracil + folinic acid in the treatment of colorectal cancer.
    Journal of clinical nursing, 1998, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Aged; Alopecia; Antidotes; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Di

1998
Rapid-fractionation preoperative chemoradiation, pancreaticoduodenectomy, and intraoperative radiation therapy for resectable pancreatic adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1998, Volume: 16, Issue:12

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Combined Modality Therapy; Dose Fractionatio

1998
cis-Diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro.
    Cancer immunology, immunotherapy : CII, 1998, Volume: 47, Issue:4

    Topics: Adenocarcinoma; Animals; Antibodies; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplat

1998
Biochemical modulation therapy for pancreatic cancer.
    Journal of hepato-biliary-pancreatic surgery, 1998, Volume: 5, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Cisplati

1998
[Does neoadjuvant radiochemotherapy augment the resectability of pancreatic cancers?].
    Chirurgie; memoires de l'Academie de chirurgie, 1998, Volume: 123, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combine

1998
[Nursing situation in outpatient chemotherapy following surgery for gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1998, Volume: 25 Suppl 4

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cispla

1998
Detection of multiple hepatic micrometastases in pancreatic adenocarcinoma with a solitary liver metastasis by direct sequencing of the K-ras gene: a case report.
    Surgery, 1999, Volume: 125, Issue:1

    Topics: Adenocarcinoma; Aged; Base Sequence; Combined Modality Therapy; Dose Fractionation, Radiation; Femal

1999
Supraventricular arrhythmia: a complication of 5-fluorouracil therapy.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1998, Volume: 10, Issue:6

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Arrhythmia, Sinus; Arrhythmias, Cardiac; Atr

1998
Adjuvant chemotherapy for patients with resected Dukes' C and high-risk B2 colon cancer with fluorouracil and levamisole.
    Annals of the Academy of Medicine, Singapore, 1998, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Colonic Neoplasms; Female;

1998
Effect of 5-fluorouracil on gastrointestinal carcinogenesis induced by N-methyl-N'-nitro-N-nitrosoguanidine in rats.
    Digestive diseases and sciences, 1999, Volume: 44, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Carcinogens; Carcinoma, Squamous Cell; Flu

1999
[A case of unresectable pancreatic cancer responding to MTX/5-FU sequential therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1999
Rationale of the so-called extended resection for pancreatic invasive ductal carcinoma.
    Digestion, 1999, Volume: 60 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Femal

1999
Clonogenic inactivation of colon cancer-derived cells treated with 5-fluorouracil and indomethacin in hybrid spheroids.
    Acta oncologica (Stockholm, Sweden), 1998, Volume: 37, Issue:7-8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Cyclooxygenase In

1998
[Successful treatment of metastatic bone cancer from colon with combination treatment (radiation and 5-FU); a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Colonic Ne

1999
[A case of multiple liver metastases showing good response by administration of carmofur alone in an aged patient with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Colonic Neopla

1999
[A case of advanced gallbladder cancer responding to neoadjuvant intra-arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1999
[Neoadjuvant chemotherapy FEC-HD in locally advanced breast cancer].
    Bulletin du cancer, 1999, Volume: 86, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal,

1999
[Neoplasm-inhibiting effect and sensitivity-promoting effect of indomethacin in vitro].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 1997, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Division; Co

1997
Inguinal lymph node metastases from rectal adenocarcinoma.
    Journal of surgical oncology, 1999, Volume: 70, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colostomy; Combined Mod

1999
Endoscopic ultrasound cannot determine suitability for esophagectomy after aggressive chemoradiotherapy for esophageal cancer.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1999
Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells.
    Acta haematologica, 1999, Volume: 101, Issue:2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Colonic Neoplasms

1999
Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach.
    Medical physics, 1999, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Aorta; Colorectal Neoplasms; Female; Fluorine Ra

1999
[A case report: modified PMUE therapy might be effective for advanced gastric carcinoma with pulmonary carcinomatous lymphangitis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

1999
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Oncogene, 1999, Apr-01, Volume: 18, Issue:13

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal

1999
Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer.
    International journal of oncology, 1999, Volume: 14, Issue:6

    Topics: 3T3 Cells; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blotting, Northern;

1999
[Thrombotic microangiopathy associated with cancer is an oncologic emergency: a case report].
    La Revue de medecine interne, 1999, Volume: 20, Issue:5

    Topics: Adenocarcinoma; Adult; Anticoagulants; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Ch

1999
Electrochemotherapy against colorectal carcinoma: comparison of in vitro cytotoxicity of 5-fluorouracil, cisplatin and bleomycin.
    International journal of oncology, 1999, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Cell Membrane Permeability; Cisplatin; Co

1999
Rapid development of hepatic metastasis with high incidence following orthotopic transplantation of murine colon 38 carcinoma as intact tissue in syngeneic C57BL/6 mice.
    Journal of surgical oncology, 1999, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic

1999
Clinical significance of serum p53 antibody detection on chemosensitivity assay in human colorectal cancer.
    Journal of surgical oncology, 1999, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Antibodies, Neoplasm; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cispla

1999
[A case of type 4 gastric cancer with peritoneal dissemination treated with intra-aortic chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female

1999
Combination effects of tamoxifen plus 5-fluorouracil on gastric cancer cell lines in vitro.
    Cancer letters, 1999, Jun-01, Volume: 140, Issue:1-2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cell Di

1999
Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.
    Cancer research, 1999, Jul-15, Volume: 59, Issue:14

    Topics: Adenocarcinoma; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Induction; Floxuridine; Fluorouracil; G

1999
Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.
    International journal of radiation oncology, biology, physics, 1999, Jul-15, Volume: 44, Issue:5

    Topics: Adenocarcinoma; Aged; Ampulla of Vater; Antimetabolites, Antineoplastic; Biomarkers, Tumor; CA-19-9

1999
[Total pelvic exenteration and rectal cancer. Apropos of 20 cases].
    Chirurgie; memoires de l'Academie de chirurgie, 1999, Volume: 124, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antidotes; Antimetabolites, Antineoplastic; Antineoplastic Combined Che

1999
Selective inflammatory effect of systemic fluorouracil in actinic keratosis.
    Cutis, 1999, Volume: 64, Issue:1

    Topics: Adenocarcinoma; Administration, Topical; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; F

1999
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 24-1999. Neurologic disorder in a 65-year-old man after treatment of colon cancer.
    The New England journal of medicine, 1999, Aug-12, Volume: 341, Issue:7

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain; Brain Diseases; Cogniti

1999
Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus.
    Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 1999, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chem

1999
FDG PET evaluation of residual masses and regrowth of abdominal lymph node metastases from colon cancer compared with CT during chemotherapy.
    Clinical nuclear medicine, 1999, Volume: 24, Issue:4

    Topics: Abdominal Neoplasms; Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents,

1999
Increased cytotoxicity and bystander effect of 5-fluorouracil and 5-deoxy-5-fluorouridine in human colorectal cancer cells transfected with thymidine phosphorylase.
    British journal of cancer, 1999, Volume: 80, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Survival; Cloning, Molecular; Colorectal Neoplasms; DNA,

1999
[A case of local recurrence of rectal cancer responding to local intraarterial infusion therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:9

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Huma

1999
Increased cytotoxicity and decreased in vivo toxicity of FdUMP[10] relative to 5-FU.
    Nucleosides & nucleotides, 1999, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biotransformation; Body Weight; Chromatogr

1999
High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma.
    International journal of radiation oncology, biology, physics, 1999, Sep-01, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brac

1999
Pathology of rectal adenocarcinoma following preoperative adjuvant radiotherapy and chemotherapy.
    The Ulster medical journal, 1999, Volume: 68, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biopsy; Female; Fibrosis;

1999
Inhibition of angiogenesis and intrahepatic growth of colon cancer by TAC-101.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Be

1999
Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; C

1999
5-fluorouracil-induced small bowel toxicity in patients with colorectal carcinoma.
    Cancer, 1999, Oct-01, Volume: 86, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Diarrhea; Female

1999
The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma.
    British journal of cancer, 1999, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biom

1999
Resected pancreatic cancer treated with adjuvant radiotherapy with or without 5-fluorouracil: treatment results and patterns of failure.
    American journal of clinical oncology, 1999, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Female; Flu

1999
[Contribution of gemcitabine in the treatment of advanced pancreatic cancer].
    La Revue de medecine interne, 1999, Volume: 20, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deo

1999
The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix.
    Cancer, 1999, Oct-15, Volume: 86, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma,

1999
Peritonectomy and intraperitoneal chemotherapy in appendiceal and colorectal cancer.
    The Australian and New Zealand journal of surgery, 1999, Volume: 69, Issue:10

    Topics: Abscess; Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic;

1999
Pre-operative chemoradiotherapy in locally advanced rectal cancer.
    The Australian and New Zealand journal of surgery, 1999, Volume: 69, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomosis, Surgical; Antimetabolites, Antineoplast

1999
Preoperative combined radiotherapy and chemotherapy for rectal cancer does not affect early postoperative morbidity and mortality in low anterior resection.
    Diseases of the colon and rectum, 1999, Volume: 42, Issue:10

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carboplatin; Case-Control St

1999
Resectable esophageal carcinoma: local control with neoadjuvant chemotherapy and radiation therapy.
    Radiology, 1999, Volume: 213, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1999
[Chemotherapy and surgery compared to surgery alone in localized cancer of the esophagus].
    Chirurgie; memoires de l'Academie de chirurgie, 1999, Volume: 124, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chem

1999
Advanced gallbladder carcinoma with liver metastasis showing a favorable response after intra-arterial infusion chemotherapy: report of a case.
    Surgery today, 1999, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplatin;

1999
Gemcitabine and cancer of the pancreas: new preparation. Helpful or not?
    Prescrire international, 1999, Volume: 8, Issue:41

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Deoxycytidine; Fluorourac

1999
[Long partial response (PR) in a case of multiple liver metastasis from colon cancer effectively treated by continuous hepatic intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouraci

1999
[A long-survival case of gastric cancer with multiple liver metastasis: usefulness of intraoperative multimodality therapy and post-operative intra-arterial chemotherapy for liver lesions].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Drug Administration Sche

1999
Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Adminis

1999
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1999
Rectal cancer and inguinal metastases: prognostic role and therapeutic indications.
    Diseases of the colon and rectum, 1999, Volume: 42, Issue:11

    Topics: Abdominal Neoplasms; Adenocarcinoma; Aged; Aged, 80 and over; Biopsy; Female; Fluorouracil; Follow-U

1999
Anaphylactic reaction to oxaliplatin: a case report.
    The American journal of gastroenterology, 1999, Volume: 94, Issue:11

    Topics: Adenocarcinoma; Anaphylaxis; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic

1999
Apoptosis of colorectal adenocarcinoma induced by 5-FU and/or IFN-gamma through caspase 3 and caspase 8.
    International journal of oncology, 1999, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Apoptosis Regulatory Proteins; Blotting,

1999
Complete response of a gastric primary after a short but toxic course of 'S-1' EORTC Early Clinical Studies Group.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1999, Volume: 10, Issue:9

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Drug Combinations; Female; Fluorouracil; Huma

1999
[A case of advanced gastric cancer with abdominal para-aortic lymph node metastasis successfully treated with FLP therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta, Abdominal; Carcinoma, S

1999
Intra-arterial infusion of 5-fluorouracil, leucovorin and cisplatin for primary adenocarcinoma of the urinary bladder.
    International journal of urology : official journal of the Japanese Urological Association, 1999, Volume: 6, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Chemotherapy, Adjuvant; Cisp

1999
Role for alpha1,2-fucosyltransferase and histo-blood group antigen H type 2 in resistance of rat colon carcinoma cells to 5-fluorouracil.
    International journal of cancer, 2000, Jan-01, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Animals; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dru

2000
Histological indications of a favorable prognosis with far-advanced gastric carcinomas after preoperative chemotherapy.
    Journal of cancer research and clinical oncology, 1999, Volume: 125, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cisplatin; Comb

1999
[Curative treatment of non-metastatic esophageal cancer: concomitant chemoradiotherapy and high-dose-rate endoluminal curietherapy boost].
    Gastroenterologie clinique et biologique, 1999, Volume: 23, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agen

1999
Overexpression of Bcl-x(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model.
    The American journal of pathology, 1999, Volume: 155, Issue:6

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Drug Resistance,

1999
Adenocarcinoma of the head of the pancreas: effects of surgical and nonsurgical therapy on survival--a ten-year experience.
    The American surgeon, 1999, Volume: 65, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluorouracil; Humans; Life

1999
Malar metastasis from rectal carcinoma: a case report.
    The American surgeon, 1999, Volume: 65, Issue:12

    Topics: Adenocarcinoma; Antidotes; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fatal Outcome; Female

1999
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
    Journal of experimental & clinical cancer research : CR, 1999, Volume: 18, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemother

1999
Changes in apoptotic and mitotic activity in rectal carcinoma after short-term cytostatic therapy as possible predictive factors.
    Neoplasma, 1999, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Apoptosis; Carcinoembryonic Antigen; Female;

1999
[A case of stage IV (A3) cervical and upper thoracic esophageal adenocarcinoma successfully treated with concurrent chemoradiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1999, Volume: 26, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1999
[Two cases of recurrent gastric cancer for which combination chemotherapy with pirarubicin, cis-platinum and 5-fluorouracil were markedly effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2000
[A case of recurrent pancreatic cancer brought into a complete response by a multimodal treatment with intraarterial chemotherapy and radiotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2000
[Long-term complete response in a case of unresectable rectal cancer following chemoradiation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2000
Preoperative chemoradiation for patients with pancreatic cancer: toxicity of endobiliary stents.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Ampulla of Vater; Antimetabolites, Antineoplastic; A

2000
[Prognosis and adjuvant chemotherapy of axillary node-negative breast cancer patients].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1997, Volume: 35, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal,

1997
Cisplatin-5-fluorouracil therapy with remarkable effect and 5-year survival for paraaortic lymph node metastases of rectal carcinoma in females: a case report.
    Japanese journal of clinical oncology, 1999, Volume: 29, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Female; Fluo

1999
Thirty-four patients with carcinoma of the cervical esophagus treated with chemoradiation therapy.
    Archives of otolaryngology--head & neck surgery, 2000, Volume: 126, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2000
Primary chemo-radiotherapy and selective oesophagectomy for oesophageal cancer: goal of cure with organ preservation.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2000, Volume: 54, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

2000
[A case of stage IVb (H2P0N4T4) gastric cancer successfully treated with neoadjuvant chemotherapy (PMFE therapy)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Etoposide; Fluorour

2000
[A case of gastric cancer with liver metastasis responding to low-dose CDDP/5-FU combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Admi

2000
[A case of diffusely infiltrating carcinoma of the sigmoid colon associated with lymphangitis carcinomatosa effectively treated with sequential MTX.5-FU and 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

2000
[Complete remission in a case of sigmoid colon cancer with multiple liver metastases-treatment with arterial chemotherapy and percutaneous microwave coagulation therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Admi

2000
Combined radiotherapy and chemotherapy (cisplatin and 5-fluorouracil) as palliative treatment for localized unresectable or adjuvant treatment for resected pancreatic adenocarcinoma: results of a feasibility study.
    International journal of radiation oncology, biology, physics, 2000, Mar-01, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; C

2000
[Staging laparoscopy for a patient with advanced gastric cancer whose serum CA 19-9 level decreased remarkably after 2 courses of F/P therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Cisplatin; Drug Adm

2000
Intraperitoneal chemotherapy: biologic implications for clinical outcome.
    Annals of surgery, 2000, Volume: 231, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colonic Neoplasms; Fluorouracil; Humans; Infusions,

2000
Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole.
    Acta oncologica (Stockholm, Sweden), 2000, Volume: 39, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dementia, Vascula

2000
Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.
    International journal of radiation oncology, biology, physics, 1999, May-01, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy;

1999
A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin.
    The American journal of gastroenterology, 2000, Volume: 95, Issue:4

    Topics: Adenocarcinoma; Adult; Anticoagulants; Antimetabolites, Antineoplastic; Drug Interactions; Drug Ther

2000
Preoperative carcinoembryonic antigen level as an independent prognostic factor in colorectal cancer: Taiwan experience.
    Japanese journal of clinical oncology, 2000, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Age Factors; Analysis of Variance; Antimetabolites, Antineoplastic; Carcinoembryonic

2000
Morphological change, loss of deltapsi(m) and activation of caspases upon apoptosis of colorectal adenocarcinoma induced by 5-FU.
    Cancer letters, 2000, May-29, Volume: 153, Issue:1-2

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; Caspases; Cell Nucleus; Colorectal Neopl

2000
Differential role of Fas/Fas ligand interactions in cytolysis of primary and metastatic colon carcinoma cell lines by human antigen-specific CD8+ CTL.
    Journal of immunology (Baltimore, Md. : 1950), 2000, May-01, Volume: 164, Issue:9

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunolog

2000
[A patient with advanced gastric cancer who obtained downstaging and underwent radical surgery by neoadjuvant chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

2000
[Chemosensitivity test for 170 human breast carcinoma samples].
    Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University, 1998, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

1998
Unresectable adenocarcinoma of the pancreas: patterns of failure and treatment results.
    Cancer investigation, 2000, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease Pro

2000
Expression of Escherichia coli uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity.
    Cancer gene therapy, 2000, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Animals; Cell Survival; Colonic Neoplasms; Escherichia coli; Fluorouracil; Lymphoma;

2000
Hepatic arterial infusion of chemotherapy for metastatic colorectal cancer.
    The New England journal of medicine, 2000, May-18, Volume: 342, Issue:20

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Data Interpret

2000
[Role of radiotherapy in the multidisciplinary approach to pancreatic adenocarcinoma].
    Revue medicale de Liege, 2000, Volume: 55, Issue:3

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouracil; Humans; In

2000
[Histoculture drug response assay on non-small cell lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Camptothecin; Carcinoma, Non-

2000
[A case of AFP-producing gastric cancer after curative operation effectively treated with chemotherapies including hepatic arterial infusion therapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Ad

2000
[A case study of alpha feto protein (AFP)-producing gastric carcinoma with multiple liver metastases, in which chemotherapy was effective enough to once save a life in rapid decline].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:5

    Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluor

2000
Treatment of stage D2 hormone refractory carcinoma of the prostate with 5-fluorouracil and Roferon-A: a Southwest Oncology Group study.
    Cancer biotherapy & radiopharmaceuticals, 1996, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fluorouraci

1996
Increased expression of an ATP-binding cassette superfamily transporter, multidrug resistance protein 2, in human colorectal carcinomas.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:6

    Topics: Adenocarcinoma; Adenosine Triphosphate; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic;

2000
Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs.
    Proceedings of the National Academy of Sciences of the United States of America, 2000, Jul-18, Volume: 97, Issue:15

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Culture Media, Conditioned; Doxorubic

2000
[A case of gastric cancer with multiple liver metastasis responding to combined chemotherapy with low-dose cisplatin and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2000
[Weekly low-dose CPT-11 and HCFU for advanced colorectal cancer on an outpatient treatment basis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Pr

2000
Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Anti-cancer drugs, 2000, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Chronotherapy;

2000
Colon carcinoma with synchronous ovarian metastasis--report and discussion of five cases.
    Anti-cancer drugs, 2000, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring

2000
Perfusion of the oesophagus and stomach during hepatic artery chemotherapy via an aberrant gastric artery.
    Australasian radiology, 1999, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Angiography; Antimetabolites, Antineoplastic; Catheterization; Colonic Neoplasms; Em

1999
Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression.
    Gene therapy, 2000, Volume: 7, Issue:14

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cytosine Deaminase; Dose-Response Relationship, Drug; Dr

2000
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1998, Volume: 20, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast

1998
High-dose-rate intraoperative brachytherapy for recurrent colorectal cancer.
    International journal of radiation oncology, biology, physics, 2000, Aug-01, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brachytherapy; Colonic Neopla

2000
Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 2000, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Epirubicin;

2000
Bcl-X(L) antisense sensitizes human colon cancer cell line to 5-fluorouracil.
    Japanese journal of cancer research : Gann, 2000, Volume: 91, Issue:8

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Apoptosis; bcl-X Protein; Colonic Neoplasms; Drug I

2000
[Lymph node and peritoneum metastases of bile duct cancer responding to chronochemotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cisplatin

2000
[A patient with gastric cancer with para-aortic lymph node metastases surviving for 9 years after effective preoperative chemotherapy and radical operation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:9

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aorta; Fluorouracil; Gastrectomy; Humans; Lymph Nod

2000
[A case of metastatic colon carcinoma in which a continuous intrahepatic artery-infusion of 5-FU leucovorin and cisplatin, and systemic chemotherapy with CPT-11 was very effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; C

2000
Concurrent chemotherapy and radiotherapy in invasive cervical cancer patients with high risk factors.
    Journal of Korean medical science, 2000, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma,

2000
[A case of advanced rectal cancer with unresectable liver metastasis for which chemotherapy was markedly effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Combined Modal

2000
[A case of colonic cancer with multiple liver metastases effectively treated by intra-arterial chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal

2000
Dihydropyrimidine dehydrogenase activity and mRNA expression in advanced gastric cancer analyzed in relation to effectiveness of preoperative 5-fluorouracil-based chemotherapy.
    International journal of oncology, 2000, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chemotherapy, Adjuvant; Co

2000
Absorbable mesh sling prevents radiation-induced bowel injury during "sandwich" chemoradiation for rectal cancer.
    Archives of surgery (Chicago, Ill. : 1960), 2000, Volume: 135, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Case-Control Studies; Chemotherapy, Adjuvant; Dose-Response Relationshi

2000
Retrospective evaluation of 5-fluorouracil-interferon-a aTreatment of advanced colorectal cancer patients.
    Pathology oncology research : POR, 2000, Volume: 6, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2000
Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Pharmacotherapy, 2000, Volume: 20, Issue:10

    Topics: Abdominal Pain; Adenocarcinoma; Antimetabolites, Antineoplastic; Ascites; Catheters, Indwelling; Chr

2000
Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    British journal of cancer, 2000, Volume: 83, Issue:10

    Topics: Adenocarcinoma; Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma; Cell Cycle; Dose

2000
Severe heart failure secondary to 5-fluorouracil and low-doses of folinic acid: usefulness of an intra-aortic balloon pump.
    Critical care medicine, 2000, Volume: 28, Issue:10

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Critical Care; Drug Monitoring; Drug Therapy,

2000
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
    Annals of surgery, 2000, Volume: 232, Issue:5

    Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura

2000
Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region.
    Annals of surgery, 2000, Volume: 232, Issue:5

    Topics: Adenocarcinoma; Ampulla of Vater; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Fluoroura

2000
[Postoperative simultaneous radiochemotherapy improves survival in patients with cervical carcinoma].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2000, Volume: 176, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Aden

2000
[Cancer of the ethmoid sinus].
    La Revue du praticien, 2000, Sep-15, Volume: 50, Issue:14

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2000
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival.
    International journal of radiation oncology, biology, physics, 2000, Nov-01, Volume: 48, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant;

2000
Heat shock protein expression in human tumours grown in severe combined immunodeficient mice.
    Cancer letters, 2000, Dec-08, Volume: 161, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Colonic Neoplasms; Femal

2000
[Case report--efficacy of short-term intraarterial 5-fluorouracil for liver metastasis from colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Combined Modality Therapy; Dr

2000
[Intra-arterial infusion therapy for unresectable liver metastasis of colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Carcinoembryonic Antigen; Colonic Neop

2000
[A case of pulmonary metastases of breast cancer responding remarkably to combined chemotherapy with 5-fluorouracil and low-dose cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Drug Ad

2000
[Induced hypertensive chemotherapy with angiotensin II found effective for mediastinal lymph node metastases of unknown origin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2000, Volume: 27, Issue:14

    Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Doxo

2000
Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Colonic Neoplasms; Colorectal Neoplasm

2000
Intraoperative radiation therapy for locally advanced recurrent rectal or rectosigmoid cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2001, Volume: 58, Issue:1

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Combined Modality Therapy; Disease-Free Survival; D

2001
[Anaphylactoid shock due to folinic acid during treatment of metastatic colorectal cancer].
    Gastroenterologie clinique et biologique, 2000, Volume: 24, Issue:12

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anaphylaxis; Antimetabolites, Antineoplastic; Colorectal Ne

2000
Adenocarcinoma of the ethmoidal sinus complex: surgical debulking and topical fluorouracil may be the optimal treatment.
    Archives of otolaryngology--head & neck surgery, 2001, Volume: 127, Issue:2

    Topics: Adenocarcinoma; Administration, Topical; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineopla

2001
Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer.
    Archives of surgery (Chicago, Ill. : 1960), 2001, Volume: 136, Issue:2

    Topics: Adenocarcinoma; Aged; Anal Canal; Antimetabolites, Antineoplastic; Case-Control Studies; Female; Flu

2001
[A case of advanced gastric cancer with Virchow's and paraaortic lymph node metastases successfully resected after combined chemotherapy of low-dose CDDP and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Aorta; Cisplatin; Drug Administratio

2001
[Long survival in a case of unresectable hepatic metastasis from rectal carcinoma treated with second-look hepatectomy plus pharmacokinetic modulating chemotherapy (PMC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dru

2001
Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy.
    Cancer research, 2001, Feb-01, Volume: 61, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemo

2001
Options for investigative postsurgical therapy for gastric cancer, and case report of using the option for combined immunotherapy and chemotherapy.
    American journal of clinical oncology, 2001, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Aged; Antineoplastic Combined Chemotherapy Protocols; Combin

2001
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
    Annals of surgical oncology, 2001, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Deoxycytid

2001
[Long-term survival of a patient with postoperative liver metastasis of stage IVa gallbladder cancer responding to hepatic arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C

2001
Undifferentiated leukemia following treatment of gastric cancer with 5 fluorouracil, doxorubicin, mitomycin C chemotherapy.
    The Journal of the Association of Physicians of India, 2000, Volume: 48, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow;

2000
Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma.
    Cancer research, 2001, Mar-15, Volume: 61, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Fluorouraci

2001
The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Bindin

2001
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antimetabolites, Antineoplastic; Apoptosis; Biomark

2001
External beam radiotherapy for synchronous rectal and prostatic tumors.
    Urology, 2001, Volume: 57, Issue:4

    Topics: Adenocarcinoma; Aged; Chemotherapy, Adjuvant; Fluorouracil; Follow-Up Studies; Humans; Male; Neoplas

2001
Gastric cancer with Virchow's and multiple lung metastases showing a remarkable response to preoperative chemotherapy: report of a case.
    Surgery today, 2001, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality T

2001
[Effective combination chemotherapy for a recurrent case of carcinoma of the remnant stomach].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration

2001
[Curative resection of advanced gastric cancer responding to preoperative chemotherapy--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

2001
Neoadjuvant therapy for adenocarcinoma of the rectum: tumor response and acute toxicity.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm

2001
Image analysis for quantitation of solid tumor drug sensitivity.
    International journal of surgical investigation, 1999, Volume: 1, Issue:2

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Dose-Response Relations

1999
Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience.
    Annals of surgery, 2001, Volume: 233, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

2001
Node-positive mucosal gastric cancer: a follow-up study.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Signet Ring Cell; Chemotherapy, Adjuvant; Female; Fluorourac

2001
Adjuvant postoperative 5-fluorouracil chemotherapy combined with pelvic radiation for rectal cancer: results from an Asian population.
    Cancer investigation, 2001, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Agranulocytosis; Antimetabolites, Antineoplastic; Ch

2001
Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:6

    Topics: Adenocarcinoma; Adjuvants, Immunologic; Adult; Aged; Antibiotics, Antineoplastic; Antibodies, Monocl

2001
p21 Waf1/Cip1 can protect human colon carcinoma cells against p53-dependent and p53-independent apoptosis induced by natural chemopreventive and therapeutic agents.
    Oncogene, 2001, Jun-07, Volume: 20, Issue:26

    Topics: Adenocarcinoma; Alleles; Amino Acid Chloromethyl Ketones; Anticarcinogenic Agents; Antineoplastic Ag

2001
Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
    Onkologie, 2001, Volume: 24, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

2001
A pilot study of preoperative chemoradiotherapy for resectable gastric cancer.
    Annals of surgical oncology, 2001, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Adjuvant; Feasibility Studies; Female; Fluorouracil; Gast

2001
Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy.
    The Surgical clinics of North America, 2001, Volume: 81, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineopl

2001
Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    The Journal of surgical research, 2001, Volume: 99, Issue:2

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Antineopla

2001
Long-term cultivation of colorectal carcinoma cells with anti-cancer drugs induces drug resistance and telomere elongation: an in vitro study.
    BMC cancer, 2001, Volume: 1

    Topics: Adenocarcinoma; Antineoplastic Agents; Carrier Proteins; Cell Division; Cisplatin; Clone Cells; Colo

2001
[Therapy results of locoregional recurrences in rectal cancer].
    Zentralblatt fur Chirurgie, 2001, Volume: 126, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antimetabolites, Antineoplastic; Combined Modality Therapy

2001
A phase I study of raltitrexed (Tomudex) combined with carmofur in metastatic colorectal cancer.
    Oncology, 2001, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

2001
Expression of metallothionein in colorectal cancers and synchronous liver metastases.
    Oncology, 2001, Volume: 61, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispla

2001
Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications.
    Diseases of the colon and rectum, 2001, Volume: 44, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Chemotherapy, Adjuv

2001
p53 nuclear accumulation and multiploidy are adverse prognostic factors in surgically resected stage II colorectal cancers independent of fluorouracil-based adjuvant therapy.
    American journal of clinical pathology, 2001, Volume: 116, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Cell Nucleus; Chemotherapy, Adjuvant; Colorectal Neopla

2001
Experimental chemotherapy against canine mammary cancer xenograft in SCID mice and its prediction of clinical effect.
    The Journal of veterinary medical science, 2001, Volume: 63, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisp

2001
Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil.
    The American journal of medicine, 2001, Volume: 111, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

2001
A case of bone metastasis from gastric carcinoma after a nine-year disease-free interval.
    Japanese journal of clinical oncology, 2001, Volume: 31, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined

2001
Schedule-dependent reversion of cisplatin resistance by 5-fluorouracil in a cisplatin-resistant human lung adenocarcinoma cell line A549DDP.
    Chinese medical journal, 1999, Volume: 112, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dr

1999
Issues of normal tissue toxicity in patient and animal studies--effect of carbogen breathing in rats after 5-fluorouracil treatment.
    Acta oncologica (Stockholm, Sweden), 2001, Volume: 40, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Biological Availability; Bone Marrow; Carb

2001
A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy.
    Journal of clinical pathology, 2001, Volume: 54, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2001
Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum.
    Annals of surgery, 2001, Volume: 234, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Anastomosis, Surgical; Antineoplastic Agents; Colon; Combin

2001
Prophylaxis of peritoneal carcinomatosis in experimental investigations.
    International journal of colorectal disease, 2001, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Fluorouracil; Infusions, Parenteral; Male

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
Long-term follow-up of RTOG 92-10: cervical cancer with positive para-aortic lymph nodes.
    International journal of radiation oncology, biology, physics, 2001, Nov-15, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Carcinom

2001
[Adjuvant short-term continuous hepatoarterial infusion of 5-FU for advanced colorectal cancer using a removable hepatoarterial catheter].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2001, Volume: 28, Issue:11

    Topics: Adenocarcinoma; Aged; Animals; Antimetabolites, Antineoplastic; Catheterization; Chemotherapy, Adjuv

2001
Cardiac tamponade as the first manifestation of gastric cancer and remission after chemotherapy.
    Digestive diseases and sciences, 2001, Volume: 46, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin;

2001
Spontaneous and inducible apoptosis in oesophageal adenocarcinoma.
    British journal of cancer, 2001, Nov-30, Volume: 85, Issue:11

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cisplatin; Combined

2001
Management of a 16-year-old boy with adenocarcinoma at the esophageal gastric junction.
    Medical and pediatric oncology, 2001, Volume: 37, Issue:6

    Topics: Adenocarcinoma; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diagnosis, Di

2001
Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma.
    British journal of cancer, 2001, Dec-14, Volume: 85, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Cell Differentiation; Cell Nucleus; Co

2001
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas: great logic, grim reality.
    Annals of surgical oncology, 2001, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Fluorouracil; Humans; Immunosuppressive Agents; Neoadjuvant Therapy; Neoplasm Stagin

2001
Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas.
    Annals of surgical oncology, 2001, Volume: 8, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Female; Fluorouraci

2001
Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Carcinoma, Adenosquamous; Female; Fluorouraci

2002
The dose-volume relationship of acute small bowel toxicity from concurrent 5-FU-based chemotherapy and radiation therapy for rectal cancer.
    International journal of radiation oncology, biology, physics, 2002, Jan-01, Volume: 52, Issue:1

    Topics: Acute Disease; Adenocarcinoma; Analysis of Variance; Antimetabolites, Antineoplastic; Combined Modal

2002
Epirubicin, cisplatin, and prolonged or brief infusional 5-fluorouracil in the treatment of carcinoma of unknown primary site.
    Medical oncology (Northwood, London, England), 2001, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-19-9 Antigen; Carcin

2001
In vitro models of a three-drug regimen (epirubicin, cisplatin and fluorouracil) for the treatment of colorectal cancer.
    Chemotherapy, 2001, Volume: 47, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Count; Cisplatin; Colonic Neopl

2001
[Prognosis of pancreatic adenocarcinoma].
    Gastroenterologie clinique et biologique, 2001, Volume: 25, Issue:2 Pt 2

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Combin

2001
[Adenocarcinomas of the distal esophagus and gastric cardia: what chemotherapy or chemoradiotherapy for recurrent or metastatic disease?].
    Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 2001, Volume: 5 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardia; Cisplatin; Combined Modality

2001
Relationship between Fas/FasL expression and apoptosis of colon adenocarcinoma cell lines.
    World journal of gastroenterology, 2001, Volume: 7, Issue:1

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents;

2001
N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2001, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartate Carbamoyltran

2001
[The effect of blood-pancreatic juice barrier on 5-fluorouracil in post-pancreatoduodenectomy patients].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1999, Volume: 37, Issue:3

    Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Combined Modality Th

1999
Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, Volume: 39, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Colonic Neoplasms;

2002
[Three cases of advanced gastric cancer treated by TS-1 in combination with low-dose cisplatinum].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Sched

2002
Construct validity of medicare chemotherapy claims: the case of 5FU.
    Medical care, 2002, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Chi-Square Distribution; Colonic Neoplasms; D

2002
Overexpression of pyrimidine nucleoside phosphorylase enhances the sensitivity to 5'-deoxy-5-fluorouridine in tumour cells in vitro and in vivo.
    European journal of cancer (Oxford, England : 1990), 2002, Volume: 38, Issue:5

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Survival; Colonic Neoplasms; Combined

2002
Rationale for a phase I/II radiation dose-escalation study with concurrent amifostine (Ethyol) and infusional 5-FU chemotherapy for preoperative treatment of unresectable or locally recurrent rectal carcinoma.
    Seminars in radiation oncology, 2002, Volume: 12, Issue:1 Suppl 1

    Topics: Adenocarcinoma; Amifostine; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Clin

2002
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
    Clinical & experimental metastasis, 2002, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; bcl-X Pr

2002
Predictors of short-term survival and progression to chemotherapy in patients with advanced colorectal cancer treated with 5-fluorouracil-based regimens.
    American journal of clinical oncology, 2002, Volume: 25, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

2002
Treatment of advanced gastric cancer by palliative gastrectomy, cytoreductive therapy and postoperative intraperitoneal chemotherapy.
    The British journal of surgery, 2002, Volume: 89, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Chil

2002
Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer?
    International journal of radiation oncology, biology, physics, 2002, Apr-01, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Deoxycytidine; Disease Progression; Female;

2002
[Value of postoperative radiochemotherapy with 5-fluorouracil plus leucovorin in stage IB-IV M0 stomach carcinoma].
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2002, Volume: 178, Issue:3

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Gastrectomy; Humans

2002
Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer.
    The British journal of surgery, 2002, Volume: 89, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chem

2002
[A case of liver metastasis of rectal cancer demonstrating complete response to 5-FU + Leucovorin + UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug C

2002
Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake.
    Acta oncologica (Stockholm, Sweden), 2002, Volume: 41, Issue:1

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Blood Flow Velocity; Fibroblast Growth Fac

2002
Preoperative radiation with or without chemotherapy and full-thickness transanal excision for selected T2 and T3 distal rectal cancers.
    International journal of colorectal disease, 2002, Volume: 17, Issue:1

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Combined Modality Therapy; Comorbidity; Femal

2002
A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies.
    International journal of radiation oncology, biology, physics, 2002, Jul-01, Volume: 53, Issue:3

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, S

2002
mdm2-p53 Interaction: lack of correlation with the response to 5-fluorouracil in advanced colorectal cancer.
    Oncology, 2002, Volume: 62, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Apoptosis; Colorectal Neoplasms; Femal

2002
Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
    British journal of cancer, 2002, May-20, Volume: 86, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transport

2002
[A case of unresectable gastric cancer complicated by a serious hepatic disorder and Virchow lymph node metastasis in which FP therapy and TS-1 administration were effective].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol

2002
[A case of advanced colon cancer with para-aortic lymph node metastasis responding greatly to treatment by adjuvant chemotherapy of low-dose CPT-11 on an outpatient basis].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Chemot

2002
Letter: Neurotoxicity of 5-fluorouracil.
    Lancet (London, England), 1975, Feb-15, Volume: 1, Issue:7903

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Male; Parkin

1975
Treatment of carcinoma of the pancreas with radon seed implantation and intra-arterial infusion of 5-FUDR.
    The Surgical clinics of North America, 1975, Volume: 55, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Fluorouracil; Humans; Infusions, Parenteral; Male; Middle Aged; Neoplas

1975
[Chemoradiation therapy of inoperable lung cancer].
    Voprosy onkologii, 1975, Volume: 21, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Dactinomycin; Fl

1975
Bleomycin (NSC-125066) followed by cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and 5-fllorouracil (NSC-19893) for non-oat cell bronchogenic carcinoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell;

1976
[Recent personal results in advanced bronchial cancer. Palliative immuno-chemotherapy. 63 cases].
    Annales de medecine interne, 1976, Volume: 127, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamou

1976
Cardiotoxicity of 5-fluorouracil.
    Lancet (London, England), 1977, Aug-20, Volume: 2, Issue:8034

    Topics: Adenocarcinoma; Adult; Angina Pectoris; Cecal Neoplasms; Female; Fluorouracil; Humans

1977
Enhancement of the cancer chemotherapeutic effect by anticancer agents in the form of fat emulsion.
    The Tohoku journal of experimental medicine, 1977, Volume: 123, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Animals; Bleomycin; Breast Neoplasms; Carcinoma,

1977
Adriamycin alone or in combination in 100 patients with carcinoma of the cervix or vagina.
    American journal of obstetrics and gynecology, 1978, Jun-01, Volume: 131, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Cyclophosphamide; Dactin

1978
[Chemotherapy of colorectal carcinomas].
    Deutsche medizinische Wochenschrift (1946), 1978, Sep-22, Volume: 103, Issue:38

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Palli

1978
Management of carcinoma of the extrahepatic bile ducts.
    Canadian journal of surgery. Journal canadien de chirurgie, 1978, Volume: 21, Issue:6

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo

1978
[Therapeutic advances in digestive oncology. III. Chemotherapy of digestive system cancers].
    Medecine & chirurgie digestives, 1979, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Digestive System Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Neoplas

1979
Cell proliferation in dimethylhydrazine-induced colonic adenocarcinomata following cytotoxic drug treatment.
    Virchows Archiv. B, Cell pathology, 1978, Aug-25, Volume: 28, Issue:2

    Topics: 5,7-Dihydroxytryptamine; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cimetidine;

1978
Effect of nutritional status and 5-fluorouracil on protein synthesis in parenterally alimented LEW/Mai rats.
    Journal of the National Cancer Institute, 1979, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Animals; Fluorouracil; Neoplasm Proteins; Neoplasms, Experimental; Nutritional Physi

1979
Combined modality therapy of hepatic metastasis. Northern California Oncology Group Pilot Study.
    Cancer, 1979, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow; Doxorubicin; Drug Evaluation; Drug Therapy, Comb

1979
Adjuvant therapy of gastric cancer: the 40742 clinical trial of the EORTC Gastro-intestinal Tract Cooperative Group.
    Frontiers of gastrointestinal research, 1979, Volume: 5

    Topics: Adenocarcinoma; Drug Administration Schedule; Fluorouracil; Humans; Radiotherapy, High-Energy; Stoma

1979
Immunobiology and therapeutic manipulation of heterotransplanted Nb rat prostatic adenocarcinoma. Chemotherapy of autonomous tumor, 102 Pr, heterotransplanted into congenitally athymic (nude) mice and syngeneic Nb rats.
    Cancer chemotherapy and pharmacology, 1979, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Animals; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms,

1979
Sensitivity tests of tumors to cytostatic agents. I. Comparative investigations on transplanted tumors in vivo and in vitro.
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1975, Volume: 83, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cell Division; Cricetinae; Da

1975
The chemotherapy of urologic cancer.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Doxorubicin; Drug Therapy, Co

1975
Chemotherapy studies in autochthonous rat tumors intestinal cancer.
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1978, Aug-24, Volume: 92, Issue:1

    Topics: Adenocarcinoma; Animals; Cyclophosphamide; Dimethylhydrazines; Dimethylnitrosamine; Doxorubicin; Dru

1978
Prolonged and continuous percutaneous intra-arterial hepatic infusion chemotherapy in advanced metastatic liver adenocarcinoma from colorectal primary.
    Cancer, 1979, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Colonic Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery; Humans; Infusi

1979
Current status of regional arterial infusion chemotherapy.
    The Medical clinics of North America, 1975, Volume: 59, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Hepatocellular; Carotid Arteries; Catheterization;

1975
[Determination of individual sensitivity of gastric cancer to 5-fluorouracil by tumor tissue respiratory and glycolytic indices].
    Voprosy onkologii, 1975, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Fluorouracil; Glycol

1975
Chemotherapy of urogenital cancer.
    Surgery annual, 1976, Volume: 8

    Topics: Adenocarcinoma; Adult; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Hum

1976
[Experiences with drug therapy of advanced metastatic carcinoma of the breast (author's transl)].
    Medizinische Klinik, 1976, Oct-01, Volume: 71, Issue:40

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Car

1976
Combination chemotherapy with methyl-CCNU, 5-fluorouracil, and vincristine in adenocarcinoma and large cell carcinoma of the lung.
    Cancer treatment reports, 1976, Volume: 60, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Small Cell; Drug Therapy, Combination; Female; Fluorouracil;

1976
Internal radiation therapy of liver cancer (90-Yttrium resin spheres intra-arterially) to supplement external radiation therapy, local and systemic chemotherapy.
    Journal of the Medical Association of Georgia, 1977, Volume: 66, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Carcinoma, Hepatocellular; Female; Fluorourac

1977
Case report: Liver scintigraphy in the follow-up of a patient on cytotoxic therapy.
    European journal of nuclear medicine, 1976, Dec-30, Volume: 1, Issue:4

    Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma, Small Cell; Cyclophosphamide; Fluorouracil; Humans;

1976
Chemotherapy of metastatic gastrointestinal neoplasms with 5-fluorouracil and streptozotocin.
    Cancer treatment reports, 1977, Volume: 61, Issue:7

    Topics: Adenocarcinoma; Adenoma, Bile Duct; Adenoma, Islet Cell; Adult; Aged; Bile Duct Neoplasms; Carcinoid

1977
Mastectomy as an adjunct to combination chemotherapy.
    Archives of surgery (Chicago, Ill. : 1960), 1978, Volume: 113, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Int

1978
[5-fluorouracil inhibits the collagenolytic activity of invasive colonic adenocarcinomas in vitro].
    Onkologie, 1978, Volume: 1, Issue:4

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Enzyme Inhibitors; Fluorouracil; Humans; Microbial Colla

1978
5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas: COG protocol 7230.
    Journal of surgical oncology, 1979, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adenoma, Islet Cell; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil;

1979
Remissions of mammary adenocarcinoma in hypothyroid mice given 5-fluorouracil and chloroquine phosphate.
    Journal of the National Cancer Institute, 1979, Volume: 62, Issue:6

    Topics: Adenocarcinoma; Animals; Chloroquine; Drug Therapy, Combination; Female; Fluorouracil; Hypothyroidis

1979
[Therapeutic effect of ftorafur].
    Veterinariia, 1977, Issue:1

    Topics: Adenocarcinoma; Animals; Cat Diseases; Cats; Dog Diseases; Dogs; Female; Fluorouracil; Mammary Gland

1977
Iv methyl-CCNU and ftorafur with or without methanol-extracted residue of BCG for metastatic adenocarcinoma of the colon.
    Cancer treatment reports, 1977, Volume: 61, Issue:8

    Topics: Adenocarcinoma; BCG Vaccine; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intravenous; Leuko

1977
[Comparative assessment of the effectiveness of the preparations CCNU, 5-fluorouracil, ftorafur and their combinations in inoperable stomach cancer].
    Vestnik Akademii meditsinskikh nauk SSSR, 1978, Issue:9

    Topics: Adenocarcinoma; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; Nitrosourea Compounds; S

1978
Phase II evaluation of ftorafur in previously untreated colorectal cancer: a Southwest Oncology Group Study.
    Cancer, 1979, Volume: 44, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Central Nervous System; Colonic Neoplasms; Drug Evaluation; Female; Flu

1979
Phase I-II study of ftorafur and methyl-CCNU in advanced colorectal cancer.
    Cancer, 1979, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Colonic Neoplasms; Digestive System; Drug Evaluation; Drug

1979
A phase II trial of ftorafur: adriamycin and mitomycin-C (FAM II) in advanced gastric adenocarcinoma.
    Cancer, 1979, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Marrow; Central Nervous System; Digestive S

1979
Heterologous growth of human ovarian cancer. A new in vivo testing system.
    Acta obstetricia et gynecologica Scandinavica, 1977, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Humans; Injections, Intramuscular; Injections, Intrap

1977
Studies on mechanisms of 5-fluorouracil resistance in murine and human tumors.
    Bulletin du cancer, 1979, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Animals; Breast Neoplasms; Drug Resistance; Fluorodeoxyuridylate; Fluorouracil; Huma

1979
Chemotherapy of Nb rat adenocarcinoma of the prostate heterotransplanted into congenitally athymic (nude) mice: report of 5-fluorouracil and cyclophosphamide.
    The Journal of surgical research, 1979, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Animals; Cyclophosphamide; Disease Models, Animal; Fluorouracil; Male; Mice; Mice, N

1979
[Nonsurgical treatments of colonic cancers: chemotherapy, immunotherapy, radiotherapy].
    La Revue du praticien, 1979, Mar-01, Volume: 29, Issue:13

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Follow-Up Studies; Human

1979
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for adenocarcinoma of the lung.
    Cancer, 1979, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Doxorubicin; Drug Administration Schedule; Drug

1979
Treatment of advanced gastrointestinal cancer with 5-fluorouracil and mitomycin C.
    Cancer, 1979, Volume: 43, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Female; Fluorouracil; Gas

1979
Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Colonic Neoplasms; Daunorubicin; Drug Evaluation; Drug Therapy, Combination; Female;

1979
Effect of preoperative intralesional BCG and postoperative 5-FU chemotherapy in three adenocarcinoma lines in rats.
    Journal of surgical oncology, 1979, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Animals; BCG Vaccine; Colonic Neoplasms; Female; Fluorouracil; Male; Mammary Neoplas

1979
5-fluorouracil, adriamycin, and mitomycin-C (FAM) combination chemotherapy in the treatment of advanced gastric cancer.
    Cancer, 1979, Volume: 44, Issue:1

    Topics: Adenocarcinoma; Aged; Bone Marrow; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil; Hum

1979
Five-day continuous infusion of 5-fluorouracil for advanced colorectal, gastric, and pancreatic adenocarcinoma.
    Journal of surgical oncology, 1979, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Humans; Infus

1979
Basal cell nevus syndrome and adenocarcinoma of the colon. Response to systemic fluorouracil.
    International journal of dermatology, 1979, Volume: 18, Issue:5

    Topics: Adenocarcinoma; Adult; Carcinoma, Basal Cell; Colonic Neoplasms; Female; Fluorouracil; Humans; Nevus

1979
The effect of 5-fluorouracil and adriamycin on heterotransplantation of Noble rat prostatic tumors in congenitally athymic (nude) mice.
    Cancer, 1979, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Animals; Doxorubicin; Fluorouracil; Male; Mice; Mice, Nude; Neoplasm Transplantation

1979
Chemotherapy for adenocarcinoma of the lung with 5-fluorouracil, cyclophosphamide, and CCNU (FCC).
    Cancer, 1979, Volume: 44, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Bone Marrow; Cyclophospham

1979
Combination chemotherapy for advanced pancreatic carcinoma.
    Texas medicine, 1979, Volume: 75, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fem

1979
The cytocidal action of metronidazole in combination with other antineoplastic agents.
    Cancer treatment reviews, 1979, Volume: 6 Suppl

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Colonic Neoplasms; D

1979
Therapeutic manipulation of Nb rat prostatic adenocarcinomas: chemotherapeutic evaluation of autonomous tumors.
    Investigative urology, 1979, Volume: 17, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cyclophosphamide; Doxorubicin; Evaluation Studies as

1979
Cyclophosphamide, doxorubicin hydrochloride and 5-fluorouracil in advanced carcinoma of the prostate.
    The Journal of urology, 1979, Volume: 122, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Neoplasms; Cyclophosphamide; Doxorubicin; Drug The

1979
Transplantation of experimental ovarian tumors and their sensitivity to carcinostatics.
    The Kurume medical journal, 1979, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Granulosa Cell Tumor; Humans; Male; Mitomycins; Neopl

1979
Improved combination chemotherapy in advanced gastric cancer.
    British medical journal, 1979, Dec-08, Volume: 2, Issue:6203

    Topics: Adenocarcinoma; Adult; Aged; Carmustine; Doxorubicin; Drug Therapy, Combination; Female; Fluorouraci

1979
Prostate adenocarcinoma model: Nb rat chemotherapy.
    Surgical forum, 1979, Volume: 30

    Topics: Adenocarcinoma; Animals; Castration; Cyclophosphamide; Dactinomycin; Disease Models, Animal; Doxorub

1979
[Early results of polychemotherapy in advanced ovarian tumors].
    Ginekologia polska, 1979, Volume: 50, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Carcinoma, Papillary; Cyclophosphamide; Cyst

1979
[Combined drug therapy in transplanted colonic mice tumors].
    Revista clinica espanola, 1979, Dec-15, Volume: 155, Issue:5

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Cyclophosphamide; Drug Evaluation, Preclinical; Drug The

1979
[A case with gastric cancer by OK-MF'C therapy (author's transl)].
    Igaku kenkyu. Acta medica, 1979, Volume: 49, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans;

1979
[Preoperative irradiation of rectal carcinoma wit 5-fluorouracil].
    Strahlentherapie. Sonderbande, 1978, Volume: 75

    Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Infusions, Parenteral; Preoperative Care

1978
Heparin and polychemotherapy for treatment of lung cancer.
    Cancer treatment reports, 1977, Volume: 61, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell;

1977
Adjuvant postoperative chemotherapy with 5-fluorouracil and methotrexate: effect of schedule of administration on metastasis of 13762 mammary adenocarcinoma.
    Journal of surgical oncology, 1977, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Animals; BCG Vaccine; Drug Administration Schedule; Drug Therapy, Combination; Femal

1977
Combination chemotherapy for solid tumors using 5-fluorouracil, chromomycin-A, and prednisolone.
    Gan, 1977, Volume: 68, Issue:4

    Topics: Adenocarcinoma; Breast Neoplasms; Chromomycins; Colonic Neoplasms; Drug Therapy, Combination; Evalua

1977
Chemotherapy of ovarian cancer.
    International surgery, 1978, Volume: 63, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Drug Therapy, Combination; Fe

1978
Chemotherapy trial with comp-F regimen in advanced adenocarcinoma of prostate.
    Urology, 1978, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hu

1978
Sequential 5-fluorouracil and hydroxyurea therapy for metastatic colorectal adenocarcinoma.
    The Journal of the American Osteopathic Association, 1978, Volume: 77, Issue:8

    Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Humans; Hydroxyurea; Neoplasm Metastasis; Rectal Ne

1978
Evaluation of chemotherapeutic effects on gastric cancer in relation to the histological pattern.
    The Japanese journal of surgery, 1978, Volume: 8, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Cytarabine; Drug Therapy, Combination; Fluorouracil; Huma

1978
[The primary appendix carcinoma].
    Fortschritte der Medizin, 1978, Jun-15, Volume: 96, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Appendiceal Neoplasms; Colostomy; Cyclophosphamide; Female; Fluorouraci

1978
[Evaluation of radiation therapy and chemotherapy combined with nephrectomy for renal cell carcinoma (author's transl)].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1978, Volume: 69, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Cytarabine; Drug Therapy, Combination; Evaluation Studies as Topic; Fem

1978
Histological evaluation of the effect of 5-FU emulsion on lymph node metastasis of stomach cancer.
    The Japanese journal of surgery, 1978, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Carcinoma; Emulsions; Fluorouracil; Humans; Lymph Nodes; Lymph

1978
Treatment of advanced colorectal cancer with a combination of 5-fluorouracil and methyl-CCNU.
    Medical and pediatric oncology, 1978, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Nitrosourea Comp

1978
Phase II study of melphalan in colorectal carcinoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Humans; Male;

1978
Combination of constant-infusion 5-fluorouracil, methyl-CCNU, mitomycin C, and vincristine in advanced colorectal carcinoma.
    Cancer treatment reports, 1978, Volume: 62, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; H

1978
Heterogeneity in drug sensitivity among tumor cell subpopulations of a single mammary tumor.
    Cancer research, 1978, Volume: 38, Issue:11 Pt 1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Drug Resistance; Fluoro

1978
Chemotherapy for colorectal cancer with a combination of 5-fluorouracil, mitomycin C, adriamycin, and cytosine arabinoside: a pilot study.
    Cancer treatment reports, 1978, Volume: 62, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Doxorubicin; Drug Therapy, Com

1978
Tumor 5-fluorodeoxyuridylate concentration as a determinant of 5-fluorouracil response.
    Biochemical pharmacology, 1978, Volume: 27, Issue:16

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; DNA, Neoplasm; Fluorodeoxyuridy

1978
Therapeutic consequences of antitumour drug interactions: methotrexate and 5-fluorouracil in the chemotherapy of C3H mice with transplanted mammary adenocarcinoma.
    Cancer letters, 1978, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Animals; Drug Interactions; Drug Therapy, Combination; Female; Fluorouracil; Mammary

1978
Cancer of the pancreas in young adults.
    The Medical journal of Australia, 1978, Dec-30, Volume: 2, Issue:14

    Topics: Adenocarcinoma; Adult; Biopsy, Needle; Female; Fluorouracil; Humans; Laparotomy; Liver Neoplasms; Ne

1978
Management of urinary bladder cancer.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1978, Oct-28, Volume: 54, Issue:18

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Fem

1978
Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion.
    British journal of cancer, 1978, Volume: 38, Issue:6

    Topics: Adenocarcinoma; Colonic Neoplasms; Fluorouracil; Gastrointestinal Neoplasms; Humans; Infusions, Pare

1978
Antitumor activity of 1-alkylcarbamoyl derivatives of 5-fluorouracil in a variety of mouse tumors.
    Cancer chemotherapy and pharmacology, 1978, Volume: 1, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Fluorouracil; Leukemia, Ex

1978
Further experience with chemotherapy in the Dunning prostatic adenocarcinoma.
    Transactions of the American Association of Genito-Urinary Surgeons, 1978, Volume: 70

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Dactinomycin; Doxoru

1978
Chemoimmunotherapy of syngeneic mouse mammary carcinomas employing methanol extraction residue.
    Annals of the New York Academy of Sciences, 1976, Volume: 277, Issue:00

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; BCG Vaccine; Cyclophosphamide; Female; Fluorouracil;

1976
Intravenous hyperalimentation as an adjunct to cancer chemotherapy.
    American journal of surgery, 1975, Volume: 129, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Body Weight; Cachexia; Evaluation Studies as Topic; Fe

1975
Intravenous hyperalimentation as an adjunct to cancer chemotherapy with 5-fluorouracil.
    The Journal of surgical research, 1975, Volume: 18, Issue:4

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Digestive System; Fluorouracil; Humans; Male; Neoplasms;

1975
Use of arterial infusion of 5-fluorouracil either alone or in combination with supervoltage radiation as a treatment for carcinoma of the prostate and bladder.
    American journal of surgery, 1975, Volume: 130, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Drug Administration Sc

1975
[Continuous local application of cytostatics for bronchial carcinoma and mediastinal lymph node metastasisization (author's transl)].
    MMW, Munchener medizinische Wochenschrift, 1976, Jul-30, Volume: 118, Issue:31

    Topics: Adenocarcinoma; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regi

1976
Comparison of adjuvant chemotherapeutic activity against primary and metastatic spontaneous murine tumors.
    Cancer research, 1977, Volume: 37, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Female; Fluo

1977
The treatment of gastric cancer with combined surgical resection and chemotherapy.
    Journal of surgical oncology, 1977, Volume: 9, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Prognosis

1977
Oculomotor disturbances associated with 5-fluorouracil chemotherapy.
    American journal of ophthalmology, 1977, Volume: 83, Issue:6

    Topics: Adenocarcinoma; Adult; Brain Stem; Cerebellar Diseases; Colonic Neoplasms; Eye Movements; Female; Fl

1977
Combination chemotherapy of advanced endometrial adenocarcinoma with adriamycin, cyclophosphamide, 5-fluorouracil, and medroxyprogesterone acetate.
    Obstetrics and gynecology, 1977, Volume: 50, Issue:1 Suppl

    Topics: Adenocarcinoma; Aged; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Fluorouracil

1977
Chemotherapy of carcinoma of the cervix.
    Gynecologic oncology, 1977, Volume: 5, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow; Carcinoma, Squamous Cel

1977
Primary adenocarcinoma of the small intestine.
    American journal of surgery, 1977, Volume: 134, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; BCG Vaccine; Female; Fluorouracil; Follow-Up Studies; Humans; Intestina

1977
Treatment of advanced adenocarcinoma of the endometrium with melphalan, 5-fluorouracil, and medroxyprogesterone acetate: a preliminary study.
    Obstetrics and gynecology, 1977, Volume: 50, Issue:4

    Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Female; Fluorouracil; Humans; Medroxyprogesterone;

1977
Chemoprophylaxis for patients with colorectal cancer. Prospective study with five-year follow-up.
    JAMA, 1976, Jun-28, Volume: 235, Issue:26

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Follow-Up Stu

1976
[Multifactorial immunological treatment of cancer in urology].
    Helvetica chirurgica acta, 1976, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Cobalt Radioisotopes; Female; Fluorouracil; Humans;

1976
[Late results of lung cancer therapy (according to material from the Kazakh Scientific Research Institute of Oncology and Radiology)].
    Voprosy onkologii, 1976, Volume: 22, Issue:6

    Topics: Adenocarcinoma; Carcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Fluorouracil; Follow-Up Studi

1976
[Combination chemotherapy in the treatment of polymetastic breast cancer. Comparison of therapeutic effects of 2 methods of sequential drug administration. Role of adriamycin in these combinations].
    La Nouvelle presse medicale, 1976, Oct-09, Volume: 5, Issue:9 Oct 76

    Topics: Adenocarcinoma; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Drug Tol

1976
Doxorubicin hydrochloride, cyclophosphamide, and 5-fluorouracil combination in advanced prostate and transitional cell carcinoma.
    Urology, 1976, Volume: 8, Issue:5

    Topics: Acid Phosphatase; Adenocarcinoma; Aged; Carcinoma, Transitional Cell; Cyclophosphamide; Doxorubicin;

1976
Phase II trial of 5-fluorouracil (NSC-19893), adriamycin (NSC-123127), and methotrexate (NSC-740) in lung adenocarcinoma.
    Cancer treatment reports, 1976, Volume: 60, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Doxorubicin; Drug Therapy, Combination; Fluorouracil; Humans;

1976
Serial carcinoembryonic antigen assays in patients with metastatic carcinoma of prostate being treated with chemotherapy.
    Urology, 1976, Volume: 8, Issue:6

    Topics: Acid Phosphatase; Adenocarcinoma; Carcinoembryonic Antigen; Drug Therapy, Combination; Fluorouracil;

1976
Acute cardiac pain and electrocardiographic changes following cytotoxic treatment for metastatic carcinoma.
    Clinical oncology, 1976, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Breast Neoplasms; Coronary Disease; Cyclophosphamide;

1976
Antitumor activity of 1-hexylcarbamoyl-5-fluorouracil in a variety of experimental tumors.
    Gan, 1976, Volume: 67, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Animals; Ascites; Carcinoma, Ehrlich Tumor; Female; Fluorourac

1976
Systemic chemotherapy of advanced head and neck malignancies.
    Cancer, 1975, Volume: 35, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytarabine; Doxor

1975
Adenocarcinoma of the bile ducts. Relationship of anatomic location to clinical features.
    The American journal of digestive diseases, 1975, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Alkaline Phosphatase; Bile Duct Neoplasms; Bile Ducts; Bile Ducts, Intr

1975
[Conservative treatment of lung cancer].
    Voprosy onkologii, 1975, Volume: 21, Issue:3

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cyclophosphamide; Drug Therapy, Combination; Drug-Related

1975
Combination chemotherapy in metastatic carcinoma of the breast. Results with a three-drug combination.
    Cancer, 1975, Volume: 36, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Ethylnit

1975
Arterial infusion of 5-FU as a therapeutic adjunct in the treatment of advanced carcinoma of bladder and prostate.
    Virginia medical monthly, 1975, Volume: 102, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Female; Fluorou

1975
Sequential therapy for advanced ovarian adenocarcinoma: operation, chemotherapy, second-look laparotomy, and radiation therapy.
    American journal of obstetrics and gynecology, 1975, Jun-01, Volume: 122, Issue:3

    Topics: Adenocarcinoma; Chlorambucil; Cyclophosphamide; Dactinomycin; Female; Fluorouracil; Laparotomy; Melp

1975
The effect of cytostatic drugs on the synthesis of DNA in adenocarcinomas of the stomach. An in vitro study.
    Acta chirurgica Scandinavica, 1975, Volume: 141, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Cells, Cultured; Depression, Chemical; DNA, Neoplasm; Fluorou

1975
Heterogeneity of human adenocarcinomas of the colon and the stomach as regards sensitivity to cytostatic drugs.
    Neoplasma, 1975, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphala

1975
[1st report on programmed chemotherapy of ovarian carcinoma].
    Fortschritte der Medizin, 1975, Oct-09, Volume: 93, Issue:28

    Topics: Adenocarcinoma; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinoma; Cystadenoma; Drug Thera

1975
Resolution of pulmonary lymphangitic carcinoma of the breast.
    Chest, 1976, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Breast Neoplasms; Castration; Female; Fluorouracil; Humans; Lung Neoplasms; L

1976
The gasteointestinal oncology clinic. A multidisciplinary approach to cancer diagnosis and management at a University Medical Center.
    The Surgical clinics of North America, 1976, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Colitis, Ulcerative; Colonic Neoplasms; Cyclophosphamide; Drug Therapy, Combination;

1976
Neurotoxicity from 5-fluorouracil (NSC-19893) administration reproduced by mitomycin C (NSC-26980).
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Adenocarcinoma; Aged; Ataxia; Blood-Brain Barrier; Cerebellar Ataxia; Colonic Neoplasms; Fluorouraci

1976
Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
    Cancer research, 1976, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Dise

1976
Current thoughts on the surgical treatment of rectal cancer.
    The American journal of gastroenterology, 1976, Volume: 65, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Female; Fluorouracil;

1976
Radiation therapy and 5-fluorouracil modulated by leucovorin for adenocarcinoma of the pancreas. A phase I study.
    International journal of pancreatology : official journal of the International Association of Pancreatology, 1992, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antigens, Tumor-Associated, Carbohydrate; Combined Modality Therapy; Fe

1992
Standardized kinetic microassay to quantify differential chemosensitivity on the basis of proliferative activity.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Ce

1992
[Sequential MTX and 5-FU therapy of gastric cancer with systemic bone metastasis and disseminated intravascular coagulation].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1992
Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression.
    Cancer research, 1992, Apr-01, Volume: 52, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Northern; Blotting, Southern; Camptothecin; Carcino

1992
Pattern of 2-deoxy-2-[18F]-fluro-D-glucose accumulation in liver tumours: primary, metastatic and after chemotherapy.
    Nuclear medicine communications, 1992, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colonic Neoplasms; Deoxyglucose; Fluorodeoxyglucose F18;

1992
Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.
    British journal of cancer, 1992, Volume: 65, Issue:6

    Topics: Adenocarcinoma; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cisplatin; DNA Damage; Drug Re

1992
[Preoperative regional radiofrequency thermochemotherapy of colorectal cancer: clinical and pathological studies].
    Zhonghua wai ke za zhi [Chinese journal of surgery], 1992, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Chemotherapy, Adjuvant; Colorectal Neoplasms; Diathermy; F

1992
Effects of preoperative chemotherapy on gastric adenocarcinomas. A morphologic study of 25 cases.
    Cancer, 1992, Nov-01, Volume: 70, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1992
In vitro enhancement of fluoropyrimidine-induced cytotoxicity by leucovorin in colorectal and gastric carcinoma cell lines but not in non-small-cell lung carcinoma cell lines.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Survival; Colony-Forming Units Assay; Colorecta

1992
Activities of thymidylate synthetase and thymidine kinase in gastric cancer.
    Surgical oncology, 1992, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Linear

1992
Overexpression of erbB-2 protein in gastric adenocarcinoma--a potential role in therapeutic response to adjuvant 5-FU-doxorubicin regimen.
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:8 Suppl

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adj

1992
Intraportal 5-fluorouracil for colorectal cancer: the AXIS trial.
    Lancet (London, England), 1992, Oct-17, Volume: 340, Issue:8825

    Topics: Adenocarcinoma; Clinical Trials as Topic; Colorectal Neoplasms; Fluorouracil; Humans

1992
Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas.
    Archives of surgery (Chicago, Ill. : 1960), 1992, Volume: 127, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Cancer Care Facilities; Chemotherapy, Adjuvant; Combined Modality Thera

1992
5-Fluorouracil-induced pseudoporphyria.
    Australian and New Zealand journal of medicine, 1992, Volume: 22, Issue:4

    Topics: Adenocarcinoma; Diagnosis, Differential; Fluorouracil; Humans; Leucovorin; Lung Neoplasms; Male; Mid

1992
Influence of chemotherapy on hormone receptor concentration in a xenotransplanted endometrial cancer.
    European journal of obstetrics, gynecology, and reproductive biology, 1992, Jul-03, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bleomycin; Carboplatin; Cyclophosphamide; Endometria

1992
Combined isodose curves of high-dose rate interstitial brachytherapy with external-beam radiation therapy in pancreatic carcinoma.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1992, Volume: 168, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Chemotherapy, Adjuvan

1992
In vivo antitumor effects of fluoropyrimidines on colon adenocarcinoma 38 and enhancement by leucovorin.
    Japanese journal of cancer research : Gann, 1992, Volume: 83, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Cell Div

1992
The effect of liver macrophages on in vitro cytolytic activity of 5FU and FUdR on colon carcinoma cells: evidence of macrophage activation.
    International journal of immunopharmacology, 1992, Volume: 14, Issue:5

    Topics: Acetylmuramyl-Alanyl-Isoglutamine; Adenocarcinoma; Animals; Colonic Neoplasms; Cytotoxicity, Immunol

1992
Nonresectable adenocarcinoma of the rectum assessed by MR imaging before and after chemotherapy and irradiation.
    Acta radiologica (Stockholm, Sweden : 1987), 1992, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1992
Identification and characterization of osteoclast progenitors by clonal analysis of hematopoietic cells.
    Blood, 1992, Oct-01, Volume: 80, Issue:7

    Topics: Adenocarcinoma; Animals; Bone Marrow Cells; Cells, Cultured; Colony-Forming Units Assay; Culture Med

1992
Factors that influence the therapeutic activity of 5-fluorouracil [6RS]leucovorin combinations in colon adenocarcinoma xenografts.
    Cancer chemotherapy and pharmacology, 1992, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour

1992
Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5-fluorouracil/leucovorin combination.
    Journal of chemotherapy (Florence, Italy), 1992, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neopl

1992
Interferon alpha-2a shows antitumor activity in combination with 5-fluorouracil against human colon carcinoma xenografts: a study in reference to thymidylate synthetase activity inhibition.
    Surgery today, 1992, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Res

1992
Decreased catabolism of fluorouracil in peripheral blood mononuclear cells during combination therapy with fluorouracil, leucovorin, and interferon alpha-2a.
    Journal of the National Cancer Institute, 1992, Dec-02, Volume: 84, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chromatography, High Pressure Liquid

1992
Advantages of the Papillon protocol in the preoperative treatment of rectal carcinoma.
    American journal of surgery, 1992, Volume: 164, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Protocols; Com

1992
[Case report of a successful stage reduction of gastric carcinoma preoperatively treated by combined chemotherapy of 5-FU(UFT) and cisplatin].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:14

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fem

1992
[Hypertrichosis lanuginosa acquisita in ulcerative colitis with colon cancer].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1992, Volume: 43, Issue:11

    Topics: Adenocarcinoma; Adult; Biopsy; Cecal Neoplasms; Chemotherapy, Adjuvant; Colectomy; Colitis, Ulcerati

1992
[Multimodal treatment for advanced, ovarian cancer patients with poor performance status--its effectiveness and limitations].
    Nihon Sanka Fujinka Gakkai zasshi, 1992, Volume: 44, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cispl

1992
Hypertriglyceridemia during long-term interferon-alpha therapy: efficacy of diet and gemfibrosil treatment. A case report.
    Tumori, 1992, Oct-31, Volume: 78, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Combined Mo

1992
[Multifocal leukoencephalopathy following adjuvant therapy with fluorouracil and levamisole].
    Deutsche medizinische Wochenschrift (1946), 1992, Sep-04, Volume: 117, Issue:36

    Topics: Adenocarcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Fluorouracil; Humans; Leukoenceph

1992
Antitumor effect of PSK at a distant site: tumor-specific immunity and combination with other chemotherapeutic agents.
    Japanese journal of cancer research : Gann, 1992, Volume: 83, Issue:7

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols

1992
Complete disappearance of metastatic abdominal tumors from gastric cancer after treatment with irsogladine maleate.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:8

    Topics: Abdominal Neoplasms; Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pro

1992
The pre-operative treatment of oesophageal carcinoma with synchronously administered chemotherapy and radiotherapy.
    Annals of the Academy of Medicine, Singapore, 1992, Volume: 21, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1992
[Chemotherapy-associated hemolytic uremic syndrome--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1992
Adjuvant postoperative radiation therapy for rectal adenocarcinoma.
    American journal of clinical oncology, 1992, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Fol

1992
Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy.
    American journal of clinical oncology, 1992, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combi

1992
Intratumor treatment of C3H mouse mammary carcinoma with 5-fluorouracil adsorbed on activated charcoal particles.
    Anti-cancer drugs, 1992, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adsorption; Animals; Charcoal; Female; Fluorouracil; Mammary Neoplasms, Experimental

1992
Antitumor effect and tumor level of 5-fluoro-2'-deoxyuridylate following oral administration of tetradecyl 2'-deoxy-5-fluoro-5'-uridylate.
    Anti-cancer drugs, 1992, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Colonic Neoplasms; Fluorodeoxy

1992
Mitomycin C, 5-fluorouracil and radiation in advanced, locally recurrent rectal cancer.
    The British journal of radiology, 1992, Volume: 65, Issue:770

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1992
[Histological evaluation of intra-arterial infusion and systemic chemotherapy of pancreatic carcinomas].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy

1992
[Borrmann 4 gastric cancer treated with l-LV and 5-FU combination--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

1992
Combined modality preoperative therapy for unresectable rectal cancer.
    Connecticut medicine, 1992, Volume: 56, Issue:1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Fem

1992
[Adjuvant treatment of rectal carcinoma: also a step forward?].
    Nederlands tijdschrift voor geneeskunde, 1992, Mar-14, Volume: 136, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal

1992
[Sequential methotrexate and 5-fluorouracil, doxorubicin, and cisplatin for advanced urothelial cancer].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1992, Volume: 83, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1992
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P

1992
Preoperative chemotherapy and radiotherapy for esophageal carcinoma.
    The Journal of thoracic and cardiovascular surgery, 1992, Volume: 103, Issue:5

    Topics: Actuarial Analysis; Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Com

1992
[CT guided direct intervention chemotherapy of lung cancer].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1992, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisp

1992
[A case report of complete remission of liver metastasis from rectal carcinoma treated with intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1992, Volume: 19, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion

1992
Regression of liver metastases following treatment with yttrium-90 microspheres.
    The Australian and New Zealand journal of surgery, 1992, Volume: 62, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Carcinoembryonic Antigen; Chemotherapy, Cancer, Regional Perfusion; Col

1992
Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 1992, Volume: 23, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Combined

1992
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
    Oncology research, 1992, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replic

1992
Patterns of treatment failure and prognostic factors associated with the treatment of esophageal carcinoma with chemotherapy and radiotherapy either as sole treatment or followed by surgery .
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carc

1992
Continuous-infusion 5-fluorouracil combined with doxorubicin and cyclophosphamide: feasibility study.
    Medical and pediatric oncology, 1992, Volume: 20, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1992
Possible interactions between warfarin and 5-fluorouracil.
    American journal of hematology, 1992, Volume: 40, Issue:3

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Drug Interactions; Fluorouracil; Humans; Male; Warfarin

1992
High-dose folinic acid and 5-fluorouracil plus cisplatin on a weekly schedule in the treatment of advanced cancer of the head and neck.
    Journal of cancer research and clinical oncology, 1992, Volume: 118, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, Squamous Cell;

1992
Levamisole plus 5-fluorouracil inhibits the growth of human colorectal xenografts in nude mice.
    European journal of cancer (Oxford, England : 1990), 1992, Volume: 28A, Issue:6-7

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour

1992
Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole.
    Annals of neurology, 1992, Volume: 31, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Biopsy; Brain; Chemoth

1992
Post-mastectomy radiotherapy following adjuvant chemotherapy and autologous bone marrow transplantation for breast cancer patients with greater than or equal to 10 positive axillary lymph nodes. Cancer and Leukemia Group B.
    International journal of radiation oncology, biology, physics, 1992, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;

1992
Radiosensitization of cultured human colon adenocarcinoma cells by 5-fluorouracil: effects on cell survival, DNA repair, and cell recovery.
    International journal of radiation oncology, biology, physics, 1992, Volume: 23, Issue:5

    Topics: Adenocarcinoma; Cell Survival; Cesium Radioisotopes; Colonic Neoplasms; DNA Repair; Dose-Response Re

1992
[Platelet aggregation during adjuvant chemotherapy with CMF].
    Minerva medica, 1991, Volume: 82, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1991
Chemotherapy for pancreatic carcinoma.
    Lancet (London, England), 1991, Jan-19, Volume: 337, Issue:8734

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1991
Heavy water enhances the antineoplastic effect of 5-fluoro-uracil and bleomycin in nude mice bearing human carcinoma.
    International journal of cancer, 1990, Mar-15, Volume: 45, Issue:3

    Topics: Adenocarcinoma; Animals; Bleomycin; Carcinoma, Squamous Cell; Colonic Neoplasms; Deuterium; Drug Syn

1990
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
    American journal of clinical oncology, 1990, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin;

1990
Schedule dependent potentiation of antitumor drug effects by alpha-difluoromethylornithine in human gastric carcinoma cells in vitro.
    Investigational new drugs, 1990, Volume: 8 Suppl 1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Cell Cycle; Cell Survival; Doxorubicin; Drug Admin

1990
Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line.
    Cancer research, 1990, Sep-15, Volume: 50, Issue:18

    Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; Drug Interactions; Drug Resistance; Fluorodeo

1990
Long-term results of infusional 5-FU, mitomycin-C and radiation as primary management of esophageal carcinoma.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma;

1991
Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer.
    Journal of endocrinological investigation, 1991, Volume: 14, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Betamethas

1991
Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1992
Concurrent preoperative chemotherapy and radiation therapy in localized esophageal adenocarcinoma.
    Cancer, 1992, Jan-15, Volume: 69, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Esophageal Neoplasms; Esophagectomy; Female;

1992
Response of pancreatic carcinoma to 5-fluorouracil and leucovorin.
    The American journal of medicine, 1992, Volume: 92, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Leucovo

1992
Preoperative radiation therapy for locally advanced carcinoma of the rectum. Clinicopathologic correlative review.
    Diseases of the colon and rectum, 1992, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Lymphatic Metastasis; Neoplasm Stag

1992
Increased drug resistance of cultured human cancer cell lines in three-dimensional cellular growth assay using collagen gel matrix.
    Journal of surgical oncology, 1992, Volume: 49, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Collagen; Colonic Neoplasms; Culture Media; Doxoru

1992
A phase II study of 5-fluorouracil, adriamycin and mitomycin-C in adenocarcinoma of the oesophagus.
    Clinical oncology (Royal College of Radiologists (Great Britain)), 1991, Volume: 3, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dox

1991
5-Fluorouracil (FU) and mitomycin C (MMC) in the management of colorectal carcinoma. Part II. In vitro activity of the two drugs in short-term tumor cultures.
    Medical oncology and tumor pharmacotherapy, 1991, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; DNA, Neoplasm;

1991
Radiation myelitis: a complication of concurrent cisplatin and 5-fluorouracil chemotherapy with extended field radiotherapy for carcinoma of the uterine cervix.
    Gynecologic oncology, 1991, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cis

1991
Anticancer effects of a Chinese herbal medicine, juzen-taiho-to, in combination with or without 5-fluorouracil derivative on DNA-synthesizing enzymes in 1,2-dimethylhydrazine induced colonic cancer in rats.
    The American journal of Chinese medicine, 1991, Volume: 19, Issue:3-4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Eva

1991
Choroidal metastases as a presenting sign after 24 years of a primary breast cancer.
    Indian journal of cancer, 1991, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Choroid Neoplasms;

1991
Comparative DNA strand breakage induced by FUra and FdUrd in human ileocecal adenocarcinoma (HCT-8) cells: relevance to cell growth inhibition.
    Cancer communications, 1991, Volume: 3, Issue:2

    Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; DNA; DNA Damage; Dose-Response Relationship, Drug;

1991
[5-Fluorouracil level and pyrimidine nucleoside phosphorylase activity in cancer patients after oral administration of doxifluridine (5'-DFUR)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Colonic Neop

1991
In vivo drug intracellular localisation by analytical ion microscopy: preliminary study in gastric adenocarcinomas treated with 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Fluorouracil; Humans; Microscopy, Electron; Stomach Neoplasms

1991
Painful, red hands. A side effect of 5-fluorouracil by continuous perfusion.
    International journal of dermatology, 1991, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Colonic Neoplasms; Drug Eruptions; Female; Fluorouracil; Hand Dermatoses; Humans; Mi

1991
Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Female; Fluorouracil; Gastrointestinal Diseases; Hep

1991
MMAF for advanced gastric cancer.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin;

1991
[Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1991
Pre-treatment prognostic factors in stage III non-small cell lung cancer patients receiving combined modality treatment.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carc

1991
Schedule-dependent in vitro combination effects of methotrexate and 5-fluorouracil in human tumor cell lines.
    International journal of cancer, 1991, Feb-01, Volume: 47, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols;

1991
Experimental model of colon cancer: recurrences after surgery alone or associated with intraperitoneal 5-fluorouracil chemotherapy.
    Diseases of the colon and rectum, 1991, Volume: 34, Issue:8

    Topics: Adenocarcinoma; Animals; Azoxymethane; Colectomy; Colonic Neoplasms; Combined Modality Therapy; Dise

1991
Preoperative chemoradiotherapy for adenocarcinoma of the pancreas. Rationale and technique.
    American journal of clinical oncology, 1991, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adult; Biopsy, Needle; Clinical Protocols; Combined Modality Therapy; Decision Trees

1991
Interaction between 5-fluorouracil, [6RS]leucovorin, and recombinant human interferon-alpha 2a in cultured colon adenocarcinoma cells.
    Cancer communications, 1991, Volume: 3, Issue:7

    Topics: Adenocarcinoma; Cell Survival; Colonic Neoplasms; Drug Synergism; Fluorouracil; Folic Acid; Interfer

1991
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

1991
In vitro response of a human colon tumor xenograft and a lung adenocarcinoma cell line to alpha-difluoromethylornithine alone and in combination with 5-fluorouracil and doxorubicin.
    Journal of surgical oncology, 1991, Volume: 48, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Colonic Neoplasms; Do

1991
Resectable gastric carcinoma. An evaluation of preoperative and postoperative chemotherapy.
    Cancer, 1991, Oct-01, Volume: 68, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1991
Antitumor activity of fluoropyrimidines and thymidylate synthetase inhibition.
    Japanese journal of cancer research : Gann, 1991, Volume: 82, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma; Colonic Neoplasms; Enzyme Activation; Flu

1991
Subrenal capsule assay using nude mice as a predictor of the response of the gastric cancer to chemotherapy.
    Journal of surgical oncology, 1991, Volume: 47, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Fluorouracil; Huma

1991
[A long-term survival case of advanced gastric cancer undergoing radical gastrectomy by second-look operation after successful chemotherapy (CDDP, MMC, 5-FU)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1991
[Long-term arterial infusion chemotherapy combined with external irradiation therapy for unresectable pancreatic cancer--a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:11

    Topics: Adenocarcinoma; Aged; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Combined Modal

1991
A less toxic regimen of 5-fluorouracil and high-dose folinic acid for advanced gastrointestinal adenocarcinomas.
    British journal of cancer, 1991, Volume: 64, Issue:3

    Topics: Adenocarcinoma; Fluorouracil; Gastrointestinal Neoplasms; Leucovorin; Lymphatic Metastasis; Neoplasm

1991
Disappearance of hyperplastic polyposis after resection of rectal cancer. Report of two cases.
    Diseases of the colon and rectum, 1991, Volume: 34, Issue:9

    Topics: Adenocarcinoma; Aged; Anastomosis, Surgical; Brachytherapy; Colonic Neoplasms; Colonoscopy; Combined

1991
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug

1991
[Hepatic arterial infusion of farmorubicin (FARM) and 5-fluorouracil (5-FU) in a patient with massive hepatic metastasis from gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:13

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorourac

1991
Combined radiation therapy, mitomycin C, and 5-fluorouracil for locally recurrent rectal carcinoma: results of a pilot study.
    International journal of radiation oncology, biology, physics, 1991, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1991
Extrahepatic biliary system cancer: an update of a combined modality approach.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Brach

1991
Primary breast cancer after prophylactic mastectomy.
    American journal of clinical oncology, 1991, Volume: 14, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Mod

1991
Response to doxorubicin/methotrexate/fluorouracil in advanced adenocarcinoma of pancreas or biliary tract.
    Lancet (London, England), 1990, Jul-14, Volume: 336, Issue:8707

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Doxo

1990
Doxorubicin/methotrexate/fluorouracil in advanced pancreatic cancer.
    Lancet (London, England), 1990, Dec-08, Volume: 336, Issue:8728

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Humans; M

1990
Adenocarcinoma of the urachus associated with elevated levels of CA 125.
    The Journal of urology, 1991, Volume: 145, Issue:1

    Topics: Adenocarcinoma; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Combined Chemotherapy

1991
Intrapericardial infusion of 5-fluorouracil. An unusual complication of a Hickman catheter.
    Cancer, 1991, Feb-01, Volume: 67, Issue:3

    Topics: Adenocarcinoma; Arrhythmias, Cardiac; Catheterization, Central Venous; Colonic Neoplasms; Female; Fl

1991
Sphincter preservation in rectal cancer by local excision and postoperative radiation therapy.
    Cancer, 1991, Feb-15, Volume: 67, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Brachytherapy; Combined Modality Therapy; Female; Fluoroura

1991
5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells.
    International journal of radiation oncology, biology, physics, 1991, Volume: 20, Issue:2

    Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Fluorour

1991
Combined-modality therapy for rectal carcinoma--the time has come.
    The New England journal of medicine, 1991, Mar-14, Volume: 324, Issue:11

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal

1991
Selective uptake of toxic nucleoside (125IUdR) by resistant cancer.
    The British journal of radiology, 1991, Volume: 64, Issue:757

    Topics: Adenocarcinoma; Animals; Cell Line; Choriocarcinoma; Colon; Colonic Neoplasms; Cytarabine; Drug Resi

1991
Cancer chemotherapy: hormonal changes and recurring asthma.
    The Journal of allergy and clinical immunology, 1991, Volume: 87, Issue:3

    Topics: Adenocarcinoma; Adult; Amenorrhea; Antineoplastic Combined Chemotherapy Protocols; Asthma; Breast Ne

1991
Adenocarcinoma of the pancreas: current management of resectable and locally advanced disease.
    Southern medical journal, 1991, Volume: 84, Issue:5

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N

1991
A pilot study of sphincter-sparing management of adenocarcinoma of the rectum.
    Archives of surgery (Chicago, Ill. : 1960), 1991, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Anal Canal; Combined Modality Therapy; Female; Fluorouracil; Humans; Ma

1991
High-dose folinic acid, 5-fluorouracil bolus and continuous infusion in poor-prognosis patients with advanced measurable gastric cancer.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; H

1991
5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bili

1991
[Ectasing cholangitis and secondary biliary cirrhosis following intra-arterial hepatic chemotherapy. Treatment by liver transplantation].
    Gastroenterologie clinique et biologique, 1991, Volume: 15, Issue:4

    Topics: Adenocarcinoma; Adult; Cholangitis, Sclerosing; Female; Fluorouracil; Humans; Infusions, Intra-Arter

1991
A pilot study of neoadjuvant chemotherapy with 5-fluorouracil and cisplatin with surgical resection and postoperative radiation therapy and/or chemotherapy in adenocarcinoma of the esophagus.
    Cancer, 1991, Aug-01, Volume: 68, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1991
Different effects of sequential combinations of N-methylformamide with 5-fluorouracil on human colon carcinoma cells growing in nude mice.
    Journal of cancer research and clinical oncology, 1991, Volume: 117, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell

1991
[Chemotherapy in cancers of the gallbladder and bile ducts].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1991, Volume: 18, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cytarabine;

1991
Continuous infusion 5-fluorouracil plus weekly cisplatin for pancreatic carcinoma. A Mid-Atlantic Oncology Program study.
    Cancer, 1991, Jul-15, Volume: 68, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisp

1991
Chest pain in a cancer patient on chemotherapy.
    Hospital practice (Office ed.), 1991, Jul-15, Volume: 26, Issue:7

    Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Male; Myocardial Infarction; Strepto

1991
Stimulation of clonal growth of human colorectal tumor cells by IL-3 and GM-CSF. Modulation of 5-FU cytotoxicity by GM-CSF.
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colorectal Neoplasms; Combined Modality The

1990
[Myocardial infarcts within the scope of 5-fluorouracil therapy].
    Onkologie, 1990, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Adult; Electrocardiography; Fluorouracil; Humans; Infusions, Intravenous; Liver Neop

1990
Carmofur-induced organic mental disorders.
    The Japanese journal of psychiatry and neurology, 1990, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Electroencephalography; Female; Fluorouracil; Follow-U

1990
Open phase II with 5-fluorouracil, 4-epi-doxorubicin and mitomycin C (FEM) in advanced gastric cancer.
    Tumori, 1990, Feb-28, Volume: 76, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu

1990
Acute non-lymphocytic leukemia following FAM combination adjuvant chemotherapy for gastric and lung adenocarcinoma.
    Nouvelle revue francaise d'hematologie, 1990, Volume: 32, Issue:3

    Topics: Adenocarcinoma; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemotherap

1990
[Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans;

1990
Treatment of experimental liver metastases in the rat by continuous intraportal infusion of 5-fluorouracil and heparin: a pilot study.
    Anti-cancer drugs, 1990, Volume: 1, Issue:2

    Topics: Adenocarcinoma; Animals; Anticoagulants; Drug Therapy, Combination; Fluorouracil; Heparin; Humans; I

1990
Hyperfractionated radiation and chemotherapy for unresectable localized adenocarcinoma of the pancreas. The Gastrointestinal Tumor Study Group experience.
    Cancer, 1990, Apr-01, Volume: 65, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1990
Differential effects of 2,2'-anhydro-5-ethyluridine, a uridine phosphorylase inhibitor, on the antitumor activity of 5-fluorouridine and 5-fluoro-2'-deoxyuridine.
    Biochemical pharmacology, 1990, Apr-01, Volume: 39, Issue:7

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Interactions; Floxuridine; Fluorouracil; Humans; Ki

1990
[A study on preoperative administration of doxifluridine in carcinoma of the colon and rectum].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1990, Volume: 17, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Colorectal Neoplasms; Floxuridine; Fluorouracil; Humans; Lymph

1990
Differential oncogene amplification in tumor cells from a patient treated with cisplatin and 5-fluorouracil.
    European journal of cancer (Oxford, England : 1990), 1990, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female;

1990
Optimal treatment regimens for 5'-deoxy-5-fluorouridine, with or without (E)-5-(2-bromovinyl)-2'-deoxyuridine, against various tumors in mice.
    Japanese journal of cancer research : Gann, 1990, Volume: 81, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antiviral Agents; Bromodeoxyuridine; Colonic Neoplas

1990
Biochemical modulation of 5-fluoropyrimidine toxicity by dehydroepiandrosterone in human colonic adenocarcinoma cells.
    Cancer communications, 1990, Volume: 2, Issue:6

    Topics: Adenocarcinoma; Carbon Radioisotopes; Colonic Neoplasms; Dehydroepiandrosterone; Fluorouracil; Human

1990
Appendiceal adenocarcinoid with ovarian metastasis.
    Gynecologic oncology, 1990, Volume: 38, Issue:2

    Topics: Adenocarcinoma; Adult; Appendiceal Neoplasms; Female; Fluorouracil; Humans; Ovarian Neoplasms; Strep

1990
Clinical trials referral resource. Adjuvant therapy for colon cancer.
    Oncology (Williston Park, N.Y.), 1990, Volume: 4, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colo

1990
Comparison of pyrimidine nucleotide synthetic enzymes involved in 5-fluorouracil metabolism between human adenocarcinomas and squamous cell carcinomas.
    Cancer, 1990, Jul-01, Volume: 66, Issue:1

    Topics: Adenocarcinoma; Carbon-Nitrogen Ligases; Carcinoma, Squamous Cell; DCMP Deaminase; DNA-Directed DNA

1990
Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human lung cancer cell lines.
    International journal of cancer, 1990, Jul-15, Volume: 46, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Carcinoma, Squamous Cell; Cell Line; Dose-Respo

1990
A phase I trial of cisplatin in hypertonic saline and escalating doses of 5-fluorouracil by continuous intravenous infusion in patients with advanced malignancies.
    Cancer, 1990, Oct-15, Volume: 66, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1990
A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma.
    American journal of clinical oncology, 1990, Volume: 13, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1990
Preoperative chemotherapy is beneficial for geriatric patients with locally advanced and metastatic breast cancer.
    The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society, 1990, Volume: 142, Issue:9

    Topics: Adenocarcinoma; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neo

1990
[Effective continuous intraarterial chemotherapy for a patient with FIGO stage IIIb cervical adenocarcinoma invasing the bladder wall].
    Nihon Gan Chiryo Gakkai shi, 1990, Oct-20, Volume: 25, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Hum

1990
5-fluorouracil (5-FU) plus high dose folinic acid (FA): a modified scheme with reduced toxicity.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Leucovorin; Male; Middle

1990
Tumor trapping of 5-fluorouracil: in vivo 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits.
    Proceedings of the National Academy of Sciences of the United States of America, 1990, Volume: 87, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic N

1990
Gastric adenocarcinoma presenting with soft tissue masses.
    The American journal of gastroenterology, 1990, Volume: 85, Issue:1

    Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Male; Soft Tissue Neoplasms; Stomach Neoplasms; Thigh

1990
Synergism between 5-fluorouracil and N-methylformamide in HT29 human colon cancer line.
    British journal of cancer, 1990, Volume: 61, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Colonic Neoplasm

1990
[Combination radiotherapy and chemotherapy in the treatment of locally advanced adenocarcinoma of the pancreas. Experiences of the Gustave Roussy Institute].
    Bulletin du cancer, 1990, Volume: 77, Issue:3

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cis

1990
Cellular pharmacology of 5-fluorouracil in a human colon adenocarcinoma cell line selected for thymidine kinase deficiency.
    Biochemical pharmacology, 1990, Jun-01, Volume: 39, Issue:11

    Topics: Adenocarcinoma; Cell Division; Colonic Neoplasms; Cytosol; Fluorouracil; Humans; Kinetics; Thymidine

1990
Locally advanced unresectable gastric cancer successfully resected after neoadjuvant chemotherapy with FADE regimen.
    Yonsei medical journal, 1990, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy

1990
[Reversible cardiogenic shock due to 5FU. Apropos of a case report].
    Revue medicale de Bruxelles, 1990, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Agents; Fluorouracil;

1990
Influence of dose of [6RS]leucovorin on reduced folate pools and 5-fluorouracil-mediated thymidylate synthase inhibition in human colon adenocarcinoma xenografts.
    Cancer research, 1990, Jul-01, Volume: 50, Issue:13

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil;

1990
[A case of non-functioning adrenocortical tumor].
    Gan no rinsho. Japan journal of cancer clinics, 1990, Volume: 36, Issue:7

    Topics: Adenocarcinoma; Adrenal Cortex Hormones; Adrenal Cortex Neoplasms; Combined Modality Therapy; Female

1990
Evaluation of pre- and postoperative chemotherapy for resectable adenocarcinoma of the esophagus or gastroesophageal junction.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1990
Adjuvant 5-FU and MeCCNU improves survival following curative gastrectomy for adenocarcinoma.
    The American surgeon, 1990, Volume: 56, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemot

1990
[Assessment of individual sensitivity to chemotherapy of human pulmonary tumors transplanted to subrenal capsule of CBA mice].
    Eksperimental'naia onkologiia, 1990, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid

1990
Chemosensitivity and DNA content as prognostic factors in ovarian cancer: preliminary results.
    European journal of gynaecological oncology, 1990, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Aged; Colony-Forming Units Assay; Doxorubicin; Female; Fluorouracil; Folic Acid; Hum

1990
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa

1990
[5-Fluorouracil (5-FU) concentration in prostatic tissue of rats and in prostatic cancer patients after oral administration of 5-FU].
    Hinyokika kiyo. Acta urologica Japonica, 1990, Volume: 36, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Animals; Fluorouracil; Humans; Linear

1990
[Chemoradiation treatment of pancreatic cancer].
    Meditsinskaia radiologiia, 1985, Volume: 30, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1985
[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil].
    Klinische Wochenschrift, 1986, Aug-01, Volume: 64, Issue:15

    Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Chemotherapy, Cancer, Regional

1986
[Alternating combination chemotherapy (VIP-DMF) in patients with advanced adenocarcinoma of the prostate].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Doxorubicin; Drug A

1987
[Combination therapy with lentinan, mitomycin c, 5-fluorouracil and radiation--a case of long-term survival of pancreas cancer after palliative surgery].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:5 Pt 1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Flu

1987
External beam radiotherapy for rectal adenocarcinoma.
    The British journal of surgery, 1987, Volume: 74, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A

1987
Establishment of a human urachal adenocarcinoma cell line (KO-BT-1) and its chemosensitivity.
    Cancer research, 1987, Sep-15, Volume: 47, Issue:18

    Topics: Adenocarcinoma; Adult; Animals; Cell Line; Fluorouracil; Humans; Interferons; Male; Mice; Mice, Inbr

1987
Nonsurgical management of esophageal cancer: report of a study of combined radiotherapy and chemotherapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:11

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma,

1987
[Combination chemotherapy including cisplatin in lung cancer by bronchial artery infusion].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

1988
5-Fluorouracil incorporation into RNA of a rat liver adenocarcinoma after hepatic artery injection together with degradable starch microspheres.
    Cancer drug delivery, 1987, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Female; Fluorouracil; Injections, Intra-Arterial; Liver

1987
Chemotherapy for paranasal sinus carcinoma. A 10-year experience at Wayne State University.
    Cancer, 1988, Jul-01, Volume: 62, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, S

1988
Effects of dosage and infusion time on the incorporation of 5-fluorouracil into DNA and RNA of normal tissues and an adenocarcinoma transplanted to rat liver.
    Journal of surgical oncology, 1988, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Animals; DNA; DNA, Neoplasm; Dose-Response Relationship, Drug; Female; Fluorouracil;

1988
Interferon effects upon the adenocarcinoma 38 and HL-60 cell lines: antiproliferative responses and synergistic interactions with halogenated pyrimidine antimetabolites.
    Cancer research, 1988, Sep-01, Volume: 48, Issue:17

    Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Division; Drug Synergism; Floxuridine; Fluorou

1988
Effective palliation of metastatic adenocarcinoma to the liver: a case report.
    Journal of the Mississippi State Medical Association, 1988, Volume: 29, Issue:10

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions,

1988
The combined effect of interferon and 5-FU on tumor-cell metastasis in the nude mouse.
    Diseases of the colon and rectum, 1989, Volume: 32, Issue:4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Fluor

1989
Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma.
    Gynecologic oncology, 1989, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleo

1989
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
    Cancer research, 1989, Aug-15, Volume: 49, Issue:16

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid

1989
Cisplatin, epirubicin and 5-fluorouracil combination chemotherapy for recurrent carcinoma of the salivary gland.
    Tumori, 1989, Jun-30, Volume: 75, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, A

1989
Alternating 5-FU-mitomycin C/5-FU-dacarbazine in advanced colorectal adenocarcinoma: a phase II study.
    Oncology, 1989, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1989
Postoperative adjuvant chemotherapy and radiotherapy for cancer of the large bowel and rectum.
    American journal of surgery, 1989, Volume: 157, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cecal Neoplasms; Colonic Neop

1989
[The concentration of 5-fluorouracil in blood and tissues of the patients with carcinoma of the cervix after administration of UFT and 5-fluorouracil].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:4 Pt 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1989
Phase I and II studies of the combination of recombinant human interferon-gamma and 5-fluorouracil in patients with advanced colorectal carcinoma.
    Journal of biological response modifiers, 1989, Volume: 8, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Colonic Neop

1989
Cisplatin, 5-fluorouracil, mitomycin C, and concurrent radiation therapy with and without esophogectomy for esophageal carcinoma.
    Cancer, 1989, Aug-01, Volume: 64, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1989
Concurrent radiation and chemotherapy in vulvar carcinoma.
    Gynecologic oncology, 1989, Volume: 34, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone

1989
Distributions of tegafur in tissues of gastric adenocarcinoma patients: tissue uptakes and concentrations in plasma after oral and rectal administrations.
    Japanese journal of clinical oncology, 1989, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Administration, Rectal; Adult; Aged; Female; Fluorouracil; Hum

1989
Adjuvant therapy for colon carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Female; Fluorouracil; Humans; Interfer

1989
Preoperative irradiation with and without chemotherapy (MFL) in the treatment of primarily non-resectable adenocarcinoma of the rectum. Results from two consecutive studies.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1989
[Effects of chemo-endocrine therapy on DMBA-induced rat mammary carcinoma].
    Nihon Geka Gakkai zasshi, 1989, Volume: 90, Issue:10

    Topics: 9,10-Dimethyl-1,2-benzanthracene; Adenocarcinoma; Animals; Drug Evaluation; Drug Therapy, Combinatio

1989
5-Fluoropyrimidine-induced DNA damage in human colon adenocarcinoma and its augmentation by the nucleoside transport inhibitor dipyridamole.
    Cancer research, 1989, Mar-01, Volume: 49, Issue:5

    Topics: Adenocarcinoma; Colonic Neoplasms; Dipyridamole; DNA; DNA Damage; Floxuridine; Fluorouracil; Humans;

1989
Enhanced antitumor effect of 5'-deoxy-5-fluorouridine by oral administration with L-cysteine.
    Japanese journal of cancer research : Gann, 1989, Volume: 80, Issue:2

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Chrom

1989
[Two cases of gastrointestinal cancers with major responses to sequential methotrexate 5-FU plus 5'-DFUR].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antigen; Colonic Ne

1989
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5'-deoxy-5-fluorouridine against adenocarcinoma 755 in mice. Correlation with pharmacokinetics of plasma 5-fluorouracil levels.
    Biochemical pharmacology, 1989, Jun-15, Volume: 38, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bromodeoxyuridine; Chromatography, High Pressure Liq

1989
MTX-5-FU combination therapy compared to FUDR monotherapy in nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female;

1989
Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colony-Forming Un

1989
Intra-arterial hepatic chemotherapy for metastatic liver from colo-rectal carcinoma origin.
    Selective cancer therapeutics, 1989, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Colorectal Neoplasms; Female; Floxuridine; Fluorouracil; Hepatic Artery

1989
Comparative antitumor activity of 5-fluorouracil and 5'-deoxy-5-fluorouridine in combination with radiation therapy in mice bearing colon 26 adenocarcinoma.
    Japanese journal of cancer research : Gann, 1989, Volume: 80, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Colonic Neoplasms; Combined Modality Th

1989
[In vitro studies of 5-FU sensitivity on uterine cervical cancer cell lines--comparison between squamous cell carcinoma and adenocarcinoma].
    Nihon Sanka Fujinka Gakkai zasshi, 1989, Volume: 41, Issue:9

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Survival; DNA, Neoplasm; Drug Screening Assays, Antit

1989
Clinical trials referral resource. Adjuvant therapy of breast cancer.
    Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:6

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Buserelin;

1989
[Effect of human epidermal factor (hEGF) on antitumor activity of 5-fluorouracil (5-FU) in human gastric cancer cell lines].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cell Division; Cell Line; Cell Survival; Drug Screening As

1989
[Metastatic liver cancer from the stomach successfully treated by combined immunochemotherapy and transarterial embolization].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cytarabin

1989
[Two cases of digestive cancer demonstrated remarkable regression by hyperthermia with systemic chemotherapy].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1989, Volume: 86, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Colonic N

1989
Clinical trials referral resource. Adjuvant treatment of colon cancer.
    Oncology (Williston Park, N.Y.), 1989, Volume: 3, Issue:9

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Clinical Trials as Topic;

1989
[Current status in the treatment of inoperable non-small cell lung cancer (NSCLC)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small Cell; Ca

1985
Combined effect of 5-fluorouracil and interferon on experimental liver metastases of rat colon carcinoma.
    Journal of cancer research and clinical oncology, 1985, Volume: 109, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorour

1985
Adenocarcinoma of the small intestine presenting as an ovarian mass. A case report.
    The Journal of reproductive medicine, 1989, Volume: 34, Issue:11

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Femal

1989
Phase I trial of semustine plus weekly fluorouracil and high-dose leucovorin calcium in patients with advanced colorectal cancer.
    Journal of the National Cancer Institute, 1989, Dec-06, Volume: 81, Issue:23

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Evaluatio

1989
Phase II trial of combination chemotherapy with fluorouracil (F), doxorubicin (A), and cisplatin (P) (Fap) in hormonally resistant metastatic prostatic adenocarcinoma.
    Oncology, 1989, Volume: 46, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Drug E

1989
A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; D

1989
[Various doses cisplatin combined with multi-drug chemotherapy of malignant solid tumors].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1989, Volume: 11, Issue:3

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neop

1989
[Synchronous hepatic metastases of colorectal adenocarcinoma: what is the course? Apropos of 36 cases].
    Helvetica chirurgica acta, 1989, Volume: 56, Issue:4

    Topics: Adenocarcinoma; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Infusions, In

1989
[120-hour continuous 5-FU infusion and cisplatin in the treatment of advanced esophageal carcinoma--clinical analysis of 19 cases].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1989, Volume: 11, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1989
Transplantable mouse mammary adenocarcinoma 16/c as a model in experimental cancer therapy. III. Sensitivity to antitumor drugs.
    Archivum immunologiae et therapiae experimentalis, 1989, Volume: 37, Issue:3-4

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubic

1989
Adjuvant chemotherapy after resection of adenocarcinoma of the periampullary region and the head of the pancreas. A non-randomized pilot study.
    Journal of cancer research and clinical oncology, 1989, Volume: 115, Issue:2

    Topics: Activities of Daily Living; Adenocarcinoma; Aged; Ampulla of Vater; Antineoplastic Combined Chemothe

1989
Application of a new radiometric system for identification of potentially useful drug combinations for treatment of human gastrointestinal adenocarcinoma.
    Oncology, 1989, Volume: 46, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cytarabine; Drug Screenin

1989
Radiation therapy with/without simultaneous weekly 5 F.U. in locally recurrent carcinoma of the recto-sigmoid.
    The West Virginia medical journal, 1989, Volume: 85, Issue:4

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrence, Local; Rectal

1989
Phase II study of adriamycin with sequential methotrexate and 5-fluorouracil (AMF) in gastric carcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu

1989
Sequential moderate-dose methotrexate and 5-fluorouracil in advanced gastric adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Fema

1989
Increased contraenvironmental-pressure cell division capability: a decisive force in metastasis and invasion of mouse lung adenocarcinoma cell lines.
    Invasion & metastasis, 1989, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Animals; Cell Division; Cell Line; Clone Cells; Fluorouracil; Lung Neoplasms; Mice;

1989
Adenocarcinoma of the ethmoid sinuses. Results of a new protocol based on inductive chemotherapy combined with surgery. Four years experience.
    Acta neurochirurgica, 1989, Volume: 98, Issue:3-4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Mod

1989
Treatment with 5-FU, VCR and BCNU in tumor bearing nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Adenocarcinoma; Animals; Carmustine; Colorectal Neoplasms; Female; Fluorouracil; Humans; Mice; Mice,

1989
Human-alpha-interferon on xenotransplanted human colonic adenocarcinomas in nude mice.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 1989, Volume: 165, Issue:7

    Topics: Adenocarcinoma; Animals; Carmustine; Colonic Neoplasms; Female; Fluorouracil; Humans; Interferon Typ

1989
Nucleoside analogues: 8. Some isomers of B.3839, the original 5-fluorouracil/nitrosourea molecular combination, and their effect on colon, breast and lung tumours in mice.
    Anti-cancer drug design, 1989, Volume: 4, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Colonic Neoplasms; Dr

1989
Phase II trial of methotrexate-FAM (m-FAM) in adenocarcinoma of unknown primary.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu

1989
Efficacy of high-dose oral leucovorin and 5-fluorouracil in advanced colorectal carcinoma. Plasma and tissue pharmacokinetics.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

1989
Clinical experience with leucovorin and 5-fluorouracil.
    Cancer, 1989, Mar-15, Volume: 63, Issue:6 Suppl

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1989
Refractory metastatic breast cancer: salvage therapy with fluorouracil and high-dose continuous infusion leucovorin calcium.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Breast Neoplasms; Female; Fluorouracil; Humans; Infu

1989
Phase II evaluation of 5-fluorouracil, folinic acid and cisplatin in advanced-stage colorectal adenocarcinoma.
    Oncology, 1989, Volume: 46, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal N

1989
Treatment of metastatic colorectal adenocarcinoma with fluorouracil and high-dose leucovorin: a pilot study.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1989, Volume: 43, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; F

1989
Intrahepatic 5-FU retreatment of liver metastases of colorectal cancer that were progressive under previous systemic chemotherapy.
    American journal of clinical oncology, 1989, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Cause of Death; Colorectal Neoplasms; Female; Fluorouracil; Hepatic Art

1989
Nucleoside analogues. 9. Seco-nucleoside analogues of some 5-fluorouracil/nitrosourea molecular combinations having uracil as base: synthesis and anti-tumour activity.
    Anti-cancer drug design, 1989, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Chemical Phenomena; Chemistry; Colonic Neo

1989
Treatment of metastatic colorectal carcinoma. Recent advances in use of fluorouracil.
    Postgraduate medicine, 1989, Nov-01, Volume: 86, Issue:6

    Topics: Adenocarcinoma; Colorectal Neoplasms; Fluorouracil; Humans; Infusion Pumps; Leucovorin

1989
[Combination chemotherapy with ifosfamide, 5-fluorouracil, cisplatin for stage D2 prostatic cancer].
    Hinyokika kiyo. Acta urologica Japonica, 1989, Volume: 35, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Fluorouracil; Human

1989
Biological features and chemosensitivity of human colorectal cancer xenografted in nude mice.
    Gastroenterologia Japonica, 1987, Volume: 22, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Carcinoembryonic Antigen;

1987
Perianal Paget's disease. Report of three cases.
    Diseases of the colon and rectum, 1988, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anus Neoplasms; Female; Fluorouracil; Humans; Male; Neoplas

1988
Radiation therapy for advanced gastric cancer.
    International journal of radiation oncology, biology, physics, 1988, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over;

1988
Preoperative combined modality therapy for stage III M0 non-small cell lung carcinoma.
    International journal of radiation oncology, biology, physics, 1988, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce

1988
[Experimental chemotherapy of human gastric cancer cell lines in vitro and in nude mice].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1988, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Allyl Compounds; Animals; Antibiotics, Antineoplastic; Cel

1988
Simultaneous chemotherapy-radiotherapy with prophylactic cranial irradiation for inoperable adeno and large cell lung carcinoma: a Southwest Oncology Group Study.
    International journal of radiation oncology, biology, physics, 1988, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcin

1988
Combination chemotherapy of cisplatin and 5-fluorouracil for advanced colorectal adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1989
Low-dose continuous infusion 5-fluorouracil. Evaluation in advanced breast carcinoma.
    Cancer, 1989, Feb-01, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Cycloph

1989
Adverse effects of intraperitoneal fluorouracil in patients with optimal residual ovarian cancer after second-look laparotomy: a Gynecologic Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1989, Volume: 7, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling;

1989
Intra-arterial infusion of 5-fluorouracil for recurrent adenocarcinoma of bladder.
    Urology, 1989, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Fluorouracil; Follow-Up Studies; Humans; Infusions, Intra-Arterial; Male; Middle Age

1989
Nucleoside analogues: 7. Effect on colon, breast and lung tumours in mice of 5-fluorouracil/nitrosourea molecular combinations incorporating alkoxy and oxidized sulphur functions.
    Anti-cancer drug design, 1989, Volume: 3, Issue:4

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Drug Combinations; Drug Evaluation, Preclinical; Fluorou

1989
[Observation on the curative effect postoperatively of late gastric cancer by the fu zheng anti-cancer method combined with chemotherapy].
    Zhong xi yi jie he za zhi = Chinese journal of modern developments in traditional medicine, 1985, Volume: 5, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Medicine

1985
On the differential affinities of two anticancer analogues to their target.
    Drugs under experimental and clinical research, 1985, Volume: 11, Issue:2

    Topics: Adenocarcinoma; Chromatography, High Pressure Liquid; Colonic Neoplasms; Female; Floxuridine; Fluoro

1985
Noninvasive fluorine-19 NMR study of fluoropyrimidine metabolism in cell cultures of human pancreatic and colon adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:1

    Topics: Adenocarcinoma; Cells, Cultured; Colonic Neoplasms; Floxuridine; Fluorine; Fluorouracil; Humans; Mac

1986
Adjuvant therapy for breast cancer.
    The Journal of the Arkansas Medical Society, 1987, Volume: 83, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide;

1987
Myocardial ischemia with fluorouracil and floxuridine therapy.
    Clinical pharmacy, 1987, Volume: 6, Issue:8

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Coronary Disease; Electrocardiography; Floxuridine; Fluorou

1987
[Locoregional chemotherapy of hepatic metastases of colorectal cancer].
    Annales de gastroenterologie et d'hepatologie, 1987, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Infusion Pumps; I

1987
Increased levels of DNA lesions induced by leucovorin-5-fluoropyrimidine in human colon adenocarcinoma.
    Cancer research, 1988, Aug-01, Volume: 48, Issue:15

    Topics: Adenocarcinoma; Aphidicolin; Cell Line; Cell Survival; Colonic Neoplasms; Diterpenes; DNA; DNA Damag

1988
[Status of estrogen receptors in breast cancer and prediction of chemotherapy sensitivity].
    Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae, 1988, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Drug Screening Assays, Antitumor; Female; Fluorouraci

1988
Cisplatin, methotrexate, and 5-fluorouracil combination chemotherapy for advanced ovarian cancer.
    Gynecologic oncology, 1985, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1985
Chemical cholecystitis associated with hepatic arterial chemotherapy delivered by a permanently implanted pump.
    Human pathology, 1985, Volume: 16, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Arteritis; Carcinoma, Hepatocellular; Cholecystitis; Ch

1985
[Low-dose intermittent intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:10

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Dox

1985
[Sequential chemotherapy with low-dose methotrexate and 5-fluorouracil in advanced gastric cancer].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:10

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocol

1985
[Postoperative chemotherapy of pathological stage I non-small cell carcinoma of the lung].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell;

1986
Relationship between 5-fluoro-2'-deoxyuridylate, 2'-deoxyuridylate, and thymidylate synthase activity subsequent to 5-fluorouracil administration, in xenografts of human colon adenocarcinomas.
    Biochemical pharmacology, 1986, Apr-15, Volume: 35, Issue:8

    Topics: Adenocarcinoma; Adenosine Monophosphate; Animals; Cell Line; Colonic Neoplasms; Deoxyuracil Nucleoti

1986
A phase II study of combined 5-fluorouracil, doxorubicin, and cisplatin in the treatment of advanced upper gastrointestinal adenocarcinomas.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellul

1986
Combination chemotherapy with CDDP and 5-FU in head and neck cancer.
    Auris, nasus, larynx, 1986, Volume: 13 Suppl 1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenoid Cyst

1986
cis-platinum, 5-fluorouracil, and hydroxyurea in the treatment of advanced non-small-cell lung cancer. A phase II study.
    American journal of clinical oncology, 1987, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung

1987
[UFT in the treatment of primary lung cancer--5-FU concentration in the tissue and side effects].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:6 Pt 1

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Female;

1987
Poorly differentiated human gastric carcinoma is more sensitive to antitumor drugs than is well differentiated carcinoma.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:3

    Topics: Aclarubicin; Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Papillary; Antineoplastic Age

1987
5-Fluorouracil, doxorubicin, and mitomycin-C in the treatment of adenocarcinoma and large cell carcinoma of the lung.
    Cancer, 1987, Sep-15, Volume: 60, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell;

1987
[Combined effects of radiation and 5-FU derivatives].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:3 Pt 1

    Topics: Adenocarcinoma; Animals; Cell Division; Fluorouracil; Male; Mice; Radiotherapy Dosage; Tegafur

1986
Combined preoperative neoadjuvant radiotherapy and chemotherapy for anal and rectal cancer.
    American journal of surgery, 1986, Volume: 151, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Carcinoma, Squ

1986
[A case of multiple liver metastases from sigmoid carcinoma treated successfully with arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:7

    Topics: Adenocarcinoma; Angiotensin II; Antineoplastic Combined Chemotherapy Protocols; Catheterization; Dru

1986
Potentiation of the chemotherapeutic action of tegafur against solid adenocarcinoma 755 by combination with L-cystine.
    Journal of cancer research and clinical oncology, 1986, Volume: 111, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbon Radioisotopes; Cyste

1986
Microangiopathic hemolytic anemia, noncardiac pulmonary edema, and renal failure after treatment of metastatic adenocarcinoma of the colon with 5-fluorouracil and mitomycin-C: report of a case.
    The Journal of the American Osteopathic Association, 1986, Volume: 86, Issue:8

    Topics: Adenocarcinoma; Anemia, Hemolytic; Colonic Neoplasms; Female; Fluorouracil; Humans; Kidney Failure,

1986
[Studies on oral-adjuvant chemotherapy of uterine cervical cancer after surgical treatment].
    Nihon Sanka Fujinka Gakkai zasshi, 1986, Volume: 38, Issue:9

    Topics: Adenocarcinoma; Administration, Oral; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Eval

1986
Prognostic factors in metastatic carcinoma of unknown primary.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:11

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma;

1986
[Determination of the individual sensitivity of human stomach cancer cells to fluoropyrimidines by the cytomorphological criteria of heterotransplants in diffusion chambers].
    Eksperimental'naia onkologiia, 1986, Volume: 8, Issue:6

    Topics: Adenocarcinoma; Animals; Carcinoma; Colony-Forming Units Assay; Dose-Response Relationship, Drug; Fe

1986
[A model for the sensitivity determination of anticancer agents against human cancer using nude mice].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:3 Pt 1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Division; Cell Line; Cisplatin; Colonic Neoplas

1987
[Successful treatment of advanced gastric cancer by combined cisplatinum, mitomycin C and 5-FU administration. A case report].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:3 Pt 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouracil; Gas

1987
Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Intraoperative Period; Pancreatic N

1987
[Improved quality of life in a patient with Borrmann type 4 gastric cancer treated with combination chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:6 Pt 1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Methot

1987
[Advanced gastric cancer with DIC and multiple bone metastasis treated with surgical resection and chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:6 Pt 1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Co

1987
[FO-152].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:7

    Topics: Absorption; Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line; Dogs; Drug Evaluation; Female

1987
Esophageal carcinoma: modest benefits from combined modality therapy.
    Radiology, 1987, Volume: 164, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel

1987
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil and ftorafur against adenocarcinoma 755 in mice.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Cysteine

1987
Successful treatment of multiple liver metastases by liver perfusion.
    British medical journal (Clinical research ed.), 1987, Sep-12, Volume: 295, Issue:6599

    Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Fluorouracil; Heparin;

1987
[A case of gastric cancer with multiple liver metastases responding to combination therapy of recombinant interferon-gamma (KW-2202) and 5-FU].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1987, Volume: 14, Issue:12

    Topics: Adenocarcinoma; Aged; Drug Therapy, Combination; Fluorouracil; Humans; Interferon-gamma; Liver Neopl

1987
[A case of recurrent sigmoid colon cancer successfully treated with 5-FU and UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Humans; Lympha

1988
[Inhibitory effect of UFT on postoperative lung metastasis of mammary adenocarcinoma in SHR rats].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Flu

1988
Cure of advanced gastric cancer by combined chemotherapy with cisplatinum, mitomycin C, and 5-fluorouracil.
    Journal of surgical oncology, 1988, Volume: 38, Issue:1

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorourac

1988
Effect of endocrine treatment on prostatic blood flow in patients with prostatic adenocarcinoma.
    The Journal of urology, 1988, Volume: 140, Issue:1

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Combined Modality Therap

1988
[A case of intrahepatic bile duct cancer responding to 5-fluorouracil, adriamycin and mitomycin C chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Int

1988
5-Fluorouracil, high-dose folinic acid, and mitomycin C combination chemotherapy in advanced gastrointestinal adenocarcinomas. A pilot study.
    Oncology, 1988, Volume: 45, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule;

1988
[Complete response in a case of unresectable gastric cancer with a combination of tegafur, 5-fluorouracil and mitomycin C].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:9

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Infusion

1988
Combined modality preoperative therapy in poor prognostic rectal adenocarcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1988, Volume: 13, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Comb

1988
[Hemolytic-uremic syndrome caused by mitomycin C].
    Sangre, 1988, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Hemolytic-Uremic Syndr

1988
[A case of variant angina induced by 5-fluorouracil and Tegafur].
    Kokyu to junkan. Respiration & circulation, 1988, Volume: 36, Issue:11

    Topics: Adenocarcinoma; Angina Pectoris, Variant; Coronary Vasospasm; Electrocardiography; Fluorouracil; Hum

1988
[Three cases of renal failure associated with microangiopathic hemolytic anemia after mitomycin C therapy].
    Nihon Jinzo Gakkai shi, 1988, Volume: 30, Issue:7

    Topics: Adenocarcinoma; Aged; Anemia, Hemolytic; Breast Neoplasms; Female; Fluorouracil; Glomerulonephritis,

1988
Long-term, ambulatory, continuous IV infusion of 5-FU for the treatment of advanced adenocarcinomas.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Breast Neoplasms; Drug Eruptions; Female; Fluorouracil

1985
The efficacy of 5-fluorouracil in human colorectal cancer is not enhanced by thymidylate synthetase inhibition with CB3717 (N10-propargyl-5,8 dideazafolic acid).
    British journal of cancer, 1988, Volume: 58, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluo

1988
Mechanisms of innate resistance to thymidylate synthase inhibition after 5-fluorouracil.
    Cancer research, 1988, Oct-15, Volume: 48, Issue:20

    Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Resistance; Fluor

1988
Modulation of the cytotoxic effect of 5-fluorouracil by N-methylformamide on a human colon carcinoma cell line.
    Cancer research, 1988, Nov-01, Volume: 48, Issue:21

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Colonic Neoplasms; Cy

1988
[Portable infusion pump for ambulatory cytostatic therapy in inoperable liver metastases].
    Deutsche medizinische Wochenschrift (1946), 1988, Oct-21, Volume: 113, Issue:42

    Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Infusion Pumps; Live

1988
Postoperative radiation therapy with weekly 5 fluorouracil.
    The West Virginia medical journal, 1988, Volume: 84, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum

1988
Phase I-II study of prophylactic hepatic irradiation with local irradiation and systemic chemotherapy for adenocarcinoma of the pancreas.
    International journal of radiation oncology, biology, physics, 1988, Volume: 15, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Fluorouracil; Humans; Liver Neoplasms; Middl

1988
Regional injection of 5-fluorouracil and starch microspheres in colorectal cancer.
    Acta chirurgica Scandinavica, 1988, Volume: 154, Issue:9

    Topics: Adenocarcinoma; Chemotherapy, Cancer, Regional Perfusion; Colorectal Neoplasms; Fluorouracil; Humans

1988
Treatment of probable subclinical liver metastases and gross pancreatic carcinoma with hepatic artery 5-fluorouracil infusion and radiation therapy.
    Acta oncologica (Stockholm, Sweden), 1988, Volume: 27, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Hepatic Artery; Humans

1988
Duodenal carcinoma--a curable disease.
    Upsala journal of medical sciences, 1988, Volume: 93, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Duodenal Neoplasms; Female; Fluorouracil; Fo

1988
[Intraarterial infusion of oncostasis in patients with advanced cervical adenocarcinoma--two case reports].
    Nihon Sanka Fujinka Gakkai zasshi, 1988, Volume: 40, Issue:12

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Fluorouraci

1988
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
    Experimental pathology, 1988, Volume: 33, Issue:4

    Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia

1988
Treatment of advanced-stage colorectal adenocarcinoma with fluorouracil and high-dose leucovorin calcium: a pilot study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Administrati

1988
Continuous infusion 5-fluorouracil and folinic acid in disseminated colorectal cancer.
    Cancer investigation, 1988, Volume: 6, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug

1988
High-dose folinic acid and 5-fluorouracil in the treatment of advanced colon cancer.
    American journal of clinical oncology, 1988, Volume: 11, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bloo

1988
High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1988
Pharmacodynamics of 5-fluorouracil and leucovorin.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Animals; Bone Marrow; Colonic Neoplasms; Deoxyuracil Nucleotides; Fluorodeoxyuridyla

1988
Selectivity of CF and 5-fluorouracil: critical role of polyglutamylation.
    Advances in experimental medicine and biology, 1988, Volume: 244

    Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Fluorouracil; Folic Acid; Humans; Leucovorin;

1988
[Ethmoidal adenocarcinoma surgically treated in one stage by transfacial and subfrontal approach after inductive chemotherapy. Preliminary results of a new therapeutic approach].
    Neuro-Chirurgie, 1987, Volume: 33, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Transplantation; Ethmoid Sinus;

1987
Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction.
    Cancer, 1988, Feb-15, Volume: 61, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Eso

1988
Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients.
    Cancer, 1988, Feb-15, Volume: 61, Issue:4

    Topics: Adenocarcinoma; Adult; Age Factors; Colonic Neoplasms; Female; Fluorouracil; France; Humans; Male; R

1988
External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer.
    Cancer, 1988, Mar-15, Volume: 61, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Female; Fluorouracil; Hum

1988
[A case of dermatomyositis associated with breast cancer].
    Gan no rinsho. Japan journal of cancer clinics, 1988, Volume: 34, Issue:4

    Topics: Adenocarcinoma; Breast Neoplasms; Combined Modality Therapy; Dermatomyositis; Doxorubicin; Female; F

1988
Enhancing effect of bromovinyldeoxyuridine on antitumor activity of 5-fluorouracil against adenocarcinoma 755 in mice. Increased therapeutic index and correlation with increased plasma 5-fluorouracil levels.
    Biochemical pharmacology, 1988, Apr-15, Volume: 37, Issue:8

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Bromodeoxyuridine; Chromato

1988
Effective treatment for adenocarcinoma of the stomach when surgery is contraindicated.
    The American journal of gastroenterology, 1988, Volume: 83, Issue:6

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Female; Fluorouracil; Humans; Stomach Neoplasms

1988
5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu

1988
Basic investigations on interaction of 5-fluorouracil and tumor ischemia in the treatment of liver malignancies.
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1988, Volume: 110

    Topics: Adenocarcinoma; Animals; Combined Modality Therapy; Female; Fluorouracil; Humans; Ischemia; Liver Ne

1988
Continuous 5-fluorouracil infusion in advanced gastric carcinoma.
    American journal of clinical oncology, 1988, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Drug Evaluation; Female; Fluorouracil; Humans; Infusions, Intravenous;

1988
[Clinical evaluation of implantable drug delivery system (Port-A-Cath) in cancer chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1988, Volume: 15, Issue:8 Pt 2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1988
Advanced colorectal carcinoma--5 year survival of 76 cases treated at the Department of Therapeutic Radiology, Singapore General Hospital.
    Annals of the Academy of Medicine, Singapore, 1987, Volume: 16, Issue:3

    Topics: Actuarial Analysis; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma; Colonic Neoplasms; Co

1987
[Treatment of 63 advanced ovarian carcinomas].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1987, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1987
The 6 day subrenal capsule assay is of no value with primary surgical explants from gastric cancer.
    British journal of cancer, 1986, Volume: 54, Issue:3

    Topics: Adenocarcinoma; Animals; Cisplatin; Doxorubicin; Drug Evaluation, Preclinical; Epirubicin; Fluoroura

1986
An EORTC Gastrointestinal Group phase II evaluation of epirubicin combined with 5-fluorouracil in advanced adenocarcinoma of the pancreas.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evaluation; Epirub

1987
Sequential methotrexate, 5-fluorouracil, and calcium leucovorin in colorectal carcinoma.
    American journal of clinical oncology, 1986, Volume: 9, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fema

1986
Continuous 5-fluorouracil infusion and pulse methotrexate/leucovorin for colorectal adenocarcinoma. A report of excessive toxicity.
    American journal of clinical oncology, 1987, Volume: 10, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; C

1987
A phase II trial of 5-fluorouracil and high-dose intravenous leucovorin in gastric carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Adenocarcinoma; Bone Marrow Diseases; Diarrhea; Drug Evaluation; Erythema; Fluorouracil; Humans; Inj

1987
Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:9

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colo

1987
Biologic modulation of 5-fluorouracil with high-dose leucovorin and combination chemotherapy of 5-fluorouracil and cisplatin in metastatic colorectal adenocarcinoma.
    NCI monographs : a publication of the National Cancer Institute, 1987, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neoplasms; Dose-R

1987
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil and high-dose folinic acid.
    NCI monographs : a publication of the National Cancer Institute, 1987, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Fluorouracil; Gas

1987
Cannulation of the portal vein for cytotoxic liver perfusion in colorectal carcinomas: an alternative approach.
    Annals of the Royal College of Surgeons of England, 1987, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Catheterization; Colonic Neoplasms; Fluorouracil; Humans; Liv

1987
Combination chemotherapy in the treatment of adenocarcinoma of unknown primary origin.
    Cancer treatment reports, 1987, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Fluo

1987
Regional adjuvant irradiation for adenocarcinoma of the cecum.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:6

    Topics: Adenocarcinoma; Cecal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Neoplasm Recurrenc

1987
Determination of thymidylate synthase activity in colon tumor tissues after treatment with 5-fluorouracil.
    Biochemical pharmacology, 1987, Apr-15, Volume: 36, Issue:8

    Topics: Adenocarcinoma; Charcoal; Colonic Neoplasms; Fluorodeoxyuridylate; Fluorouracil; Humans; Thymidylate

1987
Fatal acute tumor lysis syndrome with metastatic breast carcinoma.
    Cancer, 1987, Aug-15, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Autopsy; Breast Neoplasms; Cyclophos

1987
Early adjuvant intraportal chemotherapy after curative hepatectomy for colorectal liver metastases--a pilot study.
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 1987, Volume: 13, Issue:3

    Topics: Adenocarcinoma; Colonic Neoplasms; Combined Modality Therapy; Fluorouracil; Hepatectomy; Humans; Inf

1987
5-Fluorouracil-induced coronary vasospasm.
    American heart journal, 1987, Volume: 114, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Coronary Vasospas

1987
Treatment of advanced gastric cancer with DDP (cisplatin), adriamycin, and 5-fluorouracil (DAF).
    Oncology, 1987, Volume: 44, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin;

1987
[Chemotherapy of metastatic gastric cancer--x-ray follow-up].
    Der Radiologe, 1987, Volume: 27, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Follow-Up

1987
Effects of cyclophosphamide alone and scheduled methotrexate-5-fluorouracil combination chemotherapy on transplantable R-3327 prostatic adenocarcinoma in F1 hybrid male rat.
    Urology, 1987, Volume: 30, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Fluoroura

1987
Adjuvant chemotherapy in gastric cancer.
    World journal of surgery, 1987, Volume: 11, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Combined Modality

1987
Cisplatin and 5-fluorouracil combination chemotherapy in advanced and/or metastatic colorectal carcinoma: a phase II study.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop

1987
Combination chemotherapy for metastatic or recurrent adenocarcinoma of the cervix.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:10

    Topics: Adenocarcinoma; Adult; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; D

1987
Phase II trial of sequential chemotherapy and low-dose radiotherapy in advanced gastric adenocarcinoma. A Southwest Oncology Group Pilot Study.
    American journal of clinical oncology, 1987, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carm

1987
Mechanism of potentiation of antitumor activity of 5-fluorouracil by guanine ribonucleotides against adenocarcinoma 755.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:7

    Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; DNA, Neoplasm; Drug Synergi

1987
Comparison of three treatment strategies for esophageal cancer within a single institution.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin;

1987
Hyperthermic pelvic isolation-perfusion in the treatment of refractory pelvic cancer.
    Archives of surgery (Chicago, Ill. : 1960), 1987, Volume: 122, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Fe

1987
Concurrent allopurinol and 5-fluorouracil: 5-fluoro-2'-deoxyuridylate formation and thymidylate synthase inhibition in rat colon carcinoma and in regenerating rat liver.
    Cancer chemotherapy and pharmacology, 1987, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Allopurinol; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Female; Fluorodeox

1987
Ankyloblepharon associated with systemic 5-fluorouracil treatment.
    Annals of ophthalmology, 1987, Volume: 19, Issue:10

    Topics: Adenocarcinoma; Blepharitis; Eyelid Diseases; Fluorouracil; Humans; Male; Middle Aged; Skin Ulcer; S

1987
Urachal carcinoma: a response to chemotherapy.
    British journal of urology, 1987, Volume: 60, Issue:4

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Fluorouracil; Humans; Male; Middle A

1987
Sequential methotrexate/5-FU: FdUMP formation and TS inhibition in a transplantable rodent colon adenocarcinoma.
    Cancer chemotherapy and pharmacology, 1986, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Deoxyuracil Nucleotides; Drug Interactions; Female; Fluo

1986
Combined 5-fluorouracil (5-FU) and radiation therapy following resection of locally advanced gastric carcinoma.
    Journal of surgical oncology, 1986, Volume: 31, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Combined Modality Therapy; Female; Fluorouracil; Humans; Male; Middle A

1986
Failure of allopurinol to provide clinically significant protection against the hematologic toxicity of a bolus 5-FU schedule.
    Oncology, 1986, Volume: 43, Issue:4

    Topics: Adenocarcinoma; Adult; Allopurinol; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Administration

1986
[Comparison of in vitro assays for the cytotoxic effect of anticancer drugs].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 1986, Volume: 8, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Cell Count; Cell Line; Colony-Forming Units Assay; Diterpenes

1986
[Cytostatic treatment of gastrointestinal tumors].
    Schweizerische Rundschau fur Medizin Praxis = Revue suisse de medecine Praxis, 1986, Jul-01, Volume: 75, Issue:27

    Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Moda

1986
5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Evalu

1986
[Experimental and clinical studies on a sensitivity test of anticancer agents by 3H-thymidine autoradiography using a human malignant tumor transplanted to nude mice].
    Nihon Geka Gakkai zasshi, 1986, Volume: 87, Issue:2

    Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Autoradiography; Cyclophosphamide; Drug Evalua

1986
Cardiac tamponade as the only initial feature of malignancy: a case report and review of the literature.
    Journal of surgical oncology, 1986, Volume: 32, Issue:2

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Common Col

1986
Chemotherapy improves pulmonary function in a patient with gastric cancer.
    The British journal of clinical practice, 1986, Volume: 40, Issue:6

    Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hum

1986
125I interstitial implant, precision high-dose external beam therapy, and 5-FU for unresectable adenocarcinoma of pancreas and extrahepatic biliary tree.
    Cancer, 1986, Nov-15, Volume: 58, Issue:10

    Topics: Adenocarcinoma; Aged; Bile Duct Neoplasms; Brachytherapy; Female; Fluorouracil; Humans; Male; Middle

1986
Adenocarcinoma of the cecum. Analysis of 106 cases.
    Cancer, 1986, Oct-15, Volume: 58, Issue:8

    Topics: Adenocarcinoma; Cecal Neoplasms; Combined Modality Therapy; Fluorouracil; Humans; Prognosis; Retrosp

1986
[Sequential dose of methotrexate and 5-fluorouracil in advanced gastric cancer--response, survival time and toxicity].
    Nihon Gan Chiryo Gakkai shi, 1986, May-20, Volume: 21, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Sch

1986
5-Fluorouracil, adriamycin, and mitomycin-C (FAM) in the treatment of inoperable adenocarcinoma of the lung.
    American journal of clinical oncology, 1986, Volume: 9, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Admin

1986
Chemotherapy in colorectal cancer.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1986, Volume: 5, Issue:5

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo

1986
Adjuvant effects of calmodulin antagonists to 5-fluorouracil on tumor cell proliferation and the mechanisms.
    Gynecologic oncology, 1987, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Calmodulin; Cell Division; Cell Line; Female; Fluorouracil; Humans; Ovarian Neoplasm

1987
Development and characterization of a human colon adenocarcinoma xenograft deficient in thymidine salvage.
    Cancer research, 1987, Apr-15, Volume: 47, Issue:8

    Topics: Adenocarcinoma; Animals; Carcinoembryonic Antigen; Colonic Neoplasms; Fluorouracil; Humans; Isoenzym

1987
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
    The American journal of medicine, 1985, Volume: 78, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclo

1985
[Chemotherapy of bronchopulmonary and pleural adenocarcinoma. Apropos of 31 cases].
    Revue de pneumologie clinique, 1985, Volume: 41, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha

1985
Gastric cancer: complete chemotherapy response in an elderly woman: current status of treatment.
    The American journal of gastroenterology, 1985, Volume: 80, Issue:11

    Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fema

1985
The effects of cyclophosphamide, ketoconazole, aclacinomycin-A, methotrexate, and scheduled methotrexate-5-fluorouracil combination chemotherapy on the transplantable R-3327 prostatic adenocarcinoma in the F1 hybrid male rat.
    Cancer, 1985, Sep-01, Volume: 56, Issue:5

    Topics: Aclarubicin; Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphami

1985
[Chronic myelogenous leukemia following therapy of early gastric cancer].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1985, Volume: 26, Issue:5

    Topics: Adenocarcinoma; Fluorouracil; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasms, Multiple Prim

1985
Treatment of advanced colorectal and gastric adenocarcinomas with 5-fluorouracil combined with high-dose folinic acid. An update.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1985, Volume: 4, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Female; Fl

1985
[Clinical study on the permeability of FT-207 and 5-FU in primary lung cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Cell Membrane Permeability; Female; Fluoroura

1985
[A case of complete regression of gastric carcinoma and liver metastases by treatment with tegafur].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:4

    Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Liver Neoplasms; Male; Stomach Neoplasms; Tegafur

1985
[Phase II study of sustained released granules of tegafur (SF-SP) on inoperable or recurrent gastric cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Delayed-Action Preparations; Drug Administration Schedule; Drug Evaluat

1985
[Level of 5-FU in cancerous and normal tissues of nude mice after oral administration of tegafur coadministered with uracil (UFT)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:5

    Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug

1985
Cyclic combination chemotherapy in advanced adenocarcinoma of the lung: comparison of two FAM schedules.
    Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Female; Fl

1985
Erosive gastroduodenitis with marked epithelial atypia after hepatic arterial infusion chemotherapy.
    The American journal of gastroenterology, 1985, Volume: 80, Issue:6

    Topics: Adenocarcinoma; Aluminum; Cimetidine; Colonic Neoplasms; Fluorouracil; Gastric Mucosa; Humans; Infus

1985
Enhancement of antitumor effect of cytotoxic agents by bestatin.
    The Journal of antibiotics, 1985, Volume: 38, Issue:3

    Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neop

1985
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1985
[Evaluation of combined radiotherapy of gastric carcinoma].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera

1985
[A long survival case of carcinoma of the colon with hepatic metastasis following intra-arterial infusion chemotherapy].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:8

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Calcinosis; Colonic Neoplasms; Fluor

1985
Chemoradiation therapy and resection for carcinoma of the esophagus: short-term results.
    The Annals of thoracic surgery, 1985, Volume: 40, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Proto

1985
[A case of advanced male breast cancer treated effectively with estrogen].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Breast Neoplasms; Combined Modality The

1985
[A case of advanced gastric cancer showing complete cure by immunochemotherapy with FT-207 and OK-432 confirmed by thorough histologic examination of total gastrectomy matter].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:7

    Topics: Adenocarcinoma; Biological Products; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intrader

1985
Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C.
    Urology, 1985, Volume: 26, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1985
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
    Gynecologic oncology, 1985, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin

1985
[Clinical application of local hyperthermia combined with antineoplastic agents].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Papillary; Adult; Aged; Antineoplastic Agents; Body Temperature; Cis

1985
[Level of 5-FU in uterine cervical cancer tissue after oral administration of UFT].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cervix Ute

1985
[A case of long-term survival of liver metastasis of breast cancer successfully treated with chemotherapy and endocrine therapy].
    Gan no rinsho. Japan journal of cancer clinics, 1985, Volume: 31, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Cy

1985
Long-term ambulatory treatment of metastatic colorectal adenocarcinoma by continuous intravenous infusion of 5-fluorouracil.
    Journal of surgical oncology, 1985, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Ambulatory Care; Colonic Neoplasms; Female; Fluorouracil; Humans; Infus

1985
5-Fluorouracil treatment of a human colon adenocarcinoma implanted in the subrenal capsule site of athymic mice.
    Cancer research, 1986, Volume: 46, Issue:2

    Topics: Adenocarcinoma; Animals; Colonic Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil;

1986
The increased cytotoxicity in colon adenocarcinoma of methotrexate-5-fluorouracil is not associated with increased induction of lesions in DNA by 5-fluorouracil.
    Biochemical pharmacology, 1986, Jan-15, Volume: 35, Issue:2

    Topics: Adenocarcinoma; Cell Division; Cell Survival; Cells, Cultured; Colonic Neoplasms; DNA, Neoplasm; Dru

1986
[Distribution of 1-hexycarbamoyl-5-fluorouracil in rats and human patients, and clinical results in patients with colorectal cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1986, Volume: 13, Issue:3 Pt 1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Fluorouracil; Humans; Mal

1986
Mechanism of potentiation of antitumor activity of 5-fluorouracil against adenocarcinoma 755 by L-cysteine.
    Biochemical pharmacology, 1986, Mar-01, Volume: 35, Issue:5

    Topics: Adenocarcinoma; Animals; Cysteine; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism;

1986
Adjuvant intrahepatic chemotherapy with mitomycin and 5-FU combined with hepatic irradiation in high-risk patients with carcinoma of the colon: a Southwest Oncology Group phase II pilot study.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neo

1985
Hepatic resection of colorectal metastases. Influence of clinical factors and adjuvant intraperitoneal 5-fluorouracil via Tenckhoff catheter on survival.
    Annals of surgery, 1985, Volume: 201, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoembryonic Antigen; Colonic Neoplasms; Combined Modal

1985
Adjuvant chemotherapy of gastric carcinoma: a pilot study of oral administration of injectable 5-fluorouracil.
    Journal of surgical oncology, 1985, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Female; Fluorouracil; Humans; Liver; Male; Middle

1985
Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration.
    Cancer treatment reports, 1985, Volume: 69, Issue:3

    Topics: Acute Kidney Injury; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic N

1985
[Therapy-induced tumor regression. Morphological findings in malignant primary and secondary liver tumors following intensive regional cytostatic treatment].
    Der Pathologe, 1985, Volume: 6, Issue:1

    Topics: Adenocarcinoma; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perfusion; Colonic Neoplasms; Doxoru

1985
Cardiotoxicity as a result of 5-fluorouracil therapy.
    Tumori, 1985, Feb-28, Volume: 71, Issue:1

    Topics: Adenocarcinoma; Adult; Fluorouracil; Heart; Humans; Male; Myocardial Infarction; Sigmoid Neoplasms;

1985
Histopathologic effect of preoperative chemotherapy using 5-Fu fat emulsion in gastric cancer.
    Journal of surgical oncology, 1985, Volume: 29, Issue:1

    Topics: Adenocarcinoma; Combined Modality Therapy; Fluorouracil; Humans; Stomach Neoplasms

1985
[Experimental studies with the use of metastatic clones isolated from mouse tumors].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Animals; Clone Cells; Colonic Neoplasms; Doxorubicin; Fluorouracil; Lung Neoplasms;

1985
Sequential methotrexate and 5-fluorouracil in the treatment of non-small cell carcinoma of the lung.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Drug Evalu

1985
Comparative radiopharmacokinetics of 18F-5-fluorouracil administered i.v. to rats bearing a mammary tumor.
    International journal of nuclear medicine and biology, 1985, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Animals; Female; Fluorine; Fluorouracil; Injections, Intravenous; Kinetics; Mammary

1985
Pharmacokinetics of 5-fluorouracil during hyperthermic pelvic isolation-perfusion.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Chemotherapy, Cancer, Regional Perfusion; Chromatography,

1985
Phase I-II clinical trial of thymidine, 5-FU, and PALA given in combination.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colonic

1985
Treatment of metastatic colorectal carcinoma with cisplatin and 5-FU.
    Cancer treatment reports, 1985, Volume: 69, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colonic Neop

1985
Phase II trial of 5-fluorouracil, adriamycin and cisplatin (FAP) in advanced gastric cancer.
    Cancer chemotherapy and pharmacology, 1985, Volume: 15, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cisplatin;

1985
A pilot study to determine clinical tolerability of intensive combined modality therapy for locally unresectable gastric cancer.
    International journal of radiation oncology, biology, physics, 1985, Volume: 11, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Doxorubicin; Female; Fluorouracil; Humans; Lomustine; Male; Middle Aged

1985
Immunochemosurgery for gastric cancer.
    Seminars in surgical oncology, 1985, Volume: 1, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Combined Modali

1985
Cisplatin plus 5-FU for the treatment of adenocarcinoma of the colon.
    Cancer treatment reports, 1985, Volume: 69, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoembryonic Antige

1985
Phase II study with high-dose N5-10-methyltetrahydrofolate and 5-fluorouracil in advanced colorectal cancer.
    European journal of cancer & clinical oncology, 1985, Volume: 21, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug

1985
Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    American journal of clinical oncology, 1985, Volume: 8, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Carcinom

1985
Cisplatin bolus and 5-FU infusion chemotherapy for non-small cell lung cancer.
    Cancer treatment reports, 1985, Volume: 69, Issue:11

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Carcinoma, S

1985
Cerebellar ataxia with weekly 5-fluorouracil administration.
    Lancet (London, England), 1971, Jan-16, Volume: 1, Issue:7690

    Topics: Adenocarcinoma; Cerebellar Ataxia; Colonic Neoplasms; Female; Fluorouracil; Humans; Middle Aged; Neo

1971
[Combined treatment of patients with inoperable stomach cancer].
    Voprosy onkologii, 1970, Volume: 16, Issue:11

    Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Aged; Carcinoma, Squamous Cell; Female; Fluorourac

1970
[Esophageal tumors--therapeutic problems].
    Strahlentherapie, 1972, Volume: 144, Issue:3

    Topics: Adenocarcinoma; Bleomycin; Carcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Esophageal Neoplasm

1972
Chemotherapy and hormone therapy in gynecologic cancer.
    Southern medical journal, 1973, Volume: 66, Issue:6

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Choriocarcinoma; Dactinomycin; F

1973
Chemotherapy of lung cancer: the experience of the National Cancer Institute of Milan.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Bleomycin; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Doxorubicin; Fluoroura

1973
Radiation therapy in the treatment of irresectable adenocarcinoma of the pancreas.
    Cancer, 1973, Volume: 32, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Cobalt Radioisotopes; Evaluation Studies as Topic; Female; Fluorouracil

1973
[Three years of experience in the polychemotherapy of inoperable bronchial carcinoma].
    Wiener medizinische Wochenschrift (1946), 1974, Jul-27, Volume: 124, Issue:30

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Austria; Br

1974
The roles of radiotherapy and cytotoxic drugs in the management of carcinoma of the esophagus.
    The Australian and New Zealand journal of surgery, 1973, Volume: 42, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Squamous Cell; Esophageal Neoplas

1973
The treatment of hepatic metastases by long-term chemotherapeutic infusions.
    Aktuelle Probleme in der Chirurgie, 1970, Volume: 14

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Evaluation Studies as Topic; Female;

1970
Continuous arterial infusion chemotherapy. Experience with 44 cases.
    The American surgeon, 1967, Volume: 33, Issue:8

    Topics: Adenocarcinoma; Arteries; Brain Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Cath

1967
[Study of the action of antitumor compounds on primary explants from human tumors].
    Antibiotiki, 1967, Volume: 12, Issue:9

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; An

1967
[Method and results of experimental chemotherapy of a human colonic carcinoma (H.Ad.No. 1) in the cheek pouch of the golden hamster].
    Arzneimittel-Forschung, 1969, Volume: 19, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Aziridines; Cheek; Colonic Neoplasms; Cricetinae; Cy

1969
5-Fluorouracil and radiotherapy for gastrointestinal cancer.
    Lancet (London, England), 1970, Feb-07, Volume: 1, Issue:7641

    Topics: Adenocarcinoma; Esophagogastric Junction; Fluorouracil; Humans; Male; Stomach Neoplasms

1970
Treatment of secondary hepatic tumours by ligation of hepatic artery and infusion of cytotoxic drugs.
    Lancet (London, England), 1970, Jul-25, Volume: 2, Issue:7665

    Topics: Adenocarcinoma; Aged; Angiography; Aortography; Carcinoid Tumor; Chemotherapy, Cancer, Regional Perf

1970
Chemotherapy for lung cancer at the Institute of Experimental and Clinical Oncology, Academy of Medical Sciences, USSR.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcino

1973
Pseudomyxoma peritonaei: a report of ten cases.
    Annals of surgery, 1973, Volume: 178, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Appendectomy; Appendiceal Neoplasms; Castration; Cystadenoma; Female; F

1973
Carcinoma of the duodenum: comparison of surgery, radiotherapy, and chemotherapy.
    The British journal of surgery, 1973, Volume: 60, Issue:11

    Topics: Adenocarcinoma; Age Factors; Aged; Barium Sulfate; Duodenal Neoplasms; Female; Fluorouracil; Humans;

1973
Intravenous hyperalimentation in cancer patients.
    The Journal of surgical research, 1974, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Body Weight; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Ne

1974
Infusion of fluorinated pyrimidines into hepatic artery for treatment of metastatic carcinoma of liver.
    Cancer, 1967, Volume: 20, Issue:11

    Topics: Adenocarcinoma; Catheterization; Floxuridine; Fluorouracil; Gastrointestinal Neoplasms; Hepatic Arte

1967
Responses of freshly cultured tumour cells to certain selected chemotherapeutic agents.
    The Journal of obstetrics and gynaecology of the British Commonwealth, 1968, Volume: 75, Issue:12

    Topics: Adenocarcinoma; Antineoplastic Agents; Chlorambucil; Colchicine; Culture Techniques; Cyclophosphamid

1968
Combination chemotherapy in gastrointestinal cancer.
    Cancer research, 1970, Volume: 30, Issue:5

    Topics: Adenocarcinoma; Adult; Alopecia; Appendiceal Neoplasms; Diarrhea; Drug Eruptions; Fluorouracil; Gall

1970
Growth inhibition by chemotherapeutic agents on stilbestrol-induced hamster kidney tumor.
    Surgical forum, 1971, Volume: 22

    Topics: Adenocarcinoma; Animals; Cricetinae; Cyclophosphamide; Dactinomycin; Diethylstilbestrol; Fluorouraci

1971
Effect of resection of the primary neoplasm on responsiveness to chemotherapy of patients with large bowel cancer.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:4

    Topics: Adenocarcinoma; Colonic Neoplasms; Floxuridine; Fluorouracil; Humans; Nitrosourea Compounds; Rectal

1972
The response of the stilbestrol-induced renal tumor to chemotherapeutic agents.
    Journal of surgical oncology, 1973, Volume: 5, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Diethyls

1973
5-Fluorouracil and derivatives in cancer chemotherapy. 3. In vivo enhancement of antitumor activity of 5-fluorouracil (FU) and 5-fluoro-2'-deoxyuridine (FUDR).
    Journal of pharmaceutical sciences, 1973, Volume: 62, Issue:12

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromatography, Thin Layer; Deoxycytidine; Deoxyurid

1973
Adenocarcinomas of stomach, pancreas, liver, and biliary tracts. Survival of 328 patients treated with fluoropyrimidine therapy.
    Cancer, 1974, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Evaluation Studies as Topic; Floxuridine

1974
Conservative management of malignant pericardial effusion.
    Cancer, 1974, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cardiomegaly; Female; Fluorouracil; Follow-Up Studies

1974
Hypercalcemia in cancer: response to therapy.
    American family physician, 1974, Volume: 10, Issue:5

    Topics: Adenocarcinoma; Adult; Allopurinol; Antineoplastic Agents; Calcium; Cyclophosphamide; Fluorouracil;

1974
Infusion chemotherapy in hepatoma and metastatic liver tumors.
    American journal of surgery, 1967, Volume: 113, Issue:3

    Topics: Adenocarcinoma; Adolescent; Aged; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury;

1967
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate and 5-fluorouracil in solid tumors.
    Cancer, 1969, Volume: 23, Issue:3

    Topics: Adenocarcinoma; Adult; Carcinoma, Squamous Cell; Cyclophosphamide; Female; Fibrosarcoma; Fluorouraci

1969
[Polychemotherapy of malignant tumors and hemoblastoses].
    Wiener Zeitschrift fur innere Medizin und ihre Grenzgebiete, 1968, Volume: 49, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Antineoplastic Agents; Bronchial Neoplasms; Carcinom

1968
Chemotherapy in the treatment of cancer of the ovary.
    American journal of obstetrics and gynecology, 1970, Jul-01, Volume: 107, Issue:5

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Cyclophosphamide; Cystadenocarcinoma; Dactinomycin; Female

1970
[Pathologic anatomy of rectal cancer treated by intra-arterial administration of 5-fluoruracil].
    Arkhiv patologii, 1970, Volume: 32, Issue:8

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Female;

1970
Carcinoma of the colon and rectum in patients up to 25 years of age.
    The American surgeon, 1971, Volume: 37, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adolescent; Adult; Age Factors; Colonic Neoplasms; Female;

1971
Catheterization of the umbilical vein and its use for hepatography.
    Clinical radiology, 1971, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Angiography; Breast Neoplasms; Catheterization; Diatrizoate; Female; Fl

1971
[Effect of 5-fluorouracil on protein metabolism of tumors and normal tissues in culture].
    Zeitschrift fur Krebsforschung, 1970, Volume: 74, Issue:1

    Topics: Adenocarcinoma; Animals; Autoradiography; Carcinoma, Basal Cell; Cell Line; Cell Transformation, Neo

1970
Cancer chemotherapy in urology.
    Urologia internationalis, 1971, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Chlorambucil; Cobal

1971
Integrated therapy in the treatment of ovarian cancer with surgery, radiation and chemotherapy.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Ascites; Chlorambucil; Cobalt Isotopes; Cyclophosphamide;

1972
Chemotherapy of ovarian cancer. New approaches to treatment.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Antineoplastic Agents; Cyclophosphamide; Cystadenocarcinom

1972
Clinical management of advanced gastrointestinal cancer.
    Seminars in drug treatment, 1973,Summer, Volume: 3, Issue:1

    Topics: Adenocarcinoma; Alkylating Agents; Biliary Tract; Carcinoid Tumor; Carcinoma, Hepatocellular; Fluoro

1973
[Determination of the individual sensitivity of gastric cancerous tumors to 5-fluorouracil according to respiratory and glycolytic indices].
    Vrachebnoe delo, 1974, Volume: 5, Issue:0

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Carcinoma; Drug Evaluation, Pre

1974
Chemotherapy for adenocarcinoma and alveolar cell carcinoma of the lung.
    The Annals of thoracic surgery, 1974, Volume: 18, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Female; Fluorouracil; Follow-Up Studies;

1974
[Treatment of liver cancer with oral administration of N-(2'-furanidyl)-5 fluorouracil (FT207) (author's transl)].
    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 1974, Volume: 71, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Aged; Carcinoma, Hepatocellular; Fluorouracil; Humans; Liver N

1974
[5-Fluorouracil in the treatment of gastrointestinal tumors].
    Turk Tip Dernegi dergisi, 1973, Volume: 39, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Fluorouracil; Gastrointestinal Neoplasms; Humans

1973
Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Oncology, 1974, Volume: 29, Issue:3

    Topics: Adenocarcinoma; Administration, Oral; Carmustine; Colonic Neoplasms; Diarrhea; Fluorouracil; Hematoc

1974
Diagnosis, treatment and prognosis of renal cell carcinoma.
    The Tohoku journal of experimental medicine, 1974, Volume: 113, Issue:4

    Topics: Adenocarcinoma; Angiography; Blood Sedimentation; Chromomycins; Female; Fluorouracil; Humans; Kidney

1974
[Determination of the sensitivity of cancerous tumors of the stomach to 5-fluorouracil in vitro].
    Vrachebnoe delo, 1974, Issue:1

    Topics: Adenocarcinoma; Aged; Drug Evaluation, Preclinical; Female; Fluorouracil; Humans; In Vitro Technique

1974
In vitro estimate of sensitivity of individual human tumors to antitumor agents.
    Oncology, 1974, Volume: 30, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arsenicals; Benzoates; Breast Neoplasms; Carbon Radi

1974
Endometrial cancer: approach to development of effective chemotherapy.
    Gynecologic oncology, 1974, Volume: 2, Issue:2-3

    Topics: Acrylates; Adenocarcinoma; Adolescent; Adult; Aged; Alkylating Agents; Cyclophosphamide; Doxorubicin

1974
Liver scanning for the detection of metastases following colo-rectal cancer surgery.
    The Australian and New Zealand journal of surgery, 1973, Volume: 43, Issue:1

    Topics: Adenocarcinoma; Adult; Celiac Artery; Colonic Neoplasms; Female; Fluorouracil; Gold Isotopes; Hepate

1973
Arterial infusion and radiation therapy in the treatment of advanced cancer of the nasal cavity and paranasal sinuses.
    American journal of surgery, 1973, Volume: 126, Issue:4

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Carotid Artery, External; Carotid Artery, Internal; Chemot

1973
The gallbladder as a conduit between the liver and intestine.
    Surgery, 1973, Volume: 74, Issue:4

    Topics: Adenocarcinoma; Adolescent; Adult; Bile Ducts; Carcinoma; Cholangiography; Common Bile Duct; Drainag

1973
Acute leukemia following cytotoxic chemotherapy.
    JAMA, 1972, Volume: 219, Issue:1

    Topics: Adenocarcinoma; Adult; Female; Fluorouracil; Humans; Leukemia, Myeloid, Acute; Methotrexate; Ovarian

1972
Renal carcinoma (hypernephroma) occurring in 5 siblings.
    The Journal of urology, 1972, Volume: 108, Issue:1

    Topics: Adenocarcinoma; Adult; Biopsy; Female; Fluorouracil; Humans; Kidney; Kidney Neoplasms; Male; Middle

1972
Cancer chemotherapy. I. Methods, agents and overall results in 400 patients.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Amides; Androgens; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Estrogens;

1972
[Polychemotherapy of broncho-pulmonary cancer: report of clinical research].
    L'union medicale du Canada, 1972, Volume: 101, Issue:8

    Topics: Adenocarcinoma; Adult; Aged; Bronchial Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Hu

1972
[Principles, technic and clinical performance of synchronized radiotherapy].
    Strahlentherapie, 1972, Volume: 144, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Androstanols; Bone Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, S

1972
[Preliminary results of the use of 5-fluoruracil to prevent recurrences and metastases following radical surgery for stomach cancer].
    Vestnik Akademii meditsinskikh nauk SSSR, 1972, Volume: 27, Issue:10

    Topics: Adenocarcinoma; Female; Fluorouracil; Gastrectomy; Humans; Male; Middle Aged; Neoplasm Metastasis; N

1972
Treatment of the patient with adenocarcinoma of unknown origin.
    Cancer, 1972, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Autopsy; Carmustine; Female; Fluorouracil; Human

1972
The value of megavolt therapy in carcinoma of the stomach.
    Strahlentherapie, 1972, Volume: 144, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma; Cardia; Cell Division; Cobalt Isotopes; Female; Fluorouracil

1972
Five-drug combination chemotherapy for disseminated adenocarcinoma.
    Cancer chemotherapy reports, 1972, Volume: 56, Issue:6

    Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Drug

1972
The treatment of metastatic carcinoma of the liver by the percutaneous selective hepatic artery infusion of 5-fluorouracil.
    Surgery, 1973, Volume: 73, Issue:1

    Topics: Adenocarcinoma; Fluorouracil; Hepatic Artery; Humans; Infusions, Parenteral; Injections, Intra-Arter

1973
Nonbacterial pneumonitis with multidrug antineoplastic therapy in breast carcinoma.
    Canadian Medical Association journal, 1973, Mar-17, Volume: 108, Issue:6

    Topics: Adenocarcinoma; Adrenalectomy; Adult; Breast Neoplasms; Cyclophosphamide; Female; Fluorouracil; Huma

1973
Combination therapy of solid tumors using 1,3-bis(2-chloroethyl)-1-nitrosourea (NCNU), vincristine, methotrexate, and 5-fluorouracil.
    Cancer, 1973, Volume: 31, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Squamous Cell; Carmustine; Female; Fluorouracil; Gastrointes

1973
FIVB--a new combination of drugs in the treatment of cancer.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1973, Jun-16, Volume: 47, Issue:23

    Topics: Adenocarcinoma; Aged; Amides; Breast Neoplasms; Colonic Neoplasms; Female; Fluorouracil; Humans; Imi

1973
[Cytostatic therapy of metastazing rectal carcinoma].
    Therapeutische Umschau. Revue therapeutique, 1973, Volume: 30, Issue:6

    Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Fluorouracil; Humans; Injections, Intra

1973
Radiotherapy for bronchogenic carcinoma: actual difficulties and plans for the future.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:2

    Topics: Adenocarcinoma; Brain Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Cyclophosphamide

1973
Disseminated breast carcinoma. Treatment with combination chemotherapy.
    Archives of internal medicine, 1973, Volume: 132, Issue:4

    Topics: Adenocarcinoma; Adult; Breast Neoplasms; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Fem

1973
Therapy of advanced gastrointestinal cancer with the nitrosoureas.
    Cancer chemotherapy reports. Part 3, 1973, Volume: 4, Issue:3

    Topics: Adenocarcinoma; Antineoplastic Agents; Bone Marrow Diseases; Carmustine; Colonic Neoplasms; Cyclohex

1973
Timing of administration of 5-fluorouracil in combination with irradiation in the treatment of advanced adenocarcinoma. Comparison of methods used to assess radiological response to the treatment of pulmonary metastases.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1973, Dec-29, Volume: 47, Issue:51

    Topics: Adenocarcinoma; Cobalt Radioisotopes; Fluorouracil; Humans; Lung Neoplasms; Male; Methods; Middle Ag

1973
The administration of 5-fluorouracil by mouth.
    Cancer, 1974, Volume: 33, Issue:1

    Topics: Adenocarcinoma; Administration, Oral; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Heart

1974
Proceedings: Evaluation of combination vs. sequential cytotoxic chemotherapy in the treatment of advanced breast cancer.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Female;

1974
Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
    Cancer, 1974, Volume: 33, Issue:2

    Topics: Adenocarcinoma; Carmustine; Drug Therapy, Combination; Female; Fluorouracil; Humans; Leukopenia; Mal

1974
Serial liver scanning. Metastatic disease.
    Minnesota medicine, 1974, Volume: 57, Issue:2

    Topics: Adenocarcinoma; Adult; Colonic Neoplasms; Fluorouracil; Humans; Injections, Intra-Arterial; Injectio

1974
Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU).
    Annals of surgery, 1974, Volume: 179, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Biopsy; Carmustine; Drug Therapy, Combination; Evaluation Studies as To

1974
The effects of hormones and chemotherapeutic agents on rat uterine adenocarcinoma cells in tissue culture.
    American journal of obstetrics and gynecology, 1974, Jul-01, Volume: 119, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chromomycins; Clone Cells; Culture Media; Culture Te

1974
The effects of cytostatic drugs on transplanted tumours. An investigation of the correlation between in vivo and in vitro results.
    Archiv fur Geschwulstforschung, 1974, Volume: 43, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Cricetinae; Cytarabine; Dauno

1974
Systemic chemotherapy for carcinoma of the cervix.
    American journal of obstetrics and gynecology, 1967, Mar-15, Volume: 97, Issue:6

    Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Fema

1967
Cytotoxic and antifungal agents: their body distribution and tissue affinity.
    Nature, 1968, Apr-27, Volume: 218, Issue:5139

    Topics: Adenocarcinoma; Animals; Antifungal Agents; Antineoplastic Agents; Autoradiography; Bacillus cereus;

1968
[Our experiences with polychemotherapy of malignant endothoracic tumors (103 cases)].
    Le Poumon et le coeur, 1968, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Androgens; Antineoplastic Agents; Azirines; Bronchial Neoplasms; Carcinoma; C

1968
[Clinico-morphologic analysis of the results of long-term intra-arterial chemotherapy of the far advanced stages of rectal cancer].
    Voprosy onkologii, 1968, Volume: 14, Issue:11

    Topics: Adenocarcinoma; Adult; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fluoroura

1968
Gastroscopic color photography in cancer chemotherapy.
    Gastrointestinal endoscopy, 1970, Volume: 16, Issue:3

    Topics: Adenocarcinoma; Color; Cyclophosphamide; Fluorouracil; Follow-Up Studies; Gastroscopy; Humans; Lymph

1970
[Time factor in evaluating antineoplastic agents].
    Farmakologiia i toksikologiia, 1972, Volume: 35, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma 256, Walker; Dactinomycin; Fluorouracil; M

1972
Enhancement of tumor growth and immunosuppression in mice with 5-fluorouracil.
    The American journal of the medical sciences, 1972, Volume: 263, Issue:4

    Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Immunosuppression Therapy; Mammary Neoplasms, Experim

1972
Chemotherapy in the management of metastatic cancer of unknown primary site.
    Oncology, 1972, Volume: 26, Issue:2

    Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho

1972
Treatment with 5-fluorouracil in prophylaxis of relapses and metastases of stomach cancer.
    Neoplasma, 1972, Volume: 19, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Gastrectomy; Humans; Injections, Intravenous; Mal

1972
Calusterone in the therapy for advanced breast cancer.
    JAMA, 1972, Jan-24, Volume: 219, Issue:4

    Topics: Adenocarcinoma; Axilla; Bone Neoplasms; Breast Neoplasms; Castration; Drug Synergism; Female; Fluoro

1972
Antitumor activity of cyclocytidine in a variety of tumors.
    Gan, 1972, Volume: 63, Issue:3

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line; Cyclization; Cy

1972
Treatment of cancer with weekly intravenous 5-fluorouracil. Study by the Western Cooperative Cancer Chemotherapy Group (WCCCG).
    Cancer, 1971, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Breast Neoplasms; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal D

1971
[Lung cancer].
    Naika. Internal medicine, 1971, Volume: 27, Issue:6

    Topics: Adenocarcinoma; Aged; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Cobalt Isotopes; Cyclop

1971
Circulating cancer cells: pre- and post-chemotherapy observations.
    Cancer, 1971, Volume: 28, Issue:3

    Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Filtration; Fluorouracil; Humans; Male;

1971
[Continuous intra-arterial perfusion of renal tumors with chemotherapeutic agents].
    Nihon Hinyokika Gakkai zasshi. The japanese journal of urology, 1971, Volume: 62, Issue:8

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Humans; Injections, Intra-Arterial; Kidney Neoplasms; Ma

1971
5-fluorouracil given once weekly: comparison of intravenous and oral administration.
    Cancer, 1971, Volume: 28, Issue:4

    Topics: Adenocarcinoma; Administration, Oral; Biliary Tract Diseases; Breast Neoplasms; Female; Fluorouracil

1971
Radiation plus 5-fluorouracil (NSC-19893): clinical demonstration of an additive effect in bronchogenic carcinoma.
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:3

    Topics: Adenocarcinoma; Aged; Carcinoma, Bronchogenic; Carcinoma, Squamous Cell; Female; Fluorouracil; Human

1971
[Villous tumors of the jejunum and ileum].
    Journal de chirurgie, 1971, Volume: 102, Issue:3

    Topics: Adenocarcinoma; Cell Transformation, Neoplastic; Female; Fluorouracil; Humans; Ileum; Intestinal Neo

1971
Lack of effect of warfarin (NSC-59813) alone or in combination with 5-fluorouracil (NSC-19893) on primary and metastatic L1210 leukemia and adenocarcinoma 755.
    Cancer chemotherapy reports, 1971, Volume: 55, Issue:1

    Topics: Adenocarcinoma; Animals; Female; Fluorouracil; Leukemia L1210; Mice; Neoplasm Metastasis; Neoplasm T

1971
[Hypernephroma metastases of the skin and therapeutic possiblities].
    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 1971, Volume: 22, Issue:10

    Topics: Adenocarcinoma; Aged; Fluorouracil; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Nose Neopla

1971
[Gallbladder cancer].
    La Presse medicale, 1971, Dec-04, Volume: 79, Issue:52

    Topics: Adenocarcinoma; Adenoma; Carcinoma; Cholelithiasis; Fluorouracil; Gallbladder Neoplasms; Humans; Mel

1971
Association of cancer of the breast and acute myelocytic leukemia.
    Cancer, 1967, Volume: 20, Issue:7

    Topics: Adenocarcinoma; Adult; Aged; Anti-Bacterial Agents; Breast Neoplasms; Carcinoma; Female; Fluorouraci

1967
[5-Fluorouracil(5-FU) in the treatment of adenocarcinomas of the digestive tract (apropos of 13 cases)].
    Hospital (Rio de Janeiro, Brazil), 1967, Volume: 71, Issue:2

    Topics: Adenocarcinoma; Aged; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Middle Aged

1967
Bronchial artery infusion therapy for lung cancer.
    Cancer, 1969, Volume: 24, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Bronchial Arteries; Bronchial Neoplasms; Carcinoma, Squamous Cell; Cath

1969
[Distribution of 5-fluorouracil in the bodies of mice with tumors of different sensitivities to the drug].
    Voprosy onkologii, 1970, Volume: 16, Issue:4

    Topics: Adenocarcinoma; Animals; Fluorouracil; Kidney; Liver; Mammary Neoplasms, Experimental; Melanoma; Mic

1970
Local chemotherapy of cutaneous neoplasms.
    Proceedings. National Cancer Conference, 1970, Volume: 6

    Topics: Adenocarcinoma; Allergy and Immunology; Antineoplastic Agents; Carcinoma, Squamous Cell; Dactinomyci

1970
[Submicroscopic changes in the cells of mammary gland adenocarcinoma in mice caused by 5-fluorouracil].
    Tsitologiia, 1970, Volume: 12, Issue:3

    Topics: Adenocarcinoma; Animals; Cell Nucleolus; Cell Nucleus; Endoplasmic Reticulum; Fluorouracil; Mammary

1970
Preferential attack on cancer by selected SH inhibitors.
    JAMA, 1970, Oct-05, Volume: 214, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Ascites; Breast Neoplasms; Carcinoma, Ehrlich Tumor;

1970
Treatment of hepatic tumours.
    Digestion, 1970, Volume: 3, Issue:5

    Topics: Adenocarcinoma; Antineoplastic Agents; Female; Fluorouracil; Hepatic Artery; Humans; Laparotomy; Lei

1970
Immunosuppression by 5-fluorouracil.
    Cancer, 1970, Volume: 26, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Antibody Formation; Antigens; Blood Bactericidal Activity; Blood Platel

1970
An evaluation of combination chemotherapy with procarbazine (NSC-77213) and 5-fluorouracil (NSC-19893) in advanced carcinoma of the lung.
    Cancer chemotherapy reports, 1970, Volume: 54, Issue:5

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Benzoates; Blood Cell Count; Carcinoma; Carcinoma, Bro

1970
Differential effects of anti-tumour drugs on human tumour and spleen DNA synthesis in vitro.
    Archives internationales de pharmacodynamie et de therapie, 1971, Volume: 190, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Culture Techniques; Disease Model

1971
[Experience with the treatment of patients with malignant tumors with 5-fluorouracil].
    Voprosy onkologii, 1967, Volume: 13, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Colonic Neoplasms; Duodenal Neoplasms; Female; Fluorouracil; Humans; In

1967
[Internal cancer therapy: cooperative clinical studies. Principles, organization and first results of the Swiss chemotherapy group].
    Praxis, 1967, Dec-14, Volume: 56, Issue:50

    Topics: Adenocarcinoma; Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Car

1967
Carcinoma of the colon and rectum.
    American journal of surgery, 1968, Volume: 116, Issue:1

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic

1968
Liver regeneration after major hepatectomy. Effect of chemotherapy on growth and function--case report.
    Cancer, 1968, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Female; Fluorouracil; Gallbladder Neoplasms; Gold Isotopes; Hepatectomy; Humans; Liv

1968
[Modalities and results of anticancer polychemotherapy in 73 cases of advanced broncho-pleuro-pulmonary cancer].
    Le Poumon et le coeur, 1968, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Bronchial Neoplasms

1968
A radioisotopic method for determining optimum non-surgical therapy for advanced cancer. II. Clinical experience.
    Annals of surgery, 1968, Volume: 168, Issue:3

    Topics: Adenocarcinoma; Breast Neoplasms; Diethylstilbestrol; Female; Fluorouracil; Fluoxymesterone; Gastroi

1968
Oral administration of fluorouracil. A preliminary trial.
    Archives of surgery (Chicago, Ill. : 1960), 1968, Volume: 97, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Alopecia; Bile Duct Neoplasms; Colonic Neoplasms; Diarrhea; Fluorouraci

1968
5-fluorouracil therapy for cancer of the stomaach.
    Oncology, 1968, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Metastasis; S

1968
[218 cases of prolonged polychemotherapy in advanced cancer (especially bronchopulmonary). Modalities and results].
    Le Poumon et le coeur, 1968, Volume: 24, Issue:1

    Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neop

1968
Combination of 5-fluorouracil and radiation as primary therapy of carcinoma of the cervix.
    Obstetrics and gynecology, 1968, Volume: 32, Issue:5

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cobalt Isotopes; Female; Fluorouracil; Humans; Mesonephrom

1968
Further studies on human bladder and kidney tumors transplanted to the hamster cheek pouch.
    The Journal of urology, 1969, Volume: 101, Issue:4

    Topics: Adenocarcinoma; Animals; Computers; Cricetinae; Female; Fluorouracil; Humans; Kidney Neoplasms; Male

1969
The use of parenteral 5-fluorouracil in solid tumours. A preliminary report.
    Journal of the Indian Medical Association, 1969, Jan-01, Volume: 52, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Female; Fluorouracil; Gastrointestinal Neoplasms; Genital

1969
Response of recurrent carcinoma of the colon to combined deep x-ray therapy and chemotherapy with 5-fluorouracil.
    Medical radiography and photography, 1969, Volume: 45, Issue:1

    Topics: Adenocarcinoma; Aged; Colonic Neoplasms; Female; Fluorouracil; Humans

1969
Local injection of fluorouracil in skin cancer.
    JAMA, 1969, Apr-21, Volume: 208, Issue:3

    Topics: Adenocarcinoma; Fluorouracil; Humans; Injections; Male; Middle Aged; Neoplasm Recurrence, Local; Per

1969
Fluorouracil toxicity following gastrointestinal surgery.
    Archives of surgery (Chicago, Ill. : 1960), 1965, Volume: 91, Issue:6

    Topics: Adenocarcinoma; Colitis, Ulcerative; Colostomy; Fluorouracil; Humans; Intestinal Mucosa; Intestinal

1965
Kinetics of proliferation of cancer cells in neoplastic effusions in man.
    Cancer, 1965, Volume: 18, Issue:10

    Topics: Adenocarcinoma; Antineoplastic Agents; Autoradiography; Cell Division; DNA, Neoplasm; Exudates and T

1965
Chemotherapy for liver cancer by protracted ambulatory infusion.
    JAMA, 1965, Nov-01, Volume: 194, Issue:5

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Colonic Neoplasms; Fluorouracil; Hepatic Artery; Humans

1965
[The use of 5-fluorouracil in the therapy of some epithelial tumors].
    Minerva medica, 1966, Mar-28, Volume: 57, Issue:25

    Topics: Adenocarcinoma; Breast Neoplasms; Carcinosarcoma; Fluorouracil; Humans; Intestinal Neoplasms; Lung N

1966